PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Shields, BM; Dennis, JM; Angwin, CD; Warren, F; Henley, WE; Farmer, AJ; Sattar, N; Holman, RR; Jones, AG; Pearson, ER; Hattersley, AT; TriMaster Study Grp				Shields, Beverley M. M.; Dennis, John M. M.; Angwin, Catherine D. D.; Warren, Fiona; Henley, William E. E.; Farmer, Andrew J. J.; Sattar, Naveed; Holman, Rury R. R.; Jones, Angus G. G.; Pearson, Ewan R. R.; Hattersley, Andrew T. T.; TriMaster Study Group			Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study	NATURE MEDICINE			English	Article; Early Access							PRECISION MEDICINE; EUROPEAN ASSOCIATION; CONSENSUS REPORT; HYPERGLYCEMIA; POPULATION; EFFICACY; MODELS; IMPACT; GLP-1; ADA	Precision medicine aims to treat an individual based on their clinical characteristics. A differential drug response, critical to using these features for therapy selection, has never been examined directly in type 2 diabetes. In this study, we tested two hypotheses: (1) individuals with body mass index (BMI) > 30 kg/m(2), compared to BMI & LE; 30 kg/m(2), have greater glucose lowering with thiazolidinediones than with DPP4 inhibitors, and (2) individuals with estimated glomerular filtration rate (eGFR) 60-90 ml/min/1.73 m(2), compared to eGFR > 90 ml/min/1.73 m(2), have greater glucose lowering with DPP4 inhibitors than with SGLT2 inhibitors. The primary endpoint for both hypotheses was the achieved HbA1c difference between strata for the two drugs. In total, 525 people with type 2 diabetes participated in this UK-based randomized, double-blind, three-way crossover trial of 16 weeks of treatment with each of sitagliptin 100 mg once daily, canagliflozin 100 mg once daily and pioglitazone 30 mg once daily added to metformin alone or metformin plus sulfonylurea. Overall, the achieved HbA1c was similar for the three drugs: pioglitazone 59.6 mmol/mol, sitagliptin 60.0 mmol/mol and canagliflozin 60.6 mmol/mol (P = 0.2). Participants with BMI > 30 kg/m(2), compared to BMI & LE; 30 kg/m(2), had a 2.88 mmol/mol (95% confidence interval (CI): 0.98, 4.79) lower HbA1c on pioglitazone than on sitagliptin (n = 356, P = 0.003). Participants with eGFR 60-90 ml/min/1.73 m(2), compared to eGFR > 90 ml/min/1.73 m(2), had a 2.90 mmol/mol (95% CI: 1.19, 4.61) lower HbA1c on sitagliptin than on canagliflozin (n = 342, P = 0.001). There were 2,201 adverse events reported, and 447/525 (85%) randomized participants experienced an adverse event on at least one of the study drugs. In this precision medicine trial in type 2 diabetes, our findings support the use of simple, routinely available clinical measures to identify the drug class most likely to deliver the greatest glycemic reduction for a given patient.	[Shields, Beverley M. M.; Dennis, John M. M.; Angwin, Catherine D. D.; Jones, Angus G. G.; Hattersley, Andrew T. T.] Univ Exeter, Dept Clin & Biomed Sci, Exeter, England; [Warren, Fiona] Univ Exeter, Clin Trials Unit, Med Sch, Exeter, England; [Warren, Fiona; Henley, William E. E.] Univ Exeter Med Sch, Inst Hlth Res, Exeter, England; [Farmer, Andrew J. J.] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford, England; [Sattar, Naveed] Univ Glasgow, Sch Cardiovasc & Metab Hlth, Glasgow, Scotland; [Holman, Rury R. R.] Univ Oxford, Radcliffe Dept Med, Diabet Trials Unit, Oxford, England; [Pearson, Ewan R. R.] Univ Dundee, Sch Med, Populat Hlth & Genom, Dundee, Scotland	University of Exeter; University of Exeter; University of Oxford; University of Glasgow; University of Oxford; University of Dundee	Hattersley, AT (corresponding author), Univ Exeter, Dept Clin & Biomed Sci, Exeter, England.	a.t.Hattersley@exeter.ac.uk		Pearson, Ewan/0000-0001-9237-8585; Jones, Angus/0000-0002-0883-7599; Sattar, Naveed/0000-0002-1604-2593	UK Medical Research Council [MR/N00633X/1]; National Institute for Health and Care Research Exeter Biomedical Research Centre; National Institute for Health and Care Research Exeter Clinical Research Facility	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health and Care Research Exeter Biomedical Research Centre; National Institute for Health and Care Research Exeter Clinical Research Facility	We thank all study participants. We gratefully acknowledge the TriMaster central coordinating team, all members of the TriMaster study group, the MASTERMIND consortium, the Data Monitoring Committee and the Trial Steering Committee (Supplementary Information). In particular, we thank S. Senn for invaluable guidance on the analysis for this trial. In addition, we thank the Exeter NIHR Clinical Research Facility and the Exeter Clinical Trials Unit (CTU), particularly L. Quinn and S. Creanor, for their support with the study, and the CTU Data Team. We thank A. Kerridge and S. Todd of the R & D and Pharmacy Departments at the Royal Devon and Exeter NHS Foundation Trust for support and sponsorship.This trial is part of the MASTERMIND (MRC APBI Stratification and Extreme Response Mechanism in Diabetes) consortium and is supported by UK Medical Research Council study grant number MR/N00633X/1 (B.M., J.D., C.A., W.H., A.F., N.S., R.H., A.J., E.P. and A.H.). The TriMaster trial was supported by the National Institute for Health and Care Research Exeter Biomedical Research Centre and the National Institute for Health and Care Research Exeter Clinical Research Facility. The funders had no role in study design, data collection, data analysis, data interpretation, decision to publish or preparation of the manuscript. The views expressed are those of the author(s) and not necessarily those of the MRC, the NIHR or the Department of Health and Social Care. For the purpose of open access, the corresponding author has applied a Creative Commons Attribution (CC BY) license to any Author Accepted Manuscript version arising.	Alssema M, 2013, EUR J ENDOCRINOL, V169, P421, DOI 10.1530/EJE-13-0487; Angwin C, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-042784; Bell John, 2014, Lancet, V383 Suppl 1, pS3, DOI 10.1016/S0140-6736(14)60115-X; Buse JB, 2020, DIABETOLOGIA, V63, P221, DOI 10.1007/s00125-019-05039-w; Cherney DZI, 2018, KIDNEY INT, V93, P231, DOI 10.1016/j.kint.2017.06.017; Chung WK, 2020, DIABETES CARE, V43, P1617, DOI 10.2337/dci20-0022; Davies MJ, 2018, DIABETES CARE, V41, P2669, DOI 10.2337/dci18-0033; Dennis JM, 2020, DIABETES, V69, P2075, DOI 10.2337/dbi20-0002; Dennis JM, 2019, LANCET DIABETES ENDO, V7, P442, DOI 10.1016/S2213-8587(19)30087-7; Dennis JM, 2019, DIABETES OBES METAB, V21, P1576, DOI 10.1111/dom.13687; Dennis JM, 2018, CLIN EPIDEMIOL, V10, P1869, DOI 10.2147/CLEP.S179555; Dennis JM, 2018, DIABETES CARE, V41, P1844, DOI 10.2337/dc18-0344; Dennis JM, 2018, DIABETES CARE, V41, P705, DOI 10.2337/dc17-1827; Donnelly LA, 2018, DIABETOLOGIA, V61, P607, DOI 10.1007/s00125-017-4519-5; Ferrannini E, 2013, DIABETES CARE, V36, P1260, DOI 10.2337/dc12-1503; Gilbert RE, 2016, CAN J DIABETES, V40, P247, DOI 10.1016/j.jcjd.2015.11.005; Gloyn AL, 2018, LANCET DIABETES ENDO, V6, P891, DOI 10.1016/S2213-8587(18)30052-4; Goldenberg RM, 2017, CLIN THER, V39, P2438, DOI 10.1016/j.clinthera.2017.10.016; Hattersley AT, 2017, DIABETOLOGIA, V60, P769, DOI 10.1007/s00125-017-4226-2; Hinton W, 2019, DIABETES OBES METAB, V21, P1661, DOI 10.1111/dom.13710; Jackson SE, 2015, INT J CANCER, V137, P262, DOI 10.1002/ijc.28940; Kang ZF, 2013, DIABETOLOGIA, V56, P423, DOI 10.1007/s00125-012-2776-x; Le P, 2020, DIABETES CARE, V43, P1227, DOI 10.2337/dc19-2424; Matikainen N, 2014, DIABETES CARE, V37, P242, DOI 10.2337/dc13-1283; Pearson ER, 2003, LANCET, V362, P1275, DOI 10.1016/S0140-6736(03)14571-0; Senn S., 2002, CROSS OVER TRIALS CL; Shields B.M., 2022, NAT MED; Shields BM, 2017, DIABETES CARE, V40, P1017, DOI 10.2337/dc17-0224; Smith U, 2001, INT J CLIN PRACT, P13; Xu GF, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k1497; Yan X, 2009, J BIOPHARM STAT, V19, P1085, DOI 10.1080/10543400903243009	31	0	0	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02120-7	http://dx.doi.org/10.1038/s41591-022-02120-7		DEC 2022	26	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	6V4AI	36477733	hybrid, Green Submitted			2022-12-27	WOS:000894992500002
J	Attia, ZI; Friedman, PA				Attia, Zachi I.; Friedman, Paul A.			AI detection of cardiac dysfunction from consumer watch ECG recordings	NATURE MEDICINE			English	Editorial Material; Early Access							ARTIFICIAL-INTELLIGENCE	To enable large-scale screening for left ventricular dysfunction-a serious and under-detected cardiac disease-we applied artificial intelligence to electrocardiograms recorded by patients using their own Apple watches in a prospective, digital, remote study. We found that patients engaged with the system and that the watch electrocardiograms effectively screened for the disease.	[Attia, Zachi I.; Friedman, Paul A.] Mayo Clin, Rochester, MN USA	Mayo Clinic	Attia, ZI (corresponding author), Mayo Clin, Rochester, MN USA.			Yao, Xiaoxi/0000-0001-9906-7106; Attia, Zachi/0000-0002-9706-7900; Lerman, Amir/0000-0002-9446-5313; Harmon, David/0000-0002-8102-3380				Attia ZI, 2021, EUR HEART J, V42, P4717, DOI 10.1093/eurheartj/ehab649; Attia ZI, 2019, NAT MED, V25, P70, DOI 10.1038/s41591-018-0240-2; Noseworthy PA, 2020, CIRC-ARRHYTHMIA ELEC, V13, DOI 10.1161/CIRCEP.119.007988; Siontis KC, 2021, NAT REV CARDIOL, V18, P465, DOI 10.1038/s41569-020-00503-2; Yao XX, 2021, NAT MED, V27, P815, DOI 10.1038/s41591-021-01335-4	5	1	1	3	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02053-1	http://dx.doi.org/10.1038/s41591-022-02053-1		NOV 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	6E2MY	36376461				2022-12-27	WOS:000883217400001
J	Ng, MY; Kapur, S; Blizinsky, KD; Hernandez-Boussard, T				Ng, Madelena Y.; Kapur, Supriya; Blizinsky, Katherine D.; Hernandez-Boussard, Tina			The AI life cycle: a holistic approach to creating ethical AI for health decisions Comment	NATURE MEDICINE			English	Editorial Material; Early Access							MODELS	The ethical impact of AI algorithms in healthcare should be assessed at each phase, from data creation to model deployment, so that their use narrows rather than widens inequalities.	[Ng, Madelena Y.; Hernandez-Boussard, Tina] Stanford Univ, Dept Med, Stanford, CA 94305 USA; [Kapur, Supriya; Blizinsky, Katherine D.] NIH, All Us Res Program, Bldg 10, Bethesda, MD 20892 USA	Stanford University; National Institutes of Health (NIH) - USA	Hernandez-Boussard, T (corresponding author), Stanford Univ, Dept Med, Stanford, CA 94305 USA.	boussard@stanford.edu		Hernandez-Boussard, Tina/0000-0001-6553-3455; Ng, Madelena/0000-0003-3824-9349	Agency for Health Research Quality [R01HS027434]; Ethics, Society, and Technology Hub at Stanford University; Gordon and Betty Moore Foundation [10848]	Agency for Health Research Quality; Ethics, Society, and Technology Hub at Stanford University; Gordon and Betty Moore Foundation(Gordon and Betty Moore Foundation)	Research reported in this publication was supported by the Agency for Health Research & Quality under award no. R01HS027434; the Ethics, Society, and Technology Hub at Stanford University; and the Gordon and Betty Moore Foundation under grant number 10848 The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders.	Bozkurt S, 2020, J AM MED INFORM ASSN, V27, P1878, DOI 10.1093/jamia/ocaa164; Challen R, 2019, BMJ QUAL SAF, V28, P231, DOI 10.1136/bmjqs-2018-008370; Futoma J, 2020, LANCET DIGIT HEALTH, V2, pE489, DOI 10.1016/S2589-7500(20)30186-2; Goldstein BA, 2017, J AM MED INFORM ASSN, V24, P198, DOI 10.1093/jamia/ocw042; Gordon M. L., 2022, PREPRINT, DOI [10.48550/arXiv.2202.02950, DOI 10.48550/ARXIV.2202.02950]; Nsoesie EO, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.2658; Obermeyer Z, 2019, SCIENCE, V366, P447, DOI 10.1126/science.aax2342; Pfohl SR, 2021, J BIOMED INFORM, V113, DOI 10.1016/j.jbi.2020.103621; Roosli E, 2022, SCI DATA, V9, DOI 10.1038/s41597-021-01110-7; Sam Corbett-Davies, 2018, Arxiv, DOI arXiv:1808.00023; Sujan M, 2019, BMJ HEALTH CARE INFO, V26, DOI 10.1136/bmjhci-2019-100081	11	1	1	3	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01993-y	http://dx.doi.org/10.1038/s41591-022-01993-y		SEP 2022	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4V9JQ	36163298				2022-12-27	WOS:000859786500001
J	Diamond, MB; Keshaviah, A; Bento, AI; Conroy-Ben, O; Driver, EM; Ensor, KB; Halden, RU; Hopkins, LP; Kuhn, KG; Moe, CL; Rouchka, EC; Smith, T; Stevenson, BS; Susswein, Z; Vogel, JR; Wolfe, MK; Stadler, LB; Scarpino, SV				Diamond, Megan B.; Keshaviah, Aparna; Bento, Ana, I; Conroy-Ben, Otakuye; Driver, Erin M.; Ensor, Katherine B.; Halden, Rolf U.; Hopkins, Loren P.; Kuhn, Katrin G.; Moe, Christine L.; Rouchka, Eric C.; Smith, Ted; Stevenson, Bradley S.; Susswein, Zachary; Vogel, Jason R.; Wolfe, Marlene K.; Stadler, Lauren B.; Scarpino, Samuel, V			Wastewater surveillance of pathogens can inform public health responses	NATURE MEDICINE			English	Editorial Material; Early Access							STATES	Wastewater monitoring has been used to identify SARS-CoV-2 outbreaks and track new variants. This sentinel system should be expanded to monitor other pathogens and boost public health preparedness.	[Diamond, Megan B.; Bento, Ana, I; Susswein, Zachary; Scarpino, Samuel, V] Rockefeller Fdn, New York, NY 10018 USA; [Keshaviah, Aparna] Mathematica, Princeton, NJ 08540 USA; [Bento, Ana, I] Indiana Univ, Bloomington, IN USA; [Conroy-Ben, Otakuye] Arizona State Univ, Sch Sustainable Engn & Built Environm, Tempe, AZ USA; [Driver, Erin M.; Halden, Rolf U.] Arizona State Univ, Biodesign Ctr Environm Hlth Engn, Tempe, AZ USA; [Driver, Erin M.; Halden, Rolf U.] AquaVitas, Scottsdale, AZ USA; [Ensor, Katherine B.; Hopkins, Loren P.] Rice Univ, Dept Stat, Houston, TX 77251 USA; [Halden, Rolf U.] Arizona State Univ Fdn, OneWaterOneHlth, Tempe, AZ USA; [Halden, Rolf U.] Arizona State Univ, Global Futures Lab, Tempe, AZ USA; [Hopkins, Loren P.] City Houston Hlth Dept, Houston, TX USA; [Kuhn, Katrin G.] Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA; [Moe, Christine L.; Wolfe, Marlene K.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; [Rouchka, Eric C.; Smith, Ted] Univ Louisville, Louisville, KY 40292 USA; [Stevenson, Bradley S.] Northwestern Univ, Evanston, IL USA; [Vogel, Jason R.] Univ Oklahoma, Norman, OK 73019 USA; [Stadler, Lauren B.] Rice Univ, Civil & Environm Engn Dept, Houston, TX USA; [Scarpino, Samuel, V] Northeastern Univ, Boston, MA 02115 USA; [Scarpino, Samuel, V] Univ Vermont, Burlington, VT 05405 USA; [Scarpino, Samuel, V] Santa Fe Inst, Santa Fe, NM 87501 USA	Mathematica; Indiana University System; Indiana University Bloomington; Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe; Rice University; Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe; University of Oklahoma System; University of Oklahoma Health Sciences Center; Emory University; Rollins School Public Health; University of Louisville; Northwestern University; University of Oklahoma System; University of Oklahoma - Norman; Rice University; Northeastern University; University of Vermont; The Santa Fe Institute	Diamond, MB; Scarpino, SV (corresponding author), Rockefeller Fdn, New York, NY 10018 USA.; Keshaviah, A (corresponding author), Mathematica, Princeton, NJ 08540 USA.; Scarpino, SV (corresponding author), Northeastern Univ, Boston, MA 02115 USA.; Scarpino, SV (corresponding author), Univ Vermont, Burlington, VT 05405 USA.; Scarpino, SV (corresponding author), Santa Fe Inst, Santa Fe, NM 87501 USA.	mdiamond@rockfound.org; akeshaviah@mathematica-mpr.com; sscarpino@rockfound.org		Driver, Erin/0000-0001-9675-9764; Keshaviah, Aparna/0000-0002-4324-6807; Hopkins (previously Raun), Loren/0000-0003-0626-9775; Ensor, Katherine/0000-0002-3964-0465	Rockefeller Foundation	Rockefeller Foundation	This work was funded in part by a contract with Mathematica by The Rockefeller Foundation. All authors are part of the Wastewater Action Group, which is composed of grantees funded by The Rockefeller Foundation. The views and findings are those of the author and not those of The Rockefeller Foundation or the Pandemic Prevention Institute.	Amman F, 2022, NAT BIOTECHNOL, DOI 10.1038/s41587-022-01387-y; Barras C, 2018, NAT MED, V24, P1484, DOI 10.1038/s41591-018-0218-0; Baz-Lomba JA, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3686-5; Callaway Ewen, 2021, Nature, DOI 10.1038/d41586-021-02177-3; Deepak SA, 2007, CURR GENOMICS, V8, P234; Feng SC, 2021, ACS EST WATER, V1, P1955, DOI 10.1021/acsestwater.1c00160; Fouz N, 2020, TROP MED INFECT DIS, V5, DOI 10.3390/tropicalmed5010033; Franz E., 2015, SCI REP-UK, V5, P1, DOI 10.1038/srep14372; Groseclose SL, 2017, ANNU REV PUBL HEALTH, V38, P57, DOI 10.1146/annurev-publhealth-031816-044348; Karthikeyan S, 2022, NATURE, V609, P101, DOI 10.1038/s41586-022-05049-6; Keshaviah A., 2022, US; Kirby AE, 2021, MMWR-MORBID MORTAL W, V70, P1242, DOI 10.15585/mmwr.mm7036a2; Kuhn KG, 2022, SCI TOTAL ENVIRON, V812, DOI 10.1016/j.scitotenv.2021.151431; Lou EG, 2022, SCI TOTAL ENVIRON, V833, DOI 10.1016/j.scitotenv.2022.155059; Mascola JR, 2021, JAMA-J AM MED ASSOC, V325, P1261, DOI 10.1001/jama.2021.2088; Milobedzka A, 2022, J HAZARD MATER, V424, DOI 10.1016/j.jhazmat.2021.127407; Naughton C. C., 2021, SHOW US DATA GLOBAL, DOI [10.1101/2021.03.14.21253564, DOI 10.1101/2021.03.14.21253564]; Paul JR, 1939, SCIENCE, V90, P258, DOI 10.1126/science.90.2333.258; Rader B, 2022, MMWR-MORBID MORTAL W, V71, P489, DOI 10.15585/mmwr.mm7113e1; Rousis NI, 2017, WATER RES, V121, P270, DOI 10.1016/j.watres.2017.05.044; Schmidt C, 2020, NAT BIOTECHNOL, V38, P917, DOI 10.1038/s41587-020-0620-2; Shah S, 2022, SCI TOTAL ENVIRON, V804, DOI 10.1016/j.scitotenv.2021.150060; Sinclair RG, 2008, ADV APPL MICROBIOL, V65, P249, DOI 10.1016/S0065-2164(08)00609-6; Sulej-Suchomska AM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61628-5; Tebbens RJD, 2017, FOOD ENVIRON VIROL, V9, P361, DOI 10.1007/s12560-017-9314-4; Venkatesan AK, 2014, SCI REP-UK, V4, DOI 10.1038/srep03731; Weidhaas J, 2021, SCI TOTAL ENVIRON, V775, DOI 10.1016/j.scitotenv.2021.145790; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3; Xiao A, 2022, WATER RES, V212, DOI 10.1016/j.watres.2022.118070	29	0	0	5	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01940-x	http://dx.doi.org/10.1038/s41591-022-01940-x		SEP 2022	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4J6DA	36076085	Bronze			2022-12-27	WOS:000851351400001
J	Puntmann, VO; Martin, S; Shchendrygina, A; Hoffmann, J; Ka, MM; Giokoglu, E; Vanchin, B; Holm, N; Karyou, A; Laux, GS; Arendt, C; De Leuw, P; Zacharowski, K; Khodamoradi, Y; Vehreschild, MJGT; Rohde, G; Zeiher, AM; Vogl, TJ; Schwenke, C; Nagel, E				Puntmann, Valentina O.; Martin, Simon; Shchendrygina, Anastasia; Hoffmann, Jedrzej; Ka, Mame Madjiguene; Giokoglu, Eleni; Vanchin, Byambasuren; Holm, Niels; Karyou, Argyro; Laux, Gerald S.; Arendt, Christophe; De Leuw, Philipp; Zacharowski, Kai; Khodamoradi, Yascha; Vehreschild, Maria J. G. T.; Rohde, Gernot; Zeiher, Andreas M.; Vogl, Thomas J.; Schwenke, Carsten; Nagel, Eike			Long-term cardiac pathology in individuals with mild initial COVID-19 illness	NATURE MEDICINE			English	Article; Early Access							MYOCARDIAL FIBROSIS; AORTIC STIFFNESS; NATIVE T1; CMR; INFLAMMATION; SOCIETY; UPDATE; GENDER	Cardiac symptoms are increasingly recognized as late complications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in previously well individuals with mild initial illness, but the underlying pathophysiology leading to long-term cardiac symptoms remains unclear. In this study, we conducted serial cardiac assessments in a selected population of individuals with Coronavirus Disease 2019 (COVID-19) with no previous cardiac disease or notable comorbidities by measuring blood biomarkers of heart injury or dysfunction and by performing magnetic resonance imaging. Baseline measurements from 346 individuals with COVID-19 (52% females) were obtained at a median of 109 days (interquartile range (IQR), 77-177 days) after infection, when 73% of participants reported cardiac symptoms, such as exertional dyspnea (62%), palpitations (28%), atypical chest pain (27%) and syncope (3%). Symptomatic individuals had higher heart rates and higher imaging values or contrast agent accumulation, denoting inflammatory cardiac involvement, compared to asymptomatic individuals. Structural heart disease or high levels of biomarkers of cardiac injury or dysfunction were rare in symptomatic individuals. At follow-up (329 days (IQR, 274-383 days) after infection), 57% of participants had persistent cardiac symptoms. Diffuse myocardial edema was more pronounced in participants who remained symptomatic at follow-up as compared to those who improved. Female gender and diffuse myocardial involvement on baseline imaging independently predicted the presence of cardiac symptoms at follow-up. Ongoing inflammatory cardiac involvement may, at least in part, explain the lingering cardiac symptoms in previously well individuals with mild initial COVID-19 illness. In individuals with long-term cardiac symptoms after an initially mild course of COVID-19 illness, magnetic resonance imaging and measurement of cardiac injury biomarkers commonly detected ongoing cardiac inflammation but not structural heart disease.	[Puntmann, Valentina O.; Martin, Simon; Shchendrygina, Anastasia; Hoffmann, Jedrzej; Ka, Mame Madjiguene; Giokoglu, Eleni; Vanchin, Byambasuren; Holm, Niels; Karyou, Argyro; Laux, Gerald S.; Arendt, Christophe; Nagel, Eike] Goethe Univ Frankfurt, Univ Hosp Frankfurt, Inst Expt & Translat Cardiovasc Imaging, DZHK Ctr Cardiovasc Imaging, Frankfurt, Germany; [Martin, Simon; Arendt, Christophe; Vogl, Thomas J.] Univ Hosp Frankfurt, Dept Diagnost & Intervent Radiol, Frankfurt, Germany; [Hoffmann, Jedrzej; Zeiher, Andreas M.] Goethe Univ Frankfurt, Inst Cardiovasc Regenerat, Frankfurt, Germany; [De Leuw, Philipp] Infektiologikum, Frankfurt, Germany; [Zacharowski, Kai] Goethe Univ Frankfurt, Univ Hosp Frankfurt, Dept Anesthesiol Intens Care Med & Pain Therapy, Frankfurt, Germany; [Khodamoradi, Yascha; Vehreschild, Maria J. G. T.] Goethe Univ Frankfurt, Univ Hosp Frankfurt, Dept Internal Med, Infect Dis, Frankfurt, Germany; [Rohde, Gernot] Goethe Univ Frankfurt, Univ Hosp Frankfurt, Dept Internal Med, Resp Med, Frankfurt, Germany; [Schwenke, Carsten] SCO SSiS Stat Consulting, Berlin, Germany	German Centre for Cardiovascular Research; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Goethe University Frankfurt; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Goethe University Frankfurt; Goethe University Frankfurt Hospital	Puntmann, VO (corresponding author), Goethe Univ Frankfurt, Univ Hosp Frankfurt, Inst Expt & Translat Cardiovasc Imaging, DZHK Ctr Cardiovasc Imaging, Frankfurt, Germany.	vppapers@icloud.com	Rohde, Gernot GU/F-3060-2013; Shchendrygina, Anastasia/GZM-7504-2022; Vehreschild, Maria/HGB-6948-2022; Puntmann, Valentina/J-4868-2014	Rohde, Gernot GU/0000-0002-5193-7755; Shchendrygina, Anastasia/0000-0002-8220-0350; Khodamoradi, Yascha/0000-0001-5972-0967; Puntmann, Valentina/0000-0002-6044-7002	German Ministry of Education and Research via the German Center for Cardiovascular Research (DZHK) partner site RheinMain; Deutsche Herzstiftung e.V.; Cardio-Pulmonary Institute, EXC 2026 [390649896]; Bayer AG; EACVI Research Grant [App000071230]	German Ministry of Education and Research via the German Center for Cardiovascular Research (DZHK) partner site RheinMain; Deutsche Herzstiftung e.V.; Cardio-Pulmonary Institute, EXC 2026; Bayer AG(Bayer AG); EACVI Research Grant	We acknowledge the dedicated support of clinical research support staff, including T. Wolf, T. Azdad, F. Weis, I. Kruckemeier, P. Kupferling, D. Desik and L. Laghchioua of the Institute of Experimental and Translational Cardiovascular Imaging; F. Eberhardt, M. Fahim and I. Wieters of the Department of Infectious Diseases; T. Euler, A. Grunewaldt, C. Hugel and W. Gleiber of the Department of Respiratory Medicine; and our colleagues in the Department of Anesthesiology, Intensive Care Medicine & Pain Therapy, all University Hospital Frankfurt, for their dedication and support. Contributors were not compensated for their work. Funding: German Ministry of Education and Research via the German Center for Cardiovascular Research (DZHK) partner site RheinMain to E.N., V.P., S.M. and C.A.; Deutsche Herzstiftung e.V. to E.N. and V.P.; Cardio-Pulmonary Institute, EXC 2026, project ID: 390649896 to E.N.; Bayer AG to E.N. and V.P.; and EACVI Research Grant (App000071230) to A.S.	Abidin H. Z., 2019, ESC C 2019; Al-Aly Z, 2021, NATURE, V594, P259, DOI 10.1038/s41586-021-03553-9; ARETZ HT, 1987, HUM PATHOL, V18, P619; Basso C, 2020, EUR HEART J, V41, P3827, DOI 10.1093/eurheartj/ehaa664; Bell V, 2015, CURR HYPERTENS REP, V17, DOI 10.1007/s11906-015-0580-y; Blomberg B, 2021, NAT MED, V27, P1607, DOI 10.1038/s41591-021-01433-3; Brito D, 2021, JACC-CARDIOVASC IMAG, V14, P541, DOI 10.1016/j.jcmg.2020.10.023; Callard F, 2021, SOC SCI MED, V268, DOI 10.1016/j.socscimed.2020.113426; Child N, 2018, EUR HEART J-CARD IMG, V19, P768, DOI 10.1093/ehjci/jex309; Chung KF, 2014, EUR RESPIR J, V43, P343, DOI 10.1183/09031936.00202013; Daniels CJ, 2021, JAMA CARDIOL, V6, P1078, DOI 10.1001/jamacardio.2021.2065; de Leuw P, 2021, JACC-CARDIOVASC IMAG, V14, P1548, DOI 10.1016/j.jcmg.2021.01.042; Dorian P, 2006, CAN J CARDIOL, V22, P383, DOI 10.1016/S0828-282X(06)70922-9; Francone M, 2014, JACC-CARDIOVASC IMAG, V7, P254, DOI 10.1016/j.jcmg.2013.10.011; Frenneaux M, 2007, PROG CARDIOVASC DIS, V49, P252, DOI 10.1016/j.pcad.2006.08.004; Giannitsis E, 2010, CLIN CHEM, V56, P254, DOI 10.1373/clinchem.2009.132654; Gluckman TJ, 2022, J AM COLL CARDIOL, V79, P1717, DOI 10.1016/j.jacc.2022.02.003; Heinke R, 2019, BMC CARDIOVASC DISOR, V19, DOI 10.1186/s12872-019-1255-4; Huang CL, 2021, LANCET, V397, P220, DOI 10.1016/S0140-6736(20)32656-8; Klok FA, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01494-2020; Kramer CM, 2020, J CARDIOVASC MAGN R, V22, DOI 10.1186/s12968-020-00607-1; Lala A, 2020, J AM COLL CARDIOL, V76, P533, DOI [10.1016/j.jacc.2020.06.007, 10.1101/2020.04.20.20072702]; Lopez-Leon S, 2021, SCI REP-UK, V11, DOI [10.1038/s41598-021-95565-8, 10.1101/2021.01.27.21250617]; Manali ED, 2008, RESP MED, V102, P586, DOI 10.1016/j.rmed.2007.11.008; Mandal S, 2021, THORAX, V76, P396, DOI 10.1136/thoraxjnl-2020-215818; Nadkarni GN, 2020, J AM COLL CARDIOL, V76, P1815, DOI 10.1016/j.jacc.2020.08.041; Nagel E, 2020, JACC-CARDIOVASC IMAG, V13, P163, DOI 10.1016/j.jcmg.2019.10.023; Nagel E, 2019, NEW ENGL J MED, V380, P2418, DOI 10.1056/NEJMoa1716734; Nalbandian A, 2021, NAT MED, V27, P601, DOI 10.1038/s41591-021-01283-z; Petersen SE, 2017, J CARDIOVASC MAGN R, V19, DOI 10.1186/s12968-017-0327-9; Puntmann VG, 2018, J AM COLL CARDIOL, V71, P766, DOI 10.1016/j.jacc.2017.12.020; Puntmann VO, 2020, JAMA CARDIOL, V5, P1265, DOI 10.1001/jamacardio.2020.3557; Puntmann VO, 2014, HYPERTENSION, V64, P762, DOI 10.1161/HYPERTENSIONAHA.114.03928; Puntmann VO, 2013, CIRC-CARDIOVASC IMAG, V6, P295, DOI 10.1161/CIRCIMAGING.112.000151; Puntmann VO, 2012, HYPERTENSION, V59, P712, DOI 10.1161/HYPERTENSIONAHA.111.183335; Qaseem A, 2011, ANN INTERN MED, V155, P179, DOI 10.7326/0003-4819-155-3-201108020-00008; Regitz-Zagrosek V, 2007, PROG CARDIOVASC DIS, V49, P241, DOI 10.1016/j.pcad.2006.08.011; Rogers T, 2013, J CARDIOVASC MAGN R, V15, DOI 10.1186/1532-429X-15-78; Satterfield BA, 2022, NAT REV CARDIOL, V19, P332, DOI 10.1038/s41569-021-00631-3; Schulz-Menger J, 2020, J CARDIOVASC MAGN R, V22, DOI 10.1186/s12968-020-00610-6; Selzer F, 2001, HYPERTENSION, V37, P1075, DOI 10.1161/01.HYP.37.4.1075; Starekova J, 2021, JAMA CARDIOL, V6, P945, DOI 10.1001/jamacardio.2020.7444; Sudre CH, 2021, NAT MED, V27, DOI 10.1038/s41591-021-01292-y; Sweitzer NK, 2013, AM J HYPERTENS, V26, P866, DOI 10.1093/ajh/hpt043; Vidalakis E, 2020, CURR CARDIOVASC IMAG, V13, DOI 10.1007/s12410-020-9535-z; Winau L, 2018, ANN RHEUM DIS, V77, P1590, DOI 10.1136/annrheumdis-2018-213661; World Health Organization, 2020, LAB TESTING 2019 NOV	47	3	3	4	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02000-0	http://dx.doi.org/10.1038/s41591-022-02000-0		SEP 2022	19	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4H6VV	36064600	Green Published, hybrid			2022-12-27	WOS:000850016600001
J	Subissi, L; von Gottberg, A; Thukral, L; Worp, N; Munnink, BBO; Rathore, S; Abu-Raddad, LJ; Aguilera, X; Alm, E; Archer, BN; Cohen, HA; Barakat, A; Barclay, WS; Bhiman, JN; Caly, L; Chand, M; Chen, M; Cullinane, A; de Oliveira, T; Drosten, C; Druce, J; Effler, P; El Masry, I; Faye, A; Gaseitsiwe, S; Ghedin, E; Grant, R; Haagmans, BL; Herring, BL; Iyer, SS; Kassamali, Z; Kakkar, M; Kondor, RJ; Leite, JA; Leo, YS; Leung, GM; Marklewitz, M; Moyo, S; Mendez-Rico, J; Melhem, NM; Munster, V; Nahapetyan, K; Oh, DY; Pavlin, BI; Peacock, TP; Peiris, M; Peng, ZB; Poon, LLM; Rambaut, A; Sacks, J; Shen, YZ; Siqueira, MM; Tessema, SK; Volz, EM; Thiel, V; van der Werf, S; Briand, S; Perkins, MD; Van Kerkhove, MD; Koopmans, MPG; Agrawal, A				Subissi, Lorenzo; von Gottberg, Anne; Thukral, Lipi; Worp, Nathalie; Munnink, Bas B. Oude; Rathore, Surabhi; Abu-Raddad, Laith J.; Aguilera, Ximena; Alm, Erik; Archer, Brett N.; Cohen, Homa Attar; Barakat, Amal; Barclay, Wendy S.; Bhiman, Jinal N.; Caly, Leon; Chand, Meera; Chen, Mark; Cullinane, Ann; de Oliveira, Tulio; Drosten, Christian; Druce, Julian; Effler, Paul; El Masry, Ihab; Faye, Adama; Gaseitsiwe, Simani; Ghedin, Elodie; Grant, Rebecca; Haagmans, Bart L.; Herring, Belinda L.; Iyer, Shilpa S.; Kassamali, Zyleen; Kakkar, Manish; Kondor, Rebecca J.; Leite, Juliana A.; Leo, Yee-Sin; Leung, Gabriel M.; Marklewitz, Marco; Moyo, Sikhulile; Mendez-Rico, Jairo; Melhem, Nada M.; Munster, Vincent; Nahapetyan, Karen; Oh, Djin-Ye; Pavlin, Boris, I; Peacock, Thomas P.; Peiris, Malik; Peng, Zhibin; Poon, Leo L. M.; Rambaut, Andrew; Sacks, Jilian; Shen, Yinzhong; Siqueira, Marilda M.; Tessema, Sofonias K.; Volz, Erik M.; Thiel, Volker; van der Werf, Sylvie; Briand, Sylvie; Perkins, Mark D.; Van Kerkhove, Maria D.; Koopmans, Marion P. G.; Agrawal, Anurag			An early warning system for emerging SARS-CoV-2 variants	NATURE MEDICINE			English	Editorial Material							RECEPTOR-BINDING DOMAIN; MUTATIONS		[Subissi, Lorenzo; Archer, Brett N.; Cohen, Homa Attar; Grant, Rebecca; Pavlin, Boris, I; Sacks, Jilian; Briand, Sylvie; Perkins, Mark D.; Van Kerkhove, Maria D.] World Hlth Org, Geneva, Switzerland; [von Gottberg, Anne; Bhiman, Jinal N.] Natl Inst Communicable Dis, Johannesburg, South Africa; [von Gottberg, Anne] Univ Witwatersrand, Fac Hlth Sci, Sch Pathol, Johannesburg, South Africa; [Thukral, Lipi; Rathore, Surabhi; Kassamali, Zyleen] CSIR Inst Genom & Integrat Biol, Delhi, India; [Worp, Nathalie; Munnink, Bas B. Oude; Haagmans, Bart L.; Koopmans, Marion P. G.] Erasmus MC, Rotterdam, Netherlands; [Worp, Nathalie; Munnink, Bas B. Oude; Haagmans, Bart L.; Koopmans, Marion P. G.] Pandem & Disaster Preparedness Res Ctr, Rotterdam, Netherlands; [Abu-Raddad, Laith J.] Weill Cornell Med Qatar Cornell Univ, Doha, Qatar; [Aguilera, Ximena; Druce, Julian] Univ Desarollo, Epidemiol & Hlth Policy Ctr, Santiago, Chile; [Alm, Erik] European Ctr Dis Prevent & Control, Stockholm, Sweden; [Barakat, Amal] World Hlth Org Reg Off Eastern Mediterranean, Cairo, Egypt; [Barclay, Wendy S.; Peacock, Thomas P.; Volz, Erik M.] Imperial Coll London, London, England; [Caly, Leon] Victorian Infect Dis Reference Lab, Melbourne, Vic, Australia; [Bhiman, Jinal N.; Chand, Meera; Peacock, Thomas P.] UK Hlth Secur Agcy, London, England; [Chen, Mark; Leo, Yee-Sin] Natl Ctr Infect Dis, Singapore, Singapore; [Cullinane, Ann] World Org Anim Hlth, Paris, France; [de Oliveira, Tulio] Stellenbosch Univ, Ctr Epidem Response & Innovat, Stellenbosch, South Africa; [Drosten, Christian] Charite Med Ctr, Berlin, Germany; [Effler, Paul] Univ Western Australia, Perth, WA, Australia; [El Masry, Ihab] Food & Agr Org, Rome, Italy; [Faye, Adama] Univ Cheikh Anta Diop, Inst Sante & Dev, Dakar, Senegal; [Gaseitsiwe, Simani; Moyo, Sikhulile] Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana; [Gaseitsiwe, Simani; Moyo, Sikhulile] Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA USA; [Ghedin, Elodie] NIAID, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Herring, Belinda L.] World Hlth Org Reg Off Africa, Brazzaville, Rep Congo; [Iyer, Shilpa S.] World Hlth Org Reg Off Western Pacific, Manila, Philippines; [Kakkar, Manish] World Hlth Org Reg Off South East Asia, New Delhi, India; [Kondor, Rebecca J.] US Ctr Dis Control & Prevent, Atlanta, GA USA; [Leite, Juliana A.; Mendez-Rico, Jairo] World Hlth Org Reg Off Amer, Washington, DC USA; [Leung, Gabriel M.; Peiris, Malik; Poon, Leo L. M.] Univ Hong Kong, LKS Fac Med, Sch Publ Hlth, Hong Kong, Peoples R China; [Marklewitz, Marco; Nahapetyan, Karen] World Hlth Org Reg Off Europe, Copenhagen, Denmark; [Melhem, Nada M.] Amer Univ Beirut, Beirut, Lebanon; [Munster, Vincent] NIAID, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA; [Oh, Djin-Ye] Robert Koch Inst, Berlin, Germany; [Peng, Zhibin] Chinese Ctr Dis Control & Prevent, Beijing, Peoples R China; [Rambaut, Andrew] Univ Edinburgh, Edinburgh, Midlothian, Scotland; [Shen, Yinzhong] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Shanghai, Peoples R China; [Siqueira, Marilda M.] Fiocruz MS, Oswald Cruz Inst, Rio De Janeiro, Brazil; [Tessema, Sofonias K.] Africa Ctr Dis Control & Prevent, Addis Ababa, Ethiopia; [Thiel, Volker] Univ Bern, Multidisciplinary Ctr Infect Dis, Bern, Switzerland; [Thiel, Volker] Inst Virol & Immunol, Mittelhausern, Switzerland; [Thiel, Volker] Inst Virol & Immunol, Bern, Switzerland; [van der Werf, Sylvie] Univ Paris Cite, Inst Pasteur, Paris, France; [Agrawal, Anurag] Ashoka Univ, Trivedi Sch Biosci, Sonipat, India	World Health Organization; National Institute for Communicable Diseases (NICD); University of Witwatersrand; Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Genomics & Integrative Biology (IGIB); Erasmus University Rotterdam; Erasmus MC; Qatar Foundation (QF); Weill Cornell Medical College Qatar; European Centre for Disease Prevention & Control; World Health Organization; Imperial College London; Victorian Infectious Diseases Reference Laboratory; National Centre for Infectious Diseases Singapore; Stellenbosch University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Western Australia; Food & Agriculture Organization of the United Nations (FAO); University Cheikh Anta Diop Dakar; Botswana-Harvard AIDS Institute Partnership; Harvard University; Harvard T.H. Chan School of Public Health; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); World Health Organization; World Health Organization; World Health Organization; Centers for Disease Control & Prevention - USA; University of Hong Kong; World Health Organization; American University of Beirut; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Robert Koch Institute; Chinese Center for Disease Control & Prevention; University of Edinburgh; Fudan University; Fundacao Oswaldo Cruz; University of Bern; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Van Kerkhove, MD (corresponding author), World Hlth Org, Geneva, Switzerland.	vankerkhovem@who.int	Haagmans, Bart/E-9791-2015; Poon, Leo/AAP-6887-2020; Moyo, Sikhulile/E-1464-2015; Archer, Brett Nicholas/A-5610-2012; Munster, Vincent/I-7607-2018; Aguilera, Ximena/D-9861-2014	Haagmans, Bart/0000-0001-6221-2015; Moyo, Sikhulile/0000-0003-3821-4592; Archer, Brett Nicholas/0000-0002-4144-1094; Barclay, Wendy/0000-0002-3948-0895; Rathore, Surabhi/0000-0002-3137-6006; Abu-Raddad, Laith/0000-0003-0790-0506; Munster, Vincent/0000-0002-2288-3196; Leite, Juliana/0000-0002-8620-114X; von Gottberg, Anne/0000-0002-0243-7455; Aguilera, Ximena/0000-0002-8153-6733; de Oliveira, Tulio/0000-0002-3027-5254; Oude Munnink, Bas/0000-0002-9394-1189				Andreano E, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2103154118; Baum A, 2020, SCIENCE, V369, P1014, DOI 10.1126/science.abd0831; Cao YL, 2022, NATURE, V602, P657, DOI 10.1038/s41586-021-04385-3; Carreno JM, 2021, EBIOMEDICINE, V73, DOI 10.1016/j.ebiom.2021.103626; Chen RTE, 2021, NAT MED, V27, DOI 10.1038/s41591-021-01294-w; Collier DA, 2021, NATURE, V593, P136, DOI 10.1038/s41586-021-03412-7; Corey L, 2021, NEW ENGL J MED, V385, P562, DOI 10.1056/NEJMsb2104756; Davies NG, 2021, NATURE, V593, P270, DOI [10.1038/s41586-021-03426-1, 10.1101/2021.02.01.21250959]; Deng XD, 2021, CELL, V184, P3426, DOI 10.1016/j.cell.2021.04.025; Escalera A, 2022, CELL HOST MICROBE, V30, P373, DOI 10.1016/j.chom.2022.01.006; Gao Y, 2022, NAT MED, V28, P472, DOI 10.1038/s41591-022-01700-x; Grabowski F, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13030392; Greaney AJ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24435-8; Greaney AJ, 2021, CELL HOST MICROBE, V29, P463, DOI 10.1016/j.chom.2021.02.003; Harvey WT, 2021, NAT REV MICROBIOL, V19, P409, DOI 10.1038/s41579-021-00573-0; Haslwanter D, 2021, MBIO, V12, DOI 10.1128/mBio.02473-21; He W., BIORXIV, DOI [10.1101/2021.09.08.459480(2021, DOI 10.1101/2021.09.08.459480(2021]; Hou YXJ, 2020, SCIENCE, V370, P1464, DOI 10.1126/science.abe8499; Bergeri I, 2022, medRxiv, DOI 10.1101/2021.12.14.21267791; Iketani S, 2022, NATURE, V604, P553, DOI 10.1038/s41586-022-04594-4; Keeton R, 2022, NATURE, V603, P488, DOI 10.1038/s41586-022-04460-3; Kitchin D, 2022, CELL REP MED, V3, DOI 10.1016/j.xcrm.2022.100535; Konings F, 2021, NAT MICROBIOL, V6, P821, DOI 10.1038/s41564-021-00932-w; Li QQ, 2021, CELL, V184, P2362, DOI 10.1016/j.cell.2021.02.042; Liu S., 2019, SCI REP, V9, P1, DOI [DOI 10.1038/S41598-018-36430-Z, DOI 10.1038/s41598-018-38051-y, 10.1038/s41598-018, DOI 10.1038/S41598-018]; Liu Y, 2022, CELL REP, V39, DOI 10.1016/j.celrep.2022.110829; Liu Y, 2022, NATURE, V602, P294, DOI 10.1038/s41586-021-04245-0; Liu ZM, 2021, CELL HOST MICROBE, V29, P477, DOI 10.1016/j.chom.2021.01.014; Lubinski B, 2022, ISCIENCE, V25, DOI 10.1016/j.isci.2021.103589; Maher MC, 2022, SCI TRANSL MED, V14, DOI 10.1126/scitranslmed.abk3445; McCallum M, 2021, CELL, V184, P2332, DOI [10.1101/2021.01.14.426475, 10.1016/j.cell.2021.03.028]; McCarthy KR, 2021, SCIENCE, V371, P1139, DOI 10.1126/science.abf6950; Meng B, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.109292; Motozono C, 2021, CELL HOST MICROBE, V29, P1124, DOI 10.1016/j.chom.2021.06.006; Munnink BBO, 2021, SCIENCE, V371, P172, DOI 10.1126/science.abe5901; Munoz-Fontela Cesar, 2022, PLoS Pathog, V18, pe1010161, DOI 10.1371/journal.ppat.1010161; Munster VJ, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abj3627; Munnink BBO, 2021, NAT MED, V27, P1518, DOI 10.1038/s41591-021-01472-w; Rappazzo CG, 2021, SCIENCE, V371, P823, DOI 10.1126/science.abf4830; Riou C, 2022, SCI TRANSL MED, V14, DOI 10.1126/scitranslmed.abj6824; Saito A, 2022, NATURE, V602, P300, DOI 10.1038/s41586-021-04266-9; Starr T.N., BIORXIV, DOI [10.1101/2022.02.24.481899(2022, DOI 10.1101/2022.02.24.481899(2022]; Starr TN, 2021, SCIENCE, V371, P850, DOI 10.1126/science.abf9302; Starr TN, 2020, CELL, V182, P1295, DOI 10.1016/j.cell.2020.08.012; Syed AM, 2021, SCIENCE, V374, P1626, DOI 10.1126/science.abl6184; Tada T, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.797589; Twohig KA, 2022, LANCET INFECT DIS, V22, P35, DOI 10.1016/S1473-3099(21)00475-8; Viana R, 2022, NATURE, V603, P679, DOI 10.1038/s41586-022-04411-y; Volz E, 2021, CELL, V184, P64, DOI 10.1016/j.cell.2020.11.020; Wang MY, 2022, EMERG MICROBES INFEC, V11, P18, DOI 10.1080/22221751.2021.2008775; Wang PF, 2021, NATURE, V593, P130, DOI 10.1038/s41586-021-03398-2; Wang Zijun, 2021, bioRxiv, DOI [10.1038/s41586-021-03324-6, 10.1101/2021.01.15.426911]; Weisblum Y, 2020, ELIFE, V9, DOI 10.7554/eLife.61312; West Anthony P Jr, 2021, bioRxiv, DOI [10.1038/s41467-021-25168-4, 10.1101/2021.02.14.431043]; Wibmer CK, 2021, NAT MED, V27, DOI [10.1038/s41591-021-01285-x, 10.1101/2021.01.18.427166]; World Health Organization, TRACKINGARS COV 2 VA; World Health Organization, WHO BIOHUB; World Health Organization, 2015, US; World Health Organization, NOVEL CORONAVIRUS 20; World Health Organization, 2021, TERMS REFERENCE TECH	60	5	5	6	11	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2022	28	6					1110	1115		10.1038/s41591-022-01836-w	http://dx.doi.org/10.1038/s41591-022-01836-w		MAY 2022	6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E9IE	35637337	Bronze, Green Published			2022-12-27	WOS:000802851000002
J	Yang, WY; Zhu, DL; Gan, SL; Dong, XL; Su, JP; Li, WH; Jiang, HW; Zhao, WN; Yao, MX; Song, WH; Lu, YB; Zhang, XZ; Li, HF; Wang, GX; Qiu, W; Yuan, GY; Ma, JH; Li, W; Li, ZL; Wang, XY; Zeng, JE; Yang, Z; Liu, JD; Liang, YQ; Lu, S; Zhang, HL; Liu, H; Liu, P; Fan, KL; Jiang, XZ; Li, YF; Su, Q; Ning, T; Tan, HW; An, ZM; Jiang, ZS; Liu, LJ; Zhou, ZH; Zhang, Q; Li, XF; Shan, ZY; Xue, YM; Mao, H; Shi, LX; Ye, SD; Zhang, XM; Sun, J; Li, P; Yang, T; Li, F; Lin, JN; Zhang, ZO; Zhao, Y; Li, RN; Guo, XH; Yao, Q; Lu, WP; Qu, S; Li, HM; Tan, LL; Wang, WB; Yao, YL; Chen, DX; Li, YL; Gao, JL; Hu, W; Fei, XQ; Wu, TF; Dong, S; Jin, WL; Li, CZ; Zhao, D; Feng, B; Zhao, Y; Zhang, Y; Li, XY; Chen, L				Yang, Wenying; Zhu, Dalong; Gan, Shenglian; Dong, Xiaolin; Su, Junping; Li, Wenhui; Jiang, Hongwei; Zhao, Wenjuan; Yao, Minxiu; Song, Weihong; Lu, Yibing; Zhang, Xiuzhen; Li, Huifang; Wang, Guixia; Qiu, Wei; Yuan, Guoyue; Ma, Jianhua; Li, Wei; Li, Ziling; Wang, Xiaoyue; Zeng, Jiao'e; Yang, Zhou; Liu, Jingdong; Liang, Yongqian; Lu, Song; Zhang, Huili; Liu, Hui; Liu, Ping; Fan, Kuanlu; Jiang, Xiaozhen; Li, Yufeng; Su, Qing; Ning, Tao; Tan, Huiwen; An, Zhenmei; Jiang, Zhaoshun; Liu, Lijun; Zhou, Zunhai; Zhang, Qiu; Li, Xuefeng; Shan, Zhongyan; Xue, Yaoming; Mao, Hong; Shi, Lixin; Ye, Shandong; Zhang, Xiaomei; Sun, Jiao; Li, Ping; Yang, Tao; Li, Feng; Lin, Jingna; Zhang, Zhinong; Zhao, Ying; Li, Ruonan; Guo, Xiaohui; Yao, Qi; Lu, Weiping; Qu, Shen; Li, Hongmei; Tan, Liling; Wang, Wenbo; Yao, Yongli; Chen, Daoxiong; Li, Yulan; Gao, Jialin; Hu, Wen; Fei, Xiaoqiang; Wu, Tianfeng; Dong, Song; Jin, Wenlong; Li, Chenzhong; Zhao, Dong; Feng, Bo; Zhao, Yu; Zhang, Yi; Li, Xiaoying; Chen, Li			Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial	NATURE MEDICINE			English	Article							GLUCOKINASE ACTIVATOR AZD1656; GLYCEMIC CONTROL; PLASMA-GLUCOSE; MELLITUS; PIRAGLIATIN; INSULIN; ISLETS	Metformin, the first-line therapy for type 2 diabetes (T2D), decreases hepatic glucose production and reduces fasting plasma glucose levels. Dorzagliatin, a dual-acting orally bioavailable glucokinase activator targeting both the pancreas and liver glucokinase, decreases postprandial glucose in patients with T2D. In this randomized, double-blind, placebo-controlled phase 3 trial, the efficacy and safety of dorzagliatin as an add-on therapy to metformin were assessed in patients with T2D who had inadequate glycemic control using metformin alone. Eligible patients with T2D (n = 767) were randomly assigned to receive dorzagliatin or placebo (1:1 ratio) as an add-on to metformin (1,500 mg per day) for 24-weeks of double-blind treatment, followed by 28 weeks of open-label treatment with dorzagliatin for all patients. The primary efficacy endpoint was the change in glycated hemoglobin (HbA1c) levels from baseline to week 24, and safety was assessed throughout the trial. At week 24, the least-squares mean change from baseline in HbA1c (95% confidence interval (CI)) was -1.02% (-1.11, -0.93) in the dorzagliatin group and -0.36% (-0.45, -0.26) in the placebo group (estimated treatment difference, -0.66%; 95% CI: -0.79, -0.53; P < 0.0001). The incidence of adverse events was similar between groups. There were no severe hypoglycemia events or drug-related serious adverse events in the dorzagliatin and metformin combined therapy group. In patients with T2D who experienced inadequate glycemic control with metformin alone, dorzagliatin resulted in effective glycemic control with good tolerability and safety profile (NCT03141073).	[Yang, Wenying] China Japan Friendship Hosp, Beijing, Peoples R China; [Zhu, Dalong; Li, Ping] Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Nanjing, Peoples R China; [Gan, Shenglian] First Peoples Hosp Changde City, Changde, Peoples R China; [Dong, Xiaolin] Shandong First Med Univ, Jinan Cent Hosp, Jinan, Peoples R China; [Su, Junping] Cangzhou Peoples Hosp, Cangzhou, Peoples R China; [Li, Wenhui] Peking Union Med Coll Hosp, Beijing, Peoples R China; [Jiang, Hongwei] Henan Univ Sci & Technol, Affiliated Hosp 1, Luoyang, Peoples R China; [Jiang, Hongwei] Henan Univ Sci & Technol, Coll Clin Med, Luoyang, Peoples R China; [Zhao, Wenjuan] Qingdao Univ, Affiliated Hosp, Qingdao, Peoples R China; [Yao, Minxiu] Qingdao Cent Hosp, Qingdao, Peoples R China; [Song, Weihong] Chenzhou First Peoples Hosp, Chenzhou, Peoples R China; [Lu, Yibing] Nanjing Med Univ, Affiliated Hosp 2, Nanjing, Peoples R China; [Zhang, Xiuzhen] Tongji Univ, Tongji Hosp, Shanghai, Peoples R China; [Li, Huifang] Kunming Med Univ, Affiliated Hosp 1, Kunming, Yunnan, Peoples R China; [Wang, Guixia] Jilin Univ, Bethune Hosp 1, Changchun, Peoples R China; [Qiu, Wei] Huzhou Cent Hosp, Huzhou, Peoples R China; [Yuan, Guoyue] Jiangsu Univ, Affiliated Hosp, Zhenjiang, Jiangsu, Peoples R China; [Ma, Jianhua] Nanjing First Hosp, Nanjing, Peoples R China; [Li, Wei] Xuzhou Med Univ, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China; [Li, Ziling] Inner Mongolia Baogang Hosp, Baotou, Peoples R China; [Wang, Xiaoyue] First Peoples Hosp Yue Yang, Yueyang, Peoples R China; [Zeng, Jiao'e] Yangtze Univ, Jingzhou Hosp, Jingzhou, Peoples R China; [Yang, Zhou] Jiangxi Pingxiang Peoples Hosp, Pingxiang, Peoples R China; [Liu, Jingdong] Jiangxi Prov Peoples Hosp, Nanchang, Jiangxi, Peoples R China; [Liang, Yongqian] First Peoples Hosp Shunde, Foshan, Peoples R China; [Lu, Song] Chongqing Gen Hosp, Chongqing, Peoples R China; [Zhang, Huili] Qinghai Univ, Affiliated Hosp, Xining, Peoples R China; [Liu, Hui] Luoyang Cent Hosp, Luoyang, Peoples R China; [Liu, Ping] Ningxia Med Univ, Gen Hosp, Yinchuan, Ningxia, Peoples R China; [Fan, Kuanlu] Gen Hosp, Xuzhou City Min Grp, Xuzhou, Jiangsu, Peoples R China; [Jiang, Xiaozhen] Shanghai Pudong New Area Peoples Hosp, Shanghai, Peoples R China; [Li, Yufeng] Capital Med Univ, Beijing Friendship Hosp Pinggu Campus, Beijing, Peoples R China; [Su, Qing] Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Shanghai, Peoples R China; [Ning, Tao] Baotou Cent Hosp, Baotou, Peoples R China; [Tan, Huiwen; An, Zhenmei] Sichuan Univ, West China Hosp, Chengdu, Peoples R China; [Jiang, Zhaoshun] PLA Joint Logist Support Force, 960th Hosp, Jinan, Peoples R China; [Liu, Lijun] Yiyang Cent Hosp, Yiyang, Peoples R China; [Zhou, Zunhai] Tongji Univ, Yangpu Hosp, Shanghai, Peoples R China; [Zhang, Qiu] Anhui Med Univ, Affiliated Hosp 1, Hefei, Peoples R China; [Li, Xuefeng] Hubei Univ Med, Taihe Hosp, Shiyan, Peoples R China; [Shan, Zhongyan] China Med Univ, Hosp 1, Shenyang, Peoples R China; [Xue, Yaoming] Southern Med Univ, Nanfang Hosp, Guangzhou, Peoples R China; [Mao, Hong] Cent Hosp Wuhan, Wuhan, Peoples R China; [Shi, Lixin] Guizhou Med Univ, Affiliated Hosp, Guiyang, Peoples R China; [Ye, Shandong] Anhui Prov Hosp, Hefei, Peoples R China; [Zhang, Xiaomei] First Affiliated Hosp, Bengbu Med Coll, Bengbu, Peoples R China; [Sun, Jiao] Fudan Univ, Huadong Hosp, Shanghai, Peoples R China; [Yang, Tao] Jiangsu Prov Hosp, Nanjing, Peoples R China; [Li, Feng] Jining 1 Peoples Hosp, Jining, Peoples R China; [Lin, Jingna] Tianjin Peoples Hosp, Tianjin, Peoples R China; [Zhang, Zhinong] First Hosp Qiqihar, Qiqihar, Peoples R China; [Zhao, Ying] Jilin Cent Gen Hosp, Jilin, Jilin, Peoples R China; [Li, Ruonan] Third Peoples Hosp Yunnan Prov, Kunming, Yunnan, Peoples R China; [Guo, Xiaohui] Peking Univ First Hosp, Beijing, Peoples R China; [Yao, Qi] Ningbo First Hosp, Ningbo, Peoples R China; [Lu, Weiping] Nanjing Med Univ, Affiliated Huaian Peoples Hosp 1, Huaian, Peoples R China; [Qu, Shen] Shanghai Tenth Peoples Hosp, Shanghai, Peoples R China; [Li, Hongmei] Emergency Gen Hosp, Beijing, Peoples R China; [Tan, Liling] Hainan Med Univ, Affiliated Hosp 1, Haikou, Hainan, Peoples R China; [Wang, Wenbo] Peking Univ, Shougang Hosp, Beijing, Peoples R China; [Yao, Yongli] Qinghai Prov Peoples Hosp, Xining, Peoples R China; [Chen, Daoxiong] Hainan Gen Hosp, Haikou, Hainan, Peoples R China; [Li, Yulan] Liuzhou Peoples Hosp, Liuzhou, Peoples R China; [Gao, Jialin] Wannan Med Univ, Affiliated Hosp 1, Yijishan Hosp, Wuhu, Peoples R China; [Hu, Wen] Second Peoples Hosp Huaian, Huaian, Peoples R China; [Fei, Xiaoqiang] Jiangsu Taizhou Peoples Hosp, Taizhou, Peoples R China; [Wu, Tianfeng] Zhejiang Hosp, Hangzhou, Peoples R China; [Dong, Song] Aerosp Ctr Hosp, Beijing, Peoples R China; [Jin, Wenlong] Yanbian Univ Hosp, Yanji, Peoples R China; [Li, Chenzhong] Southern Med Univ, Affiliated Hosp 3, Guangzhou, Peoples R China; [Zhao, Dong] Capital Med Univ, Beijing Luhe Hosp, Beijing, Peoples R China; [Feng, Bo] Tongji Univ, Shanghai East Hosp, Shanghai, Peoples R China; [Zhao, Yu; Zhang, Yi; Chen, Li] Hua Med Shanghai Ltd, Shanghai, Peoples R China; [Li, Xiaoying] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China	China-Japan Friendship Hospital; Nanjing University; Shandong First Medical University & Shandong Academy of Medical Sciences; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; Henan University of Science & Technology; Henan University of Science & Technology; Qingdao University; Nanjing Medical University; Tongji University; Kunming Medical University; Jilin University; Huzhou University; Jiangsu University; Xuzhou Medical University; Yangtze University; Qinghai University; Zhengzhou University; Ningxia Medical University; Capital Medical University; Shanghai Jiao Tong University; Sichuan University; Tongji University; Anhui Medical University; Hubei University of Medicine; China Medical University; Southern Medical University - China; Guizhou Medical University; Bengbu Medical College; Fudan University; Nanjing Medical University; Peking University; Nanjing Medical University; Hainan Medical University; Peking University; Wannan Medical College; Yanbian University; Southern Medical University - China; Capital Medical University; Tongji University; Fudan University	Zhu, DL (corresponding author), Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Nanjing, Peoples R China.; Chen, L (corresponding author), Hua Med Shanghai Ltd, Shanghai, Peoples R China.; Li, XY (corresponding author), Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China.	zhudalong@nju.edu.cn; xiaoying_li@hotmail.com; lichen@huamedicine.com	Lu, Wei/AAE-2921-2022; Li, yu/HHZ-5236-2022; li, yu/HGL-9518-2022	Lu, Wei/0000-0002-4150-8674; JIANG, HONGWEI/0000-0003-3807-7989; Li, Xiaoying/0000-0002-9383-5757; Yang, Wenying/0000-0002-7997-9404	Hua Medicine - National Major Scientific and Technological Special Project for Significant New Drugs Development [2014ZX09101002004, 2018ZX09711002-012-001]; Shanghai Science and Technology Innovation Action Project [14431908300, 15XD1520500, 17DZ1910200, 19431905200]; Shanghai Pudong District Science and Technology Innovation Action Project [PKJ2014-S06]; Shanghai Municipal Commission of Economy and Informatization Innovation Action Project [XC-ZXSJ-01-2015-02, 18XI-18]	Hua Medicine - National Major Scientific and Technological Special Project for Significant New Drugs Development; Shanghai Science and Technology Innovation Action Project; Shanghai Pudong District Science and Technology Innovation Action Project; Shanghai Municipal Commission of Economy and Informatization Innovation Action Project	The study sponsor was Hua Medicine. We thank J. Chen for providing medical writing and editing support, which was funded by Hua Medicine; C. Geng, L. Yuan and L. Li (Hua Medicine) for assistance with the efficacy data; A. Wang (Hua Medicine) for assistance with the safety data; X. Liu (Hua Medicine) for assistance with the statistical analyses; and G. Yu and F. Tang, who reviewed an earlier version of the manuscript on behalf of Hua Medicine. Hua Medicine participated in the design, conduct, data analysis and interpretation of the clinical study, the preparation of the manuscript and the decision to publish. This study was also partially funded by grants from the National Major Scientific and Technological Special Project for Significant New Drugs Development (2014ZX09101002004 and 2018ZX09711002-012-001), the Shanghai Science and Technology Innovation Action Project (14431908300, 15XD1520500, 17DZ1910200 and 19431905200), the Shanghai Pudong District Science and Technology Innovation Action Project (PKJ2014-S06) and the Shanghai Municipal Commission of Economy and Informatization Innovation Action Project (XC-ZXSJ-01-2015-02 and 18XI-18).	Agius L, 2008, BIOCHEM J, V414, P1, DOI 10.1042/BJ20080595; Amer Diabet Assoc, 2013, DIABETES CARE, V36, pS11, DOI 10.2337/dc13-S011; Amin NB, 2015, DIABETES OBES METAB, V17, P751, DOI 10.1111/dom.12474; [Anonymous], 2021, STUDY EVALUATE SAFET; Bonadonna RC, 2010, J CLIN ENDOCR METAB, V95, P5028, DOI 10.1210/jc.2010-1041; Chen L, 2021, DIABETES, V70, DOI 10.2337/db21-117-LB; Chen L, 2019, DIABETES, V68, DOI 10.2337/db19-1151-P; Chen L, 2018, DIABETES, V67, DOI 10.2337/db18-2310-PUB; Cosentino F., 2020, EUR HEART J, V41, P255, DOI [10.1093/eurheartj/ehz486, DOI 10.1093/eurheartj/ehz486]; Fonseca VA, 2009, DIABETES CARE, V32, pS151, DOI 10.2337/dc09-S301; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; Grimsby J, 2003, SCIENCE, V301, P370, DOI 10.1126/science.1084073; Haeusler RA, 2015, MOL METAB, V4, P222, DOI 10.1016/j.molmet.2014.12.007; International Diabetes Federation, 2021, IDF DIABETES ATLAS, V10th; Katz L, 2016, DIABETES OBES METAB, V18, P191, DOI 10.1111/dom.12586; Kiyosue A, 2013, DIABETES OBES METAB, V15, P923, DOI 10.1111/dom.12100; Lenzen S, 2014, J BIOL CHEM, V289, P12189, DOI 10.1074/jbc.R114.557314; Li CH, 2013, J BIOL CHEM, V288, P3938, DOI 10.1074/jbc.M112.385682; Matschinsky FM, 2002, DIABETES, V51, pS394, DOI 10.2337/diabetes.51.2007.S394; Matschinsky FM, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00148; Matschinsky FM, 2009, NAT REV DRUG DISCOV, V8, P399, DOI 10.1038/nrd2850; MedDRA Maintenance and Support Services Organization, 2022, INTR GUID MEDDRA; Meininger GE, 2011, DIABETES CARE, V34, P2560, DOI 10.2337/dc11-1200; Rena G, 2017, DIABETOLOGIA, V60, P1577, DOI 10.1007/s00125-017-4342-z; SEED Study Group, NAT MED; Sharma Raman, 2014, Drug Metab Dispos, V42, P1926, DOI 10.1124/dmd.114.060087; Turner RC, 1999, JAMA-J AM MED ASSOC, V281, P2005, DOI 10.1001/jama.281.21.2005; Wilding JPH, 2013, DIABETES OBES METAB, V15, P750, DOI 10.1111/dom.12088; Xu HR, 2016, DRUG DES DEV THER, V10, P1619, DOI 10.2147/DDDT.S105021; Yang WY, 2014, LANCET DIABETES ENDO, V2, P992, DOI 10.1016/S2213-8587(14)70136-6; Zhi JG, 2016, J CLIN PHARMACOL, V56, DOI 10.1002/jcph.589; Zhu DL, 2018, LANCET DIABETES ENDO, V6, P627, DOI 10.1016/S2213-8587(18)30105-0; Zhu XX, 2018, DIABETES OBES METAB, V20, P2113, DOI 10.1111/dom.13338	33	4	5	27	35	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2022	28	5					974	+		10.1038/s41591-022-01803-5	http://dx.doi.org/10.1038/s41591-022-01803-5		MAY 2022	19	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	1J3AM	35551292	Green Submitted, Green Published, hybrid			2022-12-27	WOS:000794108200005
J	Mir, O; Ferrua, M; Fourcade, A; Mathivon, D; Duflot-Boukobza, A; Dumont, S; Baudin, E; Delaloge, S; Malka, D; Albiges, L; Pautier, P; Robert, C; Planchard, D; de Botton, S; Scotte, F; Lemare, F; Abbas, M; Guillet, M; Puglisi, V; Di Palma, M; Minvielle, E				Mir, Olivier; Ferrua, Marie; Fourcade, Aude; Mathivon, Delphine; Duflot-Boukobza, Adeline; Dumont, Sarah; Baudin, Eric; Delaloge, Suzette; Malka, David; Albiges, Laurence; Pautier, Patricia; Robert, Caroline; Planchard, David; de Botton, Stephane; Scotte, Florian; Lemare, Francois; Abbas, May; Guillet, Marilene; Puglisi, Vanessa; Di Palma, Mario; Minvielle, Etienne			Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial	NATURE MEDICINE			English	Article							REPORTED OUTCOMES; DOSE INTENSITY; CANCER; QUESTIONNAIRE; COORDINATION; PERCEPTIONS; VALIDATION; MANAGEMENT; ADHERENCE; SURVIVAL	The phase 3 CAPRI clinical trial evaluating the impact of a digital nurse navigator-led system in patients receiving oral anticancer treatment shows that remote monitoring using a smartphone app results in an improved patient care experience and optimizes healthcare resources. Strategies that individualize the care of cancer patients receiving oral anticancer agents offer opportunities to improve treatment adherence and patient care. However, the impact of digital remote monitoring systems in this setting has not been evaluated. Here, we report the results of a phase 3 trial (CAPRI, NCT02828462) to assess the impact of a nurse navigator-led program on treatment delivery for patients with metastatic cancer. Patients receiving approved oral anticancer agents were randomized (1:1) to an intervention combining a nurse navigator-led follow-up system and a web portal-smartphone application on top of usual care, or to usual symptom monitoring at the discretion of the treating oncologist, for a duration of 6 months. The primary objective included optimization of the treatment dose. Secondary objectives were grade >= 3 toxicities, patient experience, rates and duration of hospitalization, response and survival, and quality of life. In 559 evaluable patients the relative dose intensity was higher in the experimental arm (93.4% versus 89.4%, P = 0.04). The intervention improved the patient experience (Patient Assessment of Chronic Illness Care score, 2.94 versus 2.67, P = 0.01), reduced the days of hospitalization (2.82 versus 4.44 days, P = 0.02), and decreased treatment-related grade >= 3 toxicities (27.6% versus 36.9%, P = 0.02). These findings show that patient-centered care through remote monitoring of symptoms and treatment may improve patient outcomes and experience.	[Mir, Olivier; Ferrua, Marie; Fourcade, Aude; Mathivon, Delphine; Duflot-Boukobza, Adeline; Lemare, Francois; Guillet, Marilene; Puglisi, Vanessa; Di Palma, Mario] Gustave Roussy, Dept Ambulatory Canc Care, Villejuif, France; [Mir, Olivier; Mathivon, Delphine; Duflot-Boukobza, Adeline; Scotte, Florian; Abbas, May; Puglisi, Vanessa; Di Palma, Mario; Minvielle, Etienne] Gustave Roussy, Div Interdisciplinary Patients Care Pathways DIOP, Villejuif, France; [Dumont, Sarah; Delaloge, Suzette; Malka, David; Albiges, Laurence; Pautier, Patricia; Robert, Caroline; Planchard, David] Gustave Roussy, Div Canc Med, Villejuif, France; [Baudin, Eric] Gustave Roussy, Dept Endocrine Oncol, Villejuif, France; [de Botton, Stephane] Gustave Roussy, Div Hematol, Villejuif, France; [Minvielle, Etienne] Ecole Polytech, Inst Interdisciplinaire Innovat, i3 Ctr Rech Gest, UMR 9217, Palaiseau, France	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Humanities & Social Sciences (INSHS); Institut Polytechnique de Paris	Mir, O (corresponding author), Gustave Roussy, Dept Ambulatory Canc Care, Villejuif, France.; Mir, O (corresponding author), Gustave Roussy, Div Interdisciplinary Patients Care Pathways DIOP, Villejuif, France.	olivier.mir@gustaveroussy.fr	Mir, Olivier/GNP-7828-2022; Robert, Caroline/G-6157-2018	Mir, Olivier/0000-0002-6761-4002; Robert, Caroline/0000-0002-9493-0238; Delaloge, Suzette/0000-0003-2106-9165	French National Research Agency (ANR); Agence Regionale de Sante (ARS) Ile-de-France; Philanthropia Lombard Odier Foundation; Novartis; AstraZeneca	French National Research Agency (ANR)(French National Research Agency (ANR)); Agence Regionale de Sante (ARS) Ile-de-France; Philanthropia Lombard Odier Foundation; Novartis(Novartis); AstraZeneca(AstraZeneca)	The authors wish to thank the clinical and research teams at Gustave Roussy, and the patients and their families. The authors also wish to thank A. Chamseddine for his support in reviewing the manuscript. Public Health Expertise performed the statistical analyses. The study was funded by the French National Research Agency (ANR), the Agence Regionale de Sante (ARS) Ile-de-France, Philanthropia Lombard Odier Foundation, Novartis and AstraZeneca. The funding bodies were not involved in the study design.	Agboola S, 2014, JMIR RES PROTOC, V3, DOI 10.2196/resprot.4041; Banna GL, 2010, CANCER TREAT REV, V36, P595, DOI 10.1016/j.ctrv.2010.04.005; Basch E, 2020, JCO CLIN CANCER INFO, V4, P947, DOI 10.1200/CCI.20.00081; Basch E, 2016, J CLIN ONCOL, V34, P557, DOI 10.1200/JCO.2015.63.0830; Bergmo Trine S, 2009, Cost Eff Resour Alloc, V7, P18, DOI 10.1186/1478-7547-7-18; Berwick DM, 2008, HEALTH AFFAIR, V27, P759, DOI 10.1377/hlthaff.27.3.759; Chaudhry SI, 2010, NEW ENGL J MED, V363, P2301, DOI 10.1056/NEJMoa1010029; Clegg LX, 2009, CANCER CAUSE CONTROL, V20, P417, DOI 10.1007/s10552-008-9256-0; Davalos ME, 2009, TELEMED J E-HEALTH, V15, P933, DOI 10.1089/tmj.2009.0067; Denis F, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx029; Dicker AP, 2018, JCO CLIN CANCER INFO, V2, DOI 10.1200/CCI.18.00070; Doolin JW, 2021, JCO CLIN CANCER INFO, V5, P631, DOI 10.1200/CCI.20.00191; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Ferrua M, 2021, SUPPORT CARE CANCER, V29, P4485, DOI 10.1007/s00520-020-05968-y; Ferrua M, 2020, BMC HEALTH SERV RES, V20, DOI 10.1186/s12913-020-05293-4; Garg S, 2018, JCO CLIN CANCER INFO, V2, DOI 10.1200/CCI.17.00159; Gerves-Pinquie C, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2066-x; Girault A, 2015, EUR J CANCER, V51, P551, DOI 10.1016/j.ejca.2014.12.001; Glasgow RE, 2005, MED CARE, V43, P436, DOI 10.1097/01.mlr.0000160375.47920.8c; Groenvold M, 1997, J CLIN EPIDEMIOL, V50, P441, DOI 10.1016/S0895-4356(96)00428-3; Guerard E, 2021, JCO CLIN CANCER INFO, V5, P435, DOI 10.1200/CCI.20.00163; Havrilesky LJ, 2015, CRIT REV ONCOL HEMAT, V93, P203, DOI 10.1016/j.critrevonc.2014.10.006; Husereau D, 2013, VALUE HEALTH, V16, pE1, DOI 10.1016/j.jval.2013.02.010; Kroenke K, 2010, JAMA-J AM MED ASSOC, V304, P163, DOI 10.1001/jama.2010.944; Lairson DR, 2013, EVAL PROGRAM PLANN, V39, P51, DOI 10.1016/j.evalprogplan.2013.04.001; Liu JF, 2018, JCO CLIN CANCER INFO, V2, DOI 10.1200/CCI.17.00153; Maguire R, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n1647; McCann L, 2009, EUR J CANCER CARE, V18, P156, DOI 10.1111/j.1365-2354.2008.00938.x; McLean Susannah, 2011, BMJ, V342, pd120, DOI 10.1136/bmj.d120; Mecklai K, 2021, NEW ENGL J MED, V384, P1384, DOI 10.1056/NEJMp2033275; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007; National Cancer Institute Division of Cancer Treatment and Diagnosis, CTEP CANC THER EV PR; Nielson CM, 2021, ONCOLOGIST, V26, pE1609, DOI 10.1002/onco.13822; Pistilli B, 2020, J CLIN ONCOL, V38, P2762, DOI 10.1200/JCO.19.01758; Porta C, 2014, CANCER MED-US, V3, P1517, DOI 10.1002/cam4.302; Potdar R, 2020, SUPPORT CARE CANCER, V28, P5455, DOI 10.1007/s00520-020-05393-1; Rauh Stephen S, 2011, N Engl J Med, V365, pe48, DOI 10.1056/NEJMp1111662; Ruddy K, 2009, CA-CANCER J CLIN, V59, P56, DOI 10.3322/caac.20004; Schneider Susan M, 2011, Semin Oncol Nurs, V27, P133, DOI 10.1016/j.soncn.2011.02.005; Sun W, 2021, JCO CLIN CANCER INFO, V5, P701, DOI 10.1200/CCI.20.00151; U.S. Food and Drug Administration, NOVEL DRUG APPROVALS; van Hezewijk M, 2012, BREAST, V21, P693, DOI 10.1016/j.breast.2012.09.009; Ward E, 2004, CA-CANCER J CLIN, V54, P78, DOI 10.3322/canjclin.54.2.78; Weaver A, 2014, SUPPORT CARE CANCER, V22, P2677, DOI 10.1007/s00520-014-2224-1; Weingart SN, 2007, BRIT MED J, V334, P407, DOI 10.1136/bmj.39069.489757.55; Wildiers H, 2011, CRIT REV ONCOL HEMAT, V77, P221, DOI 10.1016/j.critrevonc.2010.02.002; Yatim F, 2017, SUPPORT CARE CANCER, V25, P863, DOI 10.1007/s00520-016-3474-x	48	2	2	2	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2022	28	6					1224	+		10.1038/s41591-022-01788-1	http://dx.doi.org/10.1038/s41591-022-01788-1		APR 2022	17	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E9IE	35469070	Bronze			2022-12-27	WOS:000787119400002
J	Hao, LM; Kraft, P; Berriz, GF; Hynes, ED; Koch, C; Kumar, PKV; Parpattedar, SS; Steeves, M; Yu, WF; Antwi, AA; Brunette, CA; Danowski, M; Gala, MK; Green, RC; Jones, NE; Lewis, ACF; Lubitz, SA; Natarajan, P; Vassy, JL; Lebo, MS				Hao, Limin; Kraft, Peter; Berriz, Gabriel F.; Hynes, Elizabeth D.; Koch, Christopher; Kumar, Prathik; Parpattedar, Shruti S.; Steeves, Marcie; Yu, Wanfeng; Antwi, Ashley A.; Brunette, Charles A.; Danowski, Morgan; Gala, Manish K.; Green, Robert C.; Jones, Natalie E.; Lewis, Anna C. F.; Lubitz, Steven A.; Natarajan, Pradeep; Vassy, Jason L.; Lebo, Matthew S.			Development of a clinical polygenic risk score assay and reporting workflow	NATURE MEDICINE			English	Article							CORONARY-HEART-DISEASE; AMERICAN-COLLEGE; MEDICAL GENETICS; TASK-FORCE; ASSOCIATION; PREDICTION; RECOMMENDATION; VALIDATION; GUIDELINES; STANDARDS	The first report from the prospective GenoVA Study provides preliminary insights into the development of a polygenic risk score assay in a clinical setting and discusses the challenges of generating, interpreting and reporting results. Implementation of polygenic risk scores (PRS) may improve disease prevention and management but poses several challenges: the construction of clinically valid assays, interpretation for individual patients, and the development of clinical workflows and resources to support their use in patient care. For the ongoing Veterans Affairs Genomic Medicine at Veterans Affairs (GenoVA) Study we developed a clinical genotype array-based assay for six published PRS. We used data from 36,423 Mass General Brigham Biobank participants and adjustment for population structure to replicate known PRS-disease associations and published PRS thresholds for a disease odds ratio (OR) of 2 (ranging from 1.75 (95% CI: 1.57-1.95) for type 2 diabetes to 2.38 (95% CI: 2.07-2.73) for breast cancer). After confirming the high performance and robustness of the pipeline for use as a clinical assay for individual patients, we analyzed the first 227 prospective samples from the GenoVA Study and found that the frequency of PRS corresponding to published OR > 2 ranged from 13/227 (5.7%) for colorectal cancer to 23/150 (15.3%) for prostate cancer. In addition to the PRS laboratory report, we developed physician- and patient-oriented informational materials to support decision-making about PRS results. Our work illustrates the generalizable development of a clinical PRS assay for multiple conditions and the technical, reporting and clinical workflow challenges for implementing PRS information in the clinic.	[Hao, Limin; Berriz, Gabriel F.; Hynes, Elizabeth D.; Koch, Christopher; Kumar, Prathik; Parpattedar, Shruti S.; Steeves, Marcie; Yu, Wanfeng; Lebo, Matthew S.] Mass Gen Brigham Personalized Med, Lab Mol Med, Cambridge, MA USA; [Kraft, Peter] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; [Steeves, Marcie] Massachusetts Gen Hosp, Med Genet, Boston, MA 02114 USA; [Antwi, Ashley A.; Brunette, Charles A.; Danowski, Morgan; Jones, Natalie E.; Vassy, Jason L.] Vet Affairs Boston Healthcare Syst, Boston, MA 02130 USA; [Gala, Manish K.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA; [Gala, Manish K.; Green, Robert C.; Natarajan, Pradeep; Vassy, Jason L.; Lebo, Matthew S.] Harvard Med Sch, Boston, MA 02115 USA; [Jones, Natalie E.] Broad Inst Harvard Cambridge, Cambridge, MA USA; [Jones, Natalie E.; Lubitz, Steven A.; Natarajan, Pradeep] MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Green, Robert C.; Vassy, Jason L.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA; [Green, Robert C.; Vassy, Jason L.] Populat Hlth, Ariadne Labs, Boston, MA 02130 USA; [Lewis, Anna C. F.] Harvard Univ, EJ Safra Ctr Eth, Cambridge, MA 02138 USA; [Lubitz, Steven A.; Natarajan, Pradeep] Broad Inst Harvard, Cardiovasc Dis Initiat, Cambridge, MA USA; [Lubitz, Steven A.; Natarajan, Pradeep] Massachusetts Gen Hosp, Res Ctr, Boston, MA 02114 USA; [Lubitz, Steven A.] Massachusetts Gen Hosp, Demoulas Ctr Cardiac Arrhythmias, Boston, MA 02114 USA; [Lebo, Matthew S.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Harvard University; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital	Vassy, JL (corresponding author), Vet Affairs Boston Healthcare Syst, Boston, MA 02130 USA.; Vassy, JL (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.; Vassy, JL (corresponding author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.; Vassy, JL (corresponding author), Populat Hlth, Ariadne Labs, Boston, MA 02130 USA.	jvassy@bwh.harvard.edu	Brunette, Charles/AAD-8633-2022; Kraft, Peter/GQH-8448-2022; Natarajan, Pradeep/H-9764-2019	Natarajan, Pradeep/0000-0001-8402-7435; Antwi, Ashley/0000-0002-2591-4410; Lebo, Matthew/0000-0002-9733-5207; Brunette, Charles/0000-0003-1620-3526; Duffy Hynes, Elizabeth/0000-0002-3817-2145; Kraft, Peter/0000-0002-4472-8103	NIH National Human Genome Research Institute [R35HG010706]; NIH [R01HL139731, R01HL157635, U01HG008685, R01HG010372, R01HL143295, OT2OD02750, U41HG006834, U01TR003201]; American Heart Association [18SFRN34250007]; National Heart, Lung and Blood Institute [R01HL142711, R01HL148050, R01HL151283, R01HL127564, R01HL148565, R01HL135242, R01HL151152]; National Institute of Diabetes and Digestive and Kidney Diseases [R01DK125782]; Fondation Leducq [TNE-18CVD04]; Massachusetts General Hospital	NIH National Human Genome Research Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); National Heart, Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Fondation Leducq(Leducq Foundation); Massachusetts General Hospital(General Electric)	This work was supported by NIH National Human Genome Research Institute grant R35HG010706 (J.L.V.). S.A.L. is supported by NIH grants R01HL139731, R01HL157635 and American Heart Association 18SFRN34250007. P.N. is supported by grants from the National Heart, Lung and Blood Institute (R01HL142711, R01HL148050, R01HL151283, R01HL127564, R01HL148565, R01HL135242, R01HL151152), National Institute of Diabetes and Digestive and Kidney Diseases (R01DK125782), Fondation Leducq (TNE-18CVD04) and Massachusetts General Hospital (Fireman Chair). M.S.L. is supported by NIH grants U01HG008685, R01HG010372, R01HL143295, OT2OD02750, U41HG006834 and U01TR003201, all unrelated to the present work.	All Us Res Program Investigators, 2019, NEW ENGL J MED, V381, P668, DOI 10.1056/NEJMsr1809937; Ambry Product Team, IMP DISC NOT AMBRYSC; Amer Diabet Assoc, 2021, DIABETES CARE, V44, pS15, DOI 10.2337/dc21-S002; Armstrong KA, 2020, ANN INTERN MED, V172, P610, DOI 10.7326/M19-3496; Blau A, 2016, J PERS MED, V6, DOI 10.3390/jpm6010010; Bowling KM, 2021, GENET MED, V23, P280, DOI 10.1038/s41436-020-00976-z; Boyle EA, 2017, CELL, V169, P1177, DOI 10.1016/j.cell.2017.05.038; Brockman DG, 2021, BMC MED GENOMICS, V14, DOI 10.1186/s12920-021-01056-0; Chang CC, 2015, GIGASCIENCE, V4, DOI 10.1186/s13742-015-0047-8; Chen SF, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00801-x; Choi SW, 2020, NAT PROTOC, V15, P2759, DOI 10.1038/s41596-020-0353-1; Conti DV, 2021, NAT GENET, V53, P11, DOI 10.1038/s41588-020-00748-0; Das S, 2016, NAT GENET, V48, P1284, DOI 10.1038/ng.3656; Davidson KW, 2021, JAMA-J AM MED ASSOC, V325, P1965, DOI 10.1001/jama.2021.6238; Delaneau O, 2013, NAT METHODS, V10, P5, DOI 10.1038/nmeth.2307; Dikilitas O, 2020, AM J HUM GENET, V106, P707, DOI 10.1016/j.ajhg.2020.04.002; Farmer GD, 2020, EUR J HUM GENET, V28, P885, DOI 10.1038/s41431-020-0579-y; Fritsche LG, 2020, AM J HUM GENET, V107, P815, DOI 10.1016/j.ajhg.2020.08.025; Gainer VS, 2016, J PERS MED, V6, DOI 10.3390/jpm6010011; Ge T, VALIDATION TRANSANCE, DOI [10.1101/2021.09.11.21263413 (2021, DOI 10.1101/2021.09.11.21263413(2021]; Goff DC, 2014, J AM COLL CARDIOL, V63, P2935, DOI [10.1016/j.jacc.2013.11.005, 10.1161/01.cir.0000437741.48606.98]; Grossman DC, 2018, JAMA-J AM MED ASSOC, V319, P1901, DOI 10.1001/jama.2018.3710; Homburger JR, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0682-2; Hughes E, 2020, JCO PRECIS ONCOL, V4, P585, DOI 10.1200/PO.19.00360; Huyghe JR, 2019, NAT GENET, V51, P76, DOI 10.1038/s41588-018-0286-6; Inouye M, 2018, J AM COLL CARDIOL, V72, P1883, DOI 10.1016/j.jacc.2018.07.079; Kalia SS, 2017, GENET MED, V19, P249, DOI 10.1038/gim.2016.190; Karlson EW, 2016, J PERS MED, V6, DOI 10.3390/jpm6010002; Khera AV, 2019, CIRCULATION, V139, P1593, DOI 10.1161/CIRCULATIONAHA.118.035658; Khera AV, 2018, NAT GENET, V50, P1219, DOI 10.1038/s41588-018-0183-z; Klarin D, 2019, NAT GENET, V51, P1574, DOI 10.1038/s41588-019-0519-3; Kowalski MH, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008500; Lambert SA, 2021, NAT GENET, V53, P420, DOI 10.1038/s41588-021-00783-5; Lee A, 2019, GENET MED, V21, P1708, DOI 10.1038/s41436-018-0406-9; Lewis ACF, 2021, HUM GENET GENOM ADV, V2, DOI 10.1016/j.xhgg.2021.100047; Lewis ACF, 2021, GENOME MED, V13, DOI 10.1186/s13073-021-00829-7; Lewis CM, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00742-5; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Libiger Ondrej, 2013, Frontiers in Genetics, V3, P322, DOI 10.3389/fgene.2012.00322; Loh PR, 2016, NAT GENET, V48, P1443, DOI 10.1038/ng.3679; Manolio TA, 2019, AM J HUM GENET, V105, P233, DOI 10.1016/j.ajhg.2019.07.008; Marnetto D, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15464-w; Martin AR, 2019, NAT GENET, V51, P584, DOI 10.1038/s41588-019-0379-x; Mavaddat N, 2019, AM J HUM GENET, V104, P21, DOI 10.1016/j.ajhg.2018.11.002; McLaughlin HM, 2014, BMC MED GENET, V15, DOI 10.1186/s12881-014-0134-1; Meigs JB, 2008, NEW ENGL J MED, V359, P2208, DOI 10.1056/NEJMoa0804742; Michailidou K, 2017, NATURE, V551, P92, DOI 10.1038/nature24284; Miller DT, 2021, GENET MED, V23, P1381, DOI 10.1038/s41436-021-01172-3; Mosley JD, 2020, JAMA-J AM MED ASSOC, V323, P627, DOI 10.1001/jama.2019.21782; National Human Genome Research Institute, GAUCHER DIS; National Human Genome Research Institute (NHGRI), 2020, EL MED REC GEN EMERG; Poplin R., 2018, BIORXIV, DOI [DOI 10.1101/201178, 10.1101/201178, DOI 10.1101/201178V3]; Ray T., 2021, GENOMEWEB; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Ripatti S, 2010, LANCET, V376, P1393, DOI 10.1016/S0140-6736(10)61267-6; Rivera-Munoz EA, 2018, HUM MUTAT, V39, P1614, DOI 10.1002/humu.23645; Ruan Y, IMPROVING POLYGENIC, DOI [10.1101/2020.12.27.20248738 (2021, DOI 10.1101/2020.12.27.20248738(2021]; Scheuner MT, 2013, GENET MED, V15, P444, DOI 10.1038/gim.2012.151; Schumacher FR, 2018, NAT GENET, V50, P928, DOI 10.1038/s41588-018-0142-8; Seibert TM, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.j5757; Senol-Cosar O, 2019, GENET MED, V21, P2765, DOI 10.1038/s41436-019-0560-8; Shendure J, 2019, CELL, V177, P45, DOI 10.1016/j.cell.2019.02.003; Shi LM, 2010, NAT BIOTECHNOL, V28, P827, DOI 10.1038/nbt.1665; Shieh Y, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw290; Siu AL, 2016, ANN INTERN MED, V164, P279, DOI 10.7326/M15-2886; Sniderman AD, 2013, MAYO CLIN PROC, V88, P1108, DOI 10.1016/j.mayocp.2013.07.012; Stone NJ, 2014, J AM COLL CARDIOL, V63, P2889, DOI 10.1016/j.jacc.2013.11.002; Van der Auwera G. A., 2020, GENOMICS CLOUD USING, V1st; Vassy JL, 2014, DIABETES, V63, P2172, DOI 10.2337/db13-1663; Vilhjalmsson BJ, 2015, AM J HUM GENET, V97, P576, DOI 10.1016/j.ajhg.2015.09.001; Wand H, 2021, NATURE, V591, P211, DOI 10.1038/s41586-021-03243-6; Weedon MN, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n214; Yu S, 2018, J AM MED INFORM ASSN, V25, P54, DOI 10.1093/jamia/ocx111; Yu S, 2015, J AM MED INFORM ASSN, V22, P993, DOI 10.1093/jamia/ocv034; Zheng SL, 2008, NEW ENGL J MED, V358, P910, DOI 10.1056/NEJMoa075819; Zook JM, 2016, SCI DATA, V3, DOI 10.1038/sdata.2016.25	76	4	4	4	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2022	28	5					1006	+		10.1038/s41591-022-01767-6	http://dx.doi.org/10.1038/s41591-022-01767-6		APR 2022	22	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	1J3AM	35437332	Green Submitted, hybrid, Green Published			2022-12-27	WOS:000784384300001
J	Barro, F; Rooke, L; Bekes, F; Gras, P; Tatham, AS; Fido, R; Lazzeri, PA; Shewry, PR; Barcelo, P				Barro, F; Rooke, L; Bekes, F; Gras, P; Tatham, AS; Fido, R; Lazzeri, PA; Shewry, PR; Barcelo, P			Transformation of wheat with high molecular weight subunit genes results in improved functional properties	NATURE BIOTECHNOLOGY			English	Article						agricultural genetic engineering; glutenin subunits; dough elasticity	BREAD-MAKING QUALITY; GLUTENIN; EXPRESSION; MEMBER; FAMILY; DOUGH	The high molecular weight (HMW) subunits of wheat glutenin are major determinants of the elastic properties of gluten that allow the use of wheat doughs to make bread, pasta, and a range of other foods. There are both quantitative and qualitative effects of HMW subunits on the quality of the grain, the former being related to differences in the number of expressed HMW subunit genes. We have transformed bread wheat in order to increase the proportions of the HMW subunits and improve the functional properties of the flour A range of transgene expression levels was obtained with some of the novel subunits present at considerably higher levels than the endogenous subunits. Analysis of T-2 seeds expressing transgenes for one or two additional HMW subunits showed stepwise increases in dough elasticity, demonstrating the improvement of the functional properties of wheat by genetic engineering.	Univ Bristol, Long Ashton Res Stn, Dept Agr Sci, IACR, Bristol BS18 9AF, Avon, England; AFRC, Inst Arable Crops Res, Harpenden AL5 2JQ, Herts, England; CSIRO, Plant Sci CRC, N Ryde, NSW 2113, Australia	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of Bristol; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Shewry, PR (corresponding author), Univ Bristol, Long Ashton Res Stn, Dept Agr Sci, IACR, Bristol BS18 9AF, Avon, England.	peter.shewry@bbscr.ac.uk; barcelo@bbsrc.ac.uk	Bekes, Ferenc/B-5933-2009; Barro, Francisco/J-3254-2014; Barro, Francisco/E-8572-2017	Barro, Francisco/0000-0002-7652-229X; Tatham, Arthur/0000-0001-5080-5585				Altpeter F, 1996, NAT BIOTECHNOL, V14, P1155, DOI 10.1038/nbt0996-1155; ANDERSON OD, 1989, NUCLEIC ACIDS RES, V17, P461, DOI 10.1093/nar/17.1.461; Barcelo P, 1995, Methods Mol Biol, V49, P113; BEKES F, 1992, CEREAL CHEM, V69, P229; Blechl AE, 1996, NAT BIOTECHNOL, V14, P875, DOI 10.1038/nbt0796-875; Christensen AH, 1996, TRANSGENIC RES, V5, P213, DOI 10.1007/BF01969712; DOVIDIO R, 1994, THEOR APPL GENET, V88, P759, DOI 10.1007/BF01253982; DOvidio R, 1996, THEOR APPL GENET, V93, P1048, DOI 10.1007/BF00230123; Fido Roger J., 1995, V49, P423; GRAS PW, 1990, CEREAL FOOD WORLD, V35, P568; GRAS PW, 1996, GLUTEN 96, P506; HALFORD NG, 1992, THEOR APPL GENET, V83, P373, DOI 10.1007/BF00224285; HALFORD NG, 1989, PLANT SCI, V62, P207, DOI 10.1016/0168-9452(89)90083-6; LAWRENCE GJ, 1988, J CEREAL SCI, V7, P109, DOI [10.1016/S0733-5210(88)80012-2, 10.1006/jcrs.1997.0158]; PAYNE PI, 1987, ANNU REV PLANT PHYS, V38, P141, DOI 10.1146/annurev.pp.38.060187.001041; RASCOGAUNT S, IN PRESS METHODS MOL, V6; SEILMEIER W, 1991, Z LEBENSM UNTERS FOR, V192, P124, DOI 10.1007/BF01202625; Shewry P, 1995, METHODS MOL BIOL PLA, V49, P423; SHEWRY PR, 1995, BIO-TECHNOL, V13, P1185, DOI 10.1038/nbt1195-1185; SHEWRY PR, 1992, J CEREAL SCI, V15, P105, DOI 10.1016/S0733-5210(09)80062-3; Stacey J, 1994, Methods Mol Biol, V28, P9; Tatham A. S., 1990, Advances in Cereal Science and Technology, V10, P1	22	248	323	1	38	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1997	15	12					1295	1299		10.1038/nbt1197-1295	http://dx.doi.org/10.1038/nbt1197-1295			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YQ046	9359115				2022-12-27	WOS:000071342000034
J	DeLisi, C; Cantor, C; Weng, ZP				DeLisi, C; Cantor, C; Weng, ZP			Hedgehogs, foxes, and a new science	NATURE BIOTECHNOLOGY			English	Editorial Material											DeLisi, C (corresponding author), BOSTON UNIV,COLL ENGN,44 CUMMINGTON ST,BOSTON,MA 02215, USA.								0	0	0	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1997	15	9					819	819		10.1038/nbt0997-819	http://dx.doi.org/10.1038/nbt0997-819			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XW410	9306387	Bronze			2022-12-27	WOS:A1997XW41000004
J	Fox, JL				Fox, JL			Summer recess might squeeze FDA reform bill	NATURE BIOTECHNOLOGY			English	News Item																			0	0	0	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					715	716		10.1038/nbt0897-715	http://dx.doi.org/10.1038/nbt0897-715			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9333520				2022-12-27	WOS:A1997XM70700012
J	Hoyle, R				Hoyle, R			Clinton's cloning ban may threaten genetic research	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	0	0	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1997	15	7					600	600		10.1038/nbt0797-600	http://dx.doi.org/10.1038/nbt0797-600			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XH583	9219249	Bronze			2022-12-27	WOS:A1997XH58300004
J	Guo, Z; Liu, QH; Smith, LM				Guo, Z; Liu, QH; Smith, LM			Enhanced discrimination of single nucleotide polymorphisms by artificial mismatch hybridization	NATURE BIOTECHNOLOGY			English	Article						PCR; specificity; fluorescence; 3-nitropyrrole	REFRACTORY MUTATION SYSTEM; BASE-PAIR MISMATCHES; SYNTHETIC OLIGONUCLEOTIDES; UNIVERSAL NUCLEOSIDE; PCR-AMPLIFICATION; DUPLEX STABILITY; DNA DUPLEXES; SEQUENCE; TRANSPLANTATION; PRIMERS	In order to increase the discrimination of single nucleotide polymorphisms in DNA hybridization, artificial mismatches are inserted into probe oligonucleotides using the base analog 3-nitropyrrole. Differences in thermal stability (Delta T-m) between hybrids formed with normal and single-nucleotide-variant DNA targets are increased by as much as 200% over conventional hybridization, and are strongly dependent upon the spacing between mismatches. The increased specificity is demonstrated by hybridization analysis and allele-specific amplification within the HLA-DRB locus.	UNIV WISCONSIN,DEPT CHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison								BAXTERLOWE LA, 1989, J CLIN INVEST, V84, P613, DOI 10.1172/JCI114206; BEIN G, 1992, TISSUE ANTIGENS, V39, P68, DOI 10.1111/j.1399-0039.1992.tb01909.x; BERGSTROM DE, 1995, J AM CHEM SOC, V117, P1201, DOI 10.1021/ja00109a003; BODMER JG, 1992, TISSUE ANTIGENS, V39, P161, DOI 10.1111/j.1399-0039.1992.tb01932.x; BRESLAUER KJ, 1986, P NATL ACAD SCI USA, V83, P3746, DOI 10.1073/pnas.83.11.3746; CONNER BJ, 1983, P NATL ACAD SCI-BIOL, V80, P278, DOI 10.1073/pnas.80.1.278; DOKTYCZ MJ, 1995, J BIOL CHEM, V270, P8439, DOI 10.1074/jbc.270.15.8439; *DYN INC, 1989, DYN M 280 TECHN HDB, V6; EBEL S, 1992, BIOCHEMISTRY-US, V31, P12083, DOI 10.1021/bi00163a017; GUO Z, 1994, NUCLEIC ACIDS RES, V22, P5456, DOI 10.1093/nar/22.24.5456; IKUTA S, 1987, NUCLEIC ACIDS RES, V15, P797, DOI 10.1093/nar/15.2.797; ISHIKAWA Y, 1995, HUM IMMUNOL, V42, P315, DOI 10.1016/0198-8859(94)00119-B; JACOBS JW, 1994, TRENDS BIOTECHNOL, V12, P19, DOI 10.1016/0167-7799(94)90007-8; KE SH, 1993, NUCLEIC ACIDS RES, V21, P5137, DOI 10.1093/nar/21.22.5137; LEONARD GA, 1990, NUCLEIC ACIDS RES, V18, P5617, DOI 10.1093/nar/18.19.5617; MCGRAW RA, 1990, BIOTECHNIQUES, V8, P674; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; NICHOLS R, 1994, NATURE, V369, P492, DOI 10.1038/369492a0; OLERUP O, 1992, TISSUE ANTIGENS, V39, P225, DOI 10.1111/j.1399-0039.1992.tb01940.x; SAIKI RK, 1989, P NATL ACAD SCI USA, V86, P6230, DOI 10.1073/pnas.86.16.6230; SMITH LM, 1987, METHOD ENZYMOL, V155, P260; SOUTHERN EM, 1994, NUCLEIC ACIDS RES, V22, P1368, DOI 10.1093/nar/22.8.1368; TIBANYENDA N, 1984, EUR J BIOCHEM, V139, P19, DOI 10.1111/j.1432-1033.1984.tb07970.x; WALLACE RB, 1981, NUCLEIC ACIDS RES, V9, P879, DOI 10.1093/nar/9.4.879; WENHAM PR, 1991, CLIN CHEM, V37, P241; WERNTGES H, 1986, NUCLEIC ACIDS RES, V14, P3773, DOI 10.1093/nar/14.9.3773	26	112	193	0	19	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1997	15	4					331	335		10.1038/nbt0497-331	http://dx.doi.org/10.1038/nbt0497-331			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WQ554	9094133				2022-12-27	WOS:A1997WQ55400032
J	Estruch, JJ; Carozzi, NB; Desai, N; Duck, NB; Warren, GW; Koziel, MG				Estruch, JJ; Carozzi, NB; Desai, N; Duck, NB; Warren, GW; Koziel, MG			Transgenic plants: An emerging approach to pest control	NATURE BIOTECHNOLOGY			English	Review						Bacillus thuringiensis; delta-endotoxins	INSECT CONTROL PROTEIN; BACILLUS-THURINGIENSIS; CHOLESTEROL OXIDASE; FIELD PERFORMANCE; SPODOPTERA-EXIGUA; TOMATO PLANTS; BOLL-WEEVIL; EXPRESSION; RESISTANCE; GENE	Insect pests are a major cause of damage to the world's commercially important agricultural crops, Current strategies aimed at reducing crop losses rely primarily on chemical pesticides. Alternatively transgenic crops with intrinsic pest resistance offer a promising alternative and continue to be developed. The first generation of insect-resistant transgenic plants are based on insecticidal proteins from Bacillus thuringiensis (Bt). A second generation of insect-resistant plants under development include both Bt and non-Bt proteins with novel modes of action and different spectra of activity against insect pests.			Estruch, JJ (corresponding author), CIBA AGR BIOTECHNOL,INSECT CONTROL SEEDS,3054 CORNWALLIS RD,DURHAM,NC 27709, USA.							ADANG MJ, 1993, PLANT MOL BIOL, V21, P1131, DOI 10.1007/BF00023609; BOULTER D, 1993, PHYTOCHEMISTRY, V34, P1453, DOI 10.1016/S0031-9422(00)90828-8; Cavalieri A., 1995, U.S. Patent, Patent No. [5,407,454, 5407454]; Chapman R.F., 1985, P165; Cho HJ, 1995, APPL MICROBIOL BIOT, V44, P133, DOI 10.1007/BF00164492; CHRISPEELS MJ, 1991, PLANT CELL, V3, P1, DOI 10.1105/tpc.3.1.1; CORBIN DR, 1994, APPL ENVIRON MICROB, V60, P4239, DOI 10.1128/AEM.60.12.4239-4244.1994; CORBIN DR, 1995, Patent No. 01098; CZAPLA TH, 1990, J ECON ENTOMOL, V83, P2480, DOI 10.1093/jee/83.6.2480; DELANNAY X, 1989, BIO-TECHNOL, V7, P1265; DING X, 1995, THESIS KANSAS STATE, P73; Estruch JJ, 1996, P NATL ACAD SCI USA, V93, P5389, DOI 10.1073/pnas.93.11.5389; FELTON GW, 1992, J INSECT PHYSIOL, V38, P277, DOI 10.1016/0022-1910(92)90128-Z; FISCHHOFF DA, 1987, BIO-TECHNOL, V5, P807, DOI 10.1038/nbt0887-807; GILL SS, 1992, ANNU REV ENTOMOL, V37, P615, DOI 10.1146/annurev.en.37.010192.003151; GREENPLATE JT, 1995, ENTOMOL EXP APPL, V74, P253, DOI 10.1007/BF02381789; HARPER SM, 1995, J ECON ENTOMOL, V88, P1197, DOI 10.1093/jee/88.5.1197; HILDER VA, 1987, NATURE, V330, P160, DOI 10.1038/330160a0; HUESING JE, 1991, PLANT PHYSIOL, V96, P993, DOI 10.1104/pp.96.3.993; JOHNSON R, 1989, P NATL ACAD SCI USA, V86, P9871, DOI 10.1073/pnas.86.24.9871; JONGSMA MA, 1995, P NATL ACAD SCI USA, V92, P8041, DOI 10.1073/pnas.92.17.8041; KANOST M, 1996, NEW DIRECTIONS INVER, P45; KLEE H, 1987, ANNU REV PLANT PHYS, V38, P467, DOI 10.1146/annurev.pp.38.060187.002343; KOZIEL MG, 1993, BIO-TECHNOL, V11, P194, DOI 10.1038/nbt0293-194; KOZIEL MG, 1997, IN PRESS PLANT MOL B; Koziel Michael G., 1993, V11, P171; LINDER R, 1982, ARCH BIOCHEM BIOPHYS, V213, P395, DOI 10.1016/0003-9861(82)90565-3; LUCKMANN WH, 1982, INTRO INSECT PEST MA, P499; LUTTRELL RG, 1994, ANNU REV ENTOMOL, V39, P517, DOI 10.1146/annurev.en.39.010194.002505; MADDOCK SE, 1991, 3 INT C PLANT MOL BI; Moberg W. K., 1990, ACS SYM SER, P3; OERKE EC, 1994, CROP PRODUCTION CROP, P72; PEFEROEN M, 1992, BIOTECHNOLOGY AGR, P135; PERKINS JH, 1980, SCIENCE, V207, P1044, DOI 10.1126/science.207.4435.1044; PERLAK FJ, 1991, P NATL ACAD SCI USA, V88, P3324, DOI 10.1073/pnas.88.8.3324; PERLAK FJ, 1993, PLANT MOL BIOL, V22, P313, DOI 10.1007/BF00014938; PERLAK FJ, 1990, BIO-TECHNOL, V8, P939, DOI 10.1038/nbt1090-939; POTRYKUS I, 1991, ANNU REV PLANT PHYS, V42, P205, DOI 10.1146/annurev.pp.42.060191.001225; PURCELL JP, 1993, BIOCHEM BIOPH RES CO, V196, P1406, DOI 10.1006/bbrc.1993.2409; RANDOLPHANDERSO.B, 1995, BIORAD US EG B, V2015; RYAN CA, 1990, ANNU REV PHYTOPATHOL, V28, P425, DOI 10.1146/annurev.py.28.090190.002233; SCHNEPF HE, 1981, P NATL ACAD SCI-BIOL, V78, P2893, DOI 10.1073/pnas.78.5.2893; SHAH DM, 1995, TRENDS BIOTECHNOL, V13, P362, DOI 10.1016/S0167-7799(00)88982-9; SHELTON AM, 1993, J ECON ENTOMOL, V86, P697, DOI 10.1093/jee/86.3.697; Umbeck PF, 1992, United States Patent, Patent No. [5, 159:135, 5159135]; VAECK M, 1987, NATURE, V328, P33, DOI 10.1038/328033a0; WARREN GW, 1992, J ECON ENTOMOL, V85, P1651, DOI 10.1093/jee/85.5.1651; WARREN GW, 1996, Patent No. 10083; WILSON FD, 1992, J ECON ENTOMOL, V85, P1516, DOI 10.1093/jee/85.4.1516; YU CG, 1997, IN PRESS APPL ENV MI, V63; [No title captured]	51	173	217	2	37	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1997	15	2					137	141		10.1038/nbt0297-137	http://dx.doi.org/10.1038/nbt0297-137			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WE998	9035137				2022-12-27	WOS:A1997WE99800018
J	Koyama, S; Haruyama, T; Kobatake, E; Aizawa, M				Koyama, S; Haruyama, T; Kobatake, E; Aizawa, M			Electrically induced NGF production by astroglial cells	NATURE BIOTECHNOLOGY			English	Article						astroglial cells; nerve growth factor; electric stimulation; protein kinase C	NERVE GROWTH-FACTOR; FACTOR SECRETION; GENE-EXPRESSION; ASTROCYTES; ELECTRODE; CULTURES; SURFACE	A controlled culture system has been developed to induce nerve growth factor (NGF) production in astroglial cells that are cultured on an electrode surface. The electrode potential is alternatively modulated at an amplitude of 300 mV and a frequency of 10 Hz. The electric stimulation triggers NGF production and secretion. The mechanism of the electrically induced NGF production is discussed in association with protein kinase C (PKC) activation.			Koyama, S (corresponding author), TOKYO INST TECHNOL,DEPT BIOENGN,MIDORI KU,YOKOHAMA,KANAGAWA 226,JAPAN.							BOWMAN CL, 1992, BRAIN RES, V584, P272, DOI 10.1016/0006-8993(92)90906-P; CARMANKRZAN M, 1991, J NEUROCHEM, V56, P636, DOI 10.1111/j.1471-4159.1991.tb08197.x; FURUKAWA S, 1986, BIOCHEM BIOPH RES CO, V136, P57, DOI 10.1016/0006-291X(86)90876-4; FURUKAWA Y, 1993, J NEUROSCI RES, V35, P522, DOI 10.1002/jnr.490350508; Gilchrest BA, 1996, PHOTOCHEM PHOTOBIOL, V63, P1, DOI 10.1111/j.1751-1097.1996.tb02988.x; HALLAHAN DE, 1993, J BIOL CHEM, V268, P4903; JACQUIERSARLIN MR, 1995, J BIOL CHEM, V270, P14094, DOI 10.1074/jbc.270.23.14094; KOJIMA J, 1992, BIOTECHNOL BIOENG, V39, P27, DOI 10.1002/bit.260390106; KOJIMA J, 1991, J BIOTECHNOL, V18, P129, DOI 10.1016/0168-1656(91)90241-M; Lindholm D, 1990, Neuroreport, V1, P9; LU B, 1991, J NEUROSCI, V11, P318; PSHENICHKIN SP, 1995, J BIOL CHEM, V270, P5994, DOI 10.1074/jbc.270.11.5994; TANAKA C, 1994, ANNU REV NEUROSCI, V17, P551, DOI 10.1146/annurev.ne.17.030194.003003; YAMAZAKI T, 1995, J CLIN INVEST, V96, P438, DOI 10.1172/JCI118054; YOSHIDA K, 1991, BRAIN RES, V538, P118, DOI 10.1016/0006-8993(91)90385-9	15	42	47	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1997	15	2					164	166		10.1038/nbt0297-164	http://dx.doi.org/10.1038/nbt0297-164			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WE998	9035143				2022-12-27	WOS:A1997WE99800024
J	Miller, HI				Miller, HI			The end of big government?	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	1	1	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1997	15	2					111	111		10.1038/nbt0297-111	http://dx.doi.org/10.1038/nbt0297-111			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WE998	9035118				2022-12-27	WOS:A1997WE99800004
J	Horie, K; Barthelemy, NR; Spina, S; VandeVrede, L; He, YX; Paterson, RW; Wright, BA; Day, GS; Davis, AA; Karch, CM; Seeley, WW; Perrin, RJ; Koppisetti, RK; Shaikh, F; Lago, AL; Heuer, HW; Ghoshal, N; Gabelle, A; Miller, BL; Boxer, AL; Bateman, RJ; Sato, C				Horie, Kanta; Barthelemy, Nicolas R.; Spina, Salvatore; VandeVrede, Lawren; He, Yingxin; Paterson, Ross W.; Wright, Brenton A.; Day, Gregory S.; Davis, Albert A.; Karch, Celeste M.; Seeley, William W.; Perrin, Richard J.; Koppisetti, Rama K.; Shaikh, Faris; Lago, Argentina Lario; Heuer, Hilary W.; Ghoshal, Nupur; Gabelle, Audrey; Miller, Bruce L.; Boxer, Adam L.; Bateman, Randall J.; Sato, Chihiro			CSF tau microtubule-binding region identifies pathological changes in primary tauopathies	NATURE MEDICINE			English	Article; Early Access							BIOMARKER; DISEASE; RATIO; KINETICS	Despite recent advances in fluid biomarker research in Alzheimer's disease (AD), there are no fluid biomarkers or imaging tracers with utility for diagnosis and/or theragnosis available for other tauopathies. Using immunoprecipitation and mass spectrometry, we show that 4 repeat (4R) isoform-specific tau species from microtubule-binding region (MTBR-tau(275) and MTBR-tau(282)) increase in the brains of corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), frontotemporal lobar degeneration (FTLD)-MAPT and AD but decrease inversely in the cerebrospinal fluid (CSF) of CBD, FTLD-MAPT and AD compared to control and other FTLD-tau (for example, Pick's disease). CSF MTBR-tau measures are reproducible in repeated lumbar punctures and can be used to distinguish CBD from control (receiver operating characteristic area under the curve (AUC) = 0.889) and other FTLD-tau, such as PSP (AUC = 0.886). CSF MTBR-tau(275) and MTBR-tau(282) may represent the first affirmative biomarkers to aid in the diagnosis of primary tauopathies and facilitate clinical trial designs. Cerebrospinal fluid measures of isoform-specific tau species from the microtubule-binding region serve as the first fluid biomarkers of primary tauopathy.	[Horie, Kanta; Barthelemy, Nicolas R.; He, Yingxin; Davis, Albert A.; Perrin, Richard J.; Koppisetti, Rama K.; Shaikh, Faris; Ghoshal, Nupur; Bateman, Randall J.; Sato, Chihiro] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Horie, Kanta; Barthelemy, Nicolas R.; He, Yingxin; Bateman, Randall J.; Sato, Chihiro] Washington Univ, Sch Med, Tracy Family Stable Isotope Labeling Quantitat Ct, St Louis, MO 63110 USA; [Spina, Salvatore; VandeVrede, Lawren; Seeley, William W.; Lago, Argentina Lario; Heuer, Hilary W.; Miller, Bruce L.; Boxer, Adam L.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Paterson, Ross W.] UCL, Queen Sq Inst Neurol, Dept Neurol, London, England; [Wright, Brenton A.] Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA; [Day, Gregory S.] Mayo Clin Florida, Dept Neurol, Jacksonville, FL USA; [Davis, Albert A.; Karch, Celeste M.; Perrin, Richard J.; Bateman, Randall J.] Hope Ctr Neurol Disorders, St Louis, MO 63110 USA; [Karch, Celeste M.; Koppisetti, Rama K.; Ghoshal, Nupur] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; [Karch, Celeste M.; Perrin, Richard J.; Bateman, Randall J.] Washington Univ, Sch Med, Charles F & Joanne Knight Alzheimer Dis Res Ctr, St Louis, MO 63130 USA; [Perrin, Richard J.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA; [Gabelle, Audrey] Univ Montpellier, Univ Hosp Montpellier, Neurosci Inst Montpellier, Memory Res & Resources Ctr,Dept Neurol, Montpellier, France	Washington University (WUSTL); Washington University (WUSTL); University of California System; University of California San Francisco; University of London; University College London; University of California System; University of California San Diego; Mayo Clinic; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Universite de Montpellier; CHU de Montpellier	Bateman, RJ; Sato, C (corresponding author), Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA.; Bateman, RJ; Sato, C (corresponding author), Washington Univ, Sch Med, Tracy Family Stable Isotope Labeling Quantitat Ct, St Louis, MO 63110 USA.; Bateman, RJ (corresponding author), Hope Ctr Neurol Disorders, St Louis, MO 63110 USA.; Bateman, RJ (corresponding author), Washington Univ, Sch Med, Charles F & Joanne Knight Alzheimer Dis Res Ctr, St Louis, MO 63130 USA.	batemanr@wustl.edu; satochihiro@wustl.ee	; Day, Gregory/I-3439-2019	Davis, Albert/0000-0003-2042-8445; Koppisetti, Rama K/0000-0002-7539-4572; Spina, Salvatore/0000-0003-3570-9143; Karch, Celeste/0000-0002-6854-5547; HE, Yingxin/0000-0003-2543-4553; VandeVrede, Lawren/0000-0002-8304-6711; Day, Gregory/0000-0001-5133-5538; Paterson, Ross William/0000-0001-9372-3635	Rainwater Charitable Foundation; National Institutes of Health (NIH)/National Institute on Aging (NIA) [K01AG062796]; Barnes Jewish Hospital Foundation (BJHF) [3945]; Tau Foundation plan Alzheimer; NIH/NIA [P01 AG019724, K23 AG064029, K08 AG052648, U19AG063911, R01AG038791, R01 AG073482, U24AG057437, P01 AG03991, P30 AG066444, P01 AG026276, P50 AG023501]; NIH/National Institute of Neurological Disorders and Stroke (NINDS) [K08 NS101118]; NIH/NINDS [NS110890, R01NS065667, R01NS095773]; Alzheimer Disease Research Center [P30 AG066444]; Association for Frontotemporal Degeneration; NIH/National Institute of General Medical Sciences [P41 GM103422]; Bluefield Project	Rainwater Charitable Foundation; National Institutes of Health (NIH)/National Institute on Aging (NIA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Barnes Jewish Hospital Foundation (BJHF); Tau Foundation plan Alzheimer; NIH/NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIH/National Institute of Neurological Disorders and Stroke (NINDS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIH/NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Alzheimer Disease Research Center; Association for Frontotemporal Degeneration; NIH/National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Bluefield Project	This work was supported by the Rainwater Charitable Foundation (R.J.B., C.S., A.L.B., N.G., R.W.P., C.M.K., B.L.M., L.V., S.S.), National Institutes of Health (NIH)/National Institute on Aging (NIA) K01AG062796 (C.S.) and Barnes Jewish Hospital Foundation (BJHF) pilot grant no. 3945 (C.S.). Additionally, samples analyzed in this study were obtained with support from the Tau Foundation plan Alzheimer (A.G.), BIRCWH K12 HD001459 (N.G.), NIH/NIA K23 AG064029 (G.S.D.), NIH/NIA K08 AG052648 (S.S.), NIH/National Institute of Neurological Disorders and Stroke (NINDS) K08 NS101118 (A.A.D.), NIH/NINDS R01NS065667 (R.J.B.), NIH/NINDS R01NS095773 (R.J.B.), Alzheimer Disease Research Center grant no. P30 AG066444 (C.M.K.), NIH/NINDS NS110890 (C.M.K.), Association for Frontotemporal Degeneration (R.J.B., C.S., A.L.B., N.G., R.W.P., B.L.M.), NIH/NIA U19AG063911 (A.L.B.), NIH/NIA R01AG038791 (A.L.B.), NIH/NIA R01 AG073482 (A.L.B.) and NIH/NIA U24AG057437 (A.L.B.). This work was supported by resources and effort provided by the Tracy Family Stable Isotope Labeling Quantitation Center (principal investigator: R.J.B.) established by the Tracy Family, R. Frimel and G. Werths, GHR Foundation, D. Payne and the Willman Family brought together by The Foundation for Barnes-Jewish Hospital. This work was also supported by cores, resources and effort provided by Washington University Biomedical Mass Spectrometry Research Facility (NIH/National Institute of General Medical Sciences P41 GM103422) and access to equipment made possible by the Hope Center for Neurological Disorders and the Departments of Neurology and Psychiatry at the Washington University School of Medicine. Resources and effort provided by the Translational Human Neurodegenerative Disease Research Laboratory of Washington University were supported by NIH/NIA P01 AG03991 (Healthy Aging and Senile Dementia), NIH/NIA P30 AG066444 (Alzheimer's Disease Research Center) or NIH/NIA P01 AG026276 (the Adult Children Study). The UCSF Neurodegenerative Disease Brain Bank is supported by NIH/NIA P50 AG023501 and NIH/NIA P01 AG019724, Rainwater Charitable Foundation and the Bluefield Project to Cure FTD. We thank the participants and families for their contribution to this study. We thank Y. Li for advice on the power analyses. We thank M. Li and M. Sullivan for enrolling participants for the repeat lumbar puncture study. We thank the Clinical, Biomarker and Imaging Cores at the Washington University School of Medicine for participant evaluation, samples and data collection.	Bang J, 2015, LANCET, V386, P1672, DOI 10.1016/S0140-6736(15)00461-4; Barthelemy NR, 2020, J EXP MED, V217, DOI 10.1084/jem.20200861; Barthelemy NR, 2020, ALZHEIMERS RES THER, V12, DOI 10.1186/s13195-020-00596-4; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blennow K, 2020, BRAIN, V143, P650, DOI 10.1093/brain/awz346; Borroni B, 2015, AMYOTROPH LAT SCL FR, V16, P86, DOI 10.3109/21678421.2014.971812; Dickson D. W., 1999, Journal of Neurology, V246; Falcon B, 2019, NATURE, V568, P420, DOI 10.1038/s41586-019-1026-5; Falcon B, 2018, NATURE, V561, P137, DOI 10.1038/s41586-018-0454-y; Fitzpatrick AWP, 2017, NATURE, V547, P185, DOI 10.1038/nature23002; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Horie K, 2021, BRAIN, V144, P515, DOI 10.1093/brain/awaa373; Horie K, 2020, ACTA NEUROPATHOL COM, V8, DOI 10.1186/s40478-020-01019-z; Hu WT, 2013, NEUROLOGY, V81, P1945, DOI 10.1212/01.wnl.0000436625.63650.27; Irwin DJ, 2017, ANN NEUROL, V82, P247, DOI 10.1002/ana.24996; Janelidze S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15436-0; Janelidze S, 2020, NAT MED, V26, P379, DOI 10.1038/s41591-020-0755-1; Kouri N, 2011, NAT REV NEUROL, V7, P263, DOI 10.1038/nrneurol.2011.43; Kovacs GG, 2020, ACTA NEUROPATHOL, V140, P99, DOI 10.1007/s00401-020-02158-2; Ling H, 2016, J MOV DISORD, V9, P3, DOI 10.14802/jmd.15060; Mintun MA, 2021, NEW ENGL J MED, V384, P1691, DOI 10.1056/NEJMoa2100708; Miyagawa T, 2020, ALZHEIMERS DEMENT, V16, P106, DOI 10.1002/alz.12033; Nakamura A, 2018, NATURE, V554, P249, DOI 10.1038/nature25456; Ovod V, 2017, ALZHEIMERS DEMENT, V13, P841, DOI 10.1016/j.jalz.2017.06.2266; Palmqvist S, 2020, JAMA-J AM MED ASSOC, V324, P772, DOI 10.1001/jama.2020.12134; Salloway S, 2021, NAT MED, V27, P1187, DOI 10.1038/s41591-021-01369-8; Sato C, 2021, ANN CLIN TRANSL NEUR, V8, P1817, DOI 10.1002/acn3.51435; Sato C, 2018, NEURON, V97, P1284, DOI 10.1016/j.neuron.2018.02.015; Scholl M, 2019, MOL CELL NEUROSCI, V97, P18, DOI 10.1016/j.mcn.2018.12.001; Shi Y, 2021, NATURE, V598, P359, DOI 10.1038/s41586-021-03911-7; Spillantini MG, 1998, AM J PATHOL, V153, P1359, DOI 10.1016/S0002-9440(10)65721-5; Swanson CJ, 2021, ALZHEIMERS RES THER, V13, DOI 10.1186/s13195-021-00813-8; Thijssen EH, 2020, NAT MED, V26, P387, DOI 10.1038/s41591-020-0762-2; Togo T, 2002, J NEUROPATH EXP NEUR, V61, P547, DOI 10.1093/jnen/61.6.547; Villemagne VL, 2018, NAT REV NEUROL, V14, P225, DOI 10.1038/nrneurol.2018.9; Wagshal D, 2015, J NEUROL NEUROSUR PS, V86, P244, DOI 10.1136/jnnp-2014-308004; Wiltfang J, 2007, J NEUROCHEM, V101, P1053, DOI 10.1111/j.1471-4159.2006.04404.x; Zhang WJ, 2020, NATURE, V580, P283, DOI 10.1038/s41586-020-2043-0	38	0	0	3	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02075-9	http://dx.doi.org/10.1038/s41591-022-02075-9		NOV 2022	18	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	6L0UJ	36424467	hybrid, Green Published			2022-12-27	WOS:000887904600001
J	Master, H; Brittain, E				Master, Hiral; Brittain, Evan			Fitbit step counts clarify the association between activity and chronic disease risk	NATURE MEDICINE			English	Editorial Material; Early Access									[Master, Hiral; Brittain, Evan] Vanderbilt Univ, Med Ctr, Nashville, TN 37232 USA	Vanderbilt University	Master, H (corresponding author), Vanderbilt Univ, Med Ctr, Nashville, TN 37232 USA.							All Us Res Program Investigators, 2019, NEW ENGL J MED, V381, P668, DOI 10.1056/NEJMsr1809937; Hall KS, 2020, INT J BEHAV NUTR PHY, V17, DOI 10.1186/s12966-020-00978-9; Piercy KL, 2018, JAMA-J AM MED ASSOC, V320, P2020, DOI 10.1001/jama.2018.14854	3	0	0	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02013-9	http://dx.doi.org/10.1038/s41591-022-02013-9		OCT 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	5E8YH	36221009				2022-12-27	WOS:000865907200001
J	Meijnikman, AS; Davids, M; Herrema, H; Aydin, O; Tremaroli, V; Rios-Morales, M; Levels, H; Bruin, S; de Brauw, M; Verheij, J; Kemper, M; Holleboom, AG; Tushuizen, ME; Schwartz, TW; Nielsen, J; Brandjes, D; Dirinck, E; Weyler, J; Verrijken, A; De Block, CEM; Vonghia, L; Francque, S; Beuers, U; Gerdes, VEA; Backhed, F; Groen, AK; Nieuwdorp, M				Meijnikman, Abraham S.; Davids, Mark; Herrema, Hilde; Aydin, Omrum; Tremaroli, Valentina; Rios-Morales, Melany; Levels, Han; Bruin, Sjoerd; de Brauw, Maurits; Verheij, Joanne; Kemper, Marleen; Holleboom, Adriaan G.; Tushuizen, Maarten E.; Schwartz, Thue W.; Nielsen, Jens; Brandjes, Dees; Dirinck, Eveline; Weyler, Jonas; Verrijken, An; De Block, Christophe E. M.; Vonghia, Luisa; Francque, Sven; Beuers, Ulrich; Gerdes, Victor E. A.; Backhed, Fredrik; Groen, Albert K.; Nieuwdorp, Max			Microbiome-derived ethanol in nonalcoholic fatty liver disease	NATURE MEDICINE			English	Article; Early Access							ALCOHOL; STEATOSIS; FERMENTATION; PATHOGENESIS; METABOLISM; BENEFITS; GLUCOSE; MICE	A new study examines microbiome-generated ethanol in individuals with and without nonalcoholic fatty liver disease (NAFLD), concluding that microbial ethanol might contribute to pathogenesis in some patients with NAFLD. To test the hypothesis that the gut microbiota of individuals with nonalcoholic fatty liver disease (NAFLD) produce enough ethanol to be a driving force in the development and progression of this complex disease, we performed one prospective clinical study and one intervention study. Ethanol was measured while fasting and 120 min after a mixed meal test (MMT) in 146 individuals. In a subset of 37 individuals and in an external validation cohort, ethanol was measured in portal vein blood. In an intervention study, ten individuals with NAFLD and ten overweight but otherwise healthy controls were infused with a selective alcohol dehydrogenase (ADH) inhibitor before an MMT. When compared to fasted peripheral blood, median portal vein ethanol concentrations were 187 (interquartile range (IQR), 17-516) times higher and increased with disease progression from 2.1 mM in individuals without steatosis to 8.0 mM in NAFL 21.0 mM in nonalcoholic steatohepatitis. Inhibition of ADH induced a 15-fold (IQR,1.6- to 20-fold) increase in peripheral blood ethanol concentrations in individuals with NAFLD, although this effect was abolished after antibiotic treatment. Specifically, Lactobacillaceae correlated with postprandial peripheral ethanol concentrations (Spearman's rho, 0.42; P < 10(-5)) in the prospective study. Our data show that the first-pass effect obscures the levels of endogenous ethanol production, suggesting that microbial ethanol could be considered in the pathogenesis of this highly prevalent liver disease.	[Meijnikman, Abraham S.; Davids, Mark; Herrema, Hilde; Aydin, Omrum; Rios-Morales, Melany; Levels, Han; Holleboom, Adriaan G.; Brandjes, Dees; Gerdes, Victor E. A.; Groen, Albert K.; Nieuwdorp, Max] Univ Amsterdam, Dept Internal, Locat AMC, Med Ctr, Amsterdam, Netherlands; [Meijnikman, Abraham S.; Davids, Mark; Herrema, Hilde; Aydin, Omrum; Rios-Morales, Melany; Levels, Han; Holleboom, Adriaan G.; Brandjes, Dees; Gerdes, Victor E. A.; Groen, Albert K.; Nieuwdorp, Max] Univ Amsterdam, Dept Expt Vasc Med, Locat AMC, Med Ctr, Amsterdam, Netherlands; [Meijnikman, Abraham S.; Aydin, Omrum; Bruin, Sjoerd; de Brauw, Maurits; Gerdes, Victor E. A.; Nieuwdorp, Max] Spaarne Hosp, Dept Surg, Hoofddorp, Netherlands; [Tremaroli, Valentina; Backhed, Fredrik] Univ Gothenburg, Sahlgrenska Acad, Dept Mol & Clin Med, Wallenberg Lab, Gothenburg, Sweden; [Verheij, Joanne] Univ Amsterdam, Canc Ctr Amsterdam, Dept Pathol, UMC, Amsterdam, Netherlands; [Kemper, Marleen] Univ Amsterdam, Med Ctr, Dept Clin Pharmacol, Locat AMC, Amsterdam, Netherlands; [Tushuizen, Maarten E.] Leiden Univ, Med Ctr, Dept Gastroenterol & Hepatol, Leiden, Netherlands; [Schwartz, Thue W.; Backhed, Fredrik] Univ Copenhagen, Novo Nordisk Fdn Ctr Basic Metab Res, Fac Hlth & Med Sci, Copenhagen, Denmark; [Nielsen, Jens] Chalmers Univ Technol, Dept Biol & Biol Engn, Syst & Synthet Biol, Gothenburg, Sweden; [Dirinck, Eveline; Verrijken, An; De Block, Christophe E. M.] Univ Hosp Antwerp, Dept Diabetol & Endocrinol, Antwerp, Belgium; [Weyler, Jonas; Vonghia, Luisa; Francque, Sven] Univ Hosp Antwerp, Dept Gastroenterol & Hepatol, Antwerp, Belgium; [Beuers, Ulrich] Univ Amsterdam, Dept Gastroenterol & Hepatol, Med Ctr, Amsterdam, Netherlands	University of Amsterdam; University of Amsterdam; Spaarne Hospital; University of Gothenburg; University of Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Novo Nordisk Foundation; University of Copenhagen; Chalmers University of Technology; University of Antwerp; University of Antwerp; University of Amsterdam	Nieuwdorp, M (corresponding author), Univ Amsterdam, Dept Internal, Locat AMC, Med Ctr, Amsterdam, Netherlands.; Nieuwdorp, M (corresponding author), Univ Amsterdam, Dept Expt Vasc Med, Locat AMC, Med Ctr, Amsterdam, Netherlands.; Nieuwdorp, M (corresponding author), Spaarne Hosp, Dept Surg, Hoofddorp, Netherlands.	m.nieuwdorp@amsterdamumc.nl	Tremaroli, Valentina/AAE-8001-2019	Tremaroli, Valentina/0000-0002-9150-4233; Aydin, Omrum/0000-0003-0296-5968; Meijnikman, Abraham Stijn/0000-0002-6015-4656; Rios-Morales, Melany/0000-0002-3028-7562; Davids, Mark/0000-0003-3081-9124	ZONMW VICI grant 2020 [09150182010020]; Senior Fellowship of the Dutch Diabetes Research Foundation [2019.82.004]; Lilly/EFSD grant for Young Investigators; Le Ducq consortium [17CVD01]; Dutch Heart Foundation CVON IN CONTROL-2 consortium grant; Fund for Scientific Research (FWO) Flanders [1802154N]; Amsterdam UMC Fellowship; Healthsimilar toHolland; Gilead Research Scholar grant; NNF [NNF15OC0016798]	ZONMW VICI grant 2020; Senior Fellowship of the Dutch Diabetes Research Foundation; Lilly/EFSD grant for Young Investigators; Le Ducq consortium; Dutch Heart Foundation CVON IN CONTROL-2 consortium grant; Fund for Scientific Research (FWO) Flanders(FWO); Amsterdam UMC Fellowship; Healthsimilar toHolland; Gilead Research Scholar grant(Gilead Sciences); NNF	M.N. is supported by a ZONMW VICI grant 2020 (number 09150182010020). H.H. is supported by a Senior Fellowship of the Dutch Diabetes Research Foundation (2019.82.004). A.S.M. is supported by a Lilly/EFSD grant for Young Investigators. O.A. and V.T. are appointed on a NNF GUTMMM grant 2016 NNF15OC0016798 (to M.N., T.W.S. and F.B.). The study reported here was additionally supported by Le Ducq consortium grant 17CVD01 to F.B. and M.N. M.N, H.H. and A.K.G. are supported by a Dutch Heart Foundation CVON IN CONTROL-2 consortium grant. S.F. has a senior clinical research mandate from the Fund for Scientific Research (FWO) Flanders (1802154N). A.G.H. is supported by the Amsterdam UMC Fellowship, two TKI-PPP grants from Health~Holland and the Gilead Research Scholar grant.	Amaretti A, 2007, APPL ENVIRON MICROB, V73, P3637, DOI 10.1128/AEM.02914-06; Bedossa P, 2014, HEPATOLOGY, V60, P565, DOI 10.1002/hep.27173; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Bray NL, 2016, NAT BIOTECHNOL, V34, P525, DOI 10.1038/nbt.3519; Cederbaum AI, 2012, CLIN LIVER DIS, V16, P667, DOI 10.1016/j.cld.2012.08.002; Chamberlain Scott A, 2013, F1000Res, V2, P191, DOI 10.12688/f1000research.2-191.v1; Cope K, 2000, GASTROENTEROLOGY, V119, P1340, DOI 10.1053/gast.2000.19267; Costea PI, 2017, NAT BIOTECHNOL, V35, P1069, DOI 10.1038/nbt.3960; de Medeiros IC, 2015, MED HYPOTHESES, V85, P148, DOI 10.1016/j.mehy.2015.04.021; Del Chierico F, 2017, HEPATOLOGY, V65, P451, DOI 10.1002/hep.28572; Deschasaux M, 2018, NAT MED, V24, P1526, DOI 10.1038/s41591-018-0160-1; Diehl AM, 2017, NEW ENGL J MED, V377, P2063, DOI 10.1056/NEJMra1503519; Edgar RC, 2016, BIORXIV, DOI [10.1101/081257, DOI 10.1101/081257]; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Elshaghabee FMF, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00047; Engstler AJ, 2016, GUT, V65, P1564, DOI 10.1136/gutjnl-2014-308379; European Assoc Study Liver, 2018, J HEPATOL, V69, P154, DOI 10.1016/j.jhep.2018.03.018; Farrell GC, 2006, HEPATOLOGY, V43, pS99, DOI 10.1002/hep.20973; Fell JC, 2017, ALCOHOL CLIN EXP RES, V41, P2128, DOI 10.1111/acer.13501; Francque SM, 2021, NEW ENGL J MED, V385, P1547, DOI 10.1056/NEJMoa2036205; FRANTZ JC, 1979, J BACTERIOL, V137, P1263, DOI 10.1128/JB.137.3.1263-1270.1979; Fuchs HF, 2015, J LAPAROENDOSC ADV S, V25, P196, DOI 10.1089/lap.2014.0639; He Y, 2018, NAT MED, V24, P1532, DOI 10.1038/s41591-018-0164-x; Jeon S, 2020, J LIPID RES, V61, P470, DOI 10.1194/jlr.R119000547; Karlsson FH, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003706; Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701; Krautkramer KA, 2021, NAT REV MICROBIOL, V19, P77, DOI 10.1038/s41579-020-0438-4; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Mardinoglu A, 2018, CELL METAB, V27, P559, DOI 10.1016/j.cmet.2018.01.005; Meijnikman AS, 2020, J INTERN MED, V288, P699, DOI 10.1111/joim.13137; Nascimbeni F, 2020, J HEPATOL, V72, P828, DOI 10.1016/j.jhep.2019.12.008; Nosova T, 1996, ALCOHOL ALCOHOLISM, V31, P555; Oksanen J., 2019, R PACKAGE VERSION, P5; Pyo JH, 2021, J GASTROEN HEPATOL, V36, P1235, DOI 10.1111/jgh.15236; Quast C, 2013, NUCLEIC ACIDS RES, V41, pD590, DOI 10.1093/nar/gks1219; RCore Team, 2020, R LANG ENV STAT COMP; Seitz HK, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0014-7; Simic M, 2012, FORENSIC SCI INT, V216, P97, DOI 10.1016/j.forsciint.2011.09.003; Soverini M, 2019, BMC GENOMICS, V20, DOI 10.1186/s12864-019-5883-y; Syn WK, 2009, SEMIN LIVER DIS, V29, P200, DOI 10.1055/s-0029-1214375; Van Olden CC, 2021, J INTERN MED, V289, P340, DOI 10.1111/joim.13157; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; WEIMER PJ, 1977, APPL ENVIRON MICROB, V33, P289, DOI 10.1128/AEM.33.2.289-297.1977; Wilson DF, 2020, MED HYPOTHESES, V140, DOI 10.1016/j.mehy.2020.109638; Younossi Z, 2019, HEPATOLOGY, V69, P2672, DOI 10.1002/hep.30251; Yuan J, 2019, CELL METAB, V30, P675, DOI 10.1016/j.cmet.2019.08.018; Zhu LX, 2013, HEPATOLOGY, V57, P601, DOI 10.1002/hep.26093	49	2	2	16	16	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02016-6	http://dx.doi.org/10.1038/s41591-022-02016-6		OCT 2022	24	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	5E6FW	36216942				2022-12-27	WOS:000865719400002
J	Bartsch, R; Berghoff, AS; Furtner, J; Marhold, M; Bergen, ES; Roider-Schur, S; Starzer, AM; Forstner, H; Rottenmanner, B; Dieckmann, K; Bago-Horvath, Z; Haslacher, H; Widhalm, G; Ilhan-Mutlu, A; Minichsdorfer, C; Fuereder, T; Szekeres, T; Oehler, L; Gruenberger, B; Singer, CF; Weltermann, A; Puhr, R; Preusser, M				Bartsch, Rupert; Berghoff, Anna Sophie; Furtner, Julia; Marhold, Maximilian; Bergen, Elisabeth Sophie; Roider-Schur, Sophie; Starzer, Angelika Martina; Forstner, Heidrun; Rottenmanner, Beate; Dieckmann, Karin; Bago-Horvath, Zsuzsanna; Haslacher, Helmuth; Widhalm, Georg; Ilhan-Mutlu, Aysegul; Minichsdorfer, Christoph; Fuereder, Thorsten; Szekeres, Thomas; Oehler, Leopold; Gruenberger, Birgit; Singer, Christian F.; Weltermann, Ansgar; Puhr, Rainer; Preusser, Matthias			Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial	NATURE MEDICINE			English	Article							NEURON-SPECIFIC ENOLASE; LAPATINIB PLUS CAPECITABINE; EMTANSINE T-DM1; DIAGNOSIS; GUIDELINES; EFFICACY; CRITERIA	Findings from the TUXEDO-1 trial demonstrate efficacy of the antibody-drug conjugate trastuzumab deruxtecan for treatment of brain metastases in patients with HER2-positive breast cancer. Trastuzumab deruxtecan is an antibody-drug conjugate with high extracranial activity in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. We conducted the prospective, open-label, single-arm, phase 2 TUXEDO-1 trial. We enrolled patients aged >= 18 years with HER2-positive breast cancer and newly diagnosed untreated brain metastases or brain metastases progressing after previous local therapy, previous exposure to trastuzumab and pertuzumab and no indication for immediate local therapy. Patients received trastuzumab deruxtecan intravenously at the standard dose of 5.4 mg per kg bodyweight once every 3 weeks. The primary endpoint was intracranial response rate measured according to the response assessment in neuro-oncology brain metastases criteria. A Simon two-stage design was used to compare a null hypothesis of <26% response rate against an alternative of 61%. Fifteen patients were enrolled in the intention-to-treat population of patients who received at least one dose of study drug. Two patients (13.3%) had a complete intracranial response, nine (60%) had a partial intracranial response and three (20%) had stable disease as the best intracranial response, with a best overall intracranial response rate of 73.3% (95% confidential interval 48.1-89.1%), thus meeting the predefined primary outcome. No new safety signals were observed and global quality-of-life and cognitive functioning were maintained over the treatment duration. In the TUXEDO-1 trial (NCT04752059, EudraCT 2020-000981-41), trastuzumab deruxtecan showed a high intracranial response rate in patients with active brain metastases from HER2-positive breast cancer and should be considered as a treatment option in this setting.	[Bartsch, Rupert; Berghoff, Anna Sophie; Marhold, Maximilian; Bergen, Elisabeth Sophie; Starzer, Angelika Martina; Forstner, Heidrun; Rottenmanner, Beate; Ilhan-Mutlu, Aysegul; Minichsdorfer, Christoph; Fuereder, Thorsten; Puhr, Rainer; Preusser, Matthias] Med Univ Vienna, Dept Med 1, Div Oncol, Vienna, Austria; [Furtner, Julia] Med Univ Vienna, Dept Radiol, Vienna, Austria; [Roider-Schur, Sophie; Oehler, Leopold] St Josephs Hosp, Dept Oncol, Vienna, Austria; [Dieckmann, Karin] Med Univ Vienna, Dept Radiooncol, Vienna, Austria; [Bago-Horvath, Zsuzsanna] Med Univ Vienna, Dept Pathol, Vienna, Austria; [Haslacher, Helmuth; Szekeres, Thomas] Med Univ Vienna, Dept Lab Med, Vienna, Austria; [Widhalm, Georg] Med Univ Vienna, Dept Neurosurg, Vienna, Austria; [Gruenberger, Birgit] LKH Wiener Neustadt, Dept Oncol, Wiener Neustadt, Austria; [Singer, Christian F.] Med Univ Vienna, Dept Gynaecol, Vienna, Austria; [Weltermann, Ansgar] Elisabethinen Hosp Linz, Dept Med 1, Ordensklinkum Linz, Linz, Austria	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Ordensklinikum Linz Elisabethinen	Preusser, M (corresponding author), Med Univ Vienna, Dept Med 1, Div Oncol, Vienna, Austria.	matthias.preusser@meduniwien.ac.at	Widhalm, Georg/AFK-1669-2022; Haslacher, Helmuth/D-4233-2013; Preusser, Matthias/C-8530-2011	Widhalm, Georg/0000-0001-6014-0273; Haslacher, Helmuth/0000-0003-4605-2503; Preusser, Matthias/0000-0003-3541-2315; Berghoff, Anna Sophie/0000-0001-9379-6797; Starzer, Angelika/0000-0001-5867-8461	Medical University of Vienna, Department of Medicine I; Daiichi Sankyo	Medical University of Vienna, Department of Medicine I; Daiichi Sankyo(Daiichi Sankyo Company Limited)	The Medical University of Vienna, Department of Medicine I, as an academic, nonprofit organization, was the regulatory sponsor of this investigator-initiated trial. Daiichi Sankyo provided financial funding and trastuzumab deruxtecan. The present study was designed and conducted by the Division of Oncology, Department of Medicine I, Medical University of Vienna. Daiichi Sankyo was not involved in the collection, management, analysis and interpretation of the data. The authors prepared and approved the article and decided to submit the article for publication.	Arvold ND, 2016, NEURO-ONCOLOGY, V18, P1043, DOI 10.1093/neuonc/now127; Askoxylakis V, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv313; Bachelot T, 2013, LANCET ONCOL, V14, P64, DOI 10.1016/S1470-2045(12)70432-1; Bartsch R, 2012, BRIT J CANCER, V106, P25, DOI 10.1038/bjc.2011.531; Bartsch R, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.SABCS14-P6-16-10; Bender R, 2001, J CLIN EPIDEMIOL, V54, P343, DOI 10.1016/S0895-4356(00)00314-0; Brastianos HC, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-014-0518-9; Center For Drug Evaluation and Research, APPL NUMB 761139ORIG; Cortes Javier, 2022, N Engl J Med, V386, P1143, DOI 10.1056/NEJMoa2115022; Corti C, 2022, CANCER TREAT REV, V103, DOI 10.1016/j.ctrv.2021.102324; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Freedman RA, 2019, J CLIN ONCOL, V37, P1081, DOI 10.1200/JCO.18.01511; Gennari A, 2021, ANN ONCOL, V32, P1475, DOI 10.1016/j.annonc.2021.09.019; Hurvitz S., 2022, CANCER RES, V82; Jacot W, 2016, BREAST CANCER RES TR, V157, P307, DOI 10.1007/s10549-016-3828-6; Kurihara H, 2015, EJNMMI RES, V5, DOI 10.1186/s13550-015-0082-6; Le Rhun E, 2021, ANN ONCOL, V32, P1332, DOI 10.1016/j.annonc.2021.07.016; Lin NU, 2007, CLIN CANCER RES, V13, P1648, DOI 10.1158/1078-0432.CCR-06-2478; Lin NU, 2021, J CLIN ONCOL, V39, P2667, DOI 10.1200/JCO.20.02822; Lin NU, 2015, LANCET ONCOL, V16, pE270, DOI 10.1016/S1470-2045(15)70057-4; Lin NU, 2009, CLIN CANCER RES, V15, P1452, DOI 10.1158/1078-0432.CCR-08-1080; Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363; Massaron S, 1998, TUMOR BIOL, V19, P261, DOI 10.1159/000030016; Modi S, 2020, NEW ENGL J MED, V382, P610, DOI 10.1056/NEJMoa1914510; Montemurro F, 2020, ANN ONCOL, V31, P1350, DOI 10.1016/j.annonc.2020.06.020; Murthy RK, 2020, NEW ENGL J MED, V382, P597, DOI 10.1056/NEJMoa1914609; Ogitani Y, 2016, CLIN CANCER RES, V22, P5097, DOI 10.1158/1078-0432.CCR-15-2822; Percy DB, 2011, INVEST RADIOL, V46, P718, DOI 10.1097/RLI.0b013e318226c427; Perez-Garcia JM, 2022, NEURO-ONCOLOGY, DOI 10.1093/neuonc/noac144; Pivot X, 2015, J CLIN ONCOL, V33, P1564, DOI 10.1200/JCO.2014.57.1794; ROSNER D, 1986, CANCER, V58, P832, DOI 10.1002/1097-0142(19860815)58:4<832::AID-CNCR2820580404>3.0.CO;2-W; Saleem A, 2015, EJNMMI RES, V5, DOI 10.1186/s13550-015-0103-5; Sanna G, 2007, ANTICANCER RES, V27, P2865; Sheheryar K, 2022, CANCER RES, V82; SIMON R, 1989, CONTROL CLIN TRIALS, V10, P1, DOI 10.1016/0197-2456(89)90015-9; Soffietti R, 2017, NEURO-ONCOLOGY, V19, P162, DOI 10.1093/neuonc/now241; Ufen MP, 2014, ANN ONCOL, V25, P95, DOI 10.1093/annonc/mdt429; Van Swearingen AED, 2018, BREAST CANCER RES TR, V171, P637, DOI 10.1007/s10549-018-4852-5; Vogelbaum MA, 2022, J CLIN ONCOL, V40, P492, DOI 10.1200/JCO.21.02314; Vos MJ, 2004, ANTICANCER RES, V24, P2511; Weil RJ, 2005, AM J PATHOL, V167, P913, DOI 10.1016/S0002-9440(10)61180-7	41	6	6	6	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2022	28	9					1840	+		10.1038/s41591-022-01935-8	http://dx.doi.org/10.1038/s41591-022-01935-8		AUG 2022	15	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4S0LI	35941372	Green Published, hybrid			2022-12-27	WOS:000837551000001
J	Padron, LJ; Maurer, DM; O'Hara, MH; O'Reilly, EM; Wolff, RA; Wainberg, ZA; Ko, AH; Fisher, G; Rahma, O; Lyman, JP; Cabanski, CR; Yu, JX; Pfeiffer, SM; Spasic, M; Xu, JY; Gherardini, PF; Karakunnel, J; Mick, R; Alanio, C; Byrne, KT; Hollmann, TJ; Moore, JS; Jones, DD; Tognetti, M; Chen, RO; Yang, XD; Salvador, L; Wherry, EJ; Dugan, U; O'Donnell-Tormey, J; Butterfield, LH; Hubbard-Lucey, VM; Ibrahim, R; Fairchild, J; Bucktrout, S; LaVallee, TM; Vonderheide, RH				Padron, Lacey J.; Maurer, Deena M.; O'Hara, Mark H.; O'Reilly, Eileen M.; Wolff, Robert A.; Wainberg, Zev A.; Ko, Andrew H.; Fisher, George; Rahma, Osama; Lyman, Jaclyn P.; Cabanski, Christopher R.; Yu, Jia Xin; Pfeiffer, Shannon M.; Spasic, Marko; Xu, Jingying; Gherardini, Pier Federico; Karakunnel, Joyson; Mick, Rosemarie; Alanio, Cecile; Byrne, Katelyn T.; Hollmann, Travis J.; Moore, Jonni S.; Jones, Derek D.; Tognetti, Marco; Chen, Richard O.; Yang, Xiaodong; Salvador, Lisa; Wherry, E. John; Dugan, Ute; O'Donnell-Tormey, Jill; Butterfield, Lisa H.; Hubbard-Lucey, Vanessa M.; Ibrahim, Ramy; Fairchild, Justin; Bucktrout, Samantha; LaVallee, Theresa M.; Vonderheide, Robert H.			Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial	NATURE MEDICINE			English	Article							T-CELL IMMUNITY; MONOCLONAL-ANTIBODY; DENDRITIC CELLS; NAB-PACLITAXEL; SURVIVAL; ADENOCARCINOMA; FRAMEWORK; SUBSETS; SAFETY	Chemotherapy combined with immunotherapy has improved the treatment of certain solid tumors, but effective regimens remain elusive for pancreatic ductal adenocarcinoma (PDAC). We conducted a randomized phase 2 trial evaluating the efficacy of nivolumab (nivo; anti-PD-1) and/or sotigalimab (sotiga; CD40 agonistic antibody) with gemcitabine/nab-paclitaxel (chemotherapy) in patients with first-line metastatic PDAC (NCT03214250). In 105 patients analyzed for efficacy, the primary endpoint of 1-year overall survival (OS) was met for nivo/chemo (57.7%, P = 0.006 compared to historical 1-year OS of 35%, n = 34) but was not met for sotiga/chemo (48.1%, P = 0.062, n = 36) or sotiga/nivo/chemo (41.3%, P = 0.223, n = 35). Secondary endpoints were progression-free survival, objective response rate, disease control rate, duration of response and safety. Treatment-related adverse event rates were similar across arms. Multi-omic circulating and tumor biomarker analyses identified distinct immune signatures associated with survival for nivo/chemo and sotiga/chemo. Survival after nivo/chemo correlated with a less suppressive tumor microenvironment and higher numbers of activated, antigen-experienced circulating T cells at baseline. Survival after sotiga/chemo correlated with greater intratumoral CD4 T cell infiltration and circulating differentiated CD4 T cells and antigen-presenting cells. A patient subset benefitting from sotiga/nivo/chemo was not identified. Collectively, these analyses suggest potential treatment-specific correlates of efficacy and may enable biomarker-selected patient populations in subsequent PDAC chemoimmunotherapy trials.	[Padron, Lacey J.; Maurer, Deena M.; Lyman, Jaclyn P.; Cabanski, Christopher R.; Yu, Jia Xin; Pfeiffer, Shannon M.; Spasic, Marko; Xu, Jingying; Gherardini, Pier Federico; Karakunnel, Joyson; Dugan, Ute; Butterfield, Lisa H.; Ibrahim, Ramy; Fairchild, Justin; Bucktrout, Samantha; LaVallee, Theresa M.] Parker Inst Canc Immunotherapy, San Francisco, CA 94129 USA; [O'Hara, Mark H.; Mick, Rosemarie; Alanio, Cecile; Byrne, Katelyn T.; Moore, Jonni S.; Jones, Derek D.; Wherry, E. John; Vonderheide, Robert H.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [O'Reilly, Eileen M.; Hollmann, Travis J.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Wolff, Robert A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Wainberg, Zev A.] Univ Calif Los Angeles, Los Angeles, CA USA; [Ko, Andrew H.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Fisher, George] Stanford Univ, Stanford, CA 94305 USA; [Rahma, Osama] Dana Farber Canc Inst, Boston, MA 02115 USA; [Alanio, Cecile; Byrne, Katelyn T.; Wherry, E. John; Vonderheide, Robert H.] Univ Penn, Parker Inst Canc Immunotherapy, Philadelphia, PA 19104 USA; [Alanio, Cecile; Wherry, E. John] Univ Penn, Perelman Sch Med, Dept Syst Pharmacol & Translat Therapeut, Philadelphia, PA 19104 USA; [Alanio, Cecile; Wherry, E. John; Vonderheide, Robert H.] Univ Penn, Perelman Sch Med, Inst Immunol, Philadelphia, PA 19104 USA; [Tognetti, Marco] Biognosys AG, Schlieren, Switzerland; [Chen, Richard O.] Personalis Inc, Menlo Pk, CA USA; [Yang, Xiaodong] Apexigen Inc, San Carlos, CA USA; [Salvador, Lisa] Bristol Myers Squibb, New York, NY USA; [O'Donnell-Tormey, Jill; Hubbard-Lucey, Vanessa M.] Canc Res Inst, New York, NY USA	University of Pennsylvania; Pennsylvania Medicine; Memorial Sloan Kettering Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California San Francisco; Stanford University; Harvard University; Dana-Farber Cancer Institute; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Bristol-Myers Squibb	Padron, LJ (corresponding author), Parker Inst Canc Immunotherapy, San Francisco, CA 94129 USA.; Vonderheide, RH (corresponding author), Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.; Vonderheide, RH (corresponding author), Univ Penn, Parker Inst Canc Immunotherapy, Philadelphia, PA 19104 USA.; Vonderheide, RH (corresponding author), Univ Penn, Perelman Sch Med, Inst Immunol, Philadelphia, PA 19104 USA.	lpadron@parkerici.org; rhv@upenn.edu		Chen, Richard/0000-0002-2842-4476	Parker Institute for Cancer Immunotherapy (PICI); Cancer Research Institute; Bristol Myers Squibb; PICI	Parker Institute for Cancer Immunotherapy (PICI); Cancer Research Institute; Bristol Myers Squibb(Bristol-Myers Squibb); PICI	This study was sponsored by the Parker Institute for Cancer Immunotherapy (PICI) and funded by the Cancer Research Institute, Bristol Myers Squibb and PICI. Study drugs were provided by Bristol Myers Squibb and Apexigen. We extend our gratitude to the patients, their families, the clinical investigators and their site staff members who are making this trial possible. We would also like to thank S. Nawabi at PICI for operations leadership of the trial. We thank C. Spencer, M. Travers and R. Kageyama at PICI for aiding in data analysis review and figure formatting; D. DaSilva at PICI for writing and collaborating with the authors on the Methods section of the manuscript; and the Research Operations team at PICI for sample management. We thank S. M. Domchek from the Basser Center of the University of Pennsylvania for expertise and discussion on genomic alterations in patients with mPDAC. We thank R. Schretzenmair, J. Jakobowski and G. Brake-Silla from the University of Pennsylvania Flow Core for handling and running X50 analysis on patient PBMC samples. We thank A. Ruiz and Y. Li from Memorial Sloan Kettering Cancer Center for handling and tissue preparation and analysis of patient tumor biopsies for Vectra analysis. We thank C. Abbott, L. McDaniel and S. Boyle at Personalis for whole-exome sequencing and transcriptomics analyses of patient biopsies and thoughtful discussions. We thank K. Sklodowski, R. Bruderer and L. Reiter from Biognosys for their contributions in mass spectrometry proteomic data. We thank Sean Parker for his support and helpful scientific discussions. We thank Bristol Myers Squibb and Apexigen for collaboration and study drugs.	[Anonymous], 2018, NAT REV DRUG DISCOV, V17, P854, DOI 10.1038/nrd.2018.210; Assarsson E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095192; Balachandran VP, 2017, NATURE, V551, P512, DOI 10.1038/nature24462; Balli D, 2017, CLIN CANCER RES, V23, P3129, DOI 10.1158/1078-0432.CCR-16-2128; Beltra JC, 2020, IMMUNITY, V52, P825, DOI 10.1016/j.immuni.2020.04.014; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Brahmer JR, 2010, J CLIN ONCOL, V28, P3167, DOI 10.1200/JCO.2009.26.7609; Byrne KT, 2021, CLIN CANCER RES, V27, P4574, DOI 10.1158/1078-0432.CCR-21-1047; Byrne KT, 2016, CELL REP, V15, P2719, DOI 10.1016/j.celrep.2016.05.058; Choueiri TK, 2016, CLIN CANCER RES, V22, P5461, DOI 10.1158/1078-0432.CCR-15-2839; Cohn L, 2013, J EXP MED, V210, P1049, DOI 10.1084/jem.20121251; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Diamond MS, 2021, CANCER IMMUNOL RES, V9, P877, DOI 10.1158/2326-6066.CIR-20-0785; Ding CL, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3813; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Filbert EL, 2021, CANCER IMMUNOL IMMUN, V70, P1853, DOI 10.1007/s00262-020-02814-2; Haniffa M, 2012, IMMUNITY, V37, P60, DOI 10.1016/j.immuni.2012.04.012; Hartmann FJ, 2019, CELL REP, V28, P819, DOI 10.1016/j.celrep.2019.06.049; Li JY, 2018, IMMUNITY, V49, P178, DOI 10.1016/j.immuni.2018.06.006; Lyman JP, 2022, J CLIN ONCOL, V40, DOI 10.1200/JCO.2022.40.4_suppl.528; Mathew D, 2020, SCIENCE, V369, P1209, DOI 10.1126/science.abc8511; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; O'Hara MH, 2021, LANCET ONCOL, V22, P118, DOI 10.1016/S1470-2045(20)30532-5; O'Reilly EM, 2019, JAMA ONCOL, V5, P1431, DOI 10.1001/jamaoncol.2019.1588; Patnaik A, 2015, CLIN CANCER RES, V21, P4286, DOI 10.1158/1078-0432.CCR-14-2607; Patwardhan A, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0197-4; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Ribas A, 2017, CELL, V170, P1109, DOI 10.1016/j.cell.2017.08.027; Romero P, 2007, J IMMUNOL, V178, P4112, DOI 10.4049/jimmunol.178.7.4112; Royal RE, 2010, J IMMUNOTHER, V33, P828, DOI 10.1097/CJI.0b013e3181eec14c; Sharma P, 2007, P NATL ACAD SCI USA, V104, P3967, DOI 10.1073/pnas.0611618104; Sharma P, 2021, CANCER DISCOV, V11, P838, DOI 10.1158/2159-8290.CD-20-1680; Spitzer MH, 2015, SCIENCE, V349, DOI 10.1126/science.1259425; Stebegg M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02469; Stromnes IM, 2017, CANCER IMMUNOL RES, V5, P978, DOI 10.1158/2326-6066.CIR-16-0322; Tempero M, 2021, ANN ONCOL, V32, P600, DOI 10.1016/j.annonc.2021.01.070; Tokito T, 2016, EUR J CANCER, V55, P7, DOI 10.1016/j.ejca.2015.11.020; Upadhaya S, 2021, NAT REV DRUG DISCOV, V20, P168, DOI 10.1038/d41573-020-00204-y; van Hooren L, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24347-7; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Wainberg ZA, 2020, CLIN CANCER RES, V26, P4814, DOI 10.1158/1078-0432.CCR-20-0099; Winograd R, 2015, CANCER IMMUNOL RES, V3, P399, DOI 10.1158/2326-6066.CIR-14-0215; Yang ZY, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.695006	43	13	13	6	10	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2022	28	6					1167	+		10.1038/s41591-022-01829-9	http://dx.doi.org/10.1038/s41591-022-01829-9		JUN 2022	32	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E9IE	35662283	hybrid, Green Published			2022-12-27	WOS:000805744500001
J	Bolivar, F				Bolivar, F			Biotechnology in Mexico: Planning for the future	NATURE BIOTECHNOLOGY			English	Article											Bolivar, F (corresponding author), NATL AUTONOMOUS UNIV MEXICO,MEXICO CITY 04510,DF,MEXICO.								0	0	0	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					742	743		10.1038/nbt0897-742	http://dx.doi.org/10.1038/nbt0897-742			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255787				2022-12-27	WOS:A1997XM70700024
J	Nord, K; Gunneriusson, E; Ringdahl, J; Stahl, S; Uhlen, M; Nygren, PA				Nord, K; Gunneriusson, E; Ringdahl, J; Stahl, S; Uhlen, M; Nygren, PA			Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain	NATURE BIOTECHNOLOGY			English	Article						combinatorial chemistry; phage display,; staphylococcal protein A	AFFINITY HUMAN-ANTIBODIES; PEPTIDE LIBRARIES; ESCHERICHIA-COLI; IGG; FRAGMENT; COMPLEX	Small protein domains, capable of specific binding to different target proteins have been selected using combinatorial approaches. These binding proteins, Galled affibodies, were designed by randomization of 13 solvent-accessible surface residues of a stable alpha-helical bacterial receptor domain Z, derived from staphylococcal protein A. Repertoires of mutant Z domain genes were assembled and inserted into a phagemid vector adapted for monovalent phage display. Two libraries, each comprising approximately 4x10(7) transformants, were constructed using either an NN(G/T) or an alternative (C/A/G)NN degeneracy Biopanning against: the target proteins Tag DNA polymerase, human insulin, and a human apolipoprotein A-1 variant, showed that in all cases significant enrichments were obtained by file selection procedures. Selected clones were subsequently expressed in Escherichia coli and analyzed by SDS-PAGE, circular dichroism spectroscopy, and binding studies to their respective targets by biospecific interaction analysis. The affibodies have a secondary structure similar to the native Z domain and have micromolar dissociation constants (K-D) for their respective targets.	ROYAL INST TECHNOL,DEPT BIOCHEM & BIOTECHNOL,KTH,S-10044 STOCKHOLM,SWEDEN	Royal Institute of Technology			Uhlen, Mathias/B-3262-2016; Nygren, Per-Åke/AAM-7888-2020; Uhlen, Mathias/AAV-8746-2021	Uhlen, Mathias/0000-0002-4858-8056; Nygren, Per-Åke/0000-0003-4214-6991; 				ALEXANDER P, 1992, BIOCHEMISTRY-US, V31, P3597, DOI 10.1021/bi00129a007; Berkower I, 1996, CURR OPIN BIOTECH, V7, P622, DOI 10.1016/S0958-1669(96)80073-5; BIANCHI E, 1995, J MOL BIOL, V247, P154, DOI 10.1006/jmbi.1994.0129; Braisted AC, 1996, P NATL ACAD SCI USA, V93, P5688, DOI 10.1073/pnas.93.12.5688; CALABRESI L, 1994, J BIOL CHEM, V269, P32168; CEDERGREN L, 1993, PROTEIN ENG, V6, P441, DOI 10.1093/protein/6.4.441; CLACKSON T, 1994, TRENDS BIOTECHNOL, V12, P173, DOI 10.1016/0167-7799(94)90079-5; CUNNINGHAM BC, 1994, EMBO J, V13, P2508, DOI 10.1002/j.1460-2075.1994.tb06540.x; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DJOJONEGORO BM, 1994, BIO-TECHNOL, V12, P169, DOI 10.1038/nbt0294-169; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; Dunn IS, 1996, CURR OPIN BIOTECH, V7, P547, DOI 10.1016/S0958-1669(96)80060-7; GOUDA H, 1992, BIOCHEMISTRY-US, V31, P9665, DOI 10.1021/bi00155a020; Graslund T, 1997, PROTEIN EXPRES PURIF, V9, P125, DOI 10.1006/prep.1996.0674; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; JENDEBERG L, 1995, J MOL RECOGNIT, V8, P270, DOI 10.1002/jmr.300080405; JENDEBERG L, 1996, J MOL RECOGNIT, V35, P22; Kraulis PJ, 1996, FEBS LETT, V378, P190, DOI 10.1016/0014-5793(95)01452-7; KU J, 1995, P NATL ACAD SCI USA, V92, P6552, DOI 10.1073/pnas.92.14.6552; KUSHWAHA A, 1994, GENE, V151, P45, DOI 10.1016/0378-1119(94)90631-9; LU ZJ, 1995, BIO-TECHNOL, V13, P366, DOI 10.1038/nbt0495-366; LYONS BA, 1993, BIOCHEMISTRY-US, V32, P7839, DOI 10.1021/bi00082a001; Makrides SC, 1996, J PHARMACOL EXP THER, V277, P534; Markland W, 1996, BIOCHEMISTRY-US, V35, P8058, DOI 10.1021/bi952629y; Markland W, 1996, BIOCHEMISTRY-US, V35, P8045, DOI 10.1021/bi9526286; MARKS JD, 1992, BIO-TECHNOL, V10, P779, DOI 10.1038/nbt0792-779; MARTIN F, 1994, EMBO J, V13, P5303, DOI 10.1002/j.1460-2075.1994.tb06864.x; Martin F, 1996, J MOL BIOL, V255, P86, DOI 10.1006/jmbi.1996.0008; MAURER R, 1980, J MOL BIOL, V139, P147, DOI 10.1016/0022-2836(80)90302-2; MCCONNELL SJ, 1995, J MOL BIOL, V250, P460, DOI 10.1006/jmbi.1995.0390; MOKS T, 1986, EUR J BIOCHEM, V156, P637, DOI 10.1111/j.1432-1033.1986.tb09625.x; NILSSON B, 1987, PROTEIN ENG, V1, P107, DOI 10.1093/protein/1.2.107; Nilsson J, 1997, BIOTECHNIQUES, V22, P744, DOI 10.2144/97224rr04; Nilsson J, 1996, J MOL RECOGNIT, V9, P585, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<585::AID-JMR306>3.0.CO;2-Z; NILSSON J, 1994, EUR J BIOCHEM, V224, P103, DOI 10.1111/j.1432-1033.1994.tb20000.x; NORD K, 1995, PROTEIN ENG, V8, P601, DOI 10.1093/protein/8.6.601; NYGREN PA, 1991, VACCINES, V91, P363; OLSSON A, 1987, EUR J BIOCHEM, V168, P319, DOI 10.1111/j.1432-1033.1987.tb13423.x; PINILLA C, 1995, BIOPOLYMERS, V37, P221, DOI 10.1002/bip.360370306; RICHARDSON JH, 1995, TRENDS BIOTECHNOL, V13, P306, DOI 10.1016/S0167-7799(00)88970-2; RUTHER U, 1982, NUCLEIC ACIDS RES, V10, P5765, DOI 10.1093/nar/10.19.5765; Samuelsson E, 1996, NAT BIOTECHNOL, V14, P751, DOI 10.1038/nbt0696-751; SAMUELSSON E, 1994, BIOCHEMISTRY-US, V33, P4207, DOI 10.1021/bi00180a013; SAUERERIKSSON AE, 1995, STRUCTURE, V3, P265, DOI 10.1016/S0969-2126(01)00157-5; Schier R, 1996, J MOL BIOL, V255, P28, DOI 10.1006/jmbi.1996.0004; Stahl S, 1997, PATHOL BIOL, V45, P66; STAHL S, 1993, CURR OPIN IMMUNOL, V5, P272, DOI 10.1016/0952-7915(93)90017-M; TASHIRO M, 1995, CURR OPIN STRUC BIOL, V5, P471, DOI 10.1016/0959-440X(95)80031-X; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309	51	495	639	1	67	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					772	777		10.1038/nbt0897-772	http://dx.doi.org/10.1038/nbt0897-772			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255793				2022-12-27	WOS:A1997XM70700030
J	Karp, A; Edwards, KJ; Bruford, M; Funk, S; Vosman, B; Morgante, M; Seberg, O; Kremer, A; Boursot, P; Arctander, P; Tautz, D; Hewitt, GM				Karp, A; Edwards, KJ; Bruford, M; Funk, S; Vosman, B; Morgante, M; Seberg, O; Kremer, A; Boursot, P; Arctander, P; Tautz, D; Hewitt, GM			Molecular technologies for biodiversity evaluation: Opportunities and challenges	NATURE BIOTECHNOLOGY			English	Article							DNA; MITOCHONDRIAL; CONSERVATION; DIVERSITY; GENETICS; REGIONS; MARKERS		ZOOL SOC LONDON,INST ZOOL,LONDON NW1 4RY,ENGLAND; DLO,CPRO,NL-6700 AA WAGENINGEN,NETHERLANDS; UNIV UDINE,I-33100 UDINE,ITALY; BOT LAB,DK-1123 COPENHAGEN,DENMARK; INRA,STN RECH BORDEAUX CESTAS,LAB GENET AMELIORAT,PIERROTON,FRANCE; UNIV MONTPELLIER 2,CNRS URA,F-34095 MONTPELLIER 5,FRANCE; UNIV COPENHAGEN,INST POPULAT BIOL,DK-2100 COPENHAGEN,DENMARK; UNIV MUNICH,INST ZOOL,D-8000 MUNICH,GERMANY; UNIV E ANGLIA,NORWICH NR4 7JJ,NORFOLK,ENGLAND	Zoological Society of London; University of Udine; INRAE; Universite de Montpellier; University of Copenhagen; University of Munich; University of East Anglia	Karp, A (corresponding author), UNIV BRISTOL,LONG ASHTON RES STN,IACR,DEPT AGR SCI,BRISTOL BS18 9AF,AVON,ENGLAND.		Bruford, Michael/Y-7463-2019; Tautz, Diethard/D-4304-2011; Seberg, Ole/A-5111-2013; Tautz, Diethard/H-8436-2014; Karp, Angela/D-1119-2017; Boursot, Pierre/D-5860-2011; Vosman, Ben/C-5494-2013; Bruford, Michael W/D-3750-2009; Kremer, Antoine/G-2272-2018	Bruford, Michael/0000-0001-6357-6080; Seberg, Ole/0000-0001-9675-4090; Tautz, Diethard/0000-0002-0460-5344; Karp, Angela/0000-0001-6897-2672; Boursot, Pierre/0000-0001-6366-2341; Vosman, Ben/0000-0003-4942-8342; Bruford, Michael W/0000-0001-6357-6080; MORGANTE, Michele/0000-0003-2591-2156; Kremer, Antoine/0000-0002-3372-3235				Avise John C., 1994, pi; Bruford M.W., 1992, MOL GENETIC ANAL POP; CAETANOANOLLES G, 1994, PLANT MOL BIOL, V25, P1011, DOI 10.1007/BF00014674; CLARK AG, 1993, MOL BIOL EVOL, V10, P1096; DEMESURE B, 1995, MOL ECOL, V4, P129, DOI 10.1111/j.1365-294X.1995.tb00201.x; GOLDSTEIN DB, 1995, GENETICS, V139, P463; HELENTJARIS T, 1985, PLANT MOL BIOL, V5, P109, DOI 10.1007/BF00020093; Hillis David M., 1996, P515; HILLIS DM, 1991, Q REV BIOL, V66, P411, DOI 10.1086/417338; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; KARP A, ANN BOT, V78, P143; LANDE R, 1988, SCIENCE, V241, P14515; LYNCH M, 1990, MOL BIOL EVOL, V7, P377; MILLIGAN BG, 1994, MOL ECOL, V3, P423, DOI 10.1111/j.1365-294X.1994.tb00082.x; MORGANTE M, 1993, PLANT J, V3, P175, DOI 10.1111/j.1365-313X.1993.tb00020.x; MORITZ C, 1994, MOL ECOL, V3, P401, DOI 10.1111/j.1365-294X.1994.tb00080.x; TAUTZ D, 1989, NUCLEIC ACIDS RES, V17, P6463, DOI 10.1093/nar/17.16.6463; VANEWRIGHT RI, 1991, BIOL CONSERV, V55, P235, DOI 10.1016/0006-3207(91)90030-D; VOS P, 1995, NUCLEIC ACIDS RES, V23, P4407, DOI 10.1093/nar/23.21.4407; WEIR BS, 1984, EVOLUTION, V38, P1358, DOI 10.1111/j.1558-5646.1984.tb05657.x	20	129	138	0	13	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1997	15	7					625	628		10.1038/nbt0797-625	http://dx.doi.org/10.1038/nbt0797-625			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XH583	9219262				2022-12-27	WOS:A1997XH58300023
J	Mackensen, A; Muller, F; Mougiakakos, D; Boltz, S; Wilhelm, A; Aigner, M; Volkl, S; Simon, D; Kleyer, A; Munoz, L; Kretschmann, S; Kharboutli, S; Gary, R; Reimann, H; Rosler, W; Uderhardt, S; Bang, H; Herrmann, M; Ekici, AB; Buettner, C; Habenicht, KM; Winkler, TH; Kronke, G; Schett, G				Mackensen, Andreas; Mueller, Fabian; Mougiakakos, Dimitrios; Boeltz, Sebastian; Wilhelm, Artur; Aigner, Michael; Voelkl, Simon; Simon, David; Kleyer, Arnd; Munoz, Luis; Kretschmann, Sascha; Kharboutli, Soraya; Gary, Regina; Reimann, Hannah; Roesler, Wolf; Uderhardt, Stefan; Bang, Holger; Herrmann, Martin; Ekici, Arif Buelent; Buettner, Christian; Habenicht, Katharina Maria; Winkler, Thomas H.; Kroenke, Gerhard; Schett, Georg			Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus	NATURE MEDICINE			English	Article							DISEASE-ACTIVITY; B-CELLS; RITUXIMAB; ANTIBODY; CD19; AUTOANTIBODIES; POPULATION; MODEL; ONSET	Results from a study of five patients with refractory systemic lupus erythematosus, who were treated with anti-CD19 CAR T cell therapy under a compassionate-use program, demonstrate remission of SLE disease with follow-up of up to 17 months. Systemic lupus erythematosus (SLE) is a life-threatening autoimmune disease characterized by adaptive immune system activation, formation of double-stranded DNA autoantibodies and organ inflammation. Five patients with SLE (four women and one man) with a median (range) age of 22 (6) years, median (range) disease duration of 4 (8) years and active disease (median (range) SLE disease activity index Systemic Lupus Erythematosus Disease Activity Index: 16 (8)) refractory to several immunosuppressive drug treatments were enrolled in a compassionate-use chimeric antigen receptor (CAR) T cell program. Autologous T cells from patients with SLE were transduced with a lentiviral anti-CD19 CAR vector, expanded and reinfused at a dose of 1 x 10(6) CAR T cells per kg body weight into the patients after lymphodepletion with fludarabine and cyclophosphamide. CAR T cells expanded in vivo, led to deep depletion of B cells, improvement of clinical symptoms and normalization of laboratory parameters including seroconversion of anti-double-stranded DNA antibodies. Remission of SLE according to DORIS criteria was achieved in all five patients after 3 months and the median (range) Systemic Lupus Erythematosus Disease Activity Index score after 3 months was 0 (2). Drug-free remission was maintained during longer follow-up (median (range) of 8 (12) months after CAR T cell administration) and even after the reappearance of B cells, which was observed after a mean (+/- s.d.) of 110 +/- 32 d after CAR T cell treatment. Reappearing B cells were naive and showed non-class-switched B cell receptors. CAR T cell treatment was well tolerated with only mild cytokine-release syndrome. These data suggest that CD19 CAR T cell transfer is feasible, tolerable and highly effective in SLE.	[Mackensen, Andreas; Mueller, Fabian; Mougiakakos, Dimitrios; Aigner, Michael; Voelkl, Simon; Kretschmann, Sascha; Kharboutli, Soraya; Gary, Regina; Reimann, Hannah; Roesler, Wolf] Friedrich Alexander Univ Erlangen Nuremberg FAU, Dept Internal Med Hematol & Oncol 5, Erlangen, Germany; [Mackensen, Andreas; Mueller, Fabian; Mougiakakos, Dimitrios; Boeltz, Sebastian; Wilhelm, Artur; Aigner, Michael; Voelkl, Simon; Simon, David; Kleyer, Arnd; Munoz, Luis; Kretschmann, Sascha; Kharboutli, Soraya; Gary, Regina; Reimann, Hannah; Roesler, Wolf; Uderhardt, Stefan; Herrmann, Martin; Ekici, Arif Buelent; Buettner, Christian; Kroenke, Gerhard; Schett, Georg] Univ Klinikum Erlangen, Erlangen, Germany; [Mackensen, Andreas; Mueller, Fabian; Mougiakakos, Dimitrios; Boeltz, Sebastian; Wilhelm, Artur; Aigner, Michael; Voelkl, Simon; Simon, David; Kleyer, Arnd; Munoz, Luis; Kretschmann, Sascha; Kharboutli, Soraya; Gary, Regina; Reimann, Hannah; Roesler, Wolf; Uderhardt, Stefan; Herrmann, Martin; Kroenke, Gerhard; Schett, Georg] Friedrich Alexander Univ Erlangen Nuremberg, Deutsch Zentrum Immuntherapie DZI, Erlangen, Germany; [Mougiakakos, Dimitrios] Otto von Guericke Univ Magdeburg OVGU, Dept Hematol & Oncol, Magdeburg, Germany; [Boeltz, Sebastian; Wilhelm, Artur; Simon, David; Kleyer, Arnd; Munoz, Luis; Uderhardt, Stefan; Herrmann, Martin; Kroenke, Gerhard; Schett, Georg] Friedrich Alexander Univ Erlangen Nuremberg, Dept Internal Med Rheumatol & Immunol 3, Erlangen, Germany; [Bang, Holger] Orgentec, Mainz, Germany; [Ekici, Arif Buelent; Buettner, Christian] Friedrich Alexander Univ Erlangen Nuremberg, Inst Human Genet, Erlangen, Germany; [Habenicht, Katharina Maria; Winkler, Thomas H.] Friedrich Alexander Univ Erlangen Nuremberg, Div Genet, Erlangen, Germany	University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Erlangen Nuremberg; Otto von Guericke University; University of Erlangen Nuremberg; University of Erlangen Nuremberg; University of Erlangen Nuremberg	Schett, G (corresponding author), Univ Klinikum Erlangen, Erlangen, Germany.; Schett, G (corresponding author), Friedrich Alexander Univ Erlangen Nuremberg, Deutsch Zentrum Immuntherapie DZI, Erlangen, Germany.; Schett, G (corresponding author), Friedrich Alexander Univ Erlangen Nuremberg, Dept Internal Med Rheumatol & Immunol 3, Erlangen, Germany.	georg.schett@uk-erlangen.de	Munoz, Luis E/E-7725-2010; Boeltz, Sebastian/H-3594-2014	Munoz, Luis E/0000-0002-5395-804X; /0000-0001-8168-7542; Mackensen, Andreas/0000-0002-0685-4483; Simon, David/0000-0001-8310-7820; Reimann, Hannah/0000-0002-7336-2008; Wilhelm, Artur/0000-0002-4637-1582; Muller, Fabian/0000-0001-5487-5839; Boeltz, Sebastian/0000-0001-5227-8707	Deutsche Forschungsgemeinschaft [FOR2886, CRC1181, TRR221]; Bundesministerium fur Bildung und Forschung (BMBF); European Union (ERC Synergy grant 4D Nanoscope, ERC Consolidator grant INSPIRE); IMI	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Bundesministerium fur Bildung und Forschung (BMBF)(Federal Ministry of Education & Research (BMBF)); European Union (ERC Synergy grant 4D Nanoscope, ERC Consolidator grant INSPIRE); IMI	The study was supported by the Deutsche Forschungsgemeinschaft (FOR2886, CRC1181 and TRR221), the Bundesministerium fur Bildung und Forschung (BMBF; MASCARA), the European Union (ERC Synergy grant 4D Nanoscope, ERC Consolidator grant INSPIRE) and the IMI-funded project RTCure. We thank S. Miltenyi for fruitful discussions and S. Winkler for technical assistance.	Abramson JS, 2020, LANCET, V396, P839, DOI 10.1016/S0140-6736(20)31366-0; Arbuckle MR, 2003, NEW ENGL J MED, V349, P1526, DOI 10.1056/NEJMoa021933; Aringer M, 2019, ARTHRITIS RHEUMATOL, V71, P1400, DOI [10.1002/art.40930, 10.1136/annrheumdis-2018-214819]; Banchereau R, 2016, CELL, V165, P551, DOI 10.1016/j.cell.2016.03.008; Bethge WA, 2022, BLOOD, V140, P349, DOI 10.1182/blood.2021015209; Biermann MHC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00989; Franklyn K, 2016, ANN RHEUM DIS, V75, P1615, DOI 10.1136/annrheumdis-2015-207726; Frodlund M, 2020, CLIN EXP IMMUNOL, V199, P245, DOI 10.1111/cei.13402; Furie R, 2011, ARTHRITIS RHEUM-US, V63, P3918, DOI 10.1002/art.30613; Furie RA, 2022, ANN RHEUM DIS, V81, P100, DOI 10.1136/annrheumdis-2021-220920; Jacobi AM, 2008, ARTHRITIS RHEUM-US, V58, P1762, DOI 10.1002/art.23498; Jin XX, 2021, CELL MOL IMMUNOL, V18, P1896, DOI 10.1038/s41423-020-0472-1; June CH, 2018, NEW ENGL J MED, V379, P64, DOI 10.1056/NEJMra1706169; Kalos M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002842; Kamburova EG, 2013, AM J TRANSPLANT, V13, P1503, DOI 10.1111/ajt.12220; Kansal R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav1648; Leandro MJ, 2006, ARTHRITIS RHEUM-US, V54, P613, DOI 10.1002/art.21617; Li W, 2017, CURR OPIN RHEUMATOL, V29, P434, DOI 10.1097/BOR.0000000000000412; Locatelli F, 2018, EUR J IMMUNOL, V48, P216, DOI 10.1002/eji.201870029; Majzner RG, 2019, NAT MED, V25, P1341, DOI 10.1038/s41591-019-0564-6; Manson JJ, 2006, ORPHANET J RARE DIS, V1, DOI 10.1186/1750-1172-1-6; Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866; Mei HE, 2015, BLOOD, V125, P1739, DOI 10.1182/blood-2014-02-555169; Mistry P, 2019, P NATL ACAD SCI USA, V116, P25222, DOI 10.1073/pnas.1908576116; Morand EF, 2020, NEW ENGL J MED, V382, P211, DOI 10.1056/NEJMoa1912196; Mougiakakos D, 2021, NEW ENGL J MED, V385, P567, DOI 10.1056/NEJMc2107725; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; Nickerson KM, 2010, J IMMUNOL, V184, P1840, DOI 10.4049/jimmunol.0902592; Park JH, 2018, NEW ENGL J MED, V378, P449, DOI 10.1056/NEJMoa1709919; Parker KR, 2020, CELL, V183, P126, DOI 10.1016/j.cell.2020.08.022; Pisetsky DS, 2020, NAT REV RHEUMATOL, V16, P565, DOI 10.1038/s41584-020-0480-7; Porter DL, 2011, NEW ENGL J MED, V365, P725, DOI 10.1056/NEJMoa1103849; Ramos CA, 2020, J CLIN ONCOL, V38, P3794, DOI 10.1200/JCO.20.01342; Rejeski K, 2021, BLOOD, V138, P2499, DOI 10.1182/blood.2020010543; Sanchez ARP, 2022, NAT REV RHEUMATOL, V18, P146, DOI 10.1038/s41584-021-00739-3; Schubert ML, 2021, ANN ONCOL, V32, P34, DOI 10.1016/j.annonc.2020.10.478; Schuster SJ, 2019, NEW ENGL J MED, V380, P45, DOI 10.1056/NEJMoa1804980; TEDDER TE, 1994, IMMUNOL TODAY, V15, P450, DOI 10.1016/0167-5699(94)90276-3; Thurlings RM, 2008, ANN RHEUM DIS, V67, P917, DOI 10.1136/ard.2007.080960; Tipton CM, 2015, NAT IMMUNOL, V16, P755, DOI 10.1038/ni.3175; Urbonaviciute V, 2008, J EXP MED, V205, P3007, DOI 10.1084/jem.20081165; van Vollenhoven RF, 2021, LUPUS SCI MED, V8, DOI 10.1136/lupus-2021-000538; Yee CS, 2011, RHEUMATOLOGY, V50, P982, DOI 10.1093/rheumatology/keq376	43	14	13	28	28	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2022	28	10								10.1038/s41591-022-02017-5	http://dx.doi.org/10.1038/s41591-022-02017-5		SEP 2022	20	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	5X5RM	36109639				2022-12-27	WOS:000854720900008
J	Haradhvala, NJ; Leick, MB; Maurer, K; Gohil, SH; Larson, RC; Yao, N; Gallagher, KME; Katsis, K; Frigault, MJ; Southard, J; Li, SQ; Kann, MC; Silva, H; Jan, M; Rhrissorrakrai, K; Utro, F; Levovitz, C; Jacobs, RA; Slowik, K; Danysh, BP; Livak, KJ; Parida, L; Ferry, J; Jacobson, C; Wu, CJ; Getz, G; Maus, MV				Haradhvala, Nicholas J.; Leick, Mark B.; Maurer, Katie; Gohil, Satyen H.; Larson, Rebecca C.; Yao, Ning; Gallagher, Kathleen M. E.; Katsis, Katelin; Frigault, Matthew J.; Southard, Jackson; Li, Shuqiang; Kann, Michael C.; Silva, Harrison; Jan, Max; Rhrissorrakrai, Kahn; Utro, Filippo; Levovitz, Chaya; Jacobs, Raquel A.; Slowik, Kara; Danysh, Brian P.; Livak, Kenneth J.; Parida, Laxmi; Ferry, Judith; Jacobson, Caron; Wu, Catherine J.; Getz, Gad; Maus, Marcela, V			Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma	NATURE MEDICINE			English	Article							CRITERIA	Single-cell transcriptomics analyses of pretreatment and post-treatment peripheral blood mononuclear cells from patients treated with CD19 chimeric antigen receptor (CAR)-T products reveal a role for CAR-T regulatory cells in treatment relapse. Chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of hematologic malignancies. Approximately half of patients with refractory large B cell lymphomas achieve durable responses from CD19-targeting CAR-T treatment; however, failure mechanisms are identified in only a fraction of cases. To gain new insights into the basis of clinical response, we performed single-cell transcriptome sequencing of 105 pretreatment and post-treatment peripheral blood mononuclear cell samples, and infusion products collected from 32 individuals with large B cell lymphoma treated with either of two CD19 CAR-T products: axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel). Expansion of proliferative memory-like CD8 clones was a hallmark of tisa-cel response, whereas axi-cel responders displayed more heterogeneous populations. Elevations in CAR-T regulatory cells among nonresponders to axi-cel were detected, and these populations were capable of suppressing conventional CAR-T cell expansion and driving late relapses in an in vivo model. Our analyses reveal the temporal dynamics of effective responses to CAR-T therapy, the distinct molecular phenotypes of CAR-T cells with differing designs, and the capacity for even small increases in CAR-T regulatory cells to drive relapse.	[Haradhvala, Nicholas J.] Harvard Univ, Harvard Grad Program Biophys, Cambridge, MA 02138 USA; [Haradhvala, Nicholas J.; Maurer, Katie; Gohil, Satyen H.; Yao, Ning; Li, Shuqiang; Jacobs, Raquel A.; Slowik, Kara; Danysh, Brian P.; Wu, Catherine J.; Getz, Gad; Maus, Marcela, V] Broad Inst, Canc Program, Cambridge, MA 02142 USA; [Leick, Mark B.; Larson, Rebecca C.; Gallagher, Kathleen M. E.; Katsis, Katelin; Frigault, Matthew J.; Kann, Michael C.; Silva, Harrison; Jan, Max; Ferry, Judith; Getz, Gad; Maus, Marcela, V] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA; [Leick, Mark B.; Larson, Rebecca C.; Gallagher, Kathleen M. E.; Frigault, Matthew J.; Jan, Max; Getz, Gad; Maus, Marcela, V] Harvard Med Sch, Boston, MA 02115 USA; [Maurer, Katie; Gohil, Satyen H.; Southard, Jackson; Li, Shuqiang; Livak, Kenneth J.; Jacobson, Caron; Wu, Catherine J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Gohil, Satyen H.] Univ Coll London Hosp, Dept Haematol, London, England; [Yao, Ning] Harvard TH Chan Sch Publ Hlth, Program Computat Biol & Quantitat Genet, Boston, MA USA; [Rhrissorrakrai, Kahn; Utro, Filippo; Levovitz, Chaya; Parida, Laxmi] IBM Res, New York, NY USA	Harvard University; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; University College London Hospitals NHS Foundation Trust; University of London; University College London; Harvard University; Harvard T.H. Chan School of Public Health; International Business Machines (IBM)	Wu, CJ; Getz, G; Maus, MV (corresponding author), Broad Inst, Canc Program, Cambridge, MA 02142 USA.; Getz, G; Maus, MV (corresponding author), Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA.; Getz, G; Maus, MV (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.; Wu, CJ (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.	cwu@partners.org; gadgetz@broadinstitute.org; mvmaus@mgh.harvard.edu		Kann, Michael/0000-0002-5917-0296; Haradhvala, Nicholas/0000-0003-1113-3135; Frigault, Matthew/0000-0002-6774-5694; Maurer, Alexandria/0000-0002-4160-181X	Broad/IBM Cancer Resistance Research Project; National Institutes of Health (NIH) [R01CA252940]; Landry Cancer Biology Consortium fellowship; National Cancer Institute Research Specialist Award [R50CA251956]; NIH [T32 AI007529]	Broad/IBM Cancer Resistance Research Project(International Business Machines (IBM)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Landry Cancer Biology Consortium fellowship; National Cancer Institute Research Specialist Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank E. Berg, M. O'Reilly and the rest of the Broad Institute Patterns team for their contributions to the figure design. This work was partially supported by the Broad/IBM Cancer Resistance Research Project (principal investigators (PIs): G.G., L.P.) and by National Institutes of Health (NIH) R01CA252940 (PIs: M.V.M. and G.G.). A special thank you to S. Arrom and D. Oran for their thoughtful donation that helped to support a portion of this work. N.J.H. was partially funded by the Landry Cancer Biology Consortium fellowship. S.L. is supported by the National Cancer Institute Research Specialist Award (R50CA251956). R.C.L. is supported by NIH T32 AI007529. BioRender. com was utilized for Extended Data Fig. 6c.	Abramson JS, 2020, LANCET, V396, P839, DOI 10.1016/S0140-6736(20)31366-0; Boroughs AC, 2020, MOL THER, V28, P2577, DOI 10.1016/j.ymthe.2020.07.023; Boroughs AC, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126194; Brown CE, 2019, NAT REV IMMUNOL, V19, P73, DOI 10.1038/s41577-018-0119-y; Buttner M, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-27150-6; Cappell KM, 2021, NAT REV CLIN ONCOL, V18, P715, DOI 10.1038/s41571-021-00530-z; Chandran S, 2017, AM J TRANSPLANT, V17, P2945, DOI 10.1111/ajt.14415; Cheson BD, 2007, J CLIN ONCOL, V25, P579, DOI 10.1200/JCO.2006.09.2403; Das RK, 2019, CANCER DISCOV, V9, P492, DOI 10.1158/2159-8290.CD-18-1314; Deng Q, 2020, NAT MED, V26, DOI 10.1038/s41591-020-1061-7; Derman BA, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000286; Dufva O, 2020, BLOOD, V135, P597, DOI 10.1182/blood.2019002121; Florek M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145763; Fraietta JA, 2018, NAT MED, V24, P563, DOI 10.1038/s41591-018-0010-1; Gauthier J, 2021, BLOOD, V137, P323, DOI 10.1182/blood.2020006770; Golab Karolina, 2018, Oncotarget, V9, P9728, DOI 10.18632/oncotarget.23887; Golab K, 2013, INT IMMUNOPHARMACOL, V16, P371, DOI 10.1016/j.intimp.2013.02.001; Jain MD, 2021, BLOOD, V137, P2621, DOI 10.1182/blood.2020007445; June C. H., 2017, European Patent., Patent No. [3214091B1, 3214091]; Kafri R, 2013, NATURE, V494, P480, DOI 10.1038/nature11897; Khan O, 2019, NATURE, V571, P211, DOI 10.1038/s41586-019-1325-x; Kochenderfer JN, 2009, J IMMUNOTHER, V32, P689, DOI 10.1097/CJI.0b013e3181ac6138; Korsunsky I, 2019, NAT METHODS, V16, P1289, DOI 10.1038/s41592-019-0619-0; Larson RC, 2021, NAT REV CANCER, V21, P145, DOI 10.1038/s41568-020-00323-z; Lee JC, 2011, CANCER RES, V71, P2871, DOI 10.1158/0008-5472.CAN-10-0552; Lindner SE, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz3223; Martin MD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02692; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; Melenhorst JJ, 2022, NATURE, V602, P503, DOI 10.1038/s41586-021-04390-6; Monfrini C, 2022, CLIN CANCER RES, V28, P3378, DOI 10.1158/1078-0432.CCR-22-0164; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; Orlando EJ, 2018, NAT MED, V24, P1504, DOI 10.1038/s41591-018-0146-z; Pachter L., 2011, MODELS TRANSCRIPT QU, P11043889, DOI 10.48550/arXiv.1104.3889; Palmer DC, 2015, J EXP MED, V212, P2095, DOI 10.1084/jem.20150304; Plaks V, 2021, BLOOD, V138, P1081, DOI 10.1182/blood.2021010930; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Salter AI, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aat6753; SCHUSTER SJ, 2017, NEW ENGL J MED, V377, P2545, DOI [10.1056/NEJMoa1708566, DOI 10.1056/NEJMOA1708566]; Schuster SJ, 2019, NEW ENGL J MED, V380, P45, DOI 10.1056/NEJMoa1804980; Seo H, 2021, NAT IMMUNOL, V22, P983, DOI 10.1038/s41590-021-00964-8; Shah NN, 2019, NAT REV CLIN ONCOL, V16, P372, DOI 10.1038/s41571-019-0184-6; Singh N, 2020, CANCER DISCOV, V10, P552, DOI 10.1158/2159-8290.CD-19-0813; Squair JW, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25960-2; Talleur Aimee C, 2022, Blood Adv, V6, P5737, DOI 10.1182/bloodadvances.2021006293; Tirkes T, 2013, RADIOGRAPHICS, V33, P1323, DOI 10.1148/rg.335125214; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Todo S, 2016, HEPATOLOGY, V64, P632, DOI 10.1002/hep.28459; Togashi Y, 2019, NAT REV CLIN ONCOL, V16, P356, DOI 10.1038/s41571-019-0175-7; Traag VA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41695-z; Wang Y, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20696-x; Wolf FA, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-017-1382-0; Wolock SL, 2019, CELL SYST, V8, P281, DOI 10.1016/j.cels.2018.11.005; Yang DW, 2020, CELL MOL IMMUNOL, V17, P356, DOI 10.1038/s41423-019-0237-x; Yigit B, 2019, CANCER IMMUNOL RES, V7, P1485, DOI 10.1158/2326-6066.CIR-18-0664; Zhan YF, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01809; Zhang J, 2020, ADV THER, V37, P3040, DOI 10.1007/s12325-020-01397-9; Zhao ZG, 2015, CANCER CELL, V28, P415, DOI 10.1016/j.ccell.2015.09.004	58	1	1	9	9	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2022	28	9					1848	+		10.1038/s41591-022-01959-0	http://dx.doi.org/10.1038/s41591-022-01959-0		SEP 2022	35	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4S0LI	36097221	Green Submitted			2022-12-27	WOS:000852940800003
J	Chaib, S; Tchkonia, T; Kirkland, JL				Chaib, Selim; Tchkonia, Tamar; Kirkland, James L.			Cellular senescence and senolytics: the path to the clinic	NATURE MEDICINE			English	Review; Early Access							SECRETORY PHENOTYPE; BCL-XL; CELLS INDUCE; LIFE-SPAN; FIBROBLASTS; INHIBITION; CLEARANCE; CANCER; MODEL; IDENTIFICATION	Interlinked and fundamental aging processes appear to be a root-cause contributor to many disorders and diseases. One such process is cellular senescence, which entails a state of cell cycle arrest in response to damaging stimuli. Senescent cells can arise throughout the lifespan and, if persistent, can have deleterious effects on tissue function due to the many proteins they secrete. In preclinical models, interventions targeting those senescent cells that are persistent and cause tissue damage have been shown to delay, prevent or alleviate multiple disorders. In line with this, the discovery of small-molecule senolytic drugs that selectively clear senescent cells has led to promising strategies for preventing or treating multiple diseases and age-related conditions in humans. In this Review, we outline the rationale for senescent cells as a therapeutic target for disorders across the lifespan and discuss the most promising strategies-including recent and ongoing clinical trials-for translating small-molecule senolytics and other senescence-targeting interventions into clinical use. Cellular senescence has emerged as a promising therapeutic target for disorders across the lifespan; this Review highlights the most promising strategies for translating senescence-targeting interventions into clinical use in the near future.	[Chaib, Selim; Tchkonia, Tamar; Kirkland, James L.] Mayo Clin, Dept Physiol & Biomed Engn, Rochester, MN 55905 USA; [Kirkland, James L.] Mayo Clin, Dept Med, Div Gen Internal Med, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Kirkland, JL (corresponding author), Mayo Clin, Dept Physiol & Biomed Engn, Rochester, MN 55905 USA.; Kirkland, JL (corresponding author), Mayo Clin, Dept Med, Div Gen Internal Med, Rochester, MN 55905 USA.	kirkland.james@mayo.edu		Tchkonia, Tamar/0000-0003-4623-7145; Chaib, Selim/0000-0003-0497-2002	US National Institutes of Health [R37AG013925, R33AG061456, R01AG072301, R01AG061414, P01AG062413, UH3AG056933]; Connor Fund; Noaber Foundation	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Connor Fund; Noaber Foundation	This work was supported by the US National Institutes of Health (grants R37AG013925, R33AG061456, R01AG072301, R01AG061414, P01AG062413 and UH3AG056933), the Connor Fund, Robert J. and Theresa W. Ryan and the Noaber Foundation.	Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784; Afreen S, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-019-2203-z; Aguayo-Mazzucato C, 2019, CELL METAB, V30, P129, DOI 10.1016/j.cmet.2019.05.006; American Federation for Aging Research, 2022, TARG BIOL AG USH NEW; Amor C, 2020, NATURE, V583, P127, DOI 10.1038/s41586-020-2403-9; Anderson R, 2019, EMBO J, V38, DOI 10.15252/embj.2018100492; Baar MP, 2017, CELL, V169, P132, DOI 10.1016/j.cell.2017.02.031; Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600; Barnes PJ, 2019, AM J RESP CRIT CARE, V200, P556, DOI 10.1164/rccm.201810-1975TR; Basisty N, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000599; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Bessler H, 2002, CANCER LETT, V179, P103, DOI 10.1016/S0304-3835(01)00868-0; Bitto A, 2016, ELIFE, V5, DOI 10.7554/eLife.16351; Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x; Brighton PJ, 2017, ELIFE, V6, DOI 10.7554/eLife.31274; Bussian TJ, 2018, NATURE, V562, P578, DOI 10.1038/s41586-018-0543-y; Camell CD, 2021, SCIENCE, V373, DOI 10.1126/science.abe4832; Caprioli J, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12716; Caron M, 2007, CELL DEATH DIFFER, V14, P1759, DOI 10.1038/sj.cdd.4402197; Cavalcante MB, 2020, AGING-US, V12, P2711, DOI 10.18632/aging.102772; Chaib S., 2021, HDB EXPT PHARM, P165; Chandra A, 2022, AGING CELL, V21, DOI 10.1111/acel.13602; Chandra A, 2020, J BONE MINER RES, V35, P1119, DOI 10.1002/jbmr.3978; Chang JH, 2016, NAT MED, V22, P78, DOI 10.1038/nm.4010; Chen LS, 2010, BIOCHEM PHARMACOL, V80, P1936, DOI 10.1016/j.bcp.2010.07.039; Chien YC, 2011, GENE DEV, V25, P2125, DOI 10.1101/gad.17276711; Childs BG, 2016, SCIENCE, V354, P472, DOI 10.1126/science.aaf6659; Chini C, 2019, BIOCHEM BIOPH RES CO, V513, P486, DOI 10.1016/j.bbrc.2019.03.199; Chini CCS, 2020, NAT METAB, V2, DOI 10.1038/s42255-020-00298-z; Chinta SJ, 2018, CELL REP, V22, P930, DOI 10.1016/j.celrep.2017.12.092; Christopher LJ, 2008, DRUG METAB DISPOS, V36, P1357, DOI 10.1124/dmd.107.018267; Cianflone E, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9061558; Conley SM, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00197; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Covre LP, 2020, AGING CELL, V19, DOI 10.1111/acel.13272; Crespo-Garcia S, 2021, CELL METAB, V33, P818, DOI 10.1016/j.cmet.2021.01.011; Cupit-Link MC, 2017, ESMO OPEN, V2, DOI 10.1136/esmoopen-2017-000250; De Cecco M, 2019, NATURE, V572, pE5, DOI [10.1038/s41586-019-1350-9, 10.1038/s41586-018-0784-9]; Decout A, 2021, NAT REV IMMUNOL, V21, P548, DOI 10.1038/s41577-021-00524-z; Demaria M, 2017, CANCER DISCOV, V7, P165, DOI 10.1158/2159-8290.CD-16-0241; Demaria M, 2014, DEV CELL, V31, P722, DOI 10.1016/j.devcel.2014.11.012; Deschenes-Simard X, 2019, AGING CELL, V18, DOI 10.1111/acel.12889; Dorr JR, 2013, NATURE, V501, P421, DOI 10.1038/nature12437; Dookun E, 2020, AGING CELL, V19, DOI 10.1111/acel.13249; Dou ZX, 2017, NATURE, V550, P402, DOI 10.1038/nature24050; Duggal NA, 2019, NAT REV IMMUNOL, V19, P563, DOI 10.1038/s41577-019-0177-9; Dungan CM, 2022, GEROSCIENCE, V44, P1925, DOI 10.1007/s11357-022-00542-2; Efeyan A, 2007, CANCER RES, V67, P7350, DOI 10.1158/0008-5472.CAN-07-0200; De Ycaza AEE, 2021, OBESITY, V29, P1320, DOI 10.1002/oby.23202; Faget DV, 2019, NAT REV CANCER, V19, P439, DOI 10.1038/s41568-019-0156-2; Fang JQ, 2018, AGING CELL, V17, DOI 10.1111/acel.12765; Farr JN, 2019, J BONE MINER RES, V34, P1407, DOI 10.1002/jbmr.3729; Farr JN, 2017, NAT MED, V23, P1072, DOI 10.1038/nm.4385; Farr JN, 2016, J BONE MINER RES, V31, P1920, DOI 10.1002/jbmr.2892; Fatt MP, 2022, STEM CELL REP, V17, P259, DOI 10.1016/j.stemcr.2021.12.010; Faust HJ, 2020, J CLIN INVEST, V130, P5493, DOI 10.1172/JCI134091; Florian-Rodriguez ME, 2022, FEMALE PELVIC MED RE, V28, P341, DOI 10.1097/SPV.0000000000001131; Franceschi C, 2014, J GERONTOL A-BIOL, V69, pS4, DOI 10.1093/gerona/glu057; Fu QL, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003869; Fuhrmann-Stroissnigg H, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00314-z; Garrett-Bakelman FE, 2019, SCIENCE, V364, P144, DOI 10.1126/science.aau8650; Gasek Nathan S, 2021, Nat Aging, V1, P870, DOI 10.1038/s43587-021-00121-8; Georgilis A, 2018, CANCER CELL, V34, P85, DOI 10.1016/j.ccell.2018.06.007; Gerdes EOW, 2021, MECH AGEING DEV, V200, DOI 10.1016/j.mad.2021.111591; Gerdes EOW, 2020, INT REV NEUROBIOL, V155, P203, DOI 10.1016/bs.irn.2020.03.019; Gonzalez-Gualda E, 2020, AGING CELL, V19, DOI 10.1111/acel.13142; Gorgoulis V, 2019, CELL, V179, P813, DOI 10.1016/j.cell.2019.10.005; Govoni S, 2010, CURR PHARM DESIGN, V16, P660, DOI 10.2174/138161210790883732; Graefe EU, 2001, J CLIN PHARMACOL, V41, P492, DOI 10.1177/00912700122010366; Green CL, 2022, NAT REV MOL CELL BIO, V23, P56, DOI 10.1038/s41580-021-00411-4; Grosse L, 2020, CELL METAB, V32, P87, DOI 10.1016/j.cmet.2020.05.002; Guerrero A, 2020, AGING CELL, V19, DOI 10.1111/acel.13133; Guerrero A, 2019, NAT METAB, V1, P1074, DOI 10.1038/s42255-019-0122-z; Guida JL, 2021, JNCI-J NATL CANCER I, V113, P112, DOI 10.1093/jnci/djaa060; Hadley EC, 2017, J GERONTOL A-BIOL, V72, P980, DOI 10.1093/gerona/glx015; Hall BM, 2017, AGING-US, V9, P1867, DOI 10.18632/aging.101268; Hansel C, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22137064; Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Hernandez-Segura A, 2018, TRENDS CELL BIOL, V28, P436, DOI 10.1016/j.tcb.2018.02.001; Hernandez-Segura A, 2017, CURR BIOL, V27, P2652, DOI 10.1016/j.cub.2017.07.033; Hickson LJ, 2019, EBIOMEDICINE, V47, P446, DOI 10.1016/j.ebiom.2019.08.069; Hoare M, 2016, NAT CELL BIOL, V18, P979, DOI 10.1038/ncb3397; Houssaini A, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.93203; Igarashi Hideki, 2015, Reproductive Medicine and Biology, V14, P159, DOI 10.1007/s12522-015-0209-5; Iske J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18039-x; Jeon OH, 2017, NAT MED, V23, P775, DOI 10.1038/nm.4324; Johmura Y, 2021, SCIENCE, V371, P265, DOI 10.1126/science.abb5916; Josefsson EC, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207591; Justice JN, 2019, EBIOMEDICINE, V40, P554, DOI 10.1016/j.ebiom.2018.12.052; Justice JN, 2018, J GERONTOL A-BIOL, V73, P939, DOI 10.1093/gerona/glx134; Kandhaya-Pillai R, 2022, AGING CELL, V21, DOI 10.1111/acel.13646; Kang C, 2015, SCIENCE, V349, DOI 10.1126/science.aaa5612; Karin O, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13192-4; Kennedy BK, 2014, CELL, V159, P708, DOI 10.1016/j.cell.2014.10.039; Khosla S, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI154888; Khosla S, 2020, NAT REV ENDOCRINOL, V16, P263, DOI 10.1038/s41574-020-0335-y; Kim SR, 2021, J AM SOC NEPHROL, V32, P1987, DOI 10.1681/ASN.2020091373; Kim SR, 2020, AM J PHYSIOL-RENAL, V318, pF1167, DOI 10.1152/ajprenal.00535.2019; Kim SR, 2019, TRANSL RES, V213, P112, DOI 10.1016/j.trsl.2019.07.005; Kirkland JL, 2020, J INTERN MED, V288, P518, DOI 10.1111/joim.13141; Kirkland JL, 2017, EBIOMEDICINE, V21, P21, DOI 10.1016/j.ebiom.2017.04.013; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Krzystyniak A, 2022, AGING-US, V14, P572, DOI 10.18632/aging.203835; Kulkarni AS, 2020, CELL METAB, V32, P15, DOI 10.1016/j.cmet.2020.04.001; Kurosu H, 2005, SCIENCE, V309, P1829, DOI 10.1126/science.1112766; Lagnado A, 2021, EMBO J, V40, DOI 10.15252/embj.2020106048; Lamming DW, 2013, J CLIN INVEST, V123, P980, DOI 10.1172/JCI64099; Larsson L, 2019, PHYSIOL REV, V99, P427, DOI 10.1152/physrev.00061.2017; Lau A, 2019, J CLIN INVEST, V129, P4, DOI 10.1172/JCI123946; Lee S, 2021, NATURE, V599, P283, DOI 10.1038/s41586-021-03995-1; Lewis-McDougall FC, 2019, AGING CELL, V18, DOI 10.1111/acel.12931; Liton PB, 2005, EXP GERONTOL, V40, P745, DOI 10.1016/j.exger.2005.06.005; Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039; Madeo F, 2019, CELL METAB, V29, P592, DOI 10.1016/j.cmet.2019.01.018; Mannick JB, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aaq1564; Martini H, 2022, FEBS J, DOI 10.1111/febs.16361; Masayoshi Suda IS, 2021, NAT AGING, V1, P1117, DOI DOI 10.1038/S43587-021-00151-2; Meharena HS, 2022, CELL STEM CELL, V29, P116, DOI 10.1016/j.stem.2021.12.002; Minamino T, 2009, NAT MED, V15, P1082, DOI 10.1038/nm.2014; Moiseeva O, 2013, AGING CELL, V12, P489, DOI 10.1111/acel.12075; Moncsek A, 2018, HEPATOLOGY, V67, P247, DOI 10.1002/hep.29464; Munoz-Espin D, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201809355; Munoz-Espin D, 2014, NAT REV MOL CELL BIO, V15, P482, DOI 10.1038/nrm3823; Musi N, 2018, AGING CELL, V17, DOI 10.1111/acel.12840; Mylonas KJ, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abb0203; Naqvi K, 2020, CANCER-AM CANCER SOC, V126, P67, DOI 10.1002/cncr.32504; Nath KA, 2018, AM J PHYSIOL-RENAL, V315, pF1493, DOI 10.1152/ajprenal.00308.2018; Nawa N, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219592; Neff F, 2013, J CLIN INVEST, V123, P3272, DOI 10.1172/JCI67674; Ness KK, 2015, CANCER-AM CANCER SOC, V121, P1540, DOI 10.1002/cncr.29211; Newman JC, 2019, J AM GERIATR SOC, V67, P1934, DOI 10.1111/jgs.16055; Niccoli T, 2012, CURR BIOL, V22, pR741, DOI 10.1016/j.cub.2012.07.024; Novais EJ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25453-2; Novelle MG, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a025932; Nyunoya T, 2006, AM J RESP CELL MOL, V35, P681, DOI 10.1165/rcmb.2006-0169OC; Ogrodnik M, 2021, AGING CELL, V20, DOI 10.1111/acel.13296; Ogrodnik M, 2019, CELL METAB, V29, P1061, DOI [10.1016/j.cmet.2018.12.008, 10.1016/j.cmet.2019.01.013]; Ogrodnik M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15691; Ottmann O, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408-018-0122-3; Palmer AK, 2021, ENDOCRINOLOGY, V162, DOI 10.1210/endocr/bqab058; Palmer AK, 2019, DIABETOLOGIA, V62, P1835, DOI 10.1007/s00125-019-4934-x; Palmer AK, 2019, AGING CELL, V18, DOI 10.1111/acel.12950; Pan J, 2017, INT J RADIAT ONCOL, V99, P353, DOI 10.1016/j.ijrobp.2017.02.216; Pang SHM, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26834-3; Parikh P, 2019, AM J RESP CELL MOL, V61, P51, DOI 10.1165/rcmb.2018-0176OC; Patil P, 2019, AGING CELL, V18, DOI 10.1111/acel.12927; Pereira BI, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10335-5; Phatak NR, 2016, MOL VIS, V22, P1048; Poblocka M, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-99852-2; Prasanna PG, 2021, JNCI-J NATL CANCER I, V113, P1285, DOI 10.1093/jnci/djab064; Prata Larissa G P Langhi, 2018, Semin Immunol, V40, P101275, DOI 10.1016/j.smim.2019.04.003; Rahman M, 2022, MOL CANCER RES, V20, P938, DOI 10.1158/1541-7786.MCR-21-0029; Rajman L, 2018, CELL METAB, V27, P529, DOI 10.1016/j.cmet.2018.02.011; Rocha LR, 2020, AGING CELL, V19, DOI 10.1111/acel.13089; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Roos CM, 2016, AGING CELL, V15, P973, DOI 10.1111/acel.12458; Saccon TD, 2021, J GERONTOL A-BIOL, V76, P1895, DOI 10.1093/gerona/glab002; Salaami O, 2021, MAYO CLIN PROC, V96, P3021, DOI 10.1016/j.mayocp.2021.06.025; Saul D, 2021, ELIFE, V10, DOI [10.7554/eLife.69958, 10.7554/eLife.69958.sa1, 10.7554/eLife.69958.sa2]; Schafer MJ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14532; Schafer MJ, 2016, DIABETES, V65, P1606, DOI 10.2337/db15-0291; Schultz MB, 2016, CELL METAB, V23, P965, DOI 10.1016/j.cmet.2016.05.022; Scott AJ., 2021, NAT AGING, V1, P616, DOI [10.1038/s43587-021-00080-0, DOI 10.1038/S43587-021-00080-0]; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sfeir JG, 2021, JBMR PLUS, V5, DOI 10.1002/jbm4.10538; Sharpless NE, 2015, NAT REV CANCER, V15, P397, DOI 10.1038/nrc3960; Spinelli R, 2022, AGING CELL, V21, DOI 10.1111/acel.13557; St Sauver JL, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006413; Stiepan D., 2020, TAKING MAYO CLIN RES; Stokes KL, 2019, ONCOGENESIS, V8, DOI 10.1038/s41389-019-0133-3; Stout MB, 2017, J GERONTOL A-BIOL, V72, P3, DOI 10.1093/gerona/glv309; Sugihara H, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73315-6; Sun S, 2019, AGING-US, V11, P4323, DOI 10.18632/aging.102039; Suvakov S, 2021, EBIOMEDICINE, V70, DOI 10.1016/j.ebiom.2021.103536; Suvakov S, 2019, BIOL SEX DIFFER, V10, DOI 10.1186/s13293-019-0263-5; Tabibian JH, 2014, HEPATOLOGY, V59, P2263, DOI 10.1002/hep.26993; Tchkonia Tamar, 2021, Journal of Clinical Endocrinology & Metabolism, V106, pE1481, DOI 10.1210/clinem/dgaa728; Tchkonia T, 2018, JAMA-J AM MED ASSOC, V320, P1319, DOI 10.1001/jama.2018.12440; Tchkonia T, 2013, J CLIN INVEST, V123, P966, DOI 10.1172/JCI64098; Tilstra JS, 2012, J CLIN INVEST, V122, P2601, DOI 10.1172/JCI45785; Touil YS, 2011, BIOCHEM PHARMACOL, V82, P1731, DOI 10.1016/j.bcp.2011.07.097; Triana-Martinez F, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12888-x; Tripathi U, 2021, AGING-US, V13, P21838, DOI 10.18632/aging.203560; Tripathi U, 2021, MECH AGEING DEV, V198, DOI 10.1016/j.mad.2021.111548; Tsuji S., 2022, NAT AGING, DOI [10.1038/s43587-022-00170-7, DOI 10.1038/S43587-022-00170-7]; Tullius SG, 2018, NEW ENGL J MED, V378, P1920, DOI 10.1056/NEJMra1507080; van der Feen DE, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaw4974; van Willigenburg H, 2018, PHARMACOL RES, V130, P322, DOI 10.1016/j.phrs.2018.02.015; Vazquez-Villasenor I, 2020, NEUROPATH APPL NEURO, V46, P171, DOI 10.1111/nan.12559; Vizioli MG, 2020, GENE DEV, V34, P428, DOI 10.1101/gad.331272.119; Walaszczyk A, 2019, AGING CELL, V18, DOI 10.1111/acel.12945; Wang Binsheng, 2021, Nat Aging, V1, P962, DOI 10.1038/s43587-021-00107-6; Wang BS, 2020, AGING CELL, V19, DOI 10.1111/acel.13106; WANG E, 1995, CANCER RES, V55, P2284; Wang HT, 2022, J BONE MINER RES, V37, P95, DOI 10.1002/jbmr.4458; Wang LC, 2022, CELL METAB, V34, P75, DOI 10.1016/j.cmet.2021.11.002; Wiley CD, 2016, CELL METAB, V23, P1013, DOI 10.1016/j.cmet.2016.05.010; Wilson WH, 2010, LANCET ONCOL, V11, P1149, DOI 10.1016/S1470-2045(10)70261-8; Gerdes EOW, 2020, FEBS J, V287, P2418, DOI 10.1111/febs.15264; Wong CH, 2019, BIOSTATISTICS, V20, P273, DOI 10.1093/biostatistics/kxx069; World Health Organization, AG HLTH; Xu M, 2018, NAT MED, V24, P1246, DOI 10.1038/s41591-018-0092-9; Xu M, 2017, J GERONTOL A-BIOL, V72, P780, DOI 10.1093/gerona/glw154; Xu M, 2015, ELIFE, V4, DOI 10.7554/eLife.12997; Xu M, 2015, P NATL ACAD SCI USA, V112, pE6301, DOI 10.1073/pnas.1515386112; Xu QX, 2021, NAT METAB, V3, P1706, DOI 10.1038/s42255-021-00491-8; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Fang Y, 2022, bioRxiv, DOI 10.1101/2021.11.08.467509; Yoshida S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16347-w; Yousefzadeh M, 2021, ELIFE, V10, DOI 10.7554/eLife.62852; Yousefzadeh MJ, 2021, NATURE, V594, P100, DOI 10.1038/s41586-021-03547-7; Yousefzadeh MJ, 2020, AGING CELL, V19, DOI 10.1111/acel.13094; Yousefzadeh MJ, 2018, EBIOMEDICINE, V36, P18, DOI 10.1016/j.ebiom.2018.09.015; Yu SS, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/8875729; Zhang Boyi, 2021, Nat Aging, V1, P454, DOI 10.1038/s43587-021-00063-1; Zhang L, 2019, METHODS MOL BIOL, V1896, P231, DOI 10.1007/978-1-4939-8931-7_18; Zhang PS, 2019, NAT NEUROSCI, V22, P719, DOI 10.1038/s41593-019-0372-9; Zhao Y, 2021, NAT IMMUNOL, V22, P1219, DOI 10.1038/s41590-021-01027-8; Zhu Y, 2022, EBIOMEDICINE, V77, DOI 10.1016/j.ebiom.2022.103912; Zhu Y, 2017, AGING-US, V9, P955, DOI 10.18632/aging.101202; Zhu Y, 2016, AGING CELL, V15, P428, DOI 10.1111/acel.12445; Zhu Y, 2015, AGING CELL, V14, P644, DOI 10.1111/acel.12344	223	11	11	39	39	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01923-y	http://dx.doi.org/10.1038/s41591-022-01923-y		AUG 2022	13	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3S4NQ	35953721	Green Accepted, Bronze			2022-12-27	WOS:000839575100005
J	Nicholls, SJ; Ditmarsch, M; Kastelein, JJ; Rigby, SP; Kling, D; Curcio, DL; Alp, NJ; Davidson, MH				Nicholls, Stephen J.; Ditmarsch, Marc; Kastelein, John J.; Rigby, Scott P.; Kling, Douglas; Curcio, Danielle L.; Alp, Nicholas John; Davidson, Michael H.			Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial	NATURE MEDICINE			English	Article; Early Access							ESTER TRANSFER PROTEIN; HIGH-RISK; CHOLESTEROL; PHARMACODYNAMICS; PHARMACOKINETICS; ANACETRAPIB; TA-8995; EVACETRAPIB	Global guidelines for the management of high-cardiovascular-risk patients include aggressive goals for low-density lipoprotein cholesterol (LDL-C). Statin therapy alone is often insufficient to reach goals and nonstatin options have limitations. Here, we tested the lipid-lowering effects of the cholesteryl ester transfer protein (CETP) inhibitor drug obicetrapib in a randomized, double-blind, placebo-controlled trial in dyslipidaemic patients (n = 120, median LDL-C 88 mg dl(-1)) with background high-intensity statin treatment (NCT04753606). Over the course of 8 weeks, treatment with 5 mg or 10 mg obicetrapib resulted in a significant decrease as compared with placebo in median LDL-C concentration (by up to 51%; P < 0.0001), the primary trial outcome. As compared with placebo, obicetrapib treatment also significantly (P < 0.0001) decreased apolipoprotein B (by up to 30%) and non-high-density lipoprotein cholesterol (non-HDL-C) concentration (by up to 44%), and significantly (P < 0.0001) increased HDL-C concentration (by up to 165%; the secondary trial outcomes) and had an acceptable safety profile. These results support the potential of obicetrapib to address an unmet medical need for high-cardiovascular-risk patients. In a phase 2 randomized clinical trial, an inhibitor of cholesteryl ester transfer protein (CETP), obicetrapib, lowered low-density lipoprotein cholesterol when administered in conjunction with high-intensity statins, paving the way for studies investigating the effects of obicetrapib on cardiovascular events.	[Nicholls, Stephen J.] Monash Univ, Victorian Heart Inst, Clayton, Vic, Australia; [Ditmarsch, Marc; Kling, Douglas; Curcio, Danielle L.; Davidson, Michael H.] NewAmsterdam Pharma BV, Naarden, Netherlands; [Kastelein, John J.] Acad Med Ctr, Amsterdam, Netherlands; [Rigby, Scott P.] Summit Res Grp, Stow, OH USA; [Alp, Nicholas John] Medpace, Cincinnati, OH USA	Monash University; University of Amsterdam; Academic Medical Center Amsterdam	Nicholls, SJ (corresponding author), Monash Univ, Victorian Heart Inst, Clayton, Vic, Australia.	Stephen.Nicholls@monash.edu			New Amsterdam Pharma	New Amsterdam Pharma	This trial was funded by New Amsterdam Pharma. We thank the contributions of the study patients, the dedicated study physicians and the New Amsterdam Pharma operations team.	[Anonymous], 2020, LDL CALC; [Anonymous], 2020, CKD EPI EQ GLOM FILT; Arnett DK, 2019, CIRCULATION, V140, pE596, DOI [10.1161/CIR.0000000000000678, 10.1016/j.jacc.2019.03.009, 10.1161/CIR.0000000000000677, 10.1016/j.jacc.2019.03.010]; Banerjee S, 2021, DRUG DISCOV TODAY, V26, P1759, DOI 10.1016/j.drudis.2021.03.016; Barter PJ, 2007, NEW ENGL J MED, V357, P2109, DOI 10.1056/NEJMoa0706628; Cannon CP, 2021, JAMA CARDIOL, V6, P1060, DOI 10.1001/jamacardio.2021.1810; Davidson M, 2013, J LIPID RES, V54, P467, DOI 10.1194/jlr.M032615; Ference BA, 2017, JAMA-J AM MED ASSOC, V318, P947, DOI 10.1001/jama.2017.11467; Ference BA, 2017, EUR HEART J, V38, P2459, DOI 10.1093/eurheartj/ehx144; Ford J, 2014, BRIT J CLIN PHARMACO, V78, P498, DOI 10.1111/bcp.12380; Hovingh GK, 2015, LANCET, V386, P452, DOI 10.1016/S0140-6736(15)60158-1; Krishna R, 2008, CLIN PHARMACOL THER, V84, P679, DOI 10.1038/clpt.2008.109; Krishna R, 2009, BRIT J CLIN PHARMACO, V68, P535, DOI 10.1111/j.1365-2125.2009.03465.x; Lincoff AM, 2017, NEW ENGL J MED, V376, P1933, DOI 10.1056/NEJMoa1609581; Liu SP, 2012, J BIOL CHEM, V287, P37321, DOI 10.1074/jbc.M112.380063; Mach F, 2020, EUR HEART J, V41, P111, DOI [10.15829/1560-4071-2020-3826, 10.1093/eurheartj/ehz455]; Martin SS, 2013, JAMA-J AM MED ASSOC, V310, P2061, DOI 10.1001/jama.2013.280532; Millar JS, 2016, J CLIN INVEST, V126, P1603, DOI 10.1172/JCI87364; Nordestgaard LT, 2022, JAMA CARDIOL, V7, P55, DOI 10.1001/jamacardio.2021.3728; Nurmohamed N.S., CARDIOVASC RES, DOI [10.1093/cvr/cvab350(2021), DOI 10.1093/CVR/CVAB350(2021)]; Nurmohamed NS, 2021, J AM COLL CARDIOL, V77, P1564, DOI 10.1016/j.jacc.2020.11.079; Packard C, 2021, HEART, V107, P1369, DOI 10.1136/heartjnl-2020-318760; Ray KK, 2021, EUR J PREV CARDIOL, V28, P1279, DOI 10.1093/eurjpc/zwaa047; Schmidt AF, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25703-3; Schwartz GG, 2012, NEW ENGL J MED, V367, P2089, DOI 10.1056/NEJMoa1206797; Shrestha S, 2018, J LIPID RES, V59, P772, DOI 10.1194/jlr.R082735; Suico JG, 2014, J PHARM PHARMACOL, V66, P1576, DOI 10.1111/jphp.12287; Tall AR, 2018, CIRC RES, V122, P106, DOI 10.1161/CIRCRESAHA.117.311978; Thomas T, 2017, ARTERIOSCL THROM VAS, V37, P1770, DOI 10.1161/ATVBAHA.117.309549; van Capelleveen JC, 2016, J CLIN LIPIDOL, V10, P1137, DOI 10.1016/j.jacl.2016.06.006; Voight BF, 2012, LANCET, V380, P572, DOI 10.1016/S0140-6736(12)60312-2	33	2	2	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01936-7	http://dx.doi.org/10.1038/s41591-022-01936-7		AUG 2022	12	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3S4NQ	35953719	Bronze			2022-12-27	WOS:000839575100001
J	Montgomery, RA; Mehta, SA; Parent, B; Griesemer, A				Montgomery, Robert A.; Mehta, Sapna A.; Parent, Brendan; Griesemer, Adam			Next steps for the xenotransplantation of pig organs into humans	NATURE MEDICINE			English	Editorial Material; Early Access							FIBROBLASTS; PROGRESS	Pigs offer a potentially plentiful supply of organs for humans, but widespread xenotransplantation will require a collaborative and iterative approach to research, as well as involvement of transplant patients and the public.	[Montgomery, Robert A.; Mehta, Sapna A.; Griesemer, Adam] NYU Langone Hlth, NYU Langone Transplant Inst, New York, NY 10016 USA; [Parent, Brendan] NYU Langone Hlth, Dept Populat Hlth, New York, NY USA	NYU Langone Medical Center; NYU Langone Medical Center	Montgomery, RA (corresponding author), NYU Langone Hlth, NYU Langone Transplant Inst, New York, NY 10016 USA.	robert.montgomery@nyulangone.org	Griesemer, Adam/N-5183-2016	Griesemer, Adam/0000-0003-4894-2024				Adams AB, 2021, ANN SURG, V274, P473, DOI 10.1097/SLA.0000000000004996; [Anonymous], 1999, NAT MED, V5, P465; [Anonymous], ORGAN PROCUREMENT TR; BAILEY LL, 1985, JAMA-J AM MED ASSOC, V254, P3321, DOI 10.1001/jama.254.23.3321; COOPER DKC, 1994, IMMUNOL REV, V141, P31, DOI 10.1111/j.1600-065X.1994.tb00871.x; DeGrazia David, 1991, Kennedy Inst Ethics J, V1, P48; Griesemer A, 2014, IMMUNOL REV, V258, P241, DOI 10.1111/imr.12152; Kim NY, 2009, VIRUS GENES, V39, P210, DOI 10.1007/s11262-009-0377-7; Kolber-Simonds D, 2004, P NATL ACAD SCI USA, V101, P7335, DOI 10.1073/pnas.0307819101; Mitchell C, 2020, XENOTRANSPLANTATION, V27, DOI 10.1111/xen.12583; Montgomery RA, 2022, NEW ENGL J MED, V386, P1889, DOI 10.1056/NEJMoa2120238; Parent B, 2020, J MED ETHICS, V46, P199, DOI 10.1136/medethics-2019-105674; Paris W., 2020, CLIN XENOTRANSPLANTA, P277; Porrett PM, 2022, AM J TRANSPLANT, V22, P1037, DOI 10.1111/ajt.16930; REEMTSMA K, 1964, ANN SURG, V160, P384, DOI 10.1097/00000658-196409000-00006; Regalado A., 2022, MIT TECHNOL REV; Tector AJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00622; Wang LR, 2018, TRANSPLANTATION, V102, P1050, DOI 10.1097/TP.0000000000002171; Whitteker JL, 2008, TRANSPLANTATION, V86, P155, DOI 10.1097/TP.0b013e31817d4823; Wijkstrom M, 2017, KIDNEY INT, V91, P790, DOI 10.1016/j.kint.2016.08.035; Yamada K., 2005, TRANSPLANT REV-ORLAN, V19, P164, DOI [10.1016/j.trre.2005.10.004, DOI 10.1016/J.TRRE.2005.10.004]; Yamamoto T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66311-3	22	0	0	4	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01896-y	http://dx.doi.org/10.1038/s41591-022-01896-y		AUG 2022	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3P5AJ	35941375				2022-12-27	WOS:000837551000006
J	Fu, B; Liao, JY; Chen, SH; Li, W; Wang, QD; Hu, J; Yang, F; Hsiao, SL; Jiang, YH; Wang, LR; Chen, FP; Zhang, YJ; Wang, X; Li, DL; Liu, MY; Wu, YX				Fu, Bin; Liao, Jiaoyang; Chen, Shuanghong; Li, Wei; Wang, Qiudao; Hu, Jian; Yang, Fei; Hsiao, Shenlin; Jiang, Yanhong; Wang, Liren; Chen, Fangping; Zhang, Yuanjin; Wang, Xin; Li, Dali; Liu, Mingyao; Wu, Yuxuan			CRISPR-Cas9-mediated gene editing of the BCL11A enhancer for pediatric beta(0)/beta(0) transfusion-dependent beta-thalassemia	NATURE MEDICINE			English	Article; Early Access							FETAL-HEMOGLOBIN; IN-VIVO; TRANSPLANTATION; HEMATOPOIESIS	Preliminary results from a phase 1/2 trial with 18-month follow-up show that transplantation of CRISPR-Cas9 BCL11A-edited autologous hematopoietic cells in two children with beta-thalassemia was safe and achieved transfusion independence. Gene editing to disrupt the GATA1-binding site at the +58 BCL11A erythroid enhancer could induce gamma-globin expression, which is a promising therapeutic strategy to alleviate beta-hemoglobinopathy caused by HBB gene mutation. In the present study, we report the preliminary results of an ongoing phase 1/2 trial (NCT04211480) evaluating safety and efficacy of gene editing therapy in children with blood transfusion-dependent beta-thalassemia (TDT). We transplanted BCL11A enhancer-edited, autologous, hematopoietic stem and progenitor cells into two children, one carrying the beta(0)/beta(0) genotype, classified as the most severe type of TDT. Primary endpoints included engraftment, overall survival and incidence of adverse events (AEs). Both patients were clinically well with multilineage engraftment, and all AEs to date were considered unrelated to gene editing and resolved after treatment. Secondary endpoints included achieving transfusion independence, editing rate in bone marrow cells and change in hemoglobin (Hb) concentration. Both patients achieved transfusion independence for >18 months after treatment, and their Hb increased from 8.2 and 10.8 g dl(-1) at screening to 15.0 and 14.0 g dl(-1) at the last visit, respectively, with 85.46% and 89.48% editing persistence in bone marrow cells. Exploratory analysis of single-cell transcriptome and indel patterns in edited peripheral blood mononuclear cells showed no notable side effects of the therapy.	[Fu, Bin; Hu, Jian; Chen, Fangping] Cent South Univ, Xiangya Hosp, Changsha, Hunan, Peoples R China; [Liao, Jiaoyang; Chen, Shuanghong; Wang, Qiudao; Yang, Fei; Hsiao, Shenlin; Jiang, Yanhong; Wang, Liren; Li, Dali; Liu, Mingyao; Wu, Yuxuan] East China Normal Univ, Shanghai Frontiers Sci Ctr Genome Editing & Cell, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, Shanghai, Peoples R China; [Liao, Jiaoyang; Chen, Shuanghong; Wang, Qiudao; Yang, Fei; Hsiao, Shenlin; Jiang, Yanhong; Wang, Liren; Zhang, Yuanjin; Wang, Xin; Li, Dali; Liu, Mingyao; Wu, Yuxuan] East China Normal Univ, Sch Life Sci, Shanghai, Peoples R China; [Li, Wei; Li, Dali; Liu, Mingyao] Bioray Labs Inc, Shanghai, Peoples R China; [Zhang, Yuanjin; Wang, Xin] East China Normal Univ, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, Shanghai, Peoples R China	Central South University; East China Normal University; East China Normal University; East China Normal University	Fu, B (corresponding author), Cent South Univ, Xiangya Hosp, Changsha, Hunan, Peoples R China.; Li, DL; Liu, MY; Wu, YX (corresponding author), East China Normal Univ, Shanghai Frontiers Sci Ctr Genome Editing & Cell, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, Shanghai, Peoples R China.; Li, DL; Liu, MY; Wu, YX (corresponding author), East China Normal Univ, Sch Life Sci, Shanghai, Peoples R China.; Li, DL; Liu, MY (corresponding author), Bioray Labs Inc, Shanghai, Peoples R China.	fu.bin@csu.edu.cn; dlli@bio.ecnu.edu.cn; myliu@bio.ecnu.edu.cn; yxwu@bio.ecnu.edu.cn	Wang, liren/GQQ-5391-2022; WANG, XIN/B-6572-2011	WANG, XIN/0000-0001-8079-8638; Fu, Bin/0000-0002-3119-7497	Shanghai Bioray Laboratories Inc.; National Key R&D Program of China [2019YFA0802800, 2019YFA0110803, 2019YFA0109900, 2019YFA0109901, 2019YFA0802802]; Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning [11300-412214-20009]; Innovation program of Shanghai Municipal Education Commission [2019-01-07-00-05-E00054]; Shanghai pujiang program [11300-412213-19B08]	Shanghai Bioray Laboratories Inc.; National Key R&D Program of China; Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning; Innovation program of Shanghai Municipal Education Commission(Innovation Program of Shanghai Municipal Education Commission); Shanghai pujiang program(Shanghai Pujiang Program)	We thank all the patients and their families for their participation in the present study and the staff at Xiangya Hopital for their contributions to the care of the patients. This trial was sponsored by Shanghai Bioray Laboratories Inc. The sponsor was involved in clinical protocol design, data analysis, hematopoietic stem cell collection and cell production. We thank current and previous employees of Shanghai Bioray Laboratories Inc. and East China Normal University for helpful discussions. We thank S. Siwko for scientific editing and comments. We also thank D. E. Bauer for helpful suggestions to enhance our manuscript. We appreciate the support of grants from National Key R&D Program of China (grant nos. 2019YFA0802800, 2019YFA0110803, 2019YFA0109900 and 2019YFA0109901 to Y.W. and 2019YFA0802802 to M.L.), the Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning (no. 11300-412214-20009 to Y.W.), the Innovation program of Shanghai Municipal Education Commission (no. 2019-01-07-00-05-E00054 to D.L.) and the Shanghai pujiang program (no. 11300-412213-19B08 to Y.W.).	Bauer DE, 2015, CURR OPIN GENET DEV, V33, P62, DOI 10.1016/j.gde.2015.08.001; Bauer DE, 2013, SCIENCE, V342, P253, DOI 10.1126/science.1242088; Biasco L, 2016, CELL STEM CELL, V19, P107, DOI 10.1016/j.stem.2016.04.016; Brendel C, 2020, MOL THER-METH CLIN D, V17, P589, DOI 10.1016/j.omtm.2020.03.015; Brendel C, 2016, J CLIN INVEST, V126, P3868, DOI 10.1172/JCI87885; Brinkman EK, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku936; Busch K, 2016, CURR OPIN HEMATOL, V23, P295, DOI 10.1097/MOH.0000000000000250; Canver MC, 2015, NATURE, V527, P192, DOI 10.1038/nature15521; Cao A, 2010, GENET MED, V12, P61, DOI [10.1097/GIM.0b013e3181cd68ed, 10.1038/gim.2016.173]; Clement K, 2019, NAT BIOTECHNOL, V37, P224, DOI 10.1038/s41587-019-0032-3; Demirci S, 2020, J CLIN INVEST, V130, P6677, DOI 10.1172/JCI140189; Esrick EB, 2021, NEW ENGL J MED, V384, P205, DOI 10.1056/NEJMoa2029392; Frangoul H, 2021, NEW ENGL J MED, V384, P252, DOI 10.1056/NEJMoa2031054; Goncalves TL, 2009, OXID MED CELL LONGEV, V2, P82, DOI 10.4161/oxim.2.2.8355; Jillella AP, 2000, BONE MARROW TRANSPL, V26, P925, DOI 10.1038/sj.bmt.1702658; Li CF, 2019, BLOOD ADV, V3, P2562, DOI 10.1182/bloodadvances.2019000291; Liu PT, 2003, NAT IMMUNOL, V4, P525, DOI 10.1038/ni925; Modell B, 2000, LANCET, V355, P2051, DOI 10.1016/S0140-6736(00)02357-6; Neunert CE, 2019, PEDIATR BLOOD CANCER, V66, DOI 10.1002/pbc.27569; Piel FB, 2016, HEMATOL ONCOL CLIN N, V30, P327, DOI 10.1016/j.hoc.2015.11.004; Sankaran VG, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a011643; Scala S, 2018, NAT MED, V24, P1683, DOI 10.1038/s41591-018-0195-3; Schafflick D, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14118-w; Taher AT, 2018, LANCET, V391, P155, DOI 10.1016/S0140-6736(17)31822-6; Thein SL, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a011700; Uda M, 2008, P NATL ACAD SCI USA, V105, P1620, DOI 10.1073/pnas.0711566105; Wang LR, 2020, CELL RES, V30, P276, DOI 10.1038/s41422-019-0267-z; Wu YX, 2019, NAT MED, V25, P776, DOI 10.1038/s41591-019-0401-y; Yin XL, 2011, PEDIATR BLOOD CANCER, V57, P1174, DOI 10.1002/pbc.23101; Yu Y, 2012, J EXP MED, V209, P2467, DOI 10.1084/jem.20121846	30	4	4	22	22	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01906-z	http://dx.doi.org/10.1038/s41591-022-01906-z		AUG 2022	24	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3M6SJ	35922667				2022-12-27	WOS:000835588900001
J	Henry, KE; Adams, R; Parent, C; Soleimani, H; Sridharan, A; Johnson, L; Hager, DN; Cosgrove, SE; Markowski, A; Klein, EY; Chen, ES; Saheed, MO; Henley, M; Miranda, S; Houston, K; Linton, RC; Ahluwalia, AR; Wu, AW; Saria, S				Henry, Katharine E.; Adams, Roy; Parent, Cassandra; Soleimani, Hossein; Sridharan, Anirudh; Johnson, Lauren; Hager, David N.; Cosgrove, Sara E.; Markowski, Andrew; Klein, Eili Y.; Chen, Edward S.; Saheed, Mustapha O.; Henley, Maureen; Miranda, Sheila; Houston, Katrina; Linton, Robert C., II; Ahluwalia, Anushree R.; Wu, Albert W.; Saria, Suchi			Factors driving provider adoption of the TREWS machine learning-based early warning system and its effects on sepsis treatment timing	NATURE MEDICINE			English	Article							RISK; AUTOMATION; TRUST; PERFORMANCE; MEDICINE; MODELS	Prospective evaluation of a machine learning-based early warning system for sepsis, deployed at five hospitals, showed that healthcare providers interacted with the system at a high rate and that this interaction was associated with faster antibiotic ordering. Machine learning-based clinical decision support tools for sepsis create opportunities to identify at-risk patients and initiate treatments at early time points, which is critical for improving sepsis outcomes. In view of the increasing use of such systems, better understanding of how they are adopted and used by healthcare providers is needed. Here, we analyzed provider interactions with a sepsis early detection tool (Targeted Real-time Early Warning System), which was deployed at five hospitals over a 2-year period. Among 9,805 retrospectively identified sepsis cases, the early detection tool achieved high sensitivity (82% of sepsis cases were identified) and a high rate of adoption: 89% of all alerts by the system were evaluated by a physician or advanced practice provider and 38% of evaluated alerts were confirmed by a provider. Adjusting for patient presentation and severity, patients with sepsis whose alert was confirmed by a provider within 3 h had a 1.85-h (95% CI 1.66-2.00) reduction in median time to first antibiotic order compared to patients with sepsis whose alert was either dismissed, confirmed more than 3 h after the alert or never addressed in the system. Finally, we found that emergency department providers and providers who had previous interactions with an alert were more likely to interact with alerts, as well as to confirm alerts on retrospectively identified patients with sepsis. Beyond efforts to improve the performance of early warning systems, efforts to improve adoption are essential to their clinical impact and should focus on understanding providers' knowledge of, experience with and attitudes toward such systems.	[Henry, Katharine E.; Saria, Suchi] Johns Hopkins Univ, Dept Comp Sci, Baltimore, MD 21218 USA; [Henry, Katharine E.; Adams, Roy; Saria, Suchi] Johns Hopkins Univ, Malone Ctr Engn Healthcare, Baltimore, MD 21218 USA; [Adams, Roy] Johns Hopkins Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; [Parent, Cassandra] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21218 USA; [Soleimani, Hossein] Univ Calif San Francisco, Hlth Informat, San Francisco, CA 94143 USA; [Sridharan, Anirudh; Linton, Robert C., II] Howard Cty Gen Hosp, Columbia, MD USA; [Johnson, Lauren; Houston, Katrina; Ahluwalia, Anushree R.] Johns Hopkins Univ Hosp, Dept Qual Improvement, Baltimore, MD 21218 USA; [Hager, David N.; Cosgrove, Sara E.; Chen, Edward S.; Wu, Albert W.; Saria, Suchi] Johns Hopkins Sch Med, Dept Med, Baltimore, MD 21218 USA; [Markowski, Andrew] Suburban Hosp, Bethesda, MD USA; [Klein, Eili Y.; Saheed, Mustapha O.] Johns Hopkins Sch Med, Dept Emergency Med, Baltimore, MD 21218 USA; [Chen, Edward S.] Johns Hopkins Univ Hosp, Dept Med, Baltimore, MD USA; [Wu, Albert W.; Saria, Suchi] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA; [Wu, Albert W.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; [Wu, Albert W.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA; [Saria, Suchi] Bayesian Hlth, New York, NY 10005 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; University of California System; University of California San Francisco; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Saria, S (corresponding author), Johns Hopkins Univ, Dept Comp Sci, Baltimore, MD 21218 USA.; Saria, S (corresponding author), Johns Hopkins Univ, Malone Ctr Engn Healthcare, Baltimore, MD 21218 USA.; Wu, AW; Saria, S (corresponding author), Johns Hopkins Sch Med, Dept Med, Baltimore, MD 21218 USA.; Wu, AW; Saria, S (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA.; Wu, AW (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA.; Wu, AW (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA.; Saria, S (corresponding author), Bayesian Hlth, New York, NY 10005 USA.	awu@jhu.edu; ssaria@cs.jhu.edu		Klein, Eili/0000-0002-1304-5289; Henry, Katharine/0000-0002-0446-9717	Gordon and Betty Moore Foundation [3926]; National Science Foundation Future of Work at the Human-technology Frontier [1840088]; Alfred P. Sloan Foundation	Gordon and Betty Moore Foundation(Gordon and Betty Moore Foundation); National Science Foundation Future of Work at the Human-technology Frontier; Alfred P. Sloan Foundation(Alfred P. Sloan Foundation)	The authors thank Y. Ahmad, A. Zhang, M. Yeo and Y. Karklin whose work significantly contributed to early iterations of the development of the deployed system. We also thank R. Demski, K. D'Souza, A. Kachalia, A. Chen and clinical and quality stakeholders who contributed to tool deployment, education and championing the work. The authors gratefully acknowledge the following sources of funding: the Gordon and Betty Moore Foundation (award 3926), the National Science Foundation Future of Work at the Human-technology Frontier (award 1840088) and the Alfred P. Sloan Foundation research fellowship (2018). This information or content and conclusions are those of the authors and should not be construed as the official position or policy of, nor should any endorsements be inferred by the NSF the US Government.	Abramoff MD, 2020, AM J OPHTHALMOL, V214, P134, DOI 10.1016/j.ajo.2020.02.022; Abramoff MD, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0040-6; Adams R, 2022, NAT MED, V28, P1455, DOI 10.1038/s41591-022-01894-0; Adams R, 2022, CRIT CARE MED, V50, P705; Amland RC, 2018, AM J MED QUAL, V33, P50, DOI 10.1177/1062860617692034; [Anonymous], HOSP INP SPEC MAN SE; Bansal G., 2019, P AAAI C HUMAN COMPU, V7, P2; Bates DW, 2014, HEALTH AFFAIR, V33, P1123, DOI 10.1377/hlthaff.2014.0041; Bauer M, 2019, LANCET PSYCHIAT, V6, P338, DOI 10.1016/S2215-0366(19)30041-0; Beam AL, 2018, JAMA-J AM MED ASSOC, V319, P1317, DOI 10.1001/jama.2017.18391; Cai CJ, 2019, CHI 2019: PROCEEDINGS OF THE 2019 CHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS, DOI 10.1145/3290605.3300234; Carspecken W, 2013, PEDIATRICS, V131, pE1970, DOI 10.1542/peds.2012-3252; Castaneda Christian, 2015, J Clin Bioinforma, V5, P4, DOI 10.1186/s13336-015-0019-3; Celi LA, 2019, LANCET DIGIT HEALTH, V1, pE255, DOI 10.1016/s2589-7500(19)30127-x; Churpek MM, 2016, RESUSCITATION, V102, P1, DOI 10.1016/j.resuscitation.2016.02.005; Downing NL, 2019, BMJ QUAL SAF, V28, P762, DOI 10.1136/bmjqs-2018-008765; Escobar GJ, 2020, NEW ENGL J MED, V383, P1951, DOI 10.1056/NEJMsa2001090; Evans IVR, 2018, JAMA-J AM MED ASSOC, V320, P358, DOI 10.1001/jama.2018.9071; Finlayson SG, 2021, NEW ENGL J MED, V385, P283, DOI 10.1056/NEJMc2104626; Gaube S., NPJ DIGIT MED, DOI [10.1038/s41746-021-00385-9(2021), DOI 10.1038/S41746-021-00385-9(2021)]; Giannini HM, 2019, CRIT CARE MED, V47, P1485, DOI 10.1097/CCM.0000000000003891; Ginestra JC, 2019, CRIT CARE MED, V47, P1477, DOI 10.1097/CCM.0000000000003803; Greenes RA, 2018, J BIOMED INFORM, V78, P134, DOI 10.1016/j.jbi.2017.12.005; Guy J. S., 2020, NEJM CATAL INNOV CAR, DOI [10.1056/CAT.19.1036, DOI 10.1056/CAT.19.1036]; Henry K., 2017, AM J RESP CRIT CARE, V195, P7016; Henry KE, 2022, NPJ DIGIT MED, V5, DOI 10.1038/s41746-022-00597-7; Henry Katharine E, 2019, Crit Care Explor, V1, pe0053, DOI 10.1097/CCE.0000000000000053; Henry KE, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab3719; Hoff KA, 2015, HUM FACTORS, V57, P407, DOI 10.1177/0018720814547570; Jacobs M, 2021, CHI '21: PROCEEDINGS OF THE 2021 CHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS, DOI 10.1145/3411764.3445385; Jacobs M, 2021, TRANSL PSYCHIAT, V11, DOI 10.1038/s41398-021-01224-x; JORDAN MI, 1994, NEURAL COMPUT, V6, P181, DOI 10.1162/neco.1994.6.2.181; Kelly CJ, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1426-2; Khairat S, 2018, JMIR MED INF, V6, P25, DOI 10.2196/medinform.8912; Khan Sundas, 2019, JMIR Hum Factors, V6, pe10245, DOI 10.2196/10245; Kitzmiller RR, 2019, APPL CLIN INFORM, V10, P295, DOI 10.1055/s-0039-1688478; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kumar A, 2006, CRIT CARE MED, V34, P1589, DOI 10.1097/01.CCM.0000217961.75225.E9; Kwan JL, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3216; Lee JD, 2004, HUM FACTORS, V46, P50, DOI 10.1518/hfes.46.1.50.30392; Levy MM, 2018, CRIT CARE MED, V46, P997, DOI 10.1097/CCM.0000000000003119; Liang HY, 2019, NAT MED, V25, P433, DOI 10.1038/s41591-018-0335-9; Liu VX, 2017, AM J RESP CRIT CARE, V196, P856, DOI 10.1164/rccm.201609-1848OC; Mann D, 2020, J GEN INTERN MED, V35, P788, DOI 10.1007/s11606-020-06096-3; Mann D, 2019, DIGIT HEALTH, V5, DOI 10.1177/2055207619827716; McCoy Andrea, 2017, BMJ Open Qual, V6, pe000158, DOI 10.1136/bmjoq-2017-000158; Mertz L, 2015, IEEE PULSE, V6, P4, DOI 10.1109/MPUL.2015.2456251; Metcalfe D, 2019, BMC MED RES METHODOL, V19, DOI 10.1186/s12874-019-0753-5; Moja L, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.17094; Murphy Elizabeth V., 2014, Yale Journal of Biology and Medicine, V87, P187; Norton EC, 2013, STATA J, V13, P492, DOI 10.1177/1536867X1301300304; Peltan ID, 2019, CHEST, V155, P938, DOI 10.1016/j.chest.2019.02.008; Perlin JB, 2020, JT COMM J QUAL PATIE, V46, P381, DOI 10.1016/j.jcjq.2020.04.006; Pierson E, 2021, NAT MED, V27, P136, DOI 10.1038/s41591-020-01192-7; Rhee C., 2018, BMJ QUAL SAF, DOI [10.1002/sca.20201, DOI 10.1002/SCA.20201]; Rhee C, 2021, CLIN INFECT DIS, V72, P541, DOI 10.1093/cid/ciaa059; Rhee C, 2019, CRIT CARE MED, V47, P307, DOI 10.1097/CCM.0000000000003521; Rhee C, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.7571; Rhee C, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1266-9; Ruppel H, 2019, BMJ QUAL SAF, V28, P693, DOI 10.1136/bmjqs-2019-009463; Saria S, 2020, CRIT CARE MED, V48, P137, DOI 10.1097/CCM.0000000000004144; Schaefer KE, 2016, HUM FACTORS, V58, P377, DOI 10.1177/0018720816634228; Schulam P., 2019, 22 INT C ART INT STA, V89, P1022; Seabold S, 2010, P 9 PYTHON SCI C; Sendak MP, 2020, JMIR MED INF, V8, DOI 10.2196/15182; Seymour CW, 2017, NEW ENGL J MED, V376, P2235, DOI 10.1056/NEJMoa1703058; Shimabukuro DW, 2017, BMJ OPEN RESPIR RES, V4, DOI 10.1136/bmjresp-2017-000234; Shortliffe EH, 2018, JAMA-J AM MED ASSOC, V320, P2199, DOI 10.1001/jama.2018.17163; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Sittig DF, 2008, J BIOMED INFORM, V41, P387, DOI 10.1016/j.jbi.2007.09.003; Soleimani H, 2018, IEEE T PATTERN ANAL, V40, P1948, DOI 10.1109/TPAMI.2017.2742504; Subbaswamy A, 2019, PR MACH LEARN RES, V89; Subbaswamy A, 2020, BIOSTATISTICS, V21, P345, DOI 10.1093/biostatistics/kxz041; Tomasev N, 2019, NATURE, V572, P116, DOI 10.1038/s41586-019-1390-1; Topiwala Raj, 2019, Crit Care Explor, V1, pe0046, DOI 10.1097/CCE.0000000000000046; Topol EJ, 2019, NAT MED, V25, P44, DOI 10.1038/s41591-018-0300-7; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Wong A, 2021, JAMA INTERN MED, V181, P1065, DOI 10.1001/jamainternmed.2021.2626; Wright A, 2016, J AM MED INFORM ASSN, V23, P1068, DOI 10.1093/jamia/ocw005	79	4	4	2	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2022	28	7					1447	+		10.1038/s41591-022-01895-z	http://dx.doi.org/10.1038/s41591-022-01895-z		JUL 2022	20	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3E5PS	35864251				2022-12-27	WOS:000828446700007
J	Dardani, C; Rai, D				Dardani, Christina; Rai, Dheeraj			Uncovering links between parental inflammatory bowel disease and autism in children	NATURE MEDICINE			English	Editorial Material; Early Access								Findings from a nationwide cohort study in Sweden, polygenic risk score analyses in a general population-based cohort in the United Kingdom, Mendelian randomization analyses and genetic correlation (linkage disequilibrium) analyses suggest a link between parental diagnosis of and genetic liability to inflammatory bowel disease and autism in children.	[Dardani, Christina; Rai, Dheeraj] Univ Bristol, Populat Hlth Sci, Bristol Med Sch, Bristol, Avon, England	University of Bristol	Dardani, C (corresponding author), Univ Bristol, Populat Hlth Sci, Bristol Med Sch, Bristol, Avon, England.							Lawlor DA, 2016, INT J EPIDEMIOL, V45, P1866, DOI 10.1093/ije/dyw314; Lee H., EUR CHILD ADOLES PSY, DOI [10.1007/s00787-021-01860-0(2021, DOI 10.1007/S00787-021-01860-0(2021]; Osokine I, 2017, TRENDS MOL MED, V23, P1070, DOI 10.1016/j.molmed.2017.10.008; Roda G, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-020-0156-2; Taku K, 2020, NAT REV DIS PRIM, V6	5	0	0	2	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01884-2	http://dx.doi.org/10.1038/s41591-022-01884-2		JUL 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2W1XM	35831517	hybrid, Green Published			2022-12-27	WOS:000824325300001
J	Sadik, A; Dardani, C; Pagoni, P; Havdahl, A; Stergiakouli, E; Khandaker, GM; Sullivan, SA; Zammit, S; Jones, HJ; Smith, GD; Dalman, C; Karlsson, H; Gardner, RM; Rai, D				Sadik, Aws; Dardani, Christina; Pagoni, Panagiota; Havdahl, Alexandra; Stergiakouli, Evie; Khandaker, Golam M.; Sullivan, Sarah A.; Zammit, Stan; Jones, Hannah J.; Davey Smith, George; Dalman, Christina; Karlsson, Hakan; Gardner, Renee M.; Rai, Dheeraj		IPSYCH Autism Spectrum Disorder Wo	Parental inflammatory bowel disease and autism in children	NATURE MEDICINE			English	Article							GENOME-WIDE ASSOCIATION; SPECTRUM DISORDERS; MENDELIAN RANDOMIZATION; AUTOIMMUNE-DISEASES; MICRONUTRIENT DEFICIENCIES; RISK; COHORT; CYTOKINES; PATHWAY; VARIANT	Evidence from four complementary methodological approaches, harnessing genotype and phenotype data, identifies potential causal links between inflammatory bowel disease in parents and autism in children. Evidence linking parental inflammatory bowel disease (IBD) with autism in children is inconclusive. We conducted four complementary studies to investigate associations between parental IBD and autism in children, and elucidated their underlying etiology. Conducting a nationwide population-based cohort study using Swedish registers, we found evidence of associations between parental diagnoses of IBD and autism in children. Polygenic risk score analyses of the Avon Longitudinal Study of Parents and Children suggested associations between maternal genetic liability to IBD and autistic traits in children. Two-sample Mendelian randomization analyses provided evidence of a potential causal effect of genetic liability to IBD, especially ulcerative colitis, on autism. Linkage disequilibrium score regression did not indicate a genetic correlation between IBD and autism. Triangulating evidence from these four complementary approaches, we found evidence of a potential causal link between parental, particularly maternal, IBD and autism in children. Perinatal immune dysregulation, micronutrient malabsorption and anemia may be implicated.	[Sadik, Aws; Dardani, Christina; Pagoni, Panagiota; Stergiakouli, Evie; Khandaker, Golam M.; Sullivan, Sarah A.; Zammit, Stan; Jones, Hannah J.; Davey Smith, George; Rai, Dheeraj] Univ Bristol, Bristol Med Sch, Populat Hlth Sci, Bristol, Avon, England; [Sadik, Aws; Khandaker, Golam M.; Rai, Dheeraj] Avon & Wiltshire Partnership NHS Mental Hlth Trus, Bath, Avon, England; [Pagoni, Panagiota; Havdahl, Alexandra; Stergiakouli, Evie; Khandaker, Golam M.; Jones, Hannah J.; Davey Smith, George] Univ Bristol, Bristol Med Sch, MRC, Integrat Epidemiol Unit, Bristol, Avon, England; [Havdahl, Alexandra] Norwegian Inst Publ Hlth, Dept Mental Disorders, Oslo, Norway; [Havdahl, Alexandra] Lovisenberg Diakonale Hosp, Nic Waals Inst, Oslo, Norway; [Havdahl, Alexandra] Univ Oslo, Dept Psychol, PROMENTA Res Ctr, Oslo, Norway; [Khandaker, Golam M.] Univ Cambridge, Dept Psychiat, Cambridge, England; [Khandaker, Golam M.] Cambridgeshire & Peterborough NHS Fdn Trust, Cambridge, England; [Khandaker, Golam M.; Sullivan, Sarah A.; Zammit, Stan; Jones, Hannah J.; Davey Smith, George; Rai, Dheeraj] Univ Hosp, NIH, Bristol & Weston NHS Fdn Trust, Bristol, Avon, England; [Khandaker, Golam M.; Sullivan, Sarah A.; Zammit, Stan; Jones, Hannah J.; Davey Smith, George; Rai, Dheeraj] Univ Hosp, Care Res Biomed Res Ctr, Bristol & Weston NHS Fdn Trust, Bristol, Avon, England; [Khandaker, Golam M.; Sullivan, Sarah A.; Zammit, Stan; Jones, Hannah J.; Davey Smith, George; Rai, Dheeraj] Univ Bristol, Bristol, Avon, England; [Zammit, Stan] Cardiff Univ, Div Psychol Med & Clin Neurosci, Cardiff, Wales; [Dalman, Christina] Karolinska Inst, Dept Global Publ Hlth, Stockholm, Sweden; [Dalman, Christina] Ctr Epidemiol & Community Med, Stockholm Cty Council, Stockholm, Sweden; [Karlsson, Hakan] Karolinska Inst, Dept Neurosci, Stockholm, Sweden	University of Bristol; University of Bristol; Norwegian Institute of Public Health (NIPH); University of Oslo; University of Cambridge; University of Bristol; Cardiff University; Karolinska Institutet; Stockholm County Council; Karolinska Institutet	Dardani, C (corresponding author), Univ Bristol, Bristol Med Sch, Populat Hlth Sci, Bristol, Avon, England.	christina.dardani@bristol.ac.uk	Davey Smith, George/A-7407-2013; Karlsson, Hakan/AAH-8798-2019; Grove, Jakob/K-8112-2015	Davey Smith, George/0000-0002-1407-8314; Sullivan, Sarah/0000-0002-1446-8478; Havdahl, Alexandra/0000-0002-9268-0423; Rai, Dheeraj/0000-0002-7239-3523; Stergiakouli, Evangelia/0000-0003-3586-0927; Zammit, Stanley/0000-0002-2647-9211; Pagoni, Panagiota/0000-0002-8090-512X; Grove, Jakob/0000-0003-2284-5744; Dardani, Christina/0000-0002-2019-7897	University of Bristol [MC_UU_00011/1, MC_UU_00011/3, MC_UU_00011/5, MC_UU_00011/6]; Biomedical Research Centre at University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol; MRC UK [MR/W014416/1, MR/S037675/1]; Lundbeck Foundation [R102-A9118, R155-2014-1724, R248-2017-2003]; NIMH [1U01MH109514-01]; University and University Hospital of Aarhus; Novo Nordisk Foundation; Swedish Research Council [VR2017-02900, 2018-02907, 523-2010-1052, 2021-01306]; southeastern Norway Regional Health Authority [2020022, 2018059]; Research Council of Norway [274611, 288083]; Hjarnfonden [FO2020-0019]; Wellcome [217065/Z/19/Z]; 23andMe; Wellcome Trust [215379/Z/19/Z, 201486/Z/16/Z]; Medical Research Council (MRC) [MC_UU_00011/1, MC_UU_00011/3, MC_UU_00011/5, MC_UU_00011/6]; University and University Hospital of Copenhagen; UK Medical Research Council [217065/Z/19/Z]	University of Bristol; Biomedical Research Centre at University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol; MRC UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Lundbeck Foundation(Lundbeckfonden); NIMH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); University and University Hospital of Aarhus; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Swedish Research Council(Swedish Research CouncilEuropean Commission); southeastern Norway Regional Health Authority; Research Council of Norway(Research Council of Norway); Hjarnfonden; Wellcome; 23andMe; Wellcome Trust(Wellcome Trust); Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); University and University Hospital of Copenhagen; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The Medical Research Council (MRC) and the University of Bristol support the MRC Integrative Epidemiology Unit (MC_UU_00011/1, MC_UU_00011/3, MC_UU_00011/5, MC_UU_00011/6; P.P., A.H., E.S., G.M.K., H.J.J., G.D.S.). G.D.S., H.J., D.R., S.S., and S.Z. are supported by the NIHR Biomedical Research Centre at University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol. C. Dardani acknowledges the support of Wellcome Trust (215379/Z/19/Z). G.M.K. acknowledges funding support from the Wellcome Trust (201486/Z/16/Z), and the MRC UK (MR/W014416/1 and MR/S037675/1). The iPSYCH team was supported by grants from the Lundbeck Foundation (R102-A9118, R155-2014-1724, and R248-2017-2003), NIMH (1U01MH109514-01), and the Universities and University Hospitals of Aarhus and Copenhagen. The Danish National Biobank resource was supported by the Novo Nordisk Foundation. High-performance computer capacity for handling and statistical analysis of iPSYCH data on the GenomeDK HPC facility was provided by the Center for Genomics and Personalized Medicine and the Center for Integrative Sequencing, iSEQ, Aarhus University, Denmark. R.G. acknowledges funding support from the Swedish Research Council (VR2017-02900). A.H. was supported by grants from the southeastern Norway Regional Health Authority (2020022, 2018059) and the Research Council of Norway (274611, 288083). H.K. is supported by grants from the Swedish Research Council (2018-02907) and Hjarnfonden (FO2020-0019). C. Dalman acknowledges funding from the Swedish Research Council (523-2010-1052) to support the Psychiatry Sweden register linkage and for further support of studies of the role of the early life immune system in autism (2021-01306). The UK Medical Research Council and Wellcome [Grant ref: 217065/Z/19/Z] and the University of Bristol provide core support for ALSPAC. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf).GWAS data was generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe. We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, and nurses.	Abdallah MW, 2012, J NEUROIMMUNOL, V252, P75, DOI 10.1016/j.jneuroim.2012.07.013; Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; Amiet C, 2008, BIOL PSYCHIAT, V64, P577, DOI 10.1016/j.biopsych.2008.04.030; Andersen ABT, 2014, CLIN EXP GASTROENTER, V7, P105, DOI 10.2147/CEG.S59360; Atladottir HO, 2009, PEDIATRICS, V124, P687, DOI 10.1542/peds.2008-2445; Bakheet SA, 2017, MOL NEUROBIOL, V54, P5201, DOI 10.1007/s12035-016-0066-1; Balzola F., 2012, NAT GENET, V12, P126; Bottema-Beutel K, 2021, AUTISM ADULTHOOD, V3, P18, DOI 10.1089/aut.2020.0014; Bowden J, 2016, GENET EPIDEMIOL, V40, P304, DOI 10.1002/gepi.21965; Bowden J, 2015, INT J EPIDEMIOL, V44, P512, DOI 10.1093/ije/dyv080; Boyd A, 2013, INT J EPIDEMIOL, V42, P111, DOI 10.1093/ije/dys064; Bulik-Sullivan B, 2015, NAT GENET, V47, P1236, DOI 10.1038/ng.3406; Bulik-Sullivan BK, 2015, NAT GENET, V47, P291, DOI 10.1038/ng.3211; Buxbaum Joseph D, 2009, Dialogues Clin Neurosci, V11, P35; Chen GB, 2017, BMC MED GENET, V18, DOI 10.1186/s12881-017-0451-2; Chen SY, 2021, INT J EPIDEMIOL, V50, P459, DOI 10.1093/ije/dyaa212; Choi GB, 2016, SCIENCE, V351, P933, DOI 10.1126/science.aad0314; Choi SW, 2020, NAT PROTOC, V15, P2759, DOI 10.1038/s41596-020-0353-1; Croen LA, 2005, ARCH PEDIAT ADOL MED, V159, P151, DOI 10.1001/archpedi.159.2.151; Davey Smith G, 2014, HUM MOL GENET, V23, pR89, DOI 10.1093/hmg/ddu328; de Lange KM, 2017, NAT GENET, V49, P256, DOI 10.1038/ng.3760; DEMPSTER ER, 1950, GENETICS, V35, P212; DeVilbiss EA, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j4273; Dudbridge F, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003348; FALCONER DS, 1965, ANN HUM GENET, V29, P51, DOI 10.1111/j.1469-1809.1965.tb00500.x; Feliciano P, 2018, NEURON, V97, P488, DOI 10.1016/j.neuron.2018.01.015; Fischbach GD, 2010, NEURON, V68, P192, DOI 10.1016/j.neuron.2010.10.006; Fraser A, 2013, INT J EPIDEMIOL, V42, P97, DOI 10.1093/ije/dys066; Gao X, 2019, EUR PSYCHIAT, V60, P79, DOI 10.1016/j.eurpsy.2019.05.004; Glanville Kylie P, 2021, Biol Psychiatry Glob Open Sci, V1, P48, DOI 10.1016/j.bpsgos.2021.03.002; Graham DB, 2020, NATURE, V578, P527, DOI 10.1038/s41586-020-2025-2; Grove J, 2019, NAT GENET, V51, P431, DOI 10.1038/s41588-019-0344-8; Hartwig FP, 2017, INT J EPIDEMIOL, V46, P1985, DOI 10.1093/ije/dyx102; Haycock PC, 2016, AM J CLIN NUTR, V103, P965, DOI 10.3945/ajcn.115.118216; Hemani G, 2018, ELIFE, V7, DOI 10.7554/eLife.34408; Holingue C, 2018, AUTISM RES, V11, P24, DOI 10.1002/aur.1854; Idring S, 2014, INT J EPIDEMIOL, V43, P107, DOI 10.1093/ije/dyt262; Ikram MK, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001184; Jones HJ, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.6118; Keil A, 2010, EPIDEMIOLOGY, V21, P805, DOI 10.1097/EDE.0b013e3181f26e3f; Kenny L, 2016, AUTISM, V20, P442, DOI 10.1177/1362361315588200; Lasconi C, 2021, CELL MOL GASTROENTER, V11, P667, DOI 10.1016/j.jcmgh.2020.10.004; Lawlor DA, 2016, INT J EPIDEMIOL, V45, P1866, DOI 10.1093/ije/dyw314; Lee M, 2018, J AUTISM DEV DISORD, V48, P1523, DOI 10.1007/s10803-017-3409-5; Lim KJH, 2000, FERTIL STERIL, V73, P136, DOI 10.1016/S0015-0282(99)00457-4; Madley-Dowd P, 2020, J CLIN EPIDEMIOL, V118, P9, DOI 10.1016/j.jclinepi.2019.10.008; Magnusson C, 2012, BRIT J PSYCHIAT, V201, P109, DOI 10.1192/bjp.bp.111.095125; Mouridsen SE, 2007, DEV MED CHILD NEUROL, V49, P429, DOI 10.1111/j.1469-8749.2007.00429.x; Mubashir S., 2020, Malta Medical Journal, V32, P56; Northstone Kate, 2019, Wellcome Open Res, V4, P51, DOI 10.12688/wellcomeopenres.15132.1; Osokine I, 2017, TRENDS MOL MED, V23, P1070, DOI 10.1016/j.molmed.2017.10.008; Pedersen CB, 2018, MOL PSYCHIATR, V23, P6, DOI 10.1038/mp.2017.196; Pierce BL, 2013, AM J EPIDEMIOL, V178, P1177, DOI 10.1093/aje/kwt084; Rai D, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.1465; Rai D, 2018, JAMA PSYCHIAT, V75, P835, DOI 10.1001/jamapsychiatry.2018.1323; Rai D, 2017, OBSTET GYNECOL SURV, V72, P689, DOI 10.1097/01.ogx.0000527930.12186.9d; Rai D, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2059; Rai D, 2012, J AM ACAD CHILD PSY, V51, P467, DOI 10.1016/j.jaac.2012.02.012; Rom AL, 2018, J AM ACAD CHILD PSY, V57, P28, DOI 10.1016/j.jaac.2017.10.002; Saito S, 2010, AM J REPROD IMMUNOL, V63, P601, DOI 10.1111/j.1600-0897.2010.00852.x; Sanders SJ, 2015, NEURON, V87, P1215, DOI 10.1016/j.neuron.2015.09.016; Sanderson E, 2022, NAT REV METHOD PRIME, V2, DOI 10.1038/s43586-021-00092-5; Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070; Smith GD, 2019, AM J EPIDEMIOL, V188, P1410, DOI 10.1093/aje/kwz064; Smith GD, 2012, INT J EPIDEMIOL, V41, P236, DOI 10.1093/ije/dys016; Steer CD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012633; Stergiakouli E, 2014, OBESITY, V22, P2252, DOI 10.1002/oby.20840; Sterne JAC, 2001, BMJ-BRIT MED J, V322, P226, DOI 10.1136/bmj.322.7280.226; Sun M., 2016, NATURE, V530, P171, DOI [10.1038/nature16931, DOI 10.1038/NATURE16931]; Tan M, 2020, REPROD TOXICOL, V91, P109, DOI 10.1016/j.reprotox.2019.11.009; Wang T., 2005, WORLD CHIN J DIG, V13, P72, DOI DOI 10.11569/WCJD.V13.I1.72; Wang WJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02025; Weisshof R, 2015, CURR OPIN CLIN NUTR, V18, P576, DOI 10.1097/MCO.0000000000000226; Wiegersma AM, 2019, JAMA PSYCHIAT, V76, P1294, DOI 10.1001/jamapsychiatry.2019.2309; Xie S, 2020, AUTISM RES, V13, P2242, DOI 10.1002/aur.2417; Yoon SM, 2016, INTEST RES, V14, P109, DOI 10.5217/ir.2016.14.2.109	76	0	0	3	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2022	28	7					1406	+		10.1038/s41591-022-01845-9	http://dx.doi.org/10.1038/s41591-022-01845-9		JUN 2022	24	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3E5PS	35654906	Green Published, Green Submitted, Green Accepted, hybrid			2022-12-27	WOS:000805079400003
J	Klein, KR; Buse, JB				Klein, Klara R.; Buse, John B.			A new class of drug in the diabetes toolbox	NATURE MEDICINE			English	Editorial Material							MOLECULE GLUCOKINASE ACTIVATORS		[Klein, Klara R.; Buse, John B.] Univ N Carolina, Sch Med, Div Endocrinol & Metab, Chapel Hill, NC 27515 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Buse, JB (corresponding author), Univ N Carolina, Sch Med, Div Endocrinol & Metab, Chapel Hill, NC 27515 USA.	john_buse@med.unc.edu	Buse, John Bernard/J-9742-2019; Klein, Klara/GWM-4884-2022	Buse, John Bernard/0000-0002-9723-3876; 				American Diabetes Association Professional Practice Committee, 2022, DIABETES CARE, V45; Chen L, 2021, DIABETES, V70, DOI 10.2337/db21-117-LB; De Ceuninck F, 2013, BRIT J PHARMACOL, V168, P339, DOI 10.1111/j.1476-5381.2012.02184.x; Grimsby J, 2003, SCIENCE, V301, P370, DOI 10.1126/science.1084073; Guertin KR, 2006, CURR MED CHEM, V13, P1839, DOI 10.2174/092986706777452551; Klein KR, 2021, DIABETES CARE, V44, P960, DOI 10.2337/dc20-2684; Matschinsky FM, 2013, TRENDS PHARMACOL SCI, V34, P90, DOI 10.1016/j.tips.2012.11.007; Miao J, 2022, CTS-CLIN TRANSL SCI, V15, P548, DOI 10.1111/cts.13174; The Dawn Study Group, NAT MED, DOI [10.1038/s41591-022-01803-5(2022), DOI 10.1038/S41591-022-01803-5(2022)]; The SEED Study Group, NAT MED, DOI [10.1038/s41591-022-01802-6(2022), DOI 10.1038/S41591-022-01802-6(2022)]; Vella A, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau3441; Zhu DL, 2018, LANCET DIABETES ENDO, V6, P627, DOI 10.1016/S2213-8587(18)30105-0	12	0	0	1	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2022	28	5					901	902		10.1038/s41591-022-01783-6	http://dx.doi.org/10.1038/s41591-022-01783-6		MAY 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	1J3AM	35551293				2022-12-27	WOS:000794108200004
J	Zhu, DL; Li, XY; Ma, JH; Zeng, JE; Gan, SL; Dong, XL; Yang, J; Lin, XH; Cai, HQ; Song, WH; Li, XF; Zhang, KQ; Zhang, Q; Lu, YB; Bu, RF; Shao, HG; Wang, GX; Yuan, GY; Ran, XW; Liao, L; Zhao, WN; Li, P; Sun, L; Shi, LX; Jiang, ZS; Xue, YM; Jiang, HW; Li, QN; Li, ZB; Fu, MX; Liang, ZR; Guo, L; Liu, M; Xu, C; Li, WH; Yu, XF; Qin, GJ; Yang, Z; Su, BL; Zeng, LY; Geng, HF; Shi, YQ; Zhao, Y; Zhang, Y; Yang, WY; Chen, L				Zhu, Dalong; Li, Xiaoying; Ma, Jianhua; Zeng, Jiao'e; Gan, Shenglian; Dong, Xiaolin; Yang, Jing; Lin, Xiaohong; Cai, Hanqing; Song, Weihong; Li, Xuefeng; Zhang, Keqin; Zhang, Qiu; Lu, Yibing; Bu, Ruifang; Shao, Huige; Wang, Guixia; Yuan, Guoyue; Ran, Xingwu; Liao, Lin; Zhao, Wenjuan; Li, Ping; Sun, Li; Shi, Lixin; Jiang, Zhaoshun; Xue, Yaoming; Jiang, Hongwei; Li, Quanmin; Li, Zongbao; Fu, Maoxiong; Liang, Zerong; Guo, Lian; Liu, Ming; Xu, Chun; Li, Wenhui; Yu, Xuefeng; Qin, Guijun; Yang, Zhou; Su, Benli; Zeng, Longyi; Geng, Houfa; Shi, Yongquan; Zhao, Yu; Zhang, Yi; Yang, Wenying; Chen, Li			Dorzagliatin in drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial	NATURE MEDICINE			English	Article							GLUCOKINASE ACTIVATOR AZD1656; POSTPRANDIAL PLASMA-GLUCOSE; HEPATIC GLUCOKINASE; BETA-CELL; INSULIN-SECRETION; HYPERGLYCEMIA; ISLETS; PHARMACOKINETICS; PHARMACODYNAMICS; TOLERABILITY	Improving glucose sensitivity remains an unmet medical need in treating type 2 diabetes (T2D). Dorzagliatin is a dual-acting, orally bioavailable glucokinase activator that enhances glucokinase activity in a glucose-dependent manner, improves glucose-stimulated insulin secretion and demonstrates effects on glycemic control in patients with T2D. We report the findings of a randomized, double-blind, placebo-controlled phase 3 clinical trial to evaluate the efficacy and safety of dorzagliatin in patients with T2D. Eligible drug-naive patients with T2D (n = 463) were randomly assigned to the dorzagliatin or placebo group at a ratio of 2:1 for 24 weeks of double-blind treatment, followed by 28 weeks of open-label treatment with dorzagliatin for all patients. The primary efficacy endpoint was the change in glycated hemoglobin from baseline to week 24. Safety was assessed throughout the trial. At week 24, the least-squares mean change in glycated hemoglobin from baseline (95% confidence interval) was -1.07% (-1.19%, -0.95%) in the dorzagliatin group and -0.50% (-0.68%, -0.32%) in the placebo group (estimated treatment difference, -0.57%; 95% confidence interval: -0.79%, -0.36%; P < 0.001). The incidence of adverse events was similar between the two groups. There were no severe hypoglycemia events or drug-related serious adverse events in the dorzagliatin group. In summary, dorzagliatin improved glycemic control in drug-naive patients with T2D and showed a good tolerability and safety profile. The SEED study is a phase 3 clinical trial demonstrating a beneficial effect on glycemic control of dorzagliatin, a glucokinase activator, in drug-naive patients with newly diagnosed type 2 diabetes.	[Zhu, Dalong; Li, Ping] Nanjing Univ, Affiliated Drum Tower Hosp, Sch Med, Nanjing, Peoples R China; [Li, Xiaoying] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China; [Ma, Jianhua] Nanjing First Hosp, Nanjing, Peoples R China; [Zeng, Jiao'e] Yangtze Univ, Jingzhou Hosp, Jingzhou, Peoples R China; [Gan, Shenglian] First Peoples Hosp Changde City, Changde, Peoples R China; [Dong, Xiaolin] Shandong First Med Univ, Jinan Cent Hosp, Jinan, Peoples R China; [Yang, Jing] Shanxi Med Univ, Hosp 1, Taiyuan, Peoples R China; [Lin, Xiaohong] Zhuzhou Cent Hosp, Zhuzhou, Peoples R China; [Cai, Hanqing] Jilin Univ, Hosp 2, Changchun, Peoples R China; [Song, Weihong] Chenzhou First Peoples Hosp, Chenzhou, Peoples R China; [Li, Xuefeng] Hubei Univ Med, Taihe Hosp, Shiyan, Peoples R China; [Zhang, Keqin] Tongji Univ, Tongji Hosp, Shanghai, Peoples R China; [Zhang, Qiu] Anhui Med Univ, Affiliated Hosp 1, Hefei, Peoples R China; [Lu, Yibing] Nanjing Med Univ, Affiliated Hosp 2, Nanjing, Peoples R China; [Bu, Ruifang] Wuxi Peoples Hosp, Wuxi, Jiangsu, Peoples R China; [Shao, Huige] Changsha Cent Hosp, Changsha, Peoples R China; [Wang, Guixia] Jilin Univ, Hosp 1, Changchun, Peoples R China; [Yuan, Guoyue] Jiangsu Univ, Affiliated Hosp, Zhenjiang, Jiangsu, Peoples R China; [Ran, Xingwu] Sichuan Univ, West China Hosp, Chengdu, Peoples R China; [Liao, Lin] Shandong First Med Univ, Affiliated Hosp 1, Jinan, Peoples R China; [Liao, Lin] Shandong Prov Qianfoshan Hosp, Jinan, Peoples R China; [Zhao, Wenjuan] Qingdao Univ, Affiliated Hosp, Qingdao, Peoples R China; [Sun, Li] China Med Univ, Siping Hosp, Siping, Peoples R China; [Shi, Lixin] Guizhou Med Univ, Affiliated Hosp, Guiyang, Peoples R China; [Jiang, Zhaoshun] PLA Joint Logist Support Force, 960th Hosp, Jinan, Peoples R China; [Xue, Yaoming] Southern Med Univ, Nanfang Hosp, Guangzhou, Peoples R China; [Jiang, Hongwei] Henan Univ Sci & Technol, Affiliated Hosp 1, Luoyang, Peoples R China; [Jiang, Hongwei] Henan Univ Sci & Technol, Coll Clin Med, Luoyang, Peoples R China; [Li, Quanmin] PLA Rocket Force Characterist Med Ctr, Beijing, Peoples R China; [Li, Zongbao] Sanya Cent Hosp, Sanya, Peoples R China; [Fu, Maoxiong] Hainan Med Univ, Affiliated Hosp 2, Haikou, Hainan, Peoples R China; [Liang, Zerong] Chongqing Red Cross Hosp, Chongqing, Peoples R China; [Guo, Lian] Chongqing Univ, Three Gorges Cent Hosp, Chongqing, Peoples R China; [Liu, Ming] Tianjin Med Univ, Gen Hosp, Tianjin, Peoples R China; [Xu, Chun] Peoples Liberat Army Gen Hosp, Med Ctr 3, Beijing, Peoples R China; [Li, Wenhui] Peking Union Med Coll Hosp, Beijing, Peoples R China; [Yu, Xuefeng] HUST, Tongji Med Coll, Tongji Hosp, Wuhan, Peoples R China; [Qin, Guijun] Zhengzhou Univ, Affiliated Hosp, Zhengzhou, Peoples R China; [Yang, Zhou] Jiangxi Pingxiang Peoples Hosp, Pingxiang, Peoples R China; [Su, Benli] Dalian Med Univ, Hosp 2, Dalian, Peoples R China; [Zeng, Longyi] Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou, Peoples R China; [Geng, Houfa] Xuzhou Cent Hosp, Xuzhou, Jiangsu, Peoples R China; [Shi, Yongquan] Shanghai Changzheng Hosp, Shanghai, Peoples R China; [Zhao, Yu; Zhang, Yi; Chen, Li] Hua Med, Shanghai, Peoples R China; [Yang, Wenying] China Japan Friendship Hosp, Beijing, Peoples R China	Nanjing University; Fudan University; Yangtze University; Shandong First Medical University & Shandong Academy of Medical Sciences; Shanxi Medical University; Jilin University; Hubei University of Medicine; Tongji University; Anhui Medical University; Nanjing Medical University; Jiangnan University; Jilin University; Jiangsu University; Sichuan University; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences; Qingdao University; Guizhou Medical University; Southern Medical University - China; Henan University of Science & Technology; Henan University of Science & Technology; Hainan Medical University; Chongqing University; Tianjin Medical University; Chinese People's Liberation Army General Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; Huazhong University of Science & Technology; Zhengzhou University; Dalian Medical University; Sun Yat Sen University; Naval Medical University; China-Japan Friendship Hospital	Zhu, DL (corresponding author), Nanjing Univ, Affiliated Drum Tower Hosp, Sch Med, Nanjing, Peoples R China.; Chen, L (corresponding author), Hua Med, Shanghai, Peoples R China.; Yang, WY (corresponding author), China Japan Friendship Hosp, Beijing, Peoples R China.	zhudalong@nju.edu.cn; ywying_1010@126.com; lichen@huamedicine.com	Li, yu/HHZ-5236-2022	JIANG, HONGWEI/0000-0003-3807-7989; Li, Xiaoying/0000-0002-9383-5757	Hua Medicine - Hua Medicine; National Major Scientific and Technological Special Project for Significant New Drug Development [2014ZX09101002004, 2018ZX09711002-012-001]; Shanghai Science and Technology Innovation Action Project [14431908300, 15XD1520500, 17DZ1910200, 19431905200]; Shanghai Pudong District Science and Technology Innovation Action Project [PKJ2014-S06]; Shanghai Municipal Commission of Economy and Informatization Innovation Action Project [XC-ZXSJ-01-2015-02, 18XI-18]	Hua Medicine - Hua Medicine; National Major Scientific and Technological Special Project for Significant New Drug Development; Shanghai Science and Technology Innovation Action Project; Shanghai Pudong District Science and Technology Innovation Action Project; Shanghai Municipal Commission of Economy and Informatization Innovation Action Project	This study was sponsored by Hua Medicine. We thank J. Chen for medical writing and editing support, funded by Hua Medicine; L. Li, C. Geng and L. Yuan (Hua Medicine) for assistance with the efficacy data; A. Wang (Hua Medicine) for assistance with the safety data; X. Liu (Hua Medicine) for assistance with the statistical analyses; and G. Yu and F. Tang, who reviewed an earlier version of the manuscript on behalf of Hua Medicine. Hua Medicine participated in the design, conduct and data analysis and interpretation of the clinical study, the preparation of the manuscript, and were involved in making the decision to publish. The study was also funded in part, by grants from the National Major Scientific and Technological Special Project for Significant New Drug Development (2014ZX09101002004 and 2018ZX09711002-012-001), the Shanghai Science and Technology Innovation Action Project (14431908300, 15XD1520500, 17DZ1910200 and 19431905200), the Shanghai Pudong District Science and Technology Innovation Action Project (PKJ2014-S06) and the Shanghai Municipal Commission of Economy and Informatization Innovation Action Project (XC-ZXSJ-01-2015-02 and 18XI-18).	Agius L, 2008, BIOCHEM J, V414, P1, DOI 10.1042/BJ20080595; Agius L, 2009, DIABETES, V58, P18, DOI 10.2337/db08-1470; Amin NB, 2015, DIABETES OBES METAB, V17, P751, DOI 10.1111/dom.12474; Atlas D., 2015, IDF DIABETES ATLAS, V7th; Basco D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03034-0; Basu A, 2000, DIABETES, V49, P272, DOI 10.2337/diabetes.49.2.272; Basu A, 2001, DIABETES, V50, P1351, DOI 10.2337/diabetes.50.6.1351; Basu A, 2009, DIABETES CARE, V32, P866, DOI 10.2337/dc08-1826; Chen L., 2016, PROG PHARM SCI, V40, P161; Chen L, 2021, DIABETES, V70, DOI 10.2337/db21-117-LB; Chen L, 2019, DIABETES, V68, DOI 10.2337/db19-1151-P; 中华医学会糖尿病学分会, 2021, [中华糖尿病杂志, Chinese Journal of Diabetes Mellitus], V13, P315; Davis EA, 1999, DIABETOLOGIA, V42, P1175, DOI 10.1007/s001250051289; DAWN Study Group, NAT MED, V2022; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; Denney WS, 2016, CLIN PHARM DRUG DEV, V5, P517, DOI 10.1002/cpdd.261; Eiki J, 2011, MOL PHARMACOL, V80, P1156, DOI 10.1124/mol.111.074401; Ericsson H, 2012, INT J CLIN PHARM TH, V50, P765, DOI 10.5414/CP201747; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; Glaser B, 1998, NEW ENGL J MED, V338, P226, DOI 10.1056/NEJM199801223380404; Grimsby J, 2003, SCIENCE, V301, P370, DOI 10.1126/science.1084073; Haeusler RA, 2015, MOL METAB, V4, P222, DOI 10.1016/j.molmet.2014.12.007; Heimberg H, 1996, P NATL ACAD SCI USA, V93, P7036, DOI 10.1073/pnas.93.14.7036; Jiang MH, 2008, DIABETOLOGIA, V51, P1525, DOI 10.1007/s00125-008-1034-8; Kahn SE, 2001, J CLIN ENDOCR METAB, V86, P5824, DOI 10.1210/jc.86.12.5824; Katz L, 2016, DIABETES OBES METAB, V18, P191, DOI 10.1111/dom.12586; Kiyosue A, 2013, DIABETES OBES METAB, V15, P923, DOI 10.1111/dom.12100; Klein KR, 2021, DIABETES CARE, V44, P960, DOI 10.2337/dc20-2684; Li CH, 2013, J BIOL CHEM, V288, P3938, DOI 10.1074/jbc.M112.385682; Mather KJ, 2019, DIABETES CARE, V42, P1742, DOI 10.2337/dc19-0556; MATSCHIN.FM, 1968, J BIOL CHEM, V243, P2730; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; Matschinsky FM, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00148; Matschinsky FM, 2009, NAT REV DRUG DISCOV, V8, P399, DOI 10.1038/nrd2850; Matschinsky Franz M, 2005, Curr Diab Rep, V5, P171, DOI 10.1007/s11892-005-0005-4; McCafferty K, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2021-049650; MedDRA Maintenance and Support Services Organization, 2020, INTRO GUIDE MEDDRA V; Meininger GE, 2011, DIABETES CARE, V34, P2560, DOI 10.2337/dc11-1200; Miao J, 2022, CTS-CLIN TRANSL SCI, V15, P548, DOI 10.1111/cts.13174; Moede T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-76863-z; Pino MF, 2007, J BIOL CHEM, V282, P13906, DOI 10.1074/jbc.M610094200; Raimondo A, 2014, HUM MOL GENET, V23, P6432, DOI 10.1093/hmg/ddu360; Rizza RA, 2010, DIABETES, V59, P2697, DOI 10.2337/db10-1032; Sarabu R, 2012, J MED CHEM, V55, P7021, DOI 10.1021/jm3008689; Scheen AJ, 2018, LANCET DIABETES ENDO, V6, P591, DOI 10.1016/S2213-8587(18)30133-5; Schwartz SS, 2016, DIABETES CARE, V39, P179, DOI 10.2337/dc15-1585; Vella A, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau3441; Wajchenberg BL, 2007, ENDOCR REV, V28, P187, DOI 10.1210/er.2006-0038; Wang LM, 2017, JAMA-J AM MED ASSOC, V317, P2515, DOI 10.1001/jama.2017.7596; Wang P, 2017, J DIABETES RES, V2017, DOI 10.1155/2017/5812607; Wilding JPH, 2013, DIABETES OBES METAB, V15, P750, DOI 10.1111/dom.12088; Xu HR, 2016, DRUG DES DEV THER, V10, P1619, DOI 10.2147/DDDT.S105021; Zhai S, 2016, CLIN PHARM DRUG DEV, V5, P552, DOI 10.1002/cpdd.276; Zheng S, 2020, CLIN DRUG INVEST, V40, P1155, DOI 10.1007/s40261-020-00971-x; Zhi J, 2008, DIABETOLOGIA, V51, pS23; Zhi JG, 2016, J CLIN PHARMACOL, V56, DOI 10.1002/jcph.589; Zhu D. L, 2015, DIABETES, DOI [10.2337/db15-932-1471, DOI 10.2337/DB15-932-1471]; Zhu DL, 2018, LANCET DIABETES ENDO, V6, P627, DOI 10.1016/S2213-8587(18)30105-0; Zhu XX, 2018, DIABETES OBES METAB, V20, P2113, DOI 10.1111/dom.13338	59	2	3	33	43	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2022	28	5					965	+		10.1038/s41591-022-01802-6	http://dx.doi.org/10.1038/s41591-022-01802-6		MAY 2022	20	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	1J3AM	35551294	Bronze, Green Submitted			2022-12-27	WOS:000794108200003
J	Neri, D; Carnemolla, B; Nissim, A; Leprini, A; Querze, G; Balza, E; Pini, A; Tarli, L; Halin, C; Neri, P; Zardi, L; Winter, G				Neri, D; Carnemolla, B; Nissim, A; Leprini, A; Querze, G; Balza, E; Pini, A; Tarli, L; Halin, C; Neri, P; Zardi, L; Winter, G			Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform	NATURE BIOTECHNOLOGY			English	Article						antibody engineering; single-chain antibody; oncofetal protein	SINGLE-CHAIN FV; ESCHERICHIA-COLI; FILAMENTOUS PHAGE; MESSENGER-RNA; PROTEINS; IMMUNIZATION; INVOLVEMENT; TECHNOLOGY; LIBRARY; SURFACE	The oncofetal fibronectin (B-FN) isoform is present in vessels of neoplastic tissues during angiogenesis but not in mature vessels, B-FN could therefore provide a target for diagnostic imaging and therapy of cancer, Phage display libraries have been used to isolate human antibody fragments with pan-species recognition of this isoform, We describe the use of these fragments in nude mice to target an aggressive tumor (grafted Fg murine teratocarcinoma). Imaging in real time was done by infrared photodetection of a chemically coupled fluorophore, The targeting was improved by use of affinity-matured fragments with law kinetic dissociation rates (k(off)=1.5x10(-4) s(-1)) and also by engineering dimeric fragments via a C-terminal amphipathic helix.	Univ Cambridge, Ctr Mrc, Cambridge Ctr Prot Engn, Cambridge CB2 2QH, England; ETH Honggerberg, Inst Mol Biol & Biophys, CH-8093 Zurich, Switzerland; Ist Nazl Ric Canc, Lab Biol Cellulare, I-16132 Genoa, Italy; Univ Siena, Dipartimento Biol Mol, Ctr Didatt Loc Scotte, I-53100 Siena, Italy	University of Cambridge; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Genoa; IRCCS AOU San Martino IST; University of Siena	Neri, D (corresponding author), Univ Cambridge, Ctr Mrc, Cambridge Ctr Prot Engn, Hills Rd, Cambridge CB2 2QH, England.		Neri, Dario/P-4368-2016; Pini, Alessandro/R-1359-2018	Neri, Dario/0000-0001-5234-7370; Pini, Alessandro/0000-0002-3832-8349; Halin, Cornelia/0000-0002-7899-2850				ADAMS GP, 1993, CANCER RES, V53, P4026; Begent RHJ, 1996, NAT MED, V2, P979, DOI 10.1038/nm0996-979; BENNETT VD, 1991, J BIOL CHEM, V266, P5918; Berkower I, 1996, CURR OPIN BIOTECH, V7, P622, DOI 10.1016/S0958-1669(96)80073-5; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; CARNEMOLLA B, 1989, J CELL BIOL, V108, P1139, DOI 10.1083/jcb.108.3.1139; Carnemolla B, 1996, INT J CANCER, V68, P397, DOI 10.1002/(SICI)1097-0215(19961104)68:3<397::AID-IJC20>3.3.CO;2-D; CARTER P, 1992, BIO-TECHNOL, V10, P163, DOI 10.1038/nbt0292-163; CASEY JL, 1995, J IMMUNOL METHODS, V179, P105, DOI 10.1016/0022-1759(94)00278-5; CASTELLANI P, 1994, INT J CANCER, V59, P612, DOI 10.1002/ijc.2910590507; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLLI S, 1994, CANCER RES, V54, P2643; Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764; GEORGE AJT, 1995, P NATL ACAD SCI USA, V92, P8358, DOI 10.1073/pnas.92.18.8358; Gibson T., 1984, THESIS U CAMBRIDGE C; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; Hu SZ, 1996, CANCER RES, V56, P3055; HUANG H, 1997, SCIENCE, V275, P547; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KING DJ, 1994, CANCER RES, V54, P6176; LIBERATORE M, 1995, EUR J NUCL MED, V22, P1326, DOI 10.1007/BF00801622; Low NM, 1996, J MOL BIOL, V260, P359, DOI 10.1006/jmbi.1996.0406; MALONEY DG, 1994, BLOOD, V84, P2457; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; MARKS JD, 1992, BIO-TECHNOL, V10, P779, DOI 10.1038/nbt0792-779; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; Neri D, 1996, BIOTECHNIQUES, V20, P708; NERI D, 1996, NAT BIOTECHNOL, V14, P385; NERI D, 1997, IN PRESS THERAPY MAL; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; PACK P, 1993, BIO-TECHNOL, V11, P1271; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542; Peters JH, 1996, CELL ADHES COMMUN, V4, P127, DOI 10.3109/15419069609010767; PRESS OW, 1995, LANCET, V346, P336, DOI 10.1016/S0140-6736(95)92225-3; RISAU W, 1988, DEV BIOL, V125, P441, DOI 10.1016/0012-1606(88)90225-4; RIVA P, 1994, CANCER-AM CANCER SOC, V73, P1076, DOI 10.1002/1097-0142(19940201)73:3+<1076::AID-CNCR2820731347>3.0.CO;2-Z; SCHNEIDERGADICKE E, 1995, EUR J CANCER, V31A, P1326, DOI 10.1016/0959-8049(95)00279-R; VANDENHOOFF A, 1988, ADV CANCER RES, V50, P159, DOI 10.1016/S0065-230X(08)60437-6; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; YOKOTA T, 1992, CANCER RES, V52, P3402	46	247	295	0	16	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1997	15	12					1271	1275		10.1038/nbt1197-1271	http://dx.doi.org/10.1038/nbt1197-1271			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YQ046	9359110				2022-12-27	WOS:000071342000029
J	Varley, AW; Geiszler, SM; Gaynor, RB; Munford, RS				Varley, AW; Geiszler, SM; Gaynor, RB; Munford, RS			A two-component expression system that responds to inflammatory stimuli in vivo	NATURE BIOTECHNOLOGY			English	Article						gene therapy; inflammatory response; acute phase response	TUMOR-NECROSIS-FACTOR; ADENOVIRUS-MEDIATED TRANSFER; GENE-EXPRESSION; TAT PROTEIN; MICE; ACTIVATION; BLOCKADE; THERAPY	A therapeutic dilemma often complicates the management of inflammatory diseases; the benefits gained from reducing inflammation must be balanced against the potentially harmful consequences of chronic immunosuppression. Gene therapy might address this dilemma by producing anti-inflammatory proteins in response to a patient's endogenous signals, so that recombinant drug production is linked to the intensity and duration of the inflammatory condition. To test this, we have developed inflammation-inducible systems for regulating recombinant protein production in vivo. We describe a two-component expression construct in which (1) the murine complement factor 3 (C3) promoter regulates production of the human immunodeficiency virus (HIV) transactivator of transcription (Tat), and (2) the Tat protein then stimulates protein expression from genes inserted downstream of the the HIV promoter. When incorporated into a nonreplicating adenovirus (Ad.CS-tat/HIV-luc) and studied in a murine model, the construct produces large amounts of recombinant protein in vivo in response to two different inflammatory stimuli.	UNIV TEXAS,SW MED CTR,MOL HOST DEF LAB,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DIV MOL VIROL,DEPT INTERNAL MED,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIAID NIH HHS [AI38596] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038596] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Brigham K L, 1995, New Horiz, V3, P321; CONARY JT, 1994, J CLIN INVEST, V93, P1834, DOI 10.1172/JCI117169; Coulthard MG, 1996, INFECT IMMUN, V64, P1510, DOI 10.1128/IAI.64.5.1510-1515.1996; Fantuzzi G, 1996, J LEUKOCYTE BIOL, V59, P489, DOI 10.1002/jlb.59.4.489; GARCIA JA, 1987, EMBO J, V6, P3761, DOI 10.1002/j.1460-2075.1987.tb02711.x; GERARD RD, 1995, DNA CLONING PRACTICA, P285; Greenberger MJ, 1996, J IMMUNOL, V157, P3006; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HUARD J, 1995, GENE THER, V2, P107; KAWAMURA N, 1992, BIOCHEM J, V283, P705, DOI 10.1042/bj2830705; KOLLS J, 1994, P NATL ACAD SCI USA, V91, P215, DOI 10.1073/pnas.91.1.215; KOLLS JK, 1995, J INFECT DIS, V171, P570, DOI 10.1093/infdis/171.3.570; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Ott M, 1997, SCIENCE, V275, P1481, DOI 10.1126/science.275.5305.1481; OU SHI, 1995, RETROVIRIDAE, V4, P97; ROGY MA, 1995, J EXP MED, V181, P2289, DOI 10.1084/jem.181.6.2289; SALKOWSKI CA, 1995, J IMMUNOL, V155, P3168; SCALA G, 1994, J EXP MED, V179, P961, DOI 10.1084/jem.179.3.961; Tripathy SK, 1996, NAT MED, V2, P545, DOI 10.1038/nm0596-545; VARLEY AW, 1995, P NATL ACAD SCI USA, V92, P5346, DOI 10.1073/pnas.92.12.5346; Verhoef K, 1996, VIROLOGY, V225, P316, DOI 10.1006/viro.1996.0606; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; Worgall S, 1997, HUM GENE THER, V8, P37, DOI 10.1089/hum.1997.8.1-37; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407	25	31	32	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1997	15	10					1002	1006		10.1038/nbt1097-1002	http://dx.doi.org/10.1038/nbt1097-1002			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XZ285	9335054				2022-12-27	WOS:A1997XZ28500033
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			World Wide Web sites in biotechnology	NATURE BIOTECHNOLOGY			English	Editorial Material									MASSACHUSETTS GEN HOSP, DEPT MED, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital									0	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1997	15	5					475	475						1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WX237	9131630				2022-12-27	WOS:A1997WX23700035
J	Gbewonyo, K				Gbewonyo, K			The case for commercial biotechnology in sub-Saharan Africa - Agriculture is just one of many opportunities for biotechnology in Africa.	NATURE BIOTECHNOLOGY			English	Article																		BOYE G, 1990, EC MED PLANT RES, V4, P27; COHEN JI, 1989, TRENDS BIOTECHNOL, V7, P295, DOI 10.1016/0167-7799(89)90111-X; DEW DW, 1993, GENMINS COMMERCIALIZ, P229; *E LILL PRESS REL, 1995, JOINT CORP ED VENT I; GBEWONYO K, 1995, WORLD J MICROB BIOT, V11, P251, DOI 10.1007/BF00367093; GBEWONYO K, 1994, CONSERVATION PLANT G, V2, P245; Guillet P., 1990, Bacterial control of mosquitoes & black flies: biochemistry, genetics & applications of Bacillus thuringiensis israelensis and Bacillus sphaericus., P187; HOUGARD JM, 1992, PARASITOL TODAY, V8, P364, DOI 10.1016/0169-4758(92)90168-2; KURTAK D, 1989, Israel Journal of Entomology, V23, P21; RAWLINGS DE, 1995, BIO-TECHNOL, V13, P773, DOI 10.1038/nbt0895-773; TOENNIESSEN GH, 1995, TRENDS BIOTECHNOL, V13, P404, DOI 10.1016/S0167-7799(00)88989-1; *WORLD BANK, 1993, WORLD DEV REP 1993, P208	12	1	1	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1997	15	4					325	327		10.1038/nbt0497-325	http://dx.doi.org/10.1038/nbt0497-325			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WQ554	9094131				2022-12-27	WOS:A1997WQ55400030
J	Sezonov, G; Blanc, V; BamasJacques, N; Friedmann, A; Pernodet, JL; Guerineau, M				Sezonov, G; Blanc, V; BamasJacques, N; Friedmann, A; Pernodet, JL; Guerineau, M			Complete conversion of antibiotic precursor to pristinamycin IIA by overexpression of Streptomyces pristinaespiralis biosynthetic genes	NATURE BIOTECHNOLOGY			English	Article						pristinamycin; pSAM2; Streptomyces pristinaespiralis	SITE-SPECIFIC INTEGRATION; PLASMID PSAM2; ELEMENT PSAM2; RP 59500; HYBRID ANTIBIOTICS; COELICOLOR A3(2); AMBOFACIENS; CLONING; REPLICATION; MECHANISM	A Streptomyces pristinaespiralis strain, which produces a streptogramin antibiotic pristinamycin II (PII) as a mixture of two biologically active molecules PIIB and Pll(A) was genetically engineered to produce exclusively PIIA. The snaA,B genes, which encode a PIIA synthase that performs oxidation of the precursor (PIIB) to the final product (PIIA), were integrated in the chromosome of S. pristinaespiralis using an integrative derivative of the pSAM2 genetic element from Streptomyces ambofaciens. Integration was due to site-specific recombination at the attB site of S. pristinaespiralis, and no homologous recombination at the snaA,B locus was observed. The attB site of S. pristinaespiralis was sequenced and found to overlap the 3' end of a pro-tRNA gene. The integrants were stable in industrial conditions of pristinamycin production and showed no decrease in PII biosynthesis. Western blot analysis showed a constant production of the PIIA synthase in the overall fermentation process due to expression of the cloned snaA,B genes from the constitutive ermE* promoter. This allows the complete conversion of the PIIB form into PIIA.	RHONE POULENC RORER SA,CTR RECH VITRY ALFORTVILLE,MOL BIOL UNIT,F-94403 VITRY SUR SEINE,FRANCE	Sanofi-Aventis; Sanofi France	Sezonov, G (corresponding author), UNIV PARIS 11,LAB BIOL & GENET MOL,INST MICROBIOL & GENET,CNRS,URA 2225,BATIMENT 400,F-91405 ORSAY,FRANCE.		Sezonov, Guennadi/ABB-5734-2020; Pernodet, Jean-Luc/A-4074-2015	Sezonov, Guennadi/0000-0002-2016-6126; Pernodet, Jean-Luc/0000-0002-6129-7093				ALEGRE MT, 1994, APPL ENVIRON MICROB, V60, P4279, DOI 10.1128/AEM.60.12.4279-4283.1994; Alvarez MA, 1996, NAT BIOTECHNOL, V14, P335, DOI 10.1038/nbt0396-335; AUMERCIER M, 1992, J ANTIMICROB CHEMOTH, V30, P9, DOI 10.1093/jac/30.suppl_A.9; BARRIERE JC, 1992, J ANTIMICROB CHEMOTH, V30, P1; BIBB MJ, 1986, GENE, V41, pE357, DOI 10.1016/0378-1119(86)90122-8; BIBB MJ, 1994, MOL MICROBIOL, V14, P533, DOI 10.1111/j.1365-2958.1994.tb02187.x; BLANC V, 1995, J BACTERIOL, V177, P5206, DOI 10.1128/jb.177.18.5206-5214.1995; BLANC V, 1995, MOL MICROBIOL, V17, P989, DOI 10.1111/j.1365-2958.1995.mmi_17050989.x; BOCCARD F, 1989, EMBO J, V8, P973, DOI 10.1002/j.1460-2075.1989.tb03460.x; BOCCARD F, 1989, PLASMID, V21, P59, DOI 10.1016/0147-619X(89)90087-5; BOCCARD F, 1988, MOL GEN GENET, V212, P432, DOI 10.1007/BF00330847; COCITO C, 1985, J ANTIMICROB CHEMOTH, V16, P35, DOI 10.1093/jac/16.suppl_A.35; COCITO C, 1979, MICROBIOL REV, V43, P145, DOI 10.1128/MMBR.43.2.145-192.1979; COX KL, 1990, J CELL BIOCH A S, V14; GRAMAJO HC, 1993, MOL MICROBIOL, V7, P837, DOI 10.1111/j.1365-2958.1993.tb01174.x; HAGEGE J, 1993, J BACTERIOL, V175, P5529; HAGEGE J, 1993, MOL MICROBIOL, V10, P799, DOI 10.1111/j.1365-2958.1993.tb00950.x; HAGEGE J, 1994, PLASMID, V31, P166, DOI 10.1006/plas.1994.1018; Hopwood D. A., 1985, GENETIC MANIPULATION; HOPWOOD DA, 1985, NATURE, V314, P642, DOI 10.1038/314642a0; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; KAY R, 1987, NUCLEIC ACIDS RES, V15, P2778, DOI 10.1093/nar/15.6.2778; KUHSTOSS S, 1989, J BACTERIOL, V171, P16, DOI 10.1128/jb.171.1.16-23.1989; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAZODIER P, 1990, MOL GEN GENET, V222, P431, DOI 10.1007/BF00633850; MCDANIEL R, 1995, NATURE, V375, P549, DOI 10.1038/375549a0; PERNODET JL, 1984, MOL GEN GENET, V198, P35, DOI 10.1007/BF00328697; Preud'homme J, 1968, Bull Soc Chim Fr, V2, P585; PREUDHOM.J, 1965, CR HEBD ACAD SCI, V260, P1309; SALAHBEY K, 1995, MOL MICROBIOL, V17, P1001, DOI 10.1111/j.1365-2958.1995.mmi_17051001.x; Sambrook J., 2002, MOL CLONING LAB MANU; SEZONOV G, 1995, MOL MICROBIOL, V17, P533, DOI 10.1111/j.1365-2958.1995.mmi_17030533.x; SEZONOV G, 1995, BIOTECHNOLOGIA, V7, P80; SMOKVINA T, 1990, GENE, V94, P53, DOI 10.1016/0378-1119(90)90467-6; SMOKVINA T, 1991, PLASMID, V25, P40, DOI 10.1016/0147-619X(91)90005-H; SMOKVINA T, 1990, THESIS U PARIS SUD; SOUSSY CJ, 1992, J ANTIMICROB CHEMOTH, V30, P53, DOI 10.1093/jac/30.suppl_A.53; TAKANO E, 1992, MOL MICROBIOL, V6, P2797, DOI 10.1111/j.1365-2958.1992.tb01459.x; THIBAUT D, 1995, J BACTERIOL, V177, P5199, DOI 10.1128/jb.177.18.5199-5205.1995; THOMAS DI, 1991, J GEN MICROBIOL, V137, P2331, DOI 10.1099/00221287-137-10-2331; THOMPSON CJ, 1980, NATURE, V286, P525, DOI 10.1038/286525a0; VALLINS WJS, 1985, J GEN MICROBIOL, V131, P1657; VAZQUEZ D, 1975, ANTIBIOTICS, V3, P521	43	33	38	1	11	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1997	15	4					349	353		10.1038/nbt0497-349	http://dx.doi.org/10.1038/nbt0497-349			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WQ554	9094136				2022-12-27	WOS:A1997WQ55400035
J	Hoban, TJ				Hoban, TJ			Consumer acceptance of biotechnology: An international perspective	NATURE BIOTECHNOLOGY			English	Article											Hoban, TJ (corresponding author), N CAROLINA STATE UNIV,DEPT SOCIOL & ANTHROPOL,RALEIGH,NC 27695, USA.							*FOOD MARK I, 1995, TRENDS US CONS ATT S; *FOOD MARK I, 1995, TRENDS EUR CONS ATT; *FOOD MARK I, 1996, TRENDS US CONS ATT S; HOBAN T, 1994, CONSUMER AWARENESS A; Hoban T. J., 1996, Journal of Food Distribution Research, V27, P1; Hoban T. J., 1993, CONSUMER ATTITUDES F; Hoban TJ, 1996, FOOD TECHNOL-CHICAGO, V50, P85; *US OFF TECHN ASS, 1987, NEW DIR BIOT PUBL PE	8	89	93	0	11	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1997	15	3					232	234		10.1038/nbt0397-232	http://dx.doi.org/10.1038/nbt0397-232			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WM050	9062920				2022-12-27	WOS:A1997WM05000024
J	Zaeck, LM; Lamers, MM; Verstrepen, BE; Bestebroer, TM; van Royen, ME; Gotz, H; Shamier, MC; van Leeuwen, LPM; Schmitz, KS; Alblas, K; van Efferen, S; Bogers, S; Scherbeijn, S; Rimmelzwaan, GF; van Gorp, ECM; Koopmans, MPG; Haagmans, BL; GeurtsvanKessel, CH; de Vries, RD				Zaeck, Luca M.; Lamers, Mart M.; Verstrepen, Babs E.; Bestebroer, Theo M.; van Royen, Martin E.; Gotz, Hannelore; Shamier, Marc C.; van Leeuwen, Leanne P. M.; Schmitz, Katharina S.; Alblas, Kimberley; van Efferen, Suzanne; Bogers, Susanne; Scherbeijn, Sandra; Rimmelzwaan, Guus F.; van Gorp, Eric C. M.; Koopmans, Marion P. G.; Haagmans, Bart L.; GeurtsvanKessel, Corine H.; de Vries, Rory D.			Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals	NATURE MEDICINE			English	Article; Early Access							MODIFIED-VACCINIA-VIRUS; SMALLPOX VACCINE; ANKARA; PROTECTION; IMMUNITY; IMMUNOGENICITY; CHALLENGE	In July 2022, the ongoing monkeypox (MPX) outbreak was declared a public health emergency of international concern. Modified vaccinia Ankara-Bavarian Nordic (MVA-BN, also known as Imvamune, JYNNEOS or Imvanex) is a third-generation smallpox vaccine that is authorized and in use as a vaccine against MPX. To date, there are no data showing MPX virus (MPXV)-neutralizing antibodies in vaccinated individuals nor vaccine efficacy against MPX. Here we show that MPXV-neutralizing antibodies can be detected after MPXV infection and after historic smallpox vaccination. However, a two-shot MVA-BN immunization series in non-primed individuals yields relatively low levels of MPXV-neutralizing antibodies. Dose-sparing of an MVA-based influenza vaccine leads to lower MPXV-neutralizing antibody levels, whereas a third vaccination with the same MVA-based vaccine significantly boosts the antibody response. As the role of MPXV-neutralizing antibodies as a correlate of protection against disease and transmissibility is currently unclear, we conclude that cohort studies following vaccinated individuals are necessary to assess vaccine efficacy in at-risk populations. Historic smallpox vaccination and monkeypox virus (MPXV) infection elicit MPXV-neutralizing antibodies, but MPXV-neutralizing antibodies are less frequent and of lower magnitude after vaccination with MVA-BN-the vaccine approved and in use for protection against MPXV and smallpox.	[Zaeck, Luca M.; Lamers, Mart M.; Verstrepen, Babs E.; Bestebroer, Theo M.; Shamier, Marc C.; van Leeuwen, Leanne P. M.; Schmitz, Katharina S.; Alblas, Kimberley; van Efferen, Suzanne; Bogers, Susanne; Scherbeijn, Sandra; van Gorp, Eric C. M.; Koopmans, Marion P. G.; Haagmans, Bart L.; GeurtsvanKessel, Corine H.; de Vries, Rory D.] Erasmus MC, Dept Virosci, Rotterdam, Netherlands; [van Royen, Martin E.] Erasmus MC, Dept Pathol, Rotterdam, Netherlands; [Gotz, Hannelore] Municipal Publ Hlth Serv Rotterdam Rijnmond GGD R, Dept Infect Dis Control, Rotterdam, Netherlands; [Rimmelzwaan, Guus F.] Univ Vet Med Hannover, Res Ctr Emerging Infect & Zoonoses, Hannover, Germany	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; University of Veterinary Medicine Hannover, Foundation	GeurtsvanKessel, CH (corresponding author), Erasmus MC, Dept Virosci, Rotterdam, Netherlands.	c.geurtsvankessel@erasmusmc.nl	de Vries, Rory D/L-2264-2015; Zaeck, Luca M./AAO-4958-2020; Haagmans, Bart/E-9791-2015; Shamier, Marc/ABF-4002-2021	de Vries, Rory D/0000-0003-2817-0127; Zaeck, Luca M./0000-0001-7997-493X; Haagmans, Bart/0000-0001-6221-2015; Shamier, Marc/0000-0002-3421-6833; van Royen, Martin/0000-0002-6814-0996; Schmitz, Katharina S./0000-0002-8537-0646; Verstrepen, Babs E/0000-0002-4666-0798	European Union [965313, 874735]	European Union(European Commission)	We acknowledge Bas Oude Munnink for sequence analysis of the MPXV clinical material. This work was partially funded by the European Union's Horizon 2020 Grant for ECRAID-Base (grant agreement no. 965313; awarded to M.P.G.K.), in preparation for possible clinical studies and trials after the decision to activate Ecraid to outbreak mode 2. The sequencing work was supported by the European Union's Horizon 2020 Grant VEO (grant no. 874735 awarded to M.P.G.K.). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Earl PL, 2008, P NATL ACAD SCI USA, V105, P10889, DOI 10.1073/pnas.0804985105; Earl PL, 2004, NATURE, V428, P182, DOI 10.1038/nature02331; Edghill-Smith Y, 2005, NAT MED, V11, P740, DOI 10.1038/nm1261; Hammarlund E, 2005, NAT MED, V11, P1005, DOI 10.1038/nm1273; JEZEK Z, 1988, B WORLD HEALTH ORGAN, V66, P465; Kreijtz JHCM, 2014, LANCET INFECT DIS, V14, P1196, DOI [10.1016/s1473-3099(14)70963-6, 10.1016/S1473-3099(14)70963-6]; Kremer Melanie, 2012, Methods Mol Biol, V890, P59, DOI 10.1007/978-1-61779-876-4_4; Kupferschmidt K, 2022, SCIENCE, V377, P696, DOI 10.1126/science.ade3371; Manischewitz J, 2003, J INFECT DIS, V188, P440, DOI 10.1086/376557; MEYER H, 1991, J GEN VIROL, V72, P1031, DOI 10.1099/0022-1317-72-5-1031; Paran N, 2009, HUM VACCINES, V5, P824, DOI 10.4161/hv.10295; Pittman PR, 2019, NEW ENGL J MED, V381, P1897, DOI 10.1056/NEJMoa1817307; Smith GL, 2002, J GEN VIROL, V83, P2915, DOI 10.1099/0022-1317-83-12-2915; Stittelaar KJ, 2005, J VIROL, V79, P7845, DOI 10.1128/JVI.79.12.7845-7851.2005; Taub DD, 2008, AM J MED, V121, P1058, DOI 10.1016/j.amjmed.2008.08.019; Thornhill JP, 2022, LANCET NEUROL, V21, P872, DOI 10.1056/NEJMoa2207323; Townsend MB, 2013, J VIROL, V87, P900, DOI 10.1128/JVI.02089-12; Volz A, 2017, ADV VIRUS RES, V97, P187, DOI 10.1016/bs.aivir.2016.07.001; Wenham Clare, 2023, Lancet, V400, P2169, DOI 10.1016/S0140-6736(22)01437-4	19	1	1	1	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02090-w	http://dx.doi.org/10.1038/s41591-022-02090-w		OCT 2022	25	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	6A2QO	36257333	hybrid, Green Submitted			2022-12-27	WOS:000880503800001
J	Dai, XC; Gil, GF; Reitsma, MB; Ahmad, NS; Anderson, JA; Bisignano, C; Carr, S; Feldman, R; Hay, SI; He, JW; Iannucci, V; Lawlor, HR; Malloy, MJ; Marczak, LB; McLaughlin, SA; Morikawa, L; Mullany, EC; Nicholson, SI; O'Connell, EM; Okereke, C; Sorensen, RJD; Whisnant, J; Aravkin, AY; Zheng, P; Murray, CJL; Gakidou, E				Dai, Xiaochen; Gil, Gabriela F.; Reitsma, Marissa B.; Ahmad, Noah S.; Anderson, Jason A.; Bisignano, Catherine; Carr, Sinclair; Feldman, Rachel; Hay, Simon, I; He, Jiawei; Iannucci, Vincent; Lawlor, Hilary R.; Malloy, Matthew J.; Marczak, Laurie B.; McLaughlin, Susan A.; Morikawa, Larissa; Mullany, Erin C.; Nicholson, Sneha, I; O'Connell, Erin M.; Okereke, Chukwuma; Sorensen, Reed J. D.; Whisnant, Joanna; Aravkin, Aleksandr Y.; Zheng, Peng; Murray, Christopher J. L.; Gakidou, Emmanuela			Health effects associated with smoking: a Burden of Proof study	NATURE MEDICINE			English	Article; Early Access							TYPE-2 DIABETES-MELLITUS; FATAL PROSTATE-CANCER; MIDDLE-AGED JAPANESE; OBSTRUCTIVE PULMONARY-DISEASE; OCCUPATIONAL RISK-FACTORS; CORONARY-HEART-DISEASE; SITE-SPECIFIC CANCER; LIFE-STYLE FACTORS; LUNG-CANCER; CIGARETTE-SMOKING	As a leading behavioral risk factor for numerous health outcomes, smoking is a major ongoing public health challenge. Although evidence on the health effects of smoking has been widely reported, few attempts have evaluated the dose-response relationship between smoking and a diverse range of health outcomes systematically and comprehensively. In the present study, we re-estimated the dose-response relationships between current smoking and 36 health outcomes by conducting systematic reviews up to 31 May 2022, employing a meta-analytic method that incorporates between-study heterogeneity into estimates of uncertainty. Among the 36 selected outcomes, 8 had strong-to-very-strong evidence of an association with smoking, 21 had weak-to-moderate evidence of association and 7 had no evidence of association. By overcoming many of the limitations of traditional meta-analyses, our approach provides comprehensive, up-to-date and easy-to-use estimates of the evidence on the health effects of smoking. These estimates provide important information for tobacco control advocates, policy makers, researchers, physicians, smokers and the public. A meta-analysis using the Burden of proof method reported consistent evidence supporting harmful associations between smoking and 28 different health outcomes.	[Dai, Xiaochen; Gil, Gabriela F.; Reitsma, Marissa B.; Ahmad, Noah S.; Anderson, Jason A.; Bisignano, Catherine; Carr, Sinclair; Feldman, Rachel; Hay, Simon, I; He, Jiawei; Iannucci, Vincent; Lawlor, Hilary R.; Malloy, Matthew J.; Marczak, Laurie B.; McLaughlin, Susan A.; Morikawa, Larissa; Mullany, Erin C.; Nicholson, Sneha, I; O'Connell, Erin M.; Okereke, Chukwuma; Sorensen, Reed J. D.; Whisnant, Joanna; Aravkin, Aleksandr Y.; Zheng, Peng; Murray, Christopher J. L.; Gakidou, Emmanuela] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA; [Dai, Xiaochen; Hay, Simon, I; He, Jiawei; Zheng, Peng; Murray, Christopher J. L.; Gakidou, Emmanuela] Univ Washington, Sch Med, Dept Hlth Metr Sci, Seattle, WA 98195 USA; [Aravkin, Aleksandr Y.] Univ Washington, Dept Appl Math, Seattle, WA 98195 USA	Institute for Health Metrics & Evaluation; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Dai, XC (corresponding author), Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA.; Dai, XC (corresponding author), Univ Washington, Sch Med, Dept Hlth Metr Sci, Seattle, WA 98195 USA.	xdai88@uw.edu	Hay, Simon Iain/F-8967-2015	Hay, Simon Iain/0000-0002-0611-7272; Carr, Sinclair/0000-0003-0421-3145; Dai, Xiaochen/0000-0002-0289-7814	Bill & Melinda Gates Foundation; Bloomberg Philanthropies	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); Bloomberg Philanthropies	Research reported in this publication was supported by the Bill & Melinda Gates Foundation and Bloomberg Philanthropies. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders. The study funders had no role in study design, data collection, data analysis, data interpretation, writing of the final report or the decision to publish.	Abbafati C, 2020, LANCET, V396, P1135, DOI 10.1016/S0140-6736(20)31404-5; Akter S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132166; Ando M, 2003, INT J CANCER, V105, P249, DOI 10.1002/ijc.11043; [Anonymous], 2009, MMWR-MORBID MORTAL W, V58, P1227; Armadans-Gil L, 1999, INT J EPIDEMIOL, V28, P614, DOI 10.1093/ije/28.4.614; Arthur R, 2017, BREAST CANCER RES TR, V165, P623, DOI 10.1007/s10549-017-4347-9; Aune D, 2016, EUR J EPIDEMIOL, V31, P643, DOI 10.1007/s10654-016-0124-z; Bae JM, 2013, J KOREAN MED SCI, V28, P636, DOI 10.3346/jkms.2013.28.4.636; Band PR, 1999, J OCCUP ENVIRON MED, V41, P224, DOI 10.1097/00043764-199904000-00004; Barbone F, 1997, CHEST, V112, P1474, DOI 10.1378/chest.112.6.1474; Barengo NC, 2019, PREV MED REP, V14, DOI 10.1016/j.pmedr.2019.100875; BECHER H, 1991, CANCER CAUSE CONTROL, V2, P381, DOI 10.1007/BF00054298; Bero LA, 1997, ANN INTERN MED, V127, P37, DOI 10.7326/0003-4819-127-1-199707010-00007; Biggerstaff BJ, 1997, STAT MED, V16, P753, DOI 10.1002/(SICI)1097-0258(19970415)16:7<753::AID-SIM494>3.0.CO;2-G; Bjerkaas E, 2013, CANCER CAUSE CONTROL, V24, P1347, DOI 10.1007/s10552-013-0213-1; BMJ Best Practice, 2021, WHAT IS GRADE; Boffetta P, 2011, CANCER CAUSE CONTROL, V22, P73, DOI 10.1007/s10552-010-9676-5; BROCKMOLLER J, 1993, CANCER RES, V53, P1004; BROWNSON RC, 1987, AM J EPIDEMIOL, V125, P25, DOI 10.1093/oxfordjournals.aje.a114509; Butler LM, 2009, CANCER CAUSE CONTROL, V20, P1967, DOI 10.1007/s10552-009-9391-2; Carlsson S, 2004, DIABETOLOGIA, V47, P1953, DOI 10.1007/s00125-004-1554-9; Cascorbi I, 1996, CANCER RES, V56, P3961; Cerhan JR, 1997, CANCER CAUSE CONTROL, V8, P229, DOI 10.1023/A:1018428531619; Chan-Yeung M, 2003, LUNG CANCER-J IASLC, V40, P131, DOI 10.1016/S0169-5002(03)00036-9; Chao H, 2021, TOB INDUC DIS, V19, DOI 10.18332/tid/133704; CHIAZZE L, 1992, BRIT J IND MED, V49, P326; CHU SY, 1990, AM J EPIDEMIOL, V131, P244, DOI 10.1093/oxfordjournals.aje.a115494; CHYOU PH, 1992, AM J PUBLIC HEALTH, V82, P37, DOI 10.2105/AJPH.82.1.37; CHYOU PH, 1993, ARCH ENVIRON HEALTH, V48, P69, DOI 10.1080/00039896.1993.9938396; Conlon MSC, 2010, CANCER EPIDEMIOL, V34, P142, DOI 10.1016/j.canep.2010.02.001; Dai XC, 2022, TOB CONTROL, V31, P129, DOI 10.1136/tobaccocontrol-2021-056535; De Matteis S, 2013, AM J EPIDEMIOL, V177, P601, DOI 10.1093/aje/kws445; Deng XW, 2017, INT J CHRONIC OBSTR, V12, P259, DOI 10.2147/COPD.S116313; DeStefani E, 1996, CANCER EPIDEM BIOMAR, V5, P679; DeStefani E, 1996, CANCER EPIDEM BIOMAR, V5, P515; DeStefani E, 1997, CANCER CAUSE CONTROL, V8, P913, DOI 10.1023/A:1018424614723; Di Cicco ME, 2016, BREATHE, V12, P275, DOI 10.1183/20734735.013416; Dikshit RP, 2000, INT J EPIDEMIOL, V29, P609, DOI 10.1093/ije/29.4.609; Doi Y, 2012, DIABETIC MED, V29, P107, DOI 10.1111/j.1464-5491.2011.03376.x; DOLL R, 1950, BRIT MED J, V2, P739, DOI 10.1136/bmj.2.4682.739; Doll R, 2004, BMJ-BRIT MED J, V328, P1519, DOI 10.1136/bmj.38142.554479.AE; Dosemeci M, 1997, CANCER CAUSE CONTROL, V8, P729, DOI 10.1023/A:1018479304728; Dossus L, 2014, INT J CANCER, V134, P1871, DOI 10.1002/ijc.28508; Efron B, 2004, ANN STAT, V32, P407, DOI 10.1214/009053604000000067; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Ellingjord-Dale M, 2017, CANCER EPIDEM BIOMAR, V26, P1736, DOI 10.1158/1055-9965.EPI-17-0611; Everatt R, 2014, EUR J CANCER PREV, V23, P579, DOI 10.1097/CEJ.0000000000000018; Forey BA, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-36; Freedman ND, 2016, INT J EPIDEMIOL, V45, P846, DOI 10.1093/ije/dyv175; Gammon MD, 1998, CANCER CAUSE CONTROL, V9, P583, DOI 10.1023/A:1008868922799; Ganbold C, 2021, INT J CHRONIC OBSTR, V16, P2857, DOI 10.2147/COPD.S320841; Gandini S, 2008, INT J CANCER, V122, P155, DOI 10.1002/ijc.23033; GBD 2019 Tobacco Collaborators, 2021, LANCET, V397, P2337, DOI DOI 10.1016/S0140-6736(21)01169-7; Giovannucci E, 1999, CANCER EPIDEM BIOMAR, V8, P277; GRADE Working Group, 2013, GRADE HDB; Gram IT, 2016, BRIT J CANCER, V115, P616, DOI 10.1038/bjc.2016.154; Gram IT, 2005, CANCER EPIDEM BIOMAR, V14, P61; Guo LW, 2022, LUNG CANCER, V163, P27, DOI 10.1016/j.lungcan.2021.11.015; Guo Y, 2019, MOVEMENT DISORD, V34, P876, DOI 10.1002/mds.27665; Hansen MS, 2021, BRIT J CANCER, V124, P658, DOI 10.1038/s41416-020-01131-w; Hansen MS, 2018, AM J EPIDEMIOL, V187, P971, DOI 10.1093/aje/kwx339; Hawrysz I, 2020, NUTRIENTS, V12, DOI 10.3390/nu12123788; Hbejan Khaled, 2011, Heart Views, V12, P1, DOI 10.4103/1995-705X.81547; He Y, 2014, AM J EPIDEMIOL, V179, P1060, DOI 10.1093/aje/kwu011; HIATT RA, 1994, CANCER CAUSE CONTROL, V5, P66, DOI 10.1007/BF01830728; Hilawe EH, 2015, J EPIDEMIOL, V25, P99, DOI 10.2188/jea.JE20140055; Hirayama T, 1990, LIFE STYLE MORTALITY; Hosseini M, 2009, INT J EPIDEMIOL, V38, P989, DOI 10.1093/ije/dyp218; Hou XH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149234; HSING AW, 1990, CANCER RES, V50, P6836; HSING AW, 1991, AM J EPIDEMIOL, V133, P437, DOI 10.1093/oxfordjournals.aje.a115910; Hu FB, 2001, NEW ENGL J MED, V345, P790, DOI 10.1056/NEJMoa010492; Hu JF, 1997, INT J CANCER, V71, P924, DOI 10.1002/(SICI)1097-0215(19970611)71:6&lt;924::AID-IJC2&gt;3.0.CO;2-#; Huang CC, 2022, GENES-BASEL, V13, DOI 10.3390/genes13050836; Huang CC, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-08800-w; Huh Y, 2022, NICOTINE TOB RES, V24, P1234, DOI 10.1093/ntr/ntac044; Huxley RR, 2011, LANCET, V378, P1297, DOI 10.1016/S0140-6736(11)60781-2; Jee SH, 2010, DIABETES CARE, V33, P2567, DOI 10.2337/dc10-0261; Jia GC, 2021, CARCINOGENESIS, V42, P874, DOI 10.1093/carcin/bgab018; Jin KX, 2019, TRANSL ONCOL, V12, P819, DOI 10.1016/j.tranon.2019.03.001; JOCKEL KH, 1992, INT J EPIDEMIOL, V21, P202, DOI 10.1093/ije/21.2.202; Jockel KH, 1998, INT J EPIDEMIOL, V27, P549, DOI 10.1093/ije/27.4.549; Johannessen A, 2005, INT J TUBERC LUNG D, V9, P926; JONAS MA, 1992, CIRCULATION, V86, P1664, DOI 10.1161/01.CIR.86.5.1664; Jones ME, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0908-4; Kanazir M, 2010, TUMORI J, V96, P911, DOI 10.1177/548.6508; Kawai M, 2014, CANCER-AM CANCER SOC, V120, P1026, DOI 10.1002/cncr.28402; Kawakami N, 1997, AM J EPIDEMIOL, V145, P103; Khan SS, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.121.021751; Kontopantelis E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069930; Kreuzer M, 2003, INT J EPIDEMIOL, V32, P263, DOI 10.1093/ije/dyg064; Kreuzer M, 1998, AM J EPIDEMIOL, V147, P1028; Kubik AK, 2002, PREV MED, V34, P436, DOI 10.1006/pmed.2001.1002; Lai CY, 2019, EUR J CANCER PREV, V28, P316, DOI [10.1097/CEJ.0000000000000464, 10.1097/cej.0000000000000464]; Lawania S, 2017, FUTURE ONCOL, V13, P2645, DOI 10.2217/fon-2017-0211; Lee PN, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-385; Leem AY, 2018, INT J CHRONIC OBSTR, V13, P509, DOI 10.2147/COPD.S148618; Lei YX, 1996, LUNG CANCER-J IASLC, V14, pS121, DOI 10.1016/S0169-5002(96)90218-4; Lemogne C, 2013, AM J EPIDEMIOL, V178, P1712, DOI 10.1093/aje/kwt217; Li CI, 2005, CANCER CAUSE CONTROL, V16, P975, DOI 10.1007/s10552-005-2906-6; Li L, 2019, J GENE MED, V21, DOI 10.1002/jgm.3106; Liaw KM, 1998, TOB CONTROL, V7, P141, DOI 10.1136/tc.7.2.141; LIU ZY, 1991, INT J EPIDEMIOL, V20, P26, DOI 10.1093/ije/20.1.26; Lotufo PA, 2000, INT J CANCER, V87, P141, DOI 10.1002/1097-0215(20000701)87:1<141::AID-IJC21>3.0.CO;2-A; Luo JH, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1016; Lv J, 2017, INT J EPIDEMIOL, V46, P1410, DOI 10.1093/ije/dyx074; Macacu A, 2015, BREAST CANCER RES TR, V154, P213, DOI 10.1007/s10549-015-3628-4; Magnusson C, 2007, BRIT J CANCER, V97, P1287, DOI 10.1038/sj.bjc.6604007; Manson JE, 2000, AM J MED, V109, P538, DOI 10.1016/S0002-9343(00)00568-4; Mao Y, 2001, INT J EPIDEMIOL, V30, P809, DOI 10.1093/ije/30.4.809; Marugame T, 2005, CANCER SCI, V96, P120, DOI 10.1111/j.1349-7006.2005.00013.x; Matos E, 1998, LUNG CANCER-J IASLC, V21, P155, DOI 10.1016/S0169-5002(98)00055-5; Meisinger C, 2006, DIABETOLOGIA, V49, P1770, DOI 10.1007/s00125-006-0298-0; Meyer J, 2015, CANCER EPIDEM BIOMAR, V24, P1516, DOI 10.1158/1055-9965.EPI-15-0415; Mezzoiuso AG, 2021, J CANCER, V12, P3136, DOI 10.7150/jca.54624; Moher D, 2010, INT J SURG, V8, P658, DOI 10.1016/j.ijsu.2010.07.299; Morabia A, 1996, AM J EPIDEMIOL, V143, P918, DOI 10.1093/oxfordjournals.aje.a008835; Naghibzadeh-Tahami A, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07296-0; Nakanishi N, 2000, ANN INTERN MED, V133, P183, DOI 10.7326/0003-4819-133-3-200008010-00009; Nilsen TIL, 2000, BRIT J CANCER, V82, P1358; Nishino Y, 2004, J EPIDEMIOL, V14, pS7, DOI 10.2188/jea.14.S7; Nomura AMY, 2000, CANCER EPIDEM BIOMAR, V9, P883; Nordlund LA, 1999, SCAND J PUBLIC HEALT, V27, P56, DOI 10.1177/14034948990270010301; Omori H, 2011, INTERNAL MED, V50, P1537, DOI 10.2169/internalmedicine.50.4412; Ozasa K, 2007, ASIAN PAC J CANCER P, V8, P89; Page MJ, 2021, BMJ-BRIT MED J, V372, DOI [10.1136/bmj.n71, 10.1016/j.ijsu.2021.105906]; Papadopoulos A, 2011, LUNG CANCER, V74, P369, DOI 10.1016/j.lungcan.2011.04.013; Park Chang-Hae, 2008, J Prev Med Public Health, V41, P249, DOI 10.3961/jpmph.2008.41.4.249; Park EY, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.611674; Park SY, 2015, CANCER CAUSE CONTROL, V26, P1507, DOI 10.1007/s10552-015-0644-y; Parker AS, 1999, EPIDEMIOLOGY, V10, P452, DOI 10.1097/00001648-199907000-00019; Patja K, 2005, J INTERN MED, V258, P356, DOI 10.1111/j.1365-2796.2005.01545.x; Pawlega J, 1997, ACTA ONCOL, V36, P471, DOI 10.3109/02841869709001301; PerezPadilla R, 1996, AM J RESP CRIT CARE, V154, P701, DOI 10.1164/ajrccm.154.3.8810608; Pesch B, 2012, INT J CANCER, V131, P1210, DOI 10.1002/ijc.27339; Petrick JL, 2018, BRIT J CANCER, V118, P1005, DOI 10.1038/s41416-018-0007-z; Pirie K, 2013, LANCET, V381, P133, DOI 10.1016/S0140-6736(12)61720-6; Potter J D, 1992, Ann Epidemiol, V2, P587, DOI 10.1016/1047-2797(92)90003-9; PROCHASKA JO, 1991, CLIN CHEST MED, V12, P727; Pujades-Rodriguez M, 2015, INT J EPIDEMIOL, V44, P129, DOI 10.1093/ije/dyu218; Putnam SD, 2000, ANN EPIDEMIOL, V10, P361, DOI 10.1016/S1047-2797(00)00057-0; Pytynia KB, 2004, J CLIN ONCOL, V22, P3981, DOI 10.1200/jco.2004.02.133; Qin L, 2017, HEMATOLOGY, V22, P193, DOI 10.1080/10245332.2016.1232011; Rachtan J, 2002, LUNG CANCER-J IASLC, V35, P129, DOI 10.1016/S0169-5002(01)00330-0; Radzeviciene L, 2018, WOMEN HEALTH, V58, P884, DOI 10.1080/03630242.2017.1358794; Rasouli B, 2016, DIABETES CARE, V39, P794, DOI 10.2337/dc15-2348; Reynolds P, 2004, JNCI-J NATL CANCER I, V96, P29, DOI 10.1093/jnci/djh002; RIMM EB, 1995, BRIT MED J, V310, P555, DOI 10.1136/bmj.310.6979.555; RISCH HA, 1993, AM J EPIDEMIOL, V138, P281, DOI 10.1093/oxfordjournals.aje.a116857; Rodriguez C, 1997, AM J EPIDEMIOL, V145, P466, DOI 10.1093/oxfordjournals.aje.a009129; Rohrmann S, 2013, BRIT J CANCER, V108, P708, DOI 10.1038/bjc.2012.520; Rohrmann S, 2007, UROLOGY, V69, P721, DOI 10.1016/j.urology.2006.12.020; Rucker G, 2011, BIOMETRICAL J, V53, P351, DOI 10.1002/bimj.201000151; Rusmaully J, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-08433-z; Sairenchi T, 2004, AM J EPIDEMIOL, V160, P158, DOI 10.1093/aje/kwh183; SANKARANARAYANAN R, 1994, INT J CANCER, V58, P644, DOI 10.1002/ijc.2910580505; Sawada N, 2014, INT J CANCER, V134, P971, DOI 10.1002/ijc.28423; Sawada SS, 2003, DIABETES CARE, V26, P2918, DOI 10.2337/diacare.26.10.2918; Schwartz AG, 2015, J THORAC ONCOL, V10, P1004, DOI 10.1097/JTO.0000000000000558; Shi H, 2019, EUR REV MED PHARMACO, V23, P10049, DOI 10.26355/eurrev_201911_19572; Shimatani K, 2020, JPN J CLIN ONCOL, V50, P1009, DOI 10.1093/jjco/hyaa083; Shimazu T, 2008, CANCER CAUSE CONTROL, V19, P1095, DOI 10.1007/s10552-008-9173-2; SIEMIATYCKI J, 1994, EPIDEMIOLOGY, V5, P57, DOI 10.1097/00001648-199401000-00010; SIEMIATYCKI J, 1995, INT J EPIDEMIOL, V24, P504, DOI 10.1093/ije/24.3.504; Simonato L, 2001, INT J CANCER, V91, P876, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1139>3.0.CO;2-7; Spijkerman AMW, 2014, DIABETES CARE, V37, P3164, DOI 10.2337/dc14-1020; Sreeja L, 2005, J HUM GENET, V50, P618, DOI 10.1007/s10038-005-0303-3; Stevens GA, 2016, LANCET, V388, pE19, DOI 10.1016/S0140-6736(16)30388-9; SUZUKI I, 1994, LUNG CANCER-J IASLC, V11, P179, DOI 10.1016/0169-5002(94)90538-X; Taghizadeh N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153310; Tan JB, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15051026; Teratani T, 2012, DRUG ALCOHOL DEPEN, V125, P276, DOI 10.1016/j.drugalcdep.2012.03.002; Thomson B, 2021, INT J EPIDEMIOL, V50, P955, DOI 10.1093/ije/dyab013; Thun M. J., 1997, TOBACCO CONTROL MONO, V8; Thun MJ, 2013, NEW ENGL J MED, V368, P351, DOI 10.1056/NEJMsa1211127; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; Tindle HA, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djy041; Tolstrup JS, 2014, AM J PUBLIC HEALTH, V104, P96, DOI 10.2105/AJPH.2012.301091; Tse LA, 2022, BMC CANCER, V22, DOI 10.1186/s12885-022-09678-y; Uchimoto S, 1999, DIABETIC MED, V16, P951, DOI 10.1046/j.1464-5491.1999.00173.x; United States Department of Health Education and Welfare, 1964, REP ADV COMM SMOK HL; United States Public Health Service Office of the Surgeon General National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health., 2020, SMOK CESS REP SURG G; van den Brandt PA, 2017, EUR J EPIDEMIOL, V32, P683, DOI 10.1007/s10654-017-0282-7; van Durme YMTA, 2009, CHEST, V135, P368, DOI 10.1378/chest.08-0684; Veierod MB, 1997, INT J CANCER, V73, P634, DOI 10.1002/(SICI)1097-0215(19971127)73:5&lt;634::AID-IJC4&gt;3.0.CO;2-Y; VENA JE, 1985, CANCER, V56, P910, DOI 10.1002/1097-0142(19850815)56:4<910::AID-CNCR2820560436>3.0.CO;2-4; Viner B, 2019, CANCER CAUSE CONTROL, V30, P1313, DOI 10.1007/s10552-019-01226-7; von Hippel PT, 2015, BMC MED RES METHODOL, V15, DOI 10.1186/s12874-015-0024-z; Waki K, 2005, DIABETIC MED, V22, P323, DOI 10.1111/j.1464-5491.2004.01403.x; Wannamethee SG, 2001, DIABETES CARE, V24, P1590, DOI 10.2337/diacare.24.9.1590; Watters JL, 2009, CANCER EPIDEM BIOMAR, V18, P2427, DOI 10.1158/1055-9965.EPI-09-0252; Weber MF, 2021, INT J CANCER, V149, P1076, DOI 10.1002/ijc.33685; White AJ, 2017, CANCER CAUSE CONTROL, V28, P667, DOI 10.1007/s10552-017-0903-1; White WB, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.007413; Will JC, 2001, INT J EPIDEMIOL, V30, P540, DOI 10.1093/ije/30.3.540; World Health Assembly, 2003, WHO FRAM CONV TOB CO; Wu ZJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168990; Wunsch V, 1998, SCAND J WORK ENV HEA, V24, P118; Xue F, 2011, ARCH INTERN MED, V171, P125, DOI 10.1001/archinternmed.2010.503; Yong LC, 1997, AM J EPIDEMIOL, V146, P231, DOI 10.1093/oxfordjournals.aje.a009258; Yun YD, 2016, LUNG, V194, P281, DOI 10.1007/s00408-015-9836-1; Zatloukal P, 2003, LUNG CANCER-J IASLC, V41, P283, DOI 10.1016/S0169-5002(03)00234-4; Zhang PD, 2022, BRIT J CANCER, V126, P1637, DOI 10.1038/s41416-022-01736-3; Zhang XR, 2022, BRIT J NUTR, V128, P721, DOI 10.1017/S000711452100372X; Zheng P., 2022, NAT MED; Zheng P, 2021, J COMPUT GRAPH STAT, V30, P544, DOI 10.1080/10618600.2020.1868303	206	2	2	7	7	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01978-x	http://dx.doi.org/10.1038/s41591-022-01978-x		OCT 2022	23	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	5E6IE	36216941	Green Published, hybrid			2022-12-27	WOS:000865725700002
J	Bucktrout, SL; Banovich, NE; Butterfield, LH; Cimen-Bozkus, C; Giles, JR; Good, Z; Goodman, D; Jonsson, VD; Lareau, C; Marson, A; Maurer, DM; Munson, PV; Stubbington, M; Taylor, S; Cutchin, A				Bucktrout, Samantha L.; Banovich, Nicholas E.; Butterfield, Lisa H.; Cimen-Bozkus, Cansu; Giles, Josephine R.; Good, Zinaida; Goodman, Daniel; Jonsson, Vanessa D.; Lareau, Caleb; Marson, Alexander; Maurer, Denna M.; Munson, Paul, V; Stubbington, Mike; Taylor, Sarah; Cutchin, Abbey			Advancing T cell-based cancer therapy with single-cell technologies	NATURE MEDICINE			English	Editorial Material							STATES; CAR	To accelerate the development of T cell-based immunotherapies that are effective for more patients with cancer, there is an urgent need to decipher the precise attributes of the ideal therapeutic T cell. In March 2021, the Parker Institute of Cancer Immunotherapy and 10x Genomics partnered to bring together a group of T cell immunotherapy researchers and single-cell-technology innovators for a day's workshop. Participants evaluated the current cutting edge of knowledge, identified areas for focused technology development, and put forward a call to action to the field. Insights were provided on how to best leverage single-cell technologies and key areas for future development were proposed - with the goal of facilitating a better understanding of T cell research and translation of this research into effective cancer immunotherapies. The key points of discussion that emerged from this workshop are summarized here.	[Bucktrout, Samantha L.; Butterfield, Lisa H.; Cimen-Bozkus, Cansu; Giles, Josephine R.; Good, Zinaida; Goodman, Daniel; Lareau, Caleb; Marson, Alexander; Maurer, Denna M.; Munson, Paul, V] Parker Inst Canc Immunotherapy, San Francisco, CA 94129 USA; [Banovich, Nicholas E.] Translat Genom Res Inst, Integrated Canc Genom Div, Phoenix, AZ USA; [Cimen-Bozkus, Cansu] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA; [Giles, Josephine R.] Univ Penn, Dept Syst Pharmacol & Translat Therapeut, Philadelphia, PA 19104 USA; [Giles, Josephine R.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Good, Zinaida] Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA USA; [Good, Zinaida] Stanford Univ, Sch Med, Dept Biomed Data Sci, Stanford, CA USA; [Goodman, Daniel] Univ Calif San Francisco, Sch Med, Microbiol & Immunol, San Francisco, CA USA; [Jonsson, Vanessa D.] Univ Calif Santa Cruz, Dept Appl Math, Santa Cruz, CA 95064 USA; [Jonsson, Vanessa D.] Univ Calif Santa Cruz, Dept Biomol Engn, Santa Cruz, CA 95064 USA; [Jonsson, Vanessa D.] Univ Calif Santa Cruz, Genom Inst, Santa Cruz, CA 95064 USA; [Lareau, Caleb] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA USA; [Marson, Alexander] Gladstone UCSF Inst Genom Immunol, San Francisco, CA USA; [Stubbington, Mike; Taylor, Sarah; Cutchin, Abbey] 10x Genom, Pleasanton, CA USA	Translational Genomics Research Institute; Icahn School of Medicine at Mount Sinai; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Stanford Cancer Institute; Stanford University; Stanford University; University of California System; University of California San Francisco; University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz; Stanford University	Bucktrout, SL (corresponding author), Parker Inst Canc Immunotherapy, San Francisco, CA 94129 USA.	sbucktrout@parkerici.org		Cimen Bozkus, Cansu/0000-0001-7834-4792; Lareau, Caleb/0000-0003-4179-4807; Good, Zinaida/0000-0003-2343-5771; Butterfield, Lisa/0000-0002-3439-9844; Marson, Alexander/0000-0002-2734-5776				Azizi E, 2018, CELL, V174, P1293, DOI 10.1016/j.cell.2018.05.060; Ben-Chetrit N., 2022, BIORXIV, DOI [10.1101/2022.03.15.484516, DOI 10.1101/2022.03.15.484516]; Cable DM, 2022, NAT BIOTECHNOL, V40, P517, DOI 10.1038/s41587-021-00830-w; Chen PL, 2016, CANCER DISCOV, V6, P827, DOI 10.1158/2159-8290.CD-15-1545; Dixit A, 2016, CELL, V167, P1853, DOI 10.1016/j.cell.2016.11.038; Dries R, 2021, GENOME BIOL, V22, DOI 10.1186/s13059-021-02286-2; Elosua-Bayes M, 2021, NUCLEIC ACIDS RES, V49, DOI 10.1093/nar/gkab043; Eyquem J, 2017, NATURE, V543, P113, DOI 10.1038/nature21405; Gielis S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02820; Giles JR, 2022, IMMUNITY, V55, P557, DOI 10.1016/j.immuni.2022.02.004; Grosselin K, 2019, NAT GENET, V51, P1060, DOI 10.1038/s41588-019-0424-9; Hudson WH, 2019, IMMUNITY, V51, P1043, DOI 10.1016/j.immuni.2019.11.002; Jokinen E, 2021, PLOS COMPUT BIOL, V17, DOI 10.1371/journal.pcbi.1008814; Lareau CA, 2021, NAT BIOTECHNOL, V39, P451, DOI 10.1038/s41587-020-0645-6; Lee Y, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abg4755; Lopez R., 2019, PREPRINT, DOI DOI 10.48550/ARXIV.1905.02269; Mimitou EP, 2021, NAT BIOTECHNOL, V39, P1246, DOI 10.1038/s41587-021-00927-2; Montemurro A, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-02610-3; Pai J. A., 2021, BIORXIV, DOI [10.1101/2021.09.27.461389, DOI 10.1101/2021.09.27.461389]; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Philip M, 2022, NAT REV IMMUNOL, V22, P209, DOI 10.1038/s41577-021-00574-3; Roth TL, 2020, CELL, V181, P728, DOI 10.1016/j.cell.2020.03.039; Satpathy AT, 2019, NAT BIOTECHNOL, V37, P925, DOI 10.1038/s41587-019-0206-z; Sharpe AH, 2018, NAT REV IMMUNOL, V18, P153, DOI 10.1038/nri.2017.108; Stadtmauer EA, 2020, SCIENCE, V367, P1001, DOI 10.1126/science.aba7365; Stoeckius M, 2017, NAT METHODS, V14, P865, DOI [10.1038/nmeth.4380, 10.1038/NMETH.4380]; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Sudmeier LJ, 2022, CELL REP MED, V3, DOI 10.1016/j.xcrm.2022.100620; Tang J, 2018, NAT REV DRUG DISCOV, V17, P465, DOI 10.1038/nrd.2018.74; Upadhaya S, 2022, NAT REV DRUG DISCOV, V21, P482, DOI 10.1038/d41573-022-00030-4; Wang WL, 2020, P NATL ACAD SCI USA, V117, P5442, DOI 10.1073/pnas.1919259117; Weber EW, 2020, CELL, V181, P46, DOI 10.1016/j.cell.2020.03.001; Yost KE, 2019, NAT MED, V25, P1251, DOI 10.1038/s41591-019-0522-3; ZHENG GX, 2017, NATURE, V0008	35	0	0	8	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2022	28	9					1761	1764		10.1038/s41591-022-01986-x	http://dx.doi.org/10.1038/s41591-022-01986-x		SEP 2022	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4S0LI	36127419				2022-12-27	WOS:000855618400001
J	Mendenhall, E; Kohrt, BA; Logie, CH; Tsai, AC				Mendenhall, Emily; Kohrt, Brandon A.; Logie, Carmen H.; Tsai, Alexander C.			Syndemics and clinical science	NATURE MEDICINE			English	Article							PSYCHOSOCIAL PROBLEMS; EMPIRICAL TESTS; HIV RISK; COVID-19	The theory of syndemics has received increasing attention in clinical medicine since the onset of the COVID-19 pandemic, due to the synergistic interactions of the disease with pre-existing political, structural, social and health conditions. In simple terms, syndemics are synergistically interacting epidemics that occur in a particular context with shared drivers. When policymakers ask why some communities have higher death rates from COVID-19 compared with other communities, those working from a syndemics framework argue that multiple factors synergistically work in tandem, and populations with the highest morbidity and mortality experience the greatest impact of these interactions. In this Perspective, we use specific case examples to illustrate these concepts. We discuss the emergence of syndemics, how epidemics interact, and what scientists, clinicians and policymakers can do with this information. This Perspective delivers an introduction to syndemic thinking, and provides insights into how epidemics interact and what scientists, clinicians and policymakers can do with this information.	[Mendenhall, Emily] Georgetown Univ, Edmund A Walsh Sch Foreign Serv, Washington, DC 20057 USA; [Mendenhall, Emily] Univ Witwatersrand, SAMRC Wits Dev Pathways Hlth Res Unit, Fac Hlth Sci, Johannesburg, South Africa; [Kohrt, Brandon A.] George Washington Univ, Dept Psychiat, Washington, DC 20057 USA; [Logie, Carmen H.] Univ Toronto, Factor Inwentash Fac Social Work, Toronto, ON, Canada; [Logie, Carmen H.] Ctr Gender & Sexual Hlth Equity, Vancouver, BC, Canada; [Logie, Carmen H.] United Nations Univ Inst Water, Environm & Hlth, Hamilton, ON, Canada; [Tsai, Alexander C.] Massachusetts Gen Hosp, Ctr Global Hlth & Mongan Inst, Boston, MA 02114 USA; [Tsai, Alexander C.] Harvard Med Sch, Boston, MA 02115 USA; [Tsai, Alexander C.] Mbarara Univ Sci & Technol, Mbarara, Uganda	Georgetown University; University of Witwatersrand; George Washington University; University of Toronto; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Mbarara University of Science & Technology	Mendenhall, E (corresponding author), Georgetown Univ, Edmund A Walsh Sch Foreign Serv, Washington, DC 20057 USA.; Mendenhall, E (corresponding author), Univ Witwatersrand, SAMRC Wits Dev Pathways Hlth Res Unit, Fac Hlth Sci, Johannesburg, South Africa.	em1061@georgetown.edu	Tsai, Alexander C./F-4247-2015	Tsai, Alexander C./0000-0001-6397-7917; Mendenhall, Emily/0000-0002-5826-1321				Bhardwaj A, 2020, CURR OPIN HIV AIDS, V15, P226, DOI 10.1097/COH.0000000000000627; Corona G, 2021, REV ENDOCR METAB DIS, V22, P275, DOI 10.1007/s11154-021-09630-8; Dhanani LY, 2022, PUBLIC HEALTH, V207, P31, DOI 10.1016/j.puhe.2022.03.012; Gandhi M, 2019, JAMA-J AM MED ASSOC, V321, P1356, DOI 10.1001/jama.2019.2945; Ghinai I, 2013, GLOB PUBLIC HEALTH, V8, P1138, DOI 10.1080/17441692.2013.859720; Gravlee CC, 2020, AM J HUM BIOL, V32, DOI 10.1002/ajhb.23482; Harding, 2022, CS CS HB 1557 PAR RI; Hatzenbuehler ML, 2012, AM J PUBLIC HEALTH, V102, P285, DOI 10.2105/AJPH.2011.300382; Horton R, 2020, LANCET, V396, P874, DOI 10.1016/S0140-6736(20)32000-6; Huang YT, 2022, INT J PUBLIC HEALTH, V67, DOI 10.3389/ijph.2022.1604489; Ikeda DJ, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2021-007212; Islam N, 2021, J EPIDEMIOL COMMUN H, V75, P496, DOI 10.1136/jech-2020-215626; Jindal HA, 2021, J EDUC HEALTH PROMOT, V10, DOI 10.4103/jehp.jehp_142_21; Karmacharya R, 2020, EUR PSYCHIAT, V63, DOI 10.1192/j.eurpsy.2020.64; Link BG, 2001, ANNU REV SOCIOL, V27, P363, DOI 10.1146/annurev.soc.27.1.363; Logie CH, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25341; Logie CH, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001124; McDaid LM, 2020, SSM-POPUL HLTH, V10, DOI 10.1016/j.ssmph.2019.100519; Mendenhall, 2020, LANCET, V30, P17848; Mendenhall E., 2012, SYNDEMIC SUFFERING S, DOI DOI 10.4324/9781315419459; Mendenhall E, 2022, NAT HUM BEHAV, V6, P64, DOI 10.1038/s41562-021-01242-1; Mendenhall E, 2020, CURR OPIN HIV AIDS, V15, P213, DOI 10.1097/COH.0000000000000628; Mendenhall E, 2017, LANCET, V389, P951, DOI 10.1016/S0140-6736(17)30402-6; Mendenhall E, 2016, MED ANTHROPOL Q, V30, P462, DOI 10.1111/maq.12215; Metzl JM, 2014, SOC SCI MED, V103, P126, DOI 10.1016/j.socscimed.2013.06.032; Ogunbajo A, 2021, GLOB PUBLIC HEALTH, V16, P1696, DOI 10.1080/17441692.2020.1834598; Ogunbajo A, 2020, SLEEP HEALTH, V6, P662, DOI 10.1016/j.sleh.2020.02.010; Organista KC, 2020, AIDS BEHAV, V24, P3176, DOI 10.1007/s10461-020-02876-4; Poteat TC, 2021, LANCET, V397, P2031, DOI 10.1016/S0140-6736(21)01057-6; Ranney ML, 2019, NEW ENGL J MED, V380, P405, DOI 10.1056/NEJMp1815462; Remien RH, 2019, AIDS, V33, P1411, DOI 10.1097/QAD.0000000000002227; Rudd KE, 2022, JAMA-J AM MED ASSOC, V327, P33, DOI 10.1001/jama.2021.22583; Safren SA, 2020, AIDS BEHAV, V24, P3264, DOI 10.1007/s10461-020-02900-7; Scheim AI, 2020, LANCET PUBLIC HEALTH, V5, pE196, DOI 10.1016/S2468-2667(20)30032-3; Schwartz SR, 2015, LANCET HIV, V2, pE299, DOI 10.1016/S2352-3018(15)00078-8; SINGER M, 1994, SOC SCI MED, V39, P931, DOI 10.1016/0277-9536(94)90205-4; Singer M., 1996, FREE INQ CREAT SOCIO, V24, P99, DOI [10.1093/jn/nxaa361, DOI 10.1093/jn/nxaa361]; Singer M, 2017, LANCET, V389, P941, DOI 10.1016/S0140-6736(17)30003-X; Stall R, 2003, AM J PUBLIC HEALTH, V93, P939, DOI 10.2105/AJPH.93.6.939; Stall R, 2015, SOC SCI MED, V145, P129, DOI 10.1016/j.socscimed.2015.07.016; Taft TH, 2016, CLIN EXP GASTROENTER, V9, P49, DOI 10.2147/CEG.S83533; Tsai AC, 2018, SOC SCI MED, V206, P117, DOI 10.1016/j.socscimed.2018.03.040; Tsai AC, 2017, LANCET, V389, P978, DOI 10.1016/S0140-6736(17)30403-8; Tsai AC, 2016, AIDS BEHAV, V20, P423, DOI 10.1007/s10461-015-1260-2; Tsai AC, 2015, SOC SCI MED, V139, P26, DOI 10.1016/j.socscimed.2015.06.024; Wonodi C, 2022, VACCINE, V40, P2114, DOI 10.1016/j.vaccine.2022.02.005	46	1	1	2	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2022	28	7					1359	1362		10.1038/s41591-022-01888-y	http://dx.doi.org/10.1038/s41591-022-01888-y		JUL 2022	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3E5PS	35864249	Bronze			2022-12-27	WOS:000828446700003
J	Khan, A; Kiryluk, K				Khan, Atlas; Kiryluk, Krzysztof			Cross-ancestry genome-wide polygenic score predicts chronic kidney disease	NATURE MEDICINE			English	Editorial Material; Early Access								A new genome-wide polygenic risk score for chronic kidney disease (CKD) that combines APOL1 risk genotypes with polygenic effects was validated in 15 diverse cohorts. The top 2% of the score reproducibly conveyed a threefold higher risk of CKD across all ancestries, a degree of risk that is equivalent to a positive family history of kidney disease.	[Khan, Atlas; Kiryluk, Krzysztof] Columbia Univ, Vagelos Coll Phys & Surg, New York, NY 10027 USA	Columbia University	Khan, A (corresponding author), Columbia Univ, Vagelos Coll Phys & Surg, New York, NY 10027 USA.							Neugut YD, 2019, ANN INTERN MED, V171, P659, DOI 10.7326/M19-1389; Parsa A, 2013, NEW ENGL J MED, V369, P2183, DOI 10.1056/NEJMoa1310345; Shang N, 2021, NPJ DIGIT MED, V4, DOI 10.1038/s41746-021-00428-1; Wand H, 2021, NATURE, V591, P211, DOI 10.1038/s41586-021-03243-6; Wuttke M, 2019, NAT GENET, V51, P957, DOI 10.1038/s41588-019-0407-x	5	0	0	1	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01871-7	http://dx.doi.org/10.1038/s41591-022-01871-7		JUN 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2I4PS	35739270				2022-12-27	WOS:000814962700002
J	Lewnard, JA; Hong, VX; Patel, MM; Kahn, R; Lipsitch, M; Tartof, SY				Lewnard, Joseph A.; Hong, Vennis X.; Patel, Manish M.; Kahn, Rebecca; Lipsitch, Marc; Tartof, Sara Y.			Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California	NATURE MEDICINE			English	Article							DISEASE SEVERITY; UNITED-STATES; IMPACT	Comparison of outcomes of SARS-CoV-2 Delta and Omicron infections shows reduced severity of Omicron infections, most notably in unvaccinated individuals, and no differential risk of severe outcomes between subvariants BA.1 and BA.2. The findings highlight the importance of continual assessment of clinical outcomes associated with SARS-CoV-2 variants of concern to inform both medical interventions and healthcare resource management. Epidemiologic surveillance has revealed decoupling of Coronavirus Disease 2019 (COVID-19) hospitalizations and deaths from case counts after emergence of the Omicron (B.1.1.529) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant globally. However, assessment of the relative severity of Omicron variant infections presents challenges because of differential acquired immune protection against Omicron and prior variants and because longer-term changes have occurred in testing and healthcare practices. Here we show that Omicron variant infections were associated with substantially reduced risk of progression to severe clinical outcomes relative to time-matched Delta (B.1.617.2) variant infections within a large, integrated healthcare system in Southern California. Adjusted hazard ratios (aHRs) for any hospital admission, symptomatic hospital admission, intensive care unit admission, mechanical ventilation and death comparing individuals with Omicron versus Delta variant infection were 0.59 (95% confidence interval: 0.51-0.69), 0.59 (0.51-0.68), 0.50 (0.29-0.87), 0.36 (0.18-0.72) and 0.21 (0.10-0.44), respectively. This reduced severity could not be explained by differential history of prior infection among individuals with Omicron or Delta variant infection and was starkest among individuals not previously vaccinated against COVID-19 (aHR = 0.40 (0.33-0.49) for any hospital admission and 0.14 (0.07-0.28) for death). Infections with the Omicron BA.2 subvariant were not associated with differential risk of severe outcomes in comparison to BA.1/BA.1.1 subvariant infections. Lower risk of severe clinical outcomes among individuals with Omicron variant infection should inform public health response amid establishment of the Omicron variant as the dominant SARS-CoV-2 lineage globally.	[Lewnard, Joseph A.] Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol, Berkeley, CA 94720 USA; [Lewnard, Joseph A.] Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis & Vaccinol, Berkeley, CA 94720 USA; [Lewnard, Joseph A.] Univ Calif Berkeley, Coll Engn, Ctr Computat Biol, Berkeley, CA 94720 USA; [Hong, Vennis X.; Tartof, Sara Y.] Kaiser Permanente Southern Calif, Dept Res & Evaluat, Pasadena, CA 91188 USA; [Patel, Manish M.; Kahn, Rebecca; Lipsitch, Marc] Ctr Dis Control & Prevent, COVID 19 Response Team, Atlanta, GA USA; [Tartof, Sara Y.] Kaiser Permanente Bernard J Tyson Sch Med, Dept Hlth Syst Sci, Pasadena, CA 91101 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Kaiser Permanente; Centers for Disease Control & Prevention - USA; Kaiser Permanente	Lewnard, JA (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol, Berkeley, CA 94720 USA.; Lewnard, JA (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, Div Infect Dis & Vaccinol, Berkeley, CA 94720 USA.; Lewnard, JA (corresponding author), Univ Calif Berkeley, Coll Engn, Ctr Computat Biol, Berkeley, CA 94720 USA.; Tartof, SY (corresponding author), Kaiser Permanente Southern Calif, Dept Res & Evaluat, Pasadena, CA 91188 USA.; Tartof, SY (corresponding author), Kaiser Permanente Bernard J Tyson Sch Med, Dept Hlth Syst Sci, Pasadena, CA 91101 USA.	jLewnard@berkeley.edu; sara.Y.Tartof@kp.org			US Centers for Disease Control and Prevention (CDC) [75D3-121C11520]; National Institute for Allergy and Infectious Diseases (US National Institutes of Health) [R01-AI14812701A1]	US Centers for Disease Control and Prevention (CDC)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); National Institute for Allergy and Infectious Diseases (US National Institutes of Health)	This work was funded by the US Centers for Disease Control and Prevention (CDC) (grant 75D3-121C11520 to S.Y.T.); M.L., R.J.K. and M.M.P. are employees of this agency. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. J.A.L. was supported by grant R01-AI14812701A1 from the National Institute for Allergy and Infectious Diseases (US National Institutes of Health), which had no role in design or conduct of the study or the decision to submit for publication.	Abdelnabi R, 2022, ANTIVIR RES, V198, DOI 10.1016/j.antiviral.2022.105253; Altarawneh HN, 2022, NEW ENGL J MED, V386, P1288, DOI 10.1056/NEJMc2200133; Andrejko KL, 2022, CLIN INFECT DIS, V74, P1382, DOI 10.1093/cid/ciab640; Andrews N, 2022, NEW ENGL J MED, V386, P1532, DOI [10.1056/NEJMoa2119451, 10.1016/S1473-3099(22)00309-7]; [Anonymous], 2021, SARS COV 2 VAR CONC; Bager P, 2022, LANCET INFECT DIS, V22, P967, DOI 10.1016/S1473-3099(22)00154-2; Bhattacharyya RP, 2022, NEW ENGL J MED, V386, DOI 10.1056/NEJMp2119682; Burnham KP, 2004, SOCIOL METHOD RES, V33, P261, DOI 10.1177/0049124104268644; California Department of Public Health, VAR CAL COVID 19 RES; Carreno JM, 2022, NATURE, V602, P682, DOI 10.1038/s41586-022-04399-5; Clarke KEN, 2022, MMWR-MORBID MORTAL W, V71, P606, DOI 10.15585/mmwr.mm7117e3; Davies NG, 2021, NATURE, V593, P270, DOI [10.1038/s41586-021-03426-1, 10.1101/2021.02.01.21250959]; Davies NG, 2021, SCIENCE, V372, P149, DOI 10.1126/science.abg3055; Feikin DR, 2022, LANCET, V399, P924, DOI 10.1016/S0140-6736(22)00152-0; Garvey Mark I, 2021, J Infect, V83, pe21, DOI 10.1016/j.jinf.2021.04.026; Gozzi N., 2022, PREPRINT, DOI [10.1101/2022.01.04.22268721v1, DOI 10.1101/2022.01.04.22268721V1]; Griffith Gareth J, 2020, Nat Commun, V11, P5749, DOI 10.1038/s41467-020-19478-2; Honaker J, 2011, J STAT SOFTW, V45, P1; Hui KPY, 2022, NATURE, V603, P715, DOI 10.1038/s41586-022-04479-6; Huynh Dan Ngoc, 2021, Perm J, V25, DOI 10.7812/TPP/20.281; Iuliano AD, 2022, MMWR-MORBID MORTAL W, V71, P146, DOI [10.1101/2021.12.30.21268560v2, 10.15585/mmwr.mm7104e4]; Klann J. G., PREPRINT, DOI 10.22270728v1(2022); Koebnick Corinna, 2012, Perm J, V16, P37; Kurum E, 2017, EPIDEMIOLOGY, V28, P889, DOI 10.1097/EDE.0000000000000719; Lamba K, 2021, OPEN FORUM INFECT DI, V8, DOI 10.1093/ofid/ofab379; Lauring AS, 2022, BMJ-BRIT MED J, V376, DOI 10.1136/bmj-2021-069761; Laxminarayan R, 2021, LANCET INFECT DIS, V21, P1665, DOI 10.1016/S1473-3099(21)00393-5; Leon TM, 2022, MMWR-MORBID MORTAL W, V71, DOI [10.1101/2021.12.30.21268565v1, 10.15585/mmwr.mm7104e1externalicon, 10.15585/mmwr.mm7104e1]; Madhi SA, 2022, NEW ENGL J MED, V386, P1314, DOI 10.1056/NEJMoa2119658; McCallum M, 2022, SCIENCE, V375, P864, DOI 10.1126/science.abn8652; Nemet I, 2022, NEW ENGL J MED, V386, P492, DOI 10.1056/NEJMc2119358; Nyberg T, 2022, LANCET, V399, P1303, DOI 10.1016/S0140-6736(22)00462-7; Pearson C. A. B., PREPRINT, DOI [10.1101/2021.12.19.21268038v1(2021), DOI 10.1101/2021.12.19.21268038V1(2021)]; Peralta-Santos A., PREPRINT, DOI [10.1101/2022.01.20.22269406v1(2022), DOI 10.1101/2022.01.20.22269406V1(2022)]; Pulliam JRC, 2022, SCIENCE, V376, P596, DOI 10.1126/science.abn4947; Qassim S. H., PREPRINT, DOI [10.1101/2022.03.02.22271771v1(2022), DOI 10.1101/2022.03.02.22271771V1(2022)]; Rossler A, 2022, NEW ENGL J MED, V386, P698, DOI 10.1056/NEJMc2119236; Rubin DB, 1996, J AM STAT ASSOC, V91, P473, DOI 10.1080/01621459.1996.10476908; Schmidt F, 2022, NEW ENGL J MED, V386, P599, DOI 10.1056/NEJMc2119641; Scott L, 2021, SCIENCE, V374, P1454, DOI 10.1126/science.abn4543; Sheikh A, 2022, LANCET INFECT DIS, V22, P959, DOI 10.1016/S1473-3099(22)00141-4; Sigal A, 2022, NAT REV IMMUNOL, V22, P267, DOI 10.1038/s41577-022-00720-5; Smith DJ, 2022, MMWR-MORBID MORTAL W, V71, P545, DOI [10.46234/ccdcw2022.071, 10.15585/mmwr.mm7115e1]; Statistics New Zealand, COVID 19 DAT PORT; Stensrud MJ, 2020, JAMA-J AM MED ASSOC, V323, P1401, DOI 10.1001/jama.2020.1267; Stralin K, 2022, J INFECTION, V84, pE3, DOI 10.1016/j.jinf.2021.08.043; Tartof SY, 2021, LANCET, V398, P1407, DOI 10.1016/S0140-6736(21)02183-8; TARTOF SY, 2022, LANCET RESP MED, DOI DOI 10.1016/S2213-2600(22)00101-1; Taylor Luke, 2022, BMJ, V376, po66, DOI 10.1136/bmj.o66; The COVID Tracking Project, LONG TERM CAR COVID; Therneau T. M., 2022, PACKAGE SURVIVAL SUR; Tseng HF, 2022, NAT MED, V28, P1063, DOI 10.1038/s41591-022-01753-y; Ulloa AC, 2022, JAMA-J AM MED ASSOC, V327, P1286, DOI 10.1001/jama.2022.2274; US Centers for Disease Control and Prevention, COVID 19 DAT TRACK T; US Centers for Disease Control and Prevention, 2021, 1 CONF CAS OM VAR DE; US Centers for Disease Control and Prevention, 2022, COVID 19 DAT TRACK V; Vandenbroucke JP, 2016, INT J EPIDEMIOL, V45, P1776, DOI 10.1093/ije/dyv341; Wolter N., PREPRINT, DOI [10.1101/2022.02.17.22271030v1(2022), DOI 10.1101/2022.02.17.22271030V1(2022)]; Wolter N, 2022, LANCET, V399, P437, DOI 10.1016/S0140-6736(22)00017-4; World Health Organization, UPD OM VAR	60	36	36	12	18	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2022	28	9					1933	+		10.1038/s41591-022-01887-z	http://dx.doi.org/10.1038/s41591-022-01887-z		JUN 2022	17	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4S0LI	35675841	Bronze			2022-12-27	WOS:000840602800001
J	Wells, M				Wells, Mary			Key components of successful digital remote monitoring in oncology	NATURE MEDICINE			English	Article							CANCER	A phase 3 trial highlights the importance of problem-led design, multidisciplinary commitment and patient-reported outcomes - with skilled oncology nurses having a crucial role.	[Wells, Mary] Imperial Coll London, Dept Surg & Canc, London, England; [Wells, Mary] Imperial Coll Healthcare NHS Trust, Nursing Directorate, London, England	Imperial College London; Imperial College London	Wells, M (corresponding author), Imperial Coll London, Dept Surg & Canc, London, England.; Wells, M (corresponding author), Imperial Coll Healthcare NHS Trust, Nursing Directorate, London, England.	mary.wells@imperial.ac.uk		Wells, Mary/0000-0001-5789-2773	Imperial Biomedical Research Centre (BRC)	Imperial Biomedical Research Centre (BRC)	M.W. is supported by the Imperial Biomedical Research Centre (BRC).	[Anonymous], 2018, CLASSIFICATION DIGIT; [Anonymous], 2021, GLOBAL STRATEGY DIGI; Bestsennyy O., 2020, TELEHEALTH Q TRILLIO; Chan RJ, 2020, BMJ SUPPORT PALLIAT, V10, P276, DOI 10.1136/bmjspcare-2019-002120; Charalambous A, 2018, INT J NURS STUD, V86, P36, DOI 10.1016/j.ijnurstu.2018.05.014; Cheng C, 2020, J MED INTERNET RES, V22, DOI 10.2196/18476; Ferrua M, 2020, BMC HEALTH SERV RES, V20, DOI 10.1186/s12913-020-05293-4; Maguire R, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n1647; McGregor BA, 2020, CUREUS, V12, DOI 10.7759/cureus.10156; Mir O, 2022, NAT MED, V28, P1224, DOI 10.1038/s41591-022-01788-1; Moghaddam N, 2016, SUPPORT CARE CANCER, V24, P3609, DOI 10.1007/s00520-016-3221-3; Schrag D, 2020, JAMA-J AM MED ASSOC, V323, P2005, DOI 10.1001/jama.2020.6236	12	0	0	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2022	28	6					1128	1129		10.1038/s41591-022-01841-z	http://dx.doi.org/10.1038/s41591-022-01841-z		JUN 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E9IE	35668178	Bronze			2022-12-27	WOS:000806681900003
J	Van Gelder, RN; Chiang, MF; Dyer, MA; Greenwell, TN; Levin, LA; Wong, RO; Svendsen, CN				Van Gelder, Russell N.; Chiang, Michael F.; Dyer, Michael A.; Greenwell, Thomas N.; Levin, Leonard A.; Wong, Rachel O.; Svendsen, Clive N.			Regenerative and restorative medicine for eye disease	NATURE MEDICINE			English	Review							RETINAL GANGLION-CELLS; MACULAR DEGENERATION; PIGMENT EPITHELIUM; VISUAL RESPONSES; MULLER GLIA; STEM-CELLS; TRANSPLANTATION; SINGLE; SAFETY; DIFFERENTIATION	Restoration of visual function in degenerative retinal disease may be an attainable goal, thanks to advances in cell-based therapy, gene therapy, and prosthetics. This Review discusses the most promising strategies that will probably reach clinical use in the next decade. Causes of blindness differ across the globe; in higher-income countries, most blindness results from the degeneration of specific classes of cells in the retina, including retinal pigment epithelium (RPE), photoreceptors, and retinal ganglion cells. Advances over the past decade in retinal regenerative medicine have allowed each of these cell types to be produced ex vivo from progenitor stem cells. Here, we review progress in applying these technologies to cell replacement - with the goal of vision restoration in degenerative disease. We discuss the landscape of human clinical trials for RPE transplantation and advanced preclinical studies for other cell types. We also review progress toward in situ repair of retinal degeneration using endogenous progenitor cells. Finally, we provide a high-level overview of progress toward prosthetic ocular vision restoration, including advanced photovoltaic devices, opsin-based gene therapy, and small-molecule photoswitches. Progress in each of these domains is at or near the human clinical-trial stage, bringing the audacious goal of vision restoration within sight.	[Van Gelder, Russell N.; Wong, Rachel O.] Univ Washington, Dept Ophthalmol, Karalis Johnson Retina Ctr, Sch Med, Seattle, WA 98195 USA; [Van Gelder, Russell N.; Wong, Rachel O.] Univ Washington, Dept Biol Struct, Sch Med, Seattle, WA 98195 USA; [Van Gelder, Russell N.] Univ Washington, Dept Pathol & Lab Med, Sch Med, Seattle, WA 98195 USA; [Van Gelder, Russell N.] Univ Washington, Roger & Angie Karalis Johnson Retina Ctr, Sch Med, Seattle, WA 98195 USA; [Chiang, Michael F.; Greenwell, Thomas N.] NEI, Natl Inst Hlth, Bethesda, MD USA; [Dyer, Michael A.] St Judes Res Hosp, Dept Dev Neurobiol, Memphis, TN USA; [Levin, Leonard A.] Dept Ophthalmol & Visual Sci, Madison, WI USA; [Levin, Leonard A.] McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ, Canada; [Svendsen, Clive N.] Board Governors Regenerat Med Inst, Los Angeles, CA USA; [Svendsen, Clive N.] Cedars Sinai Med Ctr, Dept Biomed Sci, Los Angeles, CA 90048 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); St Jude Children's Research Hospital; McGill University; Cedars Sinai Medical Center	Van Gelder, RN (corresponding author), Univ Washington, Dept Ophthalmol, Karalis Johnson Retina Ctr, Sch Med, Seattle, WA 98195 USA.; Van Gelder, RN (corresponding author), Univ Washington, Dept Biol Struct, Sch Med, Seattle, WA 98195 USA.; Van Gelder, RN (corresponding author), Univ Washington, Dept Pathol & Lab Med, Sch Med, Seattle, WA 98195 USA.; Van Gelder, RN (corresponding author), Univ Washington, Roger & Angie Karalis Johnson Retina Ctr, Sch Med, Seattle, WA 98195 USA.	russvg@uw.edu		Van Gelder, Russell/0000-0001-5368-3659	Research to Prevent Blindness; Mark Daly, MD Research Fund	Research to Prevent Blindness(Research to Prevent Blindness (RPB)); Mark Daly, MD Research Fund	Special thanks to P. Sieving for conceptualizing the Audacious Goals Initiative and pushing the field of regenerative medicine in the eye forward. Thanks also to S. Becker for shepherding the vision of AGI and its progress. R.N.V.G. acknowledges support of an unrestricted grant from Research to Prevent Blindness and the Mark Daly, MD Research Fund.	Aboulizadeh E, 2020, STEM CELL REP, V15, P482, DOI 10.1016/j.stemcr.2020.06.019; Ahuja AK, 2011, BRIT J OPHTHALMOL, V95, P539, DOI 10.1136/bjo.2010.179622; Ayton LN, 2020, CLIN NEUROPHYSIOL, V131, P1383, DOI 10.1016/j.clinph.2019.11.029; Berry MH, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09124-x; Bourne RRA, 2021, LANCET GLOB HEALTH, V9, pE130, DOI 10.1016/S2214-109X(20)30425-3; Bucher K, 2021, PROG RETIN EYE RES, V83, DOI 10.1016/j.preteyeres.2020.100915; Capowski EE, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.171686; Caras IW, 2021, STEM CELL TRANSL MED, V10, P1581, DOI 10.1002/sctm.21-0239; Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152; Chao JR, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.3.4; Chew EY, 2019, OPHTHALMOLOGY, V126, P540, DOI 10.1016/j.ophtha.2018.09.041; Chirco KR, 2017, ACTA BIOMATER, V57, P293, DOI 10.1016/j.actbio.2017.05.011; Cideciyan AV, 2013, P NATL ACAD SCI USA, V110, pE517, DOI 10.1073/pnas.1218933110; Dagnelie G, 2017, CLIN EXP OPHTHALMOL, V45, P152, DOI 10.1111/ceo.12812; de Lima S, 2012, P NATL ACAD SCI USA, V109, P9149, DOI 10.1073/pnas.1119449109; Dyer MA, 2000, NAT NEUROSCI, V3, P873, DOI 10.1038/78774; Fligor CM, 2021, STEM CELL REP, V16, P2228, DOI 10.1016/j.stemcr.2021.05.009; Gabriel E, 2021, CELL STEM CELL, V28, P1740, DOI 10.1016/j.stem.2021.07.010; Glennon E, 2020, CURR OPIN NEUROBIOL, V60, P108, DOI 10.1016/j.conb.2019.11.003; Haruta M, 2004, INVEST OPHTH VIS SCI, V45, P1020, DOI 10.1167/iovs.03-1034; Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002; Jorstad NL, 2017, NATURE, V548, P103, DOI 10.1038/nature23283; Kashani AH, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.10.13; Kauper K, 2012, INVEST OPHTH VIS SCI, V53, P7484, DOI 10.1167/iovs.12-9970; Koga K, 2020, INFLAMM REGEN, V40, DOI 10.1186/s41232-020-00132-9; Koss MJ, 2016, GRAEF ARCH CLIN EXP, V254, P1553, DOI 10.1007/s00417-016-3386-y; Kuppermann BD, 2018, INVEST OPHTH VIS SCI, V59; Lahne M, 2020, ANNU REV VIS SCI, V6, P171, DOI 10.1146/annurev-vision-121219-081808; Lin B, 2018, EXP EYE RES, V174, P13, DOI 10.1016/j.exer.2018.05.017; Lingam S, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-021-02539-8; Liu Y, 2021, NEURAL REGEN RES, V16, P1138, DOI 10.4103/1673-5374.300329; Liu ZL, 2021, INVEST OPHTH VIS SCI, V62, P34, DOI 10.1167/iovs.62.3.34; Livesey FJ, 2001, NAT REV NEUROSCI, V2, P109, DOI 10.1038/35053522; Lorach H, 2015, NAT MED, V21, P476, DOI 10.1038/nm.3851; Luo J, 2014, J BIOL CHEM, V289, P6362, DOI 10.1074/jbc.M113.513713; Maguire AM, 2019, OPHTHALMOLOGY, V126, P1273, DOI 10.1016/j.ophtha.2019.06.017; Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9; Mehat MS, 2018, OPHTHALMOLOGY, V125, P1765, DOI 10.1016/j.ophtha.2018.04.037; Miltner AM, 2019, DEV DYNAM, V248, P118, DOI 10.1002/dvdy.24672; Morgan J., 1995, WEBVISION ORG RETINA; Morgan JL, 2006, NAT NEUROSCI, V9, P85, DOI 10.1038/nn1615; Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009; Nanduri D, 2012, INVEST OPHTH VIS SCI, V53, P205, DOI 10.1167/iovs.11-8401; Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51; Palanker D, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-28125-x; Palanker D, 2020, OPHTHALMOLOGY, V127, P1097, DOI 10.1016/j.ophtha.2020.02.024; Palczewska G, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121555; Pandiyan VP, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc1124; Peng YR, 2019, CELL, V176, P1222, DOI 10.1016/j.cell.2019.01.004; Petoe MA, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.10.12; Polosukhina A, 2012, NEURON, V75, P271, DOI 10.1016/j.neuron.2012.05.022; Rein DB, 2022, OPHTHALMOLOGY, V129, P369, DOI 10.1016/j.ophtha.2021.09.010; Ribeiro J, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.109022; Rossi EA, 2017, P NATL ACAD SCI USA, V114, P586, DOI 10.1073/pnas.1613445114; Russell S, 2017, LANCET, V390, P849, DOI 10.1016/S0140-6736(17)31868-8; Sahel JA, 2021, NAT MED, V27, P1223, DOI 10.1038/s41591-021-01351-4; SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225; Scholler J, 2020, LIGHT-SCI APPL, V9, DOI 10.1038/s41377-020-00375-8; Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3; Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2; Sekirnjak C, 2011, J NEUROPHYSIOL, V105, P2560, DOI 10.1152/jn.01061.2010; Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580; Shekhar K, 2016, CELL, V166, P1308, DOI 10.1016/j.cell.2016.07.054; Shirai H, 2016, P NATL ACAD SCI USA, V113, pE81, DOI 10.1073/pnas.1512590113; Stingl K, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00445; Hoang T, 2020, SCIENCE, V370, P934, DOI 10.1126/science.abb8598; Tochitsky I, 2016, NEURON, V92, P100, DOI 10.1016/j.neuron.2016.08.038; Tochitsky I, 2014, NEURON, V81, P800, DOI 10.1016/j.neuron.2014.01.003; Todd L, 2021, CELL REP, V37, DOI 10.1016/j.celrep.2021.109857; Van Gelder Russell N, 2021, Int Ophthalmol Clin, V61, P209, DOI 10.1097/IIO.0000000000000386; Venugopalan P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10472; Wu YR, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.13.26; Xiao DC, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.755544; Yungher BJ, 2017, INVEST OPHTH VIS SCI, V58, P1743, DOI 10.1167/iovs.16-19873; Zhong XF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5047	75	3	3	10	11	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2022	28	6					1149	1156		10.1038/s41591-022-01862-8	http://dx.doi.org/10.1038/s41591-022-01862-8			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E9IE	35715505				2022-12-27	WOS:000812533400020
J	Nair, ATN; Wesolowska-Andersen, A; Brorsson, C; Rajendrakumar, AL; Hapca, S; Gan, S; Dawed, AY; Donnelly, LA; McCrimmon, R; Doney, ASF; Palmer, CNA; Mohan, V; Anjana, RM; Hattersley, AT; Dennis, JM; Pearson, ER				Nair, Anand Thakarakkattil Narayanan; Wesolowska-Andersen, Agata; Brorsson, Caroline; Rajendrakumar, Aravind Lathika; Hapca, Simona; Gan, Sushrima; Dawed, Adem Y.; Donnelly, Louise A.; McCrimmon, Rory; Doney, Alex S. F.; Palmer, Colin N. A.; Mohan, Viswanathan; Anjana, Ranjit M.; Hattersley, Andrew T.; Dennis, John M.; Pearson, Ewan R.			Heterogeneity in phenotype, disease progression and drug response in type 2 diabetes	NATURE MEDICINE			English	Article							PROGNOSTIC MODELS; ASSOCIATION; ISSUES; GRAPH	A new analysis of patients newly diagnosed with diabetes uses a data dimenionality reduction approach to understand how phenotypic variation drives diseaese onset, clinical outcomes and responses to glycemic-lowering medications. Type 2 diabetes (T2D) is a complex chronic disease characterized by considerable phenotypic heterogeneity. In this study, we applied a reverse graph embedding method to routinely collected data from 23,137 Scottish patients with newly diagnosed diabetes to visualize this heterogeneity and used partitioned diabetes polygenic risk scores to gain insight into the underlying biological processes. Overlaying risk of progression to outcomes of insulin requirement, chronic kidney disease, referable diabetic retinopathy and major adverse cardiovascular events, we show how these risks differ by patient phenotype. For example, patients at risk of retinopathy are phenotypically different from those at risk of cardiovascular events. We replicated our findings in the UK Biobank and the ADOPT clinical trial, also showing that the pattern of diabetes drug monotherapy response differs for different drugs. Overall, our analysis highlights how, in a European population, underlying phenotypic variation drives T2D onset and affects subsequent diabetes outcomes and drug response, demonstrating the need to incorporate these factors into personalized treatment approaches for the management of T2D.	[Nair, Anand Thakarakkattil Narayanan; Rajendrakumar, Aravind Lathika; Hapca, Simona; Gan, Sushrima; Dawed, Adem Y.; Donnelly, Louise A.; McCrimmon, Rory; Doney, Alex S. F.; Palmer, Colin N. A.; Pearson, Ewan R.] Univ Dundee, Sch Med, Div Populat Hlth & Genom, Dundee, Scotland; [Wesolowska-Andersen, Agata] Univ Oxford, Wellcome Ctr Human Genet, Oxford, England; [Brorsson, Caroline] Univ Copenhagen, Novo Nordisk Ctr Prot Res, Copenhagen, Denmark; [Mohan, Viswanathan; Anjana, Ranjit M.] Madras Diabet Res Fdn, Chennai, Tamil Nadu, India; [Hattersley, Andrew T.; Dennis, John M.] Univ Exeter, Royal Devon & Exeter Hosp, Inst Biomed & Clin Sci, Exeter, Devon, England	University of Dundee; University of Oxford; Wellcome Centre for Human Genetics; University of Copenhagen; Madras Diabetes Research Foundation; University of Exeter	Pearson, ER (corresponding author), Univ Dundee, Sch Med, Div Populat Hlth & Genom, Dundee, Scotland.	e.z.pearson@dundee.ac.uk	; Palmer, Colin/C-7053-2008	Brorsson, Caroline Anna/0000-0003-3473-1744; DAWED, ADEM YESUF/0000-0003-0224-2428; Pearson, Ewan/0000-0001-9237-8585; Dennis, John/0000-0002-7171-732X; McCrimmon, Rory/0000-0002-3957-1981; Palmer, Colin/0000-0002-6415-6560; THAKARAKKATTIL NARAYANAN NAIR, ANAND/0000-0002-1979-1477	National Institute for Health Research [INSPIRED 16/136/102]; Health Data Research UK from HDR UK Ltd. - UK Medical Research Council [HDR-5012]; Engineering and Physical Sciences Research Council; Economic and Social Research Council; Department of Health and Social Care (England); Chief Scientist Office of the Scottish Government Health and Social Care Directorates; Health and Social Care Research and Development Division (Welsh Government); Public Health Agency (Northern Ireland); British Heart Foundation; Wellcome Trust; Wellcome Trust New Investigator Award; Wellcome Trust [102820/Z/13/Z]; Research England's Expanding Excellence in England (E3) fund	National Institute for Health Research(National Institute for Health Research (NIHR)); Health Data Research UK from HDR UK Ltd. - UK Medical Research Council; Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Department of Health and Social Care (England); Chief Scientist Office of the Scottish Government Health and Social Care Directorates; Health and Social Care Research and Development Division (Welsh Government); Public Health Agency (Northern Ireland); British Heart Foundation(British Heart Foundation); Wellcome Trust(Wellcome Trust); Wellcome Trust New Investigator Award(Wellcome Trust); Wellcome Trust(Wellcome Trust); Research England's Expanding Excellence in England (E3) fund	We thank all personnel at the Health Informatics Centre for linking different datasets, maintaining all statistical packages and providing the data. The research was supported by the National Institute for Health Research using Official Development Assistance funding (INSPIRED 16/136/102) and Health Data Research UK, which receives its funding from HDR UK Ltd. (HDR-5012), funded by the UK Medical Research Council, the Engineering and Physical Sciences Research Council, the Economic and Social Research Council, the Department of Health and Social Care (England), the Chief Scientist Office of the Scottish Government Health and Social Care Directorates, the Health and Social Care Research and Development Division (Welsh Government), the Public Health Agency (Northern Ireland), the British Heart Foundation and the Wellcome Trust. The views expressed in this publication are those of the authors and not necessarily those of the National Institute for Health Research or the UK Department of Health and Social Care. J.M.D. is supported by an independent fellowship funded by Research England's Expanding Excellence in England (E3) fund. E.R.P. holds a Wellcome Trust New Investigator Award. This research was funded in whole or in part by the Wellcome Trust (102820/Z/13/Z).	Ahlqvist E, 2018, LANCET DIABETES ENDO, V6, P361, DOI 10.1016/S2213-8587(18)30051-2; Aly DM, 2021, NAT GENET, DOI 10.1038/s41588-021-00948-2; Amod A, 2020, DIABETES THER, V11, P53, DOI [10.2337/dci19-0066, 10.1007/s13300-019-00715-x]; Andrassy KM, 2013, KIDNEY INT, V84, P622, DOI 10.1038/ki.2013.243; Anjana RM, 2020, BMJ OPEN DIAB RES CA, V8, DOI 10.1136/bmjdrc-2020-001506; [Anonymous], SCOTTISH CARE INFORM; Austin PC, 2016, CIRCULATION, V133, P601, DOI 10.1161/CIRCULATIONAHA.115.017719; Bizzotto R, 2021, DIABETES CARE, V44, P511, DOI 10.2337/dc20-1567; Cushman WC, 2010, NEW ENGL J MED, V362, P1575, DOI 10.1056/NEJMoa1001286; Dennis JM, 2019, LANCET DIABETES ENDO, V7, P442, DOI 10.1016/S2213-8587(19)30087-7; Dennis JM, 2018, DIABETES CARE, V41, P1844, DOI 10.2337/dc18-0344; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Hebert HL, 2018, INT J EPIDEMIOL, V47, P380, DOI 10.1093/ije/dyx140; HUBERT L, 1985, J CLASSIF, V2, P193, DOI 10.1007/BF01908075; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Li L, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa9364; Lugner M, 2021, DIABETOLOGIA, V64, P1973, DOI 10.1007/s00125-021-05485-5; Mahajan A, 2018, NAT GENET, V50, P559, DOI 10.1038/s41588-018-0084-1; Mao Q., 2015, KDD15 P 21 ACM; Mao Q, 2017, IEEE T PATTERN ANAL, V39, P2227, DOI 10.1109/TPAMI.2016.2635657; McCarthy MI, 2017, DIABETOLOGIA, V60, P793, DOI 10.1007/s00125-017-4210-x; NHS Health Research Authority, UK BIOBANK LARGE SCA; ORD JK, 1995, GEOGR ANAL, V27, P286, DOI 10.1111/j.1538-4632.1995.tb00912.x; Owen KR, 2003, DIABETIC MED, V20, P823, DOI 10.1046/j.1464-5491.2003.01034.x; Pearson ER, 2019, DIABETOLOGIA, V62, P1107, DOI 10.1007/s00125-019-4909-y; Prasad RB, 2022, DIABETOLOGIA, V65, P65, DOI 10.1007/s00125-021-05543-y; Qiu XJ, 2017, NAT METHODS, V14, P979, DOI [10.1038/NMETH.4402, 10.1038/nmeth.4402]; Qiu XJ, 2017, NAT METHODS, V14, P309, DOI [10.1038/NMETH.4150, 10.1038/nmeth.4150]; R Core Team, 2021, R LANGUAGE ENV STAT; Slieker RC, 2021, DIABETOLOGIA, V64, P1982, DOI 10.1007/s00125-021-05490-8; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Sudlow C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001779; Tan VYF, 2013, IEEE T PATTERN ANAL, V35, P1592, DOI 10.1109/TPAMI.2012.240; Trapnell C, 2014, NAT BIOTECHNOL, V32, P381, DOI 10.1038/nbt.2859; Udler MS, 2019, ENDOCR REV, V40, P1500, DOI 10.1210/er.2019-00088; Udler MS, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002654; UK Biobank, 2019, UK BIOB PRIM CAR LIN; Viberti G, 2002, DIABETES CARE, V25, P1737, DOI 10.2337/diacare.25.10.1737; Wolbers M, 2009, EPIDEMIOLOGY, V20, P555, DOI 10.1097/EDE.0b013e3181a39056; Zachariah Sonia, 2015, Community Eye Health, V28, P72; Zaharia OP, 2019, LANCET DIABETES ENDO, V7, P684, DOI 10.1016/S2213-8587(19)30187-1; Zhou KX, 2014, DIABETES CARE, V37, P718, DOI 10.2337/dc13-1995; Zou XT, 2019, LANCET DIABETES ENDO, V7, P9, DOI 10.1016/S2213-8587(18)30316-4	44	3	3	5	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2022	28	5					982	+		10.1038/s41591-022-01790-7	http://dx.doi.org/10.1038/s41591-022-01790-7		MAY 2022	23	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	1J3AM	35534565	Green Submitted			2022-12-27	WOS:000792548400001
J	Vasey, B; Nagendran, M; Campbell, B; Clifton, DA; Collins, GS; Denaxas, S; Denniston, AK; Faes, L; Geerts, B; Ibrahim, M; Liu, XX; Mateen, BA; Mathur, P; McCradden, MD; Morgan, L; Ordish, J; Rogers, C; Saria, S; Ting, DSW; Watkinson, P; Weber, W; Wheatstone, P; McCulloch, P				Vasey, Baptiste; Nagendran, Myura; Campbell, Bruce; Clifton, David A.; Collins, Gary S.; Denaxas, Spiros; Denniston, Alastair K.; Faes, Livia; Geerts, Bart; Ibrahim, Mudathir; Liu, Xiaoxuan; Mateen, Bilal A.; Mathur, Piyush; McCradden, Melissa D.; Morgan, Lauren; Ordish, Johan; Rogers, Campbell; Saria, Suchi; Ting, Daniel S. W.; Watkinson, Peter; Weber, Wim; Wheatstone, Peter; McCulloch, Peter		DECIDE-AI Expert Grp	Reporting guideline for the early-stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI	NATURE MEDICINE			English	Article							DELPHI; STATEMENT	The DECIDE-AI checklist, resulting from a multi-stakeholder group of experts in a Delphi process and following the EQUATOR Network's recommendations, includes key items that should be reported in early-stage clinical studies of AI-based decision support systems, to ensure a responsible and transparent deployment of AI systems in healthcare. A growing number of artificial intelligence (AI)-based clinical decision support systems are showing promising performance in preclinical, in silico evaluation, but few have yet demonstrated real benefit to patient care. Early-stage clinical evaluation is important to assess an AI system's actual clinical performance at small scale, ensure its safety, evaluate the human factors surrounding its use and pave the way to further large-scale trials. However, the reporting of these early studies remains inadequate. The present statement provides a multi-stakeholder, consensus-based reporting guideline for the Developmental and Exploratory Clinical Investigations of DEcision support systems driven by Artificial Intelligence (DECIDE-AI). We conducted a two-round, modified Delphi process to collect and analyze expert opinion on the reporting of early clinical evaluation of AI systems. Experts were recruited from 20 pre-defined stakeholder categories. The final composition and wording of the guideline was determined at a virtual consensus meeting. The checklist and the Explanation & Elaboration (E&E) sections were refined based on feedback from a qualitative evaluation process. In total, 123 experts participated in the first round of Delphi, 138 in the second round, 16 in the consensus meeting and 16 in the qualitative evaluation. The DECIDE-AI reporting guideline comprises 17 AI-specific reporting items (made of 28 subitems) and ten generic reporting items, with an E&E paragraph provided for each. Through consultation and consensus with a range of stakeholders, we developed a guideline comprising key items that should be reported in early-stage clinical studies of AI-based decision support systems in healthcare. By providing an actionable checklist of minimal reporting items, the DECIDE-AI guideline will facilitate the appraisal of these studies and replicability of their findings.	[Vasey, Baptiste; Ibrahim, Mudathir; McCulloch, Peter] Univ Oxford, Nuffield Dept Surg Sci, Oxford, England; [Vasey, Baptiste; Clifton, David A.] Univ Oxford, Inst Biomed Engn, Dept Engn Sci, Oxford, England; [Vasey, Baptiste; Liu, Xiaoxuan; Watkinson, Peter] Univ Oxford, Nuffield Dept Clin Neurosci, Crit Care Res Grp, Oxford, England; [Nagendran, Myura] Imperial Coll London, UKRI Ctr Doctoral Training AI Healthcare, London, England; [Campbell, Bruce] Univ Exeter, Med Sch, Exeter, Devon, England; [Campbell, Bruce] Royal Devon & Exeter Hosp, Exeter, Devon, England; [Collins, Gary S.] Univ Oxford, Ctr Stat Med, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Oxford, England; [Denaxas, Spiros; Mateen, Bilal A.] UCL, Inst Hlth Informat, London, England; [Denaxas, Spiros] British Heart Fdn Data Sci Ctr, London, England; [Denaxas, Spiros] Hlth Data Res England, London, England; [Denaxas, Spiros] UCL Hosp Biomed Res Ctr, London, England; [Denniston, Alastair K.; Liu, Xiaoxuan] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England; [Denniston, Alastair K.] Univ Birmingham, Acad Unit Ophthalmol, Coll Med & Dent Sci, Inst Inflammat & Ageing, Birmingham, W Midlands, England; [Denniston, Alastair K.; Faes, Livia] Moorfields Eye Hosp NHS Fdn Trust, London, England; [Geerts, Bart] Healthplusai R&D BV, Amsterdam, Netherlands; [Ibrahim, Mudathir] Maimonides Hosp, Dept Surg, Brooklyn, NY 11219 USA; [Mateen, Bilal A.] Wellcome Trust Res Labs, London, England; [Mateen, Bilal A.] Alan Turing Inst, London, England; [Mathur, Piyush] Cleveland Clin, Dept Gen Anesthesiol, Anesthesiol Inst, Cleveland, OH 44106 USA; [McCradden, Melissa D.] Hosp Sick Children, Toronto, ON, Canada; [McCradden, Melissa D.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Morgan, Lauren] Morgan Human Syst Ltd, Shrewsbury, Salop, England; [Ordish, Johan] Med & Healthcare Prod Regulatory Agcy, London, England; [Rogers, Campbell] HeartFlow Inc, Redwood City, CA USA; [Saria, Suchi] Johns Hopkins Univ, Dept Comp Sci, Baltimore, MD 21218 USA; [Saria, Suchi] Johns Hopkins Univ, Dept Stat, Baltimore, MD USA; [Saria, Suchi] Johns Hopkins Univ, Dept Hlth Policy, Baltimore, MD USA; [Saria, Suchi] Johns Hopkins Univ, Div Informat, Baltimore, MD USA; [Saria, Suchi] Bayesian Hlth, New York, NY USA; [Ting, Daniel S. W.] Singapore Eye Res Inst, Singapore Natl Eye Ctr, Singapore, Singapore; [Ting, Daniel S. W.] Natl Univ Singapore, Duke NUS Med Sch, Singapore, Singapore; [Watkinson, Peter] Oxford Univ Hosp NHS Trust, NIHR Biomed Res Ctr Oxford, Oxford, England; [Weber, Wim] The BMJ, London, England; [Wheatstone, Peter] Univ Leeds, Sch Med, Leeds, W Yorkshire, England	University of Oxford; University of Oxford; University of Oxford; Imperial College London; University of Exeter; University of Exeter; University of Oxford; University of London; University College London; University of London; University College London; University of Birmingham; University of Birmingham; University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust; Maimonides Medical Center; Cleveland Clinic Foundation; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; The Medicines & Healthcare Products Regulatory Agency; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; National University of Singapore; Singapore National Eye Center; National University of Singapore; Oxford University Hospitals NHS Foundation Trust; University of Leeds	Vasey, B (corresponding author), Univ Oxford, Nuffield Dept Surg Sci, Oxford, England.; Vasey, B (corresponding author), Univ Oxford, Inst Biomed Engn, Dept Engn Sci, Oxford, England.; Vasey, B (corresponding author), Univ Oxford, Nuffield Dept Clin Neurosci, Crit Care Res Grp, Oxford, England.	baptiste.vasey@gmail.com	Paez, Arsenio/AAC-7767-2019; IBRAHIM, MUDATHIR/AAZ-1557-2020; Neri, Emanuele/N-1378-2019; Collins, Gary Stephen/A-2258-2014; Vasey, Baptiste/AAY-8765-2020	Paez, Arsenio/0000-0002-7984-514X; IBRAHIM, MUDATHIR/0000-0002-6345-1533; Neri, Emanuele/0000-0001-7950-4559; Collins, Gary Stephen/0000-0002-2772-2316; Vasey, Baptiste/0000-0002-0017-8891; Denniston, Alastair/0000-0001-7849-0087; Denaxas, Spiros/0000-0001-9612-7791; Newcombe, Virginia/0000-0001-6044-9035; Fowler, George/0000-0002-4133-802X; Guan, Pujun/0000-0002-7288-9369	IDEAL Collaboration; Berrow Foundation Lord Florey scholarship; UKRI CDT in AI for Healthcare [P/S023283/1]; Wellcome Trust; AstraZeneca; RCUK; GlaxoSmithKline; NIHR Biomedical Research Centre; Oxford; Cancer Research UK [C49297/A27294]; Maimonides Medical Center Research fellowship; National Institute of Health Research/NHSX/Health Foundation; Alan Turing Institute; MHRA; NICE; EPSRC [EP/N510129/]; Dalla Lana School of Public Health; Leong Centre for Healthy Children; NHSX; Regulators' Pioneer Fund (Department for Business, Energy and Industrial Strategy); National Science Foundation; American Heart Association; National Institutes of Health; Sloan Foundation; National Medical Research Council, Singapore [NMRC/HSRG/0087/2018, MOH-000655-00]; National Health Innovation Centre, Singapore [NHIC-COV19-2005017]; SingHealth Fund Limited Foundation [SHF/HSR113/2017]; Duke-NUS Medical School [Duke-NUS/RSF/2021/0018, 05/FY2020/EX/15-A58]; Agency for Science, Technology and Research [A20H4g2141, H20C6a0032]; Medtronic	IDEAL Collaboration; Berrow Foundation Lord Florey scholarship; UKRI CDT in AI for Healthcare(UK Research & Innovation (UKRI)); Wellcome Trust(Wellcome Trust); AstraZeneca(AstraZeneca); RCUK(UK Research & Innovation (UKRI)); GlaxoSmithKline(GlaxoSmithKline); NIHR Biomedical Research Centre(National Institute for Health Research (NIHR)); Oxford; Cancer Research UK(Cancer Research UK); Maimonides Medical Center Research fellowship; National Institute of Health Research/NHSX/Health Foundation; Alan Turing Institute; MHRA; NICE; EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Dalla Lana School of Public Health; Leong Centre for Healthy Children; NHSX; Regulators' Pioneer Fund (Department for Business, Energy and Industrial Strategy); National Science Foundation(National Science Foundation (NSF)); American Heart Association(American Heart Association); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Sloan Foundation(Alfred P. Sloan Foundation); National Medical Research Council, Singapore(National Medical Research Council, SingaporeUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Health Innovation Centre, Singapore; SingHealth Fund Limited Foundation; Duke-NUS Medical School; Agency for Science, Technology and Research(Agency for Science Technology & Research (A*STAR)); Medtronic(Medtronic)	The authors would like to thank all Delphi participants and experts who participated in the guideline qualitative evaluation. B.V. would also like to thank B. Beddoe (Sheffield Teaching Hospital), N. Bilbro (Maimonides Medical Center), N. Marlow (Oxford University Hospitals), E. Taylor (Nuffield Department of Surgical Sciences, University of Oxford) and S. Ursprung (Department for Radiology, Tubingen University Hospital) for their support in the initial stage of the project. This work was supported by the IDEAL Collaboration. B.V. is funded by a Berrow Foundation Lord Florey scholarship. M.N. is supported by the UKRI CDT in AI for Healthcare (http://ai4health.io; grant P/S023283/1). D.C. receives funding from the Wellcome Trust, AstraZeneca, RCUK and GlaxoSmithKline. G.S.C. is supported by the NIHR Biomedical Research Centre, Oxford, and Cancer Research UK (program grant C49297/A27294). M.I. is supported by a Maimonides Medical Center Research fellowship. X.L. receives funding from the Wellcome Trust, the National Institute of Health Research/NHSX/Health Foundation, the Alan Turing Institute, the MHRA and NICE. B.A.M. is a fellow of the Alan Turing Institute, supported by EPSRC grant EP/N510129/, and holds a Wellcome Trust-funded honorary post at University College London for the purposes of carrying out independent research. M.M. receives funding from the Dalla Lana School of Public Health and the Leong Centre for Healthy Children. J.O. is employed by the Medicines and Healthcare products Regulatory Agency, which is the competent authority responsible for regulating medical devices and medicines in the United Kingdom. Elements of the work relating to the regulation of AI as a medical device are funded by grants from NHSX and the Regulators' Pioneer Fund (Department for Business, Energy and Industrial Strategy). S.S. receives grants from the National Science Foundation, the American Heart Association, the National Institutes of Health and the Sloan Foundation. D.S.W.T. is supported by the National Medical Research Council, Singapore (NMRC/HSRG/0087/2018;MOH-000655-00), the National Health Innovation Centre, Singapore (NHIC-COV19-2005017), the SingHealth Fund Limited Foundation (SHF/HSR113/2017), the Duke-NUS Medical School (Duke-NUS/RSF/2021/0018;05/FY2020/EX/15-A58) and the Agency for Science, Technology and Research (A20H4g2141; H20C6a0032). P. Watkinson is supported by the NIHR Biomedical Research Centre, Oxford, and holds grants from the NIHR and Wellcome. P. McCulloch receives grants from Medtronic (unrestricted educational grant to Oxford University for the IDEAL Collaboration) and the Oxford Biomedical Research Centre. The views expressed in this guideline are those of the authors, Delphi participants and experts who participated in the qualitative evaluation of the guideline. These views do not necessarily reflect those of their institutions or funders.	Asan O, 2021, JMIR HUM FACTORS, V8, DOI 10.2196/28236; Bilbro NA, 2021, ANN SURG, V273, P82, DOI 10.1097/SLA.0000000000004180; Boel A, 2021, J CLIN EPIDEMIOL, V129, P31, DOI 10.1016/j.jclinepi.2020.09.034; Collins GS, 2019, LANCET, V393, P1577, DOI 10.1016/S0140-6736(19)30037-6; DALKEY N, 1963, MANAGE SCI, V9, P458, DOI 10.1287/mnsc.9.3.458; Felmingham CM, 2021, AM J CLIN DERMATOL, V22, P233, DOI 10.1007/s40257-020-00574-4; Finlayson SG, 2021, NEW ENGL J MED, V385, P283, DOI 10.1056/NEJMc2104626; Freeman K, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n1872; Ghassemi M, 2021, LANCET DIGIT HEALTH, V3, pE745, DOI 10.1016/S2589-7500(21)00208-9; Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Higgins D, 2020, ADV INTELL SYST-GER, V2, DOI 10.1002/aisy.202000052; High-Level Independent Group on Artificial Intelligence (AI HLEG), 2019, ETH GUID TRUSTW AI, V32; Hirst A, 2019, ANN SURG, V269, P211, DOI 10.1097/SLA.0000000000002794; Hopper AN, 2007, POSTGRAD MED J, V83, P777, DOI 10.1136/pgmj.2007.057190; IMDRF Medical Device Clinical Evaluation Working Group, 2019, CLIN EVALUATION; IMDRF Medical Device Clinical Evaluation Working Group, 2019, CLIN INVESTIGATION; IMDRF Software as Medical Device (SaMD) Working Group, 2014, SOFTW MED DEV POSS F; International Organization for Standardization, INF TECHN INT AIB AI; International Organization for Standardization, 2019, ERG HUM INT 210 HUM; International Organization for Standardization, 2018, ERG HUM INT 11 US DE; Kapur Narinder, 2016, JRSM Open, V7, p2054270415616548, DOI 10.1177/2054270415616548; Keane PA, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0048-y; Lim Sol, 2016, Proc Hum Factors Ergon Soc Annu Meet, V60, P970, DOI 10.1177/1541931213601224; Lipton ZC, 2018, COMMUN ACM, V61, P36, DOI 10.1145/3233231; Liu XX, 2020, NAT MED, V26, P1364, DOI 10.1038/s41591-020-1034-x; Liu XX, 2019, LANCET DIGIT HEALTH, V1, pE271, DOI 10.1016/S2589-7500(19)30123-2; McCradden MD, 2020, NAT MED, V26, P1325, DOI 10.1038/s41591-020-1035-9; McCulloch P, 2009, LANCET, V374, P1105, DOI 10.1016/S0140-6736(09)61116-8; McIntosh C, 2021, NAT MED, V27, P999, DOI 10.1038/s41591-021-01359-w; Medicines & Healthcare products Regulatory Agency (MHRA), GUID APPL HUM FACT U; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1992, DOI 10.1001/jama.285.15.1992; Morley J, 2020, SCI ENG ETHICS, V26, P2141, DOI 10.1007/s11948-019-00165-5; Nagendran M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m689; NICE, 2019, EV STAND FRAM DIG HL; Norgeot B, 2020, NAT MED, V26, P1320, DOI 10.1038/s41591-020-1041-y; Norman D, 1986, USER CTR SYSTEM DESI; Nowell LS, 2017, INT J QUAL METH, V16, DOI 10.1177/1609406917733847; Page MJ, 2021, BMJ-BRIT MED J, V372, DOI [10.1136/bmj.n71, 10.1016/j.ijsu.2021.105906]; Park SH, 2018, RADIOLOGY, V288, P910, DOI 10.1148/radiol.2018181310; Rivera SC, 2020, NAT MED, V26, P1351, DOI 10.1038/s41591-020-1037-7; Sedrakyan A, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2372; Sendak M. P, 2020, EUR MED J; Skivington K, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n2061; Sounderajah V, 2020, NAT MED, V26, P807, DOI 10.1038/s41591-020-0941-1; Stanton NA, 2010, HUMAN FACTORS IN THE DESIGN AND EVALUATION OF CENTRAL CONTROL ROOM OPERATIONS, P1; Subbaswamy A, 2020, BIOSTATISTICS, V21, P345, DOI 10.1093/biostatistics/kxz041; Sujan M., 2021, HUMAN FACTORS ERGONO; Sujan M, 2019, BMJ HEALTH CARE INFO, V26, DOI 10.1136/bmjhci-2019-100081; US Food and Drug Administration (FDA), 2016, APPL HUM FACT US ENG; US Food and Drug Administration (FDA), 2019, CLIN DECISION SUPPOR; Vasey B, 2022, OPEN SCI FRAMEWORK, DOI [10.17605/OSF.IO/TP9QV, DOI 10.17605/OSF.IO/TP9QV]; Vasey B, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.1276; Vasey B, 2021, NAT MED, V27, P186, DOI 10.1038/s41591-021-01229-5; Vollmer S, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.l6927; von Elm E, 2007, BMJ-BRIT MED J, V335, P806; Winkler J, 2016, TECHNOL FORECAST SOC, V105, P63, DOI 10.1016/j.techfore.2016.01.021; Wronikowska MW, 2021, J EVAL CLIN PRACT, V27, P1403, DOI 10.1111/jep.13582; Xie YC, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.22	61	12	12	9	9	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2022	28	5					924	+		10.1038/s41591-022-01772-9	http://dx.doi.org/10.1038/s41591-022-01772-9			12	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	1J3AM	35585198	Green Published, Bronze, Green Submitted			2022-12-27	WOS:000797792500016
J	Klebanoff, CA; Chandran, SS				Klebanoff, Christopher A.; Chandran, Smita S.			PIK3CA hotspot mutation generates a shared neoantigen targetable by TCR gene therapy	NATURE MEDICINE			English	Article; Early Access								PIK3CA gain-of-function mutations are among the most common alterations in human solid cancers. Through the use of stimulation-induced functional T cell receptor (TCR) sequencing (SIFT-seq), a panel of TCRs that bind a mutant PI3K alpha shared neoantigen was identified, including a potential clinical candidate that engages cancer cells via a distinctive CDR3 beta loop.	[Klebanoff, Christopher A.; Chandran, Smita S.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Klebanoff, CA (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.							Andre F, 2019, NEW ENGL J MED, V380, P1929, DOI 10.1056/NEJMoa1813904; Bear AS, 2021, CANCER RES, V81, DOI 10.1038/s41467-021-24562-2; Chandran SS, 2019, IMMUNOL REV, V290, P127, DOI 10.1111/imr.12772; Priestley P, 2019, NATURE, V575, P210, DOI 10.1038/s41586-019-1689-y; Tran E, 2014, SCIENCE, V344, P641, DOI 10.1126/science.1251102	5	0	0	2	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01806-2	http://dx.doi.org/10.1038/s41591-022-01806-2		APR 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0V6LL	35484265				2022-12-27	WOS:000788453200001
J	Xiong, SD; Gerloni, M; Zanetti, M				Xiong, SD; Gerloni, M; Zanetti, M			Engineering vaccines with heterologous B and T cell epitopes using immunoglobulin genes	NATURE BIOTECHNOLOGY			English	Article						vaccine design; antibody engineering; rational protein design	FALCIPARUM CIRCUMSPOROZOITE PROTEIN; IMMUNODEFICIENCY-VIRUS TYPE-1; 3-DIMENSIONAL STRUCTURE; HYPERVARIABLE REGIONS; SYNTHETIC VACCINE; IMMUNE-RESPONSES; MALARIA VACCINE; ANTIBODY; IMMUNOGENICITY; IMMUNIZATION	Antibodies engineered in their variable domain to express epitopes of heterologous antigens-antigenized antibodies-function as immunogens. Only the third complementarity-determining region (CDR3) of the H chain has been used as the site of epitope expression, as this loop has the highest natural variability in length and amino acid composition. We demonstrate that the CDR2 can be engineered to express a 12-amino acid peptide, which is a T-cell determinant that enhances the response to a B-cell epitope peptide of Plasmodium falciparum expressed in the CDR3 of the same variable domain. Mice with this gene inoculated into the spleen mounted an antibody response against the B-cell epitope higher than mice receiving the gene coding for the B-cell epitope only. In vitro studies established that the two epitopes were independently immunogenic in vivo.	UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR CANC,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego			Gerloni, Mara/AAG-1526-2020		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI036467] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36467] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALZARI PM, 1988, ANNU REV IMMUNOL, V6, P555; BALLOU WR, 1987, LANCET, V1, P1277; BILLETTA R, 1995, EUR J IMMUNOL, V25, P776, DOI 10.1002/eji.1830250323; BILLETTA R, 1991, P NATL ACAD SCI USA, V88, P4713, DOI 10.1073/pnas.88.11.4713; BILLETTA R, 1992, IMMUNOMETHODS, V1, P41; BRADLEY LM, 1993, J IMMUNOL, V150, P3119; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CONRY RM, 1994, CANCER RES, V54, P1164; DAVIS HL, 1994, VACCINE, V12, P1503, DOI 10.1016/0264-410X(94)90073-6; EISENBRAUN MD, 1993, DNA CELL BIOL, V12, P791, DOI 10.1089/dna.1993.12.791; FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478; Gerloni M, 1997, DNA CELL BIOL, V16, P611, DOI 10.1089/dna.1997.16.611; Gerloni M, 1997, NAT BIOTECHNOL, V15, P876, DOI 10.1038/nbt0997-876; GLASEL JA, 1995, BIOTECHNIQUES, V18, P62; HERRINGTON DA, 1987, NATURE, V328, P257, DOI 10.1038/328257a0; HERRINGTON DA, 1992, VACCINE, V10, P841, DOI 10.1016/0264-410X(92)90047-N; KABAT EA, 1987, PROTEINS IMMUNOLOGIC; LANZA P, 1993, P NATL ACAD SCI USA, V90, P11683, DOI 10.1073/pnas.90.24.11683; MITCHISON N A, 1971, European Journal of Immunology, V1, P18, DOI 10.1002/eji.1830010104; MORRISON SL, 1985, SCIENCE, V229, P1202, DOI 10.1126/science.3929380; MUNESINGHE DY, 1991, EUR J IMMUNOL, V21, P3015, DOI 10.1002/eji.1830211217; NARDIN EH, 1989, SCIENCE, V246, P1603, DOI 10.1126/science.2480642; POLJAK RJ, 1973, P NATL ACAD SCI USA, V70, P3305, DOI 10.1073/pnas.70.12.3305; RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519; RIGAUDY P, 1994, DNA CELL BIOL, V13, P585, DOI 10.1089/dna.1994.13.585; Sambrook J., 2002, MOL CLONING LAB MANU; SEDEGAH M, 1994, P NATL ACAD SCI USA, V91, P9866, DOI 10.1073/pnas.91.21.9866; SOLLAZZO M, 1990, PROTEIN ENG, V4, P215, DOI 10.1093/protein/4.2.215; SOLLAZZO M, 1989, EUR J IMMUNOL, V19, P453, DOI 10.1002/eji.1830190307; SOLLAZZO M, 1990, PROTEIN ENG, V3, P531, DOI 10.1093/protein/3.6.531; TAM JP, 1990, J EXP MED, V171, P299, DOI 10.1084/jem.171.1.299; TAM JP, 1989, P NATL ACAD SCI USA, V86, P9084, DOI 10.1073/pnas.86.23.9084; TOGNA AR, 1986, J IMMUNOL, V137, P2956; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; WANG B, 1993, P NATL ACAD SCI USA, V90, P4156, DOI 10.1073/pnas.90.9.4156; Xiong SD, 1997, P NATL ACAD SCI USA, V94, P6352, DOI 10.1073/pnas.94.12.6352; ZAGHOUANI H, 1993, SCIENCE, V259, P224, DOI 10.1126/science.7678469; ZAGHOUANI H, 1995, P NATL ACAD SCI USA, V92, P631, DOI 10.1073/pnas.92.2.631; ZANETTI M, 1992, IMMUNOL REV, V130, P125, DOI 10.1111/j.1600-065X.1992.tb01524.x; ZANETTI M, 1992, NATURE, V355, P466; ZAVALA F, 1985, SCIENCE, V228, P1436, DOI 10.1126/science.2409595	43	41	61	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1997	15	9					882	886		10.1038/nbt0997-882	http://dx.doi.org/10.1038/nbt0997-882			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XW410	9306404				2022-12-27	WOS:A1997XW41000031
J	Yang, XDW; Model, P; Heintz, N				Yang, XDW; Model, P; Heintz, N			Homologous recombination based modification in Escherichia coli and germline transmission in transgenic mice of a bacterial artificial chromosome	NATURE BIOTECHNOLOGY			English	Article						BAC; homologous recombination; RU 49; transgenic	DNA FRAGMENTS; MESSENGER-RNA; CONSTRUCTION; YEAST; CLONING; YACS; TRANSFORMATION; PROPAGATION; EXPRESSION; SEGMENTS	Escherichia coli-based artificial chromosomes have become important tools for physical mapping and sequencing in various genome projects. The lack of a general method to modify these large bacterial clones, however, has limited their utility in functional studies. We developed a simple method to modify bacterial artificial chromosomes directly in the recombination-deficient E. coli host strain by homologous recombination for in vivo studies. The IRES-LacZ marker gene was introduced into a 131 kb BAC containing the murine zinc finger gene, RU49. No rearrangements or deletions were detected in the modified BACs. Furthermore, transgenic mice were generated by pronuclear injection of the modified BAG, and germline transmission of the intact BAC has been obtained. Proper expression of the lacZ transgene in the brain has been observed, which could not be obtained with conventional transgenic constructs.	ROCKEFELLER UNIV,MOL BIOL LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,GENET LAB,NEW YORK,NY 10021; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Rockefeller University; Rockefeller University; Howard Hughes Medical Institute; Rockefeller University					PHS HHS [MG07739] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BOCHNER BR, 1980, J BACTERIOL, V143, P926, DOI 10.1128/JB.143.2.926-933.1980; Bradley A, 1996, NAT GENET, V14, P121, DOI 10.1038/ng1096-121; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; GNIRKE A, 1993, GENOMICS, V15, P659, DOI 10.1006/geno.1993.1121; GREEN ED, 1991, GENOMICS, V11, P658, DOI 10.1016/0888-7543(91)90073-N; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HASHIMOTOGOTOH T, 1977, J BACTERIOL, V131, P405, DOI 10.1128/JB.131.2.405-412.1977; HIEFER P, 1990, GENOME ANAL GENETIC, V1, P83; HOGAN B, 1986, MANIPULATING MOUSE E; HOSODA F, 1990, NUCLEIC ACIDS RES, V18, P3863, DOI 10.1093/nar/18.13.3863; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; JAENISCH R, 1988, SCIENCE, V240, P1468, DOI 10.1126/science.3287623; KENNISON JA, 1993, TRENDS GENET, V9, P75, DOI 10.1016/0168-9525(93)90227-9; KIM DG, 1992, MOL CELL BIOL, V12, P3636, DOI 10.1128/MCB.12.8.3636; Kim UJ, 1996, P NATL ACAD SCI USA, V93, P6297, DOI 10.1073/pnas.93.13.6297; KOUPRINA N, 1994, GENOMICS, V21, P7, DOI 10.1006/geno.1994.1218; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; LARIONOV V, 1994, NUCLEIC ACIDS RES, V22, P4154, DOI 10.1093/nar/22.20.4154; MALOY SR, 1981, J BACTERIOL, V145, P110; MONACO AP, 1994, TRENDS BIOTECHNOL, V12, P280, DOI 10.1016/0167-7799(94)90140-6; OCONNOR M, 1989, SCIENCE, V244, P1307, DOI 10.1126/science.2660262; PALMITER RD, 1985, CELL, V41, P343, DOI 10.1016/S0092-8674(85)80004-0; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Peterson KR, 1997, TRENDS GENET, V13, P61, DOI 10.1016/S0168-9525(97)01003-2; SCHEDL A, 1993, NUCLEIC ACIDS RES, V21, P4383; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; Spencer F., 1993, Methods (Orlando), V5, P161, DOI 10.1006/meth.1993.1021; TSLEN JZ, 1996, CELL, V87, P1317; WANG M, 1994, GENOMICS, V24, P527, DOI 10.1006/geno.1994.1662; WILSON C, 1990, ANNU REV CELL BIOL, V6, P679, DOI 10.1146/annurev.cellbio.6.1.679; WOO SS, 1994, NUCLEIC ACIDS RES, V22, P4922, DOI 10.1093/nar/22.23.4922; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Yang XW, 1996, DEVELOPMENT, V122, P555	34	428	496	0	18	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1997	15	9					859	865		10.1038/nbt0997-859	http://dx.doi.org/10.1038/nbt0997-859			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XW410	9306400				2022-12-27	WOS:A1997XW41000027
J	Abraham, D				Abraham, D			Combining legal and business strategies to develop combinatorial chemistry businesses	NATURE BIOTECHNOLOGY			English	Editorial Material											Abraham, D (corresponding author), WILSON SONSINI GOODRICH & ROSATI PC,650 PAGE MILL RD,PALO ALTO,CA 94304, USA.								0	0	0	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1997	15	7					679	682		10.1038/nbt0797-679	http://dx.doi.org/10.1038/nbt0797-679			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XH583	9219273				2022-12-27	WOS:A1997XH58300034
J	Robinson, K; Chamberlain, LM; Schofield, KM; Wells, JM; LePage, RWF				Robinson, K; Chamberlain, LM; Schofield, KM; Wells, JM; LePage, RWF			Oral vaccination of mice against tetanus with recombinant Lactococcus lactis	NATURE BIOTECHNOLOGY			English	Article						vaccine design; Lactococcus lactis; tetanus toxin	ANTIBODY-RESPONSES; ESCHERICHIA-COLI; IMMUNE-RESPONSES; IMMUNIZATION; BACTERIAL; MUCOSAL; ANTIGEN; IMMUNOGENICITY; INACTIVATION; PROTEIN	To determine whether a protective immune response could be elicited by oral delivery of a recombinant bacterial vaccine, tetanus toxin fragment C (TTFC) was expressed constitutively in Lactococcus lactis and administered orally to C57 BL/6 mice. The antibody titers elicited were lower than those following intranasal immunization (a route already known to result in high-level systemic anti-TTFC immune responses) but the protective efficacy was the same order of magnitude. The serum antibody isotypes elicited were predominantly IgG1 and IgG2a. TTFC-specific fecal IgA responses could be detected following oral Or intranasal immunization. Chemically killed lactococci administered via the intranasal route were also able to elicit serum antibody responses of similar levels and kinetics to those induced by live bacteria.	UNIV CAMBRIDGE,DEPT PATHOL,DIV MICROBIOL & PARASITOL,CAMBRIDGE CB2 1QP,ENGLAND	University of Cambridge				Robinson, Karen/0000-0002-6329-9340	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BACHMANN MF, 1993, J VIROL, V67, P3917, DOI 10.1128/JVI.67.7.3917-3922.1993; BALLOUL JM, 1987, J IMMUNOL, V138, P3448; CHALLACOMBE SJ, 1992, IMMUNOLOGY, V76, P164; CHALLACOMBE SJ, 1983, ANN NY ACAD SCI, V409, P177, DOI 10.1111/j.1749-6632.1983.tb26868.x; CHAMBERLAIN LM, 1995, IMMUNOLOGY S1, V86, P139; CRYZ SJ, 1982, INFECT IMMUN, V38, P21, DOI 10.1128/IAI.38.1.21-26.1982; DITOMMASO A, 1994, INFECT IMMUN, V62, P1830, DOI 10.1128/IAI.62.5.1830-1834.1994; EISENBERG GHG, 1977, INFECT IMMUN, V15, P124, DOI 10.1128/IAI.15.1.124-131.1977; FAIRWEATHER NF, 1987, INFECT IMMUN, V55, P2541, DOI 10.1128/IAI.55.11.2541-2545.1987; GASSON MJ, 1983, J BACTERIOL, V154, P1; Gruzza M, 1992, Microb Releases, V1, P165; HOHMANN A, 1979, INFECT IMMUN, V25, P27, DOI 10.1128/IAI.25.1.27-33.1979; LAGRANDERIE M, 1993, VACCINE, V11, P1283, DOI 10.1016/0264-410X(93)90096-G; MARTEAU P, 1993, FEMS MICROBIOL REV, V12, P207, DOI [10.1016/0168-6445(93)90064-G, 10.1111/j.1574-6976.1993.tb00019.x]; MCGHEE JR, 1992, VACCINE, V10, P75, DOI 10.1016/0264-410X(92)90021-B; MEDAGLINI D, 1995, P NATL ACAD SCI USA, V92, P6868, DOI 10.1073/pnas.92.15.6868; NEWBY TJ, 1984, VET IMMUNOL IMMUNOP, V6, P67, DOI 10.1016/0165-2427(84)90049-7; NORTON PM, 1994, FEMS MICROBIOL LETT, V120, P249, DOI 10.1111/j.1574-6968.1994.tb07041.x; TARKKANEN J, 1986, J IMMUNOL, V137, P2428; VanCott JL, 1996, J IMMUNOL, V156, P1504; WELLS JM, 1993, MOL MICROBIOL, V8, P1155, DOI 10.1111/j.1365-2958.1993.tb01660.x; WELLS JM, 1993, J APPL BACTERIOL, V74, P629, DOI 10.1111/j.1365-2672.1993.tb05195.x; Wells JM, 1995, INT DAIRY J, V5, P1071, DOI 10.1016/0958-6946(95)00045-3; WELLS JM, 1996, NATO ASI SERIES H, V98, P37; WOLD AE, 1989, INFECT IMMUN, V57, P2666, DOI 10.1128/IAI.57.9.2666-2673.1989	25	205	226	0	12	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1997	15	7					653	657		10.1038/nbt0797-653	http://dx.doi.org/10.1038/nbt0797-653			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XH583	9219268	Bronze			2022-12-27	WOS:A1997XH58300029
J	Schein, CH				Schein, CH			From housekeeper to microsurgeon: The diagnostic and therapeutic potential of ribonucleases	NATURE BIOTECHNOLOGY			English	Review						Ampligen; Angiogenin; antiviral drugs; cancer therapy; immunotoxins; interferons; Onconase; Oragen; pancreatic ribonuclease; ribonucleases; RNase E; RNase H; RNase L; RNase P	DOUBLE-STRANDED-RNA; EOSINOPHIL-DERIVED NEUROTOXIN; BOVINE SEMINAL RIBONUCLEASE; HUMAN LEUKEMIA-CELLS; MESSENGER-RNA; ESCHERICHIA-COLI; INTERFERON-GAMMA; GENE-EXPRESSION; POSTTRANSCRIPTIONAL MODIFICATION; REVERSE-TRANSCRIPTASE	The RNA population in cells is controlled post-transcriptionally by ribonucleases (RNases) of varying specificity. Angiogenin, neurotoxins, and plant allergens are among many proteins with RNase activity or significant homology to known RNases. RNase activity in serum and cell extracts is elevated in a variety of cancers and infectious diseases. RNases are regulated by specific activators and inhibitors, including interferons. Many of these regulatory molecules are useful lead compounds for the design of drugs to control tumor angiogenesis, allergic reactions, and viral replication. One RNase (Onconase) and several RNase activators are now in clinical trials for cancer treatment or inhibition of chronic virus infections. Several others, alone or conjugated with specific cell binding molecules, are being developed for their antifungal, antiviral, and antitumor cell activity.			Schein, CH (corresponding author), UNIV TEXAS,MED BRANCH,GALVESTON,TX 77546, USA.		Schein, Catherine H/A-1426-2012	Schein, Catherine/0000-0002-8290-2109				ALBANESE AA, 1972, NY STATE J MED, V19, P1595; ALLINQUANT B, 1984, ACTA NEUROL SCAND, V70, P12; AUGUSTYNS K, 1993, NUCLEIC ACIDS RES, V21, P4670, DOI 10.1093/nar/21.20.4670; BARTHOLEYNS J, 1975, EUR J BIOCHEM, V60, P385, DOI 10.1111/j.1432-1033.1975.tb21014.x; BARZILAY G, 1995, NUCLEIC ACIDS RES, V23, P1544, DOI 10.1093/nar/23.9.1544; BESANCON F, 1994, AM J PHYSIOL-CELL PH, V267, pC1398, DOI 10.1152/ajpcell.1994.267.5.C1398; BISBAL C, 1995, J BIOL CHEM, V270, P13308, DOI 10.1074/jbc.270.22.13308; BLAIN SW, 1995, J VIROL, V69, P5113, DOI 10.1128/JVI.69.8.5113-5116.1995; BLAIN SW, 1993, J BIOL CHEM, V268, P23585; Boeck R, 1996, J BIOL CHEM, V271, P432, DOI 10.1074/jbc.271.1.432; Boix E, 1996, J MOL BIOL, V257, P992, DOI 10.1006/jmbi.1996.0218; BOIX E, 1994, J BIOL CHEM, V269, P25229; BORK P, 1993, FEBS LETT, V334, P149, DOI 10.1016/0014-5793(93)81701-Z; Brown JW, 1996, P NATL ACAD SCI USA, V93, P3001, DOI 10.1073/pnas.93.7.3001; Brown JW, 1996, NUCLEIC ACIDS RES, V24, P236, DOI 10.1093/nar/24.1.236; Bufe A, 1996, PLANTA, V199, P413, DOI 10.1007/BF00195733; BUFE A, 1997, IN PRESS NEW HORIZON; Capasso S, 1996, J MOL BIOL, V257, P492, DOI 10.1006/jmbi.1996.0179; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; Carroll SS, 1996, J BIOL CHEM, V271, P4988; CAZENAVE C, 1994, J BIOL CHEM, V269, P25185; CHENEY P, 1994, IN VIVO, V8, P599; Cheung JI, 1996, FEBS LETT, V386, P60, DOI 10.1016/0014-5793(96)00404-8; CHOW J, 1994, MOL MICROBIOL, V11, P919, DOI 10.1111/j.1365-2958.1994.tb00371.x; Cole JL, 1996, J BIOL CHEM, V271, P3979; Confalone E, 1995, J MOL EVOL, V41, P850, DOI 10.1007/BF00173164; Dementiev AA, 1996, BIOCHEM MOL BIOL INT, V39, P159; DONG BH, 1994, J BIOL CHEM, V269, P14153; FINGEROTE RJ, 1995, J GEN VIROL, V76, P373, DOI 10.1099/0022-1317-76-2-373; FRANCESCONI M, 1984, CANCER, V53, P1927, DOI 10.1002/1097-0142(19840501)53:9<1927::AID-CNCR2820530920>3.0.CO;2-#; GESSANI S, 1991, J VIROL, V65, P989, DOI 10.1128/JVI.65.2.989-991.1991; GILES RV, 1995, ANTISENSE RES DEV, V5, P23, DOI 10.1089/ard.1995.5.23; GILES RV, 1995, NUCLEIC ACIDS RES, V23, P954, DOI 10.1093/nar/23.6.954; GOTTE M, 1995, EMBO J, V14, P833, DOI 10.1002/j.1460-2075.1995.tb07061.x; HATZELMANN A, 1995, BRIT J PHARMACOL, V114, P821, DOI 10.1111/j.1476-5381.1995.tb13278.x; HAUGG M, 1992, NUCLEIC ACIDS RES, V20, P612, DOI 10.1093/nar/20.3.612; HERTLER AA, 1989, J CLIN ONCOL, V7, P1932, DOI 10.1200/JCO.1989.7.12.1932; HOFSTEENGE J, 1994, CURR OPIN STRUC BIOL, V4, P807, DOI 10.1016/0959-440X(94)90260-7; HUBBELL HR, 1994, ANTICANCER RES, V14, P341; HUE KK, 1995, J BACTERIOL, V177, P3465, DOI 10.1128/jb.177.12.3465-3471.1995; Huynh QK, 1996, BIOCHEM J, V316, P723, DOI 10.1042/bj3160723; JAIN C, 1995, GENE DEV, V9, P84, DOI 10.1101/gad.9.1.84; Jinno H, 1996, CANCER CHEMOTH PHARM, V38, P303, DOI 10.1007/s002800050487; Karawya EM, 1996, SAUDI MED J, V17, P42; KASAMA T, 1995, J INVEST MED, V43, P58; Kijima H, 1995, PHARMACOL THERAPEUT, V68, P247, DOI 10.1016/0163-7258(95)02008-X; Kim JS, 1995, J BIOL CHEM, V270, P31097, DOI 10.1074/jbc.270.52.31097; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOWALAK JA, 1994, BIOCHEMISTRY-US, V33, P7869, DOI 10.1021/bi00191a014; KOWALAK JA, 1993, NUCLEIC ACIDS RES, V21, P4577, DOI 10.1093/nar/21.19.4577; KUFEL J, 1994, J MOL BIOL, V244, P511, DOI 10.1006/jmbi.1994.1749; LAPPIN DF, 1992, BIOCHEM J, V281, P437, DOI 10.1042/bj2810437; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; Lequin O, 1996, BIOCHEMISTRY-US, V35, P8870, DOI 10.1021/bi960022r; Liao YD, 1996, PROTEIN EXPRES PURIF, V7, P194, DOI 10.1006/prep.1996.0027; LIU DK, 1983, INT J BIOCHEM, V15, P1273, DOI 10.1016/0020-711X(83)90218-5; LIU FY, 1995, GENE DEV, V9, P471, DOI 10.1101/gad.9.4.471; MCDOWELL KJ, J MOL BIOL, V255, P349; MELKOHOVETS YF, 1996, NUCLEIC ACIDS RES, V24, P1908; MENELLA MR, 1977, ANDROLOGIA, V9, P15; MORLEY DJ, 1983, HUM PATHOL, V14, P969, DOI 10.1016/S0046-8177(83)80176-2; MORRIS KN, 1992, P NATL ACAD SCI USA, V89, P4869, DOI 10.1073/pnas.89.11.4869; Mosimann SC, 1996, J MOL BIOL, V260, P540, DOI 10.1006/jmbi.1996.0420; MOSIMANN SC, 1994, J MOL BIOL, V236, P1141, DOI 10.1016/0022-2836(94)90017-5; Moussaoui M, 1996, J BIOL CHEM, V271, P4687; MURPHY NR, 1995, BIOTECHNIQUES, V1, P1068; NADANO D, 1994, ARCH BIOCHEM BIOPHYS, V312, P421, DOI 10.1006/abbi.1994.1328; NAKAI C, 1994, FEBS LETT, V339, P67, DOI 10.1016/0014-5793(94)80386-2; Naskalski J W, 1989, Z Med Lab Diagn, V30, P425; Newton DL, 1996, BIOCHEMISTRY-US, V35, P545, DOI 10.1021/bi951650w; Newton DL, 1996, INT J ONCOL, V8, P1095; NEWTON DL, 1994, J NEUROSCI, V14, P538; Ogawa T, 1996, NAT BIOTECHNOL, V14, P1566, DOI 10.1038/nbt1196-1566; OKADA N, 1995, J BIOL CHEM, V270, P16464, DOI 10.1074/jbc.270.27.16464; Okorokov AL, 1996, FEBS LETT, V384, P143, DOI 10.1016/0014-5793(96)00299-2; PALANIAPPAN C, 1995, J BIOL CHEM, V270, P4861, DOI 10.1074/jbc.270.9.4861; Parente D, 1996, EUR J BIOCHEM, V239, P272, DOI 10.1111/j.1432-1033.1996.0272u.x; PRESUTTI C, 1995, EMBO J, V14, P4022, DOI 10.1002/j.1460-2075.1995.tb00073.x; PY B, 1994, MOL MICROBIOL, V14, P717, DOI 10.1111/j.1365-2958.1994.tb01309.x; RADZIOCH D, 1991, MOL CELL BIOL, V11, P2718, DOI 10.1128/MCB.11.5.2718; REDDI KK, 1975, BIOCHEM BIOPH RES CO, V67, P110, DOI 10.1016/0006-291X(75)90290-9; ROSENBERG HF, 1995, NUCLEIC ACIDS RES, V23, P4290, DOI 10.1093/nar/23.21.4290; ROSENBERG HF, 1995, J BIOL CHEM, V270, P21539, DOI 10.1074/jbc.270.37.21539; Royo J, 1996, MOL GEN GENET, V250, P180; Rybak SM, 1996, J NATL CANCER I, V88, P747, DOI 10.1093/jnci/88.11.747; Sassa H, 1996, MOL GEN GENET, V250, P547; SCHEIN CH, 1995, BIOCHEM J, V307, P123, DOI 10.1042/bj3070123; SCHEIN CH, 1990, FEBS LETT, V270, P229, DOI 10.1016/0014-5793(90)81275-S; SCHEIN CH, 1997, IN PRESS IN VITRO TO; SCHNEIDER R, 1992, MOL GEN GENET, V233, P315, DOI 10.1007/BF00587594; SOBOL RW, 1995, J BIOL CHEM, V270, P5963, DOI 10.1074/jbc.270.11.5963; SOHLBERG B, 1993, P NATL ACAD SCI USA, V90, P277, DOI 10.1073/pnas.90.1.277; STOECKLE MY, 1993, NUCLEIC ACIDS RES, V21, P1613, DOI 10.1093/nar/21.7.1613; SUHADOLNIK RJ, 1994, CLIN INFECT DIS    S, V1, pS96; SZEWCZAK AA, 1993, P NATL ACAD SCI USA, V90, P9581, DOI 10.1073/pnas.90.20.9581; THARUN S, 1995, NUCLEIC ACIDS RES, V23, P641, DOI 10.1093/nar/23.4.641; Tiffany HL, 1996, J BIOL CHEM, V271, P12387, DOI 10.1074/jbc.271.21.12387; TOMASSINI M, 1994, OPHTHALMOLOGY, V101, P1808; TrabesingerRuef N, 1996, FEBS LETT, V382, P319, DOI 10.1016/0014-5793(96)00191-3; Truffert JC, 1996, TETRAHEDRON, V52, P3005, DOI 10.1016/0040-4020(96)00018-X; TURNAY J, 1993, MOL CELL BIOCHEM, V122, P39, DOI 10.1007/BF00925735; USHIJIMA H, 1993, J INTERFERON RES, V13, P161, DOI 10.1089/jir.1993.13.161; Usman N, 1996, CURR OPIN STRUC BIOL, V6, P527, DOI 10.1016/S0959-440X(96)80119-9; Walter MH, 1996, EUR J BIOCHEM, V239, P281, DOI 10.1111/j.1432-1033.1996.0281u.x; Wang LM, 1995, CLIN CANCER RES, V1, P1421; WATANABE Y, 1995, FEBS LETT, V372, P165, DOI 10.1016/0014-5793(95)00901-K; WEICKMANN JL, 1982, J BIOL CHEM, V257, P8705; WENNBORG A, 1995, P NATL ACAD SCI USA, V92, P7322, DOI 10.1073/pnas.92.16.7322; WOOL IG, 1984, TRENDS BIOCHEM SCI, V9, P14, DOI 10.1016/0968-0004(84)90040-9; Ye ZH, 1996, PLANT MOL BIOL, V30, P697, DOI 10.1007/BF00019005; YOULE RJ, 1994, P NATL ACAD SCI USA, V91, P6012, DOI 10.1073/pnas.91.13.6012; ZELENKO O, 1994, NUCLEIC ACIDS RES, V22, P2731, DOI 10.1093/nar/22.14.2731; HOUSTON BIOTECHNOLOG	113	93	102	1	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1997	15	6					529	536		10.1038/nbt0697-529	http://dx.doi.org/10.1038/nbt0697-529			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XC772	9181574				2022-12-27	WOS:A1997XC77200027
J	MacQuitty, JJ				MacQuitty, JJ			Embryo research - The real implications of Dolly	NATURE BIOTECHNOLOGY			English	Editorial Material											MacQuitty, JJ (corresponding author), GENPHARM INT,855 CALIFORNIA AVE,SUITE C,PALO ALTO,CA 94304, USA.								0	2	2	2	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1997	15	4					294	294		10.1038/nbt0497-294	http://dx.doi.org/10.1038/nbt0497-294			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WQ554	9094106	Bronze			2022-12-27	WOS:A1997WQ55400004
J	Hallin, J; Bowcut, V; Calinisan, A; Briere, DM; Hargis, L; Engstrom, LD; Laguer, J; Medwid, J; Vanderpool, D; Lifset, E; Trinh, D; Hoffman, N; Wang, X; Lawson, JD; Gunn, RJ; Smith, CR; Thomas, NC; Martinson, M; Bergstrom, A; Sullivan, F; Bouhana, K; Winski, S; He, L; Fernandez-Banet, J; Pavlicek, A; Haling, JR; Rahbaek, L; Marx, MA; Olson, P; Christensen, JG				Hallin, Jill; Bowcut, Vickie; Calinisan, Andrew; Briere, David M.; Hargis, Lauren; Engstrom, Lars D.; Laguer, Jade; Medwid, James; Vanderpool, Darin; Lifset, Ella; Trinh, David; Hoffman, Natalie; Wang, Xiaolun; Lawson, J. David; Gunn, Robin J.; Smith, Christopher R.; Thomas, Nicole C.; Martinson, Matthew; Bergstrom, Alex; Sullivan, Francis; Bouhana, Karyn; Winski, Shannon; He, Leo; Fernandez-Banet, Julio; Pavlicek, Adam; Haling, Jacob R.; Rahbaek, Lisa; Marx, Matthew A.; Olson, Peter; Christensen, James G.			Anti-tumor efficacy of a potent and selective non-covalent KRAS(G12D) inhibitor	NATURE MEDICINE			English	Article							MOLECULAR SUBTYPES; KRAS; RAF	Recent progress in targeting KRAS(G12C) has provided both insight and inspiration for targeting alternative KRAS mutants. In this study, we evaluated the mechanism of action and anti-tumor efficacy of MRTX1133, a potent, selective and non-covalent KRAS(G12D) inhibitor. MRTX1133 demonstrated a high-affinity interaction with GDP-loaded KRAS(G12D) with K-D and IC50 values of similar to 0.2 pM and <2 nM, respectively, and similar to 700-fold selectivity for binding to KRAS(G12D) as compared to KRAS(WT). MRTX1133 also demonstrated potent inhibition of activated KRAS(G12D) based on biochemical and co-crystal structural analyses. MRTX1133 inhibited ERK1/2 phosphorylation and cell viability in KRAS(G12D)-mutant cell lines, with median IC50 values of similar to 5 nM, and demonstrated >1,000-fold selectivity compared to KRAS(WT) cell lines. MRTX1133 exhibited dose-dependent inhibition of KRAS-mediated signal transduction and marked tumor regression (>= 30%) in a subset of KRAS(G12D)-mutant cell-line-derived and patient-derived xenograft models, including eight of 11 (73%) pancreatic ductal adenocarcinoma (PDAC) models. Pharmacological and CRISPR-based screens demonstrated that co-targeting KRAS(G12D) with putative feedback or bypass pathways, including EGFR or PI3K alpha, led to enhanced anti-tumor activity. Together, these data indicate the feasibility of selectively targeting KRAS mutants with non-covalent, high-affinity small molecules and illustrate the therapeutic susceptibility and broad dependence of KRAS(G12D) mutation-positive tumors on mutant KRAS for tumor cell growth and survival.	[Hallin, Jill; Bowcut, Vickie; Calinisan, Andrew; Briere, David M.; Hargis, Lauren; Engstrom, Lars D.; Laguer, Jade; Medwid, James; Vanderpool, Darin; Lifset, Ella; Trinh, David; Hoffman, Natalie; Wang, Xiaolun; Lawson, J. David; Gunn, Robin J.; Smith, Christopher R.; Thomas, Nicole C.; Haling, Jacob R.; Rahbaek, Lisa; Marx, Matthew A.; Olson, Peter; Christensen, James G.] Mirati Therapeut Inc, San Diego, CA 92121 USA; [Martinson, Matthew; Bergstrom, Alex; Sullivan, Francis; Bouhana, Karyn; Winski, Shannon] Pfizer, Array BioPharma Inc, Boulder, CO USA; [He, Leo; Fernandez-Banet, Julio; Pavlicek, Adam] Monoceros Biosyst LLC, San Diego, CA USA	Pfizer; Array BioPharma	Christensen, JG (corresponding author), Mirati Therapeut Inc, San Diego, CA 92121 USA.	christensenj@mirati.com		Wang, Xiaolun/0000-0001-9576-7746; Lawson, J David/0000-0002-5232-4539	National Institute of General Medical Sciences from the NIH [P30 GM124165]; NIH-ORIP High-End Instrumentation grant [S10OD021527]; DOE Office of Science by Argonne National Laboratory [DE-AC02-06CH11357]	National Institute of General Medical Sciences from the NIH; NIH-ORIP High-End Instrumentation grant; DOE Office of Science by Argonne National Laboratory(United States Department of Energy (DOE))	The authors thank Crown Bioscience and Molecular Diagnostic Services for animal study support and Flagship Biosciences for immunohistochemistry and image analysis. The authors thank InviCRO, LLC, for BLI and MRI imaging and analysis of pancreatic orthotopic models. The X-ray crystallography work described herein is based upon research conducted at the Northeastern Collaborative Access Team beamlines, which is funded by the National Institute of General Medical Sciences from the NIH (P30 GM124165). The Eiger 16M detector on 24-ID-E is funded by an NIH-ORIP High-End Instrumentation grant (S10OD021527). This research used resources of the Advanced Photon Source, a US Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under contract number DE-AC02-06CH11357.	Afonine PV, 2012, ACTA CRYSTALLOGR D, V68, P352, DOI 10.1107/S0907444912001308; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Campbell JD, 2016, NAT GENET, V48, P607, DOI 10.1038/ng.3564; Cancer Genome Atlas Network, 2012, NATURE, V487, P330, DOI [10.1038/nature11252, DOI 10.1038/NATURE11252]; Chalmers ZR, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0424-2; Christensen J., 2021, DISCOVERY CHARACTERI; Clark NA, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3689-3; Conway T, 2012, BIOINFORMATICS, V28, pI172, DOI 10.1093/bioinformatics/bts236; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Feldmann G, 2007, J HEPATO-BILIARY-PAN, V14, P224, DOI 10.1007/s00534-006-1166-5; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; He LY, 2018, METHODS MOL BIOL, V1711, P351, DOI 10.1007/978-1-4939-7493-1_17; Hunter JC, 2015, MOL CANCER RES, V13, P1325, DOI 10.1158/1541-7786.MCR-15-0203; Ihle NT, 2012, JNCI-J NATL CANCER I, V104, P228, DOI 10.1093/jnci/djr523; Janes MR, 2018, CELL, V172, P578, DOI 10.1016/j.cell.2018.01.006; Janne P., 2020, KRYSTAL 1 UPDATED SA; Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337; Kanda M, 2012, GASTROENTEROLOGY, V142, P730, DOI 10.1053/j.gastro.2011.12.042; Li SQ, 2018, NAT REV CANCER, V18, P767, DOI 10.1038/s41568-018-0076-6; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; Lito P, 2016, SCIENCE, V351, P604, DOI 10.1126/science.aad6204; Navas C, 2012, CANCER CELL, V22, P318, DOI 10.1016/j.ccr.2012.08.001; Olson P, 2009, SCIENCE, V324, P1400, DOI 10.1126/science.1175940; Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796; Patricelli MP, 2016, CANCER DISCOV, V6, P316, DOI 10.1158/2159-8290.CD-15-1105; Peng X, 2020, SOFT MATTER, V16, P54, DOI 10.1039/c9sm01847f; Rieder S, 2011, ANTI-CANCER AGENT ME, V11, P427, DOI 10.2174/187152011795677454; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rozengurt E, 2010, CLIN CANCER RES, V16, P2505, DOI 10.1158/1078-0432.CCR-09-2229; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; Schneider VA, 2017, GENOME RES, V27, P849, DOI 10.1101/gr.213611.116; Simanshu DK, 2017, CELL, V170, P17, DOI 10.1016/j.cell.2017.06.009; Skoulidis F, 2021, NEW ENGL J MED, V384, P2371, DOI 10.1056/NEJMoa2103695; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tran TH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21422-x; Ulanet DB, 2010, P NATL ACAD SCI USA, V107, P10791, DOI 10.1073/pnas.0914076107; Cespedes MV, 2006, CARCINOGENESIS, V27, P2190, DOI 10.1093/carcin/bgl063; Wang XL, 2021, J MED CHEM, DOI 10.1021/acs.jmedchem.1c01688; Weiss J., 2021, KRYSTAL 1 ADAGRASIB; Whatcott C. J., 2012, PANCREATIC CANC TUMO; Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749; Yaeger R, 2018, CANCER CELL, V33, P125, DOI 10.1016/j.ccell.2017.12.004; Ye JW, 2019, J PHARM ANAL, V9, P217, DOI 10.1016/j.jpha.2019.05.004; Zill OA, 2018, CLIN CANCER RES, V24, P3528, DOI 10.1158/1078-0432.CCR-17-3837	45	4	4	18	18	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2022	28	10								10.1038/s41591-022-02007-7	http://dx.doi.org/10.1038/s41591-022-02007-7		OCT 2022	37	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	6U5KV	36216931	Green Submitted			2022-12-27	WOS:000865725700006
J	Hopewell, S; Boutron, I; Chan, AW; Collins, GS; de Beyer, JA; Hrobjartsson, A; Nejstgaard, CH; Ostengaard, L; Schulz, KF; Tunn, R; Moher, D				Hopewell, Sally; Boutron, Isabelle; Chan, An-Wen; Collins, Gary S.; de Beyer, Jennifer A.; Hrobjartsson, Asbjorn; Nejstgaard, Camilla Hansen; Ostengaard, Lasse; Schulz, Kenneth F.; Tunn, Ruth; Moher, David			An update to SPIRIT and CONSORT reporting guidelines to enhance transparency in randomized trials comment	NATURE MEDICINE			English	Editorial Material							REDUCING WASTE; STATEMENT; QUALITY; PATIENT; DESIGN	Results from clinical trials can be deemed trustworthy only if they are properly conducted and their methods are fully reported. The SPIRIT and CONSORT checklists, which have improved clinical trial design, conduct and reporting, are being updated to reflect recent advances and improve the assessment of healthcare interventions.	[Hopewell, Sally; Tunn, Ruth] Univ Oxford, Ctr Stat Med, Oxford Clin Trials Res Unit, Oxford, England; [Boutron, Isabelle] Univ Paris Cite, Ctr Rech Epidemiol & Stat, INRAE, INSERM, Paris, France; [Boutron, Isabelle] Hop Hotel Dieu, AP HP, Ctr Epidemiol Clin, Paris, France; [Chan, An-Wen] Univ Toronto, Womens Coll, Res Inst, Dept Med, Toronto, ON, Canada; [Collins, Gary S.; de Beyer, Jennifer A.] Univ Oxford, Ctr Stat Med, UK EQUATOR Ctr, Oxford, England; [Hrobjartsson, Asbjorn; Nejstgaard, Camilla Hansen; Ostengaard, Lasse] Univ Southern Denmark, Dept Clin Res, Ctr Evidence Based Med Odense & Cochrane Denmark, Odense, Denmark; [Hrobjartsson, Asbjorn; Nejstgaard, Camilla Hansen; Ostengaard, Lasse] Odense Univ Hosp, Open Patient Data Explorat Network, Odense, Denmark; [Schulz, Kenneth F.] Univ N Carolina, Sch Med, Dept Obstet & Gynecol, Chapel Hill, NC 27515 USA; [Moher, David] Ottawa Hosp, Res Inst, Ctr Journalol, Clin Epidemiol Program, Ottawa, ON, Canada	University of Oxford; INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Toronto; Women's College Research Institute; University of Oxford; University of Southern Denmark; University of Southern Denmark; Odense University Hospital; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Ottawa; Ottawa Hospital Research Institute	Hopewell, S (corresponding author), Univ Oxford, Ctr Stat Med, Oxford Clin Trials Res Unit, Oxford, England.	sally.hopewell@csm.ox.ac.uk	Hróbjartsson, Asbjørn/HCH-3635-2022; Collins, Gary Stephen/A-2258-2014; Ostengaard, Lasse/N-5419-2018	Collins, Gary Stephen/0000-0002-2772-2316; Hopewell, Sally/0000-0002-6881-6984; Hansen Nejstgaard, Camilla/0000-0001-8574-9528; Ostengaard, Lasse/0000-0001-7033-3722	Medical Research Council-National Institute for Health Research Better Methods, Better Research [MR/W020483/1]; Cancer Research UK [C49297/A29084]; National Institute for Health Research Biomedical Research Centre, Oxford	Medical Research Council-National Institute for Health Research Better Methods, Better Research; Cancer Research UK(Cancer Research UK); National Institute for Health Research Biomedical Research Centre, Oxford(National Institute for Health Research (NIHR))	Supported by the Medical Research Council-National Institute for Health Research Better Methods, Better Research (MR/W020483/1] (S.H., R.T, J.A.d.B. and G.S.C.). This funder is not involved in any aspect of the research work. J.A.d.B. and G.S.C. are supported by Cancer Research UK (C49297/A29084). G.S.C. is supported by the National Institute for Health Research Biomedical Research Centre, Oxford. The reporting guideline under development is registered on the EQUATOR Network database. Approval for the Delphi survey was obtained from the Central University Research Ethics Committee, University of Oxford (20 July 2022; R76421/RE001].	Altman DG, 1996, BRIT MED J, V313, P570; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Butcher NJ, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04440-w; Caulley L, 2020, J CLIN EPIDEMIOL, V127, P96, DOI 10.1016/j.jclinepi.2020.07.013; Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583; Chan AW, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.e7586; Gabriel SE, 2012, NEW ENGL J MED, V367, P787, DOI 10.1056/NEJMp1207437; Gamble C, 2017, JAMA-J AM MED ASSOC, V318, P2337, DOI 10.1001/jama.2017.18556; Ghosn L, 2019, J CLIN EPIDEMIOL, V113, P168, DOI 10.1016/j.jclinepi.2019.05.030; Glasziou P, 2014, LANCET, V383, P267, DOI 10.1016/S0140-6736(13)62228-X; Goldacre B., COMPARE; Goodman SN, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf5027; Hoffmann TC, 2014, BMJ-BRIT MED J, V348, DOI [10.1136/bmj.g1687, 10.1055/s-0041-111066]; Ioannidis JPA, 2014, LANCET, V383, P166, DOI 10.1016/S0140-6736(13)62227-8; Ioannidis JPA, 2004, ANN INTERN MED, V141, P781, DOI 10.7326/0003-4819-141-10-200411160-00009; Kapp P., PREPRINT, DOI [10.1101/2022.02.03.22270357v1(2022), DOI 10.1101/2022.02.03.22270357V1(2022)]; Moher D, 2001, BMC Med Res Methodol, V1, P2, DOI 10.1186/1471-2288-1-2; Moher David, 2012, Int J Surg, V10, P28, DOI 10.1016/j.ijsu.2011.10.001; Savovic J, 2012, ANN INTERN MED, V157, P429, DOI 10.7326/0003-4819-157-6-201209180-00537; Schulz KF, 2010, J CLIN EPIDEMIOL, V63, P834, DOI [10.1016/j.jclinepi.2010.02.005, 10.1186/1741-7015-8-18, 10.1016/j.ijsu.2011.09.004, 10.4103/0976-500X.72352]; SCOPUS, SCOPUSCOM; Turner Lucy, 2012, Syst Rev, V1, P60, DOI 10.1186/2046-4053-1-60; Yordanov Y, 2015, BMJ-BRIT MED J, V350, DOI [10.1136/BMJ.h809, 10.1136/bmj.h809]	25	2	2	1	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2022	28	9					1740	1743		10.1038/s41591-022-01989-8	http://dx.doi.org/10.1038/s41591-022-01989-8		SEP 2022	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4S0LI	36109642	Bronze			2022-12-27	WOS:000854720900006
J	Anagnostou, T; Brody, JD				Anagnostou, Theodora; Brody, Joshua D.			In CAR T cell-treated lymphomas, the T cell rich get richer	NATURE MEDICINE			English	Editorial Material								In patients with large B cell lymphomas, immune features of the tumor microenviroment predict clinical outcomes after CAR T cell therapy; as the number of patients treated with CAR T cells is set to increase, refinement of these and other biomarkers will be crucial.	[Anagnostou, Theodora; Brody, Joshua D.] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA; [Brody, Joshua D.] Icahn Sch Med Mt Sinai, Precis Immunol Inst, New York, NY 10029 USA; [Brody, Joshua D.] Icahn Sch Med Mt Sinai, Icahn Genom Inst, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Brody, JD (corresponding author), Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.; Brody, JD (corresponding author), Icahn Sch Med Mt Sinai, Precis Immunol Inst, New York, NY 10029 USA.; Brody, JD (corresponding author), Icahn Sch Med Mt Sinai, Icahn Genom Inst, New York, NY 10029 USA.	joshua.brody@mssm.edu		Brody, Joshua/0000-0002-0850-6730				Bruni D, 2020, NAT REV CANCER, V20, P662, DOI 10.1038/s41568-020-0285-7; Cao YQ, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00767; Hawkins ER, 2021, BIOL-TARGETS THER, V15, P95, DOI 10.2147/BTT.S291768; Kline J, 2020, BLOOD, V135, P523, DOI 10.1182/blood.2019000847; Lacy SE, 2020, BLOOD, V135, P1759, DOI 10.1182/blood.2019003535; Locke FL, 2022, NEW ENGL J MED, V386, P640, DOI 10.1056/NEJMoa2116133; Locke FL, 2020, BLOOD ADV, V4, P4898, DOI 10.1182/bloodadvances.2020002394; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; Neelapu SS, 2022, NAT MED, V28, P735, DOI 10.1038/s41591-022-01731-4; Scholler N, 2022, NAT MED, V28, P1872, DOI 10.1038/s41591-022-01916-x; Shalabi H, 2018, HAEMATOLOGICA, V103, pE215, DOI 10.3324/haematol.2017.183459; Sterner RC, 2021, BLOOD CANCER J, V11, DOI 10.1038/s41408-021-00459-7	12	0	0	4	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2022	28	9					1757	1758		10.1038/s41591-022-01922-z	http://dx.doi.org/10.1038/s41591-022-01922-z		AUG 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4S0LI	36038630				2022-12-27	WOS:000847267200001
J	Sousos, N; Leathlobhair, MN; Karali, CS; Louka, E; Bienz, N; Royston, D; Clark, SA; Hamblin, A; Howard, K; Mathews, V; George, B; Roy, A; Psaila, B; Wedge, DC; Mead, AJ				Sousos, Nikolaos; Leathlobhair, Maire Ni; Karali, Christina Simoglou; Louka, Eleni; Bienz, Nicola; Royston, Daniel; Clark, Sally-Ann; Hamblin, Angela; Howard, Kieran; Mathews, Vikram; George, Biju; Roy, Anindita; Psaila, Bethan; Wedge, David C.; Mead, Adam J.			In utero origin of myelofibrosis presenting in adult monozygotic twins	NATURE MEDICINE			English	Article							MUTATIONS; CELLS	Lineage tracing analyses of cells from two monozygotic twins presenting with myelofibrosis in adulthood provide evidence of in utero transplacental transmission of the tumorigenic clone. The latency between acquisition of an initiating somatic driver mutation by a single-cell and clinical presentation with cancer is largely unknown. We describe a remarkable case of monozygotic twins presenting with CALR mutation-positive myeloproliferative neoplasms (MPNs) (aged 37 and 38 years), with a clinical phenotype of primary myelofibrosis. The CALR mutation was absent in T cells and dermal fibroblasts, confirming somatic acquisition. Whole-genome sequencing lineage tracing revealed a common clonal origin of the CALR-mutant MPN clone, which occurred in utero followed by twin-to-twin transplacental transmission and subsequent similar disease latency. Index sorting and single-colony genotyping revealed phenotypic hematopoietic stem cells (HSCs) as the likely MPN-propagating cell. Furthermore, neonatal blood spot analysis confirmed in utero origin of the JAK2V617F mutation in a patient presenting with polycythemia vera (aged 34 years). These findings provide a unique window into the prolonged evolutionary dynamics of MPNs and fitness advantage exerted by MPN-associated driver mutations in HSCs.	[Sousos, Nikolaos; Karali, Christina Simoglou; Louka, Eleni; Roy, Anindita; Psaila, Bethan; Mead, Adam J.] Univ Oxford, Natl Inst Hlth Res, MRC Weatherall Inst Mol Med, Med Res Council MRC,Mol Haematol Unit,Biomed Res, Oxford, England; [Sousos, Nikolaos; Hamblin, Angela; Psaila, Bethan; Mead, Adam J.] Oxford Univ Hosp NHS Fdn Trust, Churchill Hosp, Canc & Haematol Ctr, Oxford, England; [Leathlobhair, Maire Ni; Wedge, David C.] Univ Oxford, Li Ka Shing Ctr Hlth Informat & Discovery, Big Data Inst, Oxford, England; [Leathlobhair, Maire Ni] Univ Oxford, Ludwig Inst Canc Res, Oxford, England; [Leathlobhair, Maire Ni] Trinity Coll Dublin, Sch Genet & Microbiol, Moyne Inst Prevent Med, Dept Microbiol, Dublin, Ireland; [Bienz, Nicola] Frimley Hlth NHS Fdn Trust, Haematol Serv, Wexham Pk Hosp, Slough, Berks, England; [Royston, Daniel] Oxford Univ Hosp NHS Fdn Trust, John Radcliffe Hosp, Dept Cellular Pathol, Oxford, England; [Clark, Sally-Ann] Univ Oxford, MRC Weatherall Inst Mol Med, Flow Cytometry Facil, Oxford, England; [Hamblin, Angela; Howard, Kieran] Univ Oxford, Natl Inst Hlth Res, Biomed Res Ctr, Oxford, England; [Mathews, Vikram; George, Biju] Christian Med Coll & Hosp, Dept Haematol, Vellore, Tamil Nadu, India; [Roy, Anindita] Univ Oxford, MRC Weatherall Inst Mol Med, Dept Paediat, Oxford, England; [Wedge, David C.] Univ Manchester, Manchester Canc Res Ctr, Manchester, Lancs, England	University of Oxford; Oxford University Hospitals NHS Foundation Trust; University of Oxford; University of Oxford; Ludwig Institute for Cancer Research; University of Oxford; Trinity College Dublin; Oxford University Hospitals NHS Foundation Trust; University of Oxford; University of Oxford; University of Oxford; Christian Medical College & Hospital (CMCH) Vellore; University of Oxford; University of Manchester	Mead, AJ (corresponding author), Univ Oxford, Natl Inst Hlth Res, MRC Weatherall Inst Mol Med, Med Res Council MRC,Mol Haematol Unit,Biomed Res, Oxford, England.; Mead, AJ (corresponding author), Oxford Univ Hosp NHS Fdn Trust, Churchill Hosp, Canc & Haematol Ctr, Oxford, England.; Wedge, DC (corresponding author), Univ Oxford, Li Ka Shing Ctr Hlth Informat & Discovery, Big Data Inst, Oxford, England.; Wedge, DC (corresponding author), Univ Manchester, Manchester Canc Res Ctr, Manchester, Lancs, England.	David.Wedge@manchester.ac.uk; adam.mead@imm.ox.ac.uk		Howard, Kieran/0000-0003-3335-4940; Louka, Eleni/0000-0002-0543-7397; Simoglou Karali, Christina/0000-0003-2169-6580; Mathews, Vikram/0000-0001-9417-2353; Ni Leathlobhair, Maire/0000-0002-8523-4935	Hellenic Society of Haematology Foundation Fellowship; Cancer Research UK Oxford Centre Clinical Research Training Fellowship [C130623/A249471]; Junior Research Fellowship (Trinity College, University of Oxford); Medical Research Council (MRC) Senior Clinical Fellowship [MR/L006340/1]; Cancer Research UK Senior Cancer Research Fellowship [C42639/A26988]; MRC Molecular Haematology Unit core award [MC_UU_12009/5]; MRC Human Immunology Unit; MRC Molecular Haematology Unit [MC_UU_12009]; National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC); Kay Kendall Leukaemia Fund [KKL1057]; John Fell Fund [131/030, 101/517]; EPA fund [CF182, CF170, CF268]; MRC WIMM Strategic Alliance [G0902418, MC_UU_12025]; Wellcome Trust Core Award [203141/Z/16/Z]; NIHR Oxford BRC	Hellenic Society of Haematology Foundation Fellowship; Cancer Research UK Oxford Centre Clinical Research Training Fellowship; Junior Research Fellowship (Trinity College, University of Oxford); Medical Research Council (MRC) Senior Clinical Fellowship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK Senior Cancer Research Fellowship(Cancer Research UK); MRC Molecular Haematology Unit core award(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC Human Immunology Unit(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC Molecular Haematology Unit(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC)(National Institute for Health Research (NIHR)); Kay Kendall Leukaemia Fund; John Fell Fund; EPA fund; MRC WIMM Strategic Alliance; Wellcome Trust Core Award(Wellcome Trust); NIHR Oxford BRC	This work was funded by a Hellenic Society of Haematology Foundation Fellowship and a Cancer Research UK Oxford Centre Clinical Research Training Fellowship (C130623/A249471) to N.S., a Junior Research Fellowship (Trinity College, University of Oxford) to M.N.L. and a Medical Research Council (MRC) Senior Clinical Fellowship (MR/L006340/1), a Cancer Research UK Senior Cancer Research Fellowship (C42639/A26988) and the MRC Molecular Haematology Unit core award (MC_UU_12009/5) to A.J.M. We acknowledge the flow cytometry facility at the MRC Weatherall Institute of Molecular Medicine (WIMM), which is supported by the MRC Human Immunology Unit, the MRC Molecular Haematology Unit (MC_UU_12009), the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), the Kay Kendall Leukaemia Fund (KKL1057), the John Fell Fund (131/030 and 101/517), the EPA fund (CF182 and CF170) and the MRC WIMM Strategic Alliance awards G0902418 and MC_UU_12025. We also acknowledge the contribution of the WIMM Sequencing Facility, supported by the MRC Human Immunology Unit and by the EPA fund (CF268). The computational aspects of this research were supported by the Wellcome Trust Core Award 203141/Z/16/Z and the NIHR Oxford BRC to D.C.W. and A.J.M. The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR or the Department of Health.	Abu-Zeinah G, 2021, LEUKEMIA, V35, P2592, DOI 10.1038/s41375-021-01183-8; Adzhubei Ivan, 2013, Curr Protoc Hum Genet, VChapter 7, DOI 10.1002/0471142905.hg0720s76; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Andersen MA, 2018, ACTA HAEMATOL-BASEL, V139, P195, DOI 10.1159/000488384; Babicki S, 2016, NUCLEIC ACIDS RES, V44, pW147, DOI 10.1093/nar/gkw419; Bao EL, 2020, NATURE, V586, DOI 10.1038/s41586-020-2786-7; Benjamin D., 2019, PREPRINT, DOI 10.1101/861054; Bergstrom EN, 2019, BMC GENOMICS, V20, DOI 10.1186/s12864-019-6041-2; Blokzijl F, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0539-0; Bolli N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms3997; Carpenter B, 2017, J STAT SOFTW, V76, P1, DOI 10.18637/jss.v076.i01; Chen XY, 2016, BIOINFORMATICS, V32, P1220, DOI 10.1093/bioinformatics/btv710; Chiang C, 2015, NAT METHODS, V12, P966, DOI [10.1038/nmeth.3505, 10.1038/NMETH.3505]; Cooke DP, 2021, NAT BIOTECHNOL, V39, P885, DOI 10.1038/s41587-021-00861-3; Cordua S, 2019, BLOOD, V134, P469, DOI 10.1182/blood.2019001113; Danial-Farran N, 2018, EUR J HUM GENET, V26, P1840, DOI 10.1038/s41431-018-0218-z; Fabre MA, 2020, BLOOD, V135, P269, DOI 10.1182/blood.2019001807; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Geoffroy V, 2018, BIOINFORMATICS, V34, P3572, DOI 10.1093/bioinformatics/bty304; Gerstung M, 2020, NATURE, V578, P122, DOI 10.1038/s41586-019-1907-7; Greaves M, 2018, EVOL MED PUBLIC HLTH, P106, DOI 10.1093/emph/eoy011; Gronau QF, 2020, J STAT SOFTW, V92, P1, DOI 10.18637/jss.v092.i10; Hansen JW, 2020, BLOOD, V135, P261, DOI 10.1182/blood.2019001793; Hong DL, 2008, SCIENCE, V319, P336, DOI 10.1126/science.1150648; Jaiswal S, 2019, SCIENCE, V366, P586, DOI 10.1126/science.aan4673; Kim S, 2018, NAT METHODS, V15, P591, DOI 10.1038/s41592-018-0051-x; Klampfl T, 2013, NEW ENGL J MED, V369, P2379, DOI 10.1056/NEJMoa1311347; Kuhn RM, 2013, BRIEF BIOINFORM, V14, P144, DOI 10.1093/bib/bbs038; Layer RM, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-6-r84; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4; Mead AJ, 2017, BLOOD, V129, P1607, DOI 10.1182/blood-2016-10-696005; Mitchell TJ, 2018, CELL, V173, P611, DOI 10.1016/j.cell.2018.02.020; Molenaar RJ, 2018, LEUKEMIA, V32, P952, DOI 10.1038/leu.2017.323; Nangalia J, 2013, NEW ENGL J MED, V369, P2391, DOI 10.1056/NEJMoa1312542; Nangalia J, 2017, HEMATOL-AM SOC HEMAT, P470, DOI 10.1182/asheducation-2017.1.470; NIKZAINAL S, 2012, CELL, V149; Papaemmanuil E, 2016, NEW ENGL J MED, V374, P2209, DOI 10.1056/NEJMoa1516192; Pich O., 2020, PREPRINT, DOI [10.1101/2020, 10.1101/2020.10.22.350140]; Rentzsch P, 2019, NUCLEIC ACIDS RES, V47, pD886, DOI 10.1093/nar/gky1016; Rodriguez-Meira A, 2019, MOL CELL, V73, P1292, DOI 10.1016/j.molcel.2019.01.009; Rustad EH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15740-9; Silveira DRA, 2020, BLOOD ADV, V4, P2339, DOI 10.1182/bloodadvances.2019001419; Ueda K, 2017, BLOOD ADV, V1, P1001, DOI 10.1182/bloodadvances.2017004457; Valdes-Mas R, 2016, BLOOD, V128, P1894, DOI 10.1182/blood-2016-06-724252; Van Egeren D, 2021, CELL STEM CELL, V28, P514, DOI 10.1016/j.stem.2021.02.001; Vaser R, 2016, NAT PROTOC, V11, P1, DOI 10.1038/nprot.2015.123; Williams N, 2022, NATURE, V602, P162, DOI 10.1038/s41586-021-04312-6; Yates LR, 2017, CANCER CELL, V32, P169, DOI 10.1016/j.ccell.2017.07.005	49	1	1	2	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2022	28	6					1207	+		10.1038/s41591-022-01793-4	http://dx.doi.org/10.1038/s41591-022-01793-4		MAY 2022	18	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E9IE	35637336	Green Published, hybrid			2022-12-27	WOS:000802851000001
J	Garriga, R; Mas, J; Abraha, S; Nolan, J; Harrison, O; Tadros, G; Matic, A				Garriga, Roger; Mas, Javier; Abraha, Semhar; Nolan, Jon; Harrison, Oliver; Tadros, George; Matic, Aleksandar			Machine learning model to predict mental health crises from electronic health records	NATURE MEDICINE			English	Article							RISK; PATIENT; CURVE; TIME	The timely identification of patients who are at risk of a mental health crisis can lead to improved outcomes and to the mitigation of burdens and costs. However, the high prevalence of mental health problems means that the manual review of complex patient records to make proactive care decisions is not feasible in practice. Therefore, we developed a machine learning model that uses electronic health records to continuously monitor patients for risk of a mental health crisis over a period of 28 days. The model achieves an area under the receiver operating characteristic curve of 0.797 and an area under the precision-recall curve of 0.159, predicting crises with a sensitivity of 58% at a specificity of 85%. A follow-up 6-month prospective study evaluated our algorithm's use in clinical practice and observed predictions to be clinically valuable in terms of either managing caseloads or mitigating the risk of crisis in 64% of cases. To our knowledge, this study is the first to continuously predict the risk of a wide range of mental health crises and to explore the added value of such predictions in clinical practice. Machine learning applied on electronic health records can predict mental health crises 28 days in advance and become a clinically valuable tool for managing caseloads and mitigating the risk of crisis.	[Garriga, Roger; Mas, Javier; Harrison, Oliver; Matic, Aleksandar] Koa Hlth, Barcelona, Spain; [Garriga, Roger] Univ Pompeu Fabra, Dept Informat & Commun Technol, Barcelona, Spain; [Mas, Javier] Kannact, Barcelona, Spain; [Abraha, Semhar; Nolan, Jon; Tadros, George] Birmingham & Solihull Mental Hlth NHS Fdn Trust, Birmingham, W Midlands, England; [Abraha, Semhar] Univ Warwick, Warwick, England; [Tadros, George] Aston Univ, Aston Med Sch, Aston, England	Pompeu Fabra University; University of Warwick; Aston University	Garriga, R; Matic, A (corresponding author), Koa Hlth, Barcelona, Spain.; Garriga, R (corresponding author), Univ Pompeu Fabra, Dept Informat & Commun Technol, Barcelona, Spain.	roger.garrigacalleja@koahealth.com; aleksandar.matic@koahealth.com		Harrison, Oliver/0000-0001-6947-2581; Abraha, Semhar/0000-0002-3581-8959; Mas Adell, Javier/0000-0002-5836-5534; Matic, Aleksandar/0000-0002-8752-4098; Garriga, Roger/0000-0003-3206-6293	Health Foundation [709246]; Birmingham and Solihull Mental Health Foundation NHS Trust; Koa Health	Health Foundation; Birmingham and Solihull Mental Health Foundation NHS Trust; Koa Health	This work was supported by a Health Foundation grant (Call: Round 1 Advancing Applied Analytics Programme, award reference number 709246; project title: Using predictive analysis to prevent mental health crisis) and Koa Health (formerly Telefonica Alpha). We gratefully acknowledge the support of the Birmingham and Solihull Mental Health Foundation NHS Trust, and, in particular, we thank P. Presland, L. Hudson, E. Patterson, R. Russell, J. S. Panesar and S. Rahim for their work on this study. We also thank O. Smith (Koa Health) for key assistance with the study logistics and the algorithm fairness analysis and P. Weinberger (previously with Telefonica Alpha) for conducting data analyses during the initial study phase and contributing to the development of the first algorithms. We thank all the clinicians who participated in the prospective study for their time, support and contribution.	[Anonymous], 2018, NAVIGATING MENTAL HL; Arcadu F, 2019, NPJ DIGIT MED, V2, DOI 10.1038/s41746-019-0172-3; Ashfaq A, 2019, J BIOMED INFORM, V97, DOI 10.1016/j.jbi.2019.103256; Barak-Corren Y, 2017, AM J PSYCHIAT, V174, P154, DOI 10.1176/appi.ajp.2016.16010077; Bardram JE, 2020, IEEE PERVAS COMPUT, V19, P62, DOI 10.1109/MPRV.2019.2925338; Benjamini Y, 2006, BIOMETRIKA, V93, P491, DOI 10.1093/biomet/93.3.491; Bergstra J. S., 2011, ADV NEURAL INFORM PR, V24; Boyd Kendrick, 2013, Machine Learning and Knowledge Discovery in Databases. European Conference, ECML PKDD 2013. Proceedings: LNCS 8190, P451, DOI 10.1007/978-3-642-40994-3_29; BRAMER G R, 1988, World Health Statistics Quarterly, V41, P32; Brier G. W., 1950, MONTHLY WEATHER REVI, V78, P1, DOI DOI 10.1175/1520-0493(1950)078<0001:VOFEIT>2.0.CO;2; Chen Q, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003416; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Duan L, 2020, LANCET PSYCHIAT, V7, P300, DOI 10.1016/S2215-0366(20)30073-0; Le DV, 2018, J BIOMED INFORM, V86, P49, DOI 10.1016/j.jbi.2018.08.007; Fernandes AC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25773-2; Fiorillo A, 2020, EUR PSYCHIAT, V63, DOI 10.1192/j.eurpsy.2020.35; Friedman JH, 2001, ANN STAT, V29, P1189, DOI 10.1214/aos/1013203451; GRAHAM A, 2020, AM PSYCHOL, V75; Graham AK, 2020, TRANSL BEHAV MED, V10, P598, DOI 10.1093/tbm/ibz140; Ha N., 2016, TREE BOOSTING XGBOOS; He ZL, 2020, CRIT CARE MED, V48, pE1337, DOI 10.1097/CCM.0000000000004644; Horwitz LI, 2019, NEW ENGL J MED, V381, P1175, DOI 10.1056/NEJMsb1900856; Hyland SL, 2020, NAT MED, V26, P364, DOI 10.1038/s41591-020-0789-4; Jamei M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181173; James SL, 2018, LANCET, V392, P1789, DOI [10.1016/S0140-6736(18)32279-7, 10.1016/s0140-6736(18)32279-7]; Kessler RC, 2015, JAMA PSYCHIAT, V72, P49, DOI 10.1001/jamapsychiatry.2014.1754; Li X, 2020, CRIT CARE MED, V48, pE884, DOI 10.1097/CCM.0000000000004494; LIN HE, 2017, INT J INTEGR CARE; Lin YW, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218942; Lundberg SM, 2017, ADV NEUR IN, V30; Lundberg SM, 2020, NAT MACH INTELL, V2, P56, DOI 10.1038/s42256-019-0138-9; Miller V., 1991, AUST OCCUP THER J, V38, P143, DOI [10.1111/j.1440-1630.1991.tb01710.x, DOI 10.1111/J.1440-1630.1991.TB01710.X]; Miotto R, 2016, SCI REP-UK, V6, DOI 10.1038/srep26094; Mohr DC, 2018, JAMA PSYCHIAT, V75, P113, DOI 10.1001/jamapsychiatry.2017.3838; Morgan DJ, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.0348; Olfson M, 2013, AM J PSYCHIAT, V170, P1442, DOI 10.1176/appi.ajp.2013.12121506; Ozenne B, 2015, J CLIN EPIDEMIOL, V68, P855, DOI 10.1016/j.jclinepi.2015.02.010; Paton F, 2016, HEALTH TECHNOL ASSES, V20, P1, DOI 10.3310/hta20030; Pfefferbaum B, 2020, NEW ENGL J MED, V383, P510, DOI 10.1056/NEJMp2008017; Poulin C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085733; Rajkomar A, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0029-1; Raket LL, 2020, LANCET DIGIT HEALTH, V2, pE229, DOI 10.1016/S2589-7500(20)30024-8; de Pablo GS, 2021, SCHIZOPHRENIA BULL, V47, P284, DOI 10.1093/schbul/sbaa120; Simon GE, 2018, AM J PSYCHIAT, V175, P434, DOI [10.1176/appi.ajp.2017.17080844, 10.1176/appi.ajp.2018.17101167]; Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2; Su C, 2020, TRANSL PSYCHIAT, V10, DOI 10.1038/s41398-020-01100-0; Su C, 2020, TRANSL PSYCHIAT, V10, DOI 10.1038/s41398-020-0780-3; Suchting R, 2018, PSYCHIAT RES, V268, P217, DOI 10.1016/j.psychres.2018.07.004; van Walraven C, 2011, CAN MED ASSOC J, V183, pE391, DOI 10.1503/cmaj.101860; Vickers AJ, 2006, MED DECIS MAKING, V26, P565, DOI 10.1177/0272989X06295361; Wainberg ML, 2017, CURR PSYCHIAT REP, V19, DOI 10.1007/s11920-017-0780-z; Walsh CG, 2017, CLIN PSYCHOL SCI, V5, P457, DOI 10.1177/2167702617691560; Ye CY, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.9268; Zadrozny, 2002, PROC 8 ACM SIGKDD IN	54	1	1	10	13	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2022	28	6					1240	+		10.1038/s41591-022-01811-5	http://dx.doi.org/10.1038/s41591-022-01811-5		MAY 2022	29	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E9IE	35577964	Green Submitted, Green Accepted, Green Published, hybrid			2022-12-27	WOS:000796324500003
J	Hajek, P; Przulj, D; Pesola, F; Griffiths, C; Walton, R; McRobbie, H; Coleman, T; Lewis, S; Whitemore, R; Clark, M; Ussher, M; Sinclair, L; Seager, E; Cooper, S; Bauld, L; Naughton, F; Sasieni, P; Manyonda, I; Smith, KM				Hajek, Peter; Przulj, Dunja; Pesola, Francesca; Griffiths, Chris; Walton, Robert; McRobbie, Hayden; Coleman, Tim; Lewis, Sarah; Whitemore, Rachel; Clark, Miranda; Ussher, Michael; Sinclair, Lesley; Seager, Emily; Cooper, Sue; Bauld, Linda; Naughton, Felix; Sasieni, Peter; Manyonda, Isaac; Smith, Katie Myers			Electronic cigarettes versus nicotine patches for smoking cessation in pregnancy: a randomized controlled trial	NATURE MEDICINE			English	Article							REPLACEMENT THERAPY; DOUBLE-BLIND; SMOKERS; INTERVENTION; EXPOSURE; METABOLISM; TOBACCO; INFANT; FETAL	A randomized controlled trial comparing the efficacy of electronic cigarettes and nicotine patches for smoking cessation in pregnant women found no differences between the interventions. However, electronic cigarettes were found to have some benefit when only the data from women who adhered strictly to the trial protocol were analyzed. Nicotine replacement therapy, in the form of nicotine patches, is commonly offered to pregnant women who smoke to help them to stop smoking, but this approach has limited efficacy in this population. Electronic cigarettes (e-cigarettes) are also used by pregnant women who smoke but their safety and efficacy in pregnancy are unknown. Here, we report the results of a randomized controlled trial in 1,140 participants comparing refillable e-cigarettes with nicotine patches. Pregnant women who smoked were randomized to e-cigarettes (n = 569) or nicotine patches (n = 571). In the unadjusted analysis of the primary outcome, validated prolonged quit rates at the end of pregnancy in the two study arms were not significantly different (6.8% versus 4.4% in the e-cigarette and patch arms, respectively; relative risk (RR) = 1.55, 95%CI: 0.95-2.53, P = 0.08). However, some participants in the nicotine patch group also used e-cigarettes during the study. In a pre-specified sensitivity analysis excluding abstinent participants who used non-allocated products, e-cigarettes were more effective than patches (6.8% versus 3.6%; RR = 1.93, 95%CI: 1.14-3.26, P = 0.02). Safety outcomes included adverse events and maternal and birth outcomes. The safety profile was found to be similar for both study products, however, low birthweight (<2,500 g) was less frequent in the e-cigarette arm (14.8% versus 9.6%; RR = 0.65, 95%CI: 0.47-0.90, P = 0.01). Other adverse events and birth outcomes were similar in the two study arms. E-cigarettes might help women who are pregnant to stop smoking, and their safety for use in pregnancy is similar to that of nicotine patches. ISRCTN62025374.	[Hajek, Peter; Przulj, Dunja; Pesola, Francesca; Griffiths, Chris; Walton, Robert; Seager, Emily; Smith, Katie Myers] Queen Mary Univ London, Wolfson Inst Populat Hlth, London, England; [McRobbie, Hayden] Univ New South Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW, Australia; [Coleman, Tim; Lewis, Sarah; Whitemore, Rachel; Clark, Miranda; Cooper, Sue] Univ Nottingham, Fac Med & Hlth Sci, Nottingham, England; [Ussher, Michael] St Georges Univ London, Div Populat Heath Sci & Educ, London, England; [Ussher, Michael] Univ Stirling, Inst Social Mkt & Hlth, Stirling, Scotland; [Sinclair, Lesley; Bauld, Linda] Univ Edinburgh, Usher Inst, Edinburgh, Midlothian, Scotland; [Sinclair, Lesley; Bauld, Linda] Univ Edinburgh, SPECTRUM Consortium, Edinburgh, Midlothian, Scotland; [Naughton, Felix] Univ East Anglia, Sch Hlth Sci, Norwich, Norfolk, England; [Sasieni, Peter] Kings Coll London, Kings Clin Trials Unit, London, England; [Manyonda, Isaac] St Georges Healthcare NHS Trust, London, England	University of London; Queen Mary University London; University of New South Wales Sydney; University of Nottingham; St Georges University London; University of Stirling; University of Edinburgh; University of Edinburgh; University of East Anglia; University of London; King's College London; St Georges University London	Pesola, F (corresponding author), Queen Mary Univ London, Wolfson Inst Populat Hlth, London, England.	f.pesola@qmul.ac.uk	Smith, Katie Elizabeth/GXH-2114-2022; McRobbie, Hayden/B-4552-2018	Sasieni, Peter/0000-0003-1509-8744; Clark, Miranda/0000-0002-6179-046X; Griffiths, Chris/0000-0001-7935-8694; Coleman, Tim/0000-0002-7303-4805; Przulj, Dunja/0000-0003-1133-8835; McRobbie, Hayden/0000-0002-7777-1845	National Institute of Health Research, Health Technology Programme [15/57/85]	National Institute of Health Research, Health Technology Programme	The study was funded by the National Institute of Health Research, Health Technology Programme (ref. no. 15/57/85). The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication. The following authors were in receipt of this funding: P.H., D.P., C.G., R.Wa., H.M., T.C., S.L, M.U., L.S., S.C., L.B., F.N., P.S., I.M. and K.M.S. Tim Coleman is a National Institute for Health Research (NIHR) Senior Investigator.	Abraham M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170946; Bar-Zeev Y, 2018, MED J AUSTRALIA, V208, P46, DOI 10.5694/mja17.00446; Bates C., QEIOS, DOI [10.32388/ZGVHM7.3(2021, DOI 10.32388/ZGVHM7.3(2021]; Beard E, 2016, ADDICTION, V111, P2230, DOI 10.1111/add.13501; Benowitz NL, 2020, NICOTINE TOB RES, V22, P1086, DOI 10.1093/ntr/ntz132; Benowitz NL, 2000, TOB CONTROL, V9, P91, DOI 10.1136/tc.9.suppl_3.iii91; Benowitz NL, 2004, NICOTINE TOB RES, V6, pS189, DOI 10.1080/14622200410001669169; Berlin I, 2016, J SUBST ABUSE TREAT, V63, P18, DOI 10.1016/j.jsat.2015.12.008; Berlin Ivan, 2014, BMJ, V348, pg1622, DOI 10.1136/bmj.g1622; Bowker K, 2021, BJOG-INT J OBSTET GY, V128, P984, DOI 10.1111/1471-0528.16553; Bowker K, 2015, ADDICTION, V110, P1827, DOI 10.1111/add.13029; Brown J, 2014, LANCET RESP MED, V2, P997, DOI 10.1016/S2213-2600(14)70195-X; Bruin JE, 2010, TOXICOL SCI, V116, P364, DOI 10.1093/toxsci/kfq103; Caraballo RS, 2017, PREV CHRONIC DIS, V14, DOI 10.5888/pcd14.160600; Claire R, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010078.pub3; Cohen G, 2005, P NATL ACAD SCI USA, V102, P3817, DOI 10.1073/pnas.0409782102; Coleman T, 2004, BMJ-BRIT MED J, V328, P965, DOI 10.1136/bmj.328.7446.965; Coleman T, 2012, NEW ENGL J MED, V366, P808, DOI 10.1056/NEJMoa1109582; Cooper S, 2014, LANCET RESP MED, V2, P728, DOI 10.1016/S2213-2600(14)70157-2; Dejmek J, 2000, ENVIRON HEALTH PERSP, V108, P1159, DOI 10.2307/3434828; Dempsey D, 2002, J PHARMACOL EXP THER, V301, P594, DOI 10.1124/jpet.301.2.594; Dempsey DA, 2001, DRUG SAFETY, V24, P277, DOI 10.2165/00002018-200124040-00005; Eaton DL, 2018, PUBLIC HLTH CONSEQUE; El-Mohandes AAE, 2013, MATERN CHILD HLTH J, V17, P897, DOI 10.1007/s10995-012-1069-9; Fagerstrom K, 2012, NICOTINE TOB RES, V14, P75, DOI 10.1093/ntr/ntr137; Fahy SJ, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-107; Fish LJ, 2009, NICOTINE TOB RES, V11, P514, DOI 10.1093/ntr/ntp032; Froggatt S, 2020, ECLINICALMEDICINE, V28, DOI 10.1016/j.eclinm.2020.100602; Gartner C, 2020, DRUG ALCOHOL REV, V39, P3, DOI 10.1111/dar.13024; Hajek P, 2001, ADDICTION, V96, P485, DOI 10.1046/j.1360-0443.2001.96348511.x; Hajek Peter, 2018, Psychopharmacology (Berl), V235, P1083, DOI 10.1007/s00213-017-4826-z; Hajek P, 2019, NEW ENGL J MED, V380, P629, DOI 10.1056/NEJMoa1808779; Hajek P, 2017, PSYCHOPHARMACOLOGY, V234, P773, DOI 10.1007/s00213-016-4512-6; Hajek P, 2014, ADDICTION, V109, P1801, DOI 10.1111/add.12659; Hajek P, 2010, ADDICTION, V105, P1016, DOI 10.1111/j.1360-0443.2010.02964.x; Hartmann-Boyce J, 2021, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010216.pub5; Hotham ED, 2006, ADDICT BEHAV, V31, P641, DOI 10.1016/j.addbeh.2005.05.042; Jones M, 2016, ADDICTION, V111, P981, DOI 10.1111/add.13309; Kapur B, 2001, CURR THER RES CLIN E, V62, P274, DOI 10.1016/S0011-393X(01)80011-4; Koslow M, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.19366; Lindson N, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013308; Marufu TC, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1552-5; McDonnell BP, 2020, BJOG-INT J OBSTET GY, V127, P750, DOI 10.1111/1471-0528.16110; McEwen A., 2006, MANUAL SMOKING CESSA; McNeill A, 2021, VAPING ENGLAND EVIDE; Myers K, 2012, SMOKING CESSATION IN; Nanovskaya TN, 2017, AM J OBSTET GYNECOL, V216, DOI 10.1016/j.ajog.2016.11.1036; Oncken C, 2008, OBSTET GYNECOL, V112, P859, DOI 10.1097/AOG.0b013e318187e1ec; Oncken C, 2019, AM J OBST GYNEC MFM, V1, P10, DOI 10.1016/j.ajogmf.2019.03.006; Opondo C, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0252817; Phillips-Waller A, 2021, PSYCHOPHARMACOLOGY, V238, P825, DOI 10.1007/s00213-020-05734-2; Pollak KI, 2007, AM J PREV MED, V33, P297, DOI 10.1016/j.amepre.2007.05.006; Regan AK, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-92930-5; Robson, 2020, VAPING ENGLAND EVIDE; Rogers John M., 2008, Birth Defects Research, V84, P1, DOI 10.1002/bdrc.20119; ROWELL PP, 1982, TOXICOL APPL PHARM, V66, P30, DOI 10.1016/0041-008X(82)90058-8; Saddleson ML, 2016, ADDICT BEHAV, V54, P33, DOI 10.1016/j.addbeh.2015.11.012; Salihu HM, 2007, EARLY HUM DEV, V83, P713, DOI 10.1016/j.earlhumdev.2007.08.002; Smith KM, 2022, ADDICTION, V117, P224, DOI 10.1111/add.15628; SRNT Subcommittee on Biochemical Verification, 2002, Nicotine Tob Res, V4, P149, DOI 10.1080/14622200210123581; Stotts AL, 2015, AM J PERINAT, V32, P351, DOI 10.1055/s-0034-1386635; Sullivan TR, 2018, STAT METHODS MED RES, V27, P2610, DOI 10.1177/0962280216683570; Taylor L, 2021, ADDICTION, V116, P239, DOI 10.1111/add.15185; Ussher M, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2145; West R, 2005, ADDICTION, V100, P299, DOI 10.1111/j.1360-0443.2004.00995.x; White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067; Whitemore R, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3341-4; Whittington JR, 2018, OBSTET GYNECOL SURV, V73, P544, DOI 10.1097/OGX.0000000000000595; Wisborg K, 2000, OBSTET GYNECOL, V96, P967, DOI 10.1016/S0029-7844(00)01071-1; Yang I, 2019, WOMEN HEALTH, V59, P1026, DOI 10.1080/03630242.2019.1584145	70	4	4	4	7	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2022	28	5					958	+		10.1038/s41591-022-01808-0	http://dx.doi.org/10.1038/s41591-022-01808-0		MAY 2022	13	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	1J3AM	35577966	Green Published, Green Accepted, hybrid			2022-12-27	WOS:000796324500002
J	Gilbert, SC; Plebanski, M; Harris, SJ; Allsopp, CEM; Thomas, R; Layton, GT; Hill, AVS				Gilbert, SC; Plebanski, M; Harris, SJ; Allsopp, CEM; Thomas, R; Layton, GT; Hill, AVS			A protein particle vaccine containing multiple malaria epitopes	NATURE BIOTECHNOLOGY			English	Article						vaccine design; antigen presentation	VIRUS-LIKE PARTICLES; CYTOTOXIC-T-LYMPHOCYTES; PLASMODIUM-FALCIPARUM; CIRCUMSPOROZOITE PROTEIN; VIRAL-PROTEINS; RESPONSES; CELLS; INDUCTION; IMMUNIZATION; ANTIGEN	Ty virus-like particles consist of a single protein species that can be produced in yeast. Recombinant Ty-VLPs carrying a string of up to 15 defined cytotoxic T lymphocyte (CTL) epitopes from Plasmodium species prime protective CTL responses in mice following a single administration without adjuvant. Effective processing of epitopes from the string was demonstrated in vitro and in vivo and was not affected by flanking sequences.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Inst Mol Med,Mol Immunol Grp, Oxford OX3 9DU, England; Univ Oxford, Nuffield Dept Med, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; British Biotech Pharmaceut Ltd, Oxford OX4 5LY, England	University of Oxford; University of Oxford; Wellcome Centre for Human Genetics	Hill, AVS (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Inst Mol Med,Mol Immunol Grp, Oxford OX3 9DU, England.		Gilbert, Sarah C./H-2857-2019; Plebanski, Magdalena/AAU-3144-2021; HILL, Adrian V>S>/C-1306-2008	Gilbert, Sarah C./0000-0002-6823-9750; , Magdalena/0000-0001-6889-3667	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMS SE, 1987, NATURE, V329, P68, DOI 10.1038/329068a0; AIDOO M, 1995, LANCET, V345, P1003, DOI 10.1016/S0140-6736(95)90754-8; Allsopp CEM, 1996, EUR J IMMUNOL, V26, P1951, DOI 10.1002/eji.1830260841; Bachmann MF, 1996, EUR J IMMUNOL, V26, P2595, DOI 10.1002/eji.1830261109; BORDIGNON PP, 1989, EUR J IMMUNOL, V19, P2237; DELVAL M, 1991, CELL, V66, P1145, DOI 10.1016/0092-8674(91)90037-Y; Gilbert SC, 1997, PARASITOL TODAY, V13, P302, DOI 10.1016/S0169-4758(97)01091-0; Harris SJ, 1997, INT IMMUNOL, V9, P273, DOI 10.1093/intimm/9.2.273; Klavinskis LS, 1996, J IMMUNOL, V157, P2521; LALVANI A, 1994, RES IMMUNOL, V145, P461, DOI 10.1016/S0923-2494(94)80177-0; Layton GT, 1996, IMMUNOLOGY, V87, P171, DOI 10.1046/j.1365-2567.1996.464539.x; LAYTON GT, 1993, J IMMUNOL, V151, P1097; MARTIN SJ, 1993, AIDS, V7, P1315, DOI 10.1097/00002030-199310000-00003; MULLER HM, 1993, EMBO J, V12, P2881, DOI 10.1002/j.1460-2075.1993.tb05950.x; MUNESINGHE DY, 1991, EUR J IMMUNOL, V21, P3015, DOI 10.1002/eji.1830211217; NARDIN E, 1992, MEM I O CRUZ, V3, P223; NARDIN EH, 1993, ANNU REV IMMUNOL, V11, P687, DOI 10.1146/annurev.iy.11.040193.003351; PLEBANSKI M, 1994, J IMMUNOL METHODS, V170, P15, DOI 10.1016/0022-1759(94)90241-0; PLEBANSKI M, 1995, EUR J IMMUNOL, V25, P1783, DOI 10.1002/eji.1830250645; ROBSON KJH, 1995, EMBO J, V14, P3883, DOI 10.1002/j.1460-2075.1995.tb00060.x; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; SCHIRMBECK R, 1995, VACCINE, V13, P857, DOI 10.1016/0264-410X(94)00038-O; SETTE A, 1994, ANNU REV IMMUNOL, V12, P413, DOI 10.1146/annurev.immunol.12.1.413; SUTTER G, 1992, P NATL ACAD SCI USA, V89, P10847, DOI 10.1073/pnas.89.22.10847; THOMSON SA, 1995, P NATL ACAD SCI USA, V92, P5845, DOI 10.1073/pnas.92.13.5845; VORDERMEIER HM, 1992, EUR J IMMUNOL, V22, P2631, DOI 10.1002/eji.1830221024; WHITTON JL, 1993, J VIROL, V67, P348, DOI 10.1128/JVI.67.1.348-352.1993; WIDMANN C, 1992, J IMMUNOL METHODS, V155, P95, DOI 10.1016/0022-1759(92)90275-X	28	134	156	1	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1997	15	12					1280	1284		10.1038/nbt1197-1280	http://dx.doi.org/10.1038/nbt1197-1280			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YQ046	9359112				2022-12-27	WOS:000071342000031
J	Scangos, G				Scangos, G			Drug discovery in the postgenomic era	NATURE BIOTECHNOLOGY			English	Editorial Material							GENOME		Exelixis Pharmaceut, S San Francisco, CA 94080 USA	Exelixis, Inc.	Scangos, G (corresponding author), Exelixis Pharmaceut, 260 Littlefield Ave, S San Francisco, CA 94080 USA.							Aaronson JS, 1996, GENOME RES, V6, P829, DOI 10.1101/gr.6.9.829; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Bassett DE, 1997, NAT GENET, V15, P339, DOI 10.1038/ng0497-339; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Brown MS, 1996, SCIENCE, V272, P629, DOI 10.1126/science.272.5262.629; CHRISTINE M, 1997, CELL, V90, P281; DUOJIA P, 1997, CELL, V90, P271; Fey R, 1996, LANCET, V347, P1389, DOI 10.1016/S0140-6736(96)91019-3; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; HODGKIN J, 1995, SCIENCE, V270, P410, DOI 10.1126/science.270.5235.410; Karim FD, 1996, GENETICS, V143, P315; Miklos GLG, 1996, CELL, V86, P521, DOI 10.1016/S0092-8674(00)80126-9; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X	13	8	12	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1997	15	12					1220	1221		10.1038/nbt1197-1220	http://dx.doi.org/10.1038/nbt1197-1220			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YQ046	9359092				2022-12-27	WOS:000071342000003
J	Takasaki, W; Kajino, Y; Kajino, K; Murali, R; Greene, MI				Takasaki, W; Kajino, Y; Kajino, K; Murali, R; Greene, MI			Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNF alpha binding to its receptor	NATURE BIOTECHNOLOGY			English	Article						rational drug design; TNF inhibitor; inflammation	TUMOR-NECROSIS-FACTOR; COLLAGEN-INDUCED ARTHRITIS; MONOCLONAL-ANTIBODIES; RHEUMATOID-ARTHRITIS; MUTATIONAL ANALYSIS; SYNTHETIC PEPTIDE; FUSION PROTEINS; SEPTIC SHOCK; DISEASE; IDENTIFICATION	Exocyclic small peptidomimetics corresponding to three critical binding sites of tumor necrosis factor (TNF)-receptor(I) have been designed based on atomic features deduced from the crystal structures of TNF alpha. and the TNF beta/TNF-receptor(I) complex and a model of an anti-TNF alpha monoclonal antibody. TNF alpha antagonistic activities were evaluated by binding assays using soluble receptor or intact receptor on cells as well as an apoptosis/cytotoxicity assay. The most critical interaction site for rational design of peptidomimetics was localized to the loop1/domain3 of the TNF-receptor, The best antagonist showed 5 mu M inhibition in the binding assay, Biologically, the mimetics inhibited TNF alpha-mediated apoptosis.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Murali, R (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 252 John Morgan Bldg,36th & Hamilton Walk, Philadelphia, PA 19104 USA.		Murali, Ramachandran/D-1132-2009; Kajino, Kiichi/F-6873-2012	Murali, Ramachandran/0000-0002-8384-2793	NATIONAL CANCER INSTITUTE [P30CA016520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK019525] Funding Source: NIH RePORTER; NCI NIH HHS [CA-16520] Funding Source: Medline; NIDDK NIH HHS [DK-19525] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGELETTI RH, 1996, TECHNIQUES PROTEIN C, V7, P81; BAKER D, 1994, EUR J IMMUNOL, V24, P2040, DOI 10.1002/eji.1830240916; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Baumgartner S., 1996, Arthritis and Rheumatism, V39, pS74; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BEUTLER B, 1995, J INVEST MED, V43, P227; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; DORING E, 1994, MOL IMMUNOL, V31, P1059, DOI 10.1016/0161-5890(94)90101-5; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; HABEEB AFSA, 1973, ANAL BIOCHEM, V56, P60, DOI 10.1016/0003-2697(73)90169-3; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HENNET T, 1993, BIOCHEM J, V289, P587, DOI 10.1042/bj2890587; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; HWANG C, 1991, P ROY SOC B-BIOL SCI, V245, P115, DOI 10.1098/rspb.1991.0096; JESPERS LS, 1994, BIO-TECHNOL, V12, P899, DOI 10.1038/nbt0994-899; Jones E Y, 1992, Immunol Ser, V56, P93; KNIGHT DM, 1993, MOL IMMUNOL, V30, P1443, DOI 10.1016/0161-5890(93)90106-L; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LIE BL, 1992, BIOCHEM BIOPH RES CO, V188, P503, DOI 10.1016/0006-291X(92)91084-4; Lorenz HM, 1996, J IMMUNOL, V156, P1646; MAINI RN, 1995, IMMUNOL REV, V144, P195, DOI 10.1111/j.1600-065X.1995.tb00070.x; McDonnell JM, 1996, NAT STRUCT BIOL, V3, P419, DOI 10.1038/nsb0596-419; ORFANOUDAKIS G, 1993, MOL IMMUNOL, V30, P1519, DOI 10.1016/0161-5890(93)90460-S; PEPPEL K, 1991, J EXP MED, V174, P1483, DOI 10.1084/jem.174.6.1483; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; Reinhart K, 1996, CRIT CARE MED, V24, P733, DOI 10.1097/00003246-199605000-00003; SARAGOVI HU, 1991, SCIENCE, V253, P792, DOI 10.1126/science.1876837; SARAGOVI HU, 1992, IMMUNOMETHODS, V1, P5; SCALLON BJ, 1995, CYTOKINE, V7, P759, DOI 10.1006/cyto.1995.0091; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SUFFREDINI AF, 1995, J IMMUNOL, V155, P5038; SUITTERS AJ, 1994, J EXP MED, V179, P849, DOI 10.1084/jem.179.3.849; Tak PP, 1996, ARTHRITIS RHEUM, V39, P1077, DOI 10.1002/art.1780390702; TAUB R, 1992, BIOCHEMISTRY-US, V31, P7431, DOI 10.1021/bi00148a001; VANOSTADE X, 1991, EMBO J, V10, P527; Walker RE, 1996, J INFECT DIS, V174, P63, DOI 10.1093/infdis/174.1.63; WILLIAMS RO, 1995, IMMUNOLOGY, V84, P433; WILLIAMS RO, 1992, P NATL ACAD SCI USA, V89, P9784, DOI 10.1073/pnas.89.20.9784; YAMAGISHI J, 1990, PROTEIN ENG, V3, P713, DOI 10.1093/protein/3.8.713; YONE K, 1995, J BIOL CHEM, V270, P19509, DOI 10.1074/jbc.270.33.19509; Zhang X, 1997, NAT BIOTECHNOL, V15, P150, DOI 10.1038/nbt0297-150; Zhang X, 1996, NAT BIOTECHNOL, V14, P472, DOI 10.1038/nbt0496-472; ZHANG XM, 1992, J BIOL CHEM, V267, P24069	46	111	145	0	19	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1997	15	12					1266	1270		10.1038/nbt1197-1266	http://dx.doi.org/10.1038/nbt1197-1266			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YQ046	9359109				2022-12-27	WOS:000071342000028
J	Kondo, K; Miura, Y; Sone, H; Kobayashi, K; Iijima, H				Kondo, K; Miura, Y; Sone, H; Kobayashi, K; Iijima, H			High-level expression of a sweet protein, monellin, in the food yeast Candida utilis	NATURE BIOTECHNOLOGY			English	Article						Candida utilis; heterologous gene expression; monellin; food yeast	COPY-NUMBER INTEGRATION; SACCHAROMYCES-CEREVISIAE; RIBOSOMAL DNA; GENE; TRANSFORMATION; VECTOR	We describe the heterologous expression of monellin in the yeast Candida utilis. A single-chain monellin gene was expressed under the control of the glyceraldehyde-3-phosphate decarboxylase gene promoter from C. utilis. A promoter-deficient marker gene allowed high-copy-number integration of vectors into either the rDNA locus or the URA3 gene locus. Monellin was produced at a high level, accounting for >50% of the soluble protein. No significant decrease in the production level of monellin was detected in transformants after 50 generations of nonselective growth.	KIRIN BREWERY CO LTD,APPL BIORES CTR,TAKASAKI,GUMMA 37012,JAPAN; KIRIN BREWERY CO LTD,PHARMACEUT RES LABS,TAKASAKI,GUMMA 37012,JAPAN	Kirin Brewery Company Limited; Kirin Brewery Company Limited	Kondo, K (corresponding author), KIRIN BREWERY CO LTD,CENT LABS KEY TECHNOL,KANAZAWA KU,1-13-5 FUKUURA,YOKOHAMA,KANAGAWA 236,JAPAN.							BOHAK Z, 1976, BIOCHIM BIOPHYS ACTA, V427, P153, DOI 10.1016/0005-2795(76)90293-2; BOZE H, 1992, CRIT REV BIOTECHNOL, V12, P65, DOI 10.3109/07388559209069188; BUCKHOLZ RG, 1991, BIO-TECHNOL, V9, P1067, DOI 10.1038/nbt1191-1067; CREGG JM, 1993, BIO-TECHNOL, V11, P905, DOI 10.1038/nbt0893-905; HARTLEY JL, 1980, NATURE, V286, P860, DOI 10.1038/286860a0; ICHII T, 1993, J FERMENT BIOENG, V75, P375, DOI 10.1016/0922-338X(93)90137-W; KIM SH, 1989, PROTEIN ENG, V2, P571, DOI 10.1093/protein/2.8.571; KOHMURA M, 1990, AGR BIOL CHEM TOKYO, V54, P2219, DOI 10.1080/00021369.1990.10870299; KONDO K, 1995, J BACTERIOL, V177, P7171, DOI 10.1128/jb.177.24.7171-7177.1995; KONDO K, 1991, J BIOL CHEM, V266, P17537; LEE JH, 1988, BIOCHEMISTRY-US, V27, P5101, DOI 10.1021/bi00414a023; Lopes TS, 1996, YEAST, V12, P467, DOI 10.1002/(SICI)1097-0061(199604)12:5<467::AID-YEA933>3.0.CO;2-3; LOPES TS, 1991, GENE, V105, P83, DOI 10.1016/0378-1119(91)90516-E; LOPES TS, 1989, GENE, V79, P199, DOI 10.1016/0378-1119(89)90202-3; MORRIS JA, 1972, BIOCHIM BIOPHYS ACTA, V261, P114, DOI 10.1016/0304-4165(72)90320-0; PENARRUBIA L, 1992, BIO-TECHNOL, V10, P561, DOI 10.1038/nbt0592-561; Sambrook J., 2002, MOL CLONING LAB MANU; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; YAMANO S, 1994, J BIOTECHNOL, V32, P165, DOI 10.1016/0168-1656(94)90179-1; ZEMANEK EC, 1995, CRIT REV FOOD SCI, V35, P455, DOI 10.1080/10408399509527709	20	61	82	1	15	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1997	15	5					453	457		10.1038/nbt0597-453	http://dx.doi.org/10.1038/nbt0597-453			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WX237	9131625				2022-12-27	WOS:A1997WX23700030
J	Goel, A; Kumar, G; Payne, GF; Dube, SK				Goel, A; Kumar, G; Payne, GF; Dube, SK			Plant cell biodegradation of a xenobiotic nitrate ester, nitroglycerin	NATURE BIOTECHNOLOGY			English	Article						phytoremediation; nitroglycerin; xenobiotic; nitrate ester; Beta vulgaris	GLUTATHIONE-S-TRANSFERASE; NITRIC-OXIDE FORMATION; GLYCERYL TRINITRATE; PHANEROCHAETE-CHRYSOSPORIUM; ORGANIC-CHEMICALS; NITROAROMATIC COMPOUNDS; METABOLIC-FATE; INVOLVEMENT; SYSTEMS; DEGRADATION	The ability of plants to metabolize the xenobiotic nitrate ester, glycerol trinitrate (GTN, nitroglycerin), was examined using cultured plant cells and plant cell extracts. Intact cells rapidly degrade GTN with the initial formation of glycerol dinitrate (GDN) and the later formation of glycerol mononitrate (GMN). A material balance analysis of these intermediates indicates little, if any, formation of reduced, conjugated or cell-bound carbonaceous metabolites. Cell extracts were shown to be capable of degrading GTN with the simultaneous formation of GDN in stoichiometric amounts. The intermediates observed, and the timing of their appearance, are consistent with a sequential denitration pathway that has been reported for the microbial degradation of nitrate esters. The degradative activities of plant cells are only tenfold less than those reported for bacterial GTN degradation. These results suggest that plants may serve a direct degradative function for the phytoremediation of sites contaminated by organic nitrate esters.	UNIV MARYLAND BALTIMORE CTY,DEPT CHEM & BIOCHEM ENGN,BALTIMORE,MD 21228; UNIV MARYLAND,CTR AGR BIOTECHNOL,COLLEGE PK,MD 20742	University System of Maryland; University of Maryland Baltimore County; University System of Maryland; University of Maryland College Park								ANDERSON TA, 1993, ENVIRON SCI TECHNOL, V27, P2630, DOI 10.1021/es00049a001; BELLIN CA, 1990, J ENVIRON QUAL, V19, P598, DOI 10.2134/jeq1990.00472425001900030040x; Binks PR, 1996, APPL ENVIRON MICROB, V62, P1214, DOI 10.1128/AEM.62.4.1214-1219.1996; Bokern M, 1996, J AGR FOOD CHEM, V44, P1123, DOI 10.1021/jf950376+; BRIGGS GG, 1982, PESTIC SCI, V13, P495, DOI 10.1002/ps.2780130506; Cunningham SD, 1996, PLANT PHYSIOL, V110, P715, DOI 10.1104/pp.110.3.715; CUNNINGHAM SD, 1993, IN VITRO CELL DEV-PL, V29P, P207, DOI 10.1007/BF02632036; DUCROCQ C, 1989, FEMS MICROBIOL LETT, V65, P219, DOI 10.1111/j.1574-6968.1989.tb03625.x; DUCROCQ C, 1990, BIOTECHNOL APPL BIOC, V12, P325; FEELISCH M, 1987, EUR J PHARMACOL, V139, P19, DOI 10.1016/0014-2999(87)90493-6; HABIG WH, 1975, BIOCHEM BIOPH RES CO, V64, P501, DOI 10.1016/0006-291X(75)90349-6; HALL DR, 1992, TETRAHEDRON LETT, V33, P4811, DOI 10.1016/S0040-4039(00)61292-3; HARMS H, 1977, Z NATURFORSCH C, V32, P321; HARMS H, 1986, PLANT SCI, V45, P157, DOI 10.1016/0168-9452(86)90135-4; HARMS HH, 1992, PESTIC SCI, V35, P277, DOI 10.1002/ps.2780350313; Hegde RS, 1996, CHEMOSPHERE, V32, P2471, DOI 10.1016/0045-6535(96)00144-0; HILL KE, 1992, BIOCHEM PHARMACOL, V43, P561, DOI 10.1016/0006-2952(92)90579-8; HUGHES JB, IN PRESS ENV SCI TEC; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; INGERSOL LJC, 1996, PLANT CELL REP, V15, P836; KAPLAN DL, 1982, APPL ENVIRON MICROB, V43, P144, DOI 10.1128/AEM.43.1.144-150.1982; KOMOSSA D, 1992, PESTIC BIOCHEM PHYS, V43, P85, DOI 10.1016/0048-3575(92)90022-R; LANGEBARTELS C, 1985, ECOTOX ENVIRON SAFE, V10, P268, DOI 10.1016/0147-6513(85)90073-9; LAU DTW, 1990, DRUG METAB DISPOS, V18, P292; LEE I, 1992, PLANT CELL REP, V11, P97, DOI 10.1007/BF00235262; LEO A, 1971, CHEM REV, V71, P525, DOI 10.1021/cr60274a001; MARVINSIKKEMA FD, 1994, APPL MICROBIOL BIOT, V42, P499; MENG M, 1995, APPL ENVIRON MICROB, V61, P2548, DOI 10.1128/AEM.61.7.2548-2553.1995; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; NAIR DR, 1993, J ENVIRON ENG, V119, P842, DOI 10.1061/(ASCE)0733-9372(1993)119:5(842); OCONNOR GA, 1990, J ENVIRON QUAL, V19, P113, DOI 10.2134/jeq1990.00472425001900010016x; PATERSON S, 1990, CHEMOSPHERE, V21, P297, DOI 10.1016/0045-6535(90)90002-B; PESARI H, 1993, BIOTECHNOL BIOENG, V41, P79, DOI 10.1002/bit.260410111; Ramos JL, 1996, NAT BIOTECHNOL, V14, P320, DOI 10.1038/nbt0396-320; RYAN JA, 1988, CHEMOSPHERE, V17, P2299, DOI 10.1016/0045-6535(88)90142-7; SANDERMANN H, 1992, TRENDS BIOCHEM SCI, V17, P82, DOI 10.1016/0968-0004(92)90507-6; SCHMIDT B, 1994, PESTIC SCI, V40, P231, DOI 10.1002/ps.2780400310; Schnoor J.L., 1995, ENV SCI TECH, V29, P318; SERVENT D, 1992, BIOTECHNOL APPL BIOC, V15, P257; SERVENT D, 1989, BIOCHEM BIOPH RES CO, V163, P1210, DOI 10.1016/0006-291X(89)91106-6; SERVENT D, 1991, BIOCHIM BIOPHYS ACTA, V1074, P320, DOI 10.1016/0304-4165(91)90170-L; SHIMP JF, 1993, CRIT REV ENV SCI TEC, V23, P41, DOI 10.1080/10643389309388441; SMETS BF, 1995, J ENERG MATS, V13, P385; SPAIN JC, 1995, ANNU REV MICROBIOL, V49, P523, DOI 10.1146/annurev.mi.49.100195.002515; Sun WQ, 1996, APPL MICROBIOL BIOT, V45, P525; TOPP E, 1986, ECOTOX ENVIRON SAFE, V11, P219, DOI 10.1016/0147-6513(86)90066-7; WALTON B T, 1992, Current Opinion in Biotechnology, V3, P267, DOI 10.1016/0958-1669(92)90102-O; WENDT TM, 1978, APPL ENVIRON MICROB, V36, P693, DOI 10.1128/AEM.36.5.693-699.1978; WETZEL A, 1994, ARCH BIOCHEM BIOPHYS, V314, P323, DOI 10.1006/abbi.1994.1449; White GF, 1996, APPL ENVIRON MICROB, V62, P637, DOI 10.1128/AEM.62.2.637-642.1996; WHITE GF, 1993, J GEN MICROBIOL, V139, P1947, DOI 10.1099/00221287-139-9-1947; WILKEN A, 1995, ENVIRON TOXICOL CHEM, V14, P2017, DOI [10.1897/1552-8618(1995)14[2017:MODPCI]2.0.CO;2, 10.1002/etc.5620141203]; YEATES RA, 1989, BIOCHEM PHARMACOL, V38, P1749, DOI 10.1016/0006-2952(89)90408-5	53	45	52	0	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1997	15	2					174	177		10.1038/nbt0297-174	http://dx.doi.org/10.1038/nbt0297-174			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WE998	9035145				2022-12-27	WOS:A1997WE99800026
J	Kuwabara, I; Maruyama, H; Mikawa, YG; Zuberi, RI; Liu, FT; Maruyama, IN				Kuwabara, I; Maruyama, H; Mikawa, YG; Zuberi, RI; Liu, FT; Maruyama, IN			Efficient epitope mapping by bacteriophage lambda surface display	NATURE BIOTECHNOLOGY			English	Article						phage surface expression; fusion protein; human galectin-3; animal lectin	PEPTIDE LIBRARIES; BINDING-PROTEIN; PHAGE; EXPRESSION; VECTORS; FUSIONS; MAC-2	A bacteriophage lambda surface expression system, lambda foo, was used for epitope mapping of human galectin-3. We constructed random epitope and peptide libraries and compared their efficiencies in the mapping, The galectin-3 cDNA was randomly digested by DNase I to make random epitope libraries, The libraries were screened by affinity selection using a microtiter plate coated with monoclonal antibodies. Direct DNA sequencing of the selected clones defined two distinct epitope sites consisting of nine and 11 amino-acid residues. Affinity selection of random peptide libraries recovered a number of sequences that were similar to each other but distinct from the galectin-3 sequence, These results demonstrate that a single affinity selection of epitope libraries with antibodies is able to define an epitope determinant as small as nine residues long and is more efficient in epitope mapping than random peptide libraries.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT MOL & EXPT MED, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute			Maruyama, Ichiro/G-5947-2015; Liu, FU-TONG/A-5749-2019	Maruyama, Ichiro/0000-0002-5112-1342; Liu, FU-TONG/0000-0002-3354-1001	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020958] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK050959] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20958] Funding Source: Medline; NIDDK NIH HHS [DK50959] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CORTESE R, 1994, TRENDS BIOTECHNOL, V12, P262, DOI 10.1016/0167-7799(94)90137-6; DUNN IS, 1995, J MOL BIOL, V248, P497, DOI 10.1006/jmbi.1995.0237; HUGHES RC, 1994, GLYCOBIOLOGY, V4, P5, DOI 10.1093/glycob/4.1.5; KASAHARA N, 1994, SCIENCE, V266, P1373, DOI 10.1126/science.7973726; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LANE DP, 1993, CURR OPIN IMMUNOL, V5, P268, DOI 10.1016/0952-7915(93)90016-L; LENSTRA JA, 1990, ARCH VIROL, V110, P1, DOI 10.1007/BF01310699; Liu FT, 1996, BIOCHEMISTRY-US, V35, P6073, DOI 10.1021/bi952716q; LU ZJ, 1995, BIO-TECHNOL, V13, P366, DOI 10.1038/nbt0495-366; MARUYAMA IN, 1994, P NATL ACAD SCI USA, V91, P8273, DOI 10.1073/pnas.91.17.8273; MARUYAMA IN, 1995, J MOL BIOL, V253, P530, DOI 10.1006/jmbi.1995.0571; Mikawa YG, 1996, J MOL BIOL, V262, P21; Petersen G, 1995, MOL GEN GENET, V249, P425, DOI 10.1007/BF00287104; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; Sambrook J., 2002, MOL CLONING LAB MANU; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; STANLEY KK, 1987, EMBO J, V6, P1951, DOI 10.1002/j.1460-2075.1987.tb02457.x; STERNBERG N, 1995, P NATL ACAD SCI USA, V92, P1609, DOI 10.1073/pnas.92.5.1609; vanZonneveld AJ, 1995, GENE, V167, P49, DOI 10.1016/0378-1119(95)00614-1; WANG JL, 1992, BIOCHEM SOC T, V20, P269, DOI 10.1042/bst0200269; WANG LF, 1995, J IMMUNOL METHODS, V178, P1, DOI 10.1016/0022-1759(94)00235-O; Wells J. A., 1992, CURR OPIN STRUC BIOL, V2, P597; WOO HJ, 1990, J BIOL CHEM, V265, P7097; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	25	30	32	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1997	15	1					74	78		10.1038/nbt0197-74	http://dx.doi.org/10.1038/nbt0197-74			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WA729	9035110				2022-12-27	WOS:A1997WA72900027
J	Lieschke, GJ; Rao, PK; Gately, MK; Mulligan, RC				Lieschke, GJ; Rao, PK; Gately, MK; Mulligan, RC			Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo	NATURE BIOTECHNOLOGY			English	Article						interleukin; cytokine; fusion protein; retrovirus; tumor immunotherapy	IL-12 P40 HOMODIMER; MOUSE INTERLEUKIN-12; CELL-SURFACE; IN-VIVO; T-CELLS; FIBROBLASTS; TUMORS; GENES; RETROVIRUSES; COEXPRESSION	Interleukin-12 (IL-12) is unique amongst cytokines in being a disulfide-linked heterodimer of two separately encoded subunits (p35 and p40). We expressed single chain IL-12 proteins from retroviral constructs in which the two IL-12 subunits were linked by a 6-15 amino acid polypeptide linker, with deletion of the 22 amino acid leader sequence of the,trailing subunit. The murine fusion protein IL-12.p40.L.Delta p35 containing a (Gly(4)Ser)(3) linker was stably expressed, bioactive in vitro, and had an apparent specific activity comparable to that of native and recombinant IL-12. Western blotting confirmed that murine IL-12.p40.L.Delta p35 retained the linking polypeptide sequences. The analogous human IL-12.p40.L.Delta p35 fusion protein containing a Gly(6)Ser linker was bioactive with an apparent specific activity comparable to recombinant human IL-12. In a preexisting CMS-5 tumor model, CMS-5 cells secreting either native or fusion protein forms of IL-12 prolonged survival and led to complete tumor regression.	HOFFMANN LA ROCHE INC,DEPT INFLAMMAT AUTOIMMUNE DIS,NUTLEY,NJ 07110; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142	Roche Holding; Massachusetts Institute of Technology (MIT); Whitehead Institute				Lieschke, Graham/0000-0003-0325-798X	NCI NIH HHS [CA-63399] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063399] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bramson J, 1996, HUM GENE THER, V7, P333, DOI 10.1089/hum.1996.7.3-333; BRUNDA MJ, 1993, J EXP MED, V178, P1223, DOI 10.1084/jem.178.4.1223; Bueler H, 1996, MOL MED, V2, P545, DOI 10.1007/BF03401639; CHEN TT, 1995, J IMMUNOL, V154, P3105; Colombo MP, 1996, CANCER RES, V56, P2531; CURTIS BM, 1991, P NATL ACAD SCI USA, V88, P5809, DOI 10.1073/pnas.88.13.5809; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DELEO AB, 1977, J EXP MED, V146, P720, DOI 10.1084/jem.146.3.720; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; FIDLER IJ, 1975, CANCER RES, V35, P218; FREBOURG T, 1994, CANCER RES, V54, P878; GATELY MK, 1995, CURRENT PROTOCOLS IM, V1; GATELY MK, 1994, INT IMMUNOL, V6, P1257; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; GILLESSEN S, 1995, EUR J IMMUNOL, V25, P200, DOI 10.1002/eji.1830250133; GUBLER U, 1991, P NATL ACAD SCI USA, V88, P4143, DOI 10.1073/pnas.88.10.4143; Huston J S, 1993, Int Rev Immunol, V10, P195, DOI 10.3109/08830189309061696; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; JENKS S, 1966, J NATL CANCER I, V88, P576; KAI K, 1986, VIROLOGY, V150, P509, DOI 10.1016/0042-6822(86)90315-6; LING P, 1995, J IMMUNOL, V154, P116; MARTINOTTI A, 1995, EUR J IMMUNOL, V25, P137, DOI 10.1002/eji.1830250124; MATTNER F, 1993, EUR J IMMUNOL, V23, P2202, DOI 10.1002/eji.1830230923; MILLER LL, 1996, P AM SOC CLIN ONCOL, V14, P1718; NASTALA CL, 1994, J IMMUNOL, V153, P1679; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rakhmilevich AL, 1996, P NATL ACAD SCI USA, V93, P6291, DOI 10.1073/pnas.93.13.6291; RIVIERE I, 1995, P NATL ACAD SCI USA, V92, P7633; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOENHAUT DS, 1992, J IMMUNOL, V148, P3433; TAHARA H, 1995, J IMMUNOL, V154, P6466; TAHARA H, 1994, CANCER RES, V54, P182; TRINCHIERI G, 1994, BLOOD, V84, P4008, DOI 10.1182/blood.V84.12.4008.bloodjournal84124008; Wigginton JM, 1996, JNCI-J NATL CANCER I, V88, P38, DOI 10.1093/jnci/88.1.38; Wilkinson VL, 1996, J IMMUNOL METHODS, V189, P15, DOI 10.1016/0022-1759(95)00223-5; WOLF SF, 1991, J IMMUNOL, V146, P3074; WU CY, 1994, J IMMUNOL, V152, P1141; ZITVOGEL L, 1995, J IMMUNOL, V155, P1393; ZITVOGEL L, 1994, HUM GENE THER, V5, P1493, DOI 10.1089/hum.1994.5.12-1493; ZOU JJ, 1995, J BIOL CHEM, V270, P5864, DOI 10.1074/jbc.270.11.5864	40	109	142	0	16	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1997	15	1					35	40		10.1038/nbt0197-35	http://dx.doi.org/10.1038/nbt0197-35			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WA729	9035103				2022-12-27	WOS:A1997WA72900020
J	Jeemon, P; Harikrishnan, S				Jeemon, Panniyammakal; Harikrishnan, Sivadasanpillai			Systolic blood pressure and cardiovascular health	NATURE MEDICINE			English	Editorial Material; Early Access							RISK-FACTORS; DISEASES		[Jeemon, Panniyammakal] Sree Chitra Tirunal Inst Med Sci & Technol, Achutha Menon Ctr Hlth Sci Studies, Trivandrum, Kerala, India; [Harikrishnan, Sivadasanpillai] Sree Chitra Tirunal Inst Med Sci & Technol, Dept Cardiol, Trivandrum, Kerala, India	Department of Science & Technology (India); Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST); Department of Science & Technology (India); Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST)	Jeemon, P (corresponding author), Sree Chitra Tirunal Inst Med Sci & Technol, Achutha Menon Ctr Hlth Sci Studies, Trivandrum, Kerala, India.	jeemon@sctimst.ac.in						Adhikari B, 2021, INT J HYG ENVIR HEAL, V237, DOI 10.1016/j.ijheh.2021.113820; Brodmann M., 2020, J AM COLL CARDIOL, V76, P2982, DOI [10.1016/j.jacc.2020.11.010, DOI 10.1016/J.JACC.2020.11.010]; Frieden TR, 2020, GLOB HEART, V15, DOI 10.5334/gh.531; Jeemon Panniyammakal, 2021, Glob Heart, V16, P63, DOI 10.5334/gh.1066; Malik R, 2021, HYPERTENSION, V77, P2004, DOI 10.1161/HYPERTENSIONAHA.120.16534; Marklund M, 2022, HYPERTENSION, V79, P2188, DOI 10.1161/HYPERTENSIONAHA.122.19072; McCracken JP, 2007, ENVIRON HEALTH PERSP, V115, P996, DOI 10.1289/ehp.9888; Rapsomaniki E, 2014, LANCET, V383, P1899, DOI 10.1016/S0140-6736(14)60685-1; Razo C, 2022, NAT MED, DOI 10.1038/s41591-022-01974-1; Rodgers A, 2004, PLOS MED, V1, P44, DOI 10.1371/journal.pmed.0010027; Thom S, 2013, JAMA-J AM MED ASSOC, V310, P918, DOI 10.1001/jama.2013.277064; Yang B-Y., 2018, ENVIRON POLLUT, V235, P576, DOI [10.1016/j.envpol.2018.01.001, DOI 10.1016/J.ENVPOL.2018.01.001]	12	0	0	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02005-9	http://dx.doi.org/10.1038/s41591-022-02005-9		OCT 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	5E6IE	36216944				2022-12-27	WOS:000865725700003
J	Lavelle, A; Sokol, H				Lavelle, Aonghus; Sokol, Harry			Understanding and predicting the efficacy of FMT	NATURE MEDICINE			English	Editorial Material							FECAL MICROBIOTA TRANSPLANTATION; RECURRENT; REMISSION; DONOR	Clinical evaluation of FMT is progressing without an adequate understanding of the underlying ecological dynamics; studies are now beginning to fill these gaps, but consensus will be needed on many fronts.	[Lavelle, Aonghus] Univ Coll Cork, APC Microbiome Ireland, Cork, Ireland; [Lavelle, Aonghus] Univ Coll Cork, Dept Anat & Neurosci, Cork, Ireland; [Sokol, Harry] Sorbonne Univ, St Antoine Hosp, AP HP,CRSA, INSERM,Ctr Rech St Antoine,Gastroenterol Dept, Paris, France; [Sokol, Harry] Paris Ctr Microbiome Med FHU, Paris, France; [Sokol, Harry] INRA, UMR1319 Micalis, Jouy En Josas, France; [Sokol, Harry] AgroParisTech, Jouy En Josas, France	University College Cork; University College Cork; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; INRAE; UDICE-French Research Universities; Universite Paris Saclay; AgroParisTech; UDICE-French Research Universities; Universite Paris Saclay	Sokol, H (corresponding author), Sorbonne Univ, St Antoine Hosp, AP HP,CRSA, INSERM,Ctr Rech St Antoine,Gastroenterol Dept, Paris, France.; Sokol, H (corresponding author), Paris Ctr Microbiome Med FHU, Paris, France.; Sokol, H (corresponding author), INRA, UMR1319 Micalis, Jouy En Josas, France.; Sokol, H (corresponding author), AgroParisTech, Jouy En Josas, France.	harry.sokol@aphp.fr	sokol, harry/E-2290-2019	sokol, harry/0000-0002-2914-1822				Baruch EN, 2021, SCIENCE, V371, P602, DOI 10.1126/science.abb5920; Costello SP, 2017, GASTROENTEROLOGY, V152, pS198, DOI 10.1016/S0016-5085(17)30969-1; Danne C, 2021, NAT REV GASTRO HEPAT, V18, P503, DOI 10.1038/s41575-021-00441-5; Goll R, 2020, GUT MICROBES, V12, DOI 10.1080/19490976.2020.1794263; Ianiro G, 2022, NAT MED, V28, P1913, DOI 10.1038/s41591-022-01964-3; Kong LJ, 2020, GASTROENTEROLOGY, V159, DOI 10.1053/j.gastro.2020.08.045; Li SS, 2016, SCIENCE, V352, P586, DOI 10.1126/science.aad8852; Mullish BH, 2018, J HOSP INFECT, V100, pS1, DOI 10.1016/j.jhin.2018.07.037; Schmidt TSB, 2022, NAT MED, V28, P1902, DOI 10.1038/s41591-022-01913-0; Sokol H, 2020, MICROBIOME, V8, DOI 10.1186/s40168-020-0792-5; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; Vrieze A, 2012, GASTROENTEROLOGY, V143, P913, DOI 10.1053/j.gastro.2012.06.031	12	0	0	3	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2022	28	9					1759	1760		10.1038/s41591-022-01991-0	http://dx.doi.org/10.1038/s41591-022-01991-0		SEP 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4S0LI	36109641				2022-12-27	WOS:000854720900009
J	Jukarainen, S; Ganna, A				Jukarainen, Sakari; Ganna, Andrea			A framework to assess the effects of genetic risk factors on disability-adjusted life years	NATURE MEDICINE			English	Editorial Material; Early Access								Using population data on genetics and diseases and estimates of disability-adjusted life years, we generated a framework for estimating the effects of genetic factors on healthy life years, similar to the risk assessment framework for traditional modifiable epidemiological risk factors. This framework will help to inform the development and implementation of genetic-based clinical applications.	[Jukarainen, Sakari; Ganna, Andrea] Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki, Finland	University of Helsinki	Jukarainen, S (corresponding author), Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki, Finland.							Abbafati C, 2020, LANCET, V396, P1135, DOI 10.1016/S0140-6736(20)31404-5; Vos T, 2020, LANCET, V396, P1562	2	0	0	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01958-1	http://dx.doi.org/10.1038/s41591-022-01958-1		SEP 2022	1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4L9HT	36097222				2022-12-27	WOS:000852940800002
J	Feigin, A; Evans, EE; Fisher, TL; Leonard, JE; Smith, ES; Reader, A; Mishra, V; Manber, R; Walters, KA; Kowarski, L; Oakes, D; Siemers, E; Kieburtz, KD; Zauderer, M				Feigin, Andrew; Evans, Elizabeth E.; Fisher, Terrence L.; Leonard, John E.; Smith, Ernest S.; Reader, Alisha; Mishra, Vikas; Manber, Richard; Walters, Kimberly A.; Kowarski, Lisa; Oakes, David; Siemers, Eric; Kieburtz, Karl D.; Zauderer, Maurice		Huntington Study Grp SIGNAL Invest	Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial	NATURE MEDICINE			English	Article; Early Access							RATING-SCALE; TRACK-HD; SEGMENTATION APPLICATION; COGNITIVE IMPAIRMENT; CLINICAL-TRIALS; MOUSE MODEL; PREMANIFEST; 4D; SEMAPHORINS; PROGRESSION	SIGNAL is a multicenter, randomized, double-blind, placebo-controlled phase 2 study (no. NCT02481674) established to evaluate pepinemab, a semaphorin 4D (SEMA4D)-blocking antibody, for treatment of Huntington's disease (HD). The trial enrolled a total of 265 HD gene expansion carriers with either early manifest (EM, n = 179) or late prodromal (LP, n = 86) HD, randomized (1:1) to receive 18 monthly infusions of pepinemab (n = 91 EM, 41 LP) or placebo (n = 88 EM, 45 LP). Pepinemab was generally well tolerated, with a relatively low frequency of serious treatment-emergent adverse events of 5% with pepinemab compared to 9% with placebo, including both EM and LP participants. Coprimary efficacy outcome measures consisted of assessments within the EM cohort of (1) a two-item HD cognitive assessment family comprising one-touch stockings of Cambridge (OTS) and paced tapping (PTAP) and (2) clinical global impression of change (CGIC). The differences between pepinemab and placebo in mean change (95% confidence interval) from baseline at month 17 for OTS were -1.98 (-4.00, 0.05) (one-sided P = 0.028), and for PTAP 1.43 (-0.37, 3.23) (one-sided P = 0.06). Similarly, because a significant treatment effect was not observed for CGIC, the coprimary endpoint, the study did not meet its prespecified primary outcomes. Nevertheless, a number of other positive outcomes and post hoc subgroup analyses-including additional cognitive measures and volumetric magnetic resonance imaging and fluorodeoxyglucose-positron-emission tomography imaging assessments-provide rationale and direction for the design of a phase 3 study and encourage the continued development of pepinemab in patients diagnosed with EM HD. The SIGNAL Phase 2 study of pepinemab immunotherapy in early Huntington's disease (HD) did not meet its coprimary clinical efficacy endpoints, but had a favorable safety profile and showed a significant treatment-related reduction in caudate brain atrophy and reversal of the characteristic decline in brain metabolic activity that is typical of HD progression.	[Feigin, Andrew] New York Univ Langone Hlth, New York, NY USA; [Feigin, Andrew] Marlene & Paolo Fresco Inst Parkinsons & Movement, New York, NY USA; [Evans, Elizabeth E.; Fisher, Terrence L.; Leonard, John E.; Smith, Ernest S.; Reader, Alisha; Mishra, Vikas; Zauderer, Maurice] Vaccinex Inc, Res, Rochester, NY 14620 USA; [Manber, Richard] IXICO, London, England; [Walters, Kimberly A.; Kowarski, Lisa] WCG Stat Collaborat Inc, Washington, DC USA; [Oakes, David; Kieburtz, Karl D.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA; [Siemers, Eric] Siemers Integrat LLC, Zionsville, IN USA	New York University; University of Rochester	Zauderer, M (corresponding author), Vaccinex Inc, Res, Rochester, NY 14620 USA.	mzauderer@vaccinex.com		Leonard, John/0000-0003-2154-750X; Kowarski, Lisa/0000-0003-2392-0494; Fisher, Terrence/0000-0001-9326-6606; Walters, Kimberly A./0000-0002-2699-0124; Mishra, Vikas/0000-0002-4555-0132; Evans, Elizabeth/0000-0002-9287-9221	Vaccinex, Inc.	Vaccinex, Inc.	We thank the patient volunteers and their families for their initiative and enthusiasm in participating in this research, and their courage in confronting the burdens of this disease. We also thank the clinical coordinators who played an indispensable role in the accurate and timely execution of this study at each of the participating sites. We thank A. Williams, A. Howell, C. Reilly and L. Mueller for drug release and bioanalytical assays, and Y. Lerman and W. Bigham for their important assistance with clinical safety evaluation and drug supply. All funding was provided by the sponsor, Vaccinex, Inc.	Basile JR, 2007, J BIOL CHEM, V282, P34888, DOI 10.1074/jbc.M705467200; Baudic S, 2006, DEMENT GERIATR COGN, V21, P316, DOI 10.1159/000091523; Boussicault L, 2014, J CEREBR BLOOD F MET, V34, P1500, DOI 10.1038/jcbfm.2014.110; Brandt J, 2001, HOPKINS VERBAL LEARN; Callaghan J, 2015, J NEUROPSYCH CLIN N, V27, P59, DOI 10.1176/appi.neuropsych.13070169; Chapoval SP, 2017, INFLAMM RES, V66, P111, DOI 10.1007/s00011-016-0983-5; Chen WW, 2016, MOL MED REP, V13, P3391, DOI 10.3892/mmr.2016.4948; Clark IC, 2021, SCIENCE, V372, P360, DOI 10.1126/science.abf1230; Cognition C. CANTABeclipse, 2006, TEST ADM GUID MAN VE; Denis HL, 2019, MOL PSYCHIATR, V24, P364, DOI 10.1038/s41380-018-0021-9; EKMAN P, 1976, ENVIRON PSYCH NONVER, V1, P56, DOI 10.1007/BF01115465; Feigin A, 2007, BRAIN, V130, P2858, DOI 10.1093/brain/awm217; FEIGIN A, 1995, MOVEMENT DISORD, V10, P211, DOI 10.1002/mds.870100213; Fisher TL, 2016, MABS-AUSTIN, V8, P150, DOI 10.1080/19420862.2015.1102813; Freeborough PA, 1997, IEEE T MED IMAGING, V16, P623, DOI 10.1109/42.640753; Giraudon P, 2005, NEUROMOL MED, V7, P207, DOI 10.1385/NMM:7:3:207; Giraudon P, 2004, J IMMUNOL, V172, P1246, DOI 10.4049/jimmunol.172.2.1246; Glidden A, 2017, MOVEMENT DISORD, V32; Guy W., 1976, ASSESSMENT MANUAL PS, P218, DOI DOI 10.1186/1471-244X-7-7; Hanseeuw BJ, 2017, ANN NEUROL, V81, P583, DOI 10.1002/ana.24910; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800; Johnson EB, 2021, BIOL PSYCHIAT, V89, P807, DOI 10.1016/j.biopsych.2020.11.009; Johnson SA, 2007, BRAIN, V130, P1732, DOI 10.1093/brain/awm107; Jutten RJ, 2022, FRONT AGING NEUROSCI, V13, DOI 10.3389/fnagi.2021.800126; Khosravi M, 2019, J ALZHEIMERS DIS, V70, P1197, DOI 10.3233/JAD-190220; Kieburtz K, 1996, MOVEMENT DISORD, V11, P136, DOI 10.1002/mds.870110204; Labrijn AF, 2009, NAT BIOTECHNOL, V27, P767, DOI 10.1038/nbt.1553; LaGanke C, 2017, NEUROL-NEUROIMMUNOL, V4, DOI 10.1212/NXI.0000000000000367; Landau SM, 2011, NEUROBIOL AGING, V32, P1207, DOI 10.1016/j.neurobiolaging.2009.07.002; Ledig C, 2015, MED IMAGE ANAL, V21, P40, DOI 10.1016/j.media.2014.12.003; Leonard JE, 2015, MOL CANCER THER, V14, P964, DOI 10.1158/1535-7163.MCT-14-0924; Liang XQ, 2004, J NEUROSCI, V24, P7140, DOI 10.1523/JNEUROSCI.5319-03.2004; McGarry A, 2017, NEUROLOGY, V88, P152, DOI 10.1212/WNL.0000000000003478; Okuno T, 2010, J IMMUNOL, V184, P1499, DOI 10.4049/jimmunol.0903302; Patnaik A, 2016, CLIN CANCER RES, V22, P827, DOI 10.1158/1078-0432.CCR-15-0431; Polyzos AA, 2019, CELL METAB, V29, P1258, DOI 10.1016/j.cmet.2019.03.004; Posner K, 2011, AM J PSYCHIAT, V168, P1266, DOI 10.1176/appi.ajp.2011.10111704; Reilmann R, 2019, LANCET NEUROL, V18, P165, DOI 10.1016/S1474-4422(18)30391-0; Reilmann R, 2017, HAND CLINIC, V144, P209, DOI 10.1016/B978-0-12-801893-4.00018-3; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rowe KC, 2010, NEUROPSYCHOLOGY, V24, P435, DOI 10.1037/a0018905; Rub U, 2016, BRAIN PATHOL, V26, P726, DOI 10.1111/bpa.12426; Samaroo A, 2020, ALZH DEMENT-DADM, V12, DOI 10.1002/dad2.12132; Schobel SA, 2021, CHDI FDN ANN THER C; Shafique MR, 2021, CLIN CANCER RES, V27, P3630, DOI 10.1158/1078-0432.CCR-20-4792; Siesling S, 1998, MOVEMENT DISORD, V13, P915, DOI 10.1002/mds.870130609; Simpson JA, 2016, J HUNTINGTONS DIS, V5, P395, DOI 10.3233/JHD-160228; Smith A., 1982, SYMBOL DIGIT MODALIT; Smith ES, 2015, NEUROBIOL DIS, V73, P254, DOI 10.1016/j.nbd.2014.10.008; Southwell AL, 2015, NEUROBIOL DIS, V76, P46, DOI 10.1016/j.nbd.2015.01.002; Stout JC, 2014, MOVEMENT DISORD, V29, P1281, DOI 10.1002/mds.25964; Stout JC, 2012, J NEUROL NEUROSUR PS, V83, P687, DOI 10.1136/jnnp-2011-301940; Tabrizi SJ, 2013, LANCET NEUROL, V12, P637, DOI 10.1016/S1474-4422(13)70088-7; Tabrizi SJ, 2012, LANCET NEUROL, V11, P42, DOI 10.1016/S1474-4422(11)70263-0; Tabrizi SJ, 2011, LANCET NEUROL, V10, P31, DOI 10.1016/S1474-4422(10)70276-3; Tabrizi SJ, 2009, LANCET NEUROL, V8, P791, DOI 10.1016/S1474-4422(09)70170-X; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Tang CC, 2013, J CLIN INVEST, V123, P4076, DOI 10.1172/JCI69411; Toguchi M, 2009, NEUROCHEM INT, V55, P573, DOI 10.1016/j.neuint.2009.05.013; Watkins LHA, 2000, NEUROPSYCHOLOGIA, V38, P1112, DOI 10.1016/S0028-3932(00)00028-2; Wilson H, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00011; Wilton DK, 2020, NEUROBIOL DIS, V143, DOI 10.1016/j.nbd.2020.104963; Wolz R, 2010, NEUROIMAGE, V52, P109, DOI 10.1016/j.neuroimage.2010.04.006; Wolz R, 2010, NEUROIMAGE, V49, P1316, DOI 10.1016/j.neuroimage.2009.09.069; Wu MF, 2016, EXPERT OPIN THER TAR, V20, P885, DOI 10.1517/14728222.2016.1139083; Zhang Y, 2011, AM J MED GENET B, V156B, P751, DOI 10.1002/ajmg.b.31232; Zimmer ER, 2017, NAT NEUROSCI, V20, P393, DOI 10.1038/nn.4492	67	1	1	1	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01919-8	http://dx.doi.org/10.1038/s41591-022-01919-8		AUG 2022	28	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3P5AJ	35941373	hybrid, Green Published			2022-12-27	WOS:000837551000007
J	Todo, T; Ito, H; Ino, Y; Ohtsu, H; Ota, Y; Shibahara, J; Tanaka, M				Todo, Tomoki; Ito, Hirotaka; Ino, Yasushi; Ohtsu, Hiroshi; Ota, Yasunori; Shibahara, Junji; Tanaka, Minoru			Intratumoral oncolytic herpes virus G47 increment for residual or recurrent glioblastoma: a phase 2 trial	NATURE MEDICINE			English	Article; Early Access							IMMUNE CHECKPOINT INHIBITORS; SIMPLEX-VIRUS; MALIGNANT GLIOMA; VECTOR G47-DELTA; BREAST-CANCER; III TRIAL; EFFICACY; THERAPY; COMBINATION; SAFETY	Results from a pivotal single-arm phase 2 trial show that the repeated intratumoral administration of the oncolytic herpes virus G47 increment in residual or recurrent glioblastoma exhibits survival benefit and a safe profile. This investigator-initiated, phase 2, single-arm trial primarily assessed the efficacy of G47 increment , a triple-mutated, third-generation oncolytic herpes simplex virus type 1, in 19 adult patients with residual or recurrent, supratentorial glioblastoma after radiation therapy and temozolomide (UMIN-CTR Clinical Trial Registry UMIN000015995). G47 Delta was administered intratumorally and repeatedly for up to six doses. The primary endpoint of 1-yr survival rate after G47 increment initiation was 84.2% (95% confidence interval, 60.4-96.6; 16 of 19). The prespecified endpoint was met and the trial was terminated early. Regarding secondary endpoints, the median overall survival was 20.2 (16.8-23.6) months after G47 increment initiation and 28.8 (20.1-37.5) months from the initial surgery. The most common G47 increment -related adverse event was fever (17 of 19) followed by vomiting, nausea, lymphocytopenia and leukopenia. On magnetic resonance imaging, enlargement of and contrast-enhancement clearing within the target lesion repeatedly occurred after each G47 increment administration, which was characteristic to this therapy. Thus, the best overall response in 2 yr was partial response in one patient and stable disease in 18 patients. Biopsies revealed increasing numbers of tumor-infiltrating CD4(+)/CD8(+) lymphocytes and persistent low numbers of Foxp3(+) cells. This study showed a survival benefit and good safety profile, which led to the approval of G47 increment as the first oncolytic virus product in Japan.	[Todo, Tomoki; Ito, Hirotaka; Ino, Yasushi] Univ Tokyo, Div Innovat Canc Therapy, Adv Clin Res Ctr, Tokyo, Japan; [Todo, Tomoki; Ito, Hirotaka; Ino, Yasushi; Tanaka, Minoru] Univ Tokyo, Inst Med Sci, Dept Surg Neurooncol, Tokyo, Japan; [Ohtsu, Hiroshi] Natl Ctr Global Hlth & Med Japan, Dept Data Sci, Tokyo, Japan; [Ohtsu, Hiroshi] Juntendo Univ, Leading Ctr Dev & Res Canc Med, Tokyo, Japan; [Ota, Yasunori] Univ Tokyo, Inst Med Sci, Dept Pathol, Tokyo, Japan; [Shibahara, Junji] Kyorin Univ, Sch Med, Dept Pathol, Tokyo, Japan	University of Tokyo; University of Tokyo; Juntendo University; University of Tokyo; Kyorin University	Todo, T (corresponding author), Univ Tokyo, Div Innovat Canc Therapy, Adv Clin Res Ctr, Tokyo, Japan.	toudou-nsu@umin.ac.jp	Ohtsu, Hiroshi/ABF-2536-2021	Ohtsu, Hiroshi/0000-0003-3261-8828; Todo, Tomoki/0000-0003-0523-8010	Japanese Agency for Medical Research and Development (AMED) [JP15ck0106144, JP18ck0106416, JP20lm0203140]; Division of Innovative Cancer Therapy, the Institute of Medical Science, the University of Tokyo	Japanese Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Division of Innovative Cancer Therapy, the Institute of Medical Science, the University of Tokyo	We thank M. Iwai, S. Kanayama, H. Momota, L. Chalise, K. Saiga, E. Ozaki and the members of the Division of Innovative Cancer Therapy, the members of the Therapeutic Vector Development Center and the staff of the Center for Translational Research, the Institute of Medical Science, the University of Tokyo, for their support and assistance in carrying out this clinical study. We also thank R. Nishikawa (Saitama Medical University), S. Aoki (Juntendo University) and K. Yoshimura (Kanazawa University) for serving the Independent Data Monitoring Committee, and Y. Furukawa (the University of Tokyo) for helping us with the genome sequencing of G47.. This research was supported in part by the Japanese Agency for Medical Research and Development (AMED) `Innovative Cancer Medical Practical Research Project' (2015-2020) under grant nos. JP15ck0106144 and JP18ck0106416 and `Translational Research Program' under grant no. JP20lm0203140 to T.T. We thank Y. Okamoto and M. Snape of inScience Communications, Springer Healthcare, for helping us write the first draft of the manuscript. This medical writing assistance was funded by the Division of Innovative Cancer Therapy, the Institute of Medical Science, the University of Tokyo.	Aghi M, 2007, CANCER RES, V67, P440, DOI 10.1158/0008-5472.CAN-06-3145; Andtbacka RHI, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0623-z; Ballman KV, 2007, NEURO-ONCOLOGY, V9, P29, DOI 10.1215/15228517-2006-025; Brahm CG, 2020, CANCERS, V12, DOI 10.3390/cancers12030586; Carpenter AB, 2021, ANN ONCOL, V32, P968, DOI 10.1016/j.annonc.2021.03.197; Carson J, 2010, DRUG FUTURE, V35, P183, DOI 10.1358/dof.2010.035.03.1470166; Chahlavi A, 1999, GENE THER, V6, P1751, DOI 10.1038/sj.gt.3301003; Coutinho AE, 2011, MOL CELL ENDOCRINOL, V335, P2, DOI 10.1016/j.mce.2010.04.005; Dario A, 2006, CURR DRUG SAF, V1, P205, DOI 10.2174/157488606776930535; De Bonis P, 2012, ACTA NEUROCHIR, V154, P1371, DOI 10.1007/s00701-012-1413-2; Desjardins A, 2018, NEW ENGL J MED, V379, P150, DOI 10.1056/NEJMoa1716435; Friedman GK, 2021, NEW ENGL J MED, V384, P1613, DOI 10.1056/NEJMoa2024947; Friedman HS, 2009, J CLIN ONCOL, V27, P4733, DOI 10.1200/JCO.2008.19.8721; Fukuhara H, 2005, CLIN CANCER RES, V11, P7886, DOI 10.1158/1078-0432.CCR-05-1090; Fukuhara H, 2016, CANCER SCI, V107, P1373, DOI 10.1111/cas.13027; Ikegami N, 2011, LANCET, V378, P1106, DOI 10.1016/S0140-6736(11)60828-3; Ishino R, 2021, MOL THER, V29, P762, DOI 10.1016/j.ymthe.2020.09.041; Koga T, 2012, CANCER-AM CANCER SOC, V118, P4193, DOI 10.1002/cncr.27372; Lang FF, 2018, J CLIN ONCOL, V36, P1419, DOI 10.1200/JCO.2017.75.8219; Li Yi, 2017, Brain Tumor Res Treat, V5, P1, DOI 10.14791/btrt.2017.5.1.1; Liu R, 2005, GENE THER, V12, P647, DOI 10.1038/sj.gt.3302445; Louis DN, 2021, NEURO-ONCOLOGY, V23, P1231, DOI 10.1093/neuonc/noab106; Ma WQ, 2018, BMC IMMUNOL, V19, DOI 10.1186/s12865-018-0281-9; Mandel JJ, 2016, J NEURO-ONCOL, V129, P147, DOI 10.1007/s11060-016-2157-2; Markert JM, 2014, MOL THER, V22, P1048, DOI 10.1038/mt.2014.22; Markert JM, 2009, MOL THER, V17, P199, DOI 10.1038/mt.2008.228; Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205; Oku M, 2021, BRIT J HAEMATOL, V192, P343, DOI 10.1111/bjh.17173; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Roy S, 2015, SOUTH ASIAN J CANCER, V4, P163, DOI 10.4103/2278-330X.175953; Saha D, 2016, CANCER IMMUNOL RES, V4, DOI 10.1158/2326-6066.IMM2016-B116; Stupp R, 2017, JAMA-J AM MED ASSOC, V318, P2306, DOI 10.1001/jama.2017.18718; Stupp R, 2012, EUR J CANCER, V48, P2192, DOI 10.1016/j.ejca.2012.04.011; Sugawara K, 2021, MOL THER-ONCOLYTICS, V22, P129, DOI 10.1016/j.omto.2021.05.004; Sugawara K, 2020, MOL THER-ONCOLYTICS, V17, P205, DOI 10.1016/j.omto.2020.03.022; Todo T, 1999, HUM GENE THER, V10, P2869, DOI 10.1089/10430349950016591; Todo T, 2001, P NATL ACAD SCI USA, V98, P6396, DOI 10.1073/pnas.101136398; Todo T., NATURE COMMUN; Uchihashi T, 2021, MOL THER-ONCOLYTICS, V22, P388, DOI 10.1016/j.omto.2021.06.008; Van Gool F, 2019, IMMUNITY, V50, P362, DOI 10.1016/j.immuni.2018.12.016; Westphal M, 2006, ACTA NEUROCHIR, V148, P269, DOI 10.1007/s00701-005-0707-z; Westphal M, 2003, NEURO-ONCOLOGY, V5, P79, DOI 10.1215/15228517-5-2-79; Wick A, 2009, J NEUROL, V256, P734, DOI 10.1007/s00415-009-5006-9; Wolchok JD, 2009, CLIN CANCER RES, V15, P7412, DOI 10.1158/1078-0432.CCR-09-1624; Wu A, 2001, CANCER RES, V61, P3009; Yajima S, 2021, MOL THER-ONCOLYTICS, V23, P402, DOI 10.1016/j.omto.2021.10.012; Yamada T, 2020, MOL THER-ONCOLYTICS, V18, P535, DOI 10.1016/j.omto.2020.08.010	47	13	13	5	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01897-x	http://dx.doi.org/10.1038/s41591-022-01897-x		JUL 2022	25	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3C2GI	35864254	Green Published, hybrid			2022-12-27	WOS:000828446700008
J	Guthridge, JM; Wagner, CA; James, JA				Guthridge, Joel M.; Wagner, Catriona A.; James, Judith A.			The promise of precision medicine in rheumatology	NATURE MEDICINE			English	Review							SYSTEMIC-LUPUS-ERYTHEMATOSUS; GENE-EXPRESSION PATTERNS; NECROSIS FACTOR THERAPY; INTERFERON TYPE-I; SJOGRENS-SYNDROME; MONOCLONAL-ANTIBODY; TREATMENT RESPONSE; CLUSTER-ANALYSIS; DISEASE-ACTIVITY; DOUBLE-BLIND	Precision medicine for rheumatic diseases is still in its infancy, but recent advances are enabling comprehensive profiling and mechanistic insights. This Review outlines the progress, promises, and challenges of translating these findings into the clinic. Systemic autoimmune rheumatic diseases (SARDs) exhibit extensive heterogeneity in clinical presentation, disease course, and treatment response. Therefore, precision medicine - whereby treatment is tailored according to the underlying pathogenic mechanisms of an individual patient at a specific time - represents the 'holy grail' in SARD clinical care. Current strategies include treat-to-target therapies and autoantibody testing for patient stratification; however, these are far from optimal. Recent innovations in high-throughput 'omic' technologies are now enabling comprehensive profiling at multiple levels, helping to identify subgroups of patients who may taper off potentially toxic medications or better respond to current molecular targeted therapies. Such advances may help to optimize outcomes and identify new pathways for treatment, but there are many challenges along the path towards clinical translation. In this Review, we discuss recent efforts to dissect cellular and molecular heterogeneity across multiple SARDs and future directions for implementing stratification approaches for SARD treatment in the clinic.	[Guthridge, Joel M.; Wagner, Catriona A.; James, Judith A.] Oklahoma Med Res Fdn, Arthritis & Clin Immunol, 825 NE 13th St, Oklahoma City, OK 73104 USA; [Guthridge, Joel M.; James, Judith A.] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA; [Guthridge, Joel M.; James, Judith A.] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73106 USA	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	James, JA (corresponding author), Oklahoma Med Res Fdn, Arthritis & Clin Immunol, 825 NE 13th St, Oklahoma City, OK 73104 USA.; James, JA (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA.; James, JA (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73106 USA.	Judith-James@omrf.org		James, Judith/0000-0002-9574-7355	NIH [P30AR073750, U54GM104938, UC2AR081032, UM1AI144292]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank S. Slight-Webb for critical review of the manuscript. We would like to thank the scientists in the Accelerating Medicines Partnerships in RA/Lupus and in Autoimmune and Immune Mediated Disease Networks, along with the NIAID Autoimmunity Centers of Excellence Network. This work is supported by NIH grants P30AR073750, U54GM104938, UC2AR081032, UM2AR067678, and UM1AI144292.	Andreoletti G, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-02000-9; [Anonymous], 2015, Nat Rev Dis Primers, V1, P15053, DOI 10.1038/nrdp.2015.53; Arazi A, 2019, NAT IMMUNOL, V20, P902, DOI 10.1038/s41590-019-0398-x; Artim-Esen B, 2014, J RHEUMATOL, V41, P1304, DOI 10.3899/jrheum.130984; Assassi S, 2015, ARTHRITIS RHEUMATOL, V67, P3016, DOI 10.1002/art.39289; Baechler EC, 2003, P NATL ACAD SCI USA, V100, P2610, DOI 10.1073/pnas.0337679100; Banchereau R, 2016, CELL, V165, P551, DOI 10.1016/j.cell.2016.03.008; Barturen G, 2021, ARTHRITIS RHEUMATOL, V73, P1073, DOI 10.1002/art.41610; Barturen G, 2018, NAT REV RHEUMATOL, V14, P75, DOI 10.1038/nrrheum.2017.220; Belasco J, 2015, ARTHRITIS RHEUMATOL, V67, P934, DOI 10.1002/art.38995; Bodewes ILA, 2018, RHEUMATOLOGY, V57, P921, DOI 10.1093/rheumatology/kex490; Bonventre JV, 2018, KIDNEY INT, V94, P1040, DOI 10.1016/j.kint.2018.07.029; Brito-Zeron P, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.47; Brkic Z, 2013, ANN RHEUM DIS, V72, P728, DOI 10.1136/annrheumdis-2012-201381; Buckley CD, 2021, NAT REV RHEUMATOL, V17, P195, DOI 10.1038/s41584-020-00570-2; Castillo R, 2020, CLIN IMMUNOL, V217, DOI 10.1016/j.clim.2020.108470; Catalina MD, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.140380; Chakravarty EF, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0669-3; Cheng LY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.709178; Chung L, 2009, ARTHRITIS RHEUM-US, V60, P584, DOI 10.1002/art.24221; Cocco E, 2018, NAT REV CLIN ONCOL, V15, P731, DOI 10.1038/s41571-018-0113-0; Cohen SB, 2006, ARTHRITIS RHEUM-US, V54, P2793, DOI 10.1002/art.22025; Coit P, 2015, J AUTOIMMUN, V61, P29, DOI 10.1016/j.jaut.2015.05.003; Croft AP, 2019, NATURE, V570, P246, DOI 10.1038/s41586-019-1263-7; Dalbeth N, 2019, NAT REV DIS PRIMERS, V5, DOI [10.1038/s41572-019-0115-y, 10.1038/s41572-019-0124-x]; Dennis G, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4555; Der E, 2019, NAT IMMUNOL, V20, P915, DOI 10.1038/s41590-019-0386-1; Diani M, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/7692024; Emamian ES, 2009, GENES IMMUN, V10, P285, DOI 10.1038/gene.2009.20; Fava A, 2022, ARTHRITIS RHEUMATOL, V74, P829, DOI 10.1002/art.42023; Fava A, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138345; Fernando MMA, 2005, ANN RHEUM DIS, V64, P524, DOI 10.1136/ard.2003.015248; Figgett WA, 2019, CLIN TRANSL IMMUNOL, V8, DOI 10.1002/cti2.1093; Franks JM, 2019, ARTHRITIS RHEUMATOL, V71, P1701, DOI 10.1002/art.40898; Furie R, 2017, ARTHRITIS RHEUMATOL, V69, P376, DOI 10.1002/art.39962; Furie R, 2011, ARTHRITIS RHEUM-US, V63, P3918, DOI 10.1002/art.30613; Furie RA, 2019, LANCET RHEUMATOL, V1, pE208, DOI 10.1016/S2665-9913(19)30076-1; Gardner H, 2006, ARTHRITIS RHEUM-US, V54, P1961, DOI 10.1002/art.21894; Gottenberg JE, 2006, P NATL ACAD SCI USA, V103, P2770, DOI 10.1073/pnas.0510837103; Guthridge JM, 2020, ECLINICALMEDICINE, V20, DOI 10.1016/j.eclinm.2020.100291; Hall JC, 2015, ARTHRITIS RHEUMATOL, V67, P2437, DOI 10.1002/art.39204; Hall JC, 2012, P NATL ACAD SCI USA, V109, P17609, DOI 10.1073/pnas.1209724109; Hinchcliff M, 2013, J INVEST DERMATOL, V133, P1979, DOI 10.1038/jid.2013.130; Hjelmervik TOR, 2005, ARTHRITIS RHEUM, V52, P1534, DOI 10.1002/art.21006; Humby F, 2021, LANCET, V397, P305, DOI 10.1016/S0140-6736(20)32341-2; Humby F, 2019, ANN RHEUM DIS, V78, P761, DOI 10.1136/annrheumdis-2018-214539; Isenberg DA, 2011, ANN RHEUM DIS, V70, P54, DOI 10.1136/ard.2010.132068; Jadon DR, 2020, NAT REV RHEUMATOL, V16, P609, DOI 10.1038/s41584-020-00507-9; James JA, 2020, RHEUMATOLOGY, V59, P860, DOI 10.1093/rheumatology/kez335; Jeffries MA, 2011, EPIGENETICS-US, V6, P593, DOI 10.4161/epi.6.5.15374; Jennette JC, 2013, ARTHRITIS RHEUM-US, V65, P1, DOI 10.1002/art.37715; Johnson ME, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0114017; Johnson SR, 2007, J RHEUMATOL, V34, P1855; Jones RB, 2019, ANN RHEUM DIS, V78, P399, DOI 10.1136/annrheumdis-2018-214245; Kayser C, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00167; Kessel A, 2009, SEMIN ARTHRITIS RHEU, V39, P66, DOI 10.1016/j.semarthrit.2008.03.003; Khanna D, 2020, ARTHRITIS RHEUMATOL, V72, P125, DOI 10.1002/art.41055; Kim N, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11081161; Kuo D, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau8587; Lakhanpal A, 2021, CURR OPIN RHEUMATOL, V33, P58, DOI 10.1097/BOR.0000000000000767; Leclair V, 2016, J SCLERODERMA RELAT, V1, P298, DOI 10.5301/jsrd.5000212; LEROY EC, 1988, J RHEUMATOL, V15, P202; Lewis MJ, 2019, CELL REP, V28, P2455, DOI 10.1016/j.celrep.2019.07.091; Lewis MJ, 2017, RHEUMATOLOGY, V56, P67, DOI 10.1093/rheumatology/kew399; Lyons PA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12515-9; Lyons PA, 2012, NEW ENGL J MED, V367, P214, DOI 10.1056/NEJMoa1108735; Lyons PA, 2010, ANN RHEUM DIS, V69, P1208, DOI 10.1136/ard.2009.108043; Mahoney JM, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004005; Manthiram K, 2017, NAT IMMUNOL, V18, P832, DOI 10.1038/ni.3777; Martin-Gutierrez L, 2021, ARTHRITIS RHEUMATOL, V73, P1626, DOI 10.1002/art.41708; Martyanov V, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187580; McKinney EF, 2015, NATURE, V523, P612, DOI 10.1038/nature14468; McKinney EF, 2010, NAT MED, V16, P586, DOI 10.1038/nm.2130; Mease PJ, 2015, NEW ENGL J MED, V373, P1329, DOI 10.1056/NEJMoa1412679; Merrill JT, 2022, NEW ENGL J MED, V386, P1034, DOI 10.1056/NEJMoa2106535; Merrill JT, 2017, ARTHRITIS RHEUMATOL, V69, P1257, DOI 10.1002/art.40086; Milano A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002696; Miyagawa I, 2019, RHEUMATOLOGY, V58, P336, DOI 10.1093/rheumatology/key069; Mizoguchi F, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02892-y; Morand EF, 2020, NEW ENGL J MED, V382, P211, DOI 10.1056/NEJMoa1912196; Navarra SV, 2011, LANCET, V377, P721, DOI 10.1016/S0140-6736(10)61354-2; Nehar-Belaid D, 2020, NAT IMMUNOL, V21, P1094, DOI 10.1038/s41590-020-0743-0; Nerviani A, 2021, ANN RHEUM DIS, V80, P591, DOI 10.1136/annrheumdis-2020-218186; Nerviani A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00845; Nezos A, 2015, J AUTOIMMUN, V63, P47, DOI 10.1016/j.jaut.2015.07.002; Ngo ST, 2014, FRONT NEUROENDOCRIN, V35, P347, DOI 10.1016/j.yfrne.2014.04.004; Ocampo D Vanessa, 2019, F1000Res, V8, DOI 10.12688/f1000research.19144.1; Orange DE, 2020, NEW ENGL J MED, V383, P218, DOI 10.1056/NEJMoa2004114; Orange DE, 2018, ARTHRITIS RHEUMATOL, V70, P690, DOI 10.1002/art.40428; Pacheco Y, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1345-y; Panousis NI, 2019, ANN RHEUM DIS, V78, P1079, DOI 10.1136/annrheumdis-2018-214379; Pendergrass SA, 2012, J INVEST DERMATOL, V132, P1363, DOI 10.1038/jid.2011.472; Perez RK, 2022, SCIENCE, V376, P153, DOI 10.1126/science.abf1970; Pitzalis C, 2020, NAT REV RHEUMATOL, V16, P590, DOI 10.1038/s41584-020-0491-4; Rao DA, 2017, NATURE, V542, P110, DOI 10.1038/nature20810; Renauer P, 2015, LUPUS SCI MED, V2, DOI 10.1136/lupus-2015-000101; Reynolds JA, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075-018-1666-0; Ritchlin C, 2014, ANN RHEUM DIS, V73, P990, DOI 10.1136/annrheumdis-2013-204655; Robinson GA, 2020, LANCET RHEUMATOL, V2, pE485, DOI 10.1016/S2665-9913(20)30168-5; Ronnblom L, 2019, LUPUS SCI MED, V6, DOI 10.1136/lupus-2018-000270; Rosenblum MD, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003504; Sandling JK, 2021, ANN RHEUM DIS, V80, P109, DOI 10.1136/annrheumdis-2020-218636; Simon Q, 2021, ARTHRITIS RHEUMATOL, V73, P1550, DOI 10.1002/art.41697; Singh JA, 2012, ARTHRIT CARE RES, V64, P625, DOI 10.1002/acr.21641; Sirota M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001318; Slight-Webb S., ARTHRIT CARE RES, DOI [10.1002/acr.24795(2021, DOI 10.1002/ACR.24795(2021]; Sobanski V, 2019, ARTHRITIS RHEUMATOL, V71, P1553, DOI 10.1002/art.40906; Soret P, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23472-7; Stephenson W, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02659-x; Stone JH, 2010, NEW ENGL J MED, V363, P221, DOI 10.1056/NEJMoa0909905; Suwanchote S, 2018, CLIN RHEUMATOL, V37, P875, DOI 10.1007/s10067-018-4062-x; Taroni JN, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0417-1; Taroni JN, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0695-1; Toro-Dominguez D, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51616-9; Toro-Dominguez D, 2018, ARTHRITIS RHEUMATOL, V70, P2025, DOI 10.1002/art.40653; Unizony S, 2016, ANN RHEUM DIS, V75, P1166, DOI 10.1136/annrheumdis-2015-208073; van Baarsen LGM, 2010, ARTHRITIS RHEUM-US, V62, P1602, DOI 10.1002/art.27415; van der Kroef M, 2020, EUR J IMMUNOL, V50, P119, DOI 10.1002/eji.201948129; Wei KV, 2020, NATURE, V582, P259, DOI 10.1038/s41586-020-2222-z; Whitfield ML, 2003, P NATL ACAD SCI USA, V100, P12319, DOI 10.1073/pnas.1635114100; Wildenberg ME, 2008, EUR J IMMUNOL, V38, P2024, DOI 10.1002/eji.200738008; Yang CY, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.587773; Yazar S, 2022, SCIENCE, V376, P154, DOI 10.1126/science.abf3041; Zhang F, 2019, NAT IMMUNOL, V20, P928, DOI 10.1038/s41590-019-0378-1	124	2	2	3	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2022	28	7					1363	1371		10.1038/s41591-022-01880-6	http://dx.doi.org/10.1038/s41591-022-01880-6		JUL 2022	9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3E5PS	35788174				2022-12-27	WOS:000820578500002
J	Donlin, LT				Donlin, Laura T.			Inching closer to precision treatment for rheumatoid arthritis	NATURE MEDICINE			English	Editorial Material								Biopsies from synovial joints - and the abundance of B cells and macrophages therein - may instruct more effective treatment decisions for individuals with rheumatoid arthritis.	[Donlin, Laura T.] IHSS Res Inst, New York, NY 10029 USA; [Donlin, Laura T.] Weill Cornell Med, New York, NY 10021 USA	Cornell University	Donlin, LT (corresponding author), IHSS Res Inst, New York, NY 10029 USA.; Donlin, LT (corresponding author), Weill Cornell Med, New York, NY 10021 USA.	DonlinL@hss.edu						Aletaha D, 2018, JAMA-J AM MED ASSOC, V320, P1360, DOI 10.1001/jama.2018.13103; Alivernini S, 2020, NAT MED, V26, P1295, DOI 10.1038/s41591-020-0939-8; Burmester GR, 2017, LANCET, V389, P2338, DOI 10.1016/S0140-6736(17)31491-5; Bykerk V, 2010, ARTHRITIS RHEUM-US, V62, P3519, DOI 10.1002/art.27691; Donlin LT, 2019, NAT REV RHEUMATOL, V15, P327, DOI 10.1038/s41584-019-0217-7; Fraenkel L, 2021, ARTHRITIS RHEUMATOL, V73, P1108, DOI [10.1002/acr.24596, 10.1002/art.41752]; Humby F, 2021, LANCET, V397, P305, DOI 10.1016/S0140-6736(20)32341-2; Kuo D, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau8587; Pitzalis C, 2020, NAT REV RHEUMATOL, V16, P590, DOI 10.1038/s41584-020-0491-4; Rivellese F, 2022, NAT MED, V28, P1256, DOI 10.1038/s41591-022-01789-0; Smolen JS, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.1; Zhang F., 2022, BIORXIV, DOI [10.1101/2022.02.25.481990, DOI 10.1101/2022.02.25.481990]	12	1	1	2	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2022	28	6					1129	1131		10.1038/s41591-022-01857-5	http://dx.doi.org/10.1038/s41591-022-01857-5		JUN 2022	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E9IE	35681106				2022-12-27	WOS:000808417500001
J	Marshall, A				Marshall, A			Laying the foundations for personalized medicines	NATURE BIOTECHNOLOGY			English	Article																		Kalow Werner, 1963, PHARMACOGENETICS HER; LICHTER J, 1995, CURR OPIN BIOTECH, V6, P715, DOI 10.1016/0958-1669(95)80117-0; MEYER UA, 1997, IN PRESS EVOLUTION H; MOTULSKY AG, 1957, JAMA-J AM MED ASSOC, V165, P835, DOI 10.1001/jama.1957.72980250010016; VESSELL E S, 1971, Clinical Pharmacology and Therapeutics, V12, P192; WEBER WW, 1997, PHARMACOGENETICS	6	47	53	0	9	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1997	15	10					954	957		10.1038/nbt1097-954	http://dx.doi.org/10.1038/nbt1097-954			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XZ285	9335043				2022-12-27	WOS:A1997XZ28500022
J	Vindigni, A; Dang, QD; DiCera, E				Vindigni, A; Dang, QD; DiCera, E			Site-specific dissection of substrate recognition by thrombin	NATURE BIOTECHNOLOGY			English	Article						drug design; plasmin; serine proteases; trypsin	CHEMICAL SYNTHESIS; CRYSTAL-STRUCTURE; SURFACE RESIDUES; SERINE PROTEASES; BINDING; IDENTIFICATION; GEOMETRY	Current approaches to enzyme specificity focus on the identification of consensus sequences from combinatorial chemistry libraries or phage display. These synthetic substrates can also be used as sensitive probes for the molecular environment of the enzyme specificity sites to determine how they contribute to recognition in the transition state. Libraries constructed to include all relevant species for a site-specific analysis contain a relatively smart number of substrates and provide quantitative information on the energetics of recognition that can be exploited in studies of structure-function relations and rational drug design. We have constructed a library of substrates carrying substitutions at P1, P2, and P3 to probe the response of the specificity sites S1, S2, and S3 of thrombin. The library has been used to identify differences between the anticoagulant slow and procoagulant fast forms of thrombin and the structural origin of the effects, The results also offer new guidelines for the design of active-site inhibitors of thrombin.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOL BIOPHYS,ST LOUIS,MO 63110	Washington University (WUSTL)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049413, R29HL049413, R01HL058141] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49413, HL58141] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANFIELD DK, 1992, P NATL ACAD SCI USA, V89, P2779, DOI 10.1073/pnas.89.7.2779; BARTUNIK HD, 1989, J MOL BIOL, V210, P813, DOI 10.1016/0022-2836(89)90110-1; BODE W, 1992, PROTEIN SCI, V1, P426; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CLAESON G, 1994, BLOOD COAGUL FIBRIN, V5, P411; Dang QD, 1996, P NATL ACAD SCI USA, V93, P10653, DOI 10.1073/pnas.93.20.10653; Dang QD, 1997, NAT BIOTECHNOL, V15, P146, DOI 10.1038/nbt0297-146; DEFILIPPIS V, 1995, BIOCHEMISTRY-US, V34, P9552, DOI 10.1021/bi00029a032; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; Di Cera E., 1995, THERMODYNAMIC THEORY; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; Guinto ER, 1997, BIOPHYS CHEM, V64, P103, DOI 10.1016/S0301-4622(96)02211-9; GUINTO ER, 1995, P NATL ACAD SCI USA, V92, P11185, DOI 10.1073/pnas.92.24.11185; MALIKAYIL JA, 1997, BIOCHEMISTRY-US, V26, P1034; PERONA JJ, 1995, PROTEIN SCI, V4, P337; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SHARMA SK, 1990, THROMB RES, V57, P127, DOI 10.1016/0049-3848(90)90201-M; Smith GP, 1997, CHEM REV, V97, P391, DOI 10.1021/cr960065d; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; TSIANG M, 1995, J BIOL CHEM, V270, P16854, DOI 10.1074/jbc.270.28.16854; Tucker TJ, 1997, J MED CHEM, V40, P830, DOI 10.1021/jm960762y; Vindigni A, 1997, BIOCHEMISTRY-US, V36, P6674, DOI 10.1021/bi962766a; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; Wells JA, 1996, SCIENCE, V273, P449, DOI 10.1126/science.273.5274.449; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; ZHANG E, 1997, BIOPHYS CHEM, V63, P186	27	63	66	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1997	15	9					891	895		10.1038/nbt0997-891	http://dx.doi.org/10.1038/nbt0997-891			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XW410	9306406				2022-12-27	WOS:A1997XW41000033
J	Zufferey, R; Nagy, D; Mandel, RJ; Naldini, L; Trono, D				Zufferey, R; Nagy, D; Mandel, RJ; Naldini, L; Trono, D			Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo	NATURE BIOTECHNOLOGY			English	Article						gene therapy; retroviral vectors; HIV	HUMAN-IMMUNODEFICIENCY-VIRUS; NUCLEAR-LOCALIZATION SIGNAL; PROVIRAL DNA-SYNTHESIS; NEF GENE; NONDIVIDING CELLS; MATRIX PROTEIN; T-LYMPHOCYTES; VPR GENE; TYPE-1; INFECTION	Retroviral vectors derived from lentiviruses such as HIV-1 are promising tools for human gene therapy because they mediate the in vivo delivery and long-term expression of transgenes in nondividing tissues. We describe an HIV vector system in which the virulence genes env, vif, vpr, vpu, and nef have been deleted. This multiply attenuated vector conserved the ability to transduce growth-arrested cells and monocyte-derived macrophages in culture, and could efficiently deliver genes in vivo into adult neurons. These data demonstrate the potential of lentiviral vectors in human gene therapy.	CELL GENESYS,FOSTER CITY,CA 94404; SALK INST BIOL STUDIES,LA JOLLA,CA 92037	Cell Genesys Inc; Salk Institute			Naldini, Luigi/E-9083-2012	NALDINI, Luigi/0000-0002-7835-527X				Aiken C, 1997, J VIROL, V71, P5871, DOI 10.1128/JVI.71.8.5871-5877.1997; AIKEN C, 1995, J VIROL, V69, P5048, DOI 10.1128/JVI.69.8.5048-5056.1995; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; CHOWERS MY, 1995, VIROLOGY, V212, P451, DOI 10.1006/viro.1995.1502; CRYSTAL RG, 1995, SCIENCE, V270, P404, DOI 10.1126/science.270.5235.404; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; Fletcher TM, 1996, EMBO J, V15, P6155, DOI 10.1002/j.1460-2075.1996.tb01003.x; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; Gallay P, 1996, J VIROL, V70, P1027, DOI 10.1128/JVI.70.2.1027-1032.1996; GALLAY P, IN PRESS P NATL ACAD; GHEYSEN D, 1989, CELL, V59, P103, DOI 10.1016/0092-8674(89)90873-8; GIBBS JS, 1994, AIDS RES HUM RETROV, V10, P607, DOI 10.1089/aid.1994.10.607; GOTTLINGER HG, 1993, P NATL ACAD SCI USA, V90, P7381, DOI 10.1073/pnas.90.15.7381; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KLIMKAIT T, 1990, J VIROL, V64, P621, DOI 10.1128/JVI.64.2.621-629.1990; LANG SM, 1993, J VIROL, V67, P902, DOI 10.1128/JVI.67.2.902-912.1993; LEIDEN JM, 1995, NEW ENGL J MED, V333, P871, DOI 10.1056/NEJM199509283331310; LEVY DN, 1993, CELL, V72, P541, DOI 10.1016/0092-8674(93)90073-Y; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510-516.1994; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; Miller RH, 1997, NAT MED, V3, P389, DOI 10.1038/nm0497-389; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; PARK IW, 1994, J ACQ IMMUN DEF SYND, V7, P1228; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; SANDERS WR, 1995, NAT MED, V1, P1137; SCHWARTZ O, 1995, J VIROL, V69, P4053, DOI 10.1128/JVI.69.7.4053-4059.1995; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; TRONO D, 1995, CELL, V82, P189, DOI 10.1016/0092-8674(95)90306-2; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; VONSCHWEDLER U, 1994, P NATL ACAD SCI USA, V91, P6992, DOI 10.1073/pnas.91.15.6992; Wang B, 1996, VIROLOGY, V223, P224, DOI 10.1006/viro.1996.0471; Wyand MS, 1997, NAT MED, V3, P32, DOI 10.1038/nm0197-32	40	1488	1701	3	96	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1997	15	9					871	875		10.1038/nbt0997-871	http://dx.doi.org/10.1038/nbt0997-871			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XW410	9306402				2022-12-27	WOS:A1997XW41000029
J	Hodgson, J				Hodgson, J			Markl opens Max-Planck's doors	NATURE BIOTECHNOLOGY			English	Article																			0	0	0	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					741	741		10.1038/nbt0897-741	http://dx.doi.org/10.1038/nbt0897-741			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255786	Bronze			2022-12-27	WOS:A1997XM70700023
J	Parikh, A; Gillam, EMJ; Guengerich, FP				Parikh, A; Gillam, EMJ; Guengerich, FP			Drug metabolism by Escherichia coli expressing human cytochromes P450	NATURE BIOTECHNOLOGY			English	Article						drug metabolism; cytochrome P450; NADPH-cytochrome P450; bicistronic constructs	REDUCTASE; PURIFICATION; RAT; 4-HYDROXYLATION; OXIDOREDUCTASE; HYDROXYLATION; DEBRISOQUINE; PROTEINS; P-450	The broad substrate specificity of the cytochrome P450 (P450) enzyme superfamily of heme-thiolate proteins lends itself to diverse environmental and pharmaceutical applications. Until recently, the primary drawback in using living bacteria to catalyze mammalian P450-mediated reactions has been the paucity of electron transport from NADPH to P450 via endogenous flavoproteins. We report the functional expression in Escherichia coli of bicistronic constructs consisting of a human microsomal P450 enzyme encoded by the first cistron and the auxiliary protein NADPH-P450 reductase by the second. Expression levels of P450s ranged from 35 nmol per liter culture to 350 nmol per liter culture, with expression of NADPH-P450 reductase typically ranging from 50% to 100% of that of P450. Transformed bacteria metabolized a number of typical P450 substrates at levels comparable to isolated bacterial membranes fortified with an NADPH-generating system. These rates compare favorably with those obtained using human liver microsomes as well as those of reconstituted in vitro systems composed of purified proteins, lipids, and cofactors.	VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; UNIV QUEENSLAND,DEPT PHYSIOL & PHARMACOL,BRISBANE,QLD 4072,AUSTRALIA; VANDERBILT UNIV,SCH MED,CTR MOL TOXICOL,NASHVILLE,TN 37232	Vanderbilt University; University of Queensland; Vanderbilt University			GILLAM, ELIZABETH/D-1011-2016	GILLAM, ELIZABETH/0000-0003-0378-793X	NCI NIH HHS [R35 CA44353] Funding Source: Medline; NIEHS NIH HHS [P30 ES00267] Funding Source: Medline; NIGMS NIH HHS [GM07347] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; Blake JAR, 1996, FEBS LETT, V397, P210, DOI 10.1016/S0014-5793(96)01196-9; BODDUPALLI SS, 1990, J BIOL CHEM, V265, P4233; BURKE MD, 1983, CHEM-BIOL INTERACT, V45, P243; BURKE MD, 1975, DRUG METAB DISPOS, V3, P245; CHOC MG, 1982, J BIOL CHEM, V257, P865; Chun YJ, 1996, ARCH BIOCHEM BIOPHYS, V330, P48, DOI 10.1006/abbi.1996.0224; DISTLERATH LM, 1985, J BIOL CHEM, V260, P9057; Dong JS, 1996, ARCH BIOCHEM BIOPHYS, V327, P254, DOI 10.1006/abbi.1996.0118; GILLAM EMJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P540, DOI 10.1006/abbi.1995.1329; GOLD L, 1990, METHOD ENZYMOL, V185, P11; Guengerich F. Peter, 1995, P473; Guengerich F. Peter, 1994, P1259; GUENGERICH FP, 1981, BIOCHEMISTRY-US, V20, P2379, DOI 10.1021/bi00512a003; Guengerich FP, 1996, METHOD ENZYMOL, V272, P35, DOI 10.1016/S0076-6879(96)72006-2; Guengerich FP, 1996, CRIT REV TOXICOL, V26, P551, DOI 10.3109/10408449609037477; JENKINS CM, 1994, J BIOL CHEM, V269, P27401; JOSEPHY PD, 1995, CANCER RES, V55, P799; KNODELL RG, 1987, J PHARMACOL EXP THER, V241, P1112; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARREY D, 1984, BIOCHEMISTRY-US, V23, P2787, DOI 10.1021/bi00307a039; LARSON JR, 1991, J BIOL CHEM, V266, P7321; Lieschke GJ, 1997, NAT BIOTECHNOL, V15, P35, DOI 10.1038/nbt0197-35; Metz MZ, 1996, VIROLOGY, V217, P230, DOI 10.1006/viro.1996.0110; MURAKAMI H, 1987, DNA-J MOLEC CELL BIO, V6, P189, DOI 10.1089/dna.1987.6.189; OLINS PO, 1990, METHOD ENZYMOL, V185, P115; OMURA T, 1964, J BIOL CHEM, V239, P2370; Parikh A, 1997, PROTEIN EXPRES PURIF, V9, P346, DOI 10.1006/prep.1997.0721; PORTER TD, 1987, ARCH BIOCHEM BIOPHYS, V254, P353, DOI 10.1016/0003-9861(87)90111-1; Riley M., 1996, ESCHERICHIA COLI SAL, P2118; Sambrook J., 2002, MOL CLONING LAB MANU; SCHENKMAN JB, 1967, MOL PHARMACOL, V3, P113; SCHONER BE, 1990, METHOD ENZYMOL, V185, P94; SHEN AL, 1989, J BIOL CHEM, V264, P7584; SHET MS, 1993, P NATL ACAD SCI USA, V90, P11748, DOI 10.1073/pnas.90.24.11748; Shet MS, 1997, ARCH BIOCHEM BIOPHYS, V339, P218, DOI 10.1006/abbi.1996.9868; SHI Y, 1994, P NATL ACAD SCI USA, V91, P2767, DOI 10.1073/pnas.91.7.2767; TARRAGONAFIOL A, 1992, GENE, V118, P239, DOI 10.1016/0378-1119(92)90194-T; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YAMAZAKI H, 1995, BIOCHEMISTRY-US, V34, P8380, DOI 10.1021/bi00026a020; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337	41	267	276	3	28	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					784	788		10.1038/nbt0897-784	http://dx.doi.org/10.1038/nbt0897-784			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255795				2022-12-27	WOS:A1997XM70700032
J	Drucker, DJ; Shi, Q; Crivici, A; SumnerSmith, M; Tavares, W; Hill, M; DeForest, L; Cooper, S; Brubaker, PL				Drucker, DJ; Shi, Q; Crivici, A; SumnerSmith, M; Tavares, W; Hill, M; DeForest, L; Cooper, S; Brubaker, PL			Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV	NATURE BIOTECHNOLOGY			English	Article						protein modeling; protease inactivation; growth factor; intestine; therapeutic	HORMONE RELEASING HORMONE; INTESTINAL ADAPTATION; ENZYMATIC DEGRADATION; RAT STRAIN; IN-VITRO; EXPRESSION; PLASMA; POLYPEPTIDE; ANALOGS	Species-specific differences in the enzymatic inactivation of peptides is an important consideration in the evaluation of therapeutic efficacy. We demonstrate that glucagon-like peptide 2 (GLP-2), shown to be highly intestinotrophic in mice, promotes an increase in intestinal villus height but has no trophic effect on small bowel weight in rats. The reduced intestinotrophic activity of GLP-5 in rats is attributable to inactivation by the enzyme dipeptidyl peptidase IV (DPP-IV), GLP-2(1-33) was degraded to GLP-2(3-33) following incubation with human placental DPP-IV or rat serum but not by serum from DPP-IV-deficient rats, Administration of rat GLP-2 to DPP-IV-deficient rats was associated with markedly increased bioactivity of rat GLP-2 resulting in a significant increase in small bowel weight. A synthetic GLP-2 analog, r[Gly(2)]GLP-2, with an alanine to glycine substitution at position 2, was resistant to cleavage by both DPP-IV and rat serum in vitro. Treatment of wild-type rats with r[Gly(2)]GLP-2 produced a statistically significant increase in small bowel mass. DPP-IV-mediated inactivation of GLP-5 is a critical determinant of the growth factor-like properties of GLP-2.	UNIV TORONTO,TORONTO HOSP,DEPT PHYSIOL,BANTING & BEST DIABET CTR,TORONTO,ON,CANADA; ALLELIX BIOPHARMACEUT INC,MISSISSAUGA,ON,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto	Drucker, DJ (corresponding author), UNIV TORONTO,TORONTO HOSP,DEPT MED,BANTING & BEST DIABET CTR,100 COLL ST,TORONTO,ON,CANADA.		Drucker, Daniel J/A-4092-2010					BAI JPF, 1994, PHARMACEUT RES, V11, P897, DOI 10.1023/A:1018946228432; BESTERMAN HS, 1982, GUT, V23, P854, DOI 10.1136/gut.23.10.854; BLOOM SR, 1982, SCAND J GASTROENTERO, V17, P93; BONGERS J, 1992, BIOCHIM BIOPHYS ACTA, V1122, P147, DOI 10.1016/0167-4838(92)90317-7; DARMOUL D, 1994, BIOCHEM BIOPH RES CO, V203, P1224, DOI 10.1006/bbrc.1994.2313; DARMOUL D, 1991, AM J PHYSIOL, V261, pG763, DOI 10.1152/ajpgi.1991.261.5.G763; DEACON CF, 1995, J CLIN ENDOCR METAB, V80, P952, DOI 10.1210/jc.80.3.952; Drucker DJ, 1996, P NATL ACAD SCI USA, V93, P7911, DOI 10.1073/pnas.93.15.7911; EHRLICH P, 1994, AM J PHYSIOL-ENDOC M, V267, pE662, DOI 10.1152/ajpendo.1994.267.5.E662; ERICKSON RH, 1992, J BIOL CHEM, V267, P21623; FROHMAN LA, 1989, J CLIN INVEST, V83, P1533, DOI 10.1172/JCI114049; FROHMAN LA, 1986, J CLIN INVEST, V78, P906, DOI 10.1172/JCI112679; FULLER PJ, 1993, GASTROENTEROLOGY, V104, P459, DOI 10.1016/0016-5085(93)90414-8; GLEESON MH, 1971, GUT, V12, P773, DOI 10.1136/gut.12.10.773; HILDEBRANDT M, 1991, BIOCHEM J, V277, P331, DOI 10.1042/bj2770331; KIEFFER TJ, 1995, ENDOCRINOLOGY, V136, P3585, DOI 10.1210/en.136.8.3585; Knudsen LB, 1996, EUR J PHARMACOL, V318, P429, DOI 10.1016/S0014-2999(96)00795-9; LANCE VA, 1984, BIOCHEM BIOPH RES CO, V119, P265, DOI 10.1016/0006-291X(84)91647-4; MENTLEIN R, 1993, EUR J BIOCHEM, V214, P829, DOI 10.1111/j.1432-1033.1993.tb17986.x; ORSKOV C, 1987, SCAND J CLIN LAB INV, V47, P165; STEVENS FM, 1984, GUT, V25, P784, DOI 10.1136/gut.25.7.784; TAYLOR RG, 1994, BAILLIERE CLIN ENDOC, V8, P165, DOI 10.1016/S0950-351X(05)80230-7; THOMPSON NL, 1991, BIOCHEM J, V273, P497, DOI 10.1042/bj2730497; Tsai CH, 1997, AM J PHYSIOL-GASTR L, V272, pG662, DOI 10.1152/ajpgi.1997.272.3.G662; WATANABE Y, 1987, EXPERIENTIA, V43, P400, DOI 10.1007/BF01940426	25	220	235	0	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1997	15	7					673	677		10.1038/nbt0797-673	http://dx.doi.org/10.1038/nbt0797-673			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XH583	9219272				2022-12-27	WOS:A1997XH58300033
J	Boder, ET; Wittrup, KD				Boder, ET; Wittrup, KD			Yeast surface display for screening combinatorial polypeptide libraries	NATURE BIOTECHNOLOGY			English	Article						antibody engineering; combinatorial library; surface display; affinity maturation; scFv	SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; CELL-WALL; HETEROLOGOUS PROTEIN; PHAGE ANTIBODIES; ALPHA-AGGLUTININ; A-AGGLUTININ; AFFINITY; SELECTION; BINDING	Display on the yeast cell wall is well suited for engineering mammalian cell-surface and secreted proteins (e.g., antibodies, receptors, cytokines) that require endoplasmic reticulum-specific post-translational processing for efficient folding and activity. C-terminal fusion to the Aga2p mating adhesion receptor of Saccharomyces cerevisiae has been used for the selection of scFv antibody fragments with threefold decreased antigen dissociation rate from a randomly mutated library. A eukaryotic host should alleviate expression biases present in bacterially propagated combinatorial libraries. Quantitative flow cytometric analysis enables fine discrimination of kinetic parameters for protein binding to soluble ligands.	UNIV ILLINOIS,DEPT CHEM ENGN,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign			Boder, Eric T./E-9635-2015	Boder, Eric T./0000-0003-4095-5680				BARBAS SM, 1994, FIBRINOLYSIS, V8, P245, DOI 10.1016/0268-9499(94)90722-6; BURTON DR, 1993, ACCOUNTS CHEM RES, V26, P405, DOI 10.1021/ar00032a003; CAPPELLARO C, 1994, EMBO J, V13, P4737, DOI 10.1002/j.1460-2075.1994.tb06799.x; DENG SJ, 1995, P NATL ACAD SCI USA, V92, P4992, DOI 10.1073/pnas.92.11.4992; FRANCISCO JA, 1993, P NATL ACAD SCI USA, V90, P10444, DOI 10.1073/pnas.90.22.10444; Georgiou G, 1997, NAT BIOTECHNOL, V15, P29, DOI 10.1038/nbt0197-29; Gietz RD, 1995, METHOD MOL CELL BIOL, V5, P255; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; GRIFFITHS AD, 1993, EMBO J, V12, P725, DOI 10.1002/j.1460-2075.1993.tb05706.x; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; HAWKINS RE, 1993, J MOL BIOL, V234, P958, DOI 10.1006/jmbi.1993.1650; HOCKNEY RC, 1994, TRENDS BIOTECHNOL, V12, P456, DOI 10.1016/0167-7799(94)90021-3; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KRETZSCHMAR T, 1995, ANAL BIOCHEM, V224, P413, DOI 10.1006/abio.1995.1059; Low NM, 1996, J MOL BIOL, V260, P359, DOI 10.1006/jmbi.1996.0406; LU CF, 1995, J CELL BIOL, V128, P333, DOI 10.1083/jcb.128.3.333; PAREKH R, 1995, PROTEIN EXPRES PURIF, V6, P537, DOI 10.1006/prep.1995.1071; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; ROY A, 1991, MOL CELL BIOL, V11, P4196, DOI 10.1128/MCB.11.8.4196; Schier R, 1996, J MOL BIOL, V255, P28, DOI 10.1006/jmbi.1996.0004; SCHLOM J, 1992, CANCER RES, V52, P1067; SCHREUDER MP, 1993, YEAST, V9, P399, DOI 10.1002/yea.320090410; Schreuder MP, 1996, TRENDS BIOTECHNOL, V14, P115, DOI 10.1016/0167-7799(96)10017-2; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; ULRICH HD, 1995, P NATL ACAD SCI USA, V92, P11907, DOI 10.1073/pnas.92.25.11907; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245	28	1149	1524	5	249	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1997	15	6					553	557		10.1038/nbt0697-553	http://dx.doi.org/10.1038/nbt0697-553			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XC772	9181578				2022-12-27	WOS:A1997XC77200031
J	Cook, CJ				Cook, CJ			Real-time measurements of corticosteroids in conscious animals using an antibody-based electrode	NATURE BIOTECHNOLOGY			English	Article						immunosensor; cortisol; antibody; electrochemical; hormone	MICRODIALYSIS; RELEASE; ACID	An electrochemical immunosensor for real-time determination of corticosteroids, a group of steroidal hormones, is reported. The sensor measures competitive binding of endogenous corticosteroid and a corticosteroid-peroxidase conjugate with antibodies, immobilized on a platinum electrode, by monitoring of peroxidase activity. The electrode is encased within a dialysate membrane, which separates the electrode environment from the sampled fluid, allowing corticosteroid to equilibrate across the membrane. This permits measurements to be made in vivo. The small size of the probe (350 mu m D) allows implantation into tissue or circulatory systems. The electrode was viable for 200 to 400 sequential measurements and at least 48 h in vivo. Detection sensitivity is 0.2 to 0.6 mu g/100 ml of cortisol or corticosterone. The results suggest the possibility of monitoring hormones in real-time within the blood or organ systems of conscious animals.	HORTRES,ENGN DEV GRP,HAMILTON,NEW ZEALAND	New Zealand Institute for Plant & Food Research Ltd	Cook, CJ (corresponding author), MEAT IND RES INST NEW ZEALAND INC,ANIM STRESS & WELFARE PROGRAMME,PRIVATE BAG 3123,HAMILTON,NEW ZEALAND.			Cook, Christian/0000-0001-9677-0306				ALBERY WJ, 1992, J CHEM SOC CHEM COMM, V12, P900; BENVENISTE H, 1989, J NEUROCHEM, V52, P1667, DOI 10.1111/j.1471-4159.1989.tb07243.x; BROOKE SM, 1994, NEUROENDOCRINOLOGY, V60, P134, DOI 10.1159/000126743; COOK CJ, 1995, MEAT SCI, V40, P137, DOI 10.1016/0309-1740(94)00043-7; COOK CJ, 1995, NEW ZEAL VET J, V43, P248, DOI 10.1080/00480169.1995.35902; Cook CJ, 1996, RES VET SCI, V60, P255, DOI 10.1016/S0034-5288(96)90050-8; Cook CJ, 1996, PHYSIOL BEHAV, V60, P741; COOK CJ, 1997, IN PRESS J NEUROSCIE; Dzantiev BB, 1996, BIOSENS BIOELECTRON, V11, P179, DOI 10.1016/0956-5663(96)83725-0; FRANEK M, 1994, J AGR FOOD CHEM, V42, P1369, DOI 10.1021/jf00042a024; GOODROW M, 1990, J AGR FOOD CHEM, V35, P990; GREEN MJ, 1987, BIOSENSORS FUNDAMENT, P57; KENDRICK KM, 1990, J NEUROSCI METH, V34, P35, DOI 10.1016/0165-0270(90)90040-M; KENDRICK KM, 1989, METHOD ENZYMOL, V168, P182; OBRENOVITCH TP, 1995, J NEUROCHEM, V64, P1884; Petrie NJ, 1996, NEW ZEAL VET J, V44, P4, DOI 10.1080/00480169.1996.35923; Sapolsky RM, 1992, STRESS AGING BRAIN M; WILLS MR, 1983, LAB INVESTIGATIONS E; ZILKHA E, 1995, J NEUROSCI METH, V60, P1, DOI 10.1016/0165-0270(94)00214-2	19	46	49	3	29	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1997	15	5					467	471		10.1038/nbt0597-467	http://dx.doi.org/10.1038/nbt0597-467			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WX237	9131628				2022-12-27	WOS:A1997WX23700033
J	Eng, C; Vijg, J				Eng, C; Vijg, J			Genetic testing: The problems and the promise	NATURE BIOTECHNOLOGY			English	News Item							GRADIENT GEL-ELECTROPHORESIS; HEREDITARY RETINOBLASTOMA; SUSCEPTIBILITY GENE; GERMLINE MUTATIONS; OSTEO-SARCOMA; BREAST-CANCER; HUMAN DNA; RB1 GENE; SPECTRUM; CLEAVAGE		BETH ISRAEL HOSP,GERONTOL DIV,MOL GENET SECT,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center	Eng, C (corresponding author), DANA FARBER CANC INST,DIV CANC EPIDEMIOL & CONTROL,44 BINNEY ST,BOSTON,MA 02115, USA.			Eng, Charis/0000-0002-3693-5145	NIA NIH HHS [1P01AG10829-01, 1P30AG13314-01] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG013314, P01AG010829] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abbott A, 1996, NATURE, V379, P390; Beattie WG, 1995, MOL BIOTECHNOL, V4, P213, DOI 10.1007/BF02779015; BLANQUET V, 1995, HUM MOL GENET, V4, P383, DOI 10.1093/hmg/4.3.383; Brown ML, 1996, INT J CANCER, V69, P55, DOI 10.1002/(SICI)1097-0215(19960220)69:1<55::AID-IJC14>3.0.CO;2-J; CHANG JC, 1982, NEW ENGL J MED, V307, P30, DOI 10.1056/NEJM198207013070105; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; CHETVERIN AB, 1994, BIO-TECHNOL, V12, P1093, DOI 10.1038/nbt1194-1093; Collins FS, 1996, NEW ENGL J MED, V334, P186, DOI 10.1056/NEJM199601183340311; Couch FJ, 1996, NAT GENET, V13, P123, DOI 10.1038/ng0596-123; FISCHER SG, 1979, CELL, V16, P191, DOI 10.1016/0092-8674(79)90200-9; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GULDBERG P, 1993, GENOMICS, V17, P141, DOI 10.1006/geno.1993.1295; Hacia JG, 1996, NAT GENET, V14, P441, DOI 10.1038/ng1296-441; Kozal MJ, 1996, NAT MED, V2, P753, DOI 10.1038/nm0796-753; LERMAN C, 1996, JAMA-J AM MED ASSOC, V275, P85; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; LIAW D, 1997, IN PRESS NATURE GENE; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LIU B, 1994, CANCER RES, V54, P4590; LIU Q, 1995, BIOTECHNIQUES, V18, P470; LIU ZX, 1995, GENE CHROMOSOME CANC, V14, P277, DOI 10.1002/gcc.2870140406; LOHMANN DR, 1994, HUM GENET, V94, P349; Lohmann DR, 1996, AM J HUM GENET, V58, P940; LOHMANN DR, 1994, HUM MOL GENET, V3, P2187, DOI 10.1093/hmg/3.12.2187; MASHAL RD, 1995, NAT GENET, V9, P177, DOI 10.1038/ng0295-177; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Noorani HZ, 1996, AM J HUM GENET, V59, P301; NystromLahti M, 1996, HUM MOL GENET, V5, P763, DOI 10.1093/hmg/5.6.763; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; Phelan CM, 1996, NAT GENET, V13, P120, DOI 10.1038/ng0596-120; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARKAR G, 1992, GENOMICS, V13, P441, DOI 10.1016/0888-7543(92)90266-U; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; SIDRANSKY D, 1992, CANCER RES, V52, P2984; STERN HJ, 1995, CLIN BIOCHEM, V28, P470, DOI 10.1016/0009-9120(95)00016-3; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; TONIN P, 1996, NAT MED, V2, P117; VanOrsouw NJ, 1996, HUM MOL GENET, V5, P755, DOI 10.1093/hmg/5.6.755; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Wu Y, 1996, HUM MUTAT, V8, P160; WU Y, 1997, IN PRESS GENES CHROM; Xia L, 1996, CANCER RES, V56, P2289; YOUIL R, 1995, P NATL ACAD SCI USA, V92, P87, DOI 10.1073/pnas.92.1.87	46	86	89	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1997	15	5					422	426		10.1038/nbt0597-422	http://dx.doi.org/10.1038/nbt0597-422			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WX237	9131618				2022-12-27	WOS:A1997WX23700023
J	Strohman, RC				Strohman, RC			The coming Kuhnian revolution in biology - Commentary	NATURE BIOTECHNOLOGY			English	Editorial Material							EVOLUTION				Strohman, RC (corresponding author), UNIV CALIF BERKELEY, DEPT MOL & CELL BIOL, 229 STANLEY HALL, BERKELEY, CA 94720 USA.							Bak P., 1995, NATURE WORKS; Boveri T., 1914, FRAGE ENTSTEHUNG MAL; CAVALIERSMITH T, 1997, TRENDS GENET, V13, P7; CRAM LS, 1983, CANCER RES, V43, P4828; Crick F., 1966, MOL MEN; DYSON FJ, 1993, AM SCHOLAR, V62, P513; Eddington A., 1928, NATURE PHYSICAL WORL; ELSASSER WM, 1987, REFLECTIONS THEORY O; FEYNMAN RP, 1965, CHARACTER PHYSICAL L; GERMAN J, 1974, CHROMOSOMES CANC; GOULD SJ, 1993, LOGIC LIFE; Holland, 1995, HIDDEN ORDER; HOLLIDAY R, 1990, PHILOS T ROY SOC B, V326, P329, DOI 10.1098/rstb.1990.0015; Jablonka E., 1995, EPIGENETIC INHERITAN; Kauffman S. A., 1993, ORIGINS ORDER; KELSO JAS, 1994, DYNAMIC PATTERNS; KINZLER WK, 1996, NATURE, V382, P672; Lenoir T., 1982, STRATEGY LIFE TELEOL; Lewontin R., 1992, NEW YORK REV BO 0528; LEWONTIN RC, 1974, AM J HUM GENET, V26, P400; MCCLINTOCK B, 1984, SCIENCE, V226, P792, DOI 10.1126/science.15739260; MIKLOS, 1996, CELL, V86, P521; OYAMA S, 1985, ONTOGENY INFORMATION; POLANYI M, 1968, SCIENCE, V160, P1308, DOI 10.1126/science.160.3834.1308; Riggs A. D., 1996, EPIGENETIC MECH GENE, P29; SAPP J, 1987, GENE; SHAPIRO JA, 1992, GENETICA, V86, P99, DOI 10.1007/BF00133714; Sing CF, 1996, CIBA F SYMP, V197, P211; STENT GS, 1981, ANNU REV NEUROSCI, V4, P163, DOI 10.1146/annurev.ne.04.030181.001115; STROHMAN R, 1994, BIO-TECHNOL, V12, P156, DOI 10.1038/nbt0294-156; Tononi G, 1996, P NATL ACAD SCI USA, V93, P3422, DOI 10.1073/pnas.93.8.3422; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; Wilkins AS, 1996, BIOESSAYS, V18, P695, DOI 10.1002/bies.950180902; WRIGHT S, 1945, AM NATURALIST    JUL, V783, P289	34	183	190	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1997	15	3					194	+		10.1038/nbt0397-194	http://dx.doi.org/10.1038/nbt0397-194			0	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WM050	9062910				2022-12-27	WOS:A1997WM05000004
J	Brooks, AI; Muhkerjee, B; Panahian, N; CorySlechta, D; Federoff, HJ				Brooks, AI; Muhkerjee, B; Panahian, N; CorySlechta, D; Federoff, HJ			Nerve growth factor somatic mosaicism produced by herpes virus-directed expression of cre recombinase	NATURE BIOTECHNOLOGY			English	Article						NGF; cre/loxP; gene transfer; herpes virus	GENE-TRANSFER; BETA-GALACTOSIDASE; VECTOR; PROMOTER; NEURONS; REGION; RECEPTOR; PROTEIN; TYPE-1; BRAIN	Focal molecular genetic alteration of the intact mammalian brain will be required to elucidate gene product function in cells comprising synaptic networks. To this end, a somatic mosaic approach has been developed for the mouse whereby a dormant germline transgene is activated by the somatic delivery and expression of cre recombinase. Transgenic mice harboring a recombinational substrate, the germline-transmitted nerve growth factor excision activation transgene (NGF-XAT) were generated. Somatic delivery of virus vectors expressing cre recombinase into the brain of NGF-XAT mice resulted in regional recombination and activation of the transgene as demonstrated at the DNA level by PCR and at the protein level by both immunocytochemistry and ELISA. This approach has been used to evaluate a behavioral correlate of unilateral NGF mosaicism within the dorsal hippocampal formation. NGF-XAT mice activated by expression of cre recombinase manifest increased locomotor activity compared with NGF-XAT mice transduced by a control virus expressing Escherichia coli beta-galactosidase. These data indicate that focally increased expression of NGF in one part of a synaptic network can elicit changes in behavior presumably by altering the overall function of NGF-responsive neural circuitry. This approach should have broad application to other gene products and promises to provide the unprecedented ability to create and study discrete genetic modifications in the context of an intact adult mammal.	UNIV ROCHESTER, MED CTR, DEPT MICROBIOL & IMMUNOL, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, MED CTR, DEPT NEUROL, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, MED CTR, DEPT NEUROBIOL & ANAT, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, MED CTR, DEPT MED, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester			Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD031300] Funding Source: NIH RePORTER; NICHD NIH HHS [HD31300] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ashburner M., 1989, DROSOPHILA LAB HDB; BATTLEMAN DS, 1993, J NEUROSCI, V13, P941; BERGOLD PJ, 1993, P NATL ACAD SCI USA, V90, P6165, DOI 10.1073/pnas.90.13.6165; BYRNES AP, 1995, NEUROSCIENCE, V66, P1015, DOI 10.1016/0306-4522(95)00068-T; CONNER JM, 1992, J COMP NEUROL, V319, P454, DOI 10.1002/cne.903190310; DAI YF, 1995, P NATL ACAD SCI USA, V92, P1401, DOI 10.1073/pnas.92.5.1401; FEDEROFF HJ, 1992, P NATL ACAD SCI USA, V89, P1636, DOI 10.1073/pnas.89.5.1636; FORSSPETTER S, 1990, NEURON, V5, P187, DOI 10.1016/0896-6273(90)90308-3; GELLER AI, 1988, SCIENCE, V241, P1667, DOI 10.1126/science.2843986; GESCHWIND M, 1994, PROVIDING PHARM ACCE, P462; Geschwind MD, 1996, HUM GENE THER, V7, P173, DOI 10.1089/hum.1996.7.2-173; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; Jin BK, 1996, HUM GENE THER, V7, P2015, DOI 10.1089/hum.1996.7.16-2015; JOHNSON PA, 1992, J VIROL, V66, P2952, DOI 10.1128/JVI.66.5.2952-2965.1992; KAPLITT MG, 1994, P NATL ACAD SCI USA, V91, P8979, DOI 10.1073/pnas.91.19.8979; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; PALMER TD, 1993, NUCLEIC ACIDS RES, V21, P3451, DOI 10.1093/nar/21.15.3451; PATERSON T, 1990, J GEN VIROL, V71, P1775, DOI 10.1099/0022-1317-71-8-1775; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; TANTRAVAHI J, 1993, MOL CELL BIOL, V13, P578, DOI 10.1128/MCB.13.1.578; Wang Y, 1996, P NATL ACAD SCI USA, V93, P3932, DOI 10.1073/pnas.93.9.3932; XU H, 1994, DEV BIOL, V163, P152, DOI 10.1006/dbio.1994.1131; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995	23	31	31	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1997	15	1					57	62		10.1038/nbt0197-57	http://dx.doi.org/10.1038/nbt0197-57			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WA729	9035107				2022-12-27	WOS:A1997WA72900024
J	Ural, BB; Caron, DP; Dogra, P; Wells, SB; Szabo, PA; Granot, T; Senda, T; Poon, MML; Lam, N; Thapa, P; Lee, YS; Kubota, M; Matsumoto, R; Farber, DL				Ural, Basak B.; Caron, Daniel P.; Dogra, Pranay; Wells, Steven B.; Szabo, Peter A.; Granot, Tomer; Senda, Takashi; Poon, Maya M. L.; Lam, Nora; Thapa, Puspa; Lee, Yoon Seung; Kubota, Masaru; Matsumoto, Rei; Farber, Donna L.			Inhaled particulate accumulation with age impairs immune function and architecture in human lung lymph nodes	NATURE MEDICINE			English	Article; Early Access							AIR-POLLUTION; APOPTOTIC CELLS; MACROPHAGES; RESPONSES; MATTER; MICE; INFLAMMATION; DISEASES; TISSUES	Carbon-containing particulates accumulate with age in a subset of macrophages in human lung-associated lymph nodes, decrease macrophage phagocytic capacity and turnover and disrupt lymphoid tissue structure, potentially compromising adaptive immune responses. Older people are particularly susceptible to infectious and neoplastic diseases of the lung and it is unclear how lifelong exposure to environmental pollutants affects respiratory immune function. In an analysis of human lymph nodes (LNs) from 84 organ donors aged 11-93 years, we found a specific age-related decline in lung-associated, but not gut-associated, LN immune function linked to the accumulation of inhaled atmospheric particulate matter. Increasing densities of particulates were found in lung-associated LNs with age, but not in the corresponding gut-associated LNs. Particulates were specifically contained within CD68(+)CD169(-) macrophages, which exhibited decreased activation, phagocytic capacity, and altered cytokine production compared with non-particulate-containing macrophages. The structures of B cell follicles and lymphatic drainage were also disrupted in lung-associated LNs with particulates. Our results reveal that the cumulative effects of environmental exposure and age may compromise immune surveillance of the lung via direct effects on immune cell function and lymphoid architecture.	[Ural, Basak B.; Caron, Daniel P.; Dogra, Pranay; Szabo, Peter A.; Poon, Maya M. L.; Lam, Nora; Thapa, Puspa; Lee, Yoon Seung; Farber, Donna L.] Columbia Univ, Irving Med Ctr, Dept Microbiol & Immunol, New York, NY 10027 USA; [Wells, Steven B.] Columbia Univ, Irving Med Ctr, Dept Syst Biol, New York, NY USA; [Granot, Tomer] Columbia Univ, Columbia Ctr Translat Immunol, New York, NY USA; [Senda, Takashi; Kubota, Masaru; Matsumoto, Rei; Farber, Donna L.] Columbia Univ, Irving Med Ctr, Dept Surg, New York, NY 10027 USA	Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; Columbia University; NewYork-Presbyterian Hospital	Farber, DL (corresponding author), Columbia Univ, Irving Med Ctr, Dept Microbiol & Immunol, New York, NY 10027 USA.; Farber, DL (corresponding author), Columbia Univ, Irving Med Ctr, Dept Surg, New York, NY 10027 USA.	df2396@cumc.columbia.edu		Szabo, Peter Anthony/0000-0003-1603-761X; Wells, Steven/0000-0001-5428-0683; , Maya/0000-0002-7927-5853; Caron, Daniel/0000-0002-1500-8713	National Institutes of Health (NIH) [HL145547, AI106697, AI128949]; NIH [S10RR027050, T32HL105323, 30 CA01369]; Cancer Research Institute Irvington Postdoctoral Fellowship; National Science Foundation Graduate Research Fellowship Program; Canadian Institutes of Health Research Fellowship; Columbia Center for Translational Immunology Flow Cytometry Core	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Research Institute Irvington Postdoctoral Fellowship; National Science Foundation Graduate Research Fellowship Program(National Science Foundation (NSF)); Canadian Institutes of Health Research Fellowship(Canadian Institutes of Health Research (CIHR)); Columbia Center for Translational Immunology Flow Cytometry Core	This work was supported by National Institutes of Health (NIH) grants HL145547, AI106697 and AI128949 awarded to D.L.F. B.B.U. was supported by NIH T32HL105323. P.D. was supported by a Cancer Research Institute Irvington Postdoctoral Fellowship. N.L. is supported by the National Science Foundation Graduate Research Fellowship Program. P.A.S. is supported by the Canadian Institutes of Health Research Fellowship. This study also used the Confocal and Specialized Microscopy Shared Resource core supported by NIH P30 CA013696 and the Columbia Center for Translational Immunology Flow Cytometry Core supported in part by NIH S10RR027050. We thank M. J. Gastinger (Imaris) for the Python code used in the B cell imaging analysis, A. Urso for previous help with confocal microscopy, S. Ghosh for the THP-1 cell line, and the transplant coordinators at LiveOnNY and the donor families for making this study possible.	Akbar AN, 2020, SCIENCE, V369, P256, DOI 10.1126/science.abb0762; Arandjelovic S, 2015, NAT IMMUNOL, V16, P907, DOI 10.1038/ni.3253; Baratin M, 2017, IMMUNITY, V47, P349, DOI 10.1016/j.immuni.2017.07.019; Bellomo A, 2018, CELL IMMUNOL, V330, P168, DOI 10.1016/j.cellimm.2018.01.010; Boe DM, 2017, CLIN EXP IMMUNOL, V187, P16, DOI 10.1111/cei.12881; Brandt EB, 2015, J ALLERGY CLIN IMMUN, V136, P295, DOI 10.1016/j.jaci.2014.11.043; Buettner M, 2012, CLIN EXP IMMUNOL, V169, P205, DOI 10.1111/j.1365-2249.2012.04602.x; Carpenter DJ, 2018, AM J TRANSPLANT, V18, P74, DOI 10.1111/ajt.14434; Cohen AJ, 2017, LANCET, V389, P1907, DOI [10.1016/s0140-6736(17)30505-6, 10.1016/S0140-6736(17)30505-6]; Cox N, 2021, ANNU REV IMMUNOL, V39, P313, DOI 10.1146/annurev-immunol-093019-111748; Davies LC, 2013, NAT IMMUNOL, V14, P986, DOI 10.1038/ni.2705; Davies ML, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006435; Dogra P, 2020, CELL, V180, P749, DOI 10.1016/j.cell.2020.01.022; Ensan S, 2016, NAT IMMUNOL, V17, P159, DOI 10.1038/ni.3343; Erdman LK, 2009, J IMMUNOL, V183, P6452, DOI 10.4049/jimmunol.0901374; Etzerodt A, 2013, ANTIOXID REDOX SIGN, V18, P2352, DOI 10.1089/ars.2012.4834; Farber DL, 2021, NATURE, V593, P506, DOI 10.1038/d41586-021-01396-y; Frasca D, 2016, BIOGERONTOLOGY, V17, P7, DOI 10.1007/s10522-015-9578-8; Granot T, 2017, IMMUNITY, V46, P504, DOI 10.1016/j.immuni.2017.02.019; Gray EE, 2012, J INNATE IMMUN, V4, P424, DOI 10.1159/000337007; Guarnieri M, 2014, LANCET, V383, P1581, DOI 10.1016/S0140-6736(14)60617-6; Hadamitzky C, 2010, J ANAT, V216, P556, DOI 10.1111/j.1469-7580.2010.01213.x; Haghani A, 2021, ALZHEIMERS DEMENT, V17, P175, DOI 10.1002/alz.12230; Haghani A, 2020, J ALZHEIMERS DIS, V76, P773, DOI 10.3233/JAD-200377; Hashimoto D, 2013, IMMUNITY, V38, P792, DOI 10.1016/j.immuni.2013.04.004; Huang QZ, 2019, ADV IMMUNOL, V144, P155, DOI 10.1016/bs.ai.2019.08.008; Kaneko N, 2020, CELL, V183, P143, DOI 10.1016/j.cell.2020.08.025; Kumar BV, 2018, IMMUNITY, V48, P202, DOI 10.1016/j.immuni.2018.01.007; Kurosaka K, 2003, J IMMUNOL, V171, P4672, DOI 10.4049/jimmunol.171.9.4672; Legge KL, 2005, IMMUNITY, V23, P649, DOI 10.1016/j.immuni.2005.11.006; Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039; LUSCIETI P, 1980, J CLIN PATHOL, V33, P454, DOI 10.1136/jcp.33.5.454; Martinez-Pomares L, 2012, TRENDS IMMUNOL, V33, P66, DOI 10.1016/j.it.2011.11.001; Masters AR, 2019, J GERONTOL A-BIOL, V74, P1734, DOI 10.1093/gerona/glz029; Matthews NC, 2016, AM J RESP CELL MOL, V54, P250, DOI 10.1165/rcmb.2015-0084OC; Medina-Contreras O, 2011, J CLIN INVEST, V121, P4787, DOI 10.1172/JCI59150; Metcalf CJE, 2022, ROY SOC OPEN SCI, V9, DOI 10.1098/rsos.211498; Miron M, 2018, J IMMUNOL, V201, P2132, DOI 10.4049/jimmunol.1800716; National Institute on Ageing, 2007, WHY POPULATION AGING; Nikolich-Zugich J, 2014, J IMMUNOL, V193, P2622, DOI 10.4049/jimmunol.1401174; O'Driscoll M, 2020, NATURE, DOI 10.1038/s41586-020-2918-0; O'Neill ASG, 2013, IMMUNOLOGY, V138, P198, DOI 10.1111/imm.12042; Paik DH, 2021, J EXP MED, V218, DOI 10.1084/jem.20200218; Petrova TV, 2020, SCIENCE, V369, P157, DOI 10.1126/science.aax4063; Poon MML, 2021, CELL REP, V37, DOI 10.1016/j.celrep.2021.110071; Pop-Vicas A, 2011, GERONTOLOGY, V57, P397, DOI 10.1159/000319033; Popescu M, 2019, J IMMUNOL, V203, P2415, DOI 10.4049/jimmunol.1900484; Presley Carolyn J, 2017, Am Soc Clin Oncol Educ Book, V37, P587, DOI 10.14694/EDBK_179850; Schacht V, 2003, EMBO J, V22, P3546, DOI 10.1093/emboj/cdg342; Schantz MM, 2016, ANAL BIOANAL CHEM, V408, P4257, DOI 10.1007/s00216-016-9519-7; Schneider JL, 2021, CELL, V184, P1990, DOI 10.1016/j.cell.2021.03.005; Schulz D, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38127-9; Scieszka D, 2022, TOXICOL SCI, V186, P149, DOI 10.1093/toxsci/kfab147; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Sommar JN, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-046040; Thome JJC, 2014, CELL, V159, P814, DOI 10.1016/j.cell.2014.10.026; Tremble LF, 2020, BRIT J CANCER, V123, P1553, DOI 10.1038/s41416-020-01037-7; Ural BB, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aax8756; Weisberg SP, 2021, CELL, V184, P1517, DOI 10.1016/j.cell.2021.01.042; Williams AE, 2015, AM J PHYSIOL-LUNG C, V308, pL539, DOI 10.1152/ajplung.00141.2014	60	0	0	1	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02073-x	http://dx.doi.org/10.1038/s41591-022-02073-x		NOV 2022	26	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	6I5OA	36411343	Bronze			2022-12-27	WOS:000886175500001
J	Carrasco-Zanini, J; Langenberg, C				Carrasco-Zanini, Julia; Langenberg, Claudia			Broad-capture proteomics and machine learning for early detection of type 2 diabetes risk	NATURE MEDICINE			English	Editorial Material; Early Access								Impaired glucose tolerance (IGT) is a common condition that affects glucose control after sugar consumption. Isolated IGT is undetected by screening and diagnostic strategies, leaving affected individuals at high risk of developing diabetes. Here, a machine-learning framework identifies a three-protein signature for detecting isolated IGT from a single blood sample.	[Carrasco-Zanini, Julia; Langenberg, Claudia] Univ Cambridge, MRC Epidemiol Unit, Cambridge, England; [Langenberg, Claudia] Charite Univ Med Berlin, Berlin Inst Hlth, Berlin, Germany	University of Cambridge; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Carrasco-Zanini, J (corresponding author), Univ Cambridge, MRC Epidemiol Unit, Cambridge, England.			Carrasco-Zanini Sanchez, Julia/0000-0002-3988-7505				Cowie CC, 2010, DIABETES CARE, V33, P562, DOI 10.2337/dc09-1524; Gong QH, 2019, LANCET DIABETES ENDO, V7, P452, DOI 10.1016/S2213-8587(19)30093-2; Lee CMY, 2019, BMJ OPEN DIAB RES CA, V7, DOI 10.1136/bmjdrc-2019-000794; Valabhji J, 2020, DIABETES CARE, V43, P152, DOI 10.2337/dc19-1425; Williams SA, 2019, NAT MED, V25, P1851, DOI 10.1038/s41591-019-0665-2	5	0	0	5	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02056-y	http://dx.doi.org/10.1038/s41591-022-02056-y		NOV 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	6B8KC	36357678				2022-12-27	WOS:000881574700006
J	Zheng, P; Afshin, A; Biryukov, S; Bisignano, C; Brauer, M; Bryazka, D; Burkart, K; Cercy, KM; Cornaby, L; Dai, XC; Dirac, MA; Estep, K; Fay, KA; Feldman, R; Ferrari, AJ; Gakidou, E; Gil, GF; Griswold, M; Hay, SI; He, JW; Irvine, CMS; Kassebaum, NJ; LeGrand, KE; Lescinsky, H; Lim, SS; Lo, J; Mullany, EC; Ong, KL; Rao, PC; Razo, C; Reitsma, MB; Roth, GA; Santomauro, DF; Sorensen, RJD; Srinivasan, V; Stanaway, JD; Vollset, SE; Vos, T; Wang, N; Welgan, CA; Wozniak, SS; Aravkin, AY; Murray, CJL				Zheng, Peng; Afshin, Ashkan; Biryukov, Stan; Bisignano, Catherine; Brauer, Michael; Bryazka, Dana; Burkart, Katrin; Cercy, Kelly M.; Cornaby, Leslie; Dai, Xiaochen; Dirac, M. Ashworth; Estep, Kara; Fay, Kairsten A.; Feldman, Rachel; Ferrari, Alize J.; Gakidou, Emmanuela; Gil, Gabriela Fernanda; Griswold, Max; Hay, Simon, I; He, Jiawei; Irvine, Caleb M. S.; Kassebaum, Nicholas J.; LeGrand, Kate E.; Lescinsky, Haley; Lim, Stephen S.; Lo, Justin; Mullany, Erin C.; Ong, Kanyin Liane; Rao, Puja C.; Razo, Christian; Reitsma, Marissa B.; Roth, Gregory A.; Santomauro, Damian F.; Sorensen, Reed J. D.; Srinivasan, Vinay; Stanaway, Jeffrey D.; Vollset, Stein Emil; Vos, Theo; Wang, Nelson; Welgan, Catherine A.; Wozniak, Sarah S.; Aravkin, Aleksandr Y.; Murray, Christopher J. L.			The Burden of Proof studies: assessing the evidence of risk	NATURE MEDICINE			English	Article; Early Access							HETEROGENEITY; METAANALYSIS; MORTALITY; MODEL; BIAS	A new Burden of Proof meta-analytic method that accounts for between-study heterogeneity and corrects for bias between different study designs is used to interpret the strength of evidence between different pairs of risk factors and health outcomes. Exposure to risks throughout life results in a wide variety of outcomes. Objectively judging the relative impact of these risks on personal and population health is fundamental to individual survival and societal prosperity. Existing mechanisms to quantify and rank the magnitude of these myriad effects and the uncertainty in their estimation are largely subjective, leaving room for interpretation that can fuel academic controversy and add to confusion when communicating risk. We present a new suite of meta-analyses-termed the Burden of Proof studies-designed specifically to help evaluate these methodological issues objectively and quantitatively. Through this data-driven approach that complements existing systems, including GRADE and Cochrane Reviews, we aim to aggregate evidence across multiple studies and enable a quantitative comparison of risk-outcome pairs. We introduce the burden of proof risk function (BPRF), which estimates the level of risk closest to the null hypothesis that is consistent with available data. Here we illustrate the BPRF methodology for the evaluation of four exemplar risk-outcome pairs: smoking and lung cancer, systolic blood pressure and ischemic heart disease, vegetable consumption and ischemic heart disease, and unprocessed red meat consumption and ischemic heart disease. The strength of evidence for each relationship is assessed by computing and summarizing the BPRF, and then translating the summary to a simple star rating. The Burden of Proof methodology provides a consistent way to understand, evaluate and summarize evidence of risk across different risk-outcome pairs, and informs risk analysis conducted as part of the Global Burden of Diseases, Injuries, and Risk Factors Study.	[Zheng, Peng; Afshin, Ashkan; Biryukov, Stan; Bisignano, Catherine; Brauer, Michael; Bryazka, Dana; Burkart, Katrin; Cercy, Kelly M.; Cornaby, Leslie; Dai, Xiaochen; Dirac, M. Ashworth; Estep, Kara; Fay, Kairsten A.; Feldman, Rachel; Ferrari, Alize J.; Gakidou, Emmanuela; Gil, Gabriela Fernanda; Griswold, Max; Hay, Simon, I; He, Jiawei; Irvine, Caleb M. S.; Kassebaum, Nicholas J.; LeGrand, Kate E.; Lescinsky, Haley; Lim, Stephen S.; Lo, Justin; Mullany, Erin C.; Ong, Kanyin Liane; Rao, Puja C.; Razo, Christian; Reitsma, Marissa B.; Roth, Gregory A.; Santomauro, Damian F.; Sorensen, Reed J. D.; Srinivasan, Vinay; Stanaway, Jeffrey D.; Vollset, Stein Emil; Vos, Theo; Welgan, Catherine A.; Wozniak, Sarah S.; Aravkin, Aleksandr Y.; Murray, Christopher J. L.] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA; [Zheng, Peng; Afshin, Ashkan; Brauer, Michael; Burkart, Katrin; Dai, Xiaochen; Dirac, M. Ashworth; Ferrari, Alize J.; Gakidou, Emmanuela; Hay, Simon, I; Kassebaum, Nicholas J.; Lim, Stephen S.; Roth, Gregory A.; Santomauro, Damian F.; Stanaway, Jeffrey D.; Vollset, Stein Emil; Vos, Theo; Aravkin, Aleksandr Y.; Murray, Christopher J. L.] Univ Washington, Sch Med, Dept Hlth Metr Sci, Seattle, WA 98195 USA; [Brauer, Michael] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada; [Ferrari, Alize J.; Santomauro, Damian F.] Univ Queensland, Sch Publ Hlth, Brisbane, Qld, Australia; [Ferrari, Alize J.; Santomauro, Damian F.] Queensland Ctr Mental Hlth Res, Wacol, Qld, Australia; [Kassebaum, Nicholas J.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA; [Roth, Gregory A.] Univ Washington, Div Cardiol, Seattle, WA 98195 USA; [Wang, Nelson] Univ New South Wales, George Inst Global Hlth, Sydney, NSW, Australia; [Aravkin, Aleksandr Y.] Univ Washington, Dept Appl Math, Seattle, WA 98195 USA	Institute for Health Metrics & Evaluation; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of British Columbia; University of Queensland; Queensland Centre for Mental Health Research; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; George Institute for Global Health; University of New South Wales Sydney; University of Sydney; University of Washington; University of Washington Seattle	Murray, CJL (corresponding author), Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA.; Murray, CJL (corresponding author), Univ Washington, Sch Med, Dept Hlth Metr Sci, Seattle, WA 98195 USA.	cjlm@uw.edu	Hay, Simon Iain/F-8967-2015	Hay, Simon Iain/0000-0002-0611-7272; Lo, Justin/0000-0003-2145-6528; Brauer, Michael/0000-0002-9103-9343; Dai, Xiaochen/0000-0002-0289-7814; Welgan, Katie/0000-0002-4310-1632	Bill & Melinda Gates Foundation; Bloomberg Philanthropies; University of Melbourne; Queensland Department of Health, Australia; National Health and Medical Research Council, Australia; Public Health England; Norwegian Institute of Public Health; Cardiovascular Medical Research and Education Fund; National Institute on Ageing of the National Institutes of Health (NIH) [P30AG047845]; National Institute of Mental Health of the NIH [R01MH110163]	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); Bloomberg Philanthropies; University of Melbourne(University of Melbourne); Queensland Department of Health, Australia; National Health and Medical Research Council, Australia(National Health and Medical Research Council (NHMRC) of Australia); Public Health England; Norwegian Institute of Public Health; Cardiovascular Medical Research and Education Fund; National Institute on Ageing of the National Institutes of Health (NIH); National Institute of Mental Health of the NIH	Research reported in this publication was supported by the Bill & Melinda Gates Foundation; Bloomberg Philanthropies; the University of Melbourne; Queensland Department of Health, Australia; the National Health and Medical Research Council, Australia; Public Health England; the Norwegian Institute of Public Health; St Jude Children's Research Hospital; the Cardiovascular Medical Research and Education Fund; the National Institute on Ageing of the National Institutes of Health (NIH; award P30AG047845); and the National Institute of Mental Health of the NIH (award R01MH110163). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders. The funders of the study had no role in study design, data collection, data analysis, data interpretation, writing of the final report or the decision to publish.	Abbafati C, 2020, LANCET, V396, P1135, DOI 10.1016/S0140-6736(20)31404-5; Aravkin A, 2020, MATH OPER RES, V45, P292, DOI 10.1287/moor.2019.0992; Biggerstaff BJ, 1997, STAT MED, V16, P753, DOI 10.1002/(SICI)1097-0258(19970415)16:7<753::AID-SIM494>3.0.CO;2-G; Bracken MB, 2009, J ROY SOC MED, V102, P120, DOI 10.1258/jrsm.2008.08k033; CHOUINARD E, 1995, J CLIN EPIDEMIOL, V48, P245, DOI 10.1016/0895-4356(94)00132-A; Crippa A, 2019, STAT METHODS MED RES, V28, P1579, DOI 10.1177/0962280218773122; Crippa A, 2016, J STAT SOFTW, V72, DOI 10.18637/jss.v072.c01; Cumpston M, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000142; Dai XC, 2022, NAT MED, DOI 10.1038/s41591-022-01978-x; De Boor C., 1978, A practical guide to splines; Deaton A, 2018, SOC SCI MED, V210, P2, DOI 10.1016/j.socscimed.2017.12.005; Efron B, 2004, ANN STAT, V32, P407, DOI 10.1214/009053604000000067; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Flegal KM, 2013, JAMA-J AM MED ASSOC, V309, P71, DOI 10.1001/jama.2012.113905; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P407, DOI 10.1016/j.jclinepi.2010.07.017; Hernan M. A., 2023, CAUSAL INFERENCE WHA; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Huber P. H., 1981, ROBUST STAT; Ioannidis JPA, 2007, BRIT MED J, V335, P914, DOI 10.1136/bmj.39343.408449.80; Ioannidis JPA, 2018, JAMA-J AM MED ASSOC, V320, P969, DOI 10.1001/jama.2018.11025; Johnston BC, 2019, ANN INTERN MED, V171, P756, DOI 10.7326/M19-1621; Kontopantelis E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069930; Lescinsky H, 2022, NAT MED, DOI 10.1038/s41591-022-01968-z; Liu Q, 2009, COMPUT STAT DATA AN, V53, P4157, DOI 10.1016/j.csda.2009.05.001; Micha R, 2010, CIRCULATION, V121, P2271, DOI 10.1161/CIRCULATIONAHA.109.924977; Moolgavkar SH, 2018, RISK ANAL, V38, P777, DOI 10.1111/risa.12865; Motzkin T. S., 2016, CONTRIBUTIONS THEORY, V2; Murray Christopher JL, 2003, Popul Health Metr, V1, P1, DOI 10.1186/1478-7954-1-1; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Orsini N, 2012, AM J EPIDEMIOL, V175, P66, DOI 10.1093/aje/kwr265; Pope CA, 2020, ENVIRON RES, V183, DOI 10.1016/j.envres.2019.108924; Razo C, 2022, NAT MED, DOI 10.1038/s41591-022-01974-1; Rothstein HR, 2005, PUBLICATION BIAS IN META-ANALYSIS: PREVENTION, ASSESSMENT AND ADJUSTMENTS, P1, DOI 10.1002/0470870168; Rousseeuw P. J., 1985, MATH STAT APPL, P283; Rousseeuw P.J., 2005, ROBUST REGRESSION OU, P589, DOI DOI 10.1002/0471725382; ROUSSEEUW PJ, 1984, J AM STAT ASSOC, V79, P871, DOI 10.2307/2288718; Schunemann H., 2013, GRADE HDB GRADING QU; Siemieniuk R., 2021, BMJ BEST PRACTICE; Stanaway JD, 2022, NAT MED, DOI 10.1038/s41591-022-01970-5; Stanley K, 2007, CIRCULATION, V115, P1819, DOI 10.1161/CIRCULATIONAHA.106.618603; Stevens GA, 2016, PLOS MED, V13, DOI [10.1371/journal.pmed.1002116, 10.1371/journal.pmed.1002056]; Tenny S., 2021, STATPEARLS; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; Zheng P., 2021, XSPLINE ADV SPLINE T; Zheng P., 2020, LIMETR LINEAR MIXED; Zheng P, 2021, J COMPUT GRAPH STAT, V30, P544, DOI 10.1080/10618600.2020.1868303	47	2	2	3	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01973-2	http://dx.doi.org/10.1038/s41591-022-01973-2		OCT 2022	25	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	5E6IE	36216935	hybrid, Green Published			2022-12-27	WOS:000865725700005
J	Eils, R; Landmesser, U				Eils, Roland; Landmesser, Ulf			Simultaneous prediction of risk for multiple common diseases using metabolomics	NATURE MEDICINE			English	Editorial Material; Early Access									[Eils, Roland; Landmesser, Ulf] Charite Univ Med Berlin, Berlin Inst Hlth, Berlin, Germany	Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Eils, R (corresponding author), Charite Univ Med Berlin, Berlin Inst Hlth, Berlin, Germany.							Deelen J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11311-9; Fry A, 2017, AM J EPIDEMIOL, V186, P1026, DOI 10.1093/aje/kwx246; Pietzner M, 2021, NAT MED, V27, P471, DOI 10.1038/s41591-021-01266-0; Sudlow C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001779	5	0	0	3	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01992-z	http://dx.doi.org/10.1038/s41591-022-01992-z		SEP 2022	1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4S2QB	36151213				2022-12-27	WOS:000857290900001
J	Wang, RX; Lin, HT				Wang, Ruixin; Lin, Haotian			Anonymizing facial images to improve patient privacy	NATURE MEDICINE			English	Editorial Material; Early Access								To minimize the risks of inappropriately disclosing facial images of patients, we developed the digital mask to erase identifiable features while retaining disease-relevant features needed for diagnosis. The digital mask has shown the ability to evade recognition by human researchers and existing facial-recognition algorithms, and improves patients' willingness to share medical information.	[Wang, Ruixin; Lin, Haotian] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Guangdong, Peoples R China	Sun Yat Sen University	Wang, RX (corresponding author), Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Guangdong, Peoples R China.							[Anonymous], 1996, HLTH INS PORT ACC AC; Cao C, 2014, IEEE T VIS COMPUT GR, V20, P413, DOI 10.1109/TVCG.2013.249; Mason J., 2020, ARRAY, V8, P100042, DOI [10.1016/j.array.2020.100042, DOI 10.1016/J.ARRAY.2020.100042]; Wen Q, 2017, ACM T GRAPHIC, V36, DOI 10.1145/3130800.3130837; Wen Q, 2017, IEEE T VIS COMPUT GR, V23, P2586, DOI 10.1109/TVCG.2016.2641442	5	0	0	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01967-0	http://dx.doi.org/10.1038/s41591-022-01967-0		SEP 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4O5EL	36109640	hybrid			2022-12-27	WOS:000854720900005
J	Peters, S; Dziadziuszko, R; Morabito, A; Felip, E; Gadgeel, SM; Cheema, P; Cobo, M; Andric, Z; Barrios, CH; Yamaguchi, M; Dansin, E; Danchaivijitr, P; Johnson, M; Novello, S; Mathisen, MS; Shagan, SM; Schleifman, E; Wang, J; Yan, M; Mocci, S; Voong, D; Fabrizio, DA; Shames, DS; Riehl, T; Gandara, DR; Mok, T				Peters, Solange; Dziadziuszko, Rafal; Morabito, Alessandro; Felip, Enriqueta; Gadgeel, Shirish M.; Cheema, Parneet; Cobo, Manuel; Andric, Zoran; Barrios, Carlos H.; Yamaguchi, Masafumi; Dansin, Eric; Danchaivijitr, Pongwut; Johnson, Melissa; Novello, Silvia; Mathisen, Michael S.; Shagan, Sarah M.; Schleifman, Erica; Wang, Jin; Yan, Mark; Mocci, Simonetta; Voong, David; Fabrizio, David A.; Shames, David S.; Riehl, Todd; Gandara, David R.; Mok, Tony			Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial	NATURE MEDICINE			English	Article							CELL LUNG-CANCER; OPEN-LABEL; TMB; MULTICENTER; NEOANTIGENS; DOCETAXEL; BLOCKADE; EFFICACY; 1L	In a phase 3 trial, selection of non-small cell lung cancer patients based on high blood-based tumor mutation burden did not improve clinical response to the checkpoint blockade inhibitor atezolizumab, as compared with standard of care platinum-based chemotherapy. Tumor mutational burden (TMB) is being explored as a predictive biomarker for cancer immunotherapy outcomes in non-small cell lung cancer. BFAST (NCT03178552)-an open-label, global, multicohort trial-evaluated the safety and efficacy of first-line targeted therapies or immunotherapy in patients with unresectable Stage IIIB or IV advanced or metastatic non-small cell lung cancer who were selected for biomarker status using blood-based targeted next-generation sequencing. In the Phase 3 cohort C evaluating blood-based (b)TMB as a biomarker of atezolizumab efficacy, patients with bTMB of >= 10 (N = 471) were randomized 1:1 to receive atezolizumab or platinum-based chemotherapy per local standard of care. Cohort C did not meet its primary endpoint of investigator-assessed progression-free survival in the population with bTMB of >= 16 (hazard ratio, 0.77; 95% confidence interval: 0.59, 1.00; P = 0.053). Adverse events leading to treatment withdrawal occurred in 10% of patients in the atezolizumab arm and 20% in the chemotherapy arm. Adverse events of special interest occurred in 42% of patients in the atezolizumab arm and 26% in the chemotherapy arm. A prespecified exploratory analysis compared the bTMB clinical trial assay with the FoundationOne Liquid Companion Diagnostic assay and showed high concordance between assays. Additional exploration of bTMB to identify optimal cutoffs, confounding factors, assay improvements or cooperative biomarkers is warranted.	[Peters, Solange] Lausanne Univ, CHU Vaudois, Lausanne, Switzerland; [Dziadziuszko, Rafal] Med Univ Gdansk, Gdansk, Poland; [Morabito, Alessandro] IRCCS, Ist Nazl Tumori, Fdn G Pascale, Naples, Italy; [Felip, Enriqueta] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain; [Gadgeel, Shirish M.] Henry Ford Hlth Syst, Henry Ford Canc Inst, Detroit, MI USA; [Cheema, Parneet] Univ Toronto, William Osler Hlth Syst, Brampton, ON, Canada; [Cobo, Manuel] IBIMA, Hosp Univ Reg & Virgen Victoria, Unidad Gest Clin Interctr Oncol Med, Malaga, Spain; [Andric, Zoran] Univ Hosp, Med Ctr Bezanijska Kosa, Belgrade, Serbia; [Barrios, Carlos H.] Oncol Res Ctr HSL PUCRS, Porto Alegre, RS, Brazil; [Yamaguchi, Masafumi] Natl Hosp Org Kyushu Canc Ctr, Fukuoka, Japan; [Dansin, Eric] Ctr Oscar Lambret, Lille, France; [Danchaivijitr, Pongwut] Siriraj Hosp, Fac Med, Bangkok, Thailand; [Johnson, Melissa] Sarah Cannon Res Inst, Nashville, TN USA; [Novello, Silvia] Univ Turin, S Luigi Gonzaga Hosp, Orbassano, Italy; [Mathisen, Michael S.; Shagan, Sarah M.] Genentech Inc, San Francisco, CA 94080 USA; [Schleifman, Erica; Wang, Jin; Mocci, Simonetta; Voong, David; Shames, David S.; Riehl, Todd] F Hoffmann La Roche Ltd, Basel, Switzerland; [Yan, Mark] Fdn Med Inc, Cambridge, MA USA; [Gandara, David R.] UC Davis Comprehens Canc Ctr, Sacramento, CA USA; [Mok, Tony] Chinese Univ Hong Kong, State Key Lab Translat Oncol, Dept Clin Oncol, Hong Kong, Peoples R China; [Mocci, Simonetta] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Fahrenheit Universities; Medical University Gdansk; Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Fondazione Pascale; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO); Henry Ford Health System; Henry Ford Hospital; University of Toronto; Universidad de Malaga; Kyushu Cancer Center; UNICANCER; Centre Oscar Lambret; Mahidol University; Sarah Cannon Research Institute; University of Turin; Roche Holding; Genentech; Roche Holding; Foundation Medicine; Chinese University of Hong Kong; Gilead Sciences	Peters, S (corresponding author), Lausanne Univ, CHU Vaudois, Lausanne, Switzerland.	solange.peters@chuv.ch			F. Hoffmann-La Roche, Ltd.	F. Hoffmann-La Roche, Ltd.(Hoffmann-La Roche)	Todd Riehl was a founding member of the BFAST program and is now deceased. The authors would like to acknowledge S. Gong of FMI and X. Hou of Genentech, Inc, for conducting the bTMB concordance and related clinical outcomes analyses and V. Prasad of Genentech, Inc, for his review and insights in the writing of this manuscript. Support for third-party writing assistance for this manuscript-by C. Lum, PhD, of Health Interactions, Inc-was provided by F. Hoffmann-La Roche, Ltd. This study was sponsored by F. Hoffmann-La Roche, Ltd.	Abe T, 2013, MOL CELL, V50, P5, DOI 10.1016/j.molcel.2013.01.039; ALTMAN DG, 1994, BRIT MED J, V309, P102, DOI 10.1136/bmj.309.6947.102; [Anonymous], CAT SOM MUT CANC COS; Borghaei H, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.9001; Budczies J, 2019, ANN ONCOL, V30, P1496, DOI 10.1093/annonc/mdz205; Budczies J, 2020, LUNG CANCER, V142, P114, DOI 10.1016/j.lungcan.2020.01.019; Campbell JD, 2016, NAT GENET, V48, P607, DOI 10.1038/ng.3564; Carbone DP, 2017, NEW ENGL J MED, V376, P2415, DOI 10.1056/NEJMoa1613493; Chan TA, 2019, ANN ONCOL, V30, P44, DOI 10.1093/annonc/mdy495; Fedorov V, 2009, PHARM STAT, V8, P50, DOI 10.1002/pst.331; Gandara DR, 2018, NAT MED, V24, P1441, DOI 10.1038/s41591-018-0134-3; Gutierrez ME, 2017, CLIN LUNG CANCER, V18, P651, DOI 10.1016/j.cllc.2017.04.004; Hellmann MD, 2019, NEW ENGL J MED, V381, P2020, DOI 10.1056/NEJMoa1910231; Hellmann Matthew D, 2018, N Engl J Med, V378, P2093, DOI 10.1056/NEJMoa1801946; Herbst RS, 2020, NEW ENGL J MED, V383, P1328, DOI 10.1056/NEJMoa1917346; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kazdal D, 2019, J THORAC ONCOL, V14, P1935, DOI 10.1016/j.jtho.2019.07.006; Keytruda (pembrolizumab), 2020, PRESCRIBING INFORM; Kim JH, 2017, ONCOTARGET, V8, P93149, DOI 10.18632/oncotarget.18703; Kitapma S, 2019, CANCER DISCOV, V9, P34, DOI 10.1158/2159-8290.CD-18-0689; Kowanetz M, 2017, J THORAC ONCOL, V12, pS321, DOI 10.1016/j.jtho.2016.11.343; Kris MG, 2014, JAMA-J AM MED ASSOC, V311, P1998, DOI 10.1001/jama.2014.3741; Litchfield K, 2021, CELL, V184, P596, DOI 10.1016/j.cell.2021.01.002; Liu YS, 2021, BIOMETRICS, DOI 10.1111/biom.13550; Marabelle A, 2020, LANCET ONCOL, V21, P1353, DOI 10.1016/S1470-2045(20)30445-9; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; McGrail DJ, 2021, ANN ONCOL, V32, P661, DOI 10.1016/j.annonc.2021.02.006; Mok TSK, 2019, LANCET, V393, P1819, DOI 10.1016/S0140-6736(18)32409-7; Montesion Meagan, 2021, Cancer Discov, V11, P282, DOI 10.1158/2159-8290.CD-20-0672; Nabet BY, 2020, CELL, V183, P363, DOI 10.1016/j.cell.2020.09.001; Peters S, 2021, ANN ONCOL, V32, P687, DOI 10.1016/j.annonc.2021.03.195; Razavi P, 2019, NAT MED, V25, P1928, DOI 10.1038/s41591-019-0652-7; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Rizvi NA, 2020, JAMA ONCOL, V6, P661, DOI 10.1001/jamaoncol.2020.0237; Rizvi NA, 2019, J CLIN ONCOL, V37; Samstein RM, 2019, NAT GENET, V51, P202, DOI 10.1038/s41588-018-0312-8; Schuette W, 2005, J CLIN ONCOL, V23, P8389, DOI 10.1200/JCO.2005.02.3739; Shim JH, 2020, ANN ONCOL, V31, P902, DOI 10.1016/j.annonc.2020.04.004; Sholl LM, 2020, J THORAC ONCOL, V15, P1409, DOI 10.1016/j.jtho.2020.05.019; Socinski M, 2019, ANN ONCOL, V30, P919; Socinski MA, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.AM2019-CT194; Stenzinger A, 2019, GENE CHROMOSOME CANC, V58, P578, DOI 10.1002/gcc.22733; Swanton C, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.12003; Tie Y, 2019, DRUG DES DEV THER, V13, P523, DOI 10.2147/DDDT.S188893; Turajlic S, 2017, LANCET ONCOL, V18, P1009, DOI 10.1016/S1470-2045(17)30516-8; Ward JP, 2016, ADV IMMUNOL, V130, P25, DOI 10.1016/bs.ai.2016.01.001; Willis Connor, 2019, Oncotarget, V10, P6604, DOI 10.18632/oncotarget.27287; Yarchoan M, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126908; Yarchoan M, 2017, NEW ENGL J MED, V377, P2500, DOI 10.1056/NEJMc1713444	49	4	4	4	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2022	28	9					1831	+		10.1038/s41591-022-01933-w	http://dx.doi.org/10.1038/s41591-022-01933-w		AUG 2022	23	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4S0LI	35995953	hybrid, Green Published			2022-12-27	WOS:000842907100002
J	Mila-Aloma, M; Ashton, NJ; Shekari, M; Salvado, G; Ortiz-Romero, P; Montoliu-Gaya, L; Benedet, AL; Karikari, TK; Lantero-Rodriguez, J; Vanmechelen, E; Day, TA; Gonzalez-Escalante, A; Sanchez-Benavides, G; Minguillon, C; Fauria, K; Molinuevo, JL; Dage, JL; Zetterberg, H; Gispert, JD; Suarez-Calvet, M; Blennow, K				Mila-Aloma, Marta; Ashton, Nicholas J.; Shekari, Mahnaz; Salvado, Gemma; Ortiz-Romero, Paula; Montoliu-Gaya, Laia; Benedet, Andrea L.; Karikari, Thomas K.; Lantero-Rodriguez, Juan; Vanmechelen, Eugeen; Day, Theresa A.; Gonzalez-Escalante, Armand; Sanchez-Benavides, Gonzalo; Minguillon, Carolina; Fauria, Karine; Molinuevo, Jose Luis; Dage, Jeffrey L.; Zetterberg, Henrik; Gispert, Juan Domingo; Suarez-Calvet, Marc; Blennow, Kaj			Plasma p-tau231 and p-tau217 as state markers of amyloid-beta pathology in preclinical Alzheimer's disease	NATURE MEDICINE			English	Article							PHOSPHORYLATED TAU 181; BIOMARKER	A comprehensive comparison of Alzheimer's disease blood biomarkers in cognitively unimpaired individuals reveals that plasma p-tau231 and p-tau217 capture very early A beta changes, showing promise as markers to enrich a preclinical population for Alzheimer's disease clinical trials Blood biomarkers indicating elevated amyloid-beta (A beta) pathology in preclinical Alzheimer's disease are needed to facilitate the initial screening process of participants in disease-modifying trials. Previous biofluid data suggest that phosphorylated tau231 (p-tau231) could indicate incipient A beta pathology, but a comprehensive comparison with other putative blood biomarkers is lacking. In the ALFA+ cohort, all tested plasma biomarkers (p-tau181, p-tau217, p-tau231, GFAP, NfL and A beta 42/40) were significantly changed in preclinical Alzheimer's disease. However, plasma p-tau231 reached abnormal levels with the lowest A beta burden. Plasma p-tau231 and p-tau217 had the strongest association with A beta positron emission tomography (PET) retention in early accumulating regions and associated with longitudinal increases in A beta PET uptake in individuals without overt A beta pathology at baseline. In summary, plasma p-tau231 and p-tau217 better capture the earliest cerebral A beta changes, before overt A beta plaque pathology is present, and are promising blood biomarkers to enrich a preclinical population for Alzheimer's disease clinical trials.	[Mila-Aloma, Marta; Shekari, Mahnaz; Salvado, Gemma; Ortiz-Romero, Paula; Gonzalez-Escalante, Armand; Sanchez-Benavides, Gonzalo; Minguillon, Carolina; Fauria, Karine; Molinuevo, Jose Luis; Gispert, Juan Domingo; Suarez-Calvet, Marc] Pasqual Maragall Fdn, BarcelonaBeta Brain Res Ctr BBRC, Barcelona, Spain; [Mila-Aloma, Marta; Shekari, Mahnaz; Salvado, Gemma; Ortiz-Romero, Paula; Gonzalez-Escalante, Armand; Sanchez-Benavides, Gonzalo; Minguillon, Carolina; Gispert, Juan Domingo; Suarez-Calvet, Marc] IMIM Hosp del Mar, Med Res Inst, Barcelona, Spain; [Mila-Aloma, Marta; Shekari, Mahnaz; Salvado, Gemma; Sanchez-Benavides, Gonzalo; Minguillon, Carolina; Fauria, Karine; Gispert, Juan Domingo; Suarez-Calvet, Marc] Inst Salud Carlos III, Ctr Invest Biomed Red Fragilidad & Envejecimiento, Madrid, Spain; [Mila-Aloma, Marta; Shekari, Mahnaz] Univ Pompeu Fabra, Barcelona, Spain; [Ashton, Nicholas J.; Montoliu-Gaya, Laia; Benedet, Andrea L.; Karikari, Thomas K.; Lantero-Rodriguez, Juan; Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Molndal, Sweden; [Ashton, Nicholas J.] Univ Gothenburg, Wallenberg Ctr Mol & Translat Med, Gothenburg, Sweden; [Ashton, Nicholas J.] Kings Coll London, Inst Psychiat Psychol & Neurosci, Maurice Wohl Clin Neurosci Inst, London, England; [Ashton, Nicholas J.] South London & Maudsley NHS Fdn, NIHR Biomed Res Ctr Mental Hlth, London, England; [Ashton, Nicholas J.] South London & Maudsley NHS Fdn, Biomed Res Unit Dementia, London, England; [Benedet, Andrea L.] McGill Univ, McGill Ctr Studies Aging, Translat Neuroimaging Lab, Montreal, PQ, Canada; [Karikari, Thomas K.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA; [Vanmechelen, Eugeen] ADx NeuroSci NV, Ghent, Belgium; [Day, Theresa A.; Dage, Jeffrey L.] Eli Lilly & Co, Idly Res Labs, Indianapolis, IN 46285 USA; [Dage, Jeffrey L.] Indiana Univ Sch Med, Stark Neurosci Res Inst, Indianapolis, IN 46202 USA; [Zetterberg, Henrik; Blennow, Kaj] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden; [Zetterberg, Henrik] UCL Inst Neurol, Dept Neurodegenerat Dis, London, England; [Zetterberg, Henrik] UK Dementia Res Inst UCL, London, England; [Gispert, Juan Domingo] Ctr Invest Biomed Red Bioingn Biomat & Nanomed, Madrid, Spain; [Suarez-Calvet, Marc] Hosp Mar, Serv Neurol, Barcelona, Spain	Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; CIBER - Centro de Investigacion Biomedica en Red; CIBERFES; Instituto de Salud Carlos III; Pompeu Fabra University; University of Gothenburg; University of Gothenburg; University of London; King's College London; University of London; King's College London; McGill University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Eli Lilly; Indiana University System; Indiana University Bloomington; Sahlgrenska University Hospital; University of London; University College London; University of London; University College London; CIBER - Centro de Investigacion Biomedica en Red; CIBERBBN; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar	Suarez-Calvet, M (corresponding author), Pasqual Maragall Fdn, BarcelonaBeta Brain Res Ctr BBRC, Barcelona, Spain.; Suarez-Calvet, M (corresponding author), IMIM Hosp del Mar, Med Res Inst, Barcelona, Spain.; Suarez-Calvet, M (corresponding author), Inst Salud Carlos III, Ctr Invest Biomed Red Fragilidad & Envejecimiento, Madrid, Spain.; Blennow, K (corresponding author), Univ Gothenburg, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Molndal, Sweden.; Blennow, K (corresponding author), Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden.; Suarez-Calvet, M (corresponding author), Hosp Mar, Serv Neurol, Barcelona, Spain.	msuarez@barcelonabeta.org; kaj.blennow@neuro.gu.se	Molinuevo, Jose Luis/HCH-3881-2022		'la Caixa' Foundation [100010434, LCF/PR/GN17/10300004]; Alzheimer's Association [ADSF-21-831376-C, ADSF-21-831381-C, ADSF-21-831377-C]; international anonymous charity foundation through the TriBEKa Imaging Platform project [TriBEKa-17-519007]; Flanders Innovation and Entrepreneurship (VLAIO) [140105]; EURO-FINGERS, a EU Joint Programme-Neurodegenerative Disease Research (JPND) project; Finland: Academy of Finland; Germany: Federal Ministry of Education and Research; Spain: National Institute of Health Carlos III; Luxembourg: National Research Fund; Hungary: National Research, Development and Innovation Office; Netherlands: Netherlands Organisation for Health Research and Development (ZonMW-Memorabel) [733051102]; Swedish Research Council [2018-02532]; European Research Council (ERC) [681712]; Swedish State Support for Clinical Research [ALFGBG-720931]; Alzheimer Drug Discovery Foundation (ADDF), USA [201809-2016862]; AD Strategic Fund; Olav Thon Foundation; Erling-Persson Family Foundation; Stiftelsen for Gamla Tjanarinnor, Hjarnfonden, Sweden [FO2019-0228]; EU's Horizon 2020 research and innovation program under the Marie Skodowska-Curie grant [860197]; UK Dementia Research Institute at University College London (UCL); Spanish Ministry of Economy and Competitiveness [RYC-2013-13054]; EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD [115952]; Ministerio de Ciencia, Innovacion y Universidades [RTI2018-102261]; European Research Council (ERC) under the European Union's 'la Caixa' Foundation [100010434]; EU [847648, LCF/BQ/PR21/11840004]; ADDF, USA [RDAPB-201809-2016615]; Swedish Alzheimer Foundation [AF-742881, AF-930351, AF-939721, AF-968270]; Hjarnfonden, Sweden [FO2017-0243, ALZ2022-0006]; Swedish government [ALFGBG-715986, ALFGBG-965240]; Swedish County Councils, the ALF agreement [ALFGBG-715986, ALFGBG-965240]; EU Joint Program for Neurodegenerative Disorders [JPND2019-466-236]; National Institutes of Health [1R01AG068398-01]; Alzheimer's Association 2021 Zenith Award [ZEN-21-848495]	'la Caixa' Foundation(La Caixa Foundation); Alzheimer's Association(Alzheimer's Association); international anonymous charity foundation through the TriBEKa Imaging Platform project; Flanders Innovation and Entrepreneurship (VLAIO); EURO-FINGERS, a EU Joint Programme-Neurodegenerative Disease Research (JPND) project; Finland: Academy of Finland; Germany: Federal Ministry of Education and Research; Spain: National Institute of Health Carlos III; Luxembourg: National Research Fund(Luxembourg National Research Fund); Hungary: National Research, Development and Innovation Office; Netherlands: Netherlands Organisation for Health Research and Development (ZonMW-Memorabel); Swedish Research Council(Swedish Research CouncilEuropean Commission); European Research Council (ERC)(European Research Council (ERC)European Commission); Swedish State Support for Clinical Research; Alzheimer Drug Discovery Foundation (ADDF), USA; AD Strategic Fund; Olav Thon Foundation; Erling-Persson Family Foundation; Stiftelsen for Gamla Tjanarinnor, Hjarnfonden, Sweden; EU's Horizon 2020 research and innovation program under the Marie Skodowska-Curie grant; UK Dementia Research Institute at University College London (UCL); Spanish Ministry of Economy and Competitiveness(Spanish Government); EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD; Ministerio de Ciencia, Innovacion y Universidades(Spanish Government); European Research Council (ERC) under the European Union's 'la Caixa' Foundation(European Research Council (ERC)); EU(European Commission); ADDF, USA; Swedish Alzheimer Foundation; Hjarnfonden, Sweden; Swedish government; Swedish County Councils, the ALF agreement; EU Joint Program for Neurodegenerative Disorders; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Alzheimer's Association 2021 Zenith Award	We thank the ALFA project participants and relatives without whom this research would have not been possible. Collaborators of the ALFA study are: M. Akinci, F. Anastasi, A. Beteta, R. Cacciaglia, A. Canas, M. Del Campo, C. Deulofeu, I. Cumplido, R. Dominguez, M. Emilio, C. Falcon, S. Fuentes, O. Grau-Rivera, L. Hernandez, G. Huesa, J. Huguet, E. M. Arenaza-Urquijo, P. Marne, T. Menchon, G. Operto, C. Pena-Gomez, E. Palpatzis, A. Polo, B. Rodriguez-Fernandez, W. Pelkmans, S. Pradas, I. Sadeghi, A. Soteras, L. Stankeviciute, N. Tort-Colet, M. Vilanova and N. Vilor-Tejedor. We thank Roche Diagnostics International Ltd for providing the kits to measure CSF biomarkers. ELECSYS, COBAS, and COBAS E are trademarks of Roche. The Roche NeuroToolKit is a panel of exploratory prototype assays designed to robustly evaluate biomarkers associated with key pathological events characteristic of AD and other neurological disorders, used for research purposes only and not approved for clinical use. We also thank GE Healthcare for kindly providing the [18F]flutemetamol doses for the ALFA+ study participants. We thank R. Burchfield and N. K. Proctor from Eli Lilly and Company for technical support. The research leading to these results received funding from `la Caixa' Foundation (ID 100010434), under agreement LCF/PR/GN17/10300004 and the Alzheimer's Association, and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007). E.V. was supported by Flanders Innovation and Entrepreneurship (VLAIO grant no. 140105). C.M. received funding within the context of EURO-FINGERS, a EU Joint ProgrammeNeurodegenerative Disease Research ( JPND) project. The EURO-FINGERS project is supported through the following funding organizations under the aegis of JPND-www. jpnd.eu: Finland: Academy of Finland; Germany: Federal Ministry of Education and Research; Spain: National Institute of Health Carlos III; Luxembourg: National Research Fund; Hungary: National Research, Development and Innovation Office; and The Netherlands: Netherlands Organisation for Health Research and Development (ZonMW-Memorabel no. 733051102). H.Z. is a Wallenberg Scholar supported by grants from the Swedish Research Council (grant no. 2018-02532), the European Research Council (ERC, grant no. 681712), Swedish State Support for Clinical Research (grant no. ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (grant no. 201809-2016862), the AD Strategic Fund and the Alzheimer's Association (grant nos. ADSF-21-831376-C, ADSF-21-831381-C and ADSF-21-831377-C), the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen for Gamla Tjanarinnor, Hjarnfonden, Sweden (grant no. FO2019-0228), the EU's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement no. 860197 (MIRIADE) and the UK Dementia Research Institute at University College London (UCL). J.D.G. is supported by the Spanish Ministry of Economy and Competitiveness (RYC-2013-13054) and received research support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD (grant no. 115952) and from Ministerio de Ciencia, Innovacion y Universidades (grant no. RTI2018-102261). M.S.C. receives funding from the European Research Council (ERC) under the European Union's `la Caixa' Foundation (ID 100010434) and from the EU's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant (no. 847648, LCF/BQ/ PR21/11840004). K.B. is supported by the Swedish Research Council (grant no.; 201700915), the ADDF, USA (grant no. RDAPB-201809-2016615), the Swedish Alzheimer Foundation (grant no. AF-742881) (grant nos. AF-930351, AF-939721 and AF-968270), Hjarnfonden, Sweden (grant nos. FO2017-0243 and ALZ2022-0006), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF agreement (grant nos. ALFGBG-715986 and ALFGBG-965240), the EU Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the National Institutes of Health (grant no. 1R01AG068398-01) and the Alzheimer's Association 2021 Zenith Award (ZEN-21-848495).	Amadoru S, 2020, ALZHEIMERS RES THER, V12, DOI 10.1186/s13195-020-00587-5; Ashton NJ, 2022, EBIOMEDICINE, V76, DOI 10.1016/j.ebiom.2022.103836; Ashton Nicholas J, 2021, Nat Commun, V12, P3400, DOI 10.1038/s41467-021-23620-z; Ashton NJ, 2021, ACTA NEUROPATHOL, V141, P709, DOI 10.1007/s00401-021-02275-6; Benedet AL, 2021, JAMA NEUROL, V78, P1471, DOI 10.1001/jamaneurol.2021.3671; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blennow K, 2003, LANCET NEUROL, V2, P605, DOI 10.1016/S1474-4422(03)00530-1; Bullich S, 2021, ALZHEIMERS RES THER, V13, DOI 10.1186/s13195-021-00807-6; Chatterjee P, 2022, ALZHEIMERS DEMENT, V18, P1141, DOI 10.1002/alz.12447; Donohue MC, 2014, JAMA NEUROL, V71, P961, DOI 10.1001/jamaneurol.2014.803; Jack CR, 2018, ALZHEIMERS DEMENT, V14, P535, DOI 10.1016/j.jalz.2018.02.018; Janelidze S, 2020, NAT MED, V26, P379, DOI 10.1038/s41591-020-0755-1; Jonaitis EM, 2019, ALZH DEMENT-DADM, V11, P74, DOI 10.1016/j.dadm.2018.11.006; Karikari TK, 2020, LANCET NEUROL, V19, P422, DOI 10.1016/S1474-4422(20)30071-5; Klunk WE, 2015, ALZHEIMERS DEMENT, V11, P1, DOI 10.1016/j.jalz.2014.07.003; La Joie R, 2019, ALZHEIMERS DEMENT, V15, P205, DOI 10.1016/j.jalz.2018.09.001; Rodriguez JL, 2020, ACTA NEUROPATHOL, V140, P267, DOI 10.1007/s00401-020-02195-x; Lim Yen Ying, 2016, Alzheimers Dement (Amst), V2, P19, DOI 10.1016/j.dadm.2015.11.003; Mielke MM, 2018, ALZHEIMERS DEMENT, V14, P989, DOI 10.1016/j.jalz.2018.02.013; Mila-Aloma M, 2021, ALZHEIMERS RES THER, V13, DOI 10.1186/s13195-021-00863-y; Mila-Aloma M, 2020, ALZHEIMERS DEMENT, V16, P1358, DOI 10.1002/alz.12131; Molinuevo Jose Luis, 2016, Alzheimers Dement (N Y), V2, P82, DOI 10.1016/j.trci.2016.02.003; Palmqvist S, 2020, JAMA-J AM MED ASSOC, V324, P772, DOI 10.1001/jama.2020.12134; Palmqvist S, 2016, BRAIN, V139, P1226, DOI 10.1093/brain/aww015; Papp Kathryn V, 2017, Alzheimers Dement (N Y), V3, P668, DOI 10.1016/j.trci.2017.10.004; Pemberton HG, 2022, EUR J NUCL MED MOL I, V49, P3508, DOI 10.1007/s00259-022-05784-y; Pereira JB, 2021, BRAIN, V144, P3505, DOI 10.1093/brain/awab223; Salvado G, 2019, ALZHEIMERS RES THER, V11, DOI 10.1186/s13195-019-0478-z; Suarez-Calvet M, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012921; Teunissen CE, 2014, CLIN BIOCHEM, V47, P288, DOI 10.1016/j.clinbiochem.2013.12.024; Therriault J, 2021, BRAIN COMMUN, V3, DOI 10.1093/braincomms/fcab136; Thijssen EH, 2021, LANCET NEUROL, V20, P739, DOI 10.1016/S1474-4422(21)00214-3	32	6	6	14	14	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2022	28	9					1797	+		10.1038/s41591-022-01925-w	http://dx.doi.org/10.1038/s41591-022-01925-w		AUG 2022	16	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4S0LI	35953717	hybrid, Green Published			2022-12-27	WOS:000839575100007
J	Jung, H; Lee, SY; Lim, S; Choi, HR; Choi, Y; Kim, M; Kim, S; Lee, Y; Han, KH; Chung, WS; Kim, CH				Jung, Hyuncheol; Lee, Se Young; Lim, Seongjoon; Choi, Hyeong Ryeol; Choi, Yeseong; Kim, Minjin; Kim, Segi; Lee, Yujean; Han, Kyung Ho; Chung, Won-Suk; Kim, Chan Hyuk			Anti-inflammatory clearance of amyloid-beta by a chimeric Gas6 fusion protein	NATURE MEDICINE			English	Article							TAM RECEPTORS; MOUSE MODEL; PHAGOCYTOSIS; MYELINOGENESIS; INFLAMMATION; MODULATION	An engineered protein engages the efferocytosis pathway to induce amyloid-beta engulfment, resulting in behavioral rescue in Alzheimer's disease mouse models without the increased inflammation or vascular pathology associated with conventional antibody therapy Clearing amyloid-beta (A beta) through immunotherapy is one of the most promising therapeutic approaches to Alzheimer's disease (AD). Although several monoclonal antibodies against A beta have been shown to substantially reduce A beta burden in patients with AD, their effects on improving cognitive function remain marginal. In addition, a significant portion of patients treated with A beta-targeting antibodies experience brain edema and microhemorrhage associated with antibody-mediated Fc receptor activation in the brain. Here, we develop a phagocytosis inducer for A beta consisting of a single-chain variable fragment of an A beta-targeting monoclonal antibody fused with a truncated receptor binding domain of growth arrest-specific 6 (Gas6), a bridging molecule for the clearance of dead cells via TAM (TYRO3, AXL, and MERTK) receptors. This chimeric fusion protein (alpha A beta-Gas6) selectively eliminates A beta plaques through TAM receptor-dependent phagocytosis without inducing NF-kB-mediated inflammatory responses or reactive gliosis. Furthermore, alpha A beta-Gas6 can induce synergistic clearance of A beta by activating both microglial and astrocytic phagocytosis, resulting in better behavioral outcomes with substantially reduced synapse elimination and microhemorrhage in AD and cerebral amyloid angiopathy model mice compared with A beta antibody treatment. Our results suggest that alpha A beta-Gas6 could be a novel immunotherapeutic agent for AD that overcomes the side effects of conventional antibody therapy.	[Jung, Hyuncheol; Lee, Se Young; Lim, Seongjoon; Choi, Hyeong Ryeol; Choi, Yeseong; Kim, Minjin; Kim, Segi; Lee, Yujean; Han, Kyung Ho; Chung, Won-Suk; Kim, Chan Hyuk] Korea Adv Inst Sci & Technol KAIST, Dept Biol Sci, Daejeon, South Korea; [Chung, Won-Suk] Korea Adv Inst Sci & Technol, KAIST Stem Cell Ctr, Daejeon, South Korea; [Han, Kyung Ho] Hannam Univ, Dept Biol Sci & Biotechnol, Daejeon, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST); Hannam University	Chung, WS; Kim, CH (corresponding author), Korea Adv Inst Sci & Technol KAIST, Dept Biol Sci, Daejeon, South Korea.; Chung, WS (corresponding author), Korea Adv Inst Sci & Technol, KAIST Stem Cell Ctr, Daejeon, South Korea.	wonsuk.chung@kaist.ac.kr; kimchanhyuk@kaist.ac.kr	Chung, Won-Suk/B-9011-2016	Chung, Won-Suk/0000-0003-1060-9007; HAN, KYUNG HO/0000-0001-6907-1462	Global Singularity Research Program (Prep Research); International Collaboration Initiative grant - KAIST [KAIST-N11210255]; Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI); Korea Dementia Research Center (KDRC) - Ministry of Health & Welfare (MOHW), Republic of Korea [HU20C0290]; KAIST Bio Core Center; Korea Dementia Research Center (KDRC) - MSIT, Republic of Korea [HU20C0290]	Global Singularity Research Program (Prep Research); International Collaboration Initiative grant - KAIST; Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI)(Korea Health Industry Development Institute (KHIDI)); Korea Dementia Research Center (KDRC) - Ministry of Health & Welfare (MOHW), Republic of Korea; KAIST Bio Core Center; Korea Dementia Research Center (KDRC) - MSIT, Republic of Korea	We thank all members of the Chung and Kim laboratory for helpful discussions. This work was supported by the Global Singularity Research Program (Prep Research) (C.H.K.) and an International Collaboration Initiative grant (no. KAIST-N11210255) (W.-S.C.) supported by KAIST, and the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) and Korea Dementia Research Center (KDRC), funded by the Ministry of Health & Welfare (MOHW) and MSIT, Republic of Korea (HU20C0290) (W.-S.C.). Imaris software and slide scanner were supported by KAIST Bio Core Center.	Bohlen CJ, 2017, NEURON, V94, P759, DOI 10.1016/j.neuron.2017.04.043; Boisvert MM, 2018, CELL REP, V22, P269, DOI 10.1016/j.celrep.2017.12.039; Bolton JL, 2022, CELL REP, V38, DOI 10.1016/j.celrep.2022.110600; Busche MA, 2020, NAT NEUROSCI, V23, P1183, DOI 10.1038/s41593-020-0687-6; Byun YG, 2018, JOVE-J VIS EXP, DOI 10.3791/56647; Chen Y, 2021, J EXP MED, V218, DOI 10.1084/jem.20202717; Diaz-Aparicio I, 2020, J NEUROSCI, V40, P1453, DOI 10.1523/JNEUROSCI.0993-19.2019; Doran AC, 2020, NAT REV IMMUNOL, V20, P254, DOI 10.1038/s41577-019-0240-6; Dorman L. C., BIORXIV, DOI [10.1101/2021.04.29.441889(2022, DOI 10.1101/2021.04.29.441889(2022]; Dransfield I, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.18; Duyckaerts C, 2009, ACTA NEUROPATHOL, V118, P5, DOI 10.1007/s00401-009-0532-1; Elegheert J, 2018, NAT PROTOC, V13, P2991, DOI 10.1038/s41596-018-0075-9; Esposito NJ, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.2.7; Feng W, 2002, J BIOL CHEM, V277, P17016, DOI 10.1074/jbc.M107876200; Fourgeaud L, 2016, NATURE, V532, P240, DOI 10.1038/nature17630; Fuchs Y, 2011, CELL, V147, P742, DOI 10.1016/j.cell.2011.10.033; Fuller JP, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00235; Gilles JF, 2017, METHODS, V115, P55, DOI 10.1016/j.ymeth.2016.11.016; Goshi N, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01819-z; Habib N, 2020, NAT NEUROSCI, V23, P701, DOI 10.1038/s41593-020-0624-8; Hafizi S, 2006, FEBS J, V273, P5231, DOI 10.1111/j.1742-4658.2006.05529.x; Hagemeyer N, 2017, ACTA NEUROPATHOL, V134, P441, DOI 10.1007/s00401-017-1747-1; Halle M, 2015, J IMMUNOL METHODS, V424, P64, DOI 10.1016/j.jim.2015.05.002; Huang YT, 2021, NAT IMMUNOL, V22, P586, DOI 10.1038/s41590-021-00913-5; Keren-Shaul H, 2017, CELL, V169, P1276, DOI 10.1016/j.cell.2017.05.018; Klawonn AM, 2021, IMMUNITY, V54, P225, DOI 10.1016/j.immuni.2020.12.016; Kojima Y, 2017, CIRCULATION, V135, P476, DOI 10.1161/CIRCULATIONAHA.116.025684; Lall D, 2021, NEURON, V109, P2275, DOI 10.1016/j.neuron.2021.05.020; Lee JH, 2021, NATURE, V590, DOI 10.1038/s41586-020-03060-3; Lee SH, 2016, CELL REP, V16, P1690, DOI 10.1016/j.celrep.2016.06.099; Lemke G, 2019, NAT REV IMMUNOL, V19, P539, DOI 10.1038/s41577-019-0167-y; Lemke G, 2017, TRENDS BIOCHEM SCI, V42, P738, DOI 10.1016/j.tibs.2017.06.004; Lemke G, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a009076; Leng FD, 2021, NAT REV NEUROL, V17, P157, DOI 10.1038/s41582-020-00435-y; Lew ED, 2014, ELIFE, V3, DOI 10.7554/eLife.03385; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Linger RMA, 2008, ADV CANCER RES, V100, P35, DOI 10.1016/S0065-230X(08)00002-X; Long JM, 2019, CELL, V179, P312, DOI 10.1016/j.cell.2019.09.001; Mahan TE, 2022, MOL NEURODEGENER, V17, DOI 10.1186/s13024-022-00516-0; Mintun MA, 2021, NEW ENGL J MED, V384, P1691, DOI 10.1056/NEJMoa2100708; Pinto B, 2020, NEURON, V108, P887, DOI 10.1016/j.neuron.2020.09.010; Polanco JC, 2018, NAT REV NEUROL, V14, P22, DOI 10.1038/nrneurol.2017.162; Rothlin CV, 2007, CELL, V131, P1124, DOI 10.1016/j.cell.2007.10.034; Scearce-Levie K, 2020, NAT REV DRUG DISCOV, V19, P447, DOI 10.1038/s41573-020-0065-9; Sevigny J, 2016, NATURE, V537, P50, DOI 10.1038/nature19323; Sharif MN, 2006, J EXP MED, V203, P1891, DOI 10.1084/jem.20051725; Shi Y, 2017, NATURE, V549, P523, DOI 10.1038/nature24016; Sosic D, 2003, CELL, V112, P169, DOI 10.1016/S0092-8674(03)00002-3; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Tibrewal N, 2008, J BIOL CHEM, V283, P3618, DOI 10.1074/jbc.M706906200; Trudler, P NATL ACAD SCI USA, DOI [10.1073/pnas.2025847118(2021, DOI 10.1073/PNAS.2025847118(2021]; Uehara H, 2008, J IMMUNOL, V180, P2522, DOI 10.4049/jimmunol.180.4.2522; van der Meer JHM, 2014, BLOOD, V123, P2460, DOI 10.1182/blood-2013-09-528752; Wang C, 2021, NEURON, V109, P1657, DOI 10.1016/j.neuron.2021.03.024; Weninger S, 2020, ALZH DEMENT-TRCI, V6, DOI 10.1002/trc2.12090; Wilcock DM, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-24; Wlodarczyk A, 2017, EMBO J, V36, P3292, DOI 10.15252/embj.201696056; Xiong M, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abd7522; Yuan QJ, 2020, BRAIN BEHAV IMMUN, V89, P628, DOI 10.1016/j.bbi.2020.07.038	59	1	1	16	16	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2022	28	9					1802	+		10.1038/s41591-022-01926-9	http://dx.doi.org/10.1038/s41591-022-01926-9		AUG 2022	36	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4S0LI	35927581				2022-12-27	WOS:000836112500001
J	Strauss, KA; Farrar, MA; Muntoni, F; Saito, K; Mendell, JR; Servais, L; McMillan, HJ; Finkel, RS; Swoboda, KJ; Kwon, JM; Zaidman, CM; Chiriboga, CA; Iannaccone, ST; Krueger, JM; Parsons, JA; Shieh, PB; Kavanagh, S; Tauscher-Wisniewski, S; McGill, BE; Macek, TA				Strauss, Kevin A.; Farrar, Michelle A.; Muntoni, Francesco; Saito, Kayoko; Mendell, Jerry R.; Servais, Laurent; McMillan, Hugh J.; Finkel, Richard S.; Swoboda, Kathryn J.; Kwon, Jennifer M.; Zaidman, Craig M.; Chiriboga, Claudia A.; Iannaccone, Susan T.; Krueger, Jena M.; Parsons, Julie A.; Shieh, Perry B.; Kavanagh, Sarah; Tauscher-Wisniewski, Sitra; McGill, Bryan E.; Macek, Thomas A.			Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial	NATURE MEDICINE			English	Article							GENE-REPLACEMENT THERAPY; NATURAL-HISTORY; COPY NUMBER; SINGLE-ARM; OPEN-LABEL; MULTICENTER; PRINCIPLES; SMA	SPR1NT (NCT03505099) was a Phase III, multicenter, single-arm study to investigate the efficacy and safety of onasemnogene abeparvovec for presymptomatic children with biallelic SMN1 mutations treated at <= 6 weeks of life. Here, we report final results for 14 children with two copies of SMN2, expected to develop spinal muscular atrophy (SMA) type 1. Efficacy was compared with a matched Pediatric Neuromuscular Clinical Research natural-history cohort (n = 23). All 14 enrolled infants sat independently for >= 30 seconds at any visit <= 18 months (Bayley-III item #26; P < 0.001; 11 within the normal developmental window). All survived without permanent ventilation at 14 months as per protocol; 13 maintained body weight (>= 3rd WHO percentile) through 18 months. No child used nutritional or respiratory support. No serious adverse events were considered related to treatment by the investigator. Onasemnogene abeparvovec was effective and well-tolerated for children expected to develop SMA type 1, highlighting the urgency for universal newborn screening.	[Strauss, Kevin A.] Clin Special Children, Strasburg, PA 17579 USA; [Strauss, Kevin A.] Penn Med Lancaster Gen Hosp, Lancaster, PA 17602 USA; [Strauss, Kevin A.] Univ Massachusetts, Sch Med, Dept Pediat, Worcester, MA 01655 USA; [Strauss, Kevin A.] Univ Massachusetts, Sch Med, Dept Mol Cell & Canc Biol, Worcester, MA 01655 USA; [Farrar, Michelle A.] Sydney Childrens Hosp Network, Dept Neurol, Sydney, NSW, Australia; [Farrar, Michelle A.] UNSW Sydney, Sch Clin Med, UNSW Med & Hlth, Sydney, NSW, Australia; [Muntoni, Francesco] UCL, Dubowitz Neuromuscular Ctr, Great Ormond St Inst Child Hlth, London, England; [Muntoni, Francesco] UCL, Dubowitz Neuromuscular Ctr, Great Ormond St Hosp, London, England; [Muntoni, Francesco] Great Ormond St Hosp Biomed Res Ctr, Natl Inst Hlth Res, London, England; [Saito, Kayoko] Tokyo Womens Med Univ, Inst Med Genet, Tokyo, Japan; [Mendell, Jerry R.] Nationwide Childrens Hosp, Ctr Gene Therapy, Columbus, OH USA; [Mendell, Jerry R.] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Mendell, Jerry R.] Ohio State Univ, Dept Neurol, Columbus, OH 43210 USA; [Servais, Laurent] MDUK Oxford Neuromuscular Ctr, Dept Paediat, Oxford, England; [Servais, Laurent] CHU, Neuromuscular Reference Ctr, Dept Pediat, Liege, Belgium; [Servais, Laurent] Univ Liege, Liege, Belgium; [McMillan, Hugh J.] McGill Univ Hlth Ctr, Montreal Childrens Hosp, Dept Pediat, Montreal, PQ, Canada; [McMillan, Hugh J.] McGill Univ Hlth Ctr, Montreal Childrens Hosp, Dept Neurol, Montreal, PQ, Canada; [McMillan, Hugh J.] McGill Univ Hlth Ctr, Montreal Childrens Hosp, Dept Neurosurg, Montreal, PQ, Canada; [Finkel, Richard S.] Nemours Childrens Hosp, Dept Pediat, Orlando, FL USA; [Finkel, Richard S.] St Jude Childrens Res Hosp, Ctr Expt Neurotherapeut, 332 N Lauderdale St, Memphis, TN 38105 USA; [Swoboda, Kathryn J.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Kwon, Jennifer M.] Univ Wisconsin, Dept Neurol, Sch Med & Publ Hlth, Madison, WI 53706 USA; [Zaidman, Craig M.] Washington Univ, Sch Med, St Louis, MO USA; [Chiriboga, Claudia A.] Columbia Univ Med Ctr, Div Pediat Neurol, New York, NY USA; [Iannaccone, Susan T.] Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Dallas, TX USA; [Krueger, Jena M.] Helen DeVos Childrens Hosp, Dept Neurol, Grand Rapids, MI USA; [Parsons, Julie A.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA; [Shieh, Perry B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; [Kavanagh, Sarah; Tauscher-Wisniewski, Sitra; Macek, Thomas A.] Novartis Gene Therapies Inc, Bannockburn, IL USA; [McGill, Bryan E.] Novartis Inst BioMed Res, Translat Med, Cambridge, MA USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of New South Wales Sydney; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Tokyo Women's Medical University; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Liege; University of Liege; McGill University; McGill University; McGill University; St Jude Children's Research Hospital; Harvard University; Massachusetts General Hospital; University of Wisconsin System; University of Wisconsin Madison; Washington University (WUSTL); Columbia University; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Colorado System; University of Colorado Anschutz Medical Campus; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Novartis	Strauss, KA (corresponding author), Clin Special Children, Strasburg, PA 17579 USA.; Strauss, KA (corresponding author), Penn Med Lancaster Gen Hosp, Lancaster, PA 17602 USA.; Strauss, KA (corresponding author), Univ Massachusetts, Sch Med, Dept Pediat, Worcester, MA 01655 USA.; Strauss, KA (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Cell & Canc Biol, Worcester, MA 01655 USA.	kstrauss@clinicforspecialchildren.org	McMillan, Hugh/AAA-1989-2021	McMillan, Hugh/0000-0001-8927-2018; Swoboda, Kathryn/0000-0002-4593-6342; Saito, Kayoko/0000-0003-2632-0873; Finkel, Richard/0000-0002-9351-7054; Servais, Laurent/0000-0001-9270-4061; Farrar, Michelle/0000-0002-4472-0902	Novartis Gene Therapies; Luminesce Alliance; NSW Government; Novartis Gene Therapies, Inc.	Novartis Gene Therapies; Luminesce Alliance; NSW Government; Novartis Gene Therapies, Inc.	The authors wish to thank the investigators, site coordinators and study teams, administrators of newborn screening programs, and most importantly, the patients, families, and caregivers for their participation in these studies. The authors also thank M. Milton of Novartis Institutes for BioMedical Research, who provided critical review and input on content related to biodistribution, immune response, and safety; S. P. Reyna, who provided critical review and input on care of patients with SMA; and M. Wolf of Novartis Gene Therapies, who provided functional outcome measure expertise and contributions to study conduct and oversight. Medical writing assistance and editorial support was provided by M. Heitzer of Kay Square Scientific, and M. Nissen, of Novartis Gene Therapies. This support was funded by Novartis Gene Therapies. The NSW Pilot NBS study was funded by Luminesce Alliance, a not-for-profit cooperative joint venture across the Sydney Children's Hospital Network, Children's Medical Research Institute, and Children's Cancer Institute, established with the support of the NSW Government. Luminesce Alliance is also affiliated with UNSW Sydney and The University of Sydney. The SPR1NT study was designed and funded by Novartis Gene Therapies, Inc., which was involved in the study design, data collection, data analysis, data interpretation, and writing of all related reports and publications. Novartis Gene Therapies, Inc., sponsored this study.	Al-Zaidy SA, 2019, J NEUROMUSCULAR DIS, V6, P307, DOI 10.3233/JND-190403; Amato AA, 2020, NEW ENGL J MED, V383, P1657, DOI 10.1056/NEJMra2023935; Audic F, 2020, Arch Pediatr, V27, p7S15, DOI 10.1016/S0929-693X(20)30271-2; Bayley N, 1993, BAYLEY SCALES INFANT; Boemer F, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-99496-2; Calucho M, 2018, NEUROMUSCULAR DISORD, V28, P208, DOI 10.1016/j.nmd.2018.01.003; Chand D, 2021, J HEPATOL, V74, P560, DOI 10.1016/j.jhep.2020.11.001; Chien YH, 2017, J PEDIATR-US, V190, P124, DOI 10.1016/j.jpeds.2017.06.042; Coovert DD, 1997, HUM MOL GENET, V6, P1205, DOI 10.1093/hmg/6.8.1205; Czibere L, 2020, EUR J HUM GENET, V28, P23, DOI 10.1038/s41431-019-0476-4; D'Silva AM, 2022, DEV MED CHILD NEUROL, V64, P625, DOI 10.1111/dmcn.15117; Dangouloff T, 2021, NEUROMUSCULAR DISORD, V31, P574, DOI 10.1016/j.nmd.2021.03.007; Dangouloff T, 2020, NEUROMUSCULAR DISORD, V30, P93, DOI 10.1016/j.nmd.2019.11.002; Day JW, 2021, DRUG SAFETY, V44, P1109, DOI 10.1007/s40264-021-01107-6; Day JW, 2021, LANCET NEUROL, V20, P284, DOI 10.1016/S1474-4422(21)00001-6; De Vivo DC, 2019, NEUROMUSCULAR DISORD, V29, P842, DOI 10.1016/j.nmd.2019.09.007; Dobrow MJ, 2018, CAN MED ASSOC J, V190, pE422, DOI 10.1503/cmaj.171154; Dobrowolski SF, 2012, CLIN CHEM, V58, P1033, DOI 10.1373/clinchem.2012.183038; Fidzianska A, 2002, ACTA NEUROPATHOL, V104, P363, DOI 10.1007/s00401-002-0566-0; Finkel RS, 2014, PEDIATR PULM, V49, P1234, DOI 10.1002/ppul.22997; Finkel RS, 2014, NEUROLOGY, V83, P810, DOI 10.1212/WNL.0000000000000741; Foust KD, 2009, NAT BIOTECHNOL, V27, P59, DOI 10.1038/nbt.1515; Govoni A, 2018, MOL NEUROBIOL, V55, P6307, DOI 10.1007/s12035-017-0831-9; Harding BN, 2015, J NEUROPATH EXP NEUR, V74, P15, DOI 10.1097/NEN.0000000000000144; Kariyawasam DST, 2021, ECLINICALMEDICINE, V33, DOI 10.1016/j.eclinm.2021.100742; Kariyawasam DST, 2020, GENET MED, V22, P557, DOI 10.1038/s41436-019-0673-0; Kay DM, 2020, GENET MED, V22, P1296, DOI 10.1038/s41436-020-0824-3; Kolb SJ, 2017, ANN NEUROL, V82, P883, DOI 10.1002/ana.25101; Kong LL, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abb6871; Kraszewski JN, 2018, GENET MED, V20, P608, DOI 10.1038/gim.2017.152; Lin YM, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.01255; Lowes LP, 2019, PEDIATR NEUROL, V98, P39, DOI 10.1016/j.pediatrneurol.2019.05.005; Mailman MD, 2002, GENET MED, V4, P20, DOI 10.1097/00125817-200201000-00004; Martorell R, 2006, ACTA PAEDIATR, V95, P86, DOI 10.1080/08035320500495563; McCandless SE, 2020, BIRTH DEFECTS RES, V112, P350, DOI 10.1002/bdr2.1653; McGrattan KE, 2021, AM J SPEECH-LANG PAT, V30, P1008, DOI 10.1044/2021_AJSLP-20-00217; Mendell JR, 2017, NEW ENGL J MED, V377, P1713, DOI 10.1056/NEJMoa1706198; Mendell JR, 2021, JAMA NEUROL, V78, P834, DOI 10.1001/jamaneurol.2021.1272; Mercuri E, 2021, LANCET NEUROL, V20, P832, DOI 10.1016/S1474-4422(21)00251-9; Mueller C, 2020, NEW ENGL J MED, V383, P151, DOI 10.1056/NEJMoa2005056; Novartis Gene Therapies, 2021, ZOLG PRESCR INF; Perez-Garcia MJ, 2017, SPINAL MUSCULAR ATROPHY: DISEASE MECHANISMS AND THERAPY, P21, DOI 10.1016/B978-0-12-803685-3.00002-1; Phan HC, 2015, SEMIN PERINATOL, V39, P217, DOI 10.1053/j.semperi.2015.03.006; Ponder KP, 2007, CURR GENE THER, V7, P403, DOI 10.2174/156652307782151434; Prior TW, 2009, AM J HUM GENET, V85, P408, DOI 10.1016/j.ajhg.2009.08.002; Ramdas S, 2020, EXPERT OPIN PHARMACO, V21, P307, DOI 10.1080/14656566.2019.1704732; Servais L, 2021, NEUROMUSCULAR DISORD, V31, pS48, DOI 10.1016/j.nmd.2021.07.021; Shih STF, 2021, J NEUROL NEUROSUR PS, V92, P1296, DOI 10.1136/jnnp-2021-326344; Simic G, 2000, J NEUROPATH EXP NEUR, V59, P398, DOI 10.1093/jnen/59.5.398; Strauss KA, 2022, NAT MED, V28, P1390, DOI 10.1038/s41591-022-01867-3; Swoboda KJ, 2005, ANN NEUROL, V57, P704, DOI 10.1002/ana.20473; THOMAS NH, 1994, NEUROMUSCULAR DISORD, V4, P497, DOI 10.1016/0960-8966(94)90090-6; Thomsen G, 2021, NAT MED, V27, P1701, DOI 10.1038/s41591-021-01483-7; Vill K, 2019, J NEUROMUSCULAR DIS, V6, P503, DOI 10.3233/JND-190428; Waldrop MA, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2020-0729; Weiss C, 2022, LANCET CHILD ADOLESC, V6, P17, DOI 10.1016/S2352-4642(21)00287-X; WILSON JMG, 1968, B OFIC SANIT PANAM, V65, P281	57	6	6	2	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2022	28	7					1381	+		10.1038/s41591-022-01866-4	http://dx.doi.org/10.1038/s41591-022-01866-4		JUN 2022	14	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3E5PS	35715566	Green Published, hybrid			2022-12-27	WOS:000812444600002
J	Duch, R; Asiedu, E; Nakamura, R; Rouyard, T; Yevenes, C; Roope, L; Violato, M; Clarke, P				Duch, Raymond; Asiedu, Edward; Nakamura, Ryota; Rouyard, Thomas; Yevenes, Carlos; Roope, Laurence; Violato, Mara; Clarke, Philip			A randomized controlled trial to test financial incentives for COVID-19 vaccination in Ghana	NATURE MEDICINE			English	Letter; Early Access									[Duch, Raymond] Univ Oxford, Nuffield Coll, Oxford, England; [Asiedu, Edward] Univ Ghana, Accra, Ghana; [Nakamura, Ryota; Rouyard, Thomas] Hitotsubashi Univ, Hitotsubashi Inst Adv Study, Tokyo, Japan; [Yevenes, Carlos] Univ Santiago Chile USACH, Ctr Expt Social Sci, Santiago, Chile; [Roope, Laurence; Violato, Mara; Clarke, Philip] Univ Oxford, Nuffield Dept Populat Hlth, Hlth Econ Res Ctr, Oxford, England; [Clarke, Philip] Univ Melbourne, Melbourne, Vic, Australia	University of Oxford; University of Ghana; Hitotsubashi University; Universidad de Santiago de Chile; University of Oxford; University of Melbourne	Clarke, P (corresponding author), Univ Oxford, Nuffield Dept Populat Hlth, Hlth Econ Res Ctr, Oxford, England.; Clarke, P (corresponding author), Univ Melbourne, Melbourne, Vic, Australia.	Philip.clarke@ndph.ox.ac.uk		Roope, Laurence/0000-0001-9098-9331; Duch, Raymond/0000-0002-1166-7674; Asiedu, Edward/0000-0003-0840-9233; Nakamura, Ryota/0000-0002-3217-6452; Violato, Mara/0000-0002-0484-7706; Clarke, Philip/0000-0002-7555-5348	NIHR Oxford Biomedical Research Centre, Hitotsubashi Institute for Advanced Study; University of Santiago, Chile; NIHR Applied Research Collaboration Oxford and Thames Valley	NIHR Oxford Biomedical Research Centre, Hitotsubashi Institute for Advanced Study; University of Santiago, Chile; NIHR Applied Research Collaboration Oxford and Thames Valley	This research was supported by funding from the NIHR Oxford Biomedical Research Centre, Hitotsubashi Institute for Advanced Study and the University of Santiago, Chile. M.V. is partly supported by the NIHR Applied Research Collaboration Oxford and Thames Valley. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.	[Anonymous], 2020, INCREASING VACCINE U; Arezki R, 2021, NATURE, V596, P9, DOI 10.1038/d41586-021-02086-5; Campos-Mercade P, 2021, SCIENCE, V374, P879, DOI 10.1126/science.abm0475; Chang T, 2021, 29403 NBER; Fletcher J, 2017, AM ECON J-ECON POLIC, V9, P144, DOI 10.1257/pol.20150573; Gibson DG, 2017, LANCET GLOB HEALTH, V5, pE428, DOI [10.1016/S2214-109X(17)30072-4, 10.1016/s2214-109x(17)30072-4]; Gine X, 2018, AM ECON J-APPL ECON, V10, P207, DOI 10.1257/app.20130480; Gneezy U, 2011, J ECON PERSPECT, V25, P191, DOI 10.1257/jep.25.4.191; Lagarde M, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008137; Promberger M, 2013, HEALTH PSYCHOL, V32, P950, DOI 10.1037/a0032727	10	0	0	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01876-2	http://dx.doi.org/10.1038/s41591-022-01876-2		JUN 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E1GB	35710990	Green Submitted			2022-12-27	WOS:000811980700005
J	Maslove, DM; Tang, B; Shankar-Hari, M; Lawler, PR; Angus, DC; Baillie, JK; Baron, RM; Bauer, M; Buchman, TG; Calfee, CS; dos Santos, CC; Giamarellos-Bourboulis, EJ; Gordon, AC; Kellum, JA; Knight, JC; Leligdowicz, A; McAuley, DF; McLean, AS; Menon, DK; Meyer, NJ; Moldawer, LL; Reddy, K; Reilly, JP; Russell, JA; Sevransky, JE; Seymour, CW; Shapiro, NI; Singer, M; Summers, C; Sweeney, TE; Thompson, BT; van der Poll, T; Venkatesh, B; Walley, KR; Walsh, TS; Ware, LB; Wong, HR; Zador, ZE; Marshall, JC				Maslove, David M.; Tang, Benjamin; Shankar-Hari, Manu; Lawler, Patrick R.; Angus, Derek C.; Baillie, J. Kenneth; Baron, Rebecca M.; Bauer, Michael; Buchman, Timothy G.; Calfee, Carolyn S.; dos Santos, Claudia C.; Giamarellos-Bourboulis, Evangelos J.; Gordon, Anthony C.; Kellum, John A.; Knight, Julian C.; Leligdowicz, Aleksandra; McAuley, Daniel F.; McLean, Anthony S.; Menon, David K.; Meyer, Nuala J.; Moldawer, Lyle L.; Reddy, Kiran; Reilly, John P.; Russell, James A.; Sevransky, Jonathan E.; Seymour, Christopher W.; Shapiro, Nathan I.; Singer, Mervyn; Summers, Charlotte; Sweeney, Timothy E.; Thompson, B. Taylor; van der Poll, Tom; Venkatesh, Balasubramanian; Walley, Keith R.; Walsh, Timothy S.; Ware, Lorraine B.; Wong, Hector R.; Zador, Zsolt E.; Marshall, John C.			Redefining critical illness	NATURE MEDICINE			English	Article							SEPTIC SHOCK; PRECISION MEDICINE; STAGING SYSTEM; SEPSIS; DEFINITIONS; OUTCOMES; TRIAL; ARDS; CLASSIFICATION; SUBPHENOTYPES	The authors propose a new conceptual model of critical illness that moves away from the current syndrome-based framework in favor of more precise biological descriptors-spurred by mounting translational evidence and insights from Coronavirus Disease 2019 (COVID-19) research. Research and practice in critical care medicine have long been defined by syndromes, which, despite being clinically recognizable entities, are, in fact, loose amalgams of heterogeneous states that may respond differently to therapy. Mounting translational evidence-supported by research on respiratory failure due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection-suggests that the current syndrome-based framework of critical illness should be reconsidered. Here we discuss recent findings from basic science and clinical research in critical care and explore how these might inform a new conceptual model of critical illness. De-emphasizing syndromes, we focus on the underlying biological changes that underpin critical illness states and that may be amenable to treatment. We hypothesize that such an approach will accelerate critical care research, leading to a richer understanding of the pathobiology of critical illness and of the key determinants of patient outcomes. This, in turn, will support the design of more effective clinical trials and inform a more precise and more effective practice at the bedside.	[Maslove, David M.] Queens Univ, Dept Crit Care Med, Kingston, ON, Canada; [Maslove, David M.] Kingston Hlth Sci Ctr, Kingston, ON, Canada; [Tang, Benjamin; McLean, Anthony S.] Nepean Hosp, Dept Intens Care Med, Sydney, NSW, Australia; [Shankar-Hari, Manu] Queens Med Res Inst, Inst Regeneration & Repair, Ctr Inflammat Res, Edinburgh, Midlothian, Scotland; [Shankar-Hari, Manu; Baillie, J. Kenneth] Royal Infirm Edinburgh NHS Trust, Intensive Care Med, NHS Lothian, Edinburgh, Midlothian, Scotland; [Lawler, Patrick R.] Univ Hlth Network, Peter Munk Cardiac Ctr, Cardiac Intens Care Unit, Toronto, ON, Canada; [Lawler, Patrick R.; dos Santos, Claudia C.; Marshall, John C.] Univ Toronto, Interdepart Div Crit Care Med, Toronto, ON, Canada; [Angus, Derek C.; Kellum, John A.; Seymour, Christopher W.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA; [Angus, Derek C.] Univ Pittsburgh Med Ctr, Pittsburgh, PA USA; [Baillie, J. Kenneth] Univ Edinburgh, Roslin Inst, Edinburgh, Midlothian, Scotland; [Baillie, J. Kenneth] Univ Edinburgh, Ctr Inflammat Res, Pandem Sci Hub, Edinburgh, Midlothian, Scotland; [Baron, Rebecca M.] Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA USA; [Baron, Rebecca M.; Shapiro, Nathan I.; Thompson, B. Taylor] Harvard Med Sch, Boston, MA USA; [Bauer, Michael] Jena Univ Hosp, Dept Anesthesiol & Intens Care Med, Jena, Germany; [Bauer, Michael] Jena Univ Hosp, Ctr Sepsis Care & Control, Jena, Germany; [Buchman, Timothy G.; Sevransky, Jonathan E.] Emory Univ, Emory Crit Care Ctr, Atlanta, GA USA; [Buchman, Timothy G.] Santa Fe Inst, Santa Fe, NM USA; [Calfee, Carolyn S.] Univ Calif San Francisco, Dept Med, Div Pulm Crit Care Allergy & Sleep Med, San Francisco, CA USA; [dos Santos, Claudia C.] Unity Hlth Toronto, Keenan Ctr Biomed Res St Michaels Hosp, Toronto, ON, Canada; [Giamarellos-Bourboulis, Evangelos J.] Natl & Kapodistrian Univ Athens, Med Sch, Dept Internal Med 4, Athens, Greece; [Gordon, Anthony C.] Imperial Coll London, Div Anaesthet Pain Med & Intensive Care, London, England; [Knight, Julian C.] Univ Oxford, Wellcome Ctr Human Genet, Oxford, England; [Leligdowicz, Aleksandra] Univ Western Ontario, Dept Med, Div Crit Care, London, ON, Canada; [Leligdowicz, Aleksandra] Univ Western Ontario, Dept MicroBiol & Immunol, London, ON, Canada; [McAuley, Daniel F.; Reddy, Kiran] Royal Victoria Hosp, Reg Intens Care Unit, Belfast, North Ireland; [McAuley, Daniel F.; Reddy, Kiran] Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, Belfast, Antrim, North Ireland; [Menon, David K.] Univ Cambridge, Dept Med, Div Anaesthesia, Cambridge, England; [Meyer, Nuala J.; Reilly, John P.] Univ Penn, Dept Med Pulm Allergy & Crit Care Div, Philadelphia, PA USA; [Moldawer, Lyle L.] Univ Florida, Sepsis & Crit Illness Res Ctr, Dept Surg, Coll Med, Gainesville, FL USA; [Russell, James A.; Walley, Keith R.] Univ British Columbia, Ctr Heart Lung Innovat & Crit Care Med, Vancouver, BC, Canada; [Sevransky, Jonathan E.] Emory Univ, Sch Med, Div Pulm Allergy Crit Care & Sleep, Atlanta, GA USA; [Shapiro, Nathan I.] Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA USA; [Singer, Mervyn] UCL, Bloomsbury Inst Intens Care Med, Div Med, London, England; [Summers, Charlotte] Univ Cambridge, Dept Med, Sch Med, Cambridge, England; [Sweeney, Timothy E.] Inflammatix Inc, Burlingame, CA USA; [Thompson, B. Taylor] Massachusetts Gen Hosp, Divis BioStat & Pulm, Crit Care Med, Boston, MA USA; [van der Poll, Tom] Univ Amsterdam, Amsterdam UMC, Amsterdam, Netherlands; [Venkatesh, Balasubramanian] Wesley & Princess Alexandra Hosp, Dept Intens Care, Brisbane, Qld, Australia; [Venkatesh, Balasubramanian] Univ New South Wales, George Inst Global Hlth, Sydney, NSW, Australia; [Walsh, Timothy S.] Univ Edinburgh, Deanery Mol Genet & Populat Hlth Sci, Usher Inst Populat Hlth Sci, Edinburgh, Midlothian, Scotland; [Ware, Lorraine B.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN USA; [Ware, Lorraine B.] Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN USA; [Ware, Lorraine B.] Vanderbilt Univ, Sch Med, Dept Microbiol, Nashville, TN USA; [Ware, Lorraine B.] Vanderbilt Univ, Sch Med, Dept Immunol, Nashville, TN USA; [Wong, Hector R.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH USA; [Zador, Zsolt E.; Marshall, John C.] Univ Toronto, Dept Surg, Toronto, ON, Canada; [Marshall, John C.] Unity Hlth Toronto, Dept Surg, Toronto, ON, Canada; [Marshall, John C.] Unity Hlth Toronto, Dept Crit Care Med, Toronto, ON, Canada	Queens University - Canada; Nepean Hospital; University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh; University of Toronto; Peter Munk Cardiac Centre; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; University of Edinburgh; University of Edinburgh; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Emory University; The Santa Fe Institute; University of California System; University of California San Francisco; National & Kapodistrian University of Athens; Imperial College London; University of Oxford; Wellcome Centre for Human Genetics; Western University (University of Western Ontario); Western University (University of Western Ontario); Queens University Belfast; University of Cambridge; University of Pennsylvania; State University System of Florida; University of Florida; University of British Columbia; Emory University; Harvard University; Beth Israel Deaconess Medical Center; University of London; University College London; University of Cambridge; Harvard University; Massachusetts General Hospital; University of Amsterdam; Wesley Hospital; George Institute for Global Health; University of New South Wales Sydney; University of Sydney; University of Edinburgh; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Cincinnati Children's Hospital Medical Center; University of Toronto	Maslove, DM (corresponding author), Queens Univ, Dept Crit Care Med, Kingston, ON, Canada.; Maslove, DM (corresponding author), Kingston Hlth Sci Ctr, Kingston, ON, Canada.	david.maslove@queensu.ca	Shankar-Hari, Manu/I-6948-2012; Kellum, John A/HCH-2944-2022; Baillie, Kenneth/AEK-6650-2022; Baillie, John Kenneth/F-3124-2011; Leligdowicz, Aleksandra/GLS-9028-2022; Summers, Charlotte/A-6973-2012; Knight, Julian/W-2399-2019	Shankar-Hari, Manu/0000-0002-5338-2538; Kellum, John A/0000-0003-1995-2653; Baillie, Kenneth/0000-0001-5258-793X; Baillie, John Kenneth/0000-0001-5258-793X; Leligdowicz, Aleksandra/0000-0001-6055-4644; Maslove, David/0000-0002-0765-7158; Reddy, Kiran/0000-0002-1621-1481; Tang, Benjamin/0000-0002-1469-9540; Summers, Charlotte/0000-0002-7269-2873; dos Santos, Claudia/0000-0002-6446-8791; Knight, Julian/0000-0002-0377-5536; Ware, Lorraine/0000-0002-9429-4702; Buchman, Timothy/0000-0001-7350-5921; Bauer, Michael/0000-0002-1521-3514				Antcliffe DB, 2019, AM J RESP CRIT CARE, V199, P980, DOI 10.1164/rccm.201807-1419OC; Bakhirev AG, 2014, ARCH PATHOL LAB MED, V138, P538, DOI 10.5858/arpa.2012-0663-OA; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; BERNARD GR, 1994, INTENS CARE MED, V20, P225, DOI 10.1007/BF01704707; Berry SM, 2015, JAMA-J AM MED ASSOC, V313, P1619, DOI 10.1001/jama.2015.2316; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Calfee CS, 2022, NAT MED, V28, P9, DOI 10.1038/s41591-021-01617-x; Calfee CS, 2016, AM J RESP CRIT CARE, V194, P137, DOI 10.1164/rccm.201604-0697ED; Calfee CS, 2015, CHEST, V147, P1539, DOI 10.1378/chest.14-2454; Calfee CS, 2014, LANCET RESP MED, V2, P611, DOI 10.1016/S2213-2600(14)70097-9; Cohen MJ, 2010, CRIT CARE, V14, DOI 10.1186/cc8864; Davenport EE, 2016, LANCET RESP MED, V4, P259, DOI 10.1016/S2213-2600(16)00046-1; Dellinger RP, 2018, JAMA-J AM MED ASSOC, V320, P1455, DOI 10.1001/jama.2018.14618; Emdin CA, 2017, JAMA-J AM MED ASSOC, V318, P1925, DOI 10.1001/jama.2017.17219; Famous KR, 2017, AM J RESP CRIT CARE, V195, P331, DOI 10.1164/rccm.201603-0645OC; Gajic O, 2018, CURR OPIN CRIT CARE, V24, P394, DOI 10.1097/MCC.0000000000000530; Goligher EC, 2021, NEW ENGL J MED, V385, P777, DOI [10.1056/NEJMoa2103417, 10.1056/NEJMoa2100433]; Gospodarowicz M, 1998, Cancer Prev Control, V2, P262; Green ED, 2015, NATURE, V526, P29, DOI 10.1038/526029a; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Kim S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6236; Kitsios GD, 2019, CRIT CARE MED, V47, P1724, DOI 10.1097/CCM.0000000000004018; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kousathanas A, 2022, NATURE, V607, P97, DOI 10.1038/s41586-022-04576-6; Lee JS, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd1554; Leligdowicz A, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2372-2; Lorne E, 2010, INTENS CARE MED, V36, P1826, DOI 10.1007/s00134-010-1983-5; Mackillop W J, 1998, Cancer Prev Control, V2, P269; Mahmood SS, 2014, LANCET, V383, P999, DOI 10.1016/S0140-6736(13)61752-3; Marshall JC, 2003, CRIT CARE MED, V31, P1560, DOI 10.1097/01.CCM.0000065186.67848.3A; Marshall JC, 2014, TRENDS MOL MED, V20, P195, DOI 10.1016/j.molmed.2014.01.007; Marshall JC, 2014, VIRULENCE, V5, P27, DOI 10.4161/viru.26908; Maslove DM, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1653-x; Maslove DM, 2014, TRENDS MOL MED, V20, P204, DOI 10.1016/j.molmed.2014.01.006; Maslove DM, 2012, CRIT CARE, V16, DOI 10.1186/cc11667; Matthay MA, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0069-0; Migden MR, 2018, CANCER TREAT REV, V64, P1, DOI 10.1016/j.ctrv.2017.12.009; Neyton LPA, 2022, ANN SURG, V275, pE453, DOI 10.1097/SLA.0000000000003974; Oh J, 2018, PHYSIOL MEAS, V39, DOI 10.1088/1361-6579/aaab07; Opal SM, 2013, JAMA-J AM MED ASSOC, V309, P1154, DOI 10.1001/jama.2013.2194; Pairo-Castineira E, 2021, NATURE, V591, P92, DOI 10.1038/s41586-020-03065-y; Park JW, 2016, NEW ENGL J MED, V375, P11, DOI 10.1056/NEJMoa1513750; Prescott HC, 2016, AM J RESP CRIT CARE, V194, P147, DOI 10.1164/rccm.201512-2544CP; Reilly JP, 2017, AM J RESP CRIT CARE, V196, P1113, DOI 10.1164/rccm.201702-0405CP; Russell Clark D, 2017, Curr Opin Syst Biol, V2, P140, DOI 10.1016/j.coisb.2017.04.003; Scicluna BP, 2017, LANCET RESP MED, V5, P816, DOI 10.1016/S2213-2600(17)30294-1; Seymour CW, 2019, JAMA-J AM MED ASSOC, V321, P2003, DOI 10.1001/jama.2019.5791; Seymour CW, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1836-5; Shankar-Hari M, 2021, JAMA-J AM MED ASSOC, V326, P499, DOI 10.1001/jama.2021.11330; Shankar-Hari M, 2019, CURR OPIN CRIT CARE, V25, P489, DOI 10.1097/MCC.0000000000000641; Simonis FD, 2018, JAMA-J AM MED ASSOC, V320, P1872, DOI 10.1001/jama.2018.14280; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Sweeney TE, 2021, CRIT CARE MED, V49, pE170, DOI 10.1097/CCM.0000000000004786; Sweeney TE, 2018, CRIT CARE MED, V46, P915, DOI 10.1097/CCM.0000000000003084; Sweeney TE, 2017, CRIT CARE MED, V45, P934, DOI 10.1097/CCM.0000000000002402; van der Made CI, 2020, JAMA-J AM MED ASSOC, V324, P663, DOI 10.1001/jama.2020.13719; Wong HCR, 2021, CRIT CARE MED, V49, pE98, DOI 10.1097/CCM.0000000000004709; Wong HR, 2017, AM J RESP CRIT CARE, V196, P258, DOI 10.1164/rccm.201701-0143ED; Wong HR, 2016, CRIT CARE MED, V44, pE1000, DOI 10.1097/CCM.0000000000001833; Wong HR, 2015, AM J RESP CRIT CARE, V191, P309, DOI 10.1164/rccm.201410-1864OC; Wong HR, 2011, CRIT CARE MED, V39, P2511, DOI 10.1097/CCM.0b013e3182257675; Wong HR, 2010, CRIT CARE MED, V38, P1955, DOI 10.1097/CCM.0b013e3181eb924f; Wong HR, 2010, PEDIATR CRIT CARE ME, V11, P349, DOI 10.1097/PCC.0b013e3181c519b4; Wong HR, 2009, CRIT CARE MED, V37, P1558, DOI 10.1097/CCM.0b013e31819fcc08; Wong HR, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-34; Wu AC, 2018, AM J RESP CRIT CARE, V198, pE116, DOI 10.1164/rccm.201810-1895ST; Xiao WZ, 2011, J EXP MED, V208, P2581, DOI 10.1084/jem.20111354	67	14	14	8	9	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2022	28	6					1141	1148		10.1038/s41591-022-01843-x	http://dx.doi.org/10.1038/s41591-022-01843-x			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E9IE	35715504	Green Accepted, Green Submitted, Bronze			2022-12-27	WOS:000812533400019
J	Bar-Or, A; Banwell, B; Berger, JR; Lieberman, PM				Bar-Or, Amit; Banwell, Brenda; Berger, Joseph R.; Lieberman, Paul M.			Guilty by association: Epstein-Barr virus in multiple sclerosis	NATURE MEDICINE			English	Editorial Material								Two new studies provide robust epidemiological evidence and a mechanistic link, with potential implications for strategies that target Epstein-Barr virus.	[Bar-Or, Amit; Berger, Joseph R.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Bar-Or, Amit; Banwell, Brenda] Univ Penn, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Lieberman, Paul M.] Wistar Inst Anat & Biol, Philadelphia, PA USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; The Wistar Institute	Bar-Or, A (corresponding author), Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.; Bar-Or, A (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.	amitbar@pennmedicine.upenn.edu						Banwell B, 2011, LANCET NEUROL, V10, P436, DOI 10.1016/S1474-4422(11)70045-X; Bar-Or A, 2020, TRENDS MOL MED, V26, P296, DOI 10.1016/j.molmed.2019.11.003; Bjornevik K, 2022, SCIENCE, V375, P296, DOI 10.1126/science.abj8222; Cencioni MT, 2021, NAT REV NEUROL, V17, P399, DOI 10.1038/s41582-021-00498-5; Goodin, 2021, MED RES ARCH, V9, P29, DOI [10.18103/mra.v9i6.2413, DOI 10.18103/MRA.V9I6.2413]; Lanz TV, 2022, NATURE, DOI 10.1038/s41586-022-04432-7; Lassmann H, 2011, BRAIN, V134, P2772, DOI 10.1093/brain/awr197; Levin LI, 2010, ANN NEUROL, V67, P824, DOI 10.1002/ana.21978; Messick TE, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau5612; Nourbakhsh B, 2021, ANN NEUROL, V89, P1234, DOI 10.1002/ana.26062; Soldan Samantha S, 2020, Drug Discov Today Dis Models, V32, P35, DOI 10.1016/j.ddmod.2020.01.001; Veroni C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.665718	12	3	3	2	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2022	28	5					904	906		10.1038/s41591-022-01823-1	http://dx.doi.org/10.1038/s41591-022-01823-1		MAY 2022	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	1J3AM	35538259				2022-12-27	WOS:000793025400003
J	Smith, TF; Zhang, XL				Smith, TF; Zhang, XL			The challenges of genome sequence annotation or "the devil is in the details"	NATURE BIOTECHNOLOGY			English	Editorial Material									Boston Univ, Coll Engn, BioMol Engn Res Ctr, Boston, MA 02215 USA	Boston University	Smith, TF (corresponding author), Boston Univ, Coll Engn, BioMol Engn Res Ctr, 36 Cummington St, Boston, MA 02215 USA.							NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0	1	44	537	0	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1997	15	12					1222	1223		10.1038/nbt1197-1222	http://dx.doi.org/10.1038/nbt1197-1222			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YQ046	9359093				2022-12-27	WOS:000071342000004
J	Hoyle, R				Hoyle, R			The biosafety protocol slouches toward Montreal	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	0	0	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					694	694		10.1038/nbt0897-694	http://dx.doi.org/10.1038/nbt0897-694			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255771	Bronze			2022-12-27	WOS:A1997XM70700003
J	Xie, MH; Yuan, J; Adams, C; Gurney, A				Xie, MH; Yuan, J; Adams, C; Gurney, A			Direct demonstration of MuSK involvement in acetylcholine receptor clustering through identification of agonist ScFv	NATURE BIOTECHNOLOGY			English	Article						tyrosine kinase; MuSK; agonist; ScFv; receptor	TORPEDO ELECTRIC ORGAN; AGRIN; EXPRESSION; ANTIBODY; MUSCLE; DOMAIN	MuSK is a tyrosine kinase localized to the postsynaptic surface of the neuromuscular junction. We have searched for modulators of MuSK function using a library of human single chain variable region antibodies (scFv) that can be displayed on M13 phage or expressed as soluble protein, A panel of 21 independent MuSK-specific scFv, identified in a screen for binding to MuSK-Fe immunoadhesin, were examined for ability to induce proliferation in a factor dependent cell line (Ba/F3) through a chimeric receptor, MuSK-MpI, Four of the scFv induced a proliferative response, suggesting an ability to induce dimerization of MuSK, These scFv were also able to induce tyrosine phosphorylation of full-length MuSK and retained this ability when re-engineered to be expressed as authentic (and dimeric) human IgG molecules., Addition of agonist scFv to a cultured myo tube cell line induced AChR clustering and tyrosine phosphorylation. These results provide direct evidence that MuSK activation is capable of triggering a key event in neuromuscular junction formation and further demonstrate that large libraries of phage-displayed scFv provide a robust method for generating highly specific agonist agents.	GENENTECH INC,DEPT MOL BIOL,SAN FRANCISCO,CA 94080	Roche Holding; Genentech								ALFTHAN K, 1995, PROTEIN ENG, V8, P725, DOI 10.1093/protein/8.7.725; BOWE MA, 1995, ANNU REV NEUROSCI, V18, P443; CARTER SC, 1996, ANNU REV PHYSIOL, V58, P187; CLACKSON T, 1991, NATURE, V352, P642; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; Gautam M, 1996, CELL, V85, P525, DOI 10.1016/S0092-8674(00)81253-2; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; GODFREY EW, 1984, J CELL BIOL, V99, P615, DOI 10.1083/jcb.99.2.615; GRIFFITHS AD, 1993, EMBO J, V12, P725, DOI 10.1002/j.1460-2075.1993.tb05706.x; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; KLEIMAN J, 1996, CELL, V85, P461; KORTT AA, 1994, EUR J BIOCHEM, V221, P151, DOI 10.1111/j.1432-1033.1994.tb18724.x; Mark MR, 1996, J BIOL CHEM, V271, P9785, DOI 10.1074/jbc.271.16.9785; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; OTTOLE JJ, 1996, P NATL ACAD SCI USA, V93, P7369; RUEGG MA, 1992, NEURON, V8, P691, DOI 10.1016/0896-6273(92)90090-Z; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; TSIM KWK, 1992, NEURON, V8, P677, DOI 10.1016/0896-6273(92)90089-V; VALENZUELA DM, 1995, NEURON, V15, P573, DOI 10.1016/0896-6273(95)90146-9	21	48	79	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					768	771		10.1038/nbt0897-768	http://dx.doi.org/10.1038/nbt0897-768			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255792				2022-12-27	WOS:A1997XM70700029
J	Li, M				Li, M			Use of a modified bacteriophage to probe the interactions between peptides and ion channel receptors in mammalian cells	NATURE BIOTECHNOLOGY			English	Article						NMDA receptors; random peptide display; receptor detection	LIBRARY; EXPRESSION; LIGANDS; PHAGE; IDENTIFICATION; AFFINITY; SURFACE	Besides natural peptide ligands, screening of random peptide libraries has yielded novel bioactive peptides for cell surface receptors. A method is described that uses a modified bacteriophage as a detection reagent to monitor the expression of receptor channels in mammalian cells and to probe the molecular interaction between phage-tethered peptides (Phi T-peptides) and specific receptor targets. By taking advantage of a specific multivalent interaction between Phi T-peptides and the receptor target, assays have been developed that use Phi T-peptides specific for the N-methyl-D-aspartate glutamate receptor, an important ligand-gated ion channel in the nervous system, to monitor the receptor expression in cultured mammalian cells. Combining these Phi T-peptide binding assays with fluorescence-activated cell sorting, 10(4) random glutamate receptor mutants were screened and candidate interaction residues were identified. This dual heterologous expression system offers a powerful approach to the molecular studies of protein-protein interactions.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205	Johns Hopkins University	Li, M (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,725 N WOLFE ST,BALTIMORE,MD 21205, USA.							Barry MA, 1996, NAT MED, V2, P299, DOI 10.1038/nm0396-299; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; CIK M, 1993, BIOCHEM J, V296, P877, DOI 10.1042/bj2960877; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEDMAN JR, 1993, J BIOL CHEM, V268, P23025; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; GEYSEN HM, 1986, MOL IMMUNOL, V23, P709, DOI 10.1016/0161-5890(86)90081-7; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; KAY BK, 1993, GENE, V128, P59, DOI 10.1016/0378-1119(93)90153-T; Leung DW, 1989, TECHNIQUE, V1, P11; Li M, 1996, NAT BIOTECHNOL, V14, P986, DOI 10.1038/nbt0896-986; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; RICE GC, 1992, P NATL ACAD SCI USA, V89, P5467, DOI 10.1073/pnas.89.12.5467; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; WHITEHORN EA, 1995, BIO-TECHNOL, V13, P1215, DOI 10.1038/nbt1195-1215; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458	18	8	9	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1997	15	6					559	563		10.1038/nbt0697-559	http://dx.doi.org/10.1038/nbt0697-559			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XC772	9181579				2022-12-27	WOS:A1997XC77200032
J	Coloma, MJ; Morrison, SL				Coloma, MJ; Morrison, SL			Design and production of novel tetravalent bispecific antibodies	NATURE BIOTECHNOLOGY			English	Article						antibody engineering; single chain Fvs; bispecific	GENETICALLY-ENGINEERED ANTIBODIES; SITE-DIRECTED MUTAGENESIS; MURINE IGG1 MOLECULE; F(AB'-GAMMA)2 ANTIBODY; OVERLAP EXTENSION; ESCHERICHIA-COLI; HINGE REGION; BINDING-SITE; CH2 DOMAIN; FRAGMENTS	We have produced novel bispecific antibodies by fusing the DNA encoding a single chain antibody (ScFv) after the C terminus (C(H)3-ScFv) or after the hinge (Hinge-ScFv) with an antibody of a different specificity, The fusion protein is expressed by gene transfection in the context of a murine variable region, Transfectomas secrete a homogeneous population of the recombinant antibody with two different specificities, one at the N terminus (anti-dextran) and one at the C terminus (anti-dansyl). The C(H)3-ScFv antibody, which maintains the constant region of human IgG3, has some of the associated effector functions such as long half-life and Fc receptor binding, The Hinge-ScFv antibody which lacks the C(H)2 and C(H)3 domains has no known effector functions.	UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOL GENET, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, INST MOL BIOL, LOS ANGELES, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles								AYALA M, 1995, BIOTECHNIQUES, V18, P832; AYALA M, 1992, BIOTECHNIQUES, V13, P790; CANFIELD SM, 1991, J EXP MED, V173, P1483, DOI 10.1084/jem.173.6.1483; CHAPPEL MS, 1991, P NATL ACAD SCI USA, V88, P9036, DOI 10.1073/pnas.88.20.9036; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P1066, DOI 10.1073/pnas.87.3.1066; DANGL JL, 1982, CYTOMETRY, V2, P395; DUNCAN AR, 1988, NATURE, V332, P738, DOI 10.1038/332738a0; DUNCAN AR, 1994, J EXP MED, V180, P1087; FLAVELL DJ, 1991, BRIT J CANCER, V64, P274, DOI 10.1038/bjc.1991.291; GEORGE AJT, 1994, J IMMUNOL, V152, P1802; GLENNIE MJ, 1988, J IMMUNOL, V141, P3662; GLENNIE MJ, 1987, J IMMUNOL, V139, P2367; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLTON TA, 1991, NUCL ACIDS RES, V19; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; HUSTON JS, 1989, GENE, V77, P51; KIM JK, 1994, SCAND J IMMUNOL, V40, P457, DOI 10.1111/j.1365-3083.1994.tb03488.x; KIM JK, 1994, EUR J IMMUNOL, V24, P542, DOI 10.1002/eji.1830240308; KIM JK, 1995, MOL IMMUNOL, V32, P467, DOI 10.1016/0161-5890(95)00019-B; KONTSEKOVA E, 1992, HYBRIDOMA, V11, P461, DOI 10.1089/hyb.1992.11.461; LLOYD F, 1991, J NATL MED ASSOC, V83, P901; MARTINIS J, 1982, PROTIDES BIOL FLUIDS, P311; MILSTEIN C, 1983, NATURE, V305, P537, DOI 10.1038/305537a0; NIETO A, 1984, MOL IMMUNOL, V21, P537, DOI 10.1016/0161-5890(84)90070-1; PACK P, 1992, BIOCHEMISTRY-US, V31, P1579, DOI 10.1021/bi00121a001; RASO V, 1981, CANCER RES, V41, P2073; READING CL, 1983, HYBRIDOMAS CELLULAR, P235; Runge MS, 1990, BIOCONJUGATE CHEM, V1, P274, DOI 10.1021/bc00004a008; SHIN SU, 1989, METHOD ENZYMOL, V178, P459; SHIN SU, 1992, IMMUNOL REV, V130, P87, DOI 10.1111/j.1600-065X.1992.tb01522.x; SMITH RIF, 1994, BIO-TECHNOL, V12, P683, DOI 10.1038/nbt0794-683; TADA H, 1994, J BIOTECHNOL, V33, P157, DOI 10.1016/0168-1656(94)90108-2; TAO MH, 1993, J EXP MED, V178, P661, DOI 10.1084/jem.178.2.661; TAO MH, 1989, J IMMUNOL, V143, P2595; TAO MH, 1991, J EXP MED, V173, P1025, DOI 10.1084/jem.173.4.1025; WALLICK SC, 1988, J IMMUNOL, V141, P3516; WRIGHT A, 1994, J EXP MED, V180, P1087, DOI 10.1084/jem.180.3.1087; WRIGHT A, 1992, CRIT REV IMMUNOL, V12, P125	38	173	360	1	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1997	15	2					159	163		10.1038/nbt0297-159	http://dx.doi.org/10.1038/nbt0297-159			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WE998	9035142				2022-12-27	WOS:A1997WE99800023
J	Shields, BM; Angwin, CD; Shepherd, MH; Britten, N; Jones, AG; Sattar, N; Holman, R; Pearson, ER; Hattersley, AT				Shields, Beverley M.; Angwin, Catherine D.; Shepherd, Maggie H.; Britten, Nicky; Jones, Angus G.; Sattar, Naveed; Holman, Rury; Pearson, Ewan R.; Hattersley, Andrew T.			Patient preference for second- and third-line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study	NATURE MEDICINE			English	Article; Early Access							N-OF-1 TRIALS; EFFICACY; MULTICENTER; MANAGEMENT; INJECTION; CROSSOVER; INSULIN; PEOPLE; SAFETY	Patient preference is very important for medication selection in chronic medical conditions, like type 2 diabetes, where there are many different drugs available. Patient preference balances potential efficacy with potential side effects. As both aspects of drug response can vary markedly between individuals, this decision could be informed by the patient personally experiencing the alternative medications, as occurs in a crossover trial. In the TriMaster (NCT02653209, ISRCTN12039221), randomized double-blind, three-way crossover trial patients received three different second- or third-line once-daily type 2 diabetes glucose-lowering drugs (pioglitazone 30 mg, sitagliptin 100 mg and canagliflozin 100 mg). As part of a prespecified secondary endpoint, we examined patients' drug preference after they had tried all three drugs. In total, 448 participants were treated with all three drugs which overall showed similar glycemic control (HbA1c on pioglitazone 59.5 sitagliptin 59.9, canagliflozin 60.5 mmol mol(-1), P = 0.19). In total, 115 patients (25%) preferred pioglitazone, 158 patients (35%) sitagliptin and 175 patients (38%) canagliflozin. The drug preferred by individual patients was associated with a lower HbA1c (mean: 4.6; 95% CI: 3.9, 5.3) mmol mol(-1) lower versus nonpreferred) and fewer side effects (mean: 0.50; 95% CI: 0.35, 0.64) fewer side effects versus nonpreferred). Allocating therapy based on the individually preferred drugs, rather than allocating all patients the overall most preferred drug (canagliflozin), would result in more patients achieving the lowest HbA1c for them (70% versus 30%) and the fewest side effects (67% versus 50%). When precision approaches do not predict a clear optimal therapy for an individual, allowing patients to try potential suitable medications before they choose long-term therapy could be a practical alternative to optimizing treatment for type 2 diabetes.	[Shields, Beverley M.; Angwin, Catherine D.; Shepherd, Maggie H.; Jones, Angus G.; Hattersley, Andrew T.] Univ Exeter, Dept Clin & Biomed Sci, Exeter, England; [Shepherd, Maggie H.] Royal Devon Univ Healthcare NHS Fdn Trust, Exeter, England; [Britten, Nicky] Univ Exeter, Inst Hlth Res, Med Sch, Exeter, England; [Sattar, Naveed] Univ Glasgow, Sch Cardiovasc & Metab Hlth, Glasgow, Scotland; [Holman, Rury] Univ Oxford, Radcliffe Dept Med, Diabet Trials Unit, Oxford, England; [Pearson, Ewan R.] Univ Dundee, Sch Med, Populat Hlth & Genom, Dundee, Scotland	University of Exeter; University of Exeter; University of Glasgow; University of Oxford; University of Dundee	Hattersley, AT (corresponding author), Univ Exeter, Dept Clin & Biomed Sci, Exeter, England.	a.t.hattersley@exeter.ac.uk		Sattar, Naveed/0000-0002-1604-2593; Pearson, Ewan/0000-0001-9237-8585; Jones, Angus/0000-0002-0883-7599	UK Medical Research Council [MR/N00633X/1]; National Institute for Health and Care Research Exeter Biomedical Research Centre; National Institute for Health and Care Research Exeter Clinical Research Facility	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health and Care Research Exeter Biomedical Research Centre; National Institute for Health and Care Research Exeter Clinical Research Facility	We thank all study participants. We gratefully acknowledge the TriMaster central coordinating team, all members of the TriMaster study group, MASTERMIND consortium, the Data Monitoring Committee and the Trial Steering Committee. In particular, we thank S. Senn for his invaluable guidance on the analysis of this trial. In addition, we thank the Exeter NIHR Clinical Research Facility and the Exeter Clinical Trials Unit (CTU), particularly L. Quinn and S. Creanor for their support with the study, and the CTU Data Team. We thank A. Kerridge and S. Todd of the R&D and Pharmacy Departments at the Royal Devon and Exeter NHS Foundation Trust for support and sponsorship. Full acknowledgements of all members of the trial study group and committees are listed in the primary paper15. This trial is part of the MASTERMIND (MRC APBI Stratification and Extreme Response Mechanism IN Diabetes) consortium and is supported by the UK Medical Research Council under study grant MR/N00633X/1. The TriMaster trial was supported by the National Institute for Health and Care Research Exeter Biomedical Research Centre and National Institute for Health and Care Research Exeter Clinical Research Facility. The funder had no role in study design, data collection, data analysis, data interpretation and decision to publish or preparation of the manuscript. The views expressed are those of the author(s) and not necessarily those of the MRC, the NIHR or the Department of Health and Social Care. For the purpose of open access, the author has applied a `Creative Commons Attribution (CC BY) license to any author-accepted manuscript version arising.	Angwin C, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-042784; Bogelund M, 2011, CURR MED RES OPIN, V27, P2175, DOI 10.1185/03007995.2011.625404; Bohannon N, 2011, DIABETES TECHNOL THE, V13, P1031, DOI 10.1089/dia.2011.0047; Davies MJ, 2022, DIABETOLOGIA, V65, P1925, DOI 10.1007/s00125-022-05787-2; Dennis JM, 2020, DIABETES, V69, P2075, DOI 10.2337/dbi20-0002; Dennis JM, 2018, CLIN EPIDEMIOL, V10, P1869, DOI 10.2147/CLEP.S179555; Dennis JM, 2018, DIABETES CARE, V41, P1844, DOI 10.2337/dc18-0344; Gabler NB, 2011, MED CARE, V49, P761, DOI 10.1097/MLR.0b013e318215d90d; Gentile S, 2018, EXPERT OPIN DRUG SAF, V17, P445, DOI 10.1080/14740338.2018.1453495; Hauber AB, 2009, DIABETIC MED, V26, P416, DOI 10.1111/j.1464-5491.2009.02696.x; Korytkowski M, 2003, CLIN THER, V25, P2836, DOI 10.1016/S0149-2918(03)80337-5; Lillie EO, 2011, PERS MED, V8, P161, DOI 10.2217/PME.11.7; Ludemann J, 2015, THER ADV ENDOCRINOL, V6, P141, DOI 10.1177/2042018815595584; Matza LS, 2020, DIABETES OBES METAB, V22, P355, DOI 10.1111/dom.13902; Meguro S, 2019, CURR MED RES OPIN, V35, P2071, DOI 10.1080/03007995.2019.1651130; National Institute for Health and Care Excellence, 2015, TYP 2 DIAB AD MAN NI; National Research Council Committee on a Framework for Developing a New Taxonomy of Disease, 2011, PREC MED BUILD KNOWL; Nikles CJ, 2005, BRIT J GEN PRACT, V55, P175; Domecq JP, 2015, J CLIN ENDOCR METAB, V100, P363, DOI 10.1210/jc.2014-3421; Purnell TS, 2014, DIABETES CARE, V37, P2055, DOI 10.2337/dc13-2527; Samuel JP, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-1818; Scuffham PA, 2010, J GEN INTERN MED, V25, P906, DOI 10.1007/s11606-010-1352-7; Senn S., 2002, CROSS OVER TRIALS CL; Shields B.M., 2022, NAT MED; Toroski M, 2019, J DIABETES METAB DIS, V18, P643, DOI 10.1007/s40200-019-00449-4; Tsapas A, 2008, DIABETOLOGIA, V51, P921, DOI 10.1007/s00125-008-0983-2; Zaccardi F, 2016, DIABETES OBES METAB, V18, P783, DOI 10.1111/dom.12670	27	0	0	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02121-6	http://dx.doi.org/10.1038/s41591-022-02121-6		DEC 2022	20	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	6V4AI	36477734	Green Submitted			2022-12-27	WOS:000894992500001
J	Neinstein, AB				Neinstein, Aaron B.			Our AI future is better than you think	NATURE MEDICINE			English	Editorial Material; Early Access								Use of AI-driven care for patients with type 1 diabetes has freed up clinicians' time to focus on patients' quality of life and provide more empathic, patient-centered care.	[Neinstein, Aaron B.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Neinstein, Aaron B.] Univ Calif San Francisco, Ctr Digital Hlth Innovat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Neinstein, AB (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.; Neinstein, AB (corresponding author), Univ Calif San Francisco, Ctr Digital Hlth Innovat, San Francisco, CA 94143 USA.	aaron.neinstein@ucsf.edu	Neinstein, Aaron/X-6909-2019	Neinstein, Aaron/0000-0002-9774-7180					0	0	0	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02021-9	http://dx.doi.org/10.1038/s41591-022-02021-9		OCT 2022	1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	5C9AF	36203002				2022-12-27	WOS:000864544200001
J	Penninx, BWJH; Benros, ME; Klein, RS; Vinkers, CH				Penninx, Brenda W. J. H.; Benros, Michael E.; Klein, Robyn S.; Vinkers, Christiaan H.			How COVID-19 shaped mental health: from infection to pandemic effects	NATURE MEDICINE			English	Review; Early Access							TERM COGNITIVE IMPAIRMENT; ANXIETY; DEPRESSION; DISORDERS; CARE; IMPACT; HOSPITALIZATION; NEUROPATHOLOGY; PREVALENCE; OUTCOMES	The Coronavirus Disease 2019 (COVID-19) pandemic has threatened global mental health, both indirectly via disruptive societal changes and directly via neuropsychiatric sequelae after SARS-CoV-2 infection. Despite a small increase in self-reported mental health problems, this has (so far) not translated into objectively measurable increased rates of mental disorders, self-harm or suicide rates at the population level. This could suggest effective resilience and adaptation, but there is substantial heterogeneity among subgroups, and time-lag effects may also exist. With regard to COVID-19 itself, both acute and post-acute neuropsychiatric sequelae have become apparent, with high prevalence of fatigue, cognitive impairments and anxiety and depressive symptoms, even months after infection. To understand how COVID-19 continues to shape mental health in the longer term, fine-grained, well-controlled longitudinal data at the (neuro)biological, individual and societal levels remain essential. For future pandemics, policymakers and clinicians should prioritize mental health from the outset to identify and protect those at risk and promote long-term resilience. This Review discusses the impact of COVID-19 on mental health, from pandemic-related societal effects to direct infection-related neuropsychiatric sequelae, highlighting the lessons learned and outstanding knowledge gaps.	[Penninx, Brenda W. J. H.; Vinkers, Christiaan H.] Vrije Univ Amsterdam, Dept Psychiat, Amsterdam UMC, Amsterdam, Netherlands; [Penninx, Brenda W. J. H.; Vinkers, Christiaan H.] Mental Hlth Program & Amsterdam Neurosci, Amsterdam Publ Hlth, Mood Anxiety Psychosis Sleep & Stress Program, Amsterdam, Netherlands; [Benros, Michael E.] Copenhagen Univ Hosp, Copenhagen Res Ctr Mental Hlth, Mental Hlth Ctr Copenhagen, Biol & Precis Psychiat, Copenhagen, Denmark; [Benros, Michael E.] Univ Copenhagen, Fac Hlth & Med Sci, Dept Immunol & Microbiol, Copenhagen, Denmark; [Klein, Robyn S.] Washington Univ, Sch Med, Dept Med, St Louis, MO USA; [Klein, Robyn S.] Washington Univ, Sch Med, Dept Pathol, St Louis, MO USA; [Klein, Robyn S.] Washington Univ, Sch Med, Dept Immunol, St Louis, MO USA; [Klein, Robyn S.] Washington Univ, Sch Med, Dept Neurosci, St Louis, MO USA	University of Amsterdam; Vrije Universiteit Amsterdam; University of Copenhagen; University of Copenhagen; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Penninx, BWJH (corresponding author), Vrije Univ Amsterdam, Dept Psychiat, Amsterdam UMC, Amsterdam, Netherlands.; Penninx, BWJH (corresponding author), Mental Hlth Program & Amsterdam Neurosci, Amsterdam Publ Hlth, Mood Anxiety Psychosis Sleep & Stress Program, Amsterdam, Netherlands.	b.penninx@amsterdamumc.nl	Benros, Michael Eriksen/N-5868-2016	Benros, Michael Eriksen/0000-0003-4939-9465	European Union [101016127]	European Union(European Commission)	The authors thank E. Giltay for assistance on data analyses and production of Fig. 1. B.W.J.H.P. discloses support for research and publication of this work from the European Union's Horizon 2020 research and innovation programme-funded RESPOND project (grant no. 101016127).	Acuff SF, 2022, PSYCHOL ADDICT BEHAV, V36, P1, DOI 10.1037/adb0000796; Aknin LB, 2022, LANCET PUBLIC HEALTH, V7, pE417, DOI 10.1016/S2468-2667(22)00060-3; Amin-Chowdhury Z, 2021, NAT MED, V27, P1129, DOI 10.1038/s41591-021-01402-w; Anderson KN, 2022, JAMA PSYCHIAT, V79, P475, DOI 10.1001/jamapsychiatry.2022.0164; [Anonymous], 2022, MENT HLTH COVID 19 E; [Anonymous], 2021, 3 ROUND GLOB PULS SU; [Anonymous], 2022, WHO CORONAVIRUS COVI; Antonelli M, 2022, LANCET INFECT DIS, V22, P43, DOI 10.1016/S1473-3099(21)00460-6; Asadi-Pooya AA, 2020, J NEUROL SCI, V413, DOI 10.1016/j.jns.2020.116832; Ayuso-Mateos J L, 2021, Epidemiol Psychiatr Sci, V30, pe49, DOI 10.1017/S2045796021000408; Badenoch JB, 2022, BRAIN COMMUN, V4, DOI 10.1093/braincomms/fcab297; Baumgart JG, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18158034; Bliddal S, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-92045-x; Bohmwald K, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00386; Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8., 10.1016/S0140-6736(20)30460-8]; Brownlee NNM, 2020, NEUROREHABILITATION, V47, P83, DOI 10.3233/NRE-203135; Carfi A, 2020, JAMA-J AM MED ASSOC, V324, P603, DOI 10.1001/jama.2020.12603; Castro V. M., MOL PSYCH; Ceban F, 2022, BRAIN BEHAV IMMUN, V101, P93, DOI 10.1016/j.bbi.2021.12.020; Clift AK, 2022, JAMA PSYCHIAT, V79, P690, DOI 10.1001/jamapsychiatry.2022.1067; Cohen GH, 2017, JAMA PSYCHIAT, V74, P1251, DOI 10.1001/jamapsychiatry.2017.3037; Cosentino G, 2021, EUR J NEUROL, V28, P3856, DOI 10.1111/ene.15045; Crook H, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n1648; Cryer MJ, 2022, CLIN APPL THROMB-HEM, V28, DOI 10.1177/10760296221074353; Dandona R, 2021, LANCET PSYCHIAT, V8, P9, DOI 10.1016/S2215-0366(20)30493-4; Daniels BP, 2014, MBIO, V5, DOI 10.1128/mBio.01476-14; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; De Picker LJ, 2021, LANCET PSYCHIAT, V8, P356, DOI 10.1016/S2215-0366(21)00046-8; Del Valle DM, 2020, NAT MED, V26, P1636, DOI [10.1038/s41591-020-1051-9, 10.1101/2020.05.28.20115758]; Douaud G, 2022, NATURE, V604, P697, DOI [10.1038/s41586-022-04569-5, 10.1101/2021.06.11.21258690]; Dragioti E, 2022, J MED VIROL, V94, P1935, DOI 10.1002/jmv.27549; Ernst M, 2022, AM PSYCHOL, V77, P660, DOI 10.1037/amp0001005; Fancourt D, 2021, LANCET PSYCHIAT, V8, P141, DOI 10.1016/S2215-0366(20)30482-X; Farhadian S, 2020, BMC NEUROL, V20, DOI 10.1186/s12883-020-01812-2; Faust JS, 2021, JAMA-J AM MED ASSOC, V326, P84, DOI 10.1001/jama.2021.8012; Flor LS, 2022, LANCET, V399, P2381, DOI 10.1016/S0140-6736(22)00008-3; Francistiova L, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.730088; Girard TD, 2018, J GEN INTERN MED, V33, P929, DOI 10.1007/s11606-017-4301-x; H. M. Rando, 2021, medRxiv, DOI 10.1101/2021.03.20.21253896; Herrman H, 2022, LANCET, V399, P957, DOI 10.1016/S0140-6736(21)02141-3; Hill JE, 2022, J ADV NURS, V78, P1551, DOI 10.1111/jan.15175; Holland KM, 2021, JAMA PSYCHIAT, V78, P372, DOI 10.1001/jamapsychiatry.2020.4402; Jia HM, 2021, MMWR-MORBID MORTAL W, V70, P1427, DOI [10.15585/mmwr.mm7040e3, 10.15585/mmwr.mm7040e3externalicon]; John Ann, 2020, F1000Res, V9, P1097, DOI 10.12688/f1000research.25522.1; Jorm AF, 2017, WORLD PSYCHIATRY, V16, P90, DOI 10.1002/wps.20388; Khaddaj-Mallat R, 2021, NEUROBIOL DIS, V161, DOI 10.1016/j.nbd.2021.105561; Kilian C, 2022, DRUG ALCOHOL REV, V41, P918, DOI 10.1111/dar.13446; Kim Y, 2022, BMC INFECT DIS, V22, DOI 10.1186/s12879-022-07062-6; Knox L, 2022, CURR OPIN PSYCHOL, V46, DOI 10.1016/j.copsyc.2022.101315; Knudsen AKS, 2021, LANCET REG HEALTH-EU, V4, DOI 10.1016/j.lanepe.2021.100071; Kok AAL, 2022, J AFFECT DISORDERS, V305, P85, DOI 10.1016/j.jad.2022.02.056; Kunzler AM, 2021, GLOBALIZATION HEALTH, V17, DOI 10.1186/s12992-021-00670-y; Lee Y, 2021, J AFFECT DISORDERS, V290, P364, DOI 10.1016/j.jad.2021.04.050; Lersy F, 2021, J INFECT DIS, V223, P600, DOI 10.1093/infdis/jiaa745; Lu YP, 2020, ECLINICALMEDICINE, V25, DOI 10.1016/j.eclinm.2020.100484; Magnusdottir I, 2022, LANCET PUBLIC HEALTH, V7, pE406, DOI 10.1016/S2468-2667(22)00042-1; Manganotti P, 2021, J MED VIROL, V93, P5432, DOI 10.1002/jmv.27061; Marvaldi M, 2021, NEUROSCI BIOBEHAV R, V126, P252, DOI 10.1016/j.neubiorev.2021.03.024; Matschke J, 2020, LANCET NEUROL, V19, P919, DOI 10.1016/S1474-4422(20)30308-2; Mazza MG, 2020, BRAIN BEHAV IMMUN, V89, P594, DOI 10.1016/j.bbi.2020.07.037; Moonis G, 2021, AM J ROENTGENOL, V217, P959, DOI 10.2214/AJR.20.24839; Nalbandian A, 2021, NAT MED, V27, P601, DOI 10.1038/s41591-021-01283-z; Nalivaeva NN, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00770; Nersesjan V, 2022, JAMA PSYCHIAT, DOI 10.1001/jamapsychiatry.2022.0284; Nersesjan V, 2021, J NEUROL, V268, P3086, DOI 10.1007/s00415-020-10380-x; Newnham EA, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17176144; Pan KY, 2021, LANCET PSYCHIAT, V8, P121, DOI 10.1016/S2215-0366(20)30491-0; Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372; Patel K, 2022, JAMA NETW OPEN, V5, DOI 10.1001/jamanetworkopen.2022.7629; Paterson RW, 2021, BRAIN COMMUN, V3, DOI 10.1093/braincomms/fcab099; Penninx BWJH, 2021, LANCET, V397, P914, DOI 10.1016/S0140-6736(21)00359-7; Petersen MB, 2021, NATURE, V598, P237, DOI 10.1038/d41586-021-02758-2; Phiri P, 2021, ECLINICALMEDICINE, V34, DOI 10.1016/j.eclinm.2021.100806; Pirkis J, 2021, LANCET PSYCHIAT, V8, P579, DOI 10.1016/S2215-0366(21)00091-2; Prati G, 2021, PSYCHOL MED, V51, P201, DOI 10.1017/S0033291721000015; Qian YS, 2021, J VIROL, V95, DOI [10.1128/JVI.01396-21, 10.1101/2021.02.14.431174]; Qin YY, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI147329; Qiu D, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.588137; Racine N, 2021, JAMA PEDIATR, V175, P1142, DOI 10.1001/jamapediatrics.2021.2482; Radka K, 2022, PREV MED REP, V26, DOI 10.1016/j.pmedr.2022.101725; Raphael J, 2021, BJPSYCH OPEN, V7, DOI 10.1192/bjo.2021.20; Rawal G, 2017, J TRANSL INTERN MED, V5, P90, DOI 10.1515/jtim-2016-0016; Reynolds JL, 2021, J NEUROIMMUNE PHARM, V16, P4, DOI 10.1007/s11481-020-09975-y; Rhea EM, 2021, NAT NEUROSCI, V24, P368, DOI 10.1038/s41593-020-00771-8; Robinson E, 2022, J AFFECT DISORDERS, V296, P567, DOI 10.1016/j.jad.2021.09.098; Romer TB, 2021, ACTA PSYCHIAT SCAND, V144, P553, DOI 10.1111/acps.13369; Santomauro DF, 2021, LANCET, V398, P1700, DOI 10.1016/S0140-6736(21)02143-7; Shivshankar P, 2022, INFLAMMATION, V45, P1430, DOI 10.1007/s10753-022-01656-7; Steeg S, 2021, ECLINICALMEDICINE, V41, DOI 10.1016/j.eclinm.2021.101175; Su YY, 2022, INT PSYCHOGERIATR, DOI 10.1017/S1041610222000199; Su ZH, 2021, GLOBALIZATION HEALTH, V17, DOI 10.1186/s12992-020-00654-4; Tanaka T, 2021, NAT HUM BEHAV, V5, P229, DOI 10.1038/s41562-020-01042-z; Taquet M, 2021, LANCET PSYCHIAT, V8, P416, DOI 10.1016/S2215-0366(21)00084-5; Thakur KT, 2021, BRAIN, V144, P2696, DOI 10.1093/brain/awab148; Thomeer MB, 2022, J RACIAL ETHN HEALTH, DOI 10.1007/s40615-022-01284-9; Tian T, 2022, JCI INSIGHT, V7, DOI 10.1172/jci.insight.155827; Titze-de-Almeida R, 2022, BMC INFECT DIS, V22, DOI 10.1186/s12879-022-07065-3; Vai B, 2021, LANCET PSYCHIAT, V8, P797, DOI 10.1016/S2215-0366(21)00232-7; van der Bles AM, 2020, P NATL ACAD SCI USA, V117, P7672, DOI 10.1073/pnas.1913678117; Varga TV, 2021, LANCET REG HEALTH-EU, V2, DOI 10.1016/j.lanepe.2020.100020; Viner R, 2022, JAMA PEDIATR, DOI 10.1001/jamapediatrics.2021.5840; Vloo A, 2021, SSM-POPUL HLTH, V15, DOI 10.1016/j.ssmph.2021.100878; Vos T, 2020, LANCET, V396, P1562; Wilson JE, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-020-00223-4; Winkler P, 2021, J PSYCHIATR RES, V139, P167, DOI 10.1016/j.jpsychires.2021.05.032; Wisnivesky JP, 2022, J GEN INTERN MED, V37, P1748, DOI 10.1007/s11606-022-07465-w; Wu JT, 2021, NAT MED, V27, P388, DOI 10.1038/s41591-021-01278-w; Xiang YT, 2020, LANCET PSYCHIAT, V7, P228, DOI 10.1016/S2215-0366(20)30046-8; Xie Y, 2022, BMJ-BRIT MED J, V376, DOI 10.1136/bmj-2021-068993; Zhang H, 2022, AM J INFECT CONTROL, V50, P809, DOI 10.1016/j.ajic.2022.01.023; Zhang SX, 2022, EPIDEMIOL PSYCH SCI, V31, DOI 10.1017/S2045796021000767; Zhang SX, 2022, EUR J PSYCHOTRAUMATO, V13, DOI 10.1080/20008198.2021.2000132; Zheng XY, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-045317	113	0	0	14	14	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02028-2	http://dx.doi.org/10.1038/s41591-022-02028-2		OCT 2022	11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	5B4ON	36192553	Green Accepted, Bronze			2022-12-27	WOS:000863550300001
J	Yang, YH; Lyu, JF; Wang, RX; Wen, Q; Zhao, LQ; Chen, WB; Bi, SW; Meng, J; Mao, KL; Xiao, Y; Liang, YY; Zeng, DQ; Du, ZJ; Wu, YX; Cui, TX; Liu, LX; Iao, WC; Li, XY; Cheung, CY; Zhou, JH; Hu, YJ; Wei, L; Lai, IF; Yu, XP; Chen, JC; Wang, ZH; Mao, Z; Ye, HJ; Xiao, W; Yang, HS; Huang, DP; Lin, XM; Zheng, WS; Wang, RX; Yu-Wai-Man, P; Xu, F; Dai, QH; Lin, HT				Yang, Yahan; Lyu, Junfeng; Wang, Ruixin; Wen, Quan; Zhao, Lanqin; Chen, Wenben; Bi, Shaowei; Meng, Jie; Mao, Keli; Xiao, Yu; Liang, Yingying; Zeng, Danqi; Du, Zijing; Wu, Yuxuan; Cui, Tingxin; Liu, Lixue; Iao, Wai Cheng; Li, Xiaoyan; Cheung, Carol Y.; Zhou, Jianhua; Hu, Youjin; Wei, Lai; Lai, Iat Fan; Yu, Xinping; Chen, Jingchang; Wang, Zhonghao; Mao, Zhen; Ye, Huijing; Xiao, Wei; Yang, Huasheng; Huang, Danping; Lin, Xiaoming; Zheng, Wei-shi; Wang, Ruixuan; Yu-Wai-Man, Patrick; Xu, Feng; Dai, Qionghai; Lin, Haotian			A digital mask to safeguard patient privacy	NATURE MEDICINE			English	Article								A deep-learning algorithm that removes patient-identifying information from facial images, while retaining sufficient information for accurate disease diagnosis, has the potential to protect patient privacy and facilitate public acceptance of facial imaging for use in digital medicine. The storage of facial images in medical records poses privacy risks due to the sensitive nature of the personal biometric information that can be extracted from such images. To minimize these risks, we developed a new technology, called the digital mask (DM), which is based on three-dimensional reconstruction and deep-learning algorithms to irreversibly erase identifiable features, while retaining disease-relevant features needed for diagnosis. In a prospective clinical study to evaluate the technology for diagnosis of ocular conditions, we found very high diagnostic consistency between the use of original and reconstructed facial videos (kappa >= 0.845 for strabismus, ptosis and nystagmus, and kappa = 0.801 for thyroid-associated orbitopathy) and comparable diagnostic accuracy (P >= 0.131 for all ocular conditions tested) was observed. Identity removal validation using multiple-choice questions showed that compared to image cropping, the DM could much more effectively remove identity attributes from facial images. We further confirmed the ability of the DM to evade recognition systems using artificial intelligence-powered re-identification algorithms. Moreover, use of the DM increased the willingness of patients with ocular conditions to provide their facial images as health information during medical treatment. These results indicate the potential of the DM algorithm to protect the privacy of patients' facial images in an era of rapid adoption of digital health technologies.	[Yang, Yahan; Wang, Ruixin; Zhao, Lanqin; Chen, Wenben; Bi, Shaowei; Meng, Jie; Mao, Keli; Zeng, Danqi; Wu, Yuxuan; Cui, Tingxin; Liu, Lixue; Iao, Wai Cheng; Li, Xiaoyan; Hu, Youjin; Wei, Lai; Yu, Xinping; Chen, Jingchang; Wang, Zhonghao; Mao, Zhen; Ye, Huijing; Xiao, Wei; Yang, Huasheng; Huang, Danping; Lin, Xiaoming; Lin, Haotian] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Guangdong Prov Clin Res Ctr Ocular Dis, State Key Lab Ophthalmol,Guangdong Prov Key Lab O, Guangzhou, Peoples R China; [Lyu, Junfeng; Wen, Quan; Xu, Feng] Tsinghua Univ, Sch Software, Beijing, Peoples R China; [Lyu, Junfeng; Wen, Quan; Xu, Feng; Dai, Qionghai] Tsinghua Univ, BNRist, Beijing, Peoples R China; [Xiao, Yu; Liang, Yingying; Du, Zijing] Southern Med Univ, Guangdong Prov Peoples Hosp, Dept Ophthalmol, Guangzhou, Peoples R China; [Xiao, Yu; Liang, Yingying; Du, Zijing] Southern Med Univ, Guangdong Acad Med Sci, Guangzhou, Peoples R China; [Cheung, Carol Y.] Chinese Univ Hong Kong, Fac Med, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China; [Zhou, Jianhua] Sun Yat Sen Univ, Sch Biomed Engn, Shenzhen Campus, Shenzhen, Peoples R China; [Lai, Iat Fan] Kiang Wu Hosp, Ophthalm Ctr, Macau, Peoples R China; [Zheng, Wei-shi; Wang, Ruixuan] Sun Yat Sen Univ, Sch Comp Sci & Engn, Guangzhou, Peoples R China; [Yu-Wai-Man, Patrick] Univ Cambridge, Cambridge Ctr Brain Repair, Cambridge, England; [Yu-Wai-Man, Patrick] Univ Cambridge, MRC Mitochondrial Biol Unit, Dept Clin Neurosci, Cambridge, England; [Yu-Wai-Man, Patrick] Cambridge Univ Hosp, Addenbrookes Hosp, Cambridge Eye Unit, Cambridge, England; [Yu-Wai-Man, Patrick] Moorfields Eye Hosp, London, England; [Yu-Wai-Man, Patrick] UCL, UCL Inst Ophthalmol, London, England; [Xu, Feng; Dai, Qionghai] Beijing Municipal Educ Commiss, Beijing Lab Brain & Cognit Intelligence, Beijing, Peoples R China; [Dai, Qionghai] Tsinghua Univ, Dept Automat, Beijing, Peoples R China; [Lin, Haotian] Sun Yat Sen Univ, Hainan Eye Hosp, Haikou, Hainan, Peoples R China; [Lin, Haotian] Sun Yat Sen Univ, Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, Haikou, Hainan, Peoples R China; [Lin, Haotian] Sun Yat Sen Univ, Ctr Precis Med, Zhongshan Sch Med, Guangzhou, Peoples R China; [Lin, Haotian] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Genet & Biomed Informat, Guangzhou, Peoples R China	Sun Yat Sen University; Tsinghua University; Tsinghua University; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Southern Medical University - China; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Southern Medical University - China; Chinese University of Hong Kong; Sun Yat Sen University; Sun Yat Sen University; University of Cambridge; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust; University of London; University College London; Tsinghua University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Lin, HT (corresponding author), Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Guangdong Prov Clin Res Ctr Ocular Dis, State Key Lab Ophthalmol,Guangdong Prov Key Lab O, Guangzhou, Peoples R China.; Xu, F (corresponding author), Tsinghua Univ, Sch Software, Beijing, Peoples R China.; Xu, F; Dai, QH (corresponding author), Tsinghua Univ, BNRist, Beijing, Peoples R China.; Xu, F; Dai, QH (corresponding author), Beijing Municipal Educ Commiss, Beijing Lab Brain & Cognit Intelligence, Beijing, Peoples R China.; Dai, QH (corresponding author), Tsinghua Univ, Dept Automat, Beijing, Peoples R China.; Lin, HT (corresponding author), Sun Yat Sen Univ, Hainan Eye Hosp, Haikou, Hainan, Peoples R China.; Lin, HT (corresponding author), Sun Yat Sen Univ, Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, Haikou, Hainan, Peoples R China.; Lin, HT (corresponding author), Sun Yat Sen Univ, Ctr Precis Med, Zhongshan Sch Med, Guangzhou, Peoples R China.; Lin, HT (corresponding author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Genet & Biomed Informat, Guangzhou, Peoples R China.	feng-xu@tsinghua.edu.cn; qhdai@tsinghua.edu.cn; linht5@mail.sysu.edu.cn	li, xiao/GSN-6181-2022; li, xiaofeng/GXF-9442-2022	Wu, Yuxuan/0000-0002-1945-3670; Zhao, Lanqin/0000-0002-5182-3678	Science and Technology Planning Projects of Guangdong Province [2018B010109008]; National Key R&D Program of China [2018YFA0704000]; National Natural Science Foundation of China [82171035, 81770967, 62088102]; Beijing Natural Science Foundation [JQ19015]; Guangzhou Key Laboratory Project [202002010006]; Institute for Brain and Cognitive Science, Tsinghua University; Beijing Laboratory of Brain and Cognitive Intelligence, Beijing Municipal Education Commission; Hainan Province Clinical Medical Center; UK National Institute of Health Research (NIHR) [NIHR301696]; Fight for Sight (UK); Isaac Newton Trust (UK); Moorfields Eye Charity [GR001376]; Addenbrooke's Charitable Trust; National Eye Research Center (UK); International Foundation for Optic Nerve Disease; NIHR as part of the Rare Diseases Translational Research Collaboration; NIHR Cambridge Biomedical Research Center [BRC-1215-20014]; NIHR Biomedical Research Center based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology	Science and Technology Planning Projects of Guangdong Province; National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation(Beijing Natural Science Foundation); Guangzhou Key Laboratory Project; Institute for Brain and Cognitive Science, Tsinghua University; Beijing Laboratory of Brain and Cognitive Intelligence, Beijing Municipal Education Commission; Hainan Province Clinical Medical Center; UK National Institute of Health Research (NIHR)(National Institute for Health Research (NIHR)); Fight for Sight (UK); Isaac Newton Trust (UK); Moorfields Eye Charity; Addenbrooke's Charitable Trust; National Eye Research Center (UK); International Foundation for Optic Nerve Disease; NIHR as part of the Rare Diseases Translational Research Collaboration; NIHR Cambridge Biomedical Research Center; NIHR Biomedical Research Center based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology	This study was supported by the Science and Technology Planning Projects of Guangdong Province (2018B010109008 to H.L.), the National Key R&D Program of China (2018YFA0704000 to F.X.), the National Natural Science Foundation of China (82171035 and 81770967 to H.L. and 62088102 to Q.D.), Beijing Natural Science Foundation (JQ19015 to F.X.), Guangzhou Key Laboratory Project (202002010006 to H.L.), the Institute for Brain and Cognitive Science, Tsinghua University (to Q.D.), Beijing Laboratory of Brain and Cognitive Intelligence, Beijing Municipal Education Commission (to Q.D.) and Hainan Province Clinical Medical Center (H.L.). These sponsors and funding organizations had no role in the design or performance of this study. P.Y.W.M. is supported by an Advanced Fellowship Award (NIHR301696) from the UK National Institute of Health Research (NIHR). P.Y.W.M. also receives funding from Fight for Sight (UK), the Isaac Newton Trust (UK), Moorfields Eye Charity (GR001376), the Addenbrooke's Charitable Trust, the National Eye Research Center (UK), the International Foundation for Optic Nerve Disease, the NIHR as part of the Rare Diseases Translational Research Collaboration, the NIHR Cambridge Biomedical Research Center (BRC-1215-20014) and the NIHR Biomedical Research Center based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.	Abel LA, 2006, CLIN EXP OPTOM, V89, P57, DOI 10.1111/j.1444-0938.2006.00024.x; [Anonymous], 2019, NATURE, V572, P5, DOI 10.1038/d41586-019-02322-z; [Anonymous], 1996, HLTH INSURANCE PORTA; Aryanto KYE, 2015, EUR RADIOL, V25, P3685, DOI 10.1007/s00330-015-3794-0; BARTLEY GB, 1995, AM J OPHTHALMOL, V119, P792, DOI 10.1016/S0002-9394(14)72787-4; Booth J, 2017, PROC CVPR IEEE, P5464, DOI 10.1109/CVPR.2017.580; Cao C, 2014, IEEE T VIS COMPUT GR, V20, P413, DOI 10.1109/TVCG.2013.249; Clover A J P, 2010, Ir Med J, V103, P243; Deng JK, 2019, PROC CVPR IEEE, P4685, DOI 10.1109/CVPR.2019.00482; Denny JC, 2021, CELL, V184, P1415, DOI 10.1016/j.cell.2021.01.015; Diaz-Manera J, 2018, CURR OPIN NEUROL, V31, P618, DOI 10.1097/WCO.0000000000000600; Gorman CA, 2020, OPHTHALMOLOGY, V127, pS160, DOI 10.1016/j.ophtha.2020.01.031; Hollander JE, 2020, NEW ENGL J MED, V382, P1679, DOI 10.1056/NEJMp2003539; Huber P., 2016, PROC CVPR IEEE, DOI DOI 10.1109/CVPR.2017.632; Kaissis GA, 2020, NAT MACH INTELL, V2, P305, DOI 10.1038/s42256-020-0186-1; Koops Bert-Jaap, 2021, Law, Innovation and Technology, V13, P29, DOI 10.1080/17579961.2021.1898299; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Latting MW, 2017, SEMIN PLAST SURG, V31, P5, DOI 10.1055/s-0037-1598188; Lin S, 2020, EUR HEART J, V41, P4400, DOI 10.1093/eurheartj/ehaa640; Liu F, 2018, PROC CVPR IEEE, P5216, DOI 10.1109/CVPR.2018.00547; Long EP, 2019, NAT BIOMED ENG, V3, P860, DOI 10.1038/s41551-019-0461-9; Lotan E, 2020, J AM COLL RADIOL, V17, P1159, DOI 10.1016/j.jacr.2020.04.007; Mason J., 2020, ARRAY, V8, P100042, DOI [10.1016/j.array.2020.100042, DOI 10.1016/J.ARRAY.2020.100042]; Pearce FC, 2017, OPHTHAL PLAST RECONS, V33, P325, DOI 10.1097/IOP.0000000000000780; Ranjan A, 2018, LECT NOTES COMPUT SC, V11207, P725, DOI 10.1007/978-3-030-01219-9_43; Sagonas C, 2013, 2013 IEEE INTERNATIONAL CONFERENCE ON COMPUTER VISION WORKSHOPS (ICCVW), P397, DOI 10.1109/ICCVW.2013.59; Schroff F, 2015, PROC CVPR IEEE, P815, DOI 10.1109/CVPR.2015.7298682; Stanberry B, 2001, COMPUT METH PROG BIO, V64, P225, DOI 10.1016/S0169-2607(00)00142-5; Tewari A., 2021, P IEEE CVF C COMP VI, P3361; THOMAS IT, 1987, J PEDIATR-US, V111, P267, DOI 10.1016/S0022-3476(87)80085-9; Tirosh E, 1998, INT J REHABIL RES, V21, P63, DOI 10.1097/00004356-199803000-00006; Wang H, 2018, PROC CVPR IEEE, P5265, DOI 10.1109/CVPR.2018.00552; Wang JD, 2021, IEEE T PATTERN ANAL, V43, P3349, DOI 10.1109/TPAMI.2020.2983686; Wen Q, 2017, ACM T GRAPHIC, V36, DOI 10.1145/3130800.3130837; Wen Q, 2017, IEEE T VIS COMPUT GR, V23, P2586, DOI 10.1109/TVCG.2016.2641442; Wood E, 2016, 2016 ACM SYMPOSIUM ON EYE TRACKING RESEARCH & APPLICATIONS (ETRA 2016), P131, DOI 10.1145/2857491.2857492; Wright K. W., 2013, PEDIAT OPHTHALMOLOGY; Wu WY, 2018, PROC CVPR IEEE, P2129, DOI 10.1109/CVPR.2018.00227; Xie SN, 2015, IEEE I CONF COMP VIS, P1395, DOI 10.1109/ICCV.2015.164; Yi D., 2014, ARXIV14117923; Zeng XX, 2019, IEEE I CONF COMP VIS, P2315, DOI 10.1109/ICCV.2019.00240	42	0	0	9	9	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2022	28	9					1883	+		10.1038/s41591-022-01966-1	http://dx.doi.org/10.1038/s41591-022-01966-1		SEP 2022	22	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4S0LI	36109638	hybrid, Green Published			2022-12-27	WOS:000854720900004
J	Sartore-Bianchi, A; Pietrantonio, F; Lonardi, S; Mussolin, B; Rua, F; Crisafulli, G; Bartolini, A; Fenocchio, E; Amatu, A; Manca, P; Bergamo, F; Tosi, F; Mauri, G; Ambrosini, M; Daniel, F; Torri, V; Vanzulli, A; Regge, D; Cappello, G; Marchio, C; Berrino, E; Sapino, A; Marsoni, S; Siena, S; Bardelli, A				Sartore-Bianchi, Andrea; Pietrantonio, Filippo; Lonardi, Sara; Mussolin, Benedetta; Rua, Francesco; Crisafulli, Giovanni; Bartolini, Alice; Fenocchio, Elisabetta; Amatu, Alessio; Manca, Paolo; Bergamo, Francesca; Tosi, Federica; Mauri, Gianluca; Ambrosini, Margherita; Daniel, Francesca; Torri, Valter; Vanzulli, Angelo; Regge, Daniele; Cappello, Giovanni; Marchio, Caterina; Berrino, Enrico; Sapino, Anna; Marsoni, Silvia; Siena, Salvatore; Bardelli, Alberto			Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial	NATURE MEDICINE			English	Article; Early Access							EGFR MONOCLONAL-ANTIBODIES; ACQUIRED-RESISTANCE; COLON-CANCER; MUTATIONS; RETREATMENT; THERAPY; LIQUID; HETEROGENEITY; REGORAFENIB; MULTICENTER	Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of resistance mutations restricts their efficacy. We previously showed that RAS, BRAF and EGFR mutant alleles, which appear in circulating tumor DNA (ctDNA) during EGFR blockade, decline upon therapy withdrawal. We hypothesized that monitoring resistance mutations in blood could rationally guide subsequent therapy with anti-EGFR antibodies. We report here the results of CHRONOS, an open-label, single-arm phase 2 clinical trial exploiting blood-based identification of RAS/BRAF/EGFR mutations levels to tailor a chemotherapy-free anti-EGFR rechallenge with panitumumab (ClinicalTrials.gov: ; EudraCT 2016-002597-12). The primary endpoint was objective response rate. Secondary endpoints were progression-free survival, overall survival, safety and tolerability of this strategy. In CHRONOS, patients with tissue-RAS WT tumors after a previous treatment with anti-EGFR-based regimens underwent an interventional ctDNA-based screening. Of 52 patients, 16 (31%) carried at least one mutation conferring resistance to anti-EGFR therapy and were excluded. The primary endpoint of the trial was met; and, of 27 enrolled patients, eight (30%) achieved partial response and 17 (63%) disease control, including two unconfirmed responses. These clinical results favorably compare with standard third-line treatments and show that interventional liquid biopsies can be effectively and safely exploited in a timely manner to guide anti-EGFR rechallenge therapy with panitumumab in patients with mCRC. Further larger and randomized trials are warranted to formally compare panitumumab rechallenge with standard-of-care therapies in this patient setting.	[Sartore-Bianchi, Andrea; Mauri, Gianluca; Vanzulli, Angelo; Siena, Salvatore] Univ Milano La Statale, Dept Oncol & Hematooncol, Milan, Italy; [Sartore-Bianchi, Andrea; Amatu, Alessio; Tosi, Federica; Siena, Salvatore] Grande Osped Metropolitano Niguarda, Dept Hematol Oncol & Mol Med, Milan, Italy; [Pietrantonio, Filippo; Manca, Paolo; Ambrosini, Margherita] Fdn IRCCS Ist Nazl Tumori, Med Oncol Dept, Milan, Italy; [Lonardi, Sara; Bergamo, Francesca; Daniel, Francesca] Veneto Inst Oncol IOV IRCCS Padua, Med Oncol Unit 1, Padua, Italy; [Mussolin, Benedetta; Rua, Francesco; Crisafulli, Giovanni; Bartolini, Alice; Fenocchio, Elisabetta; Marchio, Caterina; Berrino, Enrico; Sapino, Anna; Bardelli, Alberto] FPO IRCCS, Candiolo Canc Inst, Turin, Italy; [Crisafulli, Giovanni; Bardelli, Alberto] Univ Turin, Dept Oncol, Turin, Italy; [Mauri, Gianluca; Marsoni, Silvia] FIRC Inst Mol Oncol, IFOM, Milan, Italy; [Torri, Valter] Mario Negri Inst Pharmacol Res IRCCS, Milan, Italy; [Vanzulli, Angelo] Grande Osped Metropolitano Niguarda, Dept Serv, Milan, Italy; [Regge, Daniele] Univ Turin, Dept Surg Sci, Turin, Italy; [Regge, Daniele; Cappello, Giovanni] FPO IRCCS, Unit Radiol, Candiolo Canc Inst, Turin, Italy; [Marchio, Caterina; Berrino, Enrico; Sapino, Anna] Univ Turin, Dept Med Sci, Turin, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; IFOM - FIRC Institute of Molecular Oncology; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Bardelli, A (corresponding author), FPO IRCCS, Candiolo Canc Inst, Turin, Italy.; Bardelli, A (corresponding author), Univ Turin, Dept Oncol, Turin, Italy.	alberto.bardelli@unito.it	Crisafulli, Giovanni/AAB-6256-2019; Lonardi, Sara/F-4228-2014	Crisafulli, Giovanni/0000-0002-5511-1555; Lonardi, Sara/0000-0002-7593-8138; Berrino, Enrico/0000-0001-6728-5619; Fenocchio, Elisabetta/0000-0001-6679-0955; Rua, Francesco/0000-0002-4864-9904; Manca, Paolo/0000-0002-3813-6339	FONDAZIONE AIRC under 5 per Mille 2018 [21091]; AIRC under IG 2018 [21923]; European Research Council under the European Union 2020 research and innovation programme [101020342]; IMI [101007937]; International Accelerator Award, ACRCelerate; Cancer Research UK [A26825, A28223]; FC AECC [GEACC18004TAB]; AIRC [22795]; BiLiGeCT, Progetto PON [ARS01_00492]; Ministero della Salute Ricerca Corrente 2021-2022	FONDAZIONE AIRC under 5 per Mille 2018(Fondazione AIRC per la ricerca sul cancro); AIRC under IG 2018; European Research Council under the European Union 2020 research and innovation programme; IMI; International Accelerator Award, ACRCelerate; Cancer Research UK(Cancer Research UK); FC AECC; AIRC(Fondazione AIRC per la ricerca sul cancro); BiLiGeCT, Progetto PON; Ministero della Salute Ricerca Corrente 2021-2022	The research leading to these results received funding from: FONDAZIONE AIRC under 5 per Mille 2018 (ID 21091 program) (A.B., D.R., C.M., S.M. and S.S.); AIRC under IG 2018 (ID 21923 project) (A.B.); European Research Council under the European Union's Horizon 2020 research and innovation programme (grant agreement no. 101020342) (A.B.); IMI contract no. 101007937 PERSIST-SEQ (A.B.); International Accelerator Award, ACRCelerate, jointly funded by Cancer Research UK (A26825 and A28223), FC AECC (GEACC18004TAB) and AIRC (22795) (A.B.); BiLiGeCT, Progetto PON ARS01_00492 (A.B.); Ministero della Salute, Ricerca Corrente 2021-2022; Fondazione Oncologia Niguarda ONLUS; and Amgen that donated panitumumab for clinical use. We thank the patients and their families, all caregivers and the referring oncologists.	Ali M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15617; Alix-Panabieres C, 2020, NATURE, V579, pS9, DOI 10.1038/d41586-020-00844-5; Amatu A, 2019, ANN ONCOL, V30, pVIII5, DOI 10.1093/annonc/mdz383; Arena S, 2015, CLIN CANCER RES, V21, P2157, DOI 10.1158/1078-0432.CCR-14-2821; Argiles G, 2019, ESMO OPEN, V4, DOI 10.1136/esmoopen-2019-000495; Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558; Bertotti A, 2015, NATURE, V526, P263, DOI 10.1038/nature14969; Corti G, 2019, CLIN COLORECTAL CANC, V18, P91, DOI 10.1016/j.clcc.2019.02.008; Cremolini C, 2017, ANN ONCOL, V28, P3009, DOI 10.1093/annonc/mdx546; Cremolini C, 2019, JAMA ONCOL, V5, P343, DOI 10.1001/jamaoncol.2018.5080; Crisafulli G, 2019, ESMO OPEN, V4, DOI 10.1136/esmoopen-2019-000572; Di Nicolantonio F, 2021, NAT REV CLIN ONCOL, V18, P506, DOI 10.1038/s41571-021-00495-z; Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786; Downing A, 2017, GUT, V66, P89, DOI 10.1136/gutjnl-2015-311308; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X; Hindson BJ, 2011, ANAL CHEM, V83, P8604, DOI 10.1021/ac202028g; Ignatiadis M, 2021, NAT REV CLIN ONCOL, V18, P297, DOI 10.1038/s41571-020-00457-x; Kennedy SR, 2014, NAT PROTOC, V9, P2586, DOI 10.1038/nprot.2014.170; Khan KH, 2018, CANCER DISCOV, V8, P1270, DOI 10.1158/2159-8290.CD-17-0891; Martinelli E, 2021, JAMA ONCOL, V7, P1529, DOI 10.1001/jamaoncol.2021.2915; Mauri G, 2020, CANCER TREAT REV, V91, DOI 10.1016/j.ctrv.2020.102112; Mauri G, 2019, CANCER TREAT REV, V73, P41, DOI 10.1016/j.ctrv.2018.12.006; Mayer RJ, 2015, NEW ENGL J MED, V372, P1909, DOI 10.1056/NEJMoa1414325; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Modest DP, 2019, EUR J CANCER, V109, P70, DOI 10.1016/j.ejca.2018.12.019; Montagut C, 2018, JAMA ONCOL, V4, DOI 10.1001/jamaoncol.2017.5245; Morelli MP, 2015, ANN ONCOL, V26, P731, DOI 10.1093/annonc/mdv005; Moretto R, 2021, CLIN COLORECTAL CANC, V20, P314, DOI 10.1016/j.clcc.2021.07.001; National Comprehensive Cancer Network, 2016, NCCN CLIN PRACTICE G; Parikh AR, 2019, NAT MED, V25, P1415, DOI 10.1038/s41591-019-0561-9; Parseghian CM, 2019, ANN ONCOL, V30, P243, DOI 10.1093/annonc/mdy509; Rossini D, 2020, CLIN COLORECTAL CANC, V19, P191, DOI 10.1016/j.clcc.2020.03.009; Russo M, 2016, CANCER DISCOV, V6, P147, DOI 10.1158/2159-8290.CD-15-1283; Sartore-Bianchi A, 2019, ONCOLOGIST, V24, P1395, DOI 10.1634/theoncologist.2018-0785; Sartore-Bianchi A, 2009, CANCER RES, V69, P1851, DOI 10.1158/0008-5472.CAN-08-2466; Schmitt MW, 2012, P NATL ACAD SCI USA, V109, P14508, DOI 10.1073/pnas.1208715109; Siegel Rebecca L, 2019, CA Cancer J Clin, V69, P7, DOI 10.3322/caac.21551; Siena S, 2021, ANN ONCOL, V32, pS532, DOI 10.1016/j.annonc.2021.08.908; Siena S, 2018, ANN ONCOL, V29, P119, DOI 10.1093/annonc/mdx504; Siena S, 2020, CANCER CELL, V38, P317, DOI 10.1016/j.ccell.2020.07.012; Siravegna G, 2017, NAT REV CLIN ONCOL, V14, P531, DOI 10.1038/nrclinonc.2017.14; Siravegna G, 2016, MOL ONCOL, V10, P475, DOI 10.1016/j.molonc.2015.12.005; Siravegna G, 2015, NAT MED, V21, P795, DOI 10.1038/nm.3870; Strickler JH, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.3_suppl.TPS143; Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660; Thierry AR, 2017, CLIN CANCER RES, V23, P4578, DOI 10.1158/1078-0432.CCR-17-0232; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053; Yoshino T, 2018, ANN ONCOL, V29, P44, DOI 10.1093/annonc/mdx738	49	5	5	3	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01886-0	http://dx.doi.org/10.1038/s41591-022-01886-0		AUG 2022	18	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3L4UI	35915157	Green Published, hybrid			2022-12-27	WOS:000834757100002
J	Morgan, OW; Abdelmalik, P; Perez-Gutierrez, E; Fall, IS; Kato, M; Hamblion, E; Matsui, T; Nabeth, P; Pebody, R; Pukkila, J; Stephan, M; Ihekweazu, C				Morgan, Oliver W.; Abdelmalik, Philip; Perez-Gutierrez, Enrique; Fall, Ibrahima Soce; Kato, Masaya; Hamblion, Esther; Matsui, Tamano; Nabeth, Pierre; Pebody, Richard; Pukkila, Jukka; Stephan, Mary; Ihekweazu, Chikwe			How better pandemic and epidemic intelligence will prepare the world for future threats comment	NATURE MEDICINE			English	Editorial Material; Early Access							EVENT-BASED SURVEILLANCE; DISEASE	A new approach to pandemic and epidemic intelligence is needed that includes modern approaches to surveillance and risk assessment, as well as improved trust and cooperation between stakeholders and society.	[Morgan, Oliver W.; Abdelmalik, Philip; Ihekweazu, Chikwe] WHO Hlth Emergencies Programme, WHO Hub Pandem & Epidem Intelligence, Berlin, Germany; [Perez-Gutierrez, Enrique] WHO, Reg Off Amer, Washington, DC USA; [Fall, Ibrahima Soce; Hamblion, Esther] WHO Hlth Emergencies Programme, Div Emergency Response, Geneva, Switzerland; [Kato, Masaya] WHO, Reg Off South East Asia, New Delhi, India; [Matsui, Tamano] WHO, Reg Off Western Pacific, Manila, Philippines; [Nabeth, Pierre] WHO, Reg Off Eastern Mediterranean, Cairo, Egypt; [Pebody, Richard; Pukkila, Jukka] WHO, Reg Off Europe, Copenhagen, Denmark; [Stephan, Mary] WHO, Reg Off Africa, Brazzaville, Rep Congo	World Health Organization; World Health Organization; WHO Western Pacific Regional Office; World Health Organization; Egyptian Knowledge Bank (EKB); World Health Organization Egypt; World Health Organization; World Health Organization; World Health Organization	Morgan, OW (corresponding author), WHO Hlth Emergencies Programme, WHO Hub Pandem & Epidem Intelligence, Berlin, Germany.	omorgan@who.int	Nabeth, Pierre/AAI-9461-2021; AbdelMalik, Philip/C-8525-2017	Nabeth, Pierre/0000-0002-1567-6252; Morgan, Oliver/0000-0002-9543-3778; AbdelMalik, Philip/0000-0002-7984-2088; Perez Gutierrez, Enrique/0000-0002-7730-899X; Pebody, Richard/0000-0002-9069-2885				Balajee S, 2021, GLOB SECU, V6, P1, DOI [10.1080/23779497.2020.1848444, DOI 10.1080/23779497.2020.1848444]; Beebeejaun K, 2021, EMERG INFECT DIS, V27, P694, DOI 10.3201/eid2703.200141; Brownstein JS, 2008, PLOS MED, V5, P1019, DOI 10.1371/journal.pmed.0050151; Budd J, 2020, NAT MED, V26, P1183, DOI 10.1038/s41591-020-1011-4; Do H, 2020, WEST PAC SURVEILL RE, V11, DOI 10.5365/wpsar.2019.10.1.009; Kaiser R, 2006, EUROSURVEILLANCE, V11; Kostkova Patty, 2021, Front Digit Health, V3, P707902, DOI 10.3389/fdgth.2021.707902; Mikanatha NM, 2013, INFECTIOUS DISEASE SURVEILLANCE, 2ND EDITION, P1, DOI 10.1002/9781118543504; Moritz UG, 2022, LANCET GLOB HEALTH, DOI [10.1016/S1473-3099(22)00359-0, DOI 10.1016/S1473-3099(22)00359-0]; Ratnayake R, 2016, EMERG INFECT DIS, V22, P1431, DOI 10.3201/eid2208.160205; Salathe M, 2018, LIFE SCI SOC POLICY, V14, DOI 10.1186/s40504-017-0065-7; Smolinski Mark S, 2017, JMIR Public Health Surveill, V3, pe62, DOI 10.2196/publichealth.7540; Smolinski MS, 2015, AM J PUBLIC HEALTH, V105, P2124, DOI 10.2105/AJPH.2015.302696; Wojcik OP, 2014, EMERG THEMES EPIDEMI, V11, DOI 10.1186/1742-7622-11-7	14	1	1	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01900-5	http://dx.doi.org/10.1038/s41591-022-01900-5		JUN 2022	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2M7EB	35764683	Green Published, Bronze			2022-12-27	WOS:000817857400002
J	Harrison, SA; Manghi, FP; Smith, WB; Alpenidze, D; Aizenberg, D; Klarenbeek, N; Chen, CY; Zuckerman, E; Ravussin, E; Charatcharoenwitthaya, P; Cheng, PN; Katchman, H; Klein, S; Ben-Ari, Z; Mendonza, AE; Zhang, YM; Martic, M; Ma, SL; Kao, S; Tanner, S; Pachori, A; Badman, MK; He, YL; Ukomadu, C; Sicard, E				Harrison, Stephen A.; Manghi, Federico Perez; Smith, William B.; Alpenidze, Diana; Aizenberg, Diego; Klarenbeek, Naomi; Chen, Chi-Yi; Zuckerman, Eli; Ravussin, Eric; Charatcharoenwitthaya, Phunchai; Cheng, Pin-Nan; Katchman, Helena; Klein, Samuel; Ben-Ari, Ziv; Mendonza, Anisha E.; Zhang, Yiming; Martic, Miljen; Ma, Shenglin; Kao, Sheena; Tanner, Sandra; Pachori, Alok; Badman, Michael K.; He, YanLing; Ukomadu, Chinweike; Sicard, Eric			Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study	NATURE MEDICINE			English	Article							TYPE-2 DIABETES-MELLITUS; LIFE-STYLE MODIFICATION; CANAGLIFLOZIN; MANAGEMENT; INHIBITORS; EFFICACY; SAFETY	In a phase 2a clinical trial in patients with nonalcoholic steatohepatitis, dual inhibition of sodium-glucose cotransporters 1 and 2 with 150 mg of licogliflozin led to reductions in serum alanine aminotranferase levels. Nonalcoholic steatohepatitis (NASH) is a common chronic liver disease that may advance to fibrosis and lead to mortality; however, no pharmacotherapy is currently available. We tested the hypothesis that inhibition of both the sodium-glucose cotransporters 1 and 2 with licogliflozin would lead to improvement in NASH. A total of 107 patients with phenotypic or histologic NASH were randomized (1:2:2) to receive oral administration of either placebo (n = 21), licogliflozin 30 mg (n = 43) or 150 mg (n = 43) once daily for 12 weeks. Licogliflozin 150 mg showed a significant 32% (80% confidence interval (CI): 21-43%; P = 0.002) placebo-adjusted reduction in serum alanine aminotransferase after 12 weeks of treatment, the primary endpoint of the study. However, the 30 mg dose of licogliflozin did not meet the primary endpoint (placebo-adjusted reduction 21% (80% CI: 7-32%; P = 0.061)). Diarrhea occurred in 77% (33 of 43), 49% (21 of 43) and 43% (9 of 21) of patients treated with licogliflozin 150 mg, 30 mg and placebo, respectively, which was mostly mild in severity. No other major safety concerns were identified. Treatment with 150 mg licogliflozin led to reductions in serum alanine aminotransferase in patients with NASH. Studies of longer duration and in combination with drugs that have different mechanisms of action are needed to validate these findings and to define a role of licogliflozin as a therapeutic option for NASH. ClinicalTrials.gov identifier: NCT03205150.	[Harrison, Stephen A.] Pinnacle Clin Res, San Antonio, TX 78229 USA; [Manghi, Federico Perez] CINME, Buenos Aires, DF, Argentina; [Smith, William B.] Univ Tennessee, Med Ctr, Alliance Multispecialty Res, Knoxville, TN USA; [Alpenidze, Diana] City Outpatient Clin 117, St Petersburg, Russia; [Aizenberg, Diego] Ctr Med Viamonte, Buenos Aires, DF, Argentina; [Klarenbeek, Naomi] Ctr Human Drug Res, Leiden, Netherlands; [Chen, Chi-Yi] Chia Yi Christian Hosp, Chiayi, Taiwan; [Zuckerman, Eli] Carmel Hosp, Haifa, Israel; [Ravussin, Eric] Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA; [Charatcharoenwitthaya, Phunchai] Siriraj Hosp, Bangkok, Thailand; [Cheng, Pin-Nan] Natl Cheng Kung Univ Hosp, Tainan, Taiwan; [Katchman, Helena] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel; [Klein, Samuel] Washington Univ, Sch Med, St Louis, MO USA; [Ben-Ari, Ziv] Sheba Med Ctr, Ramat Gan, Israel; [Mendonza, Anisha E.; Ma, Shenglin; Pachori, Alok; Badman, Michael K.; He, YanLing; Ukomadu, Chinweike] Novartis Inst BioMed Res, Cambridge, MA USA; [Zhang, Yiming] Novartis Pharmaceut, E Hanover, NJ USA; [Martic, Miljen; Tanner, Sandra] Novartis Inst BioMed Res, Basel, Switzerland; [Kao, Sheena] Novartis Inst BioMed Res, Pudong Shanghai, Peoples R China; [Sicard, Eric] Altasci Algorithme Pharma, Montreal, PQ, Canada	University of Tennessee System; University of Tennessee Health Science Center; Clalit Health Services; Carmel Medical Center; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Mahidol University; National Cheng Kung University; National Cheng Kung University Hospital; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Washington University (WUSTL); Chaim Sheba Medical Center; Novartis; Novartis; Novartis	Harrison, SA (corresponding author), Pinnacle Clin Res, San Antonio, TX 78229 USA.	sharrison@pinnacleresearch.com	Zhang, Yiming/HGB-7344-2022	Ravussin, Eric/0000-0003-2129-547X; Martic, Miljen/0000-0002-0166-5421; Harrison, Stephen/0000-0001-8285-2204	Novartis Institutes for BioMedical Research, Cambridge, MA, USA; Good Publication Practice (GPP3) guidelines	Novartis Institutes for BioMedical Research, Cambridge, MA, USA; Good Publication Practice (GPP3) guidelines	We thank the patients for their participation in the study. The senior scientific writers, S. Kaur, Z. Birajdar and A. Meka of Novartis, provided medical writing and editorial support, which was funded by Novartis Institutes for BioMedical Research, Cambridge, MA, USA, in accordance with Good Publication Practice (GPP3) guidelines (http://www. ismpp.org/gpp3). The study and these analyses were funded by Novartis Institutes for BioMedical Research, Cambridge, MA, USA, which was the sponsor of the study.	Bays HE, 2020, OBESITY, V28, P870, DOI 10.1002/oby.22764; Chalasani N, 2018, HEPATOLOGY, V67, P328, DOI 10.1002/hep.29367; EASL, 2016, DIABETOLOGIA, V59, P1121, DOI 10.1007/s00125-016-3902-y; Eriksson JW, 2018, DIABETOLOGIA, V61, P1923, DOI 10.1007/s00125-018-4675-2; Friedman SL, 2018, NAT MED, V24, P908, DOI 10.1038/s41591-018-0104-9; Hallsworth K, 2019, JHEP REP, V1, P468, DOI 10.1016/j.jhepr.2019.10.008; Harrison SA, 2019, LANCET, V394, P2012, DOI 10.1016/S0140-6736(19)32517-6; Harrison SA, 2018, LANCET, V391, P1174, DOI 10.1016/S0140-6736(18)30474-4; He YL, 2019, DIABETES OBES METAB, V21, P1311, DOI 10.1111/dom.13654; He YL, 2020, CLIN PHARMACOL THER, V108, P995, DOI 10.1002/cpt.1840; Hsiang JC, 2020, CLIN GASTROENTEROL H, V18, P2168, DOI 10.1016/j.cgh.2020.05.021; Kuchay MS, 2018, DIABETES CARE, V41, P1801, DOI 10.2337/dc18-0165; Lassailly G, 2020, GASTROENTEROLOGY, V159, P1290, DOI 10.1053/j.gastro.2020.06.006; Lawitz EJ, 2018, CLIN GASTROENTEROL H, V16, P1983, DOI 10.1016/j.cgh.2018.04.042; Loomba R, 2018, GASTROENTEROLOGY, V155, P1463, DOI 10.1053/j.gastro.2018.07.027; Mashhood A, 2013, J MAGN RESON IMAGING, V37, P1359, DOI 10.1002/jmri.23928; Neuschwander-Tetri BA, 2015, LANCET, V385, P956, DOI 10.1016/S0140-6736(14)61933-4; Poulsen SB, 2015, CURR OPIN NEPHROL HY, V24, P463, DOI 10.1097/MNH.0000000000000152; Raj H, 2019, WORLD J DIABETES, V10, P114, DOI 10.4239/wjd.v10.i2.114; Seko Y, 2018, DIABET METAB SYND OB, V11, P835, DOI 10.2147/DMSO.S184767; Shimizu M, 2019, DIABETES OBES METAB, V21, P285, DOI 10.1111/dom.13520; Smith GI, 2020, J CLIN INVEST, V130, P1453, DOI 10.1172/JCI134165; Stenlof K, 2013, DIABETES OBES METAB, V15, P372, DOI 10.1111/dom.12054; Taheri H, 2020, ADV THER, V37, P4697, DOI 10.1007/s12325-020-01498-5; Vilar-Gomez E, 2015, GASTROENTEROLOGY, V149, P367, DOI 10.1053/j.gastro.2015.04.005; Williams CD, 2011, GASTROENTEROLOGY, V140, P124, DOI 10.1053/j.gastro.2010.09.038; Wong VWS, 2016, LANCET GASTROENTEROL, V1, P56, DOI 10.1016/S2468-1253(16)30011-5; Xie QS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092772; Yokoo T, 2011, RADIOLOGY, V258, P749, DOI 10.1148/radiol.10100659; Yokoo T, 2009, RADIOLOGY, V251, P67, DOI 10.1148/radiol.2511080666; Younossi Z, 2018, NAT REV GASTRO HEPAT, V15, P11, DOI 10.1038/nrgastro.2017.109; Younossi ZM, 2019, J HEPATOL, V70, P531, DOI 10.1016/j.jhep.2018.10.033	32	1	1	6	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2022	28	7					1432	+		10.1038/s41591-022-01861-9	http://dx.doi.org/10.1038/s41591-022-01861-9		JUN 2022	22	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3E5PS	35725922				2022-12-27	WOS:000813559100002
J	Garriga, R; Matic, A				Garriga, Roger; Matic, Aleksandar			Machine learning paves the way toward the prevention of mental health crises	NATURE MEDICINE			English	Editorial Material								Experiencing a mental health crisis has a detrimental impact on a patient's life. A machine learning algorithm trained retrospectively with electronic health records can predict almost 60% of mental health crises 4 weeks in advance. Prospective evaluation of the algorithm in clinical practice reveals its potential to enable preemptive interventions.	[Garriga, Roger; Matic, Aleksandar] Koa Hlth, Barcelona, Spain		Garriga, R (corresponding author), Koa Hlth, Barcelona, Spain.							Horwitz LI, 2019, NEW ENGL J MED, V381, P1175, DOI 10.1056/NEJMsb1900856; Miller V., 1991, AUST OCCUP THER J, V38, P143, DOI [10.1111/j.1440-1630.1991.tb01710.x, DOI 10.1111/J.1440-1630.1991.TB01710.X]; Paton F, 2016, HEALTH TECHNOL ASSES, V20, P1, DOI 10.3310/hta20030	3	0	0	2	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2022	28	6					1135	1136		10.1038/s41591-022-01820-4	http://dx.doi.org/10.1038/s41591-022-01820-4			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E9IE	35585331				2022-12-27	WOS:000812533400016
J	Al-Aly, Z; Bowe, B; Xie, Y				Al-Aly, Ziyad; Bowe, Benjamin; Xie, Yan			Long COVID after breakthrough SARS-CoV-2 infection	NATURE REVIEWS IMMUNOLOGY			English	Article								A new analysis using the US Department of Veterans Affairs national healthcare databases demonstrates that Long COVID can occur after breakthrough SARS-CoV-2 infection; however, the risk of death attributable to COVID and incidence of post-acute sequelae were substantially reduced (but not fully eliminated) compared to unvaccinated individuals. The post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection-also referred to as Long COVID-have been described, but whether breakthrough SARS-CoV-2 infection (BTI) in vaccinated people results in post-acute sequelae is not clear. In this study, we used the US Department of Veterans Affairs national healthcare databases to build a cohort of 33,940 individuals with BTI and several controls of people without evidence of SARS-CoV-2 infection, including contemporary (n = 4,983,491), historical (n = 5,785,273) and vaccinated (n = 2,566,369) controls. At 6 months after infection, we show that, beyond the first 30 days of illness, compared to contemporary controls, people with BTI exhibited a higher risk of death (hazard ratio (HR) = 1.75, 95% confidence interval (CI): 1.59, 1.93) and incident post-acute sequelae (HR = 1.50, 95% CI: 1.46, 1.54), including cardiovascular, coagulation and hematologic, gastrointestinal, kidney, mental health, metabolic, musculoskeletal and neurologic disorders. The results were consistent in comparisons versus the historical and vaccinated controls. Compared to people with SARS-CoV-2 infection who were not previously vaccinated (n = 113,474), people with BTI exhibited lower risks of death (HR = 0.66, 95% CI: 0.58, 0.74) and incident post-acute sequelae (HR = 0.85, 95% CI: 0.82, 0.89). Altogether, the findings suggest that vaccination before infection confers only partial protection in the post-acute phase of the disease; hence, reliance on it as a sole mitigation strategy may not optimally reduce long-term health consequences of SARS-CoV-2 infection. The findings emphasize the need for continued optimization of strategies for primary prevention of BTI and will guide development of post-acute care pathways for people with BTI.	[Al-Aly, Ziyad; Bowe, Benjamin; Xie, Yan] VA St Louis Hlth Care Syst, Clin Epidemiol Ctr Res & Dev Serv, St Louis, MO 63106 USA; [Al-Aly, Ziyad; Bowe, Benjamin; Xie, Yan] Vet Res & Educ Fdn St Louis, St Louis, MO 63103 USA; [Al-Aly, Ziyad] Washington Univ, Dept Med, Sch Med, St Louis, MO 63110 USA; [Al-Aly, Ziyad] VA St Louis Hlth Care Syst, Nephrol Sect, Med Serv, St Louis, MO 63106 USA; [Al-Aly, Ziyad] Washington Univ St Louis, Inst Publ Hlth, St Louis, MO 63110 USA; [Xie, Yan] St Louis Univ, Dept Epidemiol & Biostat, Coll Publ Hlth & Social Justice, St Louis, MO USA	Washington University (WUSTL); Washington University (WUSTL); Saint Louis University	Al-Aly, Z (corresponding author), VA St Louis Hlth Care Syst, Clin Epidemiol Ctr Res & Dev Serv, St Louis, MO 63106 USA.; Al-Aly, Z (corresponding author), Vet Res & Educ Fdn St Louis, St Louis, MO 63103 USA.; Al-Aly, Z (corresponding author), Washington Univ, Dept Med, Sch Med, St Louis, MO 63110 USA.; Al-Aly, Z (corresponding author), VA St Louis Hlth Care Syst, Nephrol Sect, Med Serv, St Louis, MO 63106 USA.; Al-Aly, Z (corresponding author), Washington Univ St Louis, Inst Publ Hlth, St Louis, MO 63110 USA.	zalaly@gmail.com	; Al-Aly, Ziyad/S-4439-2016	Xie, Yan/0000-0002-2457-9382; Al-Aly, Ziyad/0000-0002-2600-0434	US Department of Veterans Affairs; American Society of Nephrology and KidneyCure fellowship awards	US Department of Veterans Affairs(US Department of Veterans Affairs); American Society of Nephrology and KidneyCure fellowship awards	This study used data from the VA COVID-19 Shared Data Resource. This research was funded by the US Department of Veterans Affairs (Z.A.-A.) and two American Society of Nephrology and KidneyCure fellowship awards (B.B. and Y.X.). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. The contents do not represent the views of the US Department of Veterans Affairs or the US government.	Agency for Healthcare Research and Quality, HEALTHC COST UT PROJ; Al-Aly Z, 2021, NATURE, V594, P259, DOI 10.1038/s41586-021-03553-9; Alwan NA, 2021, SCIENCE, V373, P491, DOI 10.1126/science.abg7113; Aubert Carole E, 2020, Mayo Clin Proc Innov Qual Outcomes, V4, P40, DOI 10.1016/j.mayocpiqo.2019.09.002; Ayoubkhani D, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n693; Bowe B, 2021, J AM SOC NEPHROL, V32, P2851, DOI 10.1681/ASN.2021060734; Bowe B, 2021, CLIN J AM SOC NEPHRO, V16, P14, DOI 10.2215/CJN.09610620; Bowe B, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.15834; Cai M, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-047369; Cai M, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.33953; Carfi A, 2020, JAMA-J AM MED ASSOC, V324, P603, DOI 10.1001/jama.2020.12603; Daugherty SE, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1098; Davis HE, 2021, ECLINICALMEDICINE, V38, DOI 10.1016/j.eclinm.2021.101019; Greene M, 2014, J AM GERIATR SOC, V62, P447, DOI 10.1111/jgs.12695; Hacisuleyman E, 2021, NEW ENGL J MED, V384, P2212, DOI [10.1056/NEJMoa2105000, 10.1056/NEJMc2107808]; Juthani PV, 2021, LANCET INFECT DIS, V21, P1485, DOI 10.1016/S1473-3099(21)00558-2; Kind AJH, 2018, NEW ENGL J MED, V378, P2456, DOI 10.1056/NEJMp1802313; Li F, 2019, AM J EPIDEMIOL, V188, P250, DOI 10.1093/aje/kwy201; Lipsitch M, 2010, EPIDEMIOLOGY, V21, P383, DOI 10.1097/EDE.0b013e3181d61eeb; Nalbandian A, 2021, NAT MED, V27, P601, DOI 10.1038/s41591-021-01283-z; Olvey EL, 2010, CLIN PHARMACOL THER, V87, P48, DOI 10.1038/clpt.2009.198; Schneeweiss S, 2009, EPIDEMIOLOGY, V20, P512, DOI 10.1097/EDE.0b013e3181a663cc; Sharma A., 2021, PREPRINT, DOI [10.1101/2021.09.23.21263864v1, DOI 10.1101/2021.09.23.21263864V1]; Shi X, 2020, CURR EPIDEMIOL REP, V7, P190, DOI 10.1007/s40471-020-00243-4; Spudich S, 2022, SCIENCE, V375, P267, DOI 10.1126/science.abm2052; Taquet M, 2021, PLOS MED, V18, DOI 10.1371/journal.pmed.1003773; Taquet M, 2021, LANCET PSYCHIAT, V8, P416, DOI 10.1016/S2215-0366(21)00084-5; Thomas LE, 2020, JAMA-J AM MED ASSOC, V323, P2417, DOI 10.1001/jama.2020.7819; Wei YG, 2019, BMJ-BRIT MED J, V367, DOI 10.1136/bmj.l6258; Xie Y, 2022, LANCET DIABETES ENDO, V10, P311, DOI 10.1016/S2213-8587(22)00044-4; Xie Y, 2022, BMJ-BRIT MED J, V376, DOI 10.1136/bmj-2021-068993; Xie Y, 2022, NAT MED, V28, P583, DOI 10.1038/s41591-022-01689-3; Xie Y, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26513-3; Xie Y, 2021, JAMA INTERN MED, V181, P1043, DOI 10.1001/jamainternmed.2021.2488; Xie Y, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4677; Xie Y, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l1580	36	64	65	37	42	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1474-1733	1474-1741		NAT REV IMMUNOL	Nat. Rev. Immunol.	JUL	2022	22	7					410	410		10.1038/s41591-022-01840-0	http://dx.doi.org/10.1038/s41591-022-01840-0		MAY 2022	1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2P0EH	35614233	Green Submitted, Green Published, hybrid			2022-12-27	WOS:000802311300001
J	Bar-Zeev, Y				Bar-Zeev, Yael			Unclear role for e-cigarettes during pregnancy	NATURE MEDICINE			English	Editorial Material							ELECTRONIC CIGARETTES; SMOKING-CESSATION	Electronic cigarettes might be superior to nicotine replacement therapy as a quitting aid for pregnant women - but enthusiasm is hampered by low rates of smoking cessation and unknown long-term harm.	[Bar-Zeev, Yael] Hebrew Univ Jerusalem, Hadassah Med Ctr, Fac Hlth, Braun Sch Publ Hlth & Community Med, Jerusalem, Israel	Hebrew University of Jerusalem; Hadassah University Medical Center	Bar-Zeev, Y (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Ctr, Fac Hlth, Braun Sch Publ Hlth & Community Med, Jerusalem, Israel.	Yael.Bar-Zeev@mail.huji.ac.il	Bar-Zeev, Yael/B-4198-2017	Bar-Zeev, Yael/0000-0002-1916-836X				Bar-Zeev Y, 2018, MED J AUSTRALIA, V208, P46, DOI 10.5694/mja17.00446; Claire R, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010078.pub3; Goniewicz ML, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.5937; Hajek P, 2022, NAT MED, V28, P958, DOI 10.1038/s41591-022-01808-0; Hartmann-Boyce J, 2016, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD010216.pub3, 10.1002/14651858.CD010216.pub4]; Krist AH, 2021, JAMA-J AM MED ASSOC, V325, P265, DOI 10.1001/jama.2020.25019; Lauterstein DE, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13040417; Li G, 2018, TOXICS, V6, DOI 10.3390/toxics6030043; McCubbin A, 2017, HEALTH EDUC RES, V32, P22, DOI 10.1093/her/cyw059; Pierce JP, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.28810; Scherman A, 2018, THER ADV DRUG SAF, V9, P457, DOI 10.1177/2042098618775366; Snell LM, 2020, J STUD ALCOHOL DRUGS, V81, P595, DOI 10.15288/jsad.2020.81.595	12	0	0	1	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2022	28	5					900	901		10.1038/s41591-022-01795-2	http://dx.doi.org/10.1038/s41591-022-01795-2		MAY 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	1J3AM	35577965				2022-12-27	WOS:000796324500001
J	Saldanha, OL; Quirke, P; West, NP; James, JA; Loughrey, MB; Grabsch, HI; Salto-Tellez, M; Alwers, E; Cifci, D; Laleh, NG; Seibel, T; Gray, R; Hutchins, GGA; Brenner, H; van Treeck, M; Yuan, TW; Brinker, TJ; Chang-Claude, J; Khader, F; Schuppert, A; Luedde, T; Trautwein, C; Muti, HS; Foersch, S; Hoffmeister, M; Truhn, D; Kather, JN				Saldanha, Oliver Lester; Quirke, Philip; West, Nicholas P.; James, Jacqueline A.; Loughrey, Maurice B.; Grabsch, Heike, I; Salto-Tellez, Manuel; Alwers, Elizabeth; Cifci, Didem; Laleh, Narmin Ghaffari; Seibel, Tobias; Gray, Richard; Hutchins, Gordon G. A.; Brenner, Hermann; van Treeck, Marko; Yuan, Tanwei; Brinker, Titus J.; Chang-Claude, Jenny; Khader, Firas; Schuppert, Andreas; Luedde, Tom; Trautwein, Christian; Muti, Hannah Sophie; Foersch, Sebastian; Hoffmeister, Michael; Truhn, Daniel; Kather, Jakob Nikolas			Swarm learning for decentralized artificial intelligence in cancer histopathology	NATURE MEDICINE			English	Article							COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; COLONOSCOPY; RISK	A decentralized, privacy-preserving machine learning framework used to train a clinically relevant AI system identifies actionable molecular alterations in patients with colorectal cancer by use of routine histopathology slides collected in real-world settings. Artificial intelligence (AI) can predict the presence of molecular alterations directly from routine histopathology slides. However, training robust AI systems requires large datasets for which data collection faces practical, ethical and legal obstacles. These obstacles could be overcome with swarm learning (SL), in which partners jointly train AI models while avoiding data transfer and monopolistic data governance. Here, we demonstrate the successful use of SL in large, multicentric datasets of gigapixel histopathology images from over 5,000 patients. We show that AI models trained using SL can predict BRAF mutational status and microsatellite instability directly from hematoxylin and eosin (H&E)-stained pathology slides of colorectal cancer. We trained AI models on three patient cohorts from Northern Ireland, Germany and the United States, and validated the prediction performance in two independent datasets from the United Kingdom. Our data show that SL-trained AI models outperform most locally trained models, and perform on par with models that are trained on the merged datasets. In addition, we show that SL-based AI models are data efficient. In the future, SL can be used to train distributed AI models for any histopathology image analysis task, eliminating the need for data transfer.	[Saldanha, Oliver Lester; Cifci, Didem; Laleh, Narmin Ghaffari; Seibel, Tobias; van Treeck, Marko; Trautwein, Christian; Muti, Hannah Sophie; Kather, Jakob Nikolas] Univ Hosp RWTH Aachen, Dept Med 3, Aachen, Germany; [Quirke, Philip; West, Nicholas P.; Grabsch, Heike, I; Hutchins, Gordon G. A.; Kather, Jakob Nikolas] Univ Leeds, Leeds Inst Med Res St James, Pathol & Data Analyt, Leeds, W Yorkshire, England; [James, Jacqueline A.; Salto-Tellez, Manuel] Queens Univ Belfast, Patrick G Johnston Ctr Canc Res, Hlth Sci Bldg, Precis Med Ctr Excellence, Belfast, Antrim, North Ireland; [James, Jacqueline A.; Salto-Tellez, Manuel] Belfast Hlth & Social Care Trust, Reg Mol Diagnost Serv, Belfast, Antrim, North Ireland; [James, Jacqueline A.; Loughrey, Maurice B.; Salto-Tellez, Manuel] Queens Univ Belfast, Patrick G Johnston Ctr Canc Res, Belfast, Antrim, North Ireland; [Loughrey, Maurice B.] Belfast Hlth & Social Care Trust, Dept Cellular Pathol, Belfast, Antrim, North Ireland; [Loughrey, Maurice B.] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland; [Grabsch, Heike, I] Maastricht Univ, Med Ctr, Dept Pathol, Maastricht, Netherlands; [Grabsch, Heike, I] Maastricht Univ, Med Ctr, GROW Sch Oncol & Reprod, Maastricht, Netherlands; [Alwers, Elizabeth; Brenner, Hermann; Yuan, Tanwei; Hoffmeister, Michael] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany; [Gray, Richard] Univ Oxford, Nuffield Dept Populat Hlth, Clin Trial Serv Unit, Oxford, England; [Brenner, Hermann] German Canc Res Ctr, Div Prevent Oncol, Heidelberg, Germany; [Brenner, Hermann] Natl Ctr Tumor Dis NCT, Heidelberg, Germany; [Brenner, Hermann] German Canc Res Ctr, German Canc Consortium DKTK, Heidelberg, Germany; [Brinker, Titus J.] German Canc Res Ctr, Natl Ctr Tumor Dis NCT, Digital Biomarkers Oncol Grp DBO, Heidelberg, Germany; [Chang-Claude, Jenny] German Canc Res Ctr, Div Canc Epidemiol, Heidelberg, Germany; [Chang-Claude, Jenny] Univ Med Ctr Hamburg Eppendorf, Univ Canc Ctr Hamburg, Canc Epidemiol Grp, Hamburg, Germany; [Khader, Firas; Truhn, Daniel] Univ Hosp RWTH Aachen, Dept Diagnost & Intervent Radiol, Aachen, Germany; [Schuppert, Andreas] Rhein Westfal TH Aachen, Univ Hosp Aachen, Inst Computat Biomed, JRC Computat Biomed, Aachen, Germany; [Luedde, Tom] Heinrich Heine Univ Dusseldorf, Univ Hosp Dusseldorf, Med Fac, Dept Gastroenterol Hepatol & Infect Dis, Dusseldorf, Germany; [Foersch, Sebastian] Univ Med Ctr Mainz, Inst Pathol, Mainz, Germany; [Kather, Jakob Nikolas] Univ Hosp Heidelberg, Natl Ctr Tumor Dis NCT, Med Oncol, Heidelberg, Germany	RWTH Aachen University; RWTH Aachen University Hospital; University of Leeds; Queens University Belfast; Queens University Belfast; Queens University Belfast; Maastricht University; Maastricht University; Helmholtz Association; German Cancer Research Center (DKFZ); University of Oxford; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); University of Hamburg; University Medical Center Hamburg-Eppendorf; RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; Johannes Gutenberg University of Mainz; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Kather, JN (corresponding author), Univ Hosp RWTH Aachen, Dept Med 3, Aachen, Germany.; Kather, JN (corresponding author), Univ Leeds, Leeds Inst Med Res St James, Pathol & Data Analyt, Leeds, W Yorkshire, England.; Kather, JN (corresponding author), Univ Hosp Heidelberg, Natl Ctr Tumor Dis NCT, Med Oncol, Heidelberg, Germany.	jakob-nikolas.kather@alumni.dkfz.de	Luedde, Tom/AAE-9135-2022; Kather, Jakob Nikolas/D-4279-2015; Truhn, Daniel/AAG-9359-2021; Brenner, Hermann/ABE-6383-2020; Muti, Hannah/GQB-4044-2022	Luedde, Tom/0000-0002-6288-8821; Kather, Jakob Nikolas/0000-0002-3730-5348; Brenner, Hermann/0000-0002-6129-1572; Quirke, Philip/0000-0002-3597-5444; West, Nicholas/0000-0002-0346-6709; Cifci, Didem/0000-0002-2647-9959	Deutsches Krebsforschungszentrum (DKFZ)	Deutsches Krebsforschungszentrum (DKFZ)(Helmholtz Association)	Open access funding provided by Deutsches Krebsforschungszentrum (DKFZ).	Alwers E, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5842-7; Benjamens S, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-00324-0; Bilal M, 2021, LANCET DIGIT HEALTH, V3, pE763, DOI 10.1016/S2589-7500(21)00180-1; Binder A, 2021, NAT MACH INTELL, V3, P355, DOI 10.1038/s42256-021-00303-4; Boehm KM, 2022, NAT REV CANCER, V22, P114, DOI 10.1038/s41568-021-00408-3; Brenner H, 2006, GUT, V55, P1145, DOI [10.1136/gut.2005.087130, 10.1136/gut.2005087130]; Campanella G, 2019, NAT MED, V25, P1301, DOI 10.1038/s41591-019-0508-1; Carr PR, 2020, GASTROENTEROLOGY, V159, P129, DOI 10.1053/j.gastro.2020.03.016; Chen RJ, 2021, NAT BIOMED ENG, V5, P493, DOI 10.1038/s41551-021-00751-8; Coudray N, 2018, NAT MED, V24, P1559, DOI 10.1038/s41591-018-0177-5; Echle A., 2021, IMMUNOINFORMATICS, V3-4, DOI [DOI 10.1016/J.IMMUNO.2021.100008, 10.1016/j.immuno.2021.100008]; Echle A, 2021, BRIT J CANCER, V124, P686, DOI 10.1038/s41416-020-01122-x; Echle A, 2020, GASTROENTEROLOGY, V159, P1406, DOI 10.1053/j.gastro.2020.06.021; Elemento O, 2021, NAT REV CANCER, V21, P747, DOI 10.1038/s41568-021-00399-1; Findeisen P, 2005, CANCER RES, V65, P8072, DOI 10.1158/0008-5472.CAN-04-4146; Fu Y, 2020, NAT CANCER, V1, P800, DOI 10.1038/s43018-020-0085-8; Gray R, 2007, LANCET, V370, P2020, DOI 10.1016/s0140-6736(07)61866-2; Greenson JK, 2009, AM J SURG PATHOL, V33, P126, DOI 10.1097/PAS.0b013e31817ec2b1; Hoffmeister M, 2020, AM J GASTROENTEROL, V115, P2007, DOI 10.14309/ajg.0000000000000819; Howard FM, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24698-1; Hutchins G, 2011, J CLIN ONCOL, V29, P1261, DOI 10.1200/JCO.2010.30.1366; Jia M, 2016, BRIT J CANCER, V115, P1359, DOI 10.1038/bjc.2016.361; Kacew AJ, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.630953; Kaissis GA, 2020, NAT MACH INTELL, V2, P305, DOI 10.1038/s42256-020-0186-1; Kather JN, 2020, NAT REV GASTRO HEPAT, V17, P591, DOI 10.1038/s41575-020-0343-3; Kather JN, 2020, NAT CANCER, V1, P789, DOI 10.1038/s43018-020-0087-6; Kather JN, 2019, NAT MED, V25, P1054, DOI 10.1038/s41591-019-0462-y; Kleppe A, 2021, NAT REV CANCER, V21, P199, DOI 10.1038/s41568-020-00327-9; Konecn J, 2016, ARXIV PREPRINT ARXIV; Korkmaz C, 2020, 2020 SECOND INTERNATIONAL CONFERENCE ON BLOCKCHAIN COMPUTING AND APPLICATIONS (BCCA), P140, DOI 10.1109/BCCA50787.2020.9274451; Krause J, 2021, J PATHOL, V254, P70, DOI 10.1002/path.5638; Kundu S, 2021, NAT MED, V27, P1328, DOI 10.1038/s41591-021-01461-z; Laleh N. G., BENCHMARKING ARTIFIC, DOI [10.1101/2021.08.09.455633v1(2021, DOI 10.1101/2021.08.09.455633V1(2021]; Lewis CEA., 2018, OPEN J BIORESOUR, V5, P9, DOI [10.5334/ojb.47, DOI 10.5334/OJB.47]; Li YZ, 2021, IEEE NETWORK, V35, P234, DOI 10.1109/MNET.011.2000263; Loeffler CML, 2022, EUR UROL FOCUS, V8, P472, DOI 10.1016/j.euf.2021.04.007; Loughrey MB, 2021, HISTOPATHOLOGY, V78, P401, DOI 10.1111/his.14233; Lu MY, 2022, MED IMAGE ANAL, V76, DOI 10.1016/j.media.2021.102298; Lu MY, 2021, NATURE, V594, P106, DOI 10.1038/s41586-021-03512-4; Macenko M, 2009, I S BIOMED IMAGING, P1107, DOI 10.1109/ISBI.2009.5193250; Marks K, 2020, DIAGN HISTOPATHOL, V26, P47; McMahan HB, 2017, PR MACH LEARN RES, V54, P1273; Moher D, 2001, BMC Med Res Methodol, V1, P2, DOI 10.1186/1471-2288-1-2; Muti HS, 2021, LANCET DIGIT HEALTH, V3, pE654, DOI 10.1016/S2589-7500(21)00133-3; National Cancer Institute, 2019, TCGA MOL CHAR PLATF; Norgeot B, 2020, NAT MED, V26, P1320, DOI 10.1038/s41591-020-1041-y; Schmauch B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17678-4; Schrammen PL, 2022, J PATHOL, V256, P50, DOI 10.1002/path.5800; Shia J, 2017, MODERN PATHOL, V30, P599, DOI 10.1038/modpathol.2016.198; Sirinukunwattana K, 2021, GUT, V70, P544, DOI 10.1136/gutjnl-2019-319866; Taylor J, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-030618; Warnat-Herresthal S, 2021, NATURE, V594, P265, DOI 10.1038/s41586-021-03583-3; West NP, 2021, HISTOPATHOLOGY, V79, P690, DOI 10.1111/his.14390; Woerl AC, 2020, EUR UROL, V78, P256, DOI 10.1016/j.eururo.2020.04.023	54	8	8	11	16	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2022	28	6					1232	+		10.1038/s41591-022-01768-5	http://dx.doi.org/10.1038/s41591-022-01768-5		APR 2022	20	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E9IE	35469069	hybrid, Green Submitted, Green Published			2022-12-27	WOS:000787119400001
J	Finck, AV; Blanchard, T; Roselle, CP; Golinelli, G; June, CH				Finck, Amanda V.; Blanchard, Tatiana; Roselle, Christopher P.; Golinelli, Giulia; June, Carl H.			Engineered cellular immunotherapies in cancer and beyond	NATURE MEDICINE			English	Review							CAR T-CELLS; HEMATOPOIETIC STEM-CELLS; IN-VIVO; SOLID TUMORS; ANTITUMOR-ACTIVITY; BODY IRRADIATION; HOST-DISEASE; NK CELLS; PHASE-I; THERAPY	Oncology is trailblazing the field of engineered cellular therapeutics. This Review discusses the goals of cellular immunotherapy in cancer, key challenges facing the field and strategies to overcome them-paving the way for treatment of other diseases. This year marks the tenth anniversary of cell therapy with chimeric antigen receptor (CAR)-modified T cells for refractory leukemia. The widespread commercial approval of genetically engineered T cells for a variety of blood cancers offers hope for patients with other types of cancer, and the convergence of human genome engineering and cell therapy technology holds great potential for generation of a new class of cellular therapeutics. In this Review, we discuss the goals of cellular immunotherapy in cancer, key challenges facing the field and exciting strategies that are emerging to overcome these obstacles. Finally, we outline how developments in the cancer field are paving the way for cellular immunotherapeutics in other diseases.	[Finck, Amanda V.; Blanchard, Tatiana; Roselle, Christopher P.; Golinelli, Giulia; June, Carl H.] Univ Penn, Perelman Sch Med, Ctr Cellular Immunotherapies, Philadelphia, PA 19104 USA; [Finck, Amanda V.; Blanchard, Tatiana; Roselle, Christopher P.; Golinelli, Giulia; June, Carl H.] Univ Penn, Parker Inst Canc Immunotherapy, Philadelphia, PA 19104 USA; [Finck, Amanda V.] Univ Penn, Perelman Sch Med, Immunol Grad Grp, Philadelphia, PA 19104 USA; [Blanchard, Tatiana; Roselle, Christopher P.] Univ Penn, Perelman Sch Med, Pharmacol Grad Grp, Philadelphia, PA 19104 USA; [Golinelli, Giulia] Univ Hosp Modena & Reggio Emilia, Dept Med & Surg Sci Children & Adults, Lab Cellular Therapy Div Oncol, Modena, Italy	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Universita di Modena e Reggio Emilia; Universita di Modena e Reggio Emilia Hospital	Finck, AV; June, CH (corresponding author), Univ Penn, Perelman Sch Med, Ctr Cellular Immunotherapies, Philadelphia, PA 19104 USA.; Finck, AV; June, CH (corresponding author), Univ Penn, Parker Inst Canc Immunotherapy, Philadelphia, PA 19104 USA.; Finck, AV (corresponding author), Univ Penn, Perelman Sch Med, Immunol Grad Grp, Philadelphia, PA 19104 USA.	finckam@pennmedicine.upenn.edu; cjune@upenn.edu	Golinelli, Giulia/GZM-8496-2022	Golinelli, Giulia/0000-0003-2494-3778; Finck, Amanda/0000-0001-9595-8470	National Science Foundation Graduate Fellowship [DGE-1321851]; National Institute of Health [T32 CA009140]; Go for IT Fondazione CRUI/MIUR (Italy) Fellowship 2020;  [1P01CA214278];  [R01CA226983]	National Science Foundation Graduate Fellowship(National Science Foundation (NSF)); National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Go for IT Fondazione CRUI/MIUR (Italy) Fellowship 2020; ; 	The authors would like to thank R. Young for insightful discussions, and the authors apologize to colleagues for work that we were unable to cite owing to space constraints. This was supported by 1P01CA214278, R01CA226983 and the Parker Institute for Cancer Immunotherapy (C.H.J.); the National Science Foundation Graduate Fellowship DGE-1321851 (A.V.F.); the National Institute of Health T32 CA009140 (T.B.); and the Go for IT Fondazione CRUI/MIUR (Italy) Fellowship 2020 (G.G.).	Aalipour A, 2020, MOL THER-ONCOLYTICS, V17, P232, DOI 10.1016/j.omto.2020.03.018; Adusumilli PS, 2021, CANCER DISCOV, V11, P2748, DOI 10.1158/2159-8290.CD-21-0407; Agarwal S, 2020, MOL THER, V28, P1783, DOI 10.1016/j.ymthe.2020.05.005; Aghajanian H, 2019, NATURE, V573, P430, DOI 10.1038/s41586-019-1546-z; Aijaz A, 2018, NAT BIOMED ENG, V2, P362, DOI 10.1038/s41551-018-0246-6; Ajina A, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0294-6; Alfageme-Abello O, 2021, CURR OPIN HIV AIDS, V16, P88, DOI 10.1097/COH.0000000000000665; ANDERSON D, 1951, HEREDITY, V5, P379, DOI 10.1038/hdy.1951.38; [Anonymous], 2022, APPROVED CELLULAR GE; [Anonymous], COMBINATION PRODUCTS; [Anonymous], 2020, REGULATORY CONSIDERA; Baeuerle PA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10097-0; Bagchi S, 2021, ANNU REV PATHOL-MECH, V16, P223, DOI 10.1146/annurev-pathol-042020-042741; Beatty GL, 2015, CLIN CANCER RES, V21, P687, DOI 10.1158/1078-0432.CCR-14-1860; Ben-David U, 2011, NAT REV CANCER, V11, P268, DOI 10.1038/nrc3034; Benjamin R, 2020, LANCET, V396, P1885, DOI 10.1016/S0140-6736(20)32334-5; Biegert GWG, 2021, MOL THER-ONCOLYTICS, V23, P571, DOI 10.1016/j.omto.2021.11.014; Blank CU, 2019, NAT REV IMMUNOL, V19, P665, DOI 10.1038/s41577-019-0221-9; Blazar BR, 2012, NAT REV IMMUNOL, V12, P443, DOI 10.1038/nri3212; Brown LV, 2021, J R SOC INTERFACE, V18, DOI 10.1098/rsif.2020.1013; Cameron BJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006034; Caruana I, 2015, NAT MED, V21, P524, DOI 10.1038/nm.3833; Chapuis AG, 2019, NAT MED, V25, P1064, DOI 10.1038/s41591-019-0472-9; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Chmielewski M, 2017, CELL REP, V21, P3205, DOI 10.1016/j.celrep.2017.11.063; Choi BD, 2019, NAT BIOTECHNOL, V37, P1049, DOI 10.1038/s41587-019-0192-1; Ciurea SO, 2015, BIOL BLOOD MARROW TR, V21, P1392, DOI 10.1016/j.bbmt.2015.05.001; CUDKOWICZ G, 1964, IMMUNOLOGY, V7, P291; Czechowicz A, 2007, SCIENCE, V318, P1296, DOI 10.1126/science.1149726; Czechowicz A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08201-x; Dannenfelser R, 2020, CELL SYST, V11, P215, DOI 10.1016/j.cels.2020.08.002; Davenport AJ, 2015, CANCER IMMUNOL RES, V3, P483, DOI 10.1158/2326-6066.CIR-15-0048; Depil S, 2020, NAT REV DRUG DISCOV, V19, P185, DOI 10.1038/s41573-019-0051-2; DiNofia AM, 2021, NAT REV CLIN ONCOL, V18, P195, DOI 10.1038/s41571-021-00485-1; DOBZHANSKY T, 1946, GENETICS, V31, P269; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Elisseeff J, 2021, NEW ENGL J MED, V385, P2451, DOI 10.1056/NEJMra1913421; Ellebrecht CT, 2016, SCIENCE, V353, P179, DOI 10.1126/science.aaf6756; Ellis GI, 2021, NAT REV GENET, V22, P427, DOI 10.1038/s41576-021-00329-9; Esensten JH, 2018, J ALLERGY CLIN IMMUN, V142, P1710, DOI 10.1016/j.jaci.2018.10.015; Ezekian B, 2018, TRANSPLANTATION, V102, P1213, DOI 10.1097/TP.0000000000002242; Fang L, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00186; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Ferrari G, 2021, NAT REV GENET, V22, P216, DOI 10.1038/s41576-020-00298-5; Fischbach MA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005568; Fraietta JA, 2016, BLOOD, V127, P1117, DOI 10.1182/blood-2015-11-679134; Frangoul H, 2021, NEW ENGL J MED, V384, P252, DOI 10.1056/NEJMoa2031054; FRIEDMANN T, 1972, SCIENCE, V175, P949, DOI 10.1126/science.175.4025.949; Fukuhara H, 2016, CANCER SCI, V107, P1373, DOI 10.1111/cas.13027; Good CR, 2021, CELL, V184, P6081, DOI 10.1016/j.cell.2021.11.016; Griffioen M, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00100; Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134; Guedan S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02460; Haddadi MH, 2020, BLOOD REV, V41, DOI 10.1016/j.blre.2019.100645; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Harrison RP, 2019, CYTOTHERAPY, V21, P224, DOI 10.1016/j.jcyt.2019.01.003; Hataye J, 2006, SCIENCE, V312, P114, DOI 10.1126/science.1124228; Hill GR, 2021, ANNU REV IMMUNOL, V39, P19, DOI 10.1146/annurev-immunol-102119-073227; Hipp S, 2017, LEUKEMIA, V31, P1743, DOI 10.1038/leu.2016.388; Honda K, 2012, ANNU REV IMMUNOL, V30, P759, DOI 10.1146/annurev-immunol-020711-074937; Hong MH, 2020, CANCER CELL, V38, P473, DOI 10.1016/j.ccell.2020.07.005; Huntington ND, 2007, NAT REV IMMUNOL, V7, P703, DOI 10.1038/nri2154; Iriguchi S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20658-3; Jain RK, 2014, ANNU REV BIOMED ENG, V16, P321, DOI 10.1146/annurev-bioeng-071813-105259; Johnson LA, 2006, J IMMUNOL, V177, P6548, DOI 10.4049/jimmunol.177.9.6548; June CH, 2018, NEW ENGL J MED, V379, P64, DOI 10.1056/NEJMra1706169; June CH, 2017, NAT MED, V23, P540, DOI 10.1038/nm.4321; KALDOR JM, 1990, NEW ENGL J MED, V322, P1, DOI 10.1056/NEJM199001043220101; Kanda Y, 2018, J IMMUNOL, V201, P1062, DOI 10.4049/jimmunol.1700219; Khaldoyanidi S, 2021, J CLIN ONCOL, V39, P419, DOI 10.1200/JCO.20.00475; KIESSLING R, 1977, EUR J IMMUNOL, V7, P655, DOI 10.1002/eji.1830070915; Kim KH, 2013, GYNECOL ONCOL, V130, P518, DOI 10.1016/j.ygyno.2013.06.003; Kim MY, 2018, CELL, V173, P1439, DOI 10.1016/j.cell.2018.05.013; Kitazawa Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01195; Klebanoff CA, 2018, J EXP MED, V215, P5, DOI 10.1084/jem.20172188; Klichinsky M, 2020, NAT BIOTECHNOL, V38, P947, DOI 10.1038/s41587-020-0462-y; Koneru M, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.994446; Krenciute G, 2017, CANCER IMMUNOL RES, V5, P571, DOI 10.1158/2326-6066.CIR-16-0376; Kuczma MP, 2017, ONCOTARGET, V8, P111931, DOI 10.18632/oncotarget.22953; Lajoie MJ, 2020, SCIENCE, V369, P1637, DOI 10.1126/science.aba6527; Lareau CA, 2021, CANCER CELL, V39, P1553, DOI 10.1016/j.ccell.2021.11.005; Lee DW, 2019, BIOL BLOOD MARROW TR, V25, P625, DOI 10.1016/j.bbmt.2018.12.758; Levine BL, 2017, MOL THER-METH CLIN D, V4, P92, DOI 10.1016/j.omtm.2016.12.006; Levine BL, 2013, NATURE, V498, pS17, DOI 10.1038/498S17a; Li Y, 2018, CELL STEM CELL, V23, P181, DOI 10.1016/j.stem.2018.06.002; Liu CW, 2012, J IMMUNOTHER, V35, P276, DOI 10.1097/CJI.0b013e31824e7f43; Liu WT, 2012, J IMMUNOL, V188, P2703, DOI 10.4049/jimmunol.1102997; Louis CU, 2009, BLOOD, V113, P2442, DOI 10.1182/blood-2008-05-157222; Ma L, 2019, SCIENCE, V365, P162, DOI 10.1126/science.aav8692; Majzner RG, 2019, NAT MED, V25, P1341, DOI 10.1038/s41591-019-0564-6; Maldini CR, 2018, NAT REV IMMUNOL, V18, P605, DOI 10.1038/s41577-018-0042-2; Marino J, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00582; Martinez-Llordella M, 2007, AM J TRANSPLANT, V7, P309, DOI 10.1111/j.1600-6143.2006.01621.x; Matthews DC, 1999, BLOOD, V94, P1237, DOI 10.1182/blood.V94.4.1237.416k34_1237_1247; Maxwell KG, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100238; Melenhorst JJ, 2022, NATURE, V602, P503, DOI 10.1038/s41586-021-04390-6; Micklethwaite KP, 2021, BLOOD, V138, P1391, DOI 10.1182/blood.2021010858; Mougiakakos D, 2021, NEW ENGL J MED, V385, P567, DOI 10.1056/NEJMc2107725; MURPHY WJ, 1987, J EXP MED, V166, P1499, DOI 10.1084/jem.166.5.1499; Nawaz W, 2021, BLOOD CANCER J, V11, DOI 10.1038/s41408-021-00508-1; Ndung'u T, 2019, NATURE, V576, P397, DOI 10.1038/s41586-019-1841-8; Newrzela S, 2008, BLOOD, V112, P2278, DOI 10.1182/blood-2007-12-128751; Nguyen CL, 2021, CURR OPIN GENET DEV, V66, P25, DOI 10.1016/j.gde.2020.11.007; Nori S, 2015, STEM CELL REP, V4, P360, DOI 10.1016/j.stemcr.2015.01.006; Oei VYS, 2018, CANCER IMMUNOL RES, V6, P467, DOI 10.1158/2326-6066.CIR-17-0207; Okazaki T, 2001, P NATL ACAD SCI USA, V98, P13866, DOI 10.1073/pnas.231486598; Park AK, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaz1863; Parker KR, 2020, CELL, V183, P126, DOI 10.1016/j.cell.2020.08.022; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Paszkiewicz PJ, 2016, J CLIN INVEST, V126, P4262, DOI 10.1172/JCI84813; Pauken KE, 2015, TRENDS IMMUNOL, V36, P265, DOI 10.1016/j.it.2015.02.008; Peled JU, 2020, NEW ENGL J MED, V382, P822, DOI 10.1056/NEJMoa1900623; Pellenz S, 2019, HUM GENE THER, V30, P814, DOI 10.1089/hum.2018.169; Pfeiffer A, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201809158; Posey AD, 2016, IMMUNITY, V44, P1444, DOI 10.1016/j.immuni.2016.05.014; Pouyanfard S, 2021, STEM CELLS, V39, P1701, DOI 10.1002/stem.3449; Rafiq S, 2018, NAT BIOTECHNOL, V36, P847, DOI 10.1038/nbt.4195; Ranki T, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0121-5; Raulet DH, 2015, J IMMUNOL, V195, P2923, DOI 10.4049/jimmunol.1501804; Reinhard K, 2020, SCIENCE, V367, P446, DOI 10.1126/science.aay5967; Ren JT, 2017, CLIN CANCER RES, V23, P2255, DOI 10.1158/1078-0432.CCR-16-1300; Rezaei R, 2022, CANCER GENE THER, V29, P647, DOI 10.1038/s41417-021-00359-9; Ringden O, 2009, BRIT J HAEMATOL, V147, P614, DOI 10.1111/j.1365-2141.2009.07886.x; Roddie C, 2019, CYTOTHERAPY, V21, P327, DOI 10.1016/j.jcyt.2018.11.009; Rozenbaum M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01347; Ruggeri L, 2002, SCIENCE, V295, P2097, DOI 10.1126/science.1068440; Rupp LJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00462-8; Rurik JG, 2022, SCIENCE, V375, P91, DOI 10.1126/science.abm0594; Rurik JG, 2021, CIRC RES, V128, P1766, DOI 10.1161/CIRCRESAHA.121.318005; Sacks SH, 2012, NAT REV IMMUNOL, V12, P431, DOI 10.1038/nri3225; Sadeghzadeh M, 2020, LIFE SCI, V254, DOI 10.1016/j.lfs.2020.117580; Schambach A, 2021, MOL THER, V29, P2631, DOI 10.1016/j.ymthe.2021.08.013; Scholler J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003761; Seitter SJ, 2021, CLIN CANCER RES, V27, P5289, DOI 10.1158/1078-0432.CCR-21-1171; Sepich-Poore GD, 2021, SCIENCE, V371, P1331, DOI 10.1126/science.abc4552; Setton J, 2021, CANCER DISCOV, V11, P1626, DOI 10.1158/2159-8290.CD-20-1503; Shaw AR, 2017, MOL THER, V25, P2440, DOI 10.1016/j.ymthe.2017.09.010; Sheridan C, 2022, NAT BIOTECHNOL, V40, P5, DOI 10.1038/d41587-021-00027-1; Sheth VS, 2021, BONE MARROW TRANSPL, V56, P552, DOI 10.1038/s41409-020-01134-4; Singh N, 2020, CANCER DISCOV, V10, P552, DOI 10.1158/2159-8290.CD-19-0813; Siurala M, 2016, MOL THER, V24, P1435, DOI 10.1038/mt.2016.137; Smith M., NAT MED; Smith M, 2019, BIOL BLOOD MARROW TR, V25; Stadtmauer EA, 2020, SCIENCE, V367, P1001, DOI 10.1126/science.aba7365; Tang Kevin, 2021, J Immunother Precis Oncol, V4, P150, DOI 10.36401/JIPO-21-2; Tanoue T, 2019, NATURE, V565, P600, DOI 10.1038/s41586-019-0878-z; Taraseviciute A, 2018, CANCER DISCOV, V8, P750, DOI 10.1158/2159-8290.CD-17-1368; THOMAS ED, 1959, J CLIN INVEST, V38, P1709, DOI 10.1172/JCI103949; Thommen DS, 2018, CANCER CELL, V33, P547, DOI 10.1016/j.ccell.2018.03.012; Tivol E, 2005, BLOOD, V105, P4885, DOI 10.1182/blood-2004-12-4980; Uribe-Herranz M, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.94952; Van Oekelen O, 2021, NAT MED, V27, P2099, DOI 10.1038/s41591-021-01564-7; Viaud S, 2013, SCIENCE, V342, P971, DOI 10.1126/science.1240537; Watanabe K, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.99573; Wei QZ, 2018, IMMUNITY, V48, P632, DOI 10.1016/j.immuni.2018.03.024; WEIDEN PL, 1979, NEW ENGL J MED, V300, P1068, DOI 10.1056/NEJM197905103001902; Williams JZ, 2020, SCIENCE, V370, P1099, DOI 10.1126/science.abc6270; Williams TN, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a011692; Wing A, 2018, CANCER IMMUNOL RES, V6, P605, DOI 10.1158/2326-6066.CIR-17-0314; Wu SR, 2017, BLOOD, V129, P1747, DOI 10.1182/blood-2016-09-740431; Xia Y, 2016, BLOOD REV, V30, P189, DOI 10.1016/j.blre.2015.11.003; Yarmarkovich M, 2021, NATURE, V599, P477, DOI 10.1038/s41586-021-04061-6; Yin YB, 2018, MOL THER-ONCOLYTICS, V11, P20, DOI 10.1016/j.omto.2018.08.002; Yu VWC, 2016, CURR OPIN HEMATOL, V23, P331, DOI 10.1097/MOH.0000000000000265; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958; Zitvogel L, 2016, CELL, V165, P276, DOI 10.1016/j.cell.2016.03.001	166	14	13	12	25	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4					678	689		10.1038/s41591-022-01765-8	http://dx.doi.org/10.1038/s41591-022-01765-8			12	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0Q6DV	35440724				2022-12-27	WOS:000785007700024
J	Pramesh, CS; Badwe, RA; Bhoo-Pathy, N; Booth, CM; Chinnaswamy, G; Dare, AJ; de Andrade, VP; Hunter, DJ; Gopal, S; Gospodarowicz, M; Gunasekera, S; Ilbawi, A; Kapambwe, S; Kingham, P; Kutluk, T; Lamichhane, N; Mutebi, M; Orem, J; Parham, G; Ranganathan, P; Sengar, M; Sullivan, R; Swaminathan, S; Tannock, IF; Tomar, V; Vanderpuye, V; Varghese, C; Weiderpass, E				Pramesh, C. S.; Badwe, Rajendra A.; Bhoo-Pathy, Nirmala; Booth, Christopher M.; Chinnaswamy, Girish; Dare, Anna J.; de Andrade, Victor Piana; Hunter, David J.; Gopal, Satish; Gospodarowicz, Mary; Gunasekera, Sanjeeva; Ilbawi, Andre; Kapambwe, Sharon; Kingham, Peter; Kutluk, Tezer; Lamichhane, Nirmal; Mutebi, Miriam; Orem, Jackson; Parham, Groesbeck; Ranganathan, Priya; Sengar, Manju; Sullivan, Richard; Swaminathan, Soumya; Tannock, Ian F.; Tomar, Vivek; Vanderpuye, Verna; Varghese, Cherian; Weiderpass, Elisabete			Priorities for cancer research in low- and middle-income countries: a global perspective	NATURE MEDICINE			English	Article							LOW-DOSE ABIRATERONE; BREAST-CANCER; HEALTH-CARE; INDIA; QUALITY; DELIVERY; IMPROVEMENT; SURVIVAL; THERAPY; PROJECT	Radical rethinking is needed to address the burning issues in cancer care in low- and middle-income countries. In this Perspective, the authors outline the main challenges and top priorities for cancer research now and into the future. Cancer research currently is heavily skewed toward high-income countries (HICs), with little research conducted in, and relevant to, the problems of low- and middle-income countries (LMICs). This regional discordance in cancer knowledge generation and application needs to be rebalanced. Several gaps in the research enterprise of LMICs need to be addressed to promote regionally relevant research, and radical rethinking is needed to address the burning issues in cancer care in these regions. We identified five top priorities in cancer research in LMICs based on current and projected needs: reducing the burden of patients with advanced disease; improving access and affordability, and outcomes of cancer treatment; value-based care and health economics; quality improvement and implementation research; and leveraging technology to improve cancer control. LMICs have an excellent opportunity to address important questions in cancer research that could impact cancer control globally. Success will require collaboration and commitment from governments, policy makers, funding agencies, health care organizations and leaders, researchers and the public.	[Pramesh, C. S.; Badwe, Rajendra A.; Chinnaswamy, Girish; Ranganathan, Priya; Sengar, Manju] Homi Bhabha Natl Inst, Tata Mem Ctr, Mumbai, Maharashtra, India; [Bhoo-Pathy, Nirmala] Univ Malaya, Ctr Epidemiol & Evidence Based Practice, Kuala Lumpur, Malaysia; [Booth, Christopher M.] Queens Univ, Dept Oncol, Kingston, ON, Canada; [Booth, Christopher M.] Queens Univ, Dept Publ Hlth Sci, Kingston, ON, Canada; [Dare, Anna J.] Univ Toronto, Dept Surg, Toronto, ON, Canada; [de Andrade, Victor Piana] AC Camargo Canc Ctr, Sao Paulo, SP, Brazil; [Hunter, David J.] Univ Oxford, Nuffield Dept Populat Hlth, Oxford, England; [Hunter, David J.] Harvard TH Chan Sch Publ Hlth, Boston, MA USA; [Gopal, Satish] NCI, Ctr Global Hlth, Rockville, MD USA; [Gospodarowicz, Mary; Tannock, Ian F.] Princess Margaret Canc Ctr, Toronto, ON, Canada; [Gospodarowicz, Mary; Tannock, Ian F.] Univ Toronto, Toronto, ON, Canada; [Gunasekera, Sanjeeva] Natl Canc Inst Sri Lanka, Colombo, Sri Lanka; [Ilbawi, Andre; Swaminathan, Soumya; Varghese, Cherian] WHO, Geneva, Switzerland; [Kapambwe, Sharon] World Hlth Org Africa, Harare, Zimbabwe; [Kingham, Peter] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Kutluk, Tezer] Hacettepe Univ, Fac Med, Ankara, Turkey; [Kutluk, Tezer] Hacettepe Univ, Canc Inst, Ankara, Turkey; [Lamichhane, Nirmal] BP Koirala Mem Canc Hosp, Bharatpur, Nepal; [Mutebi, Miriam] Aga Khan Univ, Nairobi, Kenya; [Orem, Jackson] Uganda Canc Inst, Kampala, Uganda; [Parham, Groesbeck] Univ N Carolina, Chapel Hill, NC 27515 USA; [Sullivan, Richard] Kings Coll London, Inst Canc Policy, London, England; [Tomar, Vivek] Rise Surv Canc, New Delhi, India; [Vanderpuye, Verna] Natl Ctr Radiotherapy Oncol & Nucl Med, Accra, Ghana; [Vanderpuye, Verna] Korle Bu Teaching Hosp, Accra, Ghana; [Weiderpass, Elisabete] Int Assoc Res Canc, Lyon, France	Homi Bhabha National Institute; Tata Memorial Centre (TMC); Universiti Malaya; Queens University - Canada; Queens University - Canada; University of Toronto; A.C.Camargo Cancer Center; University of Oxford; Harvard University; Harvard T.H. Chan School of Public Health; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; World Health Organization; Memorial Sloan Kettering Cancer Center; Hacettepe University; Hacettepe University; Aga Khan University; University of North Carolina; University of North Carolina Chapel Hill; University of London; King's College London	Pramesh, CS (corresponding author), Homi Bhabha Natl Inst, Tata Mem Ctr, Mumbai, Maharashtra, India.	prameshcs@tmc.gov.in	Pathy, Nirmala Bhoo/C-1228-2010	Pathy, Nirmala Bhoo/0000-0003-0568-8863; Sullivan, Richard/0000-0002-6435-1825; Pramesh, C S/0000-0002-3635-0083; Gunasekera, Sanjeeva/0000-0002-4043-559X; Tomar, Vivek/0000-0003-4341-4839				Aggarwal A, 2018, INT J RADIAT ONCOL, V101, P767, DOI 10.1016/j.ijrobp.2018.03.009; Alonge O, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2018-001257; Andre N, 2013, LANCET ONCOL, V14, pE239, DOI 10.1016/S1470-2045(13)70056-1; Are C, 2021, SURGERY, V170, P1587, DOI 10.1016/j.surg.2021.02.006; Badwe R, 2015, LANCET ONCOL, V16, P1380, DOI 10.1016/S1470-2045(15)00135-7; Badwe R, 2011, J CLIN ONCOL, V29, P2845, DOI 10.1200/JCO.2010.33.0738; Binagwaho A, 2021, BMJ-BRIT MED J, V375, DOI 10.1136/bmj.n2658; Bodenheimer T, 1999, NEW ENGL J MED, V340, P488, DOI 10.1056/NEJM199902113400621; Booth CM, 2019, NAT REV CLIN ONCOL, V16, P312, DOI 10.1038/s41571-019-0167-7; Boshoff N, 2009, SCIENTOMETRICS, V81, P413, DOI 10.1007/s11192-008-2211-8; Bray F, 2015, INT J CANCER, V137, P2060, DOI 10.1002/ijc.29670; Bray F, 2014, PLANNING DEVELOPING; Chandra Amitabh, 2016, Forum Health Econ Policy, V19, P71, DOI 10.1515/fhep-2014-0022; Coyle C, 2016, CONTEMP CLIN TRIALS, V51, P56, DOI 10.1016/j.cct.2016.10.004; D'Cruz AK, 2015, NEW ENGL J MED, V373, P521, DOI 10.1056/NEJMoa1506007; Damani A, 2022, BMJ SUPPORT PALLIAT, V12, pE366, DOI 10.1136/bmjspcare-2019-002152; Del Paggio JC, 2021, JAMA ONCOL, V7, P728, DOI 10.1001/jamaoncol.2021.0379; Del Paggio JC, 2017, LANCET ONCOL, V18, P887, DOI 10.1016/S1470-2045(17)30415-1; Department for International Development, CAPACITY BUILDING RE; Drake TM, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00346; Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937; Fojo T, 2014, JAMA OTOLARYNGOL, V140, P1225, DOI 10.1001/jamaoto.2014.1570; Gadgil Durga, 2021, Perspect Clin Res, V12, P189, DOI 10.4103/picr.picr_48_21; Gelband H, 2016, LANCET, V387, P2133, DOI 10.1016/S0140-6736(15)00755-2; Ghoshal A, 2021, INDIAN J PALLIAT CAR, V27, P211, DOI 10.25259/IJPC_394_20; Goss PE, 2014, LANCET ONCOL, V15, P489, DOI 10.1016/S1470-2045(14)70029-4; Grol R, 2001, MED CARE, V39, pII46; Haacker M, 2020, HEALTH POLICY PLANN, V35, P107, DOI 10.1093/heapol/czz127; HAINES A, 1994, BMJ-BRIT MED J, V308, P1488, DOI 10.1136/bmj.308.6942.1488; Hawkes N, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3973; Heneghan C, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003298; Horton S, 2015, CANC DIS CONTROL PRI, V3; International Agency for Research on Cancer WHO, CANC TOMORROW; Irabor OC, 2020, JCO GLOB ONCOL, V6, P667, DOI 10.1200/JGO.19.00261; Jamison DT, 2013, LANCET, V382, P1898, DOI 10.1016/S0140-6736(13)62105-4; Joharatnam-Hogan N, 2019, LANCET GASTROENTEROL, V4, P854, DOI 10.1016/S2468-1253(19)30289-4; Lopez AD, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01526-9; Lorenz KA, 2021, J PAIN SYMPTOM MANAG, V61, P190, DOI 10.1016/j.jpainsymman.2020.08.025; Malekzadeh A, 2020, GLOBAL HEALTH ACTION, V13, DOI 10.1080/16549716.2020.1846904; Mallath MK, 2014, LANCET ONCOL, V15, pE205, DOI 10.1016/S1470-2045(14)70115-9; Mittra I, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n256; Morris MJ, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.LBA4; Munung NS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186237; Nazha Bassel, 2019, Am Soc Clin Oncol Educ Book, V39, P3, DOI 10.1200/EDBK_100021; Parker M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163579; Parkin DM, 2006, NAT REV CANCER, V6, P603, DOI 10.1038/nrc1948; Patel A, 2020, JCO GLOB ONCOL, V6, P382, DOI 10.1200/JGO.19.00341; Peng L, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1781333; Phan VH, 2009, EXPERT OPIN DRUG MET, V5, P243, DOI [10.1517/17425250902800153, 10.1517/17425250902800153 ]; Pitt C, 2016, HEALTH ECON, V25, P9, DOI 10.1002/hec.3305; Pramesh CS, 2019, LANCET ONCOL, V20, pE218, DOI 10.1016/S1470-2045(19)30092-0; Pramesh C S, 2016, Perspect Clin Res, V7, P152; Pramesh CS, 2014, INDIAN J MED PAEDIAT, V35, P226, DOI 10.4103/0971-5851.142040; Pramesh CS, 2014, LANCET ONCOL, V15, pE223, DOI 10.1016/S1470-2045(14)70117-2; Prasad V, 2017, NAT REV CLIN ONCOL, V14, P381, DOI 10.1038/nrclinonc.2017.31; Ramaswami R, 2018, J GLOB ONCOL, V4, DOI 10.1200/JGO.17.00226; Ranganathan P, 2021, LANCET ONCOL, V22, P970, DOI 10.1016/S1470-2045(21)00240-0; Renner A, 2019, J GLOB ONCOL, V5, DOI 10.1200/JGO.19.00142; Rodrigues B., 2018, J GLOB ONCOL, V4, DOI [10.1200/jgo.18.52400, DOI 10.1200/JGO.18.52400]; Rolfo C, 2016, ESMO OPEN, V1, DOI 10.1136/esmoopen-2016-000055; Ross C, 2017, IBM PITCHED WATSON R; Schuster MA, 1998, MILBANK Q, V76, P517, DOI 10.1111/1468-0009.00105; Sengar M, 2019, INDIAN J MED PAEDIAT, V40, P121, DOI 10.4103/ijmpo.ijmpo_66_18; Seruga B, 2010, ANN ONCOL, V21, P895, DOI 10.1093/annonc/mdp403; Shastri SS, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju009; Siddiqui AH, 2018, J GLOB ONCOL, V4, DOI 10.1200/JGO.18.00116; Singh AG, 2021, ECANCERMEDICALSCIENC, V15, DOI 10.3332/ecancer.2021.1252; Soerjomataram I, 2021, NAT REV CLIN ONCOL, V18, P663, DOI 10.1038/s41571-021-00514-z; Spratt DE, 2016, JAMA ONCOL, V2, P1070, DOI 10.1001/jamaoncol.2016.1854; Sullivan R, 2017, NATURE, V549, P325, DOI 10.1038/549325a; Sullivan R, 2014, LANCET ONCOL, V15, pE213, DOI 10.1016/S1470-2045(14)70109-3; Szmulewitz RZ, 2018, J CLIN ONCOL, V36, P1389, DOI 10.1200/JCO.2017.76.4381; Tannock IF, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.20.02768; Templeton AJ, 2020, J CLIN ONCOL, V38, P1651, DOI 10.1200/JCO.19.02035; The Cancer Atlas, CANC SURVEILLANCE; The UK Department for International Development, 2021, RES CAPACITY STRENGT; Van Hemelrijck M, 2021, ECANCERMEDICALSCIENC, V15, DOI 10.3332/ecancer.2021.1264; Wells JC, 2021, JAMA ONCOL, V7, P379, DOI 10.1001/jamaoncol.2020.7478; Wong JC, 2014, GLOBALIZATION HEALTH, V10, DOI 10.1186/s12992-014-0083-7; World Health Organization, 2021, WHO CIVIL REGISTRATI; World Health Organization, 2021, SELECTION USE ESSENT; World Health Organization, 2021, DOTS STRATEGY CONTRO	82	6	6	2	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4					649	657		10.1038/s41591-022-01738-x	http://dx.doi.org/10.1038/s41591-022-01738-x			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0Q6DV	35440716	Bronze			2022-12-27	WOS:000785007700021
J	Persidis, A				Persidis, A			Catalytic antibodies	NATURE BIOTECHNOLOGY			English	Editorial Material							TRANSITION-STATE ANALOG; CRYSTAL-STRUCTURE; ACTIVE-SITE; IMMUNIZATION; FAB		Argonex Inc, Charlottesville, VA 22901 USA		Persidis, A (corresponding author), Argonex Inc, 2044 India Rd,Suite 202, Charlottesville, VA 22901 USA.							ANGELES TS, 1993, BIOCHEMISTRY-US, V32, P12128, DOI 10.1021/bi00096a025; Baca M, 1997, P NATL ACAD SCI USA, V94, P10063, DOI 10.1073/pnas.94.19.10063; Cashman J R, 1997, NIDA Res Monogr, V173, P225; CHARBONNIER JB, 1995, P NATL ACAD SCI USA, V92, P11721, DOI 10.1073/pnas.92.25.11721; FRIBOULET A, 1994, APPL BIOCHEM BIOTECH, V47, P229, DOI 10.1007/BF02787937; GOLINELLIPIMPANEAU B, 1994, STRUCTURE, V2, P175, DOI 10.1016/S0969-2126(00)00019-8; GUO JC, 1995, P NATL ACAD SCI USA, V92, P1694, DOI 10.1073/pnas.92.5.1694; Jencks W. P., 1969, CATALYSIS CHEM ENZYM; Paul S, 1996, MOL BIOTECHNOL, V5, P197, DOI 10.1007/BF02900358; Persidis A, 1997, NAT BIOTECHNOL, V15, P921, DOI 10.1038/nbt0997-921; POSNER B, 1994, TRENDS BIOCHEM SCI, V19, P145, DOI 10.1016/0968-0004(94)90273-9; RAYMOND JL, 1996, P NATL ACAD SCI USA, V93, P4251; ROBERTS VA, 1995, FASEB J, V9, P94, DOI 10.1096/fasebj.9.1.7821766; STEPHENS DB, 1993, BIOCHEM BIOPH RES CO, V192, P1439, DOI 10.1006/bbrc.1993.1577; TRAMONTANO A, 1986, SCIENCE, V234, P1566, DOI 10.1126/science.3787261; Wade H, 1997, ANNU REV BIOPH BIOM, V26, P461, DOI 10.1146/annurev.biophys.26.1.461; Wentworth P, 1996, P NATL ACAD SCI USA, V93, P799, DOI 10.1073/pnas.93.2.799; WIRSCHING P, 1995, SCIENCE, V270, P1775, DOI 10.1126/science.270.5243.1775; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444	19	4	4	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1997	15	12					1313	+		10.1038/nbt1197-1313	http://dx.doi.org/10.1038/nbt1197-1313			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YQ046	9359117				2022-12-27	WOS:000071342000039
J	Jones, JT; Sullenger, BA				Jones, JT; Sullenger, BA			Evaluating and enhancing ribozyme reaction efficiency in mammalian cells	NATURE BIOTECHNOLOGY			English	Article						ribozyme; trans-splicing; gene therapy	TETRAHYMENA RIBOZYME; RNA ENZYMES; CLEAVAGE; BINDING; SEQUENCE; SPECIFICITY; SITE; FRAMEWORK; PRECURSOR; INTRON	The ability of ribozymes to cleave specific transcripts and repair defective RNAs in the test tube has engendered speculation about their potential clinical utility. Therapeutic development has been hindered by an inability to evaluate and optimize the efficiency of RNA catalysis in vivo. We describe an experimental system that has allowed us to assess and enhance the efficiency with which a trans-splicing group I ribozyme reacts with a targeted RNA in mammalian cells. These results demonstrate that the ribozyme can convert up to 49% of a specific substrate RNA to product in the cellular environment and that the efficiency of this reaction is apparently a function of the ribozyme's ability to find and bind to the substrate RNA in the cell. These observations suggest that trans-splicing ribozymes may become useful reagents to repair a therapeutically significant fraction of mutant RNAs associated with a variety of genetic diseases.	DUKE UNIV, MED CTR, DEPT EXPT SURG, CTR CELLULAR & GENET THERAPIES, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT GENET, CTR CELLULAR & GENET THERAPIES, DURHAM, NC 27710 USA	Duke University; Duke University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053525] Funding Source: NIH RePORTER; NIGMS NIH HHS [5 RO1 GM53525-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEEBE JA, 1994, BIOCHEMISTRY-US, V33, P10294, DOI 10.1021/bi00200a009; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; CECH T R, 1988, Journal of the American Medical Association, V260, P3030, DOI 10.1001/jama.260.20.3030; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; CHOWRIRA BM, 1991, BIOCHEMISTRY-US, V30, P8518, DOI 10.1021/bi00099a003; ELROYSTEIN O, 1990, P NATL ACAD SCI USA, V87, P6743, DOI 10.1073/pnas.87.17.6743; FELDSTEIN PA, 1989, GENE, V82, P53, DOI 10.1016/0378-1119(89)90029-2; FORESTER AC, 1990, SCIENCE, V249, P783; GILLILAND G, 1990, PCR PROTOCOLS GUIDE; HAMPEL A, 1990, NUCLEIC ACIDS RES, V18, P299, DOI 10.1093/nar/18.2.299; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERTEL KJ, 1994, BIOCHEMISTRY-US, V33, P3374, DOI 10.1021/bi00177a031; INOUE T, 1985, CELL, V43, P431, DOI 10.1016/0092-8674(85)90173-4; Jones JT, 1996, NAT MED, V2, P643, DOI 10.1038/nm0696-643; MURPHY FL, 1989, P NATL ACAD SCI USA, V86, P9218, DOI 10.1073/pnas.86.23.9218; PERROTTA AT, 1992, BIOCHEMISTRY-US, V31, P16, DOI 10.1021/bi00116a004; PYLE AM, 1994, BIOCHEMISTRY-US, V33, P2716, DOI 10.1021/bi00175a047; ROSSI J J, 1992, Current Opinion in Biotechnology, V3, P3, DOI 10.1016/0958-1669(92)90117-2; SULLENGER BA, 1995, CHEM BIOL, V2, P249, DOI 10.1016/1074-5521(95)90043-8; SULLENGER BA, 1994, NATURE, V371, P619, DOI 10.1038/371619a0; SULLENGER BA, 1993, SCIENCE, V262, P1566, DOI 10.1126/science.8248806; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; YARUS M, 1988, SCIENCE, V240, P1751, DOI 10.1126/science.3381099; YARUS M, 1989, BIOCHEMISTRY-US, V28, P980, DOI 10.1021/bi00429a010; YU M, 1994, GENE THER, V1, P13; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	29	51	55	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1997	15	9					902	905		10.1038/nbt0997-902	http://dx.doi.org/10.1038/nbt0997-902			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XW410	9306408				2022-12-27	WOS:A1997XW41000035
J	Delihas, N; Rokita, SE; Zheng, P				Delihas, N; Rokita, SE; Zheng, P			Natural antisense RNA target RNA interactions: Possible models for antisense oligonucleotide drug design	NATURE BIOTECHNOLOGY			English	Review						antisense; non-canonical base pairs; RNA-RNA interactions	5-S RIBOSOMAL-RNAS; OMPF MESSENGER-RNA; BASE-PAIRS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; MICF RNA; HAMMERHEAD RIBOZYME; SECONDARY STRUCTURE; GENE-EXPRESSION; MISMATCH REPAIR	Current antisense oligonucleotides designed for drug therapy rely on Watson-Crick base pairing for the specificity of interactions between antisense and target molecules. However, thermodynamically stable duplexes containing non-Watson-Crick pairs have been formed with synthetic oligonucleotides. There are also numerous examples of non-canonical base pairs that participate in stable intra- and intermolecular RNA/RNA pairing in prokaryotic and eukaryotic cells, Several natural antisense RNA/target RNA duplexes contain looped-out and bulged positions as well as non-canonical pairs as exemplified by formation of the Escherichia coli antisense micF RNA/ompF mRNA duplex, Secondary structures and the phylogenetic conservation of nucleotide sequences are well characterized in this system, Natural antisense/target interactions may serve as models for determining possible and optimal antisense/target interactions in oligonucleotide drug design.	UNIV MARYLAND, DEPT CHEM & BIOCHEM, COLLEGE PK, MD 20742 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOL PHARMACOL, BOSTON, MA 02115 USA	University System of Maryland; University of Maryland College Park; Harvard University; Harvard Medical School	Delihas, N (corresponding author), SUNY STONY BROOK, SCH MED, DEPT MOL GENET & MICROBIOL, STONY BROOK, NY 11794 USA.		Rokita, Steven E/C-4793-2009	Delihas, Nicholas/0000-0002-1704-2587				ANDERSEN J, 1990, BIOCHEMISTRY-US, V29, P9249, DOI 10.1021/bi00491a020; ANDERSEN J, 1989, J BIOL CHEM, V264, P17961; Benson DA, 1996, NUCLEIC ACIDS RES, V24, P1, DOI 10.1093/nar/24.1.1; BORDEN KLB, 1992, BIOCHEMISTRY-US, V31, P5411, DOI 10.1021/bi00138a024; Breaker RR, 1997, NAT BIOTECHNOL, V15, P427, DOI 10.1038/nbt0597-427; BROWN T, 1990, J MOL BIOL, V212, P437, DOI 10.1016/0022-2836(90)90320-L; Bruice TW, 1997, BIOCHEMISTRY-US, V36, P5004, DOI 10.1021/bi9620767; BURROWS CJ, 1994, ACCOUNTS CHEM RES, V27, P295, DOI 10.1021/ar00046a002; BURROWS CJ, 1995, NICKEL COMPLEXES PRO, P537; CHENG JW, 1992, J MOL BIOL, V228, P1037, DOI 10.1016/0022-2836(92)90312-8; Crooke ST, 1996, ANNU REV PHARMACOL, V36, P107, DOI 10.1146/annurev.pa.36.040196.000543; Dean N, 1996, CANCER RES, V56, P3499; DEAN NM, 1994, J BIOL CHEM, V269, P16416; DELIHAS N, 1984, PROG NUCLEIC ACID RE, V31, P161, DOI 10.1016/S0079-6603(08)60377-3; DELIHAS N, 1995, MOL MICROBIOL, V15, P411, DOI 10.1111/j.1365-2958.1995.tb02254.x; ESTERLING L, 1994, MOL MICROBIOL, V12, P639, DOI 10.1111/j.1365-2958.1994.tb01051.x; FAZAKERLEY GV, 1986, EMBO J, V5, P3697, DOI 10.1002/j.1460-2075.1986.tb04702.x; GUI JI, 1995, BIOCHEMISTRY-US, V35, P12538; Hall J, 1996, NUCLEIC ACIDS RES, V24, P3522, DOI 10.1093/nar/24.18.3522; HOLBROOK SR, 1991, NATURE, V353, P579, DOI 10.1038/353579a0; HUNTER WN, 1986, NATURE, V320, P552, DOI 10.1038/320552a0; Husken D, 1996, BIOCHEMISTRY-US, V35, P16591, DOI 10.1021/bi961700c; Kennard O., 1987, NUCL ACIDS MOL BIOL, V1, P25; KNEALE G, 1985, J MOL BIOL, V186, P805, DOI 10.1016/0022-2836(85)90398-5; LESNIK EA, 1995, BIOCHEMISTRY-US, V34, P10807, DOI 10.1021/bi00034a013; MASKOS K, 1993, BIOCHEMISTRY-US, V32, P3583, DOI 10.1021/bi00065a009; McDowell JA, 1996, BIOCHEMISTRY-US, V35, P14077, DOI 10.1021/bi9615710; MILLIGAN JF, 1993, J MED CHEM, V36, P1923, DOI 10.1021/jm00066a001; Milner N, 1997, NAT BIOTECHNOL, V15, P537, DOI 10.1038/nbt0697-537; MIZUNO T, 1983, P JPN ACAD B-PHYS, V59, P335, DOI 10.2183/pjab.59.335; MORFELDT E, 1995, EMBO J, V14, P4569, DOI 10.1002/j.1460-2075.1995.tb00136.x; Nyce JW, 1997, NATURE, V385, P721, DOI 10.1038/385721a0; PACE NR, 1989, GENE, V82, P65, DOI 10.1016/0378-1119(89)90031-0; PING Z, 1995, THESIS SUNY STONY BR; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; Pratt LA, 1996, MOL MICROBIOL, V20, P911, DOI 10.1111/j.1365-2958.1996.tb02532.x; Saenger W., 1984, PRINCIPLES NUCLEIC A, VDM79; Sahasrabudhe PV, 1997, BIOCHEMISTRY-US, V36, P5981, DOI 10.1021/bi9700577; SANTALUCIA J, 1993, BIOCHEMISTRY-US, V32, P12612, DOI 10.1021/bi00210a009; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; SCHMIDT M, 1995, BIOCHEMISTRY-US, V34, P3621, DOI 10.1021/bi00011a017; Schroeder S, 1996, BIOCHEMISTRY-US, V35, P16105, DOI 10.1021/bi961789m; SCHWEITZER BA, 1995, J AM CHEM SOC, V117, P1863, DOI 10.1021/ja00112a001; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; SKELLY JV, 1993, P NATL ACAD SCI USA, V90, P804, DOI 10.1073/pnas.90.3.804; STAHL DA, 1981, NUCLEIC ACIDS RES, V9, P6129, DOI 10.1093/nar/9.22.6129; STEPHENSON ML, 1978, P NATL ACAD SCI USA, V75, P285, DOI 10.1073/pnas.75.1.285; SUGIMOTO N, 1995, BIOCHEMISTRY-US, V34, P11211, DOI 10.1021/bi00035a029; Turner DH, 1996, CURR OPIN STRUC BIOL, V6, P299, DOI 10.1016/S0959-440X(96)80047-9; VARANI G, 1989, BIOCHEMISTRY-US, V28, P7760, DOI 10.1021/bi00445a036; WESTHOF E, 1989, J MOL BIOL, V207, P417, DOI 10.1016/0022-2836(89)90264-7; WIMBERLY B, 1993, BIOCHEMISTRY-US, V32, P1078, DOI 10.1021/bi00055a013; WYATT JR, 1993, RNA WORLD, P465; Zuker M, 1994, Methods Mol Biol, V25, P267; 1997, GENETIC ENG NEWS, V17	55	27	50	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					751	753		10.1038/nbt0897-751	http://dx.doi.org/10.1038/nbt0897-751			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255788				2022-12-27	WOS:A1997XM70700025
J	Heikoop, JC; vandenBoogaart, P; Mulders, JWM; Grootenhuis, PDJ				Heikoop, JC; vandenBoogaart, P; Mulders, JWM; Grootenhuis, PDJ			Structure-based design and protein engineering of intersubunit disulfide bonds in gonadotropins	NATURE BIOTECHNOLOGY			English	Article						protein engineering; rational design; molecular modeling; human choriogonadotropin; luteinizing hormone; follicle stimulating hormone	HUMAN CHORIONIC-GONADOTROPIN; GLYCOPROTEIN HORMONES; SIGNAL-TRANSDUCTION; LUTEINIZING-HORMONE; BETA-SUBUNITS; SPECIFICITY; EXPRESSION; EVOLUTION; RECEPTOR; BINDING	Pairs of cystine residues were introduced in the alpha- and beta-subunits of human choriogonadotropin at positions with optimal geometries for the formation of disulfide bonds. Using the homology with luteinizing hormone and follicle stimulating hormone, similar mutations were carried out in these glycoprotein hormones. In nearly all mutants the corresponding disulfide bonds were formed leading to a non-natural, covalent linkage between the alpha- and beta-subunits. The mutants typically display wild-type receptor binding and bioactivity. The mutants with non-natural intersubunit disulfide bonds display enhanced thermostabilities relative to the corresponding heterodimeric glycoprotein hormones, rendering them candidates for long acting gonadotropins with enhanced shelf lives.	NV ORGANON, NL-5340 BH OSS, NETHERLANDS									BenMenahem D, 1996, TRENDS ENDOCRIN MET, V7, P100, DOI 10.1016/1043-2760(96)88667-X; BLUNDELL TL, 1994, TRENDS BIOTECHNOL, V12, P145, DOI 10.1016/0167-7799(94)90073-6; BOLME I, 1997, CONVERSION HETERODIM; CHEN F, 1992, J MOL ENDOCRINOL, V8, P87, DOI 10.1677/jme.0.0080087; COMBARNOUS Y, 1992, ENDOCR REV, V13, P670, DOI 10.1210/edrv-13-4-670; CREIGHTON TE, 1995, TRENDS BIOTECHNOL, V13, P18, DOI 10.1016/S0167-7799(00)88896-4; Creighton TE, 1996, FASEB J, V10, P110, DOI 10.1096/fasebj.10.1.8566531; FIDDES JC, 1980, NATURE, V286, P684, DOI 10.1038/286684a0; HAZES B, 1988, PROTEIN ENG, V2, P119, DOI 10.1093/protein/2.2.119; Heikoop JC, 1997, EUR J BIOCHEM, V245, P656, DOI 10.1111/j.1432-1033.1997.00656.x; Higuchi R., 1989, PCR TECHNOLOGY, P61; ISAACS NW, 1995, CURR OPIN STRUC BIOL, V5, P391, DOI 10.1016/0959-440X(95)80102-2; JIA XC, 1991, MOL ENDOCRINOL, V5, P759, DOI 10.1210/mend-5-6-759; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; MATSUMURA M, 1991, METHOD ENZYMOL, V202, P336; MATZUK MM, 1989, J BIOL CHEM, V264, P2409; NARAYAN P, 1995, MOL ENDOCRINOL, V9, P1720, DOI 10.1210/me.9.12.1720; OLIJVE W, 1996, MOL HUM REPROD, V2, P374; PACE CN, 1990, TRENDS BIOCHEM SCI, V15, P14, DOI 10.1016/0968-0004(90)90124-T; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; PUETT D, 1994, GLYCOPROTEIN HORMONE, P122; Ruddon RW, 1996, PROTEIN SCI, V5, P1443, DOI 10.1002/pro.5560050801; Shaw A, 1996, CURR OPIN STRUC BIOL, V6, P546, DOI 10.1016/S0959-440X(96)80122-9; Sugahara T, 1996, J BIOL CHEM, V271, P10445, DOI 10.1074/jbc.271.18.10445; SUGAHARA T, 1995, P NATL ACAD SCI USA, V92, P2041, DOI 10.1073/pnas.92.6.2041; Sugahara T, 1996, MOL CELL ENDOCRINOL, V125, P71, DOI 10.1016/S0303-7207(96)03944-5; TALMADGE K, 1984, NATURE, V307, P37, DOI 10.1038/307037a0; VALOVE FM, 1994, ENDOCRINOLOGY, V135, P2657, DOI 10.1210/en.135.6.2657; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X	29	41	45	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1997	15	7					658	662		10.1038/nbt0797-658	http://dx.doi.org/10.1038/nbt0797-658			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XH583	9219269				2022-12-27	WOS:A1997XH58300030
J	Persidis, A; Tomczyk, MS				Persidis, A; Tomczyk, MS			Critical issues in gene therapy commercialization	NATURE BIOTECHNOLOGY			English	Editorial Material									UNIV PENN,WHARTON SCH,EMERGING TECHNOL MANAGEMENT RES PROGRAM,PHILADELPHIA,PA 19104	University of Pennsylvania	Persidis, A (corresponding author), ARGONEX INC,BUSINESS ADM,2044 INDIA RD,SUITE 202,CHARLOTTESVILLE,VA 22901, USA.								0	3	3	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1997	15	7					689	690		10.1038/nbt0797-689	http://dx.doi.org/10.1038/nbt0797-689			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XH583	9219276				2022-12-27	WOS:A1997XH58300036
J	Milner, N; Mir, KU; Southern, EM				Milner, N; Mir, KU; Southern, EM			Selecting effective antisense reagents on combinatorial oligonucleotide arrays	NATURE BIOTECHNOLOGY			English	Article						antisense; oligonucleotide; optimization; arrays; secondary structure	ANTI-MESSENGER OLIGODEOXYNUCLEOTIDES; RNA TRANSLATION; INHIBITION	An array of 1,938 oligodeoxynucleotides (ONs) ranging in length from monomers to 17-mers was fabricated on the surface of a glass plate and used to measure the potential of oligonucleotide for heteroduplex formation with rabbit beta-globin mRNA. The oligonucleotides were complementary to the first 122 bases of mRNA comprising the 5' UTR and bases 1 to 69 of the first exon. Surprisingly few oligonucleotides gave significant heteroduplex yield. Antisense activity, measured in a RNase H assay and by in vitro translation, correlated well with yield of heteroduplex on the array. These results help to explain the variable success that is commonly experienced in the choice of antisense oligonucleotides. For the optimal ON, the concentration required to inhibit translation by 50% was found to be five times less than for any other ON. We find no obvious features in the mRNA sequence or the predicted secondary structure that can explain the variation in heteroduplex yield. However, the arrays provide a simple empirical method of selecting effective antisense oligonucleotides for any RNA target of known sequence.	UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND	University of Oxford								BLAKE KR, 1985, BIOCHEMISTRY-US, V24, P6132, DOI 10.1021/bi00343a015; CAZENAVE C, 1987, NUCLEIC ACIDS RES, V15, P4717, DOI 10.1093/nar/15.12.4717; CAZENAVE C, 1989, NUCLEIC ACIDS RES, V17, P4255, DOI 10.1093/nar/17.11.4255; CAZENAVE C, 1986, BIOCHIMIE, V68, P1063, DOI 10.1016/S0300-9084(86)80180-8; Ho SP, 1996, NUCLEIC ACIDS RES, V24, P1901, DOI 10.1093/nar/24.10.1901; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; KOZAK M, 1994, J MOL BIOL, V235, P95, DOI 10.1016/S0022-2836(05)80019-1; Lima WF, 1997, J BIOL CHEM, V272, P626; LIMA WF, 1992, BIOCHEMISTRY-US, V31, P12055, DOI 10.1021/bi00163a013; MANIATIS T, 1992, MOL CLONING LAB MANU, P1418; MASKOS U, 1992, NUCLEIC ACIDS RES, V20, P1679, DOI 10.1093/nar/20.7.1679; Monia BP, 1996, NAT MED, V2, P668, DOI 10.1038/nm0696-668; PEYMAN A, 1995, BIOL CHEM H-S, V376, P195; RATMEYER L, 1994, BIOCHEMISTRY-US, V33, P5298, DOI 10.1021/bi00183a037; ROVERA G, 1978, ANAL BIOCHEM, V85, P506, DOI 10.1016/0003-2697(78)90248-8; SOUTHERN EM, 1994, NUCLEIC ACIDS RES, V22, P1368, DOI 10.1093/nar/22.8.1368; Stull RA, 1996, ANTISENSE NUCLEIC A, V6, P221, DOI 10.1089/oli.1.1996.6.221; STULL RA, 1992, NUCLEIC ACIDS RES, V20, P3501, DOI 10.1093/nar/20.13.3501; THOMPSON S, 1996, UNPUB NUC ACIDS RES; Wagner RW, 1996, NAT BIOTECHNOL, V14, P840, DOI 10.1038/nbt0796-840	20	220	364	0	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1997	15	6					537	541		10.1038/nbt0697-537	http://dx.doi.org/10.1038/nbt0697-537			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XC772	9181575				2022-12-27	WOS:A1997XC77200028
J	Schneider, EL; Thomas, JG; Bassuk, JA; Sage, EH; Baneyx, F				Schneider, EL; Thomas, JG; Bassuk, JA; Sage, EH; Baneyx, F			Manipulating the aggregation and oxidation of human SPARC in the cytoplasm of Escherichia coli	NATURE BIOTECHNOLOGY			English	Article						protein folding; chaperone; hsp; disulfide; trxB	DISULFIDE BOND FORMATION; PROTEIN; CELL; THIOREDOXIN; MUTATIONS; PEPTIDES; GROWTH	Human SPARC (secreted protein acidic and rich in cysteine), an extracellular matrix protein containing 14 cysteine residues, was found to partition equally between soluble and insoluble cellular fractions when overexpressed in the Escherichia coli cytoplasm. While the growth temperature and medium pH had little effect on inclusion body formation, co-overproduction of the dnaKJ operon, but not of the groE operon, suppressed aggregation at the expense of intracellular accumulation. Although both forms of the protein were fully reduced in wild-type cells, 70% to 85% of soluble and insoluble SPARC could be converted into oxidized species in a thioredoxin reductase (trxB) null mutant following incubation on ice. Approximately 15% to 20% of SPARC exhibited the electrophoretic mobility of the biologically active protein. Overproduction of the dnaKJ operon in trxB cells decreased the formation of disulfide-bonded SPARC multimers in the aggregated material but not in its soluble counterpart. Our results suggest that the activity responsible for disulfide bond formation in trxB mutants acts at the post-translational level and is able to freely diffuse within inclusion bodies.	UNIV WASHINGTON, DEPT CHEM ENGN, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOL STRUCT, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NIDDK NIH HHS [P50-DK-47659] Funding Source: Medline; NIGMS NIH HHS [GM40711] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK047659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040711] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; Bassuk JA, 1996, ARCH BIOCHEM BIOPHYS, V325, P8, DOI 10.1006/abbi.1996.0002; Bassuk JA, 1996, INT J BIOCHEM CELL B, V28, P1031, DOI 10.1016/1357-2725(96)00036-2; BLUM P, 1992, BIO-TECHNOL, V10, P301, DOI 10.1038/nbt0392-301; DERMAN AI, 1995, J BACTERIOL, V177, P3764, DOI 10.1128/jb.177.13.3764-3770.1995; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; FUNK SE, 1993, J CELL PHYSIOL, V154, P53, DOI 10.1002/jcp.1041540108; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; Hohenester E, 1996, NAT STRUCT BIOL, V3, P67, DOI 10.1038/nsb0196-67; LANE TF, 1990, J CELL BIOL, V111, P3065, DOI 10.1083/jcb.111.6.3065; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; Ostermeier M, 1996, J BIOL CHEM, V271, P10616, DOI 10.1074/jbc.271.18.10616; POTTGIESSER J, 1994, J MOL BIOL, V238, P563, DOI 10.1006/jmbi.1994.1315; PROBA K, 1995, GENE, V159, P203, DOI 10.1016/0378-1119(95)00018-2; Rudolph R, 1996, FASEB J, V10, P49, DOI 10.1096/fasebj.10.1.8566547; RUSSEL M, 1986, J BIOL CHEM, V261, P4997; SCHEIN CH, 1989, BIO-TECHNOL, V7, P1141; STRANDBERG L, 1991, APPL ENVIRON MICROB, V57, P1669, DOI 10.1128/AEM.57.6.1669-1674.1991; Thomas JG, 1996, J BIOL CHEM, V271, P11141, DOI 10.1074/jbc.271.19.11141; Thomas JG, 1996, MOL MICROBIOL, V21, P1185, DOI 10.1046/j.1365-2958.1996.651436.x; THOMAS JG, 1997, UNPUB BIOTECHNOL PRO; WALL JG, 1995, CURR OPIN BIOTECH, V6, P507, DOI 10.1016/0958-1669(95)80084-0	22	26	29	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1997	15	6					581	585		10.1038/nbt0697-581	http://dx.doi.org/10.1038/nbt0697-581			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XC772	9181583				2022-12-27	WOS:A1997XC77200036
J	Moore, S				Moore, Sam			Quantifying the effect of inequitable global vaccine coverage on the COVID-19 pandemic	NATURE MEDICINE			English	Editorial Material; Early Access								We used a global mathematical model simulating different scenarios to study the effects of increased COVID-19 vaccine equity during 2021. Our results indicate that vaccine nationalism leads to increased infections and mortality worldwide, and by favoring the emergence of new viral variants, in the long term it may adversely affect all countries.	[Moore, Sam] Univ Warwick, Zeeman Inst SBIDER, Coventry, W Midlands, England	University of Warwick	Moore, S (corresponding author), Univ Warwick, Zeeman Inst SBIDER, Coventry, W Midlands, England.							Moore S, 2021, PLOS COMPUT BIOL, V17, DOI 10.1371/journal.pcbi.1008849; Thompson RN, 2021, LANCET INFECT DIS, V21, P913, DOI 10.1016/S1473-3099(21)00202-4; Wagner CE, 2021, SCIENCE, V373, P1488, DOI 10.1126/science.abj7364; Wang HD, 2022, LANCET, V399, P1513, DOI 10.1016/S0140-6736(21)02796-3	4	0	0	2	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02065-x	http://dx.doi.org/10.1038/s41591-022-02065-x		NOV 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	5Y0EF	36333402	hybrid, Green Published			2022-12-27	WOS:000878964800002
J	Baloh, RH; Johnson, JP; Avalos, P; Allred, P; Svendsen, S; Gowing, G; Roxas, K; Wu, A; Donahue, B; Osborne, S; Lawless, G; Shelley, B; Wheeler, K; Prina, C; Fine, D; Kendra-Romito, T; Stokes, H; Manoukian, V; Muthukumaran, A; Garcia, L; Banuelos, MG; Godoy, M; Bresee, C; Yu, H; Drazin, D; Ross, L; Naruse, R; Babu, H; Macklin, EA; Vo, A; Elsayegh, A; Tourtellotte, W; Maya, M; Burford, M; Diaz, F; Patil, CG; Lewis, RA; Svendsen, CN				Baloh, Robert H.; Johnson, J. Patrick; Avalos, Pablo; Allred, Peggy; Svendsen, Soshana; Gowing, Genevieve; Roxas, Kristina; Wu, Amanda; Donahue, Becky; Osborne, Sheryl; Lawless, George; Shelley, Brandon; Wheeler, Koral; Prina, Carolyn; Fine, Dana; Kendra-Romito, Tami; Stokes, Haniah; Manoukian, Vicki; Muthukumaran, Abirami; Garcia, Leslie; Banuelos, Maria G.; Godoy, Marlesa; Bresee, Catherine; Yu, Hong; Drazin, Doniel; Ross, Lindsey; Naruse, Robert; Babu, Harish; Macklin, Eric A.; Vo, Ashley; Elsayegh, Ashraf; Tourtellotte, Warren; Maya, Marcel; Burford, Matthew; Diaz, Frank; Patil, Chirag G.; Lewis, Richard A.; Svendsen, Clive N.			Transplantation of human neural progenitor cells secreting GDNF into the spinal cord of patients with ALS: a phase 1/2a trial	NATURE MEDICINE			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; LONG-TERM SURVIVAL; NEUROTROPHIC FACTOR; RAT MODEL; STEM-CELLS; MOTOR-NEURONS; INFUSION; NERVE; ASTROCYTES; EXPRESSION	Amyotrophic lateral sclerosis (ALS) involves progressive motor neuron loss, leading to paralysis and death typically within 3-5 years of diagnosis. Dysfunctional astrocytes may contribute to disease and glial cell line-derived neurotrophic factor (GDNF) can be protective. Here we show that human neural progenitor cells transduced with GDNF (CNS10-NPC-GDNF) differentiated to astrocytes protected spinal motor neurons and were safe in animal models. CNS10-NPC-GDNF were transplanted unilaterally into the lumbar spinal cord of 18 ALS participants in a phase 1/2a study (NCT02943850). The primary endpoint of safety at 1 year was met, with no negative effect of the transplant on motor function in the treated leg compared with the untreated leg. Tissue analysis of 13 participants who died of disease progression showed graft survival and GDNF production. Benign neuromas near delivery sites were common incidental findings at post-mortem. This study shows that one administration of engineered neural progenitors can provide new support cells and GDNF delivery to the ALS patient spinal cord for up to 42 months post-transplantation. A phase 1/2a study shows that human neural progenitor cells modified to release the growth factor GDNF are safely transplanted into the spinal cord of patients with ALS, with cell survival and GDNF production for over 3 years.	[Baloh, Robert H.; Svendsen, Soshana; Gowing, Genevieve; Roxas, Kristina; Wu, Amanda; Donahue, Becky; Osborne, Sheryl; Lawless, George; Shelley, Brandon; Garcia, Leslie; Banuelos, Maria G.; Svendsen, Clive N.] Cedars Sinai Med Ctr, Board Governors Regenerat Med Inst, Los Angeles, CA 90048 USA; [Baloh, Robert H.; Allred, Peggy; Wheeler, Koral; Prina, Carolyn; Fine, Dana; Kendra-Romito, Tami; Stokes, Haniah; Manoukian, Vicki; Muthukumaran, Abirami; Tourtellotte, Warren; Burford, Matthew; Diaz, Frank; Lewis, Richard A.] Cedars Sinai Med Ctr, Dept Neurol, Los Angeles, CA USA; [Johnson, J. Patrick] Cedars Sinai Spine Ctr, Los Angeles, CA USA; [Bresee, Catherine] Cedars Sinai Med Ctr, Biostat Core, Los Angeles, CA USA; [Yu, Hong] Massachusetts Gen Hosp, Dept Neurol, Boston, MA USA; [Drazin, Doniel; Ross, Lindsey; Babu, Harish] Cedars Sinai Med Ctr, Dept Neurosurg, Los Angeles, CA USA; [Naruse, Robert] Cedars Sinai Med Ctr, Dept Anesthesiol, Los Angeles, CA USA; [Macklin, Eric A.] Harvard Med Sch, Massachusetts Gen Hosp, Biostat Ctr, Boston, MA USA; [Vo, Ashley] Cedars Sinai Comprehens Transplant Ctr, Los Angeles, CA USA; [Elsayegh, Ashraf] Cedars Sinai Med Ctr, Dept Pulm & Crit Care, Los Angeles, CA USA; [Tourtellotte, Warren] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA USA; [Maya, Marcel] Cedars Sinai Med Ctr, Dept Imaging, Los Angeles, CA USA; [Baloh, Robert H.; Allred, Peggy] Novartis Inst BioMed Res, Cambridge, MA USA; [Gowing, Genevieve; Shelley, Brandon] Fujifilm Cellular Dynam Inc, Madison, WI USA; [Wheeler, Koral] USC Mark & Mary Stevens Neuroimaging & Informat I, Los Angeles, CA USA; [Godoy, Marlesa] UCLA, Dept Psychiat & Biobehav Sci, Los Angeles, CA USA; [Drazin, Doniel] Providence Reg Med Ctr Everett, Dept Neurosurg, Everett, WA USA; [Babu, Harish] SUNY Upstate Med Univ, Dept Neurosurg, Syracuse, NY USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center; Harvard University; Massachusetts General Hospital; Cedars Sinai Medical Center; Cedars Sinai Medical Center; Harvard University; Harvard Medical School; Massachusetts General Hospital; Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center; Novartis; University of California System; University of California Los Angeles; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Svendsen, CN (corresponding author), Cedars Sinai Med Ctr, Board Governors Regenerat Med Inst, Los Angeles, CA 90048 USA.	Clive.svendsen@cshs.org		Godoy, Marlesa/0000-0002-7012-1612; Diaz, Frank/0000-0003-3526-1852	California Institute for Regenerative Medicine [DR2-05320, CLIN2-09284]	California Institute for Regenerative Medicine(California Institute for Regenerative Medicine)	First, we thank the ALS participants for their selfless support of this clinical trial. We thank G. Nikkah for supplying the human fetal sample, the National Gene Vector Biorepository at the Indiana University for the GMP lentivirus-GDNF construct and for the RCL assay, City of Hope (Duarte, CA) for CNS10-NPC-GDNF banking and preparation, Southern Research for performing the GDNF ELISA on patient samples, Absorption (San Diego, CA) for GLP porcine in-life and K. Nikula, at Inotiv for the sample processing. We acknowledge J. Chung, R. Zelaya and A. Nguyen for intraoperative monitoring. We recognize J. Latter, K. Staggenborg, P. Suezaki and A. Ma for help with the preclinical rodent studies. We thank A. Yi, M. Horrigan and E. Han in the Cedars-Sinai Department of Pharmacy for final product dispensing. We acknowledge the contribution from the Cedars-Sinai Biobank and the clinical pathology department for assistance with tissue processing and staining. Funding from The California Institute for Regenerative Medicine (DR2-05320; CLIN2-09284) to C.N.S.; funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Alisky JM, 2000, HUM GENE THER, V11, P2315, DOI 10.1089/104303400750038435; Andres PL, 2017, MUSCLE NERVE, V56, P710, DOI 10.1002/mus.25586; Andres PL, 2012, MUSCLE NERVE, V45, P81, DOI 10.1002/mus.22253; Andres RH, 2011, BRAIN, V134, P1777, DOI 10.1093/brain/awr094; Baloh RH, 2018, CURR OPIN NEUROL, V31, P655, DOI 10.1097/WCO.0000000000000598; Behrstock S, 2006, GENE THER, V13, P379, DOI 10.1038/sj.gt.3302679; Behrstock S, 2008, CELL TRANSPLANT, V17, P753, DOI 10.3727/096368908786516819; Berry JD, 2019, NEUROLOGY, V93, pE2294, DOI 10.1212/WNL.0000000000008620; BRUIJN LI, 1997, NEURON, V18, P327, DOI [10.1016/s0896-6273(00)80272, DOI 10.1016/S0896-6273(00)80272-X, 10.1016/S0896-6273(00)80272-X]; Cheng HT, 2010, CURR PAIN HEADACHE R, V14, P213, DOI 10.1007/s11916-010-0111-0; Clement AM, 2003, SCIENCE, V302, P113, DOI 10.1126/science.1086071; Das MM, 2016, EXP NEUROL, V280, P41, DOI 10.1016/j.expneurol.2016.03.023; DayLollini PA, 1997, EXP NEUROL, V145, P24, DOI 10.1006/exnr.1997.6448; Du ZW, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7626; Emborg ME, 2008, CELL TRANSPLANT, V17, P383; Gill SS, 2003, NAT MED, V9, P589, DOI 10.1038/nm850; Glass JD, 2016, NEUROLOGY, V87, P392, DOI 10.1212/WNL.0000000000002889; Goutman SA, 2018, ANN CLIN TRANSL NEUR, V5, P730, DOI 10.1002/acn3.567; Gowing G, 2014, NEUROREPORT, V25, P367, DOI 10.1097/WNR.0000000000000092; Gutierrez J, 2015, NEUROSURGERY, V77, P604, DOI 10.1227/NEU.0000000000000882; Harms MB, 2013, NEUROL CLIN, V31, P929, DOI 10.1016/j.ncl.2013.05.003; Hauser RA, 1999, ARCH NEUROL-CHICAGO, V56, P179, DOI 10.1001/archneur.56.2.179; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; Hovland DN, 2007, TOXICOL PATHOL, V35, P676, DOI 10.1080/01926230701481899; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Jaiswal MK, 2019, MED RES REV, V39, P733, DOI 10.1002/med.21528; Klein SM, 2005, HUM GENE THER, V16, P509, DOI 10.1089/hum.2005.16.509; Kordower JH, 1997, CELL TRANSPLANT, V6, P213, DOI 10.1016/S0963-6897(97)00019-5; KORDOWER JH, 1995, NEW ENGL J MED, V332, P1118, DOI 10.1056/NEJM199504273321702; Lepore AC, 2008, NAT NEUROSCI, V11, P1294, DOI 10.1038/nn.2210; Lepore AC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025968; Liang K-Y, 2000, SANKHYA INDIAN J S B, P134, DOI [DOI 10.2307/25053123, DOI 10.2337/DB12-0868]; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Mazzini L, 2010, EXP NEUROL, V223, P229, DOI 10.1016/j.expneurol.2009.08.007; Mazzini L, 2019, STEM CELL TRANSL MED, V8, P887, DOI 10.1002/sctm.18-0154; McBride JL, 2004, J COMP NEUROL, V475, P211, DOI 10.1002/cne.20176; Mendez I, 2005, BRAIN, V128, P1498, DOI 10.1093/brain/awh510; Miller T, 2020, NEW ENGL J MED, V383, P109, DOI 10.1056/NEJMoa2003715; Mueller C, 2020, NEW ENGL J MED, V383, P151, DOI 10.1056/NEJMoa2005056; Nichols NL, 2013, AM J RESP CRIT CARE, V187, P535, DOI 10.1164/rccm.201206-1072OC; Ostenfeld T, 2000, EXP NEUROL, V164, P215, DOI 10.1006/exnr.2000.7427; PRADAS J, 1993, NEUROLOGY, V43, P751, DOI 10.1212/WNL.43.4.751; Reith W, 2018, RADIOLOGE, V58, P142, DOI 10.1007/s00117-017-0354-4; Rushton DJ, 2017, NEUROLOGY, V89, P196, DOI 10.1212/WNL.0000000000004105; Shelley B. C., 2014, JOVE-J VIS EXP, V88; Slevin JT, 2005, J NEUROSURG, V102, P216, DOI 10.3171/jns.2005.102.2.0216; Suzuki M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000689; Svendsen CN, 1998, J NEUROSCI METH, V85, P141, DOI 10.1016/S0165-0270(98)00126-5; Svendsen CN, 1997, EXP NEUROL, V148, P135, DOI 10.1006/exnr.1997.6634; Thomsen GM, 2017, GENE THER, V24, P245, DOI 10.1038/gt.2017.9; Thomsen GM, 2018, STEM CELLS, V36, P1122, DOI 10.1002/stem.2825; Wang SM, 2008, INVEST OPHTH VIS SCI, V49, P3201, DOI 10.1167/iovs.08-1831; Winkler J, 1997, ANN NEUROL, V41, P82, DOI 10.1002/ana.410410114; Xu P, 2013, GLIA, V61, P1029, DOI 10.1002/glia.22491	54	4	4	7	7	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2022	28	9					1813	+		10.1038/s41591-022-01956-3	http://dx.doi.org/10.1038/s41591-022-01956-3		SEP 2022	29	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4S0LI	36064599	Green Published, hybrid			2022-12-27	WOS:000850016600002
J	Joutsa, J; Moussawi, K; Siddiqi, SH; Abdolahi, A; Drew, W; Cohen, AL; Ross, TJ; Deshpande, HU; Wang, HZ; Bruss, J; Stein, EA; Volkow, ND; Grafman, JH; van Wijngaarden, E; Boes, AD; Fox, MD				Joutsa, Juho; Moussawi, Khaled; Siddiqi, Shan H.; Abdolahi, Amir; Drew, William; Cohen, Alexander L.; Ross, Thomas J.; Deshpande, Harshawardhan U.; Wang, Henry Z.; Bruss, Joel; Stein, Elliot A.; Volkow, Nora D.; Grafman, Jordan H.; van Wijngaarden, Edwin; Boes, Aaron D.; Fox, Michael D.			Brain lesions disrupting addiction map to a common human brain circuit	NATURE MEDICINE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; SYMPTOMS; NETWORK; DAMAGE; CONNECTIVITY; VARIABILITY	Drug addiction is a public health crisis for which new treatments are urgently needed. In rare cases, regional brain damage can lead to addiction remission. These cases may be used to identify therapeutic targets for neuromodulation. We analyzed two cohorts of patients addicted to smoking at the time of focal brain damage (cohort 1 n = 67; cohort 2 n = 62). Lesion locations were mapped to a brain atlas and the brain network functionally connected to each lesion location was computed using human connectome data (n = 1,000). Associations with addiction remission were identified. Generalizability was assessed using an independent cohort of patients with focal brain damage and alcohol addiction risk scores (n = 186). Specificity was assessed through comparison to 37 other neuropsychological variables. Lesions disrupting smoking addiction occurred in many different brain locations but were characterized by a specific pattern of brain connectivity. This pattern involved positive connectivity to the dorsal cingulate, lateral prefrontal cortex, and insula and negative connectivity to the medial prefrontal and temporal cortex. This circuit was reproducible across independent lesion cohorts, associated with reduced alcohol addiction risk, and specific to addiction metrics. Hubs that best matched the connectivity profile for addiction remission were the paracingulate gyrus, left frontal operculum, and medial fronto-polar cortex. We conclude that brain lesions disrupting addiction map to a specific human brain circuit and that hubs in this circuit provide testable targets for therapeutic neuromodulation. Lesions resulting in addiction remission occur in multiple different brain locations but map to a specific brain circuit.	[Joutsa, Juho] Univ Turku, Clin Neurosci, Turku Brain & Mind Ctr, Turku, Finland; [Joutsa, Juho] Turku Univ Hosp, Neuroctr, Turku, Finland; [Joutsa, Juho] Turku Univ Hosp, Turku PET Ctr, Turku, Finland; [Joutsa, Juho; Siddiqi, Shan H.; Drew, William; Cohen, Alexander L.; Fox, Michael D.] Beth Israel Deaconess Med Ctr, Berenson Allen Ctr Noninvas Brain Stimulat, Boston, MA 02215 USA; [Moussawi, Khaled; Ross, Thomas J.; Deshpande, Harshawardhan U.; Stein, Elliot A.] Natl Inst Drug Abuse, Intramural Res Program, Baltimore, MD USA; [Moussawi, Khaled] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA; [Siddiqi, Shan H.; Drew, William; Cohen, Alexander L.; Fox, Michael D.] Brigham & Womens Hosp, Dept Neurol Psychiat & Radiol, Ctr Brain Circuit Therapeut, Harvard Med Sch, Boston, MA 02115 USA; [Abdolahi, Amir] Philips Healthcare, Clin Affairs, Cambridge, MA 02138 USA; [Cohen, Alexander L.] Boston Childrens Hosp, Dept Neurol, Boston, MA 02215 USA; [Cohen, Alexander L.] Boston Childrens Hosp, Harvard Med Sch, Dept Radiol, Computat Radiol Lab, Boston, MA USA; [Wang, Henry Z.] Univ Rochester, Med Ctr, Dept Imaging Sci, Rochester, NY 14642 USA; [Bruss, Joel; Boes, Aaron D.] Univ Iowa Hosp & Clin, Dept Pediat, Iowa City, IA USA; [Bruss, Joel; Boes, Aaron D.] Univ Iowa Hosp & Clin, Dept Neurol & Psychiat, Iowa City, IA USA; [Grafman, Jordan H.] Shirley Ryan AbilityLab, Chicago, IL 60611 USA; [Grafman, Jordan H.] Northwestern Univ, Dept Phys Med & Rehabil, Neurol Cognit Neurol & Alzheimers Ctr, Chicago, IL USA; [Grafman, Jordan H.] Northwestern Univ, Dept Psychiat, Feinberg Sch Med, Chicago, IL USA; [Grafman, Jordan H.] Northwestern Univ, Dept Psychol, Weinberg Coll Arts & Sci, Chicago, IL USA; [van Wijngaarden, Edwin] Univ Rochester, Med Ctr, Dept Publ Hlth Sci, Rochester, NY 14642 USA; [Volkow, Nora D.] Natl Inst Alcohol Abuse & Alcoholism, Intramural Res Program, Bethesda, MD USA	University of Turku; University of Turku; University of Turku; Harvard University; Beth Israel Deaconess Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Philips; Philips Healthcare; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard Medical School; University of Rochester; University of Iowa; University of Iowa; Shirley Ryan AbilityLab; Northwestern University; Northwestern University; Feinberg School of Medicine; Northwestern University; University of Rochester; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Joutsa, J (corresponding author), Univ Turku, Clin Neurosci, Turku Brain & Mind Ctr, Turku, Finland.; Joutsa, J (corresponding author), Turku Univ Hosp, Neuroctr, Turku, Finland.; Joutsa, J (corresponding author), Turku Univ Hosp, Turku PET Ctr, Turku, Finland.; Joutsa, J; Fox, MD (corresponding author), Beth Israel Deaconess Med Ctr, Berenson Allen Ctr Noninvas Brain Stimulat, Boston, MA 02215 USA.; Fox, MD (corresponding author), Brigham & Womens Hosp, Dept Neurol Psychiat & Radiol, Ctr Brain Circuit Therapeut, Harvard Med Sch, Boston, MA 02115 USA.	jtjout@utu.fi; foxmdphd@gmail.com		van Wijngaarden, Edwin/0000-0001-7583-4630; Cohen, Alexander/0000-0001-6557-5866; Moussawi, Khaled/0000-0001-6378-0428; Drew, William/0000-0002-9178-8731; Deshpande, Harshawardhan/0000-0001-8620-8280	Academy of Finland [295580]; Finnish Medical Foundation; Instrumentarium Research Foundation; Finnish Foundation for Alcohol Studies; National Institute on Drug Abuse (NIDA) [DA048085]; Sidney R. Baer Foundation; Brain & Behavior Research Foundation; National Institutes of Health (NIH); National Institute of Mental Health [K23MH120510]; Intramural Research Program of NIDA/NIH; NIH; National Institute on Aging [R01AG054328-01A1]; NIH [5R01NS114405-03, R01MH113929, R21MH126271, R56AG069086, R21NS123813]; Sidney R. Baer Jr. Foundation; Nancy Lurie Marks Foundation; Kaye Family Research Fund; Ellison/Baszucki Foundation; Mather's Foundation; Turku University Hospital (ERVA funds)	Academy of Finland(Academy of Finland); Finnish Medical Foundation; Instrumentarium Research Foundation; Finnish Foundation for Alcohol Studies; National Institute on Drug Abuse (NIDA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); Sidney R. Baer Foundation; Brain & Behavior Research Foundation(NARSAD); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Intramural Research Program of NIDA/NIH; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Sidney R. Baer Jr. Foundation; Nancy Lurie Marks Foundation; Kaye Family Research Fund; Ellison/Baszucki Foundation; Mather's Foundation; Turku University Hospital (ERVA funds)	We thank Y. Roth, A. Zangen and BrainsWay for sharing the electric field models of their H4 and H7 TMS coils. J.J. was funded by the Academy of Finland (no. 295580), Finnish Medical Foundation, Instrumentarium Research Foundation, Finnish Foundation for Alcohol Studies and Turku University Hospital (ERVA funds). K.M. was funded by the National Institute on Drug Abuse (NIDA) (no. DA048085). S.H.S. was funded by the Sidney R. Baer and Brain & Behavior Research Foundations. A.L.C. was funded by the National Institutes of Health (NIH) and National Institute of Mental Health (no. K23MH120510). T.J.R., H.U.D. and E.A.S. were supported by the Intramural Research Program of NIDA/NIH. H.Z.W. was supported by the NIH and National Institute on Aging (no. R01AG054328-01A1). J.B. and A.D.B. were funded by the NIH (no. 5R01NS114405-03). M.D.F. was supported by grants from the Sidney R. Baer Jr. Foundation, the NIH (R01MH113929 R01MH113929, R21MH126271, R56AG069086, R21NS123813), the Nancy Lurie Marks Foundation, the Kaye Family Research Fund, the Ellison/Baszucki Foundation, and the Mather's Foundation.	Abdolahi A, 2015, ADDICT BEHAV, V51, P24, DOI 10.1016/j.addbeh.2015.07.001; Balasubramaniam V, 1973, Neurol India, V21, P63; Boes AD, 2015, BRAIN, V138, P3061, DOI 10.1093/brain/awv228; BOWREN M, BRAIN; Chen BT, 2013, NATURE, V496, P359, DOI 10.1038/nature12024; Damasio H, 1989, LESION ANAL NEUROPSY; de Schotten MT, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18920-9; Dinur-Klein L, 2014, BIOL PSYCHIAT, V76, P742, DOI 10.1016/j.biopsych.2014.05.020; Dougherty DD, 2002, AM J PSYCHIAT, V159, P269, DOI 10.1176/appi.ajp.159.2.269; Ekhtiari H, 2019, NEUROSCI BIOBEHAV R, V104, P118, DOI 10.1016/j.neubiorev.2019.06.007; Fiocchi S, 2018, IEEE J ELECTROMAG RF, V2, P242, DOI 10.1109/JERM.2018.2874528; Fischer DB, 2017, NEUROIMAGE, V157, P34, DOI 10.1016/j.neuroimage.2017.05.060; Foulon C, 2018, GIGASCIENCE, V7, DOI 10.1093/gigascience/giy004; Fox MD, 2018, NEW ENGL J MED, V379, P2237, DOI 10.1056/NEJMra1706158; Gaznick N, 2014, NICOTINE TOB RES, V16, P445, DOI 10.1093/ntr/ntt172; Harel M, 2022, BIOL PSYCHIAT, V91, P1061, DOI 10.1016/j.biopsych.2021.11.020; Horn A, 2017, ANN NEUROL, V82, P67, DOI 10.1002/ana.24974; Hu YZ, 2019, P NATL ACAD SCI USA, V116, P9066, DOI 10.1073/pnas.1819978116; Hu YZ, 2015, JAMA PSYCHIAT, V72, P584, DOI 10.1001/jamapsychiatry.2015.1; Joutsa J, 2018, ANN NEUROL, V84, P153, DOI 10.1002/ana.25285; KANAKA TS, 1978, APPL NEUROPHYSIOL, V41, P86; Kapur N, 1996, BRAIN, V119, P1775, DOI 10.1093/brain/119.5.1775; Karnath HO, 2018, NEUROIMAGE, V165, P180, DOI 10.1016/j.neuroimage.2017.10.028; Karolis VR, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09344-1; Koob GF, 2016, LANCET PSYCHIAT, V3, P760, DOI 10.1016/S2215-0366(16)00104-8; Li N, 2013, WORLD NEUROSURG, V80, DOI 10.1016/j.wneu.2012.10.007; Luigjes J, 2019, NEUROPSYCHOL REV, V29, P116, DOI 10.1007/s11065-018-9393-5; Mawlawi O, 2001, J CEREBR BLOOD F MET, V21, P1034, DOI 10.1097/00004647-200109000-00002; McLellan AT, 2000, JAMA-J AM MED ASSOC, V284, P1689, DOI 10.1001/jama.284.13.1689; Medvedev S. V., 2003, Fiziologiya Cheloveka, V29, P117; Naqvi NH, 2007, SCIENCE, V315, P531, DOI 10.1126/science.1135926; Raymont Vanessa, 2011, Front Neurol, V2, P15, DOI 10.3389/fneur.2011.00015; Rojkova K, 2016, BRAIN STRUCT FUNCT, V221, P1751, DOI 10.1007/s00429-015-1001-3; Siddiqi S, 2021, BIOL PSYCHIAT, V89, pS99; Sorensen AG, 2007, P INT SOC MAG RESON, V15, P3720, DOI [DOI 10.1128/MCB.25.11.4371, DOI 10.1038/SJ.IJ0.0803354]; Sun B, 2015, NEUROSURGICAL TREATM; Thiebaut de Schotten Michel, 2011, Nat Neurosci, V14, P1245, DOI 10.1038/nn.2905; Thiebaut de Schotten M, 2015, CEREB CORTEX, V25, P4812, DOI 10.1093/cercor/bhv173; Thiebaut de Schotten M, 2011, NEUROIMAGE, V54, P49, DOI 10.1016/j.neuroimage.2010.07.055; Volkow ND, 2016, NEW ENGL J MED, V374, P363, DOI 10.1056/NEJMra1511480; Volkow ND, 2013, CURR OPIN NEUROBIOL, V23, P639, DOI 10.1016/j.conb.2013.01.002; Winkler AM, 2014, NEUROIMAGE, V92, P381, DOI 10.1016/j.neuroimage.2014.01.060	42	8	8	16	17	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2022	28	6					1249	+		10.1038/s41591-022-01834-y	http://dx.doi.org/10.1038/s41591-022-01834-y		JUN 2022	12	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E9IE	35697842	Green Published, hybrid			2022-12-27	WOS:000810339200001
J	Niu, LL; Thiele, M; Geyer, PE; Rasmussen, DN; Webel, HE; Santos, A; Gupta, R; Meier, F; Strauss, M; Kjaergaard, M; Lindvig, K; Jacobsen, S; Rasmussen, S; Hansen, T; Krag, A; Mann, M				Niu, Lili; Thiele, Maja; Geyer, Philipp E.; Rasmussen, Ditlev Nytoft; Webel, Henry Emanuel; Santos, Alberto; Gupta, Rajat; Meier, Florian; Strauss, Maximilian; Kjaergaard, Maria; Lindvig, Katrine; Jacobsen, Suganya; Rasmussen, Simon; Hansen, Torben; Krag, Aleksander; Mann, Matthias			Noninvasive proteomic biomarkers for alcohol-related liver disease	NATURE MEDICINE			English	Article							NONALCOHOLIC FATTY LIVER; FIBROSIS; MARKERS; BIOPSY; SYSTEM; IDENTIFICATION; COMPLICATIONS; ASSOCIATION	Interogation of mass-spectrometry-based proteomics of liver and plasma from a cohort of patients with alcohol-related liver disease identifies noninvasive biomarkers associated with early stages of disease progression, including significant fibrosis, inflammation and steatosis. Alcohol-related liver disease (ALD) is a major cause of liver-related death worldwide, yet understanding of the three key pathological features of the disease-fibrosis, inflammation and steatosis-remains incomplete. Here, we present a paired liver-plasma proteomics approach to infer molecular pathophysiology and to explore the diagnostic and prognostic capability of plasma proteomics in 596 individuals (137 controls and 459 individuals with ALD), 360 of whom had biopsy-based histological assessment. We analyzed all plasma samples and 79 liver biopsies using a mass spectrometry (MS)-based proteomics workflow with short gradient times and an enhanced, data-independent acquisition scheme in only 3 weeks of measurement time. In plasma and liver biopsy tissues, metabolic functions were downregulated whereas fibrosis-associated signaling and immune responses were upregulated. Machine learning models identified proteomics biomarker panels that detected significant fibrosis (receiver operating characteristic-area under the curve (ROC-AUC), 0.92, accuracy, 0.82) and mild inflammation (ROC-AUC, 0.87, accuracy, 0.79) more accurately than existing clinical assays (DeLong's test, P < 0.05). These biomarker panels were found to be accurate in prediction of future liver-related events and all-cause mortality, with a Harrell's C-index of 0.90 and 0.79, respectively. An independent validation cohort reproduced the diagnostic model performance, laying the foundation for routine MS-based liver disease testing.	[Niu, Lili; Webel, Henry Emanuel; Santos, Alberto; Gupta, Rajat; Strauss, Maximilian; Rasmussen, Simon; Mann, Matthias] Univ Copenhagen, Fac Hlth & Med Sci, Novo Nordisk Fdn Ctr Prot Res, Copenhagen, Denmark; [Niu, Lili; Geyer, Philipp E.; Meier, Florian; Strauss, Maximilian; Mann, Matthias] Max Planck Inst Biochem, Dept Prote & Signal Transduct, Martinsried, Germany; [Thiele, Maja; Rasmussen, Ditlev Nytoft; Kjaergaard, Maria; Lindvig, Katrine; Jacobsen, Suganya; Krag, Aleksander] Odense Univ Hosp, Dept Gastroenterol & Hepatol, Odense Liver Res Ctr, Odense, Denmark; [Thiele, Maja] Univ Southern Denmark, Dept Clin Res, Odense, Denmark; [Geyer, Philipp E.] OmicEra Diagnost, Planegg, Germany; [Meier, Florian] Jena Univ Hosp, Funct Prote, Jena, Germany; [Hansen, Torben] Univ Copenhagen, Fac Hlth & Med Sci, Novo Nordisk Fdn, Ctr Basic Metab Res, Copenhagen, Denmark; [Santos, Alberto] Univ Oxford, Big Data Inst, Nuffield Dept Med, Oxford, England; [Gupta, Rajat] Pfizer Worldwide Res & Dev, San Diego, CA 92182 USA	University of Copenhagen; Max Planck Society; University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Friedrich Schiller University of Jena; Novo Nordisk Foundation; University of Copenhagen; University of Oxford; Pfizer	Mann, M (corresponding author), Univ Copenhagen, Fac Hlth & Med Sci, Novo Nordisk Fdn Ctr Prot Res, Copenhagen, Denmark.; Mann, M (corresponding author), Max Planck Inst Biochem, Dept Prote & Signal Transduct, Martinsried, Germany.	mmann@biochem.mpg.de	Lindvig, Katrine/S-3737-2016; Strauss, Maximilian/GRR-3068-2022; Thiele, Maja/AAD-2353-2019; Jacobsen, Suganya/G-2529-2019	Lindvig, Katrine/0000-0001-7654-7748; Strauss, Maximilian/0000-0003-3320-6833; Kjaergaard, Maria/0000-0001-8452-1820; Niu, Lili/0000-0003-4571-4368; Thiele, Maja/0000-0003-1854-1924; Hansen, Torben/0000-0001-8748-3831; Lindvig, Katrine Prier/0000-0001-7891-7706; Webel, Henry/0000-0001-8833-7617; Jacobsen, Suganya/0000-0001-9392-4509; Krag, Aleksander/0000-0002-9598-4932	Novo Nordisk Foundation [NNF15CC0001, NNF14CC0001]; Copenhagen Bioscience PhD Program [NNF16CC0020906, NNF19SA0035440]; Challenge Program [NNF15OC0016692]; European Union [668031]	Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Copenhagen Bioscience PhD Program; Challenge Program; European Union(European Commission)	We thank all patients and healthy volunteers who participated in the clinical cohort. We also thank all members of the Clinical Proteomics Group and the Department of Proteomics and Signal Transduction (Max Planck Institute of Biochemistry). In particular, we thank N. J. Wewer Albrechtsen for fruitful discussions and J. Madsen, M. Rykaer and L. Drici for technical assistance. Further, we thank P. Andersen and L. Just for technical assistance and nurses and staff at Odense Liver Research Centre for assistance in clinical studies. We also thank the funding agencies that supported this study: the Novo Nordisk Foundation for the Clinical Proteomics Group (grant no. NNF15CC0001 to M.M.), the Copenhagen Bioscience PhD Program (grant nos. NNF16CC0020906 to L.N. and NNF19SA0035440 to H.E.W.) and the Challenge Program (grant no. NNF15OC0016692 to the MicrobLiver consortium (T.H., A.K. and M.M. in this study)), and the European Union Horizon 2020 research and innovation program under grant agreement no. 668031 to the GALAXY consortium (A.K. in this study). Furthermore, L.N., H.E.W. and S.R. were supported by the Novo Nordisk Foundation (grant no. NNF14CC0001 to S.R.).	Abo-elenein AM, 2020, ENDOCR METAB IMMUNE, V20, P112, DOI 10.2174/1871530319666190529092555; Aebersold R, 2016, NATURE, V537, P347, DOI 10.1038/nature19949; Altelaar AFM, 2013, NAT REV GENET, V14, P35, DOI 10.1038/nrg3356; Asphaug L, 2020, HEPATOLOGY, V71, P2093, DOI 10.1002/hep.30979; Atabaki-Pasdar N, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003149; Bache N, 2018, MOL CELL PROTEOMICS, V17, P2284, DOI 10.1074/mcp.TIR118.000853; Baker ES, 2014, MOL CELL PROTEOMICS, V13, P1119, DOI 10.1074/mcp.M113.034595; Bruderer R, 2015, MOL CELL PROTEOMICS, V14, P1400, DOI 10.1074/mcp.M114.044305; Budayeva HG, 2020, NAT REV DRUG DISCOV, V19, P414, DOI 10.1038/s41573-020-0063-y; Calamita Zamir, 1997, Arquivos de Gastroenterologia, V34, P139; Cheung KJ, 2010, EUR J GASTROEN HEPAT, V22, P1066, DOI 10.1097/MEG.0b013e328337d602; Coilly A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56235-y; Ding C, 2003, PROCEEDINGS OF THE 2003 IEEE BIOINFORMATICS CONFERENCE, P523, DOI 10.1109/CSB.2003.1227396; Nguyen-Khac E, 2018, LANCET GASTROENTEROL, V3, P614, DOI 10.1016/S2468-1253(18)30124-9; Feldstein AE, 2009, HEPATOLOGY, V50, P1072, DOI 10.1002/hep.23050; Forns X, 2002, HEPATOLOGY, V36, P986, DOI 10.1053/jhep.2002.36128; Gangadharan B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039603; Geyer PE, 2016, CELL SYST, V2, P185, DOI 10.1016/j.cels.2016.02.015; Gines P, 2022, HEPATOLOGY, V75, P219, DOI 10.1002/hep.32163; Glen J, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i4428; Grinfeld D, 2017, ANAL CHEM, V89, P1202, DOI 10.1021/acs.analchem.6b03636; Guha IN, 2008, HEPATOLOGY, V47, P455, DOI 10.1002/hep.21984; Guo TN, 2015, NAT MED, V21, P407, DOI 10.1038/nm.3807; Hou W, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20190395; Imbert-Bismut F, 2001, LANCET, V357, P1069, DOI 10.1016/S0140-6736(00)04258-6; Israelsen Mads, 2022, Clin Gastroenterol Hepatol, V20, P1784, DOI 10.1016/j.cgh.2020.11.038; Julien J, 2020, LANCET PUBLIC HEALTH, V5, pE316, DOI 10.1016/S2468-2667(20)30062-1; Kampf C, 2014, FASEB J, V28, P2901, DOI 10.1096/fj.14-250555; Karlsen TH, 2022, LANCET, V399, P61, DOI 10.1016/S0140-6736(21)01701-3; Karsdal MA, 2015, AM J PHYSIOL-GASTR L, V308, pG807, DOI 10.1152/ajpgi.00447.2014; Kasprzycka M, 2015, CELL ADHES MIGR, V9, P83, DOI 10.4161/19336918.2014.994901; Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701; Lackner C, 2021, J HEPATOL, V75, P810, DOI 10.1016/j.jhep.2021.05.029; Li CX, 2018, CANCER BIOL MED, V15, P124, DOI 10.20892/j.issn.2095-3941.2018.0018; Liu LX, 2009, WORLD J GASTROENTERO, V15, P3246, DOI 10.3748/wjg.15.3246; Madsen BS, 2021, ALIMENT PHARM THER, V54, P699, DOI 10.1111/apt.16513; Martyn-Simmons CL, 2014, BRIT J DERMATOL, V171, P267, DOI 10.1111/bjd.12782; Moon AM, 2020, CLIN GASTROENTEROL H, V18, P2650, DOI 10.1016/j.cgh.2019.07.060; Nilsson E, 2019, ALIMENT PHARM THER, V49, P1421, DOI 10.1111/apt.15255; Niu L., 2019, HUMAN GUT LIVER AXIS; Niu LL, 2022, MOL SYST BIOL, V18, DOI 10.15252/msb.202210947; Niu L, 2019, MOL SYST BIOL, V15, DOI 10.15252/msb.20188793; Pang J, 2017, ALIMENT PHARM THER, V46, P175, DOI 10.1111/apt.14119; Pavlov CS, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010542.pub2; Pencina MJ, 2008, STAT MED, V27, P157, DOI 10.1002/sim.2929; Pimpin L, 2018, J HEPATOL, V69, P718, DOI 10.1016/j.jhep.2018.05.011; Pratt DS, 2000, NEW ENGL J MED, V342, P1266, DOI 10.1056/NEJM200004273421707; Prystupa A, 2018, ANN AGR ENV MED, V25, P527, DOI 10.26444/aaem/92650; Rasmussen DN, 2021, J HEPATOL, V75, P1017, DOI 10.1016/j.jhep.2021.05.037; Rosenberg WMC, 2004, GASTROENTEROLOGY, V127, P1704, DOI 10.1053/j.gastro.2004.08.052; Sheron N, 2016, J HEPATOL, V64, P957, DOI 10.1016/j.jhep.2015.11.006; Sorbi D, 1999, AM J GASTROENTEROL, V94, P1018; Takyar V, 2017, ALIMENT PHARM THER, V45, P744, DOI 10.1111/apt.13939; Taylor RS, 2020, GASTROENTEROLOGY, V158, P1611, DOI 10.1053/j.gastro.2020.01.043; Teli MR, 1995, HEPATOLOGY, V22, P1714, DOI 10.1002/hep.1840220616; Thiele M, 2021, ALIMENT PHARM THER, V54, P1070, DOI 10.1111/apt.16567; Thiele M, 2018, GASTROENTEROLOGY, V154, P1369, DOI 10.1053/j.gastro.2018.01.005; Thiele M, 2016, GASTROENTEROLOGY, V150, P123, DOI 10.1053/j.gastro.2015.09.040; Tsuchida T, 2017, NAT REV GASTRO HEPAT, V14, P397, DOI 10.1038/nrgastro.2017.38; Tyanova S, 2016, NAT METHODS, V13, P731, DOI [10.1038/nmeth.3901, 10.1038/NMETH.3901]; Vallet-Pichard A, 2007, HEPATOLOGY, V46, P32, DOI 10.1002/hep.21669; Veyel D, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58030-6; Wai CT, 2003, HEPATOLOGY, V38, P518, DOI 10.1053/jhep.2003.50346; Wichmann C, 2019, MOL CELL PROTEOMICS, V18, P982, DOI 10.1074/mcp.TIR118.001131; Wood GC, 2017, SCI REP-UK, V7, DOI 10.1038/srep43238	65	10	10	27	38	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2022	28	6					1277	+		10.1038/s41591-022-01850-y	http://dx.doi.org/10.1038/s41591-022-01850-y		JUN 2022	26	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E9IE	35654907	Green Published, hybrid			2022-12-27	WOS:000805079400002
J	Gyawali, B; Booth, CM				Gyawali, Bishal; Booth, Christopher M.			Cancer treatments should benefit patients: a common-sense revolution in oncology	NATURE MEDICINE			English	Article							PATIENTS EXPECTATIONS; CLINICAL ONCOLOGY; AMERICAN SOCIETY; ESMO-MAGNITUDE; TRIALS; HARMS; TESTS; COST; CARE	Many newly approved cancer therapeutics offer limited clinical benefits yet are still prescribed to patients. A common-sense revolution in oncology would prioritize treatments that meaningfully improve survival and quality of life.	[Gyawali, Bishal; Booth, Christopher M.] Queens Univ, Canc Res Inst, Div Canc Care & Epidemiol, Kingston, ON, Canada; [Gyawali, Bishal; Booth, Christopher M.] Queens Univ, Dept Oncol, Kingston, ON, Canada; [Gyawali, Bishal; Booth, Christopher M.] Queens Univ, Dept Publ Hlth Sci, Kingston, ON, Canada	Queens University - Canada; Queens University - Canada; Queens University - Canada	Gyawali, B (corresponding author), Queens Univ, Canc Res Inst, Div Canc Care & Epidemiol, Kingston, ON, Canada.; Gyawali, B (corresponding author), Queens Univ, Dept Oncol, Kingston, ON, Canada.; Gyawali, B (corresponding author), Queens Univ, Dept Publ Hlth Sci, Kingston, ON, Canada.	gyawali.bishal@queensu.ca		Gyawali, Bishal/0000-0001-7444-8594	Canada Research Chair in Population Cancer Care; Ontario Institute for Cancer Research - government of Ontario	Canada Research Chair in Population Cancer Care; Ontario Institute for Cancer Research - government of Ontario	We acknowledge E. Eisenhauer (Queen's University, Kingston, Canada) and I. Tannock (Princess Margaret Cancer Centre, Toronto, Canada) for helpful comments on an earlier draft of the manuscript. C.M.B. is supported as the Canada Research Chair in Population Cancer Care. B.G. receives salary support from the Ontario Institute for Cancer Research funded by the government of Ontario.	Abola MV, 2016, MAYO CLIN PROC, V91, P1668, DOI 10.1016/j.mayocp.2016.08.015; Abola MV, 2016, JAMA ONCOL, V2, P139, DOI 10.1001/jamaoncol.2015.3931; Booth CM, 2019, NAT REV CLIN ONCOL, V16, P312, DOI 10.1038/s41571-019-0167-7; Cherny NI, 2017, ANN ONCOL, V28, P2340, DOI 10.1093/annonc/mdx310; Del Paggio JC, 2017, ANN ONCOL, V28, P157, DOI 10.1093/annonc/mdw538; Del Paggio JC, 2021, JAMA ONCOL, V7, P728, DOI 10.1001/jamaoncol.2021.0379; Del Paggio JC, 2017, LANCET ONCOL, V18, P887, DOI 10.1016/S1470-2045(17)30415-1; Fundytus A, 2021, JAMA ONCOL, V7, P1757, DOI 10.1001/jamaoncol.2021.3600; Gyawali B, 2021, ESMO OPEN, V6, DOI 10.1016/j.esmoop.2021.100117; Gyawali B, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n1959; Gyawali B, 2020, NAT CANCER, V1, P142, DOI 10.1038/s43018-020-0030-x; Gyawali Bishal, 2019, Am Soc Clin Oncol Educ Book, V39, P374, DOI 10.1200/EDBK_242229; Gyawali B, 2018, LANCET ONCOL, V19, P288, DOI 10.1016/S1470-2045(18)30076-7; Hoffmann TC, 2017, JAMA INTERN MED, V177, P407, DOI 10.1001/jamainternmed.2016.8254; Hoffmann TC, 2015, JAMA INTERN MED, V175, P274, DOI 10.1001/jamainternmed.2014.6016; Raphael MJ, 2020, NAT REV CLIN ONCOL, V17, P271, DOI 10.1038/s41571-020-0345-7; Schnipper LE, 2015, J CLIN ONCOL, V33, P2563, DOI 10.1200/JCO.2015.61.6706; Schnipper LE, 2012, J CLIN ONCOL, V30, P1715, DOI 10.1200/JCO.2012.42.8375; Sharma S, 2021, J NATL COMPR CANC NE, V19, P1258, DOI 10.6004/jnccn.2021.7016; Smith TJ, 2011, NEW ENGL J MED, V364, P2060, DOI 10.1056/NEJMsb1013826; Weeks JC, 2012, NEW ENGL J MED, V367, P1616, DOI 10.1056/NEJMoa1204410	21	3	3	0	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4					617	620		10.1038/s41591-021-01662-6	http://dx.doi.org/10.1038/s41591-021-01662-6			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0Q6DV	35440715				2022-12-27	WOS:000785007700009
J	Strohman, RC				Strohman, RC			Profit margins and epistemology	NATURE BIOTECHNOLOGY			English	Editorial Material									Univ Calif Berkeley, Dept Cell & Mol Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Strohman, RC (corresponding author), Univ Calif Berkeley, Dept Cell & Mol Biol, Stanley Hall, Berkeley, CA 94720 USA.							[Anonymous], 1996, FORM TRANSFORMATION; Bains W, 1997, NAT BIOTECHNOL, V15, P396, DOI 10.1038/nbt0597-396; Berry Wendell, 1983, STANDING WORDS, P25; Costanza, 1997, NATURE, V387, P253, DOI DOI 10.1038/387253A0; Fell D., 1997, UNDERSTANDING CONTRO; HEISENBERG W, 1958, PHYSICS PHILOS, P104; Nurse P, 1997, NATURE, V387, P657, DOI 10.1038/42600; Streelman JT, 1997, NAT BIOTECHNOL, V15, P696, DOI 10.1038/nbt0897-696; Strohman RC, 1997, NAT BIOTECHNOL, V15, P194, DOI 10.1038/nbt0397-194; Veech RL, 1996, CELL BIOCHEM FUNCT, V14, P229; Williams N, 1997, SCIENCE, V277, P476, DOI 10.1126/science.277.5325.476	11	5	5	0	1	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1997	15	12					1224	1225		10.1038/nbt1197-1224	http://dx.doi.org/10.1038/nbt1197-1224			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YQ046	9359094				2022-12-27	WOS:000071342000005
J	Fox, JL				Fox, JL			Europe and FDA agree to limited inspections	NATURE BIOTECHNOLOGY			English	News Item																			0	0	0	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					714	715		10.1038/nbt0897-714	http://dx.doi.org/10.1038/nbt0897-714			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9333519				2022-12-27	WOS:A1997XM70700011
J	Vancetto, MDC; deOliveira, JM; Prado, SMA; Fratelli, F; Higashi, HG				Vancetto, MDC; deOliveira, JM; Prado, SMA; Fratelli, F; Higashi, HG			Tetanus toxoid purification: A case study	NATURE BIOTECHNOLOGY			English	Editorial Material									INST BUTANTAN,TECHNOL DEV & PROD DIV,BR-05503900 SAO PAULO,BRAZIL	Instituto Butantan	Vancetto, MDC (corresponding author), INST BUTANTAN,ANAEROB VACCINES SECT,CAIXA POSTAL 65,BR-05503900 SAO PAULO,BRAZIL.							FRATELLI F, 1993, ARQ BIOL TECNOL, V36, P709; PRADO SMA, 1993, B BIOTECNOL, V4, P3; PRADO SMA, 1992, B BIOTECNOL, V3, P11; RAYNAUD M, 1971, ANN I PASTEUR PARIS, V120, P801; VANCETTO MDC, 1994, ARQ BIOL TECNOL, V37, P577; World Health Organization, 1977, MAN PROD CONTR VACC	6	2	2	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					807	808		10.1038/nbt0897-807	http://dx.doi.org/10.1038/nbt0897-807			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255801				2022-12-27	WOS:A1997XM70700038
J	Kontermann, RE; Wing, MG; Winter, G				Kontermann, RE; Wing, MG; Winter, G			Complement recruitment using bispecific diabodies	NATURE BIOTECHNOLOGY			English	Article						antibody engineering; diabody; complement C1q; phage display	IMMUNOSUPPRESSIVE PROPERTIES; MONOCLONAL-ANTIBODY; BINDING-SITE; PHAGOCYTOSIS; ACTIVATION; CLQ; IGG; C1Q; MODULATION; COMPONENT	We describe the engineering of antibody fragments produced in bacteria for recruitment of complement effector functions. From a phage display repertoire we isolated human antibody fragments directed against complement Clq, and linked these to lysozyme-specific antibody fragments, creating bispecific antibodies (diabodies). One diabody was able to recruit Clq, resulting in efficient lysis of lysozyme-coated sheep erythrocytes, and also induced rosette-formation of erythrocytes with human monocytes and phagocytosis after phorbol ester stimulation. These diabodies may have therapeutic applications requiring the activation of complement.	MRC,MOL IMMUNOPATHOL UNIT,CAMBRIDGE CB2 2QH,ENGLAND; MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; MRC,CTR PROT ENGN,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology; University of Cambridge			Kontermann, Roland E./F-9263-2014		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALEGRE ML, 1992, J IMMUNOL, V148, P3461; ALEGRE ML, 1994, TRANSPLANTATION, V57, P1537; BOBAK DA, 1987, J IMMUNOL, V138, P1150; BOBAK DA, 1988, J IMMUNOL, V136, P1023; BROWN EJ, 1991, CURR OPIN IMMUNOL, V3, P76, DOI 10.1016/0952-7915(91)90081-B; BURTON DR, 1992, ADV IMMUNOL, V51, P1, DOI 10.1016/S0065-2776(08)60486-1; CHATENOUD L, 1990, TRANSPLANTATION, V49, P697, DOI 10.1097/00007890-199004000-00009; COOPER NR, 1985, ADV IMMUNOL, V37, P151, DOI 10.1016/S0065-2776(08)60340-5; DUNCAN AR, 1988, NATURE, V332, P738, DOI 10.1038/332738a0; DUNCAN AR, 1988, NATURE, V332, P563, DOI 10.1038/332563a0; ERDEI A, 1988, MOL IMMUNOL, V25, P1067, DOI 10.1016/0161-5890(88)90139-3; FANGER MW, 1991, TRENDS BIOTECHNOL, V9, P375, DOI 10.1016/0167-7799(91)90129-6; FANGER MW, 1992, CRIT REV IMMUNOL, V12, P101; GUAN E, 1991, J BIOL CHEM, V266, P20345; Holliger P, 1996, PROTEIN ENG, V9, P299, DOI 10.1093/protein/9.3.299; Holliger P, 1997, NAT BIOTECHNOL, V15, P632, DOI 10.1038/nbt0797-632; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; KONTERMANN RE, 1997, IN PRESS IMMUNOTECHN; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; McGuinness BT, 1996, NAT BIOTECHNOL, V14, P1149, DOI 10.1038/nbt0996-1149; Moreau T, 1996, BRAIN, V119, P225, DOI 10.1093/brain/119.1.225; OIKI S, 1988, J IMMUNOL, V141, P3177; PERISIC O, 1994, STRUCTURE, V2, P1217, DOI 10.1016/S0969-2126(94)00123-5; TENNER AJ, 1982, J IMMUNOL, V128, P2547; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309; Wing MG, 1996, J CLIN INVEST, V98, P2819, DOI 10.1172/JCI119110; WING MG, 1997, IN PRESS THER IMMUNO; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; XIA MQ, 1991, EUR J IMMUNOL, V21, P1677, DOI 10.1002/eji.1830210714; Zhu ZP, 1996, BIO-TECHNOL, V14, P192, DOI 10.1038/nbt0296-192	30	53	60	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1997	15	7					629	631		10.1038/nbt0797-629	http://dx.doi.org/10.1038/nbt0797-629			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XH583	9219263				2022-12-27	WOS:A1997XH58300024
J	Breaker, RR				Breaker, RR			DNA enzymes	NATURE BIOTECHNOLOGY			English	Article						biocatalysis; deoxyribozyme; in vitro selection; ribosyme; RNA world	HUMAN-IMMUNODEFICIENCY-VIRUS; RNA WORLD; TERTIARY INTERACTIONS; TETRAHYMENA RIBOZYME; CATALYTIC RNAS; GAAA TETRALOOP; TELOMERIC DNA; SELECTION; THROMBIN; APTAMER	Biological catalysis is dominated by enzymes that are made of protein, but several distinct classes of catalytic RNAs are known to promote chemical transformations that are fundamental to cellular metabolism. Is biological catalysis limited only to these two biopolymers, or is DNA also capable of functioning as an enzyme in nature? To date, no DNA enzymes of natural origin have been found. However, an increasing number of catalytic DNAs, with characteristics that are similar to those of ribozymes, are being produced outside the confines of the cell. An assessment of the potential for structure formation by DNA leads to the conclusion that DNA might have considerable latent potential for enzymatic function.			Breaker, RR (corresponding author), YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06520, USA.		Breaker, Ronald/E-9679-2010	Breaker, Ronald/0000-0002-2165-536X				Altman Sidney, 1995, P67; Benkovic SJ, 1996, NATURE, V383, P23, DOI 10.1038/383023a0; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; Breaker R R, 1994, Chem Biol, V1, P223, DOI 10.1016/1074-5521(94)90014-0; BREAKER RR, 1995, CHEM BIOL, V2, P655, DOI 10.1016/1074-5521(95)90028-4; BREAKER RR, 1994, TRENDS BIOTECHNOL, V12, P268, DOI 10.1016/0167-7799(94)90138-4; Breaker RR, 1996, CURR OPIN BIOTECH, V7, P442, DOI 10.1016/S0958-1669(96)80122-4; BREAKER RR, 1995, J MOL EVOL, V40, P551, DOI 10.1007/BF00160500; BREAKER RR, 1997, IN PRESS CHEM REV; BURGSTALLER P, 1995, ANGEW CHEM INT EDIT, V34, P1189, DOI 10.1002/anie.199511891; Carmi N, 1996, CHEM BIOL, V3, P1039, DOI 10.1016/S1074-5521(96)90170-2; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; CHAPMAN KB, 1994, CURR OPIN STRUC BIOL, V4, P618, DOI 10.1016/S0959-440X(94)90227-5; CHAPMAN MS, 1995, STRUCTURE, V3, P151, DOI 10.1016/S0969-2126(01)00146-0; CHARTRAND P, 1995, NUCLEIC ACIDS RES, V23, P4092, DOI 10.1093/nar/23.20.4092; CHEONG CJ, 1990, NATURE, V346, P680, DOI 10.1038/346680a0; CONNELL GJ, 1993, ORIGINS LIFE EVOL B, V23, P291, DOI 10.1007/BF01582079; Cordes MHJ, 1996, CURR OPIN STRUC BIOL, V6, P3, DOI 10.1016/S0959-440X(96)80088-1; Corey MJ, 1996, P NATL ACAD SCI USA, V93, P11428, DOI 10.1073/pnas.93.21.11428; COSTA M, 1995, EMBO J, V14, P1276, DOI 10.1002/j.1460-2075.1995.tb07111.x; Crain PF, 1996, NUCLEIC ACIDS RES, V24, P98, DOI 10.1093/nar/24.1.98; CUENOUD B, 1995, NATURE, V375, P611, DOI 10.1038/375611a0; DERVAN P, 1989, J AM CHEM SOC, V111, P8733; EKLAND EH, 1995, SCIENCE, V269, P364, DOI 10.1126/science.7618102; ELLINGTON AD, 1992, NATURE, V355, P850, DOI 10.1038/355850a0; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; Faulhammer D, 1996, ANGEW CHEM INT EDIT, V35, P2837, DOI 10.1002/anie.199628371; Fersht A., 1985, ENZYME STRUCTURE MEC; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GOLD L, 1995, J BIOL CHEM, V270, P13581, DOI 10.1074/jbc.270.23.13581; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; GUSCHLBAUER W, 1990, J BIOMOL STRUCT DYN, V8, P491, DOI 10.1080/07391102.1990.10507825; GUTELL RR, 1988, NUCLEIC ACIDS RES, V16, pR175, DOI 10.1093/nar/16.suppl.r175; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; HILBERS CW, 1991, NUCLEOS NUCLEOT, V10, P61, DOI 10.1080/07328319108046436; HIRAO I, 1989, NUCLEIC ACIDS RES, V17, P2223, DOI 10.1093/nar/17.6.2223; HUIZENGA DE, 1995, BIOCHEMISTRY-US, V34, P656, DOI 10.1021/bi00002a033; JAEGER L, 1994, J MOL BIOL, V236, P1271, DOI 10.1016/0022-2836(94)90055-8; JENISON RD, 1994, SCIENCE, V263, P1425, DOI 10.1126/science.7510417; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; KAHN AS, 1988, SCIENCE, V241, P74; KAZAKOV SA, 1988, NATURE, V335, P186, DOI 10.1038/335186a0; KRAUT J, 1988, SCIENCE, V242, P533, DOI 10.1126/science.3051385; LATHAM JA, 1994, NUCLEIC ACIDS RES, V22, P2817, DOI 10.1093/nar/22.14.2817; Lee DH, 1996, NATURE, V382, P525, DOI 10.1038/382525a0; LI T, 1994, NATURE, V369, P218, DOI 10.1038/369218a0; Li YF, 1996, BIOCHEMISTRY-US, V35, P6911, DOI 10.1021/bi960038h; Li YF, 1996, NAT STRUCT BIOL, V3, P743, DOI 10.1038/nsb0996-743; LIN Y, 1995, P NATL ACAD SCI USA, V92, P11044, DOI 10.1073/pnas.92.24.11044; MACAYA RF, 1995, BIOCHEMISTRY-US, V34, P4478, DOI 10.1021/bi00013a041; MACAYA RF, 1993, P NATL ACAD SCI USA, V90, P3745, DOI 10.1073/pnas.90.8.3745; MATTHEWS BW, 1993, CURR OPIN STRUC BIOL, V3, P589, DOI 10.1016/0959-440X(93)90088-3; MICHEL F, 1995, ANNU REV BIOCHEM, V64, P435, DOI 10.1146/annurev.bi.64.070195.002251; Moras D, 1997, RNA, V3, P111; MURPHY FL, 1994, J MOL BIOL, V236, P49, DOI 10.1006/jmbi.1994.1117; NADEAU JG, 1985, NUCLEIC ACIDS RES, V13, P8259, DOI 10.1093/nar/13.22.8259; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; ORGEL LE, 1994, SCI AM, V271, P77, DOI 10.1038/scientificamerican1094-76; ORGEL LE, 1968, J MOL BIOL, V38, P381, DOI 10.1016/0022-2836(68)90393-8; PAQUETTE J, 1990, EUR J BIOCHEM, V189, P259, DOI 10.1111/j.1432-1033.1990.tb15485.x; PERREAULT JP, 1989, EUR J BIOCHEM, V186, P87, DOI 10.1111/j.1432-1033.1989.tb15181.x; PICCIRILLI JA, 1990, NATURE, V343, P33, DOI 10.1038/343033a0; PLEY HW, 1994, NATURE, V372, P111, DOI 10.1038/372111a0; PYLE AM, 1992, NATURE, V358, P123, DOI 10.1038/358123a0; PYLE AM, 1993, SCIENCE, V261, P709, DOI 10.1126/science.7688142; RICH A, 1993, GENE, V135, P99, DOI 10.1016/0378-1119(93)90054-7; ROBERTSON MP, 1995, SCIENCE, V268, P702, DOI 10.1126/science.7732378; SANGER W, 1984, PRINCIPLES NUCL STRU, P220; SANTALUCIA J, 1992, SCIENCE, V256, P217, DOI 10.1126/science.1373521; SCHNEIDER DJ, 1995, BIOCHEMISTRY-US, V34, P9599, DOI 10.1021/bi00029a037; SCHULTZE P, 1994, J MOL BIOL, V235, P1532, DOI 10.1006/jmbi.1994.1105; SHARP P, 1991, SCIENCE, V253, P663; SIGURDSSON ST, 1995, TRENDS BIOTECHNOL, V13, P286, DOI 10.1016/S0167-7799(00)88966-0; STROBEL SA, 1993, BIOCHEMISTRY-US, V32, P13593, DOI 10.1021/bi00212a027; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; TSIANG M, 1995, J BIOL CHEM, V270, P19370, DOI 10.1074/jbc.270.33.19370; TUERK C, 1988, P NATL ACAD SCI USA, V85, P1364, DOI 10.1073/pnas.85.5.1364; VONAHSEN U, 1993, BIOESSAYS, V15, P299, DOI 10.1002/bies.950150503; VONKIEDROWSKI G, 1986, ANGEW CHEM INT EDIT, V25, P932, DOI 10.1002/anie.198609322; WALSH CT, 1979, ENZYMATIC REACTION M; WANG KY, 1993, BIOCHEMISTRY-US, V32, P1899, DOI 10.1021/bi00059a003; WILLIAMSON JR, 1994, ANNU REV BIOPH BIOM, V23, P703, DOI 10.1146/annurev.bb.23.060194.003415; WOESE CR, 1983, MICROBIOL REV, V47, P621, DOI 10.1128/MMBR.47.4.621-669.1983; WU TF, 1992, J AM CHEM SOC, V114, P317, DOI 10.1021/ja00027a040; WYATT JR, 1994, P NATL ACAD SCI USA, V91, P1356, DOI 10.1073/pnas.91.4.1356; YANG JH, 1992, BIOCHEMISTRY-US, V31, P5005, DOI 10.1021/bi00136a013; YARUS M, 1993, FASEB J, V7, P31, DOI 10.1096/fasebj.7.1.8422972	90	283	310	4	119	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1997	15	5					427	431		10.1038/nbt0597-427	http://dx.doi.org/10.1038/nbt0597-427			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WX237	9131619				2022-12-27	WOS:A1997WX23700024
J	Golub, ES				Golub, ES			Finding a vocabulary for the extrascientific significance of technology	NATURE BIOTECHNOLOGY			English	Editorial Material											Golub, ES (corresponding author), PACIFIC CTR ETH & APPL BIOL,SAN DIEGO,CA, USA.							Golub ES, 1997, NAT BIOTECHNOL, V15, P112, DOI 10.1038/nbt0297-112	1	1	1	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1997	15	5					394	394		10.1038/nbt0597-394	http://dx.doi.org/10.1038/nbt0597-394			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WX237	9131597	Bronze			2022-12-27	WOS:A1997WX23700004
J	Robertson, D				Robertson, D			Crohn's trial shows the pros of antisense	NATURE BIOTECHNOLOGY			English	News Item																			0	10	21	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1997	15	3					209	209		10.1038/nbt0397-209	http://dx.doi.org/10.1038/nbt0397-209			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WM050	9062911	Bronze			2022-12-27	WOS:A1997WM05000006
J	Silverman, BC; Ne'eman, A; Strauss, DH; Plosky, WD; Francis, LP; Stein, MA; Bierer, BE				Silverman, Benjamin C.; Ne'eman, Ari; Strauss, David H.; Plosky, Willyanne DeCormier; Francis, Leslie P.; Stein, Michael Ashley; Bierer, Barbara E.			Supported decision-making can advance clinical research participation for people with disabilities	NATURE MEDICINE			English	Editorial Material; Early Access								Clinical research often excludes people with disabilities who have impaired decisional capacity, but they can be included through supported decision-making, where their decisions can be assisted by designated supporters of their choosing. This will promote equitable access to research.	[Silverman, Benjamin C.] Mass Gen Brigham, Human Res Affairs, Boston, MA 02199 USA; [Silverman, Benjamin C.; Bierer, Barbara E.] Harvard Med Sch, Boston, MA 02115 USA; [Ne'eman, Ari] Harvard Grad Sch Arts & Sci, Cambridge, MA USA; [Ne'eman, Ari; Stein, Michael Ashley] Harvard Law Sch Project Disabil, Cambridge, MA USA; [Ne'eman, Ari] Brandeis Univ, Lurie Inst Disabil Policy, Waltham, MA USA; [Strauss, David H.] Columbia Univ, Dept Psychiat, Vagelos Coll Phys & Surg, New York, NY USA; [Strauss, David H.; Plosky, Willyanne DeCormier; Bierer, Barbara E.] Brigham & Womens Hosp, Multireg Clin Trials Ctr, Cambridge, MA USA; [Strauss, David H.; Plosky, Willyanne DeCormier; Bierer, Barbara E.] Harvard, Cambridge, MA USA; [Francis, Leslie P.] Univ Utah, Dept Philosophy, Salt Lake City, UT USA; [Francis, Leslie P.] Univ Utah, SJ Quinney Coll Law, Salt Lake City, UT USA; [Bierer, Barbara E.] Brigham & Womens Hosp, Dept Med, Div Global Hlth Equ, 75 Francis St, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brandeis University; Columbia University; Harvard University; Brigham & Women's Hospital; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Harvard University; Brigham & Women's Hospital	Silverman, BC (corresponding author), Mass Gen Brigham, Human Res Affairs, Boston, MA 02199 USA.; Silverman, BC (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	bcsilverman@partners.org		Bierer, Barbara/0000-0001-6448-8170; Francis, Leslie P./0000-0002-7356-3459				[Anonymous], 2016, RIGHT MAKE CHOICES I; [Anonymous], 2020, IMPL SUPP DEC MAK DE; [Anonymous], 2022, SUPPORTED DECISION M; [Anonymous], 2022, SECTION504OFTHEREHAB; [Anonymous], 2014, INFORM CONSENT DRAFT; [Anonymous], YOUR STATE; [Anonymous], 2022, AMERICANS DISABILITI; [Anonymous], 2009, SUBCOMMITTEE INCLUSI; Bard JS, 2021, JLPA, V6, P489; CPR, 2022, US SUPPORTED DECISIO; Feldman MA, 2014, J INTELL DISABIL RES, V58, P800, DOI 10.1111/jir.12091; Friesen P, 2022, AM J BIOETHICS, DOI 10.1080/15265161.2022.2063434; Howell B. M, 2019, RES INVOLVING PARTIC; Office for Human Research Protections, 2018, US CODE FEDERAL REGU; Shogren KA, 2017, EDUC TRAIN AUTISM DE, V52, P144; Stein M. A., 2021, MENTAL HLTH LEGAL CA; United Nations Convention on the Rights of Persons with Disabilities (CRPD), ART 12 EQ REC LAW; Encalada AV, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18105204	18	0	0	1	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02035-3	http://dx.doi.org/10.1038/s41591-022-02035-3		OCT 2022	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	5M2FU	36271167				2022-12-27	WOS:000870918800001
J	Scheaffer, SM; Lee, D; Whitener, B; Ying, BL; Wu, K; Liang, CY; Jani, H; Martin, P; Amato, NJ; Avena, LE; Berrueta, DM; Schmidt, SD; O'Dell, S; Nasir, A; Chuang, GY; Stewart-Jones, G; Koup, RA; Doria-Rose, NA; Carfi, A; Elbashir, SM; Thackray, LB; Edwards, DK; Diamond, MS				Scheaffer, Suzanne M.; Lee, Diana; Whitener, Bradley; Ying, Baoling; Wu, Kai; Liang, Chieh-Yu; Jani, Hardik; Martin, Philippa; Amato, Nicholas J.; Avena, Laura E.; Berrueta, Daniela Montes; Schmidt, Stephen D.; O'Dell, Sijy; Nasir, Arshan; Chuang, Gwo-Yu; Stewart-Jones, Guillaume; Koup, Richard A.; Doria-Rose, Nicole A.; Carfi, Andrea; Elbashir, Sayda M.; Thackray, Larissa B.; Edwards, Darin K.; Diamond, Michael S.			Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice	NATURE MEDICINE			English	Article; Early Access							ANTIBODY	Bivalent vaccines elicit broad immune responses that neutralize ancestral SARS-CoV-2 and variants of concern and offer a customizable approach to protect from COVID-19 as new virus variants emerge. The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants in the Omicron lineage has resulted in diminished Coronavirus Disease 2019 (COVID-19) vaccine efficacy and persistent transmission. In this study, we evaluated the immunogenicity and protective efficacy of two, recently authorized, bivalent COVID-19 vaccines that contain two mRNAs encoding Wuhan-1 and either BA.1 (mRNA-1273.214) or BA.4/5 (mRNA-1273.222) spike proteins. As a primary two-dose immunization series in mice, both bivalent vaccines induced greater neutralizing antibody responses against Omicron variants than the parental, monovalent mRNA-1273 vaccine. When administered to mice as a booster at 7 months after the primary vaccination series with mRNA-1273, the bivalent vaccines induced broadly neutralizing antibody responses. Whereas most anti-Omicron receptor binding domain antibodies in serum induced by mRNA-1273, mRNA-1273.214 and mRNA-1273.222 boosters cross-reacted with the antecedent Wuhan-1 spike antigen, the mRNA-1273.214 and mRNA-1273.222 bivalent vaccine boosters also induced unique BA.1-specific and BA.4/5-specific responses, respectively. Although boosting with parental or bivalent mRNA vaccines substantially improved protection against BA.5 compared to mice receiving two vaccine doses, the levels of infection, inflammation and pathology in the lung were lowest in animals administered the bivalent mRNA vaccines. Thus, boosting with bivalent Omicron-based mRNA-1273.214 or mRNA-1273.222 vaccines enhances immunogenicity and confers protection in mice against a currently circulating SARS-CoV-2 strain.	[Scheaffer, Suzanne M.; Whitener, Bradley; Ying, Baoling; Liang, Chieh-Yu; Thackray, Larissa B.; Diamond, Michael S.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Lee, Diana; Wu, Kai; Jani, Hardik; Martin, Philippa; Amato, Nicholas J.; Avena, Laura E.; Berrueta, Daniela Montes; Nasir, Arshan; Chuang, Gwo-Yu; Stewart-Jones, Guillaume; Carfi, Andrea; Elbashir, Sayda M.; Edwards, Darin K.] Moderna Inc, Cambridge, MA 02139 USA; [Schmidt, Stephen D.; O'Dell, Sijy; Koup, Richard A.; Doria-Rose, Nicole A.] NIAID, Vaccine Res Ctr, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Diamond, Michael S.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63108 USA; [Diamond, Michael S.] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63108 USA; [Diamond, Michael S.] Washington Univ, Sch Med, Andrew M & Jane M Bursky Ctr Human Immunol & Immu, St Louis, MO 63108 USA; [Diamond, Michael S.] Washington Univ, Sch Med, Ctr Vaccines & Immun Microbial Pathogens, St Louis, MO 63108 USA	Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Thackray, LB; Diamond, MS (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.; Elbashir, SM; Edwards, DK (corresponding author), Moderna Inc, Cambridge, MA 02139 USA.; Diamond, MS (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63108 USA.; Diamond, MS (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63108 USA.; Diamond, MS (corresponding author), Washington Univ, Sch Med, Andrew M & Jane M Bursky Ctr Human Immunol & Immu, St Louis, MO 63108 USA.; Diamond, MS (corresponding author), Washington Univ, Sch Med, Ctr Vaccines & Immun Microbial Pathogens, St Louis, MO 63108 USA.	sayda.elbashir@modernatx.com; lthackray@wustl.edu; darin.edwards@modernatx.com; mdiamond@wustl.edu		Liang, Chieh-Yu/0000-0003-4624-7212	National Institutes of Health [R01 AI157155]; NIAID Centers of Excellence for Influenza Research and Response (CEIRR) [HHSN272201400008C, 75N93021C00014, 75N93019C00051]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID Centers of Excellence for Influenza Research and Response (CEIRR)	This study was supported by the National Institutes of Health (R01 AI157155, NIAID Centers of Excellence for Influenza Research and Response (CEIRR) contracts HHSN272201400008C, 75N93021C00014 and 75N93019C00051, all to M.S.D.). We thank M. Suthar for the BA.5 isolate used in this study. We also acknowledge and thank M. Whitt for support on VSV-based pseudovirus production.	Amanat F, 2021, CELL, V184, P3936, DOI 10.1016/j.cell.2021.06.005; Andrews N, 2022, NEW ENGL J MED, V386, P1532, DOI [10.1056/NEJMoa2119451, 10.1016/S1473-3099(22)00309-7]; Branche A. R., 2022, PREPRINT, DOI [10.1101/2022.07.12.22277336, DOI 10.1101/2022.07.12.22277336, 10.1101/2022.07.12.22277336v1, DOI 10.1101/2022.07.12.22277336V1]; Case JB, 2020, CELL HOST MICROBE, V28, P475, DOI 10.1016/j.chom.2020.06.021; Case JB, 2020, VIROLOGY, V548, P39, DOI 10.1016/j.virol.2020.05.015; Chalkias S, 2022, NAT MED, DOI 10.1038/s41591-022-02031-7; Chalkias S, 2022, NEW ENGL J MED, V387, P1279, DOI 10.1056/NEJMoa2208343; Chen RE, 2021, NATURE, V596, P103, DOI 10.1038/s41586-021-03720-y; Chen RTE, 2021, NAT MED, V27, DOI 10.1038/s41591-021-01294-w; Choi A, 2021, NAT MED, V27, P2025, DOI 10.1038/s41591-021-01527-y; Corbett Kizzmekia S, 2020, bioRxiv, DOI [10.1101/2020.06.11.145920, 10.1038/s41586-020-2622-0]; Khoury DS, 2022, medRxiv, DOI 10.1101/2022.08.25.22279237; Deng W, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392-022-00979-z; Ding CC, 2022, J MED VIROL, V94, P5841, DOI 10.1002/jmv.28081; Du P, 2022, J MED VIROL, V94, P4287, DOI 10.1002/jmv.27885; Bentley EG, 2021, bioRxiv, DOI 10.1101/2021.12.26.474085; Elliott P, 2022, SCIENCE, V375, P1406, DOI 10.1126/science.abn8347; Errico JM, 2022, ADV IMMUNOL, V154, P1, DOI 10.1016/bs.ai.2022.07.001; Flemming Alexandra, 2022, Nat Rev Immunol, V22, P146, DOI 10.1038/s41577-022-00690-8; Gagne M, 2022, CELL, V185, P1556, DOI 10.1016/j.cell.2022.03.038; Gorman MJ, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100405; Halfmann PJ, 2022, NATURE, V603, P687, DOI 10.1038/s41586-022-04441-6; Hassett KJ, 2019, MOL THER-NUCL ACIDS, V15, P1, DOI 10.1016/j.omtn.2019.01.013; Iketani S, 2022, NATURE, V604, P553, DOI 10.1038/s41586-022-04594-4; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Kaplonek P, 2022, IMMUNITY, V55, P355, DOI 10.1016/j.immuni.2022.01.001; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Krause PR, 2021, NEW ENGL J MED, V385, P179, DOI 10.1056/NEJMsr2105280; Caserta LC, 2022, bioRxiv, DOI 10.1101/2022.09.02.506368; Lee I.-J., 2022, BIORXIV, DOI [10.1101/2022.01.31.478406, DOI 10.1101/2022.01.31.478406]; Letko M, 2020, NAT MICROBIOL, V5, P562, DOI [10.1038/s41564-020-0688-y, 10.1101/2020.01.22.915660]; Liu Yangli, 2020, J Infect, DOI 10.1016/j.jinf.2020.02.028; Nelson J, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz6893; Pajon R, 2022, NEW ENGL J MED, V386, P1088, DOI 10.1056/NEJMc2119912; Park Young-Jun, 2022, Science, V378, P619, DOI 10.1126/science.adc9127; Pavot V, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-29219-2; Plante JA, 2021, NATURE, V592, P116, DOI 10.1038/s41586-020-2895-3; Qi H, 2022, NAT IMMUNOL, V23, P1008, DOI 10.1038/s41590-022-01248-5; Rathe JA, 2021, J INFECT DIS, V223, P1120, DOI 10.1093/infdis/jiaa797; Rossler A., 2022, LANCET MICROBE, VS2666-5247; Schiepers A., 2022, BIORXIV, DOI [10.1101/2022.08.29.505743v1, DOI 10.1101/2022.08.29.505743V1]; Shuai HP, 2022, NATURE, V603, P693, DOI 10.1038/s41586-022-04442-5; Stadlbauer Daniel, 2020, Curr Protoc Microbiol, V57, pe100, DOI 10.1002/cpmc.100; Tarke A, 2022, CELL, V185, P847, DOI 10.1016/j.cell.2022.01.015; Tseng HF, 2022, NAT MED, V28, P1063, DOI 10.1038/s41591-022-01753-y; Uraki R, 2022, NATURE, V607, P119, DOI 10.1038/s41586-022-04856-1; Valentino L, 2022, RSF-RUS SAGE J SOC S, V8, P89, DOI [10.18311/ti/2021/v28i1/24809, 10.1097/QAD.0000000000003368, 10.1016/j.vaccine.2022.07.056, 10.7758/RSF.2022.8.7.05]; VanBlargan LA, 2021, IMMUNITY, V54, P2399, DOI 10.1016/j.immuni.2021.08.016; Wang Q, 2022, NATURE, V608, P603, DOI 10.1038/s41586-022-05053-w; WEBSTER RG, 1966, J IMMUNOL, V97, P177; Whitt MA, 2010, J VIROL METHODS, V169, P365, DOI 10.1016/j.jviromet.2010.08.006; Winkler ES, 2020, NAT IMMUNOL, V21, P1327, DOI 10.1038/s41590-020-0778-2; Ying BL, 2022, CELL, V185, P1572, DOI 10.1016/j.cell.2022.03.037; Ying BL, 2022, SCI TRANSL MED, V14, DOI [10.1101/2021.08.25.457693, 10.1126/scitranslmed.abm3302]; Zang RC, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc3582	55	2	2	6	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02092-8	http://dx.doi.org/10.1038/s41591-022-02092-8		OCT 2022	26	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	6M2OV	36265510	Bronze			2022-12-27	WOS:000888714200001
J	Garvey, WT; Batterham, RL; Bhatta, M; Buscemi, S; Christensen, LN; Frias, JP; Jodar, E; Kandler, K; Rigas, G; Wadden, TA; Wharton, S				Garvey, W. Timothy; Batterham, Rachel L.; Bhatta, Meena; Buscemi, Silvio; Christensen, Louise N.; Frias, Juan P.; Jodar, Esteban; Kandler, Kristian; Rigas, Georgia; Wadden, Thomas A.; Wharton, Sean		STEP 5 Study Grp	Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial	NATURE MEDICINE			English	Article; Early Access							PLACEBO-CONTROLLED TRIAL; REACTIVE PROTEIN-LEVELS; WEIGHT-LOSS; 2.4 MG; MAINTENANCE; LIRAGLUTIDE; PREVENTION; MANAGEMENT	Results from the STEP 5 trial, testing semaglutide as an adjunct to behavioral interventions in adults with overweight or obesity, demonstrate sustained weight loss over a period of 104 weeks. The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term treatment of adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes. The co-primary endpoints were the percentage change in body weight and achievement of weight loss of >= 5% at week 104. Efficacy was assessed among all randomized participants regardless of treatment discontinuation or rescue intervention. From 5 October 2018 to 1 February 2019, 304 participants were randomly assigned to semaglutide 2.4 mg (n = 152) or placebo (n = 152), 92.8% of whom completed the trial (attended the end-of-trial safety visit). Most participants were female (236 (77.6%)) and white (283 (93.1%)), with a mean (s.d.) age of 47.3 (11.0) years, body mass index of 38.5 (6.9) kg m(-2) and weight of 106.0 (22.0) kg. The mean change in body weight from baseline to week 104 was -15.2% in the semaglutide group (n = 152) versus -2.6% with placebo (n = 152), for an estimated treatment difference of -12.6 %-points (95% confidence interval, -15.3 to -9.8; P < 0.0001). More participants in the semaglutide group than in the placebo group achieved weight loss >= 5% from baseline at week 104 (77.1% versus 34.4%; P < 0.0001). Gastrointestinal adverse events, mostly mild-to-moderate, were reported more often with semaglutide than with placebo (82.2% versus 53.9%). In summary, in adults with overweight (with at least one weight-related comorbidity) or obesity, semaglutide treatment led to substantial, sustained weight loss over 104 weeks versus placebo. NCT03693430	[Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA; [Batterham, Rachel L.] UCL, Univ Coll London Ctr Obes Res, Div Med, London, England; [Batterham, Rachel L.] UCLH Biomed Res Ctr, Natl Inst Hlth Res, London, England; [Batterham, Rachel L.] Univ Coll London Hosp, Ctr Weight Management & Metab Surg, London, England; [Bhatta, Meena; Christensen, Louise N.; Kandler, Kristian] Novo Nordisk AS, Soborg, Denmark; [Buscemi, Silvio] Policlin Univ Hosp, Unit Clin Nutr, Palermo, Italy; [Buscemi, Silvio] Univ Palermo, Dept Hlth Promot Mother & Child Care, Internal Med & Med Specialties, Palermo, Italy; [Frias, Juan P.] Natl Res Inst, Los Angeles, CA USA; [Jodar, Esteban] Univ Europea Madrid, Hosp Univ QuironSalud Madrid, Dept Endocrinol & Nutr, Madrid, Spain; [Rigas, Georgia] St George Private Hosp, Dept Bariatr Metab Surg, Sydney, NSW, Australia; [Wadden, Thomas A.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Wharton, Sean] York Univ, York, N Yorkshire, England; [Wharton, Sean] McMaster Univ, Hamilton, ON, Canada; [Wharton, Sean] Wharton Weight Management Clin, Toronto, ON, Canada	University of Alabama System; University of Alabama Birmingham; University of London; University College London; University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London; Novo Nordisk; University of Palermo; Policlinico Paolo Giaccone; University of Palermo; European University of Madrid; quironsalud Group; University of Pennsylvania; Pennsylvania Medicine; University of York - UK; McMaster University	Garvey, WT (corresponding author), Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA.	garveyt@uab.edu	Buscemi, Silvio/K-9662-2016	Buscemi, Silvio/0000-0003-0730-7649; Kandler, Kristian/0000-0003-0686-0549; Garvey, W. Timothy/0000-0003-0822-0860; Batterham, Rachel/0000-0002-5477-8585	Novo Nordisk A/S, Denmark; Novo Nordisk	Novo Nordisk A/S, Denmark(Novo Nordisk); Novo Nordisk(Novo Nordisk)	We thank the study participants, and the investigators and study site staff who conducted the study. In addition, we thank N. Beadle of Axis, a division of Spirit Medical Communications Group Limited, for medical writing and editorial assistance (funded by Novo Nordisk A/S, Denmark). The study was funded by Novo Nordisk. The funder designed the trial, oversaw its conduct, monitored trial sites, and collected and analyzed the data; investigators were responsible for trial-related medical decisions and data collection. This article was drafted under the guidance of the authors, with medical writing and editorial support paid for by the funder.	American Diabetes Association, 2017, Diabetes Care, V40, pS11, DOI 10.2337/dc15-S005; [Anonymous], 2022, WEG PRESCR INF; [Anonymous], 2022, WEG SUMM PROD CHAR; [Anonymous], 2022, REG DEC SUMM WEG; Astrup A, 2012, INT J OBESITY, V36, P843, DOI 10.1038/ijo.2011.158; Bray GA, 2017, OBES REV, V18, P715, DOI 10.1111/obr.12551; Davies M, 2021, LANCET, V397, P971, DOI 10.1016/S0140-6736(21)00213-0; Garvey WT, 2012, AM J CLIN NUTR, V95, P297, DOI 10.3945/ajcn.111.024927; Jensen MD, 2014, CIRCULATION, V129, pS102, DOI 10.1161/01.cir.0000437739.71477.ee; Kushner RF, 2020, OBESITY, V28, P1050, DOI 10.1002/oby.22794; le Roux CW, 2017, LANCET, V389, P1399, DOI 10.1016/S0140-6736(17)30069-7; Levin A, 2013, KIDNEY INT S, V3, P1, DOI [DOI 10.1038/KISUP.2012.73, 10.1038/kisup.2012.73]; MacLean PS, 2015, OBESITY, V23, P7, DOI 10.1002/oby.20967; Nauck MA, 2020, MOL METAB, V46, DOI 10.1016/j.molmet.2020.101102; Perreault Leigh, 2022, Diabetes Care, V45, P2396, DOI 10.2337/dc21-1785; Rubino D, 2021, JAMA-J AM MED ASSOC, V325, P1414, DOI 10.1001/jama.2021.3224; Rubino DM, 2022, JAMA-J AM MED ASSOC, V327, P138, DOI 10.1001/jama.2021.23619; Sjostrom L, 1998, LANCET, V352, P167, DOI 10.1016/S0140-6736(97)11509-4; Smith SR, 2010, NEW ENGL J MED, V363, P245, DOI 10.1056/NEJMoa0909809; Svetkey LP, 2008, JAMA-J AM MED ASSOC, V299, P1139, DOI 10.1001/jama.299.10.1139; Timpson NJ, 2011, INT J OBESITY, V35, P300, DOI 10.1038/ijo.2010.137; Torgerson JS, 2004, DIABETES CARE, V27, P155, DOI 10.2337/diacare.27.1.155; Visser M, 1999, JAMA-J AM MED ASSOC, V282, P2131, DOI 10.1001/jama.282.22.2131; Wadden TA, 2021, JAMA-J AM MED ASSOC, V325, P1403, DOI 10.1001/jama.2021.1831; Wadden TA, 2011, OBESITY, V19, P1987, DOI 10.1038/oby.2011.230; Wharton S, 2021, INT J OBESITY, V45, P923, DOI 10.1038/s41366-020-00733-x; Wilding JPH, 2022, DIABETES OBES METAB, V24, P1553, DOI 10.1111/dom.14725; Wilding JPH, 2021, NEW ENGL J MED, V384, P989, DOI 10.1056/NEJMoa2032183; Williamson DA, 2015, OBESITY, V23, P2319, DOI 10.1002/oby.21358; Wing RR, 2006, NEW ENGL J MED, V355, P1563, DOI 10.1056/NEJMoa061883	30	1	1	4	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02026-4	http://dx.doi.org/10.1038/s41591-022-02026-4		OCT 2022	23	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	5E6FW	36216945	Green Published, hybrid			2022-12-27	WOS:000865719400001
J	Onishchenko, D; Marlowe, RJ; Ngufor, CG; Faust, LJ; Limper, AH; Hunninghake, GM; Martinez, FJ; Chattopadhyay, I				Onishchenko, Dmytro; Marlowe, Robert J.; Ngufor, Che G.; Faust, Louis J.; Limper, Andrew H.; Hunninghake, Gary M.; Martinez, Fernando J.; Chattopadhyay, Ishanu			Screening for idiopathic pulmonary fibrosis using comorbidity signatures in electronic health records	NATURE MEDICINE			English	Article; Early Access							EARLY-DIAGNOSIS; CONFIDENCE-INTERVALS; RISK PREDICTION; SURVIVAL; MORTALITY; ONSET	Idiopathic pulmonary fibrosis (IPF) is a lethal fibrosing interstitial lung disease with a mean survival time of less than 5 years. Nonspecific presentation, a lack of effective early screening tools, unclear pathobiology of early-stage IPF and the need for invasive and expensive procedures for diagnostic confirmation hinder early diagnosis. In this study, we introduce a new screening tool for IPF in primary care settings that requires no new laboratory tests and does not require recognition of early symptoms. Using subtle comorbidity signatures identified from the history of medical encounters of individuals, we developed an algorithm, called the zero-burden comorbidity risk score for IPF (ZCoR-IPF), to predict the future risk of an IPF diagnosis. ZCoR-IPF was trained on a national insurance claims database and validated on three independent databases, comprising a total of 2,983,215 participants, with 54,247 positive cases. The algorithm achieved positive likelihood ratios greater than 30 at a specificity of 0.99 across different cohorts, for both sexes, and for participants with different risk states and history of confounding diseases. The area under the receiver-operating characteristic curve for ZCoR-IPF in predicting IPF exceeded 0.88 and was approximately 0.84 at 1 and 4 years before a conventional diagnosis, respectively. Thus, if adopted, ZCoR-IPF can potentially enable earlier diagnosis of IPF and improve outcomes of disease-modifying therapies and other interventions. A machine learning algorithm can predict the future risk of idiopathic pulmonary fibrosis, a disease that is difficult to diagnose at its early stages, based on comorbidity signatures in electronic health records.	[Onishchenko, Dmytro; Chattopadhyay, Ishanu] Univ Chicago, Dept Med, Chicago, IL 60637 USA; [Marlowe, Robert J.] Spencer Fontayne Corp, Jersey, NJ USA; [Ngufor, Che G.; Faust, Louis J.; Limper, Andrew H.] Mayo Clin, Coll Med & Sci, Rochester, MN USA; [Limper, Andrew H.] Mayo Clin, Thorac Res Unit, Coll Med & Sci, Rochester, MN USA; [Hunninghake, Gary M.] Harvard Med Sch, Brigham & Womens Hosp, Interstitial Lung Dis Program, Boston, MA USA; [Martinez, Fernando J.] Weill Cornell Med Coll, Bruce Webster Prof Internal Med, Med, New York, NY USA; [Martinez, Fernando J.] Weill Cornell Med Ctr, Div Pulm & Crit Care Med, Weill Cornell Med & New York Presbyterian, New York, NY USA; [Chattopadhyay, Ishanu] Univ Chicago, Committee Genet Genom & Syst Biol, Chicago, IL 60637 USA; [Chattopadhyay, Ishanu] Univ Chicago, Committee Quantitat Methods Social Behav & Hlth, Chicago, IL 60637 USA	University of Chicago; Mayo Clinic; Mayo Clinic; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Cornell University; Cornell University; Qatar Foundation (QF); Weill Cornell Medical College Qatar; University of Chicago; University of Chicago	Chattopadhyay, I (corresponding author), Univ Chicago, Dept Med, Chicago, IL 60637 USA.; Chattopadhyay, I (corresponding author), Univ Chicago, Committee Genet Genom & Syst Biol, Chicago, IL 60637 USA.; Chattopadhyay, I (corresponding author), Univ Chicago, Committee Quantitat Methods Social Behav & Hlth, Chicago, IL 60637 USA.	ishanu@uchicago.edu		chattopadhyay, ishanu/0000-0001-8339-8162; Onishchenko, Dmytro/0000-0001-7602-7232	Defense Advanced Research Projects Agency [HR00111890043]; Biological Sciences Division; Institute for Translational Medicine/CTSA (National Institutes of Health) at the University of Chicago [UL1 TR000430]	Defense Advanced Research Projects Agency(United States Department of DefenseDefense Advanced Research Projects Agency (DARPA)); Biological Sciences Division; Institute for Translational Medicine/CTSA (National Institutes of Health) at the University of Chicago	This work is funded in part by the Defense Advanced Research Projects Agency under project no.HR00111890043. The claims made in this study do not reflect the position or the policy of the US Government. The UCM dataset is provided by the Clinical Research Data Warehouse (CRDW) maintained by the Center for Research Informatics at the University of Chicago. The Center for Research Informatics is funded by the Biological Sciences Division, the Institute for Translational Medicine/CTSA (National Institutes of Health award no. UL1 TR000430) at the University of Chicago.	Adegunsoye A, 2019, ANN AM THORAC SOC, V16, P310, DOI 10.1513/AnnalsATS.201812-883ED; Albawi S, 2017, I C ENG TECHNOL; Alom M.Z., 2018, ARXIV; Alqarni AM, 2011, J ORTHOP SPORT PHYS, V41, P130, DOI 10.2519/jospt.2011.3457; Andrade C, 2015, J CLIN PSYCHIAT, V76, pE1469, DOI 10.4088/JCP.15f10436; [Anonymous], 2013, AAP PED COD NEWSL, DOI [10.1542/pcco_book116_document005, DOI 10.1542/PCCO_BOOK116_DOCUMENT005]; Antoniou KM, 2014, LANCET RESP MED, V2, pE1, DOI 10.1016/S2213-2600(13)70283-2; Birnbaum Z. W., 1956, P 3 BERK S MATH STAT, V1, P13; BIRNBAUM ZW, 1957, ANN MATH STAT, V28, P933, DOI 10.1214/aoms/1177706794; Chattopadhyay I, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2014.0826; Chattopadhyay I, 2013, PHILOS T R SOC A, V371, DOI 10.1098/rsta.2011.0543; Collard HR, 2007, RESP MED, V101, P1350, DOI 10.1016/j.rmed.2006.10.002; Cosgrove GP, 2018, BMC PULM MED, V18, DOI 10.1186/s12890-017-0560-x; Cottin V, 2014, EUR RESPIR REV, V23, P106, DOI 10.1183/09059180.00008613; Cottin V, 2012, EUR RESPIR J, V40, P519, DOI 10.1183/09031936.00001612; COVER T. M., 2012, ELEMENTS INFORM THEO, DOI 10.1002/0471200611; Doob J. L., 1953, STOCHASTIC PROCESSES; du Bois RM, 2011, AM J RESP CRIT CARE, V184, P459, DOI 10.1164/rccm.201011-1790OC; Esposito DB, 2015, AM J RESP CRIT CARE, V192, P1200, DOI 10.1164/rccm.201504-0818OC; Farrand E, 2021, CHEST, V159, P219, DOI 10.1016/j.chest.2020.07.035; George PM, 2020, LANCET RESP MED, V8, P925, DOI 10.1016/S2213-2600(20)30355-6; Granger C. W. J., 1980, Journal of Time Series Analysis, V1, P15, DOI 10.1111/j.1467-9892.1980.tb00297.x; Guo W, 2019, IEEE ACCESS, V7, P134236, DOI 10.1109/ACCESS.2019.2928579; HALDANE JBS, 1947, ANN EUGENIC, V14, P10, DOI 10.1111/j.1469-1809.1947.tb02374.x; Hansen L., 2017, TRUVEN HLTH MARKETSC; Hart S, 2019, LANCET RESP MED, V7, P466, DOI 10.1016/S2213-2600(19)30058-X; Hewson T, 2018, THORAX, V73, P683, DOI 10.1136/thoraxjnl-2017-210177; Holm EA, 2019, SCIENCE, V364, P26, DOI 10.1126/science.aax0162; Hoyer N, 2019, RESP RES, V20, DOI 10.1186/s12931-019-1076-0; Huang Y, 2021, PLOS COMPUT BIOL, V17, DOI 10.1371/journal.pcbi.1009363; Hyldgaard C, 2014, RESP MED, V108, P647, DOI 10.1016/j.rmed.2014.01.008; Inoue Y, 2020, CHEST, V158, P646, DOI 10.1016/j.chest.2020.03.037; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Ke GL, 2017, ADV NEUR IN, V30; Kim GHJ, 2020, EUR RADIOL, V30, P726, DOI 10.1007/s00330-019-06402-6; King TE, 2001, AM J RESP CRIT CARE, V164, P1171, DOI 10.1164/ajrccm.164.7.2003140; Kreuter M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151425; Krizhevsky A, 2017, COMMUN ACM, V60, P84, DOI 10.1145/3065386; Kropski JA, 2019, LANCET RESP MED, V7, P725, DOI 10.1016/S2213-2600(19)30256-5; KULLBACK S, 1951, ANN MATH STAT, V22, P79, DOI 10.1214/aoms/1177729694; Lamas DJ, 2011, AM J RESP CRIT CARE, V184, P842, DOI 10.1164/rccm.201104-0668OC; Lederer DJ, 2018, NEW ENGL J MED, V378, P1811, DOI 10.1056/NEJMra1705751; Ley B, 2017, ANN AM THORAC SOC, V14, P880, DOI 10.1513/AnnalsATS.201610-764OC; Ley B, 2012, AM J RESP CRIT CARE, V185, P6, DOI 10.1164/rccm.201111-1960ED; Ley B, 2011, AM J RESP CRIT CARE, V183, P431, DOI 10.1164/rccm.201006-0894CI; Lu Z, 2018, IEEE SIGNAL PROC LET, V25, P526, DOI 10.1109/LSP.2018.2810121; MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491; Miotto R, 2016, SCI REP-UK, V6, DOI 10.1038/srep26094; Mooney J, 2019, ANN AM THORAC SOC, V16, P393, DOI 10.1513/AnnalsATS.201806-376RL; Mortimer KM, 2020, RESPIRATION, V99, P108, DOI 10.1159/000504630; Newcombe RG, 1998, STAT MED, V17, P857, DOI 10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E; NEWCOMBE RG, 1994, STAT MED, V13, P1283, DOI 10.1002/sim.4780131209; Noble PW, 2011, LANCET, V377, P1760, DOI 10.1016/S0140-6736(11)60405-4; Oldham JM, 2018, ANN AM THORAC SOC, V15, P764, DOI 10.1513/AnnalsATS.201801-053RL; Oldham JM, 2014, RESP MED, V108, P819, DOI 10.1016/j.rmed.2014.03.008; Onishchenko D, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf0354; Pritchard D, 2019, RESP RES, V20, DOI 10.1186/s12931-019-1228-2; Putman RK, 2014, AM J RESP CRIT CARE, V189, P770, DOI 10.1164/rccm.201312-2219PP; Raghu G, 2019, LANCET RESP MED, V7, P926, DOI 10.1016/S2213-2600(19)30311-X; Raghu G, 2019, LANCET RESP MED, V7, P487, DOI 10.1016/S2213-2600(19)30059-1; Raghu G, 2018, AM J RESP CRIT CARE, V198, pE44, DOI 10.1164/rccm.201807-1255ST; Raghu G, 2015, EUR RESPIR J, V46, P1113, DOI 10.1183/13993003.02316-2014; Richards TJ, 2012, AM J RESP CRIT CARE, V185, P67, DOI 10.1164/rccm.201101-0058OC; Richeldi L, 2014, NEW ENGL J MED, V370, P2071, DOI 10.1056/NEJMoa1402584; Ryerson CJ, 2019, ERJ OPEN RES, V5, DOI 10.1183/23120541.00127-2018; Ryerson CJ, 2015, CHEST, V148, P1268, DOI 10.1378/chest.15-0003; Schmidhuber J, 2015, NEURAL NETWORKS, V61, P85, DOI 10.1016/j.neunet.2014.09.003; Schoenheit G, 2011, CHRON RESP DIS, V8, P225, DOI 10.1177/1479972311416382; Singh RP, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.45; Sugino K, 2021, BMC PULM MED, V21, DOI 10.1186/s12890-021-01595-3; Thickett D, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-034428; Torrisi SE, 2017, EUR RESPIR REV, V26, DOI 10.1183/16000617.0053-2017; van Dantzig D., 1951, P KNAW SERIES, V54, P1; Van Houdt G, 2020, ARTIF INTELL REV, V53, P5929, DOI 10.1007/s10462-020-09838-1; Vining Robert, 2013, J Can Chiropr Assoc, V57, P189; W.H. Organization, 1988, WKLY EPIDEMIOL REC R, V63, P343; Wallace PJ, 2014, HEALTH AFFAIR, V33, P1187, DOI 10.1377/hlthaff.2014.0038; Walsh SLF, 2020, LANCET RESP MED, V8, P1144, DOI 10.1016/S2213-2600(20)30003-5; Wells AU, 2003, AM J RESP CRIT CARE, V167, P962, DOI 10.1164/rccm.2111053; WILCOXON F, 1946, J ECON ENTOMOL, V39, P269, DOI 10.1093/jee/39.2.269; Zhang K, 2019, IEEE ACCESS, V7, P9872, DOI 10.1109/ACCESS.2018.2890127	81	0	0	3	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02010-y	http://dx.doi.org/10.1038/s41591-022-02010-y		SEP 2022	27	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	5A8VN	36175678	Green Submitted, Bronze			2022-12-27	WOS:000863159000003
J	Zhang, Y; Trang, V; Palmer, DC; Kishton, RJ; Gong, LQ; Huang, J; Nguyen, T; Chen, ZJ; Smith, C; Livak, F; Paul, R; Day, CP; Wu, C; Merlino, G; Aldape, K; Guan, XY; Jiang, P				Zhang, Yu; Trang, Vu; Palmer, Douglas C.; Kishton, Rigel J.; Gong, Lanqi; Huang, Jiao; Nguyen, Thanh; Chen, Zuojia; Smith, Cari; Livak, Ferenc; Paul, Rohit; Day, Chi-Ping; Wu, Chuan; Merlino, Glenn; Aldape, Kenneth; Guan, Xin-yuan; Jiang, Peng			A T cell resilience model associated with response to immunotherapy in multiple tumor types	NATURE MEDICINE			English	Article							TARGET DISCOVERY; REVEALS; GENE; ACTIVATION; RESISTANCE; EXHAUSTION; PROTEINS; LEUKEMIA; PROGRAM	Gene signatures associated with T cell resilience to tumor-derived immunosuppressive signals predict responses to immune-checkpoint inhibitors and adoptive cell therapy and identify FIBP as a negative regulator of T cell activity Despite breakthroughs in cancer immunotherapy, most tumor-reactive T cells cannot persist in solid tumors due to an immunosuppressive environment. We developed Tres (tumor-resilient T cell), a computational model utilizing single-cell transcriptomic data to identify signatures of T cells that are resilient to immunosuppressive signals, such as transforming growth factor-beta 1, tumor necrosis factor-related apoptosis-inducing ligand and prostaglandin E2. Tres reliably predicts clinical responses to immunotherapy in melanoma, lung cancer, triple-negative breast cancer and B cell malignancies using bulk T cell transcriptomic data from pre-treatment tumors from patients who received immune-checkpoint inhibitors (n = 38), infusion products for chimeric antigen receptor T cell therapies (n = 34) and pre-manufacture samples for chimeric antigen receptor T cell or tumor-infiltrating lymphocyte therapies (n = 84). Further, Tres identified FIBP, whose functions are largely unknown, as the top negative marker of tumor-resilient T cells across many solid tumor types. FIBP knockouts in murine and human donor CD8(+) T cells significantly enhanced T cell-mediated cancer killing in in vitro co-cultures. Further, Fibp knockout in murine T cells potentiated the in vivo efficacy of adoptive cell transfer in the B16 tumor model. Fibp knockout T cells exhibit reduced cholesterol metabolism, which inhibits effector T cell function. These results demonstrate the utility of Tres in identifying biomarkers of T cell effectiveness and potential therapeutic targets for immunotherapies in solid tumors.	[Zhang, Yu; Trang, Vu; Jiang, Peng] NCI, Canc Data Sci Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Zhang, Yu; Gong, Lanqi; Huang, Jiao; Guan, Xin-yuan] Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China; [Zhang, Yu] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Ctr Canc, Guangzhou, Peoples R China; [Palmer, Douglas C.; Kishton, Rigel J.] NCI, Surg Branch, NIH, Bldg 10, Bethesda, MD 20892 USA; [Nguyen, Thanh; Aldape, Kenneth] NCI, Pathol Lab, Ctr Canc Res, NIH, Bldg 10, Bethesda, MD 20892 USA; [Chen, Zuojia; Wu, Chuan] NCI, Expt Immunol Branch, Ctr Canc Res, NIH, Bldg 10, Bethesda, MD 20892 USA; [Smith, Cari] Leidos Biomed Res Inc, Lab Anim Sci Program, Frederick, MD USA; [Livak, Ferenc] NCI, Flow Cytometry Core, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Paul, Rohit] NCI, Off Director, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Day, Chi-Ping; Merlino, Glenn] NCI, Lab Canc Biol & Genet, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Palmer, Douglas C.] AstraZeneca, Gaithersburg, MD USA; [Kishton, Rigel J.] Lyell Immunopharma, San Francisco, CA USA; [Nguyen, Thanh] Gaia Foods, Singapore, Singapore	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Hong Kong; State Key Lab Oncology South China; Sun Yat Sen University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); AstraZeneca	Jiang, P (corresponding author), NCI, Canc Data Sci Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.	peng.jiang@nih.gov	Nguyen, Thanh Hung/M-8118-2014	Nguyen, Thanh Hung/0000-0001-8378-555X	NCI iCURE and T2I Postdoc fellowship; University of Hong Kong; NCI, NIH	NCI iCURE and T2I Postdoc fellowship; University of Hong Kong(University of Hong Kong); NCI, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank S. Rosenberg, F. Lowery, K. Sri and M. Carrington for their helpful discussions. This work utilized the computational resources of the NIH HPC Biowulf cluster. This work is supported by the intramural budget allocation from the NCI, NIH, awarded to P.J. Y.Z. is partially supported by a Bau Tsu Zung Bau Kwan Yeu Hing Research and Clinical Fellowship from the University of Hong Kong. T.V. is supported by the NCI iCURE and T2I Postdoc fellowship.	Azizi E, 2018, CELL, V174, P1293, DOI 10.1016/j.cell.2018.05.060; Blank N, 2007, J IMMUNOL, V179, P3613, DOI 10.4049/jimmunol.179.6.3613; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Caushi JX, 2021, NATURE, V596, P126, DOI 10.1038/s41586-021-03752-4; Chen GM, 2021, CANCER DISCOV, V11, P2186, DOI 10.1158/2159-8290.CD-20-1677; Chen Y, 2022, MOL CELL, V82, P1278, DOI 10.1016/j.molcel.2022.02.017; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Doering TA, 2012, IMMUNITY, V37, P1130, DOI 10.1016/j.immuni.2012.08.021; Dong MB, 2019, CELL, V178, P1189, DOI 10.1016/j.cell.2019.07.044; Duffy DJ, 2015, ONCOTARGET, V6, P43182, DOI 10.18632/oncotarget.6568; Durante MA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14256-1; Emmerich J, 2012, CANCER RES, V72, P3570, DOI 10.1158/0008-5472.CAN-12-0721; Fraietta JA, 2018, NAT MED, V24, P563, DOI 10.1038/s41591-018-0010-1; Gattinoni L, 2011, NAT MED, V17, P1290, DOI 10.1038/nm.2446; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Gicobi JK, 2020, CANCER IMMUNOL IMMUN, V69, P2165, DOI 10.1007/s00262-020-02731-4; Giordano M, 2015, EMBO J, V34, P2042, DOI 10.15252/embj.201490786; Good CR, 2021, CELL, V184, P6081, DOI 10.1016/j.cell.2021.11.016; Green DR, 2003, IMMUNOL REV, V193, P70, DOI 10.1034/j.1600-065X.2003.00051.x; Guedan S, 2019, ANNU REV IMMUNOL, V37, P145, DOI 10.1146/annurev-immunol-042718-041407; Hanada KI, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.124405; Hanna BS, 2021, IMMUNITY, V54, P2825, DOI 10.1016/j.immuni.2021.11.004; Huang YF, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0088-9; James G, 2013, SPRINGER TEXTS STAT, V103, P1, DOI 10.1007/978-1-4614-7138-7_1; Jerby-Arnon L, 2018, CELL, V175, P984, DOI 10.1016/j.cell.2018.09.006; Jiang P, 2021, NAT METHODS, V18, P1181, DOI 10.1038/s41592-021-01274-5; Jiang P, 2018, NAT MED, V24, P1550, DOI 10.1038/s41591-018-0136-1; Jiang P, 2015, P NATL ACAD SCI USA, V112, P7731, DOI 10.1073/pnas.1424272112; Kanehisa M, 2004, NUCLEIC ACIDS RES, V32, pD277, DOI 10.1093/nar/gkh063; Kidani Y, 2013, NAT IMMUNOL, V14, P489, DOI 10.1038/ni.2570; Kohlmann A, 2008, BRIT J HAEMATOL, V142, P802, DOI 10.1111/j.1365-2141.2008.07261.x; Kolpakova E, 1998, BIOCHEM J, V336, P213, DOI 10.1042/bj3360213; Krishna S, 2020, SCIENCE, V370, P1328, DOI 10.1126/science.abb9847; Lambrechts D, 2018, NAT MED, V24, P1277, DOI 10.1038/s41591-018-0096-5; Lauss M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01460-0; Lee N, 1998, P NATL ACAD SCI USA, V95, P5199, DOI 10.1073/pnas.95.9.5199; Legut M, 2022, NATURE, V603, P728, DOI 10.1038/s41586-022-04494-7; Litchfield K, 2021, CELL, V184, P596, DOI 10.1016/j.cell.2021.01.002; Liu Y, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21043-4; Lu LR, 2007, IMMUNITY, V26, P593, DOI 10.1016/j.immuni.2007.03.017; Lu S, 2019, JAMA ONCOL, V5, P1195, DOI 10.1001/jamaoncol.2019.1549; Luo J, 2020, NAT REV MOL CELL BIO, V21, P225, DOI 10.1038/s41580-019-0190-7; Ma LC, 2019, CANCER CELL, V36, P418, DOI 10.1016/j.ccell.2019.08.007; Ma XZ, 2019, CELL METAB, V30, P143, DOI 10.1016/j.cmet.2019.04.002; Marchler-Bauer A, 2017, NUCLEIC ACIDS RES, V45, pD200, DOI 10.1093/nar/gkw1129; Martinez M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00128; Mathewson ND, 2021, CELL, V184, P1281, DOI 10.1016/j.cell.2021.01.022; Naing A, 2018, CANCER CELL, V34, P775, DOI 10.1016/j.ccell.2018.10.007; Pan D, 2018, SCIENCE, V359, P770, DOI 10.1126/science.aao1710; Patel SJ, 2017, NATURE, V548, P537, DOI 10.1038/nature23477; Puram SV, 2017, CELL, V171, P1611, DOI 10.1016/j.cell.2017.10.044; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Robbins PF, 2011, J CLIN ONCOL, V29, P917, DOI 10.1200/JCO.2010.32.2537; Rodrigues NV, 2018, CANCER IMMUNOL RES, V6, P448, DOI 10.1158/2326-6066.CIR-17-0327; Rosenberg SA, 2011, CLIN CANCER RES, V17, P4550, DOI 10.1158/1078-0432.CCR-11-0116; Sade-Feldman M, 2018, CELL, V175, P998, DOI 10.1016/j.cell.2018.10.038; Santra S, 1997, CANCER IMMUNOL IMMUN, V44, P291, DOI 10.1007/s002620050385; Schaaf MB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0061-0; Schmidt R, 2022, SCIENCE, V375, P513, DOI 10.1126/science.abj4008; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Shifrut E, 2018, CELL, V175, P1958, DOI 10.1016/j.cell.2018.10.024; Silva-Filho J L, 2014, Biophys Rev, V6, P111, DOI 10.1007/s12551-013-0133-z; Soderquest K, 2011, J IMMUNOL, V186, P3304, DOI 10.4049/jimmunol.1004122; Spidlen Josef, 2012, Curr Protoc Cytom, VChapter 10, DOI 10.1002/0471142956.cy1018s61; Steen CB, 2021, CANCER CELL, V39, P1422, DOI 10.1016/j.ccell.2021.08.011; Stromnes IM, 2010, J CLIN INVEST, V120, P3722, DOI 10.1172/JCI41991; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Suva ML, 2019, MOL CELL, V75, P7, DOI 10.1016/j.molcel.2019.05.003; Tschumi BO, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0385-z; Chu VT, 2015, NAT BIOTECHNOL, V33, P543, DOI 10.1038/nbt.3198; Wehbi VL, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00222; Wu SZ, 2021, NAT GENET, V53, P1334, DOI 10.1038/s41588-021-00911-1; Xi HB, 2020, CELL STEM CELL, V27, P158, DOI [10.1016/j.stem.2020.04.017, 10.1016/j.stem.2020.06.006]; Yost KE, 2019, NAT MED, V25, P1251, DOI 10.1038/s41591-019-0522-3; Young MD, 2018, SCIENCE, V361, P594, DOI 10.1126/science.aat1699; Zhang YY, 2021, CANCER CELL, V39, P1578, DOI 10.1016/j.ccell.2021.09.010; Zheng LT, 2021, SCIENCE, V374, P1462, DOI 10.1126/science.abe6474; Zheng RB, 2019, NUCLEIC ACIDS RES, V47, pD729, DOI 10.1093/nar/gky1094; Zhou PH, 2014, NATURE, V506, P52, DOI 10.1038/nature12988	79	5	5	14	20	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2022	28	7					1421	+		10.1038/s41591-022-01799-y	http://dx.doi.org/10.1038/s41591-022-01799-y		MAY 2022	30	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3E5PS	35501486	Green Accepted			2022-12-27	WOS:000789711000001
J	Vos, JMH				Vos, JMH			The simplicity of complex MACs	NATURE BIOTECHNOLOGY			English	Review						episome; gene therapy; centromere; viral vector; transgenesis	HUMAN-CELLS; CHROMOSOMES; MINICHROMOSOMES; MAINTENANCE; DNA	The development of mammalian artificial chromosomes (MACs) would be useful for biotechnology and biomedicine, including their use in functional genomics, transgenic animals and gene therapy. By analogy to large cloning systems in microorganisms, MACs may be engineered using endogenous chromosomal elements such as the yeast-based artificial chromosomes (YACs), or exogenous extra-chromosomal components derived from viruses and other cellular parasites such as the bacterial-based artificial chromosomes (BACs) and pi artificial chromosomes (PACs).	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Vos, JMH (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.							BANERJEE S, 1995, NAT MED, V1, P1303, DOI 10.1038/nm1295-1303; BROWN W, 1995, TRENDS GENET, V11, P337, DOI 10.1016/S0168-9525(00)89100-3; DEPAMPHILIS ML, 1996, DNA REPLICATION EUKA, P45; DUSART D, 1997, IN PRESS NATURE GEN; FARR CJ, 1995, EMBO J, V14, P5444, DOI 10.1002/j.1460-2075.1995.tb00228.x; FEATHERSTONE T, 1993, GENOMICS, V17, P267, DOI 10.1006/geno.1993.1321; Harrington JJ, 1997, NAT GENET, V15, P345, DOI 10.1038/ng0497-345; Heller R, 1996, P NATL ACAD SCI USA, V93, P7125, DOI 10.1073/pnas.93.14.7125; Kipling D, 1997, TRENDS GENET, V13, P141, DOI 10.1016/S0168-9525(97)01098-6; KOSZTOLANYI G, 1991, HUM GENET, V87, P320; NONET GH, 1993, SOMAT CELL MOLEC GEN, V19, P171, DOI 10.1007/BF01233532; Simpson K, 1996, MOL CELL BIOL, V16, P5117; Sun TQ, 1996, GENE THER, V3, P1081; SUN TQ, 1994, NAT GENET, V8, P33, DOI 10.1038/ng0994-33; TOMIZUKA, 1997, NATURE GENET, V16, P133; WANG F, 1995, HUM GENE THER, V6, P1005, DOI 10.1089/hum.1995.6.8-1005	16	20	22	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1997	15	12					1257	1259		10.1038/nbt1197-1257	http://dx.doi.org/10.1038/nbt1197-1257			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YQ046	9359107				2022-12-27	WOS:000071342000026
J	Woodrow, GC; Nisbet, I; Corbett, ME				Woodrow, GC; Nisbet, I; Corbett, ME			Australia: Ready for business	NATURE BIOTECHNOLOGY			English	Article									CSL LTD,MELBOURNE,VIC 3052,AUSTRALIA; AGEN BIOMED LTD,BRISBANE,QLD 4111,AUSTRALIA	CSL	Woodrow, GC (corresponding author), BIOTECH AUSTRALIA PTY LTD,PO BOX 20,SYDNEY,NSW 2069,AUSTRALIA.								0	0	0	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					731	732		10.1038/nbt0897-731	http://dx.doi.org/10.1038/nbt0897-731			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255783				2022-12-27	WOS:A1997XM70700020
J	Sauer, U; Hatzimanikatis, V; Bailey, JE; Hochuli, M; Szyperski, T; Wuthrich, K				Sauer, U; Hatzimanikatis, V; Bailey, JE; Hochuli, M; Szyperski, T; Wuthrich, K			Metabolic fluxes in riboflavin-producing Bacillus subtilis	NATURE BIOTECHNOLOGY			English	Article						Bacillus subtilis; metabolic flux; C-13-labeling; NMR; metabolic engineering	NUCLEAR-MAGNETIC-RESONANCE; CORYNEBACTERIUM-GLUTAMICUM; ESCHERICHIA-COLI; BRANCH POINT; GROWTH; FERMENTATION; PATHWAYS; LEUCINE; VALINE; ACID	The pentose phosphate pathway and the pyruvate shunt were identified as major pathways of glucose catabolism in a recombinant, riboflavin-producing Bacillus subtilis strain. Reactions connecting the tricarboxylic acid cycle and glycolysis, catalyzed by the malic enzyme and phosphoenolpyruvate carboxykinase, consume up to 23% of the metabolized glucose. These are examples of important fluxes that can be accessed explicitly using a novel analysis based on synergistic application of flux balancing and recently introduced techniques of fractional C-13-labeling and two-dimensional nuclear magnetic resonance spectroscopy. The overall flux distribution also suggests that B. subtilis metabolism has an unusually high capacity for the reoxidation of NADPH. Under the conditions investigated, riboflavin formation in B. subtilis is limited by the fluxes through the biosynthetic rather than the central carbon pathways, which suggests a focus for future metabolic engineering of this system.	ETH ZURICH, INST BIOTECHNOL, CH-8093 ZURICH, SWITZERLAND; ETH ZURICH, INST MOL BIOL & BIOPHYS, CH-8093 ZURICH, SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich			Hatzimanikatis, Vassily/B-7646-2009; Hatzimanikatis, Vassily/G-6505-2010; Sauer, Uwe/Y-3556-2019	Hatzimanikatis, Vassily/0000-0001-6432-4694; Hochuli, Michel/0000-0001-5227-6154				BAILEY JE, 1991, SCIENCE, V252, P1668, DOI 10.1126/science.2047876; DIESTERHAFT MD, 1973, J BIOL CHEM, V248, P6062; Eggeling L., 1996, ADV BIOCHEM ENG BIOT, V54, P1; FREESE E, 1969, J BACTERIOL, V99, P745, DOI 10.1128/JB.99.3.745-756.1969; GALAZZO JL, 1990, ENZYME MICROB TECH, V12, P162, DOI 10.1016/0141-0229(90)90033-M; GOEL A, 1993, BIOTECHNOL BIOENG, V42, P686, DOI 10.1002/bit.260420603; Gottschalk G., 1986, BACTERIAL METABOLISM; Hatzimanikatis V, 1996, AICHE J, V42, P1277, DOI 10.1002/aic.690420509; HOLMS WH, 1986, CURR TOP CELL REGUL, V28, P69; ISHINO S, 1991, J GEN APPL MICROBIOL, V37, P157, DOI 10.2323/jgam.37.157; Marx A, 1996, BIOTECHNOL BIOENG, V49, P111, DOI 10.1002/(SICI)1097-0290(19960120)49:2<111::AID-BIT1>3.0.CO;2-T; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; PORTAIS JC, 1993, EUR J BIOCHEM, V217, P457, DOI 10.1111/j.1432-1033.1993.tb18265.x; ROLLIN C, 1995, EUR J BIOCHEM, V227, P488, DOI 10.1111/j.1432-1033.1995.tb20414.x; SASAJIMA K, 1984, BIOTECHNOL GENET ENG, V2, P175, DOI 10.1080/02648725.1984.10647799; Sauer U, 1996, APPL ENVIRON MICROB, V62, P3687, DOI 10.1128/AEM.62.10.3687-3696.1996; SCHLOSSER PM, 1994, BIOTECHNOL PROGR, V10, P141, DOI 10.1021/bp00026a003; SENN H, 1989, FEBS LETT, V249, P113, DOI 10.1016/0014-5793(89)80027-4; Sloma A, 1991, European patent, Patent No. [EP0405370, 0405370, 405370]; STEPHANOPOULOS G, 1993, TRENDS BIOTECHNOL, V11, P392, DOI 10.1016/0167-7799(93)90099-U; Szyperski T, 1996, TRENDS BIOTECHNOL, V14, P453, DOI 10.1016/S0167-7799(96)10056-1; SZYPERSKI T, 1995, EUR J BIOCHEM, V232, P433, DOI 10.1111/j.1432-1033.1995.433zz.x; Tsai PS, 1996, BIOTECHNOL BIOENG, V49, P139; VALLINO JJ, 1993, BIOTECHNOL BIOENG, V41, P633, DOI 10.1002/bit.260410606; VANGULIK WM, 1995, BIOTECHNOL BIOENG, V48, P681, DOI 10.1002/bit.260480617; VARMA A, 1994, BIO-TECHNOL, V12, P994, DOI 10.1038/nbt1094-994; VARMA A, 1993, BIOTECHNOL BIOENG, V42, P59, DOI 10.1002/bit.260420109; VOLK R, 1990, J BIOL CHEM, V265, P19479; WALSH K, 1984, J BIOL CHEM, V259, P9646; WOOD T, 1985, PENTOSE PHOSPHATE PA; WUTHRICH K, 1992, FRONTIERS AND NEW HORIZONS IN AMINO ACID RESEARCH, P41	31	209	219	2	36	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1997	15	5					448	452		10.1038/nbt0597-448	http://dx.doi.org/10.1038/nbt0597-448			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WX237	9131624				2022-12-27	WOS:A1997WX23700029
J	Esler, WP; Stimson, ER; Ghilardi, JR; Felix, AM; Lu, YA; Vinters, HV; Mantyh, PW; Maggio, JE				Esler, WP; Stimson, ER; Ghilardi, JR; Felix, AM; Lu, YA; Vinters, HV; Mantyh, PW; Maggio, JE			A beta deposition inhibitor screen using synthetic amyloid	NATURE BIOTECHNOLOGY			English	Article						Alzheimer's disease; A beta deposition; high-throughput screen; Congo red; structure-activity	ALZHEIMER-DISEASE; PRECURSOR PROTEIN; APOLIPOPROTEIN-E; TRANSGENIC MICE; PEPTIDE; AGGREGATION; INVITRO; PLAQUES	The formation, growth, and maturation of brain amyloid ''senile'' plaques are essential pathological processes in Alzheimer's disease (AD) and key targets for therapeutic intervention, The process of in vitro deposition of A beta at physiological concentrations onto plaques in AD brain preparations has been well characterized, but is cumbersome for drug discovery. We describe here a high-throughput screen for inhibitors of A beta deposition onto a synthetic template (synthaloid) of fibrillar A beta immobilized in a polymer matrix. Synthaloid is indistinguishable from plaques in AD brain (the natural template) in deposition kinetics, pH profile, and structure-activity relationships for both A beta analogs and inhibitors, Synthaloid, in contrast to current A beta aggregation screens, accurately predicted inhibitor potency for A beta deposition onto AD cortex preparations, validating its use in searching for agents that can slow the progression of AD and exposing a previously inaccessible target for drug discovery.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,BOSTON,MA 02115; UNIV MINNESOTA,VA MED CTR,MINNEAPOLIS,MN 55417; UNIV MINNESOTA,DEPT PSYCHIAT,MINNEAPOLIS,MN 55417; VANDERBILT UNIV,DEPT MICROBIOL & IMMUNOL,NASHVILLE,TN 37232; WILLIAM PATERSON COLL NEW JERSEY,DEPT CHEM & PHYS,WAYNE,NJ 07470; UNIV CALIF LOS ANGELES,DEPT PATHOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,LAB MED,LOS ANGELES,CA 90095	Harvard University; Harvard Medical School; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; Vanderbilt University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NIA NIH HHS [AG10123, AG12435, AG12853] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG012853, P30AG010123, P01AG012435] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CUMMINGS BJ, 1995, LANCET, V346, P1524, DOI 10.1016/S0140-6736(95)92053-6; Esler WP, 1996, J NEUROCHEM, V66, P723; Esler WP, 1996, BIOCHEMISTRY-US, V35, P749, DOI 10.1021/bi951685w; Esler WP, 1996, BIOCHEMISTRY-US, V35, P13914, DOI 10.1021/bi961302+; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; FRASER PE, 1992, BIOCHEMISTRY-US, V31, P10716, DOI 10.1021/bi00159a011; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Ghilardi JR, 1996, NEUROREPORT, V7, P2607, DOI 10.1097/00001756-199611040-00040; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HARDY J, 1991, TRENDS PHARMACOL SCI, V12, P383, DOI 10.1016/0165-6147(91)90609-V; HYMAN BT, 1995, P NATL ACAD SCI USA, V92, P3586, DOI 10.1073/pnas.92.8.3586; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; LEE JP, 1995, BIOCHEMISTRY-US, V34, P5191, DOI 10.1021/bi00015a033; Lomakin A, 1996, P NATL ACAD SCI USA, V93, P1125, DOI 10.1073/pnas.93.3.1125; Maggio JE, 1996, BRAIN PATHOL, V6, P147, DOI 10.1111/j.1750-3639.1996.tb00797.x; MAGGIO JE, 1992, P NATL ACAD SCI USA, V89, P5462, DOI 10.1073/pnas.89.12.5462; MANTYH PW, 1993, J NEUROCHEM, V61, P1171, DOI 10.1111/j.1471-4159.1993.tb03639.x; MANTYH PW, 1991, B CLIN NEUROSCI, V56, P73; Naiki H, 1996, LAB INVEST, V74, P374; PODLISNY MB, 1995, J BIOL CHEM, V270, P9564, DOI 10.1074/jbc.270.16.9564; POLLACK SJ, 1995, NEUROSCI LETT, V197, P211, DOI 10.1016/0304-3940(95)11939-T; SCHELLENBERG GD, 1995, P NATL ACAD SCI USA, V92, P8552, DOI 10.1073/pnas.92.19.8552; SCHENK DB, 1995, J MED CHEM, V38, P4141, DOI 10.1021/jm00021a001; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; Soto C, 1996, BIOCHEM BIOPH RES CO, V226, P672, DOI 10.1006/bbrc.1996.1413; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Tomiyama T, 1996, J BIOL CHEM, V271, P6839, DOI 10.1074/jbc.271.12.6839; Vinters HV, 1996, BRAIN PATHOL, V6, P179, DOI 10.1111/j.1750-3639.1996.tb00799.x; WELDON DT, 1996, SOC NEUR ABS, V22, P475; Wood SJ, 1996, J BIOL CHEM, V271, P4086; ZHENG H, 1995, CELL, V81, P525, DOI 10.1016/0092-8674(95)90073-X	37	77	80	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1997	15	3					258	263		10.1038/nbt0397-258	http://dx.doi.org/10.1038/nbt0397-258			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WM050	9062926				2022-12-27	WOS:A1997WM05000030
J	Greenstein, JL; Sachs, DH				Greenstein, JL; Sachs, DH			The use of tolerance for transplantation across xenogeneic barriers	NATURE BIOTECHNOLOGY			English	Review						xenotransplantation; immune tolerance; miniature swine	NONLETHAL PREPARATIVE REGIMEN; BONE-MARROW TRANSPLANTATION; HUMAN NATURAL ANTIBODIES; HUMAN T-CELLS; XENOGRAFT REJECTION; RENAL-ALLOGRAFTS; PIG; COMPLEMENT; CHIMERISM; ANTIGENS	The success of human organ transplantation as a clinical treatment has created a conundrum for the transplant community. It has caused a shortage of human donor organs and uncovered problems of chronic immunosuppression in those lucky enough to receive organ transplants due to their use of chronic immunosuppressive drugs. Our aim is to attempt to approach both issues by establishing specific transplantation tolerance to pig organ grafts.	HARVARD UNIV,SCH MED,BOSTON,MA 02129; MASSACHUSETTS GEN HOSP,TRANSPLANTAT BIOL RES CTR,BOSTON,MA 02129	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Greenstein, JL (corresponding author), BIOTRANSPLANT INC,BLDG 75,3RD AVE,CHARLESTOWN NAVY YARD,CHARLESTOWN,MA 02129, USA.							ALEXANDRE GPJ, 1987, TRANSPLANT P, V19, P4538; ALEXANDRE GPJ, 1989, XENOGRAFT, V25, P259; Bach FH, 1996, IMMUNOL TODAY, V17, P379, DOI 10.1016/0167-5699(96)10024-4; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BLAKELY ML, 1994, TRANSPLANTATION, V58, P1059, DOI 10.1097/00007890-199411270-00001; CALNE RY, 1970, TRANSPL P, V2, P550; COOPER DKC, 1992, CLIN TRANSPLANT, V6, P178; COZZI E, 1995, NAT MED, V1, P964, DOI 10.1038/nm0995-964; Fishman Jay A., 1994, Xenotransplantation, V1, P47, DOI 10.1111/j.1399-3089.1994.tb00049.x; FODOR WL, 1994, P NATL ACAD SCI USA, V91, P11153, DOI 10.1073/pnas.91.23.11153; Fryer J P, 1994, Transpl Immunol, V2, P87, DOI 10.1016/0966-3274(94)90033-7; GALILI U, 1988, J BIOL CHEM, V263, P17755; GALILI U, 1991, P NATL ACAD SCI USA, V88, P7401, DOI 10.1073/pnas.88.16.7401; GIOVINO MA, 1997, UNPUB XENOGENEIC BON, V2; GOOD AH, 1992, TRANSPL P, V24, P559; HAWLEY RJ, 1997, IN PRESS XENOTRANSPL; HELG C, 1994, TRANSPLANTATION, V58, P1420; HO M, 1990, PRINCIPLES PRACTICE, P2284; ILDSTAD ST, 1984, NATURE, V307, P168, DOI 10.1038/307168a0; INABA M, 1991, J EXP MED, V173, P549, DOI 10.1084/jem.173.3.549; JACOBSEN N, 1994, LANCET, V343, P800, DOI 10.1016/S0140-6736(94)91881-3; KAWAI T, 1995, TRANSPLANTATION, V59, P256, DOI 10.1097/00007890-199501270-00018; Kobayashi T, 1996, TRANSPLANT P, V28, P560; KUMAGAIBRAESCH M, 1993, CLIN TRANSPLANT, V7, P273; LANGFORD GA, 1994, TRANSPLANT P, V26, P1400; LEVENTHAL JR, 1993, TRANSPLANTATION, V56, P1, DOI 10.1097/00007890-199307000-00001; LEVENTHAL JR, 1993, TRANSPLANTATION, V55, P857, DOI 10.1097/00007890-199304000-00033; Loveland B E, 1993, Transpl Immunol, V1, P101, DOI 10.1016/0966-3274(93)90002-P; MCCURRY KR, 1995, NAT MED, V1, P423, DOI 10.1038/nm0595-423; MICHAELS MG, 1994, TRANSPLANTATION, V57, P1, DOI 10.1097/00007890-199401000-00001; MURRAY AG, 1994, IMMUNITY, V1, P57, DOI 10.1016/1074-7613(94)90009-4; ORIOL R, 1993, TRANSPLANTATION, V56, P1433, DOI 10.1097/00007890-199312000-00031; PARKER W, 1994, J IMMUNOL, V153, P3791; PLATT JL, 1991, TRANSPLANTATION, V52, P214, DOI 10.1097/00007890-199108000-00006; Platt JL, 1996, CURR OPIN IMMUNOL, V8, P721, DOI 10.1016/S0952-7915(96)80091-4; PRUITT SK, 1994, TRANSPLANTATION, V57, P363, DOI 10.1097/00007890-199402150-00009; Richards AC, 1996, LANCET, V348, P1596, DOI 10.1016/S0140-6736(05)66224-1; Sablinski Tomasz, 1995, Xenotransplantation, V2, P264, DOI 10.1111/j.1399-3089.1995.tb00107.x; Sachs David H., 1995, Xenotransplantation, V2, P234, DOI 10.1111/j.1399-3089.1995.tb00101.x; SACHS DH, 1995, NAT MED, V1, P969, DOI 10.1038/nm0995-969; SACHS DH, 1994, VET IMMUNOL IMMUNOP, V43, P185, DOI 10.1016/0165-2427(94)90135-X; SACHS DH, 1976, TRANSPLANTATION, V22, P559, DOI 10.1097/00007890-197612000-00004; SACHS DH, 1992, SWINE AS MODELS IN BIOMEDICAL RESEARCH, P3; SACHS DH, 1971, J IMMUNOL, V107, P481; SANDRIN MS, 1995, NAT MED, V1, P1261, DOI 10.1038/nm1295-1261; SANDRIN MS, 1993, P NATL ACAD SCI USA, V90, P11391, DOI 10.1073/pnas.90.23.11391; SAYEGH MH, 1991, ANN INTERN MED, V114, P954, DOI 10.7326/0003-4819-114-11-954; SHARABI Y, 1992, BONE MARROW TRANSPL, V9, P191; SHARABI Y, 1989, J EXP MED, V169, P493, DOI 10.1084/jem.169.2.493; SHARABI Y, 1990, J EXP MED, V172, P195, DOI 10.1084/jem.172.1.195; Sharma A, 1996, P NATL ACAD SCI USA, V93, P7190, DOI 10.1073/pnas.93.14.7190; TANAKA M, 1994, TRANSPLANT P, V26, P1326; THOMAS FT, 1993, ANN NY ACAD SCI, V685, P175, DOI 10.1111/j.1749-6632.1993.tb35863.x; WHITE DJG, 1996, XENO, V4, P50; YAMADA K, 1995, TRANSPL P, V27, P258; Yamada K, 1996, XENOTRANSPLANTATION, V3, P179, DOI 10.1111/j.1399-3089.1996.tb00136.x	57	21	24	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1997	15	3					235	238		10.1038/nbt0397-235	http://dx.doi.org/10.1038/nbt0397-235			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WM050	9062921				2022-12-27	WOS:A1997WM05000025
J	Holmberg, N; Lilius, G; Bailey, JE; Bulow, L				Holmberg, N; Lilius, G; Bailey, JE; Bulow, L			Transgenic tobacco expressing Vitreoscilla hemoglobin exhibits enhanced growth and altered metabolite production	NATURE BIOTECHNOLOGY			English	Article						hemoglobin; tobacco; oxygen; enhanced growth; nicotine	ESCHERICHIA-COLI; INTRACELLULAR EXPRESSION; NICOTINE; CULTURES; PLANTS; GENE	The gene for Vitreoscilla hemoglobin (VHb) has been introduced and expressed in Nicotiana tabaccum (tobacco). Transgenic tobacco plants expressing VHb exhibited enhanced growth, on average 80-100% more dry weight after 35 days of growth compaired to wild-type controls. Furthermore, germination time is reduced from 6-8 days for wild-type tobacco to 3-4 days and the growth phase from germination to flowering was 3-5 days shorter for the VHb-expressing transgenes. Transgenic plants contained, on average, 30-40% more chlorophyll and 34% more nicotine than controls. VHb expression also resulted in an altered distribution of secondary metabolites: In the transgenic tobacco plants anabasine content was decreased 80% relative to control plants.	CTR CHEM & CHEM ENGN,DEPT PURE & APPL BIOCHEM,S-22100 LUND,SWEDEN; ETH ZURICH,INST BIOTECHNOL,CH-8093 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich								AMON DI, 1949, PLANT PHYSIOL, V24, P1; Bailey JE, 1995, CHEM ENG SCI, V50, P4091, DOI 10.1016/0009-2509(96)81834-3; BAILEY JE, 1991, SCIENCE, V252, P1668, DOI 10.1126/science.2047876; BOGUSZ D, 1988, NATURE, V331, P178, DOI 10.1038/331178a0; BREULING M, 1985, PLANT CELL REP, V4, P220, DOI 10.1007/BF00269294; CHEN RZ, 1994, BIOTECHNOL PROGR, V10, P360, DOI 10.1021/bp00028a003; CHEN W, 1994, BIOTECHNOL PROGR, V10, P308, DOI 10.1021/bp00027a011; CURVALL M, 1982, J CHROMATOGR, V232, P283, DOI 10.1016/S0378-4347(00)84168-7; EDWARDS K, 1991, NUCLEIC ACIDS RES, V19, P1349, DOI 10.1093/nar/19.6.1349; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; FRIESEN JB, 1990, TETRAHEDRON LETT, V44, P6295; HOFFMAN P, 1993, PHOTOSYNTHETICA, V4, P495; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; KALLIO PT, 1994, EUR J BIOCHEM, V219, P201, DOI 10.1111/j.1432-1033.1994.tb19931.x; KHOSLA C, 1989, J MOL BIOL, V210, P79, DOI 10.1016/0022-2836(89)90292-1; KHOSLA C, 1988, NATURE, V331, P633, DOI 10.1038/331633a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; OKUBO T, 1978, JIBP SYNTHESIS, V19, P194; PENDSE GJ, 1994, BIOTECHNOL BIOENG, V44, P1367, DOI 10.1002/bit.260441114; ROGERS SG, 1986, METHOD ENZYMOL, V118, P627; SAKI RK, 1988, SCIENCE, V239, P487; Sambrook J., 1990, MOL CLONING LAB MANU, V2nd; SCHLATMANN JE, 1995, BIOTECHNOL BIOENG, V45, P435, DOI 10.1002/bit.260450508; SHEEN SJ, 1988, J FOOD SCI, V53, P1572, DOI 10.1111/j.1365-2621.1988.tb09328.x; TAYLOR ER, 1994, PLANT MOL BIOL, V24, P853, DOI 10.1007/BF00014440; Tsai PS, 1996, BIOTECHNOL BIOENG, V49, P151, DOI 10.1002/(SICI)1097-0290(19960120)49:2<151::AID-BIT4>3.0.CO;2-P; TSAI PS, 1995, BIOTECHNOL BIOENG, V49, P139; WALDEN R, 1990, Methods in Molecular and Cellular Biology, V1, P175; WEBSTER DA, 1974, J BIOL CHEM, V249, P4257; WITTENBERG JB, 1990, ANNU REV BIOPHYS BIO, V19, P217	31	98	121	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1997	15	3					244	247		10.1038/nbt0397-244	http://dx.doi.org/10.1038/nbt0397-244			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WM050	9062923				2022-12-27	WOS:A1997WM05000027
J	Jee, J; Lebow, ES; Yeh, R; Das, JP; Namakydoust, A; Paik, PK; Chaft, JE; Jayakumaran, G; Brannon, AR; Benayed, R; Zehir, A; Donoghue, M; Schultz, N; Chakravarty, D; Kundra, R; Madupuri, R; Murciano-Goroff, YR; Tu, HY; Xu, CR; Martinez, A; Wilhelm, C; Galle, J; Daly, B; Yu, HA; Offin, M; Hellmann, MD; Lito, P; Arbour, KC; Zauderer, MG; Kris, MG; Ng, KK; Eng, J; Preeshagul, I; Lai, WV; Fiore, JJ; Iqbal, A; Molena, D; Rocco, G; Park, BJ; Lim, LP; Li, M; Tong-Li, C; De Silva, M; Chan, DL; Diakos, CI; Itchins, M; Clarke, S; Pavlakis, N; Lee, A; Rekhtman, N; Chang, J; Travis, WD; Riely, GJ; Solit, DB; Gonen, M; Rusch, VW; Rimner, A; Gomez, D; Drilon, A; Scher, HI; Shah, SP; Berger, MF; Arcila, ME; Ladanyi, M; Levine, RL; Shen, R; Razavi, P; Reis-Filho, JS; Jones, DR; Rudin, CM; Isbell, JM; Li, BT				Jee, Justin; Lebow, Emily S.; Yeh, Randy; Das, Jeeban P.; Namakydoust, Azadeh; Paik, Paul K.; Chaft, Jamie E.; Jayakumaran, Gowtham; Brannon, A. Rose; Benayed, Ryma; Zehir, Ahmet; Donoghue, Mark; Schultz, Nikolaus; Chakravarty, Debyani; Kundra, Ritika; Madupuri, Ramyasree; Murciano-Goroff, Yonina R.; Tu, Hai-Yan; Xu, Chong-Rui; Martinez, Andres; Wilhelm, Clare; Galle, Jesse; Daly, Bobby; Yu, Helena A.; Offin, Michael; Hellmann, Matthew D.; Lito, Piro; Arbour, Kathryn C.; Zauderer, Marjorie G.; Kris, Mark G.; Ng, Kenneth K.; Eng, Juliana; Preeshagul, Isabel; Lai, W. Victoria; Fiore, John J.; Iqbal, Afsheen; Molena, Daniela; Rocco, Gaetano; Park, Bernard J.; Lim, Lee P.; Li, Mark; Tong-Li, Candace; De Silva, Madhawa; Chan, David L.; Diakos, Connie, I; Itchins, Malinda; Clarke, Stephen; Pavlakis, Nick; Lee, Adrian; Rekhtman, Natasha; Chang, Jason; Travis, William D.; Riely, Gregory J.; Solit, David B.; Gonen, Mithat; Rusch, Valerie W.; Rimner, Andreas; Gomez, Daniel; Drilon, Alexander; Scher, Howard, I; Shah, Sohrab P.; Berger, Michael F.; Arcila, Maria E.; Ladanyi, Marc; Levine, Ross L.; Shen, Ronglai; Razavi, Pedram; Reis-Filho, Jorge S.; Jones, David R.; Rudin, Charles M.; Isbell, James M.; Li, Bob T.			Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer	NATURE MEDICINE			English	Article; Early Access							CLINICAL-TRIALS; LIQUID BIOPSY; EGFR; ASSOCIATION; RESISTANCE; EVOLUTION; ONCOLOGY; MUTATION; UTILITY; ASSAYS	In a prospective international cohort of 1,127 patients with non-small-cell lung cancer and ctDNA-guided therapy, ctDNA detection was associated with shorter survival, independently of clinicopathologic features and metabolic tumor volume. Circulating tumor DNA (ctDNA) sequencing guides therapy decisions but has been studied mostly in small cohorts without sufficient follow-up to determine its influence on overall survival. We prospectively followed an international cohort of 1,127 patients with non-small-cell lung cancer and ctDNA-guided therapy. ctDNA detection was associated with shorter survival (hazard ratio (HR), 2.05; 95% confidence interval (CI), 1.74-2.42; P < 0.001) independently of clinicopathologic features and metabolic tumor volume. Among the 722 (64%) patients with detectable ctDNA, 255 (23%) matched to targeted therapy by ctDNA sequencing had longer survival than those not treated with targeted therapy (HR, 0.63; 95% CI, 0.52-0.76; P < 0.001). Genomic alterations in ctDNA not detected by time-matched tissue sequencing were found in 25% of the patients. These ctDNA-only alterations disproportionately featured subclonal drivers of resistance, including RICTOR and PIK3CA alterations, and were associated with short survival. Minimally invasive ctDNA profiling can identify heterogeneous drivers not captured in tissue sequencing and expand community access to life-prolonging therapy.	[Jee, Justin; Lebow, Emily S.; Yeh, Randy; Das, Jeeban P.; Namakydoust, Azadeh; Paik, Paul K.; Chaft, Jamie E.; Jayakumaran, Gowtham; Brannon, A. Rose; Benayed, Ryma; Zehir, Ahmet; Donoghue, Mark; Schultz, Nikolaus; Chakravarty, Debyani; Kundra, Ritika; Madupuri, Ramyasree; Murciano-Goroff, Yonina R.; Tu, Hai-Yan; Xu, Chong-Rui; Martinez, Andres; Wilhelm, Clare; Galle, Jesse; Daly, Bobby; Yu, Helena A.; Offin, Michael; Hellmann, Matthew D.; Lito, Piro; Arbour, Kathryn C.; Zauderer, Marjorie G.; Kris, Mark G.; Ng, Kenneth K.; Eng, Juliana; Preeshagul, Isabel; Lai, W. Victoria; Fiore, John J.; Iqbal, Afsheen; Molena, Daniela; Rocco, Gaetano; Park, Bernard J.; Rekhtman, Natasha; Chang, Jason; Travis, William D.; Riely, Gregory J.; Solit, David B.; Gonen, Mithat; Rusch, Valerie W.; Rimner, Andreas; Gomez, Daniel; Drilon, Alexander; Scher, Howard, I; Shah, Sohrab P.; Berger, Michael F.; Arcila, Maria E.; Ladanyi, Marc; Levine, Ross L.; Shen, Ronglai; Razavi, Pedram; Reis-Filho, Jorge S.; Jones, David R.; Rudin, Charles M.; Isbell, James M.; Li, Bob T.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Paik, Paul K.; Chaft, Jamie E.; Daly, Bobby; Yu, Helena A.; Offin, Michael; Hellmann, Matthew D.; Lito, Piro; Arbour, Kathryn C.; Zauderer, Marjorie G.; Kris, Mark G.; Ng, Kenneth K.; Eng, Juliana; Preeshagul, Isabel; Lai, W. Victoria; Fiore, John J.; Iqbal, Afsheen; Molena, Daniela; Rocco, Gaetano; Park, Bernard J.; Rekhtman, Natasha; Chang, Jason; Travis, William D.; Riely, Gregory J.; Solit, David B.; Rusch, Valerie W.; Rimner, Andreas; Gomez, Daniel; Drilon, Alexander; Scher, Howard, I; Arcila, Maria E.; Ladanyi, Marc; Levine, Ross L.; Razavi, Pedram; Reis-Filho, Jorge S.; Jones, David R.; Rudin, Charles M.; Isbell, James M.; Li, Bob T.] Cornell Univ, Weill Cornell Med, New York, NY 10021 USA; [Tu, Hai-Yan; Xu, Chong-Rui] Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangzhou, Peoples R China; [Tu, Hai-Yan; Xu, Chong-Rui] Guangdong Acad Med Sci, Guangzhou, Peoples R China; [Lim, Lee P.; Li, Mark] Agilent Technol, Resolut Biosci, Kirkland, WA USA; [Tong-Li, Candace; De Silva, Madhawa; Chan, David L.; Diakos, Connie, I; Itchins, Malinda; Clarke, Stephen; Pavlakis, Nick; Lee, Adrian] Univ Sydney, GenesisCare, Sydney, NSW, Australia; [Tong-Li, Candace] MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA	Memorial Sloan Kettering Cancer Center; Cornell University; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Agilent Technologies; University of Sydney; Massachusetts Institute of Technology (MIT)	Li, BT (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.; Li, BT (corresponding author), Cornell Univ, Weill Cornell Med, New York, NY 10021 USA.	lib1@mskcc.org		Jee, Justin/0000-0001-9783-0139; Tong-Li, Candace/0000-0003-2733-5225	Antidote Health Foundation for Cure of Cancer; National Institutes of Health [T32-CA009207, CTSA UL1TR00457, P50 CA247749 01, P30 CA008748]; Molecular Diagnostics Service in the Department of Pathology; Marie-Josee and Henry R. Kravis Center for Molecular Oncology	Antidote Health Foundation for Cure of Cancer; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Molecular Diagnostics Service in the Department of Pathology; Marie-Josee and Henry R. Kravis Center for Molecular Oncology	This work was supported by a grant from the Antidote Health Foundation for Cure of Cancer (BTL), the National Institutes of Health (T32-CA009207 (J.J.), CTSA UL1TR00457 (M.R.M.-G.), P50 CA247749 01 and P30 CA008748), the Molecular Diagnostics Service in the Department of Pathology, and the Marie-Josee and Henry R. Kravis Center for Molecular Oncology.	Abbosh C, 2017, NATURE, V545, P446, DOI 10.1038/nature22364; Aggarwal C, 2019, JAMA ONCOL, V5, P173, DOI 10.1001/jamaoncol.2018.4305; Alix-Panabieres C, 2021, CANCER DISCOV, V11, P858, DOI 10.1158/2159-8290.CD-20-1311; Bardelli A, 2017, CANCER CELL, V31, P172, DOI 10.1016/j.ccell.2017.01.002; Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094; Boellaard R, 2010, EUR J NUCL MED MOL I, V37, P181, DOI 10.1007/s00259-009-1297-4; Bolton Kelly L, 2020, medRxiv, DOI [10.1038/s41467-021-26138-6, 10.1101/2020.11.25.20233163]; Bolton KL, 2020, NAT GENET, V52, P1219, DOI 10.1038/s41588-020-00710-0; Bruno DS, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.9005; Chabon JJ, 2020, NATURE, V580, P245, DOI 10.1038/s41586-020-2140-0; Chabon JJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11815; Chakravarty Debyani, 2017, JCO Precis Oncol, V2017, DOI 10.1200/PO.17.00011; Chaudhuri AA, 2017, CANCER DISCOV, V7, P1394, DOI 10.1158/2159-8290.CD-17-0716; Coombs CC, 2017, CELL STEM CELL, V21, P374, DOI 10.1016/j.stem.2017.07.010; Cristiano S, 2019, NATURE, V570, P385, DOI 10.1038/s41586-019-1272-6; Gandara DR, 2018, NAT MED, V24, P1441, DOI 10.1038/s41591-018-0134-3; Goldberg SB, 2018, CLIN CANCER RES, V24, P1872, DOI 10.1158/1078-0432.CCR-17-1341; Heitzer E, 2019, NAT REV GENET, V20, P71, DOI 10.1038/s41576-018-0071-5; Howlader N, 2020, NEW ENGL J MED, V383, P640, DOI 10.1056/NEJMoa1916623; Ignatiadis M, 2021, NAT REV CLIN ONCOL, V18, P297, DOI 10.1038/s41571-020-00457-x; Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288; Kanoun S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140830; Karachaliou N, 2015, JAMA ONCOL, V1, P149, DOI 10.1001/jamaoncol.2014.257; Karczewski KJ, 2020, NATURE, V581, P434, DOI 10.1038/s41586-020-2308-7; Kris MG, 2014, JAMA-J AM MED ASSOC, V311, P1998, DOI 10.1001/jama.2014.3741; Leighl NB, 2019, CLIN CANCER RES, V25, P4691, DOI 10.1158/1078-0432.CCR-19-0624; Lennon AM, 2020, SCIENCE, V369, P49, DOI 10.1126/science.abb9601; Li BT, 2019, ANN ONCOL, V30, P597, DOI 10.1093/annonc/mdz046; Li BT, 2022, NAT MED, V28, P620, DOI 10.1038/s41591-022-01775-6; Lisberg A, 2018, J THORAC ONCOL, V13, P1138, DOI 10.1016/j.jtho.2018.03.035; Mack PC, 2020, CANCER-AM CANCER SOC, V126, P3219, DOI 10.1002/cncr.32876; Mandelker D, 2017, JAMA-J AM MED ASSOC, V318, P825, DOI 10.1001/jama.2017.11137; Mateo J, 2018, ANN ONCOL, V29, P1895, DOI 10.1093/annonc/mdy263; McGranahan N, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa1408; McNulty SN, 2019, J MOL DIAGN, V21, P903, DOI 10.1016/j.jmoldx.2019.05.005; Merker JD, 2018, J CLIN ONCOL, V36, P1631, DOI 10.1200/JCO.2017.76.8671; Morbelli S, 2017, J NUCL MED, V58, P1764, DOI 10.2967/jnumed.117.193201; Murthy VH, 2004, JAMA-J AM MED ASSOC, V291, P2720, DOI 10.1001/jama.291.22.2720; Nabet BY, 2020, CELL, V183, P363, DOI 10.1016/j.cell.2020.09.001; Nakamura Y, 2020, NAT MED, V26, DOI 10.1038/s41591-020-1063-5; Newman AM, 2016, NAT BIOTECHNOL, V34, P547, DOI 10.1038/nbt.3520; Newman AM, 2014, NAT MED, V20, P552, DOI 10.1038/nm.3519; Offin M, 2018, JCO PRECIS ONCOL, V2, DOI 10.1200/PO.18.00126; Oxnard GR, 2016, J CLIN ONCOL, V34, P3375, DOI 10.1200/JCO.2016.66.7162; Pairawan S, 2020, CLIN CANCER RES, V26, P1924, DOI 10.1158/1078-0432.CCR-19-0306; Parikh AR, 2019, NAT MED, V25, P1415, DOI 10.1038/s41591-019-0561-9; Pasche B, 2014, JAMA-J AM MED ASSOC, V311, P1975, DOI 10.1001/jama.2014.3742; Paweletz CP, 2016, CLIN CANCER RES, V22, P915, DOI 10.1158/1078-0432.CCR-15-1627-T; Piotrowska Z, 2018, CANCER DISCOV, V8, P1529, DOI 10.1158/2159-8290.CD-18-1022; Piper-Vallillo AJ, 2020, J CLIN ONCOL, V38, P2926, DOI 10.1200/JCO.19.03123; Presley CJ, 2018, JAMA-J AM MED ASSOC, V320, P469, DOI 10.1001/jama.2018.9824; Ramalingam SS, 2020, NEW ENGL J MED, V382, P41, DOI 10.1056/NEJMoa1913662; Ramalingam SS, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-CT078; Razavi P, 2019, NAT MED, V25, P1928, DOI 10.1038/s41591-019-0652-7; Remon J, 2017, ANN ONCOL, V28, P784, DOI 10.1093/annonc/mdx017; Robert NJ, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.9004; Rolfo C, 2021, J THORAC ONCOL, V16, P1647, DOI 10.1016/j.jtho.2021.06.017; Rolfo C, 2020, CANCER-AM CANCER SOC, V126, P4089, DOI 10.1002/cncr.32983; Brannon AR, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24109-5; Rothwell DG, 2019, NAT MED, V25, P738, DOI 10.1038/s41591-019-0380-z; Sabari JK, 2019, JNCI-J NATL CANCER I, V111, P575, DOI 10.1093/jnci/djy156; Sacher AG, 2016, JAMA ONCOL, V2, P1014, DOI 10.1001/jamaoncol.2016.0173; Scher KS, 2012, J CLIN ONCOL, V30, P2036, DOI 10.1200/JCO.2012.41.6727; Sedrak MS, 2021, CA-CANCER J CLIN, V71, P78, DOI 10.3322/caac.21638; Shen RL, 2019, JCO PRECIS ONCOL, V3, DOI 10.1200/PO.18.00307; Shen RL, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw520; Sheridan C, 2019, NAT BIOTECHNOL, V37, P972, DOI 10.1038/d41587-019-00022-7; Siravegna G, 2015, NAT MED, V21, P795, DOI 10.1038/nm.3870; Supplee JG, 2019, LUNG CANCER, V134, P96, DOI 10.1016/j.lungcan.2019.06.004; Syeda MM, 2021, LANCET ONCOL, V22, P370, DOI 10.1016/S1470-2045(20)30726-9; Tan AC, 2020, THORAC CANCER, V11, P511, DOI 10.1111/1759-7714.13328; Tran HT, 2021, JCO PRECIS ONCOL, V5, P1241, DOI 10.1200/PO.20.00532; Turner NC, 2020, LANCET ONCOL, V21, P1296, DOI [10.11016/S1470-2045(20)30444-7, 10.1016/S1470-2045(20)30444-7]; Yang M, 2018, ANN ONCOL, V29, P311, DOI 10.1093/annonc/mdx766; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333; Zugazagoitia J, 2019, ANN ONCOL, V30, P290, DOI 10.1093/annonc/mdy512	76	0	0	5	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02047-z	http://dx.doi.org/10.1038/s41591-022-02047-z		NOV 2022	21	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	6B8KC	36357680				2022-12-27	WOS:000881574700009
J	Gebremedhin, LT				Gebremedhin, Lia Tadesse			Investment in health data can drive economic growth	NATURE MEDICINE			English	Editorial Material; Early Access								The Global Burden of Disease provides essential data for evidence-based healthcare, but could be improved by investment in health data systems in low- and middle-income countries	[Gebremedhin, Lia Tadesse] Minist Hlth, Addis Ababa, Ethiopia		Gebremedhin, LT (corresponding author), Minist Hlth, Addis Ababa, Ethiopia.	lia.tadesse@moh.gov.et							0	0	0	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02022-8	http://dx.doi.org/10.1038/s41591-022-02022-8		OCT 2022	1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	5E6FW	36216943	Bronze			2022-12-27	WOS:000865719400004
J	Buergel, T; Steinfeldt, J; Ruyoga, G; Pietzner, M; Bizzarri, D; Vojinovic, D; zu Belzen, JU; Loock, L; Kittner, P; Christmann, L; Hollmann, N; Strangalies, H; Braunger, JM; Wild, B; Chiesa, ST; Spranger, J; Klostermann, F; van den Akker, EB; Trompet, S; Mooijaart, SP; Sattar, N; Jukema, JW; Lavrijssen, B; Kavousi, M; Ghanbari, M; Ikram, MA; Slagboom, E; Kivimaki, M; Langenberg, C; Deanfield, J; Eils, R; Landmesser, U				Buergel, Thore; Steinfeldt, Jakob; Ruyoga, Greg; Pietzner, Maik; Bizzarri, Daniele; Vojinovic, Dina; zu Belzen, Julius Upmeier; Loock, Lukas; Kittner, Paul; Christmann, Lara; Hollmann, Noah; Strangalies, Henrik; Braunger, Jana M.; Wild, Benjamin; Chiesa, Scott T.; Spranger, Joachim; Klostermann, Fabian; van den Akker, Erik B.; Trompet, Stella; Mooijaart, Simon P.; Sattar, Naveed; Jukema, J. Wouter; Lavrijssen, Birgit; Kavousi, Maryam; Ghanbari, Mohsen; Ikram, Mohammad A.; Slagboom, Eline; Kivimaki, Mika; Langenberg, Claudia; Deanfield, John; Eils, Roland; Landmesser, Ulf			Metabolomic profiles predict individual multidisease outcomes	NATURE MEDICINE			English	Article; Early Access							MAGNETIC-RESONANCE METABOLOMICS; CARDIOVASCULAR-DISEASE; RISK-FACTORS; CIRCULATING METABOLITES; MYOCARDIAL-INFARCTION; ASSOCIATION; DEMENTIA; HYPERGLYCEMIA; EPIDEMIOLOGY; PRAVASTATIN	Risk stratification is critical for the early identification of high-risk individuals and disease prevention. Here we explored the potential of nuclear magnetic resonance (NMR) spectroscopy-derived metabolomic profiles to inform on multidisease risk beyond conventional clinical predictors for the onset of 24 common conditions, including metabolic, vascular, respiratory, musculoskeletal and neurological diseases and cancers. Specifically, we trained a neural network to learn disease-specific metabolomic states from 168 circulating metabolic markers measured in 117,981 participants with -1.4 million person-years of follow-up from the UK Biobank and validated the model in four independent cohorts. We found metabolomic states to be associated with incident event rates in all the investigated conditions, except breast cancer. For 10-year outcome prediction for 15 endpoints, with and without established metabolic contribution, a combination of age and sex and the metabolomic state equaled or outperformed established predictors. Moreover, metabolomic state added predictive information over comprehensive clinical variables for eight common diseases, including type 2 diabetes, dementia and heart failure. Decision curve analyses showed that predictive improvements translated into clinical utility for a wide range of potential decision thresholds. Taken together, our study demonstrates both the potential and limitations of NMR-derived metabolomic profiles as a multidisease assay to inform on the risk of many common diseases simultaneously.	[Buergel, Thore; Ruyoga, Greg; zu Belzen, Julius Upmeier; Loock, Lukas; Kittner, Paul; Christmann, Lara; Hollmann, Noah; Strangalies, Henrik; Braunger, Jana M.; Wild, Benjamin; Eils, Roland] Charite Univ Med Berlin, Ctr Digital Hlth, Berlin Inst Hlth, Berlin, Germany; [Steinfeldt, Jakob; Landmesser, Ulf] Charite Univ Med Berlin, Dept Cardiol, Campus Benjamin Franklin, Berlin, Germany; [Steinfeldt, Jakob; Spranger, Joachim; Landmesser, Ulf] Berlin Inst Hlth, Berlin, Germany; [Pietzner, Maik; Langenberg, Claudia] Charite Univ Med Berlin, Berlin Inst Hlth, Computat Med, Berlin, Germany; [Pietzner, Maik; Langenberg, Claudia] Univ Cambridge, Inst Metab Sci, MRC Epidemiol Unit, Cambridge, England; [Bizzarri, Daniele; van den Akker, Erik B.; Slagboom, Eline] LUMC, Mol Epidemiol, Leiden, Netherlands; [Bizzarri, Daniele; van den Akker, Erik B.] LUMC, Leiden Computat Biol Ctr, Leiden, Netherlands; [Vojinovic, Dina; Lavrijssen, Birgit; Kavousi, Maryam; Ghanbari, Mohsen; Ikram, Mohammad A.] Erasmus MC Univ Med Ctr, Dept Epidemiol, Rotterdam, Netherlands; [Vojinovic, Dina] Leiden Univ Med Ctr, Dept Biomed Data Sci, Mol Epidemiol, Leiden, Netherlands; [Chiesa, Scott T.; Deanfield, John] UCL, Inst Cardiovasc Sci, London, England; [Spranger, Joachim] Charite Univ Med Berlin, Dept Endocrinol & Metab, Berlin, Germany; [Spranger, Joachim] Charite Univ Med Berlin, Ctr Cardiovasc Res, Berlin, Germany; [Klostermann, Fabian] Humboldt Univ, Dept Neurol, Berlin, Germany; [Klostermann, Fabian] Charite Univ Med Berlin, Berlin Inst Hlth, Berlin, Germany; [Klostermann, Fabian] Humboldt Univ, Sch Mind & Brain, Berlin, Germany; [van den Akker, Erik B.] Delft Univ Technol, Delft Bioinformat Lab, Delft, Netherlands; [Trompet, Stella; Mooijaart, Simon P.] Leiden Univ Med Ctr, Dept Internal Med, Div Gerontol & Geriatr, Leiden, Netherlands; [Trompet, Stella; Jukema, J. Wouter] Leiden Univ Med Ctr, Dept Cardiol, Leiden, Netherlands; [Sattar, Naveed] Univ Glasgow, Cardiovasc Res Ctr, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland; [Jukema, J. Wouter] Netherlands Heart Inst, Utrecht, Netherlands; [Lavrijssen, Birgit] Erasmus MC Univ Med Ctr, Dept Surg, Rotterdam, Netherlands; [Slagboom, Eline] Max Planck Inst Biol Ageing, Cologne, Germany; [Kivimaki, Mika] UCL, Dept Epidemiol & Publ Hlth, London, England; [Kivimaki, Mika] Univ Helsinki, Fac Med, Clinicum, Helsinki, Finland; [Eils, Roland] Heidelberg Univ Hosp, Hlth Data Sci Unit, Heidelberg, Germany; [Eils, Roland] BioQuant, Heidelberg, Germany	Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Berlin Institute of Health; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Cambridge; Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Erasmus University Rotterdam; Erasmus MC; Leiden University; Leiden University Medical Center (LUMC); University of London; University College London; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin; Delft University of Technology; Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); University of Glasgow; Erasmus University Rotterdam; Erasmus MC; Max Planck Society; University of London; University College London; University of Helsinki; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Eils, R (corresponding author), Charite Univ Med Berlin, Ctr Digital Hlth, Berlin Inst Hlth, Berlin, Germany.; Eils, R (corresponding author), Heidelberg Univ Hosp, Hlth Data Sci Unit, Heidelberg, Germany.; Eils, R (corresponding author), BioQuant, Heidelberg, Germany.	roland.eils@bih-charite.de	Chiesa, Scott/AAZ-1303-2020	Chiesa, Scott/0000-0003-4323-2189; Bizzarri, Daniele/0000-0002-6881-273X; Braunger, Jana/0000-0003-0820-9987; Upmeier zu Belzen, Julius/0000-0002-0966-4458	BMBF [01ZZ1802A-01ZZ1802Z]; Wellcome Trust [221854/Z/20/Z]; Medical Research Council [MR/R024227/1]; US National Institute on Aging [R01AG056477]; Dutch Research Council (NWO) [VENI: 09150161810095]; NHS Health Research Authority, London-Harrow Research Ethics Committee [REC 85/0938, IRAS 142374]; Erasmus University Rotterdam; Netherlands Organization for Scientific Research (NWO); Netherlands Organization for Health Research and Development (ZonMw); Research Institute for Diseases in the Elderly (RIDE); Netherlands Genomics Initiative (NGI); Ministry of Education, Culture and Science; Ministry of Health, Welfare and Sports; European Commission (DG XII); Municipality of Rotterdam; Biobanking and Biomolecular Resources Research Infrastructure (BBMRI)-NL [184.021.007]; JNPD under the project PERADES [733051021]; European Union [259679]; Innovation-Oriented Research Program on Genomics (SenterNovem) [IGE05007]; Center for Medical Systems Biology and the Netherlands Consortium for Healthy Ageing [05040202, 050-060-810]; NWO; Unilever Colworth; BBMRI-NL; Dutch government (NWO) [184.021.007]; Bristol-Myers Squibb; Established Clinical Investigator of the Netherlands Heart Foundation [2001 D032]; European Federation of Pharmaceutical Industries Associations (EFPIA); Innovative Medicines Initiative Joint undertaking; European Medical Information Framework (EMIF) [115372]; European Commission [305507]; Erasmus MC University Medical Center	BMBF(Federal Ministry of Education & Research (BMBF)); Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); US National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Dutch Research Council (NWO)(Netherlands Organization for Scientific Research (NWO)); NHS Health Research Authority, London-Harrow Research Ethics Committee; Erasmus University Rotterdam; Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); Netherlands Organization for Health Research and Development (ZonMw)(Netherlands Organization for Health Research and Development); Research Institute for Diseases in the Elderly (RIDE); Netherlands Genomics Initiative (NGI); Ministry of Education, Culture and Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Welfare and Sports; European Commission (DG XII)(European CommissionEuropean Commission Joint Research Centre); Municipality of Rotterdam; Biobanking and Biomolecular Resources Research Infrastructure (BBMRI)-NL; JNPD under the project PERADES; European Union(European Commission); Innovation-Oriented Research Program on Genomics (SenterNovem); Center for Medical Systems Biology and the Netherlands Consortium for Healthy Ageing; NWO(Netherlands Organization for Scientific Research (NWO)); Unilever Colworth(Unilever); BBMRI-NL; Dutch government (NWO); Bristol-Myers Squibb(Bristol-Myers Squibb); Established Clinical Investigator of the Netherlands Heart Foundation; European Federation of Pharmaceutical Industries Associations (EFPIA); Innovative Medicines Initiative Joint undertaking; European Medical Information Framework (EMIF); European Commission(European CommissionEuropean Commission Joint Research Centre); Erasmus MC University Medical Center	This research was conducted using data from UK Biobank, a major biomedical database (https://www.ukbiobank.ac.uk) via application no. 51157. This project was funded by Charite - Universitatsmedizin Berlin and Einstein Foundation Berlin. The study was supported by the BMBF-funded Medical Informatics Initiative (HiGHmed, nos. 01ZZ1802A-01ZZ1802Z). Resources of Flaticon.com were used in the design of the figures. M. Kivimaki received relevant founding from The Wellcome Trust (no. 221854/Z/20/Z), the Medical Research Council (no. MR/R024227/1) and the US National Institute on Aging (no. R01AG056477). E.B.v.d.A. received relevant funds from the Dutch Research Council (NWO, no. VENI: 09150161810095). The WHII study was supported by the Wellcome Trust (no. 221854/Z/20/Z), the Medical Research Council (no. MR/R024227/1) and the US National Institute on Aging (no. R01AG056477). Ethical approval for the WHII study was obtained from the University College London Hospital Committee on the Ethics of Human Research and the NHS Health Research Authority, London-Harrow Research Ethics Committee (nos. REC 85/0938 and IRAS 142374). Written informed consent from participants was obtained at each contact. The authors thank A. Ryan and M. Newbury from the DPUK platform team for their swift and immediate help with data access. The RS is supported by the Erasmus MC University Medical Center and Erasmus University Rotterdam; the Netherlands Organization for Scientific Research (NWO); the Netherlands Organization for Health Research and Development (ZonMw); the Research Institute for Diseases in the Elderly (RIDE); the Netherlands Genomics Initiative (NGI); the Ministry of Education, Culture and Science; the Ministry of Health, Welfare and Sports; the European Commission (DG XII); and the Municipality of Rotterdam. Metabolomics measurements were funded by Biobanking and Biomolecular Resources Research Infrastructure (BBMRI)-NL (no. 184.021.007) and JNPD under the project PERADES (grant no. 733051021, Defining Genetic, Polygenic and Environmental Risk for Alzheimer's Disease using multiple powerful cohorts, focused Epigenetics and Stem cell metabolomics). The RS protocol was approved by the Medical Ethics Committee of the Erasmus MC Rotterdam, the Netherlands (no. MEC 02.1015) and by the Dutch Ministry of Health, Welfare and Sport (Population Screening Act WBO, license no. 1071272-159521-PG). In accordance with the Declaration of Helsinki, the RS obtained written informed consent from all participants before their entering the study. The LLS received funding from the European Union's Seventh Framework Program (FP7/2007-2011) under grant agreement no. 259679. This study was supported by a grant from the Innovation-Oriented Research Program on Genomics (SenterNovem, no. IGE05007), the Center for Medical Systems Biology and the Netherlands Consortium for Healthy Ageing (grant nos. 05040202 and 050-060-810), all within the framework of the Netherlands Genomics Initiative, NWO, Unilever Colworth and by BBMRI-NL, a Research Infrastructure financed by the Dutch government (NWO, no. 184.021.007). The LLS protocol was approved by the Medical Ethical Committee of Leiden University Medical Center before the start of the study (no. P01.113). In accordance with the Declaration of Helsinki, the LLS obtained informed consent from all participants before their entry into the study. The PROSPER study was supported by an investigator-initiated grant obtained from Bristol-Myers Squibb. J.W.; Jukema is an Established Clinical Investigator of the Netherlands Heart Foundation (grant no. 2001 D032). PROSPER was supported by the European Federation of Pharmaceutical Industries Associations (EFPIA), Innovative Medicines Initiative Joint undertaking, European Medical Information Framework (EMIF, grant no. 115372) and the European Commission under the Health Cooperation Work Program of the 7th Framework Program (grant no. 305507) 'Heart 'omics' in AGEing' (HOMAGE). The PROSPER protocol was approved by institutional ethics review boards of Cork University (Ireland), Glasgow University (UK) and Leiden University Medical Center (the Netherlands). In accordance with the Declaration of Helsinki, the PROSPER study obtained informed consent from all participants before their entry into the study.	A. D. Hingorani, 2022, medRxiv, DOI 10.1101/2022.02.18.22271049; Ahadi S, 2020, NAT MED, V26, P83, DOI 10.1038/s41591-019-0719-5; Ahola-Olli AV, 2019, DIABETOLOGIA, V62, P2298, DOI 10.1007/s00125-019-05001-w; Ala-Korpela M, 2021, INT J EPIDEMIOL, DOI 10.1093/ije/dyab156; [Anonymous], NHS HLTH CHECK; [Anonymous], 2022, B REC; Balk EM, 2015, ANN INTERN MED, V163, P437, DOI 10.7326/M15-0452; Boski M, 2017, 2017 10TH INTERNATIONAL WORKSHOP ON MULTIDIMENSIONAL (ND) SYSTEMS (NDS); Bycroft C, 2018, NATURE, V562, P203, DOI 10.1038/s41586-018-0579-z; COX DR, 1972, J R STAT SOC B, V34, P187; Davidson-Pilon C., 2021, CAM DAVIDSON PILON L, DOI [10.5281/zenodo.4457577, DOI 10.5281/ZENODO.4457577]; de Bruijn RFAG, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0130-5; Deelen J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11311-9; Delles C, 2018, EUR J HEART FAIL, V20, P663, DOI 10.1002/ejhf.1076; Di Angelantonio E, 2019, LANCET GLOB HEALTH, V7, pE1332, DOI 10.1016/S2214-109X(19)30318-3; Elfwing S, 2018, NEURAL NETWORKS, V107, P3, DOI 10.1016/j.neunet.2017.12.012; Emwas Abdul-Hamid M, 2015, Methods Mol Biol, V1277, P161, DOI 10.1007/978-1-4939-2377-9_13; Fischer K, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001606; Fizelova M, 2015, ATHEROSCLEROSIS, V240, P272, DOI 10.1016/j.atherosclerosis.2015.03.034; Fry A, 2017, AM J EPIDEMIOL, V186, P1026, DOI 10.1093/aje/kwx246; Gilpin L.H., 2018, EXPLAINING EXPLANATI; Goff DC, 2014, CIRCULATION, V129, pS49, DOI 10.1161/01.cir.0000437741.48606.98; Hageman S, 2021, EUR HEART J, V42, P2439, DOI 10.1093/eurheartj/ehab309; He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90; Huang CX, 2021, CIRC-CARDIOVASC QUAL, V14, P1076, DOI 10.1161/CIRCOUTCOMES.120.007526; Ikram MA, 2017, EUR J EPIDEMIOL, V32, P807, DOI 10.1007/s10654-017-0321-4; Johnson CB, 2016, CAN J CARDIOL, V32, P900, DOI 10.1016/j.cjca.2016.04.008; Julkunen H, 2021, ELIFE, V10, DOI 10.7554/eLife.63033; Katzman JL, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/s12874-018-0482-1; Kettunen J, 2018, CIRC-GENOM PRECIS ME, V11, DOI 10.1161/CIRCGEN.118.002234; Kingma DP., 2014, ADAM METHOD STOCHAST; Komaromy A, 2020, CLIN CHIM ACTA, V506, P204, DOI 10.1016/j.cca.2020.03.041; Lecuyer L, 2018, INT J EPIDEMIOL, V47, P484, DOI 10.1093/ije/dyx271; Lindstrom J, 2003, DIABETES CARE, V26, P725, DOI 10.2337/diacare.26.3.725; Livingston G, 2020, LANCET, V396, P413, DOI 10.1016/S0140-6736(20)30367-6; Lundberg S., 2022, SHAP GAME THEORETIC; Lundberg SM, 2017, ADV NEUR IN, V30; Lundberg SM, 2018, NAT BIOMED ENG, V2, P749, DOI 10.1038/s41551-018-0304-0; Mahendran Y, 2013, DIABETES CARE, V36, P3732, DOI 10.2337/dc13-0800; Mahendran Y, 2013, DIABETES, V62, P3618, DOI 10.2337/db12-1363; Markley JL, 2017, CURR OPIN BIOTECH, V43, P34, DOI 10.1016/j.copbio.2016.08.001; Marmot M, 2005, INT J EPIDEMIOL, V34, P251, DOI 10.1093/ije/dyh372; Mars N, 2020, NAT MED, V26, P549, DOI 10.1038/s41591-020-0800-0; McInnes L., 2018, J OPEN SOURCE SOFTW, V3, P861, DOI [DOI 10.21105/JOSS.00861, 10.21105/joss.00861]; Moons KGM, 2015, ANN INTERN MED, V162, pW1, DOI 10.7326/M14-0698; Ngandu T, 2022, ALZHEIMERS DEMENT, V18, P1325, DOI 10.1002/alz.12492; onnx, 2022, OP STAND MACH LEARN; Patel SA, 2015, ANN INTERN MED, V163, P245, DOI 10.7326/M14-1753; Pietzner M, 2021, NAT MED, V27, P471, DOI 10.1038/s41591-021-01266-0; Qiu CX, 2011, HYPERTENSION, V57, P1094, DOI 10.1161/HYPERTENSIONAHA.111.171249; RCore Team, 2020, R LANG ENV STAT COMP; Ronit A, 2020, ARTERIOSCL THROM VAS, V40, P473, DOI 10.1161/ATVBAHA.119.313681; Rose SMSF, 2019, NAT MED, V25, P792, DOI 10.1038/s41591-019-0414-6; Schoenmaker M, 2006, EUR J HUM GENET, V14, P79, DOI 10.1038/sj.ejhg.5201508; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; Shepherd J, 1999, AM J CARDIOL, V84, P1192, DOI 10.1016/S0002-9149(99)00533-0; Shrikumar A, 2019, LEARNING IMPORTANT F; Silarova B, 2019, HEART, V105, P982, DOI 10.1136/heartjnl-2018-314211; Sindi Shireen, 2015, Alzheimers Dement (Amst), V1, P328, DOI 10.1016/j.dadm.2015.06.005; Soininen P, 2015, CIRC-CARDIOVASC GENE, V8, P192, DOI 10.1161/CIRCGENETICS.114.000216; Srivastava N, 2014, J MACH LEARN RES, V15, P1929; Steinfeldt J, 2022, LANCET DIGIT HEALTH, V4, pE84, DOI 10.1016/S2589-7500(21)00249-1; Stekhoven DJ, 2012, BIOINFORMATICS, V28, P112, DOI 10.1093/bioinformatics/btr597; Steyerberg EW, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001381; Sudlow C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001779; Tynkkynen J, 2018, ALZHEIMERS DEMENT, V14, P723, DOI 10.1016/j.jalz.2018.01.003; UMAP, 2018, UN MAN APPR PROJ DIM; van der Lee SJ, 2018, ALZHEIMERS DEMENT, V14, P707, DOI 10.1016/j.jalz.2017.11.012; van der Velde M, 2009, J AM SOC NEPHROL, V20, P852, DOI 10.1681/ASN.2008060655; Vickers AJ, 2006, MED DECIS MAKING, V26, P565, DOI 10.1177/0272989X06295361; Virtanen JK, 2014, DIABETES CARE, V37, P189, DOI 10.2337/dc13-1504; Wannamethee SG, 1997, STROKE, V28, P557, DOI 10.1161/01.STR.28.3.557; Wu JHY, 2017, LANCET DIABETES ENDO, V5, P965, DOI [10.1016/S2213-8587(17)30307-8, 10.1016/s2213-8587(17)30307-8]; Wurtz P, 2012, DIABETES CARE, V35, P1749, DOI 10.2337/dc11-1838; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9	78	1	1	9	9	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01980-3	http://dx.doi.org/10.1038/s41591-022-01980-3		SEP 2022	32	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4S2QC	36138150	Green Submitted, hybrid, Green Published			2022-12-27	WOS:000857291000001
J	De Baetselier, I; Van Dijck, C; Kenyon, C; Coppens, J; Michiels, J; de Block, T; Smet, H; Coppens, S; Vanroye, F; Bugert, JJ; Girl, P; Zange, S; Liesenborghs, L; Brosius, I; van Griensven, J; Selhorst, P; Florence, E; Van den Bossche, D; Arien, KK; Rezende, AM; Vercauteren, K; Van Esbroeck, M				De Baetselier, Irith; Van Dijck, Christophe; Kenyon, Chris; Coppens, Jasmine; Michiels, Johan; de Block, Tessa; Smet, Hilde; Coppens, Sandra; Vanroye, Fien; Bugert, Joachim Jakob; Girl, Philipp; Zange, Sabine; Liesenborghs, Laurens; Brosius, Isabel; van Griensven, Johan; Selhorst, Philippe; Florence, Eric; Van den Bossche, Dorien; Arien, Kevin K.; Rezende, Antonio Mauro; Vercauteren, Koen; Van Esbroeck, Marjan		ITM Monkeypox Study Grp	Retrospective detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in Belgium	NATURE MEDICINE			English	Article; Early Access							SMALLPOX; IMMUNITY	The magnitude of the 2022 multi-country monkeypox virus (MPXV) outbreak has surpassed any preceding outbreak. It is unclear whether asymptomatic or otherwise undiagnosed infections are fuelling this epidemic. In this study, we aimed to assess whether undiagnosed infections occurred among men attending a Belgian sexual health clinic in May 2022. We retrospectively screened 224 samples collected for gonorrhea and chlamydia testing using an MPXV PCR assay and identified MPXV-DNA-positive samples from four men. At the time of sampling, one man had a painful rash, and three men had reported no symptoms. Upon clinical examination 21-37 days later, these three men were free of clinical signs, and they reported not having experienced any symptoms. Serology confirmed MPXV exposure in all three men, and MPXV was cultured from two cases. These findings show that certain cases of monkeypox remain undiagnosed and suggest that testing and quarantining of individuals reporting symptoms may not suffice to contain the outbreak. Findings of unrecognized or asymptomatic monkeypox virus (MPXV) infections with replication-competent virus in humans suggest that a lack of recognized, clinical symptoms could play a role in virus transmission and the magnitude of the 2022 MPXV outbreak.	[De Baetselier, Irith; Van Dijck, Christophe; Kenyon, Chris; Coppens, Jasmine; de Block, Tessa; Smet, Hilde; Vanroye, Fien; Liesenborghs, Laurens; Brosius, Isabel; van Griensven, Johan; Florence, Eric; Van den Bossche, Dorien; Rezende, Antonio Mauro; Vercauteren, Koen; Van Esbroeck, Marjan] Inst Trop Med, Dept Clin Sci, Antwerp, Belgium; [Van Dijck, Christophe] Univ Antwerp, Lab Med Microbiol, Antwerp, Belgium; [Kenyon, Chris] Univ Cape Town, Div Infect Dis & HIV Med, Cape Town, South Africa; [Michiels, Johan; Coppens, Sandra; Selhorst, Philippe; Arien, Kevin K.] Inst Trop Med, Dept Biomed Sci, Virol Unit, Antwerp, Belgium; [Bugert, Joachim Jakob; Girl, Philipp; Zange, Sabine] Bundeswehr Inst Microbiol, Munich, Germany; [Rezende, Antonio Mauro; Vercauteren, Koen] Inst Trop Med, Dept Clin Sci, Clin Virol Unit, Antwerp, Belgium	Institute of Tropical Medicine (ITM); University of Antwerp; University of Cape Town; Institute of Tropical Medicine (ITM); Bundeswehr Institute of Microbiology (IMB); Institute of Tropical Medicine (ITM)	De Baetselier, I; Van Dijck, C; Vercauteren, K; Van Esbroeck, M (corresponding author), Inst Trop Med, Dept Clin Sci, Antwerp, Belgium.; Van Dijck, C (corresponding author), Univ Antwerp, Lab Med Microbiol, Antwerp, Belgium.; Vercauteren, K (corresponding author), Inst Trop Med, Dept Clin Sci, Clin Virol Unit, Antwerp, Belgium.	idebaetselier@itg.be; cvandijck@itg.be; kvercauteren@itg.be; mvesbroeck@itg.be	Van Dijck, Christophe/ABA-6157-2020	Van Dijck, Christophe/0000-0001-8010-1351; Berens-Riha, Nicole/0000-0003-4533-0081; Girl, Philipp/0000-0003-1370-4114; Zange, Sabine/0000-0001-8721-9248; Vanroye, Fien/0000-0002-7927-9221; Coppens, Jasmine/0000-0002-6685-504X; Vercauteren, Koen O.A./0000-0003-1472-9938; Liesenborghs, Laurens/0000-0001-5616-8548; Verschueren, Jacob/0000-0003-4348-1046	Medical Biological Defense Research Program of the Bundeswehr Medical Service; Department of Economy, Science, and Innovation (EWI) of the Flemish government (METATROPICS project); EWI; Research Foundation-Flanders [G096222N]	Medical Biological Defense Research Program of the Bundeswehr Medical Service; Department of Economy, Science, and Innovation (EWI) of the Flemish government (METATROPICS project); EWI; Research Foundation-Flanders(FWO)	We would like to thank the individuals in this study and all colleagues of the clinic and the clinical reference laboratory of the Institute of Tropical Medicine. We are grateful to D. Friese for excellent technical assistance at the Bundeswehr Institute of Microbiology. Orthopox virus serology was funded by the Medical Biological Defense Research Program of the Bundeswehr Medical Service. Metagenomic sequencing was developed using financial support from the Department of Economy, Science, and Innovation (EWI) of the Flemish government (METATROPICS project). EWI also supports L.L. and P.S. as members of the Institute of Tropical Medicine's Outbreak Research Team. The research was partially funded by the Research Foundation-Flanders (grant G096222N to L.L.). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Adler Hugh, 2022, Lancet Infect Dis, V22, P1153, DOI 10.1016/S1473-3099(22)00228-6; Arien KK, 2022, NPJ VACCINES, V7, DOI 10.1038/s41541-022-00459-z; Beer EM, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007791; Bunge Eveline M, 2022, PLoS Negl Trop Dis, V16, pe0010141, DOI 10.1371/journal.pntd.0010141; Castresana J, 2000, MOL BIOL EVOL, V17, P540, DOI 10.1093/oxfordjournals.molbev.a026334; Chrzastek K, 2017, VIROLOGY, V509, P159, DOI 10.1016/j.virol.2017.06.019; Danecek P, 2021, GIGASCIENCE, V10, DOI 10.1093/gigascience/giab008; De Baetselier I, 2020, ACTA CLIN BELG, V75, P91, DOI 10.1080/17843286.2018.1545376; Dilthey AT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10934-2; Dye Christopher, 2022, BMJ, V377, po1314, DOI 10.1136/bmj.o1314; FENNER F, 1980, MED J AUSTRALIA, V1, P455, DOI 10.5694/j.1326-5377.1980.tb135034.x; Fleischauer AT, 2005, CLIN INFECT DIS, V40, P689, DOI 10.1086/427805; Guagliardo SAJ, 2020, AM J TROP MED HYG, V102, P206, DOI 10.4269/ajtmh.19-0467; Hammarlund E, 2005, NAT MED, V11, P1005, DOI 10.1038/nm1273; JEZEK Z, 1986, J INFECT DIS, V154, P551, DOI 10.1093/infdis/154.4.551; JEZEK Z, 1987, AM J EPIDEMIOL, V126, P1082, DOI 10.1093/oxfordjournals.aje.a114747; JEZEK Z, 1987, J TROP MED HYG, V90, P31; Jezek Z, 1988, HUMAN MONKEYPOX; Karem KL, 2007, CLIN VACCINE IMMUNOL, V14, P1318, DOI 10.1128/CVI.00148-07; Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010; Khanna A., 2022, J OPEN SOURCE SOFTW, V7, P3722, DOI [10.21105/joss.03722, DOI 10.21105/JOSS.03722]; Li H, 2018, BIOINFORMATICS, V34, P3094, DOI 10.1093/bioinformatics/bty191; Li Y, 2010, J VIROL METHODS, V169, P223, DOI 10.1016/j.jviromet.2010.07.012; Noe S, INFECTION, DOI [10.1007/s15010-022-01874-z(2022), DOI 10.1007/S15010-022-01874-Z(2022)]; Nurk Sergey, 2022, Science, V376, P44, DOI 10.1126/science.abj6987; Page AJ, 2016, MICROB GENOMICS, V2, DOI 10.1099/mgen.0.000056; Pan D, 2022, LANCET, V399, P2345, DOI 10.1016/S0140-6736(22)01101-1; Peiro-Mestres A, 2022, EUROSURVEILLANCE, V27, DOI 10.2807/1560-7917.ES.2022.27.28.2200503; Petersen E, 2019, INFECT DIS CLIN N AM, V33, P1027, DOI 10.1016/j.idc.2019.03.001; SARKAR JK, 1973, B WORLD HEALTH ORGAN, V48, P523; Schroeder K, 2010, MOL CELL PROBE, V24, P110, DOI 10.1016/j.mcp.2009.10.008; Selhorst P., BELGIAN CASE MONKEYP; Thornhill JP, 2022, LANCET NEUROL, V21, P872, DOI 10.1056/NEJMoa2207323; World Health Organisation (WHO), 2008, COMM DIS AL RESP MAS; World Health Organization, 2022, WHO DIR GEN STAT PRE	35	24	24	10	10	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02004-w	http://dx.doi.org/10.1038/s41591-022-02004-w		AUG 2022	15	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4O5EI	35961373	Green Published, hybrid			2022-12-27	WOS:000854720600001
J	Subramanian, A; Nirantharakumar, K; Hughes, S; Myles, P; Williams, T; Gokhale, KM; Taverner, T; Chandan, JS; Brown, K; Simms-Williams, N; Shah, AOD; Singh, M; Kidy, F; Okoth, K; Hotham, R; Bashir, N; Cockburn, N; Lee, SI; Turner, GM; Gkoutos, GV; Aiyegbusi, OL; McMullan, C; Denniston, AK; Sapey, E; Lord, JM; Wraith, DC; Leggett, E; Iles, C; Marshall, T; Price, MJ; Marwaha, S; Davies, EH; Jackson, LJ; Matthews, KL; Camaradou, J; Calvert, M; Haroon, S				Subramanian, Anuradhaa; Nirantharakumar, Krishnarajah; Hughes, Sarah; Myles, Puja; Williams, Tim; Gokhale, Krishna M.; Taverner, Tom; Chandan, Joht Singh; Brown, Kirsty; Simms-Williams, Nikita; Shah, Anoop D.; Singh, Megha; Kidy, Farah; Okoth, Kelvin; Hotham, Richard; Bashir, Nasir; Cockburn, Neil; Lee, Siang Ing; Turner, Grace M.; Gkoutos, Georgios V.; Aiyegbusi, Olalekan Lee; McMullan, Christel; Denniston, Alastair K.; Sapey, Elizabeth; Lord, Janet M.; Wraith, David C.; Leggett, Edward; Iles, Clare; Marshall, Tom; Price, Malcolm J.; Marwaha, Steven; Davies, Elin Haf; Jackson, Louise J.; Matthews, Karen L.; Camaradou, Jenny; Calvert, Melanie; Haroon, Shamil			Symptoms and risk factors for long COVID in non-hospitalized adults	NATURE MEDICINE			English	Article; Early Access								A retrospective analysis of primary care records in the United Kingdom reveals individual symptoms associated with SARS-CoV-2 infections, which persisted for 12 weeks or more after infection, as well as risk factors associated with developing long COVID. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is associated with a range of persistent symptoms impacting everyday functioning, known as post-COVID-19 condition or long COVID. We undertook a retrospective matched cohort study using a UK-based primary care database, Clinical Practice Research Datalink Aurum, to determine symptoms that are associated with confirmed SARS-CoV-2 infection beyond 12 weeks in non-hospitalized adults and the risk factors associated with developing persistent symptoms. We selected 486,149 adults with confirmed SARS-CoV-2 infection and 1,944,580 propensity score-matched adults with no recorded evidence of SARS-CoV-2 infection. Outcomes included 115 individual symptoms, as well as long COVID, defined as a composite outcome of 33 symptoms by the World Health Organization clinical case definition. Cox proportional hazards models were used to estimate adjusted hazard ratios (aHRs) for the outcomes. A total of 62 symptoms were significantly associated with SARS-CoV-2 infection after 12 weeks. The largest aHRs were for anosmia (aHR 6.49, 95% CI 5.02-8.39), hair loss (3.99, 3.63-4.39), sneezing (2.77, 1.40-5.50), ejaculation difficulty (2.63, 1.61-4.28) and reduced libido (2.36, 1.61-3.47). Among the cohort of patients infected with SARS-CoV-2, risk factors for long COVID included female sex, belonging to an ethnic minority, socioeconomic deprivation, smoking, obesity and a wide range of comorbidities. The risk of developing long COVID was also found to be increased along a gradient of decreasing age. SARS-CoV-2 infection is associated with a plethora of symptoms that are associated with a range of sociodemographic and clinical risk factors.	[Subramanian, Anuradhaa; Nirantharakumar, Krishnarajah; Hughes, Sarah; Gokhale, Krishna M.; Taverner, Tom; Chandan, Joht Singh; Brown, Kirsty; Simms-Williams, Nikita; Singh, Megha; Kidy, Farah; Okoth, Kelvin; Hotham, Richard; Turner, Grace M.; Aiyegbusi, Olalekan Lee; McMullan, Christel; Marshall, Tom; Price, Malcolm J.; Jackson, Louise J.; Calvert, Melanie; Haroon, Shamil] Univ Birmingham, Inst Appl Hlth Res, Birmingham, W Midlands, England; [Nirantharakumar, Krishnarajah; Gkoutos, Georgios V.; Denniston, Alastair K.; Calvert, Melanie] Midlands Hlth Data Res UK, Birmingham, W Midlands, England; [Nirantharakumar, Krishnarajah; Gkoutos, Georgios V.; Denniston, Alastair K.; Calvert, Melanie] Univ Birmingham, DEMAND Hub, Birmingham, W Midlands, England; [Hughes, Sarah; Turner, Grace M.; Aiyegbusi, Olalekan Lee; McMullan, Christel; Denniston, Alastair K.; Calvert, Melanie] Univ Birmingham, Inst Appl Hlth Res, Ctr Patient Reported Outcomes Res, Birmingham, W Midlands, England; [Hughes, Sarah; Aiyegbusi, Olalekan Lee; Calvert, Melanie] Appl Res Collaborat ARC West Midlands, Natl Inst Hlth & Care Res NIHR, Birmingham, W Midlands, England; [Hughes, Sarah; Aiyegbusi, Olalekan Lee; Denniston, Alastair K.; Calvert, Melanie] Univ Birmingham, Birmingham Hlth Partners Ctr Regulatory Sci & Inn, Birmingham, W Midlands, England; [Hughes, Sarah; McMullan, Christel; Calvert, Melanie] Univ Birmingham, NIHR Birmingham Oxford Blood & Transplant Res Uni, Birmingham, W Midlands, England; [Myles, Puja; Williams, Tim; Leggett, Edward; Iles, Clare] Med & Healthcare Prod Regulatory Agcy, Clin Practice Res Datalink, London, England; [Brown, Kirsty] Univ Birmingham, Sch Sport Exercise & Rehabil Sci, Birmingham, W Midlands, England; [Shah, Anoop D.] UCL, Fac Populat Hlth Sci, Inst Hlth Informat, London, England; [Kidy, Farah] Univ Warwick, Warwick Med Sch, Coventry, W Midlands, England; [Bashir, Nasir] Univ Bristol, Sch Oral & Dent Sci, Bristol, Avon, England; [Turner, Grace M.; Lord, Janet M.; Calvert, Melanie] Univ Hosp Birmingham, NIHR Surg Reconstruct & Microbiol Res Ctr, Birmingham, W Midlands, England; [Turner, Grace M.; Gkoutos, Georgios V.; Lord, Janet M.; Calvert, Melanie] Univ Birmingham, Birmingham, W Midlands, England; [Gkoutos, Georgios V.] Univ Birmingham, Inst Canc & Genom Sci, Birmingham, W Midlands, England; [Gkoutos, Georgios V.; Aiyegbusi, Olalekan Lee; Denniston, Alastair K.; Lord, Janet M.; Wraith, David C.; Price, Malcolm J.; Calvert, Melanie] Univ Hosp Birmingham, NIHR Birmingham Biomed Res Ctr, Birmingham, W Midlands, England; [Gkoutos, Georgios V.; Denniston, Alastair K.; Sapey, Elizabeth] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England; [McMullan, Christel] Univ Birmingham, Ctr Trauma Sci Res, Birmingham, W Midlands, England; [Sapey, Elizabeth; Lord, Janet M.] Univ Birmingham, Inst Inflammat & Ageing, MRC Versus Arthrit Ctr Musculoskeletal Ageing Res, Birmingham, W Midlands, England; [Sapey, Elizabeth; Calvert, Melanie] Univ Birmingham, PIONEER HDR UK Data Hub Acute Care, Birmingham, W Midlands, England; [Lord, Janet M.] Univ Birmingham, UK SPINE, Birmingham, W Midlands, England; [Wraith, David C.] Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham, W Midlands, England; [Marwaha, Steven] Univ Birmingham, Inst Mental Hlth, Birmingham, W Midlands, England; [Marwaha, Steven] Birmingham & Solihull Mental Hlth NHS Fdn Trust, Birmingham, W Midlands, England; [Davies, Elin Haf] Aparito Ltd, Wrexham, Wales	University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; The Medicines & Healthcare Products Regulatory Agency; University of Birmingham; University of London; University College London; University of Warwick; University of Bristol; University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham	Nirantharakumar, K (corresponding author), Univ Birmingham, Inst Appl Hlth Res, Birmingham, W Midlands, England.; Nirantharakumar, K (corresponding author), Midlands Hlth Data Res UK, Birmingham, W Midlands, England.; Nirantharakumar, K (corresponding author), Univ Birmingham, DEMAND Hub, Birmingham, W Midlands, England.	K.Nirantharan@bham.ac.uk	Aiyegbusi, Olalekan Lee/AAO-7278-2021; Chandan, Joht Singh/D-6361-2015; Haroon, Shamil/ABA-7763-2021; Turner, Grace/K-6073-2014; McMullan, Christel/F-4948-2017; Marwaha, Steven/G-4489-2013	Aiyegbusi, Olalekan Lee/0000-0001-9122-8251; Chandan, Joht Singh/0000-0002-9561-5141; Jackson, Louise/0000-0001-8492-0020; Marshall, Tom/0000-0001-9277-5214; Price, Malcolm/0000-0002-7352-3027; Brown, Kirsty/0000-0001-9403-1593; Haroon, Shamil/0000-0002-0096-1413; Turner, Grace/0000-0002-9783-9413; Gkoutos, Georgios/0000-0002-2061-091X; Sapey, Elizabeth/0000-0003-3454-5482; Bashir, Nasir/0000-0001-7416-7610; McMullan, Christel/0000-0002-0878-1513; Hughes, Sarah/0000-0001-5656-1198; Lord, Janet/0000-0003-1030-6786; Marwaha, Steven/0000-0002-0303-9942; Denniston, Alastair/0000-0001-7849-0087	NIHR; UKRI;  [COV-LT-0013]	NIHR(National Institute for Health Research (NIHR)); UKRI(UK Research & Innovation (UKRI)); 	We thank the funders of our TLC study (COV-LT-0013), NIHR and UKRI, all the patients on the TLC Lived Experience Advisory Group and N. Mangat for supporting LEAP member recruitment. We also thank A. Walker, K. Jones and Y. Lee for providing administrative support for the study.	Aiyegbusi OL, 2021, J ROY SOC MED, V114, P428, DOI 10.1177/01410768211032850; Al-Aly Z, 2021, NATURE, V594, P259, DOI 10.1038/s41586-021-03553-9; [Anonymous], 2020, COVID 19 RAP GUID MA; Blomberg B, 2021, NAT MED, V27, P1607, DOI 10.1038/s41591-021-01433-3; Carvalho-Schneider C, 2021, CLIN MICROBIOL INFEC, V27, P258, DOI 10.1016/j.cmi.2020.09.052; Davis HE, 2021, ECLINICALMEDICINE, V38, DOI 10.1016/j.eclinm.2021.101019; del Rio C, 2020, JAMA-J AM MED ASSOC, V324, P1723, DOI 10.1001/jama.2020.19719; Galal I, 2021, EGYPT J BRONCHOL, V15, DOI 10.1186/s43168-020-00049-4; Gokhale KM, 2021, EUR J EPIDEMIOL, V36, P165, DOI 10.1007/s10654-020-00677-6; Groff D, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.28568; Haroon S, 2022, BMJ OPEN, V12, DOI 10.1136/bmjopen-2021-060413; Huang CL, 2021, LANCET, V397, P220, DOI 10.1016/S0140-6736(20)32656-8; Hughes S. E, 2022, BMJ; Hughes SE, 2022, BMJ-BRIT MED J, V377, DOI 10.1136/bmj-2022-070230; Jacobs LG, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243882; Ladds E, 2020, BMC HEALTH SERV RES, V20, DOI 10.1186/s12913-020-06001-y; Lopez-Leon S, 2021, SCI REP-UK, V11, DOI [10.1038/s41598-021-95565-8, 10.1101/2021.01.27.21250617]; Michelen M, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2021-005427; Nalbandian A, 2021, NAT MED, V27, P601, DOI 10.1038/s41591-021-01283-z; NHS, 2021, RES FIND; Nylund KL, 2007, STRUCT EQU MODELING, V14, P535, DOI 10.1080/10705510701575396; Office of National Statistics, 2020, PREVALENCE LONG COVI; Office of National Statistics, PREV ONG SYMPT FOLL; Price SJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011664; Ramos-Casals M, 2021, NAT REV RHEUMATOL, V17, P315, DOI 10.1038/s41584-021-00608-z; Soriano JB, 2022, LANCET INFECT DIS, V22, pE102, DOI 10.1016/S1473-3099(21)00703-9; Sudre CH, 2021, NAT MED, V27, DOI 10.1038/s41591-021-01292-y; Taquet M, 2021, PLOS MED, V18, DOI 10.1371/journal.pmed.1003773; Weller BE, 2020, J BLACK PSYCHOL, V46, P287, DOI 10.1177/0095798420930932; Whittaker HR, 2021, BMJ-BRIT MED J, V375, DOI 10.1136/bmj-2021-065834; Wolf A, 2019, INT J EPIDEMIOL, V48, P1740, DOI 10.1093/ije/dyz034; Wood A, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n826; Yadav K, 2021, JAMA-J AM MED ASSOC, V325, P686, DOI 10.1001/jama.2020.9151	33	14	14	18	18	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01909-w	http://dx.doi.org/10.1038/s41591-022-01909-w		JUL 2022	20	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3E1IL	35879616	Green Published, Green Submitted, hybrid			2022-12-27	WOS:000829743800001
J	Church, AJ; Corson, LB; Kao, PC; Imamovic-Tuco, A; Reidy, D; Doan, D; Kang, WJ; Pinto, N; Maese, L; Laetsch, TW; Kim, A; Colace, SI; Macy, ME; Applebaum, MA; Bagatell, R; Sabnis, AJ; Weiser, DA; Glade-Bender, JL; Homans, AC; Hipps, J; Harris, H; Manning, D; Al-Ibraheemi, A; Li, Y; Gupta, H; Cherniack, AD; Lo, YC; Strand, GR; Lee, LA; Pinches, RS; De La Vega, LL; Harden, MV; Lennon, NJ; Choi, S; Comeau, H; Harris, MH; Forrest, SJ; Clinton, CM; Crompton, BD; Kamihara, J; MacConaill, LE; Volchenboum, SL; Lindeman, NI; Van Allen, E; DuBois, SG; London, WB; Janeway, KA				Church, Alanna J.; Corson, Laura B.; Kao, Pei-Chi; Imamovic-Tuco, Alma; Reidy, Deirdre; Doan, Duong; Kang, Wenjun; Pinto, Navin; Maese, Luke; Laetsch, Theodore W.; Kim, AeRang; Colace, Susan I.; Macy, Margaret E.; Applebaum, Mark A.; Bagatell, Rochelle; Sabnis, Amit J.; Weiser, Daniel A.; Glade-Bender, Julia L.; Homans, Alan C.; Hipps, John; Harris, Haley; Manning, Danielle; Al-Ibraheemi, Alyaa; Li, Yvonne; Gupta, Hersh; Cherniack, Andrew D.; Lo, Ying-Chun; Strand, Gianna R.; Lee, Lobin A.; Pinches, R. Seth; Lazo De La Vega, Lorena; Harden, Maegan V.; Lennon, Niall J.; Choi, Seong; Comeau, Hannah; Harris, Marian H.; Forrest, Suzanne J.; Clinton, Catherine M.; Crompton, Brian D.; Kamihara, Junne; MacConaill, Laura E.; Volchenboum, Samuel L.; Lindeman, Neal I.; Van Allen, Eliezer; DuBois, Steven G.; London, Wendy B.; Janeway, Katherine A.			Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer	NATURE MEDICINE			English	Article; Early Access							MISMATCH REPAIR DEFICIENCY; TUMORS; ASSOCIATION; COMBINATION; INHIBITORS; GUIDELINE; MUTATIONS; VARIANTS; FUSION	An interim report from the GAIN/iCat2 study shows that molecular profiling of pediatric solid malignancies clarifies diagnostic classifications and provides opportunities for matched targeted therapy. To evaluate the clinical impact of molecular tumor profiling (MTP) with targeted sequencing panel tests, pediatric patients with extracranial solid tumors were enrolled in a prospective observational cohort study at 12 institutions. In the 345-patient analytical population, median age at diagnosis was 12 years (range 0-27.5); 298 patients (86%) had 1 or more alterations with potential for impact on care. Genomic alterations with diagnostic, prognostic or therapeutic significance were present in 61, 16 and 65% of patients, respectively. After return of the results, impact on care included 17 patients with a clarified diagnostic classification and 240 patients with an MTP result that could be used to select molecularly targeted therapy matched to identified alterations (MTT). Of the 29 patients who received MTT, 24% had an objective response or experienced durable clinical benefit; all but 1 of these patients received targeted therapy matched to a gene fusion. Of the diagnostic variants identified in 209 patients, 77% were gene fusions. MTP with targeted panel tests that includes fusion detection has a substantial clinical impact for young patients with solid tumors.	[Church, Alanna J.; Kao, Pei-Chi; Harris, Haley; Al-Ibraheemi, Alyaa; Lo, Ying-Chun; Pinches, R. Seth; Harris, Marian H.; Clinton, Catherine M.; London, Wendy B.] Boston Childrens Hosp, Boston, MA USA; [Church, Alanna J.; Glade-Bender, Julia L.; Al-Ibraheemi, Alyaa; Li, Yvonne; Gupta, Hersh; Cherniack, Andrew D.; Harris, Marian H.; Forrest, Suzanne J.; Crompton, Brian D.; Kamihara, Junne; MacConaill, Laura E.; Lindeman, Neal I.; Van Allen, Eliezer; DuBois, Steven G.; London, Wendy B.; Janeway, Katherine A.] Harvard Med Sch, Boston, MA 02115 USA; [Corson, Laura B.; Imamovic-Tuco, Alma; Reidy, Deirdre; Doan, Duong; Li, Yvonne; Gupta, Hersh; Cherniack, Andrew D.; Strand, Gianna R.; Lee, Lobin A.; Lazo De La Vega, Lorena; Comeau, Hannah; Forrest, Suzanne J.; Clinton, Catherine M.; Crompton, Brian D.; Kamihara, Junne; DuBois, Steven G.; Janeway, Katherine A.] Dana Farber Boston Childrens Canc & Blood Disorde, Boston, MA USA; [Corson, Laura B.; Imamovic-Tuco, Alma; Li, Yvonne; Gupta, Hersh; Cherniack, Andrew D.; Harden, Maegan V.; Lennon, Niall J.; Van Allen, Eliezer] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA; [Kang, Wenjun; Applebaum, Mark A.; Choi, Seong; Volchenboum, Samuel L.] Univ Chicago, Chicago, IL 60637 USA; [Pinto, Navin] Seattle Childrens Hosp, Seattle, WA USA; [Pinto, Navin] Univ Washington, Seattle, WA 98195 USA; [Maese, Luke] Primary Childrens Med Ctr, Salt Lake City, UT USA; [Maese, Luke] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA; [Laetsch, Theodore W.] Univ Texas Southwestern Med Ctr, Dallas, TX USA; [Laetsch, Theodore W.; Bagatell, Rochelle] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Laetsch, Theodore W.; Bagatell, Rochelle] Univ Penn, Sch Med, Philadelphia, PA 19104 USA; [Kim, AeRang] Childrens Natl Hosp, Washington, DC USA; [Kim, AeRang] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA; [Colace, Susan I.] Nationwide Childrens Hosp, Columbus, OH USA; [Colace, Susan I.] Ohio State Univ, Coll Med, Columbus, OH 43210 USA; [Macy, Margaret E.] Childrens Hosp Colorado, Aurora, CO USA; [Macy, Margaret E.] Univ Colorado, Sch Med, Aurora, CO USA; [Applebaum, Mark A.] Comer Childrens Hosp, Chicago, IL USA; [Sabnis, Amit J.] Univ Calif San Francisco, Benioff Childrens Hosp, San Francisco, CA 94143 USA; [Weiser, Daniel A.] Childrens Hosp Montefiore, New York, NY USA; [Weiser, Daniel A.] Albert Einstein Coll Med, New York, NY USA; [Glade-Bender, Julia L.] Columbia Univ, Irving Med Ctr, New York, NY USA; [Glade-Bender, Julia L.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Homans, Alan C.] Univ Vermont, Med Ctr, Burlington, VT USA; [Homans, Alan C.] Univ Vermont, Burlington, VT USA; [Hipps, John] Univ N Carolina, Med Ctr, Chapel Hill, NC 27515 USA; [Hipps, John] Univ N Carolina, Chapel Hill Sch Med, Chapel Hill, NC 27515 USA; [Manning, Danielle; Lo, Ying-Chun; MacConaill, Laura E.; Lindeman, Neal I.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Van Allen, Eliezer] Dana Farber Canc Inst, Boston, MA 02115 USA; [Corson, Laura B.] Sema4, Stamford, CT USA; [Reidy, Deirdre] Univ Connecticut, Sch Med, Farmington, CT USA; [Doan, Duong] Univ Massachusetts, Sch Med, Worcester, MA USA; [Lo, Ying-Chun] Mayo Clin, Rochester, MN USA; [Strand, Gianna R.] Loyola Univ, Chicago, IL 60611 USA; [Lee, Lobin A.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Pinches, R. Seth] Philadelphia Coll Osteopath Med, Philadelphia, PA USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; University of Chicago; Seattle Children's Hospital; University of Washington; University of Washington Seattle; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Children's National Health System; George Washington University; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; University System of Ohio; Ohio State University; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; University of California System; University of California San Francisco; Yeshiva University; Albert Einstein College of Medicine; Childrens Hospital at Montefiore; Yeshiva University; Columbia University; NewYork-Presbyterian Hospital; Memorial Sloan Kettering Cancer Center; University of Vermont; University of Vermont Medical Center; University of Vermont; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; University of Connecticut; University of Massachusetts System; University of Massachusetts Worcester; Mayo Clinic; Loyola University Chicago; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Church, AJ (corresponding author), Boston Childrens Hosp, Boston, MA USA.; Church, AJ (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	Alanna.Church@childrens.harvard.edu	Al-Ibraheemi, Alyaa/GSI-5179-2022	Al-Ibraheemi, Alyaa/0000-0003-1769-7839; Strand, Gianna/0000-0001-5715-1019; Pinto, Navin/0000-0002-8775-6710; Glade Bender, Julia/0000-0001-5316-6440; Maese, Luke/0000-0002-8739-9100; Colace, Susan/0000-0003-3868-3655; Forrest, Suzanne/0000-0002-9797-7947; Corson, Laura/0000-0003-2772-3375; Lazo de la Vega, Lorena/0000-0003-3609-0098	4C's Fund; Lamb Family Fund; C&S Wholesale Grocers; CS Charities; Alexandra Simpson Pediatric Research Fund; Precision For Kids Pan Mass Challenge Team	4C's Fund; Lamb Family Fund; C&S Wholesale Grocers; CS Charities; Alexandra Simpson Pediatric Research Fund; Precision For Kids Pan Mass Challenge Team	Funding for this study was provided by the Precision For Kids Pan Mass Challenge Team, the 4C's Fund, Lamb Family Fund, C&S Wholesale Grocers and C&S Charities and Alexandra Simpson Pediatric Research Fund. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. We also thank the study participants and their families and the research coordinators at each of the study sites.	Abo RP, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gku1211; Allen CE, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.10008; [Anonymous], 2021, GUIDELINES VERSION 4, V2021; [Anonymous], 2020, DAT SHAR OPP CHILDH; [Anonymous], 2020, INT CLASSIFICATION D; [Anonymous], 2022, AACR PROJ GENIE DAT; [Anonymous], 2017, FDA REAUTH ACT 2017; [Anonymous], 2021, NEUR ADREN TUM VERS; [Anonymous], 2022, NCCN PRACTICE GUIDEL; [Anonymous], 2021, HEP CANC VERS 5 2021; [Anonymous], 2018, NEXT GENERATION SEQU; [Anonymous], 2021, NCCN PRACTICE GUIDEL; Brandao M, 2019, ANN ONCOL, V30, P27, DOI 10.1093/annonc/mdz280; Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003; Chen YNP, 2016, NATURE, V535, P148, DOI 10.1038/nature18621; Chmielecki J, 2017, CANCER RES, V77, P509, DOI 10.1158/0008-5472.CAN-16-1106; Drilon A, 2018, NEW ENGL J MED, V378, P731, DOI 10.1056/NEJMoa1714448; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; FDA, FACT SHEET CDRHS APP; Fiala EM, 2021, NAT CANCER, V2, P357, DOI 10.1038/s43018-021-00172-1; Garcia EP, 2017, ARCH PATHOL LAB MED, V141, P751, DOI 10.5858/arpa.2016-0527-OA; Haas BJ, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1842-9; Harris MH, 2016, JAMA ONCOL, V2, P608, DOI 10.1001/jamaoncol.2015.5689; Havel JJ, 2019, NAT REV CANCER, V19, P133, DOI 10.1038/s41568-019-0116-x; Hillier K, 2019, THYROID, V29, P1704, DOI 10.1089/thy.2019.0041; Inaba H, 2020, HAEMATOLOGICA, V105, P2524, DOI 10.3324/haematol.2020.247031; Janes MR, 2018, CELL, V172, P578, DOI 10.1016/j.cell.2018.01.006; Khater F, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.2906; Laetsch TW, 2019, EXPERT REV ANTICANC, V19, P1, DOI 10.1080/14737140.2019.1538796; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Leijen S, 2016, J CLIN ONCOL, V34, P4371, DOI 10.1200/JCO.2016.67.5991; Li MM, 2017, J MOL DIAGN, V19, P4, DOI 10.1016/j.jmoldx.2016.10.002; Li Wenbin, 2021, JTO Clin Res Rep, V2, P100163, DOI 10.1016/j.jtocrr.2021.100163; Lindeman NI, 2018, J THORAC ONCOL, V13, P323, DOI 10.1016/j.jtho.2017.12.001; Mosele F, 2020, ANN ONCOL, V31, P1491, DOI 10.1016/j.annonc.2020.07.014; NCCR*Explorer, 2021, NCCR EXPL INT WEBS N; Nowak JA, 2017, J MOL DIAGN, V19, P84, DOI 10.1016/j.jmoldx.2016.07.010; Oberg JA, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0389-6; Oliveira AM, 2014, HUM PATHOL, V45, P1, DOI 10.1016/j.humpath.2013.03.005; Ortiz MV, 2020, JCO PRECIS ONCOL, V4, P341, DOI 10.1200/PO.19.00401; Parsons D. W., J CLIN ONCOL, DOI [10.1200/JCO.21.02838(2022, DOI 10.1200/JCO.21.02838(2022]; Parsons DW, 2016, JAMA ONCOL, V2, P616, DOI 10.1001/jamaoncol.2015.5699; Parsons DW, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.10011; Paulson VA, 2020, MODERN PATHOL, V33, P775, DOI 10.1038/s41379-019-0422-6; Ramaswamy V, 2016, ACTA NEUROPATHOL, V131, P821, DOI 10.1007/s00401-016-1569-6; Rodriguez-Martin B, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-016-3404-9; Schienda J, 2021, JCO PRECIS ONCOL, V5, P1840, DOI 10.1200/PO.21.00281; Sholl LM, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87062; van Tilburg CM, 2021, CANCER DISCOV, V11, P2764, DOI 10.1158/2159-8290.CD-21-0094; Wong M, 2020, NAT MED, V26, P1742, DOI 10.1038/s41591-020-1072-4; Zhang JH, 2015, NEW ENGL J MED, V373, P2336, DOI 10.1056/NEJMoa1508054	51	3	3	2	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01856-6	http://dx.doi.org/10.1038/s41591-022-01856-6		JUN 2022	24	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2I4PS	35739269				2022-12-27	WOS:000814962700003
J	Cai, J; Deng, XW; Yang, J; Sun, KY; Liu, HC; Chen, ZY; Peng, C; Chen, XH; Wu, QH; Zou, JY; Sun, RJ; Zheng, W; Zhao, ZY; Lu, WY; Liang, YX; Zhou, XY; Ajelli, M; Yu, HJ				Cai, Jun; Deng, Xiaowei; Yang, Juan; Sun, Kaiyuan; Liu, Hengcong; Chen, Zhiyuan; Peng, Cheng; Chen, Xinhua; Wu, Qianhui; Zou, Junyi; Sun, Ruijia; Zheng, Wen; Zhao, Zeyao; Lu, Wanying; Liang, Yuxia; Zhou, Xiaoyu; Ajelli, Marco; Yu, Hongjie			Modeling transmission of SARS-CoV-2 Omicron in China	NATURE MEDICINE			English	Article							STATES	Having adopted a dynamic zero-COVID strategy to respond to SARS-CoV-2 variants with higher transmissibility since August 2021, China is now considering whether, and for how long, this policy can remain in place. The debate has thus shifted towards the identification of mitigation strategies for minimizing disruption to the healthcare system in the case of a nationwide epidemic. To this aim, we developed an age-structured stochastic compartmental susceptible-latent-infectious-removed-susceptible model of SARS-CoV-2 transmission calibrated on the initial growth phase for the 2022 Omicron outbreak in Shanghai, to project COVID-19 burden (that is, number of cases, patients requiring hospitalization and intensive care, and deaths) under hypothetical mitigation scenarios. The model also considers age-specific vaccine coverage data, vaccine efficacy against different clinical endpoints, waning of immunity, different antiviral therapies and nonpharmaceutical interventions. We find that the level of immunity induced by the March 2022 vaccination campaign would be insufficient to prevent an Omicron wave that would result in exceeding critical care capacity with a projected intensive care unit peak demand of 15.6 times the existing capacity and causing approximately 1.55 million deaths. However, we also estimate that protecting vulnerable individuals by ensuring accessibility to vaccines and antiviral therapies, and maintaining implementation of nonpharmaceutical interventions could be sufficient to prevent overwhelming the healthcare system, suggesting that these factors should be points of emphasis in future mitigation policies. Estimates from a new modeling study suggest that current levels of vaccine coverage in China are insufficient to prevent overwhelming the healthcare system, and that, if left untreated, a nationwide Omicron wave could result in up to 1.55 million deaths.	[Cai, Jun; Deng, Xiaowei; Yang, Juan; Liu, Hengcong; Chen, Zhiyuan; Peng, Cheng; Chen, Xinhua; Wu, Qianhui; Zou, Junyi; Sun, Ruijia; Zheng, Wen; Zhao, Zeyao; Lu, Wanying; Liang, Yuxia; Zhou, Xiaoyu; Yu, Hongjie] Fudan Univ, Sch Publ Hlth, Key Lab Publ Hlth Safety, Minist Educ, Shanghai, Peoples R China; [Yang, Juan; Yu, Hongjie] Fudan Univ, Shanghai Inst Infect Dis & Biosecur, Shanghai, Peoples R China; [Sun, Kaiyuan] NIH, Div Int Epidemiol & Populat Studies, Fogarty Int Ctr, Bldg 10, Bethesda, MD 20892 USA; [Ajelli, Marco] Indiana Univ, Sch Publ Hlth, Lab Computat Epidemiol & Publ Hlth, Dept Epidemiol & Biostat, Bloomington, IN USA	Fudan University; Fudan University; National Institutes of Health (NIH) - USA; NIH Fogarty International Center (FIC); Indiana University System; Indiana University Bloomington	Yu, HJ (corresponding author), Fudan Univ, Sch Publ Hlth, Key Lab Publ Hlth Safety, Minist Educ, Shanghai, Peoples R China.; Yu, HJ (corresponding author), Fudan Univ, Shanghai Inst Infect Dis & Biosecur, Shanghai, Peoples R China.	yhj@fudan.edu.cn	Yu, Hongjie/GZK-5351-2022	Yang, Juan/0000-0001-5028-2227; liu, hengcong/0000-0003-2591-2201; Deng, Xiaowei/0000-0002-9892-2470; Cai, Jun/0000-0001-9495-1226	Key Program of the National Natural Science Foundation of China [82130093]	Key Program of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by grants from the Key Program of the National Natural Science Foundation of China (82130093). We would like to thank B. J. Cowling, School of Public Health, Li Ka Shing Faculty of Medicine, University of Hong Kong for providing severity parameters. We would also like to thank L. Yi for assistance in figure preparation. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the US National Institutes of Health.	[Anonymous], 2022, COVID 19 VIRT PRESS; [Anonymous], EMERGENCY APPROVAL B; [Anonymous], 2021, PFIZER 1105; [Anonymous], 2021, SARS COV 2 VARIANTS; [Anonymous], 2021, PRESS C HELD SITUATI; [Anonymous], 2022, SITUATION REGARDING; [Anonymous], 2022, RELEVANT REQUIREMENT; [Anonymous], EMERGENCY CONDITIONA; [Anonymous], 2022, PRESS RELEASES; [Anonymous], 2021, BRII BIOSC; [Anonymous], 2022, STAT 5 WAVE COVID 19; [Anonymous], 2022, PRESS C HELD SITUATI; [Anonymous], 2022, US CORONAVIRUS PANDE; [Anonymous], 2022, PROVISIONAL DATA ANA; [Anonymous], 2022, TRACKING VOC OMICRON; [Anonymous], CORONAVIRUS COVID 19, DOI DOI 1105914/CORONAVIRUS-DEATH-RATES-WORLDWIDE; [Anonymous], 2021, FAQ BOOSTER IMMUNIZA; Barnard R. C., 2021, MEDRXIV, DOI [10.1101/2021.12.15.21267858, DOI 10.1101/2021.12.15.21267858]; Buitrago-Garcia D, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003346; Cameroni E, 2022, NATURE, V602, P664, DOI [10.1038/s41586-021-04386-2, 10.1101/2021.12.12.472269]; Cao YL, 2022, CELL RES, V32, P107, DOI 10.1038/s41422-021-00596-5; Collier AY, 2021, NEW ENGL J MED, V385, P2010, DOI 10.1056/NEJMc2115596; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Davies NG, 2020, NAT MED, V26, P1205, DOI 10.1038/s41591-020-0962-9; Davis JT, 2021, NATURE, V600, P127, DOI 10.1038/s41586-021-04130-w; Deng XW, 2021, CLIN INFECT DIS, V73, pE79, DOI 10.1093/cid/ciaa578; F. P. Lyngse, 2021, medRxiv, DOI 10.1101/2021.12.27.21268278; French G, 2021, MMWR-MORBID MORTAL W, V70, P1613, DOI 10.15585/mmwr.mm7046a5; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Halloran ME., 2010, DESIGN ANAL VACCINE; Hammond J, 2022, NEW ENGL J MED, V386, P1397, DOI 10.1056/NEJMoa2118542; Hansen CH, 2021, LANCET, V397, P1204, DOI 10.1016/S0140-6736(21)00575-4; Hart WS, 2022, LANCET INFECT DIS, V22, P603, DOI 10.1016/S1473-3099(22)00001-9; Hu SX, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21710-6; Iuliano A. D., 2022, MMWR MORB MORTAL WKL, V71; J. A. Lewnard, 2022, medRxiv, DOI 10.1101/2022.01.11.22269045; Lee K, 2009, GLOB INST, P1; Lefrancq N, 2021, LANCET REG HEALTH-EU, V5, DOI 10.1016/j.lanepe.2021.100087; Levin EG, 2021, NEW ENGL J MED, V385, pE84, DOI 10.1056/NEJMoa2114583; Li L, 2019, LANCET PUBLIC HEALTH, V4, pE473, DOI 10.1016/S2468-2667(19)30163-X; Liu J, 2022, CHINA CDC WEEKLY, V4, P74, DOI 10.46234/ccdcw2022.015; Lu L, 2022, CLIN INFECT DIS, V75, pE822, DOI 10.1093/cid/ciab1041; Manica M., 2022, PREPRINT, DOI [10.2139/ssrn.4068368, DOI 10.2139/SSRN.4068368]; Marks KJ, 2022, MMWR-MORBID MORTAL W, V71, P271, DOI 10.15585/mmwr.mm7107e4; Marziano V, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-27532-w; Maslo C, 2022, JAMA-J AM MED ASSOC, V327, P583, DOI 10.1001/jama.2021.24868; McMenamin ME., 2022, PREPRINT, DOI [10.1101/2022.03.22.22272769v2, 10.1101/2022.03.22.22272769, DOI 10.1101/2022.03.22.22272769]; Mistry D, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20544-y; Modes Matthew E, 2022, MMWR Morb Mortal Wkly Rep, V71, P217, DOI 10.15585/mmwr.mm7106e2; N. Gozzi, 2022, medRxiv, DOI 10.1101/2022.01.04.22268721; National Health Commission of China, 2021, CHIN STAT YB EL POW; Ranzani OT, 2022, medRxiv, DOI 10.1101/2022.03.30.22273193; Pearson C.A., 2021, MEDRXIV, DOI [10.1101/2021.12.19.21268038v1, DOI 10.1101/2021.12.19.21268038, 10.1101/2021.12.19.21268038]; Peiris M., 2022, PREPRINT, DOI [10.21203/rs.3.rs-1207071/v1, DOI 10.21203/RS.3.RS-1207071/V1]; Perez-Then E, 2022, NAT MED, V28, P481, DOI 10.1038/s41591-022-01705-6; Piroth L, 2021, LANCET RESP MED, V9, P251, DOI 10.1016/S2213-2600(20)30527-0; Poletti P, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.1085; R. Ranjan, 2022, medRxiv, DOI 10.1101/2022.01.09.22268969; Rees EM, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01726-3; Rossman H, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22214-z; Viana R, 2022, NATURE, V603, P679, DOI 10.1038/s41586-022-04411-y; Viner RM, 2021, JAMA PEDIATR, V175, P143, DOI 10.1001/jamapediatrics.2020.4573; Wang K, 2022, NATURE, V603, P919, DOI 10.1038/s41586-022-04466-x; Wang L, 2022, JAMA PEDIATR, V176, P811, DOI 10.1001/jamapediatrics.2022.0945; Wang YC, 2022, EMERG MICROBES INFEC, V11, P1, DOI 10.1080/22221751.2021.2017757; Wheatley AK, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21444-5; Wolter N, 2022, LANCET, V399, P437, DOI 10.1016/S0140-6736(22)00017-4; Xin Q., 2021, NAT COMMUN, DOI [10.1038/s41467-022-30864-w, DOI 10.2139/SSRN.3991627, 10.2139/ssrn.3991627, DOI 10.1038/S41467-022-30864-W]; Mesfin Y, 2022, medRxiv, DOI 10.1101/2022.04.07.22273595; Yang J, 2021, NAT HUM BEHAV, V5, P1009, DOI 10.1038/s41562-021-01155-z; Zhang JJ, 2020, LANCET INFECT DIS, V20, P793, DOI 10.1016/S1473-3099(20)30230-9; Zhang YJ, 2021, LANCET INFECT DIS, V21, P181, DOI 10.1016/S1473-3099(20)30843-4	73	27	28	107	160	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2022	28	7					1468	+		10.1038/s41591-022-01855-7	http://dx.doi.org/10.1038/s41591-022-01855-7		MAY 2022	18	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3E5PS	35537471	Green Published, Green Submitted, hybrid			2022-12-27	WOS:000805524100001
J	Haun, RS				Haun, RS			Steps to building the virtual laboratory	NATURE BIOTECHNOLOGY			English	Editorial Material											Haun, RS (corresponding author), UNIV ARKANSAS MED SCI HOSP,DEPT BIOCHEM & MOL BIOL,4301 W MARKHAM,SLOT 516,LITTLE ROCK,AR 72205, USA.							SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463	1	1	1	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1997	15	7					683	684		10.1038/nbt0797-683	http://dx.doi.org/10.1038/nbt0797-683			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XH583	9219274				2022-12-27	WOS:A1997XH58300035
J	Hoyle, R				Hoyle, R			Novartis' new labeling policy creates confusion	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	0	0	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1997	15	5					395	395		10.1038/nbt0597-395	http://dx.doi.org/10.1038/nbt0597-395			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WX237	9131598	Bronze			2022-12-27	WOS:A1997WX23700005
J	Ono, M; Wada, Y; Wu, YM; Nemori, R; Jinbo, Y; Wang, H; Lo, KM; Yamaguchi, N; Brunkhorst, B; Otomo, H; Wesolowski, J; Way, JC; Itoh, I; Gillies, S; Chen, LB				Ono, M; Wada, Y; Wu, YM; Nemori, R; Jinbo, Y; Wang, H; Lo, KM; Yamaguchi, N; Brunkhorst, B; Otomo, H; Wesolowski, J; Way, JC; Itoh, I; Gillies, S; Chen, LB			FP-21399 blocks HIV envelope protein-mediated membrane fusion and concentrates in lymph nodes	NATURE BIOTECHNOLOGY			English	Article						AIDS; disulfonaphthalene; syncytia; CD4; gp120	HUMAN-IMMUNODEFICIENCY-VIRUS; NEUTRALIZING MONOCLONAL-ANTIBODY; DEXTRAN SULFATE; INFECTION; TYPE-1; GLYCOPROTEIN; REPLICATION; DERIVATIVES; LYMPHOCYTES; INHIBITION	The identification of fusin and other chemokine receptors as coreceptors for HIV-1 has renewed the interest in agents that may prevent viral entry. Polyanionic compounds such as dextran sulfate, curdlan sulfate, and suramin act on the V3 loop of the viral envelope and may prevent its interaction with fusin. These agents show activity against a wide range of HIV-1 strains, but have undesirable circulating half-life, bioavailability, and toxicity. We have developed a small molecule inhibitor of HIV-1 that has several advantages over these other agents. FP-21399 is a novel compound of the bis(disulfonaphthalene) dimethoxybenzene class that blocks entry of HIV into CD4(+) cells and blocks fusion of infected and noninfected CD4(+) cells. This compound only weakly inhibits binding of CD4 and gp120, at concentrations much greater than are required to block viral entry. Furthermore, FP-21399 can block the interaction between gp120 and antibodies directed against the V3 loop, but does not block binding of antibodies directed against the V4 loop. Animal studies demonstrate that FP-21399 is concentrated in lymph nodes, making it a promising compound for anti-HIV therapy. In SCID mice reconstituted with human immune cells, maintenance of HIV-1 infection was blocked by a 5-day treatment with low doses of FP-21399, suggesting that lymph node accumulation may contribute to antiviral activity. Finally, attempts to generate drug-resistant virus in cell culture resulted in only weakly resistant variants with IC50 values that are much lower than concentrations of FP-21399 found in lymph nodes.	FUJI IMMUNOPHARMACEUT CORP, LEXINGTON, MA 02173 USA; FUJI PHOTO FILM CO LTD, ASHIGARA RES LABS, KANAGAWA 225001, JAPAN; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA	Fujifilm Corporation; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School								AOKI T, 1992, AIDS RES HUM RETROV, V8, P605, DOI 10.1089/aid.1992.8.605; ASHORN PA, 1990, J VIROL, V64, P2149, DOI 10.1128/JVI.64.5.2149-2156.1990; BAITINIC D, 1992, J BIOL CHEM, V267, P6664; CALLAHAN LN, 1991, J VIROL, V65, P1543, DOI 10.1128/JVI.65.3.1543-1550.1991; CARDIN AD, 1991, J BIOL CHEM, V266, P13355; CHANG RS, 1988, P SOC EXP BIOL MED, V189, P304, DOI 10.3181/00379727-189-42811; CHOE H, 1996, CELL, V85, P1185; CLANTON DJ, 1992, J ACQ IMMUN DEF SYND, V5, P771; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; DOUGLAS SD, 1990, HEMOTOLOGY, P858; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FLEXNER C, 1991, ANTIMICROB AGENTS CH, V35, P2544, DOI 10.1128/AAC.35.12.2544; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HUSSEY RE, 1988, NATURE, V331, P78, DOI 10.1038/331078a0; JAPOUR AJ, 1993, ANTIMICROB AGENTS CH, V37, P1095, DOI 10.1128/AAC.37.5.1095; KINNEYTHOMAS E, 1988, AIDS, V2, P25; LEVINE AM, 1986, ANN INTERN MED, V105, P32, DOI 10.7326/0003-4819-105-1-32; Lin PF, 1996, ANTIMICROB AGENTS CH, V40, P133, DOI 10.1128/AAC.40.1.133; MATSUSHITA S, 1988, J VIROL, V62, P2107, DOI 10.1128/JVI.62.6.2107-2114.1988; MCCUNE JM, 1990, SCIENCE, V247, P564, DOI 10.1126/science.2300816; MOHAN P, 1990, AIDS, V4, P821, DOI 10.1097/00002030-199008000-00021; MOHAN P, 1991, J MED CHEM, V34, P212, DOI 10.1021/jm00105a033; MOSIER DE, 1991, SCIENCE, V251, P791, DOI 10.1126/science.1990441; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; ROMERO DL, 1991, P NATL ACAD SCI USA, V88, P8806, DOI 10.1073/pnas.88.19.8806; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SKINNER MA, 1988, AIDS RES HUM RETROV, V4, P187, DOI 10.1089/aid.1988.4.187; SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514; THALI M, 1992, J VIROL, V66, P5516, DOI 10.1128/JVI.66.9.5516-5524.1992; TRAUNECKER A, 1988, NATURE, V331, P84, DOI 10.1038/331084a0; URYU T, 1993, FRONT BIOM, V1, P101; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WYATT JR, 1994, P NATL ACAD SCI USA, V91, P1356, DOI 10.1073/pnas.91.4.1356	38	34	36	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1997	15	4					343	348		10.1038/nbt0497-343	http://dx.doi.org/10.1038/nbt0497-343			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WQ554	9094135				2022-12-27	WOS:A1997WQ55400034
J	Peters, R; Sikorski, RS				Peters, R; Sikorski, RS			Protein databases on the WWW	NATURE BIOTECHNOLOGY			English	Editorial Material											Peters, R (corresponding author), MASSACHUSETTS GEN HOSP,BOSTON,MA 02114, USA.								0	0	0	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1997	15	1					90	90		10.1038/nbt0197-90	http://dx.doi.org/10.1038/nbt0197-90			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WA729	9035114				2022-12-27	WOS:A1997WA72900031
J	Sim, SJ; Snell, KD; Hogan, SA; Stubbe, J; Rha, CK; Sinskey, AJ				Sim, SJ; Snell, KD; Hogan, SA; Stubbe, J; Rha, CK; Sinskey, AJ			PHA synthase activity controls the molecular weight and polydispersity of polyhydroxybutyrate in vivo	NATURE BIOTECHNOLOGY			English	Article						polyhydroxyalkanoates; molecular weight; PHA synthase	RECOMBINANT ESCHERICHIA-COLI; POLY-BETA-HYDROXYBUTYRATE; ALCALIGENES-EUTROPHUS H16; POLY(3-HYDROXYBUTYRIC ACID); ZOOGLOEA-RAMIGERA; PLASMA-MEMBRANES; BIOSYNTHESIS; STRAINS; POLYHYDROXYALKANOATES; IDENTIFICATION	A synthetic operon for polyhydroxyalkanoate (PHA) biosynthesis designed to yield high levels of PHA synthase activity in vivo was constructed by positioning a genetic fragment encoding beta-ketothiolase and acetoacetyl-CoA reductase behind a modified synthase gene containing an Escherichia coli promoter and ribosome binding site. Plasmids containing the synthetic operon and the native Alcaligenes eutrophus PHA operon were transformed into E. coli DH5 alpha and analyzed for polyhydroxybutyrate production. The molecular weight of polymer isolated from recombinant E. coli containing the modified synthase construct; determined by multiangle light scattering, was lower than that of the polymer from E. coli containing the native A. eutrophus operon. A further decrease in polyester molecular weight was observed with increased induction of the PHA biosynthetic genes in the synthetic operon. Comparison of the enzyme activity levels of PHA biosynthetic enzymes in a strain encoding the native operon with a strain possessing the synthetic operon indicates that the amount of polyhydroxyalkanoate synthase in a host organism plays a key role in controlling the molecular weight and the polydispersity of polymer.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; MIT,BIOMAT SCI & ENGN LAB,CAMBRIDGE,MA 02139; MIT,DEPT CHEM,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)			Sim, Sang Jun/F-6697-2013	Sim, Sang Jun/0000-0003-1045-0286; Snell, Kristi/0000-0002-8976-2823	NIGMS NIH HHS [GM 49171] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKITA S, 1976, MACROMOLECULES, V9, P774, DOI 10.1021/ma60053a017; AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; ANDERSON AJ, 1990, MICROBIOL REV, V54, P450, DOI 10.1128/MMBR.54.4.450-472.1990; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; FUKUI T, 1976, ARCH MICROBIOL, V110, P149, DOI 10.1007/BF00690222; GERNGROSS TU, 1994, BIOCHEMISTRY-US, V33, P9311, DOI 10.1021/bi00197a035; GERNGROSS TU, 1995, P NATL ACAD SCI USA, V92, P6279, DOI 10.1073/pnas.92.14.6279; GILBERT RG, 1995, TRENDS POLYM SCI, V3, P222; GRUBISIC Z, 1967, J POLYM SCI POL LETT, V5, P753, DOI 10.1002/pol.1967.110050903; HAHN SK, 1995, APPL ENVIRON MICROB, V61, P34, DOI 10.1128/AEM.61.1.34-39.1995; HAYWOOD GW, 1989, FEMS MICROBIOL LETT, V57, P1; HUISMAN GW, 1992, APPL MICROBIOL BIOT, V38, P1, DOI 10.1007/BF00169409; KALOUSEK S, 1995, CAN J MICROBIOL, V41, P216, DOI 10.1139/m95-190; KAWAGUCHI Y, 1992, MACROMOLECULES, V25, P2324, DOI 10.1021/ma00035a007; KIDWELL J, 1995, APPL ENVIRON MICROB, V61, P1391, DOI 10.1128/AEM.61.4.1391-1398.1995; KIM BS, 1992, BIOTECHNOL LETT, V14, P811, DOI 10.1007/BF01029144; LAW JH, 1961, J BACTERIOL, V82, P33, DOI 10.1128/JB.82.1.33-36.1961; LEE SY, 1995, CAN J MICROBIOL, V41, P207, DOI 10.1139/m95-189; LEE SY, 1994, BIOTECHNOL BIOENG, V44, P1337, DOI 10.1002/bit.260441110; Lee SY, 1996, BIOTECHNOL BIOENG, V49, P1; LEE SY, 1993, BIOTECHNOL LETT, V15, P971, DOI 10.1007/BF00131766; LEE SY, 1994, ANN NY ACAD SCI, V721, P43, DOI 10.1111/j.1749-6632.1994.tb47375.x; LEE SY, 1994, J BIOTECHNOL, V32, P203, DOI 10.1016/0168-1656(94)90183-X; Marchessault RH, 1996, TRENDS POLYM SCI, V4, P163; MULLER HM, 1993, ANGEW CHEM INT EDIT, V32, P477, DOI 10.1002/anie.199304771; NAWRATH C, 1994, P NATL ACAD SCI USA, V91, P12760, DOI 10.1073/pnas.91.26.12760; NISHIMURA T, 1978, ARCH MICROBIOL, V116, P21, DOI 10.1007/BF00408729; PEOPLES OP, 1989, J BIOL CHEM, V264, P15293; PEOPLES OP, 1989, J BIOL CHEM, V264, P15298; PLOUX O, 1988, EUR J BIOCHEM, V174, P177, DOI 10.1111/j.1432-1033.1988.tb14079.x; POIRIER Y, 1995, BIO-TECHNOL, V13, P142, DOI 10.1038/nbt0295-142; REUSCH R, 1987, CAN J MICROBIOL, V33, P435, DOI 10.1139/m87-073; REUSCH RN, 1995, CAN J MICROBIOL, V41, P50, DOI 10.1139/m95-167; REUSCH RN, 1988, P NATL ACAD SCI USA, V85, P4176, DOI 10.1073/pnas.85.12.4176; Sambrook J., 2002, MOL CLONING LAB MANU; SEEBACH D, 1994, EUR J BIOCHEM, V224, P317, DOI 10.1111/j.1432-1033.1994.00317.x; Seebach D, 1996, HELV CHIM ACTA, V79, P507, DOI 10.1002/hlca.19960790218; Williams SF, 1996, CHEMTECH, V26, P38; Wodzinska J, 1996, J AM CHEM SOC, V118, P6319, DOI 10.1021/ja961108a; ZHANG H, 1994, APPL ENVIRON MICROB, V60, P1198, DOI 10.1128/AEM.60.4.1198-1205.1994	40	169	188	6	66	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1997	15	1					63	67		10.1038/nbt0197-63	http://dx.doi.org/10.1038/nbt0197-63			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WA729	9035108				2022-12-27	WOS:A1997WA72900025
J	Master, H; Annis, J; Huang, S; Beckman, JA; Ratsimbazafy, F; Marginean, K; Carroll, R; Natarajan, K; Harrell, FE; Roden, DM; Harris, P; Brittain, EL				Master, Hiral; Annis, Jeffrey; Huang, Shi; Beckman, Joshua A.; Ratsimbazafy, Francis; Marginean, Kayla; Carroll, Robert; Natarajan, Karthik; Harrell, Frank E.; Roden, Dan M.; Harris, Paul; Brittain, Evan L.			Association of step counts over time with the risk of chronic disease in the All of Us Research Program	NATURE MEDICINE			English	Article							PHYSICAL-ACTIVITY; INTENSITY; ADULTS	The association between physical activity and human disease has not been examined using commercial devices linked to electronic health records. Using the electronic health records data from the All of Us Research Program, we show that step count volumes as captured by participants' own Fitbit devices were associated with risk of chronic disease across the entire human phenome. Of the 6,042 participants included in the study, 73% were female, 84% were white and 71% had a college degree, and participants had a median age of 56.7 (interquartile range 41.5-67.6) years and body mass index of 28.1 (24.3-32.9) kg m(-2). Participants walked a median of 7,731.3 (5,866.8-9,826.8) steps per day over the median activity monitoring period of 4.0 (2.2-5.6) years with a total of 5.9 million person-days of monitoring. The relationship between steps per day and incident disease was inverse and linear for obesity (n = 368), sleep apnea (n = 348), gastroesophageal reflux disease (n = 432) and major depressive disorder (n = 467), with values above 8,200 daily steps associated with protection from incident disease. The relationships with incident diabetes (n = 156) and hypertension (n = 482) were nonlinear with no further risk reduction above 8,000-9,000 steps. Although validation in a more diverse sample is needed, these findings provide a real-world evidence-base for clinical guidance regarding activity levels that are necessary to reduce disease risk. Step count monitoring with Fitbit devices in the All of Us Research Program enabled quantification of the benefits of physical activity across a wide range of chronic diseases over the course of an extended time frame-a median of 4 years.	[Master, Hiral; Annis, Jeffrey; Ratsimbazafy, Francis; Marginean, Kayla] Vanderbilt Univ, Vanderbilt Inst Clin & Translat Res, Med Ctr, Nashville, TN USA; [Huang, Shi; Harrell, Frank E.] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA; [Beckman, Joshua A.; Brittain, Evan L.] Vanderbilt Univ, Med Ctr, Div Cardiovasc Med, Nashville, TN 37235 USA; [Carroll, Robert] Vanderbilt Univ, Dept Biomed Informat, Med Ctr, Nashville, TN USA; [Natarajan, Karthik] Columbia Univ, Dept Biomed Informat, New York, NY USA; [Roden, Dan M.] Vanderbilt Univ, Med Ctr, Dept Med & Biomed Informat, Nashville, TN USA; [Harris, Paul] Vanderbilt Univ, Dept Biomed Informat Biomed Engn & Biostat, Med Ctr, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Columbia University; Vanderbilt University; Vanderbilt University	Brittain, EL (corresponding author), Vanderbilt Univ, Med Ctr, Div Cardiovasc Med, Nashville, TN 37235 USA.	evan.brittain@vumc.org		Natarajan, Karthik/0000-0002-9066-9431; Master, Hiral/0000-0003-0019-3087	National Institutes of Health, Office of the Director: Regional Medical Centers [1 OT2 OD026549, 1 OT2 OD026554, 1 OT2 OD026557, 1 OT2 OD026556, 1 OT2 OD026550, 1 OT2 OD 026552, 1 OT2 OD026553, 1 OT2 OD026548, 1 OT2 OD026551, 1 OT2 OD026555, IAA: AOD21037, AOD22003, AOD16037, AOD21041]; Federally Qualified Health Centers [HHSN263201600085U]; Data and Research Center [5 U2C OD023196]; Biobank [1 U24 OD023121]; Participant Center [U24 OD023176]; Participant Technology Systems Center [1 U24 OD023163]; Communications and Engagement [3 OT2 OD023205, 3 OT2 OD023206]; Community Partners [1 OT2 OD025277, 3 OT2 OD025315, 1 OT2 OD025337, 1 OT2 OD025276];  [R01 HL146588];  [1 R61 HL158941-01A1]	National Institutes of Health, Office of the Director: Regional Medical Centers(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Federally Qualified Health Centers; Data and Research Center; Biobank; Participant Center; Participant Technology Systems Center; Communications and Engagement; Community Partners; ; 	The All of Us Research Program would not be possible without the partnership of its participants. The All of Us Research Program is supported by the National Institutes of Health, Office of the Director: Regional Medical Centers (1 OT2 OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 OT2 OD026556; 1 OT2 OD026550; 1 OT2 OD 026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2 OD026551; 1 OT2 OD026555; IAA: AOD21037, AOD22003, AOD16037, AOD21041), Federally Qualified Health Centers (HHSN263201600085U), Data and Research Center (5 U2C OD023196), Biobank (1 U24 OD023121), The Participant Center (U24 OD023176), Participant Technology Systems Center (1 U24 OD023163), Communications and Engagement (3 OT2 OD023205; 3 OT2 OD023206) and Community Partners (1 OT2 OD025277; 3 OT2 OD025315; 1 OT2 OD025337; 1 OT2 OD025276). E.L.B. is supported by R01 HL146588 and 1 R61 HL158941-01A1.	All Us Res Program Investigators, 2019, NEW ENGL J MED, V381, P668, DOI 10.1056/NEJMsr1809937; Ballin M, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09929-2; Bassett DR, 2017, SPORTS MED, V47, P1303, DOI 10.1007/s40279-016-0663-1; Brooke SM, 2017, J STRENGTH COND RES, V31, P1097, DOI 10.1519/JSC.0000000000001571; Clemes SA, 2008, BRIT J SPORT MED, V42, P68, DOI 10.1136/bjsm.2007.038521; Freimer N, 2003, NAT GENET, V34, P15, DOI 10.1038/ng0503-15; Fuller D, 2020, JMIR MHEALTH UHEALTH, V8, DOI 10.2196/18694; Garriga A, 2022, INT J ENV RES PUB HE, V19, DOI 10.3390/ijerph19010002; Hall KS, 2020, INT J BEHAV NUTR PHY, V17, DOI 10.1186/s12966-020-00978-9; Harrell F. E., 2006, R PACKAGE VERSION; Harrell FE, 2001, REGRESSION MODELING; Klann JG, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212463; Larsen RT, 2022, BMJ-BRIT MED J, V376, DOI [10.1136/bmj.2021.068047, 10.1136/bmj-2021-068047]; Lee IM, 2019, JAMA INTERN MED, V179, P1105, DOI 10.1001/jamainternmed.2019.0899; Marrie RA, 2009, J CLIN EPIDEMIOL, V62, P511, DOI 10.1016/j.jclinepi.2008.05.015; Marshall SJ, 2009, AM J PREV MED, V36, P410, DOI 10.1016/j.amepre.2009.01.021; Mendelson M, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00073; Meyer J, 2017, PROCEEDINGS OF THE 2017 ACM SIGCHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS (CHI'17), P667, DOI 10.1145/3025453.3025690; Morris TP, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-75; Paluch AE, 2022, LANCET PUBLIC HEALTH, V7, pE219, DOI 10.1016/S2468-2667(21)00302-9; Paluch AE, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.24516; Pendergrass Sarah A, 2019, Curr Protoc Hum Genet, V100, pe80, DOI 10.1002/cphg.80; Piercy KL, 2018, JAMA-J AM MED ASSOC, V320, P2020, DOI 10.1001/jama.2018.14854; Ramirez AH, 2022, PATTERNS, V3, DOI 10.1016/j.patter.2022.100570; Saint-Maurice PF, 2020, JAMA-J AM MED ASSOC, V323, P1151, DOI 10.1001/jama.2020.1382; Schuch FB, 2018, AM J PSYCHIAT, V175, P631, DOI 10.1176/appi.ajp.2018.17111194; Tedesco S, 2019, JMIR MHEALTH UHEALTH, V7, DOI 10.2196/13084; The Observational Medical Outcomes Partnership, 2022, OMOP COMM DAT MOD; Therneau T., 2015, PACKAGE SURVIVAL ANA; Troiano RP, 2008, MED SCI SPORT EXER, V40, P181, DOI 10.1249/mss.0b013e31815a51b3; Tudor-Locke C, 2005, PREV MED, V40, P293, DOI 10.1016/j.ypmed.2004.06.003; Tudor-Locke C, 2018, BRIT J SPORT MED, V52, P776, DOI 10.1136/bjsports-2017-097628; Tudor-Locke C, 2013, J GERONTOL A-BIOL, V68, P1426, DOI 10.1093/gerona/glt116; Tudor-Locke C, 2011, INT J BEHAV NUTR PHY, V8, DOI 10.1186/1479-5868-8-66; Zheng NS, 2020, J AM MED INFORM ASSN, V27, P1675, DOI 10.1093/jamia/ocaa104	35	0	0	2	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	NOV	2022	28	11					2301	+		10.1038/s41591-022-02012-w	http://dx.doi.org/10.1038/s41591-022-02012-w		OCT 2022	25	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	6H2WM	36216933	Green Published, hybrid			2022-12-27	WOS:000865725700008
J	Sapkota, Y; Qiu, WY; Dixon, SB; Wilson, CL; Wang, ZM; Zhang, JH; Leisenring, W; Chow, EJ; Bhatia, S; Armstrong, GT; Robison, LL; Hudson, MM; Delaney, A; Yasui, Y				Sapkota, Yadav; Qiu, Weiyu; Dixon, Stephanie B.; Wilson, Carmen L.; Wang, Zhaoming; Zhang, Jinghui; Leisenring, Wendy; Chow, Eric J.; Bhatia, Smita; Armstrong, Gregory T.; Robison, Leslie L.; Hudson, Melissa M.; Delaney, Angela; Yasui, Yutaka			Genetic risk score enhances the risk prediction of severe obesity in adult survivors of childhood cancer	NATURE MEDICINE			English	Article; Early Access							BODY-MASS-INDEX; ACUTE LYMPHOBLASTIC-LEUKEMIA; JUDE LIFETIME COHORT; LONG-TERM SURVIVORS; PHYSICAL-ACTIVITY; HEART-DISEASE; POLYGENIC RISK; WEIGHT; STRATIFICATION; HYPERTENSION	A report from large cohorts of adult survivors of childhood cancer demonstrates that genetic risk scores improve the risk prediction of developing severe obesity, providing opportunities for surveillance and mitigation interventions Adult survivors of childhood cancer have high rates of obesity, which, in combination with the cardiotoxic effects of specific cancer therapies, places them at high risk for cardiovascular morbidity. Here we show the contribution of genetic risk scores (GRSs) to increase prediction of those survivors of childhood cancer who are at risk for severe obesity (body mass index >= 40 kg m(-)(2)) as an adult. Among 2,548 individuals of European ancestry from the St. Jude Lifetime Cohort Study who were 5-year survivors of childhood cancer, the GRS was found to be associated with 53-fold-higher odds of severe obesity. Addition of GRSs to risk prediction models based on cancer treatment exposures and lifestyle factors significantly improved model prediction (area under the curve increased from 0.68 to 0.75, resulting in the identification of 4.3-times more high-risk survivors), which was independently validated in 6,064 individuals from the Childhood Cancer Survivor Study. Genetic predictors improve identification of patients who could benefit from heightened surveillance and interventions to mitigate the risk of severe obesity and associated cardio-metabolic complications.	[Sapkota, Yadav; Dixon, Stephanie B.; Wilson, Carmen L.; Wang, Zhaoming; Zhang, Jinghui; Armstrong, Gregory T.; Robison, Leslie L.; Hudson, Melissa M.; Delaney, Angela; Yasui, Yutaka] St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA; [Qiu, Weiyu] Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada; [Leisenring, Wendy; Chow, Eric J.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA; [Bhatia, Smita] Univ Alabama Birmingham, Birmingham, AL USA	St Jude Children's Research Hospital; University of Alberta; Fred Hutchinson Cancer Center; University of Alabama System; University of Alabama Birmingham	Sapkota, Y; Yasui, Y (corresponding author), St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA.	yadav.sapkota@stjude.org; yutaka.yasui@stjude.org	Wang, Zhaoming/R-5527-2018; Sapkota, Yadav/O-2142-2015	Wang, Zhaoming/0000-0001-7556-3869; Sapkota, Yadav/0000-0001-5943-9454	National Cancer Institute at the National Institutes of Health [R01 CA261898, R01 CA216354, U01 CA195547, U24 CA55727]; Cancer Center Support CORE grant [CA21765]; Intramural Research Program of the National Cancer Institute, National Institutes of Health; American Lebanese Syrian Associated Charities in Memphis, Tennessee	National Cancer Institute at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Center Support CORE grant; Intramural Research Program of the National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Lebanese Syrian Associated Charities in Memphis, Tennessee	The St. Jude Lifetime Cohort (U01 CA195547: M.M.H. and K.K.N.) and the Childhood Cancer Survivor Study (U24 CA55727; G.T.A.) are supported by the National Cancer Institute at the National Institutes of Health and the Cancer Center Support CORE grant (CA21765: C. Roberts). The CCSS original cohort genotyping was supported by the Intramural Research Program of the National Cancer Institute, National Institutes of Health. This work is also supported by R01 CA261898 (Y.S.) and R01 CA216354 (Y.Y. and J.Z.) from the National Cancer Institute at the National Institutes of Health and the American Lebanese Syrian Associated Charities in Memphis, Tennessee.	Afshin A, 2017, NEW ENGL J MED, V377, P13, DOI 10.1056/NEJMoa1614362; Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393; Armstrong GT, 2016, NEW ENGL J MED, V374, P833, DOI 10.1056/NEJMoa1510795; Armstrong GT, 2013, J CLIN ONCOL, V31, P3673, DOI 10.1200/JCO.2013.49.3205; Bhakta N, 2017, LANCET, V390, P2569, DOI 10.1016/S0140-6736(17)31610-0; Bradfield JP, 2019, HUM MOL GENET, V28, P3327, DOI 10.1093/hmg/ddz161; Chang CC, 2015, GIGASCIENCE, V4, DOI 10.1186/s13742-015-0047-8; Chow EJ, 2007, CANCER-AM CANCER SOC, V110, P2313, DOI 10.1002/cncr.23050; Chow EJ, 2018, J CLIN ONCOL, V36, P44, DOI 10.1200/JCO.2017.74.8673; Chow EJ, 2015, J CLIN ONCOL, V33, P394, DOI 10.1200/JCO.2014.56.1373; Damask A, 2020, CIRCULATION, V141, P624, DOI 10.1161/CIRCULATIONAHA.119.044434; Danecek P, 2011, BIOINFORMATICS, V27, P2156, DOI 10.1093/bioinformatics/btr330; Das S, 2016, NAT GENET, V48, P1284, DOI 10.1038/ng.3656; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Flegal KM, 2013, JAMA-J AM MED ASSOC, V309, P71, DOI 10.1001/jama.2012.113905; Garmey EG, 2008, J CLIN ONCOL, V26, P4639, DOI 10.1200/JCO.2008.16.3527; Green DM, 2012, J CLIN ONCOL, V30, P246, DOI 10.1200/JCO.2010.34.4267; Howell CR, 2021, INT J EPIDEMIOL, V50, P39, DOI 10.1093/ije/dyaa203; Hudson MM, 2011, PEDIATR BLOOD CANCER, V56, P825, DOI 10.1002/pbc.22875; Inouye M, 2018, J AM COLL CARDIOL, V72, P1883, DOI 10.1016/j.jacc.2018.07.079; Janiszewski PM, 2007, J CLIN ENDOCR METAB, V92, P3816, DOI 10.1210/jc.2006-2178; Khera AV, 2019, CELL, V177, P587, DOI 10.1016/j.cell.2019.03.028; Khera AV, 2016, NEW ENGL J MED, V375, P2349, DOI 10.1056/NEJMoa1605086; Krul AJ, 2011, EUR J PUBLIC HEALTH, V21, P414, DOI 10.1093/eurpub/ckp228; Leisenring WM, 2009, J CLIN ONCOL, V27, P2319, DOI 10.1200/JCO.2008.21.1813; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Locke AE, 2015, NATURE, V518, P197, DOI 10.1038/nature14177; Marston NA, 2020, CIRCULATION, V141, P616, DOI 10.1161/CIRCULATIONAHA.119.043805; Martin AR, 2019, NAT GENET, V51, P584, DOI 10.1038/s41588-019-0379-x; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Meacham LR, 2005, CANCER-AM CANCER SOC, V103, P1730, DOI 10.1002/cncr.20960; Mega JL, 2015, LANCET, V385, P2264, DOI 10.1016/S0140-6736(14)61730-X; Monda KL, 2013, NAT GENET, V45, P690, DOI 10.1038/ng.2608; Morton LM, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx058; Natarajan P, 2017, CIRCULATION, V135, P2091, DOI 10.1161/CIRCULATIONAHA.116.024436; Ndumele CE, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.003921; Ng MCY, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006719; Oeffinger KC, 2003, J CLIN ONCOL, V21, P1359, DOI 10.1200/JCO.2003.06.131; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Petersen R, 2019, PREV CHRONIC DIS, V16, DOI 10.5888/pcd16.180579; Pharoah PDP, 2008, NEW ENGL J MED, V358, P2796, DOI 10.1056/NEJMsa0708739; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Poirier P, 2006, CIRCULATION, V113, P898, DOI 10.1161/CIRCULATIONAHA.106.171016; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Price AL, 2010, NAT REV GENET, V11, P459, DOI 10.1038/nrg2813; Pulit SL, 2019, HUM MOL GENET, V28, P166, DOI 10.1093/hmg/ddy327; Qi QB, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1610; Qi QB, 2012, NEW ENGL J MED, V367, P1387, DOI 10.1056/NEJMoa1203039; Razzouk BI, 2007, J CLIN ONCOL, V25, P1183, DOI 10.1200/JCO.2006.07.8709; Reilly JJ, 1996, INT J OBESITY, V20, P1130; Robison LL, 2014, NAT REV CANCER, V14, P61, DOI 10.1038/nrc3634; Robison LL, 2002, MED PEDIATR ONCOL, V38, P229, DOI 10.1002/mpo.1316; Sapkota Y, 2021, JACC-CARDIOONCOL, V3, P76, DOI 10.1016/j.jaccao.2021.01.007; Sapkota Y, 2021, CANCER RES, V81, P2556, DOI 10.1158/0008-5472.CAN-20-2675; Sapkota Y, 2020, CANCER RES, V80, P3755, DOI 10.1158/0008-5472.CAN-20-0093; Sapkota Y, 2019, CLIN CANCER RES, V25, P6700, DOI 10.1158/1078-0432.CCR-19-1231; Sapkota Y, 2019, J INVEST DERMATOL, V139, P2042, DOI 10.1016/j.jid.2019.02.029; Turcot V, 2018, NAT GENET, V50, P26, DOI 10.1038/s41588-017-0011-x; Tyrrell J, 2017, INT J EPIDEMIOL, V46, P559, DOI 10.1093/ije/dyw337; Vogelezang S, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008718; Wadden TA, 2012, CIRCULATION, V125, P1157, DOI 10.1161/CIRCULATIONAHA.111.039453; Wang YF, 2005, AM J CLIN NUTR, V81, P555; Wang ZM, 2018, J CLIN ONCOL, V36, P2078, DOI 10.1200/JCO.2018.77.8589; Warner JT, 1998, PEDIATR RES, V43, P607, DOI 10.1203/00006450-199805000-00008; Wilson CL, 2015, CANCER-AM CANCER SOC, V121, P2262, DOI 10.1002/cncr.29153; Yanovski SZ, 2014, JAMA-J AM MED ASSOC, V311, P74, DOI 10.1001/jama.2013.281361; Yengo L, 2018, HUM MOL GENET, V27, P3641, DOI 10.1093/hmg/ddy271	67	2	2	1	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01902-3	http://dx.doi.org/10.1038/s41591-022-01902-3		JUL 2022	25	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3E1IL	35879615				2022-12-27	WOS:000829743800002
J	Kamiza, AB; Toure, SM; Vujkovic, M; Machipisa, T; Soremekun, OS; Kintu, C; Corpas, M; Pirie, F; Young, E; Gill, D; Sandhu, MS; Kaleebu, P; Nyirenda, M; Motala, AA; Chikowore, T; Fatumo, S				Kamiza, Abram B.; Toure, Sounkou M.; Vujkovic, Marijana; Machipisa, Tafadzwa; Soremekun, Opeyemi S.; Kintu, Christopher; Corpas, Manuel; Pirie, Fraser; Young, Elizabeth; Gill, Dipender; Sandhu, Manjinder S.; Kaleebu, Pontiano; Nyirenda, Moffat; Motala, Ayesha A.; Chikowore, Tinashe; Fatumo, Segun			Transferability of genetic risk scores in African populations	NATURE MEDICINE			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; SERUM; LOCI; METAANALYSIS; WIDE	A new study reveals that polygenic scores for lipid traits derived from data of African American individuals have high predictive value in a South African Zulu cohort but are poor predictors in a cohort from Uganda, further highlighting the need to improve polygenic predictions in populations of African ancestries. The poor transferability of genetic risk scores (GRSs) derived from European ancestry data in diverse populations is a cause of concern. We set out to evaluate whether GRSs derived from data of African American individuals and multiancestry data perform better in sub-Saharan Africa (SSA) compared to European ancestry-derived scores. Using summary statistics from the Million Veteran Program (MVP), we showed that GRSs derived from data of African American individuals enhance polygenic prediction of lipid traits in SSA compared to European and multiancestry scores. However, our GRS prediction varied greatly within SSA between the South African Zulu (low-density lipoprotein cholesterol (LDL-C), R-2 = 8.14%) and Ugandan cohorts (LDL-C, R-2 = 0.026%). We postulate that differences in the genetic and environmental factors between these population groups might lead to the poor transferability of GRSs within SSA. More effort is required to optimize polygenic prediction in Africa.	[Kamiza, Abram B.; Toure, Sounkou M.; Soremekun, Opeyemi S.; Kintu, Christopher; Fatumo, Segun] MRC UVRI, African Computat Genom TACG Res Grp, Entebbe, Uganda; [Kamiza, Abram B.; Toure, Sounkou M.; Soremekun, Opeyemi S.; Kintu, Christopher; Kaleebu, Pontiano; Nyirenda, Moffat; Fatumo, Segun] LSHTM, Entebbe, Uganda; [Kamiza, Abram B.] Malawi Epidemiol & Intervent Res Unit, Lilongwe, Karonga, Malawi; [Kamiza, Abram B.; Chikowore, Tinashe] Univ Witwatersrand, Fac Hlth Sci, Sydney Brenner Inst Mol Biosci, Johannesburg, South Africa; [Toure, Sounkou M.] Univ Sci & Technol Bamako, African Ctr Excellence Bioinformat, Bamako, Mali; [Vujkovic, Marijana] McMaster Univ, Michael G DeGroote Sch Med, Dept Pathol & Mol Med, Hamilton, ON, Canada; [Machipisa, Tafadzwa] Corporal Michael J Crescenz VA Med Ctr, Philadelphia, PA USA; [Machipisa, Tafadzwa] Univ Cape Town, Dept Med, Hatter Inst Cardiovasc Dis Res Africa HICRA, Cape Town, South Africa; [Machipisa, Tafadzwa] David Braley Cardiac Vasc & Stroke Res Inst, Populat Hlth Res Inst, Hamilton, ON, Canada; [Corpas, Manuel] Univ Cambridge, IdeaSpace, Cambridge Precis Med Ltd, Biomed Innovat Hub, Cambridge, England; [Corpas, Manuel] Univ Cambridge, Inst Continuing Educ, Madingley Hall, Cambridge, England; [Corpas, Manuel] Univ Int La Rioja, Fac Ciencias Salud, Madrid, Spain; [Pirie, Fraser; Motala, Ayesha A.] Univ KwaZulu Natal, Dept Diabet & Endocrinol, Durban, South Africa; [Young, Elizabeth] Omnigen Biodata Ltd, Cambridge, England; [Gill, Dipender; Sandhu, Manjinder S.] Imperial Coll London, Sch Publ Hlth, Dept Epidemiol & Biostat, London, England; [Gill, Dipender] Univ London, Inst Med & Biomed Educ, Clin Pharmacol & Therapeut Sect, London, England; [Gill, Dipender] Univ London, Inst Infect & Immun, London, England; [Kaleebu, Pontiano; Nyirenda, Moffat; Fatumo, Segun] MRC UVRI, Entebbe, Uganda; [Chikowore, Tinashe] Univ Witwatersrand, Fac Hlth Sci, Dept Paediat, MRC Wits Dev Pathways Hlth Res Unit, Johannesburg, South Africa; [Fatumo, Segun] London Sch Hyg & Trop Med, London, England; [Fatumo, Segun] H3Afr Bioinformat Network H3ABioNet Node, Ctr Genom Res & Innovat, NABDA FMST, Abuja, Nigeria	Malawi Epidemiology and Intervention Research Unit; University of Witwatersrand; University of Science & Technology of Bamako; McMaster University; University of Cape Town; Population Health Research Institute; University of Cambridge; University of Cambridge; Universidad Internacional de La Rioja (UNIR); University of Kwazulu Natal; Imperial College London; University of London; University of London; University of Witwatersrand; University of London; London School of Hygiene & Tropical Medicine	Fatumo, S (corresponding author), MRC UVRI, African Computat Genom TACG Res Grp, Entebbe, Uganda.; Fatumo, S (corresponding author), LSHTM, Entebbe, Uganda.; Chikowore, T (corresponding author), Univ Witwatersrand, Fac Hlth Sci, Sydney Brenner Inst Mol Biosci, Johannesburg, South Africa.; Fatumo, S (corresponding author), MRC UVRI, Entebbe, Uganda.; Chikowore, T (corresponding author), Univ Witwatersrand, Fac Hlth Sci, Dept Paediat, MRC Wits Dev Pathways Hlth Res Unit, Johannesburg, South Africa.; Fatumo, S (corresponding author), London Sch Hyg & Trop Med, London, England.; Fatumo, S (corresponding author), H3Afr Bioinformat Network H3ABioNet Node, Ctr Genom Res & Innovat, NABDA FMST, Abuja, Nigeria.	tinashe.chikowore1@wits.ac.za; segun.fatumo@lshtm.ac.uk	Chikowore, Tinashe/G-5172-2018; Vujković, Marijana/S-9414-2019	Chikowore, Tinashe/0000-0002-6743-751X; Vujković, Marijana/0000-0003-4924-5714; Gill, Dipender/0000-0001-7312-7078; Corpas, Manuel/0000-0002-4417-1018	National Institutes of Health/National Human Genome Research Institute (CARDINAL grant) at The African Computational Genomics Research Group [1U01HG011717]; Medical Research Council/Uganda Virus Research Institute (MRC/UVRI); LSHTM (London School of Hygiene & Tropical Medicine Uganda Research Unit); Uganda and Malawi Epidemiology and Intervention Research Unit, Lilongwe/Karonga, Malawi; South African Medical Research Council (South African National Department of Health); UK Medical Research Council (UK Government's Newton Fund) [MRC-RFA-SHIP01/2015]; Wellcome Trust at the MRC/UVRI [220740/Z/20/Z]; LSHTM; Wellcome Trust [214205/Z/18/Z]; British Heart Foundation Centre of Research Excellence at Imperial College [RE/18/4/34215]; National Institute for Health Research Clinical Lectureship at St. George's, University of London [CL-2020-1.0.6-001]; Servier South Africa; South African Sugar Association; Victor Daitz Foundation; Fogarty International Center of the National Institutes of Health of the United States of the West African Center of Excellence for Global Health Bioinformatics Research Training [U2RTW010673]; Veterans Administration Cooperative Studies Program [G002]	National Institutes of Health/National Human Genome Research Institute (CARDINAL grant) at The African Computational Genomics Research Group; Medical Research Council/Uganda Virus Research Institute (MRC/UVRI); LSHTM (London School of Hygiene & Tropical Medicine Uganda Research Unit); Uganda and Malawi Epidemiology and Intervention Research Unit, Lilongwe/Karonga, Malawi; South African Medical Research Council (South African National Department of Health)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK Medical Research Council (UK Government's Newton Fund)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust at the MRC/UVRI(Wellcome Trust); LSHTM; Wellcome Trust(Wellcome Trust); British Heart Foundation Centre of Research Excellence at Imperial College; National Institute for Health Research Clinical Lectureship at St. George's, University of London; Servier South Africa; South African Sugar Association; Victor Daitz Foundation; Fogarty International Center of the National Institutes of Health of the United States of the West African Center of Excellence for Global Health Bioinformatics Research Training; Veterans Administration Cooperative Studies Program	A.B.K. is supported by the National Institutes of Health/National Human Genome Research Institute (CARDINAL grant 1U01HG011717) at The African Computational Genomics Research Group, Medical Research Council/Uganda Virus Research Institute (MRC/UVRI) and LSHTM (London School of Hygiene & Tropical Medicine Uganda Research Unit), Uganda and Malawi Epidemiology and Intervention Research Unit, Lilongwe/Karonga, Malawi; South African Medical Research Council (with funds received from the South African National Department of Health) and the UK Medical Research Council (with funds received from the UK Government's Newton Fund) (MRC-RFA-SHIP01/2015) for the Evolving Risk Factors for Cancers in African populations study (ERICA-SA). S.F. is an Intermediate international fellow funded by the Wellcome Trust (grant 220740/Z/20/Z) at the MRC/UVRI and LSHTM. T.C. is an international training fellow supported by the Wellcome Trust (grant 214205/Z/18/Z). D.G. was supported by the British Heart Foundation Centre of Research Excellence (RE/18/4/34215) at Imperial College and a National Institute for Health Research Clinical Lectureship (CL-2020-1.0.6-001) at St. George's, University of London. The DCC was funded by Servier South Africa, the South African Sugar Association and the Victor Daitz Foundation. We thank the Fogarty International Center of the National Institutes of Health of the United States for supporting Sounkou Mahamane Toure under grant U2RTW010673 of the West African Center of Excellence for Global Health Bioinformatics Research Training. We thank the MVP staff, researchers and volunteers who have contributed to MVP, especially participants who previously served their country in the military and generously agreed to enroll in the study (for more details, see https://www.research.va.gov/mvp/or Gaziano, J. M. et al. Million Veteran Program: a mega-biobank to study genetic influences on health and disease. J. Clin. Epidemiol. 2016;70:214-223). This research is based on data from the MVP, Office of Research and Development, Veterans Health Administration, and was supported by the Veterans Administration Cooperative Studies Program (award G002)	[Anonymous], 2013, NAT GENET, DOI DOI 10.1038/NG.2797; Asselbergs FW, 2012, AM J HUM GENET, V91, P823, DOI 10.1016/j.ajhg.2012.08.032; Bentley AR, 2020, NPJ GENOM MED, V5, DOI 10.1038/s41525-019-0111-x; Bloetzer C, 2015, PUBLIC HEALTH REV, V36, DOI 10.1186/s40985-015-0011-2; Cavazos TB, 2021, HUM GENET GENOM ADV, V2, DOI 10.1016/j.xhgg.2020.100017; Chasman DI, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000730; Choi SW, 2019, GIGASCIENCE, V8, DOI 10.1093/gigascience/giz082; Duncan L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11112-0; Gomez F, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a008524; Gurdasani D, 2019, CELL, V179, P984, DOI 10.1016/j.cell.2019.10.004; Hird TR, 2016, GLOB HEALTH EPIDEM G, V1, DOI 10.1017/gheg.2015.3; Hoffmann TJ, 2018, NAT GENET, V50, P401, DOI 10.1038/s41588-018-0064-5; Johnson L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126361; Kathiresan S, 2008, NAT GENET, V40, P189, DOI 10.1038/ng.75; Klarin D, 2018, NAT GENET, V50, P1514, DOI 10.1038/s41588-018-0222-9; Lewis CM, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00742-5; Liu DJ, 2017, NAT GENET, V49, P1758, DOI 10.1038/ng.3977; Lu XF, 2017, NAT GENET, V49, P1722, DOI 10.1038/ng.3978; Lucchese B, 2009, NAT REV NEPHROL, V5, P663, DOI 10.1038/nrneph.2009.202; Marquez-Luna C, 2017, GENET EPIDEMIOL, V41, P811, DOI 10.1002/gepi.22083; Martin AR, 2019, NAT GENET, V51, P584, DOI 10.1038/s41588-019-0379-x; R Core Team, 2021, R LANGUAGE ENV STAT; Sanna S, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002198; Sugiuchi H, 1998, CLIN CHEM, V44, P522; SUGIUCHI H, 1995, CLIN CHEM, V41, P717; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Willer CJ, 2008, NAT GENET, V40, P161, DOI 10.1038/ng.76; Yu N, 2002, GENETICS, V161, P269	28	4	4	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2022	28	6					1163	+		10.1038/s41591-022-01835-x	http://dx.doi.org/10.1038/s41591-022-01835-x		JUN 2022	16	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E9IE	35654908	Green Submitted, Green Published, Green Accepted, hybrid			2022-12-27	WOS:000805079400001
J	Routen, A; Akbari, A; Banerjee, A; Katikireddi, SV; Mathur, R; McKee, M; Nafilyan, V; Khunti, K				Routen, Ash; Akbari, Ashley; Banerjee, Amitava; Katikireddi, Srinivasa Vittal; Mathur, Rohini; McKee, Martin; Nafilyan, Vahe; Khunti, Kamlesh			Strategies to record and use ethnicity information in routine health data	NATURE MEDICINE			English	Editorial Material								Ethnicity information is often missing from health data, impeding action on inequalities. Recording and using ethnicity data will require training, efforts at standardization, and policy changes, while engaging with patients and the public.	[Routen, Ash; Khunti, Kamlesh] Univ Leicester, Leicester Gen Hosp, Diabet Res Ctr, Leicester, Leics, England; [Akbari, Ashley] Swansea Univ, Swansea Univ Med Sch, Populat Data Sci, Swansea, W Glam, Wales; [Banerjee, Amitava] UCL, Fac Populat Hlth Sci, Inst Hlth Informat, London, England; [Katikireddi, Srinivasa Vittal] Univ Glasgow, MRC CSO Social & Publ Hlth Sci Unit, Glasgow, Lanark, Scotland; [Mathur, Rohini] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London, England; [McKee, Martin] London Sch Hyg & Trop Med, Fac Publ Hlth Policy, London, England; [Nafilyan, Vahe] Off Natl Stat, Govt Bldg, Newport, Gwent, Wales	University Hospitals of Leicester NHS Trust; Leicester General Hospital; University of Leicester; Swansea University; University of London; University College London; MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNIT; University of Glasgow; University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine	Khunti, K (corresponding author), Univ Leicester, Leicester Gen Hosp, Diabet Res Ctr, Leicester, Leics, England.	kk22@leicester.ac.uk	; Banerjee, Amitava/D-4381-2014; McKee, Martin/E-6673-2018	Routen, Ash/0000-0001-5651-4228; Banerjee, Amitava/0000-0001-8741-3411; Khunti, Kamlesh/0000-0003-2343-7099; Akbari, Ashley/0000-0003-0814-0801; Nafilyan, Vahe/0000-0003-0160-217X; McKee, Martin/0000-0002-0121-9683; Katikireddi, Srinivasa/0000-0001-6593-9092	NRS Senior Clinical Fellowship [SCAF/15/02]; Medical Research Council [MC_UU_00022/2]; Scottish Government Chief Scientist Office [SPHSU17]; Wellcome Trust [201375/Z/16/Z]	NRS Senior Clinical Fellowship; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Scottish Government Chief Scientist Office; Wellcome Trust(Wellcome Trust)	The views expressed in this article are those of the author(s) and not necessarily those of UKRI, the NIHR, or the Department of Health and Social Care. S.V.K. acknowledges funding from a NRS Senior Clinical Fellowship (SCAF/15/02), the Medical Research Council (MC_UU_00022/2) and the Scottish Government Chief Scientist Office (SPHSU17). R.M. is funded by a postdoctoral fellowship from the Wellcome Trust (201375/Z/16/Z).	Abbafati C, 2020, LANCET, V396, P1204, DOI 10.1016/S0140-6736(20)30925-9; [Anonymous], OUR DATA OUR SOVEREI; [Anonymous], ETHN GROUP NAT ID RE; Balestra C., 2018, DIVERSITY STAT OECD; Bauer GR, 2014, SOC SCI MED, V110, P10, DOI 10.1016/j.socscimed.2014.03.022; Bhopal R, 1999, BRIT MED J, V319, P215, DOI 10.1136/bmj.319.7204.215; Bhopal R, 2012, PUBLIC HEALTH, V126, P241, DOI 10.1016/j.puhe.2011.11.016; Bhopal RS, 2014, MIGRATION ETHNICITY; Csepeli G, 2004, J ETHN MIGR STUD, V30, P129, DOI 10.1080/1369183032000170204; Davis F. J., 2010, WHO IS BLACK ONE NAT; Farkas L, 2017, ANAL COMP REV EQUALI, DOI 10.2838/447194; Iqbal, 2009, DIVERSITY HLTH CARE, V6, P267; Iqbal G, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-243; Katikireddi SV, 2021, J EPIDEMIOL COMMUN H, V75, P970, DOI 10.1136/jech-2020-216061; Khunti K, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4493; Lymperopoulou K, 2017, URBAN STUD, V54, P2540, DOI 10.1177/0042098016653725; Marmot M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m693; Mathur R, 2014, J PUBLIC HEALTH-UK, V36, P684, DOI 10.1093/pubmed/fdt116; McGregor-Smith R., 2017, RACE WORKPLACE MCGRE; Morrison Zoe, 2014, Inform Prim Care, V21, P118, DOI 10.14236/jhi.v21i3.63; Nafilyan V, 2021, EUR J EPIDEMIOL, V36, P605, DOI 10.1007/s10654-021-00765-1; Oltermann P., 2020, GUARDIAN; Pan D, 2020, ECLINICALMEDICINE, V23, DOI 10.1016/j.eclinm.2020.100404; Saunders CL, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002882; Scobie, 2021, ETHNICITY CODING ENG; Webb Hooper M, 2020, JAMA-J AM MED ASSOC, V323, P2466, DOI 10.1001/jama.2020.8598	26	5	5	1	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2022	28	7					1338	1342		10.1038/s41591-022-01842-y	http://dx.doi.org/10.1038/s41591-022-01842-y		MAY 2022	5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3E5PS	35641824	Green Submitted, Bronze, Green Accepted			2022-12-27	WOS:000803789900004
J	Persidis, A; Persidis, A				Persidis, A; Persidis, A			Artificial intelligence for drug design	NATURE BIOTECHNOLOGY			English	Editorial Material							GENETIC ALGORITHM		ASSETT,ATHENS 14343,GREECE		Persidis, A (corresponding author), ARGONEX INC,2044 INDIA RD,SUITE 202,CHARLOTTESVILLE,VA 22901, USA.							BRODMEIER T, 1994, J COMPUT CHEM, V15, P588, DOI 10.1002/jcc.540150604; DANDEKAR T, 1994, J MOL BIOL, V236, P844, DOI 10.1006/jmbi.1994.1193; FORREST S, 1993, SCIENCE, V261, P872, DOI 10.1126/science.8346439; GLEN RC, 1995, J COMPUT AID MOL DES, V9, P181, DOI 10.1007/BF00124408; GULTYAEV AP, 1995, J MOL BIOL, V250, P37, DOI 10.1006/jmbi.1995.0356; HOLLAND J, 1975, ADAPTATION NATURAL A; JONES G, 1995, J MOL BIOL, V245, P43, DOI 10.1016/S0022-2836(95)80037-9; MAY ACW, 1994, PROTEIN ENG, V7, P475, DOI 10.1093/protein/7.4.475; OGATA H, 1995, NUCLEIC ACIDS RES, V23, P419, DOI 10.1093/nar/23.3.419; OSHIRO CM, 1995, J COMPUT AID MOL DES, V9, P113, DOI 10.1007/BF00124402; PERSIDIS A, 1995, AI EXPERT, P9; SUN E, 1993, GENE, V137, P127, DOI 10.1016/0378-1119(93)90260-A; SUN SJ, 1993, PROTEIN SCI, V2, P762, DOI 10.1002/pro.5560020508; UNGER R, 1993, J MOL BIOL, V231, P75, DOI 10.1006/jmbi.1993.1258	14	2	2	1	19	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1997	15	10					1035	1036		10.1038/nbt1097-1035	http://dx.doi.org/10.1038/nbt1097-1035			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XZ285	9335056				2022-12-27	WOS:A1997XZ28500036
J	Erhard, M; vonDohren, H; Jungblut, P				Erhard, M; vonDohren, H; Jungblut, P			Rapid typing and elucidation of new secondary metabolites of intact cyanobacteria using MALDI-TOF mass spectrometry	NATURE BIOTECHNOLOGY			English	Article						cyanobacteria; secondary metabolites; MALDI-TOF PSD; microcystin; anabaenopeptolins	ASSISTED LASER DESORPTION/IONIZATION; 2-DIMENSIONAL ELECTROPHORESIS; MICROCYSTIS-AERUGINOSA; IDENTIFICATION; DEPSIPEPTIDES; ANABAENA; BACTERIA; PROTEINS; STRAINS	Toxic cyanobacterial blooms are a threat because of secondary metabolite production. We used matrix-assisted laser desorption/ionization time-of-flight mass spectrometry to identify intact microorganisms. Microgram quantities of prepared cells, including solvent (acetonitrile and ethanol) and alpha-cyano-4-hydroxycinnamic acid matrix, display spectra showing predominantly the secondary metabolites including known microcystins, micropeptin, and anabaenopeptolin. A new cyclic anabaenopeptolin has been identified using the Post-Source-Decay mode. Strains of various origins can easily be typed according to their cyclic peptide production, and toxic and nontoxic algal blooms can be differentiated within minutes.	TECH UNIV BERLIN, INST BIOCHEM & MOL BIOL, D-1000 BERLIN, GERMANY; MAX PLANCK INST INFECT BIOL, BERLIN, GERMANY	Technical University of Berlin; Max Planck Society			Jungblut, Peter R/A-1576-2011					Claydon MA, 1996, NAT BIOTECHNOL, V14, P1584, DOI 10.1038/nbt1196-1584; HARADA K, 1993, TETRAHEDRON LETT, V34, P6091, DOI 10.1016/S0040-4039(00)61736-7; HARADA K, 1995, TETRAHEDRON LETT, V36, P1511, DOI 10.1016/0040-4039(95)00073-L; Holland RD, 1996, RAPID COMMUN MASS SP, V10, P1227, DOI 10.1002/(SICI)1097-0231(19960731)10:10<1227::AID-RCM659>3.0.CO;2-6; ISHIDA K, 1995, TETRAHEDRON LETT, V36, P3535, DOI 10.1016/0040-4039(95)00547-P; Jungblut P, 1996, ELECTROPHORESIS, V17, P839, DOI 10.1002/elps.1150170505; Kleinkauf H, 1997, BIOTECHNOLOGY, V7, P277; KLOSE J, 1995, ELECTROPHORESIS, V16, P1034, DOI 10.1002/elps.11501601175; Krishnamurthy T, 1996, RAPID COMMUN MASS SP, V10, P883, DOI 10.1002/(SICI)1097-0231(19960610)10:8<883::AID-RCM594>3.3.CO;2-M; Liang XL, 1996, RAPID COMMUN MASS SP, V10, P1219, DOI 10.1002/(SICI)1097-0231(19960731)10:10<1219::AID-RCM660>3.0.CO;2-R; MACKINTOSH RW, 1995, FEBS LETT, V371, P236, DOI 10.1016/0014-5793(95)00888-G; MARTIN C, 1993, J ANTIBIOT, V46, P1550, DOI 10.7164/antibiotics.46.1550; Meissner K, 1996, FEMS MICROBIOL LETT, V135, P295; SANO T, 1995, TETRAHEDRON LETT, V36, P5933, DOI 10.1016/00404-0399(50)1198Q-; SHI L, 1995, ARCH MICROBIOL, V163, P7, DOI 10.1007/BF00262197; SIVONEN K, 1992, APPL ENVIRON MICROB, V58, P2495, DOI 10.1128/AEM.58.8.2495-2500.1992; Watanabe M.F., 1996, TOXIC MICROCYSTIS; Watanabe M.M., 1994, NIES COLLECTION LIST; Williams DE, 1996, J NAT PROD, V59, P570, DOI 10.1021/np960108l	19	130	135	0	40	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1997	15	9					906	909		10.1038/nbt0997-906	http://dx.doi.org/10.1038/nbt0997-906			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XW410	9306409				2022-12-27	WOS:A1997XW41000036
J	Hogan, JC				Hogan, JC			Combinatorial chemistry in drug discovery	NATURE BIOTECHNOLOGY			English	Article							GENERAL-METHOD; PEPTIDE											BALDINO CM, IN PRESS SYN LETT; *BIOINF ASS, 1995, COMM OPP COMB CHEM, P14; FURKA A, 1991, INT J PEPT PROT RES, V37, P487, DOI 10.1111/j.1399-3011.1991.tb00765.x; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; RUTENBUR E, 1985, P NATL ACAD SCI USA, V82, P1545	6	51	53	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1997	15	4					328	330		10.1038/nbt0497-328	http://dx.doi.org/10.1038/nbt0497-328			9	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WQ554	9094132				2022-12-27	WOS:A1997WQ55400031
J	Russo, MJ; Bayley, H; Toner, M				Russo, MJ; Bayley, H; Toner, M			Reversible permeabilization of plasma membranes with an engineered switchable pore	NATURE BIOTECHNOLOGY			English	Article						membrane permeabilization; metal-actuated switch; alpha-toxin; sucrose	STAPHYLOCOCCAL ALPHA-HEMOLYSIN; FORMING PROTEIN; CELL-MEMBRANES; TOXIN; AUREUS; CHANNELS; MUTAGENESIS	By using an engineered, self-assembling, proteinaceous, 2-nm pore equipped with a metal-actuated switch, a technique to reversibly permeabilize the plasma membrane to small molecules (similar to 1000 Da) has been developed. We have demonstrated the dose-dependent permeabilization of fibroblasts by pores designed to be blocked and unblocked by the addition and removal of mu M concentrations of Zn2+. Further, we have shown that the activity of the switch allows permeabilized cells to maintain viability and ultrastructural integrity following the unconstrained flux of small molecules. This ability to control the transmembrane influx and efflux of molecules and thereby vary the intracellular environment yet maintain cell viability will impact an array of biological and medical problems.	MASSACHUSETTS GEN HOSP, CTR ENGN MED & SURG SERV, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA; WORCESTER FDN BIOMED RES, SHREWSBURY, MA 01545 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Worcester Foundation for Biomedical Research				Bayley, Hagan/0000-0003-2499-6116	NIDDK NIH HHS [DK 46270] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046270, R01DK046270] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bashford CL, 1996, J MEMBRANE BIOL, V150, P37, DOI 10.1007/s002329900028; Bayley H, 1995, BIOORG CHEM, V23, P340, DOI 10.1006/bioo.1995.1023; BHAKDI S, 1993, MED MICROBIOL IMMUN, V182, P167; BHAKDI S, 1991, MICROBIOL REV, V55, P733, DOI 10.1128/MMBR.55.4.733-751.1991; BISCHOF JC, 1995, BIOPHYS J, V68, P2608, DOI 10.1016/S0006-3495(95)80445-5; CHANG CY, 1995, CHEM BIOL, V2, P391, DOI 10.1016/1074-5521(95)90220-1; GOUAUX JE, 1994, P NATL ACAD SCI USA, V91, P12828, DOI 10.1073/pnas.91.26.12828; HILDEBRAND A, 1991, J BIOL CHEM, V266, P17195; JOHNSON HL, CURRENT TOPICS NUTR, V6, P405; KUBISCH HM, 1995, J REPROD FERTIL, V104, P133, DOI 10.1530/jrf.0.1040133; LEVIN RL, 1981, CRYOBIOLOGY, V18, P32, DOI 10.1016/0011-2240(81)90004-3; MENESTRINA G, 1986, J MEMBRANE BIOL, V90, P177, DOI 10.1007/BF01869935; MORRIS AP, 1993, AM J PHYSIOL, V264, pC977, DOI 10.1152/ajpcell.1993.264.4.C977; PALMER M, 1993, J BIOL CHEM, V268, P11963; Panchal RG, 1996, NAT BIOTECHNOL, V14, P852, DOI 10.1038/nbt0796-852; PANCHAL RG, 1995, J BIOL CHEM, V270, P23072, DOI 10.1074/jbc.270.39.23072; SUNZEL B, 1995, APMIS, V103, P635, DOI 10.1111/j.1699-0463.1995.tb01416.x; TSONG TY, 1991, BIOPHYS J, V60, P297, DOI 10.1016/S0006-3495(91)82054-9; WALEV I, 1994, MICROB PATHOGENESIS, V17, P187, DOI 10.1006/mpat.1994.1065; WALKER B, 1994, PROTEIN ENG, V7, P91, DOI 10.1093/protein/7.1.91; WALKER B, 1992, J BIOL CHEM, V267, P21782; WALKER B, 1995, CHEM BIOL, V2, P99, DOI 10.1016/1074-5521(95)90282-1; WALKER B, 1994, PROTEIN ENG, V7, P655, DOI 10.1093/protein/7.5.655; WILMSEN HU, 1990, J MEMBRANE BIOL, V115, P71, DOI 10.1007/BF01869107	24	67	89	3	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1997	15	3					278	282		10.1038/nbt0397-278	http://dx.doi.org/10.1038/nbt0397-278			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WM050	9062930				2022-12-27	WOS:A1997WM05000034
J	Brower, V				Brower, V			The empire strikes back	NATURE BIOTECHNOLOGY			English	News Item																			0	2	2	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1997	15	1					23	26		10.1038/nbt0197-23	http://dx.doi.org/10.1038/nbt0197-23			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WA729	9035101				2022-12-27	WOS:A1997WA72900018
J	Yang, AG; Chen, SY				Yang, AG; Chen, SY			A new class of antigen-specific killer cells	NATURE BIOTECHNOLOGY			English	Article						gene therapy; HIV; cytotoxic cells; immunotoxin	HTLV-III/LAV ENVELOPE; PSEUDOMONAS-AERUGINOSA; CYTOTOXIC LYMPHOCYTES; FUNCTIONAL RECEPTORS; DIPHTHERIA-TOXIN; GENE-THERAPY; EXOTOXIN-A; ANTIBODY; IMMUNOGLOBULIN; EXPRESSION	A new class of antigen-specific killer cells that combines the features of antibody-mediated and cell-mediated immunity was designed. The principle and feasibility of this strategy are illustrated by creating an antigen-specific killer cell to produce and secrete targeted antibody-toxin molecules that recognize and kill human immunodeficiency virus (HIV)-1-infected cells. The transduced lymphocytes, which were able to produce and secrete the targeted toxin proteins, remained viable due to the lack of the target antigen on the cell surface. These transduced cells were found to have selective and potent cytotoxicity to the HIV-infected cells. This approach combines the specificity of antibodies, extreme potency of toxins, and effector-cell properties of T-cells to generate a new class of potent antigen-specific killer cells, which may have broad applications for the treatment of viral infection and other diseases. This study demonstrates the principle that mammalian cells can be genetically modified to produce targeted toxins, indicating that in vivo production of targeted toxins can be achieved to locally or systematically destroy targeted cells.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,CTR COMPREHENS CANC,DEPT CANC BIOL,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest Baptist Medical Center								ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BERKE G, 1994, ANNU REV IMMUNOL, V12, P735, DOI 10.1146/annurev.immunol.12.1.735; CHAUDHARY VK, 1988, NATURE, V335, P369, DOI 10.1038/335369a0; Chen JD, 1996, HUM GENE THER, V7, P1515, DOI 10.1089/hum.1996.7.13-1515; CHEN SY, 1995, GENE THER, V2, P116; CHEN SY, 1994, P NATL ACAD SCI USA, V91, P5932, DOI 10.1073/pnas.91.13.5932; CHEN SY, 1991, J VIROL, V65, P5902, DOI 10.1128/JVI.65.11.5902-5909.1991; COLLIER RJ, 1971, J BIOL CHEM, V246, P1496; CULVER K, 1991, P NATL ACAD SCI USA, V88, P3155, DOI 10.1073/pnas.88.8.3155; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; EMBRETSON J, 1993, NATURE, V362, P355; ESHHAR Z, 1993, P NATL ACAD SCI USA, V90, P720, DOI 10.1073/pnas.90.2.720; GOVERMAN J, 1990, CELL, V60, P929, DOI 10.1016/0092-8674(90)90341-B; GRAY GL, 1984, P NATL ACAD SCI-BIOL, V81, P2645, DOI 10.1073/pnas.81.9.2645; GROSS G, 1989, P NATL ACAD SCI USA, V86, P10024, DOI 10.1073/pnas.86.24.10024; LIFSON JD, 1986, NATURE, V323, P725, DOI 10.1038/323725a0; MANIATIS T, 1986, MOL CLONING; MARASCO WA, 1993, P NATL ACAD SCI USA, V90, P7889, DOI 10.1073/pnas.90.16.7889; MILLER AD, 1986, SOMAT CELL MOLEC GEN, V12, P175, DOI 10.1007/BF01560664; MILLER AD, 1992, CURR TOP MICROBIOL, V158, P1; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PASTAN I, 1991, SCIENCE, V254, P1173, DOI 10.1126/science.1683495; PEREZ P, 1985, NATURE, V316, P354, DOI 10.1038/316354a0; POLESZ BJ, 1980, P NATL ACAD SCI USA, V77, P7415; ROSENBERG SA, 1991, CANCER RES, V51, pS5074; SIEGALL CB, 1989, J BIOL CHEM, V264, P14256; SODROSKI J, 1986, NATURE, V322, P470, DOI 10.1038/322470a0; STITES DP, 1994, IMMUNOLOGY, P40; THALI M, 1991, J VIROL, V65, P6188, DOI 10.1128/JVI.65.11.6188-6193.1991; VITETTA ES, 1987, SCIENCE, V238, P1098, DOI 10.1126/science.3317828; WALDMANN TA, 1991, SCIENCE, V252, P1657, DOI 10.1126/science.2047874; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; YAMAIZUMI M, 1978, CELL, V15, P245, DOI 10.1016/0092-8674(78)90099-5; YOUNG JD, 1988, IMMUNOL TODAY, V9, P140	34	16	24	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1997	15	1					46	51		10.1038/nbt0197-46	http://dx.doi.org/10.1038/nbt0197-46			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WA729	9035105				2022-12-27	WOS:A1997WA72900022
J	Ossenkoppele, R; Binette, AP; Groot, C; Smith, R; Strandberg, O; Palmqvist, S; Stomrud, E; Tideman, P; Ohlsson, T; Jogi, J; Johnson, K; Sperling, R; Dore, V; Masters, CL; Rowe, C; Visser, D; van Berckel, BNM; van der Flier, WM; Baker, S; Jagust, WJ; Wiste, HJ; Petersen, RC; Jack, CR; Hansson, O				Ossenkoppele, Rik; Binette, Alexa Pichet; Groot, Colin; Smith, Ruben; Strandberg, Olof; Palmqvist, Sebastian; Stomrud, Erik; Tideman, Pontus; Ohlsson, Tomas; Jogi, Jonas; Johnson, Keith; Sperling, Reisa; Dore, Vincent; Masters, Colin L.; Rowe, Christopher; Visser, Denise; van Berckel, Bart N. M.; van der Flier, Wiesje M.; Baker, Suzanne; Jagust, William J.; Wiste, Heather J.; Petersen, Ronald C.; Jack, Clifford R., Jr.; Hansson, Oskar			Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline	NATURE MEDICINE			English	Article; Early Access							ALZHEIMERS-DISEASE; IMPAIRMENT; RECOMMENDATIONS; ASSOCIATIONS; BIOMARKERS; DIAGNOSIS; MEMORY; BETA	A major unanswered question in the dementia field is whether cognitively unimpaired individuals who harbor both Alzheimer's disease neuropathological hallmarks (that is, amyloid-beta plaques and tau neurofibrillary tangles) can preserve their cognition over time or are destined to decline. In this large multicenter amyloid and tau positron emission tomography (PET) study (n = 1,325), we examined the risk for future progression to mild cognitive impairment and the rate of cognitive decline over time among cognitively unimpaired individuals who were amyloid PET-positive (A(+)) and tau PET-positive (T+) in the medial temporal lobe (A(+)T(MTL)(+)) and/or in the temporal neocortex (A(+)T(NEO-T)(+)) and compared them with A(+)T(-) and A(-)T(-) groups. Cox proportional-hazards models showed a substantially increased risk for progression to mild cognitive impairment in the A(+)T(NEO-T)(+) (hazard ratio (HR) = 19.2, 95% confidence interval (CI) = 10.9-33.7), A(+)T(MTL)(+) (HR = 14.6, 95% CI = 8.1-26.4) and A(+)T(-) (HR = 2.4, 95% CI = 1.4-4.3) groups versus the A(-)T(-) (reference) group. Both A(+)T(MTL)(+) (HR = 6.0, 95% CI = 3.4-10.6) and A(+)T(NEO-T)(+) (HR = 7.9, 95% CI = 4.7-13.5) groups also showed faster clinical progression to mild cognitive impairment than the A(+)T(-) group. Linear mixed-effect models indicated that the A(+)T(NEO-T)(+) (beta = -0.056 +/- 0.005, T = -11.55, P < 0.001), A(+)T(MTL)(+) (beta = -0.024 +/- 0.005, T = -4.72, P < 0.001) and A(+)T(-) (beta = -0.008 +/- 0.002, T = -3.46, P < 0.001) groups showed significantly faster longitudinal global cognitive decline compared to the A(-)T(-) (reference) group (all P < 0.001). Both A(+)T(NEO-T)(+) (P < 0.001) and A(+)T(MTL)(+) (P = 0.002) groups also progressed faster than the A(+)T(-) group. In summary, evidence of advanced Alzheimer's disease pathological changes provided by a combination of abnormal amyloid and tau PET examinations is strongly associated with short-term (that is, 3-5 years) cognitive decline in cognitively unimpaired individuals and is therefore of high clinical relevance. Abnormal amyloid and tau PET in cognitively unimpaired individuals is strongly associated with short-term cognitive decline and subsequent development of dementia.	[Ossenkoppele, Rik; Binette, Alexa Pichet; Groot, Colin; Smith, Ruben; Strandberg, Olof; Palmqvist, Sebastian; Stomrud, Erik; Tideman, Pontus; Hansson, Oskar] Lund Univ, Clin Memory Res Unit, Lund, Sweden; [Ossenkoppele, Rik; Groot, Colin; van der Flier, Wiesje M.] Vrije Univ Amsterdam, Alzheimer Ctr Amsterdam, Amsterdam UMC Locat VUmc, Neurol, Amsterdam, Netherlands; [Ossenkoppele, Rik; Groot, Colin; Visser, Denise; van Berckel, Bart N. M.; van der Flier, Wiesje M.] Amsterdam Neurosci, Neurodegenerat, Amsterdam, Netherlands; [Palmqvist, Sebastian; Stomrud, Erik; Tideman, Pontus; Hansson, Oskar] Skane Univ Hosp, Memory Clin, Malmo, Sweden; [Ohlsson, Tomas] Skane Univ Hosp, Dept Radiat Phys, Lund, Sweden; [Jogi, Jonas] Skane Univ Hosp, Dept Clin Physiol & Nucl Med, Lund, Sweden; [Johnson, Keith; Sperling, Reisa] Massachusetts Gen Hosp, Dept Neurol, Harvard Med Sch, Boston, MA 02114 USA; [Johnson, Keith; Sperling, Reisa] Brigham & Womens Hosp, Ctr Alzheimer Res & Treatment, Dept Neurol, Harvard Med Sch, 75 Francis St, Boston, MA 02115 USA; [Johnson, Keith; Sperling, Reisa] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Harvard Med Sch, Boston, MA 02114 USA; [Johnson, Keith] Massachusetts Gen Hosp, Dept Radiol, Harvard Med Sch, Boston, MA 02114 USA; [Dore, Vincent] Australian e Hlth Res Ctr CSIRO Melbourne Victori, Melbourne, Vic, Australia; [Dore, Vincent; Rowe, Christopher] Austin Hlth Melbourne Victoria Australia, Dept Mol Imaging & Therapy, Melbourne, Vic, Australia; [Masters, Colin L.; Rowe, Christopher] Florey Inst Neurosci & Mental Hlth Melbourne Vict, Parkville, Vic, Australia; [Visser, Denise; van Berckel, Bart N. M.] Vrije Univ Amsterdam, Dept Radiol & Nucl Med, Amsterdam UMC Locat VUmc, Amsterdam, Netherlands; [van der Flier, Wiesje M.] Vrije Univ Amsterdam, Dept Epidemiol & Biostat, Amsterdam UMC Locat VUmc, Amsterdam, Netherlands; [Baker, Suzanne; Jagust, William J.] Lawrence Berkeley Natl Lab, Berkeley, CA USA; [Jagust, William J.] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA USA; [Wiste, Heather J.] Mayo Clin, Dept Quantitat Hlth Sci, Rochester, MN USA; [Petersen, Ronald C.] Mayo Clin, Dept Neurol, Rochester, MN USA; [Jack, Clifford R., Jr.] Mayo Clin, Dept Radiol, Rochester, MN USA	Lund University; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Lund University; Skane University Hospital; Lund University; Skane University Hospital; Lund University; Skane University Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Mayo Clinic; Mayo Clinic; Mayo Clinic	Ossenkoppele, R; Hansson, O (corresponding author), Lund Univ, Clin Memory Res Unit, Lund, Sweden.; Ossenkoppele, R (corresponding author), Vrije Univ Amsterdam, Alzheimer Ctr Amsterdam, Amsterdam UMC Locat VUmc, Neurol, Amsterdam, Netherlands.; Ossenkoppele, R (corresponding author), Amsterdam Neurosci, Neurodegenerat, Amsterdam, Netherlands.; Hansson, O (corresponding author), Skane Univ Hosp, Memory Clin, Malmo, Sweden.	r.ossenkoppele@amsterdamumc.nl; oskar.hansson@med.lu.se	Dore, Vincent/A-7750-2011	Dore, Vincent/0000-0002-8051-0558; Smith, Ruben/0000-0001-7147-0112; Pichet Binette, Alexa/0000-0001-5218-3337; Jogi, Jonas/0000-0002-5299-3628	Lund University	Lund University	Open access funding provided by Lund University.	Barthelemy NR, 2020, NAT MED, V26, P398, DOI 10.1038/s41591-020-0781-z; Berron D, 2021, BRAIN, V144, P2771, DOI 10.1093/brain/awab114; Biel D, 2021, ALZHEIMERS RES THER, V13, DOI 10.1186/s13195-021-00880-x; Brookmeyer R, 2018, ALZHEIMERS DEMENT, V14, P981, DOI 10.1016/j.jalz.2018.03.005; Bucci M, 2021, MOL PSYCHIATR, V26, P5888, DOI 10.1038/s41380-021-01263-2; Chen SD, 2021, TRANSL PSYCHIAT, V11, DOI 10.1038/s41398-021-01602-5; Cho H, 2019, J NUCL MED, V60, P1611, DOI 10.2967/jnumed.118.221697; Dagley A, 2017, NEUROIMAGE, V144, P255, DOI 10.1016/j.neuroimage.2015.03.069; DEKOSKY ST, 1990, ANN NEUROL, V27, P457, DOI 10.1002/ana.410270502; Donohue MC, 2017, JAMA-J AM MED ASSOC, V317, P2305, DOI 10.1001/jama.2017.6669; Donohue MC, 2014, JAMA NEUROL, V71, P961, DOI 10.1001/jamaneurol.2014.803; Dubois B, 2021, LANCET NEUROL, V20, P484, DOI 10.1016/S1474-4422(21)00066-1; Dubois B, 2018, LANCET NEUROL, V17, P335, DOI 10.1016/S1474-4422(18)30029-2; Dumitrescu Logan, 2020, Brain, V143, P2561, DOI 10.1093/brain/awaa209; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fleisher AS, 2020, JAMA NEUROL, V77, P829, DOI 10.1001/jamaneurol.2020.0528; Fowler C, 2021, J ALZHEIMERS DIS REP, V5, P443, DOI 10.3233/ADR-210005; Gordon BA, 2019, BRAIN, V142, P1063, DOI 10.1093/brain/awz019; Hanseeuw BJ, 2019, JAMA NEUROL, V76, P915, DOI 10.1001/jamaneurol.2019.1424; Heneka MT, 2015, LANCET NEUROL, V14, P388, DOI 10.1016/S1474-4422(15)70016-5; Insel PS, 2019, NEUROLOGY, V93, pE322, DOI 10.1212/WNL.0000000000007831; Jack CR, 2022, BRAIN COMMUN, V4, DOI 10.1093/braincomms/fcac017; Jack CR, 2019, JAMA-J AM MED ASSOC, V321, P2316, DOI 10.1001/jama.2019.7437; Jack CR, 2016, NEUROLOGY, V87, P539, DOI 10.1212/WNL.0000000000002923; Jack CR, 2018, ALZHEIMERS DEMENT, V14, P535, DOI 10.1016/j.jalz.2018.02.018; Jack CR, 2017, ALZHEIMERS DEMENT, V13, P205, DOI 10.1016/j.jalz.2016.08.005; Janelidze S, 2020, NAT MED, V26, P379, DOI 10.1038/s41591-020-0755-1; Johnson KA, 2016, ANN NEUROL, V79, P110, DOI 10.1002/ana.24546; Junghans C, 2007, HEART, V93, P1024, DOI 10.1136/hrt.2007.120113; Karanth S, 2020, JAMA NEUROL, V77, P1299, DOI 10.1001/jamaneurol.2020.1741; Leuzy A, 2021, EUR J NUCL MED MOL I, V48, P2121, DOI 10.1007/s00259-021-05258-7; Leuzy A, 2022, JAMA NEUROL, V79, P149, DOI 10.1001/jamaneurol.2021.4654; Leuzy A, 2020, JAMA NEUROL, V77, P955, DOI 10.1001/jamaneurol.2020.0989; McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005; Mila-Aloma M, 2022, NAT MED, V28, P1797, DOI 10.1038/s41591-022-01925-w; Moloney CM, 2021, ALZHEIMERS DEMENT, V17, P1554, DOI 10.1002/alz.12321; Nelson PT, 2012, J NEUROPATH EXP NEUR, V71, P362, DOI 10.1097/NEN.0b013e31825018f7; Ossenkoppele R, 2022, LANCET NEUROL, V21, P726, DOI 10.1016/S1474-4422(22)00168-5; Ossenkoppele R, 2021, JAMA NEUROL, V78, P961, DOI 10.1001/jamaneurol.2021.1858; Ossenkoppele R, 2019, NEUROLOGY, V92, pE601, DOI 10.1212/WNL.0000000000006875; Ossenkoppele R, 2018, JAMA-J AM MED ASSOC, V320, P1151, DOI 10.1001/jama.2018.12917; Ossenkoppele R, 2016, BRAIN, V139, P1551, DOI 10.1093/brain/aww027; Ossenkoppele R, 2014, CEREB CORTEX, V24, P2210, DOI 10.1093/cercor/bht076; Palmqvist S, 2021, NAT MED, V27, P1034, DOI 10.1038/s41591-021-01348-z; Papp Kathryn V, 2017, Alzheimers Dement (N Y), V3, P668, DOI 10.1016/j.trci.2017.10.004; Pascoal TA, 2020, BRAIN, V143, P2818, DOI 10.1093/brain/awaa180; Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x; Petersen RC, 2018, NEUROLOGY, V90, P126, DOI 10.1212/WNL.0000000000004826; Pontecorvo MJ, 2019, BRAIN, V142, P1723, DOI 10.1093/brain/awz090; Pontecorvo MJ, 2017, BRAIN, V140, P748, DOI 10.1093/brain/aww334; Roberts RO, 2008, NEUROEPIDEMIOLOGY, V30, P58, DOI 10.1159/000115751; Scholl M, 2016, NEURON, V89, P971, DOI 10.1016/j.neuron.2016.01.028; Slot RER, 2018, ALZHEIMERS RES THER, V10, DOI 10.1186/s13195-018-0390-y; Sperling RA, 2019, ANN NEUROL, V85, P181, DOI 10.1002/ana.25395; Stern Y, 2020, ALZHEIMERS DEMENT, V16, P1305, DOI 10.1016/j.jalz.2018.07.219; Strikwerda-Brown C, 2022, JAMA NEUROL, V79, P975, DOI 10.1001/jamaneurol.2022.2379; Teng E, 2021, ALZHEIMERS RES THER, V13, DOI 10.1186/s13195-021-00937-x; Vemuri P, 2012, ANN NEUROL, V72, P730, DOI 10.1002/ana.23665; Wolters EE, 2021, EUR J NUCL MED MOL I, V48, P2097, DOI 10.1007/s00259-020-05118-w; Young CB, 2022, JAMA NEUROL, V79, P592, DOI 10.1001/jamaneurol.2022.0676	60	0	0	4	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02049-x	http://dx.doi.org/10.1038/s41591-022-02049-x		NOV 2022	23	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	6B8KC	36357681	Green Published, hybrid			2022-12-27	WOS:000881574700004
J	Ossenkoppele, R; Hansson, O; Hampel, H				Ossenkoppele, Rik; Hansson, Oskar; Hampel, Harald			Amyloid-beta and tau PET scans predict clinical progression in cognitively unimpaired people	NATURE MEDICINE			English	Editorial Material; Early Access									[Ossenkoppele, Rik; Hansson, Oskar] Lund Univ, Clin Memory Res Unit, Lund, Sweden; [Hampel, Harald] Eisai Inc, Nutley, NJ USA	Lund University; Eisai Co Ltd	Ossenkoppele, R (corresponding author), Lund Univ, Clin Memory Res Unit, Lund, Sweden.		Hansson, Oskar/A-7134-2013	Hansson, Oskar/0000-0001-8467-7286				BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Dubois B, 2021, LANCET NEUROL, V20, P484, DOI 10.1016/S1474-4422(21)00066-1; Jack CR, 2018, ALZHEIMERS DEMENT, V14, P535, DOI 10.1016/j.jalz.2018.02.018; Jansen WJ, 2015, JAMA-J AM MED ASSOC, V313, P1924, DOI 10.1001/jama.2015.4668; Ossenkoppele R, 2022, LANCET NEUROL, V21, P726, DOI 10.1016/S1474-4422(22)00168-5	5	0	0	1	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02071-z	http://dx.doi.org/10.1038/s41591-022-02071-z		NOV 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	6A2QM	36352264				2022-12-27	WOS:000880503600001
J	Moore, S; Hill, EM; Dyson, L; Tildesley, MJ; Keeling, MJ				Moore, Sam; Hill, Edward M.; Dyson, Louise; Tildesley, Michael J.; Keeling, Matt J.			Retrospectively modeling the effects of increased global vaccine sharing on the COVID-19 pandemic	NATURE MEDICINE			English	Article; Early Access							DYNAMICS	The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused considerable morbidity and mortality worldwide. The protection provided by vaccines and booster doses offered a method of mitigating severe clinical outcomes and mortality. However, by the end of 2021, the global distribution of vaccines was highly heterogeneous, with some countries gaining over 90% coverage in adults, whereas others reached less than 2%. In this study, we used an age-structured model of SARS-CoV-2 dynamics, matched to national data from 152 countries in 2021, to investigate the global impact of different potential vaccine sharing protocols that attempted to address this inequity. We quantified the effects of implemented vaccine rollout strategies on the spread of SARS-CoV-2, the subsequent global burden of disease and the emergence of novel variants. We found that greater vaccine sharing would have lowered the total global burden of disease, and any associated increases in infections in previously vaccine-rich countries could have been mitigated by reduced relaxation of non-pharmaceutical interventions. Our results reinforce the health message, pertinent to future pandemics, that vaccine distribution proportional to wealth, rather than to need, may be detrimental to all. Retrospective simulation of several global COVID-19 distribution scenarios shows that equitable and altruistic vaccine sharing strategies could have substantially reduced the global burden of SARS-CoV-2 infections and associated mortality.	[Moore, Sam] Univ Warwick, Sch Life Sci, Zeeman Inst Syst Biol & Infect Dis Epidemiol Res, Coventry, W Midlands, England; Univ Warwick, Math Inst, Coventry, W Midlands, England	University of Warwick; University of Warwick	Moore, S (corresponding author), Univ Warwick, Sch Life Sci, Zeeman Inst Syst Biol & Infect Dis Epidemiol Res, Coventry, W Midlands, England.	samuel.e.moore@warwick.ac.uk	Hill, Edward/J-4477-2019	Hill, Edward/0000-0002-2992-2004; Dyson, Louise/0000-0001-9788-4858; Moore, Sam/0000-0001-7786-5342	Vaccine Efficacy Evaluation for Priority Emerging Diseases (VEEPED) project through the National Institute for Health Research using Official Development Assistance (ODA) funding; UK Research and Innovation through the JUNIPER modeling consortium [MR/V038613/1]; Engineering and Physical Sciences Research Council through the MathSys CDT [EP/S022244/1]; Biotechnology and Biological Sciences Research Council [BB/S01750X/1]; National Institute for Health Research (NIHR) (Policy Research Programme, Mathematical & Economic Modelling for Vaccination and Immunisation Evaluation, and Emergency Response) [NIHR200411]	Vaccine Efficacy Evaluation for Priority Emerging Diseases (VEEPED) project through the National Institute for Health Research using Official Development Assistance (ODA) funding; UK Research and Innovation through the JUNIPER modeling consortium; Engineering and Physical Sciences Research Council through the MathSys CDT(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); National Institute for Health Research (NIHR) (Policy Research Programme, Mathematical & Economic Modelling for Vaccination and Immunisation Evaluation, and Emergency Response)	S.E.M., M.J.K. and M.J.T. were supported by the Vaccine Efficacy Evaluation for Priority Emerging Diseases (VEEPED) project through the National Institute for Health Research using Official Development Assistance (ODA) funding. L.D., M.J.T. and M.J.K. were supported by UK Research and Innovation through the JUNIPER modeling consortium (grant no. MR/V038613/1). L.D., M.J.T. and M.J.K. were supported by the Engineering and Physical Sciences Research Council through the MathSys CDT (grant no. EP/S022244/1). M.J.K., E.M.H. and M.J.T. were supported by the Biotechnology and Biological Sciences Research Council (grant no. BB/S01750X/1). M.J.K. and S.E.M. were supported by the National Institute for Health Research (NIHR) (Policy Research Programme, Mathematical & Economic Modelling for Vaccination and Immunisation Evaluation, and Emergency Response; NIHR200411). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. M.J.K. is affiliated with the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Gastrointestinal Infections at the University of Liverpool in partnership with the UK Health Security Agency (UKHSA), in collaboration with the University of Warwick. M.J.K. is also affiliated with the NIHR HPRU in Genomics and Enabling Data at the University of Warwick in partnership with the UKHSA. The views expressed are those of the author(s) and not necessarily those of the National Health Service, the NIHR, the Department of Health and Social Care or the UKHSA. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Abbott S., 2021, PREPRINT, DOI [10.1101/2021.11.30.21267056v1.full, DOI 10.1101/2021.11.30.21267056V1.FULL]; Abecassis A, 2021, LANCET, V398, P285, DOI 10.1016/S0140-6736(21)01371-4; [Anonymous], 2012, Wkly Epidemiol Rec, V87, P461; [Anonymous], 2021, GLOB POP DEM; Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI [10.1056/NEJMoa2001316, 10.1001/jama.2020.2565]; Boettke P, 2021, SOUTH ECON J, V87, P1090, DOI 10.1002/soej.12488; Bollyky TJ, 2020, FOREIGN AFF, V99, P96; Vardavas CI, 2021, medRxiv, DOI 10.1101/2021.11.11.21266216; Cowling BJ, 2020, LANCET PUBLIC HEALTH, V5, pE279, DOI 10.1016/S2468-2667(20)30090-6; Dagpunar J.S., 2021, MEDRXIV, DOI [10.1101/2021.06.03.21258293, DOI 10.1101/2021.06.03.21258293]; Machado MDV, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.747787; Demirguc-Kunt Asli, 2020, POLICY RES WORKING P; Dolgin E, 2021, NATURE, V597, P606, DOI 10.1038/d41586-021-02532-4; Doria-Rose N.A., 2021, MEDRXIV, DOI [10.1101/2021.12.15.21267805, DOI 10.1101/2021.12.15.21267805]; Dyson L, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25915-7; Eaton L, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n292; Eccleston-Turner M, 2021, MILBANK Q, V99, P426, DOI 10.1111/1468-0009.12503; Egger D, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abe0997; Emanuel EJ, 2020, SCIENCE, V369, P1309, DOI 10.1126/science.abe2803; GISAID, TRACK HCOV 19 VAR; Global Fund, 2021, IMP COVID 19 HIV TB; Google, GOOGL COVID 19 COMM; Hale T, 2021, NAT HUM BEHAV, V5, P529, DOI 10.1038/s41562-021-01079-8; Hart R, 2022, AFRICAN NATIONS SHOU; Hossain MB, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0260821; Institute for Health Metrics and Evaluation (IHME), COVID 19 MORT INF TE; Karlinsky A, 2021, ELIFE, V10, DOI 10.7554/eLife.69336; Katz IT, 2021, NEW ENGL J MED, V384, P1281, DOI 10.1056/NEJMp2103614; Khare S, 2021, CHINA CDC WEEKLY, V3, P1049, DOI 10.46234/ccdcw2021.255; Kraemer MUG, 2021, SCIENCE, V373, P889, DOI 10.1126/science.abj0113; Mahase E, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n2082; Marziano V., 2021, PREPRINT, DOI [10.1101/2021.03.19.21253893v3, DOI 10.1101/2021.03.19.21253893V3]; Mathieu E, 2021, NAT HUM BEHAV, V5, P947, DOI 10.1038/s41562-021-01122-8; McGill University Vaccine Tracker Team, COVID 19 VACC TRACK; Moore S, 2021, PLOS COMPUT BIOL, V17, DOI 10.1371/journal.pcbi.1008849; Moore S, 2021, LANCET INFECT DIS, V21, P793, DOI 10.1016/S1473-3099(21)00143-2; N. Andrews, 2021, medRxiv, DOI 10.1101/2021.09.15.21263583; Nicolay N, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.48.2101030; P. Basak, 2022, medRxiv, DOI 10.1101/2021.12.31.21268580; de Souza LEPF, 2021, CAD SAUDE PUBLICA, V37, DOI 10.1590/0102-311X00056521; Pouwels KB, 2021, NAT MED, V27, P2127, DOI 10.1038/s41591-021-01548-7; Prem K, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005697; Rotshild V, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-02321-z; Srivastav U., 2021, PREPRINT, DOI 10.24.21265455v1.full.pdf; Thompson RN, 2021, LANCET INFECT DIS, V21, P913, DOI 10.1016/S1473-3099(21)00202-4; Toor J, 2021, CLIN INFECT DIS, V72, P1463, DOI 10.1093/cid/ciaa933; UK Health Security Agency, COVID 19 VACC WEEKL; Wagner C. E., 2021, PREPRINT, DOI [10.1101/2021.06.02.21258229v1, DOI 10.1101/2021.06.02.21258229V1]; Wang YC, 2022, EMERG MICROBES INFEC, V11, P1, DOI 10.1080/22221751.2021.2017757; Watson OJ, 2022, LANCET INFECT DIS, V22, P1293, DOI 10.1016/S1473-3099(22)00320-6; WHO, 2021, EV ASS SIN BBIBP COV; Willett BJ., 2022, PREPRINT, DOI [10.1101/2022.01.03.21268111, DOI 10.1101/2022.01.03.21268111V1, DOI 10.1101/2022.01.03.21268111]; World Bank Group, 2017, WORLD DEV IND 2017; World Health Organization, WHO COR COVID 19 DAS	55	0	0	1	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02064-y	http://dx.doi.org/10.1038/s41591-022-02064-y		OCT 2022	19	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	5R4HU	36302894	Green Published, hybrid			2022-12-27	WOS:000874473900002
J	Murray, CJL				Murray, Christopher J. L.			The Global Burden of Disease Study at 30 years	NATURE MEDICINE			English	Article; Early Access							SYSTEMATIC ANALYSIS; MATERNAL MORTALITY; LIFE EXPECTANCY; NATIONAL LEVELS; 187 COUNTRIES; RISK-FACTORS; 21 REGIONS; DISABILITY; PROJECTIONS; INJURIES	This Perspective reflects on the past, present and future of the dynamic, expanding public health endeavor that is the Global Burden of Disease Study. The Global Burden of Disease Study (GBD) began 30 years ago with the goal of providing timely, valid and relevant assessments of critical health outcomes. Over this period, the GBD has become progressively more granular. The latest iteration provides assessments of thousands of outcomes for diseases, injuries and risk factors in more than 200 countries and territories and at the subnational level in more than 20 countries. The GBD is now produced by an active collaboration of over 8,000 scientists and analysts from more than 150 countries. With each GBD iteration, the data, data processing and methods used for data synthesis have evolved, with the goal of enhancing transparency and comparability of measurements and communicating various sources of uncertainty. The GBD has many limitations, but it remains a dynamic, iterative and rigorous attempt to provide meaningful health measurement to a wide range of stakeholders.	[Murray, Christopher J. L.] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA; [Murray, Christopher J. L.] Univ Washington, Sch Med, Dept Hlth Metr Sci, Seattle, WA 98195 USA	Institute for Health Metrics & Evaluation; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Murray, CJL (corresponding author), Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA.; Murray, CJL (corresponding author), Univ Washington, Sch Med, Dept Hlth Metr Sci, Seattle, WA 98195 USA.	cjlm@uw.edu			World Bank; G. H. Brundtland, Director-General of the WHO; Bill & Melinda Gates Foundation; US National Institutes of Health; UK Government; Wellcome Trust; New Zealand Government; Norwegian Institute of Public Health; Bloomberg Foundation	World Bank(The World Bank India); G. H. Brundtland, Director-General of the WHO; Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UK Government; Wellcome Trust(Wellcome Trust); New Zealand Government; Norwegian Institute of Public Health; Bloomberg Foundation	The growth of the GBD would not have been possible without many funders and supporters. The original GBD 1990 was primarily funded by the World Bank. The GBD based at the WHO from 1998 to 2003 was primarily possible because of the leadership and support of G. H. Brundtland, Director-General of the WHO. Since 2007, the GBD has been predominantly supported by the Bill & Melinda Gates Foundation. Other funders, such as the US National Institutes of Health, the UK Government, the Wellcome Trust, the New Zealand Government, the Norwegian Institute of Public Health and the Bloomberg Foundation, have also funded aspects or extensions of the GBD. The GBD collaboration would also like to thank R. Horton of The Lancet (whose vision and mission are closely aligned with our own) for a robust, critically constructive, enduring and enjoyable relationship.	Abbafati C, 2020, LANCET, V396, P1135, DOI 10.1016/S0140-6736(20)31404-5; Abubakar I, 2022, LANCET, V399, P1155, DOI 10.1016/S0140-6736(21)02488-0; Alkema L, 2016, LANCET, V387, P462, DOI 10.1016/S0140-6736(15)00838-7; Barber RM, 2022, LANCET, V399, P2351, DOI 10.1016/S0140-6736(22)00484-6; Bill & Melinda Gates Foundation, 2021, GOALK REP; Bollyky TJ, 2022, LANCET, V399, P1489, DOI 10.1016/S0140-6736(22)00172-6; Dandona L, 2017, LANCET, V390, P2437, DOI 10.1016/S0140-6736(17)32804-0; Dandona R, 2020, LANCET, V395, P1640, DOI 10.1016/S0140-6736(20)30471-2; Department of Health, 2019, NHS LONG TERM PLAN; Flaxman AD, 2015, INTEGRATIVE METAREGR; Foreman KJ, 2012, POPUL HEALTH METR, V10, DOI 10.1186/1478-7954-10-1; Friedman J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22457-w; GBD 2015 Maternal Mortality Collaborators, 2016, LANCET, V388, P1775, DOI [10.1016/S0140-6736(16)31470-2, DOI 10.1016/S0140-6736(16)31470-2]; IHME COVID-19 Forecasting Team, 2021, NAT MED, V27, P94, DOI [10.1038/s41591-020-1132-9, DOI 10.1038/S41591-020-1132-9]; Kassebaum NJ, 2014, LANCET, V384, P2209, DOI 10.1016/S0140-6736(14)62425-9; Lim SS, 2012, LANCET, V380, P2224, DOI 10.1016/S0140-6736(12)61766-8; Lozano R, 2020, LANCET, V396, P1250, DOI 10.1016/S0140-6736(20)30750-9; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Malta DC, 2020, POPUL HEALTH METR, V18, DOI 10.1186/s12963-020-00224-1; Misganaw A, 2022, LANCET, V399, P1322, DOI 10.1016/S0140-6736(21)02868-3; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P495; Murray CJL, 1997, LANCET, V349, P1347, DOI 10.1016/S0140-6736(96)07494-6; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Ogundele B., 2022, NATION NEWSPAPER; Page MJ, 2021, BMJ-BRIT MED J, V372, DOI [10.1136/bmj.n71, 10.1016/j.ijsu.2021.105906]; Pandey A., 2021, LANCET PLANET HEALTH, V5, pe25, DOI [10.1016/S2542-5196(20)30298-9, DOI 10.1016/S2542-5196(20)30298-9]; Salomon JA, 2012, LANCET, V380, P2129, DOI 10.1016/S0140-6736(12)61680-8; Salomon JA, 2012, LANCET, V380, P2144, DOI 10.1016/S0140-6736(12)61690-0; Stevens GA, 2016, PLOS MED, V13, DOI [10.1371/journal.pmed.1002116, 10.1371/journal.pmed.1002056]; UK Health Security Agency, 2015, GBD COMP NEW DAT TOO; UK Health Security Agency, 2017, HLTH PROF ENGL TELL; Vollset SE, 2020, LANCET, V396, P1285, DOI 10.1016/S0140-6736(20)30677-2; Vos T, 2020, LANCET, V396, P1562; Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2; Wang HD, 2022, LANCET, V399, P1513, DOI 10.1016/S0140-6736(21)02796-3; Wang HD, 2020, LANCET, V396, P1160, DOI 10.1016/S0140-6736(20)30977-6; Wang HD, 2012, LANCET, V380, P2071, DOI 10.1016/S0140-6736(12)61719-X; Whiteford H, 2016, HEALTH AFFAIR, V35, P1114, DOI 10.1377/hlthaff.2016.0082; *WORLD BANK, 1993, WORLD DEV REP 1993 I; World Health Organization, 2008, The global burden of disease: 2004 update; World Health Organization (WHO), 2020, WHO STEPWISE APPR NO; Zheng P., NAT MED; Zheng P, 2021, J COMPUT GRAPH STAT, V30, P544, DOI 10.1080/10618600.2020.1868303	46	0	0	5	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01990-1	http://dx.doi.org/10.1038/s41591-022-01990-1		OCT 2022	8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	5E6IE	36216939	hybrid			2022-12-27	WOS:000865725700009
J	Tong, TYN; Papier, K; Key, TJ				Tong, Tammy Y. N.; Papier, Keren; Key, Timothy J.			Meat, vegetables and health - interpreting the evidence	NATURE MEDICINE			English	Editorial Material; Early Access									[Tong, Tammy Y. N.; Papier, Keren; Key, Timothy J.] Univ Oxford, Nuffield Dept Populat Hlth, Canc Epidemiol Unit, Oxford, England	University of Oxford	Tong, TYN (corresponding author), Univ Oxford, Nuffield Dept Populat Hlth, Canc Epidemiol Unit, Oxford, England.	tammy.tong@ndph.ox.ac.uk			Nuffield Department of Population Health Fellowship; UK Medical Research Council [MR/M012190/1]; Wellcome Trust; Our Planet Our Health (Livestock, Environment, and People (LEAP)) [205212/Z/16/Z]; Cancer Research UK [C570/A16491, A29186]	Nuffield Department of Population Health Fellowship; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); Our Planet Our Health (Livestock, Environment, and People (LEAP)); Cancer Research UK(Cancer Research UK)	T.Y.N.T. is supported by the Nuffield Department of Population Health Fellowship and the UK Medical Research Council (MR/M012190/1). K.P. is supported by the Wellcome Trust, Our Planet Our Health (Livestock, Environment, and People (LEAP); grant no. 205212/Z/16/Z) and Cancer Research UK (C570/A16491 and A29186).	Clark MA, 2019, P NATL ACAD SCI USA, V116, P23357, DOI 10.1073/pnas.1906908116; Clarke R, 1997, BRIT MED J, V314, P112, DOI 10.1136/bmj.314.7074.112; Dong Y, 2022, NATURE AGING, V2, P508, DOI [10.1038/s43587-022-00205-z, DOI 10.1038/S43587-022-00205-Z, DOI 10.1038/D41591-022-00017-Z]; Ference BA, 2012, J AM COLL CARDIOL, V60, P2631, DOI 10.1016/j.jacc.2012.09.017; Ibsen DB, 2021, AM J CLIN NUTR, V113, P294, DOI 10.1093/ajcn/nqaa315; Public Health England, 2018, US; Stanaway JD, 2022, NAT MED, DOI 10.1038/s41591-022-01970-5; Takata Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056963; United Nations Food and Agricultural Organization (FAO), 2020, US; VanderWeele TJ, 2017, EPIDEMIOLOGY, V28, P399, DOI 10.1097/EDE.0000000000000641	10	0	0	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02006-8	http://dx.doi.org/10.1038/s41591-022-02006-8		OCT 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	5E6IE	36216937				2022-12-27	WOS:000865725700004
J	Pickersgill, SJ; Msemburi, WT; Cobb, L; Ide, N; Moran, AE; Su, YF; Xu, XP; Watkins, DA				Pickersgill, Sarah J.; Msemburi, William T.; Cobb, Laura; Ide, Nicole; Moran, Andrew E.; Su, Yanfang; Xu, Xinpeng; Watkins, David A.			Modeling global 80-80-80 blood pressure targets and cardiovascular outcomes	NATURE MEDICINE			English	Article; Early Access							CORONARY-HEART-DISEASE; WORLDWIDE TRENDS; 195 COUNTRIES; MORTALITY; RISK; TERRITORIES; PREVENTION; PROGRESS; BURDEN	As the leading cause of death worldwide, cardiovascular diseases (CVDs) present major challenges for health systems. In this study, we analyzed the effects of better population blood pressure control in the context of a proposed 80-80-80 target: 80% of individuals with hypertension are screened and aware of their diagnosis; 80% of those who are aware are prescribed treatment; and 80% of those on treatment have achieved guideline-specified blood pressure targets. We developed a population CVD model using country-level evidence on CVD rates, blood pressure levels and hypertension intervention coverage. Under realistic implementation conditions, most countries could achieve 80-80-80 targets by 2040, reducing all-cause mortality by 4-7% (76-130 million deaths averted over 2022-2050) and slowing the rise in CVD expected from population growth and aging (110-200 million cases averted). Although populous middle-income countries would account for most of the reduced CVD cases and deaths, low-income countries would experience the largest reductions in disease rates. A new modeling study demonstrates that most countries could achieve 80-80-80 hypertension targets by 2040, promoting increased global equality for cardiovascular diseases with the greatest mortality benefits being seen in low-income countries.	[Pickersgill, Sarah J.; Su, Yanfang; Watkins, David A.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA; [Msemburi, William T.] WHO, Div Data Analyt & Delivery Impact, Geneva, Switzerland; [Cobb, Laura; Ide, Nicole; Moran, Andrew E.] Resolve Save Lives, New York, NY USA; [Moran, Andrew E.] Columbia Univ, Irving Med Ctr, New York, NY USA; [Xu, Xinpeng] Nanjing Med Univ, Sch Publ Hlth, Nanjing, Peoples R China; [Watkins, David A.] Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; World Health Organization; Columbia University; NewYork-Presbyterian Hospital; Nanjing Medical University; University of Washington; University of Washington Seattle	Watkins, DA (corresponding author), Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.; Watkins, DA (corresponding author), Univ Washington, Dept Med, Div Gen Internal Med, Seattle, WA 98195 USA.	davidaw@uw.edu	Watkins, David/ABC-3783-2020	Watkins, David/0000-0001-6341-9595; Xu, Xinpeng/0000-0002-5829-9960	Bill & Melinda Gates Foundation [OPP1175906]; Resolve to Save Lives	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); Resolve to Save Lives	The authors would like to acknowledge several individuals for their contributions. N. Smith and Y. Li provided critical comments on an earlier version of this work. E. Chu, F. Jin, C. Mei, H. Xiong, Z. (W.) Wang and J. Wu helped collect or clean data. This work was supported, in whole or in part, by the Bill & Melinda Gates Foundation (Grant Number OPP1175906). Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. Additional funding for this work was provided by a grant from Resolve to Save Lives (https://resolvetosavelives.org/) to D.A.W.	Al-Makki A, 2022, HYPERTENSION, V79, P293, DOI 10.1161/HYPERTENSIONAHA.121.18192; Arima H, 2006, J HYPERTENS, V24, P1201, DOI 10.1097/01.hjh.0000226212.34055.86; Balijepalli C, 2014, J HUM HYPERTENS, V28, P193, DOI 10.1038/jhh.2013.85; Bangalore S, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j4; Bennett JE, 2020, LANCET, V396, P918, DOI 10.1016/S0140-6736(20)31761-X; Bennett JE, 2018, LANCET, V392, P1072, DOI 10.1016/S0140-6736(18)31992-5; Bibbins-Domingo K, 2010, NEW ENGL J MED, V362, P590, DOI 10.1056/NEJMoa0907355; Biemba G, 2017, GLOB HEALTH-SCI PRAC, V5, P486, DOI 10.9745/GHSP-D-16-00275; Charlton KE, 2021, PREV MED REP, V23, DOI 10.1016/j.pmedr.2021.101469; Chen S, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4064; Cobb LK, 2020, J CLIN HYPERTENS, V22, P2156, DOI 10.1111/jch.14021; DHIS2, IND DAT REC TRACK; Diseases and Injuries Collaborators, 2020, LANCET, V396, P1204, DOI [10.1016/S0140-6736(20)30925-9, DOI 10.1016/S0140-6736(20)30925-9]; Ettehad D, 2016, LANCET, V387, P957, DOI 10.1016/S0140-6736(15)01225-8; Ezekowitz JA, 2009, EUR HEART J, V30, P469, DOI 10.1093/eurheartj/ehn543; Ezzati M, 2013, NEW ENGL J MED, V369, P954, DOI 10.1056/NEJMra1203528; Filippini T, 2021, CIRCULATION, V143, P1542, DOI 10.1161/CIRCULATIONAHA.120.050371; GARG R, 1995, JAMA-J AM MED ASSOC, V273, P1450, DOI 10.1001/jama.273.18.1450; Gaziano TA, 2010, CURR PROB CARDIOLOGY, V35, P72, DOI 10.1016/j.cpcardiol.2009.10.002; GBD 2017 Diet Collaborators, 2019, LANCET, V393, P1958, DOI [DOI 10.1016/S0140-6736(19)30041-8, 10.1016/S0140-6736(19)30041-8]; *GBD 2019 RISK FAC, 2019, LANCET, V0396; Gimbel S, 2020, IMPLEMENT SCI, V15, DOI 10.1186/s13012-020-0973-4; Hammitt JK, 2020, RISK ANAL, V40, P674, DOI 10.1111/risa.13427; He FJ, 2014, J HUM HYPERTENS, V28, P345, DOI 10.1038/jhh.2013.105; He FJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1325; Hyseni L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177535; Jeemon P, 2017, CARDIOVASCULAR RESP, V3rd, P22; Kishore SP, 2018, LANCET, V392, P819, DOI 10.1016/S0140-6736(18)31814-2; Kontis V, 2019, CIRCULATION, V140, P715, DOI 10.1161/CIRCULATIONAHA.118.038160; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; Lloyd-Sherlock P, 2019, LANCET GLOB HEALTH, V7, pE604, DOI 10.1016/S2214-109X(19)30069-5; Lutz W, 2008, NATURE, V451, P716, DOI 10.1038/nature06516; Marsh K, 2019, AIDS, V33, pS213, DOI 10.1097/QAD.0000000000002355; Martinez R, 2020, LANCET GLOB HEALTH, V8, pE511, DOI 10.1016/S2214-109X(20)30035-8; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Mendis S, 2007, J HYPERTENS, V25, P1578, DOI 10.1097/HJH.0b013e3282861fd3; Mills KT, 2020, NAT REV NEPHROL, V16, P223, DOI 10.1038/s41581-019-0244-2; Moran A, 2010, CIRC-CARDIOVASC QUAL, V3, P243, DOI 10.1161/CIRCOUTCOMES.109.910711; Nishtar S, 2018, LANCET, V392, P245, DOI 10.1016/S0140-6736(18)31258-3; Park HK, 2020, BMJ GLOB HEALTH, V5, DOI 10.1136/bmjgh-2019-002028; Prabhakaran D, 2018, LANCET, V391, P1224, DOI 10.1016/S0140-6736(17)32471-6; Roth GA, 2018, LANCET, V392, P1736, DOI [10.1016/S0140-6736(18)32203-7, 10.1016/s0140-6736(18)32203-7]; Roth GA, 2015, NEW ENGL J MED, V372, P1333, DOI 10.1056/NEJMoa1406656; Sankoh O, 2020, LANCET GLOB HEALTH, V8, pE33, DOI 10.1016/S2214-109X(19)30442-5; Stanaway JD, 2018, LANCET, V392, P1923, DOI 10.1016/s0140-6736(18)32225-6; Stringhini S, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3589-5; United Nations, WORLD POPULATION PRO; Vollset SE, 2020, LANCET, V396, P1285, DOI 10.1016/S0140-6736(20)30677-2; Watkins DA, 2022, LANCET, V399, P1266, DOI 10.1016/S0140-6736(21)02347-3; Watkins DA, 2018, LANCET, V392, P1434, DOI 10.1016/S0140-6736(18)32389-4; WHO, 2012, GUID SOD INT AD CHIL; WHO, 2021, GUID PHARM TREATM HY; World Bank, ANT THER COV PEOPL L; World Health Organization, 2020, IMPR HYP CONTR 3 MIL; World Health Organization, 2020, RAP ASS SERV DEL NCD; World Heart Federation, 2021, WORLD HEART FED ROAD, DOI [10.5334/gh.1066/, DOI 10.5334/GH.1066]; Yusuf S, 2020, LANCET, V395, P795, DOI 10.1016/S0140-6736(19)32008-2; Zhou B, 2017, LANCET, V389, P37, DOI 10.1016/S0140-6736(16)31919-5; Zhou B, 2021, LANCET, V398, P957, DOI 10.1016/S0140-6736(21)01330-1; Zhou B, 2021, NAT REV CARDIOL, V18, P785, DOI 10.1038/s41569-021-00559-8; Zuccala E, 2020, LANCET, V396, P939, DOI 10.1016/S0140-6736(20)31910-3	61	2	2	6	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01890-4	http://dx.doi.org/10.1038/s41591-022-01890-4		JUL 2022	15	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2Z8JL	35851877	Green Published, hybrid			2022-12-27	WOS:000826816900001
J	Kephart, JL				Kephart, Josiah L.			Rise in ambient temperature is associated with increased mortality in Latin America	NATURE MEDICINE			English	Editorial Material; Early Access							HEAT		[Kephart, Josiah L.] Drexel Univ, Philadelphia, PA 19104 USA	Drexel University	Kephart, JL (corresponding author), Drexel Univ, Philadelphia, PA 19104 USA.							Green H, 2019, ENVIRON RES, V171, P80, DOI 10.1016/j.envres.2019.01.010; Jay O, 2021, LANCET, V398, P709, DOI 10.1016/S0140-6736(21)01209-5; Tuholske C, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2024792118; Zhao Q, 2021, LANCET PLANET HEALTH, V5, pE415, DOI 10.1016/S2542-5196(21)00081-4	4	0	0	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01893-1	http://dx.doi.org/10.1038/s41591-022-01893-1		JUN 2022	1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2L4UE	35760860				2022-12-27	WOS:000817012300002
J	Strauss, KA; Farrar, MA; Muntoni, F; Saito, K; Mendell, JR; Servais, L; McMillan, HJ; Finkel, RS; Swoboda, KJ; Kwon, JM; Zaidman, CM; Chiriboga, CA; Iannaccone, ST; Krueger, JM; Parsons, JA; Shieh, PB; Kavanagh, S; Wigderson, M; Tauscher-Wisniewski, S; McGill, BE; Macek, TA				Strauss, Kevin A.; Farrar, Michelle A.; Muntoni, Francesco; Saito, Kayoko; Mendell, Jerry R.; Servais, Laurent; McMillan, Hugh J.; Finkel, Richard S.; Swoboda, Kathryn J.; Kwon, Jennifer M.; Zaidman, Craig M.; Chiriboga, Claudia A.; Iannaccone, Susan T.; Krueger, Jena M.; Parsons, Julie A.; Shieh, Perry B.; Kavanagh, Sarah; Wigderson, Melissa; Tauscher-Wisniewski, Sitra; McGill, Bryan E.; Macek, Thomas A.			Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial	NATURE MEDICINE			English	Article							GENE-THERAPY; GENOMIC MEDICINE; NATURAL-HISTORY; COPY NUMBER; SINGLE-ARM; OPEN-LABEL; SMA; TYPE-2; MULTICENTER	Most children with biallelic SMN1 deletions and three SMN2 copies develop spinal muscular atrophy (SMA) type 2. SPR1NT (NCT03505099), a Phase III, multicenter, single-arm trial, investigated the efficacy and safety of onasemnogene abeparvovec for presymptomatic children with biallelic SMN1 mutations treated within six postnatal weeks. Of 15 children with three SMN2 copies treated before symptom onset, all stood independently before 24 months (P < 0.0001; 14 within normal developmental window), and 14 walked independently (P < 0.0001; 11 within normal developmental window). All survived without permanent ventilation at 14 months; ten (67%) maintained body weight (>= 3rd WHO percentile) without feeding support through 24 months; and none required nutritional or respiratory support. No serious adverse events were considered treatment-related by the investigator. Onasemnogene abeparvovec was effective and well-tolerated for presymptomatic infants at risk of SMA type 2, underscoring the urgency of early identification and intervention.	[Strauss, Kevin A.] Clin Special Children, Strasburg, PA 17579 USA; [Strauss, Kevin A.] Penn Med Lancaster Gen Hosp, Lancaster, PA 17602 USA; [Strauss, Kevin A.] Univ Massachusetts, Sch Med, Dept Pediat, Worcester, MA 01655 USA; [Strauss, Kevin A.] Univ Massachusetts, Sch Med, Dept Mol Cell & Canc Biol, Worcester, MA 01655 USA; [Farrar, Michelle A.] Sydney Childrens Hosp Network, Dept Neurol, Sydney, NSW, Australia; [Farrar, Michelle A.] UNSW Sydney, Sch Clin Med, UNSW Med & Hlth, Sydney, NSW, Australia; [Muntoni, Francesco] UCL, Dubowitz Neuromuscular Ctr, Great Ormond St Inst Child Hlth, London, England; [Muntoni, Francesco] UCL, Dubowitz Neuromuscular Ctr, Great Ormond St Hosp, London, England; [Muntoni, Francesco] Great Ormond St Hosp Biomed Res Ctr, Natl Inst Hlth Res, London, England; [Saito, Kayoko] Tokyo Womens Med Univ, Inst Med Genet, Tokyo, Japan; [Mendell, Jerry R.] Nationwide Childrens Hosp, Ctr Gene Therapy, Columbus, OH USA; [Mendell, Jerry R.] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Mendell, Jerry R.] Ohio State Univ, Dept Neurol, Columbus, OH 43210 USA; [Servais, Laurent] MDUK Oxford Neuromuscular Ctr, Dept Paediat, Oxford, England; [Servais, Laurent] CHU, Dept Pediat, Neuromuscular Reference Ctr, Liege, Belgium; [Servais, Laurent] Univ Liege, Liege, Belgium; [McMillan, Hugh J.] McGill Univ, Dept Pediat Neurol & Neurosurg, Montreal, PQ, Canada; [Finkel, Richard S.] Nemours Childrens Hosp, Dept Pediat, Orlando, FL USA; [Finkel, Richard S.] St Jude Childrens Res Hosp, Ctr Expt Neurotherapeut, 332 N Lauderdale St, Memphis, TN 38105 USA; [Swoboda, Kathryn J.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Kwon, Jennifer M.] Univ Wisconsin, Dept Neurol, Sch Med & Publ Hlth, Madison, WI 53706 USA; [Zaidman, Craig M.] Washington Univ, Sch Med, St Louis, MO USA; [Chiriboga, Claudia A.] Columbia Univ Med Ctr, Div Pediat Neurol, New York, NY USA; [Iannaccone, Susan T.] Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Dallas, TX USA; [Krueger, Jena M.] Helen DeVos Childrens Hosp, Dept Neurol, Grand Rapids, MI USA; [Parsons, Julie A.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA; [Shieh, Perry B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; [Kavanagh, Sarah; Wigderson, Melissa; Tauscher-Wisniewski, Sitra; Macek, Thomas A.] Novartis Gene Therapies Inc, Bannockburn, IL USA; [McGill, Bryan E.] Novartis Inst BioMed Res, Translat Med, Cambridge, MA USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of New South Wales Sydney; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; Tokyo Women's Medical University; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Liege; University of Liege; McGill University; St Jude Children's Research Hospital; Harvard University; Massachusetts General Hospital; University of Wisconsin System; University of Wisconsin Madison; Washington University (WUSTL); Columbia University; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Colorado System; University of Colorado Anschutz Medical Campus; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Novartis	Strauss, KA (corresponding author), Clin Special Children, Strasburg, PA 17579 USA.; Strauss, KA (corresponding author), Penn Med Lancaster Gen Hosp, Lancaster, PA 17602 USA.; Strauss, KA (corresponding author), Univ Massachusetts, Sch Med, Dept Pediat, Worcester, MA 01655 USA.; Strauss, KA (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Cell & Canc Biol, Worcester, MA 01655 USA.	kstrauss@clinicforspecialchildren.org	McMillan, Hugh/AAA-1989-2021	McMillan, Hugh/0000-0001-8927-2018; Saito, Kayoko/0000-0003-2632-0873; Finkel, Richard/0000-0002-9351-7054; Servais, Laurent/0000-0001-9270-4061; Farrar, Michelle/0000-0002-4472-0902; Swoboda, Kathryn/0000-0002-4593-6342	Novartis Gene Therapies, Inc.; Luminesce Alliance; New South Wales Government	Novartis Gene Therapies, Inc.; Luminesce Alliance; New South Wales Government	The authors wish to thank the investigators, site coordinators, and study teams, administrators of newborn screening programs and, most importantly, the patients, families, and caregivers for their participation in these studies. The authors also thank M. Milton of Novartis Institutes for Biomedical Research, who provided critical review and input on content related to biodistribution, immune response and safety; S. P. Reyna of Novartis Gene Therapies, Inc., who provided critical review and input on SMA patient care; and M. Wolf of Novartis Gene Therapies, Inc., who provided functional outcome measure expertise and contributions to study conduct and oversight. Medical writing assistance and editorial support was provided by J. Gibson from Kay Square Scientific and M. Nissen of Novartis Gene Therapies, Inc. This support was funded by Novartis Gene Therapies, Inc. The NSW Pilot NBS study was funded by Luminesce Alliance, a not-for-profit cooperative joint venture across the Sydney Children's Hospital Network, Children's Medical Research Institute, and Children's Cancer Institute, established with the support of the New South Wales Government. Luminesce Alliance is also affiliated with UNSW Sydney and The University of Sydney. The SPR1NT study was designed and funded by Novartis Gene Therapies, Inc., which was involved in the study design, data collection, data analysis, data interpretation, and writing of all related reports and publications.	Ali HG, 2021, GENE THER, V28, P676, DOI 10.1038/s41434-021-00273-7; Annoussamy M, 2021, ANN CLIN TRANSL NEUR, V8, P359, DOI 10.1002/acn3.51281; Bayley N, 1993, BAYLEY SCALES INFANT; Calucho M, 2018, NEUROMUSCULAR DISORD, V28, P208, DOI 10.1016/j.nmd.2018.01.003; Carson VJ, 2022, MUSCLE NERVE, V65, P51, DOI 10.1002/mus.27425; Chabanon A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201004; Chand DH, 2021, J PEDIATR-US, V231, P265, DOI 10.1016/j.jpeds.2020.11.054; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; Coovert DD, 1997, HUM MOL GENET, V6, P1205, DOI 10.1093/hmg/6.8.1205; Coratti G, 2021, ORPHANET J RARE DIS, V16, DOI 10.1186/s13023-021-02065-z; D'Amico A, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-71; D'Silva AM, 2022, ANN CLIN TRANSL NEUR, V9, P339, DOI 10.1002/acn3.51519; Day JW, 2021, DRUG SAFETY, V44, P1109, DOI 10.1007/s40264-021-01107-6; Day JW, 2021, LANCET NEUROL, V20, P284, DOI 10.1016/S1474-4422(21)00001-6; De Vivo DC, 2019, NEUROMUSCULAR DISORD, V29, P842, DOI 10.1016/j.nmd.2019.09.007; Farrar MA, 2013, J PEDIATR-US, V162, P155, DOI 10.1016/j.jpeds.2012.05.067; Finkel RS, 2021, NEUROLOGY, V96; Finkel RS, 2014, NEUROLOGY, V83, P810, DOI 10.1212/WNL.0000000000000741; Friese J, 2021, J NEUROMUSCULAR DIS, V8, P209, DOI 10.3233/JND-200593; Green ED, 2011, NATURE, V470, P204, DOI 10.1038/nature09764; Guttmacher AE, 2001, AM J MED GENET, V106, P216, DOI 10.1002/ajmg.10008; Hale K, 2021, INT J NEONAT SCREEN, V7, DOI 10.3390/ijns7030033; Hall WD, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000347; Jedrzejowska M, 2020, DEGENER NEUROL NEURO, V10, P39, DOI 10.2147/DNND.S246907; Kariyawasam DST, 2020, GENET MED, V22, P557, DOI 10.1038/s41436-019-0673-0; Kaufmann P, 2012, NEUROLOGY, V79, P1889, DOI 10.1212/WNL.0b013e318271f7e4; Lander ES, 2011, NATURE, V470, P187, DOI 10.1038/nature09792; Mailman MD, 2002, GENET MED, V4, P20, DOI 10.1097/00125817-200201000-00004; Martorell R, 2006, ACTA PAEDIATR, V95, P86, DOI 10.1080/08035320500495563; Mendell JR, 2017, NEW ENGL J MED, V377, P1713, DOI 10.1056/NEJMoa1706198; Mendell JR, 2021, JAMA NEUROL, V78, P834, DOI 10.1001/jamaneurol.2021.1272; Mendell JR, 2021, MOL THER, V29, P464, DOI 10.1016/j.ymthe.2020.12.007; Mercuri E, 2021, LANCET NEUROL, V20, P832, DOI 10.1016/S1474-4422(21)00251-9; Mercuri E, 2016, NEUROMUSCULAR DISORD, V26, P126, DOI 10.1016/j.nmd.2015.10.006; Muntoni F, 2020, NEUROMUSCULAR DISORD, V30, P959, DOI 10.1016/j.nmd.2020.10.008; Prior TW, 2009, AM J HUM GENET, V85, P408, DOI 10.1016/j.ajhg.2009.08.002; Ramdas S, 2020, EXPERT OPIN PHARMACO, V21, P307, DOI 10.1080/14656566.2019.1704732; Servais L., 2021, WORLD MUSCLE SOC 202; Servais L., 2022, BRIT PAEDIAT NEUROLO; Strauss K. A., NAT MED, DOI [10.1038/s41591-022-01866-4(2022), DOI 10.1038/S41591-022-01866-4(2022)]; Swoboda KJ, 2005, ANN NEUROL, V57, P704, DOI 10.1002/ana.20473; Trucco F, 2021, NEUROLOGY, V96, pE587, DOI 10.1212/WNL.0000000000011051; Waldrop MA, 2020, PEDIATRICS, V146, DOI 10.1542/peds.2020-0729; Weiss C, 2022, LANCET CHILD ADOLESC, V6, P17, DOI 10.1016/S2352-4642(21)00287-X	44	10	10	3	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2022	28	7					1390	+		10.1038/s41591-022-01867-3	http://dx.doi.org/10.1038/s41591-022-01867-3		JUN 2022	13	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3E5PS	35715567	hybrid, Green Published			2022-12-27	WOS:000812444600001
J	Italiano, A; Bessede, A; Pulido, M; Bompas, E; Piperno-Neumann, S; Chevreau, C; Penel, N; Bertucci, F; Toulmonde, M; Bellera, C; Guegan, JP; Rey, C; Sautes-Fridman, C; Bougouin, A; Cantarel, C; Kind, M; Spalato, M; Dadone-Montaudie, B; Le Loarer, F; Blay, JY; Fridman, WH				Italiano, A.; Bessede, A.; Pulido, M.; Bompas, E.; Piperno-Neumann, S.; Chevreau, C.; Penel, N.; Bertucci, F.; Toulmonde, M.; Bellera, C.; Guegan, J. P.; Rey, C.; Sautes-Fridman, C.; Bougouin, A.; Cantarel, C.; Kind, M.; Spalato, M.; Dadone-Montaudie, B.; Le Loarer, F.; Blay, J. Y.; Fridman, W. H.			Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort	NATURE MEDICINE			English	Article							B-CELLS; IMMUNITY	Immune checkpoint inhibitors (ICIs) show limited clinical activity in patients with advanced soft-tissue sarcomas (STSs). Retrospective analysis suggests that intratumoral tertiary lymphoid structures (TLSs) are associated with improved outcome in these patients. PEMBROSARC is a multicohort phase 2 study of pembrolizumab combined with low-dose cyclophosphamide in patients with advanced STS (NCT02406781). The primary endpoint was the 6-month non-progression rate (NPR). Secondary endpoints included objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and safety. The 6-month NPR and ORRs for cohorts in this trial enrolling all comers were previously reported; here, we report the results of a cohort enrolling patients selected based on the presence of TLSs (n = 30). The 6-month NPR was 40% (95% confidence interval (CI), 22.7-59.4), so the primary endpoint was met. The ORR was 30% (95% CI, 14.7-49.4). In comparison, the 6-month NPR and ORR were 4.9% (95% CI, 0.6-16.5) and 2.4% (95% CI, 0.1-12.9), respectively, in the all-comer cohorts. The most frequent toxicities were grade 1 or 2 fatigue, nausea, dysthyroidism, diarrhea and anemia. Exploratory analyses revealed that the abundance of intratumoral plasma cells (PCs) was significantly associated with improved outcome. These results suggest that TLS presence in advanced STS is a potential predictive biomarker to improve patients' selection for pembrolizumab treatment.	[Italiano, A.; Toulmonde, M.; Spalato, M.] Inst Bergonie, Dept Med Oncol, Bordeaux, France; [Italiano, A.] Gustave Roussy, DITEP, Villejuif, France; [Italiano, A.; Le Loarer, F.] Univ Bordeaux, Bordeaux, France; [Bessede, A.; Guegan, J. P.; Rey, C.] Explicyte, Bordeaux, France; [Pulido, M.; Bellera, C.; Cantarel, C.] Inst Bergonie, Unite Rech & Epidemiol Clin, Bordeaux, France; [Pulido, M.; Bellera, C.; Cantarel, C.] INSERM CIC, Bordeaux, France; [Bompas, E.] Inst Cancerol LOuest, Dept Med Oncol, Nantes, France; [Piperno-Neumann, S.] Inst Curie, Dept Med Oncol, Paris, France; [Chevreau, C.] Oncopole Toulouse, Dept Med Oncol, Toulouse, France; [Penel, N.] Ctr Oscar Lambret, Dept Med Oncol, Lille, France; [Bertucci, F.] Inst Paoli Calmettes, Dept Med Oncol, Marseille, France; [Sautes-Fridman, C.; Bougouin, A.; Fridman, W. H.] Sorbonne Univ, Univ Paris Cite, Ctr Rech Cordeliers, INSERM, Paris, France; [Sautes-Fridman, C.; Bougouin, A.; Fridman, W. H.] Equipe Labellisee Ligue Canc, Paris, France; [Kind, M.] Inst Bergonie, Dept Imaging, Bordeaux, France; [Dadone-Montaudie, B.] Univ Hosp Ctr Nice, Dept Pathol, Nice, France; [Le Loarer, F.] Inst Bergonie, Dept Pathol, Bordeaux, France; [Blay, J. Y.] Ctr Leon Berard, Dept Med Oncol, Lyon, France	UNICANCER; Institut Bergonie; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite de Bordeaux; UNICANCER; Institut Bergonie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UNICANCER; Centre Oscar Lambret; UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UNICANCER; Institut Bergonie; CHU Nice; UNICANCER; Institut Bergonie; UNICANCER; Centre Leon Berard	Italiano, A (corresponding author), Inst Bergonie, Dept Med Oncol, Bordeaux, France.; Italiano, A (corresponding author), Gustave Roussy, DITEP, Villejuif, France.; Italiano, A (corresponding author), Univ Bordeaux, Bordeaux, France.	a.italiano@bordeaux.unicancer.fr		Spalato Ceruso, Mariella/0000-0002-7582-3365	Institut Bergonie (Bordeaux, France); MSD; Association pour la Recherche contre le Cancer; Ligue contre le Cancer; INSERM; French National Cancer Institute; Agence Nationale de la Recherche (RHU CONDOR); Sorbonne Universite; Universite de Paris	Institut Bergonie (Bordeaux, France); MSD; Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); Ligue contre le Cancer(Ligue nationale contre le cancer); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); French National Cancer Institute(Institut National du Cancer (INCA) France); Agence Nationale de la Recherche (RHU CONDOR)(French National Research Agency (ANR)); Sorbonne Universite; Universite de Paris	This study was sponsored by Institut Bergonie (Bordeaux, France). Funding was provided by MSD, the French Ministry, the Association pour la Recherche contre le Cancer, the Ligue contre le Cancer, INSERM, Sorbonne Universite, Universite de Paris, the French National Cancer Institute and the Agence Nationale de la Recherche (RHU CONDOR).	Bin Seow DY, 2020, BREAST CANCER RES TR, V180, P369, DOI 10.1007/s10549-020-05548-y; Coley W B, 1891, Ann Surg, V14, P199, DOI 10.1097/00000658-189112000-00015; D'Angelo SP, 2015, HUM PATHOL, V46, P357, DOI 10.1016/j.humpath.2014.11.001; Danaher P, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-28020-5; de Chaisemartin L, 2011, CANCER RES, V71, P6391, DOI 10.1158/0008-5472.CAN-11-0952; Domblides C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.698604; Edris B, 2012, P NATL ACAD SCI USA, V109, P6656, DOI 10.1073/pnas.1121629109; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Germain C, 2014, AM J RESP CRIT CARE, V189, P832, DOI 10.1164/rccm.201309-1611OC; Huang HY, 2018, P NATL ACAD SCI USA, V115, pE6826, DOI 10.1073/pnas.1712628115; Italiano A, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00891-5; Joshi NS, 2015, IMMUNITY, V43, P579, DOI 10.1016/j.immuni.2015.08.006; Kalergis AM, 2002, J EXP MED, V195, P1653, DOI 10.1084/jem.20020338; Kroeger DR, 2016, CLIN CANCER RES, V22, P3005, DOI 10.1158/1078-0432.CCR-15-2762; Meylan M, 2022, IMMUNITY, V55, P527, DOI 10.1016/j.immuni.2022.02.001; Montfort A, 2017, CLIN CANCER RES, V23, P250, DOI 10.1158/1078-0432.CCR-16-0081; Petitprez F, 2020, NATURE, V577, P556, DOI 10.1038/s41586-019-1906-8; Sautes-Fridman C, 2019, NAT REV CANCER, V19, P307, DOI 10.1038/s41568-019-0144-6; SIMON R, 1989, CONTROL CLIN TRIALS, V10, P1, DOI 10.1016/0197-2456(89)90015-9; Tawbi HA, 2017, LANCET ONCOL, V18, P1493, DOI 10.1016/S1470-2045(17)30624-1; Toulmonde M, 2018, JAMA ONCOL, V4, P93, DOI 10.1001/jamaoncol.2017.1617; VANGLABBEKE M, 2002, EUR J CANCER, V38, P543, DOI DOI 10.1016/S0959-8049(01)00398-7; Weiner AB, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21245-w; Yao CY, 2021, ESOPHAGUS-TOKYO, V18, P574, DOI 10.1007/s10388-021-00828-y; Zollinger DR, 2020, METHODS MOL BIOL, V2148, P331, DOI 10.1007/978-1-0716-0623-0_21	26	12	12	3	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2022	28	6					1199	+		10.1038/s41591-022-01821-3	http://dx.doi.org/10.1038/s41591-022-01821-3		MAY 2022	22	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E9IE	35618839				2022-12-27	WOS:000805514000003
J	Berry, C; Mangion, K				Berry, Colin; Mangion, Kenneth			Multisystem involvement is common in post-COVID-19 syndrome	NATURE MEDICINE			English	Article								A prospective clinical study evaluating patients 28-60 days after hospitalization for COVID-19 reveals increased cardio-renal inflammation, reduced lung function and poorer self-reported clinical outcomes in patients relative to that in control participants.	[Berry, Colin] Univ Glasgow, British Heart Fdn Glasgow Cardiovasc Res Ctr, Glasgow, Lanark, Scotland; [Mangion, Kenneth] NHS Queen Elizabeth Univ Hosp, Glasgow, Lanark, Scotland	University of Glasgow; Queen Elizabeth University Hospital (QEUH)	Berry, C (corresponding author), Univ Glasgow, British Heart Fdn Glasgow Cardiovasc Res Ctr, Glasgow, Lanark, Scotland.							Al-Aly Z, 2021, NATURE, V594, P259, DOI 10.1038/s41586-021-03553-9; Blomberg B, 2021, NAT MED, V27, P1607, DOI 10.1038/s41591-021-01433-3; Mangion K, 2020, CARDIOVASC RES, V116, P2185, DOI 10.1093/cvr/cvaa209; National Institute for Health and Care Excellence, COVID 19 RAP GUID MA; Puntmann VO, 2020, JAMA CARDIOL, V5, P1265, DOI 10.1001/jamacardio.2020.3557	5	0	0	1	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2022	28	6					1139	1140		10.1038/s41591-022-01838-8	http://dx.doi.org/10.1038/s41591-022-01838-8		MAY 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E9IE	35606552	Green Published, hybrid			2022-12-27	WOS:000800978300001
J	Sanson, C				Sanson, C			Finding a new language for bioinformatics	NATURE BIOTECHNOLOGY			English	Article								Discussion at a recent conference emphasizes the importance of harmonizing standards throughout the bioinformatics community.											0	0	0	0	0	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1997	15	12					1253	+		10.1038/nbt1197-1253	http://dx.doi.org/10.1038/nbt1197-1253			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YQ046	9359106				2022-12-27	WOS:000071342000025
J	Chahine, KG				Chahine, KG			Patenting DNA: Just when you thought it was safe	NATURE BIOTECHNOLOGY			English	Editorial Material											Chahine, KG (corresponding author), MADSON & METCALF,170 S MAIN ST,SALT LAKE CITY,UT 84101, USA.							GLOVER DM, 1985, DNA CLONING PRACTICA, V1, P4978; 1987, Patent No. 4666829	2	1	1	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1997	15	6					586	587		10.1038/nbt0697-586	http://dx.doi.org/10.1038/nbt0697-586			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XC772	9181584				2022-12-27	WOS:A1997XC77200037
J	Okun, I; Veerapandian, P				Okun, I; Veerapandian, P			New methods to mimic nature in high-throughput screening	NATURE BIOTECHNOLOGY			English	Editorial Material											Okun, I (corresponding author), AXIOM BIOTECHNOL,3550 GEN ATOM COURT,SAN DIEGO,CA 92121, USA.		Okun, Ilya/F-9889-2014	Okun, Ilya/0000-0002-8562-4044					0	11	11	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1997	15	3					287	288		10.1038/nbt0397-287	http://dx.doi.org/10.1038/nbt0397-287			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WM050	9062931				2022-12-27	WOS:A1997WM05000036
J	Dang, QD; Guinto, ER; DiCera, E				Dang, QD; Guinto, ER; DiCera, E			Rational engineering of activity and specificity in a serine protease	NATURE BIOTECHNOLOGY			English	Article						blood coagulation; protein engineering; thrombin	SUBSTRATE-SPECIFICITY; BLOOD-COAGULATION; STRUCTURAL BASIS; THROMBIN; FIBRINOGEN; THROMBOMODULIN; ANTICOAGULANT; SUBSTITUTION; ACTIVATION; EVOLUTION	The discovery of the Na+-dependent allosteric regulation in serine proteases makes it possible to control catalytic activity and specificity in this class of enzymes in a way never considered before. We demonstrate that rational site-directed mutagenesis of residues controlling Na+ binding can profoundly alter the properties of a serine protease. By suppressing Na+ binding to thrombin, we shift the balance between procoagulant and anticoagulant activities of the enzyme. Those mutants, compared to wild-type, have reduced specificity toward fibrinogen, but enhanced or slightly reduced specificity toward protein C. Because this engineering strategy targets a fundamental regulatory mechanism, it is amenable of extension to other enzymes of biological and pharmacological importance.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOL BIOPHYS,ST LOUIS,MO 63110	Washington University (WUSTL)					NHLBI NIH HHS [HL49413] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049413, R29HL049413] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Berg DT, 1996, SCIENCE, V273, P1389, DOI 10.1126/science.273.5280.1389; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; CRAIK CS, 1985, SCIENCE, V228, P291, DOI 10.1126/science.3838593; Dang QD, 1996, P NATL ACAD SCI USA, V93, P10653, DOI 10.1073/pnas.93.20.10653; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DiCera E, 1996, BIOPHYS J, V70, P174, DOI 10.1016/S0006-3495(96)79558-9; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; DOOLITTLE RF, 1987, COLD SPRING HARB SYM, V52, P869, DOI 10.1101/SQB.1987.052.01.095; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; GIBBS CS, 1995, NATURE, V378, P413, DOI 10.1038/378413a0; GUINTO ER, 1995, P NATL ACAD SCI USA, V92, P11185, DOI 10.1073/pnas.92.24.11185; Guinto ER, 1996, BIOCHEMISTRY-US, V35, P8800, DOI 10.1021/bi9608828; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; JIN YS, 1990, CELL, V60, P873, DOI 10.1016/0092-8674(90)90100-S; KREM MM, UNPUB CONSERVED WATE; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; Lesk AM, 1996, J MOL BIOL, V258, P501, DOI 10.1006/jmbi.1996.0264; MANN KG, 1990, BLOOD, V76, P1; MARTIN PD, 1992, J BIOL CHEM, V267, P7911; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P13547, DOI 10.1021/bi00250a006; MIYATA T, 1992, BIOCHEMISTRY-US, V31, P7457, DOI 10.1021/bi00148a005; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; NG AS, 1993, METHOD ENZYMOL, V222, P341; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; Patthy L, 1990, Blood Coagul Fibrinolysis, V1, P153; PERONA JJ, 1995, PROTEIN SCI, V4, P337; RAWLINGS ND, 1993, BIOCHEM J, V290, P205, DOI 10.1042/bj2900205; REID KBM, 1986, IMMUNOL TODAY, V7, P230, DOI 10.1016/0167-5699(86)90110-6; SEEGERS WH, 1980, THROMB RES, V19, P11, DOI 10.1016/0049-3848(80)90399-0; SMITH CL, 1994, NATURE, V368, P548, DOI 10.1038/368548a0; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; Vindigni A, 1996, BIOCHEMISTRY-US, V35, P4417, DOI 10.1021/bi952834d; VINDIGNI A, UNPUB ENERGETICS THR; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; WU QY, 1991, P NATL ACAD SCI USA, V88, P6775, DOI 10.1073/pnas.88.15.6775; ZHANG E, 1997, IN PRESS BIOPHYS CHE	37	93	101	0	9	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1997	15	2					146	149		10.1038/nbt0297-146	http://dx.doi.org/10.1038/nbt0297-146			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WE998	9035139				2022-12-27	WOS:A1997WE99800020
J	Pagratis, NC; Bell, C; Chang, YF; Jennings, S; Fitzwater, T; Jellinek, D; Dang, C				Pagratis, NC; Bell, C; Chang, YF; Jennings, S; Fitzwater, T; Jellinek, D; Dang, C			Potent 2'-amino-, and 2'-fluoro-2'-deoxyribonucleotide RNA inhibitors of keratinocyte growth factor	NATURE BIOTECHNOLOGY			English	Article						SELEX; pseudoknot; KGF antagonists; in vitro evolution; nuclease resistant aptamers	IN-VITRO SELECTION; HIGH-AFFINITY; REVERSE-TRANSCRIPTASE; EPITHELIAL-CELLS; FACTOR RECEPTORS; BINDING-SITE; LIGANDS; VIVO; OLIGONUCLEOTIDES; PROLIFERATION	Reiterative in vitro selection-amplification from random oligonucleotide libraries allows the identification of molecules with specific functions such as binding to specific proteins. The therapeutic usefulness of such molecules depends on their high affinity and nuclease resistance. Libraries of RNA molecules containing 2' amino-(2'NH2)- or 2'fluoro-(2'F)-2'-deoxypyrimidines could yield ligands with similar nuclease resistance but not necessarily with similar affinities. This is because the intramolecular helices containing 2'NH2 have lower melting temperatures (Tm) compared with helices containing 2'F, giving them thermodynamically less stable structures and possibly weaker affinities. We tested these ideas by isolating high-affinity ligands to human keratinocyte growth factor from libraries containing modified RNA molecules with either 2'NH2 or 2'F pyrimidines. We demonstrated that 2'F RNA ligands have affinities (K-d approximately 0.3-3 pM) and bioactivities (K-i approximately 34 pM) superior to 2'NH2 ligands (K-d approximately 400 pM and K-i approximately 10 nM). In addition, 2'F ligands have extreme thermostabilities(Tm approximately 78 degrees C in low salt, and specificities).			Pagratis, NC (corresponding author), NEXSTAR PHARMACEUT INC, 2860 WILDERNESS PL, BOULDER, CO 80301 USA.							AURUP H, 1994, NUCLEIC ACIDS RES, V22, P20, DOI 10.1093/nar/22.1.20; BINKLEY J, 1995, NUCLEIC ACIDS RES, V23, P3198, DOI 10.1093/nar/23.16.3198; BOTTARO DP, 1993, J BIOL CHEM, V268, P9180; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; Brauchle M, 1996, AM J PATHOL, V149, P521; CAPUTO JL, 1979, IN VITRO CELL DEV B, V15, P222; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2601, DOI 10.1021/bi00280a002; CULIG Z, 1994, CANCER RES, V54, P5474; Du ZH, 1996, BIOCHEMISTRY-US, V35, P4187, DOI 10.1021/bi9527350; EATON BE, 1995, CHEM BIOL, V2, P633, DOI 10.1016/1074-5521(95)90023-3; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; Finch PW, 1996, GASTROENTEROLOGY, V110, P441, DOI 10.1053/gast.1996.v110.pm8566591; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; Fitzwater T, 1996, METHOD ENZYMOL, V267, P275; GILL SC, 1991, J MOL BIOL, V220, P307, DOI 10.1016/0022-2836(91)90015-X; GOLD L, 1995, J BIOL CHEM, V270, P13581, DOI 10.1074/jbc.270.23.13581; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; GREEN L, 1995, J MOL BIOL, V247, P60, DOI 10.1006/jmbi.1994.0122; HILBERS CW, 1976, BIOCHEMISTRY-US, V15, P1874, DOI 10.1021/bi00654a013; HOUSLEY RM, 1994, J CLIN INVEST, V94, P1764, DOI 10.1172/JCI117524; ISHII H, 1994, CANCER RES, V54, P518; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; JAEGER JA, 1990, METHOD ENZYMOL, V183, P281; JELLINEK D, 1993, P NATL ACAD SCI USA, V90, P11227, DOI 10.1073/pnas.90.23.11227; JELLINEK D, 1995, BIOCHEMISTRY-US, V34, P11363, DOI 10.1021/bi00036a009; KAIGHN ME, 1979, INVEST UROL, V17, P16; KATOH M, 1992, P NATL ACAD SCI USA, V89, P2960, DOI 10.1073/pnas.89.7.2960; KAWASAKI AM, 1993, J MED CHEM, V36, P831, DOI 10.1021/jm00059a007; Klussmann S, 1996, NAT BIOTECHNOL, V14, P1112, DOI 10.1038/nbt0996-1112; LESNIK EA, 1993, BIOCHEMISTRY-US, V32, P7832, DOI 10.1021/bi00081a031; LIN Y, 1994, NUCLEIC ACIDS RES, V22, P5229, DOI 10.1093/nar/22.24.5229; LORSCH JR, 1994, BIOCHEMISTRY-US, V33, P973, DOI 10.1021/bi00170a016; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MONIA BP, 1993, J BIOL CHEM, V268, P14514; Nolte A, 1996, NAT BIOTECHNOL, V14, P1116, DOI 10.1038/nbt0996-1116; PAN WH, 1995, P NATL ACAD SCI USA, V92, P11509, DOI 10.1073/pnas.92.25.11509; PIEKEN WA, 1991, SCIENCE, V253, P314, DOI 10.1126/science.1857967; Qiu HW, 1996, BIOCHEMISTRY-US, V35, P4176, DOI 10.1021/bi9527348; RINGQUIST S, 1995, BIOCHEMISTRY-US, V34, P3640, DOI 10.1021/bi00011a019; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; Sambrock J, 1989, MOL CLONING LAB MANU, V1; SHEN LX, 1995, J MOL BIOL, V247, P963, DOI 10.1006/jmbi.1995.0193; STAIANOCOICO L, 1993, J EXP MED, V178, P865, DOI 10.1084/jem.178.3.865; TENDAM E, 1992, BIOCHEMISTRY-US, V31, P11665, DOI 10.1021/bi00162a001; TUERK C, 1992, P NATL ACAD SCI USA, V89, P6988, DOI 10.1073/pnas.89.15.6988; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; ULICH TR, 1994, AM J PATHOL, V144, P862; ULICH TR, 1994, J CLIN INVEST, V93, P1298, DOI 10.1172/JCI117086; WEISSMAN BE, 1983, CELL, V32, P599, DOI 10.1016/0092-8674(83)90479-8; WOESE CR, 1993, RNA WORLD, P91; WYATT JR, 1993, RNA WORLD, P465; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123; YI ES, 1994, AM J PATHOL, V145, P80; YI ES, 1994, AM J PATHOL, V145, P1015; YI ES, 1995, J UROLOGY, V154, P1566, DOI 10.1016/S0022-5347(01)66930-1; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	57	164	211	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1997	15	1					68	73		10.1038/nbt0197-68	http://dx.doi.org/10.1038/nbt0197-68			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WA729	9035109				2022-12-27	WOS:A1997WA72900026
J	Tsao, R; Hurley, EA				Tsao, R; Hurley, EA			Beyond the letter of the law: The US Federal Circuit interprets 271(g)(1)	NATURE BIOTECHNOLOGY			English	Editorial Material											Tsao, R (corresponding author), FISH & RICHARDSON,225 FRANKLIN ST,BOSTON,MA 02110, USA.							TSUJI T, 1979, Patent No. 4160085	1	0	0	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1997	15	1					86	87		10.1038/nbt0197-86	http://dx.doi.org/10.1038/nbt0197-86			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WA729	9035112				2022-12-27	WOS:A1997WA72900029
J	Al-Aly, Z				Al-Aly, Ziyad			Long-term neurological sequelae of SARS-CoV-2 infection	NATURE MEDICINE			English	Editorial Material; Early Access								We show that patients who survive the first 30 days of acute SARS-CoV-2 infection have an increased risk of various post-acute neurological disorders after 1 year compared with uninfected contemporaries. The burden of these sequelae (aspects of 'long COVID') has serious implications for patients as well as society.	[Al-Aly, Ziyad] Vet Affairs St Louis Healthcare Syst, Res & Dev Serv, St Louis, MO 63106 USA		Al-Aly, Z (corresponding author), Vet Affairs St Louis Healthcare Syst, Res & Dev Serv, St Louis, MO 63106 USA.							Al-Aly Z, 2021, NATURE, V594, P259, DOI 10.1038/s41586-021-03553-9; Douaud G, 2022, NATURE, V604, P697, DOI [10.1038/s41586-022-04569-5, 10.1101/2021.06.11.21258690]; Fernandez-Castaneda A, 2022, CELL, V185, P2452, DOI 10.1016/j.cell.2022.06.008; Xie Y, 2022, LANCET DIABETES ENDO, V10, P311, DOI 10.1016/S2213-8587(22)00044-4; Xie Y, 2022, NAT MED, V28, P583, DOI 10.1038/s41591-022-01689-3	5	0	0	17	17	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02018-4	http://dx.doi.org/10.1038/s41591-022-02018-4		OCT 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	5D8VV	36192556	hybrid, Green Published			2022-12-27	WOS:000865214200002
J	Puntmann, V; Nagel, E				Puntmann, Valentina; Nagel, Eike			Lingering cardiac involvement in previously well people after mild COVID-19	NATURE MEDICINE			English	Editorial Material; Early Access							HEART-FAILURE; RISK	Serial heart MRI scans conducted in previously well people with mild initial COVID-19 illness suggest that lingering cardiac symptoms may be explained, at least in part, by ongoing mild cardiac inflammation.	[Puntmann, Valentina; Nagel, Eike] Univ Hosp Frankfurt, Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital	Puntmann, V (corresponding author), Univ Hosp Frankfurt, Frankfurt, Germany.							Chang JC, 2020, SEMIN ARTHRITIS RHEU, V50, P527, DOI 10.1016/j.semarthrit.2020.03.019; Gluckman TJ, 2022, J AM COLL CARDIOL, V79, P1717, DOI 10.1016/j.jacc.2022.02.003; Hsue PY, 2016, CIRC-CARDIOVASC IMAG, V9, DOI 10.1161/CIRCIMAGING.116.004427; Kim CH, 2017, HEART, V103, P227, DOI 10.1136/heartjnl-2016-309561; Nagel E., 2020, IMAGING, V13, P163	5	0	0	6	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02002-y	http://dx.doi.org/10.1038/s41591-022-02002-y		SEP 2022	1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4V9JQ	36163297	Green Published, hybrid			2022-12-27	WOS:000859786500003
J	Tcheandjieu, C; Assimes, TL				Tcheandjieu, Catherine; Assimes, Themistocles L.			Identification of genetic correlates of coronary artery disease in diverse ancestral populations	NATURE MEDICINE			English	Editorial Material; Early Access								The largest and most genetically diverse genome-wide association study thus far for coronary artery disease, a leading cause of death worldwide, identifies many new susceptibility loci and characterizes the genetic architecture in Black and Hispanic populations for the first time.	[Tcheandjieu, Catherine] Gladstone Inst, San Francisco, CA 94158 USA; [Assimes, Themistocles L.] Stanford Univ, Sch Med, Stanford, CA USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; Stanford University	Tcheandjieu, C (corresponding author), Gladstone Inst, San Francisco, CA 94158 USA.		Assimes, Themistocles Leonard/D-9696-2015	Assimes, Themistocles Leonard/0000-0003-2349-0009				Clarke SL, 2021, CIRC-GENOM PRECIS ME, V14, DOI 10.1161/CIRCGEN.121.003178; Graham SE, 2021, NATURE, V600, P675, DOI 10.1038/s41586-021-04064-3; Koyama S, 2020, NAT GENET, V52, P1169, DOI 10.1038/s41588-020-0705-3; Peden JF, 2011, NAT GENET, V43, P339, DOI 10.1038/ng.782; van der Harst P, 2018, CIRC RES, V122, P433, DOI [10.1161/CIRCRESAHA.117.312086, 10.1161/circresaha.117.312086]	5	0	0	5	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01915-y	http://dx.doi.org/10.1038/s41591-022-01915-y		AUG 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3Q8MV	35948628	Bronze, Green Published			2022-12-27	WOS:000838479400001
J	Taki, F; Lurie, J; Kaur, G				Taki, Faten; Lurie, Jacob; Kaur, Gunisha			An ethical plan for including forcibly displaced persons in omics and digital technology research	NATURE MEDICINE			English	Editorial Material							HEALTH; PREVALENCE; REFUGEES	Forcibly displaced persons, such as refugees, are at an increased risk of physical and mental health conditions and would therefore benefit from novel healthcare technologies, research on which can be conducted under an ethical framework.	[Taki, Faten; Kaur, Gunisha] Weill Cornell Med, Dept Anesthesiol, New York, NY 10021 USA; [Lurie, Jacob] NewYork Presbyterian Hosp, New York, NY USA	Cornell University; NewYork-Presbyterian Hospital	Taki, F (corresponding author), Weill Cornell Med, Dept Anesthesiol, New York, NY 10021 USA.	fzt2004@med.cornell.edu		Taki, Faten/0000-0003-1092-3821	National Institute Of Neurological Disorders and Stroke of the National Institutes of Health (NIH) [K23NS116114]	National Institute Of Neurological Disorders and Stroke of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Research was supported by the National Institute Of Neurological Disorders and Stroke of the National Institutes of Health (NIH) under award number K23NS116114. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.	Adida C., J EXP POLIT SCI, DOI [10.1017/XPS.2021.11(2021, DOI 10.1017/XPS.2021.11(2021]; [Anonymous], 2000, GLOBAL FORUM HLTH RE; Arsenijevic J, 2020, J MED INTERNET RES, V22, DOI 10.2196/11613; Binagwaho Agnes, 2021, Lancet Glob Health, V9, pe1169, DOI 10.1016/S2214-109X(21)00180-7; Chang CS, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0554-5; Culhane-Pera KA, 2017, J COMMUN GENET, V8, P117, DOI 10.1007/s12687-017-0292-x; Frey DP, 2019, ANESTH ANALG, V128, pE93, DOI 10.1213/ANE.0000000000003649; Gopalakrishnan V, 2018, CANCER CELL, V33, P570, DOI 10.1016/j.ccell.2018.03.015; Jager J, 2017, MONOGR SOC RES CHILD, V82, P13, DOI 10.1111/mono.12296; Jeong A, 2018, ENVIRON INT, V119, P334, DOI 10.1016/j.envint.2018.06.025; Jiang C, 2018, CELL, V175, P277, DOI 10.1016/j.cell.2018.08.060; Kim JY, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.5429; LUNDE I, 1990, LANCET, V336, P289, DOI 10.1016/0140-6736(90)91814-Q; Marvel FA, 2021, CIRC-CARDIOVASC QUAL, V14, DOI 10.1161/CIRCOUTCOMES.121.007741; Patel N, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009317.pub2; Riza E, 2020, HEALTHCARE-BASEL, V8, DOI 10.3390/healthcare8020115; Singh NS, 2021, LANCET, V397, P560, DOI 10.1016/S0140-6736(21)00024-6; Talhouk R, 2020, J MED INTERNET RES, V22, DOI 10.2196/14283; Taylor J. Y., 2017, NURS SCHOLAR, DOI [10.1111/jnu.12358, DOI 10.1111/JNU.12358]; Wang CJ, 2020, PEDIATR CLIN N AM, V67, P603, DOI 10.1016/j.pcl.2020.03.001; WHO, 2018, HLTH REF MIGR REG SI; Yegros-Yegros A, 2020, HEALTH RES POLICY SY, V18, DOI 10.1186/s12961-020-00560-6; Yu KH, 2018, NAT BIOMED ENG, V2, P719, DOI 10.1038/s41551-018-0305-z; Yun K, 2012, J IMMIGR MINOR HEALT, V14, P933, DOI 10.1007/s10903-012-9618-2	24	0	0	3	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2022	28	6					1116	1120		10.1038/s41591-022-01801-7	http://dx.doi.org/10.1038/s41591-022-01801-7		MAY 2022	5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E9IE	35513531	Bronze, Green Accepted			2022-12-27	WOS:000791071600001
J	Marshall, A				Marshall, A			Getting the right drug into the right patient	NATURE BIOTECHNOLOGY			English	Article								Pharmacogenomics will help explain why drugs work better in some patients than in others. These tools should be used as early in the drug development process as possible.										*DEP HLTH HUM SERV, 1997, GUID IND DRUG MET DR; Farlow MR, 1996, ANN NY ACAD SCI, V802, P101, DOI 10.1111/j.1749-6632.1996.tb32603.x; POIRER J, 1995, P NATL ACAD SCI USA, V92, P12280; Richard F, 1997, LANCET, V349, P539, DOI 10.1016/S0140-6736(97)80089-X	4	55	83	0	8	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1997	15	12					1249	1252		10.1038/nbt1197-1249	http://dx.doi.org/10.1038/nbt1197-1249			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YQ046	9359105				2022-12-27	WOS:000071342000024
J	Gerloni, M; Ballou, WR; Billetta, R; Zanetti, M				Gerloni, M; Ballou, WR; Billetta, R; Zanetti, M			Immunity to Plasmodium falciparum malaria sporozoites by somatic transgene immunization	NATURE BIOTECHNOLOGY			English	Article						vaccine design; DNA immunization; malaria	IMMUNODEFICIENCY-VIRUS TYPE-1; DIRECT GENE-TRANSFER; PLASMID DNA; CIRCUMSPOROZOITE PROTEIN; SKELETAL-MUSCLE; T-CELL; ANTIBODY; IMMUNOGLOBULIN; IMMUNOGENICITY; PROTECTION	Immunity against the human malaria parasite Plasmodium falciparum was induced using somatic transgene immunization, a method to effectively target B lymphocytes in vivo. A single inoculation of plasmid DNA containing an immunoglobulin heavy-chain gene coding in the complementarity-determining region 3 for three repeats of the sequence Asn-Ala-Asn-Pro (NANP), a B-cell epitope of Fl falciparum sporozoites, induced antibodies against NANP in all mice. A booster with an antibody antigenized with the NANP peptide, or challenge with P. falciparum sporozoites, demonstrated the establishment of immunologic memory, Immunity to a parasite antigen can be induced by exploiting mechanisms in which B lymphocytes are both the source of the immunogen as well as the effector mechanism of immunity. The results indicate that somatic transgene immunization is a potential approach for vaccination against foreign pathogens.	UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR CANC, LA JOLLA, CA 92093 USA; WALTER REED ARMY INST RES, DEPT IMMUNOL, ROCKVILLE, MD USA	University of California System; University of California San Diego; University of California System; University of California San Diego; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)			Gerloni, Mara/AAG-1526-2020		NIAID NIH HHS [AI36467] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI036467] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson R, 1996, INFECT IMMUN, V64, P3168, DOI 10.1128/IAI.64.8.3168-3173.1996; BALLOU WR, 1987, LANCET, V1, P1277; BILLETTA R, 1991, P NATL ACAD SCI USA, V88, P4713, DOI 10.1073/pnas.88.11.4713; BILLETTA R, 1992, IMMUNOMETHODS, V1, P41; CALLE JMC, 1992, J IMMUNOL, V149, P2695; CLYDE DF, 1973, AM J MED SCI, V266, P169, DOI 10.1097/00000441-197309000-00002; COX GJM, 1993, J VIROL, V67, P5664, DOI 10.1128/JVI.67.9.5664-5667.1993; DAVIS HL, 1993, HUM GENE THER, V4, P151, DOI 10.1089/hum.1993.4.2-151; DAVIS HL, 1994, VACCINE, V12, P1503, DOI 10.1016/0264-410X(94)90073-6; Dresser D W, 1968, Adv Immunol, V8, P129, DOI 10.1016/S0065-2776(08)60466-6; EDELMAN R, 1993, J INFECT DIS, V168, P1066, DOI 10.1093/infdis/168.4.1066; EGAN JE, 1993, AM J TROP MED HYG, V49, P166, DOI 10.4269/ajtmh.1993.49.166; ETLINGER HM, 1993, PHILOS T R SOC B, V340, P69, DOI 10.1098/rstb.1993.0049; GERIONI M, 1997, DNA CELL BIOL, V16, P611; GERTONI M, 1997, IN PRESS EUR J IMMUN; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GREEN TJ, 1984, INFECT IMMUN, V46, P668, DOI 10.1128/IAI.46.3.668-672.1984; HERRINGTON DA, 1987, NATURE, V328, P257, DOI 10.1038/328257a0; HOFFMAN SL, 1991, SCIENCE, V252, P520, DOI 10.1126/science.2020852; KEMP DJ, 1987, ANNU REV MICROBIOL, V41, P181, DOI 10.1146/annurev.mi.41.100187.001145; LANZA P, 1993, P NATL ACAD SCI USA, V90, P11683, DOI 10.1073/pnas.90.24.11683; MUNESINGHE DY, 1991, EUR J IMMUNOL, V21, P3015, DOI 10.1002/eji.1830211217; NARDIN EH, 1979, SCIENCE, V206, P597, DOI 10.1126/science.386511; RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519; RIGAUDY P, 1994, DNA CELL BIOL, V13, P585, DOI 10.1089/dna.1994.13.585; ROBINSON HL, 1993, VACCINE, V11, P957, DOI 10.1016/0264-410X(93)90385-B; SALK J, 1977, SCIENCE, V195, P834, DOI 10.1126/science.320661; SEDEGAH M, 1994, P NATL ACAD SCI USA, V91, P9866, DOI 10.1073/pnas.91.21.9866; SOLLAZZO M, 1990, PROTEIN ENG, V4, P215, DOI 10.1093/protein/4.2.215; SOLLAZZO M, 1989, EUR J IMMUNOL, V19, P453, DOI 10.1002/eji.1830190307; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; WANG B, 1993, P NATL ACAD SCI USA, V90, P4156, DOI 10.1073/pnas.90.9.4156; WIRTZ RA, 1987, EXP PARASITOL, V63, P166, DOI 10.1016/0014-4894(87)90158-5; XIANG ZQ, 1994, VIROLOGY, V199, P132, DOI 10.1006/viro.1994.1105; Xiong SD, 1997, NAT BIOTECHNOL, V15, P882, DOI 10.1038/nbt0997-882; Xiong SD, 1997, P NATL ACAD SCI USA, V94, P6352, DOI 10.1073/pnas.94.12.6352; ZAGHOUANI H, 1993, SCIENCE, V259, P224, DOI 10.1126/science.7678469; ZAGHOUANI H, 1995, P NATL ACAD SCI USA, V92, P631, DOI 10.1073/pnas.92.2.631; ZANETTI M, 1992, NATURE, V355, P476, DOI 10.1038/355476a0; ZANETTI M, 1987, IMMUNOL TODAY, V8, P18, DOI 10.1016/0167-5699(87)90827-9; ZAVALA F, 1985, SCIENCE, V228, P1436, DOI 10.1126/science.2409595	42	29	38	0	1	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1997	15	9					876	881		10.1038/nbt0997-876	http://dx.doi.org/10.1038/nbt0997-876			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XW410	9306403				2022-12-27	WOS:A1997XW41000030
J	Tyshenko, MG; Doucet, D; Davies, PL; Walker, VK				Tyshenko, MG; Doucet, D; Davies, PL; Walker, VK			The antifreeze potential of the spruce budworm thermal hysteresis protein	NATURE BIOTECHNOLOGY			English	Article						antifreeze; thermal hysteresis; cryoprotection; overwintering	WINTER FLOUNDER; CHORISTONEURA-FUMIFERANA; ICE; SEQUENCE; BINDING; POLYPEPTIDE; ADSORPTION; INHIBITION; AMERICANUS; MECHANISM	Antifreeze proteins (AFP) inhibit ice growth by surface adsorption that results in a depression of the freezing point below the melting point. The maximum level of this thermal hysteresis shown by the four structurally unrelated fish AFP is approximately 1.5 degrees C. In contrast, hemolymph and crude extracts from insects can have 5 degrees to 10 degrees C of thermal hysteresis. Based on the isolation, cloning, and expression of a thermal hysteresis protein (THP) from spruce budworm (Choristoneura fumiferana), the vastly greater activity is attributable to a 9 kDa protein. This novel, threonine-and cysteine-rich THP has striking effects on ice crystal morphology, both before and during freezing. It is also 10 to 30 times more active than any known fish AFP, offering the prospect of superior antifreeze properties in cryoprotective applications.	QUEENS UNIV,DEPT BIOL,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT BIOCHEM,KINGSTON,ON K7L 3N6,CANADA	Queens University - Canada; Queens University - Canada								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; CHAKRABARTTY A, 1991, EUR J BIOCHEM, V202, P1057, DOI 10.1111/j.1432-1033.1991.tb16470.x; CHAO H, 1995, FEBS LETT, V357, P183, DOI 10.1016/0014-5793(94)01357-7; CHAO H, 1994, PROTEIN SCI, V3, P1760, DOI 10.1002/pro.5560031016; DeLuca CI, 1996, BIOPHYS J, V71, P2346, DOI 10.1016/S0006-3495(96)79476-6; DUMAN J, 1983, ANNU REV PHYSIOL, V45, P261, DOI 10.1146/annurev.ph.45.030183.001401; DUMAN J, 1991, INSECTS LOW TEMPERAT; FOURNEY RM, 1984, CAN J ZOOL, V62, P28, DOI 10.1139/z84-006; GRAHAM LA, 1997, IN PRESS NATURE; HAN EN, 1993, CAN ENTOMOL, V125, P1043, DOI 10.4039/Ent1251043-6; HEW CL, 1983, CAN J ZOOL, V61, P2324, DOI 10.1139/z83-307; HEW CL, 1992, EUR J BIOCHEM, V203, P33, DOI 10.1111/j.1432-1033.1992.tb19824.x; JLA Z, 1996, NATURE, V384, P285; JORGENSEN H, 1993, PROTEIN ENG, V6, P19, DOI 10.1093/protein/6.1.19; KNIGHT CA, 1991, BIOPHYS J, V59, P409, DOI 10.1016/S0006-3495(91)82234-2; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LI XM, 1985, J BIOL CHEM, V260, P2904; NG NF, 1986, J BIOL CHEM, V261, P5690; RAMSAY JA, 1964, PHILOS T ROY SOC B, V248, P279, DOI 10.1098/rstb.1964.0013; RAYMOND JA, 1977, P NATL ACAD SCI USA, V74, P2589, DOI 10.1073/pnas.74.6.2589; Sanders C.J., 1991, TORTRICID PESTS THEI, P579; SICHERI F, 1995, NATURE, V375, P427, DOI 10.1038/375427a0; Sonnichsen FD, 1996, STRUCTURE, V4, P1325, DOI 10.1016/S0969-2126(96)00140-2; SONNICHSEN FD, 1995, PROTEIN SCI, V4, P460; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEN DY, 1992, BIOPHYS J, V63, P1659, DOI 10.1016/S0006-3495(92)81750-2; WISHART DS, 1994, COMPUT APPL BIOSCI, V10, P121; ZACHARIASSEN KE, 1985, PHYSIOL REV, V65, P779	28	137	157	1	40	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1997	15	9					887	890		10.1038/nbt0997-887	http://dx.doi.org/10.1038/nbt0997-887			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XW410	9306405				2022-12-27	WOS:A1997XW41000032
J	DaSilva, EJ				DaSilva, EJ			Biotechnology in the Islamic world	NATURE BIOTECHNOLOGY			English	Article											DaSilva, EJ (corresponding author), UN,EDUC SCI & CULTURAL ORG,LIFE SCI SECT,PARIS,FRANCE.								0	4	4	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					733	735		10.1038/nbt0897-733	http://dx.doi.org/10.1038/nbt0897-733			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255784				2022-12-27	WOS:A1997XM70700021
J	Lee, MH; Nicholson, P				Lee, MH; Nicholson, P			Isolation of genomic DNA from plant tissues	NATURE BIOTECHNOLOGY			English	Editorial Material									NUCLEON BIOSCI,COATBRIDGE ML5 5AD,LANARK,SCOTLAND		Lee, MH (corresponding author), VECTOR LABS INC,30 INGOLD RD,BURLINGAME,CA 94010, USA.								0	1	2	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					805	806		10.1038/nbt0897-805	http://dx.doi.org/10.1038/nbt0897-805			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255800				2022-12-27	WOS:A1997XM70700037
J	Chen, GH; Guan, ZB; Chen, CT; Fu, LT; Sundaresan, V; Arnold, FH				Chen, GH; Guan, ZB; Chen, CT; Fu, LT; Sundaresan, V; Arnold, FH			A glucose-sensing polymer	NATURE BIOTECHNOLOGY			English	Article						diabetes mellitus; biosensor; copper-triazacyclononane; molecular imprinting	DISCRIMINATION; COPPER(II); SENSOR	We have prepared a robust polymer that can be used to measure glucose concentrations in complex biological media. At alkaline pH, the metal-complexing polymer binds glucose and instantly releases protons in proportion to the glucose concentration over a clinically relevant range (0 to 25 mM). The inexpensive polymer is sufficiently selective to provide an easily measurable response to glucose in porcine plasma. The polymer's ability to function at nonphysiological pH (at which the buffer capacity of biological samples is small) makes it possible to design simple and inexpensive sensing devices based on measurement of changes in proton concentration.	CALTECH,DIV CHEM & CHEM ENGN 21041,PASADENA,CA 91125	California Institute of Technology				Arnold, Frances H./0000-0002-4027-364X				BURTIS AC, 1994, TIETZ TXB CLIN CHEM, P1412; DHAL PK, 1992, MACROMOLECULES, V25, P7051, DOI 10.1021/ma00051a050; *DIAB CONTR COMPL, 1993, NEW ENGL J MED, V329, P977, DOI DOI 10.1056/NEJM199309303291401; GOUGH DA, 1995, DIABETES, V44, P1005, DOI 10.2337/diab.44.9.1005; JAMES TD, 1995, NATURE, V374, P345, DOI 10.1038/374345a0; Martell A.E., 1992, DETERMINATION USE ST; MAYES AG, 1994, ANAL BIOCHEM, V222, P483, DOI 10.1006/abio.1994.1521; Meyerhoff C, 1996, ENDOCRINOLOGIST, V6, P51, DOI 10.1097/00019616-199601000-00008; PICKUP J, 1993, TRENDS BIOTECHNOL, V11, P285, DOI 10.1016/0167-7799(93)90016-3; POMGAILO AD, 1994, SYNTHESIS POLYM META, P134; WULFF G, 1991, J ORG CHEM, V56, P395, DOI 10.1021/jo00001a071; YANAGIHARA R, 1994, TETRAHEDRON LETT, V35, P9725, DOI 10.1016/0040-4039(94)88370-X; YANG R, 1976, INORG CHEM, V15, P1499, DOI 10.1021/ic50161a007	13	117	122	1	50	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1997	15	4					354	357		10.1038/nbt0497-354	http://dx.doi.org/10.1038/nbt0497-354			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WQ554	9094137				2022-12-27	WOS:A1997WQ55400036
J	Erb, RW; Eichner, CA; WagnerDobler, I; Timmis, KN				Erb, RW; Eichner, CA; WagnerDobler, I; Timmis, KN			Bioprotection of microbial communities from toxic phenol mixtures by a genetically designed pseudomonad	NATURE BIOTECHNOLOGY			English	Article						biodegradation; genetically engineered microorganism; bioprotection	AQUATIC SEDIMENT MICROCOSMS; ENGINEERED PSEUDOMONAD; MICROORGANISMS; 4-CHLOROCATECHOL; DEGRADATION; PATHWAY	Pseudomonas sp. B13 SN45RE is a genetically engineered microorganism (GEM) that is able to simultaneously degrade mixtures of chloro- and methylaromatics ordinarily toxic for microbial communities via a designed novel ortho-cleavage pathway. The utility of the GEM was investigated in a laboratory scale sewage plant fed with mixtures of either 4-chlorophenol and 4-methyphenol or 3-chlorophenol and 4-methylphenol. In the model system the GEM significantly increased the rate and extent of degradation of the phenol mixtures. In the absence of the GEM, shock loads of the phenol mixtures (1 mM of each compound) reduced the numbers of culturable bacteria by three orders of magnitude, completely eliminated protozoa and metazoa, and caused a drastic decrease in oxygen consumption, whereas the presence of the GEM protected the indigenous microbial community and assured continued functioning of the sewage plant.	GBF,NATL RES CTR BIOTECHNOL,DEPT MICROBIOL,BRAUNSCHWEIG,GERMANY	Helmholtz Association; Helmholtz-Center for Infection Research			Wagner-Döbler, Irene/Y-1685-2019	Wagner-Dobler, Irene/0000-0001-5883-2502				BARTELS I, 1984, APPL ENVIRON MICROB, V47, P500, DOI 10.1128/AEM.47.3.500-505.1984; BLASCO R, 1995, J BIOL CHEM, V270, P29229, DOI 10.1074/jbc.270.49.29229; BUCHHOLZ KD, 1993, ENVIRON SCI TECHNOL, V27, P2844, DOI 10.1021/es00049a026; DORN E, 1974, ARCH MICROBIOL, V99, P61, DOI 10.1007/BF00696222; GUDE H, 1979, MICROB ECOL, V5, P225, DOI 10.1007/BF02013529; HEUER H, 1995, MICROB ECOL, V29, P203, DOI 10.1007/BF00167165; KNACKMUSS HJ, 1978, ARCH MICROBIOL, V117, P1, DOI 10.1007/BF00689343; KRUMME ML, 1994, ENVIRON SCI TECHNOL, V28, P1134, DOI 10.1021/es00055a025; NUSSLEIN K, 1992, APPL ENVIRON MICROB, V58, P3380; PEELEN S, 1993, EUR J BIOCHEM, V218, P345, DOI 10.1111/j.1432-1033.1993.tb18383.x; PIEPER DH, 1995, APPL ENVIRON MICROB, V61, P2159, DOI 10.1128/AEM.61.6.2159-2165.1995; PIPKE R, 1992, APPL ENVIRON MICROB, V58, P1259, DOI 10.1128/AEM.58.4.1259-1265.1992; REINEKE W, 1982, J BACTERIOL, V150, P195, DOI 10.1128/JB.150.1.195-201.1982; REINEKE W, 1988, ANNU REV MICROBIOL, V42, P263, DOI 10.1146/annurev.mi.42.100188.001403; ROJO F, 1987, SCIENCE, V238, P1395, DOI 10.1126/science.3479842; Sambrook J., 2002, MOL CLONING LAB MANU; Smith MR, 1990, BIODEGRADATION, V1, P191, DOI 10.1007/BF00058836; TIMMIS KN, 1994, ANNU REV MICROBIOL, V48, P525, DOI 10.1146/annurev.mi.48.100194.002521; VANDERMEER JR, 1992, MICROBIOL REV, V56, P677, DOI 10.1128/MMBR.56.4.677-694.1992; WAGNERDOBLER I, 1992, APPL ENVIRON MICROB, V58, P1249; WIESER M, 1994, FEMS MICROBIOL LETT, V116, P73, DOI 10.1111/j.1574-6968.1994.tb06678.x	21	48	56	1	14	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1997	15	4					378	382		10.1038/nbt0497-378	http://dx.doi.org/10.1038/nbt0497-378			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WQ554	9094142				2022-12-27	WOS:A1997WQ55400041
J	Wang, YL; DeMayo, FJ; Tsai, SY; OMalley, BW				Wang, YL; DeMayo, FJ; Tsai, SY; OMalley, BW			Ligand-inducible and liver-specific target gene expression in transgenic mice	NATURE BIOTECHNOLOGY			English	Article						inducible gene system; gene expression; transgenic mice	CELLS; ELEMENTS; RU-486; MIFEPRISTONE; DROSOPHILA; ENHANCER; PROMOTER; SYSTEM	Transgenic mice have been used as models for tissue-specific gene regulation and to examine the molecular and cellular effects of altered expression of specific genes in disease processes such as tumorigenesis. Because of the deleterious effects of constitutive expression of transgenes, which frequently result in prenatal or postnatal death, only a limited number of disease models have been established in transgenic mice. We report an inducible binary transactivation system that permits the control of transgene expression in a tissue-specific and inducible fashion in mice. In this system, transcription of the target transgene is kept silent until turned on by the administration of an exogenous compound. We also demonstrate that expression level of the target gene can be induced three to four orders of magnitude and can be controlled by the administrated compound in a dose-dependent manner.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine			DeMayo, Francesco/C-6255-2019	DeMayo, Francesco/0000-0002-9480-7336				BAIM SB, 1991, P NATL ACAD SCI USA, V88, P5072, DOI 10.1073/pnas.88.12.5072; BIENZ M, 1986, CELL, V45, P753, DOI 10.1016/0092-8674(86)90789-0; BORGDEN RN, 1993, DRUGS, V45, P384; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAI H, 1995, NATURE, V376, P533, DOI 10.1038/376533a0; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; Felsenfeld G, 1996, P NATL ACAD SCI USA, V93, P9384, DOI 10.1073/pnas.93.18.9384; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GRUNBERG SM, 1991, J NEUROSURG, V74, P861, DOI 10.3171/jns.1991.74.6.0861; HEIKINHEIMO O, 1993, ANN MED, V25, P71, DOI 10.3109/07853899309147861; KAWAI S, 1987, J PHARMACOL EXP THER, V241, P401; MAYO KE, 1982, CELL, V29, P99, DOI 10.1016/0092-8674(82)90094-0; MURAD F, 1985, GOODMAN GILMANS PHAR, P1366; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; ORNITZ DM, 1991, P NATL ACAD SCI USA, V88, P698, DOI 10.1073/pnas.88.3.698; PALMITER RD, 1983, SCIENCE, V222, P809, DOI 10.1126/science.6356363; RENEKER LXW, 1995, DEVELOPMENT, V121, P1669; SHI YE, 1993, CONTRACEPTION, V48, P133, DOI 10.1016/0010-7824(93)90004-Q; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; SPITZ IM, 1993, NEW ENGL J MED, V329, P404; WANG YL, 1994, P NATL ACAD SCI USA, V91, P8180, DOI 10.1073/pnas.91.17.8180; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x; ZHAO K, 1995, CELL, V81, P879, DOI 10.1016/0092-8674(95)90008-X	24	184	222	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1997	15	3					239	243		10.1038/nbt0397-239	http://dx.doi.org/10.1038/nbt0397-239			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WM050	9062922				2022-12-27	WOS:A1997WM05000026
J	Fiscus, PW				Fiscus, PW			Investing in risk management	NATURE BIOTECHNOLOGY			English	Editorial Material											Fiscus, PW (corresponding author), CHUBB & SON INC,TECHNOL INSURANCE GRP,HLTH & LIFE SCI SEGMENT,15 MT VIEW RD,WARREN,NJ 07059, USA.								0	0	0	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1997	15	1					88	89		10.1038/nbt0197-88	http://dx.doi.org/10.1038/nbt0197-88			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WA729	9035113				2022-12-27	WOS:A1997WA72900030
J	Georgiou, G; Stathopoulos, C; Daugherty, PS; Nayak, AR; Iverson, BL; Curtiss, R				Georgiou, G; Stathopoulos, C; Daugherty, PS; Nayak, AR; Iverson, BL; Curtiss, R			Display of heterologous proteins on the surface of microorganisms: From the screening of combinatorial libraries to live recombinant vaccines	NATURE BIOTECHNOLOGY			English	Review						protein display; library screening; live bacterial vaccines	GRAM-NEGATIVE BACTERIA; RANDOM PEPTIDE LIBRARIES; MOUTH-DISEASE VIRUS; COLI CELL-SURFACE; ESCHERICHIA-COLI; OUTER-MEMBRANE; SALMONELLA-TYPHIMURIUM; IMMUNE-RESPONSES; ATTENUATED SALMONELLA; FOREIGN POLYPEPTIDES	In recent years there has been considerable progress towards the development of expression systems for the display of heterologous polypeptides and, to a lesser extent, oligosaccharides on the surface of bacteria or yeast. The availability of protein display vectors has in turn provided the impetus for a range of exciting technologies. Polypeptide libraries can be displayed in bacteria and screened by cell sorting techniques, thus simplifying the isolation of proteins with high affinity for ligands. Expression of antigens on the surface of nonvirulent microorganisms is an attractive approach to the development of high-efficacy recombinant live vaccines. Finally, cells displaying protein receptors or antibodies are of use for analytical applications and bioseparations.	WASHINGTON UNIV, DEPT BIOL, ST LOUIS, MO 63130 USA; UNIV TEXAS, DEPT CHEM & BIOCHEM, AUSTIN, TX 78712 USA	Washington University (WUSTL); University of Texas System; University of Texas Austin	Georgiou, G (corresponding author), UNIV TEXAS, DEPT CHEM ENGN, AUSTIN, TX 78712 USA.		Cheng, Yushao/E-6256-2011					ADEY NB, 1995, GENE, V156, P27, DOI 10.1016/0378-1119(95)00058-E; AGTERBERG M, 1990, VACCINE, V8, P438, DOI 10.1016/0264-410X(90)90242-E; AGTERBERG M, 1990, GENE, V88, P37, DOI 10.1016/0378-1119(90)90057-X; BODER ET, 1996, UNPUB SURFACE DISPLA; Bonnycastle LLC, 1996, J MOL BIOL, V258, P747, DOI 10.1006/jmbi.1996.0284; BROWN S, 1992, P NATL ACAD SCI USA, V89, P8651, DOI 10.1073/pnas.89.18.8651; BURTON DR, 1994, ADV IMMUNOL, V57, P191, DOI 10.1016/S0065-2776(08)60674-4; CARDENAS L, 1992, CLIN MICROBIOL REV, V5, P328; CHARBIT A, 1988, GENE, V70, P181, DOI 10.1016/0378-1119(88)90116-3; CHARBIT A, 1987, J IMMUNOL, V139, P1644; Chen G, 1996, BIOTECHNOL PROGR, V12, P572, DOI 10.1021/bp960041s; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; CIRILLO JD, 1995, CLIN INFECT DIS, V20, P1001, DOI 10.1093/clinids/20.4.1001; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; Cornelis P, 1996, BIO-TECHNOL, V14, P203, DOI 10.1038/nbt0296-203; Crameri A, 1996, NAT MED, V2, P100, DOI 10.1038/nm0196-100; Curtiss R, 1996, ESSENTIALS OF MUCOSAL IMMUNOLOGY, P499, DOI 10.1016/B978-012394330-9/50038-7; CURTISS R, 1990, TRENDS BIOTECHNOL, V8, P237, DOI 10.1016/0167-7799(90)90184-Y; CURTISS R, 1990, NEW GENERATION VACCI, P161; DAUGHERTY P, 1997, UNPUB ISOLATION HIGH; DUNNE M, 1995, INFECT IMMUN, V63, P1611, DOI 10.1128/IAI.63.4.1611-1614.1995; Fischetti VA, 1996, ASM NEWS, V62, P405; FORMAL SB, 1981, INFECT IMMUN, V34, P746, DOI 10.1128/IAI.34.3.746-750.1981; FORTAINE A, 1990, RES MICROBIOL, V141, P907; FRANCISCO JA, 1992, P NATL ACAD SCI USA, V89, P2713, DOI 10.1073/pnas.89.7.2713; FRANCISCO JA, 1993, P NATL ACAD SCI USA, V90, P10444, DOI 10.1073/pnas.90.22.10444; Freeman A, 1996, BIOTECHNOL BIOENG, V52, P625, DOI 10.1002/(SICI)1097-0290(19961205)52:5<625::AID-BIT10>3.3.CO;2-O; FUCHS P, 1991, BIO-TECHNOL, V9, P1369, DOI 10.1038/nbt1291-1369; Georgiou G, 1996, PROTEIN ENG, V9, P239, DOI 10.1093/protein/9.2.239; GEORGIOU G, 1993, TRENDS BIOTECHNOL, V11, P6, DOI 10.1016/0167-7799(93)90068-K; GODING JW, 1978, J IMMUNOL METHODS, V20, P241, DOI 10.1016/0022-1759(78)90259-4; GOLDBERG JB, 1992, P NATL ACAD SCI USA, V89, P10716, DOI 10.1073/pnas.89.22.10716; GRIFFITHS AD, 1993, EMBO J, V12, P725, DOI 10.1002/j.1460-2075.1993.tb05706.x; HANSSON M, 1992, J BACTERIOL, V174, P4239, DOI 10.1128/JB.174.13.4239-4245.1992; HARRISON JL, 1996, METHOD ENZYMOL, V267, P109; Hess J, 1996, P NATL ACAD SCI USA, V93, P1458, DOI 10.1073/pnas.93.4.1458; HILL RH, 1996, MOL MICROBIOL, V20, P685; HOFNUNG M, 1991, METHOD CELL BIOL, V34, P77; JahnSchmid B, 1996, J BIOTECHNOL, V44, P225, DOI 10.1016/0168-1656(95)00124-7; JANSSEN R, 1994, VACCINE, V12, P406, DOI 10.1016/0264-410X(94)90115-5; JOSE J, 1995, MOL MICROBIOL, V18, P378, DOI 10.1111/j.1365-2958.1995.mmi_18020378.x; KLAUSER T, 1990, EMBO J, V9, P1991, DOI 10.1002/j.1460-2075.1990.tb08327.x; KLAUSER T, 1993, BIOESSAYS, V15, P799, DOI 10.1002/bies.950151205; KNAPPIK A, 1995, PROTEIN ENG, V8, P81, DOI 10.1093/protein/8.1.81; KORNACKER MG, 1990, MOL MICROBIOL, V4, P1101, DOI 10.1111/j.1365-2958.1990.tb00684.x; LAUKKANEN ML, 1993, PROTEIN ENG, V6, P449, DOI 10.1093/protein/6.4.449; LEARY JF, 1995, SPIE, V2678, P240; LECLERC C, 1989, VACCINE, V7, P242, DOI 10.1016/0264-410X(89)90237-5; LITTLE M, 1993, TRENDS BIOTECHNOL, V11, P3, DOI 10.1016/0167-7799(93)90067-J; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; LU ZJ, 1995, BIO-TECHNOL, V13, P366, DOI 10.1038/nbt0495-366; Markland W, 1996, BIOCHEMISTRY-US, V35, P8045, DOI 10.1021/bi9526286; MATTHEWS DJ, 1993, SCIENCE, V260, P113; MEDAGLINI D, 1995, P NATL ACAD SCI USA, V92, P6868, DOI 10.1073/pnas.92.15.6868; MESSNER P, 1992, CARBOHYD RES, V233, P175, DOI 10.1016/S0008-6215(00)90929-7; NEWTON SMC, 1989, SCIENCE, V244, P70, DOI 10.1126/science.2468182; Newton SMC, 1996, J BACTERIOL, V178, P3447, DOI 10.1128/jb.178.12.3447-3456.1996; NEWTON SMC, 1995, RES MICROBIOL, V146, P203, DOI 10.1016/0923-2508(96)80276-2; OCALLAGHAN D, 1990, RES MICROBIOL, V141, P963, DOI 10.1016/0923-2508(90)90136-E; PALLESEN L, 1995, MICROBIOL-UK, V141, P2839, DOI 10.1099/13500872-141-11-2839; POZZI G, 1992, INFECT IMMUN, V60, P1902, DOI 10.1128/IAI.60.5.1902-1907.1992; PROVENCE DL, 1997, UNPUB ANAL EXTRACELL; RANTAMAKI LK, 1995, VET IMMUNOL IMMUNOP, V45, P115, DOI 10.1016/0165-2427(94)05329-Q; RenauldMongenie G, 1996, P NATL ACAD SCI USA, V93, P7944, DOI 10.1073/pnas.93.15.7944; ROBERTS M, 1994, NOVEL DELIVERY SYSTE, P27; RUPPERT A, 1994, VACCINE, V12, P492, DOI 10.1016/0264-410X(94)90305-0; RYD M, 1992, MICROB PATHOGENESIS, V12, P399, DOI 10.1016/0882-4010(92)90002-6; SALMOND GPC, 1993, TRENDS BIOCHEM SCI, V18, P7, DOI 10.1016/0968-0004(93)90080-7; SAMUELSON P, 1995, J BACTERIOL, V177, P1470, DOI 10.1128/jb.177.6.1470-1476.1995; SCHORR J, 1991, VACCINE, V9, P675, DOI 10.1016/0264-410X(91)90194-B; SCHREUDER MP, 1993, YEAST, V9, P399, DOI 10.1002/yea.320090410; Schreuder MP, 1996, VACCINE, V14, P383, DOI 10.1016/0264-410X(95)00206-G; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SHORT MK, 1995, J BIOL CHEM, V270, P28541, DOI 10.1074/jbc.270.48.28541; SHREUDER MP, 1996, TRENDS BIOTECHNOL, V14, P115; Sousa C, 1996, NAT BIOTECHNOL, V14, P1017, DOI 10.1038/nbt0896-1017; Stathopoulos C, 1996, APPL MICROBIOL BIOT, V45, P112, DOI 10.1007/s002530050657; STEIDLER L, 1993, J BACTERIOL, V175, P7639, DOI 10.1128/JB.175.23.7639-7643.1993; STEVENSON G, 1985, FEMS MICROBIOL LETT, V28, P317, DOI 10.1111/j.1574-6968.1985.tb00813.x; STGEME JW, 1994, MOL MICROBIOL, V14, P217, DOI 10.1111/j.1365-2958.1994.tb01283.x; SU GF, 1992, INFECT IMMUN, V60, P3345, DOI 10.1128/IAI.60.8.3345-3359.1992; Suzuki T, 1995, J BIOL CHEM, V270, P30874, DOI 10.1074/jbc.270.52.30874; Tang Y, 1996, J BIOL CHEM, V271, P15682, DOI 10.1074/jbc.271.26.15682; TAYLOR IM, 1990, MOL MICROBIOL, V4, P1259, DOI 10.1111/j.1365-2958.1990.tb00705.x; VANDEVERG L, 1990, INFECT IMMUN, V58, P2002, DOI 10.1128/IAI.58.6.2002-2004.1990; VANDIE I, 1990, MOL GEN GENET, V222, P297, DOI 10.1007/BF00633832; WANG CI, 1996, METHOD ENZYMOL, V267, P28; WHITEHORN EA, 1995, BIO-TECHNOL, V13, P1215, DOI 10.1038/nbt1195-1215; WONG RSY, 1995, GENE, V158, P55, DOI 10.1016/0378-1119(95)00155-Y; YANG WP, 1995, J MOL BIOL, V254, P392, DOI 10.1006/jmbi.1995.0626	90	417	552	3	81	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1997	15	1					29	34		10.1038/nbt0197-29	http://dx.doi.org/10.1038/nbt0197-29			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WA729	9035102	Bronze			2022-12-27	WOS:A1997WA72900019
J	Lee, SW; Sullenger, BA				Lee, SW; Sullenger, BA			Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies	NATURE BIOTECHNOLOGY			English	Article						in vitro selection; decoy RNA; acetylcholine receptor; autoantibody; myasthenia gravis	IMMUNODEFICIENCY-VIRUS TYPE-1; CELL-LINE TE671; MONOCLONAL-ANTIBODIES; GRAVIS; INHIBITION; MODULATION; SELECTION; IMMUNOGLOBULIN; EXPRESSION; EPITOPE	The muscular weakness and fatigability associated with myasthenia gravis are engendered by autoantibodies directed against acetylcholine receptors on muscle cells at neuromuscular junctions. The pathogenic consequences of this immune response can potentially be modulated by molecules that bind such autoantibodies and block their interaction with these receptors. We report the isolation of a small nuclease-resistant RNA molecule that binds both a rat monoclonal antibody that recognizes the main immunogenic region on the acetylcholine receptor, and autoantibodies from patients with myasthenia gravis. Moreover, this RNA can act as a decoy and protect acetylcholine receptors on human cells from the effects of these antibodies.	DUKE UNIV, MED CTR, DEPT EXPT SURG, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT GENET, DURHAM, NC 27710 USA	Duke University; Duke University				Lee, Seong-Wook/0000-0003-1718-7601				DOUDNA JA, 1995, P NATL ACAD SCI USA, V92, P2355, DOI 10.1073/pnas.92.6.2355; DRACHMAN DB, 1982, NEW ENGL J MED, V307, P769, DOI 10.1056/NEJM198209233071301; DRACHMAN DB, 1994, NEW ENGL J MED, V330, P1797, DOI 10.1056/NEJM199406233302507; FAMBROUGH DM, 1973, SCIENCE, V182, P293, DOI 10.1126/science.182.4109.293; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; Gold L., 1993, RNA WORLD, P497; HEINEMANN S, 1977, P NATL ACAD SCI USA, V74, P3090, DOI 10.1073/pnas.74.7.3090; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; JELLINEK D, 1995, BIOCHEMISTRY-US, V34, P11363, DOI 10.1021/bi00036a009; JOYCE GF, 1989, GENE, V82, P83, DOI 10.1016/0378-1119(89)90033-4; KAO I, 1977, SCIENCE, V196, P527, DOI 10.1126/science.850793; Lee SW, 1996, J EXP MED, V184, P315, DOI 10.1084/jem.184.2.315; LEE SW, 1995, GENE THER, V2, P377; LEE SW, 1994, J VIROL, V68, P8254, DOI 10.1128/JVI.68.12.8254-8264.1994; LENNON VA, 1991, J IMMUNOL, V146, P2245; LINDSTROM J, 1988, ADV IMMUNOL, V42, P233, DOI 10.1016/S0065-2776(08)60847-0; LISZIEWICZ J, 1991, NEW BIOL, V3, P82; LUTHER MA, 1989, J NEUROSCI, V9, P1082; MAMALAKI A, 1993, EUR J IMMUNOL, V23, P1839, DOI 10.1002/eji.1830230816; PATRICK J, 1973, SCIENCE, V180, P871, DOI 10.1126/science.180.4088.871; PIEKEN WA, 1991, SCIENCE, V253, P314, DOI 10.1126/science.1857967; SAEDI MS, 1990, FEBS LETT, V267, P55, DOI 10.1016/0014-5793(90)80286-R; SOPHIANOS D, 1989, J AUTOIMMUN, V2, P777, DOI 10.1016/0896-8411(89)90004-8; STANLEY EF, 1978, SCIENCE, V200, P1285, DOI 10.1126/science.663610; STRATTON MR, 1989, CARCINOGENESIS, V10, P899, DOI 10.1093/carcin/10.5.899; SULLENGER BA, 1991, J VIROL, V65, P6811, DOI 10.1128/JVI.65.12.6811-6816.1991; SULLENGER BA, 1990, CELL, V63, P601, DOI 10.1016/0092-8674(90)90455-N; SZOSTAK JW, 1992, TRENDS BIOCHEM SCI, V17, P89, DOI 10.1016/0968-0004(92)90242-2; TSAI DE, 1992, P NATL ACAD SCI USA, V89, P8864, DOI 10.1073/pnas.89.19.8864; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; TZARTOS SJ, 1982, P NATL ACAD SCI-BIOL, V79, P188, DOI 10.1073/pnas.79.1.188; TZARTOS SJ, 1981, J BIOL CHEM, V256, P8635; VINCENT A, 1987, ANN NY ACAD SCI, V505, P106, DOI DOI 10.1111/J.1749-6632.1987.TB51286.X.PUBMED:2446546; WILLCOX N, 1993, CURR OPIN IMMUNOL, V5, P910, DOI 10.1016/0952-7915(93)90105-2	34	85	94	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1997	15	1					41	45		10.1038/nbt0197-41	http://dx.doi.org/10.1038/nbt0197-41			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WA729	9035104				2022-12-27	WOS:A1997WA72900021
J	Lescinsky, H; Afshin, A; Ashbaugh, C; Bisignano, C; Brauer, M; Ferrara, G; Hay, SI; He, JW; Iannucci, V; Marczak, LB; McLaughlin, SA; Mullany, EC; Parent, MC; Serfes, AL; Sorensen, RJD; Aravkin, AY; Zheng, P; Murray, CJL				Lescinsky, Haley; Afshin, Ashkan; Ashbaugh, Charlie; Bisignano, Catherine; Brauer, Michael; Ferrara, Giannina; Hay, Simon, I; He, Jiawei; Iannucci, Vincent; Marczak, Laurie B.; McLaughlin, Susan A.; Mullany, Erin C.; Parent, Marie C.; Serfes, Audrey L.; Sorensen, Reed J. D.; Aravkin, Aleksandr Y.; Zheng, Peng; Murray, Christopher J. L.			Health effects associated with consumption of unprocessed red meat: a Burden of Proof study	NATURE MEDICINE			English	Article; Early Access							ISCHEMIC-HEART-DISEASE; BREAST-CANCER RISK; DOSE-RESPONSE METAANALYSIS; TYPE-2 DIABETES-MELLITUS; DIETARY-PROTEIN SOURCES; ALL-CAUSE MORTALITY; PROCESSED MEAT; COLORECTAL-CANCER; HEME IRON; POSTMENOPAUSAL BREAST	Using the burden of proof analytical tool, a meta-analysis found weak or no evidence of associations between unprocessed red meat consumption and increased risk of six cardiometabolic disease and cancer outcomes. Characterizing the potential health effects of exposure to risk factors such as red meat consumption is essential to inform health policy and practice. Previous meta-analyses evaluating the effects of red meat intake have generated mixed findings and do not formally assess evidence strength. Here, we conducted a systematic review and implemented a meta-regression-relaxing conventional log-linearity assumptions and incorporating between-study heterogeneity-to evaluate the relationships between unprocessed red meat consumption and six potential health outcomes. We found weak evidence of association between unprocessed red meat consumption and colorectal cancer, breast cancer, type 2 diabetes and ischemic heart disease. Moreover, we found no evidence of an association between unprocessed red meat and ischemic stroke or hemorrhagic stroke. We also found that while risk for the six outcomes in our analysis combined was minimized at 0 g unprocessed red meat intake per day, the 95% uncertainty interval that incorporated between-study heterogeneity was very wide: from 0-200 g d(-1). While there is some evidence that eating unprocessed red meat is associated with increased risk of disease incidence and mortality, it is weak and insufficient to make stronger or more conclusive recommendations. More rigorous, well-powered research is needed to better understand and quantify the relationship between consumption of unprocessed red meat and chronic disease.	[Lescinsky, Haley; Afshin, Ashkan; Ashbaugh, Charlie; Bisignano, Catherine; Brauer, Michael; Ferrara, Giannina; Hay, Simon, I; He, Jiawei; Iannucci, Vincent; Marczak, Laurie B.; McLaughlin, Susan A.; Mullany, Erin C.; Parent, Marie C.; Serfes, Audrey L.; Sorensen, Reed J. D.; Aravkin, Aleksandr Y.; Zheng, Peng; Murray, Christopher J. L.] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA; [Afshin, Ashkan; Brauer, Michael; Hay, Simon, I; He, Jiawei; Aravkin, Aleksandr Y.; Zheng, Peng; Murray, Christopher J. L.] Univ Washington, Sch Med, Dept Hlth Metr Sci, Seattle, WA 98195 USA; [Brauer, Michael] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada; [Aravkin, Aleksandr Y.] Univ Washington, Dept Appl Math, Seattle, WA 98195 USA	Institute for Health Metrics & Evaluation; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of British Columbia; University of Washington; University of Washington Seattle	Murray, CJL (corresponding author), Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA.; Murray, CJL (corresponding author), Univ Washington, Sch Med, Dept Hlth Metr Sci, Seattle, WA 98195 USA.	cjlm@uw.edu	Hay, Simon Iain/F-8967-2015	Hay, Simon Iain/0000-0002-0611-7272	Bill & Melinda Gates Foundation; Bloomberg Philanthropies; University of Melbourne; Queensland Department of Health, Australia; National Health and Medical Research Council, Australia; Public Health England; Norwegian Institute of Public Health; St Jude Children's Research Hospital; Cardiovascular Medical Research and Education Fund; National Institute on Ageing of the National Institutes of Health [P30AG047845]; National Institute of Mental Health of the National Institutes of Health [R01MH110163]	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); Bloomberg Philanthropies; University of Melbourne(University of Melbourne); Queensland Department of Health, Australia; National Health and Medical Research Council, Australia(National Health and Medical Research Council (NHMRC) of Australia); Public Health England; Norwegian Institute of Public Health; St Jude Children's Research Hospital; Cardiovascular Medical Research and Education Fund; National Institute on Ageing of the National Institutes of Health; National Institute of Mental Health of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	Research reported in this publication was supported by the Bill & Melinda Gates Foundation; Bloomberg Philanthropies; the University of Melbourne; Queensland Department of Health, Australia; the National Health and Medical Research Council, Australia; Public Health England; the Norwegian Institute of Public Health; St Jude Children's Research Hospital; the Cardiovascular Medical Research and Education Fund; the National Institute on Ageing of the National Institutes of Health (award P30AG047845); and the National Institute of Mental Health of the National Institutes of Health (award R01MH110163). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders. The funders of the study had no role in study design, data collection, data analysis, data interpretation, writing of the final report or the decision to publish.	Abbafati C, 2020, LANCET, V396, P1135, DOI 10.1016/S0140-6736(20)31404-5; Abete I, 2014, BRIT J NUTR, V112, P762, DOI 10.1017/S000711451400124X; Al-Shaar L, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4141; Alexander DD, 2011, EUR J CANCER PREV, V20, P293, DOI 10.1097/CEJ.0b013e328345f985; Anderson JJ, 2018, EUR J CANCER, V90, P73, DOI 10.1016/j.ejca.2017.11.022; Aravkin A, 2020, MATH OPER RES, V45, P292, DOI 10.1287/moor.2019.0992; de Medeiros GCBS, 2022, CRIT REV FOOD SCI, DOI 10.1080/10408398.2022.2058461; Bechthold A, 2019, CRIT REV FOOD SCI, V59, P1071, DOI 10.1080/10408398.2017.1392288; Bellavia A, 2016, AM J CLIN NUTR, V104, P1137, DOI 10.3945/ajcn.116.135335; Bernstein AM, 2012, STROKE, V43, P637, DOI 10.1161/STROKEAHA.111.633404; Bernstein AM, 2010, CIRCULATION, V122, P876, DOI 10.1161/CIRCULATIONAHA.109.915165; Biggerstaff BJ, 1997, STAT MED, V16, P753, DOI 10.1002/(SICI)1097-0258(19970415)16:7<753::AID-SIM494>3.0.CO;2-G; Chan DSM, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0020456, 10.1371/journal.pone.0027218]; Chen GC, 2013, EUR J CLIN NUTR, V67, P91, DOI 10.1038/ejcn.2012.180; Crippa A, 2019, STAT METHODS MED RES, V28, P1579, DOI 10.1177/0962280218773122; Crippa A, 2016, J STAT SOFTW, V72, DOI 10.18637/jss.v072.c01; Demeyer D, 2016, CRIT REV FOOD SCI, V56, P2747, DOI 10.1080/10408398.2013.873886; Diallo A, 2018, INT J CANCER, V142, P230, DOI 10.1002/ijc.31046; Efron B, 2004, ANN STAT, V32, P407, DOI 10.1214/009053604000000067; Egeberg R, 2013, J NUTR, V143, P464, DOI 10.3945/jn.112.168799; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; English DR, 2004, CANCER EPIDEM BIOMAR, V13, P1509; Ericson U, 2015, AM J CLIN NUTR, V101, P1065, DOI 10.3945/ajcn.114.103010; Etemadi A, 2017, BMJ-BRIT MED J, V357, DOI 10.1136/bmj.j1957; Farvid MS, 2021, EUR J EPIDEMIOL, V36, P937, DOI 10.1007/s10654-021-00741-9; Farvid MS, 2018, INT J CANCER, V143, P2787, DOI 10.1002/ijc.31848; Fraser GE, 1999, AM J CLIN NUTR, V70, p532S, DOI 10.1093/ajcn/70.3.532s; Fretts AM, 2012, AM J CLIN NUTR, V95, P752, DOI 10.3945/ajcn.111.029942; Genkinger JM, 2013, CANCER CAUSE CONTROL, V24, P675, DOI 10.1007/s10552-013-0146-8; Gilsing AMJ, 2016, EUR J CLIN NUTR, V70, P723, DOI 10.1038/ejcn.2016.25; Gilsing AMJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep13484; Guasch-Ferre M, 2019, CIRCULATION, V139, P1828, DOI 10.1161/CIRCULATIONAHA.118.035225; Haring B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109552; Higgins JP., 2019, COCHRANE HDB SYSTEMA, DOI DOI 10.1002/9781119536604; Inoue-Choi M, 2016, INT J CANCER, V138, P1609, DOI 10.1002/ijc.29901; International Agency for Research on Cancer World Health Organization, 2015, IARC MONOGRAPHS EVAL; Jarvinen R, 2001, BRIT J CANCER, V85, P357, DOI 10.1054/bjoc.2001.1906; Johnston BC, 2019, ANN INTERN MED, V171, P756, DOI 10.7326/M19-1621; Jones RR, 2019, ENVIRON INT, V126, P242, DOI 10.1016/j.envint.2019.02.010; Kabat GC, 2007, CANCER EPIDEM BIOMAR, V16, P1306, DOI 10.1158/1055-9965.EPI-07-0086; Kaluza J, 2012, STROKE, V43, P2556, DOI 10.1161/STROKEAHA.112.663286; Kappeler R, 2013, EUR J CLIN NUTR, V67, P598, DOI 10.1038/ejcn.2013.59; Key TJ, 2019, CIRCULATION, V139, P2835, DOI 10.1161/CIRCULATIONAHA.118.038813; Kim K, 2017, J AM HEART ASSOC, V6, DOI [10.1161/JAHA.117.005983, 10.1161/jaha.117.005983]; Knuppel A, 2020, INT J EPIDEMIOL, V49, P1540, DOI 10.1093/ije/dyaa142; Kurotani K, 2013, BRIT J NUTR, V110, P1910, DOI 10.1017/S0007114513001128; Kyu HH, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i3857; Lajous M, 2012, DIABETES CARE, V35, P128, DOI 10.2337/dc11-1518; Larsson SC, 2005, INT J CANCER, V113, P829, DOI 10.1002/ijc.20658; Larsson SC, 2014, AM J EPIDEMIOL, V179, P282, DOI 10.1093/aje/kwt261; Larsson SC, 2011, AM J CLIN NUTR, V94, P417, DOI 10.3945/ajcn.111.015115; Larsson SC, 2011, STROKE, V42, P324, DOI 10.1161/STROKEAHA.110.596510; Liu Q, 2009, COMPUT STAT DATA AN, V53, P4157, DOI 10.1016/j.csda.2009.05.001; Mannisto S, 2010, BRIT J NUTR, V103, P1817, DOI 10.1017/S0007114510000073; Mehta SS, 2020, CANCER EPIDEM BIOMAR, V29, P141, DOI 10.1158/1055-9965.EPI-19-0459; Mejborn H, 2021, NUTRIENTS, V13, DOI 10.3390/nu13010032; Han MA, 2019, ANN INTERN MED, V171, P711, DOI 10.7326/M19-0699; Micha R, 2010, CIRCULATION, V121, P2271, DOI 10.1161/CIRCULATIONAHA.109.924977; MILLS P, 1989, CANCER-AM CANCER SOC, V64, P582, DOI 10.1002/1097-0142(19890801)64:3&lt;582::AID-CNCR2820640304&gt;3.0.CO;2-V; Moller SP, 2021, BRIT J NUTR, V126, P1881, DOI 10.1017/S0007114521000623; Montonen J, 2005, EUR J CLIN NUTR, V59, P441, DOI 10.1038/sj.ejcn.1602094; Morgan J, 2004, J PEDIATR GASTR NUTR, V39, P493, DOI 10.1097/00005176-200411000-00009; Mueller M, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/s12874-018-0495-9; Murray CJL, 2022, LANCET, V399, pE27, DOI 10.1016/S0140-6736(22)00518-9; Nagao M, 2012, EUR J CLIN NUTR, V66, P687, DOI 10.1038/ejcn.2012.6; Ollberding NJ, 2012, INT J CANCER, V131, pE1125, DOI 10.1002/ijc.27546; Page MJ, 2021, BMJ-BRIT MED J, V372, DOI [10.1136/bmj.n71, 10.1016/j.ijsu.2021.105906]; Pala V, 2009, AM J CLIN NUTR, V90, P602, DOI 10.3945/ajcn.2008.27173; Palli D, 2013, DIABETOLOGIA, V56, P47, DOI 10.1007/s00125-012-2718-7; Pan A, 2011, AM J CLIN NUTR, V94, P1088, DOI 10.3945/ajcn.111.018978; Pan A, 2012, ARCH INTERN MED, V172, P555, DOI 10.1001/archinternmed.2011.2287; Papier K, 2021, CRIT REV FOOD SCI, DOI 10.1080/10408398.2021.1949575; Papier K, 2021, BMC MED, V19, DOI 10.1186/s12916-021-01922-9; Parr CL, 2013, INT J CANCER, V133, P1153, DOI 10.1002/ijc.28101; Pietinen P, 1999, CANCER CAUSE CONTROL, V10, P387, DOI 10.1023/A:1008962219408; Pouchieu C, 2014, INT J EPIDEMIOL, V43, P1583, DOI 10.1093/ije/dyu134; Rajabi AA., 2022, BRIT J NUTR, V127, P607; Schunemann H., 2013, GRADE HDB GRADING QU; Schwingshackl L, 2017, EUR J EPIDEMIOL, V32, P363, DOI 10.1007/s10654-017-0246-y; Shi LY, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015987; Singh PN, 1998, AM J EPIDEMIOL, V148, P761, DOI 10.1093/oxfordjournals.aje.a009697; Stanton AV, 2022, LANCET, V399, pE23, DOI 10.1016/S0140-6736(22)00311-7; Stayner L, 2003, SCAND J WORK ENV HEA, V29, P317, DOI 10.5271/sjweh.737; Steinbrecher A, 2011, PUBLIC HEALTH NUTR, V14, P568, DOI 10.1017/S1368980010002004; Stevens GA, 2016, LANCET, V388, pE19, DOI 10.1016/S0140-6736(16)30388-9; Takata Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056963; Talaei M, 2017, AM J EPIDEMIOL, V186, P824, DOI 10.1093/aje/kwx156; Tang MH, 2014, AM J CLIN NUTR, V100, P1322, DOI 10.3945/ajcn.114.088807; Taylor EF, 2007, BRIT J CANCER, V96, P1139, DOI 10.1038/sj.bjc.6603689; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; Tiemersma EW, 2002, CANCER CAUSE CONTROL, V13, P383, DOI 10.1023/A:1015236701054; Tong TYN, 2020, EUR HEART J, V41, P2632, DOI 10.1093/eurheartj/ehaa007; US Department of Health and Human Services (US DHHS) and USDA, 2015, 2015 2020 DIET GUID, V8th; van Woudenbergh GJ, 2012, DIABETES CARE, V35, P1499, DOI 10.2337/dc11-1899; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; Villegas Raquel, 2006, Int J Med Sci, V3, P152; Virtanen HEK, 2017, BRIT J NUTR, V117, P882, DOI [10.1017/S0007114517000745, 10.1017/s0007114517000745]; Vos T, 2020, LANCET, V396, P1562; Ward HA, 2016, BRIT J NUTR, V116, P316, DOI 10.1017/S0007114516001859; Wei EK, 2004, INT J CANCER, V108, P433, DOI 10.1002/ijc.11540; Whiteman D, 1999, PUBLIC HEALTH NUTR, V2, P477, DOI 10.1017/S136898009900066X; Willett W, 2019, LANCET, V393, P447, DOI 10.1016/S0140-6736(18)31788-4; World Cancer Research Fund/American Institute for Cancer Research, 2018, DIET NUTR PHYS ACT C; World Cancer Research Fund/American Institute for Cancer Research, 2018, CONT UPD PROJ REP 20; World Cancer Research Fund / American Institute for Cancer Research, 2018, DIET NUTR PHYS ACT C; Wu J, 2016, NUTRIENTS, V8, DOI 10.3390/nu8110730; Yang CL, 2016, J STROKE CEREBROVASC, V25, P1177, DOI 10.1016/j.jstrokecerebrovasdis.2016.01.040; Yiannakou I, 2022, J NUTR, V152, P1254, DOI 10.1093/jn/nxab419; Zeraatkar D, 2019, ANN INTERN MED, V171, P703, DOI 10.7326/M19-0655; Zhang R, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph182010788; Zheng P., XSPLINE ADV SPLINE T; Zheng P., LIMETR LINEAR MIXED; Zheng P., NAT MED; Zheng P, 2021, J COMPUT GRAPH STAT, V30, P544, DOI 10.1080/10618600.2020.1868303	114	2	2	6	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01968-z	http://dx.doi.org/10.1038/s41591-022-01968-z		OCT 2022	18	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	5E6IE	36216940	hybrid, Green Published			2022-12-27	WOS:000865725700001
J	Salmon, JE				Salmon, Jane E.			Arming T cells against B cells in systemic lupus erythematosus	NATURE MEDICINE			English	Editorial Material; Early Access								Following a single infusion of CD19-targeting CAR T cells, five patients with SLE showed reduction in disease activity and disease markers; long-term follow-up of these patients and larger trials are now key priorities.	[Salmon, Jane E.] Weill Cornell Med, Dept Med, Hosp Special Surg, New York, NY 10021 USA	Cornell University	Salmon, JE (corresponding author), Weill Cornell Med, Dept Med, Hosp Special Surg, New York, NY 10021 USA.	salmonj@hss.edu		Salmon, Jane/0000-0001-9113-7122				Arbuckle MR, 2003, NEW ENGL J MED, V349, P1526, DOI 10.1056/NEJMoa021933; Barrat FJ, 2005, J EXP MED, V202, P1131, DOI 10.1084/jem.20050914; Catalina MD, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.140380; DeZern AE, 2011, MEDICINE, V90, P89, DOI 10.1097/MD.0b013e318210e685; Furie R, 2011, ARTHRITIS RHEUM-US, V63, P3918, DOI 10.1002/art.30613; Furie RA, 2022, ANN RHEUM DIS, V81, P100, DOI 10.1136/annrheumdis-2021-220920; Kiefer K, 2012, IMMUNOL CELL BIOL, V90, P498, DOI 10.1038/icb.2012.10; Mackensen A, 2022, NAT MED, V28, DOI 10.1038/s41591-022-02017-5; Mei HE, 2015, BLOOD, V125, P1739, DOI 10.1182/blood-2014-02-555169; Pisetsky DS, 2020, NAT REV RHEUMATOL, V16, P565, DOI 10.1038/s41584-020-0480-7	10	0	0	3	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02024-6	http://dx.doi.org/10.1038/s41591-022-02024-6		SEP 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4V9JQ	36163299				2022-12-27	WOS:000859786500002
J	Volovici, V; Syn, NL; Ercole, A; Zhao, JJ; Liu, N				Volovici, Victor; Syn, Nicholas L.; Ercole, Ari; Zhao, Joseph J.; Liu, Nan			Steps to avoid overuse and misuse of machine learning in clinical research comment	NATURE MEDICINE			English	Editorial Material; Early Access							MODELS; AI	Machine learning algorithms are a powerful tool in healthcare, but sometimes perform no better than traditional statistical techniques. Steps should be taken to ensure that algorithms are not overused or misused, in order to provide genuine benefit for patients.	[Volovici, Victor] Erasmus MC, Univ Med Ctr, Dept Neurosurg, Rotterdam, Netherlands; [Syn, Nicholas L.; Zhao, Joseph J.] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore, Singapore; [Syn, Nicholas L.] Natl Univ Hlth Syst, Natl Univ Hosp, Dept Surg, Singapore, Singapore; [Ercole, Ari] Univ Cambridge, Cambridge Ctr AI Med, Cambridge, England; [Liu, Nan] Duke NUS Med Sch, Programme Hlth Serv & Syst Res, Singapore, Singapore	Erasmus University Rotterdam; Erasmus MC; National University of Singapore; National University of Singapore; University of Cambridge; National University of Singapore	Volovici, V (corresponding author), Erasmus MC, Univ Med Ctr, Dept Neurosurg, Rotterdam, Netherlands.	v.volovici@erasmusmc.nl	Liu, Nan/HCS-2632-2022; Syn, Nicholas/A-3770-2017; Ercole, Ari/B-6288-2009	Liu, Nan/0000-0003-3610-4883; Syn, Nicholas/0000-0002-6343-176X; Ercole, Ari/0000-0001-8350-8093; Zhao, Joseph J/0000-0002-2002-5390				Abramoff MD, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0040-6; American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5th, DOI [10.1176/appi.books.9780890425596, DOI 10.1176/APPI.BOOKS.9780890425596]; Cho SM, 2021, CAN J CARDIOL, V37, P1207, DOI 10.1016/j.cjca.2021.02.020; Christodoulou E, 2019, J CLIN EPIDEMIOL, V110, P12, DOI 10.1016/j.jclinepi.2019.02.004; DeGrave AJ, 2021, NAT MACH INTELL, V3, P610, DOI 10.1038/s42256-021-00338-7; Futoma J, 2020, LANCET DIGIT HEALTH, V2, pE489, DOI 10.1016/S2589-7500(20)30186-2; Gravesteijn BY, 2020, J CLIN EPIDEMIOL, V122, P95, DOI 10.1016/j.jclinepi.2020.03.005; Marek S, 2022, NATURE, V603, P654, DOI 10.1038/s41586-022-04492-9; Navarro CLA, 2021, BMJ-BRIT MED J, V375, DOI 10.1136/bmj.n2281; Pisica D, 2022, WORLD NEUROSURG, V161, P230, DOI 10.1016/j.wneu.2022.02.112; Rudin C, 2019, NAT MACH INTELL, V1, P206, DOI 10.1038/s42256-019-0048-x; Shashikumar SP, 2021, NPJ DIGIT MED, V4, DOI 10.1038/s41746-021-00504-6; Shin SJ, 2021, ESC HEART FAIL, V8, P106, DOI 10.1002/ehf2.13073; Stulberg JJ, 2018, JAMA SURG, V153, P586, DOI 10.1001/jamasurg.2018.0542; Topol EJ, 2020, NAT MED, V26, P1318, DOI 10.1038/s41591-020-1042-x; Twinanda AP, 2017, IEEE T MED IMAGING, V36, P86, DOI 10.1109/TMI.2016.2593957; Uddin S, 2019, BMC MED INFORM DECIS, V19, DOI 10.1186/s12911-019-1004-8; Vasey B, 2022, NAT MED, V28, P924, DOI 10.1038/s41591-022-01772-9; Volovici V, 2019, J NEUROTRAUM, V36, P3183, DOI 10.1089/neu.2019.6474; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Wynants L, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1328; Zou J, 2018, NATURE, V559, P324, DOI 10.1038/d41586-018-05707-8	23	1	1	3	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01961-6	http://dx.doi.org/10.1038/s41591-022-01961-6		SEP 2022	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4L9HT	36097217	Green Published, Bronze			2022-12-27	WOS:000852940800008
J	Gilbert, PB; Huang, YD; deCamp, AC; Karuna, S; Zhang, YY; Magaret, CA; Giorgi, EE; Korber, B; Edlefsen, PT; Rossenkhan, R; Juraska, M; Rudnicki, E; Kochar, N; Huang, Y; Carpp, LN; Barouch, DH; Mkhize, NN; Hermanus, T; Kgagudi, P; Bekker, V; Kaldine, H; Mapengo, RE; Eaton, A; Domin, E; West, C; Feng, WH; Tang, HL; Seaton, KE; Heptinstall, J; Brackett, C; Chiong, K; Tomaras, GD; Andrew, P; Mayer, BT; Reeves, DB; Sobieszczyk, ME; Garrett, N; Sanchez, J; Gay, C; Makhema, J; Williamson, C; Mullins, JI; Hural, J; Cohen, MS; Corey, L; Montefiori, DC; Morris, L				Gilbert, Peter B.; Huang, Yunda; deCamp, Allan C.; Karuna, Shelly; Zhang, Yuanyuan; Magaret, Craig A.; Giorgi, Elena E.; Korber, Bette; Edlefsen, Paul T.; Rossenkhan, Raabya; Juraska, Michal; Rudnicki, Erika; Kochar, Nidhi; Huang, Ying; Carpp, Lindsay N.; Barouch, Dan H.; Mkhize, Nonhlanhla N.; Hermanus, Tandile; Kgagudi, Prudence; Bekker, Valerie; Kaldine, Haajira; Mapengo, Rutendo E.; Eaton, Amanda; Domin, Elize; West, Carley; Feng, Wenhong; Tang, Haili; Seaton, Kelly E.; Heptinstall, Jack; Brackett, Caroline; Chiong, Kelvin; Tomaras, Georgia D.; Andrew, Philip; Mayer, Bryan T.; Reeves, Daniel B.; Sobieszczyk, Magdalena E.; Garrett, Nigel; Sanchez, Jorge; Gay, Cynthia; Makhema, Joseph; Williamson, Carolyn; Mullins, James I.; Hural, John; Cohen, Myron S.; Corey, Lawrence; Montefiori, David C.; Morris, Lynn			Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition	NATURE MEDICINE			English	Article							PROTECTION	By integrating the serum concentration of a broadly neutralizing antibody (bNAb) with its in vitro 80% inhibitory concentration, the PT80 biomarker may be used to guide target levels of bNAbs for effective prevention of HIV-1 acquisition. The Antibody Mediated Prevention trials showed that the broadly neutralizing antibody (bnAb) VRC01 prevented acquisition of human immunodeficiency virus-1 (HIV-1) sensitive to VRC01. Using AMP trial data, here we show that the predicted serum neutralization 80% inhibitory dilution titer (PT80) biomarker-which quantifies the neutralization potency of antibodies in an individual's serum against an HIV-1 isolate-can be used to predict HIV-1 prevention efficacy. Similar to the results of nonhuman primate studies, an average PT80 of 200 (meaning a bnAb concentration 200-fold higher than that required to reduce infection by 80% in vitro) against a population of probable exposing viruses was estimated to be required for 90% prevention efficacy against acquisition of these viruses. Based on this result, we suggest that the goal of sustained PT80 <200 against 90% of circulating viruses can be achieved by promising bnAb regimens engineered for long half-lives. We propose the PT80 biomarker as a surrogate endpoint for evaluatinon of bnAb regimens, and as a tool for benchmarking candidate bnAb-inducing vaccines.	[Gilbert, Peter B.; Huang, Yunda; deCamp, Allan C.; Karuna, Shelly; Zhang, Yuanyuan; Magaret, Craig A.; Edlefsen, Paul T.; Rossenkhan, Raabya; Juraska, Michal; Rudnicki, Erika; Kochar, Nidhi; Huang, Ying; Carpp, Lindsay N.; Mayer, Bryan T.; Reeves, Daniel B.; Hural, John] Fred Hutchinson Canc Ctr, Vaccine & Infect Dis Div, Seattle, WA 98109 USA; [Gilbert, Peter B.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Huang, Yunda; Mullins, James I.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA; [Giorgi, Elena E.; Korber, Bette] Los Alamos Natl Lab, Los Alamos, NM USA; [Barouch, Dan H.] Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02215 USA; [Barouch, Dan H.] Ragon Inst Massachusetts Gen Hosp Massachusetts I, Cambridge, MA USA; [Mkhize, Nonhlanhla N.; Hermanus, Tandile; Kgagudi, Prudence; Bekker, Valerie; Kaldine, Haajira; Mapengo, Rutendo E.; Morris, Lynn] Natl Hlth Lab Serv, Natl Inst Communicable Dis, Johannesburg, South Africa; [Mkhize, Nonhlanhla N.; Hermanus, Tandile; Kgagudi, Prudence; Bekker, Valerie; Kaldine, Haajira; Mapengo, Rutendo E.; Domin, Elize; Morris, Lynn] Univ Witwatersrand, Fac Hlth Sci, Antibody Immun Res Unit, Johannesburg, South Africa; [Eaton, Amanda; Domin, Elize; West, Carley; Feng, Wenhong; Tang, Haili; Montefiori, David C.] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; [Bekker, Valerie; Seaton, Kelly E.; Heptinstall, Jack; Brackett, Caroline; Chiong, Kelvin; Tomaras, Georgia D.] Duke Univ, Duke Ctr Human Syst Immunol, Dept Surg, Durham, NC USA; [Bekker, Valerie; Seaton, Kelly E.; Heptinstall, Jack; Brackett, Caroline; Chiong, Kelvin; Tomaras, Georgia D.] Duke Univ, Duke Ctr Human Syst Immunol, Dept Immunol, Durham, NC USA; [Bekker, Valerie; Seaton, Kelly E.; Heptinstall, Jack; Brackett, Caroline; Chiong, Kelvin; Tomaras, Georgia D.] Duke Univ, Duke Ctr Human Syst Immunol, Dept Mol Genet & Micobiol, Durham, NC USA; [Andrew, Philip] Family Hlth Int, Durham, NC USA; [Sobieszczyk, Magdalena E.] Columbia Univ, Irving Med Ctr, Dept Med, Div Infect Dis, New York, NY USA; [Garrett, Nigel; Morris, Lynn] Univ KwaZulu Natal, Ctr AIDS Programme Res South Africa, Durban, South Africa; [Garrett, Nigel] Univ KwaZulu Natal, Sch Nursing & Publ Hlth, Discipline Publ Hlth Med, Durban, South Africa; [Sanchez, Jorge] Univ Nacl Mayor San Marcos, Ctr Invest Tecnol Biomed & Medioambientales, Lima, Peru; [Gay, Cynthia] Univ N Carolina, Div Infect Dis, Chapel Hill, NC 27515 USA; [Makhema, Joseph] Botswana Harvard AIDS Initiat Partnership HIV Res, Gaborone, Botswana; [Makhema, Joseph] Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA; [Williamson, Carolyn] Univ Cape Town, Fac Hlth Sci, Div Med Virol, Cape Town, South Africa; [Mullins, James I.] Univ Washington, Dept Microbiol, Seattle, WA 98195 USA; [Mullins, James I.; Corey, Lawrence] Univ Washington, Dept Med, Seattle, WA USA; [Cohen, Myron S.] Univ N Carolina, Inst Global Hlth & Infect Dis, Chapel Hill, NC 27515 USA; [Corey, Lawrence] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; [Giorgi, Elena E.] Fred Hutchinson Canc Ctr, Vaccine & Infect Dis Div, Seattle, WA USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; United States Department of Energy (DOE); Los Alamos National Laboratory; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Ragon Institute; National Health Laboratory Service; National Institute for Communicable Diseases (NICD); University of Witwatersrand; Duke University; Duke University; Duke University; Duke University; Columbia University; NewYork-Presbyterian Hospital; University of Kwazulu Natal; University of Kwazulu Natal; Universidad Nacional Mayor de San Marcos; University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Beth Israel Deaconess Medical Center; University of Cape Town; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of North Carolina; University of North Carolina Chapel Hill; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	Gilbert, PB (corresponding author), Fred Hutchinson Canc Ctr, Vaccine & Infect Dis Div, Seattle, WA 98109 USA.; Gilbert, PB (corresponding author), Univ Washington, Dept Biostat, Seattle, WA 98195 USA.	pgilbert@fredhutch.org		Edlefsen, Paul/0000-0002-8393-8103; Gilbert, Peter/0000-0002-2662-9427; Huang, Yunda/0000-0003-1546-6172; Karuna, Shelly/0000-0001-5946-9733	NIH [UM1 AI068614, UM1 AI068635, 4R37 AI054165-21, UM1 AI068618, UM1 AI068619, UM1 AI068613, UM1 AI068617, P30 AI027757, P30 AI064518, K25 AI155224]; Intramural Research Program of the National Institute of Allergy and Infectious Diseases; South African Medical Research Council; Bill & Melinda Gates Foundation [OPP1146996, INV-036842]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Intramural Research Program of the National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); South African Medical Research Council(South African Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR)	This work was supported by the NIH through award nos. UM1 AI068614 (D.H.B., L.C. and G.D.T.), UM1 AI068635 (P.B.G. and Y.H.), 4R37 AI054165-21 (P.B.G.), UM1 AI068618, UM1 AI068619 (M.S.C.), UM1 AI068613, UM1 AI068617, P30 AI027757 (J.I.M.), P30 AI064518 (G.D.T.) and K25 AI155224 (D.B.R.); and by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases and the South African Medical Research Council (L.M.). This work was also supported, in whole or in part, by the Bill & Melinda Gates Foundation (CAVD grant nos. OPP1146996 and INV-036842 (B.K.)). Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the author-accepted manuscript version that might arise from this submission. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH. We thank the trial participants and staff, study teams and community members of the clinical research sites. We also thank the HVTN Core staff, the Hutchinson Centre Research Institute of South Africa staff, the Statistical Center for HIV/AIDS Research & Prevention, the HVTN Laboratory Center, the DAIDS/NIAID Vaccine Research Program and Pharmaceutical Affairs Branch and Triclinium Clinical Development.	Amanna IJ, 2007, NEW ENGL J MED, V357, P1903, DOI 10.1056/NEJMoa066092; [Anonymous], 2022, EMERGENCY USE AUTHOR; Astronomo RD, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI146975; Bekker LG, 2020, LANCET, V395, P384, DOI 10.1016/S0140-6736(19)32682-0; Burton DR, 2021, SCIENCE, V372, P1397, DOI 10.1126/science.abf5376; Carroll R.J., 2006, MEASUREMENT ERROR NO, V2nd ed, DOI DOI 10.1201/9781420010138; Cohen YZ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219142; Corey L, 2021, NEW ENGL J MED, V384, P1003, DOI 10.1056/NEJMoa2031738; Earle Kristen A, 2021, Vaccine, V39, P4423, DOI 10.1016/j.vaccine.2021.05.063; Fong Youyi, 2022, medRxiv, DOI 10.1101/2022.04.06.22272763; Gaudinski MR, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002493; Gilbert P., 2018, PLOTKINS VACCINES, V7th; Gilbert Peter B, 2021, medRxiv, DOI 10.1101/2021.08.09.21261290; Gilbert PB, 2019, STAT MED, V38, P4503, DOI 10.1002/sim.8310; Gilbert Peter B, 2017, Stat Commun Infect Dis, V9, DOI 10.1515/scid-2016-0001; Giorgi EE, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-532; Grebe E, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4543-9; Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425; Huang YD, 2022, HUM VACC IMMUNOTHER, V18, DOI 10.1080/21645515.2021.1908030; Huang YD, 2021, EBIOMEDICINE, V64, DOI 10.1016/j.ebiom.2020.103203; Huang YD, 2020, JAIDS-J ACQ IMM DEF, V83, P434, DOI 10.1097/QAI.0000000000002272; Huang YD, 2017, MABS-AUSTIN, V9, P792, DOI 10.1080/19420862.2017.1311435; Julg B, 2022, NAT MED, V28, P1288, DOI 10.1038/s41591-022-01815-1; Karuna ST, 2020, ANNU REV MED, V71, P329, DOI 10.1146/annurev-med-110118-045506; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Li M, 2005, J VIROL, V79, P10108, DOI 10.1128/JVI.79.16.10108-10125.2005; Lin DY, 2000, BIOMETRIKA, V87, P37, DOI 10.1093/biomet/87.1.37; LIN LI, 1989, BIOMETRICS, V45, P255, DOI 10.2307/2532051; Mayer BT, 2022, PLOS COMPUT BIOL, V18, DOI 10.1371/journal.pcbi.1010003; Mayer KH, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002435; Montefiori David C., 2009, V485, P395, DOI 10.1007/978-1-59745-170-3_26; Nicely NI, 2015, EBIOMEDICINE, V2, P713, DOI 10.1016/j.ebiom.2015.06.016; Pauthner MG, 2019, IMMUNITY, V50, P241, DOI 10.1016/j.immuni.2018.11.011; Pegu A, 2019, CELL HOST MICROBE, V26, P336, DOI 10.1016/j.chom.2019.08.014; Pilcher CD, 2019, AIDS, V33, P1231, DOI [10.1097/QAD.0000000000002190, 10.1097/qad.0000000000002190]; Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10; Pollara J, 2014, J VIROL, V88, P7715, DOI 10.1128/JVI.00156-14; Reeves DB, 2020, PLOS COMPUT BIOL, V16, DOI 10.1371/journal.pcbi.1007626; Sarzotti-Kelsoe M, 2014, J IMMUNOL METHODS, V409, P131, DOI 10.1016/j.jim.2013.11.022; Stephenson KE, 2021, NAT MED, V27, P1718, DOI 10.1038/s41591-021-01509-0; Stephenson KE, 2020, ANNU REV IMMUNOL, V38, P673, DOI 10.1146/annurev-immunol-080219-023629; Tomaras GD, 2008, J VIROL, V82, P12449, DOI 10.1128/JVI.01708-08; Wagh K, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006860; Wagh K, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005520; Walter EB, 2022, NEW ENGL J MED, V386, P35, DOI 10.1056/NEJMoa2116298	45	1	1	1	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2022	28	9					1924	+		10.1038/s41591-022-01953-6	http://dx.doi.org/10.1038/s41591-022-01953-6		AUG 2022	27	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4S0LI	35995954	Green Submitted, Green Published, hybrid			2022-12-27	WOS:000842907100003
J	Aiuti, A; Pasinelli, F; Naldini, L				Aiuti, Alessandro; Pasinelli, Francesca; Naldini, Luigi			Ensuring a future for gene therapy for rare diseases	NATURE MEDICINE			English	Editorial Material; Early Access							IMMUNODEFICIENCY		[Aiuti, Alessandro; Naldini, Luigi] IRCCS San Raffaele Sci Inst, San Raffaele Telethon Inst Gene Therapy SR Tiget, Milan, Italy; [Aiuti, Alessandro; Naldini, Luigi] Univ Vita Salute San Raffaele, Milan, Italy; [Pasinelli, Francesca] Fdn Telethon, Rome, Italy	Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; Fondazione Telethon	Naldini, L (corresponding author), IRCCS San Raffaele Sci Inst, San Raffaele Telethon Inst Gene Therapy SR Tiget, Milan, Italy.; Naldini, L (corresponding author), Univ Vita Salute San Raffaele, Milan, Italy.	naldini.luigi@hsr.it			Fondazione Telethon; EU; Italian Ministry of Health; Italian Ministry of University and Research; Louis-Jeantet Foundation; Else Kroner Fresenius Foundation	Fondazione Telethon(Fondazione TelethonEuropean Commission); EU(European Commission); Italian Ministry of Health(Ministry of Health, Italy); Italian Ministry of University and Research(Ministry of Education, Universities and Research (MIUR)); Louis-Jeantet Foundation; Else Kroner Fresenius Foundation	Work in the labs of L.N. and A.A. is supported by grants from Fondazione Telethon, the EU Horizon 2020 Program, the Italian Ministry of Health, the Italian Ministry of University and Research, the Louis-Jeantet Foundation through the Jeantet-Collen Prize for Translational Medicine 2019 (to L.N.) and the Else Kroner Fresenius Foundation through the Kroner-Fresenius Prize for Medical Research 2020 (to A.A). The authors thank Michela Gabaldo, Aida Paniccia, Sara Maffioletti and Francesca Pampinella for helpful comments and support.	Aiuti A, 2017, EMBO MOL MED, V9, P737, DOI 10.15252/emmm.201707573; [Anonymous], ORCHARD THERAPEUTICS; [Anonymous], BLUEBIRD BIOPRESS RE; Castagnoli R, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00295; Cicalese MP, 2016, BLOOD, V128, P45, DOI 10.1182/blood-2016-01-688226; Ferrari G, 2021, NAT REV GENET, V22, P216, DOI 10.1038/s41576-020-00298-5; Ferrari S, 2020, NAT BIOTECHNOL, V38, P1298, DOI 10.1038/s41587-020-0551-y; Ferrua F, 2019, LANCET HAEMATOL, V6, pE239, DOI 10.1016/S2352-3026(19)30021-3; Fischer A, 2020, J EXP MED, V217, DOI 10.1084/jem.20190607; Frangoul H, 2021, NEW ENGL J MED, V384, DOI 10.1056/NEJMc2103481; Jonker AH, 2020, NAT REV DRUG DISCOV, V19, P495, DOI 10.1038/d41573-020-00060-w; Kohn DB, 2021, NEW ENGL J MED, V384, P2002, DOI 10.1056/NEJMoa2027675; Kohn DB, 2020, NAT MED, V26, P200, DOI 10.1038/s41591-019-0735-5; Lankester AC, 2022, J ALLERGY CLIN IMMUN, V149, P1744, DOI 10.1016/j.jaci.2021.10.017; Magnani A, 2022, NAT MED, V28, P71, DOI 10.1038/s41591-021-01641-x; Mamcarz E, 2019, NEW ENGL J MED, V380, P1525, DOI 10.1056/NEJMoa1815408; Notarangelo LD, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abb1662; Pai SY, 2014, NEW ENGL J MED, V371, P434, DOI 10.1056/NEJMoa1401177; Schiroli G, 2019, CELL STEM CELL, V24, P551, DOI 10.1016/j.stem.2019.02.019; Schoser B, 2019, PHARMACOECON-OPEN, V3, P479, DOI 10.1007/s41669-019-0142-3; Simoens S, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.771966; Sun D, 2022, JAMA PEDIATR, V176, P176, DOI 10.1001/jamapediatrics.2021.4583; Tichelli A, 2019, JAMA ONCOL, V5, P229, DOI 10.1001/jamaoncol.2018.4934; Tucci F, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-28762-2; Wang Y, 2020, J MED ECON, V23, P1503, DOI 10.1080/13696998.2020.1831519	25	0	0	2	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01934-9	http://dx.doi.org/10.1038/s41591-022-01934-9		AUG 2022	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3T9PT	35970921				2022-12-27	WOS:000840603000001
J	Haroon, S; Subramanian, A				Haroon, Shamil; Subramanian, Anuradhaa			Long COVID includes breathing and reproductive problems and has a range of risk factors	NATURE MEDICINE			English	Editorial Material; Early Access									[Haroon, Shamil; Subramanian, Anuradhaa] Univ Birmingham, Birmingham, W Midlands, England	University of Birmingham	Haroon, S (corresponding author), Univ Birmingham, Birmingham, W Midlands, England.							Aiyegbusi OL, 2021, J ROY SOC MED, V114, P428, DOI 10.1177/01410768211032850; Ayoubkhani D., B REPORTING PREVALEN; Haroon S, 2022, BMJ OPEN, V12, DOI 10.1136/bmjopen-2021-060413; Hughes SE, 2022, BMJ-BRIT MED J, V377, DOI 10.1136/bmj-2022-070230; Soriano JB, 2022, LANCET INFECT DIS, V22, pE102, DOI 10.1016/S1473-3099(21)00703-9	5	0	0	5	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01954-5	http://dx.doi.org/10.1038/s41591-022-01954-5		AUG 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3T0XU	35962207	Green Published, hybrid			2022-12-27	WOS:000840008300001
J	Visser-Vandewalle, V; Andrade, P; Mosley, PE; Greenberg, BD; Schuurman, R; McLaughlin, NC; Voon, V; Krack, P; Foote, KD; Mayberg, HS; Figee, M; Kopell, BH; Polosan, M; Joyce, EM; Chabardes, S; Matthews, K; Baldermann, JC; Tyagi, H; Holtzheimer, PE; Bervoets, C; Hamani, C; Karachi, C; Denys, D; Zrinzo, L; Blomstedt, P; Naesstrom, M; Abosch, A; Rasmussen, S; Coenen, VA; Schlaepfer, TE; Dougherty, DD; Domenech, P; Silburn, P; Giordano, J; Lozano, AM; Sheth, SA; Coyne, T; Kuhn, J; Mallet, L; Nuttin, B; Hariz, M; Okun, MS				Visser-Vandewalle, Veerle; Andrade, Pablo; Mosley, Philip E.; Greenberg, Benjamin D.; Schuurman, Rick; McLaughlin, Nicole C.; Voon, Valerie; Krack, Paul; Foote, Kelly D.; Mayberg, Helen S.; Figee, Martijn; Kopell, Brian H.; Polosan, Mircea; Joyce, Eileen M.; Chabardes, Stephan; Matthews, Keith; Baldermann, Juan C.; Tyagi, Himanshu; Holtzheimer, Paul E.; Bervoets, Chris; Hamani, Clement; Karachi, Carine; Denys, Damiaan; Zrinzo, Ludvic; Blomstedt, Patric; Naesstrom, Matilda; Abosch, Aviva; Rasmussen, Steven; Coenen, Volker A.; Schlaepfer, Thomas E.; Dougherty, Darin D.; Domenech, Philippe; Silburn, Peter; Giordano, James; Lozano, Andres M.; Sheth, Sameer A.; Coyne, Terry; Kuhn, Jens; Mallet, Luc; Nuttin, Bart; Hariz, Marwan; Okun, Michael S.			Deep brain stimulation for obsessive-compulsive disorder: a crisis of access	NATURE MEDICINE			English	Editorial Material; Early Access							ELECTRICAL-STIMULATION; NUCLEUS	Deep brain stimulation is an effective treatment for obsessive-compulsive disorder but is rarely used. Action is needed by psychologists, psychiatrists and insurers so that patients with otherwise intractable cases can receive this therapy to improve their mental health.	[Visser-Vandewalle, Veerle; Andrade, Pablo] Univ Cologne, Univ Hosp Cologne, Dept Stereotact & Funct Neurosurg, Cologne, Germany; [Visser-Vandewalle, Veerle; Andrade, Pablo; Baldermann, Juan C.; Kuhn, Jens] Univ Cologne, Fac Med, Cologne, Germany; [Mosley, Philip E.] QIMR Berghofer Med Res Inst, Clin Brain Networks Grp, Brisbane, Qld, Australia; [Mosley, Philip E.] Queensland Brain Inst, Brisbane, Qld, Australia; [Greenberg, Benjamin D.; McLaughlin, Nicole C.; Rasmussen, Steven] Brown Univ, Alpert Med Sch, Dept Psychiat & Human Behav, Providence, RI 02912 USA; [Greenberg, Benjamin D.] Butler Hosp, Ctr Neuromodulat, Providence, RI 02906 USA; [Greenberg, Benjamin D.] RR&D Ctr Neurorestorat & Neurotechnol, Providence, RI USA; [Schuurman, Rick] Univ Amsterdam, Med Ctr, Locat AMC, Dept Neurosurg, Amsterdam, Netherlands; [McLaughlin, Nicole C.] Butler Hosp, Behav Med & Addict Res, Providence, RI 02906 USA; [Voon, Valerie] Univ Cambridge, Dept Psychiat, Cambridge, England; [Krack, Paul] Bern Univ Hosp, Dept Neurol, Bern, Switzerland; [Krack, Paul] Univ Bern, Bern, Switzerland; [Foote, Kelly D.; Okun, Michael S.] Univ Florida Hlth, Dept Neurosurg, Gainesville, FL USA; [Foote, Kelly D.; Okun, Michael S.] Univ Florida Hlth, Norman Fixel Inst Neurol Dis, Gainesville, FL USA; [Mayberg, Helen S.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA; [Mayberg, Helen S.] Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA; [Mayberg, Helen S.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA; [Mayberg, Helen S.] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA; [Mayberg, Helen S.] Icahn Sch Med Mt Sinai, Ctr Adv Circuit Therapeut, New York, NY 10029 USA; [Figee, Martijn; Kopell, Brian H.] Icahn Sch Med Mt Sinai, Nash Family Ctr Adv Circuit Therapeut, New York, NY 10029 USA; [Polosan, Mircea] Fdn Fondamental, Creteil, France; [Polosan, Mircea] Ctr Hosp Univ Grenoble & Alpes, Ctr Expert Troubles Bipolaires, Serv Univ Psychiat, Grenoble, France; [Polosan, Mircea] Grenoble Inst Neurosci, INSERM, U836, La Tronche, France; [Joyce, Eileen M.; Zrinzo, Ludvic; Hariz, Marwan] UCL, Queen Sq Inst Neurol, Unit Funct Neurosurg, Queen Sq, London, England; [Joyce, Eileen M.; Tyagi, Himanshu; Zrinzo, Ludvic; Hariz, Marwan] UCLH, Natl Hosp Neurol & Neurosurg, Queen Sq, London, England; [Joyce, Eileen M.; Tyagi, Himanshu; Zrinzo, Ludvic; Hariz, Marwan] UCL, Queen Sq Inst Neurol, Dept Clin & Movement Neurosci, Queen Sq, London, England; [Chabardes, Stephan] Grenoble Univ Hosp, Dept Neurosurg, Grenoble, France; [Matthews, Keith] Univ Dundee, Ninewells Hosp, Sch Med, Div Mol & Clin Med, Dundee, Scotland; [Matthews, Keith] Univ Dundee, Med Sch, Dundee, Scotland; [Baldermann, Juan C.] Univ Cologne, Univ Hosp Cologne, Dept Neurol, Cologne, Germany; [Baldermann, Juan C.; Kuhn, Jens] Univ Cologne, Univ Hosp Cologne, Dept Psychiat & Psychotherapy, Cologne, Germany; [Holtzheimer, Paul E.] Geisel Sch Med Dartmouth, Dept Psychiat, Hanover, NH USA; [Holtzheimer, Paul E.] Geisel Sch Med Dartmouth, Dept Surg, Hanover, NH USA; [Bervoets, Chris] Katholieke Univ Leuven, UPC, Dept Neurosci, Adult Psychiat, Leuven, Belgium; [Hamani, Clement] Univ Toronto, Sunnybrook Res Inst, Div Neurosurg, Toronto, ON, Canada; [Karachi, Carine] Hop La Pitie Salpetriere, Grp Hosp Pitie Salpetriere, AP HP, Neurosurg Dept, Paris, France; [Denys, Damiaan] Univ Amsterdam, Acad Med Ctr, Dept Psychiat, Amsterdam, Netherlands; [Blomstedt, Patric; Hariz, Marwan] Umea Univ, Unit Deep Brain Stimulat, Umea, Sweden; [Naesstrom, Matilda] Umea Univ, Dept Clin Sci Psychiat, Umea, Sweden; [Abosch, Aviva] Univ Colorado, Dept Neurosurg, Anschutz Med Campus, Aurora, CO USA; [Abosch, Aviva] Univ Colorado, Dept Neurol, Anschutz Med Campus, Aurora, CO USA; [Rasmussen, Steven] Brown Univ, Carney Inst Brain Sci, Providence, RI 02912 USA; [Coenen, Volker A.; Schlaepfer, Thomas E.] Univ Freiburg, Fac Med, Med Ctr, Dept Stereotact & Funct Neurosurg, Freiburg, Germany; [Coenen, Volker A.; Schlaepfer, Thomas E.] Freiburg Univ, Ctr Deep Brain Stimulat, Freiburg, Germany; [Dougherty, Darin D.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02115 USA; [Domenech, Philippe] Univ Paris Est, Grp Hosp Univ Henri Mondor, AP HP, Dept Med Univ Psychiat & Addictol, Creteil, France; [Domenech, Philippe] Sorbonne Univ, CNRS, UMR 7225, INSERM,U1127,Inst Cerveau, Paris, France; [Silburn, Peter; Coyne, Terry] Univ Queensland, Queensland Brain Inst, Brisbane, Qld, Australia; [Giordano, James] Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20007 USA; [Giordano, James] Georgetown Univ, Dept Biochem & Mol & Cell Biol, Washington, DC USA; [Giordano, James] Georgetown Univ, Pellegrino Ctr Clin Bioeth, Neuroeth Studies Program, Washington, DC USA; [Lozano, Andres M.] Toronto Western Hosp, Dept Neurosurg & Neurosci, Toronto, ON, Canada; [Sheth, Sameer A.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Kuhn, Jens] Johanniter Hosp Oberhausen, Dept Psychiat Psychotherapy & Psychosomat, Oberhausen, Germany; [Mallet, Luc] Univ Paris Est Creteil, Hop Univ Henri Mondor Albert Chenevier, AP HP, Dept Med Univ Psychiat & Addictol, Creteil, France; [Mallet, Luc] Sorbonne Univ, Paris Brain Inst, CNRS, INSERM,Inst Cerveau, Paris, France; [Mallet, Luc] Univ Geneva, Global Hlth Inst, Dept Mental Hlth & Psychiat, Geneva, Switzerland; [Nuttin, Bart] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Neurosurg, Leuven, Belgium; [Okun, Michael S.] Univ Florida Hlth, Dept Neurol, Gainesville, FL USA	University of Cologne; University of Cologne; QIMR Berghofer Medical Research Institute; University of Queensland; Brown University; Butler Hospital Rhode Island; University of Amsterdam; Butler Hospital Rhode Island; University of Cambridge; University of Bern; University Hospital of Bern; University of Bern; State University System of Florida; University of Florida; State University System of Florida; University of Florida; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of London; University College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); University of Dundee; University of Dundee; University of Cologne; University of Cologne; Dartmouth College; Dartmouth College; KU Leuven; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Amsterdam; Academic Medical Center Amsterdam; Umea University; Umea University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; Brown University; University of Freiburg; University of Freiburg; Harvard University; Harvard Medical School; Massachusetts General Hospital; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of Queensland; Georgetown University; Georgetown University; Georgetown University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Baylor College of Medicine; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of Geneva; KU Leuven; University Hospital Leuven; State University System of Florida; University of Florida	Visser-Vandewalle, V (corresponding author), Univ Cologne, Univ Hosp Cologne, Dept Stereotact & Funct Neurosurg, Cologne, Germany.; Visser-Vandewalle, V (corresponding author), Univ Cologne, Fac Med, Cologne, Germany.	veerle.visser-vandewalle@uk-koeln.de	Lozano, Andres M/A-5058-2012	Krack, Paul/0000-0002-3508-7295; Lozano, Andres M./0000-0001-8257-3694; Foote, Kelly/0000-0002-2436-4138; Mayberg, Helen/0000-0002-1672-2716; bervoets, chris/0000-0001-9842-2823; Andrade, Pablo/0000-0002-2596-7301	Swiss National Science Foundation [FNS 323530_177577, FNS 2020 32003BL_ 197709-1, FNS 33IC30_198772]; US National Institutes of Health [R01 NR014852, R01NS096008, UH3NS119844, U01NS119562, R25NS108939]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	P.K. reports research or educational grants from the Swiss National Science Foundation (FNS 323530_177577, FNS 2020 32003BL_ 197709-1 and FNS 33IC30_198772), paid to his employing institution. M.S.O. has received research grants from the US National Institutes of Health (R01 NR014852, R01NS096008, UH3NS119844 and U01NS119562; training grant R25NS108939 (Principal Investigator)).	Cormier J, 2019, CAN J NEUROL SCI, V46, P303, DOI 10.1017/cjn.2019.5; Davis RA, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.706181; Denys D, 2010, ARCH GEN PSYCHIAT, V67, P1061, DOI 10.1001/archgenpsychiatry.2010.122; Graat I, 2021, BIOL PSYCHIAT, V90, P714, DOI 10.1016/j.biopsych.2020.08.018; Hirschtritt ME, 2017, JAMA-J AM MED ASSOC, V317, P1358, DOI 10.1001/jama.2017.2200; Kohl S, 2016, NEUROMODULATION, V19, P542, DOI 10.1111/ner.12461; Luyten L, 2016, MOL PSYCHIATR, V21, P1272, DOI 10.1038/mp.2015.124; Mallet L, 2008, NEW ENGL J MED, V359, P2121, DOI 10.1056/NEJMoa0708514; Moro E, 2021, MOVING, V25, P6; Mosley PE, 2021, TRANSL PSYCHIAT, V11, DOI 10.1038/s41398-021-01307-9; Naesstrom Matilda, 2017, Surg Neurol Int, V8, P298, DOI 10.4103/sni.sni_19_17; Nuttin B, 1999, LANCET, V354, P1526, DOI 10.1016/S0140-6736(99)02376-4; Nuttin B, 2014, J NEUROL NEUROSUR PS, V85, P1003, DOI 10.1136/jnnp-2013-306580; Park YS, 2019, WORLD NEUROSURG, V126, P1, DOI 10.1016/j.wneu.2019.01.254; Pellegrini L, 2021, COMPR PSYCHIAT, V108, DOI 10.1016/j.comppsych.2021.152246; Pepper J, 2019, J NEUROSURG, V11, P1; Pinckard-Dover H, 2021, FRONT SURG, V8, DOI 10.3389/fsurg.2021.642503; Provenza NR, 2021, NAT MED, V27, P2154, DOI 10.1038/s41591-021-01550-z; Tyagi H, 2019, BIOL PSYCHIAT, V85, P726, DOI 10.1016/j.biopsych.2019.01.017; US FDA, 2022, US; Welter ML, 2021, BIOL PSYCHIAT, V90, pE45, DOI 10.1016/j.biopsych.2020.07.013; Winter L, 2021, NEUROMODULATION, V24, P324, DOI 10.1111/ner.13232	22	3	3	2	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01879-z	http://dx.doi.org/10.1038/s41591-022-01879-z		JUL 2022	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2Y5IM	35840727				2022-12-27	WOS:000825930600001
J	Julg, B; Stephenson, KE; Wagh, K; Tan, SAC; Zash, R; Walsh, S; Ansel, J; Kanjilal, D; Nkolola, J; Walker-Sperling, VEK; Ophel, J; Yanosick, K; Borducchi, EN; Maxfield, L; Abbink, P; Peter, L; Yates, NL; Wesley, MS; Hassell, T; Gelderblom, HC; deCamp, A; Mayer, BT; Sato, A; Gerber, MW; Giorgi, EE; Gama, L; Koup, RA; Mascola, JR; Monczor, A; Lupo, S; Rolle, CP; Arduino, R; DeJesus, E; Tomaras, GD; Seaman, MS; Korber, B; Barouch, DH				Julg, Boris; Stephenson, Kathryn E.; Wagh, Kshitij; Tan, Sabrina C.; Zash, Rebecca; Walsh, Stephen; Ansel, Jessica; Kanjilal, Diane; Nkolola, Joseph; Walker-Sperling, Victoria E. K.; Ophel, Jasper; Yanosick, Katherine; Borducchi, Erica N.; Maxfield, Lori; Abbink, Peter; Peter, Lauren; Yates, Nicole L.; Wesley, Martina S.; Hassell, Tom; Gelderblom, Huub C.; deCamp, Allen; Mayer, Bryan T.; Sato, Alicia; Gerber, Monica W.; Giorgi, Elena E.; Gama, Lucio; Koup, Richard A.; Mascola, John R.; Monczor, Ana; Lupo, Sofia; Rolle, Charlotte-Paige; Arduino, Roberto; DeJesus, Edwin; Tomaras, Georgia D.; Seaman, Michael S.; Korber, Bette; Barouch, Dan H.			Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial	NATURE MEDICINE			English	Article							ENV CLONES; IDENTIFICATION; INFECTIONS; PROTECTION; RESPONSES; EFFICACY; VACCINES; VIREMIA; HUMANS; LONG	HIV-1 therapy with single or dual broadly neutralizing antibodies (bNAbs) has shown viral escape, indicating that at least a triple bNAb therapy may be needed for robust suppression of viremia. We performed a two-part study consisting of a single-center, randomized, double-blind, dose-escalation, placebo-controlled first-in-human trial of the HIV-1 V2-glycan-specific antibody PGDM1400 alone or in combination with the V3-glycan-specific antibody PGT121 in 24 adults without HIV in part 1, as well as a multi-center, open-label trial of the combination of PGDM1400, PGT121 and the CD4-binding-site antibody VRC07-523LS in five viremic adults living with HIV not on antiretroviral therapy (ART) in part 2 (NCT03205917). The primary endpoints were safety, tolerability and pharmacokinetics for both parts and antiviral activity among viremic adults living with HIV and not on ART for part 2 of the study. The secondary endpoints were changes in CD4(+) T cell counts and development of HIV-1 sequence variations associated with PGDM1400, PGT121 and VRC07-523LS resistance in part 2. Intravenously administered PGDM1400 was safe and well-tolerated at doses up to 30 mg kg(-1) and when given in combination with PGT121 and VRC07-523LS. A single intravenous infusion of 20 mg kg(-1) of each of the three antibodies reduced plasma HIV RNA levels in viremic individuals by a maximum mean of 2.04 log(10) copies per ml; however, viral rebound occurred in all participants within a median of 20 days after nadir. Rebound viruses demonstrated partial to complete resistance to PGDM1400 and PGT121 in vitro, whereas susceptibility to VRC07-523LS was preserved. Viral rebound occurred despite mean VRC07-523LS serum concentrations of 93 mu g ml(-1). The trial met the pre-specified endpoints. Our data suggest that future bNAb combinations likely need to achieve broad antiviral activity, while also maintaining high serum concentrations, to mediate viral control.	[Julg, Boris; Stephenson, Kathryn E.; Barouch, Dan H.] Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA; [Julg, Boris; Stephenson, Kathryn E.; Tan, Sabrina C.; Zash, Rebecca; Walsh, Stephen; Ansel, Jessica; Kanjilal, Diane; Nkolola, Joseph; Walker-Sperling, Victoria E. K.; Ophel, Jasper; Yanosick, Katherine; Borducchi, Erica N.; Maxfield, Lori; Abbink, Peter; Peter, Lauren; Seaman, Michael S.; Barouch, Dan H.] Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02215 USA; [Wagh, Kshitij; Giorgi, Elena E.; Korber, Bette] Los Alamos Natl Lab, Theoret Biol & Biophys Grp, Los Alamos, NM USA; [Wagh, Kshitij; Giorgi, Elena E.; Korber, Bette] New Mexico Consortium, Los Alamos, NM USA; [Yates, Nicole L.; Wesley, Martina S.; Tomaras, Georgia D.] Duke Univ, Duke Human Vaccine Inst, Durham, NC USA; [Hassell, Tom; Gelderblom, Huub C.] Int AIDS Vaccine Initiat, New York, NY USA; [Gelderblom, Huub C.] Icosavax Inc, Seattle, WA USA; [deCamp, Allen; Mayer, Bryan T.; Sato, Alicia; Gerber, Monica W.] Fred Hutchinson Canc Res Ctr, Stat Ctr HIV AIDS Res & Prevent, 1124 Columbia St, Seattle, WA 98104 USA; [Gama, Lucio; Koup, Richard A.; Mascola, John R.] NIH, Vaccine Res Ctr, Bldg 10, Bethesda, MD 20892 USA; [Monczor, Ana; Lupo, Sofia; Arduino, Roberto] Univ Texas Hlth Sci Ctr Houston, Houston AIDS Res Team, McGovern Med Sch, Houston, TX 77030 USA; [Rolle, Charlotte-Paige; DeJesus, Edwin] Orlando Immunol Ctr, Orlando, FL USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Ragon Institute; Harvard University; Beth Israel Deaconess Medical Center; United States Department of Energy (DOE); Los Alamos National Laboratory; Duke University; International AIDS Vaccine Initiative; Fred Hutchinson Cancer Center; National Institutes of Health (NIH) - USA; University of Texas System; University of Texas Health Science Center Houston; Orlando Immunology Center	Barouch, DH (corresponding author), Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA.; Barouch, DH (corresponding author), Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02215 USA.	dbarouch@bidmc.harvard.edu		Hyatt, Ana/0000-0001-8041-4331; Walsh, Stephen/0000-0002-0817-9370	Harvard Catalyst Clinical Research Center; Houston AIDS Research Team; Vaccine Production Program; Vaccine Immunology Program; Office of Regulatory Science of the Vaccine Research Center; Bill and Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery grants [OPP1107669, OPP1153692, OPP1146996]; National Institutes of Health [AI149670, AI145801, AI129797, AI128751, AI126603, AI124377, AI164556, OD024917, AI106408, TR001102, AI114381]; Intramural Research Program of the NIH, NIAID	Harvard Catalyst Clinical Research Center; Houston AIDS Research Team; Vaccine Production Program; Vaccine Immunology Program; Office of Regulatory Science of the Vaccine Research Center; Bill and Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery grants; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Intramural Research Program of the NIH, NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank the participants and staff at the Center for Virology and Vaccine Research Clinical Trials Unit, the Harvard Catalyst Clinical Research Center, the Orlando Immunology Clinic and the Houston AIDS Research Team. We also acknowledge the following members of the International AIDS Vaccine Initiative: F. Priddy, L. Sunner, F. Rahaman, A. Lombardo, H. Park, E. Sayeed, K. Syvertsen, V. Sharma, J. Ackland, M. Schroeter and J. Hare. At BIDMC, we would like to acknowledge the contributions of S. Walsh, R. Fogel and T. Makoni. We acknowledge K. Seaton, C. Arocena, K. Hernandez, S. Sawant, R. Thomas, J. Lucas, K. Greene, H. Gao, M. Sarzotti-Kelsoe and K. Lyons for their contributions to assay development, laboratory operations and quality assurance oversight. We also thank the Vaccine Production Program, the Vaccine Immunology Program, the Clinical Trials Program and the Office of Regulatory Science of the Vaccine Research Center and the Vaccine Clinical Materials Program/Leidos Biomedical Research for providing scientific support and investigational Good Manufacturing Practice product. This project was supported by Bill and Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery grants OPP1107669 (D.H.B.), OPP1153692 (IAVI), OPP1146996 (M.S.S., K.W., E.E.G. and B.K.) and OPP1146996 (M.W., N.L.Y. and G.T.). This project was also supported by National Institutes of Health grants AI149670, AI145801, AI129797, AI128751, AI126603, AI124377, AI164556, OD024917 (D.H.B.), AI106408 (B.J.), TR001102 (Harvard Catalyst) and AI114381 (K.E.S.). This research was also supported by the Intramural Research Program of the NIH, NIAID. The funders were involved in the study design but were not involved in study operations, data collection, data analysis, data interpretation or decision to publish or preparation of the manuscript. The bNAb program leads (D.H.B., B.J. and K.E.S.) and the data and statistical lead (A.C.) had access to all the data. B.J., K.E.S., K.W. and D.H.B. had final responsibility for the decision to submit for publication.	Andrade A, 2013, J INFECT DIS, V208, P884, DOI 10.1093/infdis/jit272; Bar KJ, 2016, NEW ENGL J MED, V375, P2037, DOI 10.1056/NEJMoa1608243; Bar-On Y, 2018, NAT MED, V24, P1701, DOI 10.1038/s41591-018-0186-4; Barouch DH, 2013, NATURE, V503, P224, DOI 10.1038/nature12744; Borducchi EN, 2018, NATURE, V563, P360, DOI 10.1038/s41586-018-0600-6; Bricault CA, 2019, CELL HOST MICROBE, V25, P59, DOI 10.1016/j.chom.2018.12.001; Caskey M, 2017, NAT MED, V23, P185, DOI 10.1038/nm.4268; Caskey M, 2015, NATURE, V522, P487, DOI 10.1038/nature14411; Corey L, 2021, NEW ENGL J MED, V384, P1003, DOI 10.1056/NEJMoa2031738; Crowell TA, 2019, LANCET HIV, V6, pE297, DOI 10.1016/S2352-3018(19)30053-0; Doria-Rose NA, 2016, J VIROL, V90, P76, DOI 10.1128/JVI.01791-15; Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425; Hoenigl M, 2016, SCI REP-UK, V6, DOI 10.1038/srep32947; Julg B, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aao4235; Julg B, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal1321; Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105; Ko SY, 2014, NATURE, V514, P642, DOI 10.1038/nature13612; Kwong PD, 2018, IMMUNITY, V48, P855, DOI 10.1016/j.immuni.2018.04.029; Lee JH, 2017, IMMUNITY, V46, P690, DOI 10.1016/j.immuni.2017.03.017; Li M, 2005, J VIROL, V79, P10108, DOI 10.1128/JVI.79.16.10108-10125.2005; Li M, 2006, J VIROL, V80, P11776, DOI 10.1128/JVI.01730-06; LIN LI, 1989, BIOMETRICS, V45, P255, DOI 10.2307/2532051; Lu CL, 2016, SCIENCE, V352, P1001, DOI 10.1126/science.aaf1279; Lynch RM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad5752; Mendoza P, 2018, NATURE, V561, P479, DOI 10.1038/s41586-018-0531-2; Montefiori DC., 2005, CURR PROTOC IMMUNOL, VChapter 12:12.11.11-12.11.15, DOI [10.1002/0471142735.im1211s64, DOI 10.1002/0471142735.IM1211S64]; Nishimura Y, 2017, NATURE, V543, P559, DOI 10.1038/nature21435; Saunders KO, 2019, SCIENCE, V366, P1215, DOI 10.1126/science.aay7199; Scheid JF, 2016, NATURE, V535, P556, DOI 10.1038/nature18929; Schoofs T, 2016, SCIENCE, V352, P997, DOI 10.1126/science.aaf0972; Seaman MS, 2010, J VIROL, V84, P1439, DOI 10.1128/JVI.02108-09; Sidak Z., 1999, THEORY RANK TESTS; Sok D, 2014, P NATL ACAD SCI USA, V111, P17624, DOI 10.1073/pnas.1415789111; Song HS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04217-5; Steichen JM, 2016, IMMUNITY, V45, P483, DOI 10.1016/j.immuni.2016.08.016; Stephenson KE, 2021, NAT MED, V27, P1718, DOI 10.1038/s41591-021-01509-0; Stephenson KE, 2020, ANNU REV IMMUNOL, V38, P673, DOI 10.1146/annurev-immunol-080219-023629; Tomaras GD, 2008, J VIROL, V82, P12449, DOI 10.1128/JVI.01708-08; Wagh K, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006860; Wagh K, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005520; Wesley MS, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.709994; Xu L, 2017, SCIENCE, V358, P85, DOI 10.1126/science.aan8630; Yates NL, 2013, MUCOSAL IMMUNOL, V6, P692, DOI 10.1038/mi.2012.107; Yoon H, 2015, NUCLEIC ACIDS RES, V43, pW213, DOI 10.1093/nar/gkv404	44	3	3	1	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2022	28	6					1288	+		10.1038/s41591-022-01815-1	http://dx.doi.org/10.1038/s41591-022-01815-1		MAY 2022	26	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E9IE	35551291	Green Published, hybrid			2022-12-27	WOS:000794108200001
J	Barton, J; Crandon, J; Kennedy, D; Miller, H				Barton, J; Crandon, J; Kennedy, D; Miller, H			A model protocol to assess the risks of agricultural introductions - A risk-based approach to rationalizing field trial regulations.	NATURE BIOTECHNOLOGY			English	Article									STANFORD UNIV,INST INT STUDIES,STANFORD,CA 94305; STANFORD UNIV,SCH LAW,STANFORD,CA 94305	Stanford University; Stanford University								FROMMER W, 1989, APPL MICROBIOL BIOT, V30, P541; HUTTNER SL, 1995, BIOTECHNOLOGY, V12, P459; MILLER HI, 1995, BIO-TECHNOL, V13, P955, DOI 10.1038/nbt0995-955; MILLER HI, 1997, POLICY CONTROVERSY B, pCH2; MILLER M, RUTGERS LAW REV, V45, P285; National Academy of Science Committee on the Introduction of Genetically Engineered Organisms into the Environment, 1987, INTRO RECOMBINANT DN; UDELMAN M, 1994, FEEDING 10 BILLION P; 1989, FIELD TESTING GENETI; 1988, BIOSAFETY MICROBIOLO	9	16	18	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1997	15	9					845	848		10.1038/nbt0997-845	http://dx.doi.org/10.1038/nbt0997-845			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XW410	9306396				2022-12-27	WOS:A1997XW41000023
J	Garabedian, TE				Garabedian, TE			Laboratory record keeping	NATURE BIOTECHNOLOGY			English	Editorial Material											Garabedian, TE (corresponding author), WIGGIN & DANA,1 CENTURY TOWER,NEW HAVEN,CT 06508, USA.								0	3	3	1	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					799	800		10.1038/nbt0897-799	http://dx.doi.org/10.1038/nbt0897-799			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255798				2022-12-27	WOS:A1997XM70700035
J	Nelson, TR; Lauber, AH				Nelson, TR; Lauber, AH			Minnesota's biotechnology portfolio	NATURE BIOTECHNOLOGY			English	Article									MAYO CLIN & MAYO FDN,DEPT LAB MED & PATHOL,DIV CLIN BIOCHEM,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT LAB MED & PATHOL,DIV IMMUNOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,MAYO MED VENTURES,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic	Nelson, TR (corresponding author), MAYO CLIN & MAYO FDN,DEPT LAB MED & PATHOL,DIV CLIN MOL GENOM,ROCHESTER,MN 55905, USA.							Blumenthal D, 1996, NEW ENGL J MED, V334, P368, DOI 10.1056/NEJM199602083340606; BLUMENTHAL D, 1986, SCIENCE, V232, P1361, DOI 10.1126/science.3715452; Haber E, 1996, NAT BIOTECHNOL, V14, P441, DOI 10.1038/nbt0496-441; MASSING DE, 1996, 5 YEAR SUMMARY TECHN	4	0	0	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					737	740		10.1038/nbt0897-737	http://dx.doi.org/10.1038/nbt0897-737			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255785	Bronze			2022-12-27	WOS:A1997XM70700022
J	Streelman, JT; Karl, SA				Streelman, JT; Karl, SA			Paradigms and the rise (or fall?) of molecular biology	NATURE BIOTECHNOLOGY			English	Editorial Material							REPETITIVE DNA; SEQUENCES; NOVELTY; BRCA1				Streelman, JT (corresponding author), UNIV S FLORIDA, DEPT BIOL, LIF 136, TAMPA, FL 33620 USA.							ALBERTSEN H, 1994, AM J HUM GENET, V54, P516; BAIRD PA, 1990, PERSPECT BIOL MED, V33, P203; BAND J, 1996, BIOESSAYS, V18, P937; BRAHMACHARI SK, 1995, ELECTROPHORESIS, V16, P1705, DOI 10.1002/elps.11501601283; BRITTEN RJ, 1971, Q REV BIOL, V46, P111, DOI 10.1086/406830; Britten RJ, 1996, P NATL ACAD SCI USA, V93, P9374, DOI 10.1073/pnas.93.18.9374; BULT CJ, 1996, SCIENCE, V273, P1053; BUSS LW, 1987, EVOLTUION INDIVIDUAL; CHARLESWORTH B, 1994, NATURE, V371, P215, DOI 10.1038/371215a0; Colwell RR, 1996, SCIENCE, V274, P2025, DOI 10.1126/science.274.5295.2025; DANLIKER PJ, 1997, SCIENCE, V275, P1465; FEDERMAN R, 1965, JOURNEY CHAOS S BECK; FONTANA W, 1994, P NATL ACAD SCI USA, V91, P757, DOI 10.1073/pnas.91.2.757; FREEMAN WH, 1989, AESTHETICS CHAOSMOS; Friedberg F, 1997, BIOESSAYS, V19, P181, DOI 10.1002/bies.950190214; HAMADA H, 1984, MOL CELL BIOL, V4, P2622, DOI 10.1128/MCB.4.12.2622; Hempel C., 1965, ASPECTS SCI EXPLANAT; Jacobs H, 1996, SCIENCE, V274, P17; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; Kuhn T., 1970, CRITICISM GROWTH KNO; LAKATOS I, 1993, CRITICISM GROWTH KNO; LEVIN DA, 1983, AM NAT, V122, P1, DOI 10.1086/284115; MASTERSON M, 1970, CRITICISM GROWTH KNO; Matzke MA, 1997, BIOESSAYS, V19, P92, DOI 10.1002/bies.950190116; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MIRSKY AE, 1951, J GEN PHYSIOL, V34, P451, DOI 10.1085/jgp.34.4.451; MNADELBROT CA, 1982, FRACTAL GEOMETRY NAT; Popper KR., 1981, CONJECTURES REFUTATI; PRINCETON NJ, 1980, GENE EXPRESSION; PRINCETON NJ, 1988, EVOLUTION COMPLEXITY; Prusiner SB, 1996, TRENDS BIOCHEM SCI, V21, P482, DOI 10.1016/S0968-0004(96)10063-3; Roush W, 1997, SCIENCE, V275, P1556, DOI 10.1126/science.275.5306.1556; Rowe C.J., 1986, PLATO PHAEDRUS; SOLTIS DE, 1989, EVOLUTION, V43, P586, DOI 10.1111/j.1558-5646.1989.tb04254.x; Strohman RC, 1997, NAT BIOTECHNOL, V15, P194, DOI 10.1038/nbt0397-194; Tsien JZ, 1996, CELL, V87, P1317, DOI 10.1016/S0092-8674(00)81826-7; Wilkins AS, 1996, BIOESSAYS, V18, P695, DOI 10.1002/bies.950180902; Witkowski JA, 1997, BIOESSAYS, V19, P181; Wu JG, 1995, Q REV BIOL, V70, P439, DOI 10.1086/419172; Yu Y, 1997, NATURE, V385, P552, DOI 10.1038/385552a0	40	6	7	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					696	697		10.1038/nbt0897-696	http://dx.doi.org/10.1038/nbt0897-696			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255773				2022-12-27	WOS:A1997XM70700005
J	Vasella, D				Vasella, D			Novartis' role in 21st century drug development	NATURE BIOTECHNOLOGY			English	Editorial Material											Vasella, D (corresponding author), NOVARTIS AG,BASEL,SWITZERLAND.								0	3	3	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1997	15	6					485	485		10.1038/nbt0697-485	http://dx.doi.org/10.1038/nbt0697-485			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XC772	9181555	Bronze			2022-12-27	WOS:A1997XC77200005
J	Hoyle, R				Hoyle, R			Bovine spongiform encephalopathy - The link between Creutzfeldt-Jakob disease and BSE	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	2	2	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1997	15	4					295	295		10.1038/nbt0497-295	http://dx.doi.org/10.1038/nbt0497-295			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WQ554	9094107	Bronze			2022-12-27	WOS:A1997WQ55400005
J	Volschenk, H; Viljoen, M; Grobler, J; Petzold, B; Bauer, F; Subden, RE; Young, RA; Lonvaud, A; Denayrolles, M; vanVuuren, HJJ				Volschenk, H; Viljoen, M; Grobler, J; Petzold, B; Bauer, F; Subden, RE; Young, RA; Lonvaud, A; Denayrolles, M; vanVuuren, HJJ			Engineering pathways for malate degradation in Saccharomyces cerevisiae	NATURE BIOTECHNOLOGY			English	Article						wine; malate; malolactic enzyme; malic enzyme; malate permease	MALOLACTIC FERMENTATION; ESCHERICHIA-COLI; SCHIZOSACCHAROMYCES-POMBE; SHUTTLE VECTORS; MALIC ENZYME; HOST STRAINS; CLONING; GENE; WINE; DEACIDIFICATION	Deacidification of grape musts is crucial for the production of well-balanced wines, especially in colder regions of the world. The major acids in wine are tartaric and malic acid. Saccharomyces cerevisiae cannot degrade malic acid efficiently due to the lack of a malate transporter and the low substrate affinity of its malic enzyme, We have introduced efficient pathways for malate degradation in S. cerevisiae by cloning and expressing the Schizosaccharomyces pombe malate permease (mae1) gene with either the S. pombe malic enzyme (mae2) or Lactococcus lactis malolactic (mleS) gene in this yeast, Under aerobic conditions, the recombinant strain expressing the mae1 and mae2 genes efficiently degraded 8 g/L of malate in a glycerol-ethanol medium within 7 days. The recombinant malolactic strain of S. cerevisiae (mae1 and mleS genes) fermented 4.5 g/L of malate in a synthetic grape must within 4 days.	UNIV STELLENBOSCH,DEPT MICROBIOL,ZA-7600 STELLENBOSCH,SOUTH AFRICA; UNIV STELLENBOSCH,INST BIOTECHNOL,ZA-7600 STELLENBOSCH,SOUTH AFRICA; UNIV GUELPH,DEPT MOL BIOL & GENET,GUELPH,ON N1G 2W1,CANADA; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; UNIV BORDEAUX 2,FAC OENOL,F-33405 TALENCE,FRANCE	Stellenbosch University; Stellenbosch University; University of Guelph; Massachusetts Institute of Technology (MIT); Whitehead Institute; UDICE-French Research Universities; Universite de Bordeaux			Bauer, Florian/A-1078-2013; Young, Richard A/F-6495-2012; Volschenk, Heinrich/L-8400-2015	Bauer, Florian/0000-0001-5764-4542; Young, Richard A/0000-0001-8855-8647; Volschenk, Heinrich/0000-0001-9287-0975; Viljoen-Bloom, Marinda/0000-0002-4825-2392; Lonvaud, Aline/0000-0002-9352-3366				Ansanay V, 1996, YEAST, V12, P215, DOI 10.1002/(SICI)1097-0061(19960315)12:3<215::AID-YEA903>3.0.CO;2-M; ANSANAY V, 1993, FEBS LETT, V332, P74, DOI 10.1016/0014-5793(93)80488-G; ARTUS NN, 1985, FEBS LETT, V182, P225, DOI 10.1016/0014-5793(85)80305-7; Beelman R. B., 1979, Advances in Food Research, V25, P1, DOI 10.1016/S0065-2628(08)60234-7; CHIRIO MC, 1990, EUR J BIOCHEM, V194, P293, DOI 10.1111/j.1432-1033.1990.tb19456.x; CROUS JM, 1995, CURR GENET, V28, P467, DOI 10.1007/BF00310817; DAVIS CR, 1985, AM J ENOL VITICULT, V36, P290; DENAYROLLES M, 1995, FEMS MICROBIOL LETT, V125, P3744; FUCK E, 1973, ARCH MIKROBIOL, V89, P223, DOI 10.1007/BF00422202; GALLANDER JF, 1977, AM J ENOL VITICULT, V28, P65; GAO C, 1995, FOOD MICROBIOL, V12, P65, DOI 10.1016/S0740-0020(95)80080-8; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Grobler J, 1995, YEAST, V11, P1485, DOI 10.1002/yea.320111503; HENICKKLING T, 1995, J APPL BACTERIOL, V79, pS29; KUNKEE RE, 1968, WINES VINES, V49, P23; LAING E, 1992, GENE, V121, P35, DOI 10.1016/0378-1119(92)90159-M; MACONI E, 1984, BIOCHEM J, V217, P685; MARTINEAU B, 1995, AM J ENOL VITICULT, V46, P385; MAYER K, 1963, ARCH MIKROBIOL, V46, P321, DOI 10.1007/BF00422193; Moore DD, 1995, GLOB MOB SURV; MURAI T, 1972, J BIOCHEM, V71, P1015, DOI 10.1093/oxfordjournals.jbchem.a129850; Radler F., 1993, WINE MICROBIOLOGY BI, VFleet, P165; Sambrook J., 2002, MOL CLONING LAB MANU; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TEMPERLI A, 1965, BIOCHIM BIOPHYS ACTA, V110, P630, DOI 10.1016/S0926-6593(65)80080-7; VANVUUREN HJJ, 1993, AM J ENOL VITICULT, V44, P99; VILJOEN M, 1994, YEAST, V10, P613, DOI 10.1002/yea.320100506; WILLIAMS SA, 1984, APPL ENVIRON MICROB, V47, P288, DOI 10.1128/AEM.47.2.288-293.1984; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	30	98	111	3	30	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1997	15	3					253	257		10.1038/nbt0397-253	http://dx.doi.org/10.1038/nbt0397-253			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WM050	9062925				2022-12-27	WOS:A1997WM05000029
J	Chahine, KG				Chahine, KG			Going beyond the native: Protecting DNA and protein patents	NATURE BIOTECHNOLOGY			English	Editorial Material											Chahine, KG (corresponding author), MADISON & METCALF,170 S MAIN ST,SALT LAKE CITY,UT 84101, USA.								0	0	0	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1997	15	2					183	&		10.1038/nbt0297-183	http://dx.doi.org/10.1038/nbt0297-183			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WE998	9035147				2022-12-27	WOS:A1997WE99800028
J	Gunst, JD; Pahus, MH; Rosas-Umbert, M; Lu, IN; Benfield, T; Nielsen, H; Johansen, IS; Mohey, R; Ostergaard, L; Klastrup, V; Khan, M; Schleimann, MH; Olesen, R; Stovring, H; Denton, PW; Kinloch, NN; Copertino, DC; Ward, AR; Alberto, WDC; Nielsen, SD; Puertas, MC; Ramos, V; Reeves, JD; Petropoulos, CJ; Martinez-Picado, J; Brumme, ZL; Jones, RB; Fox, J; Tolstrup, M; Nussenzweig, MC; Caskey, M; Fidler, S; Sogaard, OS				Gunst, Jesper D.; Pahus, Marie H.; Rosas-Umbert, Miriam; Lu, I-Na; Benfield, Thomas; Nielsen, Henrik; Johansen, Isik S.; Mohey, Rajesh; Ostergaard, Lars; Klastrup, Vibeke; Khan, Maryam; Schleimann, Mariane H.; Olesen, Rikke; Stovring, Henrik; Denton, Paul W.; Kinloch, Natalie N.; Copertino, Dennis C.; Ward, Adam R.; Alberto, Winiffer D. Conce; Nielsen, Silke D.; Puertas, Maria C.; Ramos, Victor; Reeves, Jacqueline D.; Petropoulos, Christos J.; Martinez-Picado, Javier; Brumme, Zabrina L.; Jones, R. Brad; Fox, Julie; Tolstrup, Martin; Nussenzweig, Michel C.; Caskey, Marina; Fidler, Sarah; Sogaard, Ole S.			Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial	NATURE MEDICINE			English	Article; Early Access							CD4(+) T-CELLS; VALPROIC ACID; IN-VIVO; THERAPY; RESERVOIR; ANTIBODIES; INFECTION; PERSISTENCE; VIREMIA; DRIVEN	Attempts to reduce the human immunodeficiency virus type 1 (HIV-1) reservoir and induce antiretroviral therapy (ART)-free virologic control have largely been unsuccessful. In this phase 1b/2a, open-label, randomized controlled trial using a four-group factorial design, we investigated whether early intervention in newly diagnosed people with HIV-1 with a monoclonal anti-HIV-1 antibody with a CD4-binding site, 3BNC117, followed by a histone deacetylase inhibitor, romidepsin, shortly after ART initiation altered the course of HIV-1 infection (NCT03041012). The trial was undertaken in five hospitals in Denmark and two hospitals in the United Kingdom. The coprimary endpoints were analysis of initial virus decay kinetics and changes in the frequency of CD4(+) T cells containing intact HIV-1 provirus from baseline to day 365. Secondary endpoints included changes in the frequency of infected CD4(+) T cells and virus-specific CD8(+) T cell immunity from baseline to day 365, pre-ART plasma HIV-1 3BNC117 sensitivity, safety and tolerability, and time to loss of virologic control during a 12-week analytical ART interruption that started at day 400. In 55 newly diagnosed people (5 females and 50 males) with HIV-1 who received random allocation treatment, we found that early 3BNC117 treatment with or without romidepsin enhanced plasma HIV-1 RNA decay rates compared to ART only. Furthermore, 3BNC117 treatment accelerated clearance of infected cells compared to ART only. All groups had significant reductions in the frequency of CD4(+) T cells containing intact HIV-1 provirus. At day 365, early 3BNC117 + romidepsin was associated with enhanced HIV-1 Gag-specific CD8(+) T cell immunity compared to ART only. The observed virological and immunological effects of 3BNC117 were most pronounced in individuals whose pre-ART plasma HIV-1 envelope sequences were antibody sensitive. The results were not disaggregated by sex. Adverse events were mild to moderate and similar between the groups. During a 12-week analytical ART interruption among 20 participants, 3BNC117-treated individuals harboring sensitive viruses were significantly more likely to maintain ART-free virologic control than other participants. We conclude that 3BNC117 at ART initiation enhanced elimination of plasma viruses and infected cells, enhanced HIV-1-specific CD8(+) immunity and was associated with sustained ART-free virologic control among persons with 3BNC117-sensitive virus. These findings strongly support interventions administered at the time of ART initiation as a strategy to limit long-term HIV-1 persistence.	[Gunst, Jesper D.; Pahus, Marie H.; Rosas-Umbert, Miriam; Ostergaard, Lars; Schleimann, Mariane H.; Olesen, Rikke; Nielsen, Silke D.; Tolstrup, Martin; Sogaard, Ole S.] Aarhus Univ, Dept Clin Med, Aarhus, Denmark; [Gunst, Jesper D.; Pahus, Marie H.; Rosas-Umbert, Miriam; Ostergaard, Lars; Klastrup, Vibeke; Schleimann, Mariane H.; Olesen, Rikke; Nielsen, Silke D.; Tolstrup, Martin; Sogaard, Ole S.] Aarhus Univ Hosp, Dept Infect Dis, Aarhus, Denmark; [Lu, I-Na] Univ Hosp Munster, Dept Neurol, Inst Translat Neurol, Munster, Germany; [Benfield, Thomas] Copenhagen Univ Hosp Amager & Hvidovre, Dept Infect Dis, Hvidovre, Denmark; [Nielsen, Henrik] Aalborg Univ Hosp, Dept Infect Dis, Aalborg, Denmark; [Nielsen, Henrik] Aalborg Univ, Dept Clin Med, Aalborg, Denmark; [Johansen, Isik S.] Univ Southern Denmark, Odense Univ Hosp, Dept Infect Dis, Odense, Denmark; [Mohey, Rajesh] Reg Hosp Herning, Dept Internal Med, Herning, Denmark; [Khan, Maryam; Fidler, Sarah] Imperial Coll Hosp, Dept Infect Dis, London, England; [Khan, Maryam; Fidler, Sarah] Imperial Biomed Res Ctr, Natl Inst Hlth Res, London, England; [Stovring, Henrik] Aarhus Univ, Dept Publ Hlth, Aarhus, Denmark; [Denton, Paul W.] Univ Nebraska, Dept Biol, Omaha, NE 68182 USA; [Kinloch, Natalie N.; Brumme, Zabrina L.] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC, Canada; [Kinloch, Natalie N.; Brumme, Zabrina L.] British Columbia Ctr Excellence HIV AIDS, Vancouver, BC, Canada; [Copertino, Dennis C.; Ward, Adam R.; Alberto, Winiffer D. Conce; Jones, R. Brad] Weill Cornell Med Coll, Dept Med, Infect Dis Div, New York, NY USA; [Copertino, Dennis C.; Alberto, Winiffer D. Conce; Jones, R. Brad] Weill Cornell Grad Sch Med Sci, Dept Microbiol & Immunol, New York, NY USA; [Puertas, Maria C.; Martinez-Picado, Javier] IrsiCaixa AIDS Res Inst, Badalona, Spain; [Puertas, Maria C.; Martinez-Picado, Javier] CIBERINFEC, Madrid, Spain; [Ramos, Victor; Nussenzweig, Michel C.; Caskey, Marina] Rockefeller Univ, Lab Mol Immunol, 1230 York Ave, New York, NY 10021 USA; [Reeves, Jacqueline D.; Petropoulos, Christos J.] Labcorp Monogram Biosci, San Francisco, CA USA; [Martinez-Picado, Javier] Univ Vic Cent Univ Catalonia, Vic, Spain; [Martinez-Picado, Javier] Catalan Inst Res & Adv Studies, Barcelona, Spain; [Fox, Julie] Guys & St Thomas Natl Hlth Serv Trust, Dept Genitourinary Med & Infect Dis, London, England; [Fox, Julie] Kings Coll London, Natl Inst Hlth Res Biomed Res Ctr, Dept Genitourinary Med & Infect Dis, London, England; [Nussenzweig, Michel C.] Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA	Aarhus University; Aarhus University; University of Munster; Aalborg University; Aalborg University Hospital; Aalborg University; University of Southern Denmark; Odense University Hospital; Aarhus University; Imperial College London; Aarhus University; University of Nebraska System; Simon Fraser University; B.C. Centre for Excellence in HIV/AIDS; Cornell University; Cornell University; Qatar Foundation (QF); Weill Cornell Medical College Qatar; Institut de Recerca de la Sida - IrsiCaixa; Rockefeller University; Universitat de Vic - Universitat Central de Catalunya (UVic-UCC); ICREA; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Howard Hughes Medical Institute; Rockefeller University	Sogaard, OS (corresponding author), Aarhus Univ, Dept Clin Med, Aarhus, Denmark.; Sogaard, OS (corresponding author), Aarhus Univ Hosp, Dept Infect Dis, Aarhus, Denmark.	olesoega@rm.dk		Fidler, Sarah/0000-0003-1676-7583; Nielsen, Silke/0000-0003-1374-0078; Copertino Jr, Dennis/0000-0002-3217-4713; fox, Julie/0000-0002-0583-8019; Gunst, Jesper/0000-0002-3787-0259; Olesen, Rikke/0000-0002-5157-080X; Benfield, Thomas/0000-0003-0698-9385; Rosas-Umbert, Miriam/0000-0002-2850-6586; Sogaard, Ole/0000-0001-9107-2023; Ostergaard, Lars/0000-0003-2459-0511; johansen, isik somuncu/0000-0002-2189-9823	Danish Council for Independent Research [7016-00022, 9060-00023B]; Central Region Denmark Research Fund; Danish Regions' Medicine and Treatment Fund; Aarhus University; National Institute of Allergy and Infectious Diseases of the National Institutes of Health [UM1AI164565]; Canadian Institutes for Health Research; Michael Smith Foundation for Health Research; Next Experimental Therapy Partnership	Danish Council for Independent Research(Det Frie Forskningsrad (DFF)); Central Region Denmark Research Fund; Danish Regions' Medicine and Treatment Fund; Aarhus University; National Institute of Allergy and Infectious Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Michael Smith Foundation for Health Research(Michael Smith Foundation for Health Research); Next Experimental Therapy Partnership	We thank all study participants who devoted time to our research as well as every clinical research unit involved in the study: at Aarhus University Hospital-study nurses Yordanos Yehdego, Ane SOndergaard and Ann Bach, physicians Janne T. Martinsen and Nina B. Staerke and lab technician Lene S. JOhnke; at Copenhagen University Hospital-Amager and Hvidovre-study nurses Dorthe K. Petersen and Louise Krohn-Dehli and lab technician Anna L. SOrensen; at Aalborg University Hospital-study nurses Maria R. Juhl and Kristine T. Pedersen; at Odense University Hospital-study nurses Susan O. Lindvig and Bente Ramskover; at Regional Hospital Herning-study nurses Kirsten Lillevang and Heidi G. SOrensen; at Imperial College Hospital-study nurses Rebecca Hall, Claire Petersen and Shelly Page, physician John Thornhill, lab technician Andrew O Lovell and study coordinator Tom Cole; at King's College London-study nurses Anele Waters, Rebekah Roberts, Hiromi Uzu and Andrea Berlanga and study coordinator Alice Sharp; and at the Danish Good Clinical Practice Units-monitors Lene Brandsborg, Inge M. Burmeister and Stine K. Hovgaard. We acknowledge Rockefeller University for providing 3BNC117 and Bristol-Myers Squibb Company (Celgene Corporation) for providing the RMD as well as the Labcorp-Monogram Biosciences Clinical Reference Laboratory for performing the phenotypic resistance assays with project management from Y. Lie and C. Kang. Finally, we would like to acknowledge the amazing support and help from the late Amin Alamshah, a kind and brilliant clinical project manager at the Imperial College Center for Translational and Experimental Medicine, who tragically lost his life before the completion of this study. The funders were not involved in the study design/operations, data collection/analysis/interpretation or preparation of the manuscript. This study is funded by the Danish Council for Independent Research (grant numbers: 7016-00022 and 9060-00023B to O.S.S.), the Central Region Denmark Research Fund, The Danish Regions' Medicine and Treatment Fund, Aarhus University and Next Experimental Therapy Partnership. Research reported in this publication was also supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (award number: UM1AI164565 to R.B.J.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. N.N.K. received a Vanier Award from the Canadian Institutes for Health Research. Z.L.B. received a scholar award from the Michael Smith Foundation for Health Research. Study drugs were donated free of charge by The Rockefeller University (3BNC117) and Celgene (romidepsin) for use in this trial. None of the specific sources of funding had any role in the conceptualization, design, data collection, analysis, decision to publish or preparation of the manuscript.	Abrahams MR, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw5589; Archin NM, 2012, NATURE, V487, P482, DOI 10.1038/nature11286; Archin NM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009390; Archin NM, 2008, AIDS, V22, P1131, DOI 10.1097/QAD.0b013e3282fd6df4; Archin NM, 2014, J INFECT DIS, V210, P728, DOI 10.1093/infdis/jiu155; Asokan M, 2020, P NATL ACAD SCI USA, V117, P18754, DOI 10.1073/pnas.2008236117; Austin PC, 2021, CAN J CARDIOL, V37, P1322, DOI 10.1016/j.cjca.2020.11.010; Bar-On Y, 2018, NAT MED, V24, P1701, DOI 10.1038/s41591-018-0186-4; Baxter AE, 2017, NAT PROTOC, V12, P2029, DOI 10.1038/nprot.2017.079; Baxter AE, 2016, CELL HOST MICROBE, V20, P368, DOI 10.1016/j.chom.2016.07.015; Besson GJ, 2014, CLIN INFECT DIS, V59, P1312, DOI 10.1093/cid/ciu585; Brodin J, 2016, ELIFE, V5, DOI 10.7554/eLife.18889; Brooks K, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008378; Bruner KM, 2019, NATURE, V566, P120, DOI 10.1038/s41586-019-0898-8; Buzon MJ, 2014, NAT MED, V20, P139, DOI 10.1038/nm.3445; CAMPION WM, 1989, J MARKETING RES, V26, P485, DOI 10.2307/3172772; Caskey M, 2019, NAT MED, V25, P547, DOI 10.1038/s41591-019-0412-8; Caskey M, 2017, NAT MED, V23, P185, DOI 10.1038/nm.4268; Caskey M, 2015, NATURE, V522, P487, DOI 10.1038/nature14411; Chomont N, 2009, NAT MED, V15, P893, DOI 10.1038/nm.1972; Collins DR, 2020, NAT REV IMMUNOL, V20, P471, DOI 10.1038/s41577-020-0274-9; Deeks SG, 2021, NAT MED, V27, P2085, DOI 10.1038/s41591-021-01590-5; DiLillo DJ, 2015, CELL, V161, P1035, DOI 10.1016/j.cell.2015.04.016; Dufloo J, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-28307-7; Elliott JH, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004473; Estes JD, 2017, NAT MED, V23, P1271, DOI 10.1038/nm.4411; Feng Q, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4179; Fidler S, 2020, LANCET, V395, P888, DOI 10.1016/S0140-6736(19)32990-3; Gaebler C, 2022, NATURE, V606, P368, DOI 10.1038/s41586-022-04597-1; Gaebler C, 2019, J EXP MED, V216, P2253, DOI 10.1084/jem.20190896; Gay Cynthia L, 2022, J Infect Dis, V225, P856, DOI 10.1093/infdis/jiab487; Grau-Exposito J, 2017, MBIO, V8, DOI [10.1128/mBio.00876-17, 10.1128/mbio.00876-17]; Gruell H, 2022, LANCET MICROBE, V3, pE203, DOI 10.1016/S2666-5247(21)00239-1; Gunst JD, 2017, AIDS, V31, P1665, DOI 10.1097/QAD.0000000000001524; Gunst JD, 2016, EXPERT REV ANTI-INFE, V14, P447, DOI 10.1586/14787210.2016.1164031; Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hiener B, 2017, CELL REP, V21, P813, DOI 10.1016/j.celrep.2017.09.081; Jaafoura S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6407; Jones BR, 2018, P NATL ACAD SCI USA, V115, pE8958, DOI 10.1073/pnas.1802028115; Julg B, 2019, LANCET HIV, V6, pE259, DOI 10.1016/S2352-3018(19)30052-9; Kinloch NN, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20442-3; Kroon EDMD, 2020, J VIRUS ERAD, V6, DOI 10.1016/j.jve.2020.100004; Lehrman G, 2005, LANCET, V366, P549, DOI 10.1016/S0140-6736(05)67098-5; Leth S, 2016, LANCET HIV, V3, pE463, DOI 10.1016/S2352-3018(16)30055-8; Li JZ, 2016, AIDS, V30, P343, DOI 10.1097/QAD.0000000000000953; Lu CL, 2016, SCIENCE, V352, P1001, DOI 10.1126/science.aaf1279; Markowitz M, 2014, JAIDS-J ACQ IMM DEF, V66, P140, DOI 10.1097/QAI.0000000000000111; Martin GE, 2020, J INFECT DIS, V221, P1135, DOI 10.1093/infdis/jiz563; McMahon DK, 2021, J INFECT DIS, V224, P648, DOI 10.1093/infdis/jiaa777; Mendoza P, 2018, NATURE, V561, P479, DOI 10.1038/s41586-018-0531-2; Mothe B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00823; Niessl J, 2020, NAT MED, V26, P222, DOI 10.1038/s41591-019-0747-1; Nishimura Y, 2017, NATURE, V543, P559, DOI 10.1038/nature21435; Parekh B. S., 2017, 9 IAS C HIV SCI; Petravic J, 2014, J VIROL, V88, P14050, DOI 10.1128/JVI.01701-14; Puertas MC, 2021, MBIO, V12, DOI 10.1128/mBio.00560-21; Rasmussen TA, 2014, LANCET HIV, V1, pE13, DOI 10.1016/S2352-3018(14)70014-1; Reece J, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002615; Reece JC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093330; Rosas-Umbert M., NAT COMMUN; Routy JP, 2012, HIV CLIN TRIALS, V13, P301, DOI 10.1310/hct1306-301; Royston P, 2009, STATA J, V9, P466, DOI 10.1177/1536867X0900900308; Scheid JF, 2011, SCIENCE, V333, P1633, DOI 10.1126/science.1207227; Schoofs T, 2016, SCIENCE, V352, P997, DOI 10.1126/science.aaf0972; Schulz KF, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-32; Shan L, 2012, IMMUNITY, V36, P491, DOI 10.1016/j.immuni.2012.01.014; Sogaard OS, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005142; Spencer DA, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-28250-7; Stefic K, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7030074; Stephenson KE, 2021, NAT MED, V27, P1718, DOI 10.1038/s41591-021-01509-0; Veenhuis RT, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.708355; Wang PF, 2020, P NATL ACAD SCI USA, V117, P18002, DOI 10.1073/pnas.2008190117; Wei DG, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004071	74	1	1	3	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02023-7	http://dx.doi.org/10.1038/s41591-022-02023-7		OCT 2022	36	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	5J9LQ	36253609	Bronze			2022-12-27	WOS:000869357500001
J	Li, Y; Basar, R; Wang, GH; Liu, EL; Moyes, JS; Li, L; Kerbauy, LN; Uprety, N; Fathi, M; Rezvan, A; Banerjee, PP; Muniz-Feliciano, L; Laskowski, TJ; Ensley, E; Daher, M; Shanley, M; Mendt, M; Acharya, S; Liu, B; Biederstadt, A; Rafei, H; Guo, XL; Garcia, LM; Lin, P; Ang, S; Marin, D; Chen, K; Bover, L; Champlin, RE; Varadarajan, N; Shpall, EJ; Rezvani, K				Li, Ye; Basar, Rafet; Wang, Guohui; Liu, Enli; Moyes, Judy S.; Li, Li; Kerbauy, Lucila N.; Uprety, Nadima; Fathi, Mohsen; Rezvan, Ali; Banerjee, Pinaki P.; Muniz-Feliciano, Luis; Laskowski, Tamara J.; Ensley, Emily; Daher, May; Shanley, Mayra; Mendt, Mayela; Acharya, Sunil; Liu, Bin; Biederstadt, Alexander; Rafei, Hind; Guo, Xingliang; Melo Garcia, Luciana; Lin, Paul; Ang, Sonny; Marin, David; Chen, Ken; Bover, Laura; Champlin, Richard E.; Varadarajan, Navin; Shpall, Elizabeth J.; Rezvani, Katayoun			KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape	NATURE MEDICINE			English	Article							NATURAL-KILLER-CELLS; T-CELL; RECEPTOR; IDENTIFICATION; IMMUNOTHERAPY; ACQUISITION; INTEGRATION; LYMPHOCYTES; ACTIVATION; CAPTURE	Trogocytosis is an active process that transfers surface material from targeted to effector cells. Using multiple in vivo tumor models and clinical data, we report that chimeric antigen receptor (CAR) activation in natural killer (NK) cells promoted transfer of the CAR cognate antigen from tumor to NK cells, resulting in (1) lower tumor antigen density, thus impairing the ability of CAR-NK cells to engage with their target, and (2) induced self-recognition and continuous CAR-mediated engagement, resulting in fratricide of trogocytic antigen-expressing NK cells (NKTROG+) and NK cell hyporesponsiveness. This phenomenon could be offset by a dual-CAR system incorporating both an activating CAR against the cognate tumor antigen and an NK self-recognizing inhibitory CAR that transferred a 'don't kill me' signal to NK cells upon engagement with their TROG(+) siblings. This system prevented trogocytic antigen-mediated fratricide, while sparing activating CAR signaling against the tumor antigen, and resulted in enhanced CAR-NK cell activity. A new dual-chimeric antigen receptor (CAR) system enhances the antitumor activity of CAR natural killer cells and makes them less susceptible to therapeutic resistance in preclinical models.	[Li, Ye; Basar, Rafet; Wang, Guohui; Liu, Enli; Moyes, Judy S.; Li, Li; Kerbauy, Lucila N.; Uprety, Nadima; Banerjee, Pinaki P.; Muniz-Feliciano, Luis; Laskowski, Tamara J.; Ensley, Emily; Daher, May; Shanley, Mayra; Mendt, Mayela; Acharya, Sunil; Liu, Bin; Biederstadt, Alexander; Rafei, Hind; Guo, Xingliang; Melo Garcia, Luciana; Lin, Paul; Ang, Sonny; Marin, David; Champlin, Richard E.; Shpall, Elizabeth J.; Rezvani, Katayoun] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA; [Li, Ye] Univ Texas MD Anderson Canc Ctr, Grad Sch Biomed Sci, UTHealth, Houston, TX USA; [Kerbauy, Lucila N.] Univ Sao Paulo, Biosci Inst, Dept Genet & Evolutionary Biol, Human Genome & Stem Cell Res Ctr, Sao Paulo, Brazil; [Kerbauy, Lucila N.] Hosp Israelita Albert Einstein, Dept Stem Cell Transplantat & Cellular Therapy, Sao Paulo, Brazil; [Fathi, Mohsen; Rezvan, Ali; Varadarajan, Navin] Univ Houston, Dept Chem & Biomol Engn, Houston, TX USA; [Biederstadt, Alexander] Tech Univ Munich, Dept Med Hematol & Oncol 3, Munich, Germany; [Chen, Ken] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX USA; [Bover, Laura] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX USA; [Bover, Laura] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; Universidade de Sao Paulo; Hospital Israelita Albert Einstein; University of Houston System; University of Houston; Technical University of Munich; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Rezvani, K (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA.	KRezvani@mdanderson.org		LI, YE/0000-0001-7727-0875; Fathi, Mohsen/0000-0001-9971-4166; REZVAN, ALI/0000-0002-1197-0198	Sally Cooper Murray endowment; National Institutes of Health (NIH) [1 R01CA211044-01, 5 P01CA148600-03, P50CA100632-16, R01GM143243]; CPRIT [RP180466]; Stand Up To Cancer Dream Team Research [SU2C-AACR-DT-29-19]; Leukemia Specialized Program of Research Excellence (SPORE) [P50CA100632]; NIH [P30 CA016672]; University of Texas MD Anderson Cancer Center Moon Shots Program	Sally Cooper Murray endowment; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CPRIT; Stand Up To Cancer Dream Team Research; Leukemia Specialized Program of Research Excellence (SPORE); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Texas MD Anderson Cancer Center Moon Shots Program	This work was supported in part by the generous philanthropic contributions to The University of Texas MD Anderson Cancer Center Moon Shots Program, and The Sally Cooper Murray endowment; and by grants (grant nos. 1 R01CA211044-01, 5 P01CA148600-03, P50CA100632-16 and R01GM143243) from the National Institutes of Health (NIH), CPRIT (grant no. RP180466), Stand Up To Cancer Dream Team Research (grant no. SU2C-AACR-DT-29-19) and the Leukemia Specialized Program of Research Excellence (SPORE) (grant no. P50CA100632); by a grant from the NIH to the MD Anderson Cancer Center Advanced Technology Genomics Core (ATGC) Facility (grant no. CA016672); and by the grant (no. P30 CA016672) from the NIH to the MD Anderson Cancer Center Flow Cytometry and Cellular Imaging Core Facility that assisted with the CyTOF studies. We thank E. Gokdemir, B. T. Whitfield and J. Lu for their technical assistance.	Ahmed KA, 2008, CELL MOL IMMUNOL, V5, P261, DOI 10.1038/cmi.2008.32; Alfons A, 2013, ANN APPL STAT, V7, P226, DOI 10.1214/12-AOAS575; Alhajjat Amir M, 2013, Chimerism, V4, P126, DOI 10.4161/chim.26666; Alter G, 2004, J IMMUNOL METHODS, V294, P15, DOI 10.1016/j.jim.2004.08.008; Anderson AC, 2016, IMMUNITY, V44, P989, DOI 10.1016/j.immuni.2016.05.001; Andre P, 2018, CELL, V175, P1731, DOI 10.1016/j.cell.2018.10.014; Anfossi N, 2006, IMMUNITY, V25, P331, DOI 10.1016/j.immuni.2006.06.013; Bettadapur A, 2020, INFECT IMMUN, V88, DOI 10.1128/IAI.00930-19; Bryceson YT, 2008, CURR OPIN IMMUNOL, V20, P344, DOI 10.1016/j.coi.2008.03.005; Carlsten M, 2016, CLIN CANCER RES, V22, P5211, DOI 10.1158/1078-0432.CCR-16-1108; Caumartin J, 2007, EMBO J, V26, P1423, DOI 10.1038/sj.emboj.7601570; Cheng M, 2013, CELL MOL IMMUNOL, V10, P230, DOI 10.1038/cmi.2013.10; Daher M, 2021, CLIN TRANSL IMMUNOL, V10, DOI 10.1002/cti2.1274; Daher M, 2021, BLOOD, V137, P624, DOI 10.1182/blood.2020007748; Dance A, 2019, P NATL ACAD SCI USA, V116, P17608, DOI 10.1073/pnas.1912252116; Domaica CI, 2009, EMBO REP, V10, P908, DOI 10.1038/embor.2009.92; Du X, 2007, J IMMUNOTHER, V30, P607, DOI 10.1097/CJI.0b013e318053ed8e; Elliott JM, 2011, TRENDS IMMUNOL, V32, P364, DOI 10.1016/j.it.2011.06.001; Fang F, 2017, SEMIN IMMUNOL, V31, P37, DOI 10.1016/j.smim.2017.07.009; Gardiner CM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00367; Gill S, 2012, BLOOD, V119, P5758, DOI 10.1182/blood-2012-03-415364; Good CR, 2021, CELL, V184, P6081, DOI 10.1016/j.cell.2021.11.016; Hamieh M, 2019, NATURE, V568, P112, DOI 10.1038/s41586-019-1054-1; Hochreiter-Hufford A, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008748; Hoyos V, 2010, LEUKEMIA, V24, P1160, DOI 10.1038/leu.2010.75; Hsi ED, 2008, CLIN CANCER RES, V14, P2775, DOI 10.1158/1078-0432.CCR-07-4246; Hudrisier D, 2007, J IMMUNOL, V178, P3637, DOI 10.4049/jimmunol.178.6.3637; Joly E, 2003, NAT IMMUNOL, V4, P815, DOI 10.1038/ni0903-815; Judge SJ, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00049; Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977; Kirwan SE, 2005, J IMMUNOL, V175, P5006, DOI 10.4049/jimmunol.175.8.5006; Koehl U, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1115178; Li L, 2019, BLOOD ADV, V3, P4117, DOI 10.1182/bloodadvances.2019000835; Li Y, 2018, CELL STEM CELL, V23, P181, DOI 10.1016/j.stem.2018.06.002; Liadi I, 2015, CANCER IMMUNOL RES, V3, P473, DOI 10.1158/2326-6066.CIR-14-0195; Liu E, 2018, LEUKEMIA, V32, P520, DOI 10.1038/leu.2017.226; Liu EL, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.626098; Liu EL, 2020, NEW ENGL J MED, V382, P545, DOI 10.1056/NEJMoa1910607; Lohr JG, 2012, P NATL ACAD SCI USA, V109, P3879, DOI 10.1073/pnas.1121343109; Long EO, 2013, ANNU REV IMMUNOL, V31, P227, DOI 10.1146/annurev-immunol-020711-075005; Lu T, 2021, CANCER IMMUNOL RES, V9, P1229, DOI 10.1158/2326-6066.CIR-20-1014; Ma XT, 2018, NATURE, V555, P371, DOI 10.1038/nature25795; McIntyre MSF, 2008, J IMMUNOL, V181, P2271, DOI 10.4049/jimmunol.181.4.2271; Merino A, 2019, J CLIN INVEST, V129, P3770, DOI 10.1172/JCI125916; Merouane A, 2015, BIOINFORMATICS, V31, P3189, DOI 10.1093/bioinformatics/btv355; Meyaard L, 1997, IMMUNITY, V7, P283, DOI 10.1016/S1074-7613(00)80530-0; Miner CA, 2015, J IMMUNOL, V194, P1945, DOI 10.4049/jimmunol.1402408; Miyake K, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10051255; Myers JA, 2022, JCI INSIGHT, V7, DOI 10.1172/jci.insight.150079; Myers JA, 2021, NAT REV CLIN ONCOL, V18, P85, DOI 10.1038/s41571-020-0426-7; Nakamura K, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26529; Nakamura K, 2013, P NATL ACAD SCI USA, V110, P9421, DOI 10.1073/pnas.1300140110; O'Brien KL, 2019, NAT REV IMMUNOL, V19, P282, DOI 10.1038/s41577-019-0139-2; Olson ML, 2022, LEUKEMIA, V36, P1943, DOI 10.1038/s41375-022-01585-2; Pegram HJ, 2011, IMMUNOL CELL BIOL, V89, P216, DOI 10.1038/icb.2010.78; Pesce S, 2017, J ALLERGY CLIN IMMUN, V139, P335, DOI 10.1016/j.jaci.2016.04.025; Poorebrahim M, 2021, ONCOGENE, V40, P421, DOI 10.1038/s41388-020-01501-x; Przepiorka D, 1994, Ther Immunol, V1, P77; Silence K, 2014, MABS-AUSTIN, V6, P523, DOI 10.4161/mabs.27398; Simonetta F, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00241; Tabiasco J, 2003, J IMMUNOL, V170, P5993, DOI 10.4049/jimmunol.170.12.5993; Tabiasco J, 2002, EUR J IMMUNOL, V32, P1502, DOI 10.1002/1521-4141(200205)32:5<1502::AID-IMMU1502>3.0.CO;2-Y; Tai YT, 2008, BLOOD, V112, P1329, DOI 10.1182/blood-2007-08-107292; Taylor RP, 2015, BLOOD, V125, P762, DOI 10.1182/blood-2014-10-569244; Van Gassen S, 2015, CYTOM PART A, V87A, P636, DOI 10.1002/cyto.a.22625; Vera J, 2006, BLOOD, V108, P3890, DOI 10.1182/blood-2006-04-017061; Vivier E, 2004, SCIENCE, V306, P1517, DOI 10.1126/science.1103478; Wu ZG, 2021, SCI SIGNAL, V14, DOI 10.1126/scisignal.abe5380; Zah E, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16160-5; Zenarruzabeitia O, 2015, J IMMUNOL, V194, P5053, DOI 10.4049/jimmunol.1500304	70	0	0	11	11	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2022	28	10								10.1038/s41591-022-02003-x	http://dx.doi.org/10.1038/s41591-022-02003-x		SEP 2022	30	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	6U5KV	36175679				2022-12-27	WOS:000863159000002
J	Acosta, JN; Falcone, GJ; Rajpurkar, P; Topol, EJ				Acosta, Julian N.; Falcone, Guido J.; Rajpurkar, Pranav; Topol, Eric J.			Multimodal biomedical AI	NATURE MEDICINE			English	Review							UK BIOBANK; HEALTH-CARE; BIG DATA; CLINICAL-TRIALS; PLATFORM; FUSION; TECHNOLOGY; PREDICTION; MEDICINE; COVID-19	Multimodal artificial intelligence models could unlock many exciting applications in health and medicine; this Review outlines the most promising uses and the technical pitfalls to avoid. The increasing availability of biomedical data from large biobanks, electronic health records, medical imaging, wearable and ambient biosensors, and the lower cost of genome and microbiome sequencing have set the stage for the development of multimodal artificial intelligence solutions that capture the complexity of human health and disease. In this Review, we outline the key applications enabled, along with the technical and analytical challenges. We explore opportunities in personalized medicine, digital clinical trials, remote monitoring and care, pandemic surveillance, digital twin technology and virtual health assistants. Further, we survey the data, modeling and privacy challenges that must be overcome to realize the full potential of multimodal artificial intelligence in health.	[Acosta, Julian N.; Falcone, Guido J.] Yale Sch Med, Dept Neurol, New Haven, CT USA; [Rajpurkar, Pranav] Harvard Med Sch, Dept Biomed Informat, Boston, MA 02115 USA; [Topol, Eric J.] Scripps Res, Scripps Res Translat Inst, La Jolla, CA 92037 USA	Yale University; Harvard University; Harvard Medical School; Scripps Research Institute	Rajpurkar, P (corresponding author), Harvard Med Sch, Dept Biomed Informat, Boston, MA 02115 USA.; Topol, EJ (corresponding author), Scripps Res, Scripps Res Translat Inst, La Jolla, CA 92037 USA.	pranav_rajpurkar@hms.harvard.edu; etopol@scripps.edu		Acosta, Julian/0000-0001-6497-5454; Rajpurkar, Pranav/0000-0002-8030-3727; Topol, Eric/0000-0002-1478-4729	NIH [UL1TR002550]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank A. Tamkin for invaluable feedback. NIH grant UL1TR002550 (to E.J.T.) supported this work.	1000 Genomes Project Consortium, 2015, Nature, V526, P68, DOI 10.1038/nature15393; AbbVie, 2019, SYNTH CONTR ARM END; Addington J, 2012, SCHIZOPHR RES, V142, P77, DOI 10.1016/j.schres.2012.09.012; Akbari H., 2021, ADV NEURAL INF PROCE, V34, P24206, DOI DOI 10.48550/ARXIV.2104.11178; All Us Res Program Investigators, 2019, NEW ENGL J MED, V381, P668, DOI 10.1056/NEJMsr1809937; Arges K, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-0290-y; Baevski A., PREPRINT; Bai X, 2021, NAT MACH INTELL, V3, P1081, DOI 10.1038/s42256-021-00421-z; Ballantyne A, 2020, J MED ETHICS, V46, P289, DOI 10.1136/medethics-2018-105340; Baltrusaitis T, 2019, IEEE T PATTERN ANAL, V41, P423, DOI 10.1109/TPAMI.2018.2798607; Bao H., 2022, PREPRINT; Barbieri S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58053-z; Bergenstrahle L, 2022, NAT BIOTECHNOL, V40, P476, DOI 10.1038/s41587-021-01075-3; Berisha V, 2021, NPJ DIGIT MED, V4, DOI 10.1038/s41746-021-00521-5; Bierer BE, 2017, NEW ENGL J MED, V376, P1684, DOI 10.1056/NEJMsb1616595; Bjornsson B, 2019, GENOME MED, V12, DOI 10.1186/s13073-019-0701-3; Boehm KM, 2022, NAT REV CANCER, V22, P114, DOI 10.1038/s41568-021-00408-3; Borgeaud S., 2022, ICML, V162, P2206; Boulos MNK, 2021, J PERS MED, V11, DOI 10.3390/jpm11080745; Bycroft C, 2018, NATURE, V562, P203, DOI 10.1038/s41586-018-0579-z; Casey BJ, 2013, NAT REV NEUROSCI, V14, P810, DOI 10.1038/nrn3621; Che ZP, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24271-9; Chen JH, 2017, NEW ENGL J MED, V376, P2507, DOI 10.1056/NEJMp1702071; Chen ZM, 2011, INT J EPIDEMIOL, V40, P1652, DOI 10.1093/ije/dyr120; Choi SW, 2020, NAT PROTOC, V15, P2759, DOI 10.1038/s41596-020-0353-1; Claxton S, 2021, NPJ DIGIT MED, V4, DOI 10.1038/s41746-021-00472-x; Coffey JD, 2021, NPJ DIGIT MED, V4, DOI 10.1038/s41746-021-00490-9; Coorey G, 2021, NAT REV CARDIOL, V18, P803, DOI 10.1038/s41569-021-00630-4; Damask A, 2020, CIRCULATION, V141, P624, DOI 10.1161/CIRCULATIONAHA.119.044434; Dayan I, 2021, NAT MED, V27, P1735, DOI 10.1038/s41591-021-01506-3; Dean J., 2021, INTRO PATHWAYS NEXT; Deasy J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-79142-z; Dixon Ronald F, 2020, J Diabetes Sci Technol, V14, P908, DOI 10.1177/1932296819888662; Dosovitskiy A., 2021, INT C LEARNING REPRE; Duan R, 2021, PLOS COMPUT BIOL, V17, DOI 10.1371/journal.pcbi.1009224; Dunn J, 2021, NAT MED, V27, P1105, DOI 10.1038/s41591-021-01339-0; Echle A, 2021, BRIT J CANCER, V124, P686, DOI 10.1038/s41416-020-01122-x; Esteva A, 2021, NPJ DIGIT MED, V4, DOI 10.1038/s41746-020-00376-2; Esteva A, 2019, NAT MED, V25, P24, DOI 10.1038/s41591-018-0316-z; Fisher CK, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49656-2; Fiterau Madalina, 2017, Proc Mach Learn Res, V68, P59; Food and Drug Administration, 2020, NUCL AC BAS TESTS; Food and Drug Administration, LIST CLEAR APPR COMP; Food and Drug Administration, 2017, FDA APPR 1 TREATM FO; Foundation Medicine, 2018, WHY COMPR GEN PROF; Fry A, 2017, AM J EPIDEMIOL, V186, P1026, DOI 10.1093/aje/kwx246; Garg R, 2019, J STROKE CEREBROVASC, V28, P2045, DOI 10.1016/j.jstrokecerebrovasdis.2019.02.004; Gaziano JM, 2016, J CLIN EPIDEMIOL, V70, P214, DOI 10.1016/j.jclinepi.2015.09.016; Gerke S., 2020, ARTIF INTELLI HLTH, V11326, P213; Gichoya JW, 2022, LANCET DIGIT HEALTH, V4, pE406, DOI 10.1016/S2589-7500(22)00063-2; Golbus JR, 2021, LANCET DIGIT HEALTH, V3, pE707, DOI 10.1016/S2589-7500(21)00138-2; Griffith GJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19478-2; Guu K., 2020, PROC ICML, P3929; Halldorsson B.V., 2021, BIORXIV, V2011, P468246, DOI [10.1101/2021.11.16.468246, DOI 10.1101/2021.11.16.468246]; Haneuse S, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.0184; Haque A, 2020, NATURE, V585, P193, DOI 10.1038/s41586-020-2669-y; He B, 2020, NAT BIOMED ENG, V4, P827, DOI 10.1038/s41551-020-0578-x; Heitzer E, 2019, NAT REV GENET, V20, P71, DOI 10.1038/s41576-018-0071-5; Hendricks LA, 2021, T ASSOC COMPUT LING, V9, P570, DOI 10.1162/tacl_a_00385; Hernandez-Boussard T, 2021, NAT MED, V27, P2065, DOI 10.1038/s41591-021-01558-5; Hripcsak G, 2015, STUD HEALTH TECHNOL, V216, P574, DOI 10.3233/978-1-61499-564-7-574; Huang SC, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78888-w; Huang SC, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-00341-z; Hughes JW, 2021, EBIOMEDICINE, V73, DOI 10.1016/j.ebiom.2021.103613; Inan OT, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-0302-y; Intel, 2022, EDG COMP IS DRIV ADV; Iqbal SMA, 2021, NPJ FLEX ELECTRON, V5, DOI 10.1038/s41528-021-00107-x; Jabbour S, 2022, J AM MED INFORM ASSN, V29, P1060, DOI 10.1093/jamia/ocac030; Jaegle A., 2021, P MACHINE LEARNING R, V139, P4651; Jaegle A., 2022, P INT C LEARN REPR; Janssens ACJW, 2019, HUM MOL GENET, V28, pR143, DOI 10.1093/hmg/ddz205; Johnson AEW, 2019, SCI DATA, V6, DOI 10.1038/s41597-019-0322-0; Johnson AEW, 2016, SCI DATA, V3, DOI 10.1038/sdata.2016.35; Kaissis GA, 2020, NAT MACH INTELL, V2, P305, DOI 10.1038/s42256-020-0186-1; Kang M, 2022, BRIEF BIOINFORM, V23, DOI 10.1093/bib/bbab454; Karczewski KJ, 2018, NAT REV GENET, V19, P299, DOI 10.1038/nrg.2018.4; Kaushal A, 2020, JAMA-J AM MED ASSOC, V324, P1212, DOI 10.1001/jama.2020.12067; Kellogg RA, 2018, CIRC RES, V122, P1169, DOI 10.1161/CIRCRESAHA.117.310909; Keyes KM, 2019, LANCET, V393, P1297, DOI 10.1016/S0140-6736(18)33067-8; Kihara Y., 2022, OPHTHALMOLOGY, DOI [10.1016/j.ophtha.2022.02.017, DOI 10.1016/J.OPHTHA.2022.02.017]; Klarin D, 2021, NAT REV CARDIOL, DOI 10.1038/s41569-021-00638-w; Koutsouleris N, 2021, JAMA PSYCHIAT, V78, P195, DOI 10.1001/jamapsychiatry.2020.3604; Kuchroo M, 2022, NAT BIOTECHNOL, V40, P681, DOI 10.1038/s41587-021-01186-x; Kwolek B, 2014, COMPUT METH PROG BIO, V117, P489, DOI 10.1016/j.cmpb.2014.09.005; Li, 2020, PREPRINT, DOI [10.48550/arXiv.2004.06165, DOI 10.48550/ARXIV.2004.06165]; Li J., PREPRINT; Li J, 2021, NPJ DIGIT MED, V4, DOI 10.1038/s41746-021-00518-0; Liddell K, 2021, J LAW BIOSCI, V8, DOI 10.1093/jlb/lsab023; Littlejohns TJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15948-9; Loree JM, 2019, JAMA ONCOL, V5, DOI 10.1001/jamaoncol.2019.1870; Lu K., 2021, PREPRINT; Luo Z., 2018, P MACH LEARN RES, V85, P1; Mandel JC, 2016, J AM MED INFORM ASSN, V23, P899, DOI 10.1093/jamia/ocv189; Mapes BM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234962; Marra C, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-0259-x; Marston NA, 2020, CIRCULATION, V141, P616, DOI 10.1161/CIRCULATIONAHA.119.043805; Marx V, 2021, NAT METHODS, V18, P9, DOI 10.1038/s41592-020-01033-y; Masison J, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2024287118; McCarthy S, 2016, NAT GENET, V48, P1279, DOI 10.1038/ng.3643; McDonald D, 2018, MSYSTEMS, V3, DOI 10.1128/mSystems.00031-18; Moon KR, 2019, NAT BIOTECHNOL, V37, P1482, DOI 10.1038/s41587-019-0336-3; Moore TJ, 2018, JAMA INTERN MED, V178, P1451, DOI 10.1001/jamainternmed.2018.3931; Muhammad G, 2021, INFORM FUSION, V76, P355, DOI 10.1016/j.inffus.2021.06.007; Nagai A, 2017, J EPIDEMIOL, V27, pS2, DOI 10.1016/j.je.2016.12.005; Nagrani A., 2021, P ADV NEUR INF PROC, V34, P14200; Narayanan A, 2008, P IEEE S SECUR PRIV, P111, DOI 10.1109/SP.2008.33; Nichol A. Q., 2022, PROC 39 INT C MACHIN, V162, P16784; Noah B, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-017-0002-4; Obermeyer Z, 2019, SCIENCE, V366, P447, DOI 10.1126/science.aax2342; San Omer, 2021, NAT COMPUT SCI, V1, P307, DOI 10.1038/s43588-021-00077-0; Oncotype IQ, 2020, ONC MAP PAN CANC TIS; Owen MJ, 2021, NEW ENGL J MED, V384, P2159, DOI 10.1056/NEJMc2100365; Pallmann P, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1017-7; Pandit JA, 2022, NAT BIOTECHNOL, V40, P1013, DOI 10.1038/s41587-022-01350-x; Parmar P, 2022, NPJ DIGIT MED, V5, DOI 10.1038/s41746-022-00560-6; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Patel MS, 2018, NEW ENGL J MED, V378, P214, DOI 10.1056/NEJMp1712984; Perkins DO, 2015, SCHIZOPHRENIA BULL, V41, P419, DOI 10.1093/schbul/sbu099; Potter D, 2020, JCO CLIN CANCER INFO, V4, P929, DOI 10.1200/CCI.20.00064; Quer G, 2021, NAT MED, V27, P73, DOI 10.1038/s41591-020-1123-x; Radford A, 2021, PR MACH LEARN RES, V139; Radin JM, 2020, LANCET DIGIT HEALTH, V2, pE85, DOI 10.1016/S2589-7500(19)30222-5; Rajpurkar P, 2022, NAT MED, V28, P31, DOI 10.1038/s41591-021-01614-0; Rajpurkar P, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-00322-2; Ramesh A, 2021, PR MACH LEARN RES, V139; Rannikmae K, 2020, NEUROLOGY, V95, pE697, DOI 10.1212/WNL.0000000000009924; Reed S., PREPRINT; Rieke N, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-00323-1; Rocher L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10933-3; Sandfort V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52737-x; Scheibner J, 2021, J MED INTERNET RES, V23, DOI 10.2196/25120; Sertkaya A, 2016, CLIN TRIALS, V13, P117, DOI 10.1177/1740774515625964; Shilo S, 2020, NAT MED, V26, P29, DOI 10.1038/s41591-019-0727-5; Sidransky D, 2002, NAT REV CANCER, V2, P210, DOI 10.1038/nrc755; Sirugo G, 2019, CELL, V177, P26, DOI 10.1016/j.cell.2019.02.048; Steinhubl SR, 2019, NPJ DIGIT MED, V2, DOI 10.1038/s41746-019-0203-0; Steinhubl SR, 2018, JAMA-J AM MED ASSOC, V320, P146, DOI 10.1001/jama.2018.8102; Strain T, 2020, NAT MED, V26, DOI 10.1038/s41591-020-1012-3; Swanson JM, 2012, LANCET, V380, P110, DOI 10.1016/S0140-6736(12)61179-9; Swedish Digital Twin Consortium, US; Syrowatka A, 2021, NPJ DIGIT MED, V4, DOI 10.1038/s41746-021-00459-8; Szustakowski JD, 2021, NAT GENET, V53, P942, DOI 10.1038/s41588-021-00885-0; Taliun Daniel, 2021, Nature, V590, P290, DOI 10.1038/s41586-021-03205-y; Tamkin A., 35 C NEUR INF PROC S; Tang SP, 2020, J AM MED INFORM ASSN, V27, P1921, DOI 10.1093/jamia/ocaa139; Thompson LA, 2021, ECLINICALMEDICINE, V37, DOI 10.1016/j.eclinm.2021.100936; Thorlund K, 2020, CLIN EPIDEMIOL, V12, P457, DOI 10.2147/CLEP.S242097; Tomasev N, 2019, NATURE, V572, P116, DOI 10.1038/s41586-019-1390-1; Topol EJ, 2019, NAT MED, V25, P44, DOI 10.1038/s41591-018-0300-7; Uffelmann E, 2021, NAT REV METHOD PRIME, V1, DOI 10.1038/s43586-021-00056-9; Unlearn.AI, 2019, GEN SYNTH CONTR SUBJ; US Food and Drug Administration, 2018, FRAM FDAS REAL WORLD; Vamathevan J, 2019, NAT REV DRUG DISCOV, V18, P463, DOI 10.1038/s41573-019-0024-5; van Smeden M, 2021, J CLIN EPIDEMIOL, V131, P89, DOI 10.1016/j.jclinepi.2020.11.006; Vaswani A, 2017, ADV NEUR IN, V30; Vokinger Kerstin N, 2021, Commun Med (Lond), V1, P25, DOI 10.1038/s43856-021-00028-w; Walsh J. R., 2020, PREPRINT; Walter K, 2015, NATURE, V526, P82, DOI 10.1038/nature14962; Wang C., 2017, 2017 IEEE SMARTWORLD, P1; Wang CJ, 2020, JAMA-J AM MED ASSOC, V323, P1341, DOI 10.1001/jama.2020.3151; Wang TX, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23774-w; Warnat-Herresthal S, 2021, NATURE, V594, P265, DOI 10.1038/s41586-021-03583-3; Watanabe K, 2019, NAT GENET, V51, P1339, DOI 10.1038/s41588-019-0481-0; Whitelaw S, 2020, LANCET DIGIT HEALTH, V2, pE435, DOI 10.1016/S2589-7500(20)30142-4; Wood A, 2020, ACM COMPUT SURV, V53, DOI 10.1145/3394658; Woodfield R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140533; Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9; Zhang X., 2022, INT C LEARNING REPRE; Zhang XM, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.690049; Zhang Y., 2020, PREPRINT; Zhou HY, 2022, NAT MACH INTELL, V4, P32, DOI 10.1038/s42256-021-00425-9; Zhou Z, 2019, P IEEE, V107, P1738, DOI 10.1109/JPROC.2019.2918951; Ziller A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-93030-0; Zou J, 2021, EBIOMEDICINE, V67, DOI 10.1016/j.ebiom.2021.103358	177	2	2	42	42	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2022	28	9					1773	1784		10.1038/s41591-022-01981-2	http://dx.doi.org/10.1038/s41591-022-01981-2		SEP 2022	12	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4S0LI	36109635	Bronze			2022-12-27	WOS:000854720900010
J	Chaft, JE; Oezkan, F; Kris, MG; Bunn, PA; Wistuba, II; Kwiatkowski, DJ; Owen, DH; Tang, Y; Johnson, BE; Lee, JM; Lozanski, G; Pietrzak, M; Seweryn, M; Byun, WY; Schulze, K; Nicholas, A; Johnson, A; Grindheim, J; Hilz, S; Shames, DS; Rivard, C; Toloza, E; Haura, EB; McNamee, CJ; Patterson, GA; Waqar, SN; Rusch, VW; Carbone, DP				Chaft, Jamie E.; Oezkan, Filiz; Kris, Mark G.; Bunn, Paul A.; Wistuba, Ignacio I.; Kwiatkowski, David J.; Owen, Dwight H.; Tang, Yan; Johnson, Bruce E.; Lee, Jay M.; Lozanski, Gerard; Pietrzak, Maciej; Seweryn, Michal; Byun, Woo Yul; Schulze, Katja; Nicholas, Alan; Johnson, Ann; Grindheim, Jessica; Hilz, Stephanie; Shames, David S.; Rivard, Chris; Toloza, Eric; Haura, Eric B.; McNamee, Ciaran J.; Patterson, G. Alexander; Waqar, Saiama N.; Rusch, Valerie W.; Carbone, David P.		LCMC Study Investigators	Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial	NATURE MEDICINE			English	Article; Early Access							PATHOLOGICAL RESPONSE; HLA-E; CHEMOTHERAPY; MULTICENTER; BLOCKADE; CRITERIA; COMPLEX	In an ongoing, open-label, single-arm phase II study (NCT02927301), 181 patients with untreated, resectable, stage IB-IIIB non-small cell lung cancer received two doses of neoadjuvant atezolizumab monotherapy. The primary end point was major pathological response (MPR; <= 10% viable malignant cells) in resected tumors without EGFR or ALK alterations. Of the 143 patients in the primary end point analysis, the MPR was 20% (95% confidence interval, 14-28%). With a minimum duration of follow-up of 3 years, the 3-year survival rate of 80% was encouraging. The most common adverse events during the neoadjuvant phase were fatigue (39%, 71 of 181) and procedural pain (29%, 53 of 181), along with expected immune-related toxicities; there were no unexpected safety signals. In exploratory analyses, MPR was predicted using the pre-treatment peripheral blood immunophenotype based on 14 immune cell subsets. Immune cell subsets predictive of MPR in the peripheral blood were also identified in the tumor microenvironment and were associated with MPR. This study of neoadjuvant atezolizumab in a large cohort of patients with resectable non-small cell lung cancer was safe and met its primary end point of MPR >= 15%. Data from this single-arm, non-randomized trial suggest that profiles of innate immune cells in pre-treatment peripheral blood may predict pathological response after neoadjuvant atezolizumab, but additional studies are needed to determine whether these profiles can inform patient selection and new therapeutic approaches.	[Chaft, Jamie E.; Kris, Mark G.; Rusch, Valerie W.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Chaft, Jamie E.; Kris, Mark G.] Weill Cornell Med Coll, New York, NY USA; [Oezkan, Filiz; Owen, Dwight H.; Carbone, David P.] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH 43210 USA; [Oezkan, Filiz] Univ Med Essen, Univ Duisburg Essen, Dept Intervent Pulmonol, Ruhrlandklin, Essen, Germany; [Oezkan, Filiz] German Canc Res Ctr, A420, Heidelberg, Germany; [Oezkan, Filiz] Univ Med Mannheim, Fac Univ Heidelberg, Sect Pulmonol, Med Dept 5, Mannheim, Germany; [Bunn, Paul A.; Rivard, Chris] Univ Colorado, Sch Med, Aurora, CO USA; [Wistuba, Ignacio I.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Kwiatkowski, David J.; Johnson, Bruce E.; McNamee, Ciaran J.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Kwiatkowski, David J.; Tang, Yan; Johnson, Bruce E.; McNamee, Ciaran J.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Owen, Dwight H.; Lozanski, Gerard; Pietrzak, Maciej; Seweryn, Michal; Byun, Woo Yul] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA; [Lee, Jay M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Seweryn, Michal] Univ Lodz, Dept Mol Biophys, Biobank Lab, Lodz, Poland; [Seweryn, Michal] Univ Lodz, Ctr Data Anal Modeling & Computat Sci, Lodz, Poland; [Schulze, Katja; Nicholas, Alan; Johnson, Ann; Grindheim, Jessica; Hilz, Stephanie; Shames, David S.] Genentech Inc, San Francisco, CA 94080 USA; [Toloza, Eric; Haura, Eric B.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA; [Patterson, G. Alexander; Waqar, Saiama N.] Washington Univ, Sch Med, St Louis, MO USA; [Carbone, David P.] Pelotonia Inst Immunooncol, Columbus, OH 43210 USA	Memorial Sloan Kettering Cancer Center; Cornell University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Texas System; UTMD Anderson Cancer Center; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; University System of Ohio; Ohio State University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Lodz; University of Lodz; Roche Holding; Genentech; H Lee Moffitt Cancer Center & Research Institute; Washington University (WUSTL)	Carbone, DP (corresponding author), Ohio State Univ, Comprehens Canc Ctr, Columbus, OH 43210 USA.; Carbone, DP (corresponding author), Pelotonia Inst Immunooncol, Columbus, OH 43210 USA.	david.carbone@osumc.edu		Byun, Woo Yul/0000-0001-8686-638X; Kwiatkowski, David/0000-0002-5668-5219	Deutsche Forschungsgemeinschaft [OE698/1-1]; Genentech	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Genentech(Roche HoldingGenentech)	The authors thank the patients and their families, the study investigators and clinical site staff and the collaborating laboratories for biomarker testing. The authors thank J. Minna, LCMC3 Steering Committee member and consultant. The authors thank R.L. Kitzler and R. Pearson for their contributions to the IMMUNOME analysis. Clinical trial and operations support was provided by E. Brandao, Senior Clinical Trial Leader, M. Rocha, Clinical Program Leader, A. Gopalakrishnan, Senior Biosample Operations Manager and A. Stone, Principal Biosample Operations Manager. The LCMC3 study was funded by Genentech. Medical writing support for the development of this manuscript, under the direction of the authors, was provided by Ashfield MedComms, an Ashfield Health company and was funded by Genentech. F.O. was supported by the Deutsche Forschungsgemeinschaft (OE698/1-1).	Anagnostou V, 2019, CANCER RES, V79, P1214, DOI 10.1158/0008-5472.CAN-18-1127; Andre P, 2018, CELL, V175, P1731, DOI 10.1016/j.cell.2018.10.014; Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Borst L, 2020, CLIN CANCER RES, V26, P5549, DOI 10.1158/1078-0432.CCR-19-2095; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Brierley JD, 2017, TNM CLASSIFICATION M; Carenza C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01325; Cascone T, 2021, NAT MED, V27, P504, DOI 10.1038/s41591-020-01224-2; Caushi JX, 2021, NATURE, V596, P126, DOI 10.1038/s41586-021-03752-4; Chaft JE, 2016, J THORAC ONCOL, V11, P537, DOI 10.1016/j.jtho.2015.12.104; Dacic S, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.106; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Fehlings M, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0695-9; Forde PM, 2018, NEW ENGL J MED, V378, P1976, DOI 10.1056/NEJMoa1716078; Forde PM, 2022, NEW ENGL J MED, V386, P1973, DOI 10.1056/NEJMoa2202170; Hellmann MD, 2014, LANCET ONCOL, V15, pE42, DOI 10.1016/S1470-2045(13)70334-6; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Kamiya T, 2019, J CLIN INVEST, V129, P2094, DOI 10.1172/JCI123955; Khan M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00167; Lee N, 1998, P NATL ACAD SCI USA, V95, P5199, DOI 10.1073/pnas.95.9.5199; Liu L, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.597468; Nielsen N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031959; Pataer A, 2021, J THORAC ONCOL, V16, P1289, DOI 10.1016/j.jtho.2021.03.029; Pataer A, 2012, J THORAC ONCOL, V7, P825, DOI 10.1097/JTO.0b013e318247504a; Peng Q, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18570-x; Provencio M, 2020, LANCET ONCOL, V21, P1413, DOI 10.1016/S1470-2045(20)30453-8; Rempala GA, 2013, J MATH BIOL, V67, P1339, DOI 10.1007/s00285-012-0589-7; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Scagliotti GV, 2012, J CLIN ONCOL, V30, P172, DOI 10.1200/JCO.2010.33.7089; Shu CA, 2020, LANCET ONCOL, V21, P786, DOI 10.1016/S1470-2045(20)30140-6; Socinski MA., 2018, NEW ENGL J MED, V378, P2288, DOI [DOI 10.1056/NEJMOA1716948, 10.1056/NEJMoa1716948]; The Comprehensive R Archive Network, 2021, PLSMS LIN SMOOTH PRE; Travis WD, 2020, J THORAC ONCOL, V15, P709, DOI 10.1016/j.jtho.2020.01.005; van Hall T, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0761-3; Villa-Alvarez M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02917; Voss SD, 1998, J IMMUNOL, V160, P1618; Wakelee HA, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.8500; West H, 2019, LANCET ONCOL, V20, P924, DOI 10.1016/S1470-2045(19)30167-6; Wu CL, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.608614; Wu TD, 2016, METHODS MOL BIOL, V1418, P283, DOI 10.1007/978-1-4939-3578-9_15; Wu TD, 2010, BIOINFORMATICS, V26, P873, DOI 10.1093/bioinformatics/btq057	43	2	2	5	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01962-5	http://dx.doi.org/10.1038/s41591-022-01962-5		SEP 2022	25	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4L9HT	36097216	hybrid, Green Published			2022-12-27	WOS:000852940800010
J	Prainsack, B; Forgo, N				Prainsack, Barbara; Forgo, Nikolaus			Why paying individual people for their health data is a bad idea comment	NATURE MEDICINE			English	Editorial Material; Early Access							PRIVACY	Paying individual people for their health data will widen inequalities and reduce altruism, luring people to sell their privacy. Health data should instead be treated as collective property, and commercial profits should be shared with the public.	[Prainsack, Barbara; Forgo, Nikolaus] Univ Vienna, Res Platform Governance Digital Practices, Vienna, Austria	University of Vienna	Prainsack, B (corresponding author), Univ Vienna, Res Platform Governance Digital Practices, Vienna, Austria.	barbara.prainsack@univie.ac.at		Forgo, Nikolaus/0000-0002-8176-4971; Prainsack, Barbara/0000-0002-6335-1532				AfriSight, PAN PORT; Aiello C., 2018, CNBC; [Anonymous], 2017, ECONOMIST; [Anonymous], 2020, AFRICAN UNION; Elvy SA, 2017, COLUMBIA LAW REV, V117, P1369; Hiltzik Michael, 2015, LOS ANGELES TIMES; Hummel P., 2020, PHILOS TECHNOL, V34, P545, DOI [10.1007/S13347-020-00404-9, DOI 10.1007/S13347-020-00404-9, 10.1007/s13347-020-00404-9]; Kickbusch I, 2021, LANCET, V398, P1727, DOI 10.1016/S0140-6736(21)01824-9; Kukutai T., 2016, INDIGENOUS DATA SOVE, DOI [10.22459/CAEPR38.11.2016, DOI 10.22459/CAEPR38.11.2016]; Meadows M, 2001, FDA Consum, V35, P18; Montgomery J, 2017, NEW BIOETH, V23, P81, DOI 10.1080/20502877.2017.1314893; Nemitz P., 2021, REGULATING BIG TECH, P290; Pasquale F., 2017, LAW POLITICAL EC BLO; Ralston W., 2021, WIRED; Tahir D., 2015, POLITICO; Tarran B., 2012, RESEARCHLIVE; Thimmesch AB, 2016, DENVER LAW REV, V94, P145; Walgreens, 2019, US; Weichert T, 2021, US; Wellcome Trust and Ipsos MORI Social Research Institute, 2016, US	20	0	0	1	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01955-4	http://dx.doi.org/10.1038/s41591-022-01955-4		SEP 2022	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4L9HT	36097218	Bronze			2022-12-27	WOS:000852940800005
J	Shivacharan, RS; Rolle, CE; Barbosa, DAN; Cunningham, TN; Feng, A; Johnson, ND; Safer, DL; Bohon, C; Keller, C; Buch, VP; Parker, JJ; Azagury, DE; Tass, PA; Bhati, MT; Malenka, RC; Lock, JD; Halpern, CH				Shivacharan, Rajat S.; Rolle, Camarin E.; Barbosa, Daniel A. N.; Cunningham, Tricia N.; Feng, Austin; Johnson, Noriah D.; Safer, Debra L.; Bohon, Cara; Keller, Corey; Buch, Vivek P.; Parker, Jonathon J.; Azagury, Dan E.; Tass, Peter A.; Bhati, Mahendra T.; Malenka, Robert C.; Lock, James D.; Halpern, Casey H.			Pilot study of responsive nucleus accumbens deep brain stimulation for loss-of-control eating	NATURE MEDICINE			English	Article							BARIATRIC SURGERY; DISORDER; REWARD; FOOD	Nucleus accumbens, low-frequency, responsive deep brain stimulation improved self-control of food intake and weight loss in two patients with binge eating disorder and severe obesity Cravings that precede loss of control (LOC) over food consumption present an opportunity for intervention in patients with the binge eating disorder (BED). In this pilot study, we used responsive deep brain stimulation (DBS) to record nucleus accumbens (NAc) electrophysiology during food cravings preceding LOC eating in two patients with BED and severe obesity (trial registration no. NCT03868670). Increased NAc low-frequency oscillations, prominent during food cravings, were used to guide DBS delivery. Over 6 months, we observed improved self-control of food intake and weight loss. These findings provide early support for restoring inhibitory control with electrophysiologically-guided NAc DBS. Further work with increased sample sizes is required to determine the scalability of this approach.	[Shivacharan, Rajat S.; Cunningham, Tricia N.; Feng, Austin; Johnson, Noriah D.; Buch, Vivek P.; Parker, Jonathon J.; Tass, Peter A.; Bhati, Mahendra T.] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA; [Rolle, Camarin E.; Barbosa, Daniel A. N.; Halpern, Casey H.] Univ Penn, Perelman Sch Med, Dept Neurosurg, Richards Med Res Labs,Penn Hosp, Philadelphia, PA 19104 USA; [Johnson, Noriah D.; Safer, Debra L.; Bohon, Cara; Keller, Corey; Bhati, Mahendra T.; Lock, James D.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA; [Keller, Corey] Vet Affairs Palo Alto Healthcare Syst, Palo Alto, CA USA; [Keller, Corey] Sierra Pacific Mental Illness Res Educ & Clin Ctr, Palo Alto, CA USA; [Azagury, Dan E.] Stanford Univ, Sch Med, Dept Surg, Stanford, CA 94305 USA; [Malenka, Robert C.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Nancy Pritzker Lab, Stanford, CA 94305 USA; [Halpern, Casey H.] Corporal Michael J Crescenz Vet Affairs Med Ctr, Dept Surg, Philadelphia, PA 19104 USA	Stanford University; University of Pennsylvania; Pennsylvania Medicine; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; Stanford University	Halpern, CH (corresponding author), Univ Penn, Perelman Sch Med, Dept Neurosurg, Richards Med Res Labs,Penn Hosp, Philadelphia, PA 19104 USA.; Halpern, CH (corresponding author), Corporal Michael J Crescenz Vet Affairs Med Ctr, Dept Surg, Philadelphia, PA 19104 USA.	casey.halpern@pennmedicine.upenn.edu		Buch, Vivek/0000-0003-1151-6128; Safer, Debra/0000-0002-9874-2277; Bohon, Cara/0000-0001-9978-3727; Alves Neiva Barbosa, Daniel/0000-0001-7272-1446; Keller, Corey/0000-0003-0529-3490	National Institutes of Health [5UH3NS103446-02, 1R01MH124760-01A1]; Blume Foundation; Burroughs Wellcome Fund Career Award for Medical Scientists [R01MH129018]; John A. Blume Foundation; National Institute of Mental Health [K23 MH106794]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Blume Foundation; Burroughs Wellcome Fund Career Award for Medical Scientists(Burroughs Wellcome Fund); John A. Blume Foundation; National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This work was supported by the National Institutes of Health (grant no. 5UH3NS103446-02 and 1R01MH124760-01A1 CHH). C.H.H. received funding for this work from the Blume Foundation. C.J.K. was supported by grant no. R01MH129018 and the Burroughs Wellcome Fund Career Award for Medical Scientists. P.A.T. gratefully acknowledges funding support by the John A. Blume Foundation. C.B. was supported by the National Institute of Mental Health (grant no. K23 MH106794). We thank the study subjects for their dedication and commitment to this new, human exploratory trial, and the members of the Stanford Clinical and Translational Research Unit and the Departments of Neurosurgery and Psychiatry at Stanford Medicine for space to conduct in-clinic assessments, the Suthana laboratory for in-clinic tool support, I. Kratter, T. Prieto, V. Ngo and B. Sanjanwala for support during surgery and intraoperative testing and E. Mirro, T. L. Skarpaas, N. Hasulak and T. Tcheng for providing technical support for the NeuroPace RNS System.	Adamantidis AR, 2019, NAT REV NEUROSCI, V20, P746, DOI 10.1038/s41583-019-0223-4; American psychiatric association, 2013, DIAGNOSTIC STAT MANU, DOI 10.1176/appi.books.9780890425596; Avants BB., 2009, INSIGHT J, V2, P1, DOI DOI 10.54294/UVNHIN; Barbosa D. A., 2022, MOL PSYCHIATR, P1; Bohon C, 2009, INT J EAT DISORDER, V42, P210, DOI 10.1002/eat.20615; Chao AM, 2016, OBESITY, V24, P2327, DOI 10.1002/oby.21648; Chiken S, 2016, NEUROSCIENTIST, V22, P313, DOI 10.1177/1073858415581986; Christoffel DJ, 2021, NAT COMMUN, V12, DOI [10.1038/s41467-021-22430-7, 10.1038/s41467-021-22430-7|]; Demos KE, 2012, J NEUROSCI, V32, P5549, DOI 10.1523/JNEUROSCI.5958-11.2012; Grucza RA, 2007, COMPR PSYCHIAT, V48, P124, DOI 10.1016/j.comppsych.2006.08.002; Halpern CH, 2013, J NEUROSCI, V33, P7122, DOI 10.1523/JNEUROSCI.3237-12.2013; Hudson JI, 2010, AM J CLIN NUTR, V91, P1568, DOI 10.3945/ajcn.2010.29203; Kakusa B, 2021, NEUROBIOL DIS, V154, DOI 10.1016/j.nbd.2021.105348; Mahajan UV., 2021, CLIN TRIALS INVESTIG, P1; McConnell GC, 2012, J NEUROSCI, V32, P15657, DOI 10.1523/JNEUROSCI.2824-12.2012; McCuen-Wurst C, 2018, ANN NY ACAD SCI, V1411, P96, DOI 10.1111/nyas.13467; Oishi Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00781-4; Oostenveld R, 2011, COMPUT INTEL NEUROSC, V2011, DOI 10.1155/2011/156869; Ramasubbu R, 2018, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00302; Reents J, 2021, FRONT PSYCHOL, V12, DOI 10.3389/fpsyg.2021.660880; Roitman MF, 2004, J NEUROSCI, V24, P1265, DOI 10.1523/JNEUROSCI.3823-03.2004; Smith CT, 2016, J NEUROPHYSIOL, V115, P1146, DOI 10.1152/jn.00261.2015; Sullivan CRP, 2021, NEUROIMAGE, V225, DOI 10.1016/j.neuroimage.2020.117515; Taha SA, 2006, J NEUROSCI, V26, P217, DOI 10.1523/JNEUROSCI.3227-05.2006; Telch CF, 1996, INT J EAT DISORDER, V20, P271, DOI 10.1002/(SICI)1098-108X(199611)20:3&lt;271::AID-EAT6&gt;3.0.CO;2-L; Thomas GP, 2015, MED DEVICES-EVID RES, V8, P405, DOI 10.2147/MDER.S62853; Topalovic U, 2020, NEURON, V108, P322, DOI 10.1016/j.neuron.2020.08.021; White MA, 2010, J CLIN PSYCHIAT, V71, P175, DOI 10.4088/JCP.08m04328blu; Wu H, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2109269118; Wu H, 2020, NEUROSURGERY, V87, P1277, DOI 10.1093/neuros/nyaa300; Wu H, 2018, P NATL ACAD SCI USA, V115, P192, DOI 10.1073/pnas.1712214114	31	0	0	7	7	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2022	28	9					1791	+		10.1038/s41591-022-01941-w	http://dx.doi.org/10.1038/s41591-022-01941-w		AUG 2022	13	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4S0LI	36038628	Green Published, hybrid, Green Submitted			2022-12-27	WOS:000847267200002
J	Chatila, WK; Kim, JK; Walch, H; Marco, MR; Chen, CT; Wu, F; Omer, DM; Khalil, DN; Ganesh, K; Qu, X; Luthra, A; Choi, SH; Ho, YJ; Kundra, R; Groves, KI; Chow, OS; Cercek, A; Weiser, MR; Widmar, M; Wei, IH; Pappou, EP; Nash, GM; Paty, PB; Shi, Q; Vakiani, E; Selcuklu, SD; Donoghue, MTA; Solit, DB; Berger, MF; Shia, JR; Pelossof, R; Romesser, PB; Yaeger, R; Smith, JJ; Schultz, N; Sanchez-Vega, F; Garcia-Aguilar, J				Chatila, Walid K.; Kim, Jin K.; Walch, Henry; Marco, Michael R.; Chen, Chin-Tung; Wu, Fan; Omer, Dana M.; Khalil, Danny N.; Ganesh, Karuna; Qu, Xuan; Luthra, Anisha; Choi, Seo-Hyun; Ho, Yu-Jui; Kundra, Ritika; Groves, Katharine I.; Chow, Oliver S.; Cercek, Andrea; Weiser, Martin R.; Widmar, Maria; Wei, Iris H.; Pappou, Emmanouil P.; Nash, Garrett M.; Paty, Philip B.; Shi, Qian; Vakiani, Efsevia; Duygu Selcuklu, S.; Donoghue, Mark T. A.; Solit, David B.; Berger, Michael F.; Shia, Jinru; Pelossof, Raphael; Romesser, Paul B.; Yaeger, Rona; Smith, J. Joshua; Schultz, Nikolaus; Sanchez-Vega, Francisco; Garcia-Aguilar, Julio			Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer	NATURE MEDICINE			English	Article; Early Access							PATHOLOGICAL COMPLETE RESPONSE; DOSE-ESCALATION; LANDSCAPE; SIGNATURES; HETEROGENEITY; EXPRESSION; INHIBITOR; MUTATIONS; EXCISION; INTERVAL	The incidence of rectal cancer is increasing in patients younger than 50 years. Locally advanced rectal cancer is still treated with neoadjuvant radiation, chemotherapy and surgery, but recent evidence suggests that patients with a complete response can avoid surgery permanently. To define correlates of response to neoadjuvant therapy, we analyzed genomic and transcriptomic profiles of 738 untreated rectal cancers. APC mutations were less frequent in the lower than in the middle and upper rectum, which could explain the more aggressive behavior of distal tumors. No somatic alterations had significant associations with response to neoadjuvant therapy in a treatment-agnostic manner, but KRAS mutations were associated with faster relapse in patients treated with neoadjuvant chemoradiation followed by consolidative chemotherapy. Overexpression of IGF2 and L1CAM was associated with decreased response to neoadjuvant therapy. RNA-sequencing estimates of immune infiltration identified a subset of microsatellite-stable immune hot tumors with increased response and prolonged disease-free survival. DNA and RNA sequencing in large cohorts of patients with rectal cancer treated with neoadjuvant therapies identifies biomarkers of response that could inform patient selection for non-operative treatment strategies.	[Chatila, Walid K.; Walch, Henry; Luthra, Anisha; Kundra, Ritika; Duygu Selcuklu, S.; Donoghue, Mark T. A.; Solit, David B.; Berger, Michael F.; Schultz, Nikolaus] Mem Sloan Kettering Canc Ctr, Marie Josee & Henry R Kravis Ctr Mol Oncol, 1275 York Ave, New York, NY 10021 USA; [Chatila, Walid K.; Walch, Henry; Luthra, Anisha; Kundra, Ritika; Schultz, Nikolaus; Sanchez-Vega, Francisco] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, 1275 York Ave, New York, NY 10021 USA; [Chatila, Walid K.] Weill Cornell Med Coll, Tri Inst Program Computat Biol & Med, New York, NY USA; [Kim, Jin K.; Marco, Michael R.; Chen, Chin-Tung; Wu, Fan; Omer, Dana M.; Qu, Xuan; Luthra, Anisha; Choi, Seo-Hyun; Groves, Katharine I.; Weiser, Martin R.; Widmar, Maria; Wei, Iris H.; Pappou, Emmanouil P.; Nash, Garrett M.; Paty, Philip B.; Pelossof, Raphael; Smith, J. Joshua; Sanchez-Vega, Francisco; Garcia-Aguilar, Julio] Mem Sloan Kettering Canc Ctr, Dept Surg, Colorectal Serv, 1275 York Ave, New York, NY 10021 USA; [Chen, Chin-Tung; Wu, Fan; Ganesh, Karuna; Cercek, Andrea; Weiser, Martin R.; Pappou, Emmanouil P.; Paty, Philip B.; Vakiani, Efsevia; Shia, Jinru; Pelossof, Raphael; Romesser, Paul B.; Yaeger, Rona; Smith, J. Joshua; Sanchez-Vega, Francisco; Garcia-Aguilar, Julio] Mem Sloan Kettering Canc Ctr, Colorectal Canc Res Ctr, 1275 York Ave, New York, NY 10021 USA; [Khalil, Danny N.; Ganesh, Karuna; Solit, David B.; Romesser, Paul B.; Yaeger, Rona] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA; [Khalil, Danny N.] Parker Inst Canc Immunotherapy, New York, NY USA; [Khalil, Danny N.] Weill Cornell Med, New York, NY USA; [Ho, Yu-Jui] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY USA; [Groves, Katharine I.; Berger, Michael F.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY USA; [Chow, Oliver S.] New York Presbyterian, Dept Cardiothorac Surg, Weill Cornell Med, New York, NY USA; [Shi, Qian] Mayo Clin, Dept Quantitat Hlth Sci, Rochester, MN USA; [Vakiani, Efsevia; Berger, Michael F.; Shia, Jinru] Mem Sloan Kettering Canc Ctr, Dept Pathol & Lab Med, New York, NY USA; [Romesser, Paul B.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; NewYork-Presbyterian Hospital; Mayo Clinic; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Sanchez-Vega, F (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, 1275 York Ave, New York, NY 10021 USA.; Sanchez-Vega, F; Garcia-Aguilar, J (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, Colorectal Serv, 1275 York Ave, New York, NY 10021 USA.; Sanchez-Vega, F; Garcia-Aguilar, J (corresponding author), Mem Sloan Kettering Canc Ctr, Colorectal Canc Res Ctr, 1275 York Ave, New York, NY 10021 USA.	sanchezf@mskcc.org; garciaaj@mskcc.org		Wu, Fan/0000-0002-3960-320X; Kim, Jin/0000-0002-4373-1431; Ganesh, Karuna/0000-0002-4948-1082	National Cancer Institute (NCI) Cancer Center Support Grant (CCSG) [P30 CA008748-53]; NCI Cancer Center Support Grant (CCSG) [P30 CA08748]; National Institutes of Health (NIH) [T32 GM132083]; NIH/NCI early career development award [K08 CA255574]; NIH/NCI [R37 248289]	National Cancer Institute (NCI) Cancer Center Support Grant (CCSG); NCI Cancer Center Support Grant (CCSG)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NCI early career development award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors acknowledge the use of services provided by the Molecular Cytology Core Facility, funded by the National Cancer Institute (NCI) Cancer Center Support Grant (CCSG, P30 CA008748-53). The authors also acknowledge the use of the Integrated Genomics Operation Core, funded by the NCI Cancer Center Support Grant (CCSG, P30 CA08748), Cycle for Survival, and the Marie-Josee and Henry R. Kravis Center for Molecular Oncology. W.K.C. is supported by a National Institutes of Health (NIH) research training grant (T32 GM132083). P.B.R. is supported by an NIH/NCI early career development award (K08 CA255574). J.J.S. is supported by an NIH/NCI R37 248289 award. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.	Alexandrov LB, 2020, NATURE, V578, P94, DOI 10.1038/s41586-020-1943-3; Bendell JC, 2012, J CLIN ONCOL, V30, P282, DOI 10.1200/JCO.2011.36.1360; Bielski CM, 2018, CANCER CELL, V34, P852, DOI 10.1016/j.ccell.2018.10.003; Bielski CM, 2018, NAT GENET, V50, P1189, DOI 10.1038/s41588-018-0165-1; Bindea G, 2013, IMMUNITY, V39, P782, DOI 10.1016/j.immuni.2013.10.003; Budinska E, 2013, J PATHOL, V231, P63, DOI 10.1002/path.4212; Cancer Genome Atlas Network, 2012, NATURE, V487, P330, DOI [10.1038/nature11252, DOI 10.1038/NATURE11252]; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cercek A, 2020, CLIN CANCER RES, V26, P3271, DOI 10.1158/1078-0432.CCR-19-3728; Chakravarty Debyani, 2017, JCO Precis Oncol, V2017, DOI 10.1200/PO.17.00011; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Cheng DT, 2015, J MOL DIAGN, V17, P251, DOI 10.1016/j.jmoldx.2014.12.006; Cheng LJ, 2019, J GASTROINTEST SURG, V23, P1474, DOI 10.1007/s11605-018-04072-1; Chow OS, 2016, ANN SURG ONCOL, V23, P2548, DOI 10.1245/s10434-016-5205-4; Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762; Cleary JM, 2021, CLIN CANCER RES, V27, P2996, DOI 10.1158/1078-0432.CCR-21-0066; Davoli T, 2017, SCIENCE, V355, DOI 10.1126/science.aaf8399; Durinck S, 2009, NAT PROTOC, V4, P1184, DOI 10.1038/nprot.2009.97; Eide PW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16747-x; El Din KS, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-06766-9; El Sissy C, 2020, CLIN CANCER RES, V26, P5198, DOI 10.1158/1078-0432.CCR-20-0337; Francois Y, 1999, J CLIN ONCOL, V17, P2396, DOI 10.1200/JCO.1999.17.8.2396; Ganesh K, 2020, NAT CANCER, V1, P28, DOI 10.1038/s43018-019-0006-x; Ganesh K, 2019, NAT REV GASTRO HEPAT, V16, P361, DOI 10.1038/s41575-019-0126-x; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garcia-Aguilar J, 2022, J CLIN ONCOL, V40, P2546, DOI 10.1200/JCO.22.00032; Garcia-Aguilar J, 2015, LANCET ONCOL, V16, P1537, DOI 10.1016/S1470-2045(15)00215-6; Garcia-Aguilar J, 2015, LANCET ONCOL, V16, P957, DOI 10.1016/S1470-2045(15)00004-2; Garcia-Aguilar J, 2011, ANN SURG, V254, P486, DOI 10.1097/SLA.0b013e31822b8cfa; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Infante JR, 2012, LANCET ONCOL, V13, P773, DOI 10.1016/S1470-2045(12)70270-X; Kamran SC, 2019, CLIN CANCER RES, V25, P5561, DOI 10.1158/1078-0432.CCR-19-0908; Kim JK, 2021, MOL ONCOL, V15, P2766, DOI 10.1002/1878-0261.12960; Kirilovsky Amos, 2022, Oncotarget, V13, P18, DOI 10.18632/oncotarget.28100; Korkeila E, 2009, BRIT J CANCER, V100, P874, DOI 10.1038/sj.bjc.6604949; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Lee MS, 2017, J NATL COMPR CANC NE, V15, P411, DOI 10.6004/jnccn.2017.0038; Lee-Kong SA, 2012, DIS COLON RECTUM, V55, P990, DOI 10.1097/DCR.0b013e31825bd80c; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Liu Y, 2018, CANCER CELL, V33, P721, DOI 10.1016/j.ccell.2018.03.010; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Marr R, 2005, ANN SURG, V242, P74, DOI 10.1097/01.sla.0000167926.60908.15; Mondaca S, 2020, GASTROENTEROLOGY, V159, P1975, DOI 10.1053/j.gastro.2020.07.041; Moore HG, 2004, DIS COLON RECTUM, V47, P279, DOI 10.1007/s10350-003-0062-1; Nagtegaal ID, 2005, J CLIN ONCOL, V23, P9257, DOI 10.1200/JCO.2005.02.9231; Nikolouzakis TK, 2019, ANN GASTROENTEROL, V32, P431, DOI 10.20524/aog.2019.0407; Nishimura T, 2000, CANCER CHEMOTH PHARM, V46, pS52, DOI 10.1007/PL00014051; Niu BF, 2014, BIOINFORMATICS, V30, P1015, DOI 10.1093/bioinformatics/btt755; Pages F, 2018, LANCET, V391, P2128, DOI 10.1016/S0140-6736(18)30789-X; Patel SV, 2016, J SURG ONCOL, V114, P637, DOI 10.1002/jso.24358; Probst CP, 2015, J AM COLL SURGEONS, V221, P430, DOI 10.1016/j.jamcollsurg.2015.04.010; Rahma OE, 2021, JAMA ONCOL, V7, P1225, DOI 10.1001/jamaoncol.2021.1683; Roxburgh CSD, 2019, COLORECTAL DIS, V21, P1140, DOI 10.1111/codi.14713; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; Schrag D, 2019, CLIN TRIALS, V16, P165, DOI 10.1177/1740774518824539; Shen RL, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw520; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Smith JJ, 2019, JAMA ONCOL, V5, DOI 10.1001/jamaoncol.2018.5896; Smith JJ, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1632-z; Taylor AM, 2018, CANCER CELL, V33, P676, DOI 10.1016/j.ccell.2018.03.007; Thorsson V, 2018, IMMUNITY, V48, P812, DOI [10.1016/j.immuni.2018.03.023, 10.1016/j.immuni.2019.08.004]; van Geel RMJM, 2017, CANCER DISCOV, V7, P610, DOI 10.1158/2159-8290.CD-16-0795; Yaeger R, 2018, CANCER CELL, V33, P125, DOI 10.1016/j.ccell.2017.12.004; Yang H, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07255-9; Zanella ER, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010445; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333	69	5	5	4	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01930-z	http://dx.doi.org/10.1038/s41591-022-01930-z		AUG 2022	26	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3T9PT	35970919				2022-12-27	WOS:000840603000002
J	Vrooman, LM; Diller, LR				Vrooman, Lynda M.; Diller, Lisa R.			Predicting chronic morbidity in childhood cancer survivors	NATURE MEDICINE			English	News Item; Early Access							ADULT SURVIVORS; OBESITY	Incorporating genetic factors into risk models improves the prediction of severe obesity for survivors of childhood cancer, which could promote early interventions and better long-term care.	[Vrooman, Lynda M.; Diller, Lisa R.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Vrooman, Lynda M.; Diller, Lisa R.] Boston Childrens Hosp, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital	Vrooman, LM (corresponding author), Dana Farber Canc Inst, Boston, MA 02115 USA.; Vrooman, LM (corresponding author), Boston Childrens Hosp, Boston, MA 02115 USA.	Lynda_Vrooman@dfci.harvard.edu						Armstrong GT, 2013, J CLIN ONCOL, V31, P3673, DOI 10.1200/JCO.2013.49.3205; Browne EK, 2018, CANCER-AM CANCER SOC, V124, P4248, DOI 10.1002/cncr.31736; Children's Oncology Group C., 2018, CANCERS; Chow EJ, 2018, J CLIN ONCOL, V36, P44, DOI 10.1200/JCO.2017.74.8673; Chow EJ, 2015, J CLIN ONCOL, V33, P394, DOI 10.1200/JCO.2014.56.1373; Clark RA, 2020, LANCET ONCOL, V21, P436, DOI [10.1016/S1470-2045(19)30818-6, 10.1016/51470-2045(19)30818-6]; Khera AV, 2019, CELL, V177, P587, DOI 10.1016/j.cell.2019.03.028; Lipshultz SE, 2013, CIRCULATION, V128, P1927, DOI 10.1161/CIR.0b013e3182a88099; Miller K. D., 2022, CA-CANCER J CLIN, DOI [10.3322/caac.21731(2022, DOI 10.3322/CAAC.21731(2022]; Sapkota Y, 2022, NAT MED, DOI 10.1038/s41591-022-01902-3; Turcot V, 2018, NAT GENET, V50, P26, DOI 10.1038/s41588-017-0011-x; Wilson CL, 2015, CANCER-AM CANCER SOC, V121, P2262, DOI 10.1002/cncr.29153	12	0	0	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01943-8	http://dx.doi.org/10.1038/s41591-022-01943-8		AUG 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3P5AJ	35941377				2022-12-27	WOS:000837551000004
J	Schindler, SE; Karikari, TK				Schindler, Suzanne E.; Karikari, Thomas K.			Comorbidities confound Alzheimer's blood tests	NATURE MEDICINE			English	Editorial Material								The concentrations of two key blood biomarkers for Alzheimer's disease are affected by some medical conditions, which could potentially lead to misdiagnosis.	[Schindler, Suzanne E.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Schindler, Suzanne E.] Washington Univ, Sch Med, Knight Alzheimer Dis Res Ctr, St Louis, MO 63110 USA; [Karikari, Thomas K.] Univ Gothenburg, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Clin Neurochem Lab, Molndal, Sweden; [Karikari, Thomas K.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15260 USA	Washington University (WUSTL); Washington University (WUSTL); University of Gothenburg; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Schindler, SE (corresponding author), Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA.; Schindler, SE (corresponding author), Washington Univ, Sch Med, Knight Alzheimer Dis Res Ctr, St Louis, MO 63110 USA.	schindlers@neuro.wustl.edu		Karikari, Thomas/0000-0003-1422-4358; Schindler, Suzanne/0000-0002-1680-1465				Barthelemy NR, 2020, J EXP MED, V217, DOI 10.1084/jem.20200861; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Karikari TK, 2022, NAT REV NEUROL, V18, P400, DOI 10.1038/s41582-022-00665-2; Mielke MM, 2022, NAT MED, V28, P1398, DOI 10.1038/s41591-022-01822-2; Mielke MM, 2022, ALZHEIMERS DEMENT, V18, P602, DOI 10.1002/alz.12415; Mielke MM, 2021, JAMA NEUROL, V78, P1108, DOI 10.1001/jamaneurol.2021.2293; Nianogo RA, 2022, JAMA NEUROL, V79, P584, DOI 10.1001/jamaneurol.2022.0976; Palmqvist S, 2020, JAMA-J AM MED ASSOC, V324, P772, DOI 10.1001/jama.2020.12134; Schindler SE, 2022, NEUROLOGY, V99, pE245, DOI 10.1212/WNL.0000000000200358; Syrjanen JA, 2022, ALZHEIMERS DEMENT, V18, P1128, DOI 10.1002/alz.12466; Teunissen CE, 2022, LANCET NEUROL, V21, P66, DOI 10.1016/S1474-4422(21)00361-6; Thijssen EH, 2021, LANCET NEUROL, V20, P739, DOI 10.1016/S1474-4422(21)00214-3	12	3	3	8	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2022	28	7					1349	1351		10.1038/s41591-022-01875-3	http://dx.doi.org/10.1038/s41591-022-01875-3		JUL 2022	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3E5PS	35788176				2022-12-27	WOS:000820578500001
J	Haidar, A; Lovblom, LE; Cardinez, N; Gouchie-Provencher, N; Orszag, A; Tsoukas, MA; Falappa, CM; Jafar, A; Ghanbari, M; Eldelekli, D; Rutkowski, J; Yale, JF; Perkins, BA				Haidar, Ahmad; Lovblom, Leif Erik; Cardinez, Nancy; Gouchie-Provencher, Nikita; Orszag, Andrej; Tsoukas, Michael A.; Falappa, C. Marcelo; Jafar, Adnan; Ghanbari, Milad; Eldelekli, Devrim; Rutkowski, Joanna; Yale, Jean-Francois; Perkins, Bruce A.			Empagliflozin add-on therapy to closed-loop insulin delivery in type 1 diabetes: a 2 x 2 factorial randomized crossover trial	NATURE MEDICINE			English	Article							HORMONE ARTIFICIAL PANCREAS; OPEN-LABEL; GLYCEMIC CONTROL; PUMP THERAPY; INHIBITORS; ADULTS; MULTICENTER; ADJUNCT	New data from a 2 x 2 factorial randomized, controlled trial shows that empagliflozin improves time in range in patients with type 1 diabetes using a closed-loop automated insulin delivery system. There is a need to optimize closed-loop automated insulin delivery in type 1 diabetes. We assessed the glycemic efficacy and safety of empagliflozin 25 mg d(-1) as add-on therapy to insulin delivery with a closed-loop system. We performed a 2 x 2 factorial randomized, placebo-controlled, crossover two-center trial in adults, assessing 4 weeks of closed-loop delivery versus sensor-augmented pump (SAP) therapy and empagliflozin versus placebo. The primary outcome was time spent in the glucose target range (3.9-10.0 mmol l(-1)). Primary comparisons were empagliflozin versus placebo in each of closed-loop or SAP therapy; the remaining comparisons were conditional on its significance. Twenty-four of 27 randomized participants were included in the final analysis. Compared to placebo, empagliflozin improved time in target range with closed-loop therapy by 7.2% and in SAP therapy by 11.4%. Closed-loop therapy plus empagliflozin improved time in target range compared to SAP therapy plus empagliflozin by 6.1% but by 17.5% for the combination of closed-loop therapy and empagliflozin compared to SAP therapy plus placebo. While no diabetic ketoacidosis or severe hypoglycemia occurred during any intervention, uncomplicated ketosis events were more common on empagliflozin. Empagliflozin 25 mg d(-1) added to automated insulin delivery improves glycemic control but increases ketone concentration and ketosis compared to placebo.	[Haidar, Ahmad; Jafar, Adnan; Ghanbari, Milad; Rutkowski, Joanna] McGill Univ, Dept Biomed Engn, Montreal, PQ, Canada; [Haidar, Ahmad; Gouchie-Provencher, Nikita; Tsoukas, Michael A.; Yale, Jean-Francois] Res Inst McGill Univ Hlth Ctr, Montreal, PQ, Canada; [Haidar, Ahmad; Tsoukas, Michael A.; Yale, Jean-Francois] McGill Univ, Div Endocrinol, Dept Med, Montreal, PQ, Canada; [Lovblom, Leif Erik; Cardinez, Nancy; Orszag, Andrej; Falappa, C. Marcelo; Eldelekli, Devrim; Perkins, Bruce A.] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada; [Perkins, Bruce A.] Univ Toronto, Div Endocrinol & Metab, Dept Med, Toronto, ON, Canada	McGill University; McGill University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Perkins, BA (corresponding author), Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada.; Perkins, BA (corresponding author), Univ Toronto, Div Endocrinol & Metab, Dept Med, Toronto, ON, Canada.	Bruce.Perkins@sinaihealth.ca			Juvenile Diabetes Research Foundation; Diabetes Action Canada; Canadian Institutes for Health Research (CIHR) Strategy for Patient-Oriented Research Network in Chronic Disease [4-PAR-2017-327-A-N]; Sam and Judy Pencer Family Chair in Diabetes Clinical Research, University of Toronto; Menkes Fund; David Wright Fund [950-231305]	Juvenile Diabetes Research Foundation(Juvenile Diabetes Research Foundation); Diabetes Action Canada; Canadian Institutes for Health Research (CIHR) Strategy for Patient-Oriented Research Network in Chronic Disease(Canadian Institutes of Health Research (CIHR)); Sam and Judy Pencer Family Chair in Diabetes Clinical Research, University of Toronto; Menkes Fund; David Wright Fund	This research was supported by the Juvenile Diabetes Research Foundation and by Diabetes Action Canada, a Canadian Institutes for Health Research (CIHR) Strategy for Patient-Oriented Research Network in Chronic Disease (grant no. 4-PAR-2017-327-A-N to A.H. and B.A.P.). B.A.P. holds the Sam and Judy Pencer Family Chair in Diabetes Clinical Research, University of Toronto and acknowledges research program support from the Menkes Fund and the David Wright Fund. A.H. holds the Canada Research Chair in Artificial Pancreas Systems (950-231305). We thank P. Jacob for providing the iPancreas research platform. No funder had any role in study design, data collection or interpretation, or writing of the manuscript. The study investigators had final responsibility for the decision to submit for publication.	Alva Shridhara, 2021, J Diabetes Sci Technol, V15, P768, DOI 10.1177/19322968211008185; Battelino T, 2019, DIABETES CARE, V42, P1593, DOI 10.2337/dci19-0028; Benhamou PY, 2019, LANCET DIGIT HEALTH, V1, pE17, DOI 10.1016/S2589-7500(19)30003-2; Bergenstal RM, 2021, LANCET, V397, P208, DOI 10.1016/S0140-6736(20)32514-9; Biester T, 2021, DIABETES OBES METAB, V23, P599, DOI 10.1111/dom.14258; Brown SA, 2019, NEW ENGL J MED, V381, P1707, DOI 10.1056/NEJMoa1907863; Castle JR, 2018, DIABETES CARE, V41, P1471, DOI 10.2337/dc18-0228; Cifuentes M, 2008, BIOL RES, V41, P197, DOI [10.4067/S0716-97602008000200009, /S0716-97602008000200009]; Collyns OJ, 2021, DIABETES CARE, V44, P969, DOI 10.2337/dc20-2250; Danne T, 2021, DIABETES OBES METAB, V23, P854, DOI 10.1111/dom.14271; Garg SK, 2018, DIABETES TECHNOL THE, V20, P571, DOI 10.1089/dia.2018.0246; Goldenberg RM, 2019, DIABETES OBES METAB, V21, P2192, DOI 10.1111/dom.13811; Groop PH, 2020, LANCET DIABETES ENDO, V8, P845, DOI 10.1016/S2213-8587(20)30280-1; Haidar A, 2021, DIABETES OBES METAB, V23, P1272, DOI 10.1111/dom.14335; Haidar A, 2017, DIABETES OBES METAB, V19, P713, DOI 10.1111/dom.12880; Haidar A, 2016, IEEE CONTR SYST MAG, V36, P28, DOI 10.1109/MCS.2016.2584318; Haidar A, 2015, LANCET DIABETES ENDO, V3, P17, DOI 10.1016/S2213-8587(14)70226-8; Haidar Ahmad, 2013, J Diabetes Sci Technol, V7, P1507; Heerspink HJL, 2016, CIRCULATION, V134, P752, DOI 10.1161/CIRCULATIONAHA.116.021887; Herring RA, 2020, DIABETES CARE, V43, P2128, DOI 10.2337/dc19-2579; Kaku K, 2019, DIABETES OBES METAB, V21, P2284, DOI 10.1111/dom.13807; Lind M, 2014, NEW ENGL J MED, V371, P1972, DOI 10.1056/NEJMoa1408214; Lu JL, 2019, DIABETES-METAB RES, V35, DOI 10.1002/dmrr.3169; Mathieu C, 2020, DIABETES OBES METAB, V22, P2151, DOI 10.1111/dom.14144; Mudaliar S, 2012, DIABETES CARE, V35, P2198, DOI 10.2337/dc12-0508; Musso G, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l1328; Ndefo Uche Anadu, 2015, P T, V40, P364; Nguyen Kevin T, 2022, J Diabetes Sci Technol, V16, P689, DOI 10.1177/19322968211042656; Pasqua Melissa-Rosina, 2021, J Diabetes Sci Technol, V15, P1232, DOI 10.1177/19322968211035411; Pieber TR, 2015, DIABETES OBES METAB, V17, DOI 10.1111/dom.12494; Rosenstock J, 2018, DIABETES CARE, V41, P2560, DOI 10.2337/dc18-1749; Schoelwer MJ, 2021, DIABETES TECHNOL THE, V23, P475, DOI 10.1089/dia.2020.0646; Singh Sukhmani, 2019, J Diabetes Sci Technol, V13, P605, DOI 10.1177/1932296819838875; Taylor SI, 2019, LANCET DIABETES ENDO, V7, P949, DOI 10.1016/S2213-8587(19)30154-8; Taylor SI, 2015, J CLIN ENDOCR METAB, V100, P2849, DOI 10.1210/jc.2015-1884; Thabit H, 2015, NEW ENGL J MED, V373, P2129, DOI 10.1056/NEJMoa1509351; Zhang Jennifer Y, 2021, J Diabetes Sci Technol, V15, P775, DOI 10.1177/19322968211009860	37	1	1	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2022	28	6					1269	+		10.1038/s41591-022-01805-3	http://dx.doi.org/10.1038/s41591-022-01805-3		MAY 2022	18	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E9IE	35551290	Bronze			2022-12-27	WOS:000794108200002
J	Chandran, SS; Ma, JQ; Klatt, MG; Dundar, F; Bandlamudi, C; Razavi, P; Wen, HY; Weigelt, B; Zumbo, P; Fu, SN; Banks, LB; Yi, F; Vercher, E; Etxeberria, I; Bestman, WD; Paula, AD; Aricescu, IS; Drilon, A; Betel, D; Scheinberg, DA; Baker, BM; Klebanoff, CA				Chandran, Smita S.; Ma, Jiaqi; Klatt, Martin G.; Dundar, Friederike; Bandlamudi, Chaitanya; Razavi, Pedram; Wen, Hannah Y.; Weigelt, Britta; Zumbo, Paul; Fu, Si Ning; Banks, Lauren B.; Yi, Fei; Vercher, Enric; Etxeberria, Inaki; Bestman, Watchain D.; Da Cruz Paula, Arnaud; Aricescu, Ilinca S.; Drilon, Alexander; Betel, Doron; Scheinberg, David A.; Baker, Brian M.; Klebanoff, Christopher A.			Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA	NATURE MEDICINE			English	Article							ANTITUMOR-ACTIVITY; T-CELLS; SOMATIC MUTATIONS; PD-1 BLOCKADE; HUMAN CANCER; ANTIGEN; PEPTIDE; BINDING; COMPLEX; GENE	Public neoantigens (NeoAgs) represent an elite class of shared cancer-specific epitopes derived from recurrently mutated driver genes. Here we describe a high-throughput platform combining single-cell transcriptomic and T cell receptor (TCR) sequencing to establish whether mutant PIK3CA, among the most frequently genomically altered driver oncogenes, generates an immunogenic public NeoAg. Using this strategy, we developed a panel of TCRs that recognize an endogenously processed neopeptide encompassing a common PIK3CA hotspot mutation restricted by the prevalent human leukocyte antigen (HLA)-A*03:01 allele. Mechanistically, immunogenicity to this public NeoAg arises from enhanced neopeptide/HLA complex stability caused by a preferred HLA anchor substitution. Structural studies indicated that the HLA-bound neopeptide presents a comparatively 'featureless' surface dominated by the peptide's backbone. To bind this epitope with high specificity and affinity, we discovered that a lead TCR clinical candidate engages the neopeptide through an extended interface facilitated by an unusually long CDR3 beta loop. In patients with diverse malignancies, we observed NeoAg clonal conservation and spontaneous immunogenicity to the neoepitope. Finally, adoptive transfer of TCR-engineered T cells led to tumor regression in vivo in mice bearing PIK3CA-mutant tumors but not wild-type PIK3CA tumors. Together, these findings establish the immunogenicity and therapeutic potential of a mutant PIK3CA-derived public NeoAg. A new high-throughput platform to find rare T cells that can recognize shared cancer neoantigens identifies T cell receptors specific for a conserved, immunogenic and therapeutically actionable epitope in mutant PI3K alpha, one of the most common driver oncogenes	[Chandran, Smita S.; Razavi, Pedram; Fu, Si Ning; Banks, Lauren B.; Yi, Fei; Vercher, Enric; Etxeberria, Inaki; Aricescu, Ilinca S.; Klebanoff, Christopher A.] Mem Sloan Kettering Canc Ctr, Immuno Oncol Serv, Human Oncol & Pathogenesis Program HOPP, New York, NY 10065 USA; [Chandran, Smita S.; Fu, Si Ning; Banks, Lauren B.; Yi, Fei; Klebanoff, Christopher A.] Mem Sloan Kettering Canc Ctr, Ctr Cell Engn, New York, NY 10065 USA; [Chandran, Smita S.; Klebanoff, Christopher A.] Parker Inst Canc Immunotherapy, New York, NY 10065 USA; [Ma, Jiaqi; Baker, Brian M.] Univ Notre Dame, Dept Chem & Biochem, South Bend, IN USA; [Ma, Jiaqi; Baker, Brian M.] Univ Notre Dame, Harper Canc Res Inst, South Bend, IN USA; [Klatt, Martin G.; Scheinberg, David A.] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Mol Pharmacol Program, New York, NY USA; [Dundar, Friederike; Zumbo, Paul] Weill Cornell Med, Dept Physiol & Biophys, New York, NY USA; [Dundar, Friederike; Zumbo, Paul] Weill Cornell Med, Appl Bioinformat Core, New York, NY USA; [Bandlamudi, Chaitanya] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Razavi, Pedram; Banks, Lauren B.; Bestman, Watchain D.; Drilon, Alexander; Scheinberg, David A.; Klebanoff, Christopher A.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA; [Razavi, Pedram; Drilon, Alexander; Betel, Doron; Klebanoff, Christopher A.] Weill Cornell Med, Dept Med, Div Hematol & Med Oncol, New York, NY 10065 USA; [Wen, Hannah Y.; Weigelt, Britta] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY USA; [Bestman, Watchain D.; Da Cruz Paula, Arnaud] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY USA; [Drilon, Alexander; Klebanoff, Christopher A.] Mem Sloan Kettering Canc Ctr, Early Drug Dev Serv, New York, NY 10065 USA; [Betel, Doron] Weill Cornell Med, Inst Computat Biomed, New York, NY USA; [Klebanoff, Christopher A.] Mem Sloan Kettering Canc Ctr, Cell Therapy Serv, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Notre Dame; University of Notre Dame; Memorial Sloan Kettering Cancer Center; Cornell University; Cornell University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center	Chandran, SS; Klebanoff, CA (corresponding author), Mem Sloan Kettering Canc Ctr, Immuno Oncol Serv, Human Oncol & Pathogenesis Program HOPP, New York, NY 10065 USA.; Chandran, SS; Klebanoff, CA (corresponding author), Mem Sloan Kettering Canc Ctr, Ctr Cell Engn, New York, NY 10065 USA.; Chandran, SS; Klebanoff, CA (corresponding author), Parker Inst Canc Immunotherapy, New York, NY 10065 USA.; Klebanoff, CA (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA.; Klebanoff, CA (corresponding author), Weill Cornell Med, Dept Med, Div Hematol & Med Oncol, New York, NY 10065 USA.; Klebanoff, CA (corresponding author), Mem Sloan Kettering Canc Ctr, Early Drug Dev Serv, New York, NY 10065 USA.; Klebanoff, CA (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Therapy Serv, New York, NY 10065 USA.	chandrs1@mskcc.org; klebanoc@mskcc.org	ETXEBERRIA, INAKI/I-3531-2017	ETXEBERRIA, INAKI/0000-0003-2713-0836; Chandran, Smita/0000-0001-9266-6878; Razavi, Pedram/0000-0003-4236-0576; Klatt, Martin/0000-0001-8703-7305; Dundar, Friederike/0000-0002-2301-112X; Vercher Herraez, Enric/0000-0002-1594-9898	National Institutes of Heath (NIH) [R37CA259177, P30CA008748, R01AI129543]; Parker Institute for Cancer Immunotherapy; Damon Runyon Cancer Research Foundation [CI-96-18]; Cancer Research Institute [CRI3176]; Functional Genomics Initiative Rapid Response Pilot Grant; Manhasset Women's Coalition Against Breast Cancer; Emerson Collective Cancer Fund; Breast Cancer Alliance Exceptional Project Grant; Sussman Family Fund; Intima Bioscience; Department of Energy contract [DE-AC02-06CH11357]; NIH [P30GM124165, S10OD021527, S10RR25528, S10RR028976]; German Research Foundation (DFG) [KL3118/1-1]; Conquer Cancer Foundation; Programa de Ayudas de Movilidad para la Obtencion de Mencion 'Doctor Internacional' of the University of Navarra; FUNDACIONCAJANAVARRA-Obra Social 'La Caixa'; Company of Biologists Travelling Fellowships Grant; Fundacion Alfonso Martin Escudero	National Institutes of Heath (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Parker Institute for Cancer Immunotherapy; Damon Runyon Cancer Research Foundation; Cancer Research Institute; Functional Genomics Initiative Rapid Response Pilot Grant; Manhasset Women's Coalition Against Breast Cancer; Emerson Collective Cancer Fund; Breast Cancer Alliance Exceptional Project Grant; Sussman Family Fund; Intima Bioscience; Department of Energy contract(United States Department of Energy (DOE)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); German Research Foundation (DFG)(German Research Foundation (DFG)); Conquer Cancer Foundation; Programa de Ayudas de Movilidad para la Obtencion de Mencion 'Doctor Internacional' of the University of Navarra; FUNDACIONCAJANAVARRA-Obra Social 'La Caixa'; Company of Biologists Travelling Fellowships Grant; Fundacion Alfonso Martin Escudero	This study was supported, in part, by National Institutes of Heath (NIH) grants R37CA259177 (C.A.K.), P30CA008748 (C.A.K. and D.A.S.) and R01AI129543 (B.M.B.); the Parker Institute for Cancer Immunotherapy (C.A.K.); the Damon Runyon Cancer Research Foundation CI-96-18 (C.A.K.); Cancer Research Institute CRI3176 (C.A.K); the Functional Genomics Initiative Rapid Response Pilot Grant (C.A.K.); the Manhasset Women's Coalition Against Breast Cancer (C.A.K.); the Emerson Collective Cancer Fund (C.A.K.); the Breast Cancer Alliance Exceptional Project Grant (C.A.K.); the Sussman Family Fund (C.A.K.); and a sponsored research agreement with Intima Bioscience (C.A.K.). X-ray diffraction data were collected at the Advanced Photon Source, supported by Department of Energy contract DE-AC02-06CH11357, and the NE-CAT and SER-CAT beamlines were supported by member institutions and NIH grants P30GM124165, S10OD021527, S10RR25528 and S10RR028976. M.G.K. was supported by an individual research grant from the German Research Foundation (DFG, KL3118/1-1). L.B.B. was supported, in part, by the Conquer Cancer Foundation. E.V. was supported by Programa de Ayudas de Movilidad para la Obtencion de Mencion 'Doctor Internacional' of the University of Navarra, FUNDACIONCAJANAVARRA-Obra Social 'La Caixa' and the Company of Biologists Travelling Fellowships Grant. F.Y. was supported, in part, by a fellowship from the Hearst Foundation. I.X. was supported, in part, by a fellowship from the Fundacion Alfonso Martin Escudero and the Parker Institute for Cancer Immunotherapy. We thank A. Kentsis for access to the Byonic software as well as the Proteomics Resource Center at Rockefeller University for the performance of all LC-MS/MS experiments. We thank the Last Wish Program (MSKCC) for tissue collection, the Antitumor Assessment Core (MSKCC) for PDX development and assistance with in vivo tumor models and the Epigenomics Core of Weill Cornell Medical College for enabling single-cell immune-profiling experiments. We thank M.R. Femia for technical assistance with pilot IVS screens and L. Albacker and M. Montesion for helpful discussions. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.	Aleksic M, 2012, EUR J IMMUNOL, V42, P3174, DOI 10.1002/eji.201242606; Ali M, 2019, NAT PROTOC, V14, P1926, DOI 10.1038/s41596-019-0170-6; Andre F, 2019, NEW ENGL J MED, V380, P1929, DOI 10.1056/NEJMoa1813904; Arnaud M, 2022, NAT BIOTECHNOL, V40, P656, DOI 10.1038/s41587-021-01072-6; Bagaev DV, 2020, NUCLEIC ACIDS RES, V48, pD1057, DOI 10.1093/nar/gkz874; Bailey MH, 2018, CELL, V173, P371, DOI [10.1016/j.cell.2018.02.060, 10.1016/j.cell.2018.07.034]; Baxter TK, 2004, J BIOL CHEM, V279, P29175, DOI 10.1074/jbc.M403372200; Bielski CM, 2018, CANCER CELL, V34, P852, DOI 10.1016/j.ccell.2018.10.003; Cameron BJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006034; Chandran SS, 2019, IMMUNOL REV, V290, P127, DOI 10.1111/imr.12772; Cheng DT, 2015, J MOL DIAGN, V17, P251, DOI 10.1016/j.jmoldx.2014.12.006; Chheda ZS, 2018, J EXP MED, V215, P141, DOI 10.1084/jem.20171046; Cohen CJ, 2006, CANCER RES, V66, P8878, DOI 10.1158/0008-5472.CAN-06-1450; D'Angelo SP, 2018, CANCER DISCOV, V8, P944, DOI 10.1158/2159-8290.CD-17-1417; Davis-Harrison RL, 2005, J MOL BIOL, V346, P533, DOI 10.1016/j.jmb.2004.11.063; de Castro E, 2006, NUCLEIC ACIDS RES, V34, pW362, DOI 10.1093/nar/gkl124; Devlin JR, 2020, NAT CHEM BIOL, V16, P1269, DOI 10.1038/s41589-020-0610-1; Drilon A, 2017, CANCER DISCOV, V7, P400, DOI 10.1158/2159-8290.CD-16-1237; Eubank MH, 2016, J AM MED INFORM ASSN, V23, P777, DOI 10.1093/jamia/ocw020; Garcia KC, 2005, CELL, V122, P333, DOI 10.1016/j.cell.2005.07.015; Gattinoni L, 2005, J EXP MED, V202, P907, DOI 10.1084/jem.20050732; Gee MH, 2018, CELL, V172, P549, DOI 10.1016/j.cell.2017.11.043; Gonzalez-Galarza FF, 2020, NUCLEIC ACIDS RES, V48, pD783, DOI 10.1093/nar/gkz1029; Gowthaman R, 2019, BIOINFORMATICS, V35, P5323, DOI 10.1093/bioinformatics/btz517; Hellman LM, 2016, J IMMUNOL METHODS, V432, P95, DOI 10.1016/j.jim.2016.02.016; Hsiue EHC, 2021, SCIENCE, V371, P1009, DOI 10.1126/science.abc8697; Hu Z, 2018, NAT REV IMMUNOL, V18, P168, DOI 10.1038/nri.2017.131; Johnson LA, 2009, BLOOD, V114, P535, DOI 10.1182/blood-2009-03-211714; Kang SY, 2005, P NATL ACAD SCI USA, V102, P802, DOI 10.1073/pnas.0408864102; Klatt MG, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.141264; Klebanoff CA, 2018, J EXP MED, V215, P5, DOI 10.1084/jem.20172188; Laugel B, 2007, J BIOL CHEM, V282, P23799, DOI 10.1074/jbc.M700976200; Linard B, 2002, J IMMUNOL, V168, P4802, DOI 10.4049/jimmunol.168.9.4802; Liu YC, 2014, J BIOL CHEM, V289, P16688, DOI 10.1074/jbc.M114.563502; Lu YC, 2017, J CLIN ONCOL, V35, P3322, DOI 10.1200/JCO.2017.74.5463; Malekzadeh P, 2019, J CLIN INVEST, V129, P1109, DOI 10.1172/JCI123791; Marabelle A, 2020, J CLIN ONCOL, V38, P1, DOI 10.1200/JCO.19.02105; McGranahan N, 2017, CELL, V171, P1259, DOI 10.1016/j.cell.2017.10.001; McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490; McGranahan N, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa1408; McMahon RM, 2011, ACTA CRYSTALLOGR D, V67, P447, DOI 10.1107/S0907444911007888; Miao D, 2018, NAT GENET, V50, P1271, DOI 10.1038/s41588-018-0200-2; Montesion M, 2021, CANCER DISCOV, V11, P282, DOI 10.1158/2159-8290.CD-20-0672; Nagarsheth NB, 2021, NAT MED, V27, P419, DOI 10.1038/s41591-020-01225-1; Parkhurst MR, 2019, CANCER DISCOV, V9, P1022, DOI 10.1158/2159-8290.CD-18-1494; Paulson KG, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06300-3; Peng SM, 2019, CELL REP, V28, P2728, DOI 10.1016/j.celrep.2019.07.106; Pizzolla A, 2018, J CLIN INVEST, V128, P721, DOI 10.1172/JCI96957; Priestley P, 2019, NATURE, V575, P210, DOI 10.1038/s41586-019-1689-y; Reiter JG, 2018, SCIENCE, V361, P1033, DOI 10.1126/science.aat7171; Reynisson B, 2020, NUCLEIC ACIDS RES, V48, pW449, DOI 10.1093/nar/gkaa379; Rosenbaum E, 2020, CLIN CANCER RES, V26, P5448, DOI 10.1158/1078-0432.CCR-20-0832; Rosenthal R, 2019, NATURE, V567, P479, DOI 10.1038/s41586-019-1032-7; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sarkizova S, 2020, NAT BIOTECHNOL, V38, P199, DOI 10.1038/s41587-019-0322-9; Schmidt J, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100194; Schumacher T, 2014, NATURE, V512, P324, DOI 10.1038/nature13387; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Scott DR, 2011, J MOL BIOL, V414, P385, DOI 10.1016/j.jmb.2011.10.006; Shen RL, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw520; Shin DS, 2017, CANCER DISCOV, V7, P188, DOI 10.1158/2159-8290.CD-16-1223; Shukla SA, 2015, NAT BIOTECHNOL, V33, P1152, DOI 10.1038/nbt.3344; Sidney J, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-1; Sim MJW, 2020, P NATL ACAD SCI USA, V117, P12826, DOI 10.1073/pnas.1921964117; Singh NK, 2020, BIOCHEMISTRY-US, V59, P4163, DOI 10.1021/acs.biochem.0c00689; Singh NK, 2020, PROTEINS, V88, P503, DOI 10.1002/prot.25829; Stevanovic S, 2017, SCIENCE, V356, P200, DOI 10.1126/science.aak9510; Tate JG, 2019, NUCLEIC ACIDS RES, V47, pD941, DOI 10.1093/nar/gky1015; Tran E, 2015, SCIENCE, V350, P1387, DOI 10.1126/science.aad1253; Veatch JR, 2018, J CLIN INVEST, V128, P1563, DOI 10.1172/JCI98689; Wolfl M, 2014, NAT PROTOC, V9, P950, DOI 10.1038/nprot.2014.064; Wolf Y, 2019, CELL, V179, P219, DOI 10.1016/j.cell.2019.08.032; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Wu DC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16755-y; Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958	76	6	6	6	11	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2022	28	5					946	+		10.1038/s41591-022-01786-3	http://dx.doi.org/10.1038/s41591-022-01786-3		APR 2022	32	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	1J3AM	35484264	Green Published, hybrid			2022-12-27	WOS:000788453200002
J	Petters, RM; Alexander, CA; Wells, KD; Collins, EB; Sommer, JR; Blanton, MR; Rojas, G; Hao, Y; Flowers, WL; Banin, E; Cideciyan, AV; Jacobson, SG; Wong, F				Petters, RM; Alexander, CA; Wells, KD; Collins, EB; Sommer, JR; Blanton, MR; Rojas, G; Hao, Y; Flowers, WL; Banin, E; Cideciyan, AV; Jacobson, SG; Wong, F			Genetically engineered large animal model for studying cone photoreceptor survival and degeneration in retinitis pigmentosa	NATURE BIOTECHNOLOGY			English	Article						transgenic swine; retinal degeneration; rhodopsin mutation; night blindness; eye disease	RHODOPSIN GENE; RETINAL DEGENERATION; TRANSGENIC MICE; CELL-DEATH; HUMAN ROD; MUTATION; PHOTOTRANSDUCTION; EXPRESSION; PARAMETERS; DEFICIENCY	Patients with retinitis pigmentosa (RP) typically develop night blindness early in life due to loss of rod photoreceptors. The remaining cone photoreceptors are the mainstay of their vision; however, over years or decades, these cones slowly degenerate, leading to blindness. We created transgenic pigs that express a mutated rhodopsin gene (Pro347Leu). Like RP patients with the same mutation, these pigs have early and severe rod loss; initially their cones are relatively spared, but these surviving cones slowly degenerate. By age 20 months, there is only a single layer of morphologically abnormal cones and the cone electroretinogram is markedly reduced. Given the strong similarities in phenotype to that of RP patients, these transgenic pigs will provide a large animal model for study of the protracted phase of cone degeneration found in RP and for preclinical treatment trials.	DUKE UNIV,SCH MED,DEPT OPHTHALMOL,DURHAM,NC 27706; DUKE UNIV,SCH MED,DEPT NEUROBIOL,DURHAM,NC; DUKE UNIV,SCH MED,DEPT PATHOL,DURHAM,NC; UNIV PENN,SCHEIE EYE INST,DEPT OPHTHALMOL,PHILADELPHIA,PA 19104; N CAROLINA STATE UNIV,DEPT ANIM SCI,RALEIGH,NC 27695	Duke University; Duke University; Duke University; University of Pennsylvania; Pennsylvania Medicine; University of North Carolina; North Carolina State University			Cideciyan, Artur V/A-1075-2007	Cideciyan, Artur V/0000-0002-2018-0905; Jacobson, Samuel/0000-0003-2122-169X	NATIONAL EYE INSTITUTE [R01EY009738, R01EY009047, R55EY009047] Funding Source: NIH RePORTER; NEI NIH HHS [EY09738, EY05627, EY09047] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ACLAND GM, 1989, EXP EYE RES, V49, P983, DOI 10.1016/S0014-4835(89)80021-1; Aebischer P, 1996, NAT MED, V2, P696, DOI 10.1038/nm0696-696; Apfelstedt-Sylla E, 1992, Ger J Ophthalmol, V1, P319; BERSON EL, 1991, AM J OPHTHALMOL, V111, P614, DOI 10.1016/S0002-9394(14)73708-0; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; Chen J, 1996, P NATL ACAD SCI USA, V93, P7042, DOI 10.1073/pnas.93.14.7042; Cideciyan AV, 1996, VISION RES, V36, P2609, DOI 10.1016/0042-6989(95)00327-4; DRYJA TP, 1995, INVEST OPHTH VIS SCI, V36, P1197; DRYJA TP, 1990, NEW ENGL J MED, V323, P1302, DOI 10.1056/NEJM199011083231903; FEENEYBURNS L, 1981, ARCH OPHTHALMOL-CHIC, V99, P664, DOI 10.1001/archopht.1981.03930010664013; FODOR WL, 1994, P NATL ACAD SCI USA, V91, P11153, DOI 10.1073/pnas.91.23.11153; FUJIKI K, 1992, JPN J HUM GENET, V37, P125, DOI 10.1007/BF01899733; Gal A, 1997, PROG RETIN EYE RES, V16, P51, DOI 10.1016/S1350-9462(96)00021-3; Gerke C. G. Jr., 1995, Hong Kong Medical Journal, V1, P302; Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346; HAMMER RE, 1985, NATURE, V315, P680, DOI 10.1038/315680a0; HOOD DC, 1990, VISUAL NEUROSCI, V5, P379, DOI 10.1017/S0952523800000468; HOOD DC, 1994, INVEST OPHTH VIS SCI, V35, P2948; HUANG PC, 1993, P NATL ACAD SCI USA, V90, P8484, DOI 10.1073/pnas.90.18.8484; Humphries MM, 1997, NAT GENET, V15, P216, DOI 10.1038/ng0297-216; JACOBSON SG, 1991, AM J OPHTHALMOL, V112, P256, DOI 10.1016/S0002-9394(14)76726-1; JACOBSON SG, 1994, INVEST OPHTH VIS SCI, V35, P2521; JACOBSON SG, 1986, OPHTHALMOLOGY, V93, P1604; JACOBSON SG, 1987, EXP EYE RES, V45, P481, DOI 10.1016/S0014-4835(87)80059-3; KEMP CM, 1989, EXP EYE RES, V49, P49; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMB TD, 1992, J PHYSIOL-LONDON, V449, P719, DOI 10.1113/jphysiol.1992.sp019111; Li TS, 1996, P NATL ACAD SCI USA, V93, P14176, DOI 10.1073/pnas.93.24.14176; LOLLEY RN, 1994, INVEST OPHTH VIS SCI, V35, P358; MASSOF RW, 1987, RES RETINITIS PIGMEN, V62, P29; NARFSTROM K, 1983, J HERED, V74, P273, DOI 10.1093/oxfordjournals.jhered.a109782; NATHANS J, 1992, BIOCHEMISTRY-US, V31, P4923, DOI 10.1021/bi00136a001; OLSSON JE, 1992, NEURON, V9, P815, DOI 10.1016/0896-6273(92)90236-7; PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974; Prince J.H., 1960, ANATOMY HISTOLOGY EY, P210; PURSEL VG, 1989, SCIENCE, V244, P1281, DOI 10.1126/science.2499927; Reiser MA, 1996, INVEST OPHTH VIS SCI, V37, P221; ROOF DJ, 1994, INVEST OPHTH VIS SCI, V35, P4049; Sambrook J., 1989, MOL CLONING; SempleRowland SL, 1996, FEBS LETT, V385, P47, DOI 10.1016/0014-5793(96)00345-6; SHARMA A, 1994, BIO-TECHNOL, V12, P55, DOI 10.1038/nbt0194-55; SHIONO T, 1992, JPN J OPHTHALMOL, V36, P69; Steinberg R. H., 1996, Investigative Ophthalmology and Visual Science, V37, pS698; SUBER ML, 1993, P NATL ACAD SCI USA, V90, P3968, DOI 10.1073/pnas.90.9.3968; SUNG CH, 1994, J NEUROSCI, V14, P5818; Travis GH, 1997, NAT GENET, V15, P115, DOI 10.1038/ng0297-115; TSO MOM, 1989, INVEST OPHTH VIS SCI, V30, P2430; WALL RJ, 1985, BIOL REPROD, V32, P645, DOI 10.1095/biolreprod32.3.645; Wong F, 1997, PROG RETIN EYE RES, V16, P353, DOI 10.1016/S1350-9462(96)00032-8	49	225	238	0	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1997	15	10					965	970		10.1038/nbt1097-965	http://dx.doi.org/10.1038/nbt1097-965			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XZ285	9335046				2022-12-27	WOS:A1997XZ28500025
J	Holden, PH; Asopa, V; Robertson, AGS; Clarke, AR; Tyler, S; Bennett, GS; Brain, SD; Wilcock, GK; Allen, SJ; Smith, SKF; Dawbarn, D				Holden, PH; Asopa, V; Robertson, AGS; Clarke, AR; Tyler, S; Bennett, GS; Brain, SD; Wilcock, GK; Allen, SJ; Smith, SKF; Dawbarn, D			Immunoglobulin-like domains define the nerve growth factor binding site of the TrkA receptor	NATURE BIOTECHNOLOGY			English	Article						protein folding; drug design; nerve growth factor; TrkA binding domain	LEUCINE-RICH MOTIF; EXTRACELLULAR DOMAIN; NEUROTROPHIC FACTOR; BASAL FOREBRAIN; KINASE; BRAIN; SPECIFICITY; CONFERS; FORM	Nerve growth factor (NGF) is involved in the development and maintenance of the nervous system. NGF binds with high affinity to the extracellular region of the tyrosine kinase receptor TrkA, This domain comprises leucine and cysteine rich motifs, followed by two immunoglobulin like (Ig-like) domains, We describe the expression and purification of recombinant Ig-like domains. Fluorescence and circular dichroism spectroscopy show that the protein is folded into a compact globular structure and contains mainly beta-sheet secondary structure. Recombinant protein binds to NGF and can inhibit NGF bioactivity both in vitro and in vivo.	UNIV BRISTOL,SCH MED SCI,DEPT BIOCHEM,BRISTOL BS8 1TD,AVON,ENGLAND; UNIV BRISTOL,SCH MED SCI,CTR MOL RECOGNIT,BRISTOL BS8 1TD,AVON,ENGLAND; UNIV LONDON KINGS COLL,DIV BIOMED SCI,PHARMACOL GRP,LONDON SW3 6LX,ENGLAND; UNIV LONDON KINGS COLL,DIV BIOMED SCI,VASC BIOL RES CTR,LONDON SW3 6LX,ENGLAND; FRENCHAY HOSP,DEPT CARE ELDERLY,BRISTOL BS16 1LE,AVON,ENGLAND	University of Bristol; University of Bristol; University of London; King's College London; University of London; King's College London	Holden, PH (corresponding author), UNIV BRISTOL,BRISTOL ROYAL INFIRM,DEPT MED CARE ELDERLY,MOL NEUROBIOL UNIT,BRISTOL BS2 8HW,AVON,ENGLAND.		Brain, Susan/L-3681-2013	Brain, Susan/0000-0002-9684-8342; Allen, Shelley/0000-0001-7870-740X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLEN SJ, 1994, NEUROSCIENCE, V60, P825, DOI 10.1016/0306-4522(94)90507-X; Bennett GS, 1996, BRIT J PHARMACOL, V119, pP55; BRAIN SD, 1985, BRIT J PHARMACOL, V86, P855, DOI 10.1111/j.1476-5381.1985.tb11107.x; CLARY DO, 1994, P NATL ACAD SCI USA, V91, P11133, DOI 10.1073/pnas.91.23.11133; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; FUJIMORI K, 1992, BIOSCI BIOTECH BIOCH, V56, P1985, DOI 10.1271/bbb.56.1985; HATANAKA H, 1988, DEV BRAIN RES, V39, P85, DOI 10.1016/0165-3806(88)90069-7; HEIDARAN MA, 1995, FASEB J, V9, P140, DOI 10.1096/fasebj.9.1.7821753; IKEDA K, 1968, J BIOCHEM, V63, P654, DOI 10.1093/oxfordjournals.jbchem.a128825; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEWIN B, 1995, J MOL BIOL, V7, P227; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; MacDonald JIS, 1996, MOL CELL NEUROSCI, V7, P371, DOI 10.1006/mcne.1996.0027; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MCDONALD NQ, 1995, J BIOL CHEM, V270, P19669, DOI 10.1074/jbc.270.34.19669; OLSEN L, 1992, J NEURAL TRANSM PARK, V4, P79; OTTEN U, 1984, EUR J PHARMACOL, V106, P199, DOI 10.1016/0014-2999(84)90697-6; PEREZ P, 1995, MOL CELL NEUROSCI, V6, P97, DOI 10.1006/mcne.1995.1010; RODRIGUEZTEBAR A, 1992, EMBO J, V11, P917, DOI 10.1002/j.1460-2075.1992.tb05130.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; THOENEN H, 1987, REV PHYSIOL BIOCH P, V109, P145, DOI 10.1007/BFb0031026; TREANOR JJS, 1991, NEUROSCI LETT, V121, P73, DOI 10.1016/0304-3940(91)90652-A; URFER R, 1994, EMBO J, V13, P5896, DOI 10.1002/j.1460-2075.1994.tb06935.x; URFER R, 1995, EMBO J, V14, P2795, DOI 10.1002/j.1460-2075.1995.tb07279.x; VALE RD, 1985, METHOD ENZYMOL, V109, P21; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WINDISCH JM, 1995, BIOCHEMISTRY-US, V34, P11256, DOI 10.1021/bi00035a035; WINDISCH JM, 1995, J BIOL CHEM, V270, P28133; YANG JT, 1986, METHOD ENZYMOL, V130, P208; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; ZE W, 1993, MOL CELL BIOL, V13, P5348, DOI 10.1128/MCB.13.9.5348	36	48	54	1	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1997	15	7					668	672		10.1038/nbt0797-668	http://dx.doi.org/10.1038/nbt0797-668			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XH583	9219271				2022-12-27	WOS:A1997XH58300032
J	Templeton, NS; Lasic, DD; Frederik, PM; Strey, HH; Roberts, DD; Pavlakis, GN				Templeton, NS; Lasic, DD; Frederik, PM; Strey, HH; Roberts, DD; Pavlakis, GN			Improved DNA: Liposome complexes for increased systemic delivery and gene expression	NATURE BIOTECHNOLOGY			English	Article						gene therapy; cationic liposomes; DNA delivery; in vivo gene expression	ADULT MICE; INVIVO; TRANSFECTION; EFFICIENT; VESICLES; SERIES; LIVER	To increase cationic liposome-mediated intravenous DNA delivery extruded DOTAP:cholesterol liposomes were used to form complexes with DNA, resulting in enhanced expression of the chloramphenicol acetyltransferase gene in most tissues examined. The DNA:liposome ratio, and mild sonication, heating, and extrusion steps used for liposome preparation were crucial for improved systemic delivery. Size fractionation studies showed that maximal gene expression was produced by a homogeneous population of DNA:liposome complexes between 200 to 450 nm in size. Cryo-electron microscopy examination demonstrates that the DNA:liposome complexes have a novel morphology, and that the DNA is condensed on the interior of invaginated liposomes between two lipid bilayers. This structure could account for the high efficiency of gene delivery in vivo and for the broad tissue distribution of the DNA:liposome complexes. Ligands can be placed on the outside of this structure to provide for targeted gene delivery.	LIPSOME CONSULTAT,NEWARK,CA 94560; UNIV LIMBURG,DEPT PATHOL,NL-6200 MD MAASTRICHT,NETHERLANDS; NIH,DCRT,LSB,BETHESDA,MD 20892; NIH,PATHOL LAB,BETHESDA,MD 20892	Hasselt University; Maastricht University; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA	Templeton, NS (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,POB B,BOYLES ST,BLDG 535,RM 226A,FREDERICK,MD 21702, USA.		Strey, Helmut/B-5456-2009; Templeton, Nancy S/C-9565-2011; Roberts, David D./A-9699-2008	Roberts, David D./0000-0002-2481-2981; Strey, Helmut/0000-0002-6554-5322				Aksentijevich I, 1996, HUM GENE THER, V7, P1111, DOI 10.1089/hum.1996.7.9-1111; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; DRAGSTEN PR, 1987, BIOCHIM BIOPHYS ACTA, V926, P270, DOI 10.1016/0304-4165(87)90213-3; FELGNER JH, 1994, J BIOL CHEM, V269, P2550; Felgner PL, 1996, HUM GENE THER, V7, P1791, DOI 10.1089/hum.1996.7.15-1791; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FREDERIK PM, 1991, J MICROSC-OXFORD, V161, P253, DOI 10.1111/j.1365-2818.1991.tb03088.x; GUSTAFSSON J, 1995, BBA-BIOMEMBRANES, V1235, P305, DOI 10.1016/0005-2736(95)80018-B; Hara T, 1995, GENE THER, V2, P784; Hong KL, 1997, FEBS LETT, V400, P233, DOI 10.1016/S0014-5793(96)01397-X; KANEO Y, 1991, CHEM PHARM BULL, V39, P999; Lasic DD, 1997, J AM CHEM SOC, V119, P832, DOI 10.1021/ja962713g; Lee ER, 1996, HUM GENE THER, V7, P1701, DOI 10.1089/hum.1996.7.14-1701; LIU Y, 1995, J BIOL CHEM, V270, P24864, DOI 10.1074/jbc.270.42.24864; Liu Y, 1997, NAT BIOTECHNOL, V15, P167, DOI 10.1038/nbt0297-167; Mislick KA, 1996, P NATL ACAD SCI USA, V93, P12349, DOI 10.1073/pnas.93.22.12349; Murahashi N, 1996, BIOL PHARM BULL, V19, P418; PHILIP R, 1993, J BIOL CHEM, V268, P16087; Radler JO, 1997, SCIENCE, V275, P810, DOI 10.1126/science.275.5301.810; Sambrook J., 1989, MOL CLONING; SOLODIN I, 1995, BIOCHEMISTRY-US, V34, P13537, DOI 10.1021/bi00041a033; SPANJER HH, 1984, BIOCHIM BIOPHYS ACTA, V774, P49, DOI 10.1016/0005-2736(84)90273-6; SPANJER HH, 1983, BIOCHIM BIOPHYS ACTA, V734, P40, DOI 10.1016/0005-2736(83)90072-X; STAMATATOS L, 1988, BIOCHEMISTRY-US, V27, P3917, DOI 10.1021/bi00411a005; STRIBLING R, 1992, P NATL ACAD SCI USA, V89, P11277, DOI 10.1073/pnas.89.23.11277; THIERRY AR, 1995, P NATL ACAD SCI USA, V92, P9742, DOI 10.1073/pnas.92.21.9742; TSUKAMOTO M, 1995, NAT GENET, V9, P243, DOI 10.1038/ng0395-243; Wheeler CJ, 1996, P NATL ACAD SCI USA, V93, P11454, DOI 10.1073/pnas.93.21.11454; Xu YH, 1996, BIOCHEMISTRY-US, V35, P5616, DOI 10.1021/bi9602019; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073	30	639	757	4	137	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1997	15	7					647	652		10.1038/nbt0797-647	http://dx.doi.org/10.1038/nbt0797-647			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XH583	9219267				2022-12-27	WOS:A1997XH58300028
J	Newman, SA				Newman, SA			Embryo technology - Cloning our way to ''the next level''	NATURE BIOTECHNOLOGY			English	Editorial Material											Newman, SA (corresponding author), NEW YORK MED COLL,DEPT CELL BIOL & ANAT,VALHALLA,NY 10595, USA.		Newman, Stuart/W-1617-2019					CALLAHAN D, 1997, NY TIMES        0226, pA23; Dickson D, 1997, NATURE, V386, P98, DOI 10.1038/386098a0; HUBBARD R, 1997, NATION          0324, P4; KLUGER J, 1997, TIME            0310, P67; MYHRVOLD N, 1997, SLATE           0313; TRUSSELL D, 1997, MANCHESTER GUAR 0316, P2; 1997, NATURE, V386, P1	7	0	0	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1997	15	6					488	488		10.1038/nbt0697-488	http://dx.doi.org/10.1038/nbt0697-488			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XC772	9181557	Bronze			2022-12-27	WOS:A1997XC77200008
J	Daubendiek, SL; Kool, ET				Daubendiek, SL; Kool, ET			Generation of catalytic RNAs by rolling transcription of synthetic DNA nanocircles	NATURE BIOTECHNOLOGY			English	Article						convergent synthesis; rolling circle; hammerhead ribozyme; ASBV viroid	POLYMERASE; INVITRO; OLIGORIBONUCLEOTIDE; BACTERIOPHAGE-T7; RIBOZYMES; CLEAVAGE	Small catalytic RNAs are commonly produced either by transcription of promoter-driven linear DNA templates or by stepwise chemical synthesis on solid supports. We describe a different approach, in which very small chemically synthesized circular DNAs serve as efficient templates for generation of catalytic RNAs in vitro. The circles are 83 nucleotides in size, are single stranded, and contain no canonical RNA polymerase promoters. Despite this, T7 and Escherichia coli RNA polymerases transcribe the circles by a rolling mechanism, producing long concatemeric RNAs (similar to 7,500 nt). During the transcription reaction, the repeating RNAs self-cleave, ultimately reaching monomer length. Despite having self-complementary sequences at their substrate-binding domains, these monomeric 83-nt RNAs are shown to be catalytically active ribozymes that sequence-specifically cleave RNA targets in trans. In addition, a circular vector encoding a repeating (non-self-processing) ribozyme is described; the resulting multimeric ribozyme, targeted to a sequence in the HIV-1 genome, is also catalytically active in trans. This novel approach to the synthesis of catalytic RNAs offers a number of differences and potential advantages over current approaches to RNA synthesis.	UNIV ROCHESTER,DEPT CHEM,ROCHESTER,NY 14627; UNIV ROCHESTER,DEPT BIOCHEM & BIOPHYS,ROCHESTER,NY 14627	University of Rochester; University of Rochester				Kool, Eric/0000-0002-7310-2935				ALYAR SE, 1994, J BIOL CHEM, V269, P13179; CHAMBERL.M, 1970, NATURE, V228, P227, DOI 10.1038/228227a0; CHAMBERL.M, 1973, J BIOL CHEM, V248, P2245; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; DAUBE SS, 1992, SCIENCE, V258, P1320, DOI 10.1126/science.1280856; DAUBENDIEK SL, 1995, J AM CHEM SOC, V117, P7818, DOI 10.1021/ja00134a032; DAUBENDIEK SL, 1996, UNPUB; DZIANOTT AM, 1989, P NATL ACAD SCI USA, V86, P4823, DOI 10.1073/pnas.86.13.4823; GROSSHANS CA, 1991, NUCLEIC ACIDS RES, V19, P3875, DOI 10.1093/nar/19.14.3875; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HUTCHINS CJ, 1986, NUCLEIC ACIDS RES, V14, P3627, DOI 10.1093/nar/14.9.3627; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KRUPP G, 1988, GENE, V72, P75, DOI 10.1016/0378-1119(88)90129-1; LONG DM, 1993, FASEB J, V7, P25, DOI 10.1096/fasebj.7.1.8422971; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MOLLEGAARD NE, 1994, P NATL ACAD SCI USA, V91, P3892, DOI 10.1073/pnas.91.9.3892; OHKAWA J, 1993, P NATL ACAD SCI USA, V90, P11302, DOI 10.1073/pnas.90.23.11302; RUBIN E, 1995, NUCLEIC ACIDS RES, V23, P3547, DOI 10.1093/nar/23.17.3547; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; SYMONS RH, 1981, NUCLEIC ACIDS RES, V9, P6527, DOI 10.1093/nar/9.23.6527; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; TAIRA K, 1991, NUCLEIC ACIDS RES, V19, P5125, DOI 10.1093/nar/19.19.5125; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0	24	59	90	4	36	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1997	15	3					273	277		10.1038/nbt0397-273	http://dx.doi.org/10.1038/nbt0397-273			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WM050	9062929				2022-12-27	WOS:A1997WM05000033
J	Gosse, ME; Nelson, TF				Gosse, ME; Nelson, TF			Approval times for supplemental indications for recombinant proteins	NATURE BIOTECHNOLOGY			English	Article							DRUG DEVELOPMENT; UNITED-STATES				Gosse, ME (corresponding author), TUFTS UNIV,CTR STUDY DRUG DEV,BOSTON,MA 02111, USA.			Nelson, Toben/0000-0001-9934-7546				CLINTON WJ, 1996, COMMUNICATION   0329; DIMASI JA, 1994, CLIN PHARMACOL THER, V55, P609, DOI 10.1038/clpt.1994.78; DIMASI JA, 1995, CLIN PHARMACOL THER, V58, P1, DOI 10.1016/0009-9236(95)90066-7; DIMASI JA, 1991, J HEALTH ECON, V10, P107, DOI 10.1016/0167-6296(91)90001-4; DiMasi JA, 1996, DRUG INF J, V30, P315; *GAO, 1991, GAOPEMD9114 COMM LAB; Gosse ME, 1996, CLIN PHARMACOL THER, V60, P608, DOI 10.1016/S0009-9236(96)90209-X; Gosse ME, 1996, DRUG INF J, V30, P991; KAITIN KI, 1994, J CLIN PHARMACOL, V34, P120, DOI 10.1002/j.1552-4604.1994.tb03975.x; *KIDN CANC ASS, 1996, PINK SHEET, V58, P14; RAIFORD DS, 1994, FOOD DRUG LAW J, V49, P37; Shulman SR, 1996, PHARMACOECONOMICS, V9, P121, DOI 10.2165/00019053-199609020-00004; 1996, PINK SHEET, V58, P6	13	0	0	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1997	15	2					130	&		10.1038/nbt0297-130	http://dx.doi.org/10.1038/nbt0297-130			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WE998	9035135				2022-12-27	WOS:A1997WE99800017
J	Ryabova, LA; Desplancq, D; Spirin, AS; Pluckthun, A				Ryabova, LA; Desplancq, D; Spirin, AS; Pluckthun, A			Functional antibody production using cell-free translation: Effects of protein disulfide isomerase and chaperones	NATURE BIOTECHNOLOGY			English	Article						cell-free translation system; single-chain antibody; disulfide isomerase; molecular chaperones; protein folding	ESCHERICHIA-COLI; BOND FORMATION; ENDOPLASMIC-RETICULUM; GENE ENCODES; ACTIVE-SITE; CHAIN; BINDING; THIOREDOXIN; IDENTIFICATION; INVITRO	To create a rapid system to test the effect of sequence changes on recombinant antibody binding, we have developed a procedure for producing functional scFv fragments in an Escherichia coli cell-free translation system. Functional antibodies with antigen-binding activity are obtained only if disulfide formation and rearrangement is allowed to take place during the translation reaction. The inclusion of protein disulfide isomerase (PDI) leads to a threefold increase in yield over that obtained in the presence of glutathione redox systems. DsbA had no such effect, indicating that disulfide shuffling, and not net formation, is the crucial yield-limiting step. The addition of the molecular chaperones DnaK and DnaJ increased the amount of soluble protein but not the amount of functional scFv, which appears to be limited entirely by correct disulfide formation. None of these factors significantly influenced total protein synthesis. In the presence of PDI, chaperones, reduced glutathione and oxidized glutathione, 50% of the scFv produced (about 8 mu g/ml in only 15 min) could be recovered from immobilized antigen.	UNIV ZURICH,INST BIOCHEM,CH-8057 ZURICH,SWITZERLAND; RUSSIAN ACAD SCI,INST PROT RES,PUSHCHINO 142292,MOSCOW REG,RUSSIA	University of Zurich; Russian Academy of Sciences			Plückthun, Andreas/C-2746-2009; Spirin, Alexander/A-7307-2016	Plückthun, Andreas/0000-0003-4191-5306; Ryabova, Lyubov/0000-0003-1989-203X				BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; CHEN HZ, 1983, METHOD ENZYMOL, V101, P674; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P3576, DOI 10.1021/bi00011a012; FREEDMAN RB, 1995, CURR OPIN STRUC BIOL, V5, P85, DOI 10.1016/0959-440X(95)80013-Q; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; FREUND C, 1993, FEBS LETT, V320, P97, DOI 10.1016/0014-5793(93)80070-B; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GLOCKSHUBER R, 1992, BIOCHEMISTRY-US, V31, P1270, DOI 10.1021/bi00120a002; GOTO Y, 1979, J BIOCHEM-TOKYO, V86, P1433, DOI 10.1093/oxfordjournals.jbchem.a132661; GUILHOT C, 1995, P NATL ACAD SCI USA, V92, P9895, DOI 10.1073/pnas.92.21.9895; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; Hurle Mark R., 1994, Current Opinion in Biotechnology, V5, P428, DOI 10.1016/0958-1669(94)90053-1; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KISHIGAMI S, 1995, J BIOL CHEM, V270, P17072, DOI 10.1074/jbc.270.29.17072; KITAGAWA T, 1978, J BIOCHEM-TOKYO, V84, P491, DOI 10.1093/oxfordjournals.jbchem.a132151; LABOISSIERE MCA, 1995, J BIOL CHEM, V270, P28006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Lindner Peter, 1992, Methods (Orlando), V4, P41, DOI 10.1016/1046-2023(92)90055-D; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; MISSIAKAS D, 1995, EMBO J, V14, P3415, DOI 10.1002/j.1460-2075.1995.tb07347.x; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; NICHOLLS PJ, 1993, J BIOL CHEM, V268, P5302; PLUCKTHUN A, 1992, IMMUNOL REV, V130, P151, DOI 10.1111/j.1600-065X.1992.tb01525.x; PROBA K, 1995, GENE, V159, P203, DOI 10.1016/0378-1119(95)00018-2; PRODROMOU C, 1992, PROTEIN ENG, V5, P827, DOI 10.1093/protein/5.8.827; QUAN H, 1995, J BIOL CHEM, V270, P17078, DOI 10.1074/jbc.270.29.17078; ROTH RA, 1987, BIOCHEMISTRY-US, V26, P4179, DOI 10.1021/bi00388a001; RYABOVA LA, 1995, ANAL BIOCHEM, V226, P184, DOI 10.1006/abio.1995.1208; SCHULZEGAHMEN U, 1993, J MOL BIOL, V234, P1098, DOI 10.1006/jmbi.1993.1663; SONG JL, 1995, EUR J BIOCHEM, V231, P312, DOI 10.1111/j.1432-1033.1995.tb20702.x; SPIRIN AS, 1988, SCIENCE, V242, P1162, DOI 10.1126/science.3055301; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; TOKATLIDIS K, 1995, PHILOS T ROY SOC B, V348, P89, DOI 10.1098/rstb.1995.0049; TRILL JJ, 1995, CURR OPIN BIOTECH, V6, P553, DOI 10.1016/0958-1669(95)80092-1; WUNDERLICH M, 1993, BIOCHEMISTRY-US, V32, P12251, DOI 10.1021/bi00096a039; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019	49	129	151	0	17	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1997	15	1					79	84		10.1038/nbt0197-79	http://dx.doi.org/10.1038/nbt0197-79			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WA729	9035111				2022-12-27	WOS:A1997WA72900028
J	Guida, F; Kidman, R; Ferlay, J; Schuz, J; Soerjomataram, I; Kithaka, B; Ginsburg, O; Vega, RBM; Galukande, M; Parham, G; Vaccarella, S; Canfell, K; Ilbawi, AM; Anderson, BO; Bray, F; dos-Santos-Silva, I; McCormack, V				Guida, Florence; Kidman, Rachel; Ferlay, Jacques; Schuz, Joachim; Soerjomataram, Isabelle; Kithaka, Benda; Ginsburg, Ophira; Vega, Raymond B. Mailhot; Galukande, Moses; Parham, Groesbeck; Vaccarella, Salvatore; Canfell, Karen; Ilbawi, Andre M.; Anderson, Benjamin O.; Bray, Freddie; dos-Santos-Silva, Isabel; McCormack, Valerie			Global and regional estimates of orphans attributed to maternal cancer mortality in 2020	NATURE MEDICINE			English	Article; Early Access							BREAST-CANCER; REPRODUCTIVE FACTORS; CERVICAL-CANCER; LUNG-CANCER; RISK; COUNTRIES; SURVIVAL; PARITY; DIAGNOSIS; CHILDREN	Despite women being disproportionally affected by cancer deaths at young ages, there are no global estimates of the resulting maternal orphans, who experience health and education disadvantages throughout their lives. We estimated the number of children who became maternal orphans in 2020 due to their mother dying from cancer in that year, for 185 countries worldwide and by cause of cancer-related death. Female cancer deaths-by country, cancer type and age (derived from GLOBOCAN estimates)-were multiplied by each woman's estimated number of children under the age of 18 years at the time of her death (fertility data were derived from United Nations World Population Prospects for birth cohort), accounting for child mortality and parity-cancer risk associations. Globally, there were 1,047,000 such orphans. Over half of these were orphans due to maternal deaths from breast (258,000, 25%), cervix (210,000, 20%) and upper-gastrointestinal cancers (136,000, 13%), and most occurred in Asia (48%: India 15%, China 10%, rest of Asia 23%) and Africa (35%). Globally, there were 40 new maternal orphans due to cancer per 100,000 children, with a declining trend with a higher Human Development Index (range: 121 in Malawi to 15 in Malta). An estimated 7 million children were prevalent maternal orphans due to cancer in mid-2020. Accelerating the implementation of the World Health Organization's cervical and breast cancer initiatives has the potential to avert not only millions of preventable female cancer deaths but also the associated, often-overlooked, intergenerational consequences of these deaths. According to 2020 estimates from 185 countries, Asia and Africa have the most maternal orphans due to cancer, with breast and cervical cancers responsible for almost half of maternal cancers.	[Guida, Florence; Ferlay, Jacques; Schuz, Joachim; Soerjomataram, Isabelle; Vaccarella, Salvatore; Bray, Freddie; McCormack, Valerie] Int Agcy Res Canc, Lyon, France; [Kidman, Rachel] SUNY Stony Brook, Program Publ Hlth, Stony Brook, NY 11794 USA; [Kidman, Rachel] SUNY Stony Brook, Dept Family Populat & Prevent Med, Stony Brook, NY 11794 USA; [Kithaka, Benda] Kilele Hlth Assoc, Nairobi, Kenya; [Ginsburg, Ophira] US Natl Canc Inst, Ctr Global Hlth, Rockville, MD USA; [Vega, Raymond B. Mailhot] Univ Florida, Dept Radiat Oncol, Gainesville, FL USA; [Galukande, Moses] Makerere Univ, Kampala, Uganda; [Parham, Groesbeck] Univ N Carolina, Sch Med, Dept Obstet & Gynecol, Chapel Hill, NC USA; [Canfell, Karen] Univ Sydney, Daffodil Ctr, Sydney, NSW, Australia; [Ilbawi, Andre M.; Anderson, Benjamin O.] World Hlth Org WHO, Global Breast Canc Initiat, Dept Noncommunicable Dis, Geneva, Switzerland; [dos-Santos-Silva, Isabel] London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, London, England	World Health Organization; International Agency for Research on Cancer (IARC); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); State University System of Florida; University of Florida; Makerere University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Sydney; World Health Organization; University of London; London School of Hygiene & Tropical Medicine	Guida, F; McCormack, V (corresponding author), Int Agcy Res Canc, Lyon, France.	guidaf@iarc.who.int; mccormackv@iarc.who.int	; Mailhot, Raymond/M-1172-2019	Guida, Florence/0000-0002-9652-2430; Schuz, Joachim/0000-0001-9687-2134; Mailhot, Raymond/0000-0003-0616-034X	US National Cancer Institute [R01CA244559]	US National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by the US National Cancer Institute (R01CA244559 to V.McC and I.d.S.S). The funders of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report. Where authors are identified as personnel of the International Agency for Research on Cancer and/or the World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer and/or the World Health Organization. The opinions expressed by the authors are their own and this material should not be interpreted as representing the official viewpoint of the U.S. Department of Health and Human Services, the National Institutes of Health or the National Cancer Institute.	Abnet CC, 2022, NAT REV CANCER, V22, P253, DOI 10.1038/s41568-022-00458-1; ADAMI HO, 1994, LANCET, V344, P1250, DOI 10.1016/S0140-6736(94)90749-8; Allemani C, 2018, LANCET, V391, P1023, DOI 10.1016/S0140-6736(17)33326-3; Anderson BO, 2021, LANCET ONCOL, V22, P578, DOI 10.1016/S1470-2045(21)00071-1; Arnold M, 2020, GUT, V69, P1564, DOI 10.1136/gutjnl-2020-321600; Arnold M, 2019, LANCET ONCOL, V20, P1493, DOI 10.1016/S1470-2045(19)30456-5; Beral V, 2002, LANCET, V360, P187, DOI 10.1016/S0140-6736(02)09454-0; Bergman AS, 2017, BMC PALLIAT CARE, V16, DOI 10.1186/s12904-017-0223-y; Bidoli E, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50680-5; Canfell K, 2020, LANCET, V395, P591, DOI 10.1016/S0140-6736(20)30157-4; Case A, 2004, DEMOGRAPHY, V41, P483, DOI 10.1353/dem.2004.0019; Clarke AR, 2003, J INTELL DISABIL RES, V47, P210, DOI 10.1046/j.1365-2788.2003.00470.x; Clavel-Chapelon F, 2002, BREAST CANCER RES TR, V72, P107, DOI 10.1023/A:1014891216621; Dahabreh IJ, 2012, LUNG CANCER, V76, P150, DOI 10.1016/j.lungcan.2011.10.014; Ferlay J, 2021, INT J CANCER, V149, P778, DOI 10.1002/ijc.33588; Ferlay J, 2010, BREAST CANCER EPIDEMIOLOGY, P1, DOI 10.1007/978-1-4419-0685-4_1; Fidler M. M, 2019, REDUCING SOCIAL INEQ; Foerster M, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1174-4; Fondation Lalla Salma, 2022, SCOPE ACTIVITIES SOC; Foster C, 2000, AIDS, V14, pS275; Galukande M, 2021, JAMA ONCOL, V7, P285, DOI 10.1001/jamaoncol.2020.6583; Guldin MB, 2015, JAMA PSYCHIAT, V72, P1227, DOI 10.1001/jamapsychiatry.2015.2094; Heer E, 2020, LANCET GLOB HEALTH, V8, P1027, DOI 10.1016/S2214-109X(20)30215-1; Hillis S., 2021, CHILDREN HIDDEN PAND; Hillis SD, 2021, LANCET, V398, P391, DOI 10.1016/S0140-6736(21)01253-8; IARC, 2022, GLOBAL CANC OBSERVAT; Institute for Health Metrics and Evaluation (IHME), 2020, GBD 2019 CAUS RISK; Kailaheimo-Lonnqvist S, 2020, SSM-POPUL HLTH, V11, DOI 10.1016/j.ssmph.2020.100632; Kidman R, 2021, NATURE, V596, P185, DOI 10.1038/d41586-021-02155-9; Kidman R, 2016, CHILD ABUSE NEGLECT, V51, P172, DOI 10.1016/j.chiabu.2015.10.018; Li J, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001679; Man I, 2022, LANCET ONCOL, V23, P1419, DOI 10.1016/S1470-2045(22)00543-5; McCormack V, 2020, LANCET GLOB HEALTH, V8, pE1203, DOI 10.1016/S2214-109X(20)30261-8; McKenzie F, 2018, INT J CANCER, V142, P1568, DOI 10.1002/ijc.31187; Mejia-Pailles G, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238563; Munoz N, 2002, LANCET, V359, P1093, DOI 10.1016/S0140-6736(02)08151-5; Ronsmans C, 2010, LANCET, V375, P2024, DOI 10.1016/S0140-6736(10)60704-0; Ross John, 2020, Gates Open Res, V4, P153, DOI 10.12688/gatesopenres.13177.1; Schoumaker B, 2017, DEMOGR RES, V36, P803, DOI 10.4054/DemRes.2017.36.28; Sengayi-Muchengeti M, 2020, INT J CANCER, V147, P3037, DOI 10.1002/ijc.33120; Shiels MS, 2017, CURR OPIN HIV AIDS, V12, P6, DOI 10.1097/COH.0000000000000327; Soerjomataram I, 2012, LANCET, V380, P1840, DOI 10.1016/S0140-6736(12)60919-2; UNAIDS UNICEF & USAID, 2004, CHILDR BRINK 2004 JO; UNICEF, 2022, ORPHANHOOD; United Nations Department of Economic and Social Affairs, 2022, WORLD POPULATION PRO, DOI DOI 10.18356/13BF5476-EN; Vega RBM, 2019, CANCER-AM CANCER SOC, V125, P109, DOI 10.1002/cncr.31780; Yabroff KR, 2011, CANCER EPIDEM BIOMAR, V20, P2006, DOI 10.1158/1055-9965.EPI-11-0650; Yates D., 2011, PEPFAR HKID PORTFOLI; Yin X, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09530-7	49	0	0	1	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02109-2	http://dx.doi.org/10.1038/s41591-022-02109-2		NOV 2022	24	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	6I0XG	36404355	Green Published, hybrid			2022-12-27	WOS:000885850300001
J	Christensen, JG; Hallin, J				Christensen, James G.; Hallin, Jill			The KRAS(G12D) inhibitor MRTX1133 elucidates KRAS-mediated oncogenesis	NATURE MEDICINE			English	Editorial Material; Early Access								The identification of KRAS(G12C) inhibitors has reignited interest in targeting RAS proteins. This work describes the discovery of the KRAS(G12D)-specific inhibitor MRTX1133 and demonstrates the feasibility of potently and selectively targeting this oncogenic variant. MRTX1133 treatment markedly inhibited KRAS-dependent signaling and induced tumor regression in xenograft models harboring the KRAS(G12D) mutation.	[Christensen, James G.; Hallin, Jill] Mirati Therapeut, San Diego, CA 92121 USA		Christensen, JG (corresponding author), Mirati Therapeut, San Diego, CA 92121 USA.							BOS JL, 1989, CANCER RES, V49, P4682; Fernandez-Medarde Alberto, 2011, Genes Cancer, V2, P344, DOI 10.1177/1947601911411084; Hallin J, 2020, CANCER DISCOV, V10, P54, DOI 10.1158/2159-8290.CD-19-1167; Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796; Wang XL, 2021, J MED CHEM, DOI 10.1021/acs.jmedchem.1c01688	5	0	0	15	15	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02008-6	http://dx.doi.org/10.1038/s41591-022-02008-6		OCT 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	5D5EC	36207523				2022-12-27	WOS:000864963800001
J	Van Name, M; Sherr, J				Van Name, Michelle; Sherr, Jennifer			When insulin isn't enough: targeting glucagon in type 1 diabetes	NATURE MEDICINE			English	Editorial Material; Early Access								A phase 2 study fails to meet its primary endpoint, but the treatment - a glucagon receptor antagonist - shows clinically relevant improvements in glycemic control, warranting further investigation as a potential adjunct to insulin.	[Van Name, Michelle; Sherr, Jennifer] Yale Sch Med, Dept Pediat, New Haven, CT 06510 USA	Yale University	Sherr, J (corresponding author), Yale Sch Med, Dept Pediat, New Haven, CT 06510 USA.	jennifer.sherr@yale.edu		Sherr, Jennifer/0000-0001-9301-3043				Brown RJ, 2008, DIABETES CARE, V31, P1403, DOI 10.2337/dc08-0575; Foster NC, 2019, DIABETES TECHNOL THE, V21, P66, DOI 10.1089/dia.2018.0384; GERICH JE, 1973, SCIENCE, V182, P171, DOI 10.1126/science.182.4108.171; Kelly RP, 2015, DIABETES OBES METAB, V17, P414, DOI 10.1111/dom.12446; Pearson MJ, 2016, DIABETES CARE, V39, P1075, DOI 10.2337/dci15-0033; Pettus J, 2022, NAT MED, DOI 10.1038/s41591-022-02011-x; Pettus J, 2018, DIABETES OBES METAB, V20, P1302, DOI 10.1111/dom.13202; Sherr J, 2014, DIABETES CARE, V37, P1741, DOI 10.2337/dc13-2612; Unger RH, 2010, P NATL ACAD SCI USA, V107, P16009, DOI 10.1073/pnas.1006639107	9	0	0	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02019-3	http://dx.doi.org/10.1038/s41591-022-02019-3		OCT 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	5D8VV	36192555				2022-12-27	WOS:000865214200004
J	Kasi, PM				Kasi, Pashtoon Murtaza			Liquid biopsies and tumor mutational burden: the cutoff conundrum	NATURE MEDICINE			English	Editorial Material								Assessment of tumor mutational burden through a simple blood test could help to identify which patients are most likely to benefit from immunotherapy, but optimal cutoffs are not well established.	[Kasi, Pashtoon Murtaza] Weill Cornell Med, Meyer Canc Ctr, Englander Inst Precis Med, New York, NY 10021 USA	Cornell University	Kasi, PM (corresponding author), Weill Cornell Med, Meyer Canc Ctr, Englander Inst Precis Med, New York, NY 10021 USA.	pmk4001@med.cornell.edu						Chalmers ZR, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0424-2; Chan TA, 2019, ANN ONCOL, V30, P44, DOI 10.1093/annonc/mdy495; Chen EX, 2020, JAMA ONCOL, V6, P831, DOI 10.1001/jamaoncol.2020.0910; Friedlaender A, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00142; Jardim DL, 2021, CANCER CELL, V39, P154, DOI 10.1016/j.ccell.2020.10.001; Kasi P. M., 2020, ASCO DAILY NEWS; Malla M, 2022, J CLIN ONCOL, V40, P2846, DOI 10.1200/JCO.21.02615; Marabelle A, 2020, LANCET ONCOL, V21, P1353, DOI 10.1016/S1470-2045(20)30445-9; Peters S, 2022, NAT MED, V28, P1831, DOI 10.1038/s41591-022-01933-w; Strickler JH, 2021, CLIN CANCER RES, V27, P1236, DOI 10.1158/1078-0432.CCR-20-3054	10	0	0	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2022	28	9					1753	1754		10.1038/s41591-022-01999-6	http://dx.doi.org/10.1038/s41591-022-01999-6		SEP 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4S0LI	36097224				2022-12-27	WOS:000852940800006
J	Rizas, KD; Freyer, L; Sappler, N; von Stulpnagel, L; Spielbichler, P; Krasniqi, A; Schreinlechner, M; Wenner, FN; Theurl, F; Behroz, A; Eiffener, E; Klemm, MP; Schneidewind, A; Zens, M; Dolejsi, T; Mansmann, U; Massberg, S; Bauer, A				Rizas, Konstantinos D.; Freyer, Luisa; Sappler, Nikolay; von Stuelpnagel, Lukas; Spielbichler, Peter; Krasniqi, Aresa; Schreinlechner, Michael; Wenner, Felix N.; Theurl, Fabian; Behroz, Amira; Eiffener, Elodie; Klemm, Mathias P.; Schneidewind, Annika; Zens, Martin; Dolejsi, Theresa; Mansmann, Ulrich; Massberg, Steffen; Bauer, Axel			Smartphone-based screening for atrial fibrillation: a pragmatic randomized clinical trial	NATURE MEDICINE			English	Article							MYOCARDIAL-INFARCTION; HEART-FAILURE; RISK; POPULATION	Digital smart devices have the capability of detecting atrial fibrillation (AF), but the efficacy of this type of digital screening has not been directly compared to usual care for detection of treatment-relevant AF. In the eBRAVE-AF trial (), we randomly assigned 5,551 policyholders of a German health insurance company who were free of AF at baseline (age 65 years (median; interquartile range (11) years, 31% females)) to digital screening (n = 2,860) or usual care (n = 2,691). In this siteless trial, for digital screening, participants used a certified app on their own smartphones to screen for irregularities in their pulse waves. Abnormal findings were evaluated by 14-day external electrocardiogram (ECG) loop recorders. The primary endpoint was newly diagnosed AF within 6 months treated with oral anti-coagulation by an independent physician not involved in the study. After 6 months, participants were invited to cross-over for a second study phase with reverse assignment for secondary analyses. The primary endpoint of the trial was met, as digital screening more than doubled the detection rate of treatment-relevant AF in both phases of the trial, with odds ratios of 2.12 (95% confidence interval (CI), 1.19-3.76; P = 0.010) and 2.75 (95% CI, 1.42-5.34; P = 0.003) in the first and second phases, respectively. This digital screening technology provides substantial benefits in detecting AF compared to usual care and has the potential for broad applicability due to its wide availability on ordinary smartphones. Future studies are needed to test whether digital screening for AF leads to better treatment outcomes.	[Rizas, Konstantinos D.; Freyer, Luisa; von Stuelpnagel, Lukas; Spielbichler, Peter; Krasniqi, Aresa; Wenner, Felix N.; Behroz, Amira; Eiffener, Elodie; Klemm, Mathias P.; Schneidewind, Annika; Massberg, Steffen; Bauer, Axel] LMU Univ Hosp Munich, Med Klin & Poliklin 1, Munich, Germany; [Rizas, Konstantinos D.; Freyer, Luisa; von Stuelpnagel, Lukas; Spielbichler, Peter; Krasniqi, Aresa; Wenner, Felix N.; Behroz, Amira; Eiffener, Elodie; Klemm, Mathias P.; Schneidewind, Annika; Massberg, Steffen; Bauer, Axel] German Ctr Cardiovasc Res DZHK, Partner Site Munich Heart Alliance, Munich, Germany; [Sappler, Nikolay; von Stuelpnagel, Lukas; Schreinlechner, Michael; Theurl, Fabian; Dolejsi, Theresa; Bauer, Axel] Med Univ Innsbruck, Univ Hosp Internal Med 3, Innsbruck, Austria; [Zens, Martin] Univ Klinikum Augsburg, Augsburg, Germany; [Mansmann, Ulrich] Ludwig Maximilians Univ Munchen, Inst Med Informat Proc Biometry & Epidemiol, Munich, Germany	University of Munich; German Centre for Cardiovascular Research; Munich Heart Alliance; Medical University of Innsbruck; University of Munich	Massberg, S; Bauer, A (corresponding author), LMU Univ Hosp Munich, Med Klin & Poliklin 1, Munich, Germany.; Massberg, S; Bauer, A (corresponding author), German Ctr Cardiovasc Res DZHK, Partner Site Munich Heart Alliance, Munich, Germany.; Bauer, A (corresponding author), Med Univ Innsbruck, Univ Hosp Internal Med 3, Innsbruck, Austria.	steffen.massberg@med.uni-muenchen.de; axel.bauer@i-med.ac.at		Rizas, Konstantinos/0000-0002-5993-0339; Theurl, Fabian/0000-0002-0190-5958				[Anonymous], 2022, SMARTPHONE ADOPTION; Anter E, 2009, CIRCULATION, V119, P2516, DOI 10.1161/CIRCULATIONAHA.108.821306; Benjamin EJ, 2021, CIRCULATION, V143, P372, DOI 10.1161/CIRCULATIONAHA.120.047633; Brasier N, 2019, EUROPACE, V21, P41, DOI 10.1093/europace/euy176; Chen LY, 2018, CIRCULATION, V137, pE623, DOI 10.1161/CIR.0000000000000568; Conen D, 2016, JAMA CARDIOL, V1, P389, DOI 10.1001/jamacardio.2016.0280; Davidson KW, 2022, JAMA-J AM MED ASSOC, V327, P360, DOI 10.1001/jama.2021.23732; Freyer L, 2021, AM HEART J, V241, P26, DOI 10.1016/j.ahj.2021.06.008; Guo YT, 2019, J AM COLL CARDIOL, V74, P2365, DOI 10.1016/j.jacc.2019.08.019; Halcox JPJ, 2017, CIRCULATION, V136, P1784, DOI 10.1161/CIRCULATIONAHA.117.030583; Hindricks G, 2021, EUR HEART J, V42, P373, DOI [10.1093/eurheartj/ehaa612, 10.15829/1560-4071-2021-4701]; Kaplan RM, 2019, CIRCULATION, V140, P1639, DOI 10.1161/CIRCULATIONAHA.119.041303; Koenig N, 2016, TELEMED E-HEALTH, V22, P631, DOI 10.1089/tmj.2015.0212; Kornej J, 2021, HEART, V107, P516, DOI 10.1136/heartjnl-2020-318480; Kornej J, 2020, CIRC RES, V127, P4, DOI 10.1161/CIRCRESAHA.120.316340; Krijthe BP, 2013, EUR HEART J, V34, P2746, DOI 10.1093/eurheartj/eht280; Krivoshei L, 2017, EUROPACE, V19, P753, DOI 10.1093/europace/euw125; Lubitz S., 2021, CIRCULATION, V144, P25; Lubitz SA, 2022, CIRCULATION, V145, P946, DOI 10.1161/CIRCULATIONAHA.121.057014; Lubitz SA, 2021, CIRCULATION, V144, pE570; Lutsey PL, 2018, J THROMB HAEMOST, V16, P670, DOI 10.1111/jth.13974; Massicotte-Azarniouch D, 2018, AM J KIDNEY DIS, V71, P191, DOI 10.1053/j.ajkd.2017.08.016; Matsumoto M., 1998, ACM Transactions on Modeling and Computer Simulation, V8, P3, DOI 10.1145/272991.272995; Perez MV, 2019, NEW ENGL J MED, V381, P1909, DOI 10.1056/NEJMoa1901183; Soliman EZ, 2015, CIRCULATION, V131, P1843, DOI 10.1161/CIRCULATIONAHA.114.014145; Sposato LA, 2015, LANCET NEUROL, V14, P377, DOI 10.1016/S1474-4422(15)70027-X; Steinhubl SR, 2018, JAMA-J AM MED ASSOC, V320, P146, DOI 10.1001/jama.2018.8102; Svendsen JH, 2021, LANCET, V398, P1507, DOI 10.1016/S0140-6736(21)01698-6; Svennberg E, 2021, LANCET, V398, P1498, DOI 10.1016/S0140-6736(21)01637-8; Svennberg E, 2015, CIRCULATION, V131, P2176, DOI 10.1161/CIRCULATIONAHA.114.014343; Turakhia MP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195088; Zens Martin, 2017, JMIR Res Protoc, V6, pe99, DOI 10.2196/resprot.7705	32	1	1	2	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2022	28	9					1823	+		10.1038/s41591-022-01979-w	http://dx.doi.org/10.1038/s41591-022-01979-w		AUG 2022	24	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4S0LI	36031651				2022-12-27	WOS:000846827400001
J	Subbiah, V; Cassier, PA; Siena, S; Garralda, E; Paz-Ares, L; Garrido, P; Nadal, E; Vuky, J; Lopes, G; Kalemkerian, GP; Bowles, DW; Seetharam, M; Chang, JH; Zhang, H; Green, J; Zalutskaya, A; Schuler, M; Fan, Y; Curigliano, G				Subbiah, Vivek; Cassier, Philippe A.; Siena, Salvatore; Garralda, Elena; Paz-Ares, Luis; Garrido, Pilar; Nadal, Ernest; Vuky, Jacqueline; Lopes, Gilberto; Kalemkerian, Gregory P.; Bowles, Daniel W.; Seetharam, Mahesh; Chang, Jianhua; Zhang, Hui; Green, Jennifer; Zalutskaya, Alena; Schuler, Martin; Fan, Yun; Curigliano, Giuseppe			Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial	NATURE MEDICINE			English	Article; Early Access							CELL LUNG-CANCER; MULTI-COHORT; OPEN-LABEL; IDENTIFICATION; GEMCITABINE; ALK	Oncogenic RET fusions occur in diverse cancers. Pralsetinib is a potent, selective inhibitor of RET receptor tyrosine kinase. ARROW (NCT03037385, ongoing) was designed to evaluate pralsetinib efficacy and safety in patients with advanced RET-altered solid tumors. Twenty-nine patients with 12 different RET fusion-positive solid tumor types, excluding non-small-cell lung cancer and thyroid cancer, who had previously received or were not candidates for standard therapies, were enrolled. The most common RET fusion partners in 23 efficacy-evaluable patients were CCDC6 (26%), KIF5B (26%) and NCOA4 (13%). Overall response rate, the primary endpoint, was 57% (95% confidence interval, 35-77) among these patients. Responses were observed regardless of tumor type or RET fusion partner. Median duration of response, progression-free survival and overall survival were 12 months, 7 months and 14 months, respectively. The most common grade >= 3 treatment-related adverse events were neutropenia (31%) and anemia (14%). These data validate RET as a tissue-agnostic target with sensitivity to RET inhibition, indicating pralsetinib's potential as a well-tolerated treatment option with rapid, robust and durable anti-tumor activity in patients with diverse RET fusion-positive solid tumors.	[Subbiah, Vivek] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Cassier, Philippe A.] Ctr Leon Berard, Lyon, France; [Siena, Salvatore] Univ Milano La Statale, Dept Oncol & Hematooncol, Milan, Italy; [Siena, Salvatore] Grande Osped Metropolitano Niguarda, Niguarda Canc Ctr, Milan, Italy; [Garralda, Elena] Vall dHebron Hosp, Vall dHebron Inst Oncol, Barcelona, Spain; [Paz-Ares, Luis] Hosp Univ 12 Octubre, Ciberonc, CNIO H12o Lung Canc Unit, Madrid, Spain; [Paz-Ares, Luis] Univ Complutense Madrid, Madrid, Spain; [Garrido, Pilar] IRYCIS Hosp Univ Ramon y Cajal, Ciberonc, Madrid, Spain; [Garrido, Pilar] Alcala Univ, Madrid, Spain; [Nadal, Ernest] Catalan Inst Oncol, Lhospitalet De Llobregat, Spain; [Vuky, Jacqueline] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Lopes, Gilberto] Univ Miami Hlth Syst, Miami, FL USA; [Kalemkerian, Gregory P.] Univ Michigan, Ann Arbor, MI 48109 USA; [Bowles, Daniel W.] Univ Colorado, Aurora, CO USA; [Seetharam, Mahesh] Mayo Clin, Phoenix, AZ USA; [Chang, Jianhua] Chinese Acad Med Sci, Canc Hosp, Shenzhen, Peoples R China; [Zhang, Hui; Green, Jennifer; Zalutskaya, Alena] Blueprint Med Corp, Cambridge, MA USA; [Schuler, Martin] Univ Hosp Essen, West German Canc Ctr Essen, Essen, Germany; [Schuler, Martin] German Canc Consortium DKTK, Essen, Germany; [Fan, Yun] Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou, Peoples R China; [Curigliano, Giuseppe] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy; [Curigliano, Giuseppe] IRCCS, Ist Europeo Oncol, Milan, Italy	University of Texas System; UTMD Anderson Cancer Center; UNICANCER; Centre Leon Berard; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO); CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Hospital Universitario 12 de Octubre; Complutense University of Madrid; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Hospital Universitario Ramon y Cajal; Universidad de Alcala; Catalan Institute of Oncology; Oregon Health & Science University; University of Michigan System; University of Michigan; University of Colorado System; University of Colorado Anschutz Medical Campus; Mayo Clinic; Mayo Clinic Phoenix; Chinese Academy of Medical Sciences - Peking Union Medical College; University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); Zhejiang Cancer Hospital; University of Milan; IRCCS European Institute of Oncology (IEO)	Subbiah, V (corresponding author), Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.	vsubbiah@mdanderson.org		Subbiah, Vivek/0000-0002-6064-6837; Nadal, Ernest/0000-0002-9674-5554; Garrido Lopez, Pilar/0000-0002-5899-6125	Jacquelyn A. Brady Fund; US National Institutes of Health [R01CA242845, R01CA273168]; Cancer Prevention and Research Institute of Texas [RP1100584]; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy [1U01 CA180964]; National Center for Advancing Translational Sciences grant [UL1 TR000371]; MD Anderson Cancer Center Support grant [P30 CA016672]; Blueprint Medicines; Caixa Research Advanced Oncology Research Program (Fundacio La Caixa) [LCF/PR/CE07/50610001]; Carlos III National Health Institute grant [PI21/00789]; Horizon 2020 [H2020-SC1-2019-Single-Stage-RTD]; Oncology Center of Excellence Grant/German Cancer Aid [70112273]; German Cancer Consortium, partner site: University Hospital Essen [BMBF 613-71043-1]; OPTIMA (optimal treatment for patients with solid tumors in Europe through artificial intelligence) grant [101034347]; F. Hoffmann-La Roche	Jacquelyn A. Brady Fund; US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention and Research Institute of Texas; Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy; National Center for Advancing Translational Sciences grant; MD Anderson Cancer Center Support grant; Blueprint Medicines; Caixa Research Advanced Oncology Research Program (Fundacio La Caixa); Carlos III National Health Institute grant; Horizon 2020; Oncology Center of Excellence Grant/German Cancer Aid; German Cancer Consortium, partner site: University Hospital Essen; OPTIMA (optimal treatment for patients with solid tumors in Europe through artificial intelligence) grant; F. Hoffmann-La Roche(Hoffmann-La Roche)	The authors would like to thank the patients, their families and all investigators involved in this study. V.S. is an Andrew Sabin Family Foundation Fellow at The University of Texas MD Anderson Cancer Center. V.S. acknowledges support of the Jacquelyn A. Brady Fund. V.S. is supported by US National Institutes of Health grants R01CA242845 and R01CA273168. MD Anderson Cancer Center Department of Investigational Cancer Therapeutics is supported by the Cancer Prevention and Research Institute of Texas (RP1100584), the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (1U01 CA180964), a National Center for Advancing Translational Sciences grant (UL1 TR000371) and the MD Anderson Cancer Center Support grant (P30 CA016672). Medical writing support, including assisting authors with the development of the outline as well as initial draft and incorporation of comments, was provided by N. Tracey and W. Wheddon; editorial support, including submission, was provided by E. Sims and T. Taylor, all of Paragon (Knutsford, United Kingdom), supported by Blueprint Medicines, according to Good Publication Practice guidelines. The sponsor was involved in the study design and collection, analysis and interpretation of data, as well as data checking of information provided in the article. However, ultimate responsibility for opinions, conclusions and data interpretation lies with the authors. E.G. is supported by the Caixa Research Advanced Oncology Research Program (supported by Fundacio La Caixa, LCF/PR/CE07/50610001). E.N. is supported by the Carlos III National Health Institute grant (PI21/00789) and Horizon 2020 (H2020-SC1-2019-Single-Stage-RTD). M. Schuler is supported by the Oncology Center of Excellence Grant/German Cancer Aid (70112273) and the German Cancer Consortium, partner site: University Hospital Essen (BMBF 613-71043-1). G.C. is supported by an OPTIMA (optimal treatment for patients with solid tumors in Europe through artificial intelligence) grant (101034347). The ARROW study (NCT03037385) was supported by Blueprint Medicines and F. Hoffmann-La Roche.	Ciampi R, 2007, ENDOCRINOLOGY, V148, P936, DOI 10.1210/en.2006-0921; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Drilon A, 2020, NEW ENGL J MED, V383, P813, DOI 10.1056/NEJMoa2005653; European Society for Medical Oncology, 2020, MET NONSM CELL LUNG; Filetti S, 2019, ANN ONCOL, V30, P1856, DOI 10.1093/annonc/mdz400; Gainor JF, 2021, LANCET ONCOL, V22, P959, DOI 10.1016/S1470-2045(21)00247-3; Genentech USA, 2019, ROZLYTREK ENTR CAPS; GlaxoSmithKline, 2021, JEMPERLI DOST GXLY P; Kato S, 2017, CLIN CANCER RES, V23, P1988, DOI 10.1158/1078-0432.CCR-16-1679; Kohno T, 2012, NAT MED, V18, P375, DOI 10.1038/nm.2644; Le Rolle AF, 2015, ONCOTARGET, V6, P28929, DOI 10.18632/oncotarget.4325; Lilly E., 2020, RETEVMO SELPERCATINI; Lipson D, 2012, NAT MED, V18, P382, DOI 10.1038/nm.2673; Looney AM, 2020, NAT REV DRUG DISCOV, V19, P383, DOI 10.1038/d41573-020-00015-1; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Merck Sharpe & Dohme, 2019, KEYTRUDA PEMBR INJ P; National Comprehensive Cancer Network (NCCN), 2021, THYR CARC VERS 1 202; National Comprehensive Cancer Network (NCCN), 2021, NONSM CELL LUNG CANC; Novello S, 2016, ANN ONCOL, V27, pv1, DOI 10.1093/annonc/mdw326; Padcev (enfortumabvedotin), 2020, FILGOTINIB JAPANESE; Paratala BS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07341-4; Peters S, 2017, NEW ENGL J MED, V377, P829, DOI 10.1056/NEJMoa1704795; Roche Registration. GAVRETO (pralsetinib), 2021, SUMMARY PRODUCT CHAR; Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137; Subbiah V, 2021, ANN M AM ASS CANC RE; Subbiah V, 2021, LANCET DIABETES ENDO, V9, P491, DOI 10.1016/S2213-8587(21)00120-0; Subbiah V, 2020, CANCER DISCOV, V10, P498, DOI 10.1158/2159-8290.CD-19-1116; Subbiah V, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-CT043; Subbiah V, 2018, CANCER DISCOV, V8, P836, DOI 10.1158/2159-8290.CD-18-0338; Valle J, 2010, NEW ENGL J MED, V362, P1273, DOI 10.1056/NEJMoa0908721; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369	31	4	4	7	7	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01931-y	http://dx.doi.org/10.1038/s41591-022-01931-y		AUG 2022	17	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3T0XU	35962206	Green Published, hybrid			2022-12-27	WOS:000840008300003
J	Christie, JD; Chiocca, EA				Christie, John D.; Chiocca, E. Antonio			Treat and repeat: oncolytic virus therapy for brain cancer	NATURE MEDICINE			English	Editorial Material; Early Access							GLIOBLASTOMA		[Christie, John D.; Chiocca, E. Antonio] Harvard Med Sch, Brigham & Womens Hosp, Harvey Cushing Neurooncol Labs, Dept Neurosurg, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Chiocca, EA (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Harvey Cushing Neurooncol Labs, Dept Neurosurg, Boston, MA 02115 USA.	eachiocca@bwh.harvard.edu						Alayo QA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61736-2; Alvarez-Breckenridge CA, 2012, NAT MED, V18, P1827, DOI 10.1038/nm.3013; Bagley SJ, 2022, CLIN CANCER RES, V28, P594, DOI 10.1158/1078-0432.CCR-21-2750; Chiocca EA, 2019, NEURO-ONCOLOGY, V21, P14, DOI 10.1093/neuonc/noy170; Chiocca EA, 2014, CANCER IMMUNOL RES, V2, P295, DOI 10.1158/2326-6066.CIR-14-0015; Goonan J., PRNEWSWIRE; Johnson DR, 2022, J NEURO-ONCOL, V158, P139, DOI 10.1007/s11060-021-03853-0; Milano MT, 2010, INT J RADIAT ONCOL, V78, P1147, DOI 10.1016/j.ijrobp.2009.09.018; Otani Y, 2022, CLIN CANCER RES, V28, P1460, DOI 10.1158/1078-0432.CCR-21-2347; Todo T, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-31262-y; Todo T, 2022, NAT MED, DOI 10.1038/s41591-022-01897-x; Wheeler LA, 2016, NEURO-ONCOLOGY, V18, P1137, DOI 10.1093/neuonc/now002	12	0	0	6	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01901-4	http://dx.doi.org/10.1038/s41591-022-01901-4		JUL 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3C2GI	35864255				2022-12-27	WOS:000828446700005
J	Winks, S; Woodland, JG; Pillai, G; Chibale, K				Winks, Susan; Woodland, John G.; Pillai, Goonaseelan 'Colin'; Chibale, Kelly			Fostering drug discovery and development in Africa	NATURE MEDICINE			English	Editorial Material; Early Access							MALARIA; IDENTIFICATION	The H3D Centre is a South African-based academic translational research unit that has had many successes and could provide a much-needed model for drug discovery and development in Africa.	[Winks, Susan; Woodland, John G.; Chibale, Kelly] Univ Cape Town, Holist Drug Discovery & Dev H3D Ctr, Rondebosch, South Africa; [Pillai, Goonaseelan 'Colin'] Univ Cape Town, Div Clin Pharmacol, Rondebosch, South Africa; [Pillai, Goonaseelan 'Colin'] CP Associates GmbH, Basel, Switzerland; [Chibale, Kelly] Univ Cape Town, South African Med Res Council, Drug Discovery & Dev Res Unit, Dept Chem, Cape Town, South Africa; [Chibale, Kelly] Univ Cape Town, Inst Infect Dis & Mol Med, Cape Town, South Africa	University of Cape Town; University of Cape Town; South African Medical Research Council; University of Cape Town; University of Cape Town	Chibale, K (corresponding author), Univ Cape Town, Holist Drug Discovery & Dev H3D Ctr, Rondebosch, South Africa.; Chibale, K (corresponding author), Univ Cape Town, South African Med Res Council, Drug Discovery & Dev Res Unit, Dept Chem, Cape Town, South Africa.; Chibale, K (corresponding author), Univ Cape Town, Inst Infect Dis & Mol Med, Cape Town, South Africa.	kelly.chibale@uct.ac.za		Woodland, John/0000-0001-6273-5596				African Medicines Agency (AMA), US; Aldridge BB, 2021, NAT MED, V27, P1333, DOI 10.1038/s41591-021-01442-2; [Anonymous], MERCK KGAA; Bizcommunity, US; Brunschwig C, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/AAC.00012-18, 10.1128/aac.00012-18]; International Federation of Pharmaceutical Manufacturers and Associations, US; J. C. Flowers Foundation, US; Johnson & Johnson, US; Keeton R, 2022, NATURE, V603, P488, DOI 10.1038/s41586-022-04460-3; Le Manach C, 2021, J MED CHEM, V64, P2291, DOI 10.1021/acs.jmedchem.1c00034; Mills EJ, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d7031; Nchinda AT, 2018, J MED CHEM, V61, P4213, DOI 10.1021/acs.jmedchem.8b00382; Nordling L, 2013, NAT MED, V19, P803, DOI 10.1038/nm0713-803; Okombo J, 2017, ACCOUNTS CHEM RES, V50, P1606, DOI 10.1021/acs.accounts.6b00631; Paquet T, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aad9735; Reader J., 2021, NAT COMMUN, V12, DOI [10.1038/s41467-020-20629-8, DOI 10.1038/S41467-020-20629-8]; Sehmi Kawaldip, 2022, Front Med Technol, V4, P810456, DOI 10.3389/fmedt.2022.810456; Singh V, 2021, ACCOUNTS CHEM RES, V54, P2361, DOI 10.1021/acs.accounts.0c00878; Sinxadi P, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.01896-19; Tegally H, 2021, NATURE, V592, P438, DOI 10.1038/s41586-021-03402-9; Yang T, 2021, TRENDS PARASITOL, V37, P493, DOI 10.1016/j.pt.2021.01.009	21	0	0	2	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01885-1	http://dx.doi.org/10.1038/s41591-022-01885-1		JUL 2022	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2Y5IM	35840729				2022-12-27	WOS:000825930600002
J	Arbel, R; Sergienko, R; Friger, M; Peretz, A; Beckenstein, T; Yaron, S; Netzer, D; Hammerman, A				Arbel, Ronen; Sergienko, Ruslan; Friger, Michael; Peretz, Alon; Beckenstein, Tanya; Yaron, Shlomit; Netzer, Doron; Hammerman, Ariel			Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years	NATURE MEDICINE			English	Article							OMICRON VARIANT	A retrospective analysis of data from a large healthcare insurance provider in Israel shows that a second booster shot (fourth dose) of BNT162b2 in people aged 60 years and over results in a substantial reduction in hospitalizations and deaths due to COVID-19. The rapid emergence of the B.1.1.529 (Omicron) variant of SARS-CoV-2 led to a global resurgence of coronavirus disease 2019 (COVID-19). Israeli authorities approved a fourth COVID-19 vaccine dose (second booster) for individuals aged 60 years and over who had received a first booster dose 4 or more months earlier. Evidence for the effectiveness of a second booster dose in reducing hospitalizations and mortality due to COVID-19 is warranted. This retrospective cohort study included all members of Clalit Health Services who were aged 60-100 years and who were eligible for the second booster on 3 January 2022. Hospitalizations and mortality due to COVID-19 in participants who received the second booster were compared with those for participants who received one booster dose. Cox proportional hazards regression models with time-dependent covariates were used to estimate the association between the second booster and hospitalization and death due to COVID-19 while adjusting for demographic factors and coexisting illnesses. A total of 563,465 participants met the eligibility criteria. Of those, 328,597 (58%) received a second booster dose during the 40 day study period. Hospitalization due to COVID-19 occurred in 270 of the second-booster recipients and in 550 participants who received one booster dose (adjusted hazard ratio, 0.36; 95% confidence interval (CI): 0.31-0.43). Death due to COVID-19 occurred in 92 second-booster recipients and in 232 participants who received one booster dose (adjusted hazard ratio, 0.22; 95% CI: 0.17-0.28). This study demonstrates a substantial reduction in hospitalizations and deaths due to COVID-19 conferred by a second booster in Israeli adults aged 60 years and over.	[Arbel, Ronen; Peretz, Alon; Beckenstein, Tanya; Yaron, Shlomit; Netzer, Doron; Hammerman, Ariel] Clalit Hlth Serv, Community Med Serv Div, Tel Aviv, Israel; [Arbel, Ronen] Sapir Coll, Maximizing Hlth Outcomes Res Lab, Sderot, Israel; [Sergienko, Ruslan; Friger, Michael] Ben Gurion Univ Negev, Fac Hlth Sci, Beer Sheva, Israel	Clalit Health Services; Ben Gurion University	Arbel, R (corresponding author), Clalit Hlth Serv, Community Med Serv Div, Tel Aviv, Israel.; Arbel, R (corresponding author), Sapir Coll, Maximizing Hlth Outcomes Res Lab, Sderot, Israel.	ronenarb@clalit.org.il	Hammerman, Ariel/AAG-4399-2020	Hammerman, Ariel/0000-0002-4396-5246; Arbel, Ronen/0000-0002-6058-8665				Andrews N, 2022, NAT MED, V28, P831, DOI 10.1038/s41591-022-01699-1; [Anonymous], 2019, MMWR Morb Mortal Wkly Rep, V68, P255, DOI 10.15585/mmwr.mm6810a7; [Anonymous], 2022, REUTERS 0112; Arbel R, 2021, NEW ENGL J MED, V385, P2413, DOI 10.1056/NEJMoa2115624; Bar-On YM, 2022, NEW ENGL J MED, V386, P1712, DOI 10.1056/NEJMoa2201570; Bar-On YM, 2021, NEW ENGL J MED, V385, P1393, DOI 10.1056/NEJMoa2114255; Barda N, 2021, NEW ENGL J MED, V385, P1078, DOI 10.1056/NEJMoa2110475; Booth A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247461; Burki TK, 2022, LANCET RESP MED, V10, pE19, DOI 10.1016/S2213-2600(22)00010-8; Callaway E, 2021, NATURE, V600, P197, DOI 10.1038/d41586-021-03614-z; Chagla Z, 2021, NAT MED, V27, P1659, DOI 10.1038/s41591-021-01494-4; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Dickerman B. A., 2022, New England Journal of Medicine, V386, P105, DOI 10.1056/NEJMoa2115463; European Medicines Agency, 2022, ECDC EMA ISS ADV 4 D; Gruell H, 2022, NAT MED, V28, P477, DOI 10.1038/s41591-021-01676-0; Hammerman A, 2022, NEW ENGL J MED, V386, P1221, DOI 10.1056/NEJMoa2119497; Hunter DJ, 2022, NEW ENGL J MED, DOI 10.1056/NEJMe2202547; Israel Central Bureau of Statistics, 2017, CHARACTERIZATION CLA; Magen O, 2022, NEW ENGL J MED, V386, P1603, DOI 10.1056/NEJMoa2201688; Regev-Yochay G, 2022, NEW ENGL J MED, V386, P1377, DOI 10.1056/NEJMc2202542; Rubin EJ, 2022, NEW ENGL J MED, V386, pE27, DOI 10.1056/NEJMe2202699; US Centers for Disease Control and Prevention, 2022, INT CLIN CONS US COV; US FDA, COR COVID 19 UPD FDA; Wang HD, 2022, LANCET, V399, P1513, DOI 10.1016/S0140-6736(21)02796-3; Weisband YL, 2020, ARCH DIS CHILD, V105, P1049, DOI 10.1136/archdischild-2019-318595	25	27	27	8	11	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2022	28	7					1486	+		10.1038/s41591-022-01832-0	http://dx.doi.org/10.1038/s41591-022-01832-0		APR 2022	13	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3E5PS	35468276	Green Submitted, Bronze			2022-12-27	WOS:000805524000001
J	Drews, J; Ryser, S				Drews, J; Ryser, S			The role of innovation in drug development	NATURE BIOTECHNOLOGY			English	Editorial Material									HOFFMANN LA ROCHE AG,INT RES STAFF,CH-4002 BASEL,SWITZERLAND	Roche Holding	Drews, J (corresponding author), HOFFMANN LA ROCHE AG,GLOBAL RES,CH-4002 BASEL,SWITZERLAND.							Drews J, 1997, DRUG DISCOV TODAY, V2, P365, DOI 10.1016/S1359-6446(97)01086-6; DREWS J, 1996, EX LIBRIS ROCHE; LIFTON R, 1996, EX LIBRIS ROCHE, V9; MOSSINGHOFF GJ, 1995, DRUG INF J, V29, P1077; OHSAKO S, 1990, J BIOL CHEM, V265, P4630; WEBER W, 1997, PHARMACOGENETICS, P10; WEBER W, 1997, PHARMACOGENETICS, P12	7	129	138	0	17	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1997	15	13					1318	1319		10.1038/nbt1297-1318	http://dx.doi.org/10.1038/nbt1297-1318			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YK361	9415870				2022-12-27	WOS:A1997YK36100003
J	Richins, RD; Kaneva, I; Mulchandani, A; Chen, W				Richins, RD; Kaneva, I; Mulchandani, A; Chen, W			Biodegradation of organophosphorus pesticides by surface-expressed organophosphorus hydrolase	NATURE BIOTECHNOLOGY			English	Article						bioremediation; parathion; immobilized bioreactor	ESCHERICHIA-COLI; PSEUDOMONAS-DIMINUTA; BACILLUS-SUBTILIS; GENE; PROTEIN; PHOSPHOTRIESTERASE; HYDROLYSIS; DETOXIFICATION; ENZYME; OPD	Organophosphorus hydrolase (OPH) was displayed and anchored onto the surface of Escherichia coli using an Lpp-OmpA fusion system. Production of the fusion proteins in membrane fractions was verified by immunoblotting with OmpA antisera. inclusion of the organophosphorus hydrolase signal sequence was necessary for achieving enzymatic activity on the surface. More than 80% of the OPH activity was located on the cell surface as determined by protease accessibility experiments. Whole cells expressing OPH on the cell surface degraded parathion and paraoxon very effectively without any diffusional limitation, resulting in sevenfold higher rates of parathion degradation compared with whole cells with similar levels of intracellular OPH. Immobilization of these live biocatalysts onto solid supports could provide an attractive means for pesticide detoxification in place of immobilized enzymes, affording a reduced diffusional barrier.	UNIV CALIF RIVERSIDE, DEPT CHEM ENGN, RIVERSIDE, CA 92521 USA	University of California System; University of California Riverside			Mulchandani, Ashok/R-6130-2019; Mulchandani, Ashok/B-9692-2016; Chen, Wilfred/H-4335-2013	Mulchandani, Ashok/0000-0002-2831-4154; 				ATTAWAY H, 1987, APPL ENVIRON MICROB, V53, P1685, DOI 10.1128/AEM.53.7.1685-1689.1987; BOWDEN GA, 1991, BIO-TECHNOL, V9, P725, DOI 10.1038/nbt0891-725; BUKAU B, 1993, MOL MICROBIOL, V9, P671, DOI 10.1111/j.1365-2958.1993.tb01727.x; CALDWELL SR, 1991, BIOTECHNOL BIOENG, V37, P103, DOI 10.1002/bit.260370203; Cordes C, 1996, J BACTERIOL, V178, P5235, DOI 10.1128/jb.178.17.5235-5242.1996; CURRIER TC, 1976, ANAL BIOCHEM, V76, P431, DOI 10.1016/0003-2697(76)90338-9; DAVE KI, 1993, CHEM-BIOL INTERACT, V87, P55, DOI 10.1016/0009-2797(93)90025-T; DUMAS DP, 1989, BIOTECHNOL APPL BIOC, V11, P235; DUMAS DP, 1989, J BIOL CHEM, V264, P19659; DUMAS DP, 1990, ARCH BIOCHEM BIOPHYS, V277, P155, DOI 10.1016/0003-9861(90)90564-F; FRANCISCO JA, 1993, BIO-TECHNOL, V11, P491, DOI 10.1038/nbt0493-491; FRANCISCO JA, 1992, P NATL ACAD SCI USA, V89, P2713, DOI 10.1073/pnas.89.7.2713; KARNS JS, 1987, ACS SYM SER, V334, P156; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDUC M, 1985, J BACTERIOL, V161, P627, DOI 10.1128/JB.161.2.627-635.1985; MARVIN HJP, 1989, J BACTERIOL, V171, P5262, DOI 10.1128/jb.171.10.5262-5267.1989; MCDANIEL CS, 1988, J BACTERIOL, V170, P2306, DOI 10.1128/jb.170.5.2306-2311.1988; MULBRY WW, 1989, J BACTERIOL, V171, P6740, DOI 10.1128/jb.171.12.6740-6746.1989; MULBRY WW, 1986, APPL ENVIRON MICROB, V51, P926, DOI 10.1128/AEM.51.5.926-930.1986; MUNNECKE DM, 1980, J AGR FOOD CHEM, V28, P105, DOI 10.1021/jf60227a025; MUNNECKE DM, 1979, BIOTECHNOL BIOENG, V21, P2247, DOI 10.1002/bit.260211207; PHILLIPS JP, 1990, P NATL ACAD SCI USA, V87, P8155, DOI 10.1073/pnas.87.20.8155; Sambrock J, 1989, MOL CLONING LAB MANU, V1; SERDAR CM, 1985, BIO-TECHNOL, V3, P567, DOI 10.1038/nbt0685-567; SERDAR CM, 1989, BIO-TECHNOL, V7, P1151; Stathopoulos C, 1996, APPL MICROBIOL BIOT, V45, P112, DOI 10.1007/s002530050657; STEIERT JG, 1989, BIO-TECHNOL, V7, P65, DOI 10.1038/nbt0189-65; STRAUCH MA, 1989, EMBO J, V8, P1615, DOI 10.1002/j.1460-2075.1989.tb03546.x	28	257	275	3	91	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1997	15	10					984	987		10.1038/nbt1097-984	http://dx.doi.org/10.1038/nbt1097-984			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XZ285	9335050				2022-12-27	WOS:A1997XZ28500029
J	Lahteenmaki, R; Plant, D; Michael, A				Lahteenmaki, R; Plant, D; Michael, A			Europe's enthusiasm for entrepreneurism	NATURE BIOTECHNOLOGY			English	Article																			0	2	2	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1997	15	9					852	853		10.1038/nbt0997-852	http://dx.doi.org/10.1038/nbt0997-852			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XW410	9306398				2022-12-27	WOS:A1997XW41000025
J	Roush, RT; Shelton, AM				Roush, RT; Shelton, AM			Assessing the odds: The emergence of resistance to bt transgenic plants	NATURE BIOTECHNOLOGY			English	Editorial Material							BACILLUS-THURINGIENSIS; PESTS		CORNELL UNIV,NEW YORK STATE AGR EXPT STN,DEPT ENTOMOL,GENEVA,NY 14456	Cornell University	Roush, RT (corresponding author), UNIV ADELAIDE,WAITE AGR RES INST,DEPT CROP PROTECT,GLEN OSMOND,SA 5064,AUSTRALIA.							Gould F, 1997, P NATL ACAD SCI USA, V94, P3519, DOI 10.1073/pnas.94.8.3519; Kaiser J, 1996, SCIENCE, V273, P423, DOI 10.1126/science.273.5274.423; KRATTIGER AF, 1997, ISAAA BRIEFS, V2; Perez CJ, 1997, J ECON ENTOMOL, V90, P87, DOI 10.1093/jee/90.1.87; ROUSH RT, 1994, BIOCONTROL SCI TECHN, V4, P501, DOI 10.1080/09583159409355364; Tabashnik BE, 1997, P NATL ACAD SCI USA, V94, P1640, DOI 10.1073/pnas.94.5.1640; Tabashnik BE, 1997, P NATL ACAD SCI USA, V94, P3488, DOI 10.1073/pnas.94.8.3488; TABASHNIK BE, 1990, J ECON ENTOMOL, V83, P1671, DOI 10.1093/jee/83.5.1671; Tang JD, 1996, APPL ENVIRON MICROB, V62, P564, DOI 10.1128/AEM.62.2.564-569.1996; Tang JD, 1997, J ECON ENTOMOL, V90, P732, DOI 10.1093/jee/90.3.732	10	41	45	1	13	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1997	15	9					816	817		10.1038/nbt0997-816	http://dx.doi.org/10.1038/nbt0997-816			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XW410	9306386				2022-12-27	WOS:A1997XW41000003
J	Kim, JJ; Bagarazzi, ML; Trivedi, N; Hu, Y; Kazahaya, K; Wilson, DM; Ciccarelli, R; Chattergoon, MA; Dang, KS; Mahalingam, S; Chalian, AA; Agadjanyan, MG; Boyer, JD; Wang, B; Weiner, DB				Kim, JJ; Bagarazzi, ML; Trivedi, N; Hu, Y; Kazahaya, K; Wilson, DM; Ciccarelli, R; Chattergoon, MA; Dang, KS; Mahalingam, S; Chalian, AA; Agadjanyan, MG; Boyer, JD; Wang, B; Weiner, DB			Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes	NATURE BIOTECHNOLOGY			English	Article						DNA vaccines; immune responses; costimulatory molecules	ANTIGEN-PRESENTING CELLS; HUMAN MYOBLASTS; ADHESION MOLECULES; INTERFERON-GAMMA; HEPATITIS-B; EXPRESSION; CD28; INDUCTION; MUSCLE; B7-1	Nucleic acid immunization is a novel vaccination technique to induce antigen-specific immune responses. We have developed expression cassettes for cell surface markers CD80 and CD86, two functionally related costimulatory molecules that play an important role in the induction of T cell-mediated immune responses, Coimmunization of these expression plasmids, along with plasmid DNA encoding for HIV-1 antigens, did not result in any significant change in the humoral response; however, we observed a dramatic increase in cytotoxic T-lymphocyte (CTL) induction as well as T-helper cell proliferation after the coadministration of CD86 genes. In contrast, coimmunization with a CD80 expression cassette resulted in a minor, but positive increase in T-helper cell or CTL responses. This strategy may be of value for the generation of rationally designed vaccines and immune therapeutics.	UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; UNIV PENN,DEPT CHEM ENGN,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PEDIAT,PHILADELPHIA,PA 19104; UNIV PENN,DEPT OTORHINOLARYNGOL HEAD & NECK SURG,PHILADELPHIA,PA 19104; APOLLON INC,MALVERN,PA 19355	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania			Bagarazzi, Mark L/AAU-1383-2021; Weiner, David B/H-8579-2014	Mahalingam, Sundarasamy/0000-0003-4460-3949				Agadjanyan M G, 1991, Biomed Sci, V2, P361; AZUMA M, 1992, J EXP MED, V175, P353, DOI 10.1084/jem.175.2.353; AZUMA M, 1993, NATURE, V366, P76, DOI 10.1038/366076a0; BEAUCHAMP JR, 1992, AM J PATHOL, V140, P387; BLAU HM, 1981, P NATL ACAD SCI-BIOL, V78, P5623, DOI 10.1073/pnas.78.9.5623; BRODSKY FM, 1991, ANNU REV IMMUNOL, V9, P707; Conry RM, 1996, GENE THER, V3, P67; Corr M, 1996, J EXP MED, V184, P1555, DOI 10.1084/jem.184.4.1555; DAVIS HL, 1993, HUM MOL GENET, V2, P1847, DOI 10.1093/hmg/2.11.1847; Doe B, 1996, P NATL ACAD SCI USA, V93, P8578, DOI 10.1073/pnas.93.16.8578; FREEDMAN AS, 1991, CELL IMMUNOL, V137, P429, DOI 10.1016/0008-8749(91)90091-O; FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478; GOEBELS N, 1992, J IMMUNOL, V149, P661; HOHLFELD R, 1990, AM J PATHOL, V136, P503; HOHLFELD R, 1994, IMMUNOL TODAY, V15, P269, DOI 10.1016/0167-5699(94)90006-X; Huang AYC, 1996, J EXP MED, V183, P769, DOI 10.1084/jem.183.3.769; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; Kim JJ, 1997, J IMMUNOL, V158, P816; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; KUNDIG TM, 1995, SCIENCE, V268, P1343, DOI 10.1126/science.7761853; LANIER LL, 1995, J IMMUNOL, V154, P97; LARSEN CP, 1994, J IMMUNOL, V152, P5208; LEVY DN, 1993, CELL, V72, P541, DOI 10.1016/0092-8674(93)90073-Y; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1990, P NATL ACAD SCI USA, V87, P5031, DOI 10.1073/pnas.87.13.5031; MANTEGAZZA R, 1991, NEUROLOGY, V41, P1128, DOI 10.1212/WNL.41.7.1128; MARGOLIS HS, 1993, J INFECT DIS, V168, P9, DOI 10.1093/infdis/168.1.9; MICHAELIS D, 1993, AM J PATHOL, V143, P1142; PARDOLL DM, 1995, IMMUNITY, V3, P165, DOI 10.1016/1074-7613(95)90085-3; ROY R, 1991, TRANSPLANT P, V23, P799; SHIRAI M, 1992, J IMMUNOL, V148, P1657; STACK RM, 1994, J IMMUNOL, V152, P5723; TAKAHASHI H, 1992, SCIENCE, V255, P333, DOI 10.1126/science.1372448; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; Wang B, 1995, AIDS, V9 Suppl A, pS159; WANG B, 1993, P NATL ACAD SCI USA, V90, P4156, DOI 10.1073/pnas.90.9.4156; WANG B, 1994, AIDS RES HUM RETROV, V10, pS35; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; WU TC, 1995, J EXP MED, V182, P1415, DOI 10.1084/jem.182.5.1415; Yang YP, 1996, J VIROL, V70, P6370, DOI 10.1128/JVI.70.9.6370-6377.1996; ZAROZINSKI CC, 1995, J IMMUNOL, V154, P4010	44	197	214	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1997	15	7					641	646						6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XH583	9219266				2022-12-27	WOS:A1997XH58300027
J	Mavingui, P; Flores, M; Romero, D; MartinezRomero, E; Palacios, R				Mavingui, P; Flores, M; Romero, D; MartinezRomero, E; Palacios, R			Generation of Rhizobium strains with improved symbiotic properties by random DNA amplification (RDA)	NATURE BIOTECHNOLOGY			English	Article						combinatorial chemistry; DNA amplification; bacterial selection; nodulation; symbiotic competitiveness	LEGUMINOSARUM BIOVAR PHASEOLI; NODULATION COMPETITIVENESS; HOST-RANGE; GENE AMPLIFICATION; REGIONS AMPLICONS; BACILLUS-SUBTILIS; PLASMID; MELILOTI; IDENTIFICATION; CIAT899	To select for bacterial strains with enhanced phenotypes, random fragments of a whole genome, or a defined region of the genome, are cloned in a nonreplicating vector. The resulting plasmids are integrated by recombination into the homologous DNA region of the original strain. Integration gives rise to a nontandem direct duplication of the corresponding DNA region separated by the vector moiety of the plasmid. Recombination between the direct repeats leads to tandem duplication and further amplification of the entire integrated DNA, including the vector. Bacteria harboring the amplified DNA are selected by increasing the dosage of an antibiotic corresponding to a resistance marker of the integrated vector. Pooled strains carrying amplifications are then challenged with a selective pressure for the desired phenotype. After repeated selection cycles, the most fit strains are isolated. We used this process, which we called random DNA amplification, to select Rhizobium strains with increased competitiveness for nodule formation. Derivatives containing randomly amplified DNA regions of the symbiotic plasmid of Rhizobium tropici CFN299 strain were generated. Pools of amplified strains were inoculated onto various tropical legumes. After several cycles of selection through plants, amplified derivatives showing an increased competitiveness for nodule formation with the leguminous plant Macroptilium atropurpureum were obtained.	NATL AUTONOMOUS UNIV MEXICO, NITROGEN FIXAT RES CTR, DEPT MOL GENET, CUERNAVACA, MORELOS, MEXICO	Universidad Nacional Autonoma de Mexico				Romero, David/0000-0002-1685-4305; martinez-romero, esperanza/0000-0002-2295-2606				ALBERTINI AM, 1985, J BACTERIOL, V162, P1203, DOI 10.1128/JB.162.3.1203-1211.1985; ANDERSON RP, 1977, ANNU REV MICROBIOL, V31, P473, DOI 10.1146/annurev.mi.31.100177.002353; BANFALVI Z, 1981, MOL GEN GENET, V184, P318; BEATTIE GA, 1993, J GEN MICROBIOL, V139, P529, DOI 10.1099/00221287-139-3-529; BROMFIELD ESP, 1985, J BACTERIOL, V164, P410, DOI 10.1128/JB.164.1.410-413.1985; CORN PG, 1993, J INFECT DIS, V167, P356, DOI 10.1093/infdis/167.2.356; DENARIE J, 1992, ANNU REV MICROBIOL, V46, P497, DOI 10.1146/annurev.mi.46.100192.002433; DOWLING DN, 1986, ANNU REV MICROBIOL, V40, P131, DOI 10.1146/annurev.mi.40.100186.001023; ECKHARDT T, 1978, PLASMID, V1, P584, DOI 10.1016/0147-619X(78)90016-1; FAHRAEUS G, 1957, J GEN MICROBIOL, V16, P374, DOI 10.1099/00221287-16-2-374; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; FISHER RF, 1992, NATURE, V357, P655, DOI 10.1038/357655a0; FLORES M, 1988, J BACTERIOL, V170, P1191, DOI 10.1128/jb.170.3.1191-1196.1988; FLORES M, 1993, P NATL ACAD SCI USA, V90, P4932, DOI 10.1073/pnas.90.11.4932; FLORES M, 1987, J BACTERIOL, V169, P5782, DOI 10.1128/jb.169.12.5782-5788.1987; FolchMallol JL, 1996, MOL PLANT MICROBE IN, V9, P151, DOI 10.1094/MPMI-9-0151; GENIAUX E, 1995, INT J SYST BACTERIOL, V45, P392, DOI 10.1099/00207713-45-2-392; GHOSAL D, 1985, P NATL ACAD SCI USA, V82, P1638, DOI 10.1073/pnas.82.6.1638; HERNANDEZLUCAS I, 1995, APPL ENVIRON MICROB, V61, P2775, DOI 10.1128/AEM.61.7.2775-2779.1995; HIRSCH PR, 1980, J GEN MICROBIOL, V120, P403; HOLLANDER M, 1973, NONPARAMETRIC STATIS; HONEYCUTT RJ, 1993, J BACTERIOL, V175, P6945, DOI 10.1128/jb.175.21.6945-6952.1993; KALLIO P, 1987, APPL MICROBIOL BIOT, V27, P64; Laeremans T, 1996, MOL PLANT MICROBE IN, V9, P492, DOI 10.1094/MPMI-9-0492; MARTINEZ E, 1987, J BACTERIOL, V169, P2828, DOI 10.1128/jb.169.6.2828-2834.1987; MartinezRomero E, 1996, CRIT REV PLANT SCI, V15, P113, DOI 10.1080/713608131; MARTINEZROMERO E, 1991, INT J SYST BACTERIOL, V41, P417, DOI 10.1099/00207713-41-3-417; MEKALANOS JJ, 1983, CELL, V35, P253, DOI 10.1016/0092-8674(83)90228-3; NEUBERGER MS, 1981, J GEN MICROBIOL, V122, P181; PETERSON BC, 1985, J BACTERIOL, V161, P1042, DOI 10.1128/JB.161.3.1042-1048.1985; PETES TD, 1988, ANNU REV GENET, V22, P147, DOI 10.1146/annurev.ge.22.120188.001051; ROMERO D, 1991, J BACTERIOL, V173, P2435, DOI 10.1128/jb.173.8.2435-2441.1991; ROMERO D, 1995, J BACTERIOL, V177, P973, DOI 10.1128/jb.177.4.973-980.1995; ROSENBERG C, 1981, MOL GEN GENET, V184, P326, DOI 10.1007/BF00272926; ROTH JR, 1996, ESCHERICHIA COLI SAL, P2256; SANJUAN J, 1991, MOL PLANT MICROBE IN, V4, P365, DOI 10.1094/MPMI-4-365; SCHULTZE M, 1994, INT REV CYTOL, V156, P1, DOI 10.1016/S0074-7696(08)62252-4; Simon R., 1990, Molecular biology of symbiotic nitrogen fixation., P13; SIMON R, 1986, METHOD ENZYMOL, V118, P640; SONTI RV, 1989, GENETICS, V123, P19; TRIPLETT EW, 1990, MOL PLANT MICROBE IN, V3, P199, DOI 10.1094/MPMI-3-199; VANRHIJN PJS, 1993, J BACTERIOL, V175, P438, DOI 10.1128/JB.175.2.438-447.1993; VARGAS C, 1990, MOL MICROBIOL, V4, P1899, DOI 10.1111/j.1365-2958.1990.tb02039.x; WAELKENS F, 1995, MOL PLANT MICROBE IN, V8, P147, DOI 10.1094/MPMI-8-0147	44	35	40	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1997	15	6					564	569		10.1038/nbt0697-564	http://dx.doi.org/10.1038/nbt0697-564			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XC772	9181580				2022-12-27	WOS:A1997XC77200033
J	Vivancos, A; Tabernero, J				Vivancos, Ana; Tabernero, Josep			Circulating tumor DNA as a novel prognostic indicator	NATURE MEDICINE			English	Editorial Material; Early Access							LUNG-CANCER	Circulating tumor DNA (ctDNA) informs predictive biomarkers in non-small-cell lung cancer, but the presence of ctDNA itself could also be a prognostic indicator.	[Vivancos, Ana] Vall dHebron Barcelona, Vall dHebron Inst Oncol, Canc Gen Lab, Hosp Campus, Barcelona, Spain; [Tabernero, Josep] Vall dHebron Barcelona, Vall dHebron Univ Hosp, Med Oncol Dept, Barcelona, Spain; [Tabernero, Josep] Vall dHebron Barcelona, Vall dHebron Inst Oncol, Hosp Campus, Barcelona, Spain	Vall d'Hebron Institut d'Oncologia (VHIO); Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO)	Vivancos, A (corresponding author), Vall dHebron Barcelona, Vall dHebron Inst Oncol, Canc Gen Lab, Hosp Campus, Barcelona, Spain.	avivancos@vhio.net			FERO Foundation	FERO Foundation	We thank A. Wren and J. Carmona for editorial assistance. A.V. acknowledges the FERO Foundation for their funding support to the DIAMAV (Advanced Molecular Diagnostics) Program and the Cellex Foundation for providing research facilities and equipment.	Abbosh C., 2017, NATURE, V545, P446, DOI [10.1038/nature22364, DOI 10.1038/NATURE22364]; Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094; Gray JE., 2019, CLIN CANCER RES, V25, P6644, DOI [10.1158/1078-0432.CCR-19-1126, DOI 10.1158/1078-0432.CCR-19-1126]; Gyawali B, 2022, ANN ONCOL, V33, pS417, DOI 10.1016/j.annonc.2022.05.396; Jee J., 2022, NAT MED, DOI [10.1038/s41591-022-02047-z, DOI 10.1038/S41591-022-02047-Z]; Kustanovich A, 2019, CANCER BIOL THER, V20, P1057, DOI 10.1080/15384047.2019.1598759; Lindeman NI., 2018, J THORAC ONCOL, V13, P323, DOI [10.1016/j.jtho.2017.12.001, DOI 10.1016/J.JTHO.2017.12.001]; National Comprehensive Cancer Network, US; Novello S, 2016, ANN ONCOL, V27, pv1, DOI 10.1093/annonc/mdw326; Paweletz CP, 2019, JCO PRECIS ONCOL, V3, DOI 10.1200/PO.18.00408; Rolfo C, 2021, J THORAC ONCOL, V16, P1647, DOI 10.1016/j.jtho.2021.06.017; Serrano C, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-6597-x	12	0	0	4	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02068-8	http://dx.doi.org/10.1038/s41591-022-02068-8		NOV 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	6B8KC	36357679				2022-12-27	WOS:000881574700008
J	Le Roy, T; Clement, K				Le Roy, Tiphaine; Clement, Karine			Bittersweet: artificial sweeteners and the gut microbiome	NATURE MEDICINE			English	Editorial Material; Early Access									[Le Roy, Tiphaine; Clement, Karine] Sorbonne Univ, INSERM, Nutr & Obes Syst Approaches Res Unit, Paris, France; [Clement, Karine] Hop La Pitie Salpetriere, AP HP, Dept Nutr, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Clement, K (corresponding author), Sorbonne Univ, INSERM, Nutr & Obes Syst Approaches Res Unit, Paris, France.; Clement, K (corresponding author), Hop La Pitie Salpetriere, AP HP, Dept Nutr, Paris, France.	karine.clement@inserm.fr	Le Roy, Tiphaine/C-8930-2013	Le Roy, Tiphaine/0000-0002-0874-1490				Andrade L, 2021, NUTR REV, V79, P1145, DOI 10.1093/nutrit/nuaa123; Carocho M, 2017, FOOD CHEM TOXICOL, V107, P302, DOI 10.1016/j.fct.2017.06.046; Daillere R, 2016, IMMUNITY, V45, P931, DOI 10.1016/j.immuni.2016.09.009; Harpaz D, 2018, MOLECULES, V23, DOI 10.3390/molecules23102454; Humphries P, 2008, EUR J CLIN NUTR, V62, P451, DOI 10.1038/sj.ejcn.1602866; Kovatcheva-Datchary P, 2015, CELL METAB, V22, P971, DOI 10.1016/j.cmet.2015.10.001; McGlynn ND., 2022, JAMA NETW OPEN, V5, pe222092, DOI [10.1001/jamanetworkopen.2022.2092, DOI 10.1001/JAMANETWORKOPEN.2022.2092]; Suez J, 2022, CELL, V185, P3307, DOI 10.1016/j.cell.2022.07.016; Suez J, 2014, NATURE, V514, P181, DOI 10.1038/nature13793; Wu GD, 2011, SCIENCE, V334, P105, DOI 10.1126/science.1208344	10	0	0	4	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02063-z	http://dx.doi.org/10.1038/s41591-022-02063-z		NOV 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	5W6NO	36323860				2022-12-27	WOS:000878028700001
J	Carvajal, RD; Butler, MO; Shoushtari, AN; Hassel, JC; Ikeguchi, A; Hernandez-Aya, L; Nathan, P; Hamid, O; Piulats, JM; Rioth, M; Johnson, DB; Luke, JJ; Espinosa, E; Leyvraz, S; Collins, L; Goodall, HM; Ranade, K; Holland, C; Abdullah, SE; Sacco, JJ; Sato, T				Carvajal, Richard D.; Butler, Marcus O.; Shoushtari, Alexander N.; Hassel, Jessica C.; Ikeguchi, Alexandra; Hernandez-Aya, Leonel; Nathan, Paul; Hamid, Omid; Piulats, Josep M.; Rioth, Matthew; Johnson, Douglas B.; Luke, Jason J.; Espinosa, Enrique; Leyvraz, Serge; Collins, Laura; Goodall, Howard M.; Ranade, Koustubh; Holland, Chris; Abdullah, Shaad E.; Sacco, Joseph J.; Sato, Takami			Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial	NATURE MEDICINE			English	Article; Early Access							IMMUNE-RELATED RESPONSE; SURVIVAL; TUMORS; IPILIMUMAB; BLOCKADE; IMCGP100; EFFICACY; CRITERIA	In a multicenter, single-arm, open-label phase 2 study of patients with previously treated metastatic uveal melanoma, treatment with tebentafusp, a soluble TCR bispecific (gp100xCD3) showed promising clinical activity with an acceptable safety profile. In patients with previously treated metastatic uveal melanoma, the historical 1 year overall survival rate is 37% with a median overall survival of 7.8 months. We conducted a multicenter, single-arm, open-label phase 2 study of tebentafusp, a soluble T cell receptor bispecific (gp100xCD3), in 127 patients with treatment-refractory metastatic uveal melanoma (NCT02570308). The primary endpoint was the estimation of objective response rate based on RECIST (Response Evaluation Criteria in Solid Tumours) v1.1. Secondary objectives included safety, overall survival, progression-free survival and disease control rate. All patients had at least one treatment-related adverse event, with rash (87%), pyrexia (80%) and pruritus (67%) being the most common. Toxicity was mostly mild to moderate in severity but was greatly reduced in incidence and intensity after the initial three doses. Despite a low overall response rate of 5% (95% CI: 2-10%), the 1 year overall survival rate was 62% (95% CI: 53-70%) with a median overall survival of 16.8 months (95% CI: 12.9-21.3), suggesting benefit beyond traditional radiographic-based response criteria. In an exploratory analysis, early on-treatment reduction in circulating tumour DNA was strongly associated with overall survival, even in patients with radiographic progression. Our findings indicate that tebentafusp has promising clinical activity with an acceptable safety profile in patients with previously treated metastatic uveal melanoma, and data suggesting ctDNA as an early indicator of clinical benefit from tebentafusp need confirmation in a randomized trial.	[Carvajal, Richard D.] Columbia Univ, Irving Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY USA; [Butler, Marcus O.] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada; [Shoushtari, Alexander N.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Shoushtari, Alexander N.] WeiR Cornell Med Coll, New York, NY USA; [Hassel, Jessica C.] Univ Hosp Heidelberg, Heidelberg, Germany; [Ikeguchi, Alexandra] Univ Oklahoma, Stephenson Canc Ctr, Oklahoma City, OK USA; [Hernandez-Aya, Leonel] Washington Univ, Sch Med, St Louis, MO USA; [Nathan, Paul] East & North Herts NHS Trust, Mt Vernon Canc Ctr, Northwood, Middx, England; [Hamid, Omid] Angeles Clin & Res Inst, Los Angeles, CA USA; [Piulats, Josep M.] Hosp Duran & Reynals, Inst Catala Oncol Hosp, Barcelona, Spain; [Rioth, Matthew] Univ Colorado, UC Canc Ctr, Aurora, CO USA; [Johnson, Douglas B.] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN USA; [Luke, Jason J.] Univ Pittsburgh, UPMC Hillman Canc Ctr, Pittsburgh, PA USA; [Espinosa, Enrique] Hosp Univ La Paz CIBERONC, Madrid, Spain; [Leyvraz, Serge] Charite Univ Med Berlin, Charite Comprehens Canc Ctr, Berlin, Germany; [Collins, Laura; Goodall, Howard M.] Immunocore, Abingdon On Thames, England; [Ranade, Koustubh; Holland, Chris; Abdullah, Shaad E.] Immunocore, Rockville, MD USA; [Sacco, Joseph J.] NHS Fdn Trust, Clatterbridge Canc Ctr, Wirral, Merseyside, England; [Sacco, Joseph J.] Univ Liverpool, Liverpool, Merseyside, England; [Sato, Takami] Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19144 USA	Columbia University; NewYork-Presbyterian Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Memorial Sloan Kettering Cancer Center; Ruprecht Karls University Heidelberg; University of Oklahoma System; University of Oklahoma Health Sciences Center; Washington University (WUSTL); Mount Vernon Cancer Centre; Angeles Clinic & Research Institute; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; University of Colorado System; University of Colorado Anschutz Medical Campus; Vanderbilt University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Clatterbridge Cancer Centre; Oxford University Hospitals NHS Foundation Trust; University of Liverpool; Jefferson University	Sato, T (corresponding author), Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19144 USA.	takami.sato@jefferson.edu		Nathan, Paul/0000-0002-2327-3250; Ikeguchi, Alexandra/0000-0002-4448-9755; Butler, Marcus/0000-0002-9840-7057	Memorial Sloan Kettering Cancer Center's National Cancer Institute Cancer Center Core Grant [P30CA008748]; Immunocore Ltd.	Memorial Sloan Kettering Cancer Center's National Cancer Institute Cancer Center Core Grant; Immunocore Ltd.	The authors thank the patients and their families and caregivers for participating in the study, as well as the study teams at the participating sites for their support of this trial and the following employees of Immunocore: R. Edukulla for statistical analysis support, M.L. McCully for assistance with the preparation of the manuscript, and D. Berman and M. Dar for critical review of the manuscript. A.N.S. was partly supported by Memorial Sloan Kettering Cancer Center's National Cancer Institute Cancer Center Core Grant P30CA008748. This study was funded by Immunocore Ltd.	Beylergil V, 2021, J IMMUNOTHER CANCER, V9, pA857, DOI 10.1136/jitc-2021-SITC2021.819; Bohnsack O, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.e22121; Bossi G, 2014, CANCER IMMUNOL IMMUN, V63, P437, DOI 10.1007/s00262-014-1525-z; Boudousquie C, 2017, IMMUNOLOGY, V152, P425, DOI 10.1111/imm.12779; Bratman SV, 2020, NAT CANCER, V1, P873, DOI 10.1038/s43018-020-0096-5; Butler MO, 2021, CANCER RES, V81; Carvajal R, 2017, J IMMUNOTHER CANCER, V5; Carvajal RD, 2022, J CLIN ONCOL, V40, P1939, DOI 10.1200/JCO.21.01805; Carvajal RD, 2017, BRIT J OPHTHALMOL, V101, P38, DOI 10.1136/bjophthalmol-2016-309034; Carvajal RD, 2014, JAMA-J AM MED ASSOC, V311, P2397, DOI 10.1001/jama.2014.6096; Chiou VL, 2015, J CLIN ONCOL, V33, P3541, DOI 10.1200/JCO.2015.61.6870; Dercle L, 2020, CLIN CANCER RES, V26, P2151, DOI 10.1158/1078-0432.CCR-19-2942; Di Giacomo AM, 2009, CANCER IMMUNOL IMMUN, V58, P1297, DOI 10.1007/s00262-008-0642-y; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Goldberg SB, 2018, CLIN CANCER RES, V24, P1872, DOI 10.1158/1078-0432.CCR-17-1341; Harbour JW, 2010, SCIENCE, V330, P1410, DOI 10.1126/science.1194472; Hodi FS, 2016, J CLIN ONCOL, V34, P1510, DOI 10.1200/JCO.2015.64.0391; Javed A, 2017, IMMUNOTHERAPY-UK, V9, P1323, DOI 10.2217/imt-2017-0066; Johnson CP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178189; Karlsson J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15606-0; Keller L, 2021, BRIT J CANCER, V124, P345, DOI 10.1038/s41416-020-01047-5; Khoja L, 2019, ANN ONCOL, V30, P1370, DOI 10.1093/annonc/mdz176; Kujala E, 2003, INVEST OPHTH VIS SCI, V44, P4651, DOI 10.1167/iovs.03-0538; Lee DW, 2019, BIOL BLOOD MARROW TR, V25, P625, DOI 10.1016/j.bbmt.2018.12.758; Lee JH, 2018, JAMA ONCOL, V4, P717, DOI 10.1001/jamaoncol.2017.5332; Liddy N, 2012, NAT MED, V18, P980, DOI 10.1038/nm.2764; Piulats JM, 2021, J CLIN ONCOL, V39, P586, DOI 10.1200/JCO.20.00550; Martin M, 2013, NAT GENET, V45, P933, DOI 10.1038/ng.2674; Middleton MR, 2020, CLIN CANCER RES, V26, P5869, DOI 10.1158/1078-0432.CCR-20-1247; Middleton MR, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3016; Middleton MR, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.AM2015-CT106; Milam R. W., 2018, MELANOMA, P273, DOI [10.1007/978-3-319-78310-9_16, DOI 10.1007/978-3-319-78310-9_16]; Nathan P, 2021, NEW ENGL J MED, V385, P1196, DOI 10.1056/NEJMoa2103485; O'Day S, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.18_suppl.4; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Pelster MS, 2021, J CLIN ONCOL, V39, P599, DOI 10.1200/JCO.20.00605; Raja R, 2018, CLIN CANCER RES, V24, P6212, DOI 10.1158/1078-0432.CCR-18-0386; Rantala ES, 2019, MELANOMA RES, V29, P561, DOI 10.1097/CMR.0000000000000575; Robertson AG, 2017, CANCER CELL, V32, P204, DOI 10.1016/j.ccell.2017.07.003; Sato T, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.9531; Shain AH, 2019, NAT GENET, V51, P1123, DOI 10.1038/s41588-019-0440-9; Singh M, 2018, ONCOL THER, V6, P87, DOI 10.1007/s40487-018-0056-8; Stang A, 2005, INT J CANCER, V114, P114, DOI 10.1002/ijc.20690; Vandekerkhove G, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20493-6; Virgili G, 2007, OPHTHALMOLOGY, V114, P2309, DOI 10.1016/j.ophtha.2007.01.032; Wolchok JD, 2009, CLIN CANCER RES, V15, P7412, DOI 10.1158/1078-0432.CCR-09-1624; Yang J, 2018, THER ADV MED ONCOL, V10, DOI 10.1177/1758834018757175; Zhang Q, 2020, CANCER DISCOV, V10, P1842, DOI 10.1158/2159-8290.CD-20-0047; Zou W, 2021, JCO PRECIS ONCOL, V5, P827, DOI 10.1200/PO.21.00057	50	0	0	2	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02015-7	http://dx.doi.org/10.1038/s41591-022-02015-7		OCT 2022	29	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	5H3BX	36229663	hybrid, Green Published			2022-12-27	WOS:000867558300003
J	Bachy, E; Le Gouill, S; Di Blasi, R; Sesques, P; Manson, G; Cartron, G; Beauvais, D; Roulin, L; Gros, FX; Rubio, MT; Bories, P; Bay, JO; Llorente, CC; Choquet, S; Casasnovas, RO; Mohty, M; Guidez, S; Joris, M; Loschi, M; Carras, S; Abraham, J; Chauchet, A; La Rochelle, LD; Deau-Fischer, B; Hermine, O; Gastinne, T; Tudesq, JJ; Gat, E; Broussais, F; Thieblemont, C; Houot, R; Morschhauser, F				Bachy, Emmanuel; Le Gouill, Steven; Di Blasi, Roberta; Sesques, Pierre; Manson, Guillaume; Cartron, Guillaume; Beauvais, David; Roulin, Louise; Gros, Francois Xavier; Rubio, Marie Therese; Bories, Pierre; Bay, Jacques Olivier; Llorente, Cristina Castilla; Choquet, Sylvain; Casasnovas, Rene-Olivier; Mohty, Mohamad; Guidez, Stephanie; Joris, Magalie; Loschi, Michael; Carras, Sylvain; Abraham, Julie; Chauchet, Adrien; La Rochelle, Laurianne Drieu; Deau-Fischer, Benedicte; Hermine, Olivier; Gastinne, Thomas; Tudesq, Jean Jacques; Gat, Elodie; Broussais, Florence; Thieblemont, Catherine; Houot, Roch; Morschhauser, Franck			A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma	NATURE MEDICINE			English	Article							PREINFUSION PERIOD; OUTCOMES; THERAPY; MULTICENTER; EFFICACY; SAFETY	Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have both demonstrated impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL). In this study, we analyzed the outcome of 809 patients with R/R DLBCL after two or more previous lines of treatment who had a commercial chimeric antigen receptor (CAR) T cells order for axi-cel or tisa-cel and were registered in the retrospective French DESCAR-T registry study ( NCT04328298 ). After 1:1 propensity score matching (n = 418), the best overall response rate/complete response rate (ORR/CRR) was 80%/60% versus 66%/42% for patients treated with axi-cel compared to tisa-cel, respectively (P < 0.001 for both ORR and CRR comparisons). After a median follow-up of 11.7 months, the 1-year progression-free survival was 46.6% for axi-cel and 33.2% for tisa-cel (hazard ratio (HR) = 0.61; 95% confidence interval (CI), 0.46-0.79; P = 0.0003). Overall survival (OS) was also significantly improved after axi-cel infusion compared to after tisa-cel infusion (1-year OS 63.5% versus 48.8%; HR = 0.63; 95% CI, 0.45-0.88; P = 0.0072). Similar findings were observed using the inverse probability of treatment weighting statistical approach. Grade 1-2 cytokine release syndrome was significantly more frequent with axi-cel than with tisa-cel, but no significant difference was observed for grade >= 3. Regarding immune effector cell-associated neurotoxicity syndrome (ICANS), both grade 1-2 and grade >= 3 ICANS were significantly more frequent with axi-cel than with tisa-cel. In conclusion, our matched comparison study supports a higher efficacy and also a higher toxicity of axi-cel compared to tisa-cel in the third or more treatment line for R/R DLBCL.	[Bachy, Emmanuel; Sesques, Pierre] Hosp Civils Lyon, Hematol Dept, Lyon, France; [Bachy, Emmanuel] INSERM, Int Ctr Infectiol Res CIRI, U1111, Lyon, France; [Le Gouill, Steven] Inst Curie, Hematol Dept, Paris, France; [Di Blasi, Roberta; Thieblemont, Catherine] Hop St Louis, Hematol Dept, Paris, France; [Manson, Guillaume; Houot, Roch] CHU Rennes, Hematol Dept, Rennes, France; [Cartron, Guillaume; Tudesq, Jean Jacques] CHU Montpellier, Hematol Dept, Montpellier, France; [Cartron, Guillaume; Tudesq, Jean Jacques] UMR CNRS, Montpellier, France; [Beauvais, David; Morschhauser, Franck] CHU Lille, Hematol Dept, Lille, France; [Roulin, Louise] Hop Henri Mondor, Hematol Dept, Creteil, France; [Gros, Francois Xavier] CHU Bordeaux, Hematol Dept, Bordeaux, France; [Rubio, Marie Therese] CHU Nancy, Hematol Dept, Nancy, France; [Bories, Pierre] CHU Toulouse, Hematol Dept, Toulouse, France; [Bay, Jacques Olivier] CHU Clermont Ferrand, Hematol Dept, Clermont Ferrand, France; [Llorente, Cristina Castilla] Hematol Dept, Gustave Roussy Canc Campus, Paris, France; [Choquet, Sylvain] Hop La Pitie Salpetriere, Hematol Dept, Paris, France; [Choquet, Sylvain] Sorbonne Univ, AP HP, Paris, France; [Casasnovas, Rene-Olivier] CHU Dijon, Hematol Dept, Dijon, France; [Mohty, Mohamad] Hop St Antoine, Hematol Dept, Paris, France; [Mohty, Mohamad] Sorbonne Univ, Paris, France; [Mohty, Mohamad] INSERM, UMRs 938, Paris, France; [Guidez, Stephanie] CHU Poitiers, Hematol Dept, Poitiers, France; [Joris, Magalie] CHU Amiens, Hematol Dept, Amiens, France; [Loschi, Michael] CHU Nice, Hematol Dept, Nice, France; [Carras, Sylvain] CHU Grenoble, Hematol Dept, La Tronche, France; [Carras, Sylvain] Univ Grenoble Alpes, Inst Adv Biosci, La Tronche, France; [Abraham, Julie] CHU Limoges, Hematol Dept, Limoges, France; [Chauchet, Adrien] CHU Besancon, Hematol Dept, Besancon, France; [La Rochelle, Laurianne Drieu] CHU Tours, Hematol Dept, Tours, France; [Deau-Fischer, Benedicte] Hop Cochin, Hematol Dept, Paris, France; [Hermine, Olivier] Hop Necker Enfants Malad, Hematol Dept, Paris, France; [Gastinne, Thomas] CHU Nantes, Hematol Dept, Nantes, France; [Gat, Elodie] LYSARC, Biostat Dept, Lyon, France; [Broussais, Florence] LYSARC, Med & Sci Affairs Dept, Lyon, France; [Morschhauser, Franck] Lille Univ, ULR 7365, GRITA Grp Rech Formes Injectables & Technol Assoc, Lille, France	CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Rennes; Universite de Montpellier; CHU de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Universite de Lille - ISITE; CHU Lille; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; CHU Bordeaux; CHU de Nancy; CHU de Toulouse; CHU Clermont Ferrand; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Sorbonne Universite; CHU Dijon Bourgogne; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Poitiers; Universite de Poitiers; Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens; CHU Nice; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CHU Limoges; Universite de Franche-Comte; CHU Besancon; CHU Tours; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Nantes Universite; CHU de Nantes; Universite de Lille - ISITE; Universite de Lille	Bachy, E (corresponding author), Hosp Civils Lyon, Hematol Dept, Lyon, France.; Bachy, E (corresponding author), INSERM, Int Ctr Infectiol Res CIRI, U1111, Lyon, France.	emmanuel.bachy@chu-lyon.fr	Beauvais, David/C-8198-2019; Bachy, Emmanuel/M-4678-2014	Beauvais, David/0000-0003-1866-828X; Bachy, Emmanuel/0000-0003-2694-7510; Mohty, Mohamad/0000-0002-7264-808X	Gilead; Novartis	Gilead(Gilead Sciences); Novartis(Novartis)	The authors thank the patients whose data were collected in the DESCAR-T registry and their families. The DESCAR-T registry was partly funded by Gilead and Novartis. However, they did not participate in study design, data collection, statistical analysis or interpretation, and they did not provide assistance for manuscript writing or editorial support. The authors would like to thank everyone from the LYSARC DESCAR-T study group who actively participated in the study: D. Laurenceau, C. Joubert and J. Paget from the biostatistics department; C. Vercouttre, C. Capron and F. Carlessi from the data management department; D. Ligout, K. Lanoiselee-Piffaretti and E. Robert-Eydoux from the monitoring and site management department; and D. Germain, A. Schwartzmann, K. Danno, C. de Lacheisserie, V. Girard and S. Hamy from the project management division.	Abramson JS, 2020, LANCET, V396, P839, DOI 10.1016/S0140-6736(20)31366-0; Allan V, 2020, J COMP EFFECT RES, V9, P603, DOI 10.2217/cer-2020-0013; Austin PC, 2014, STAT MED, V33, P1242, DOI 10.1002/sim.5984; Bethge WA, 2022, BLOOD, V140, P349, DOI 10.1182/blood.2021015209; Bishop MR, 2022, NEW ENGL J MED, V386, P629, DOI 10.1056/NEJMoa2116596; Cappell KM, 2021, NAT REV CLIN ONCOL, V18, P715, DOI 10.1038/s41571-021-00530-z; Cheson BD, 2014, J CLIN ONCOL, V32, P3059, DOI 10.1200/JCO.2013.54.8800; Fowler NH, 2022, NAT MED, V28, P325, DOI 10.1038/s41591-021-01622-0; Gauthier J, 2022, BLOOD, V139, P3722, DOI 10.1182/blood.2021014497; Jacobson C, 2021, BLOOD, V138, P1764, DOI 10.1182/blood-2021-148078; Jacobson CA, 2022, LANCET ONCOL, V23, P91, DOI 10.1016/S1470-2045(21)00591-X; Jacobson CA, 2020, J CLIN ONCOL, V38, P3095, DOI 10.1200/JCO.19.02103; Kawalekar OU, 2016, IMMUNITY, V44, P380, DOI 10.1016/j.immuni.2016.01.021; Lee DW, 2019, BIOL BLOOD MARROW TR, V25, P625, DOI 10.1016/j.bbmt.2018.12.758; Locke FL, 2022, NEW ENGL J MED, V386, P640, DOI 10.1056/NEJMoa2116133; Locke FL, 2020, BLOOD ADV, V4, P4898, DOI 10.1182/bloodadvances.2020002394; Locke FL, 2019, LANCET ONCOL, V20, P31, DOI 10.1016/S1470-2045(18)30864-7; Maloney DG, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01144-9; Nastoupil LJ, 2020, J CLIN ONCOL, V38, P3119, DOI 10.1200/JCO.19.02104; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; Neelapu SS, 2018, NAT REV CLIN ONCOL, V15, P47, DOI 10.1038/nrclinonc.2017.148; Oluwole OO, 2021, BRIT J HAEMATOL, V194, P690, DOI 10.1111/bjh.17527; Oluwole OO, 2020, BIOL BLOOD MARROW TR, V26, P1581, DOI 10.1016/j.bbmt.2020.06.008; Pasquini MC, 2020, BLOOD ADV, V4, P5414, DOI 10.1182/bloodadvances.2020003092; Pinnix CC, 2020, BLOOD ADV, V4, P2871, DOI 10.1182/bloodadvances.2020001837; Schuster SJ, 2021, LANCET ONCOL, V22, P1403, DOI 10.1016/S1470-2045(21)00375-2; Schuster SJ, 2019, NEW ENGL J MED, V380, P45, DOI 10.1056/NEJMoa1804980; Sesques P, 2020, AM J HEMATOL, V95, P1324, DOI 10.1002/ajh.25951; Signorovitch JE, 2012, VALUE HEALTH, V15, P940, DOI 10.1016/j.jval.2012.05.004; Swerdlow, 2008, CLASSIFICATION TUMOR; Topp MS, 2021, BRIT J HAEMATOL, V195, P388, DOI 10.1111/bjh.17673; VanderWeele TJ, 2017, ANN INTERN MED, V167, P268, DOI 10.7326/M16-2607; Vercellino L, 2020, BLOOD ADV, V4, P5607, DOI 10.1182/bloodadvances.2020003001; Wang MH, 2020, NEW ENGL J MED, V382, P1331, DOI 10.1056/NEJMoa1914347; Zhang J, 2020, BIOL BLOOD MARROW TR, V26, pE333, DOI 10.1016/j.bbmt.2020.08.032; Zhang J, 2020, ADV THER, V37, P3040, DOI 10.1007/s12325-020-01397-9	36	1	1	3	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2022	28	10								10.1038/s41591-022-01969-y	http://dx.doi.org/10.1038/s41591-022-01969-y		SEP 2022	27	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	6F7WG	36138152	hybrid, Green Published			2022-12-27	WOS:000859021700003
J	Simpson, RC; Shanahan, ER; Batten, M; Reijers, ILM; Read, M; Silva, IP; Versluis, JM; Ribeiro, R; Angelatos, AS; Tan, J; Adhikari, C; Menzies, AM; Saw, RPM; Gonzalez, M; Shannon, KF; Spillane, AJ; Velickovic, R; Lazar, AJ; Damania, AV; Mishra, AK; Chelvanambi, M; Banerjee, A; Ajami, NJ; Wargo, JA; Macia, L; Holmes, AJ; Wilmott, JS; Blank, CU; Scolyer, RA; Long, GV				Simpson, Rebecca C.; Shanahan, Erin R.; Batten, Marcel; Reijers, Irene L. M.; Read, Mark; Silva, Ines P.; Versluis, Judith M.; Ribeiro, Rosilene; Angelatos, Alexandra S.; Tan, Jian; Adhikari, Chandra; Menzies, Alexander M.; Saw, Robyn P. M.; Gonzalez, Maria; Shannon, Kerwin F.; Spillane, Andrew J.; Velickovic, Rebecca; Lazar, Alexander J.; Damania, Ashish, V; Mishra, Aditya K.; Chelvanambi, Manoj; Banerjee, Anik; Ajami, Nadim J.; Wargo, Jennifer A.; Macia, Laurence; Holmes, Andrew J.; Wilmott, James S.; Blank, Christian U.; Scolyer, Richard A.; Long, Georgina, V			Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome	NATURE MEDICINE			English	Article; Early Access							GLUCOSE-METABOLISM; COMBINED NIVOLUMAB; MELANOMA; THERAPY; IPILIMUMAB; SURVIVAL; RESISTANCE; PROBIOTICS; EFFICACY; FIBER	The gut microbiota shapes the response to immune checkpoint inhibitors (ICIs) in cancer, however dietary and geographic influences have not been well-studied in prospective trials. To address this, we prospectively profiled baseline gut (fecal) microbiota signatures and dietary patterns of 103 trial patients from Australia and the Netherlands treated with neoadjuvant ICIs for high risk resectable metastatic melanoma and performed an integrated analysis with data from 115 patients with melanoma treated with ICIs in the United States. We observed geographically distinct microbial signatures of response and immune-related adverse events (irAEs). Overall, response rates were higher in Ruminococcaceae-dominated microbiomes than in Bacteroidaceae-dominated microbiomes. Poor response was associated with lower fiber and omega 3 fatty acid consumption and elevated levels of C-reactive protein in the peripheral circulation at baseline. Together, these data provide insight into the relevance of native gut microbiota signatures, dietary intake and systemic inflammation in shaping the response to and toxicity from ICIs, prompting the need for further studies in this area. A prospective analysis of gut microbiome signatures in patients treated with neoadjuvant immunocheckpoint blockade for high risk resectable metastatic melanoma identifies new links between microbiota signatures, dietary intake and systemic inflammation in shaping the response and toxicity to immunotherapy.	[Simpson, Rebecca C.; Batten, Marcel; Silva, Ines P.; Adhikari, Chandra; Menzies, Alexander M.; Saw, Robyn P. M.; Gonzalez, Maria; Shannon, Kerwin F.; Spillane, Andrew J.; Velickovic, Rebecca; Wilmott, James S.; Scolyer, Richard A.; Long, Georgina, V] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia; [Simpson, Rebecca C.; Batten, Marcel; Menzies, Alexander M.; Saw, Robyn P. M.; Velickovic, Rebecca; Wilmott, James S.; Scolyer, Richard A.; Long, Georgina, V] Univ Sydney, Fac Med & Hlth, Sydney Med Sch, Sydney, NSW, Australia; [Simpson, Rebecca C.; Shanahan, Erin R.; Read, Mark; Ribeiro, Rosilene; Angelatos, Alexandra S.; Tan, Jian; Macia, Laurence; Holmes, Andrew J.; Wilmott, James S.; Scolyer, Richard A.; Long, Georgina, V] Univ Sydney, Charles Perkins Ctr, Sydney, NSW, Australia; [Shanahan, Erin R.; Ribeiro, Rosilene; Spillane, Andrew J.; Holmes, Andrew J.] Univ Sydney, Fac Sci, Sch Life & Environm Sci, Sydney, NSW, Australia; [Batten, Marcel] Univ Sydney, Fac Med & Hlth, Sydney, NSW, Australia; [Reijers, Irene L. M.; Versluis, Judith M.; Blank, Christian U.] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands; [Read, Mark] Univ Sydney, Sch Comp Sci, Sydney, NSW, Australia; [Read, Mark] Univ Sydney, Westmead Initiat, Sydney, NSW, Australia; [Silva, Ines P.] Westmead & Blacktown Hosp, Sydney, NSW, Australia; [Angelatos, Alexandra S.; Tan, Jian; Macia, Laurence] Univ Sydney, Fac Med & Hlth, Sch Med Sci, Sydney, NSW, Australia; [Menzies, Alexander M.; Long, Georgina, V] Royal North Shore & Mater Hosp, Dept Med Oncol, Sydney, NSW, Australia; [Saw, Robyn P. M.; Shannon, Kerwin F.] Royal Prince Alfred Hosp, Dept Melanoma & Surg Oncol, Sydney, NSW, Australia; [Spillane, Andrew J.] Royal North Shore Hosp, Breast & Melanoma Surg Dept, St Leonards, NSW, Australia; [Lazar, Alexander J.] Univ Texas MD Anderson Canc Ctr, Dept Pathol & Lab Med, Houston, TX 77030 USA; [Lazar, Alexander J.; Damania, Ashish, V; Mishra, Aditya K.; Ajami, Nadim J.; Wargo, Jennifer A.] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Platform Innovat Microbiome & Translat Res, Houston, TX 77030 USA; [Chelvanambi, Manoj; Wargo, Jennifer A.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; [Banerjee, Anik] Univ Texas MD Anderson UTHlth, Grad Sch Biomed Sci, Houston, TX USA; [Scolyer, Richard A.] Royal Prince Alfred Hosp, Tissue Pathol & Diagnost Oncol, Sydney, NSW, Australia; [Scolyer, Richard A.] NSW Hlth Pathol, Sydney, NSW, Australia	Melanoma Institute Australia; University of Sydney; University of Sydney; University of Sydney; University of Sydney; University of Sydney; Netherlands Cancer Institute; University of Sydney; University of Sydney; Blacktown & Mount Druitt Hospital; University of Sydney; Royal North Shore Hospital; Melanoma Institute Australia; University of Sydney; Royal North Shore Hospital; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Sydney	Long, GV (corresponding author), Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia.; Long, GV (corresponding author), Univ Sydney, Fac Med & Hlth, Sydney Med Sch, Sydney, NSW, Australia.; Long, GV (corresponding author), Univ Sydney, Charles Perkins Ctr, Sydney, NSW, Australia.; Long, GV (corresponding author), Royal North Shore & Mater Hosp, Dept Med Oncol, Sydney, NSW, Australia.	georgina.long@sydney.edu.au	Scolyer, Richard/AAE-8511-2019; Long, Georgina/C-1771-2013	Scolyer, Richard/0000-0002-8991-0013; Batten, Marcel/0000-0002-3726-3790; Read, Mark/0000-0002-1481-4780; Long, Georgina/0000-0001-8894-3545; Chelvanambi, Manoj/0000-0003-2130-3118; Versluis, Judith M./0000-0002-3423-9912	NHMRC Program Grant; NHMRC Practitioner Fellowship; NHMRC Investigator Grant; University of Sydney Medical Foundation; Cameron Family; Ainsworth Foundation; William Arthur Martin a Beckett Cancer Research Trust (University of Sydney Fellowship); Tour de Cure Australia project grant [RSP-00054-19/20]	NHMRC Program Grant(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Practitioner Fellowship(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Investigator Grant(National Health and Medical Research Council (NHMRC) of Australia); University of Sydney Medical Foundation(University of Sydney); Cameron Family; Ainsworth Foundation; William Arthur Martin a Beckett Cancer Research Trust (University of Sydney Fellowship); Tour de Cure Australia project grant	We thank G. Giles of the Cancer Epidemiology Division, Cancer Council Victoria, for permission to use the Cancer Council Victoria Dietary Questionnaire for Epidemiological Studies (DQES v3.2), Melbourne, Australia, 1996. We acknowledge the technical assistance provided by the Sydney Informatics Hub, a core research facility of the University of Sydney. G.V.L and R.A.S are supported by NHMRC Program Grant R.A.S is supported by an NHMRC Practitioner Fellowship and G.V.L by an NHMRC Investigator Grant. G.V.L is also supported by the University of Sydney Medical Foundation. Support from the Cameron Family and Ainsworth Foundation, as well as from colleagues at Melanoma Institute Australia, Royal Prince Alfred Hospital and NSW Health Pathology is gratefully acknowledged. E.R.S. acknowledges financial support from the The William Arthur Martin a Beckett Cancer Research Trust (University of Sydney Fellowship). Funding support was provided by a Tour de Cure Australia project grant (RSP-00054-19/20) (R.A.S, M.B., E.R.S).	Amaria RN, 2019, LANCET ONCOL, V20, pE378, DOI 10.1016/S1470-2045(19)30332-8; Andrews MC, 2021, NAT MED, V27, P1432, DOI 10.1038/s41591-021-01406-6; Arumugam M, 2011, NATURE, V473, P174, DOI 10.1038/nature09944; Bachem A, 2019, IMMUNITY, V51, P285, DOI 10.1016/j.immuni.2019.06.002; Bang C, 2015, FEMS MICROBIOL REV, V39, P631, DOI 10.1093/femsre/fuv010; Baruch EN, 2021, SCIENCE, V371, P602, DOI 10.1126/science.abb5920; Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011; Callahan BJ, 2016, NAT METHODS, V13, P581, DOI [10.1038/NMETH.3869, 10.1038/nmeth.3869]; Caspi R, 2018, NUCLEIC ACIDS RES, V46, pD633, DOI 10.1093/nar/gkx935; Chaput N, 2017, ANN ONCOL, V28, P1368, DOI 10.1093/annonc/mdx108; Chen JZ, 2019, NUTRIENTS, V11, DOI 10.3390/nu11051026; Chiba Mitsuro, 2019, Perm J, V23, P18, DOI 10.7812/TPP/18-107; Chung DJ, 2010, STAT APPL GENET MOL, V9, DOI 10.2202/1544-6115.1492; Costea PI, 2018, NAT MICROBIOL, V3, DOI 10.1038/s41564-017-0072-8; Coutzac C, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16079-x; Davar D, 2021, SCIENCE, V371, P595, DOI 10.1126/science.abf3363; Dubin K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10391; Frankel AE, 2017, NEOPLASIA, V19, P848, DOI 10.1016/j.neo.2017.08.004; Franzosa EA, 2018, NAT METHODS, V15, P962, DOI 10.1038/s41592-018-0176-y; Geirnaert A, 2015, FEMS MICROBIOL ECOL, V91, DOI 10.1093/femsec/fiv054; Gharaibeh RZ, 2019, GUT, V68, P385, DOI 10.1136/gutjnl-2018-317220; Gloor GB, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02224; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Grainger John, 2018, F1000Res, V7, DOI 10.12688/f1000research.14633.1; Harkiolaki M, 2009, IMMUNITY, V30, P348, DOI 10.1016/j.immuni.2009.01.009; He Y, 2018, NAT MED, V24, P1532, DOI 10.1038/s41591-018-0164-x; Hermann-Bank ML, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-788; Holmes I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030126; Hook SE, 2009, APPL ENVIRON MICROB, V75, P374, DOI 10.1128/AEM.01672-08; Horai R, 2015, IMMUNITY, V43, P343, DOI 10.1016/j.immuni.2015.07.014; Kovatcheva-Datchary P, 2015, CELL METAB, V22, P971, DOI 10.1016/j.cmet.2015.10.001; Lam KC, 2021, CELL, V184, P5338, DOI 10.1016/j.cell.2021.09.019; Lam YY, 2015, OBESITY, V23, P1429, DOI 10.1002/oby.21122; Larkin J, 2019, NEW ENGL J MED, V381, P1535, DOI 10.1056/NEJMoa1910836; Layton A, 2006, APPL ENVIRON MICROB, V72, P4214, DOI 10.1128/AEM.01036-05; Lee KA, 2022, NAT MED, V28, P535, DOI 10.1038/s41591-022-01695-5; Llewellyn SR, 2018, GASTROENTEROLOGY, V154, P1037, DOI 10.1053/j.gastro.2017.11.030; Long GV, 2018, LANCET ONCOL, V19, P672, DOI 10.1016/S1470-2045(18)30139-6; Long GV, 2017, LANCET ONCOL, V18, P1202, DOI 10.1016/S1470-2045(17)30428-X; Luke JJ, 2017, NAT REV CLIN ONCOL, V14, P463, DOI 10.1038/nrclinonc.2017.43; Macia L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7734; Mackie RI, 2003, APPL ENVIRON MICROB, V69, P6808, DOI 10.1128/AEM.69.11.6808-6815.2003; Mager LF, 2020, SCIENCE, V369, P1481, DOI 10.1126/science.abc3421; Marchesi JR, 2016, GUT, V65, P330, DOI 10.1136/gutjnl-2015-309990; Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290; McCulloch JA, 2022, NAT MED, V28, P545, DOI 10.1038/s41591-022-01698-2; McMurdie PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061217; Menzies AM, 2021, NAT MED, V27, P301, DOI 10.1038/s41591-020-01188-3; Metsalu T, 2015, NUCLEIC ACIDS RES, V43, pW566, DOI 10.1093/nar/gkv468; Nestel P, 2015, HEART LUNG CIRC, V24, P769, DOI 10.1016/j.hlc.2015.03.020; Ohnishi A, 2011, APPL ENVIRON MICROB, V77, P5533, DOI 10.1128/AEM.00359-11; Venegas DP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00277; Peters BA, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0672-4; Rajca S, 2014, INFLAMM BOWEL DIS, V20, P978, DOI 10.1097/MIB.0000000000000036; Ramirez-Farias C, 2009, BRIT J NUTR, V101, P541, DOI 10.1017/S0007114508019880; Rohart F, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005752; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Rozeman EA, 2021, NAT MED, V27, P256, DOI 10.1038/s41591-020-01211-7; Rozeman EA, 2019, LANCET ONCOL, V20, P948, DOI 10.1016/S1470-2045(19)30151-2; Schneeberger M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16643; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; Seidel JA, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00086; Shanahan ER, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0531-3; Sidhu P, 2017, J MED IMAG RADIAT ON, V61, P759, DOI 10.1111/1754-9485.12653; Siebelink E, 2011, BRIT J NUTR, V106, P274, DOI 10.1017/S0007114511000067; Singh RK, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1175-y; Smith M, 2022, NAT MED, V28, P713, DOI 10.1038/s41591-022-01702-9; Smith NW, 2019, GUT MICROBES, V10, P270, DOI 10.1080/19490976.2018.1546522; Spencer CN, 2021, SCIENCE, V374, P1632, DOI 10.1126/science.aaz7015; Steed AL, 2017, SCIENCE, V357, P498, DOI 10.1126/science.aam5336; Suzek BE, 2015, BIOINFORMATICS, V31, P926, DOI 10.1093/bioinformatics/btu739; Tetzlaff MT, 2018, ANN ONCOL, V29, P1861, DOI 10.1093/annonc/mdy226; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Watson H, 2018, GUT, V67, P1974, DOI 10.1136/gutjnl-2017-314968; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684; Wu GD, 2011, SCIENCE, V334, P105, DOI 10.1126/science.1208344; Yanagita K, 2003, INT J SYST EVOL MICR, V53, P1609, DOI 10.1099/ijs.0.02541-0; Yu LCH, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929-018-0483-8; Zeevi D, 2015, CELL, V163, P1079, DOI 10.1016/j.cell.2015.11.001; Zmora N, 2018, CELL, V174, P1388, DOI 10.1016/j.cell.2018.08.041; Zoll J, 2020, AM J PHYSIOL-ENDOC M, V319, pE203, DOI 10.1152/ajpendo.00037.2020	82	0	0	6	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01965-2	http://dx.doi.org/10.1038/s41591-022-01965-2		SEP 2022	28	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4U8EW	36138151				2022-12-27	WOS:000859021700001
J	Jukarainen, S; Kiiskinen, T; Kuitunen, S; Havulinna, AS; Karjalainen, J; Cordioli, M; Ramo, JT; Mars, N; Gen, F; Samocha, KE; Ollila, HM; Pirinen, M; Ganna, A				Jukarainen, Sakari; Kiiskinen, Tuomo; Kuitunen, Sara; Havulinna, Aki S.; Karjalainen, Juha; Cordioli, Mattia; Ramo, Joel T.; Mars, Nina; Gen, Finn; Samocha, Kaitlin E.; Ollila, Hanna M.; Pirinen, Matti; Ganna, Andrea			Genetic risk factors have a substantial impact on healthy life years	NATURE MEDICINE			English	Article							SEQUENCE VARIATION; POLYGENIC SCORES; ASSOCIATION; DISEASE; PREDICTION; REGISTER; QUALITY; TRAITS; LOCI; AGE	The impact of genetic variation on overall disease burden has not been comprehensively evaluated. We introduce an approach to estimate the effect of genetic risk factors on disability-adjusted life years (DALYs; 'lost healthy life years'). We use genetic information from 735,748 individuals and consider 80 diseases. Rare variants had the highest effect on DALYs at the individual level. Among common variants, rs3798220 (LPA) had the strongest individual-level effect, with 1.18 DALYs from carrying 1 versus 0 copies. Being in the top 10% versus the bottom 90% of a polygenic score for multisite chronic pain had an effect of 3.63 DALYs. Some common variants had a population-level effect comparable to modifiable risk factors such as high sodium intake and low physical activity. Attributable DALYs vary between males and females for some genetic exposures. Genetic risk factors can explain a sizable number of healthy life years lost both at the individual and population level.	[Jukarainen, Sakari; Kiiskinen, Tuomo; Kuitunen, Sara; Havulinna, Aki S.; Karjalainen, Juha; Cordioli, Mattia; Ramo, Joel T.; Mars, Nina; Ollila, Hanna M.; Pirinen, Matti; Ganna, Andrea] Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki, Finland; [Kiiskinen, Tuomo; Kuitunen, Sara; Havulinna, Aki S.] Finnish Inst Hlth & Welf, Helsinki, Finland; [Kiiskinen, Tuomo; Karjalainen, Juha; Samocha, Kaitlin E.; Ollila, Hanna M.; Ganna, Andrea] Broad Inst MIT & Harvard, Program Med & Populat Genet, Cambridge, MA 02142 USA; [Karjalainen, Juha; Ganna, Andrea] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA; [Samocha, Kaitlin E.; Ollila, Hanna M.] Massachusetts Gen Hosp, Ctr Genom Med, Boston, MA 02114 USA; [Ollila, Hanna M.] Massachusetts Gen Hosp, Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA; [Ollila, Hanna M.] Harvard Med Sch, Boston, MA 02115 USA; [Pirinen, Matti] Univ Helsinki, Dept Publ Hlth, Helsinki, Finland; [Pirinen, Matti] Univ Helsinki, Helsinki Inst Informat Technol HIIT, Helsinki, Finland; [Pirinen, Matti] Univ Helsinki, Dept Math & Stat, Helsinki, Finland	University of Helsinki; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Helsinki; Aalto University; University of Helsinki; University of Helsinki	Jukarainen, S; Ganna, A (corresponding author), Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki, Finland.; Ganna, A (corresponding author), Broad Inst MIT & Harvard, Program Med & Populat Genet, Cambridge, MA 02142 USA.	sakari.jukarainen@helsinki.fi; andrea.ganna@helsinki.fi	; Ollila, Hanna/I-8552-2017	Cordioli, Mattia/0000-0002-4872-0520; Ollila, Hanna/0000-0002-5302-6429; Pirinen, Matti/0000-0002-1664-1350; Kiiskinen, Tuomo/0000-0002-6306-8227; Ramo, Joel/0000-0002-6429-5149; Havulinna, Aki/0000-0002-4787-8959; Jukarainen, Sakari/0000-0001-8169-8954; Ganna, Andrea/0000-0002-8147-240X; Mars, Nina/0000-0002-7259-5993	University of Helsinki including Helsinki University Central Hospital	University of Helsinki including Helsinki University Central Hospital	Open Access funding provided by University of Helsinki including Helsinki University Central Hospital	Abbafati C, 2020, LANCET, V396, P1204, DOI 10.1016/S0140-6736(20)30925-9; Brown GR, 2020, JAAPA-J AM ACAD PHYS, V33, P10, DOI 10.1097/01.JAA.0000721648.46099.2c; Bycroft C, 2018, NATURE, V562, P203, DOI 10.1038/s41586-018-0579-z; Chheda H, 2017, EUR J HUM GENET, V25, P477, DOI 10.1038/ejhg.2016.205; Frangoul H, 2021, NEW ENGL J MED, V384, P252, DOI 10.1056/NEJMoa2031054; Ge T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09718-5; Giambartolomei C, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004383; Gissler M., 2004, NOR EPIDEMIOL, V14, P113, DOI DOI 10.5324/NJE.V14I1.284; Green RC, 2013, GENET MED, V15, P565, DOI 10.1038/gim.2013.73; Guo J, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-84739-z; Heinze G, 2001, BIOMETRICS, V57, P114, DOI 10.1111/j.0006-341X.2001.00114.x; Huang QQ, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-32095-5; Johnston J, 2022, NAT MED, V28, P446, DOI 10.1038/s41591-022-01743-0; Johnston KJA, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008164; Joshi PK, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11174; Kanai M., 2021, PREPRINT, DOI [10.1101/2021.09.03.21262975, DOI 10.1101/2021.09.03.21262975]; Karavani E, 2019, CELL, V179, P1424, DOI 10.1016/j.cell.2019.10.033; Karczewski KJ, 2020, NATURE, V581, P434, DOI 10.1038/s41586-020-2308-7; Khosravi A., 2021, GLOB EPIDEMIOL, V3, DOI [DOI 10.1016/J.GLOEPI.2021.100062, 10.1016/J.GLOEPI.2021.100062]; Kuchenbaecker K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12026-7; Kullo IJ, 2022, NAT REV GENET, V23, P524, DOI 10.1038/s41576-022-00470-z; Kumar A, 2022, NAT MED, V28, P513, DOI 10.1038/s41591-022-01735-0; Kurki M, 2022, FINNGEN UNIQUE GENET, DOI [10.1101/2022.03.03.22271360, DOI 10.1101/2022.03.03.22271360]; Landrum MJ, 2014, NUCLEIC ACIDS RES, V42, pD980, DOI 10.1093/nar/gkt1113; Laugesen K, 2021, CLIN EPIDEMIOL, V13, P533, DOI 10.2147/CLEP.S314959; Lee JJ, 2018, NAT GENET, V50, P1112, DOI 10.1038/s41588-018-0147-3; Leinonen MK, 2017, EUR J CANCER, V77, P31, DOI 10.1016/j.ejca.2017.02.017; Lencz Todd, 2021, Elife, V10, DOI 10.7554/eLife.64716; Lewis CM, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00742-5; Li T, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23124-w; Lim ET, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004494; Liu JZ, 2015, NAT GENET, V47, P979, DOI 10.1038/ng.3359; Liu MZ, 2019, NAT GENET, V51, P237, DOI 10.1038/s41588-018-0307-5; Loh PR, 2015, NAT GENET, V47, P284, DOI 10.1038/ng.3190; Mahajan A, 2018, NAT GENET, V50, P1505, DOI 10.1038/s41588-018-0241-6; Manchanda R, 2018, CANCERS, V10, DOI 10.3390/cancers10110424; Manichaikul A, 2010, BIOINFORMATICS, V26, P2867, DOI 10.1093/bioinformatics/btq559; Mars N, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19966-5; Mars N, 2020, NAT MED, V26, P549, DOI 10.1038/s41591-020-0800-0; Martin AR, 2019, NAT GENET, V51, P584, DOI 10.1038/s41588-019-0379-x; Marwaha S, 2022, GENOME MED, V14, DOI 10.1186/s13073-022-01026-w; Matejcic M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06863-1; McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4; Meisner A, 2020, AM J HUM GENET, V107, P418, DOI 10.1016/j.ajhg.2020.07.002; Metcalfe KA, 2018, CLIN GENET, V93, P1063, DOI 10.1111/cge.13191; Miller DT, 2021, GENET MED, V23, P1381, DOI 10.1038/s41436-021-01172-3; Mukamel RE, 2021, SCIENCE, V373, P1499, DOI [10.1126/science.abg8289, 10.1101/2021.01.19.427332]; Murray CJL, 2020, LANCET, V396, P1223, DOI 10.1016/S0140-6736(20)30752-2; Musunuru K, 2021, NATURE, V593, P429, DOI 10.1038/s41586-021-03534-y; Nikpay M, 2015, NAT GENET, V47, P1121, DOI 10.1038/ng.3396; Parn K., 2019, GENOTYPE IMPUTATION, DOI [10.17504/protocols.io.xbgfijw, DOI 10.17504/PROTOCOLS.IO.XBGFIJW]; Parn K., 2019, GENOTYPING CHIP DATA, DOI [10.17504/protocols.io.xbhfij6, DOI 10.17504/PROTOCOLS.IO.XBHFIJ6]; Patel R. A., 2021, BIORXIV, DOI [10.1101/2021.12.06.471235, DOI 10.1101/2021.12.06.471235]; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Rasmussen KL, 2018, CAN MED ASSOC J, V190, pE1033, DOI 10.1503/cmaj.180066; Ray SB, 2019, ADIPOCYTE, V8, P201, DOI 10.1080/21623945.2019.1607423; Rim JH, 2021, NEW ENGL J MED, V385, P1722, DOI 10.1056/NEJMc2114592; Ritari J, 2020, NAR GENOM BIOINFORM, V2, DOI 10.1093/nargab/lqaa030; Rowe AK, 2004, AM J PREV MED, V26, P243, DOI 10.1016/j.amepre.2003.12.007; Ruotsalainen S. E., 2021, LOSS OF FUNCTION MFG, DOI [10.1101/2021.06.23.21259381, DOI 10.1101/2021.06.23.21259381]; Sakaue S, 2020, NAT MED, V26, P542, DOI 10.1038/s41591-020-0785-8; Schlaelpfer IR, 2008, BIOL PSYCHIAT, V63, P1039, DOI 10.1016/j.biopsych.2007.10.024; Shi HWB, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21286-1; Shiffman J, 2020, LANCET, V395, P1452, DOI 10.1016/S0140-6736(20)30416-5; Spurdle AB, 2012, HUM MUTAT, V33, P2, DOI 10.1002/humu.21628; Stensrud MJ, 2020, JAMA-J AM MED ASSOC, V323, P1401, DOI 10.1001/jama.2020.1267; Sudlow C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001779; Sun LL, 2021, PLOS MED, V18, DOI 10.1371/journal.pmed.1003498; Sund R, 2007, METHOD INFORM MED, V46, P558, DOI 10.1160/ME0382; Sund R, 2012, SCAND J PUBLIC HEALT, V40, P505, DOI 10.1177/1403494812456637; Timmers PRHJ, 2019, ELIFE, V8, DOI 10.7554/eLife.39856; Turley P, 2021, OBSTET GYNECOL SURV, V76, P609, DOI 10.1097/OGX.0000000000000972; Visscher PM, 2017, AM J HUM GENET, V101, P5, DOI 10.1016/j.ajhg.2017.06.005; Vuori MA, 2020, SCAND J PUBLIC HEALT, V48, P20, DOI 10.1177/1403494819847051; Wand H, 2021, NATURE, V591, P211, DOI 10.1038/s41586-021-03243-6; Wang G, 2020, J R STAT SOC B, V82, P1273, DOI 10.1111/rssb.12388; Watanabe K, 2019, NAT GENET, V51, P1339, DOI 10.1038/s41588-019-0481-0; Witte JS, 2014, NAT REV GENET, V15, P765, DOI 10.1038/nrg3786; Wray Naomi R, 2018, Nat Genet, V50, P668, DOI 10.1038/s41588-018-0090-3; Zheng X, 2014, PHARMACOGENOMICS J, V14, P192, DOI 10.1038/tpj.2013.18; Zhou W, 2018, NAT GENET, V50, P1335, DOI 10.1038/s41588-018-0184-y	81	0	0	1	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2022	28	9					1893	+		10.1038/s41591-022-01957-2	http://dx.doi.org/10.1038/s41591-022-01957-2		SEP 2022	27	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4S0LI	36097220	Green Submitted, hybrid, Green Published			2022-12-27	WOS:000852940800001
J	Anderson, AS				Anderson, Annaliesa S.			A lightspeed approach to pandemic drug development	NATURE MEDICINE			English	Editorial Material; Early Access								Pfizer had successes during COVID-19 by streamlining decisions and running several steps in parallel, a lightspeed approach that can be applied to other diseases.	[Anderson, Annaliesa S.] Pfizer Inc, Worldwide Res Dev & Med, Pearl River, NY 10965 USA	Pfizer	Anderson, AS (corresponding author), Pfizer Inc, Worldwide Res Dev & Med, Pearl River, NY 10965 USA.	Annaliesa.Anderson@pfizer.com							0	0	0	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01945-6	http://dx.doi.org/10.1038/s41591-022-01945-6		AUG 2022	1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3S4NQ	35953720	Bronze			2022-12-27	WOS:000839575100004
J	Wagner, SJ; Matek, C; Boushehri, SS; Boxberg, M; Lamm, L; Sadafi, A; Waibel, DJE; Marr, C; Peng, TY				Wagner, Sophia J.; Matek, Christian; Shetab Boushehri, Sayedali; Boxberg, Melanie; Lamm, Lorenz; Sadafi, Ario; Waibel, Dominik J. E.; Marr, Carsten; Peng, Tingying			Make deep learning algorithms in computational pathology more reproducible and reusable	NATURE MEDICINE			English	Editorial Material								Greater emphasis on reproducibility and reusability will advance computational pathology quickly and sustainably, ultimately optimizing clinical workflows and benefiting patient health.	[Wagner, Sophia J.; Lamm, Lorenz; Marr, Carsten; Peng, Tingying] German Res Ctr Environm Hlth, Helmholtz Munich, Helmholtz AI, Neuherberg, Germany; [Wagner, Sophia J.; Boxberg, Melanie; Sadafi, Ario] Tech Univ Munich, Dept Informat, Garching, Germany; [Matek, Christian; Shetab Boushehri, Sayedali; Sadafi, Ario; Waibel, Dominik J. E.; Marr, Carsten; Peng, Tingying] German Res Ctr Environm Hlth, Helmholtz Munich, Inst AI Hlth, Neuherberg, Germany; [Matek, Christian] Univ Hosp Erlangen, Inst Pathol, Erlangen, Germany; [Shetab Boushehri, Sayedali] Tech Univ Munich, Dept Math, Garching, Germany; [Shetab Boushehri, Sayedali] Roche Innovat Ctr Munich RICM, Data Sci Pharmaceut Res & Early Dev Informat pRED, Penzberg, Germany; [Boxberg, Melanie] Tech Univ Munich, Inst Pathol, Munich, Germany; [Boxberg, Melanie] Inst Pathol Munich North, Munich, Germany; [Lamm, Lorenz] German Res Ctr Environm Hlth, Helmholtz Munich, Helmholtz Pioneer Campus, Neuherberg, Germany; [Waibel, Dominik J. E.] Tech Univ Munich, Sch Life Sci, Weihenstephan, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Erlangen Nuremberg; Technical University of Munich; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich	Marr, C; Peng, TY (corresponding author), German Res Ctr Environm Hlth, Helmholtz Munich, Helmholtz AI, Neuherberg, Germany.; Marr, C; Peng, TY (corresponding author), German Res Ctr Environm Hlth, Helmholtz Munich, Inst AI Hlth, Neuherberg, Germany.	carsten.marr@helmholtz-munich.de; tingying.peng@helmholtz-munich.de	Wagner, Sophia/HII-6467-2022	Sadafi, Ario/0000-0003-4073-1396; Shetab Boushehri, Sayedali/0000-0003-3391-9294; Marr, Carsten/0000-0003-2154-4552; Waibel, Dominik Jens Elias/0000-0002-3753-8598; Wagner, Sophia/0000-0003-3763-2282; Lamm, Lorenz/0000-0003-0698-7769	Helmholtz Association; Helmholtz Association's Initiative; F. Hoffmann-la Roche LTD.; Boehringer Ingelheim Fonds; European Research Council (ERC) under the European Union [866411]; Helmholtz AI	Helmholtz Association(Helmholtz Association); Helmholtz Association's Initiative; F. Hoffmann-la Roche LTD.(Hoffmann-La Roche); Boehringer Ingelheim Fonds(Boehringer Ingelheim); European Research Council (ERC) under the European Union(European Research Council (ERC)); Helmholtz AI	We thank P. Schuffler for feedback. S.J.W., L.L. and S.S.B. are supported by the Helmholtz Association under the joint research school "Munich School for Data Science -MUDS". S.J.W., L.L. and T.P. were funded by Helmholtz Association's Initiative and Networking Fund through Helmholtz AI. S.S.B. has received funding by F. Hoffmann-la Roche LTD (No grant number is applicable). L.L. acknowledges a fellowship from the Boehringer Ingelheim Fonds. C.M. has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant no. 866411).	Coudray N, 2018, NAT MED, V24, P1559, DOI 10.1038/s41591-018-0177-5; Echle A, 2021, BRIT J CANCER, V124, P686, DOI 10.1038/s41416-020-01122-x; Esteva A, 2017, NATURE, V542, P115, DOI 10.1038/nature21056; Forsch S, 2021, DTSCH ARZTEBL INT, V118, P199, DOI 10.3238/arztebl.m2021.0011; Fu Y, 2020, NAT CANCER, V1, P800, DOI 10.1038/s43018-020-0085-8; Fuchs TJ, 2011, COMPUT MED IMAG GRAP, V35, P515, DOI 10.1016/j.compmedimag.2011.02.006; Haibe-Kains B, 2020, NATURE, V586, pE14, DOI 10.1038/s41586-020-2766-y; Howard FM, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24698-1; Hutson M, 2018, SCIENCE, V359, P725, DOI 10.1126/science.359.6377.725; Lu MY, 2021, NATURE, V594, P106, DOI 10.1038/s41586-021-03512-4; Matek C, 2019, NAT MACH INTELL, V1, P538, DOI 10.1038/s42256-019-0101-9; McDermott MBA, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abb1655; Pineau J, 2021, J MACH LEARN RES, V22; Stodden V, 2016, SCIENCE, V354, P1240, DOI 10.1126/science.aah6168; van der Laak J, 2021, NAT MED, V27, P775, DOI 10.1038/s41591-021-01343-4; Wagner S. J., 2022, PREPRINT, DOI [10.1101/2022.05.15.22275108, DOI 10.1101/2022.05.15.22275108]; Wiens J, 2019, NAT MED, V25, P1337, DOI 10.1038/s41591-019-0548-6	17	0	0	4	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2022	28	9					1744	1746		10.1038/s41591-022-01905-0	http://dx.doi.org/10.1038/s41591-022-01905-0		AUG 2022	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4S0LI	35941376				2022-12-27	WOS:000837551000002
J	Li, XH; Tu, YY; Tang, LH; Gao, Q; Alonso, PL				Li, Xiaohong; Tu, Youyou; Tang, Linhua; Gao, Qi; Alonso, Pedro L.			The role of research in China's successful elimination of malaria	NATURE MEDICINE			English	Editorial Material								The elimination of malaria from China relied on local decision-makers who tested and implemented interventions, combined with a centralized drug discovery program. This holds lessons for other malaria-endemic countries.	[Li, Xiaohong; Alonso, Pedro L.] WHO, Global Malaria Programme, Geneva, Switzerland; [Tu, Youyou] China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing, Peoples R China; [Tang, Linhua] Chinese Ctr Dis Control & Prevent, Natl Inst Parasit Dis, Shanghai, Peoples R China; [Gao, Qi] Jiangsu Inst Parasit Dis, Wuxi, Jiangsu, Peoples R China	World Health Organization; China Academy of Chinese Medical Sciences; Institute of Chinese Materia Medica, CACMS; Chinese Center for Disease Control & Prevention; National Institute of Parasitic Diseases, Chinese Center for Disease Control & Prevention	Li, XH (corresponding author), WHO, Global Malaria Programme, Geneva, Switzerland.	lixia@who.int						[Anonymous], 1999, ROLL BACK MAL; Cai XianZheng, 2009, China Tropical Medicine, V9, P1957; Carroll SP, 2006, J AM MOSQUITO CONTR, V22, P507, DOI 10.2987/8756-971X(2006)22[507:PARBMR]2.0.CO;2; Chen C, 2014, INFECT DIS POVERTY, V3, DOI 10.1186/2049-9957-3-9; CHOU TQ, 1948, J AM CHEM SOC, V70, P1765, DOI 10.1021/ja01185a028; Han GY., 1980, CHINESE SCI BULL, V6, P285; JANG CS, 1948, NATURE, V161, P400, DOI 10.1038/161400b0; Li RH., 2013, NAT FISH WEEK 2013 C, V1, P144; Li XH, 2021, MALARIA J, V20, DOI 10.1186/s12936-021-03672-8; Li Z., 1988, P GUANGDONG I ANTIPA; LI ZZ, 1989, AM J TROP MED HYG, V40, P356; Liang XT., 1979, ACTA CHIM SINICA, V3, P215; Malaria Prevention Institute of Yunnan Province & Health Office of Menghai Commune in Menghai County, 1975, CHINESE MED J-PEKING, V5, P313; Najera JA, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000412; Su XZ, 2015, SCI CHINA LIFE SCI, V58, P1175, DOI 10.1007/s11427-015-4948-7; Sun, 1981, ACTA ECOL SIN, V1, P168; Tang L.H., 2013, MALARIA CONTROL ELIM; Wu XR., 1995, CHIN J PARASITOL PAR, V13, P115; Yu T., 2000, J PRAC PARASIT DIS, V8, P162; Zhou Z. J., 1991, STUDY MALARIA CONTRO	20	1	1	7	7	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2022	28	7					1336	1338		10.1038/s41591-022-01824-0	http://dx.doi.org/10.1038/s41591-022-01824-0		MAY 2022	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3E5PS	35641827				2022-12-27	WOS:000803789900001
J	Zeng, AGX; Bansal, S; Jin, LQ; Mitchell, A; Chen, WC; Abbas, HA; Chan-Seng-Yue, M; Voisin, V; van Galen, P; Tierens, A; Cheok, M; Preudhomme, C; Dombret, H; Daver, N; Futreal, PA; Minden, MD; Kennedy, JA; Wang, JCY; Dick, JE				Zeng, Andy G. X.; Bansal, Suraj; Jin, Liqing; Mitchell, Amanda; Chen, Weihsu Claire; Abbas, Hussein A.; Chan-Seng-Yue, Michelle; Voisin, Veronique; van Galen, Peter; Tierens, Anne; Cheok, Meyling; Preudhomme, Claude; Dombret, Herve; Daver, Naval; Futreal, P. Andrew; Minden, Mark D.; Kennedy, James A.; Wang, Jean C. Y.; Dick, John E.			A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia	NATURE MEDICINE			English	Article							SELF-RENEWAL; STEM-CELLS; CLINICAL-OUTCOMES; AML; SUBCLONES; LANDSCAPE; SIGNATURE; EVOLUTION; THERAPY; CULTURE	A novel gene expression classifier of AML heterogeneity captures patient-specific variation in leukemia cell composition and predicts clinical responses to treatment. The treatment landscape of acute myeloid leukemia (AML) is evolving, with promising therapies entering clinical translation, yet patient responses remain heterogeneous, and biomarkers for tailoring treatment are lacking. To understand how disease heterogeneity links with therapy response, we determined the leukemia cell hierarchy makeup from bulk transcriptomes of more than 1,000 patients through deconvolution using single-cell reference profiles of leukemia stem, progenitor and mature cell types. Leukemia hierarchy composition was associated with functional, genomic and clinical properties and converged into four overall classes, spanning Primitive, Mature, GMP and Intermediate. Critically, variation in hierarchy composition along the Primitive versus GMP or Primitive versus Mature axes were associated with response to chemotherapy or drug sensitivity profiles of targeted therapies, respectively. A seven-gene biomarker derived from the Primitive versus Mature axis was associated with response to 105 investigational drugs. Cellular hierarchy composition constitutes a novel framework for understanding disease biology and advancing precision medicine in AML.	[Zeng, Andy G. X.; Bansal, Suraj; Jin, Liqing; Mitchell, Amanda; Chen, Weihsu Claire; Chan-Seng-Yue, Michelle; Minden, Mark D.; Kennedy, James A.; Wang, Jean C. Y.; Dick, John E.] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada; [Zeng, Andy G. X.; Dick, John E.] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada; [Abbas, Hussein A.; Daver, Naval] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; [Voisin, Veronique] Univ Toronto, Donnelly Ctr, Toronto, ON, Canada; [van Galen, Peter] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA; [van Galen, Peter] Harvard Med Sch, Dept Med, Boston, MA 02115 USA; [van Galen, Peter] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA; [van Galen, Peter] Harvard Med Sch, Ludwig Ctr Harvard, Boston, MA 02115 USA; [Tierens, Anne] Univ Hlth Network, Lab Med Program, Hematopathol, Toronto, ON, Canada; [Cheok, Meyling; Preudhomme, Claude] Univ Lille, U1277 CANTHER Canc Heterogene Plast & Resistance, CHU Lille, CNRS,INSERM,UMR9020, Lille, France; [Dombret, Herve] Univ Paris Cite, Hop St Louis, AP HP, Dept Hematol, Paris, France; [Futreal, P. Andrew] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA; [Minden, Mark D.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Minden, Mark D.; Wang, Jean C. Y.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Minden, Mark D.; Wang, Jean C. Y.] Univ Hlth Network, Div Med Oncol & Hematol, Toronto, ON, Canada; [Kennedy, James A.] Sunnybrook Hlth Sci Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada; [Chen, Weihsu Claire] Amgen British Columbia, Biol Discovery, Burnaby, BC, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Texas System; UTMD Anderson Cancer Center; University of Toronto; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard Medical School; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Texas System; UTMD Anderson Cancer Center; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Dick, JE (corresponding author), Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada.; Dick, JE (corresponding author), Univ Toronto, Dept Mol Genet, Toronto, ON, Canada.	john.dick@uhnresearch.ca	Cheok, Meyling h/C-3822-2014	Cheok, Meyling h/0000-0002-7820-8026; van Galen, Peter/0000-0002-0735-1570; Abbas, Hussein/0000-0003-2946-3562	CIHR Vanier scholarship; Ontario Institute for Cancer Research through Government of Ontario; Canadian Institutes for Health Research [RN380110 - 409786]; International Development Research Centre Ottawa Canada; Canadian Cancer Society [703212, 706662]; Terry Fox New Frontiers Program [1106]; University of Toronto's Medicine by Design initiative; Canada First Research Excellence Fund; Canada Research Chair; Princess Margaret Cancer Centre; Princess Margaret Cancer Foundation; Ontario Ministry of Health; Wendy Eisen Princess Margaret Hospital Foundation Account; Philip Orsino Chair in Leukemia Research	CIHR Vanier scholarship(Canadian Institutes of Health Research (CIHR)); Ontario Institute for Cancer Research through Government of Ontario; Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); International Development Research Centre Ottawa Canada(CGIAR); Canadian Cancer Society(Canadian Cancer Society (CCS)); Terry Fox New Frontiers Program; University of Toronto's Medicine by Design initiative; Canada First Research Excellence Fund; Canada Research Chair(Natural Resources CanadaCanadian Forest ServiceCanada Research Chairs); Princess Margaret Cancer Centre(University of Toronto); Princess Margaret Cancer Foundation(University of Toronto); Ontario Ministry of Health(Ministry of Health and Long-Term Care, Ontario); Wendy Eisen Princess Margaret Hospital Foundation Account; Philip Orsino Chair in Leukemia Research	We thank C. Jones, A. Tikhonova, N. Iscove, S. Chan, S. Abelson, B. Haibe-Kains, M. Anders and all members of the Dick Laboratory for valuable feedback on the manuscript. We thank P. Valk and the HOVON-SAKK trial group for providing the clinical annotations associated with GSE6891. A.G.X.Z. is supported by a CIHR Vanier scholarship. J.E.D. is supported by funds from the Ontario Institute for Cancer Research through funding provided by the Government of Ontario; the Canadian Institutes for Health Research (RN380110 - 409786); the International Development Research Centre Ottawa Canada; the Canadian Cancer Society (grant 703212 (end date 2019) and grant 706662 (end date 2025)); the Terry Fox New Frontiers Program Project Grant (Project 1106); University of Toronto's Medicine by Design initiative with funding from the Canada First Research Excellence Fund; a Canada Research Chair; Princess Margaret Cancer Centre; The Princess Margaret Cancer Foundation; and the Ontario Ministry of Health. The Leukemia Tissue Bank is supported by funds to M.D.M. from the Wendy Eisen Princess Margaret Hospital Foundation Account and the Philip Orsino Chair in Leukemia Research. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Abbas HA, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26282-z; Aibar S, 2017, NAT METHODS, V14, P1083, DOI [10.1038/NMETH.4463, 10.1038/nmeth.4463]; Bolouri H, 2018, NAT MED, V24, P103, DOI 10.1038/nm.4439; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Brunetti L, 2018, CANCER CELL, V34, P499, DOI 10.1016/j.ccell.2018.08.005; BUICK RN, 1979, BLOOD, V54, P95; Castaigne S, 2012, LANCET, V379, P1508, DOI 10.1016/S0140-6736(12)60485-1; CHANG LJA, 1980, J CELL PHYSIOL, V102, P217, DOI 10.1002/jcp.1041020213; Chen WC, 2016, CANCER RES, V76, P1214, DOI 10.1158/0008-5472.CAN-15-2743; Christopher MJ, 2018, NEW ENGL J MED, V379, P2330, DOI 10.1056/NEJMoa1808777; CLARKSON B, 1967, J CLIN INVEST, V46, P506, DOI 10.1172/JCI105553; Cocciardi S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09745-2; Deshwar AG, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0602-8; Dick JE, 2008, BLOOD, V112, P4793, DOI 10.1182/blood-2008-08-077941; Docking TR, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22625-y; Elsayed AH, 2020, LEUKEMIA, V34, P735, DOI 10.1038/s41375-019-0604-8; Eppert K, 2011, NAT MED, V17, P1086, DOI 10.1038/nm.2415; Etchin J, 2016, LEUKEMIA, V30, P190, DOI 10.1038/leu.2015.194; Galkin O, 2021, HAEMATOLOGICA, V106, P279, DOI 10.3324/haematol.2019.245167; Gentles AJ, 2010, JAMA-J AM MED ASSOC, V304, P2706, DOI 10.1001/jama.2010.1862; GRIFFIN JD, 1983, BLOOD, V62, P1300; Hope KJ, 2004, NAT IMMUNOL, V5, P738, DOI 10.1038/ni1080; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Klco JM, 2014, CANCER CELL, V25, P379, DOI 10.1016/j.ccr.2014.01.031; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Lambert J, 2019, HAEMATOLOGICA, V104, P113, DOI 10.3324/haematol.2018.188888; Lambert SA, 2018, CELL, V172, P650, DOI 10.1016/j.cell.2018.01.029; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; LEE SI, 2018, J ARRYTHM, V9; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Li S, 2016, NAT MED, V22, P792, DOI 10.1038/nm.4125; Lotfollahi M, 2022, NAT BIOTECHNOL, V40, P121, DOI 10.1038/s41587-021-01001-7; LOVE MI, 2014, GENOME BIOL, V15, DOI DOI 10.1186/S13059-014-0550-8; Lun ATL, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0947-7; Marquis M, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408-018-0103-6; MCCULLOCH EA, 1983, BLOOD, V62, P1; Miller CA, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-3195-z; MINDEN MD, 1978, BLOOD, V52, P592; Nehme A, 2020, BLOOD ADV, V4, P5322, DOI 10.1182/bloodadvances.2020002042; Newman AM, 2019, NAT BIOTECHNOL, V37, P773, DOI 10.1038/s41587-019-0114-2; Ng SWK, 2022, BLOOD ADV, V6, P1064, DOI 10.1182/bloodadvances.2021005741; Ng SWK, 2016, NATURE, V540, P433, DOI 10.1038/nature20598; NOWELL PC, 1960, SCIENCE, V132, P1497; Pabst C, 2016, BLOOD, V127, P2018, DOI 10.1182/blood-2015-11-683649; Papaemmanuil E, 2016, NEW ENGL J MED, V374, P2209, DOI 10.1056/NEJMoa1516192; Pei SS, 2020, CANCER DISCOV, V10, P536, DOI 10.1158/2159-8290.CD-19-0710; Piccolo SR, 2012, GENOMICS, V100, P337, DOI 10.1016/j.ygeno.2012.08.003; PIERCE GB, 1988, CANCER RES, V48, P1996; Quek L, 2016, J EXP MED, V213, P1513, DOI 10.1084/jem.20151775; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Shlush LI, 2017, NATURE, V547, P104, DOI 10.1038/nature22993; Surka Christine, 2021, Blood, V137, P661, DOI 10.1182/blood.2020008676; Takayama N, 2021, CELL STEM CELL, V28, P488, DOI 10.1016/j.stem.2020.11.001; Tan YQ, 2019, CELL SYST, V9, P207, DOI 10.1016/j.cels.2019.06.004; Tarashansky AJ, 2019, ELIFE, V8, DOI 10.7554/eLife.48994; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; Traag VA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41695-z; Tyner JW, 2018, NATURE, V562, P526, DOI 10.1038/s41586-018-0623-z; van de Sande B, 2020, NAT PROTOC, V15, P2247, DOI 10.1038/s41596-020-0336-2; van Galen P, 2019, CELL, V176, P1265, DOI 10.1016/j.cell.2019.01.031; Verhaak RGW, 2009, HAEMATOL-HEMATOL J, V94, P131, DOI 10.3324/haematol.13299; Vosberg S, 2019, GENE CHROMOSOME CANC, V58, P839, DOI 10.1002/gcc.22806; Wagner S, 2019, BLOOD ADV, V3, P1330, DOI 10.1182/bloodadvances.2018030726; Wolf FA, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-017-1382-0; WOUTERS R, 1984, BLOOD, V63, P684; Wu JQ, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00941-y; Xie SZ, 2021, BLOOD CANCER DISCOV, V2, P32, DOI 10.1158/2643-3230.BCD-20-0155; Xie SZ, 2019, CELL STEM CELL, V25, P639, DOI 10.1016/j.stem.2019.09.008; Xu CL, 2021, MOL SYST BIOL, V17, DOI 10.15252/msb.20209620	69	9	9	9	14	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2022	28	6					1212	+		10.1038/s41591-022-01819-x	http://dx.doi.org/10.1038/s41591-022-01819-x		MAY 2022	31	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E9IE	35618837	Green Submitted			2022-12-27	WOS:000805514000002
J	Horby, P				Horby, Peter			Why preprints are good for patients	NATURE MEDICINE			English	Editorial Material								Rapid communication of clinical trial results has likely saved lives during the COVID-19 pandemic and should become the new norm.	[Horby, Peter] Univ Oxford, Pandem Sci Inst, Nuffield Dept Med, Oxford, England	University of Oxford	Horby, P (corresponding author), Univ Oxford, Pandem Sci Inst, Nuffield Dept Med, Oxford, England.	peter.horby@ndm.ox.ac.uk		Horby, Peter/0000-0002-9822-1586					0	1	1	1	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2022	28	6					1109	1109		10.1038/s41591-022-01812-4	http://dx.doi.org/10.1038/s41591-022-01812-4		MAY 2022	1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E9IE	35534569	Bronze			2022-12-27	WOS:000792548400003
J	Park, EM; Chelvanambi, M; Bhutiani, N; Kroemer, G; Zitvogel, L; Wargo, JA				Park, Elizabeth M.; Chelvanambi, Manoj; Bhutiani, Neal; Kroemer, Guido; Zitvogel, Laurence; Wargo, Jennifer A.			Targeting the gut and tumor microbiota in cancer	NATURE MEDICINE			English	Review							TERTIARY LYMPHOID STRUCTURES; DNA MISMATCH REPAIR; IMMUNE CHECKPOINT INHIBITORS; FUSOBACTERIUM-NUCLEATUM; ANTITUMOR IMMUNITY; PD-1 BLOCKADE; ACQUIRED-RESISTANCE; COLORECTAL-CANCER; STOOL MICROBIOME; THERAPY EFFICACY	There exists tremendous opportunity to target microorganisms in the gut and other niches to help treat or even prevent cancer. This Review outlines how microbial targeting could become a pillar of personalized cancer care over the next 5 to 10 years. Microorganisms within the gut and other niches may contribute to carcinogenesis, as well as shaping cancer immunosurveillance and response to immunotherapy. Our understanding of the complex relationship between different host-intrinsic microorganisms, as well as the multifaceted mechanisms by which they influence health and disease, has grown tremendously-hastening development of novel therapeutic strategies that target the microbiota to improve treatment outcomes in cancer. Accordingly, the evaluation of a patient's microbial composition and function and its subsequent targeted modulation represent key elements of future multidisciplinary and precision-medicine approaches. In this Review, we outline the current state of research toward harnessing the microbiome to better prevent and treat cancer.	[Park, Elizabeth M.] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; [Park, Elizabeth M.; Chelvanambi, Manoj; Bhutiani, Neal; Wargo, Jennifer A.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; [Kroemer, Guido] Univ Paris, Inserm CIC 1417, I Reivac, Hop Cochin,APHP, Paris, France; [Kroemer, Guido] Sorbonne Univ, Ctr Rech Cordeliers, Equipe Labellisee Ligue Canc, Univ Paris,Inserm U1138,Inst Univ France, Paris, France; [Kroemer, Guido] Univ Paris Saclay, Gustave Roussy Canc Ctr, Metabol & Cell Biol Platforms, Villejuif, France; [Kroemer, Guido] Hop Europeen Georges Pompidou, Assistance Publ Hop Paris, Pole Biol, Paris, France; [Zitvogel, Laurence] Univ Paris Saclay, Fac Med, Le Kremlin Bicetre, France; [Zitvogel, Laurence] Gustave Roussy, Villejuif, France; [Zitvogel, Laurence] Gustave Roussy, Inst Natl Sante & Rech Med, UMR1015, Villejuif, France; [Zitvogel, Laurence] Gustave Roussy, Ctr Clin Invest BIOTHERIS, INSERM CIC1428, Villejuif, France; [Wargo, Jennifer A.] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut Universitaire de France; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; University of Texas System; UTMD Anderson Cancer Center	Wargo, JA (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA.; Wargo, JA (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA.	jwargo@mdanderson.org	Kroemer, Guido/B-4263-2013	Kroemer, Guido/0000-0002-9334-4405; Chelvanambi, Manoj/0000-0003-2130-3118; Park, Elizabeth/0000-0002-1670-2299	Seerave Foundation; RHU Immunolife; ANR Ileobiome [19-CE15-0029-01]; Ligue contre le Cancer (equipe labellisee); Agence National de la Recherche (ANR)-Projets blancs; AMMICa [US23/CNRS UMS3655]; Association pour la recherche sur le cancer (ARC); Canceropole Ile-de-France; Fondation pour la Recherche Medicale (FRM); Equipex Onco-Pheno-Screen; European Joint Programme on Rare Diseases (EJPRD); Gustave Roussy Odyssea; European Union; Fondation Carrefour; Institut National du Cancer (INCa); Institut Universitaire de France; LabEx Immuno-Oncology [ANR-18-IDEX-0001]; Cancer Research ASPIRE Award from the Mark Foundation; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); SIRIC Cancer Research and Personalized Medicine (CARPEM); Universite de Paris [ANR-18-IDEX-0001]; CPRIT Training Award [RP210028]	Seerave Foundation; RHU Immunolife; ANR Ileobiome(French National Research Agency (ANR)); Ligue contre le Cancer (equipe labellisee); Agence National de la Recherche (ANR)-Projets blancs(French National Research Agency (ANR)); AMMICa; Association pour la recherche sur le cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Canceropole Ile-de-France(Region Ile-de-France); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Equipex Onco-Pheno-Screen; European Joint Programme on Rare Diseases (EJPRD); Gustave Roussy Odyssea; European Union(European Commission); Fondation Carrefour; Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Institut Universitaire de France; LabEx Immuno-Oncology; Cancer Research ASPIRE Award from the Mark Foundation; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); SIRIC Cancer Research and Personalized Medicine (CARPEM); Universite de Paris; CPRIT Training Award	The authors thank R. G. Witt, S. Cass, R. Traweek and E. Baruch for their thoughtful input and assistance with preparation of this manuscript. L.Z. and G.K. are supported by Seerave Foundation, the RHU Immunolife, ANR Ileobiome (19-CE15-0029-01), the Ligue contre le Cancer (equipe labellisee); Agence National de la Recherche (ANR)-Projets blancs; AMMICa (US23/CNRS UMS3655); Association pour la recherche sur le cancer (ARC); Canceropole Ile-de-France; Fondation pour la Recherche Medicale (FRM); a donation by Elior; Equipex Onco-Pheno-Screen; European Joint Programme on Rare Diseases (EJPRD); Gustave Roussy Odyssea, the European Union Horizon 2020 Projects Oncobiome and Crimson; Fondation Carrefour; Institut National du Cancer (INCa); Institut Universitaire de France; LabEx Immuno-Oncology (ANR-18-IDEX-0001); a Cancer Research ASPIRE Award from the Mark Foundation; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and SIRIC Cancer Research and Personalized Medicine (CARPEM). This study contributes to the IdEx Universite de Paris, ANR-18-IDEX-0001. E.M.P. was supported by the CPRIT Training Award (RP210028).	Abt MC, 2012, IMMUNITY, V37, P158, DOI 10.1016/j.immuni.2012.04.011; Andrews MC, 2021, NAT MED, V27, P1432, DOI 10.1038/s41591-021-01406-6; Andtbacka RHI, 2015, J CLIN ONCOL, V33, P2780, DOI 10.1200/JCO.2014.58.3377; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Aykut B, 2019, NATURE, V574, P264, DOI 10.1038/s41586-019-1608-2; Baek MK, 2010, CANCER LETT, V290, P123, DOI 10.1016/j.canlet.2009.08.030; Barrett KE, 2017, J PHYSIOL-LONDON, V595, P433, DOI 10.1113/JP273451; Barrett M, 2020, TRENDS CANCER, V6, P277, DOI 10.1016/j.trecan.2020.01.019; Baruch EN, 2021, CANCER IMMUNOL RES, V9, P365, DOI 10.1158/2326-6066.CIR-20-0877; Baruch EN, 2021, SCIENCE, V371, P602, DOI 10.1126/science.abb5920; BAUER H, 1963, AM J PATHOL, V42, P471; Becerril-Alarcon Y, 2019, CARDIOVASC THER, DOI 10.1155/2019/5707150; Belcheva A, 2014, CELL, V158, P288, DOI 10.1016/j.cell.2014.04.051; Bessell CA, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.135597; Besser J, 2018, CLIN MICROBIOL INFEC, V24, P335, DOI 10.1016/j.cmi.2017.10.013; Biagi E, 2015, BONE MARROW TRANSPL, V50, P992, DOI 10.1038/bmt.2015.16; Biagi E, 2019, BMC MED GENOMICS, V12, DOI 10.1186/s12920-019-0494-7; Bindels LB, 2012, BRIT J CANCER, V107, P1337, DOI 10.1038/bjc.2012.409; Blake SJ, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100464; Bodor JN, 2020, CANCER-AM CANCER SOC, V126, P260, DOI 10.1002/cncr.32468; Bouskra D, 2008, NATURE, V456, P507, DOI 10.1038/nature07450; Brahmer JR, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0382-2; Bronkhorst Abel Jacobus, 2019, Biomol Detect Quantif, V17, P100087, DOI 10.1016/j.bdq.2019.100087; Bucci V, 2014, J MOL BIOL, V426, P3907, DOI 10.1016/j.jmb.2014.03.017; Budynek P, 2010, ARCH MICROBIOL, V192, P315, DOI 10.1007/s00203-010-0559-7; Bultman SJ, 2014, CLIN CANCER RES, V20, P799, DOI 10.1158/1078-0432.CCR-13-2483; Buque A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17644-0; Cabrita R, 2020, NATURE, V577, P561, DOI 10.1038/s41586-019-1914-8; Cammarota G, 2020, NAT REV GASTRO HEPAT, V17, P635, DOI 10.1038/s41575-020-0327-3; Cao S, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0352-3; Cao Y, 2017, NPJ PRECIS ONCOL, V1, DOI 10.1038/s41698-017-0018-x; Cascone T, 2021, NAT MED, V27, P504, DOI 10.1038/s41591-020-01224-2; Chang CW, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020386; Chang MH, 2005, CLIN CANCER RES, V11, P7953, DOI 10.1158/1078-0432.CCR-05-1095; Chen GY, 2008, CANCER RES, V68, P10060, DOI 10.1158/0008-5472.CAN-08-2061; Chen PL, 2016, CANCER DISCOV, V6, P827, DOI 10.1158/2159-8290.CD-15-1545; Chen PB, 2020, NAT BIOTECHNOL, V38, P1288, DOI 10.1038/s41587-020-0549-5; Chen T, 2018, CANCER IMMUNOL IMMUN, V67, P1635, DOI 10.1007/s00262-018-2233-x; Cheng ASL, 2013, GASTROENTEROLOGY, V144, P122, DOI 10.1053/j.gastro.2012.10.002; Cherkasova E, 2016, CANCER RES, V76, P2177, DOI 10.1158/0008-5472.CAN-15-3139; Chung L, 2018, CELL HOST MICROBE, V23, P203, DOI [10.1016/j.chom.2018.01.007, 10.1016/j.chom.2018.02.004]; Cillo AR, 2020, IMMUNITY, V52, P183, DOI 10.1016/j.immuni.2019.11.014; Cogdill AP, 2018, TRENDS IMMUNOL, V39, P900, DOI 10.1016/j.it.2018.09.007; Coley W.B., 1998, P R SOC MED, V31, P456; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; Cordoba R, 2021, LANCET HAEMATOL, V8, pE840, DOI 10.1016/S2352-3026(21)00241-6; Correia JD, 2006, P NATL ACAD SCI USA, V103, P1840, DOI 10.1073/pnas.0509228103; Cuevas-Ramos G, 2010, P NATL ACAD SCI USA, V107, P11537, DOI 10.1073/pnas.1001261107; Cui M, 2017, EMBO MOL MED, V9, P448, DOI 10.15252/emmm.201606932; Das S, 2020, CANCER RES, V80, P1088, DOI 10.1158/0008-5472.CAN-19-2080; Davar D, 2021, SCIENCE, V371, P595, DOI 10.1126/science.abf3363; Davis NM, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0605-2; Dejea CM, 2018, SCIENCE, V359, P592, DOI 10.1126/science.aah3648; Deng YT, 2019, MOL IMMUNOL, V112, P266, DOI 10.1016/j.molimm.2019.06.006; Derosa L, 2022, NAT MED, V28, P315, DOI 10.1038/s41591-021-01655-5; Derosa L, 2021, CANCER DISCOV, V11, P2396, DOI 10.1158/2159-8290.CD-21-0236; Derosa L, 2020, EUR UROL, V78, P195, DOI 10.1016/j.eururo.2020.04.044; Derosa L, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.6_suppl.462; Dickson RP, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004923; Dismukes GC, 2001, P NATL ACAD SCI USA, V98, P2170, DOI 10.1073/pnas.061514798; Dizman N, 2022, NAT MED, V28, P704, DOI 10.1038/s41591-022-01694-6; Dodd MS, 2017, NATURE, V543, P60, DOI 10.1038/nature21377; Dominguez-Bello MG, 2019, GUT, V68, P1108, DOI 10.1136/gutjnl-2018-317503; Dong ZY, 2017, CLIN CANCER RES, V23, P3012, DOI 10.1158/1078-0432.CCR-16-2554; Dourson M, 2022, TOXICOL SCI, V186, P12, DOI 10.1093/toxsci/kfab134; Durazzi F, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-82726-y; Eisenhofer R, 2019, TRENDS MICROBIOL, V27, P105, DOI 10.1016/j.tim.2018.11.003; Fehrenbacher L, 2016, LANCET, V387, P1837, DOI 10.1016/S0140-6736(16)00587-0; Ferrere G, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.145207; Feuerstadt P, 2022, NEW ENGL J MED, V386, P220, DOI 10.1056/NEJMoa2106516; Flores R, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-253; Fluckiger A, 2020, SCIENCE, V369, P936, DOI 10.1126/science.aax0701; Flynn C, 2007, MOL CARCINOGEN, V46, P60, DOI 10.1002/mc.20253; Fogliano V, 2011, MOL NUTR FOOD RES, V55, pS44, DOI 10.1002/mnfr.201000360; Friedrich MJ, 2013, JAMA-J AM MED ASSOC, V309, P1447, DOI 10.1001/jama.2013.2824; Fuhrman BJ, 2014, J CLIN ENDOCR METAB, V99, P4632, DOI 10.1210/jc.2014-2222; Fullerton KM, 2021, NAT GEOSCI, V14, P301, DOI 10.1038/s41561-021-00725-0; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Garmaeva S, 2019, BMC BIOL, V17, DOI 10.1186/s12915-019-0704-y; Ge YS, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-01845-6; Geller LT, 2017, SCIENCE, V357, P1156, DOI 10.1126/science.aah5043; Gharaibeh RZ, 2019, GUT, V68, P385, DOI 10.1136/gutjnl-2018-317220; Giannakis M, 2016, CELL REP, V15, P857, DOI 10.1016/j.celrep.2016.03.075; Gide TN, 2018, CLIN CANCER RES, V24, P1260, DOI 10.1158/1078-0432.CCR-17-2267; Giles EM, 2019, NAT REV MICROBIOL, V17, P719, DOI 10.1038/s41579-019-0271-9; Glassing A, 2016, GUT PATHOG, V8, DOI 10.1186/s13099-016-0103-7; Gonzalez-Cao M, 2016, CANCER BIOL MED, V13, P483, DOI 10.20892/j.issn.2095-3941.2016.0080; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Gosiewski T, 2017, EUR J CLIN MICROBIOL, V36, P329, DOI 10.1007/s10096-016-2805-7; Goubet AG, 2021, CELL DEATH DIFFER, V28, P2276, DOI 10.1038/s41418-021-00753-8; Grajeda-Iglesias C, 2021, AGING-US, V13, P6375, DOI 10.18632/aging.202739; Griffin ME, 2021, SCIENCE, V373, P1040, DOI 10.1126/science.abc9113; Hakozaki T, 2020, CANCER IMMUNOL RES, V8, P1243, DOI 10.1158/2326-6066.CIR-20-0196; Halley A, 2020, ANTICANCER RES, V40, P4807, DOI 10.21873/anticanres.14484; Hanahan D, 2022, CANCER DISCOV, V12, P31, DOI 10.1158/2159-8290.CD-21-1059; He Y, 2021, CELL METAB, V33, P988, DOI 10.1016/j.cmet.2021.03.002; He Z, 2019, GUT, V68, P289, DOI 10.1136/gutjnl-2018-317200; Helmink BA, 2020, NATURE, V577, P549, DOI 10.1038/s41586-019-1922-8; Helmink BA, 2019, NAT MED, V25, P377, DOI 10.1038/s41591-019-0377-7; Heymann CJF, 2021, CANCER LETT, V522, P63, DOI 10.1016/j.canlet.2021.09.009; Holler E, 2014, BIOL BLOOD MARROW TR, V20, P640, DOI 10.1016/j.bbmt.2014.01.030; Hoste E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6932; Howard R, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56218-z; Huang HC, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00796-5; Huemer F, 2019, ANN ONCOL, V30, P652, DOI 10.1093/annonc/mdz021; Huhta H, 2016, ONCOTARGET, V7, P23658, DOI 10.18632/oncotarget.8151; Iida N, 2013, SCIENCE, V342, P967, DOI 10.1126/science.1240527; Inamura K, 2018, CANCERS, V10, DOI 10.3390/cancers10010026; Jalili-Firoozinezhad S, 2019, NAT BIOMED ENG, V3, P520, DOI 10.1038/s41551-019-0397-0; Jenq RR, 2015, BIOL BLOOD MARROW TR, V21, P1373, DOI 10.1016/j.bbmt.2015.04.016; Jessy Thomas, 2011, J Nat Sci Biol Med, V2, P43, DOI 10.4103/0976-9668.82318; Jin YP, 2019, J THORAC ONCOL, V14, P1378, DOI 10.1016/j.jtho.2019.04.007; Jinadasa RN, 2011, MICROBIOL-SGM, V157, P1851, DOI 10.1099/mic.0.049536-0; Kalaora S, 2021, NATURE, V592, P138, DOI 10.1038/s41586-021-03368-8; Kamada N, 2013, NAT REV IMMUNOL, V13, P321, DOI 10.1038/nri3430; Karlsson FH, 2011, TRENDS BIOTECHNOL, V29, P251, DOI 10.1016/j.tibtech.2011.01.009; Kelly CM, 2020, JAMA ONCOL, V6, P402, DOI 10.1001/jamaoncol.2019.6152; Khan U, 2021, AM J CLIN ONCOL-CANC, V44, P247, DOI 10.1097/COC.0000000000000813; Kim JH, 2020, CANCER PREV RES, V13, P25, DOI 10.1158/1940-6207.CAPR-19-0286; Kim JJ, 2002, GASTROENTEROLOGY, V123, P542, DOI 10.1053/gast.2002.34751; Kim K, 2019, MOL MED REP, V20, P1569, DOI 10.3892/mmr.2019.10431; Knippel RJ, 2021, CANCER DISCOV, V11, P2378, DOI 10.1158/2159-8290.CD-21-0324; Kopp M, 2016, J CHROMATOGR A, V1469, P48, DOI 10.1016/j.chroma.2016.09.048; Kraus B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072756; Kroemer G, 2018, CELL, V175, P605, DOI 10.1016/j.cell.2018.07.044; Krupar R, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.AM2016-LB-095; Kucerova P, 2016, ANTI-CANCER DRUG, V27, P269, DOI 10.1097/CAD.0000000000000337; Lam KC, 2021, CELL, V184, P5338, DOI 10.1016/j.cell.2021.09.019; Lathrop SK, 2011, NATURE, V478, P250, DOI 10.1038/nature10434; Laurence M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097876; Laute-Caly DL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36926-8; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Lee JA, 2021, CANCER IMMUNOL IMMUN, V70, P47, DOI 10.1007/s00262-020-02657-x; Lee KA, 2022, NAT MED, V28, P535, DOI 10.1038/s41591-022-01695-5; Legoux F, 2019, SCIENCE, V366, P494, DOI 10.1126/science.aaw2719; Lei JY, 2020, NEW ENGL J MED, V383, P1340, DOI 10.1056/NEJMoa1917338; Lemon KP, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004183; Levesque S, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1657375; Ling ZX, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00533; Liou JM, 2020, GUT, V69, P2093, DOI 10.1136/gutjnl-2020-322368; Liu D, 2019, NAT MED, V25, P1916, DOI 10.1038/s41591-019-0654-5; Lopes A, 2020, INT J CANCER, V146, P3147, DOI 10.1002/ijc.32920; Lynch SV, 2016, NEW ENGL J MED, V375, P2369, DOI 10.1056/NEJMra1600266; Ma B, 2012, ANNU REV MICROBIOL, V66, P371, DOI 10.1146/annurev-micro-092611-150157; Ma C, 2018, SCIENCE, V360, DOI 10.1126/science.aan5931; Maddocks ODK, 2013, MBIO, V4, DOI 10.1128/mBio.00152-13; Mager LF, 2020, SCIENCE, V369, P1481, DOI 10.1126/science.abc3421; Maisonneuve C, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2020.108677; Maleki S, 2020, J IMMUNOTHER CANCER, V8, pA11, DOI 10.1136/LBA2019.17; Mallick H, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10927-1; Mao JZ, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-003334; Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290; Mazmanian SK, 2005, CELL, V122, P107, DOI 10.1016/j.cell.2005.05.007; McQuade JL, 2019, LANCET ONCOL, V20, pE77, DOI 10.1016/S1470-2045(18)30952-5; Menzel A, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10030414; Mima K, 2015, JAMA ONCOL, V1, P653, DOI 10.1001/jamaoncol.2015.1377; Mitra A, 2020, INT J RADIAT ONCOL, V107, P163, DOI 10.1016/j.ijrobp.2019.12.040; Morad G, 2021, CELL, V184, P5309, DOI 10.1016/j.cell.2021.09.020; Moss EL, 2020, NAT BIOTECHNOL, V38, P701, DOI 10.1038/s41587-020-0422-6; Neish AS, 2009, GASTROENTEROLOGY, V136, P65, DOI 10.1053/j.gastro.2008.10.080; Nejman D, 2020, SCIENCE, V368, P973, DOI 10.1126/science.aay9189; Nenclares P, 2020, EUR J CANCER, V131, P9, DOI 10.1016/j.ejca.2020.02.047; Nixon AB, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0799-2; O'Dwyer DN, 2016, J IMMUNOL, V196, P4839, DOI 10.4049/jimmunol.1600279; Oliva M, 2019, ANN ONCOL, V30, P57, DOI 10.1093/annonc/mdy507; Overacre-Delgoffe AE, 2021, IMMUNITY, V54, P2812, DOI 10.1016/j.immuni.2021.11.003; Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901; Pabst O, 2006, J IMMUNOL, V177, P6824, DOI 10.4049/jimmunol.177.10.6824; Peng Z, 2020, CANCER IMMUNOL RES, V8, P1251, DOI 10.1158/2326-6066.CIR-19-1014; Pernigoni N, 2021, SCIENCE, V374, P216, DOI 10.1126/science.abf8403; Petitprez F, 2020, NATURE, V577, P556, DOI 10.1038/s41586-019-1906-8; Pflug N, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1150399; Pflughoeft KJ, 2012, ANNU REV PATHOL-MECH, V7, P99, DOI 10.1146/annurev-pathol-011811-132421; Pietrocola F, 2016, CANCER CELL, V30, P147, DOI 10.1016/j.ccell.2016.05.016; Plovier H, 2017, NAT MED, V23, P107, DOI 10.1038/nm.4236; Pomatto-Watson LCD, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26431-4; Poore GD, 2020, NATURE, V579, P567, DOI 10.1038/s41586-020-2095-1; Pushalkar S, 2018, CANCER DISCOV, V8, P403, DOI 10.1158/2159-8290.CD-17-1134; Rasmussen TS, 2020, FEMS MICROBIOL REV, V44, P507, DOI 10.1093/femsre/fuaa020; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Rha S.Y., 2020, CANCER RES, V80, pCT121, DOI 10.1158/1538-7445.AM2020-CT121; Rini BI, 2019, NEW ENGL J MED, V380, P1116, DOI 10.1056/NEJMoa1816714; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Roberti MP, 2020, NAT MED, V26, P919, DOI 10.1038/s41591-020-0882-8; Roberts NJ, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008982; Rojo D, 2015, SCI REP-UK, V5, DOI 10.1038/srep08310; ROOK G, 1992, NATURE, V357, P545, DOI 10.1038/357545a0; Rossi T, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165786; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Rubinstein MR, 2013, CELL HOST MICROBE, V14, P195, DOI 10.1016/j.chom.2013.07.012; Ruf B, 2021, CANCER IMMUNOL RES, V9, P1024, DOI 10.1158/2326-6066.CIR-20-0925; Safran H, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.e15072; Salgia NJ, 2020, EUR UROL, V78, P498, DOI 10.1016/j.eururo.2020.07.011; Sanders ME, 2019, NAT REV GASTRO HEPAT, V16, P605, DOI 10.1038/s41575-019-0173-3; Santos JC, 2017, MOL CARCINOGEN, V56, P1372, DOI 10.1002/mc.22590; Schommer NN, 2013, TRENDS MICROBIOL, V21, P660, DOI 10.1016/j.tim.2013.10.001; Scott KP, 2014, FEMS MICROBIOL ECOL, V87, P30, DOI 10.1111/1574-6941.12186; Sedighi M, 2019, CANCER MED-US, V8, P3167, DOI 10.1002/cam4.2148; Seifert L, 2016, NATURE, V532, P245, DOI 10.1038/nature17403; Selle K, 2020, MBIO, V11, DOI 10.1128/mBio.00019-20; Sender R, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002533; Sepich-Poore GD, 2021, SCIENCE, V371, P1331, DOI 10.1126/science.abc4552; Serpas V, 2020, J CLIN ONCOL, V38; Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017; Shi YY, 2020, J EXP MED, V217, DOI 10.1084/jem.20192282; Singh N, 2014, IMMUNITY, V40, P128, DOI 10.1016/j.immuni.2013.12.007; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Spencer CN, 2021, SCIENCE, V374, P1632, DOI 10.1126/science.aaz7015; Stylianopoulos T, 2018, TRENDS CANCER, V4, P292, DOI 10.1016/j.trecan.2018.02.005; Suh Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.548; Tanoue T, 2019, NATURE, V565, P600, DOI 10.1038/s41586-019-0878-z; Temraz S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174155; Nguyen TT, 2017, J CELL BIOCHEM, V118, P2958, DOI 10.1002/jcb.25955; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; van Poelgeest MIE, 2016, CANCER IMMUNOL IMMUN, V65, P1451, DOI 10.1007/s00262-016-1892-8; van Zyl DG, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00104; Vemuri R, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8040483; Verma M, 2018, FRONT NUTR, V5, DOI 10.3389/fnut.2018.00117; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Viaud S, 2013, SCIENCE, V342, P971, DOI 10.1126/science.1240537; Vitiello GA, 2019, TRENDS CANCER, V5, P670, DOI 10.1016/j.trecan.2019.10.005; Wang AP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126312; Wang DD, 2021, NAT MED, V27, P333, DOI 10.1038/s41591-020-01223-3; Wang F, 2014, CANCER LETT, V345, P196, DOI 10.1016/j.canlet.2013.08.016; Wang F, 2018, P NATL ACAD SCI USA, V115, P157, DOI 10.1073/pnas.1712901115; Wang YT, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109516; Weber D, 2017, BIOL BLOOD MARROW TR, V23, P845, DOI 10.1016/j.bbmt.2017.02.006; Weber JS, 2015, LANCET ONCOL, V16, P375, DOI 10.1016/S1470-2045(15)70076-8; Westman EL, 2012, CHEM BIOL, V19, P1255, DOI 10.1016/j.chembiol.2012.08.011; Wieland A, 2021, NATURE, V597, P274, DOI 10.1038/s41586-020-2931-3; Xiao HW, 2020, MICROBIOME, V8, DOI 10.1186/s40168-020-00845-6; Yan A, 2018, ACS INFECT DIS, V4, P68, DOI 10.1021/acsinfecdis.7b00166; Yao L, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20200382; Yin HL, 2019, MED MICROBIOL IMMUN, V208, P573, DOI 10.1007/s00430-018-0570-1; Yonekura S, 2022, CANCER DISCOV, V12, P1128, DOI 10.1158/2159-8290.CD-21-0999; Yoon HS, 2021, NAT MICROBIOL, V6, P563, DOI 10.1038/s41564-021-00880-5; Yoshimoto S, 2013, NATURE, V499, P97, DOI 10.1038/nature12347; Young VB, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j831; Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008; Zeng T, 2021, J GASTROEN HEPATOL, V36, P832, DOI 10.1111/jgh.15503; Zhang H, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.694490; Zhao Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.678476; Zheng Y, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0650-9; Zierer J, 2018, NAT GENET, V50, P790, DOI 10.1038/s41588-018-0135-7	246	19	19	47	64	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4					690	703		10.1038/s41591-022-01779-2	http://dx.doi.org/10.1038/s41591-022-01779-2			14	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0Q6DV	35440726				2022-12-27	WOS:000785007700025
J	Ball, S; Borman, N				Ball, S; Borman, N			Pharmacogenetics and drug metabolism	NATURE BIOTECHNOLOGY			English	Editorial Material									NOVARTIS PHARMACEUT,GEN & EXPT TOXICOL,E HANOVER,NJ 07936	Novartis	Ball, S (corresponding author), WYETH AYERST RES,DRUG METABOLISM,CN 8000,PRINCETON,NJ 08543, USA.							BALL SE, 1995, DRUG CHEM TOXICOL, V18, P1, DOI 10.3109/01480549509017855; DALY AK, 1995, J MOL MED-JMM, V73, P539; IDLE JR, 1979, DRUG METAB REV, V9, P301, DOI 10.3109/03602537908993896; Nebert DW, 1997, AM J HUM GENET, V60, P265; Rendic S, 1997, DRUG METAB REV, V29, P413, DOI 10.3109/03602539709037591; 1996, NAT BIOTECHNOL, V14, P1516	6	10	10	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1997	15	10					925	926		10.1038/nbt1097-925	http://dx.doi.org/10.1038/nbt1097-925			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XZ285	9335033				2022-12-27	WOS:A1997XZ28500003
J	Ciapponi, L; Maione, D; Scoumanne, A; Costa, P; Hansen, MB; Svenson, M; Bendtzen, K; Alonzi, T; Paonessa, G; Cortese, R; Ciliberto, G; Savino, R				Ciapponi, L; Maione, D; Scoumanne, A; Costa, P; Hansen, MB; Svenson, M; Bendtzen, K; Alonzi, T; Paonessa, G; Cortese, R; Ciliberto, G; Savino, R			Induction of interleukin-6 (IL-6) autoantibodies through vaccination with an engineered IL-6 receptor antagonist	NATURE BIOTECHNOLOGY			English	Article						cytokine; receptor antagonist; autoimmunity; autoantibody	FACTOR-ALPHA CA2; RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODY; MULTIPLE-MYELOMA; TRANSGENIC MICE; CELLS; EXPRESSION; BINDING; PURIFICATION; THERAPY	Neutralization of cytokine activity by monoclonal antibodies or receptor antagonists is beneficial in the treatment of immune and neoplastic diseases, but the necessity for continuous parenteral delivery of these anticytokine agents poses considerable practical limitations. A viable alternative is to induce a neutralizing antibody response, Using transgenic mice with high circulating levels of human interleukin-6 (hIL-6), we show that injection of the hIL-6 receptor antagonist Sant1 (an IL-6 variant with seven amino-acid substitutions) induces a strong anti-hIL-antibody response. The elicited antibodies bind circulating hIL-6 with very high affinity, totally masking it, and neutralize hIL-6 bioactivity both in vitro and in vivo.	IRBM P ANGELETTI,I-00040 POMEZIA,ROME,ITALY; UNIV COPENHAGEN HOSP,RIGSHOSP,INST INFLAMMAT RES,DK-2100 COPENHAGEN,DENMARK; UNIV COPENHAGEN HOSP,RIGSHOSP,DEPT CLIN IMMUNOL,DK-2100 COPENHAGEN,DENMARK	Merck & Company; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen			Ciapponi, Laura/H-6867-2013; Ciliberto, Gennaro/J-4131-2017	Ciliberto, Gennaro/0000-0003-2851-8605; Savino, Rocco/0000-0002-4046-1472; CIAPPONI, LAURA/0000-0002-0817-1862				ALLEGRETTA M, 1986, J CLIN IMMUNOL, V6, P481, DOI 10.1007/BF00915254; ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; BATAILLE R, 1995, BLOOD, V86, P685, DOI 10.1182/blood.V86.2.685.bloodjournal862685; BRAKENHOFF JPJ, 1990, J IMMUNOL, V145, P561; BRAKENHOFF JPJ, 1994, J BIOL CHEM, V269, P86; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; DEBETS R, 1994, IMMUNOL TODAY, V15, P455, DOI 10.1016/0167-5699(94)90187-2; DIAMANT M, 1994, J IMMUNOL METHODS, V173, P229, DOI 10.1016/0022-1759(94)90301-8; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; ELLIOTT MJ, 1994, LANCET, V344, P1125, DOI 10.1016/S0140-6736(94)90632-7; FATTORI E, 1994, BLOOD, V83, P2570; Fattori E, 1995, EUR J NEUROSCI, V7, P2441, DOI 10.1111/j.1460-9568.1995.tb01042.x; Feldmann M, 1996, CELL, V85, P307, DOI 10.1016/S0092-8674(00)81109-5; GREGORY B, 1994, J IMMUNOL METHODS, V170, P47, DOI 10.1016/0022-1759(94)90244-5; HANSEN MB, 1995, BLOOD, V85, P1145, DOI 10.1182/blood.V85.4.1145.bloodjournal8541145; HANSEN MB, 1993, CYTOKINE, V5, P72, DOI 10.1016/1043-4666(93)90026-2; HANSEN MB, 1991, SCAND J IMMUNOL, V33, P777, DOI 10.1111/j.1365-3083.1991.tb02552.x; HANSEN MB, 1995, LEUKEMIA, V9, P1113; HANSEN MB, 1995, EUR J IMMUNOL, V25, P348, DOI 10.1002/eji.1830250207; HERCUS TR, 1994, P NATL ACAD SCI USA, V91, P5838, DOI 10.1073/pnas.91.13.5838; HILBERT DM, 1995, J EXP MED, V182, P243, DOI 10.1084/jem.182.1.243; HIRANO T, 1990, IMMUNOL TODAY, V11, P443, DOI 10.1016/0167-5699(90)90173-7; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; MONTEROJULIAN FA, 1995, BLOOD, V85, P917, DOI 10.1182/blood.V85.4.917.bloodjournal854917; POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460-2075.1994.tb06368.x; Poplonski L, 1996, EUR J IMMUNOL, V26, P601, DOI 10.1002/eji.1830260315; RONGHWA L, 1991, J EXP MED, V173, P1433; SAVINO R, 1994, EMBO J, V13, P5863, DOI 10.1002/j.1460-2075.1994.tb06931.x; SAVINO R, 1993, P NATL ACAD SCI USA, V90, P4067, DOI 10.1073/pnas.90.9.4067; Sporeno E, 1996, BLOOD, V87, P4510, DOI 10.1182/blood.V87.11.4510.bloodjournal87114510; SUZUKI H, 1992, EUR J IMMUNOL, V22, P1989, DOI 10.1002/eji.1830220806; SVENSON M, 1993, J CLIN INVEST, V92, P2533, DOI 10.1172/JCI116862; TTRIPATHY SK, 1996, NAT MED, V2, P545; VALLBRACHT A, 1981, NATURE, V289, P496, DOI 10.1038/289496a0	35	35	36	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1997	15	10					997	1001		10.1038/nbt1097-997	http://dx.doi.org/10.1038/nbt1097-997			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XZ285	9335053				2022-12-27	WOS:A1997XZ28500032
J	Nauta, A; vandenBurg, B; Karsens, H; Venema, G; Kok, J				Nauta, A; vandenBurg, B; Karsens, H; Venema, G; Kok, J			Design of thermolabile bacteriophage repressor mutants by comparative molecular modeling	NATURE BIOTECHNOLOGY			English	Article						protein design; lactococcal phage repressor; temperature-sensitive mutants	LAMBDA-REPRESSOR; LACTOCOCCUS-LACTIS; GENE-EXPRESSION; PROTEOLYTIC-ENZYMES; ESCHERICHIA-COLI; DNA; OPERATOR; CHEESE; RECOGNITION; PREDICTION	Comparative molecular modeling was performed with repressor protein Rro of the temperate Lactococcus lactis bacteriophage r1t using the known 3D-structures of related repressors in order to obtain thermolabile derivatives of Rro. Rro residues presumed to stabilize a nonhomologous but structurally conserved hydrophobic pocket, which was shown to be important for thermostability of the Escherichia coli bacteriophage lambda repressor Cl, were randomized. Of the derivatives that exhibited various temperature-sensitive phenotypes, one was shown to hold promise for both fundamental and industrial applications that require the controlled production of (heterologous) proteins in L. lactis.	UNIV GRONINGEN, DEPT GENET, GRONINGEN BIOMOL SCI & BIOTECHNOL INST, NL-9751 NN HAREN, NETHERLANDS	University of Groningen			Kok, Jan/C-9972-2012					AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; BEAMER LJ, 1992, J MOL BIOL, V227, P177, DOI 10.1016/0022-2836(92)90690-L; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; Crow VL, 1995, INT DAIRY J, V5, P855, DOI 10.1016/0958-6946(95)00036-4; deRuyter PGGA, 1996, APPL ENVIRON MICROB, V62, P3662, DOI 10.1128/AEM.62.10.3662-3667.1996; Fox PF, 1996, ANTON LEEUW INT J G, V70, P271, DOI 10.1007/BF00395937; HECHT MH, 1984, P NATL ACAD SCI-BIOL, V81, P5685, DOI 10.1073/pnas.81.18.5685; Hendrix R. W, 1983, LAMBDA, VII; KOK J, 1993, J DAIRY SCI, V76, P2056, DOI 10.3168/jds.S0022-0302(93)77540-2; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leenhouts K, 1993, PLASMIDS PRACTICAL A, P65; LIEB M, 1981, MOL GEN GENET, V184, P364, DOI 10.1007/BF00352506; LITTLE JW, 1993, J BACTERIOL, V175, P4943, DOI 10.1128/JB.175.16.4943-4950.1993; MANDEL M, 1970, J MOL BIOL, V53, P159, DOI 10.1016/0022-2836(70)90051-3; Nauta A, 1996, MOL MICROBIOL, V19, P1331, DOI 10.1111/j.1365-2958.1996.tb02477.x; OSullivan DJ, 1996, BIO-TECHNOL, V14, P82, DOI 10.1038/nbt0196-82; PABO CO, 1979, P NATL ACAD SCI USA, V76, P1608, DOI 10.1073/pnas.76.4.1608; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PABO CO, 1982, NATURE, V298, P443, DOI 10.1038/298443a0; REIDHAAROLSON JF, 1990, PROTEINS, V7, P306, DOI 10.1002/prot.340070403; ROSENBERG M, 1983, METHOD ENZYMOL, V101, P123; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROTTLANDER E, 1970, MOL GEN GENET, V108, P47, DOI 10.1007/BF00343184; SHATZMAN AR, 1986, ANN NY ACAD SCI, V478, P233, DOI 10.1111/j.1749-6632.1986.tb15534.x; TERZAGHI BE, 1975, APPL MICROBIOL, V29, P807, DOI 10.1128/AEM.29.6.807-813.1975; VANROOIJEN RJ, 1992, J BACTERIOL, V174, P2273, DOI 10.1128/JB.174.7.2273-2280.1992; Varadarajan R, 1996, P NATL ACAD SCI USA, V93, P13908, DOI 10.1073/pnas.93.24.13908; VISSER S, 1993, J DAIRY SCI, V76, P329, DOI 10.3168/jds.S0022-0302(93)77354-3; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V	31	28	33	0	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1997	15	10					980	983		10.1038/nbt1097-980	http://dx.doi.org/10.1038/nbt1097-980			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XZ285	9335049	Green Published			2022-12-27	WOS:A1997XZ28500028
J	Roxas, VP; Smith, RK; Allen, ER; Allen, RD				Roxas, VP; Smith, RK; Allen, ER; Allen, RD			Overexpression of glutathione S-transferase glutathione peroxidase enhances the growth of transgenic tobacco seedlings during stress	NATURE BIOTECHNOLOGY			English	Article						agricultural biotechnology; plant stress; chilling; salinity	SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; REDUCTASE ACTIVITY; PLANTS; GENE; INDUCTION; HOMOLOGY	Transgenic tobacco seedlings that overexpress a cDNA encoding an enzyme with both glutathione S-transferase (GST) and glutathione peroxidase (GPX) activity had GST- and GPX-specific activities approximately twofold higher than wild-type seedlings. These GST/GPX overexpressing seedlings grew significantly faster than control seedlings when exposed to chilling or salt stress, During chilling stress, levels of oxidized glutathione (GSSG) were significantly higher in transgenic seedlings than in wild-types. Growth of wild-type seedlings was accelerated by treatment with GSSG, while treatment with reduced glutathione or other sulfhydryl-reducing agents inhibited growth, Therefore, overexpression of GST/GPX can stimulate seedling growth under chilling and salt stress, and this effect could be caused by oxidation of the glutathione pool.	TEXAS TECH UNIV,DEPT PLANT & SOIL SCI,LUBBOCK,TX 79409; TEXAS TECH UNIV,DEPT BIOL SCI,LUBBOCK,TX 79409	Texas Tech University System; Texas Tech University; Texas Tech University System; Texas Tech University								ALLEN RD, 1995, PLANT PHYSIOL, V107, P1; ALSCHER RG, 1989, PHYSIOL PLANTARUM, V77, P457, DOI 10.1111/j.1399-3054.1989.tb05667.x; AONO M, 1993, PLANT CELL PHYSIOL, V34, P129; BARTLING D, 1993, EUR J BIOCHEM, V216, P579, DOI 10.1111/j.1432-1033.1993.tb18177.x; BEEORTZAHAR T, 1995, FEBS LETT, V366, P151, DOI 10.1016/0014-5793(95)00521-A; BERHANE K, 1994, P NATL ACAD SCI USA, V91, P1480, DOI 10.1073/pnas.91.4.1480; BOWLER C, 1991, EMBO J, V10, P1723, DOI 10.1002/j.1460-2075.1991.tb07696.x; Brigellius R., 1985, OXIDATIVE STRESS, P243; BROADBENT P, 1995, PLANT J, V8, P247, DOI 10.1046/j.1365-313X.1995.08020247.x; COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605; CRIQUI MC, 1992, PLANT MOL BIOL, V18, P623, DOI 10.1007/BF00040684; DROOG FNJ, 1993, PLANT MOL BIOL, V21, P965, DOI 10.1007/BF00023595; FOYER C, 1991, PLANT PHYSIOL, V97, P863, DOI 10.1104/pp.97.3.863; FUERST EP, 1993, PLANT PHYSIOL, V102, P795, DOI 10.1104/pp.102.3.795; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; HABIG WH, 1981, METHOD ENZYMOL, V77, P735; Hatzios K. K., 1989, Crop safeners for herbicides: development, uses, and mechanisms of action., P65; HORSCH RB, 1985, SCIENCE, V227, P119; Lozano RM, 1996, PLANTA, V200, P100, DOI 10.1007/BF00196655; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MOZER TJ, 1983, BIOCHEMISTRY-US, V22, P1068, DOI 10.1021/bi00274a011; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; ROXAS VP, 1996, THESIS TEXAS TU LUBB; SENGUPTA A, 1993, PLANT PHYSIOL, V103, P1067, DOI 10.1104/pp.103.4.1067; TAKAHASHI Y, 1992, P NATL ACAD SCI USA, V89, P56, DOI 10.1073/pnas.89.1.56; Tappel A L, 1978, Methods Enzymol, V52, P506; ULMASOV T, 1995, PLANT PHYSIOL, V108, P919, DOI 10.1104/pp.108.3.919; VanCamp W, 1996, PLANT PHYSIOL, V112, P1703, DOI 10.1104/pp.112.4.1703; WEBB RW, 1995, THESIS TEXAS TU LUBB; WINGATE VPM, 1988, PLANT PHYSIOL, V87, P206, DOI 10.1104/pp.87.1.206; WOLIN MS, 1996, OXIDATIVE STRESS MOL, P21	31	400	443	2	40	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1997	15	10					988	991		10.1038/nbt1097-988	http://dx.doi.org/10.1038/nbt1097-988			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XZ285	9335051				2022-12-27	WOS:A1997XZ28500030
J	Ghetie, V; Popov, S; Borvak, J; Radu, C; Matesoi, D; Medesan, C; Ober, RJ; Ward, ES				Ghetie, V; Popov, S; Borvak, J; Radu, C; Matesoi, D; Medesan, C; Ober, RJ; Ward, ES			Increasing the serum persistence of an IgG fragment by random mutagenesis	NATURE BIOTECHNOLOGY			English	Article						antibody engineering; pharmacokinetics; phage display; surface plasmon resonance	NEONATAL FC RECEPTOR; IMMUNOGLOBULIN-G; ESCHERICHIA-COLI; BINDING-SITE; ANTIBODY; RAT; LOCALIZATION; PROTEINS; COMPLEX; FETAL	The major histocompatibility complex (MHC) class I-related receptor FcRn is involved in regulating serum gammaglobulin (IgG) levels in mice. With the aim of increasing the serum half-life of a recombinant murine Fc gamma 1 fragment, the affinity far binding to FcRn at pH 6.0 has been increased by random mutagenesis of Thr252, Thr254, and Thr256 followed by selection using bacteriophage display. These residues were chosen as they are in proximity to the FcRn-IgG (Fc) interaction site. Two mutants with higher affinity (due to lower off-rates) than the wild-type Fc have been isolated and analyzed in pharmacokinetic studies in mice. The mutant with the highest affinity has a significantly longer serum half-life than the wild type fragment, despite its lower off-rate from FcRn at pH 7.4. The results provide support for the involvement of FcRn in the homeostasis of serum IgGs in mice. The indications that a homologous FcRn regulates IgG levels in humans suggest that this approach has implications for increasing the serum persistence of therapeutic antibodies.	UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,CTR CANC IMMUNOBIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Radu, Caius/D-3936-2013	Radu, Caius/0000-0002-9338-5397; Ober, Raimund/0000-0002-1290-7430; Ward, E. Sally/0000-0003-3232-7238	NIAID NIH HHS [AI 39167] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039167] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMES GF, 1984, J BACTERIOL, V160, P1181, DOI 10.1128/JB.160.3.1181-1183.1984; BRAMBELL FW, 1964, NATURE, V203, P1352, DOI 10.1038/2031352a0; BURMEISTER WP, 1994, NATURE, V372, P379, DOI 10.1038/372379a0; DELSENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361; DUNCAN AR, 1988, NATURE, V332, P738, DOI 10.1038/332738a0; DUNCAN AR, 1988, NATURE, V332, P563, DOI 10.1038/332563a0; EDELMAN GM, 1969, P NATL ACAD SCI USA, V63, P78, DOI 10.1073/pnas.63.1.78; Ghetie V, 1996, EUR J IMMUNOL, V26, P690, DOI 10.1002/eji.1830260327; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; ISRAEL EJ, 1995, J IMMUNOL, V154, P6246; Israel EJ, 1996, IMMUNOLOGY, V89, P573, DOI 10.1046/j.1365-2567.1996.d01-775.x; Junghans RP, 1996, P NATL ACAD SCI USA, V93, P5512, DOI 10.1073/pnas.93.11.5512; Kabat EA, 1991, SEQUENCES PROTEINS I; KIM JK, 1994, EUR J IMMUNOL, V24, P2429, DOI 10.1002/eji.1830241025; KIM JK, 1994, EUR J IMMUNOL, V24, P542, DOI 10.1002/eji.1830240308; Kristoffersen EK, 1996, EUR J IMMUNOL, V26, P1668, DOI 10.1002/eji.1830260741; Leach JL, 1996, J IMMUNOL, V157, P3317; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; Medesan C, 1997, J IMMUNOL, V158, P2211; Medesan C, 1996, EUR J IMMUNOL, V26, P2533, DOI 10.1002/eji.1830261038; Popov S, 1996, MOL IMMUNOL, V33, P521, DOI 10.1016/0161-5890(96)00004-1; RAGHAVAN M, 1995, BIOCHEMISTRY-US, V34, P14649, DOI 10.1021/bi00045a005; ROBERTS DM, 1990, J CELL BIOL, V111, P1867, DOI 10.1083/jcb.111.5.1867; RODEWALD R, 1984, J CELL BIOL, V99; SARMAY G, 1992, MOL IMMUNOL, V29, P633, DOI 10.1016/0161-5890(92)90200-H; SIRNISTER NE, 1996, EUR J IMMUNOL, V26, P1527; STORY CM, 1994, J EXP MED, V180, P2377, DOI 10.1084/jem.180.6.2377; WALLACE KH, 1980, BIOCHEM J, V188, P9, DOI 10.1042/bj1880009; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0; WARD ES, 1992, J MOL BIOL, V224, P885, DOI 10.1016/0022-2836(92)90455-S; WARD ES, 1994, MOL IMMUNOL, V32, P147; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	33	191	374	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1997	15	7					637	640		10.1038/nbt0797-637	http://dx.doi.org/10.1038/nbt0797-637			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XH583	9219265				2022-12-27	WOS:A1997XH58300026
J	Wilkinson, JQ; Lanahan, MB; Clark, DG; Bleecker, AB; Chang, C; Meyerowitz, EM; Klee, HJ				Wilkinson, JQ; Lanahan, MB; Clark, DG; Bleecker, AB; Chang, C; Meyerowitz, EM; Klee, HJ			A dominant mutant receptor from Arabidopsis confers ethylene insensitivity in heterologous plants	NATURE BIOTECHNOLOGY			English	Article						ethylene; receptor; ripening; senescence; abscission	FIGWORT MOSAIC-VIRUS; NEVER-RIPE; ETR1 GENE; TOMATO; EXPRESSION; MUTATION	Ethylene (C2H4) is a gaseous hormone that affects many aspects of plant growth and development. Ethylene perception requires specific receptors and a signal transduction pathway to coordinate downstream responses. The etr1-1 gene of Arabidopsis encodes a mutated receptor that confers dominant ethylene insensitivity. Evidence is presented here that etr1-1 also causes significant delays in fruit. ripening, flower senescence, and flower abscission when expressed in tomato and petunia plants. The ability of etr1-1 to function in heterologous plants suggests that this pathway of hormone recognition and response is highly consented and can be manipulated.	UNIV FLORIDA,DEPT HORT SCI,GAINESVILLE,FL 32611; CALTECH,DIV BIOL 156 29,PASADENA,CA 91125; UNIV MARYLAND,DEPT PLANT BIOL,COLLEGE PK,MD 20742; UNIV WISCONSIN,DEPT BOT,MADISON,WI 53706; UNIV FLORIDA,DEPT ENVIRONM HORT,GAINESVILLE,FL 32611; MONSANTO CO,CEREGEN TECHNOL,CHESTERFIELD,MO 63198	State University System of Florida; University of Florida; California Institute of Technology; University System of Maryland; University of Maryland College Park; University of Wisconsin System; University of Wisconsin Madison; State University System of Florida; University of Florida; Monsanto			Meyerowitz, Elliot M/A-7118-2009; Klee, Harry/A-7912-2008					Abeles F, 1992, ETHYLENE PLANT BIOL; BARRY G, 1992, J CELL BIOCH SF, V16, P202; BLEECKER AB, 1988, SCIENCE, V241, P1086, DOI 10.1126/science.241.4869.1086; Bleecker AB, 1996, PLANT PHYSIOL, V111, P653, DOI 10.1104/pp.111.3.653; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; CLARK D, IN PRESS PLANT MOL B; ECKER JR, 1995, SCIENCE, V268, P667, DOI 10.1126/science.7732375; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; KLEE HJ, 1991, PLANT CELL, V3, P1187, DOI 10.1105/tpc.3.11.1187; LANAHAN MB, 1994, PLANT CELL, V6, P521, DOI 10.1105/tpc.6.4.521; MCCORMICK S, 1986, PLANT CELL REP, V5, P81, DOI 10.1007/BF00269239; RICHINS RD, 1987, NUCLEIC ACIDS RES, V15, P8451, DOI 10.1093/nar/15.20.8451; SANGER M, 1990, PLANT MOL BIOL, V14, P433, DOI 10.1007/BF00028779; SCHALLER GE, 1995, J BIOL CHEM, V270, P12526, DOI 10.1074/jbc.270.21.12526; SCHALLER GE, 1995, SCIENCE, V270, P1809, DOI 10.1126/science.270.5243.1809; SINGH A, 1992, PLANT PHYSIOL, V99, P38, DOI 10.1104/pp.99.1.38; TANG XY, 1994, PLANT CELL, V6, P1227, DOI 10.1105/tpc.6.9.1227; THEOLOGIS A, 1992, CELL, V70, P181, DOI 10.1016/0092-8674(92)90093-R; WILKINSON JQ, 1995, SCIENCE, V270, P1807, DOI 10.1126/science.270.5243.1807; YEN HC, 1995, PLANT PHYSIOL, V107, P1343, DOI 10.1104/pp.107.4.1343; ZAREMBINSKI TI, 1994, PLANT MOL BIOL, V26, P1579, DOI 10.1007/BF00016491	21	239	266	0	41	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1997	15	5					444	447		10.1038/nbt0597-444	http://dx.doi.org/10.1038/nbt0597-444			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WX237	9131623				2022-12-27	WOS:A1997WX23700028
J	Fender, P; Ruigrok, RWH; Gout, E; Buffet, S; Chroboczek, J				Fender, P; Ruigrok, RWH; Gout, E; Buffet, S; Chroboczek, J			Adenovirus dodecahedron, a new vector for human gene transfer	NATURE BIOTECHNOLOGY			English	Article						adenovirus penton; dodecahedron; gene therapy	PENTON BASE PROTEIN; CELLS; TYPE-2; FIBER; RELEASE; DNA; GENOME	Recombinant adenovirus is one of most efficient delivery vehicles for gene therapy. However, the initial enthusiasm for the use of recombinant adenovirus for gene therapy has been tempered by strong immune responses that develop to the virus and virus-infected cells. Even though recombinant adenoviruses are replication-defective, they introduce into the recipient cell, together with the gene of interest, viral genetes that might lead to fortuitous recombination if the recipient is infected by wild-type adenovirus, We propose the use of a dodecahedron made of adenovirus pentons or penton bases as an alternative vector for human gene therapy. The penton is a complex of two oligomeric proteins, a penton base and fiber, involved in the cell attachment, internalization, and liberation of virus into the cytoplasm, The dodecahedron retains many of the advantages of adenovirus for gene transfer such as efficiency of entry, efficient release of DNA from endosomes, and wide range of cell and tissue targets. Because it consists of only one or two adenovirus proteins instead of the 11 contained in an adenovirus virion and it does not contain the viral genome, it is potentially a safer alternative to recombinant adenovirus.	INST BIOL STRUCT,F-38027 GRENOBLE,FRANCE; EUROPEAN MOL BIOL LAB,GRENOBLE OUTSTN,F-38042 GRENOBLE 9,FRANCE	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); European Molecular Biology Laboratory (EMBL)			Chroboczek, Jadwiga/M-6554-2014	Fender, Pascal/0000-0002-6698-3367				BAI M, 1993, J VIROL, V67, P5198, DOI 10.1128/JVI.67.9.5198-5205.1993; BOUDIN ML, 1982, VIROLOGY, V116, P589, DOI 10.1016/0042-6822(82)90151-9; BOULANGER PA, 1976, INTERVIROLOGY, V7, P126, DOI 10.1159/000149946; CAILLETBOUDIN ML, 1989, J MOL BIOL, V208, P195, DOI 10.1016/0022-2836(89)90095-8; CHARDONN.Y, 1970, VIROLOGY, V40, P462, DOI 10.1016/0042-6822(70)90189-3; CHAUDHARY N, 1993, J CELL BIOL, V122, P295, DOI 10.1083/jcb.122.2.295; CUZANGE A, 1994, GENE, V146, P257, DOI 10.1016/0378-1119(94)90302-6; DEVAUX C, 1987, VIROLOGY, V161, P121, DOI 10.1016/0042-6822(87)90177-2; FITZGERALD DJP, 1983, P NATL ACAD SCI-BIOL, V80, P4134, DOI 10.1073/pnas.80.13.4134; FITZGERALD DJP, 1983, CELL, V32, P607, DOI 10.1016/0092-8674(83)90480-4; Gelderblom H, 1967, J Gen Virol, V1, P553, DOI 10.1099/0022-1317-1-4-553; Greber UF, 1996, EMBO J, V15, P1766, DOI 10.1002/j.1460-2075.1996.tb00525.x; GREBER UF, 1993, CELL, V75, P477, DOI 10.1016/0092-8674(93)90382-Z; GREBER UF, 1996, CELL, V15, P1766; HENRY L, 1994, J VIROL, V48, P5239; HONG SS, 1995, EMBO J, V14, P4714, DOI 10.1002/j.1460-2075.1995.tb00153.x; HORWITZ MS, 1990, VIROLOGY, P01679; KARAYAN L, 1994, VIROLOGY, V202, P782, DOI 10.1006/viro.1994.1400; KITTS PA, 1990, NUCLEIC ACIDS RES, V18, P5667, DOI 10.1093/nar/18.19.5667; Kochanek S, 1996, P NATL ACAD SCI USA, V93, P5731, DOI 10.1073/pnas.93.12.5731; LOUIS N, 1994, J VIROL, V68, P4104, DOI 10.1128/JVI.68.6.4104-4106.1994; LYON M, 1978, VIROLOGY, V87, P81, DOI 10.1016/0042-6822(78)90160-5; NORRBY E, 1969, J GEN VIROL, V5, P221, DOI 10.1099/0022-1317-5-2-221; NORRBY E, 1968, VIROLOGY, V36, P201, DOI 10.1016/0042-6822(68)90137-2; NORRBY E, 1964, VIROLOGY, V1, P236; PETTERSSON U, 1973, J MOL BIOL, V73, P125, DOI 10.1016/0022-2836(73)90164-2; PHILIPSON L, 1968, J VIROL, V2, P1064, DOI 10.1128/JVI.2.10.1064-1075.1968; Possee RD., 1992, BACULOVIRUS EXPRESSI; RUIGROK RWH, 1990, J MOL BIOL, V215, P289; SCHOEHN G, IN PRESS EMBO J; SETH P, 1994, J VIROL, V68, P1204, DOI 10.1128/JVI.68.2.1204-1206.1994; SIGNAS C, 1985, J VIROL, V53, P672; STEWART PL, 1991, CELL, V67, P145, DOI 10.1016/0092-8674(91)90578-M; VANOOSTRUM J, 1985, J VIROL, V56, P439, DOI 10.1128/JVI.56.2.439-448.1985; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; WOHLFART C, 1988, J VIROL, V62, P2321, DOI 10.1128/JVI.62.7.2321-2328.1988; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995; YOSHIMURA K, 1993, J BIOL CHEM, V268, P2300	38	123	130	1	15	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1997	15	1					52	56		10.1038/nbt0197-52	http://dx.doi.org/10.1038/nbt0197-52			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WA729	9035106				2022-12-27	WOS:A1997WA72900023
J	Hoyle, R				Hoyle, R			Commissioner Kessler's agbio legacy	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	0	0	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1997	15	1					2	2		10.1038/nbt0197-2	http://dx.doi.org/10.1038/nbt0197-2			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WA729	9035091	Bronze			2022-12-27	WOS:A1997WA72900003
J	Stanaway, JD; Afshin, A; Ashbaugh, C; Bisignano, C; Brauer, M; Ferrara, G; Garcia, V; Haile, D; Hay, SI; He, JW; Iannucci, V; Lescinsky, H; Mullany, EC; Parent, MC; Serfes, AL; Sorensen, RJD; Aravkin, AY; Zheng, P; Murray, CJL				Stanaway, Jeffrey D.; Afshin, Ashkan; Ashbaugh, Charlie; Bisignano, Catherine; Brauer, Michael; Ferrara, Giannina; Garcia, Vanessa; Haile, Demewoz; Hay, Simon, I; He, Jiawei; Iannucci, Vincent; Lescinsky, Haley; Mullany, Erin C.; Parent, Marie C.; Serfes, Audrey L.; Sorensen, Reed J. D.; Aravkin, Aleksandr Y.; Zheng, Peng; Murray, Christopher J. L.			Health effects associated with vegetable consumption: a Burden of Proof study	NATURE MEDICINE			English	Article; Early Access							ISCHEMIC-HEART-DISEASE; SQUAMOUS-CELL CARCINOMA; ALL-CAUSE MORTALITY; CARDIOVASCULAR-DISEASE; DIETARY FIBER; ESOPHAGEAL CANCER; UNITED-STATES; RISK-FACTORS; PLANT FOODS; VITAMIN-C	Previous research suggests a protective effect of vegetable consumption against chronic disease, but the quality of evidence underlying those findings remains uncertain. We applied a Bayesian meta-regression tool to estimate the mean risk function and quantify the quality of evidence for associations between vegetable consumption and ischemic heart disease (IHD), ischemic stroke, hemorrhagic stroke, type 2 diabetes and esophageal cancer. Increasing from no vegetable consumption to the theoretical minimum risk exposure level (306-372 g daily) was associated with a 23.2% decline (95% uncertainty interval, including between-study heterogeneity: 16.4-29.4) in ischemic stroke risk; a 22.9% (13.6-31.3) decline in IHD risk; a 15.9% (1.7-28.1) decline in hemorrhagic stroke risk; a 28.5% (-0.02-51.4) decline in esophageal cancer risk; and a 26.1% (-3.6-48.3) decline in type 2 diabetes risk. We found statistically significant protective effects of vegetable consumption for ischemic stroke (three stars), IHD (two stars), hemorrhagic stroke (two stars) and esophageal cancer (two stars). Including between-study heterogeneity, we did not detect a significant association with type 2 diabetes, corresponding to a one-star rating. Although current evidence supports increased efforts and policies to promote vegetable consumption, remaining uncertainties suggest the need for continued research. A meta-analysis using the Burden of Proof function identified modest evidence supporting a protective role of vegetable consumption against ischemic heart disease, stroke and esophageal cancer but not type 2 diabetes.	[Stanaway, Jeffrey D.; Afshin, Ashkan; Ashbaugh, Charlie; Bisignano, Catherine; Brauer, Michael; Ferrara, Giannina; Garcia, Vanessa; Haile, Demewoz; Hay, Simon, I; He, Jiawei; Iannucci, Vincent; Lescinsky, Haley; Mullany, Erin C.; Parent, Marie C.; Serfes, Audrey L.; Sorensen, Reed J. D.; Aravkin, Aleksandr Y.; Zheng, Peng; Murray, Christopher J. L.] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA; [Stanaway, Jeffrey D.; Afshin, Ashkan; Brauer, Michael; Hay, Simon, I; He, Jiawei; Zheng, Peng; Murray, Christopher J. L.] Univ Washington, Sch Med, Dept Hlth Metr Sci, Seattle, WA 98195 USA; [Brauer, Michael] Univ British Columbia, Vancouver, BC, Canada; [Aravkin, Aleksandr Y.] Univ Washington, Dept Appl Math, Seattle, WA 98195 USA	Institute for Health Metrics & Evaluation; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of British Columbia; University of Washington; University of Washington Seattle	Stanaway, JD (corresponding author), Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA.; Stanaway, JD (corresponding author), Univ Washington, Sch Med, Dept Hlth Metr Sci, Seattle, WA 98195 USA.	stanaway@uw.edu	Hay, Simon Iain/F-8967-2015	Hay, Simon Iain/0000-0002-0611-7272; Haile, Demewoz/0000-0003-0047-4276; Stanaway, Jeffrey/0000-0003-2209-8478	Bill & Melinda Gates Foundation; Bloomberg Philanthropies; University of Melbourne; Queensland Department of Health, Australia; National Health and Medical Research Council, Australia; Public Health England; Cardiovascular Medical Research and Education Fund; National Institute on Aging of the National Institutes of Health (NIH) [P30AG047845]; National Institute of Mental Health of the NIH [R01MH110163]	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); Bloomberg Philanthropies; University of Melbourne(University of Melbourne); Queensland Department of Health, Australia; National Health and Medical Research Council, Australia(National Health and Medical Research Council (NHMRC) of Australia); Public Health England; Cardiovascular Medical Research and Education Fund; National Institute on Aging of the National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Institute of Mental Health of the NIH	Research reported in this publication was supported by the Bill & Melinda Gates Foundation; Bloomberg Philanthropies; the University of Melbourne; the Queensland Department of Health, Australia; the National Health and Medical Research Council, Australia; Public Health England; the Norwegian Institute of Public Health; St. Jude Children's Research Hospital; the Cardiovascular Medical Research and Education Fund; the National Institute on Aging of the National Institutes of Health (NIH; award P30AG047845); and the National Institute of Mental Health of the NIH (award R01MH110163). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders. The funders had no role in study design, data collection, data analysis, data interpretation, writing of the final report or the decision to publish.	Abbafati C, 2020, LANCET, V396, P1135, DOI 10.1016/S0140-6736(20)31404-5; Agudo A, 2005, MEASURING INTAKE FRU; Ahmed A, 2020, J NUTR SCI, V9, DOI 10.1017/jns.2020.7; [Anonymous], 2020, DIET GUID AM 2020 20; [Anonymous], 2003, DIET NUTR PREV CHRON; [Anonymous], EAT WHOL VEG FRUIT B; [Anonymous], 2018, REC PUBL HLTH POL IM; Aune D, 2017, INT J EPIDEMIOL, V46, P1029, DOI 10.1093/ije/dyw319; Barouti AA, 2022, EUR J NUTR, V61, P3175, DOI 10.1007/s00394-022-02871-6; Bazzano LA, 2008, DIABETES CARE, V31, P1311, DOI 10.2337/dc08-0080; Bechthold A, 2019, CRIT REV FOOD SCI, V59, P1071, DOI 10.1080/10408398.2017.1392288; Bhupathiraju SN, 2013, AM J CLIN NUTR, V98, P1514, DOI 10.3945/ajcn.113.066381; Chen GC, 2018, BRIT J NUTR, V119, P1057, DOI [10.1017/S0007114518000119, 10.1017/s0007114518000119]; Cooper AJ, 2012, EUR J CLIN NUTR, V66, P1082, DOI 10.1038/ejcn.2012.85; Crippa A, 2019, STAT METHODS MED RES, V28, P1579, DOI 10.1177/0962280218773122; Crippa A, 2016, J STAT SOFTW, V72, DOI 10.18637/jss.v072.c01; Dauchet L, 2010, EUR J CLIN NUTR, V64, P578, DOI 10.1038/ejcn.2010.46; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Freedman ND, 2007, INT J CANCER, V121, P2753, DOI 10.1002/ijc.22993; Gan Y, 2015, INT J CARDIOL, V183, P129, DOI 10.1016/j.ijcard.2015.01.077; Gonzalez CA, 2006, INT J CANCER, V118, P2559, DOI 10.1002/ijc.21678; Grosso G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183787; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Halvorsen Rine Elise, 2021, BMJ Nutr Prev Health, V4, P519, DOI 10.1136/bmjnph-2020-000218; Hansen L, 2010, BRIT J NUTR, V104, P248, DOI 10.1017/S0007114510000462; Hartling L, 2013, J CLIN EPIDEMIOL, V66, P982, DOI 10.1016/j.jclinepi.2013.03.003; He FJ, 2007, J HUM HYPERTENS, V21, P717, DOI 10.1038/sj.jhh.1002212; Hodge AM, 2004, DIABETES CARE, V27, P2701, DOI 10.2337/diacare.27.11.2701; Hu D, 2014, STROKE, V45, P1613, DOI 10.1161/STROKEAHA.114.004836; Johnsen SP, 2003, AM J CLIN NUTR, V78, P57, DOI 10.1093/ajcn/78.1.57; Joshipura KJ, 1999, JAMA-J AM MED ASSOC, V282, P1233, DOI 10.1001/jama.282.13.1233; Katz DL, 2019, BMC MED RES METHODOL, V19, DOI 10.1186/s12874-019-0811-z; KNEKT P, 1994, AM J EPIDEMIOL, V139, P1180, DOI 10.1093/oxfordjournals.aje.a116964; Kobylecki CJ, 2015, AM J CLIN NUTR, V101, P1135, DOI 10.3945/ajcn.114.104497; Kurotani K, 2013, BRIT J NUTR, V109, P709, DOI 10.1017/S0007114512001705; Larsson SC, 2009, EUR J CLIN NUTR, V63, P1016, DOI 10.1038/ejcn.2009.16; Larsson SC, 2013, ATHEROSCLEROSIS, V227, P147, DOI 10.1016/j.atherosclerosis.2012.12.022; Li BL, 2014, EUR J NUTR, V53, P1511, DOI 10.1007/s00394-014-0656-5; Liu J, 2013, INT J CANCER, V133, P473, DOI 10.1002/ijc.28024; Liu MY, 2021, CLIN NUTR, V40, P5710, DOI 10.1016/j.clnu.2021.10.003; Liu Q, 2009, COMPUT STAT DATA AN, V53, P4157, DOI 10.1016/j.csda.2009.05.001; Liu S, 2000, AM J CLIN NUTR, V72, P922; Liu SM, 2004, DIABETES CARE, V27, P2993, DOI 10.2337/diacare.27.12.2993; Mamluk L, 2017, EUR J CLIN NUTR, V71, P83, DOI 10.1038/ejcn.2016.143; Meyer KA, 2000, AM J CLIN NUTR, V71, P921; Miller V, 2017, LANCET, V390, P2037, DOI [10.1016/s0140-6736(17)32253-5, 10.1016/S0140-6736(17)32253-5]; Mizrahi A, 2009, BRIT J NUTR, V102, P1075, DOI 10.1017/S0007114509359097; Montonen J, 2005, EUR J CLIN NUTR, V59, P441, DOI 10.1038/sj.ejcn.1602094; Nagura J, 2009, BRIT J NUTR, V102, P285, DOI 10.1017/S0007114508143586; National Health Service, 2022, EATW GUID; Olsson K, 2021, BRIT J NUTR, V126, P1065, DOI 10.1017/S0007114520005140; Paeratakul S, 1998, EUR J CLIN NUTR, V52, P722, DOI 10.1038/sj.ejcn.1600633; Page MJ, 2021, BMJ-BRIT MED J, V372, DOI [10.1136/bmj.n71, 10.1016/j.ijsu.2021.105906]; Perez-Cornago A, 2021, INT J EPIDEMIOL, V50, P212, DOI 10.1093/ije/dyaa155; Pham TM, 2007, PREV MED, V44, P526, DOI 10.1016/j.ypmed.2007.02.016; Pietinen P, 1996, CIRCULATION, V94, P2720, DOI 10.1161/01.CIR.94.11.2720; Qiao YX, 2014, ETHNIC HEALTH, V19, P328, DOI 10.1080/13557858.2013.797322; Rayner J, 2020, NUTR METAB CARDIOVAS, V30, P400, DOI 10.1016/j.numecd.2019.11.001; Rebello SA, 2014, AM J CLIN NUTR, V100, P53, DOI 10.3945/ajcn.113.076273; Schwingshackl L, 2017, EUR J EPIDEMIOL, V32, P363, DOI 10.1007/s10654-017-0246-y; Schwingshackl L, 2016, ADV NUTR, V7, P994, DOI 10.3945/an.116.013052; Sharma S, 2014, J NUTR HEALTH AGING, V18, P573, DOI 10.1007/s12603-014-0010-x; Sheikh M, 2019, GASTROENTEROLOGY, V156, P1416, DOI 10.1053/j.gastro.2018.12.024; Sonestedt E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126104; Steevens J, 2011, INT J CANCER, V129, P2681, DOI 10.1002/ijc.25928; Steffen LM, 2003, AM J CLIN NUTR, V78, P383, DOI 10.1093/ajcn/78.3.383; Stefler D, 2016, EUR J PREV CARDIOL, V23, P493, DOI 10.1177/2047487315582320; Stevens GA, 2016, LANCET, V388, pE19, DOI 10.1016/S0140-6736(16)30388-9; Tognon G, 2014, BRIT J NUTR, V111, P151, DOI 10.1017/S0007114513001931; Tong TYN, 2020, EUR HEART J, V41, P2632, DOI 10.1093/eurheartj/ehaa007; Tran GD, 2005, INT J CANCER, V113, P456, DOI 10.1002/ijc.20616; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; Villegas R, 2008, J NUTR, V138, P574, DOI 10.1093/jn/138.3.574; Vingeliene S, 2017, ANN ONCOL, V28, P2409, DOI 10.1093/annonc/mdx338; Willett W, 2019, LANCET, V393, P447, DOI 10.1016/S0140-6736(18)31788-4; World Cancer Research Fund and American Institute for Cancer Research, 2007, FOOD NUTR PHYS ACT P; Yamaji T, 2008, INT J CANCER, V123, P1935, DOI 10.1002/ijc.23744; Yokoyama T, 2000, STROKE, V31, P2287, DOI 10.1161/01.STR.31.10.2287; Yoshizaki T, 2020, J EPIDEMIOL, V30, P37, DOI 10.2188/jea.JE20180130; Yu DX, 2014, BRIT J NUTR, V111, P353, DOI 10.1017/S0007114513002328; Zhang HY, 2021, AM J CLIN NUTR, V114, P1837, DOI 10.1093/ajcn/nqab261; Zhang YR, 2011, ARCH INTERN MED, V171, P1811, DOI 10.1001/archinternmed.2011.443; Zheng P, 2022, NAT MED, DOI 10.1038/s41591-022-01973-2; Zheng P, 2021, J COMPUT GRAPH STAT, V30, P544, DOI 10.1080/10618600.2020.1868303; Zurbau A, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.017728	85	2	2	5	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01970-5	http://dx.doi.org/10.1038/s41591-022-01970-5		OCT 2022	18	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	5E6IE	36216936	Green Published, hybrid			2022-12-27	WOS:000865725700010
J	Staffaroni, AM; Quintana, M; Wendelberger, B; Heuer, HW; Russell, LL; Cobigo, Y; Wolf, A; Goh, SYM; Petrucelli, L; Gendron, TF; Heller, C; Clark, AL; Taylor, JC; Wise, A; Ong, E; Forsberg, L; Brushaber, D; Rojas, JC; VandeVrede, L; Ljubenkov, P; Kramer, J; Casaletto, KB; Appleby, B; Bordelon, Y; Botha, H; Dickerson, BC; Domoto-Reilly, K; Fields, JA; Foroud, T; Gavrilova, R; Geschwind, D; Ghoshal, N; Goldman, J; Graff-Radford, J; Graff-Radford, N; Grossman, M; Hall, MGH; Hsiung, GY; Huey, ED; Irwin, D; Jones, DT; Kantarci, K; Kaufer, D; Knopman, D; Kremers, W; Lago, AL; Lapid, MI; Litvan, I; Lucente, D; Mackenzie, IR; Mendez, MF; Mester, C; Miller, BL; Onyike, CU; Rademakers, R; Ramanan, VK; Ramos, EM; Rao, M; Rascovsky, K; Rankin, KP; Roberson, ED; Savica, R; Tartaglia, MC; Weintraub, S; Wong, B; Cash, DM; Bouzigues, A; Swift, IJ; Peakman, G; Bocchetta, M; Todd, EG; Convery, RS; Rowe, JB; Borroni, B; Galimberti, D; Tiraboschi, P; Masellis, M; Finger, E; van Swieten, JC; Seelaar, H; Jiskoot, LC; Sorbi, S; Butler, CR; Graff, C; Gerhard, A; Langheinrich, T; Laforce, R; Sanchez-Valle, R; de Mendonca, A; Moreno, F; Synofzik, M; Vandenberghe, R; Ducharme, S; Le Ber, I; Levin, J; Danek, A; Otto, M; Pasquier, F; Santana, I; Kornak, J; Boeve, BF; Rosen, HJ; Rohrer, JD; Boxer, AL				Staffaroni, Adam M.; Quintana, Melanie; Wendelberger, Barbara; Heuer, Hilary W.; Russell, Lucy L.; Cobigo, Yann; Wolf, Amy; Goh, Sheng-Yang Matt; Petrucelli, Leonard; Gendron, Tania F.; Heller, Carolin; Clark, Annie L.; Taylor, Jack Carson; Wise, Amy; Ong, Elise; Forsberg, Leah; Brushaber, Danielle; Rojas, Julio C.; VandeVrede, Lawren; Ljubenkov, Peter; Kramer, Joel; Casaletto, Kaitlin B.; Appleby, Brian; Bordelon, Yvette; Botha, Hugo; Dickerson, Bradford C.; Domoto-Reilly, Kimiko; Fields, Julie A.; Foroud, Tatiana; Gavrilova, Ralitza; Geschwind, Daniel; Ghoshal, Nupur; Goldman, Jill; Graff-Radford, Jonathon; Graff-Radford, Neill; Grossman, Murray; Hall, Matthew G. H.; Hsiung, Ging-Yuek; Huey, Edward D.; Irwin, David; Jones, David T.; Kantarci, Kejal; Kaufer, Daniel; Knopman, David; Kremers, Walter; Lago, Argentina Lario; Lapid, Maria, I; Litvan, Irene; Lucente, Diane; Mackenzie, Ian R.; Mendez, Mario F.; Mester, Carly; Miller, Bruce L.; Onyike, Chiadi U.; Rademakers, Rosa; Ramanan, Vijay K.; Ramos, Eliana Marisa; Rao, Meghana; Rascovsky, Katya; Rankin, Katherine P.; Roberson, Erik D.; Savica, Rodolfo; Tartaglia, M. Carmela; Weintraub, Sandra; Wong, Bonnie; Cash, David M.; Bouzigues, Arabella; Swift, Imogen J.; Peakman, Georgia; Bocchetta, Martina; Todd, Emily G.; Convery, Rhian S.; Rowe, James B.; Borroni, Barbara; Galimberti, Daniela; Tiraboschi, Pietro; Masellis, Mario; Finger, Elizabeth; van Swieten, John C.; Seelaar, Harro; Jiskoot, Lize C.; Sorbi, Sandro; Butler, Chris R.; Graff, Caroline; Gerhard, Alexander; Langheinrich, Tobias; Laforce, Robert; Sanchez-Valle, Raquel; de Mendonca, Alexandre; Moreno, Fermin; Synofzik, Matthis; Vandenberghe, Rik; Ducharme, Simon; Le Ber, Isabelle; Levin, Johannes; Danek, Adrian; Otto, Markus; Pasquier, Florence; Santana, Isabel; Kornak, John; Boeve, Bradley F.; Rosen, Howard J.; Rohrer, Jonathan D.; Boxer, Adam L.		Frontotemporal Dementia Prevention	Temporal order of clinical and biomarker changes in familial frontotemporal dementia	NATURE MEDICINE			English	Article; Early Access							NEUROFILAMENT LIGHT; DISEASE PROGRESSION; LOBAR DEGENERATION; BRAIN ATROPHY; GENFI; TAU; MUTATION; MRI; PROGRANULIN; PROFILES	Unlike familial Alzheimer's disease, we have been unable to accurately predict symptom onset in presymptomatic familial frontotemporal dementia (f-FTD) mutation carriers, which is a major hurdle to designing disease prevention trials. We developed multimodal models for f-FTD disease progression and estimated clinical trial sample sizes in C9orf72, GRN and MAPT mutation carriers. Models included longitudinal clinical and neuropsychological scores, regional brain volumes and plasma neurofilament light chain (NfL) in 796 carriers and 412 noncarrier controls. We found that the temporal ordering of clinical and biomarker progression differed by genotype. In prevention-trial simulations using model-based patient selection, atrophy and NfL were the best endpoints, whereas clinical measures were potential endpoints in early symptomatic trials. f-FTD prevention trials are feasible but will likely require global recruitment efforts. These disease progression models will facilitate the planning of f-FTD clinical trials, including the selection of optimal endpoints and enrollment criteria to maximize power to detect treatment effects. Empirically based models of disease progression in familial frontotemporal dementia reveal the relative ordering of clinical, neuroimaging, and fluid biomarker changes and facilitate novel clinical trial designs	[Staffaroni, Adam M.; Heuer, Hilary W.; Cobigo, Yann; Wolf, Amy; Goh, Sheng-Yang Matt; Clark, Annie L.; Taylor, Jack Carson; Wise, Amy; Ong, Elise; Rojas, Julio C.; VandeVrede, Lawren; Ljubenkov, Peter; Kramer, Joel; Casaletto, Kaitlin B.; Hall, Matthew G. H.; Lago, Argentina Lario; Miller, Bruce L.; Rankin, Katherine P.; Rosen, Howard J.; Boxer, Adam L.] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, Weill Inst Neurosci, San Francisco, CA 94118 USA; [Quintana, Melanie; Wendelberger, Barbara] Berry Consultants, Austin, TX USA; [Russell, Lucy L.; Heller, Carolin; Cash, David M.; Bouzigues, Arabella; Swift, Imogen J.; Peakman, Georgia; Bocchetta, Martina; Todd, Emily G.; Convery, Rhian S.; Rohrer, Jonathan D.] UCL Queen Sq London, Dept Neurodegenerat Dis, Dementia Res Ctr, London, England; [Petrucelli, Leonard; Gendron, Tania F.; Rademakers, Rosa] Mayo Clin, Dept Neurosci, Jacksonville, FL USA; [Forsberg, Leah; Botha, Hugo; Gavrilova, Ralitza; Graff-Radford, Jonathon; Jones, David T.; Kantarci, Kejal; Knopman, David; Ramanan, Vijay K.; Rao, Meghana; Savica, Rodolfo; Boeve, Bradley F.] Mayo Clin, Dept Neurol, Rochester, MN USA; [Brushaber, Danielle; Kremers, Walter; Mester, Carly] Mayo Clin, Dept Quantitat Hlth Sci, Rochester, MN USA; [Appleby, Brian] Case Western Reserve Univ, Dept Neurol, Cleveland, OH 44106 USA; [Bordelon, Yvette; Geschwind, Daniel; Mendez, Mario F.; Ramos, Eliana Marisa] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA; [Dickerson, Bradford C.; Lucente, Diane; Wong, Bonnie] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Dickerson, Bradford C.; Lucente, Diane; Wong, Bonnie] Harvard Med Sch, Boston, MA 02115 USA; [Domoto-Reilly, Kimiko] Univ Washington, Dept Neurol, Seattle, WA USA; [Fields, Julie A.; Lapid, Maria, I] Mayo Clin, Dept Psychiat & Psychol, Rochester, MN USA; [Foroud, Tatiana] Indiana Univ Sch Med, Natl Centralized Repository Alzheimers, Indianapolis, IN 46202 USA; [Geschwind, Daniel] Univ Calif Los Angeles, David Geffen Sch Med, Inst Precis Hlth, Los Angeles, CA 90095 USA; [Ghoshal, Nupur] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Goldman, Jill; Huey, Edward D.] Columbia Univ, Dept Neurol, New York, NY USA; [Graff-Radford, Neill] Mayo Clin, Dept Neurol, Jacksonville, FL USA; [Grossman, Murray; Irwin, David; Rascovsky, Katya] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; [Hsiung, Ging-Yuek] Univ British Columbia, Div Neurol, Vancouver, BC, Canada; [Kaufer, Daniel] Univ N Carolina, Dept Neurol, Chapel Hill, NC USA; [Litvan, Irene] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; [Mackenzie, Ian R.] Univ British Columbia, Dept Pathol, Vancouver, BC, Canada; [Onyike, Chiadi U.] Johns Hopkins Univ, Dept Psychiat & Behav Sci, Baltimore, MD USA; [Rademakers, Rosa] VIB, VIB Ctr Mol Neurol, Appl & Translat Neurogen Grp, Antwerp, Belgium; [Rademakers, Rosa] Univ Antwerp, Dept Biomed Sci, Antwerp, Belgium; [Roberson, Erik D.] Univ Alabama Birmingham, Dept Neurol, UAB Stn, Birmingham, AL 35294 USA; [Tartaglia, M. Carmela] Univ Toronto, Tanz Ctr Res Neurodegenerat Dis, Div Neurol, Toronto, ON, Canada; [Weintraub, Sandra] Northwestern Univ, Dept Neurol, Chicago, IL 60611 USA; [Rowe, James B.] Univ Cambridge, Dept Clin Neurosci, Cambridge, England; [Rowe, James B.] Univ Cambridge, Cambridge Univ Hosp NHS Trust, Cambridge, England; [Rowe, James B.] Univ Cambridge, Med Res Council Cognit & Brain Sci Unit, Cambridge, England; [Borroni, Barbara] Univ Brescia, Ctr Neurodegenerat Disorders, Dept Clin & Expt Sci, Brescia, Italy; [Galimberti, Daniela] Univ Milan, Dept Biomed Surg & Dent Sci, Milan, Italy; [Galimberti, Daniela] Fdn IRCCS Ca Granda, Osped Maggiore Policlin, Milan, Italy; [Tiraboschi, Pietro] Fdn IRCCS Ist Neurol Carlo Besta, Milan, Italy; [Masellis, Mario] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Med, Div Neurol, Toronto, ON, Canada; [Masellis, Mario] Univ Toronto, Sunnybrook Res Inst, Hurvitz Brain Sci Program, Toronto, ON, Canada; [Finger, Elizabeth] Univ Western Ontario, Dept Clin Neurol Sci, London, ON, Canada; [van Swieten, John C.; Seelaar, Harro; Jiskoot, Lize C.] Erasmus MC, Dept Neurol, Rotterdam, Netherlands; [Sorbi, Sandro] Univ Florence, Dept Neurofarba, Florence, Italy; [Sorbi, Sandro] IRCCS Fdn Don Carlo Gnocchi, Florence, Italy; [Butler, Chris R.] Univ Oxford, Nuffield Dept Clin Neurosci, Med Sci Div, Oxford, England; [Butler, Chris R.] Imperial Coll London, Dept Brain Sci, London, England; [Graff, Caroline] Karolinska Inst, Ctr Alzheimer Res, Dept Neurobiol Care Sci & Soc, Div Neurogeriatr,Bioclinicum, Solna, Sweden; [Graff, Caroline] Karolinska Univ Hosp, Unit Hereditary Dementias, Theme Aging, Solna, Sweden; [Gerhard, Alexander; Langheinrich, Tobias] Univ Manchester, Wolfson Mol Imaging Ctr, Div Neurosci & Expt Psychol, Manchester, Lancs, England; [Gerhard, Alexander] Univ Med Essen, Ctr Translat Neuro & Behav Sci, Dept Geriatr Med, Essen, Germany; [Gerhard, Alexander] Univ Med Essen, Ctr Translat Neuro & Behav Sci, Dept Nucl Med, Essen, Germany; [Langheinrich, Tobias] Salford Royal NHS Fdn Trust, Manchester Ctr Clin Neurosci, Cerebral Funct Unit, Salford, Lancs, England; [Laforce, Robert] Univ Laval, CHU Quebec, Dept Sci Neurol, Clin Interdisciplinaire Memoire, Quebec City, PQ, Canada; [Laforce, Robert] Univ Laval, Fac Med, Quebec City, PQ, Canada; [Sanchez-Valle, Raquel] Univ Barcelona, Hosp Clin, Inst Invest Biomed August Pi I Sunyer, Neurol Serv,Alzheimers Dis & Other Cognit Disorde, Barcelona, Spain; [de Mendonca, Alexandre] Univ Lisbon, Fac Med, Lisbon, Portugal; [Moreno, Fermin] Donostia Univ Hosp, Dept Neurol, Cognit Disorders Unit, San Sebastian, Gipuzkoa, Spain; [Moreno, Fermin] Biodonostia Hlth Res Inst, Neurosci Area, San Sebastian, Gipuzkoa, Spain; [Synofzik, Matthis] Univ Tubingen, Hertie Inst Clin Brain Res, Dept Neurodegenerat Dis, Tubingen, Germany; [Synofzik, Matthis] Univ Tubingen, Ctr Neurol, Tubingen, Germany; [Synofzik, Matthis] Ctr Neurodegenerat Dis DZNE, Tubingen, Germany; [Vandenberghe, Rik] Katholieke Univ Leuven, Lab Cognit Neurol, Dept Neurosci, Leuven, Belgium; [Vandenberghe, Rik] Univ Hosp Leuven, Neurol Serv, Leuven, Belgium; [Vandenberghe, Rik] Katholieke Univ Leuven, Leuven Brain Inst, Leuven, Belgium; [Ducharme, Simon] McGill Univ, Douglas Mental Hlth Univ Inst, Dept Psychiat, Montreal, PQ, Canada; [Ducharme, Simon] McGill Univ, McConnell Brain Imaging Ctr, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ, Canada; [Le Ber, Isabelle] Sorbonne Univ, Hop Pitie Salpetriere, AP HP,Paris Brain Inst, Inserm U1127,CNRS UMR 7225,Inst Cerveau ICM, Paris, France; [Le Ber, Isabelle] Hop La Pitie Salpetriere, AP HP, Dept Neurol, Ctr Reference Demences Rares Precoces,IM2A, Paris, France; [Le Ber, Isabelle] Hop La Pitie Salpetriere, AP HP, Dept Neurol, Paris, France; [Levin, Johannes; Danek, Adrian] Ludwig Maximilians Univ Munchen, Neurol Klin & Poliklin, Munich, Germany; [Levin, Johannes] Ctr Neurodegenerat Dis DZNE, Munich, Germany; [Levin, Johannes] Munich Cluster Syst Neurol, Munich, Germany; [Otto, Markus] Univ Ulm, Dept Neurol, Ulm, Germany; [Pasquier, Florence] Univ Lille, Lille, France; [Pasquier, Florence] INSERM, Lille, France; [Pasquier, Florence] CHU, Labex Distalz, CNR MAJ, LiCEND Lille, Lille, France; [Santana, Isabel] Univ Coimbra, Univ Hosp Coimbra HUC, Fac Med, Neurol Serv, Coimbra, Portugal; [Santana, Isabel] Univ Coimbra, Fac Med, Ctr Neurosci & Cell Biol, Coimbra, Portugal; [Kornak, John] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA	University of California System; University of California San Francisco; University of London; University College London; Mayo Clinic; Mayo Clinic; Mayo Clinic; Case Western Reserve University; University of California System; University of California Los Angeles; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Washington; University of Washington Seattle; Mayo Clinic; Indiana University System; Indiana University Bloomington; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Washington University (WUSTL); Columbia University; Mayo Clinic; University of Pennsylvania; University of British Columbia; University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California San Diego; University of British Columbia; Johns Hopkins University; Flanders Institute for Biotechnology (VIB); University of Antwerp; University of Alabama System; University of Alabama Birmingham; University of Toronto; Northwestern University; University of Cambridge; University of Cambridge; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Cambridge; University of Brescia; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Istituto Neurologico Besta; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Western University (University of Western Ontario); Erasmus University Rotterdam; Erasmus MC; University of Florence; IRCCS Fondazione Don Carlo Gnocchi Onlus; University of Oxford; Imperial College London; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; University of Manchester; Salford Royal NHS Foundation Trust; Laval University; Laval University; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Universidade de Lisboa; University Hospital Donostia; Instituto de Investigacion Sanitaria Biodonostia; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); Eberhard Karls University of Tubingen; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); KU Leuven; KU Leuven; University Hospital Leuven; KU Leuven; McGill University; McGill University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); Ulm University; Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universidade de Coimbra; Universidade de Coimbra; University of California System; University of California San Francisco	Staffaroni, AM; Boxer, AL (corresponding author), Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, Weill Inst Neurosci, San Francisco, CA 94118 USA.	adam.staffaroni@ucsf.edu; adam.boxer@ucsf.edu	PRIONI, SARA/ABR-1748-2022; Otto, Markus/F-4304-2015; Levin, Johannes/E-4052-2010; Galimberti, Daniela/K-6542-2016; Bocchetta, Martina/B-6331-2013	PRIONI, SARA/0000-0001-9632-0591; Otto, Markus/0000-0003-4273-4267; Cobigo, Yann/0000-0002-0354-4092; Levin, Johannes/0000-0001-5092-4306; Wendelberger, Barbara/0000-0003-4426-9602; Greaves, Caroline/0000-0002-6446-1960; Todd, Emily G/0000-0003-1551-5691; Galimberti, Daniela/0000-0002-9284-5953; Bouzigues, Arabella/0000-0002-0267-8590; Bocchetta, Martina/0000-0003-1814-5024	ALLFTD Consortium (National Institute on Aging) [U19: AG063911]; ALLFTD Consortium (National Institute of Neurological Diseases and Stroke) [U19: AG063911]; ARTFL Consortia (National Institute of Neurological Diseases and Stroke) [ARTFL: U54 NS092089]; ARTFL Consortia (National Center for Advancing Translational Sciences) [ARTFL: U54 NS092089]; LEFFTDS Consortia (National Institute on Aging) [LEFFTDS: U01 AG045390]; LEFFTDS Consortia (National Institute of Neurological Diseases and Stroke) [LEFFTDS: U01 AG045390]; Association for Frontotemporal Degeneration (FTD Biomarkers Initiative); Bluefield Project to Cure FTD; Larry L. Hillblom Foundation [2018-A-025-FEL]; National Institutes of Health [AG038791, AG032306, AG016976, AG062677, AG019724, AG058233, AG072122, P30 AG062422, K12 HD001459, K23AG061253, AG062422, K24AG045333]; Rainwater Charitable Foundation; National Institute on Aging (NIA) [U24 AG021886]; Medical Research Council UK GENFI grant [MR/M023664/1]; Bluefield Project; National Institute for Health Research; JPND GENFI-PROX grant [2019-02248]; European Reference Network for Rare Neurologic Diseases [739510]; National Institute for Health and Care Research (NIHR) UCL/H Biomedical Research Centre; Leonard Wolfson Experimental Neurology Centre Clinical Research Facility; UK Dementia Research Institute from UK DRI Ltd - UK Medical Research Council; Alzheimer's Society; Alzheimer's Research UK; Miriam Marks Brain Research UK Senior Fellowship; MRC Clinician Scientist Fellowship [MR/M008525/1]; NIHR Rare Disease Translational Research Collaboration [BRC149/NS/MH]; Alzheimer's Society, UK [AS-JF-19a-004-517]; Frontotemporal Dementia Research Studentships in Memory of David Blechner through The National Brain Appeal [RCN 290173]; NIHR Cambridge Biomedical Research Centre [BRC-1215-20014]; Wellcome Trust [220258]; Cambridge Centre for Parkinson-plus; Medical Research Council [SUAG/092 G116768]; ANR-PRTS PREV-DemAls; PHRC PREDICT-PGRN; European Reference Network for Rare Neurological Diseases [739510]; Deutsche Forschungsgemeinschaft (German Research Foundation) under Germany's Excellence Strategy [EXC 2145 SyNergy, 390857198]; Instituto de Salud Carlos III, Spain [PI20/00448]; Fundacio Marato TV3, Spain [20143810]; UK Medical Research Council; Italian Ministry of Health; Canadian Institutes of Health Research as part of a Centres of Excellence in Neurodegeneration grant; Canadian Institutes of Health Research [MOP- 371851, PJT-175242]; Weston Brain Institute; Canadian Institutes of Health Research; Chaire de Recherche sur les Aphasies Primaires Progressives Fondation Famille Lemaire; Swedish Frontotemporal Dementia Initiative Schorling Foundation; Swedish Research Council; JPND Prefrontals [2015-02926, 2018-02754]; Swedish Alzheimer Foundation; Swedish Brain Foundation; Karolinska Institutet Doctoral Funding; KI Strat-Neuro; Swedish Dementia Foundation; Stockholm County Council ALF/Region Stockholm; Germany's Excellence Strategy (German Research Foundation) [EXC 2145 Synergy 390857198]; Brain Research UK; Wolfson Foundation; National Institute for Health Research UCL/H Biomedical Research Centre	ALLFTD Consortium (National Institute on Aging); ALLFTD Consortium (National Institute of Neurological Diseases and Stroke); ARTFL Consortia (National Institute of Neurological Diseases and Stroke); ARTFL Consortia (National Center for Advancing Translational Sciences); LEFFTDS Consortia (National Institute on Aging); LEFFTDS Consortia (National Institute of Neurological Diseases and Stroke); Association for Frontotemporal Degeneration (FTD Biomarkers Initiative); Bluefield Project to Cure FTD; Larry L. Hillblom Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Rainwater Charitable Foundation; National Institute on Aging (NIA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Medical Research Council UK GENFI grant(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Bluefield Project; National Institute for Health Research(National Institute for Health Research (NIHR)); JPND GENFI-PROX grant; European Reference Network for Rare Neurologic Diseases; National Institute for Health and Care Research (NIHR) UCL/H Biomedical Research Centre; Leonard Wolfson Experimental Neurology Centre Clinical Research Facility; UK Dementia Research Institute from UK DRI Ltd - UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Alzheimer's Society; Alzheimer's Research UK(Alzheimer's Research UK (ARUK)); Miriam Marks Brain Research UK Senior Fellowship; MRC Clinician Scientist Fellowship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIHR Rare Disease Translational Research Collaboration; Alzheimer's Society, UK; Frontotemporal Dementia Research Studentships in Memory of David Blechner through The National Brain Appeal; NIHR Cambridge Biomedical Research Centre(National Institute for Health Research (NIHR)); Wellcome Trust(Wellcome Trust); Cambridge Centre for Parkinson-plus; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); ANR-PRTS PREV-DemAls; PHRC PREDICT-PGRN; European Reference Network for Rare Neurological Diseases; Deutsche Forschungsgemeinschaft (German Research Foundation) under Germany's Excellence Strategy(German Research Foundation (DFG)); Instituto de Salud Carlos III, Spain(Instituto de Salud Carlos III); Fundacio Marato TV3, Spain; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Italian Ministry of Health(Ministry of Health, Italy); Canadian Institutes of Health Research as part of a Centres of Excellence in Neurodegeneration grant(Canadian Institutes of Health Research (CIHR)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Weston Brain Institute; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Chaire de Recherche sur les Aphasies Primaires Progressives Fondation Famille Lemaire; Swedish Frontotemporal Dementia Initiative Schorling Foundation; Swedish Research Council(Swedish Research CouncilEuropean Commission); JPND Prefrontals; Swedish Alzheimer Foundation; Swedish Brain Foundation; Karolinska Institutet Doctoral Funding; KI Strat-Neuro; Swedish Dementia Foundation; Stockholm County Council ALF/Region Stockholm; Germany's Excellence Strategy (German Research Foundation)(German Research Foundation (DFG)); Brain Research UK; Wolfson Foundation; National Institute for Health Research UCL/H Biomedical Research Centre	Data collection and dissemination of the data presented in this paper were supported by the ALLFTD Consortium (U19: AG063911, funded by the National Institute on Aging and the National Institute of Neurological Diseases and Stroke) and the former ARTFL and LEFFTDS Consortia (ARTFL: U54 NS092089, funded by the National Institute of Neurological Diseases and Stroke and National Center for Advancing Translational Sciences; LEFFTDS: U01 AG045390, funded by the National Institute on Aging and the National Institute of Neurological Diseases and Stroke). The manuscript was reviewed by the ALLFTD Executive Committee for scientific content. The authors acknowledge the invaluable contributions of the study participants and families as well as the assistance of the support staffs at each of the participating sites. This work is also supported by the Association for Frontotemporal Degeneration (including the FTD Biomarkers Initiative), the Bluefield Project to Cure FTD, Larry L. Hillblom Foundation (2018-A-025-FEL (A.M.S.)), the National Institutes of Health (AG038791 (A.L.B.), AG032306 (H.J.R.), AG016976 (W.K.), AG062677 (Ron C. Peterson), AG019724 (B.L.M.), AG058233 (Suzee E. Lee), AG072122 (Walter Kukull), P30 AG062422 (B.L.M.), K12 HD001459 (N.G.), K23AG061253 (A.M.S.), AG062422 (RCP), K24AG045333 (H.J.R.)) and the Rainwater Charitable Foundation. Samples from the National Centralized Repository for Alzheimer Disease and Related Dementias (NCRAD), which receives government support under a cooperative agreement grant (U24 AG021886 (T.F.)) awarded by the National Institute on Aging (NIA), were used in this study. This work was also supported by Medical Research Council UK GENFI grant MR/M023664/1 (J.D.R.), the Bluefield Project, the National Institute for Health Research including awards to Cambridge and UCL Biomedical Research Centres and a JPND GENFI-PROX grant (2019-02248). Several authors of this publication are members of the European Reference Network for Rare Neurologic Diseases, project 739510. J.D.R. and L.L.R. are also supported by the National Institute for Health and Care Research (NIHR) UCL/H Biomedical Research Centre, the Leonard Wolfson Experimental Neurology Centre Clinical Research Facility and the UK Dementia Research Institute, which receives its funding from UK DRI Ltd, funded by the UK Medical Research Council, Alzheimer's Society and Alzheimer's Research UK. J.D.R. is also supported by the Miriam Marks Brain Research UK Senior Fellowship and has received funding from an MRC Clinician Scientist Fellowship (MR/M008525/1) and the NIHR Rare Disease Translational Research Collaboration (BRC149/NS/MH). M.B. is supported by a Fellowship award from the Alzheimer's Society, UK (AS-JF-19a-004-517). RC and C.G. are supported by a Frontotemporal Dementia Research Studentships in Memory of David Blechner funded through The National Brain Appeal (RCN 290173). J.B.R. is supported by NIHR Cambridge Biomedical Research Centre (BRC-1215-20014; the views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care), the Wellcome Trust (220258), the Cambridge Centre for Parkinson-plus and the Medical Research Council (SUAG/092 G116768); I.L.B. is supported by ANR-PRTS PREV-DemAls, PHRC PREDICT-PGRN, and several authors of this publication are members of the European Reference Network for Rare Neurological Diseases (project 739510). J.L.; is funded by the Deutsche Forschungsgemeinschaft (German Research Foundation) under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (EXC 2145 SyNergy - ID 390857198). R.S.-V. was funded at the Hospital Clinic de Barcelona by Instituto de Salud Carlos III, Spain (grant code PI20/00448 to RSV) and Fundacio Marato TV3, Spain (grant code 20143810 to R.S.-V.). M.M. was, in part, funded by the UK Medical Research Council, the Italian Ministry of Health and the Canadian Institutes of Health Research as part of a Centres of Excellence in Neurodegeneration grant, by Canadian Institutes of Health Research operating grants (MOP- 371851 and PJT-175242) and by funding from the Weston Brain Institute. R.L. is supported by the Canadian Institutes of Health Research and the Chaire de Recherche sur les Aphasies Primaires Progressives Fondation Famille Lemaire. C.G. is supported by the Swedish Frontotemporal Dementia Initiative Schorling Foundation, Swedish Research Council, JPND Prefrontals, 2015-02926,2018-02754, Swedish Alzheimer Foundation, Swedish Brain Foundation, Karolinska Institutet Doctoral Funding, KI Strat-Neuro, Swedish Dementia Foundation, and Stockholm County Council ALF/Region Stockholm. J.L. is supported by Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology (German Research Foundation, EXC 2145 Synergy 390857198). The Dementia Research Centre is supported by Alzheimer's Research UK, Alzheimer's Society, Brain Research UK, and The Wolfson Foundation. This work was supported by the National Institute for Health Research UCL/H Biomedical Research Centre, the Leonard Wolfson Experimental Neurology Centre Clinical Research Facility and the UK Dementia Research Institute, which receives its funding from UK DRI Ltd, funded by the UK Medical Research Council, Alzheimer's Society, and Alzheimer's Research UK.	Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Ashburner J, 2011, NEUROIMAGE, V55, P954, DOI 10.1016/j.neuroimage.2010.12.049; Barker MS, 2021, CORTEX, V139, P99, DOI 10.1016/j.cortex.2021.03.006; Bateman RJ, 2017, ALZHEIMERS DEMENT, V13, P8, DOI 10.1016/j.jalz.2016.07.005; Bateman RJ, 2012, NEW ENGL J MED, V367, P795, DOI 10.1056/NEJMoa1202753; Bocchetta M, 2021, NEUROIMAGE-CLIN, V30, DOI 10.1016/j.nicl.2021.102646; Bocchetta M, 2018, NEUROIMAGE-CLIN, V18, P675, DOI 10.1016/j.nicl.2018.02.019; Boeve B, 2020, ALZHEIMERS DEMENT, V16, P22, DOI 10.1016/j.jalz.2019.06.4947; Boeve BF, 2022, LANCET NEUROL, V21, P258, DOI 10.1016/S1474-4422(21)00341-0; Boxer AL, 2020, ALZHEIMERS DEMENT, V16, P131, DOI 10.1016/j.jalz.2019.06.4956; Bridel C, 2019, JAMA NEUROL, V76, P1035, DOI 10.1001/jamaneurol.2019.1534; Caverzasi E, 2019, J NEUROL NEUROSUR PS, V90, P1005, DOI 10.1136/jnnp-2018-320265; Chen Q, 2019, ALZH DEMENT-TRCI, V5, P338, DOI 10.1016/j.trci.2019.05.010; Chu SA, 2021, ANN CLIN TRANSL NEUR, V8, P95, DOI 10.1002/acn3.51249; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Gendron TF, 2022, CELL REP MED, V3, DOI 10.1016/j.xcrm.2022.100607; Glasmacher SA, 2020, JAMA NEUROL, V77, P367, DOI 10.1001/jamaneurol.2019.3924; Greaves CV, 2019, J NEUROL, V266, P2075, DOI 10.1007/s00415-019-09363-4; Illan-Gaia I, 2021, NEUROLOGY, V96, pE671, DOI 10.1212/WNL.0000000000011226; Jack CR, 1997, NEUROLOGY, V49, P786, DOI 10.1212/WNL.49.3.786; Knopman DS, 2011, J MOL NEUROSCI, V45, P330, DOI 10.1007/s12031-011-9538-y; Lee SE, 2017, NEUROIMAGE-CLIN, V14, P286, DOI 10.1016/j.nicl.2016.12.006; Leverenz JB, 2007, BRAIN, V130, P1360, DOI 10.1093/brain/awm069; Mercuri E, 2018, NEW ENGL J MED, V378, P625, DOI 10.1056/NEJMoa1710504; Miller T, 2020, NEW ENGL J MED, V383, P109, DOI 10.1056/NEJMoa2003715; Miyagawa T, 2020, ALZHEIMERS DEMENT, V16, P106, DOI 10.1002/alz.12033; Miyagawa T, 2020, ALZHEIMERS DEMENT, V16, P79, DOI 10.1016/j.jalz.2019.05.013; Mok K, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.08.005; Monsell SE, 2016, ALZ DIS ASSOC DIS, V30, P134, DOI 10.1097/WAD.0000000000000111; Moore K, 2022, APPL NEUROPSYCH-ADUL, V29, P112, DOI 10.1080/23279095.2020.1716357; Moore KM, 2020, LANCET NEUROL, V19, P145, DOI 10.1016/S1474-4422(19)30394-1; Olney NT, 2020, ALZHEIMERS DEMENT, V16, P49, DOI 10.1016/j.jalz.2019.08.196; Onyike CU, 2021, ADV EXP MED BIOL, V1281, P141, DOI 10.1007/978-3-030-51140-1_10; Oxtoby NP, 2018, BRAIN, V141, P1529, DOI 10.1093/brain/awy050; Paganoni S, 2022, ANN NEUROL, V91, P165, DOI 10.1002/ana.26285; Panman JL, 2021, J NEUROL NEUROSUR PS, V92, P494, DOI 10.1136/jnnp-2020-323541; Poos JM, 2022, ALZHEIMERS RES THER, V14, DOI 10.1186/s13195-022-00958-0; Pottier C, 2018, LANCET NEUROL, V17, P548, DOI 10.1016/S1474-4422(18)30126-1; Quintana M, 2019, STAT MED, V38, P1459, DOI 10.1002/sim.8050; Ramos EM, 2020, ALZHEIMERS DEMENT, V16, P118, DOI 10.1002/alz.12011; Rentz DM, 2021, ALZH DEMENT-TRCI, V7, DOI 10.1002/trc2.12181; Rohrer JD, 2021, ADV EXP MED BIOL, V1281, P113, DOI 10.1007/978-3-030-51140-1_8; Rohrer JD, 2015, LANCET NEUROL, V14, P253, DOI 10.1016/S1474-4422(14)70324-2; Rohrer JD, 2010, NEUROIMAGE, V53, P1070, DOI 10.1016/j.neuroimage.2009.12.088; Rojas JC, 2021, NEUROLOGY, V96, pE2296, DOI 10.1212/WNL.0000000000011848; Russell LL, 2020, CORTEX, V133, P384, DOI 10.1016/j.cortex.2020.08.023; Salloway S, 2021, NAT MED, V27, P1187, DOI 10.1038/s41591-021-01369-8; Saracino D, 2021, J NEUROL NEUROSUR PS, V92, P1278, DOI 10.1136/jnnp-2021-326914; Scherling CS, 2014, ANN NEUROL, V75, P116, DOI 10.1002/ana.24052; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; Staffaroni AM, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.22847; Staffaroni AM, 2020, ALZHEIMERS DEMENT, V16, P37, DOI 10.1016/j.jalz.2019.04.007; Staffaroni AM, 2020, ALZHEIMERS DEMENT, V16, P11, DOI 10.1016/j.jalz.2019.01.012; Staffaroni AM, 2019, BRAIN, V142, P443, DOI 10.1093/brain/awy319; Tsai RM, 2016, J NEUROCHEM, V138, P211, DOI 10.1111/jnc.13640; U.S. Food & Drug Administration, 2021, FDA2020D2101; van der Ende EL, 2022, BRAIN, V145, P1805, DOI 10.1093/brain/awab382; van der Ende EL, 2019, LANCET NEUROL, V18, P1103, DOI 10.1016/S1474-4422(19)30354-0; van der Zee J, 2006, BRAIN, V129, P841, DOI 10.1093/brain/awl029; Weintraub S, 2018, ALZ DIS ASSOC DIS, V32, P10, DOI 10.1097/WAD.0000000000000223; Whitwell JL, 2015, EUR J NEUROL, V22, P745, DOI 10.1111/ene.12675; Young AL, 2021, NEUROLOGY, V97, pE941, DOI 10.1212/WNL.0000000000012410; Young AL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05892-0	63	1	1	1	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01942-9	http://dx.doi.org/10.1038/s41591-022-01942-9		SEP 2022	26	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4W5PB	36138153	Green Published			2022-12-27	WOS:000860213200001
J	Zhu, AX; Abbas, AR; de Galarreta, MR; Guan, YH; Lu, S; Koeppen, H; Zhang, WJ; Hsu, CH; He, AR; Ryoo, BY; Yau, T; Kaseb, AO; Burgoyne, AM; Dayyani, F; Spahn, J; Verret, W; Finn, RS; Toh, HC; Lujambio, A; Wang, YL				Zhu, Andrew X.; Abbas, Alexander R.; de Galarreta, Marina Ruiz; Guan, Yinghui; Lu, Shan; Koeppen, Hartmut; Zhang, Wenjun; Hsu, Chih-Hung; He, Aiwu Ruth; Ryoo, Baek-Yeol; Yau, Thomas; Kaseb, Ahmed O.; Burgoyne, Adam M.; Dayyani, Farshid; Spahn, Jessica; Verret, Wendy; Finn, Richard S.; Toh, Han Chong; Lujambio, Amaia; Wang, Yulei			Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma	NATURE MEDICINE			English	Article; Early Access							REGULATORY T-CELLS; OPEN-LABEL; CANCER; MULTICENTER; DOCETAXEL; NIVOLUMAB; BLOCKADE; ANTIBODY; THERAPY	Atezolizumab (anti-programmed death-ligand 1 (PD-L1)) and bevacizumab (anti-vascular endothelial growth factor (VEGF)) combination therapy has become the new standard of care in patients with unresectable hepatocellular carcinoma. However, potential predictive biomarkers and mechanisms of response and resistance remain less well understood. We report integrated molecular analyses of tumor samples from 358 patients with hepatocellular carcinoma (HCC) enrolled in the GO30140 phase 1b or IMbrave150 phase 3 trial and treated with atezolizumab combined with bevacizumab, atezolizumab alone or sorafenib (multikinase inhibitor). Pre-existing immunity (high expression of CD274, T-effector signature and intratumoral CD8(+) T cell density) was associated with better clinical outcomes with the combination. Reduced clinical benefit was associated with high regulatory T cell (Treg) to effector T cell (Teff) ratio and expression of oncofetal genes (GPC3, AFP). Improved outcomes from the combination versus atezolizumab alone were associated with high expression of VEGF Receptor 2 (KDR), Tregs and myeloid inflammation signatures. These findings were further validated by analyses of paired pre- and post-treatment biopsies, in situ analyses and in vivo mouse models. Our study identified key molecular correlates of the combination therapy and highlighted that anti-VEGF might synergize with anti-PD-L1 by targeting angiogenesis, Treg proliferation and myeloid cell inflammation. Multiomics analysis of tumor samples from the phase 1b GO30140 and phase 3 IMbrave150 trials reveals baseline immune and genetic features that might identify patients with advanced hepatocellular carcinoma who will benefit from atezolizumab and bevacizumab combination therapy.	[Zhu, Andrew X.] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02115 USA; [Zhu, Andrew X.] Jiahui Hlth, Jiahui Int Canc Ctr, Shanghai, Peoples R China; [Abbas, Alexander R.; Guan, Yinghui; Lu, Shan; Wang, Yulei] Genentech Inc, Dept Oncol Biomarker Dev, San Francisco, CA 94080 USA; [de Galarreta, Marina Ruiz; Lujambio, Amaia] Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA; [de Galarreta, Marina Ruiz; Lujambio, Amaia] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Med, Liver Canc Program,Div Liver Dis, New York, NY 10029 USA; [de Galarreta, Marina Ruiz; Lujambio, Amaia] Icahn Sch Med Mt Sinai, Precis Immunol Inst, New York, NY 10029 USA; [Koeppen, Hartmut] Genentech Inc, Dept Pathol Res, San Francisco, CA 94080 USA; [Zhang, Wenjun] Roche Tissue Diagnost, Tucson, AZ USA; [Hsu, Chih-Hung] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan; [He, Aiwu Ruth] Georgetown Univ, Med Ctr, Div Hematol & Oncol, Washington, DC 20007 USA; [Ryoo, Baek-Yeol] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea; [Yau, Thomas] Univ Hong Kong, Li Ka Shing Fac Med, Dept Med, Hong Kong, Peoples R China; [Kaseb, Ahmed O.] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; [Burgoyne, Adam M.] UC San Diego Moores Canc Ctr, Div Hematol Oncol, La Jolla, CA USA; [Dayyani, Farshid] UC Irvine Hlth, Div Hematol Oncol, Dept Med, Orange, CA USA; [Spahn, Jessica; Verret, Wendy] Genentech Inc, Prod Dev, San Francisco, CA 94080 USA; [Finn, Richard S.] Univ Calif Los Angeles, Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA; [Toh, Han Chong] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore; [Lujambio, Amaia] Icahn Sch Med Mt Sinai, Grad Sch Biomed Sci, New York, NY 10029 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Roche Holding; Genentech; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Roche Holding; Genentech; National Taiwan University; National Taiwan University Hospital; Georgetown University; University of Ulsan; Asan Medical Center; University of Hong Kong; University of Texas System; UTMD Anderson Cancer Center; Roche Holding; Genentech; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; National Cancer Centre Singapore (NCCS); Icahn School of Medicine at Mount Sinai	Wang, YL (corresponding author), Genentech Inc, Dept Oncol Biomarker Dev, San Francisco, CA 94080 USA.	wang.yulei@gene.com		Ruiz de Galarreta, Marina/0000-0001-9666-8416; HSU, CHIH-HUNG/0000-0003-0495-973X; Dayyani, Farshid/0000-0002-4970-5189	Fundacion Alfonso Martin Escudero Fellowship; Damon Runyon-Rachleff Innovation Award [DR52-18]; R37 Merit Award [R37CA230636]; Icahn School of Medicine at Mount Sinai; Tisch Cancer Institute;  [P30 CA196521]	Fundacion Alfonso Martin Escudero Fellowship; Damon Runyon-Rachleff Innovation Award; R37 Merit Award; Icahn School of Medicine at Mount Sinai; Tisch Cancer Institute; 	D We are grateful for the participation and commitment of patients, families and doctors in biomarker studies of the GO30140 and IMbrave150 trials. Without their contribution, this study would not have been possible. We thank the following foundations for their financial support. M.R.G. was supported by Fundacion Alfonso Martin Escudero Fellowship and a Damon Runyon-Rachleff Innovation Award (no. DR52-18). A.L. was supported by a Damon Runyon-Rachleff Innovation Award (no. DR52-18), an R37 Merit Award (no. R37CA230636) and Icahn School of Medicine at Mount Sinai. The Tisch Cancer Institute and related research facilities are supported by P30 CA196521. We thank J. Munnoz-Rodriguez, X. Wang and X. Wang from Roche Tissue Diagnostics for performing and developing the digital pathology algorithm, and for data analysis of multiplex immunofluorescence assays. We also thank A. Pochiraju, N. Yang, S. Nalle and L. Ma for coordinating sample collection, assay implementation and data transfer. We thank C. V. Wong and J. Cheung for managing and coordinating preclinical studies at Mount Sinai. Figure 1 was created with BioRender.com.	Ang Celina, 2019, Oncotarget, V10, P4018, DOI 10.18632/oncotarget.26998; Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Berraondo P, 2019, CANCER DISCOV, V9, P1003, DOI 10.1158/2159-8290.CD-19-0696; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Canzler S, 2020, BMC BIOINFORMATICS, V21, DOI 10.1186/s12859-020-03910-x; Carbone DP, 2017, NEW ENGL J MED, V376, P2415, DOI 10.1056/NEJMoa1613493; de Galarreta MR, 2019, CANCER DISCOV, V9, P1124, DOI 10.1158/2159-8290.CD-19-0074; deLeeuw RJ, 2012, CLIN CANCER RES, V18, P3022, DOI 10.1158/1078-0432.CCR-11-3216; Dunham RM, 2013, J IMMUNOL, V190, P2009, DOI 10.4049/jimmunol.1201937; Fehrenbacher L, 2016, LANCET, V387, P1837, DOI 10.1016/S0140-6736(16)00587-0; Fessas P, 2021, CANCERS, V13, DOI 10.3390/cancers13092137; Finn RS, 2020, NEW ENGL J MED, V382, P1894, DOI 10.1056/NEJMoa1915745; Hack SP, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.598877; Hainsworth JD, 2018, J CLIN ONCOL, V36, P536, DOI 10.1200/JCO.2017.75.3780; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harding JJ, 2019, CLIN CANCER RES, V25, P2116, DOI 10.1158/1078-0432.CCR-18-2293; Hellmann MD, 2018, NEW ENGL J MED, V378, P2093, DOI 10.1056/NEJMoa1801946; Hellmann MD, 2018, CANCER CELL, V33, P853, DOI 10.1016/j.ccell.2018.04.001; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Kalathil SG, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.130116; Karosiene E, 2012, IMMUNOGENETICS, V64, P177, DOI 10.1007/s00251-011-0579-8; Khan KA, 2018, NAT REV CLIN ONCOL, V15, P310, DOI 10.1038/nrclinonc.2018.9; Kim YJ, 2019, LUNG CANCER, V136, P122, DOI 10.1016/j.lungcan.2019.08.031; Lachenmayer A, 2012, CLIN CANCER RES, V18, P4997, DOI 10.1158/1078-0432.CCR-11-2322; Lawrence M., PACKAGE VARIANTTOOLS; Lee HG, 2020, EXP MOL MED, V52, P1255, DOI 10.1038/s12276-020-00486-7; Lee MS, 2020, LANCET ONCOL, V21, P808, DOI 10.1016/S1470-2045(20)30156-X; Lee WS, 2020, EXP MOL MED, V52, P1475, DOI 10.1038/s12276-020-00500-y; Lei YN, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.617335; Li JL, 2011, CANCER RES, V71, P6073, DOI 10.1158/0008-5472.CAN-11-1704; Makker V, 2019, LANCET ONCOL, V20, P711, DOI 10.1016/S1470-2045(19)30020-8; McDermott DF, 2018, NAT MED, V24, P749, DOI 10.1038/s41591-018-0053-3; Motzer RJ, 2019, NEW ENGL J MED, V380, P1103, DOI 10.1056/NEJMoa1816047; Ormandy LA, 2005, CANCER RES, V65, P2457, DOI 10.1158/0008-5472.CAN-04-3232; Peng LS, 2012, CANCER IMMUNOL IMMUN, V61, P2183, DOI 10.1007/s00262-012-1277-6; Pfister D, 2021, NATURE, V592, P450, DOI 10.1038/s41586-021-03362-0; Pinato DJ, 2019, BRIT J CANCER, V120, P1033, DOI 10.1038/s41416-019-0466-x; Pinyol R, 2019, CLIN CANCER RES, V25, P2021, DOI 10.1158/1078-0432.CCR-18-3778; Rini BI, 2019, NEW ENGL J MED, V380, P1116, DOI 10.1056/NEJMoa1816714; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Sangro B, 2021, NAT REV GASTRO HEPAT, V18, P525, DOI 10.1038/s41575-021-00438-0; Sangro B, 2020, J HEPATOL, V73, P1460, DOI 10.1016/j.jhep.2020.07.026; Sharma A, 2020, CELL, V183, P377, DOI 10.1016/j.cell.2020.08.040; Shetty S, 2018, NAT REV GASTRO HEPAT, V15, P555, DOI 10.1038/s41575-018-0020-y; Shukla SA, 2015, NAT BIOTECHNOL, V33, P1152, DOI 10.1038/nbt.3344; Socinski MA, 2018, NEW ENGL J MED, V378, P2288, DOI 10.1056/NEJMoa1716948; Sohn BH, 2018, EXP MOL MED, V50, DOI 10.1038/emm.2017.174; Terme M, 2013, CANCER RES, V73, P539, DOI 10.1158/0008-5472.CAN-12-2325; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Trujillo JA, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0780-0; Wong CN, 2021, LIVER INT, V41, P192, DOI 10.1111/liv.14706; Yoon HH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042274; Zhang WJ, 2017, LAB INVEST, V97, P873, DOI 10.1038/labinvest.2017.37; Zhu AX, 2019, LANCET ONCOL, V20, P282, DOI 10.1016/S1470-2045(18)30937-9	57	16	16	27	27	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01868-2	http://dx.doi.org/10.1038/s41591-022-01868-2		JUN 2022	43	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2I4PS	35739268				2022-12-27	WOS:000814962700001
J	Reijers, ILM; Menzies, AM; van Akkooi, ACJ; Versluis, JM; van den Heuvel, NMJ; Saw, RPM; Pennington, TE; Kapiteijn, E; van der Veldt, AAM; Suijkerbuijk, KPM; Hospers, GAP; Rozeman, EA; Klop, WMC; van Houdt, WJ; Sikorska, K; van der Hage, JA; Grunhagen, DJ; Wouters, MW; Witkamp, AJ; Zuur, CL; Lijnsvelt, JM; Acosta, AT; Grijpink-Ongering, LG; Gonzalez, M; Jozwiak, K; Bierman, C; Shannon, KF; Ch'ng, S; Colebatch, AJ; Spillane, AJ; Haanen, JBAG; Rawson, RV; van de Wiel, BA; van de Poll-franse, LV; Scolyer, RA; Boekhout, AH; Long, GV; Blank, CU				Reijers, Irene L. M.; Menzies, Alexander M.; van Akkooi, Alexander C. J.; Versluis, Judith M.; van den Heuvel, Noelle M. J.; Saw, Robyn P. M.; Pennington, Thomas E.; Kapiteijn, Ellen; van der Veldt, Astrid A. M.; Suijkerbuijk, Karijn P. M.; Hospers, Geke A. P.; Rozeman, Elisa A.; Klop, Willem M. C.; van Houdt, Winan J.; Sikorska, Karolina; van der Hage, Jos A.; Grunhagen, Dirk J.; Wouters, Michel W.; Witkamp, Arjen J.; Zuur, Charlotte L.; Lijnsvelt, Judith M.; Torres Acosta, Alejandro; Grijpink-Ongering, Lindsay G.; Gonzalez, Maria; Jozwiak, Katarzyna; Bierman, Carolien; Shannon, Kerwin F.; Ch'ng, Sydney; Colebatch, Andrew J.; Spillane, Andrew J.; Haanen, John B. A. G.; Rawson, Robert V.; van de Wiel, Bart A.; van de Poll-franse, Lonneke V.; Scolyer, Richard A.; Boekhout, Annelies H.; Long, Georgina V.; Blank, Christian U.			Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial	NATURE MEDICINE			English	Article							SENTINEL LYMPH-NODE; QUALITY-OF-LIFE; BIOMARKER ANALYSES; MORBIDITY; BIOPSY; AXILLARY; DISSECTION; SURVIVAL; IMMUNOTHERAPY	Neoadjuvant ipilimumab and nivolumab induces high pathologic response rates (pRRs) in clinical stage III nodal melanoma, and pathologic response is strongly associated with prolonged relapse-free survival (RFS). The PRADO extension cohort of the OpACIN-neo trial (NCT02977052) addressed the feasibility and effect on clinical outcome of using pathologic response after neoadjuvant ipilimumab and nivolumab as a criterion for further treatment personalization. In total, 99 patients with clinical stage IIIb-d nodal melanoma were included and treated with 6 weeks of neoadjuvant ipilimumab 1 mg kg(-1) and nivolumab 3 mg kg(-1). In patients achieving major pathologic response (MPR, <= 10% viable tumor) in their index lymph node (ILN, the largest lymph node metastasis at baseline), therapeutic lymph node dissection (TLND) and adjuvant therapy were omitted. Patients with pathologic partial response (pPR; >10 to <= 50% viable tumor) underwent TLND only, whereas patients with pathologic non-response (pNR; >50% viable tumor) underwent TLND and adjuvant systemic therapy +/- synchronous radiotherapy. Primary objectives were confirmation of pRR (ILN, at week 6) of the winner neoadjuvant combination scheme identified in OpACIN-neo; to investigate whether TLND can be safely omitted in patients achieving MPR; and to investigate whether RFS at 24 months can be improved for patients achieving pNR. ILN resection and ILN-response-tailored treatment were feasible. The pRR was 72%, including 61% MPR. Grade 3-4 toxicity within the first 12 weeks was observed in 22 (22%) patients. TLND was omitted in 59 of 60 patients with MPR, resulting in significantly lower surgical morbidity and better quality of life. The 24-month relapse-free survival and distant metastasis-free survival rates were 93% and 98% in patients with MPR, 64% and 64% in patients with pPR, and 71% and 76% in patients with pNR, respectively. These findings provide a strong rationale for randomized clinical trials testing response-directed treatment personalization after neoadjuvant ipilimumab and nivolumab.	[Reijers, Irene L. M.; Versluis, Judith M.; Rozeman, Elisa A.; Lijnsvelt, Judith M.; Haanen, John B. A. G.; Blank, Christian U.] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands; [Menzies, Alexander M.; van Akkooi, Alexander C. J.; Saw, Robyn P. M.; Pennington, Thomas E.; Gonzalez, Maria; Shannon, Kerwin F.; Ch'ng, Sydney; Colebatch, Andrew J.; Spillane, Andrew J.; Rawson, Robert V.; Scolyer, Richard A.; Long, Georgina V.] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia; [Menzies, Alexander M.; van Akkooi, Alexander C. J.; Saw, Robyn P. M.; Ch'ng, Sydney; Colebatch, Andrew J.; Spillane, Andrew J.; Rawson, Robert V.; Scolyer, Richard A.; Long, Georgina V.] Univ Sydney, Fac Med & Hlth, Sydney, NSW, Australia; [Menzies, Alexander M.; Long, Georgina V.] Royal North Shore & Mater Hosp, Dept Med Oncol, Sydney, NSW, Australia; [van Akkooi, Alexander C. J.; van Houdt, Winan J.; Wouters, Michel W.] Netherlands Canc Inst, Dept Surg Oncol, Amsterdam, Netherlands; [van den Heuvel, Noelle M. J.; van de Poll-franse, Lonneke V.; Boekhout, Annelies H.] Netherlands Canc Inst, Dept Psychosocial Res & Epidemiol, Amsterdam, Netherlands; [Kapiteijn, Ellen; Haanen, John B. A. G.; Blank, Christian U.] Leiden Univ, Med Ctr, Dept Med Oncol, Leiden, Netherlands; [van der Veldt, Astrid A. M.] Erasmus MC, Dept Med Oncol, Rotterdam, Netherlands; [van der Veldt, Astrid A. M.] Erasmus MC, Dept Radiol & Nucl Med, Rotterdam, Netherlands; [Suijkerbuijk, Karijn P. M.] Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands; [Hospers, Geke A. P.] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Groningen, Netherlands; [Klop, Willem M. C.; Zuur, Charlotte L.] Netherlands Canc Inst, Dept Head & Neck Surg, Amsterdam, Netherlands; [Sikorska, Karolina; Torres Acosta, Alejandro; Grijpink-Ongering, Lindsay G.] Netherlands Canc Inst, Dept Biometr, Amsterdam, Netherlands; [van der Hage, Jos A.] Leiden Univ, Med Ctr, Dept Surg, Leiden, Netherlands; [Grunhagen, Dirk J.] Erasmus MC, Canc Inst, Dept Surg Oncol & Gastrointestinal Surg, Rotterdam, Netherlands; [Wouters, Michel W.] Leiden Univ, Med Ctr, Dept Biomed Data Sci, Leiden, Netherlands; [Witkamp, Arjen J.] Univ Med Ctr Utrecht, Dept Surg, Utrecht, Netherlands; [Zuur, Charlotte L.] Leiden Univ, Med Ctr, Dept Otorhinolaryngol Head Neck Surg, Leiden, Netherlands; [Jozwiak, Katarzyna] Brandenburg Med Sch Theodor Fontane, Inst Biostat & Registry Res, Neuruppin, Germany; [Bierman, Carolien; van de Wiel, Bart A.] Netherlands Canc Inst, Dept Pathol, Amsterdam, Netherlands; [Colebatch, Andrew J.; Rawson, Robert V.; Scolyer, Richard A.] Royal Prince Alfred Hosp, Tissue Pathol & Diagnost Oncol, Sydney, NSW, Australia; [Colebatch, Andrew J.; Rawson, Robert V.; Scolyer, Richard A.] NSW Hlth Pathol, Sydney, NSW, Australia; [Spillane, Andrew J.] Royal North Shore & Mater Hosp, Dept Breast & Melanoma Surg, Sydney, NSW, Australia; [Haanen, John B. A. G.; Blank, Christian U.] Netherlands Canc Inst, Mol Oncol & Immunol, Amsterdam, Netherlands; [van de Poll-franse, Lonneke V.] Netherlands Comprehens Canc Org, Dept Res & Dev, Utrecht, Netherlands; [van de Poll-franse, Lonneke V.] Tilburg Univ, Ctr Res Psychol & Somat Disorders CoRPS, Dept Med & Clin Psychol, Tilburg, Netherlands; [Scolyer, Richard A.; Long, Georgina V.] Univ Sydney, Charles Perkins Ctr, Sydney, NSW, Australia	Netherlands Cancer Institute; Melanoma Institute Australia; University of Sydney; University of Sydney; Royal North Shore Hospital; Netherlands Cancer Institute; Netherlands Cancer Institute; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Utrecht University; Utrecht University Medical Center; University of Groningen; Netherlands Cancer Institute; Netherlands Cancer Institute; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Utrecht University; Utrecht University Medical Center; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Netherlands Cancer Institute; University of Sydney; Royal North Shore Hospital; Netherlands Cancer Institute; Tilburg University; University of Sydney	Blank, CU (corresponding author), Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands.; Blank, CU (corresponding author), Leiden Univ, Med Ctr, Dept Med Oncol, Leiden, Netherlands.; Blank, CU (corresponding author), Netherlands Canc Inst, Mol Oncol & Immunol, Amsterdam, Netherlands.	c.blank@nki.nl	Scolyer, Richard/AAE-8511-2019; van+der+Hage, Jos/AAG-3541-2021; Long, Georgina/C-1771-2013	Scolyer, Richard/0000-0002-8991-0013; van+der+Hage, Jos/0000-0001-9040-1323; Ch'ng, Sydney/0000-0002-4011-1253; Versluis, Judith M./0000-0002-3423-9912; Jozwiak, Katarzyna/0000-0002-9614-6586; Shannon, Kerwin/0000-0001-8538-3132; Long, Georgina/0000-0001-8894-3545; Kapiteijn, Ellen/0000-0002-4814-6426; Suijkerbuijk, Karijn/0000-0003-3604-5430	National Health and Medical Research Council (NHMRC) Investigator Grant; Melanoma Institute Australia; Clinical Research Scholarship from Sydney Research; NHMRC Program Grant and Practitioner Fellowship; NHMRC Investigator Grant; University of Sydney Medical Foundation; Bristol Myers Squibb	National Health and Medical Research Council (NHMRC) Investigator Grant(National Health and Medical Research Council (NHMRC) of Australia); Melanoma Institute Australia; Clinical Research Scholarship from Sydney Research; NHMRC Program Grant and Practitioner Fellowship(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Investigator Grant(National Health and Medical Research Council (NHMRC) of Australia); University of Sydney Medical Foundation(University of Sydney); Bristol Myers Squibb(Bristol-Myers Squibb)	We thank all patients and their families for participation in the trial and the participating study teams. We gratefully acknowledge the support of all colleagues from Melanoma Institute Australia, Royal Prince Alfred Hospital, Royal North Shore and Mater Hospital, University Medical Center Utrecht, Erasmus Medical Center, Leiden University Medical Center, University Medical Center Groningen and the Netherlands Cancer Institute; B. Schermers from Sirius Medical for providing magnetic seeds and a magnetic seed detector; S. Vanhoutvin for financial management; R. Zucker, M. J. Gregorio, K. de Joode, A. M. van Eggermond, E. H. J. Tonk and J. Kingma-Veenstra for administrative support and data management; and A. Evans and B. Stegenga from Bristol Myers Squibb for scientific input and long-term support of our neoadjuvant immunotherapy efforts. A.M.M. is supported by a National Health and Medical Research Council (NHMRC) Investigator Grant, Melanoma Institute Australia and Nicholas and Helen Moore. R.P.M.S. is supported by Melanoma Institute Australia. R.V.R. is supported by a Clinical Research Scholarship from Sydney Research. R.A.S. is supported by an NHMRC Program Grant and Practitioner Fellowship. G.V.L. is supported by an NHMRC Investigator Grant and the University of Sydney Medical Foundation. Financial support for the trial was provided by Bristol Myers Squibb.	Amaria RN, 2018, NAT MED, V24, P1649, DOI 10.1038/s41591-018-0197-1; Ascierto PA, 2020, LANCET ONCOL, V21, P1465, DOI 10.1016/S1470-2045(20)30494-0; Blank CU, 2018, NAT MED, V24, P1655, DOI 10.1038/s41591-018-0198-0; CHRISTENSEN T, 1993, WORLD J SURG, V17, P220, DOI 10.1007/BF01658930; Cocks K, 2011, J CLIN ONCOL, V29, P89, DOI 10.1200/JCO.2010.28.0107; de Vries M, 2006, EJSO-EUR J SURG ONC, V32, P785, DOI 10.1016/j.ejso.2006.05.003; de Vries M, 2005, EJSO-EUR J SURG ONC, V31, P778, DOI 10.1016/j.ejso.2005.05.003; de Vries M, 2009, ANN SURG ONCOL, V16, P2840, DOI 10.1245/s10434-009-0602-6; Dummer R, 2020, LANCET ONCOL, V21, P358, DOI 10.1016/S1470-2045(20)30062-0; Eggermont AM., 2020, J CLIN ONCOL S, V38, DOI [10.1200/JCO.2020.38.15_suppl.10000, DOI 10.1200/JCO.2020.38.15_SUPPL.10000]; Fay MP, 2013, BIOSTATISTICS, V14, P723, DOI 10.1093/biostatistics/kxt016; Giesinger JM, 2020, J CLIN EPIDEMIOL, V118, P1, DOI 10.1016/j.jclinepi.2019.10.003; Gjorup CA, 2017, EUR J CANCER, V85, P122, DOI 10.1016/j.ejca.2017.07.052; Jansen YJL, 2019, ANN ONCOL, V30, P1154, DOI 10.1093/annonc/mdz110; Ji XH, 2021, GLAND SURG, V10, P3067, DOI 10.21037/gs-21-598; Kretschmer L, 2008, MELANOMA RES, V18, P16, DOI 10.1097/CMR.0b013e3282f2017d; Liu J, 2016, CANCER DISCOV, V6, P1382, DOI 10.1158/2159-8290.CD-16-0577; Long GV., 2017, J CLIN ONCOL, V35, DOI [10.1200/JCO.2017.35.15_suppl.9503, DOI 10.1200/JCO.2017.35.15_SUPPL.9503]; Menzies AM, 2021, NAT MED, V27, P301, DOI 10.1038/s41591-020-01188-3; Morton DL, 2005, ANN SURG, V242, P302, DOI 10.1097/01.sla.0000181092.50141.fa; Rawson RV, 2021, ANN ONCOL, V32, P766, DOI 10.1016/j.annonc.2021.03.006; Reijers ILM, 2022, JAMA SURG, V157, P335, DOI 10.1001/jamasurg.2021.7554; Robert C, 2020, ANN ONCOL, V31, pS734, DOI 10.1016/j.annonc.2020.08.1206; Rozeman EA, 2021, NAT MED, V27, P256, DOI 10.1038/s41591-020-01211-7; Rozeman EA, 2019, LANCET ONCOL, V20, P948, DOI 10.1016/S1470-2045(19)30151-2; Schermers B, 2019, BRIT J SURG, V106, P519, DOI 10.1002/bjs.11168; Smith S, 2021, EXPERT REV MED DEVIC, V18, P121, DOI 10.1080/17434440.2020.1852928; Swenson KK, 2002, ANN SURG ONCOL, V9, P745, DOI 10.1245/ASO.2002.02.007; Tetzlaff MT, 2018, ANN ONCOL, V29, P1861, DOI 10.1093/annonc/mdy226; van Akkooi ACJ, 2007, EJSO-EUR J SURG ONC, V33, P102, DOI 10.1016/j.ejso.2006.10.032; van Akkooi A. C. J., ANN SURG ONCOL, DOI [10.1245/s10434-021-11236-y(2022, DOI 10.1245/S10434-021-11236-Y(2022]; Versluis JM, 2021, EUR J CANCER, V148, P51, DOI 10.1016/j.ejca.2021.02.012; Weber J, 2020, BRIT J DERMATOL, V183, P559, DOI 10.1111/bjd.18739; Wrightson WR, 2003, ANN SURG ONCOL, V10, P676, DOI 10.1245/ASO.2003.10.001	34	16	16	2	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2022	28	6					1178	+		10.1038/s41591-022-01851-x	http://dx.doi.org/10.1038/s41591-022-01851-x		JUN 2022	23	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E9IE	35661157	Green Published			2022-12-27	WOS:000806128900001
J	Wrighton, NC; Balasubramanian, P; Barbone, FP; Kashyap, AK; Farrell, FX; Jolliffe, LK; Barrett, RW; Dower, WJ				Wrighton, NC; Balasubramanian, P; Barbone, FP; Kashyap, AK; Farrell, FX; Jolliffe, LK; Barrett, RW; Dower, WJ			Increased potency of an erythropoietin peptide mimetic through covalent dimerization	NATURE BIOTECHNOLOGY			English	Article						protein engineering; rational design	CELL-SURFACE RECEPTORS; HUMAN GROWTH-HORMONE; EXTRACELLULAR DOMAIN; PROTEIN HORMONE; EXPRESSION; ACTIVATION; CLONING; LIBRARY; LIGANDS; COMPLEX	We have synthesized a chemically defined, dimeric form of an erythropoietin mimetic peptide (EMP) that displays 100-fold increased affinity far the erythropoietin receptor (EPOR) and correspondingly elevated potency in cell-based assays and in mice. The dimeric EMP1 was synthesized using a C-terminal lysine residue as a branch point. A beta-alanine residue was coupled to the main-chain (alpha) amino group of the lysine residue in order to provide a pseudosymmetrical scaffold where both the side-chain and main-chain were of approximately equal length. Using an orthogonal protection system, independently disulphide-cylized EMP1 moieties were synthesized upon this scaffold. The proposed mechanism of increased potency of the dimer over the parental compound EMP1 is consistent with the structure of a cocrystal of EMP1 and the extracellular domain of the EPOR in which a noncovalent peptide dimer is seen spanning the cleft between two molecules of the EPOR extracellular domain.	Affymax Res Inst, Palo Alto, CA 94304 USA; RW Johnson Pharmaceut Res Inst, Raritan, NJ 08869 USA	Johnson & Johnson; Johnson & Johnson USA	Wrighton, NC (corresponding author), Affymax Res Inst, 4001 Miranda Ave, Palo Alto, CA 94304 USA.	nick@wrighton.com						CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CHAIET L, 1964, ARCH BIOCHEM BIOPHYS, V106, P1, DOI 10.1016/0003-9861(64)90150-X; COTES PM, 1961, NATURE, V191, P1065, DOI 10.1038/1911065a0; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; Cwirla SE, 1997, SCIENCE, V276, P1696, DOI 10.1126/science.276.5319.1696; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; GREENWOOD J, 1991, J MOL BIOL, V220, P821, DOI 10.1016/0022-2836(91)90354-9; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; JONES SS, 1990, BLOOD, V76, P31; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KRANTZ SB, 1991, BLOOD, V77, P419; LIN FK, 1985, P NATL ACAD SCI USA, V82, P7580, DOI 10.1073/pnas.82.22.7580; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; WEICH NS, 1993, EXP HEMATOL, V21, P647; WHITEHORN EA, 1995, BIO-TECHNOL, V13, P1215, DOI 10.1038/nbt1195-1215; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458	21	105	135	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1997	15	12					1261	1265		10.1038/nbt1197-1261	http://dx.doi.org/10.1038/nbt1197-1261			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YQ046	9359108				2022-12-27	WOS:000071342000027
J	Bandara, LR; Girling, R; LaThangue, NB				Bandara, LR; Girling, R; LaThangue, NB			Apoptosis induced in mammalian cells by small peptides that functionally antagonize the Rb-regulated E2F transcription factor	NATURE BIOTECHNOLOGY			English	Article						E2F antagonist; peptide therapeutics; tumor suppressor; apoptosis	RETINOBLASTOMA GENE-PRODUCT; PRB PHOSPHORYLATION; CYCLE PROGRESSION; DIRECT BINDING; S-PHASE; PROTEIN; INHIBITION; FAMILY; MICE; TRANSACTIVATION	A variety of studies implicate the E2F transcription factor as a critical regulator of the mammalian cell cycle. The E2F pathway is aberrant in most, if not all, human tumor cells; therefore, therapeutic regimes that modulate E2F activity may provide an approach for reinstating growth control in situations where normal physiological control is lost. To elucidate the role of E2F in the cell cycle and assess its value as a therapeutic target, we have introduced peptides that functionally antagonize E2F DNA binding activity into mammalian cells. Introduction of these peptides into mammalian tumor cells caused the rapid onset of apoptosis, an outcome that correlates with the inactivation of physiological E2F.	PROLIFIX LTD,LONDON NW7 1AD,ENGLAND; UNIV GLASGOW,INST BIOMED & LIFE SCI,DIV BIOCHEM & MOL BIOL,GLASGOW G12 8QQ,LANARK,SCOTLAND; NATL INST MED RES,MRC,EUKARYOT MOL GENET LAB,LONDON NW7 1AA,ENGLAND	University of Glasgow; MRC National Institute for Medical Research								BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; JACKS T, 1992, NATURE, V359, P395; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOOSS K, 1995, ONCOGENE, V10, P1529; KATO J, 1993, GENE DEV, V7, P331; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; NEVINS JR, 1992, SCIENCE, V258, P424; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU FH, 1995, J CELL SCI, V108, P2945; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	37	36	39	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1997	15	9					896	901		10.1038/nbt0997-896	http://dx.doi.org/10.1038/nbt0997-896			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XW410	9306407				2022-12-27	WOS:A1997XW41000034
J	Persidis, A				Persidis, A			Ribozyme therapeutics	NATURE BIOTECHNOLOGY			English	Editorial Material							RNA; EVOLUTION; SEQUENCE				Persidis, A (corresponding author), ARGONEX INC,BUSINESS DEV,2044 INDIA RD,SUITE 202,CHARLOTTESVILLE,VA 22901, USA.							CECH TR, 1981, CELL, V27, P487, DOI 10.1016/0092-8674(81)90390-1; Draper DE, 1996, TRENDS BIOCHEM SCI, V21, P145; EKLAND EH, 1995, NUCLEIC ACIDS RES, V23, P3231, DOI 10.1093/nar/23.16.3231; Gibson SA, 1997, MOL BIOTECHNOL, V7, P125, DOI 10.1007/BF02761748; ISHIZAKA M, 1995, BIOCHEM BIOPH RES CO, V214, P403, DOI 10.1006/bbrc.1995.2301; Jaeger L, 1997, CURR OPIN STRUC BIOL, V7, P324, DOI 10.1016/S0959-440X(97)80047-4; MAMOUNAS M, 1996, INFECT MED, V13, P817; Persidis A, 1997, NAT BIOTECHNOL, V15, P391, DOI 10.1038/nbt0497-391; PYLE AM, 1993, SCIENCE, V261, P709, DOI 10.1126/science.7688142; ROSSL JJ, 1996, TRENDS BIOTECHNOL, V13, P301; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; SIGURDSSON ST, 1995, TRENDS BIOTECHNOL, V13, P286, DOI 10.1016/S0167-7799(00)88966-0; Sun LQ, 1997, MOL BIOTECHNOL, V7, P241, DOI 10.1007/BF02740815; VISSER CM, 1984, ORIGINS LIFE EVOL B, V14, P301, DOI 10.1007/BF00933671; WILSON C, 1995, NATURE, V374, P777, DOI 10.1038/374777a0	15	20	32	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1997	15	9					921	922		10.1038/nbt0997-921	http://dx.doi.org/10.1038/nbt0997-921			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XW410	9306412				2022-12-27	WOS:A1997XW41000039
J	Wang, P; Sergeeva, MV; Lim, L; Dordick, JS				Wang, P; Sergeeva, MV; Lim, L; Dordick, JS			Biocatalytic plastics as active and stable materials for biotransformations	NATURE BIOTECHNOLOGY			English	Article						enzyme stabilization; biocatalytic plastics; organic solvents	ORGANIC-SOLVENTS; CHYMOTRYPSIN; ENZYMES; STABILITY; POLYMERS	Enzyme-containing polymeric materials have been developed that have high activity and stability in both aqueous and organic media. These biocatalytic plastics, containing oc-chymotrypsin and subtilisin Carlsberg, can contain up to 50% (w/w) total protein in plastic materials such as poly(methyl methacrylate, styrene, vinyl acetate, and ethyl vinyl ether). The activation achieved in organic solvents by incorporating proteases in plastic matrices allows for the efficient synthesis of peptides, and sugar and nucleoside esters. The marriage of enzyme technology with polymer chemistry opens up an array of unique applications for plastic enzymes, including active and stable biocatalysts in paints, coatings, resins, foams, and beads, as well as membranes, fibers, and tubings.	UNIV IOWA,DEPT CHEM & BIOCHEM ENGN,IOWA CITY,IA 52242; UNIV IOWA,CTR BIOCATALYSIS & BIOPROC,IOWA CITY,IA 52242	University of Iowa; University of Iowa								Allcock H.R., 1990, CONT POLYM CHEM; Blanch HW, 1995, BIOCH ENG; CLARK DS, 1994, TRENDS BIOTECHNOL, V12, P439, DOI 10.1016/0167-7799(94)90018-3; DORDICK JS, 1989, ENZYME MICROB TECH, V11, P194, DOI 10.1016/0141-0229(89)90094-X; FIELDS R, 1971, BIOCHEM J, V124, P581, DOI 10.1042/bj1240581; GABEL D, 1974, FEBS LETT, V49, P280, DOI 10.1016/0014-5793(74)80530-2; ITO Y, 1992, MAKROMOL CHEM-RAPID, V13, P315; ITO Y, 1993, BIOTECHNOL PROGR, V9, P128, DOI 10.1021/bp00020a003; KLIBANOV AM, 1990, ACCOUNTS CHEM RES, V23, P114, DOI 10.1021/ar00172a004; MARTINEK K, 1977, BIOCHIM BIOPHYS ACTA, V485, P1, DOI 10.1016/0005-2744(77)90188-7; MATSUURA J, 1993, J AM CHEM SOC, V115, P1261, DOI 10.1021/ja00057a006; MEYER JD, 1995, BIOPOLYMERS, V35, P451, DOI 10.1002/bip.360350504; MORIS F, 1993, J ORG CHEM, V58, P653, DOI 10.1021/jo00055a018; Odian G., 1991, PRINCIPLES POLYM, V3; ORTHGEISS E, 1990, BIOTECHNOL BIOENG, V40, P91; PARADKAR VM, 1994, J AM CHEM SOC, V116, P5009, DOI 10.1021/ja00090a065; PARADKAR VM, 1994, BIOTECHNOL BIOENG, V43, P529, DOI 10.1002/bit.260430614; PINA C, 1989, Biotechnology Techniques, V3, P333, DOI 10.1007/BF01875632; RICH JO, 1995, BIOTECHNOL BIOENG, V45, P426, DOI 10.1002/bit.260450507; Rich JO, 1996, ANN NY ACAD SCI, V799, P226, DOI 10.1111/j.1749-6632.1996.tb33205.x; Stepanov VM, 1996, PURE APPL CHEM, V68, P1335, DOI 10.1351/pac199668061335; TAKAHASHI K, 1985, J ORG CHEM, V50, P3414, DOI 10.1021/jo00218a036; TRAMPER J, 1992, BIOCATALYSIS NONCONV; Wangikar PP, 1997, J AM CHEM SOC, V119, P70, DOI 10.1021/ja962620z; Wangikar PP, 1996, BIOTECHNOL BIOENG, V50, P329; Wiseman A., 1985, HDB ENZYME BIOTECHNO; YANG Z, 1995, J AM CHEM SOC, V117, P4843, DOI 10.1021/ja00122a014	27	119	129	3	35	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					789	793		10.1038/nbt0897-789	http://dx.doi.org/10.1038/nbt0897-789			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255796				2022-12-27	WOS:A1997XM70700033
J	Miller, H				Miller, H			The EPA's war on bioremediation	NATURE BIOTECHNOLOGY			English	Editorial Material											Miller, H (corresponding author), STANFORD UNIV,INST INT STUDIES,STANFORD,CA 94305, USA.								0	6	6	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1997	15	6					486	486		10.1038/nbt0697-486	http://dx.doi.org/10.1038/nbt0697-486			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XC772	9181556	Bronze			2022-12-27	WOS:A1997XC77200006
J	Persidis, A				Persidis, A			Chiral-based therapeutics	NATURE BIOTECHNOLOGY			English	Editorial Material											Persidis, A (corresponding author), ARGONEX INC,BUSINESS DEV,2044 INDIA RD,CHARLOTTESVILLE,VA 22901, USA.							BAUM R, 1993, CHEM ENG NEWS, V71, P35, DOI 10.1021/cen-v071n026.p035; BORMAN S, 1994, CHEM ENG NEWS, V72, P37; BURGESS K, 1996, CHEM IND, V24, P988; CANNARSA MJ, 1996, CHEM IND, V10, P374; Davies I. W., 1996, CHEM IND, V11, P412; HOLMES AB, 1996, CHEM IND, V24, P988; Lalonde J, 1997, CHEMTECH, V27, P38; PERSIDIS A, 1995, BIO-TECHNOL, V13, P1172, DOI 10.1038/nbt1195-1172; Persidis A, 1997, NAT BIOTECHNOL, V15, P479, DOI 10.1038/nbt0597-479; PERSIDIS A, 1997, NAT BIOTECHNOL, V15, P492; PIFFERI G, 1995, EUR J DRUG METAB PH, V20, P15, DOI 10.1007/BF03192284	11	10	11	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1997	15	6					594	595		10.1038/nbt0697-594	http://dx.doi.org/10.1038/nbt0697-594			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XC772	9181585				2022-12-27	WOS:A1997XC77200039
J	Dalsgaard, K; Uttenthal, A; Jones, TD; Xu, F; Merryweather, A; Hamilton, WDO; Langeveld, JPM; Boshuizen, RS; Kamstrup, S; Lomonossoff, GP; Porta, C; Vela, C; Casal, JI; Meloen, RH; Rodgers, PB				Dalsgaard, K; Uttenthal, A; Jones, TD; Xu, F; Merryweather, A; Hamilton, WDO; Langeveld, JPM; Boshuizen, RS; Kamstrup, S; Lomonossoff, GP; Porta, C; Vela, C; Casal, JI; Meloen, RH; Rodgers, PB			Plant-derived vaccine protects target animals against a viral disease	NATURE BIOTECHNOLOGY			English	Article						cowpea mosaic virus; parvovirus; plant vaccine; protection; peptide epitope; chimeric virus particles	COWPEA MOSAIC-VIRUS; B-CELL EPITOPES; CANINE PARVOVIRUS; RECOMBINANT VACCINE; SYNTHETIC PEPTIDE; SURFACE; EXPRESSION; ANTIBODIES; PARTICLE; TERMINUS	The successful expression of animal or human virus epitopes on the surface of plant viruses has recently been demonstrated. These chimeric virus particles (CVPs) could represent a cost-effective and safe alternative to conventional animal cell-based vaccines. We report the insertion of oligonucleotides coding for a short linear epitope from the VP2 capsid protein of mink enteritis virus (MEV) into an infectious cDNA clone of cowpea mosaic virus and the successful expression of the epitope on the surface of CVPs when propagated in the black-eyed bean, Vigna unguiculata. The efficacy of the CVPs was established by the demonstration that one subcutaneous injection of 1 mg of the CVPs in mink conferred protection against clinical disease and virtually abolished shedding of virus after challenge with virulent MEV, demonstrating the potential utility of plant CVPs as the basis for vaccine development. The epitope used occurs in three different virus species-MEV, canine parvovirus, and feline panleukopenia virus-and thus the same vaccine could be used in three economically important viral hosts-mink, dogs, and cats, respectively.	DANISH VET LAB,DK-1790 COPENHAGEN,DENMARK; AXIS GENET PLC,CAMBRIDGE CB2 4AZ,ENGLAND; ID DLO,INST ANIM SCI & HLTH,NL-8200 AB LELYSTAD,NETHERLANDS; INGENASA,E-28037 MADRID,SPAIN; JOHN INNES CTR PLANT SCI RES,NORWICH NR4 7UH,NORFOLK,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Dalsgaard, K (corresponding author), DANISH VET INST VIRUS RES,DK-4771 KALVEHAVE,DENMARK.		Casal, Ignacio/M-2312-2014	Casal, Ignacio/0000-0003-1085-2840				CASAL JI, 1995, J VIROL, V69, P7274, DOI 10.1128/JVI.69.11.7274-7277.1995; CHRISTENSEN J, 1994, J GEN VIROL, V75, P149, DOI 10.1099/0022-1317-75-1-149; COTMORE SF, 1987, ADV VIRUS RES, V33, P91, DOI 10.1016/S0065-3527(08)60317-6; DALSGAARD K, 1974, ARCH GES VIRUSFORSCH, V44, P243, DOI 10.1007/BF01240612; DESSENS JT, 1993, J GEN VIROL, V74, P889, DOI 10.1099/0022-1317-74-5-889; DETURISO JAL, 1991, J GEN VIROL, V72, P2445, DOI 10.1099/0022-1317-72-10-2445; DETURISO JAL, 1992, J VIROL, V66, P2748; FITCHEN J, 1995, VACCINE, V13, P1051, DOI 10.1016/0264-410X(95)00075-C; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGEVELD JPM, 1994, J VIROL, V68, P4506, DOI 10.1128/JVI.68.7.4506-4513.1994; LANGEVELD JPM, 1995, VACCINE, V13, P1033, DOI 10.1016/0264-410X(95)00021-R; LANGEVELD JPM, 1993, J VIROL, V67, P765, DOI 10.1128/JVI.67.2.765-772.1993; LANGEVELD JPM, 1994, VACCINE, V12, P1473, DOI 10.1016/0264-410X(94)90158-9; Lin TW, 1996, FOLD DES, V1, P179, DOI 10.1016/S1359-0278(96)00030-2; Mason HS, 1996, P NATL ACAD SCI USA, V93, P5335, DOI 10.1073/pnas.93.11.5335; MCLAIN L, 1995, AIDS RES HUM RETROV, V11, P327, DOI 10.1089/aid.1995.11.327; McLain L, 1996, VACCINE, V14, P799, DOI 10.1016/0264-410X(95)00229-T; MELOEN RH, 1995, PEPSCAN DETERMINE T; MENGELING WL, 1979, AM J VET RES, V40, P204; PARADISO PR, 1981, J VIROL, V39, P800, DOI 10.1128/JVI.39.3.800-807.1981; PARRISH CR, 1994, SEMIN VIROL, V5, P121, DOI 10.1006/smvy.1994.1013; Pearson R. C., 1987, VIRUS INFECTIONS CAR, P349; PORTA C, 1994, VIROLOGY, V202, P949, DOI 10.1006/viro.1994.1417; Sambrook J., 2002, MOL CLONING LAB MANU; SEMANCIK JS, 1966, VIROLOGY, V30, P698, DOI 10.1016/0042-6822(66)90174-7; SORENSEN KJ, 1980, ACTA VET SCAND, V21, P312; Stauffacher C.V., 1987, CRYSTALLOGRAPHY MOL, P293; TURPEN TH, 1995, BIO-TECHNOL, V13, P53, DOI 10.1038/nbt0195-53; USHA R, 1993, VIROLOGY, V197, P366, DOI 10.1006/viro.1993.1598; UTTENTHAL A, 1988, ARCH VIROL, V99, P153, DOI 10.1007/BF01311066; VANKAMMEN A, 1978, COWPEA MOSAIC VIRUS; [No title captured]	33	200	234	2	19	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1997	15	3					248	252		10.1038/nbt0397-248	http://dx.doi.org/10.1038/nbt0397-248			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WM050	9062924				2022-12-27	WOS:A1997WM05000028
J	Liepinsh, E; Otting, G				Liepinsh, E; Otting, G			Organic solvents identify specific ligand binding sites on protein surfaces	NATURE BIOTECHNOLOGY			English	Article						nuclear magnetic resonance; protein solvation; nuclear Overhauser effect	EGG-WHITE LYSOZYME; NUCLEAR-MAGNETIC-RESONANCE; NEUTRON-DIFFRACTION; CRYSTAL-STRUCTURE; HEN LYSOZYME; HYDRATION; UREA; RESOLUTION; COMPLEXES	Enzymes frequently recognize substrates and pharmaceutical drugs through specific binding interactions in deep pockets on the protein surface. We show how the specificity-determining substrate binding site of hen egg-white lysozyme (HEWL) can be readily identified in aqueous solution by nuclear magnetic resonance spectroscopy using small organic solvent molecules as detection probes. Exchange of magnetization between the H-1 nuclei of the protein and the ligands through dipole-dipole interactions is observed which allows the modeling of their position and orientation at the binding site. Combined with site-specific binding constants measured by titration experiments with different organic solvents, the method can provide important information for rational drug design. In addition, the lifetime of nonspecific interactions of HEWL with organic solvents is shown to be in the sub-nanosecond time range.	KAROLINSKA INST, DEPT BIOCHEM & BIOPHYS, S-17177 STOCKHOLM, SWEDEN	Karolinska Institutet			Otting, Gottfried/H-8413-2014	Otting, Gottfried/0000-0002-0563-0146				Allen KN, 1996, J PHYS CHEM-US, V100, P2605, DOI 10.1021/jp952516o; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BODENHAUSEN G, 1984, J MAGN RESON, V58, P370, DOI 10.1016/0022-2364(84)90142-2; BRIAND J, 1991, CHEM PHYS LETT, V185, P276, DOI 10.1016/S0009-2614(91)85060-A; CHEETHAM JC, 1992, J MOL BIOL, V224, P613, DOI 10.1016/0022-2836(92)90548-X; EIGEN M, 1963, ADV ENZYMOL REL S BI, V25, P1; Ernst R. R., 1987, PRINCIPLES NUCL MAGN; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GEEN H, 1991, J MAGN RESON, V93, P93, DOI 10.1016/0022-2364(91)90034-Q; HADFIELD AT, 1994, J MOL BIOL, V243, P856, DOI 10.1006/jmbi.1994.1688; Imoto T., 1972, ENZYMES, V7, P665; KELLY JA, 1979, NATURE, V282, P875, DOI 10.1038/282875a0; KUNDROT CE, 1987, J MOL BIOL, V193, P157, DOI 10.1016/0022-2836(87)90634-6; LEHMANN MS, 1985, BIOCHEMISTRY-US, V24, P5862, DOI 10.1021/bi00342a026; LEHMANN MS, 1989, BIOCHEMISTRY-US, V28, P7028, DOI 10.1021/bi00443a037; LIEPINSH E, 1994, J AM CHEM SOC, V116, P9670, DOI 10.1021/ja00100a036; LUMB KJ, 1994, J MOL BIOL, V235, P1072, DOI 10.1006/jmbi.1994.1058; LUMB KJ, 1992, J MOL BIOL, V227, P9, DOI 10.1016/0022-2836(92)90677-C; MAENAKA K, 1995, J MOL BIOL, V247, P281, DOI 10.1006/jmbi.1994.0139; Mattos C, 1996, NAT BIOTECHNOL, V14, P595, DOI 10.1038/nbt0596-595; OTTING G, 1992, J AM CHEM SOC, V114, P7093, DOI 10.1021/ja00044a021; OTTING G, 1991, Journal of Biomolecular NMR, V1, P209, DOI 10.1007/BF01877232; OTTING G, 1995, ACCOUNTS CHEM RES, V28, P171, DOI 10.1021/ar00052a002; OTTING G, 1991, SCIENCE, V254, P974, DOI 10.1126/science.1948083; PIKE ACW, 1994, PROTEIN SCI, V3, P706; REDFIELD C, 1988, BIOCHEMISTRY-US, V27, P122, DOI 10.1021/bi00401a020; SMITH RJ, 1989, J CHEM SOC CHEM COMM, P682, DOI 10.1039/c39890000682; WESCOTT CR, 1994, BIOCHIM BIOPHYS ACTA, V1286, P1; XIA TH, 1992, THESIS ETH ZURICH SW; YONATH A, 1978, BIOPHYS STRUCT MECH, V4, P27, DOI 10.1007/BF00538838	30	98	100	1	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1997	15	3					264	268		10.1038/nbt0397-264	http://dx.doi.org/10.1038/nbt0397-264			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WM050	9062927				2022-12-27	WOS:A1997WM05000031
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Transgenics on the Internet	NATURE BIOTECHNOLOGY			English	Editorial Material									MASSACHUSETTS GEN HOSP, DEPT MED, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital	Sikorski, R (corresponding author), NCI, HOWARD HUGHES MED INST, BETHESDA, MD 20892 USA.								0	3	6	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1997	15	3					289	289		10.1038/nbt0397-289	http://dx.doi.org/10.1038/nbt0397-289			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WM050	9062932	Bronze			2022-12-27	WOS:A1997WM05000037
J	Golub, ES				Golub, ES			Genetically enhanced food for thought	NATURE BIOTECHNOLOGY			English	Editorial Material									PURDUE UNIV,W LAFAYETTE,IN 47907; ORTHO BIOTEC,RARITAN,NJ	Purdue University System; Purdue University; Purdue University West Lafayette Campus									0	3	3	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1997	15	2					112	112		10.1038/nbt0297-112	http://dx.doi.org/10.1038/nbt0297-112			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WE998	9035119	Bronze			2022-12-27	WOS:A1997WE99800005
J	Magliani, W; Conti, S; DeBernardis, F; Gerloni, M; Bertolotti, D; Mozzoni, P; Cassone, A; Polonelli, L				Magliani, W; Conti, S; DeBernardis, F; Gerloni, M; Bertolotti, D; Mozzoni, P; Cassone, A; Polonelli, L			Therapeutic potential of antiidiotype single chain antibodies with yeast killer toxin activity	NATURE BIOTECHNOLOGY			English	Article						yeast killer toxin; recombinant antiidiotypic antibodies; fungicidal peptides; experimental vaginitis; therapeutic treatment	ANTI-IDIOTYPIC ANTIBODIES; CANDIDA-ALBICANS; MONOCLONAL-ANTIBODIES; PHAGE; LIBRARIES; VACCINATION; RECEPTORS; INFECTION	Single chain fragment (ScFv) antiidiotypic antibodies (antilds) of a killer toxin (KT) from the yeast Pichia anomala have been produced by recombinant DNA methodology from the splenic lymphocytes of mice immunized by idiotypic vaccination with a KT-neutralizing monoclonal antibody (Mab KT4). ScFv KT-like antilds (KTIdAb) react with specific Candida albicans KT cell wall receptors (KTR) exerting a candidacidal activity in vitro could be neutralized by adsorption with Mab KT4. ScFv KTldAb displayed an effective therapeutic activity in an experimental model of rat candidal vaginitis.	UNIV PARMA,IST MICROBIOL,FAC MED & CHIRURG,I-43100 PARMA,ITALY; IST SUPER SANITA,BATTERIOL & MICOL MED LAB,I-00161 ROME,ITALY	University of Parma; Istituto Superiore di Sanita (ISS)			Gerloni, Mara/AAG-1526-2020; DE BERNARDIS, FLAVIA/C-9589-2016; Cassone, Antonio/J-4666-2019; Conti, Stefania/N-3558-2015	DE BERNARDIS, FLAVIA/0000-0001-9440-8629; Conti, Stefania/0000-0001-9973-8352				ALIOUAT EM, 1993, IMMUNOTHER INFECT DI, V5, P102; ARMSTRONG D, 1993, CLIN INFECT DIS, V17, pS318, DOI 10.1093/clinids/17.Supplement_2.S318; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; Bona CA, 1984, RECEPTOR BIOCH METHO, V14, P141; BRINKMANN U, 1994, BBA-REV CANCER, V1198, P27, DOI 10.1016/0304-419X(94)90004-3; CASSONE A, 1995, INFECT IMMUN, V63, P2619, DOI 10.1128/IAI.63.7.2619-2624.1995; CASSONE A, IN PRESS IMMUNOL TOD; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; CUTLER JE, 1991, ANNU REV MICROBIOL, V45, P187, DOI 10.1146/annurev.mi.45.100191.001155; DEBERNARDIS F, 1990, J INFECT DIS, V161, P1276, DOI 10.1093/infdis/161.6.1276; FIDEL PL, 1993, INFECT IMMUN, V61, P1990, DOI 10.1128/IAI.61.5.1990-1995.1993; GAULTON GN, 1986, ANNU REV IMMUNOL, V4, P253, DOI 10.1146/annurev.iy.04.040186.001345; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; MONROE JG, 1986, IMMUNOL INVEST, V15, P263, DOI 10.3109/08820138609026688; NISONOFF A, 1984, NEW HORIZONS MICROBI, P119; POLJAK RJ, 1994, P NATL ACAD SCI USA, V91, P1599, DOI 10.1073/pnas.91.5.1599; POLONELLI L, 1986, J CLIN MICROBIOL, V24, P866, DOI 10.1128/JCM.24.5.866-869.1986; POLONELLI L, 1990, J IMMUNOL METHODS, V132, P205, DOI 10.1016/0022-1759(90)90031-P; POLONELLI L, 1988, J CLIN MICROBIOL, V26, P602, DOI 10.1128/JCM.26.3.602-604.1988; POLONELLI L, 1991, J MED VET MYCOL, V29, P235; POLONELLI L, 1993, SCAND J IMMUNOL, V37, P105, DOI 10.1111/j.1365-3083.1993.tb01671.x; POLONELLI L, 1994, J IMMUNOL, V152, P3175; Polonelli L, 1996, J IMMUNOL, V156, P1880; POLONELLI L, 1987, J CLIN MICROBIOL, V25, P460, DOI 10.1128/JCM.25.2.460-462.1987; POLONELLI L, IN PRESS CLIN DIAGN; TETI G, 1992, HYBRIDOMA, V11, P13, DOI 10.1089/hyb.1992.11.13	28	108	116	1	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1997	15	2					155	158		10.1038/nbt0297-155	http://dx.doi.org/10.1038/nbt0297-155			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WE998	9035141				2022-12-27	WOS:A1997WE99800022
J	Huang, XG; Kong, N; Zhang, XC; Cao, YH; Langer, R; Tao, W				Huang, Xiangang; Kong, Na; Zhang, Xingcai; Cao, Yihai; Langer, Robert; Tao, Wei			The landscape of mRNA nanomedicine	NATURE MEDICINE			English	Review; Early Access							DOUBLE-STRANDED-RNA; IN-VIVO; LIPID NANOPARTICLES; CIRCULAR RNAS; NUCLEOSIDE MODIFICATIONS; CATIONIC LIPIDS; POLYMER LIBRARY; DELIVERY; TRANSLATION; RECOGNITION	Messenger RNA (mRNA) is an emerging class of therapeutic agent for the prevention and treatment of a wide range of diseases. The recent success of the two highly efficacious mRNA vaccines produced by Moderna and Pfizer-BioNTech to protect against COVID-19 highlights the huge potential of mRNA technology for revolutionizing life science and medical research. Challenges related to mRNA stability and immunogenicity, as well as in vivo delivery and the ability to cross multiple biological barriers, have been largely addressed by recent progress in mRNA engineering and delivery. In this Review, we present the latest advances and innovations in the growing field of mRNA nanomedicine, in the context of ongoing clinical translation and future directions to improve clinical efficacy. The COVID-19 mRNA vaccines have transformed the field of mRNA nanomedicine, but this new class of therapeutics has the potential to treat many other diseases. This Review profiles the latest advances and challenges.	[Huang, Xiangang; Kong, Na; Tao, Wei] Brigham & Womens Hosp, Ctr Nanomed, Harvard Med Sch, 75 Francis St, Boston, MA 02115 USA; [Huang, Xiangang; Kong, Na; Tao, Wei] Brigham & Womens Hosp, Dept Anesthesiol, Harvard Med Sch, 75 Francis St, Boston, MA 02115 USA; [Kong, Na] Zhejiang Univ, Liangzhu Lab, Med Ctr, Hangzhou, Peoples R China; [Zhang, Xingcai] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA; [Cao, Yihai] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden; [Langer, Robert] MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Langer, Robert] MIT, Dept Chem Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Zhejiang University; Harvard University; Karolinska Institutet; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Tao, W (corresponding author), Brigham & Womens Hosp, Ctr Nanomed, Harvard Med Sch, 75 Francis St, Boston, MA 02115 USA.; Tao, W (corresponding author), Brigham & Womens Hosp, Dept Anesthesiol, Harvard Med Sch, 75 Francis St, Boston, MA 02115 USA.; Langer, R (corresponding author), MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Langer, R (corresponding author), MIT, Dept Chem Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	yihai.cao@ki.se; rlanger@mit.edu; wtao@bwh.harvard.edu	; zhang, xingcai/L-9533-2017	Cao, Yihai/0000-0003-1308-0065; Langer, Robert/0000-0003-4255-0492; zhang, xingcai/0000-0001-7114-1095	US METAvivor Early Career Investigator Award [2018A020560]; American Heart Association Collaborative Sciences Award [2018A004190]; Harvard Medical School/Brigham and Women's Hospital Anesthesia Department Basic Scientist Grant [2420 BPA075]; Khoury Innovation Award [2020A003219]; Gillian Reny Stepping Strong Center for Trauma Innovation Breakthrough Award [113548]; Nanotechnology Foundation [2022A002721]; Farokhzad Family Distinguished Chair Foundation [018129]	US METAvivor Early Career Investigator Award; American Heart Association Collaborative Sciences Award(American Heart Association); Harvard Medical School/Brigham and Women's Hospital Anesthesia Department Basic Scientist Grant; Khoury Innovation Award; Gillian Reny Stepping Strong Center for Trauma Innovation Breakthrough Award; Nanotechnology Foundation; Farokhzad Family Distinguished Chair Foundation	We are supported by the US METAvivor Early Career Investigator Award (2018A020560 to W.T.), Harvard Medical School/Brigham and Women's Hospital Anesthesia Department Basic Scientist Grant (2420 BPA075 to W.T.), Khoury Innovation Award (2020A003219 to W.T.), Gillian Reny Stepping Strong Center for Trauma Innovation Breakthrough Award (113548 to W.T.), Nanotechnology Foundation (2022A002721 to W.T.), Farokhzad Family Distinguished Chair Foundation (018129 to W.T.) and American Heart Association Collaborative Sciences Award (2018A004190 to W.T.).	Abramson A, 2022, MATTER-US, V5, P975, DOI 10.1016/j.matt.2021.12.022; Akinc A, 2003, J AM CHEM SOC, V125, P5316, DOI 10.1021/ja034429c; Alameh MG, 2021, IMMUNITY, V54, P2877, DOI 10.1016/j.immuni.2021.11.001; Alden M, 2022, CURR ISSUES MOL BIOL, V44, P1115, DOI 10.3390/cimb44030073; Anderluzzi G, 2022, J CONTROL RELEASE, V342, P388, DOI 10.1016/j.jconrel.2021.12.008; Anderson BR, 2011, NUCLEIC ACIDS RES, V39, P9329, DOI 10.1093/nar/gkr586; Anderson BR, 2010, NUCLEIC ACIDS RES, V38, P5884, DOI 10.1093/nar/gkq347; Andries O, 2015, J CONTROL RELEASE, V217, P337, DOI 10.1016/j.jconrel.2015.08.051; [Anonymous], 2022, MODERNA 0607; Arcturus Therapeutics, 2022, ARCT ANN SELF AMPL C; Arcturus Therapeutics. LUNAR-OTC, 2022, ARCT THER; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Baiersdorfer M, 2019, MOL THER-NUCL ACIDS, V15, P26, DOI 10.1016/j.omtn.2019.02.018; Barbier AJ, 2022, NAT BIOTECHNOL, V40, P840, DOI 10.1038/s41587-022-01294-2; Benner NL, 2019, J AM CHEM SOC, V141, P8416, DOI 10.1021/jacs.9b03154; Billingsley MM, 2022, NANO LETT, V22, P533, DOI 10.1021/acs.nanolett.1c02503; Billingsley MM, 2020, NANO LETT, V20, P1578, DOI 10.1021/acs.nanolett.9b04246; Blanchard EL, 2021, NAT BIOTECHNOL, V39, P717, DOI 10.1038/s41587-021-00822-w; Bloom K, 2021, GENE THER, V28, P117, DOI 10.1038/s41434-020-00204-y; Bollu A, 2022, ACCOUNTS CHEM RES, V55, P1249, DOI 10.1021/acs.accounts.2c00059; Buschmann MD, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010065; Cao JC, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24436-7; Chaudhary N, 2021, NAT REV DRUG DISCOV, V20, P817, DOI 10.1038/s41573-021-00283-5; Chen GL, 2022, LANCET MICROBE, V3, pE193, DOI 10.1016/S2666-5247(21)00280-9; Chen R, 2022, NAT BIOTECHNOL, DOI 10.1038/s41587-022-01393-0; Cheng Q, 2020, NAT NANOTECHNOL, V15, P313, DOI 10.1038/s41565-020-0669-6; Cheng XW, 2016, ADV DRUG DELIVER REV, V99, P129, DOI 10.1016/j.addr.2016.01.022; Cobb M, 2015, CURR BIOL, V25, pR526, DOI 10.1016/j.cub.2015.05.032; CONRY RM, 1995, CANCER RES, V55, P1397; Corey Kristen B, 2022, Ann Allergy Asthma Immunol, V129, P246, DOI 10.1016/j.anai.2022.05.013; Cui SH, 2018, TOXICOL RES-UK, V7, P473, DOI 10.1039/c8tx00005k; Cullis PR, 2017, MOL THER, V25, P1467, DOI 10.1016/j.ymthe.2017.03.013; Cully M, 2021, NAT REV DRUG DISCOV, V20, P6, DOI 10.1038/d41573-020-00220-y; de Alwis R, 2021, MOL THER, V29, P1970, DOI 10.1016/j.ymthe.2021.04.001; Devoldere J, 2016, DRUG DISCOV TODAY, V21, P11, DOI 10.1016/j.drudis.2015.07.009; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Dilliard SA, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2109256118; DIMITRIADIS GJ, 1978, NATURE, V274, P923, DOI 10.1038/274923a0; Entos Pharmaceuticals, 2022, CHALL EFF NUCL AC DE; Enuka Y, 2016, NUCLEIC ACIDS RES, V44, P1370, DOI 10.1093/nar/gkv1367; Ferdows BE, 2022, NANOSCALE, V14, P4448, DOI 10.1039/d1nr06991h; Finn JD, 2018, CELL REP, V22, P2227, DOI 10.1016/j.celrep.2018.02.014; Food and Drug Administration, 2020, PFIZ BIONTECH COVID; Garcia MA, 2007, BIOCHIMIE, V89, P799, DOI 10.1016/j.biochi.2007.03.001; Geall AJ, 2012, P NATL ACAD SCI USA, V109, P14604, DOI 10.1073/pnas.1209367109; Gebre MS, 2022, NATURE, V601, P410, DOI 10.1038/s41586-021-04231-6; George CX, 2014, J INTERF CYTOK RES, V34, P437, DOI 10.1089/jir.2014.0001; Gillmore JD, 2021, NEW ENGL J MED, V385, P493, DOI 10.1056/NEJMoa2107454; Granot Y, 2017, SEMIN IMMUNOL, V34, P68, DOI 10.1016/j.smim.2017.08.015; Green JJ, 2008, ACCOUNTS CHEM RES, V41, P749, DOI 10.1021/ar7002336; GREF R, 1994, SCIENCE, V263, P1600, DOI 10.1126/science.8128245; Gupta A, 2021, ADV DRUG DELIVER REV, V178, DOI 10.1016/j.addr.2021.113834; Haabeth OAW, 2021, ACS CENTRAL SCI, V7, P1191, DOI 10.1021/acscentsci.1c00361; Haabeth OAW, 2018, P NATL ACAD SCI USA, V115, pE9153, DOI 10.1073/pnas.1810002115; Hajj KA, 2017, NAT REV MATER, V2, DOI 10.1038/natrevmats.2017.56; Hassett KJ, 2019, MOL THER-NUCL ACIDS, V15, P1, DOI 10.1016/j.omtn.2019.01.013; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hewitt SL, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat9143; Holtkamp S, 2006, BLOOD, V108, P4009, DOI 10.1182/blood-2006-04-015024; Hornung V, 2006, SCIENCE, V314, P994, DOI 10.1126/science.1132505; Hou XC, 2021, NAT REV MATER, V6, P1078, DOI 10.1038/s41578-021-00358-0; Huang XG, 2022, NAT NANOTECHNOL, V17, P1027, DOI 10.1038/s41565-022-01174-5; Huang XG, 2022, NAT PROTOC, V17, P748, DOI 10.1038/s41596-021-00665-4; Huang XG, 2021, NANO LETT, V21, P9706, DOI 10.1021/acs.nanolett.1c03539; Huang XG, 2020, ACS MATER LETT, V2, P1509, DOI 10.1021/acsmaterialslett.0c00375; Igyarto BZ, 2021, CURR OPIN VIROL, V48, P65, DOI 10.1016/j.coviro.2021.03.008; Islam MA, 2018, NAT BIOMED ENG, V2, P850, DOI 10.1038/s41551-018-0284-0; Jayaraman M., 2012, ANGEW CHEM INT EDIT, V124, P8657, DOI [DOI 10.1002/ANIE.201203263, 10.1002/ange.201203263]; Jiang L, 2018, NAT MED, V24, P1899, DOI 10.1038/s41591-018-0199-z; Kaczmarek JC, 2021, BIOMATERIALS, V275, DOI 10.1016/j.biomaterials.2021.120966; Kaczmarek JC, 2018, NANO LETT, V18, P6449, DOI 10.1021/acs.nanolett.8b02917; Kariko K, 2005, IMMUNITY, V23, P165, DOI 10.1016/j.immuni.2005.06.008; Kariko K, 2008, MOL THER, V16, P1833, DOI 10.1038/mt.2008.200; Kariko K, 2012, MOL THER, V20, P948, DOI 10.1038/mt.2012.7; Kariko K, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr695; Kauffman K., 2022, AM SOC GENE CELL THE; Kauffman KJ, 2016, J CONTROL RELEASE, V240, P227, DOI 10.1016/j.jconrel.2015.12.032; Kawai T, 2006, NAT IMMUNOL, V7, P131, DOI 10.1038/ni1303; Kedmi R, 2018, NAT NANOTECHNOL, V13, P214, DOI 10.1038/s41565-017-0043-5; Keener AB, 2020, NATURE, V582, pS14, DOI 10.1038/d41586-020-01769-9; Kim M, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf4398; Koch L, 2017, NAT REV GENET, V18, DOI 10.1038/nrg.2017.27; Kong N, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2112696119; Kong N, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw1565; Kormann MSD, 2011, NAT BIOTECHNOL, V29, P154, DOI 10.1038/nbt.1733; Kowalski PS, 2019, MOL THER, V27, P710, DOI 10.1016/j.ymthe.2019.02.012; Kozma GT, 2020, ADV DRUG DELIVER REV, V154, P163, DOI 10.1016/j.addr.2020.07.024; Kranz LM, 2016, NATURE, V534, P396, DOI 10.1038/nature18300; Kremsner PG, 2022, LANCET INFECT DIS, V22, P329, DOI [10.1016/S1473-3099(21)00677, 10.1016/S1473-3099(21)00677-0]; Krienke Christina, 2021, Science, V371, P145, DOI 10.1126/science.aay3638; Langel SN, 2022, SCI TRANSL MED, V14, DOI 10.1126/scitranslmed.abn6868; LANGER R, 1976, NATURE, V263, P797, DOI 10.1038/263797a0; Langer R, 2019, Q REV BIOPHYS, V52, DOI 10.1017/S0033583519000040; Larson RC, 2021, NAT REV CANCER, V21, P145, DOI 10.1038/s41568-020-00323-z; Lee BL, 2014, TRENDS CELL BIOL, V24, P360, DOI 10.1016/j.tcb.2013.12.002; Lee SM, 2021, ANGEW CHEM INT EDIT, V60, P5848, DOI 10.1002/anie.202013927; Legnini I, 2017, MOL CELL, V66, P22, DOI 10.1016/j.molcel.2017.02.017; Leppek Kathrin, 2022, Nat Commun, V13, P1536, DOI [10.1101/2021.03.29.437587, 10.1038/s41467-022-28776-w]; Li JQ, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00783-1; Li WJ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21519-3; Li Y, 2022, ADV MATER, V34, DOI 10.1002/adma.202109984; Li ZY, 2015, NAT STRUCT MOL BIOL, V22, P256, DOI 10.1038/nsmb.2959; Lin YX, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.aba9772; Linares-Fernandez S, 2020, TRENDS MOL MED, V26, P311, DOI 10.1016/j.molmed.2019.10.002; Liu L, 2008, SCIENCE, V320, P379, DOI 10.1126/science.1155406; Liu S, 2021, NAT MATER, V20, P701, DOI 10.1038/s41563-020-00886-0; Lokugamage MP, 2020, ADV MATER, V32, DOI 10.1002/adma.201904905; Lu XG, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaz6606; Lutz J, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0032-6; Lv HT, 2006, J CONTROL RELEASE, V114, P100, DOI 10.1016/j.jconrel.2006.04.014; Maier MA, 2013, MOL THER, V21, P1570, DOI 10.1038/mt.2013.124; MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077; Maruggi G, 2019, MOL THER, V27, P757, DOI 10.1016/j.ymthe.2019.01.020; Matinas BioPharma, 2022, BIONTECH MAT BIOPH A; Matinas BioPharma, 2022, LIP NAN CRYST LNC D; Maugeri M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12275-6; McHugh KJ, 2017, SCIENCE, V357, P1138, DOI 10.1126/science.aaf7447; McKay PF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17409-9; McKinlay CJ, 2018, P NATL ACAD SCI USA, V115, pE5859, DOI 10.1073/pnas.1805358115; McKinlay CJ, 2017, P NATL ACAD SCI USA, V114, pE448, DOI 10.1073/pnas.1614193114; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Miao L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16248-y; Miao L, 2019, NAT BIOTECHNOL, V37, P1174, DOI 10.1038/s41587-019-0247-3; Mitchell MJ, 2021, NAT REV DRUG DISCOV, V20, P101, DOI 10.1038/s41573-020-0090-8; Moderna, 2020, PROT MRNA 1273 P301; Moderna, 2022, MODERNA 0608; Moffett HF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00505-8; Mukherjee A., 2020, SCI ADV, V6, peabc5911; Muskula PR, 2017, CIRC-CARDIOVASC IMAG, V10, DOI 10.1161/CIRCIMAGING.116.005459; Musunuru K, 2021, NATURE, V593, P429, DOI 10.1038/s41586-021-03534-y; Nelson J, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz6893; O'Shea J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040320; OSTRO MJ, 1978, NATURE, V274, P921, DOI 10.1038/274921a0; Pamudurti NR, 2017, MOL CELL, V66, P9, DOI 10.1016/j.molcel.2017.02.021; Parayath NN, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19486-2; Pardi N, 2018, J EXP MED, V215, P1571, DOI 10.1084/jem.20171450; Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243; Pardi N, 2017, NATURE, V543, P248, DOI 10.1038/nature21428; Pardi N, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14630; Pardi Norbert, 2013, Methods Mol Biol, V969, P29, DOI 10.1007/978-1-62703-260-5_2; Park JH, 2022, ANGEW CHEM INT EDIT, V61, DOI 10.1002/anie.202113671; Parry R, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2109066118; Patel AK, 2019, ADV MATER, V31, DOI 10.1002/adma.201805116; Paunovska K, 2022, NAT REV GENET, V23, P265, DOI 10.1038/s41576-021-00439-4; Paunovska K, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba5672; Paunovska K, 2019, ADV MATER, V31, DOI 10.1002/adma.201807748; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Popowski KD., 2022, EXTRACELL VESICLE, V1, P100002; Popowski KD, 2022, MATTER-US, V5, P2960, DOI 10.1016/j.matt.2022.06.012; Qu L, 2022, CELL, V185, P1728, DOI 10.1016/j.cell.2022.03.044; Ramanathan A, 2016, NUCLEIC ACIDS RES, V44, P7511, DOI 10.1093/nar/gkw551; Ramishetti S, 2020, ADV MATER, V32, DOI 10.1002/adma.201906128; Rejman J, 2010, J CONTROL RELEASE, V147, P385, DOI 10.1016/j.jconrel.2010.07.124; Richner JM, 2017, CELL, V170, P273, DOI 10.1016/j.cell.2017.06.040; Richner JM, 2017, CELL, V168, P1114, DOI 10.1016/j.cell.2017.02.017; Riley RS, 2021, SCI ADV, V7, DOI 10.1126/sciadv.aba1028; Rosa SS, 2021, VACCINE, V39, P2190, DOI 10.1016/j.vaccine.2021.03.038; Rosenblum D, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc9450; ROSS J, 1985, BLOOD, V66, P1149; Rothgangl T, 2021, NAT BIOTECHNOL, V39, P949, DOI 10.1038/s41587-021-00933-4; Rouphael NG, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00353-0; Rui Y, 2022, SCI ADV, V8, DOI 10.1126/sciadv.abk2855; Rurik JG, 2022, SCIENCE, V375, P91, DOI 10.1126/science.abm0594; Sablad M., 2019, SOC INHERITED METABO; Sabnis S, 2018, MOL THER, V26, P1509, DOI 10.1016/j.ymthe.2018.03.010; Sahin U, 2020, NATURE, V585, P107, DOI 10.1038/s41586-020-2537-9; Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003; Sahin U, 2014, NAT REV DRUG DISCOV, V13, P759, DOI 10.1038/nrd4278; Sajid A, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abj9827; Sample PJ, 2019, NAT BIOTECHNOL, V37, P803, DOI 10.1038/s41587-019-0164-5; Sarmadi M, 2022, SCI ADV, V8, DOI 10.1126/sciadv.abn5315; Schlake T, 2019, CELL MOL LIFE SCI, V76, P301, DOI 10.1007/s00018-018-2935-4; Schlee M, 2009, IMMUNITY, V31, P25, DOI 10.1016/j.immuni.2009.05.008; Sedic M, 2018, VET PATHOL, V55, P341, DOI 10.1177/0300985817738095; Segel M, 2021, SCIENCE, V373, P882, DOI 10.1126/science.abg6155; Sharp PA, 2009, CELL, V136, P577, DOI 10.1016/j.cell.2009.02.007; Shimabukuro TT, 2021, JAMA-J AM MED ASSOC, V325, P1101, DOI 10.1001/jama.2021.1967; Shmulevitz M, 2000, EMBO J, V19, P902, DOI 10.1093/emboj/19.5.902; Silverman RH, 2007, J VIROL, V81, P12720, DOI 10.1128/JVI.01471-07; Song CQ, 2020, NAT BIOMED ENG, V4, P125, DOI 10.1038/s41551-019-0357-8; Su FY, 2022, SCI ADV, V8, DOI 10.1126/sciadv.abm7950; Sun Y, 2022, NAT CHEM, V14, P274, DOI 10.1038/s41557-021-00854-4; Szoke D, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23546-6; Tang ZM, 2021, NANO TODAY, V36, DOI 10.1016/j.nantod.2020.101019; Tang ZM, 2020, NAT REV MATER, V5, P847, DOI 10.1038/s41578-020-00247-y; Tanji H, 2015, NAT STRUCT MOL BIOL, V22, P109, DOI 10.1038/nsmb.2943; Tao W, 2022, MATTER-US, V5, P775, DOI 10.1016/j.matt.2022.02.008; Tao W, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay1063; Thess A, 2015, MOL THER, V23, P1456, DOI 10.1038/mt.2015.103; Tombacz I, 2021, MOL THER, V29, P3293, DOI 10.1016/j.ymthe.2021.06.004; Tran E, 2017, NEW ENGL J MED, V377, P2593, DOI 10.1056/NEJMe1714680; Tsui NBY, 2002, CLIN CHEM, V48, P1647; van Dulmen M, 2021, ANGEW CHEM INT EDIT, V60, P13280, DOI 10.1002/anie.202100352; Veiga N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06936-1; von Niessen AGO, 2019, MOL THER, V27, P824, DOI 10.1016/j.ymthe.2018.12.011; Wesselhoeft RA, 2019, MOL CELL, V74, P508, DOI 10.1016/j.molcel.2019.02.015; Wesselhoeft RA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05096-6; Xia DN, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2110817118; Xia YQ, 2016, BIOMATERIALS, V79, P56, DOI 10.1016/j.biomaterials.2015.11.056; Xiao YF, 2022, CHEM SOC REV, V51, P3828, DOI 10.1039/d1cs00617g; Xiao YL, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-28279-8; Xue LL, 2022, J AM CHEM SOC, V144, P9926, DOI 10.1021/jacs.2c02706; Yang ZG, 2020, NAT BIOMED ENG, V4, P69, DOI 10.1038/s41551-019-0485-1; Yin H, 2017, NAT BIOTECHNOL, V35, P1179, DOI 10.1038/nbt.4005; Zeng CX, 2020, ADV MATER, V32, DOI 10.1002/adma.202004452; Zhang DP, 2021, J AM CHEM SOC, V143, P17975, DOI 10.1021/jacs.1c09585; Zhang DP, 2021, J AM CHEM SOC, V143, P12315, DOI 10.1021/jacs.1c05813; Zhang D, 2022, NAT NANOTECHNOL, V17, P777, DOI 10.1038/s41565-022-01122-3; Zhang HX, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2005191118; Zhang LG, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2105968118; Zhang NN, 2020, CELL, V182, P1271, DOI 10.1016/j.cell.2020.07.024; Zhang SY, 2021, NANO LETT, V21, P8563, DOI 10.1021/acs.nanolett.1c01817; Zhang XP, 2020, J CLIN PHARMACOL, V60, P573, DOI 10.1002/jcph.1553; Zhang YB, 2021, CHEM REV, V121, P12181, DOI 10.1021/acs.chemrev.1c00244; Zhao XW, 2020, ANGEW CHEM INT EDIT, V59, P20083, DOI 10.1002/anie.202008082; Zhu X, 2015, P NATL ACAD SCI USA, V112, P7779, DOI 10.1073/pnas.1505629112; Zust R, 2011, NAT IMMUNOL, V12, P137, DOI 10.1038/ni.1979	217	0	0	46	46	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02061-1	http://dx.doi.org/10.1038/s41591-022-02061-1		NOV 2022	15	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	6B8KC	36357682	Bronze			2022-12-27	WOS:000881574700003
J	Bailon, L; Llano, A; Cedeno, S; Escriba, T; Rosas-Umbert, M; Parera, M; Casadella, M; Lopez, M; Perez, F; Oriol-Tordera, B; Ruiz-Riol, M; Coll, J; Perez, F; Leselbaum, AR; McGowan, I; Sengupta, D; Wee, EG; Hanke, T; Paredes, R; Alarcon-Soto, Y; Clotet, B; Noguera-Julian, M; Brander, C; Molto, J; Mothe, B; Rivero, A				Bailon, Lucia; Llano, Anuska; Cedeno, Samandhy; Escriba, Tuixent; Rosas-Umbert, Miriam; Parera, Mariona; Casadella, Maria; Lopez, Miriam; Perez, Francisco; Oriol-Tordera, Bruna; Ruiz-Riol, Marta; Coll, Josep; Perez, Felix; Leselbaum, Anne R.; McGowan, Ian; Sengupta, Devi; Wee, Edmund G.; Hanke, Tomas; Paredes, Roger; Alarcon-Soto, Yovaninna; Clotet, Bonaventura; Noguera-Julian, Marc; Brander, Christian; Molto, Jose; Mothe, Beatriz; Rivero, Angel		AELIXOO2 Study Grp	Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial	NATURE MEDICINE			English	Article; Early Access							ANTIRETROVIRAL THERAPY; PERFORMANCE; ALIGNMENT; RESERVOIR; DYNAMICS	HIVACAT T-cell immunogen (HTI) is a novel human immunodeficiency virus (HIV) vaccine immunogen designed to elicit cellular immune responses to HIV targets associated with viral control in humans. The AELIX-002 trial was a randomized, placebo-controlled trial to evaluate as a primary objective the safety of a combination of DNA.HTI (D), MVA.HTI (M) and ChAdOx1.HTI (C) vaccines in 45 early-antiretroviral (ART)-treated individuals (44 men, 1 woman; NCT03204617). Secondary objectives included T-cell immunogenicity, the effect on viral rebound and the safety of an antiretroviral treatment interruption (ATI). Adverse events were mostly mild and transient. No related serious adverse events were observed. We show here that HTI vaccines were able to induce strong, polyfunctional and broad CD4 and CD8 T-cell responses. All participants experienced detectable viral rebound during ATI, and resumed ART when plasma HIV-1 viral load reached either >100,000 copies ml(-1), >10,000 copies ml(-1) for eight consecutive weeks, or after 24 weeks of ATI. In post-hoc analyses, HTI vaccines were associated with a prolonged time off ART in vaccinees without beneficial HLA (human leukocyte antigen) class I alleles. Plasma viral load at the end of ATI and time off ART positively correlated with vaccine-induced HTI-specific T-cell responses at ART cessation. Despite limited efficacy of the vaccines in preventing viral rebound, their ability to elicit robust T-cell responses towards HTI may be beneficial in combination cure strategies, which are currently being tested in clinical trials. Vaccines that elicit HIV-specific T-cell responses did not prevent viral rebound in people living with HIV upon antiretroviral treatment (ART) interruption, but associated with longer time off ART in some trial participants, suggesting their immunogenicity may benefit future cure approaches.	[Bailon, Lucia; Lopez, Miriam; Perez, Francisco; Alarcon-Soto, Yovaninna; Clotet, Bonaventura; Molto, Jose; Mothe, Beatriz] Hosp Badalona Germans Trias & Pujol, Infect Dis Dept, Fundacio Lluita Infecc, Barcelona, Spain; [Bailon, Lucia] Autonomous Univ Barcelona, Dept Med, Catalonia, Spain; [Llano, Anuska; Cedeno, Samandhy; Escriba, Tuixent; Rosas-Umbert, Miriam; Parera, Mariona; Casadella, Maria; Oriol-Tordera, Bruna; Ruiz-Riol, Marta; Coll, Josep; Paredes, Roger; Clotet, Bonaventura; Noguera-Julian, Marc; Brander, Christian; Mothe, Beatriz] Hosp Badalona Germans Trias & Pujol, IrsiCaixa AIDS Res Inst, Barcelona, Spain; [Rosas-Umbert, Miriam] Aarhus Univ, Inst Clin Med, Aarhus, Denmark; [Ruiz-Riol, Marta; Coll, Josep; Paredes, Roger; Clotet, Bonaventura; Noguera-Julian, Marc; Brander, Christian; Molto, Jose; Mothe, Beatriz] ISCIII, CIBERINFEC, Madrid, Spain; [Coll, Josep; Perez, Felix; Leselbaum, Anne R.; Rivero, Angel] Bcn Checkpoint, Projecte Noms Hispanosida, Barcelona, Spain; [McGowan, Ian; Brander, Christian] AELIX Therapeut SL, Barcelona, Spain; [McGowan, Ian] Univ Pittsburgh, Pittsburgh, PA USA; [Sengupta, Devi] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA; [Wee, Edmund G.; Hanke, Tomas] Univ Oxford, Jenner Inst, Nuffield Dept Med, Oxford, England; [Hanke, Tomas] Kumamoto Univ, Joint Res Ctr Human Retrovirus Infect, Kumamoto, Japan; [Paredes, Roger; Clotet, Bonaventura; Noguera-Julian, Marc; Brander, Christian; Mothe, Beatriz] Cent Univ Catalonia UVic UCC, Univ Vic, Fac Med, Ctr Hlth & Social Care Res CESS, Barcelona, Spain; [Paredes, Roger; Molto, Jose; Mothe, Beatriz] Germans Trias & Pujol Res Inst, Badalona, Spain; [Alarcon-Soto, Yovaninna] Univ Politecn Catalunya BARCELONATECH, Dept Estadist & Invest Operat, Barcelona, Spain; [Brander, Christian] ICREA, Barcelona, Spain	Hospital Germans Trias i Pujol; Autonomous University of Barcelona; Hospital Germans Trias i Pujol; Institut de Recerca de la Sida - IrsiCaixa; Aarhus University; Instituto de Salud Carlos III; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Gilead Sciences; University of Oxford; Jenner Institute; Kumamoto University; Universitat de Vic - Universitat Central de Catalunya (UVic-UCC); University of Barcelona; Universitat Politecnica de Catalunya; ICREA	Molto, J (corresponding author), Hosp Badalona Germans Trias & Pujol, Infect Dis Dept, Fundacio Lluita Infecc, Barcelona, Spain.; Molto, J (corresponding author), ISCIII, CIBERINFEC, Madrid, Spain.; Molto, J (corresponding author), Germans Trias & Pujol Res Inst, Badalona, Spain.	jmolto@lluita.org	; Noguera-Julian, Marc/F-8651-2016	Rosas-Umbert, Miriam/0000-0002-2850-6586; Noguera-Julian, Marc/0000-0002-6194-1395; Perez-Tejera, Felix/0000-0002-6799-9272; Paredes, Roger/0000-0002-6553-691X; Escriba, Tuixent/0000-0001-9467-7802	AELIX Therapeutics SL; Spanish Research Agency; European Regional Development Fund [RTC-2017-6473-1]; European Union [681137-EAVI2020]; NIH [P01-AI131568]; ISCIII [RH CM20/00097, PI20/01039]	AELIX Therapeutics SL; Spanish Research Agency(Spanish Government); European Regional Development Fund(European Commission); European Union(European Commission); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ISCIII(Instituto de Salud Carlos III)	Special thanks go to all the volunteers participating in this study for their perseverance and dedication. We especially thank the SMC members E. Negredo, M. Farre and F. Garcia for their commitment to oversee the risk-mitigation plan during the challenging COVID-19 pandemic. We thank R. Ayen, L. Gomez, C. Ramirez and E. Grau from the sample processing laboratory at IrsiCaixa, Badalona, Spain for their technical assistance throughout the study. We thank B. K. Felber and G. N. Pavlakis from the NCI-Frederick, MD, USA and A. Crook from the Jenner Institute, The Nuffield Department of Medicine, University of Oxford, UK for their assistance in the construction and provision of the pre-GMP starting materials of DNA.HTI, MVA.HTI and ChAdOx1.HTI under MTA contracts. This work was supported by AELIX Therapeutics SL, and partly by grants from the Spanish Research Agency and the European Regional Development Fund under contract no. RTC-2017-6473-1 ((AEI/FEDER, UE)/(MINECO/FEDER, UE)), the European Union's Horizon 2020 research and innovation program under grant agreement 681137-EAVI2020, NIH grant P01-AI131568 and by ISCIII PI20/01039. L.B. held a PhD grant from ISCIII (RH CM20/00097) during the conduct of the study. This study was funded by AELIX Therapeutics SL, who participated in the design of the study, provided the IMP of the study, oversaw all safety monitoring activities, data analysis and interpretation, and reviewed the manuscript.	Abdel-Mohsen M, 2020, NAT MED, V26, P1339, DOI 10.1038/s41591-020-1022-1; Bayon-Gil A, 2020, J ANTIMICROB CHEMOTH, V75, P2258, DOI 10.1093/jac/dkaa139; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Borducchi EN, 2018, NATURE, V563, P360, DOI 10.1038/s41586-018-0600-6; Bruner KM, 2019, NATURE, V566, P120, DOI 10.1038/s41586-019-0898-8; Caskey M, 2020, CURR OPIN HIV AIDS, V15, P49, DOI 10.1097/COH.0000000000000600; Deng K, 2015, NATURE, V517, P381, DOI 10.1038/nature14053; Dicks MDJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040385; Dube K, 2021, HIV RES CLIN PRACT, V22, P14, DOI 10.1080/25787489.2021.1902116; Enrich E, 2018, BONE MARROW TRANSPL, V53, P741, DOI 10.1038/s41409-018-0114-8; Fajnzylber J, 2021, AIDS, V35, P2225, DOI 10.1097/QAD.0000000000002978; Fidler S, 2021, J VIRUS ERAD, V7, DOI 10.1016/j.jve.2020.100025; Fidler S, 2020, LANCET, V395, P888, DOI 10.1016/S0140-6736(19)32990-3; Fiebig EW, 2003, AIDS, V17, P1871, DOI 10.1097/00002030-200309050-00005; Gaebler C, 2021, J VIROL, V95, DOI 10.1128/JVI.01986-20; Goulder PJR, 2012, IMMUNITY, V37, P426, DOI 10.1016/j.immuni.2012.09.005; Greinacher A, 2021, NEW ENGL J MED, V384, P2092, DOI 10.1056/NEJMoa2104840; Hancock G, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004658; Hayton EJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101591; Julg B, 2019, LANCET HIV, V6, pE259, DOI 10.1016/S2352-3018(19)30052-9; Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010; Kawana-Tachikawa A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087334; Kulkarni V, 2011, VACCINE, V29, P6742, DOI 10.1016/j.vaccine.2010.12.056; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Letourneau S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000984; Lewin SR, 2021, LANCET HIV, V8, P42, DOI 10.1016/S2352-3018(20)30234-4; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Mendoza P, 2018, NATURE, V561, P479, DOI 10.1038/s41586-018-0531-2; Mothe B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00823; Mothe B, 2019, ECLINICALMEDICINE, V11, P65, DOI 10.1016/j.eclinm.2019.05.009; Mothe B, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0392-5; Mothe B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029717; Mothe B, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-208; Namazi G, 2018, J INFECT DIS, V218, P1954, DOI 10.1093/infdis/jiy479; Nishimura Y, 2017, NATURE, V543, P559, DOI 10.1038/nature21435; Noguera-Julian M, 2017, J INFECT DIS, V216, pS829, DOI 10.1093/infdis/jix397; Okoye AA, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI141677; Peluso MJ, 2021, CLIN INFECT DIS, V72, P1843, DOI 10.1093/cid/ciaa1260; Pineda-Pena AC, 2013, INFECT GENET EVOL, V19, P337, DOI 10.1016/j.meegid.2013.04.032; Posas-Umbert M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00418; Schliep KP, 2011, BIOINFORMATICS, V27, P592, DOI 10.1093/bioinformatics/btq706; SenGupta D, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abg3071; Shan L, 2012, IMMUNITY, V36, P491, DOI 10.1016/j.immuni.2012.01.014; Sneller MC, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan8848; Sogaard OS, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005142; Werner RN, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208107; Yang HB, 2012, J INFECT DIS, V206, P552, DOI 10.1093/infdis/jis379	47	0	0	5	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02060-2	http://dx.doi.org/10.1038/s41591-022-02060-2		OCT 2022	32	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	5R4HU	36302893	Bronze			2022-12-27	WOS:000874473900001
J	Elez, E; Ros, J; Fernandez, J; Villacampa, G; Moreno-Cardenas, AB; Arenillas, C; Bernatowicz, K; Comas, R; Li, SS; Kodack, DP; Fasani, R; Garcia, A; Gonzalo-Ruiz, J; Piris-Gimenez, A; Nuciforo, P; Kerr, G; Intini, R; Montagna, A; Germani, MM; Randon, G; Vivancos, A; Smits, R; Graus, D; Perez-Lopez, R; Cremolini, C; Lonardi, S; Pietrantonio, F; Dienstmann, R; Tabernero, J; Toledo, RA				Elez, Elena; Ros, Javier; Fernandez, Jose; Villacampa, Guillermo; Moreno-Cardenas, Ana Belen; Arenillas, Carlota; Bernatowicz, Kinga; Comas, Raquel; Li, Shanshan; Kodack, David Philip; Fasani, Roberta; Garcia, Ariadna; Gonzalo-Ruiz, Javier; Piris-Gimenez, Alejandro; Nuciforo, Paolo; Kerr, Grainne; Intini, Rossana; Montagna, Aldo; Germani, Marco Maria; Randon, Giovanni; Vivancos, Ana; Smits, Ron; Graus, Diana; Perez-Lopez, Raquel; Cremolini, Chiara; Lonardi, Sara; Pietrantonio, Filippo; Dienstmann, Rodrigo; Tabernero, Josep; Toledo, Rodrigo A.			RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF(V600E) metastatic colorectal cancer	NATURE MEDICINE			English	Article; Early Access							SUBGROUP ANALYSES; BRAF; SURVIVAL; INHIBITION; BEVACIZUMAB; VEMURAFENIB; ENCORAFENIB; OXALIPLATIN; CETUXIMAB; PATTERNS	Anti-BRAF/EGFR therapy was recently approved for the treatment of metastatic BRAF(V600E) colorectal cancer (mCRC(BRAF-V600E)). However, a large fraction of patients do not respond, underscoring the need to identify molecular determinants of treatment response. Using whole-exome sequencing in a discovery cohort of patients with mCRC(BRAF-V600E) treated with anti-BRAF/EGFR therapy, we found that inactivating mutations in RNF43, a negative regulator of WNT, predict improved response rates and survival outcomes in patients with microsatellite-stable (MSS) tumors. Analysis of an independent validation cohort confirmed the relevance of RNF43 mutations to predicting clinical benefit (72.7% versus 30.8%; P = 0.03), as well as longer progression-free survival (hazard ratio (HR), 0.30; 95% confidence interval (CI), 0.12-0.75; P = 0.01) and overall survival (HR, 0.26; 95% CI, 0.10-0.71; P = 0.008), in patients with MSS-RNF43(mutated) versus MSS-RNF43(wild-type) tumors. Microsatellite-instable tumors invariably carried a wild-type-like RNF43 genotype encoding p.G659fs and presented an intermediate response profile. We found no association of RNF43 mutations with patient outcomes in a control cohort of patients with MSS-mCRC(BRAF-V600E) tumors not exposed to anti-BRAF targeted therapies. Overall, our findings suggest a cross-talk between the MAPK and WNT pathways that may modulate the antitumor activity of anti-BRAF/EGFR therapy and uncover predictive biomarkers to optimize the clinical management of these patients. The presence of inactivating mutations in RNF43, a negative regulator of WNT, in tumor cells predicts improved response rates and survival outcomes in patients with metastatic BRAF(V600E) colorectal cancer treated with anti-BRAF/EGFR therapy.	[Elez, Elena; Ros, Javier; Tabernero, Josep] Vall dHebron Univ Hosp, Med Oncol Dept, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain; [Elez, Elena; Ros, Javier; Fernandez, Jose; Villacampa, Guillermo; Moreno-Cardenas, Ana Belen; Arenillas, Carlota; Bernatowicz, Kinga; Comas, Raquel; Fasani, Roberta; Garcia, Ariadna; Gonzalo-Ruiz, Javier; Piris-Gimenez, Alejandro; Nuciforo, Paolo; Vivancos, Ana; Perez-Lopez, Raquel; Dienstmann, Rodrigo; Tabernero, Josep; Toledo, Rodrigo A.] Vall dHebron Inst Oncol VHIO, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain; [Ros, Javier] Univ Campania Luigi Vanvitelli, Dipartimento Med Precis, Oncol Med, Naples, Italy; [Arenillas, Carlota; Tabernero, Josep; Toledo, Rodrigo A.] Inst Hlth Carlos III ISCIII, Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain; [Li, Shanshan; Smits, Ron] Erasmus MC Univ Med Ctr, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands; [Kodack, David Philip] Novartis Inst BioMed Res, Cambridge, MA USA; [Kerr, Grainne; Graus, Diana] Novartis, Oncol Dept, Novartis Inst Biomed Res, Basel, Switzerland; [Intini, Rossana; Montagna, Aldo; Lonardi, Sara] IRCCS, Dept Oncol, Veneto Inst Oncol, Padua, Italy; [Germani, Marco Maria; Cremolini, Chiara] Univ Pisa, Azienda Osped Univ Pisana, Dept Translat Res & New Technol Med, Unit Med Oncol, Pisa, Italy; [Randon, Giovanni; Pietrantonio, Filippo] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy; [Perez-Lopez, Raquel] Vall dHebron Univ Hosp, Radiol Dept, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain; [Tabernero, Josep] UVic UCC, IOB Quiron, Barcelona, Spain; [Graus, Diana] Ridgeline Discovery, Basel, Switzerland	Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO); Universita della Campania Vanvitelli; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Erasmus University Rotterdam; Erasmus MC; Novartis; Novartis; IRCCS Istituto Oncologico Veneto (IOV); University of Pisa; Azienda Ospedaliero Universitaria Pisana; Fondazione IRCCS Istituto Nazionale Tumori Milan; Hospital Universitari Vall d'Hebron; Universitat de Vic - Universitat Central de Catalunya (UVic-UCC)	Elez, E (corresponding author), Vall dHebron Univ Hosp, Med Oncol Dept, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain.; Elez, E; Toledo, RA (corresponding author), Vall dHebron Inst Oncol VHIO, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain.	meelez@vhio.net; rtoledo@vhio.net	Gonzalo-Ruiz, Javier/B-8418-2009	Gonzalo-Ruiz, Javier/0000-0003-4342-3815; Ros, Javier/0000-0002-8137-5415	FERO Foundation; Consorcio Centro de Investigacion Biomedica en Red de Cancer (CIBERONC) from the Institute of Health Carlos III (ISCIII), Ministry of Science and Innovation [CB16/12/00259]; Department of Health (Generalitat de Catalunya) [SLT008/18/00198, SLT008/18/00205]; State Agency for Research (Agencia Estatal de Investigacion) [CEX2020-001024-S/AEI/10.13039/501100011033]; SCITRON program; Novartis [3003145512]; Chinese Scholarship Council PhD fellowship [201909370083]; CRIS Foundation Talent Award [TALENT19-05]; Instituto de Salud Carlos III-Investigacion en Salud [PI18/01395, PI21/01019]; Prostate Cancer Foundation; Miguel Servet-I Research Award from ISCIII of the Ministry of Economy [CP17/00199]; Olga Torres Foundation [2601]; ISCIII-FEDER [PI17/00947, PI20/00968]; Fundacion AECC [CLSEN19001ELEZ]; Ministry of Science and Innovation (Europa Redes y Gestores) [ECT2020-000827]	FERO Foundation; Consorcio Centro de Investigacion Biomedica en Red de Cancer (CIBERONC) from the Institute of Health Carlos III (ISCIII), Ministry of Science and Innovation; Department of Health (Generalitat de Catalunya)(Generalitat de Catalunya); State Agency for Research (Agencia Estatal de Investigacion); SCITRON program; Novartis(Novartis); Chinese Scholarship Council PhD fellowship; CRIS Foundation Talent Award; Instituto de Salud Carlos III-Investigacion en Salud; Prostate Cancer Foundation; Miguel Servet-I Research Award from ISCIII of the Ministry of Economy; Olga Torres Foundation; ISCIII-FEDER(Spanish Government); Fundacion AECC; Ministry of Science and Innovation (Europa Redes y Gestores)	VHIO would like to acknowledge the Cellex Foundation for providing research facilities and equipment, the FERO Foundation for their funding support, the Consorcio Centro de Investigacion Biomedica en Red de Cancer (CIBERONC, CB16/12/00259) from the Institute of Health Carlos III (ISCIII), Ministry of Science and Innovation, and the Department of Health (Generalitat de Catalunya, SLT008/18/00198 and SLT008/18/00205) for their support on this research. Authors acknowledge financial support from the State Agency for Research (Agencia Estatal de Investigacion) (CEX2020-001024-S/AEI/10.13039/501100011033). This research is funded by the SCITRON program; Novartis funded the genomics characterization by WES of samples from 28 patients from the discovery cohort and had no influence on data analysis/interpretation or writing of the paper (3003145512 to R.A.T.). S.Li. is financially supported by a Chinese Scholarship Council PhD fellowship (201909370083 to S. Li). R.P.-L. is supported by a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation, the Instituto de Salud Carlos III-Investigacion en Salud (PI18/01395 and PI21/01019 to R.P.-L.) and the Prostate Cancer Foundation (Young Investigator Award). This work was supported by the Miguel Servet-I Research Award from ISCIII of the Ministry of Economy (CP17/00199 to R.A.T.), the Olga Torres Foundation Award to emerging researchers (2601 to R.A.T.), the ISCIII-FEDER (PI17/00947 and PI20/00968 to E.E.), and the Fundacion AECC (CLSEN19001ELEZ to E.E.) and Ministry of Science and Innovation (Europa Redes y Gestores, ECT2020-000827 to E.E.).	Ahronian LG, 2015, CANCER DISCOV, V5, P358, DOI 10.1158/2159-8290.CD-14-1518; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Cremolini C, 2015, LANCET ONCOL, V16, P1306, DOI 10.1016/S1470-2045(15)00122-9; Di Nicolantonio F, 2021, NAT REV CLIN ONCOL, V18, P506, DOI 10.1038/s41571-021-00495-z; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garcia Maxime, 2020, F1000Res, V9, P63, DOI 10.12688/f1000research.16665.2; Garcia-Barcena C, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00039; Hastings RK, 2021, ANN ONCOL, V32, P681, DOI 10.1016/j.annonc.2021.02.007; Hoadley KA, 2018, CELL, V173, P291, DOI 10.1016/j.cell.2018.03.022; Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309; Kabiri Z, 2018, J CLIN INVEST, V128, P3806, DOI 10.1172/JCI99325; Koo BK, 2012, NATURE, V488, P665, DOI 10.1038/nature11308; Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075; Kopetz S, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.3534; Kopetz S, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.3513; Kopetz S, 2021, J CLIN ONCOL, V39, P285, DOI 10.1200/JCO.20.01994; Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497; Li S, 2020, ONCOGENE, V39, P3458, DOI 10.1038/s41388-020-1232-5; Martincorena I, 2017, CELL, V171, P1029, DOI 10.1016/j.cell.2017.09.042; Middleton G, 2020, CLIN CANCER RES, V26, P2466, DOI 10.1158/1078-0432.CCR-19-3579; Morris V, 2014, CLIN COLORECTAL CANC, V13, P164, DOI 10.1016/j.clcc.2014.06.001; Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Radaszkiewicz T, 2021, ELIFE, V10, DOI [10.7554/eLife.65759, 10.7554/eLife.65759.sa1, 10.7554/eLife.65759.sa2]; Randon G, 2022, EUR J CANCER, V161, P90, DOI 10.1016/j.ejca.2021.11.018; Schwartz LH, 2016, EUR J CANCER, V62, P138, DOI 10.1016/j.ejca.2016.03.082; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Tabernero J, 2021, J CLIN ONCOL, V39, P273, DOI 10.1200/JCO.20.02088; Tabernero J, 2015, LANCET ONCOL, V16, P499, DOI 10.1016/S1470-2045(15)70127-0; Toledo RA, 2018, CLIN CANCER RES, V24, P3550, DOI 10.1158/1078-0432.CCR-18-0103; Tsukiyama T, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18257-3; Tu JH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54931-3; Van Cutsem E, 2014, ANN ONCOL, V25, P1, DOI 10.1093/annonc/mdu260; Van Cutsem E, 2019, J CLIN ONCOL, V37, P1460, DOI 10.1200/JCO.18.02459; Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201; van Geel RMJM, 2017, CANCER DISCOV, V7, P610, DOI 10.1158/2159-8290.CD-16-0795; Yaeger R, 2018, CANCER CELL, V33, P125, DOI 10.1016/j.ccell.2017.12.004; Yu J, 2020, CANCER RES, V80, P5619, DOI 10.1158/0008-5472.CAN-20-0957	40	1	1	5	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01976-z	http://dx.doi.org/10.1038/s41591-022-01976-z		SEP 2022	23	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4L9HT	36097219	Green Published, hybrid			2022-12-27	WOS:000852940800004
J	Glenn, JS				Glenn, Jeffrey S.			Programmable antivirals to target conserved essential shapes in pandemic viral genomes	NATURE MEDICINE			English	Editorial Material; Early Access							INFLUENZA		[Glenn, Jeffrey S.] Stanford Med, ViRx Stanford, Stanford, CA 94305 USA		Glenn, JS (corresponding author), Stanford Med, ViRx Stanford, Stanford, CA 94305 USA.							Adalja AA, 2019, CURR TOP MICROBIOL, V424, P1, DOI 10.1007/82_2019_176; Carrasco-Hernandez R, 2017, ILAR J, V58, P343, DOI 10.1093/ilar/ilx026; Cho NJ, 2020, NAT MATER, V19, P813, DOI 10.1038/s41563-020-0698-4; Johnson NPAS, 2002, B HIST MED, V76, P105, DOI 10.1353/bhm.2002.0022; Taubenberger JK, 2006, EMERG INFECT DIS, V12, P15, DOI 10.3201/eid1209.05-0979	5	0	0	1	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01910-3	http://dx.doi.org/10.1038/s41591-022-01910-3		AUG 2022	1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3Z7NO	36008723	Bronze, Green Published			2022-12-27	WOS:000844603700002
J	Sumner, CJ; Crawford, TO				Sumner, Charlotte J.; Crawford, Thomas O.			Early treatment is a lifeline for infants with SMA	NATURE MEDICINE			English	Editorial Material							SPINAL MUSCULAR-ATROPHY; ABEPARVOVEC GENE-THERAPY; SINGLE-ARM; OPEN-LABEL; MULTICENTER	In the phase 3 SPR1NT trial, pre-symptomatic gene therapy demonstrated impressive clinical outcomes in infants with a genetic diagnosis of spinal muscular atrophy (SMA); long-term safety follow-up of these patients must now be a key priority.	[Sumner, Charlotte J.; Crawford, Thomas O.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Sumner, Charlotte J.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; [Crawford, Thomas O.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Sumner, CJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA.; Sumner, CJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.	csumner1@jhmi.edu		Sumner, Charlotte/0000-0001-5088-6012				[Anonymous], 2020, LONG TERM FOLL UP AD; Crawford TO, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI152817; Das A, 2022, J VIROL, V96, DOI 10.1128/JVI.02039-21; Day JW, 2021, LANCET NEUROL, V20, P284, DOI 10.1016/S1474-4422(21)00001-6; De Vivo DC, 2019, NEUROMUSCULAR DISORD, V29, P842, DOI 10.1016/j.nmd.2019.09.007; Finkel RS, 2021, NEUROLOGY, V96; Kong LL, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abb6871; Mercuri E, 2021, LANCET NEUROL, V20, P832, DOI 10.1016/S1474-4422(21)00251-9; Ramos DM, 2019, J CLIN INVEST, V129, P4817, DOI 10.1172/JCI124120; Strauss KA, 2022, NAT MED, V28, P1381, DOI 10.1038/s41591-022-01866-4; Strauss KA, 2022, NAT MED, V28, P1390, DOI 10.1038/s41591-022-01867-3; Thomsen G, 2021, NAT MED, V27, P1701, DOI 10.1038/s41591-021-01483-7; Uchitel J, 2020, PEDIATR NEUROL, V110, P5, DOI 10.1016/j.pediatrneurol.2020.04.010	13	0	0	1	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2022	28	7					1348	1349		10.1038/s41591-022-01889-x	http://dx.doi.org/10.1038/s41591-022-01889-x		JUL 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3E5PS	35840728				2022-12-27	WOS:000825930600003
J	Singer, DS				Singer, Dinah S.			A new phase of the Cancer Moonshot to end cancer as we know it	NATURE MEDICINE			English	Editorial Material									[Singer, Dinah S.] NCI, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Singer, DS (corresponding author), NCI, Bethesda, MD 20892 USA.	singerd@mail.nih.gov						[Anonymous], 2022, WHITE HOUSE BRIEFING; [Anonymous], CANC MOONSHOT SM BIO; Bell-Brown Ari, 2022, Front Health Serv, V1, DOI 10.3389/frhs.2021.799816; Boone MA, 2021, ONCOGENE, V40, P4759, DOI 10.1038/s41388-021-01876-5; Damnernsawad A, 2022, HAEMATOLOGICA, V107, P77, DOI 10.3324/haematol.2020.257964; Jessup J, 2022, IEEE T VIS COMPUT GR, V28, P259, DOI 10.1109/TVCG.2021.3114786; Jiang HL, 2022, GASTROENTEROLOGY, V162, P590, DOI 10.1053/j.gastro.2021.09.066; Menon Usha, 2022, Implement Sci Commun, V3, P6, DOI 10.1186/s43058-022-00253-x; Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565; Mohamed MR, 2021, J GERIATR ONCOL, V12, P1208, DOI 10.1016/j.jgo.2021.06.007; Nathalie H, 2021, BMC HEALTH SERV RES, V21, DOI 10.1186/s12913-021-07195-5; Pieper AA, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-002715; Porras C, 2022, VACCINE, V40, P76, DOI 10.1016/j.vaccine.2021.11.041; Seong BKA, 2021, CANCER CELL, V39, P1262, DOI 10.1016/j.ccell.2021.07.003; Sun H, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25177-3; Vasileva E, 2022, ELIFE, V11, DOI 10.7554/eLife.69734; Xue, 2020, CANCER EPIDEMIOL, V147, P2416; Zheng SS, 2022, BLOOD CANCER DISCOV, V3, P103, DOI 10.1158/2643-3230.BCD-21-0087; Zullig LL, 2021, BMC FAM PRACT, V22, DOI 10.1186/s12875-021-01569-8	19	0	0	2	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2022	28	7					1345	1347		10.1038/s41591-022-01881-5	http://dx.doi.org/10.1038/s41591-022-01881-5		JUN 2022	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3E5PS	35760861	Bronze, Green Published			2022-12-27	WOS:000817012300001
J	deRuyter, PGGA; Kuipers, OP; Meijer, WC; deVos, WM				deRuyter, PGGA; Kuipers, OP; Meijer, WC; deVos, WM			Food-grade controlled lysis of Lactococcus lactis for accelerated cheese ripening	NATURE BIOTECHNOLOGY			English	Article						cheese ripening; lysin; holin; Lactococcus lactis	BACTERIOPHAGE LYSIS; AMINOPEPTIDASE-N; GENE-EXPRESSION; ACID BACTERIA; SYSTEMS; CLONING; HOLINS; NISIN; PHAGE	An attractive approach to accelerate cheese ripening is to induce lysis of Lactococcus lactis starter strains for facilitated release of intracellular enzymes involved in flavor formation. Controlled expression of the lytic genes lytA and lytH, which encode the lysin and the holin proteins of the lactococcal bacteriophage Phi US3, respectively, was accomplished by application of a food-grade nisin-inducible expression system. Simultaneous production of lysin and holin is essential to obtain efficient lysis and concomitant release of intracellular enzymes as exemplified by complete release of the debittering intracellular aminopeptidase N. Production of holin alone leads to partial lysis of the host cells, whereas production of lysin alone does not cause significant lysis. Model cheese experiments in which the inducible holin-lysin overproducing strain was used showed a fourfold increase in release of L-lactate dehydrogenase activity into the curd relative to the control strain and the holin-overproducing strain, demonstrating the suitability of the system for cheese applications.	NIZO,DEPT BIOPHYS CHEM,GENET GRP,NL-6710 BA EDE,NETHERLANDS; NIZO,DEPT MICROBIOL,NL-6710 BA EDE,NETHERLANDS	NIZO Food Research; NIZO Food Research			Kuipers, Oscar/B-6752-2009	Kuipers, Oscar/0000-0001-5596-7735				Blasi U, 1996, MOL MICROBIOL, V21, P675, DOI 10.1046/j.1365-2958.1996.331395.x; BUIST G, 1995, J BACTERIOL, V177, P1554, DOI 10.1128/jb.177.6.1554-1563.1995; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; deRuyter PGGA, 1996, J BACTERIOL, V178, P3434, DOI 10.1128/jb.178.12.3434-3439.1996; deRuyter PGGA, 1996, APPL ENVIRON MICROB, V62, P3662, DOI 10.1128/AEM.62.10.3662-3667.1996; DEVOS WM, 1994, ENETICS BIOTECHNOLOG, P52; Gasson MJ, 1996, ANTON LEEUW INT J G, V70, P147, DOI 10.1007/BF00395931; HILLIER AJ, 1982, METHOD ENZYMOL, V89, P362; KUIPERS OP, 1995, J BIOL CHEM, V270, P27299, DOI 10.1074/jbc.270.45.27299; OSullivan DJ, 1996, BIO-TECHNOL, V14, P82, DOI 10.1038/nbt0196-82; Platteeuw C, 1996, APPL ENVIRON MICROB, V62, P1008, DOI 10.1128/AEM.62.3.1008-1013.1996; PLATTEEUW C, 1992, GENE, V118, P115, DOI 10.1016/0378-1119(92)90257-P; SABLE S, 1995, APPL MICROBIOL BIOT, V43, P1, DOI [10.1007/BF00170613, 10.1007/s002530050360]; Sambrok J., 1989, MOL CLONING LAB MANU; SHEARMAN CA, 1994, APPL ENVIRON MICROB, V60, P3063, DOI 10.1128/AEM.60.9.3063-3073.1994; SHEARMAN CA, 1992, BIO-TECHNOL, V10, P196, DOI 10.1038/nbt0292-196; TAN PST, 1993, APPL ENVIRON MICROB, V59, P1430, DOI 10.1128/AEM.59.5.1430-1436.1993; VANALENBOERRIGTER IJ, 1991, APPL ENVIRON MICROB, V57, P2555, DOI 10.1128/AEM.57.9.2555-2561.1991; VOS P, 1989, J BACTERIOL, V171, P2795, DOI 10.1128/jb.171.5.2795-2802.1989; WELLS JM, 1993, J APPL BACTERIOL, V74, P629, DOI 10.1111/j.1365-2672.1993.tb05195.x; YOUNG R, 1995, FEMS MICROBIOL REV, V17, P191, DOI 10.1016/0168-6445(94)00079-4; YOUNG RY, 1992, MICROBIOL REV, V56, P430, DOI 10.1128/MMBR.56.3.430-481.1992	22	121	129	1	15	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1997	15	10					976	979		10.1038/nbt1097-976	http://dx.doi.org/10.1038/nbt1097-976			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XZ285	9335048	Green Published			2022-12-27	WOS:A1997XZ28500027
J	Dibner, MD; Sollod, CJ				Dibner, MD; Sollod, CJ			From bench to business: Career opportunities in biotechnology	NATURE BIOTECHNOLOGY			English	Article											Dibner, MD (corresponding author), INST BIOTECHNOL INFORMAT,RES TRIANGLE PK,NC 27709, USA.							DIBNER M, 1997, BIOTECHNOLOGY GUIDE; DIBNER MD, 1987, BIO-TECHNOL, V5, P571, DOI 10.1038/nbt0687-571; DIBNER MD, 1991, BIOTECHNOLOGY GUIDE; National Academy of Sciences National Academy of Engineering Institute of Medicine, 1995, RESH GRAD ED SCI ENG; ROBBINSROTH C, 1997, IN PRESS ALTERNATIVE	5	0	0	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1997	15	10					958	960		10.1038/nbt1097-958	http://dx.doi.org/10.1038/nbt1097-958			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XZ285	9335044				2022-12-27	WOS:A1997XZ28500023
J	Segovia, L				Segovia, L			Protein structure prediction on the Web	NATURE BIOTECHNOLOGY			English	Editorial Material											Segovia, L (corresponding author), Univ Nacl Autonoma Mexico, INST BIOTECNOL, DEPT MOL RECOGNIT & BIOSTRUCT, MEXICO CITY, DF, MEXICO.		Segovia, Lorenzo/A-5206-2008	Segovia, Lorenzo/0000-0002-4291-4711					0	0	0	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1997	15	9					915	915		10.1038/nbt0997-915	http://dx.doi.org/10.1038/nbt0997-915			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XW410	9306411	Bronze			2022-12-27	WOS:A1997XW41000038
J	Crameri, A; Dawes, G; Rodriguez, E; Silver, S; Stemmer, WPC				Crameri, A; Dawes, G; Rodriguez, E; Silver, S; Stemmer, WPC			Molecular evolution of an arsenate detoxification pathway DNA shuffling	NATURE BIOTECHNOLOGY			English	Article						combinatorial chemistry; sexual PCR; molecular libraries; metabolic engineering	IN-VITRO; PROTEIN; RESISTANCE	Functional evolution of an arsenic resistance operon has been accomplished by DNA shuffling, involving multiple rounds of in vitro recombination and mutation of a pool of related sequences, followed by selection for increased resistance in vivo. Homologous recombination is achieved by random fragmentation of the PCR templates and reassembly by primerless PCR. Plasmid-determined arsenate resistance from plasmid pl258 encoded by genes arsR, arsB, and arsC was evolved in Escherichia coli. Three rounds of shuffling and selection resulted in cells that grew in up to 0.5 M arsenate, a 40-fold increase in resistance, Whereas the native plasmid remained episomal, the evolved operon reproducibly integrated into the bacterial chromosome. In the absence of shuffling, no increase in resistance was observed after four selection cycles, and the control plasmid remained episomal. The integrated ars operon had 13 mutations. Ten mutations were located in arsB, encoding the arsenite membrane pump, resulting in a fourfold to sixfold increase in arsenite resistance, While arsC, the arsenate reductase gene, contained no mutations, its expression level was increased, and the rate of arsenate reduction was increased 12-fold. These results show that DNA shuffling can improve the function of pathways by complex and unexpected mutational mechanisms that may be activated by point mutation. These mechanisms may be difficult to explain and are likely to be overlooked by rational design.	MAXYGEN INC,SANTA CLARA,CA 95051; AFFYMAX RES INST,PALO ALTO,CA 94304; UNIV ILLINOIS,DEPT IMMUNOL & MICROBIOL,CHICAGO,IL 60680	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital				Silver, Simon/0000-0002-5692-3125				CERVANTES C, 1994, FEMS MICROBIOL REV, V15, P355, DOI 10.1016/0168-6445(94)90069-8; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; Crameri A, 1996, NAT MED, V2, P100, DOI 10.1038/nm0196-100; JI GY, 1992, J BACTERIOL, V174, P3684, DOI 10.1128/JB.174.11.3684-3694.1992; JI GY, 1992, P NATL ACAD SCI USA, V89, P9474, DOI 10.1073/pnas.89.20.9474; RAWLINGS DE, 1995, BIO-TECHNOL, V13, P773, DOI 10.1038/nbt0895-773; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; STEMMER WPC, 1995, BIO-TECHNOL, V13, P549, DOI 10.1038/nbt0695-549; WU JH, 1992, J BIOL CHEM, V267, P12570; ZHANG J, 1997, IN PRESS P NATL ACAD	11	130	351	0	24	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1997	15	5					436	438		10.1038/nbt0597-436	http://dx.doi.org/10.1038/nbt0597-436			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WX237	9131621				2022-12-27	WOS:A1997WX23700026
J	Brown, S				Brown, S			Metal-recognition by repeating polypeptides	NATURE BIOTECHNOLOGY			English	Article						biosensors; peptide display; LamB; Escherichia coli; gold; chromium	ESCHERICHIA-COLI; ALKALINE-PHOSPHATASE; PROTEINS; GENE; GOLD; ACID; MUTAGENESIS; REPLICATION; INSERTION; RECEPTOR	Attachment of proteins to metal surfaces has the potential to improve our understanding of protein adhesion and has applications in sensor technology. Repeating polypeptides able to bind to metallic gold or chromium were selected from a population of approximately 5 million different polypeptides. Each polypeptide contained several direct repeats of identical peptide units 14 or 28 amino acids long. The metal-recognizing polypeptides were found to retain their binding properties when freed from the protein used to select them. One gold-binding polypeptide's avidity for gold was found to be dependent on the number of repeats and the presence of salt.			Brown, S (corresponding author), UNIV COPENHAGEN,DEPT MOL CELL BIOL,OSTER FARIMAGSGADE 2A,DK-1353 COPENHAGEN K,DENMARK.		Brown, Stanley/F-2728-2011	Brown, Stanley/0000-0002-8453-8144				BOUGESBOCQUET B, 1984, J CELL BIOCHEM, V24, P217, DOI 10.1002/jcb.240240304; BOULAIN JC, 1986, MOL GEN GENET, V205, P339, DOI 10.1007/BF00430448; BROWN S, 1992, P NATL ACAD SCI USA, V89, P8651, DOI 10.1073/pnas.89.18.8651; BROWN S, 1987, CELL, V49, P825, DOI 10.1016/0092-8674(87)90620-9; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; COUGHLIN RT, 1983, BIOCHEMISTRY-US, V22, P2002, DOI 10.1021/bi00277a041; Creighton T. E., 1993, PROTEINS STRUCTURES; DUCANCEL F, 1989, PROTEIN ENG, V3, P139, DOI 10.1093/protein/3.2.139; FENTER P, 1994, SCIENCE, V266, P1216, DOI 10.1126/science.266.5188.1216; FIRE A, 1995, P NATL ACAD SCI USA, V92, P4641, DOI 10.1073/pnas.92.10.4641; GEDDES NJ, 1994, J IMMUNOL METHODS, V175, P149, DOI 10.1016/0022-1759(94)90358-1; GILLET D, 1992, PROTEIN ENG, V5, P273, DOI 10.1093/protein/5.3.273; HANDLEY DA, 1983, P SOC EXP BIOL MED, V174, P1; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KREJCHI MT, 1994, SCIENCE, V265, P1427, DOI 10.1126/science.8073284; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE H, 1971, BIOCHIM BIOPHYS ACTA, V242, P519, DOI 10.1016/0005-2744(71)90144-6; LOCKSHON D, 1985, J MOL BIOL, V181, P63, DOI 10.1016/0022-2836(85)90324-9; LUCAS F, 1957, BIOCHEM J, V66, P468, DOI 10.1042/bj0660468; MCCONNELL SJ, 1995, J MOL BIOL, V250, P460, DOI 10.1006/jmbi.1995.0390; Miller J.H., 1972, EXPT MOL GENETICS; NAKAI H, 1988, J BIOL CHEM, V263, P9831; PAABO S, 1990, J BIOL CHEM, V265, P4718; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sigal GB, 1996, ANAL CHEM, V68, P490, DOI 10.1021/ac9504023; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WATTERSON JR, 1994, GEOLOGY, V22, P1144, DOI 10.1130/0091-7613(1994)022<1144:ARBBPI>2.3.CO;2; Wells JA, 1996, SCIENCE, V273, P449, DOI 10.1126/science.273.5274.449	29	391	430	2	104	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAR	1997	15	3					269	272		10.1038/nbt0397-269	http://dx.doi.org/10.1038/nbt0397-269			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WM050	9062928				2022-12-27	WOS:A1997WM05000032
J	Fischer, M; Goldschmitt, J; Peschel, C; Brakenhoff, JPG; Kallen, KJ; Wollmer, A; Grotzinger, J; RoseJohn, S				Fischer, M; Goldschmitt, J; Peschel, C; Brakenhoff, JPG; Kallen, KJ; Wollmer, A; Grotzinger, J; RoseJohn, S			A bioactive designer cytokine for human hematopoietic progenitor cell expansion	NATURE BIOTECHNOLOGY			English	Article						cytokine; cytokine receptor; designer protein; expansion; hematopoietic progenitor cells	CILIARY NEUROTROPHIC FACTOR; HUMAN IL-6 RECEPTOR; SIGNAL-TRANSDUCTION; HUMAN INTERLEUKIN-6; BINDING; INVOLVEMENT; CLONING; CHAIN; GP130	Efficient expansion of hematopoietic progenitor cells requires, at least, the simultaneous stimulation of the receptors c-kit and gp130, While c-kit is activated by SCF; gp130, in cells which do not express sufficient amounts of IL-6R, can be activated by the complex of soluble IL-6R (sIL-6R) and IL-6, The therapeutic use of IL-6/sIL-6R, however, has been hampered by the high concentrations of the sIL-6R protein required, We have designed a fusion protein of sIL-6R and IL-6, linked by a flexible peptide chain, that was expressed to high levels, On gp130 expressing cells the fusion protein turned out to be fully active at 100 to 1,000-fold lower concentration than the combination of unlinked IL-6 and IL-6R. The fusion protein was used to effectively expand human hematopoietic progenitor cells ex vivo in a dose dependent fashion.	UNIV MAINZ, DEPT MED 1, SECT PATHOPHYSIOL, D-55101 MAINZ, GERMANY; UNIV MAINZ, DEPT MED 3, D-55101 MAINZ, GERMANY; CENT LAB NETHERLANDS, NL-1066 CX AMSTERDAM, NETHERLANDS; RHEIN WESTFAL TH AACHEN, DEPT BIOCHEM, D-52057 AACHEN, GERMANY	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; RWTH Aachen University			Rose-John, Stefan/A-7998-2010	Rose-John, Stefan/0000-0002-7519-3279				BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; BRAKENHOFF JPJ, 1990, J IMMUNOL, V145, P561; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; EHLERS M, 1994, J IMMUNOL, V153, P1744; GEARING DP, 1994, P NATL ACAD SCI USA, V91, P1119, DOI 10.1073/pnas.91.3.1119; GROTZINGER J, 1996, IN PRESS PROTEINS; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; Hirota H, 1996, J EXP MED, V183, P2627, DOI 10.1084/jem.183.6.2627; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; ISHIBASHI T, 1989, BLOOD, V74, P1241; KELLER U, 1994, BLOOD, V84, P2189; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KRUTTGEN A, 1990, FEBS LETT, V262, P323, DOI 10.1016/0014-5793(90)80219-9; MACKIEWICZ A, 1995, P N Y ACAD SCI, V762, P1; Oppmann B, 1996, J IMMUNOL METHODS, V195, P153, DOI 10.1016/0022-1759(96)00110-X; PORGADOR A, 1992, CANCER RES, V52, P3679; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; ROSEJOHN S, 1990, EUR J BIOCHEM, V190, P79, DOI 10.1111/j.1432-1033.1990.tb15548.x; SUI XW, 1995, P NATL ACAD SCI USA, V92, P2859, DOI 10.1073/pnas.92.7.2859; Tajima S, 1996, J EXP MED, V184, P1357, DOI 10.1084/jem.184.4.1357; Toniatti C, 1996, EMBO J, V15, P2726, DOI 10.1002/j.1460-2075.1996.tb00633.x; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; VANDAM M, 1993, J BIOL CHEM, V268, P15285; Vollmer P, 1996, J IMMUNOL METHODS, V199, P47, DOI 10.1016/S0022-1759(96)00163-9; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YASUKAWA K, 1990, J BIOCHEM-TOKYO, V108, P673, DOI 10.1093/oxfordjournals.jbchem.a123261; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x	31	421	477	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1997	15	2					142	145		10.1038/nbt0297-142	http://dx.doi.org/10.1038/nbt0297-142			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WE998	9035138				2022-12-27	WOS:A1997WE99800019
J	Pettus, J; Boeder, SC; Christiansen, MP; Denham, DS; Bailey, TS; Akturk, HK; Klaff, LJ; Rosenstock, J; Cheng, MHM; Bode, BW; Bautista, ED; Xu, R; Yan, H; Thai, D; Garg, SK; Klein, S				Pettus, Jeremy; Boeder, Schafer C.; Christiansen, Mark P.; Denham, Douglas S.; Bailey, Timothy S.; Akturk, Halis K.; Klaff, Leslie J.; Rosenstock, Julio; Cheng, Mickie H. M.; Bode, Bruce W.; Bautista, Edgar D.; Xu, Ren; Yan, Hai; Thai Dung; Garg, Satish K.; Klein, Samuel			Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial	NATURE MEDICINE			English	Editorial Material; Early Access							EFFICACY; LY2409021; INSULIN; SAFETY; ANTIBODY; GLUCOSE; ISLETS; MICE	Hyperglucagonemia contributes to hyperglycemia in patients with type 1 diabetes (T1D); however, novel therapeutics that block glucagon action could improve glycemic control. This phase 2 study evaluated the safety and efficacy of volagidemab, an antagonistic monoclonal glucagon receptor (GCGR) antibody, as an adjunct to insulin therapy in adults with T1D. The primary endpoint was change in daily insulin use at week 12. Secondary endpoints included changes in hemoglobin A1c (HbA1c) at week 13, in average daily blood glucose concentration and time within target range as assessed by continuous blood glucose monitoring (CGM) and seven-point glucose profile at week 12, incidence of hypoglycemic events, the proportion of subjects who achieve HbA1c reduction of >= 0.4%, volagidemab drug concentrations and incidence of anti-drug antibodies. Eligible participants (n = 79) were randomized to receive weekly subcutaneous injections of placebo, 35 mg volagidemab or 70 mg volagidemab. Volagidemab produced a reduction in total daily insulin use at week 12 (35 mg volagidemab: -7.59 units (U) (95% confidence interval (CI) -11.79, -3.39; P = 0.040 versus placebo); 70 mg volagidemab: -6.64 U (95% CI -10.99, -2.29; P = 0.084 versus placebo); placebo: -1.27 U (95% CI -5.4, 2.9)) without meeting the prespecified significance level (P < 0.025). At week 13, the placebo-corrected reduction in HbA1c percentage was -0.53 (95% CI -0.89 to -0.17, nominal P = 0.004) in the 35 mg volagidemab group and -0.49 (95% CI -0.85 to -0.12, nominal P = 0.010) in the 70 mg volagidemab group. No increase in hypoglycemia was observed with volagidemab therapy; however, increases in serum transaminases, low-density lipoprotein (LDL)-cholesterol and blood pressure were observed. Although the primary endpoint did not meet the prespecified significance level, we believe that the observed reduction in HbA1c and tolerable safety profile provide a rationale for further randomized studies to define the long-term efficacy and safety of volagidemab in patients with T1D.	[Pettus, Jeremy; Boeder, Schafer C.] Univ Calif San Diego, Div Endocrinol, La Jolla, CA 92093 USA; [Christiansen, Mark P.] Diablo Clin Res, Walnut Creek, CA USA; [Denham, Douglas S.] Clin Trials Texas, San Antonio, TX USA; [Bailey, Timothy S.] AMCR Inst, Escondido, CA USA; [Akturk, Halis K.; Garg, Satish K.] Univ Colorado, Barbara Davis Ctr Diabet, Anschutz Campus, Aurora, CO USA; [Klaff, Leslie J.] Rainier Clin Res Ctr, Renton, WA USA; [Rosenstock, Julio] Dallas Diabet Res Ctr, Dallas, TX USA; [Cheng, Mickie H. M.] Marin Endocrine Care & Res, Greenbrae, CA USA; [Bode, Bruce W.] Atlanta Diabet Associates, Atlanta, GA USA; [Bautista, Edgar D.; Xu, Ren; Yan, Hai; Thai Dung] REMD Biotherapeut, Camarillo, CA USA; [Klein, Samuel] Washington Univ, Sch Med, Ctr Human Nutr, St Louis, MO 63110 USA; [Klein, Samuel] Sansum Diabet Res Inst, Santa Barbara, CA USA	University of California System; University of California San Diego; University of Colorado System; University of Colorado Anschutz Medical Campus; Diabetes & Endocrine Center; Washington University (WUSTL); William Sansum Diabetes Center	Pettus, J (corresponding author), Univ Calif San Diego, Div Endocrinol, La Jolla, CA 92093 USA.	jpettus@health.ucsd.edu	Akturk, Halis Kaan/I-5179-2019	Akturk, Halis Kaan/0000-0003-4518-5179; Boeder, Schafer/0000-0002-6221-7796; Bailey, Timothy/0000-0003-4178-3462	REMD Biotherapeutics; National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health [R44DK108305]	REMD Biotherapeutics; National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This study was sponsored and funded by REMD Biotherapeutics. REMD Biotherapeutics was directly involved in the design, conduct, analysis and reporting of the study. Research reported in this publication was also supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under award number R44DK108305. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Medical writing support, under the direction of the authors, was provided by J. Leonoudakis and was funded by REMD Biotherapeutics in accordance with Good Publication Practice guidelines.	Althunian TA, 2020, CLIN THER, V42, P1588, DOI 10.1016/j.clinthera.2020.06.004; Arcaro G, 2002, CIRCULATION, V105, P576, DOI 10.1161/hc0502.103333; Brissova M, 2005, J HISTOCHEM CYTOCHEM, V53, P1087, DOI 10.1369/jhc.5C6684.2005; Cabrera O, 2006, P NATL ACAD SCI USA, V103, P2334, DOI 10.1073/pnas.0510790103; Dandona P, 2017, LANCET DIABETES ENDO, V5, P864, DOI 10.1016/S2213-8587(17)30308-X; Engel SS, 2011, DIABETES, V60, pA85; Fredheim S, 2015, DIABETOLOGIA, V58, P828, DOI 10.1007/s00125-014-3486-3; Garg SK, 2017, NEW ENGL J MED, V377, P2337, DOI 10.1056/NEJMoa1708337; Gelling RW, 2003, P NATL ACAD SCI USA, V100, P1438, DOI 10.1073/pnas.0237106100; Gregory JM, 2019, DIABETES, V68, P1565, DOI 10.2337/db19-0324; Gu W, 2009, J PHARMACOL EXP THER, V331, P871, DOI 10.1124/jpet.109.157685; Guan HP, 2015, J LIPID RES, V56, P2183, DOI 10.1194/jlr.M060897; Guzman CB, 2017, DIABETES OBES METAB, V19, P1521, DOI 10.1111/dom.12958; Holt RIG, 2021, DIABETOLOGIA, V64, P2609, DOI [10.1007/s00125-021-05568-3, 10.2337/dci21-0043]; Janah L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133314; Kazda CM, 2017, DIABETES OBES METAB, V19, P1071, DOI 10.1111/dom.12904; Kazda CM, 2016, DIABETES CARE, V39, P1241, DOI 10.2337/dc15-1643; Levetan CS, 2013, ENDOCR PRACT, V19, P301, DOI 10.4158/EP12138.RA; Mathieu C, 2016, DIABETES CARE, V39, P1702, DOI 10.2337/dc16-0691; MURTAGH JG, 1970, BRIT HEART J, V32, P307; Navarro VJ, 2006, NEW ENGL J MED, V354, P731, DOI 10.1056/NEJMra052270; Pettus J, 2018, DIABETES OBES METAB, V20, P1302, DOI 10.1111/dom.13202; Unger RH, 2012, J CLIN INVEST, V122, P4, DOI 10.1172/JCI60016; Van der Schueren B, 2021, LANCET DIABETES ENDO, V9, P776, DOI 10.1016/S2213-8587(21)00246-1; Wang MY, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2022142118; Wang MY, 2015, P NATL ACAD SCI USA, V112, P2503, DOI 10.1073/pnas.1424934112; Yan H, 2009, J PHARMACOL EXP THER, V329, P102, DOI 10.1124/jpet.108.147009	27	1	1	1	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02011-x	http://dx.doi.org/10.1038/s41591-022-02011-x		OCT 2022	17	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	5D8VV	36192552				2022-12-27	WOS:000865214200003
J	Scholler, N; Perbost, R; Locke, FL; Jain, MD; Turcan, S; Danan, C; Chang, EC; Neelapu, SS; Miklos, DB; Jacobson, CA; Lekakis, LJ; Lin, Y; Ghobadi, A; Kim, JJ; Chou, J; Plaks, V; Wang, ZX; Xue, AE; Mattie, M; Rossi, JM; Bot, A; Galon, J				Scholler, Nathalie; Perbost, Regis; Locke, Frederick L.; Jain, Michael D.; Turcan, Sarah; Danan, Corinne; Chang, Edmund C.; Neelapu, Sattva S.; Miklos, David B.; Jacobson, Caron A.; Lekakis, Lazaros J.; Lin, Yi; Ghobadi, Armin; Kim, Jenny J.; Chou, Justin; Plaks, Vicki; Wang, Zixing; Xue, Allen; Mattie, Mike; Rossi, John M.; Bot, Adrian; Galon, Jerome			Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma	NATURE MEDICINE			English	Article							COLORECTAL-CANCER; MICROENVIRONMENT; THERAPY; ACCUMULATION; IMMUNOSCORE; EXPRESSION; SURVIVAL; SUBTYPES	Axicabtagene ciloleucel (axi-cel) is an anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved for relapsed/refractory large B cell lymphoma (LBCL) and has treatment with similar efficacy across conventional LBCL subtypes. Toward patient stratification, we assessed whether tumor immune contexture influenced clinical outcomes after axi-cel. We evaluated the tumor microenvironment (TME) of 135 pre-treatment and post-treatment tumor biopsies taken from 51 patients in the ZUMA-1 phase 2 trial. We uncovered dynamic patterns that occurred within 2 weeks after axi-cel. The biological associations among Immunoscore (quantification of tumor-infiltrating T cell density), Immunosign 21 (expression of pre-defined immune gene panel) and cell subsets were validated in three independent LBCL datasets. In the ZUMA-1 trial samples, clinical response and overall survival were associated with pre-treatment immune contexture as characterized by Immunoscore and Immunosign 21. Circulating CAR T cell levels were associated with post-treatment TME T cell exhaustion. TME enriched for chemokines (CCL5 and CCL22), gamma-chain receptor cytokines (IL-15, IL-7 and IL-21) and interferon-regulated molecules were associated with T cell infiltration and markers of activity. Finally, high density of regulatory T cells in pre-treatment TME associated with reduced axi-cel-related neurologic toxicity. These findings advance the understanding of LBCL TME characteristics associated with clinical responses to anti-CD19 CAR T cell therapy and could foster biomarker development and treatment optimization for patients with LBCL. Analysis of tumor biopsies from the pivotal phase 1/2 ZUMA-1 trial identifies pre-treatment T cell-related characteristics that are associated with clinical response and neurologic toxicity after anti-CD19 CAR T cell therapy in patients with large B cell lymphoma.	[Scholler, Nathalie; Chang, Edmund C.; Kim, Jenny J.; Chou, Justin; Plaks, Vicki; Wang, Zixing; Xue, Allen; Mattie, Mike; Rossi, John M.; Bot, Adrian] Kite, Santa Monica, CA USA; [Scholler, Nathalie] Gilead Sci, Foster City, CA USA; [Perbost, Regis; Turcan, Sarah; Danan, Corinne; Galon, Jerome] Veracyte SAS, Marseille, France; [Locke, Frederick L.; Jain, Michael D.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA; [Neelapu, Sattva S.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Miklos, David B.] Stanford Univ, Sch Med, Stanford, CA 94305 USA; [Jacobson, Caron A.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Lekakis, Lazaros J.] Univ Miami Hlth Syst, Sylvester Comprehens Canc Ctr, Miami, FL USA; [Lin, Yi] Mayo Clin, Rochester, MN USA; [Ghobadi, Armin] Washington Univ, Sch Med, St Louis, MO USA; [Bot, Adrian] Capstan Therapeut, San Diego, CA USA; [Galon, Jerome] Sorbonne Univ, Univ Paris Cite, Ctr Rech Cordeliers,Equipe Labellisee Ligue Canc, Lab Integrat Canc Immunol,INSERM, Paris, France	Gilead Sciences; H Lee Moffitt Cancer Center & Research Institute; University of Texas System; UTMD Anderson Cancer Center; Stanford University; Harvard University; Dana-Farber Cancer Institute; Mayo Clinic; Washington University (WUSTL); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Galon, J (corresponding author), Veracyte SAS, Marseille, France.; Galon, J (corresponding author), Sorbonne Univ, Univ Paris Cite, Ctr Rech Cordeliers,Equipe Labellisee Ligue Canc, Lab Integrat Canc Immunol,INSERM, Paris, France.	jerome.galon@crc.jussieu.fr	Jain, Michael/AAI-2741-2020	Jain, Michael/0000-0002-7789-1257; Miklos, David/0000-0003-0717-4305; Locke, Frederick/0000-0001-9063-6691	Kite, a Gilead company	Kite, a Gilead company	The authors thank G. Houghton and G. Rahimi for support with sample inventory, tracking and consent. They also thank INSERM, Cancer Research for Personalized Medicine (CARPEM), LabEx Immuno-Oncology, the National Cancer Institute of France, La Ligue Contre le Cancer, Association pour la Recherche Contre le Cancer (ARC), the Louis Jeantet Prize foundation and the patients and their caregivers. Medical writing support was provided by A. Skorusa and S. Franco of Nexus Global Group Science, funded by Kite, a Gilead company. This study was funded by Kite, a Gilead company.	Agocs GR, 2021, J PERS MED, V11, DOI 10.3390/jpm11080749; Amor C, 2020, NATURE, V583, P127, DOI 10.1038/s41586-020-2403-9; Angel H, 2013, CURR OPIN IMMUNOL, V25, P261, DOI 10.1016/j.coi.2013.03.004; Angell HK, 2020, CLIN CANCER RES, V26, P332, DOI 10.1158/1078-0432.CCR-18-1851; Angelova M, 2018, CELL, V175, P751, DOI 10.1016/j.cell.2018.09.018; Arpaia N, 2015, CELL, V162, P1078, DOI 10.1016/j.cell.2015.08.021; Autio M, 2021, HAEMATOLOGICA, V106, P718, DOI 10.3324/haematol.2019.243626; Bedognetti D, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0602-4; Bindea G, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.27456; Brudno JN, 2020, NAT MED, V26, P270, DOI 10.1038/s41591-019-0737-3; Bruni D, 2020, NAT REV CANCER, V20, P662, DOI 10.1038/s41568-020-0285-7; Campbell C, 2020, CELL METAB, V31, P18, DOI 10.1016/j.cmet.2019.09.010; Cappell KM, 2020, J CLIN ONCOL, V38, P3805, DOI 10.1200/JCO.20.01467; Carbone A, 2014, ANN HEMATOL, V93, P1263, DOI 10.1007/s00277-014-2116-y; Chen PH, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.134612; Chou CSK, 2020, EXPERT OPIN BIOL TH, V20, P653, DOI 10.1080/14712598.2020.1729735; Conlon KC, 2019, J INTERF CYTOK RES, V39, P6, DOI 10.1089/jir.2018.0019; Coutinho R, 2015, HAEMATOLOGICA, V100, P363, DOI 10.3324/haematol.2014.110189; Dunbar CE, 2018, SCIENCE, V359, P175, DOI 10.1126/science.aan4672; Faramand R, 2020, CLIN CANCER RES, V26, P4823, DOI 10.1158/1078-0432.CCR-20-1434; Fu K, 2008, J CLIN ONCOL, V26, P4587, DOI 10.1200/JCO.2007.15.9277; Galon J, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1029-z; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Galon J, 2007, CANCER RES, V67, P1883, DOI 10.1158/0008-5472.CAN-06-4806; Galon J, 2020, IMMUNITY, V52, P55, DOI 10.1016/j.immuni.2019.12.018; Galon J, 2019, NAT REV DRUG DISCOV, V18, P197, DOI 10.1038/s41573-018-0007-y; Galon J, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.3025; Galon J, 2013, IMMUNITY, V39, P11, DOI 10.1016/j.immuni.2013.07.008; Hashimoto A, 2021, CLIN CANCER RES, V27, P5961, DOI 10.1158/1078-0432.CCR-21-0986; Hudolin T, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-123; Jain MD, 2021, BLOOD, V137, P2621, DOI 10.1182/blood.2020007445; Jensen MC, 2014, IMMUNOL REV, V257, P127, DOI 10.1111/imr.12139; June CH, 2018, SCIENCE, V359, P1361, DOI 10.1126/science.aar6711; Khaja ASS, 2017, ONCOTARGET, V8, P33159, DOI 10.18632/oncotarget.16565; Khan O, 2019, NATURE, V571, P211, DOI 10.1038/s41586-019-1325-x; Kirilovsky A, 2016, INT IMMUNOL, V28, P373, DOI 10.1093/intimm/dxw021; Kochenderfer JN, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2016.71.3024; Lanitis E, 2020, CURR OPIN BIOTECH, V65, P75, DOI 10.1016/j.copbio.2020.01.009; Lenz G, 2008, NEW ENGL J MED, V359, P2313, DOI 10.1056/NEJMoa0802885; Liu WY, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10154; Liu Y, 2019, AM J HEMATOL, V94, P604, DOI 10.1002/ajh.25460; Locke FL, 2022, NEW ENGL J MED, V386, P640, DOI 10.1056/NEJMoa2116133; Locke FL, 2020, BLOOD ADV, V4, P4898, DOI 10.1182/bloodadvances.2020002394; Locke FL, 2019, LANCET ONCOL, V20, P31, DOI 10.1016/S1470-2045(18)30864-7; Locke FL, 2017, MOL THER, V25, P285, DOI 10.1016/j.ymthe.2016.10.020; Maestre L, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229743; Marliot F, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000272; Marmey M, 2006, HUM PATHOL, V37, P68, DOI 10.1016/j.humpath.2005.09.016; Mascaux C, 2019, NATURE, V571, P570, DOI 10.1038/s41586-019-1330-0; Mizukami Y, 2008, INT J CANCER, V122, P2286, DOI 10.1002/ijc.23392; Moschella F, 2013, CLIN CANCER RES, V19, P4249, DOI 10.1158/1078-0432.CCR-12-3666; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; Okeke EB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00680; Okuyama K, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008280; Pages F, 2018, LANCET, V391, P2128, DOI 10.1016/S0140-6736(18)30789-X; Panda Anshuman, 2018, J Natl Cancer Inst, V110, P316, DOI 10.1093/jnci/djx213; Park HY, 2016, ONCOTARGET, V7, P86433, DOI 10.18632/oncotarget.13239; Plaks V, 2021, BLOOD, V138, P1081, DOI 10.1182/blood.2021010930; Scott DW, 2014, BLOOD, V123, P1214, DOI 10.1182/blood-2013-11-536433; Sharma P, 2021, CANCER DISCOV, V11, P838, DOI 10.1158/2159-8290.CD-20-1680; Singh N, 2020, CANCER DISCOV, V10, P552, DOI 10.1158/2159-8290.CD-19-0813; Spranger S, 2018, NAT REV CANCER, V18, P139, DOI 10.1038/nrc.2017.117; STAMENKOVIC I, 1990, J EXP MED, V172, P641, DOI 10.1084/jem.172.2.641; Sugiyama D, 2013, P NATL ACAD SCI USA, V110, P17945, DOI 10.1073/pnas.1316796110; Teater M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02595-w; Upadhyay R, 2021, CANCER DISCOV, V11, P599, DOI 10.1158/2159-8290.CD-20-0756; Van den Eynde M, 2018, CANCER CELL, V34, P1012, DOI 10.1016/j.ccell.2018.11.003; Whitehurst AW, 2014, ANNU REV PHARMACOL, V54, P251, DOI 10.1146/annurev-pharmtox-011112-140326; Xia SH, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03853-y; Yang JC, 2016, ADV IMMUNOL, V130, P279, DOI 10.1016/bs.ai.2015.12.006; Yomoda T, 2019, ANN SURG ONCOL, V26, P415, DOI 10.1245/s10434-018-07110-z; Yuan JP, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0957-0	72	6	6	9	9	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2022	28	9					1872	+		10.1038/s41591-022-01916-x	http://dx.doi.org/10.1038/s41591-022-01916-x		AUG 2022	33	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4S0LI	36038629	hybrid, Green Published			2022-12-27	WOS:000847267200003
J	Liu, RS; Rizzo, S; Waliany, S; Garmhausen, MR; Pal, N; Huang, Z; Chaudhary, N; Wang, LS; Harbron, C; Neal, J; Copping, R; Zou, J				Liu, Ruishan; Rizzo, Shemra; Waliany, Sarah; Garmhausen, Marius Rene; Pal, Navdeep; Huang, Zhi; Chaudhary, Nayan; Wang, Lisa; Harbron, Chris; Neal, Joel; Copping, Ryan; Zou, James			Systematic pan-cancer analysis of mutation-treatment interactions using large real-world clinicogenomics data	NATURE MEDICINE			English	Article; Early Access							METASTATIC UROTHELIAL CARCINOMA; RB-PATHWAY DISRUPTION; NEOADJUVANT CHEMOTHERAPY; TP53 MUTATIONS; OPEN-LABEL; ATEZOLIZUMAB; MULTICENTER; PROGNOSIS; ASSOCIATION; EXPRESSION	Quantifying the effectiveness of different cancer therapies in patients with specific tumor mutations is critical for improving patient outcomes and advancing precision medicine. Here we perform a large-scale computational analysis of 40,903 US patients with cancer who have detailed mutation profiles, treatment sequences and outcomes derived from electronic health records. We systematically identify 458 mutations that predict the survival of patients on specific immunotherapies, chemotherapy agents or targeted therapies across eight common cancer types. We further characterize mutation-mutation interactions that impact the outcomes of targeted therapies. This work demonstrates how computational analysis of large real-world data generates insights, hypotheses and resources to enable precision oncology. A large-scale computational analysis of over 40,000 patients with cancer who have detailed mutation profiles, treatment sequences and outcomes derived from electronic health records provides insights into a rich resource that will help to enable precision oncology.	[Liu, Ruishan; Zou, James] Stanford Univ, Dept Elect Engn, Stanford, CA 94305 USA; [Liu, Ruishan; Zou, James] Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA; [Rizzo, Shemra; Garmhausen, Marius Rene; Pal, Navdeep; Chaudhary, Nayan; Wang, Lisa; Copping, Ryan] Genentech Inc, San Francisco, CA USA; [Waliany, Sarah; Neal, Joel] Stanford Univ, Sch Med, Stanford, CA USA; [Harbron, Chris] Roche Pharmaceut, Welwyn Garden City, Herts, England	Stanford University; Stanford University; Roche Holding; Genentech; Stanford University; Roche Holding	Zou, J (corresponding author), Stanford Univ, Dept Elect Engn, Stanford, CA 94305 USA.; Zou, J (corresponding author), Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA.	jamesz@stanford.edu		RIZZO, SHEMRA/0000-0002-2413-1131; Huang, Zhi/0000-0001-6982-8285; Waliany, Sarah/0000-0001-5960-8801	Roche; National Science Foundation CAREER; Sloan Fellowship; Emerson Collective; Chan-Zuckerberg Investigator award	Roche(Roche Holding); National Science Foundation CAREER(National Science Foundation (NSF)); Sloan Fellowship(Alfred P. Sloan Foundation); Emerson Collective; Chan-Zuckerberg Investigator award	We thank A. Gentles, L. Zou, D. Hibar, M. Taylor, Y. Lu and J. Caswell-Jin for comments and discussions. S.R., M.R.G., N.P., C.H, L.W., C.H. and R.C. are supported by funding from Roche. J.Z. is supported by National Science Foundation CAREER, a Sloan Fellowship, a grant from the Emerson Collective and the Chan-Zuckerberg Investigator award.	Andre F, 2017, CANCER DISCOV, V7, P818, DOI 10.1158/2159-8290.CD-17-0151; Balar AV, 2017, LANCET, V389, P67, DOI 10.1016/S0140-6736(16)32455-2; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Carbuccia N, 2009, LEUKEMIA, V23, P2183, DOI 10.1038/leu.2009.141; Carrigan G, 2020, CLIN PHARMACOL THER, V107, P369, DOI 10.1002/cpt.1586; Carrigan G, 2019, PHARMACOEPIDEM DR S, V28, P572, DOI 10.1002/pds.4758; Carvill GL, 2013, NAT GENET, V45, P1073, DOI 10.1038/ng.2727; Cavanna Luigi, 2019, Oncotarget, V10, P209, DOI 10.18632/oncotarget.26541; Chakravarty D, 2017, JCO PRECIS ONCOL, V1; Chen K, 2020, CLIN TRANSL ONCOL, V22, P576, DOI 10.1007/s12094-019-02163-2; Curtis MD, 2018, HEALTH SERV RES, V53, P4460, DOI 10.1111/1475-6773.12872; Danaei G, 2018, J CLIN EPIDEMIOL, V96, P12, DOI 10.1016/j.jclinepi.2017.11.021; de Bruin EC, 2014, CANCER DISCOV, V4, P606, DOI 10.1158/2159-8290.CD-13-0741; Dong ZY, 2017, CLIN CANCER RES, V23, P3012, DOI 10.1158/1078-0432.CCR-16-2554; Endele S, 2010, NAT GENET, V42, P1021, DOI 10.1038/ng.677; Eng C, 2021, J CLIN ONCOL, V39, P259, DOI 10.1200/JCO.20.03043; Ertel A, 2010, CELL CYCLE, V9, P4153, DOI 10.4161/cc.9.20.13454; Frampton GM, 2013, NAT BIOTECHNOL, V31, P1023, DOI 10.1038/nbt.2696; Garraway LA, 2013, J CLIN ONCOL, V31, P1803, DOI 10.1200/JCO.2013.49.4799; Guibert N, 2019, LUNG CANCER, V137, P1, DOI 10.1016/j.lungcan.2019.09.005; He J, 2016, BLOOD, V127, P3004, DOI 10.1182/blood-2015-08-664649; Hernan MA, 2016, AM J EPIDEMIOL, V183, P758, DOI 10.1093/aje/kwv254; Hodson R, 2016, NATURE, V537, pS49, DOI 10.1038/537S49a; Hsu CP, 2011, EJSO-EUR J SURG ONC, V37, P140, DOI 10.1016/j.ejso.2010.12.003; Kron A, 2018, ANN ONCOL, V29, P2068, DOI 10.1093/annonc/mdy333; Liu CM, 2020, CANCER LETT, V470, P95, DOI 10.1016/j.canlet.2019.10.027; Liu RS, 2021, NATURE, V592, P629, DOI 10.1038/s41586-021-03430-5; Marquart J, 2018, JAMA ONCOL, V4, P1093, DOI 10.1001/jamaoncol.2018.1660; Mazieres J, 2019, ANN ONCOL, V30, P1321, DOI 10.1093/annonc/mdz167; McGough SF, 2021, STAT MED, V40, P5487, DOI 10.1002/sim.9136; Morash M, 2018, J PERS MED, V8, DOI 10.3390/jpm8030030; Odogwu L, 2018, ONCOLOGIST, V23, P740, DOI 10.1634/theoncologist.2017-0642; Okamoto I, 2018, LUNG CANCER, V117, P14, DOI 10.1016/j.lungcan.2018.01.005; Papillon-Cavanagh S, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000706; Peters S, 2017, J CLIN ONCOL, V35, P2781, DOI 10.1200/JCO.2016.71.9476; Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302; Powles T, 2018, LANCET, V391, P748, DOI 10.1016/S0140-6736(17)33297-X; Raponi M, 2008, CURR OPIN PHARMACOL, V8, P413, DOI 10.1016/j.coph.2008.06.006; Rastelli F, 2008, TUMORI J, V94, P370; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Rossi G, 2020, CANCERS, V12, DOI 10.3390/cancers12051125; Singal G, 2019, JAMA-J AM MED ASSOC, V321, P1391, DOI 10.1001/jama.2019.3241; Suissa S, 2008, AM J EPIDEMIOL, V167, P492, DOI 10.1093/aje/kwm324; Sun LV, 2021, JAMA ONCOL, V7, P937, DOI 10.1001/jamaoncol.2021.0546; Tanioka M, 2014, BREAST CANCER RES TR, V147, P513, DOI 10.1007/s10549-014-3121-5; Tsao MS, 2007, J CLIN ONCOL, V25, P5240, DOI 10.1200/JCO.2007.12.6953; Wang WX, 2018, J THORAC DIS, V10, P2991, DOI 10.21037/jtd.2018.04.98; West H, 2019, LANCET ONCOL, V20, P924, DOI 10.1016/S1470-2045(19)30167-6; Witkiewicz AK, 2012, CLIN CANCER RES, V18, P5110, DOI 10.1158/1078-0432.CCR-12-0903; Wolfer A, 2010, P NATL ACAD SCI USA, V107, P3698, DOI 10.1073/pnas.0914203107; Woodhouse R, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237802; Zhang QY, 2021, HEALTH SERV RES, V56, P1281, DOI 10.1111/1475-6773.13669; Zhao R, 2016, EBIOMEDICINE, V8, P30, DOI 10.1016/j.ebiom.2016.04.017	53	0	0	11	11	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01873-5	http://dx.doi.org/10.1038/s41591-022-01873-5		JUN 2022	18	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2O8CP	35773542				2022-12-27	WOS:000819280900001
J	Mielke, MM; Dage, JL; Frank, RD; Algeciras-Schimnich, A; Knopman, DS; Lowe, VJ; Bu, GJ; Vemuri, P; Graff-Radford, J; Jack, CR; Petersen, RC				Mielke, Michelle M.; Dage, Jeffrey L.; Frank, Ryan D.; Algeciras-Schimnich, Alicia; Knopman, David S.; Lowe, Val J.; Bu, Guojun; Vemuri, Prashanthi; Graff-Radford, Jonathan; Jack, Clifford R., Jr.; Petersen, Ronald C.			Performance of plasma phosphorylated tau 181 and 217 in the community	NATURE MEDICINE			English	Article							BLOOD-BASED BIOMARKERS; ALZHEIMERS-DISEASE; PET	Plasma phosphorylated tau 181 (P-tau181) and 217 (P-tau217) are indicators of both amyloid and tau pathology in clinical settings, but their performance in heterogeneous community-based populations is unclear. We examined P-tau181 and P-tau217 (n = 1,329, aged 30-98 years), in the population-based Mayo Clinic Study of Aging. Continuous, unadjusted plasma P-tau181 and P-tau217 predicted abnormal amyloid positron-emission tomography (PET) (area under the receiver operating characteristic curve (AUROC) = 0.81-0.86) and tau PET entorhinal cortex (AUROC > 0.80), but was less predictive of a tau PET temporal region of interest (AUROC < 0.70). Multiple comorbidities were associated with higher plasma P-tau181 and P-tau217 levels; the difference between participants with and without chronic kidney disease (CKD) was similar to the difference between participants with and without elevated brain amyloid. The exclusion of participants with CKD and other comorbidities affected the establishment of a normal reference range and cutpoints. Understanding the effect of comorbidities on P-tau181 and P-tau217 levels is important for their future interpretation in the context of clinical screening, diagnosis or prognosis at the population level. Multiple comorbidities are associated with higher plasma P-tau181 and P-tau217 levels, and affects their normal reference ranges and cutpoints.	[Mielke, Michelle M.; Petersen, Ronald C.] Mayo Clin, Div Epidemiol, Dept Quantitat Hlth Sci, Rochester, MN 55905 USA; [Mielke, Michelle M.; Knopman, David S.; Graff-Radford, Jonathan; Petersen, Ronald C.] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA; [Mielke, Michelle M.] Wake Forest Univ, Bowman Gray Sch Med, Dept Epidemiol & Prevent, Winston Salem, NC 27109 USA; [Dage, Jeffrey L.] Indiana Univ, Sch Med, Stark Neurosci Res Inst, Indianapolis, IN USA; [Frank, Ryan D.] Mayo Clin, Div Clin Trials & Biostat, Dept Quantitat Hlth Sci, Rochester, MN USA; [Algeciras-Schimnich, Alicia] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA; [Lowe, Val J.; Vemuri, Prashanthi; Jack, Clifford R., Jr.] Mayo Clin, Dept Radiol, Rochester, MN USA; [Bu, Guojun] Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA	Mayo Clinic; Mayo Clinic; Wake Forest University; Wake Forest Baptist Medical Center; Indiana University System; Indiana University-Purdue University Indianapolis; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Mielke, MM (corresponding author), Mayo Clin, Div Epidemiol, Dept Quantitat Hlth Sci, Rochester, MN 55905 USA.; Mielke, MM (corresponding author), Mayo Clin, Dept Neurol, Rochester, MN 55905 USA.; Mielke, MM (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Epidemiol & Prevent, Winston Salem, NC 27109 USA.	mmielke@wakehealth.edu	Jack, Clifford R/F-2508-2010	Jack, Clifford R/0000-0001-7916-622X; Mielke, Michelle/0000-0001-7177-1185; Knopman, David/0000-0002-6544-066X	National Institutes of Health (NIH) [U01 AG006786, R37 AG011378, R01 NS097495, P30 AG062677, RF1 AG069052, R01 AG041851]; GHR Foundation; NIH National Institute on Aging [R01 AG034676]	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); GHR Foundation; NIH National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Funding for this study was provided by grants from the National Institutes of Health (NIH) (U01 AG006786 to M.M.M., C.R.J. and R.C.P.; R37 AG011378 to C.R.J.; R01 NS097495 to P.V.; P30 AG062677 to R.C.P.; RF1 AG069052 to M.M.M., J.G-R. and P.V.; and R01 AG041851 to C.R.J. and D.S.K.) and the GHR Foundation (to R.C.P.). This study was made possible using the resources of the REP, which is supported by the NIH National Institute on Aging under award no.R01 AG034676. Meso Scale Discovery P-tau181 and P-tau217 assays were performed at Eli Lilly and Company. The funders of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report. The corresponding author had full access to all data in the study, and all authors had final responsibility for the decision to submit for publication.	[Anonymous], 2013, DIAGN STAT MAN MENT, DOI [10.1176/appi.books.9780890425596, DOI 10.1176/APPI.BOOKS.9780890425596]; Barthelemy NR, 2020, J EXP MED, V217, DOI 10.1084/jem.20200861; Beck A., 1993, BECK ANXIETY INVENTO; Beck AT., 1996, MANUAL BECK DEPRESSI; Benussi A, 2020, J NEUROL NEUROSUR PS, V91, P960, DOI 10.1136/jnnp-2020-323487; Brickman AM, 2021, ALZHEIMERS DEMENT, V17, P1353, DOI 10.1002/alz.12301; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Ivnik RJ., 1992, CLIN NEUROPSYCHOL, V6, P83, DOI DOI 10.1080/13854049208401880; Jack CR, 2017, ALZHEIMERS DEMENT, V13, P205, DOI 10.1016/j.jalz.2016.08.005; Jack CR, 2008, BRAIN, V131, P665, DOI 10.1093/brain/awm336; Janelidze S, 2020, NAT MED, V26, P379, DOI 10.1038/s41591-020-0755-1; Karikari TK, 2020, LANCET NEUROL, V19, P422, DOI 10.1016/S1474-4422(20)30071-5; Lowe VJ, 2020, ALZHEIMERS DEMENT, V16, P561, DOI 10.1016/j.jalz.2019.09.079; Lowe VJ, 2009, J NUCL MED, V50, P878, DOI 10.2967/jnumed.108.058529; Manrai AK, 2018, JAMA-J AM MED ASSOC, V319, P1981, DOI 10.1001/jama.2018.2009; Mattsson-Carlgren N, 2020, BRAIN, V143, P3234, DOI 10.1093/brain/awaa286; McNamee RL, 2009, J NUCL MED, V50, P348, DOI 10.2967/jnumed.108.057612; Mielke MM, 2021, JAMA NEUROL, V78, P1108, DOI 10.1001/jamaneurol.2021.2293; Mielke MM, 2020, J APPL LAB MED, V5, P158, DOI 10.1373/jalm.2019.030023; Mielke MM, 2018, ALZHEIMERS DEMENT, V14, P989, DOI 10.1016/j.jalz.2018.02.013; Moscoso A, 2021, BRAIN, V144, P325, DOI 10.1093/brain/awaa399; O'Bryant SE, 2017, ALZHEIMERS DEMENT, V13, P45, DOI 10.1016/j.jalz.2016.09.014; Ossenkoppele R, 2021, EMBO MOL MED, V13, DOI 10.15252/emmm.202114398; Ozarda Y, 2016, BIOCHEM MEDICA, V26, P5, DOI 10.11613/BM.2016.001; Palmqvist S, 2020, JAMA-J AM MED ASSOC, V324, P772, DOI 10.1001/jama.2020.12134; Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x; Price JC, 2005, J CEREBR BLOOD F MET, V25, P1528, DOI 10.1038/sj.jcbfm.9600146; Roberts RO, 2008, NEUROEPIDEMIOLOGY, V30, P58, DOI 10.1159/000115751; Simren J, 2021, ALZHEIMERS DEMENT, V17, P1145, DOI 10.1002/alz.12283; St Sauver JL, 2012, INT J EPIDEMIOL, V41, P1614, DOI 10.1093/ije/dys195; Syrjanen JA, 2022, ALZHEIMERS DEMENT, V18, P1128, DOI 10.1002/alz.12466; Teunissen CE, 2022, LANCET NEUROL, V21, P66, DOI 10.1016/S1474-4422(21)00361-6; Thijssen EH, 2021, LANCET NEUROL, V20, P739, DOI 10.1016/S1474-4422(21)00214-3; Thijssen EH, 2020, NAT MED, V26, P387, DOI 10.1038/s41591-020-0762-2; Yoshihara T, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18168683	35	14	14	4	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2022	28	7					1398	+		10.1038/s41591-022-01822-2	http://dx.doi.org/10.1038/s41591-022-01822-2		MAY 2022	19	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3E5PS	35618838				2022-12-27	WOS:000805514000001
J	Mullainathan, S; Obermeyer, Z				Mullainathan, Sendhil; Obermeyer, Ziad			Solving medicine's data bottleneck: Nightingale Open Science	NATURE MEDICINE			English	Editorial Material								Open datasets, curated around unsolved medical problems, are vital to the development of computational research in medicine, but remain in short supply. Nightingale Open Science, a non-profit computing platform, was founded to catalyse research in this nascent field.	[Mullainathan, Sendhil] Univ Chicago, Booth Sch Business, Chicago, IL 60637 USA; [Obermeyer, Ziad] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA	University of Chicago; University of California System; University of California Berkeley	Obermeyer, Z (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA.	zobermeyer@berkeley.edu			Schmidt Futures; Gordon and Betty Moore Foundation; National Institute on Aging [P01AG005842]; McGovern Foundation	Schmidt Futures; Gordon and Betty Moore Foundation(Gordon and Betty Moore Foundation); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); McGovern Foundation	We thank K. Haynes, N. Foster, N. Juergens, W. Lane, K. Lin, J. Risley, and C. Simonian for their contributions to Nightingale Open Science. We are deeply grateful to T. Kalil for his vision and support, and thank T. Stewart for inspiring this Comment. We acknowledge financial support from Schmidt Futures, the Gordon and Betty Moore Foundation, Ken Griffin (private philanthropy), the National Institute on Aging grant P01AG005842, and the McGovern Foundation.	[Anonymous], 2020, COVID DAT TRACK; Beck AH, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002564; Bifulco C, 2021, NIGHTINGALE OPEN SCI, DOI [10.48815/N5159B, DOI 10.48815/N5159B]; Chugh SS, 2018, CIRCULATION, V137, P7, DOI 10.1161/CIRCULATIONAHA.117.029932; Donoho D, 2017, J COMPUT GRAPH STAT, V26, P745, DOI 10.1080/10618600.2017.1384734; Huang C, 2021, NIGHTINGALE OPEN SCI, DOI [10.48815/N5WC7D, DOI 10.48815/N5WC7D]; Kaushal A, 2020, JAMA-J AM MED ASSOC, V324, P1212, DOI 10.1001/jama.2020.12067; Lungren M., 2021, NIGHTINGALE OPEN SCI, DOI [10.48815/N5RP44, DOI 10.48815/N5RP44]; McDermott MBA, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abb1655; Mullainathan S., 2017, AEA PAPERS P, V107; Mullainathan S., 2021, AEA PAPERS P, V111, P3742; Ouyang DV, 2020, NATURE, V580, P252, DOI 10.1038/s41586-020-2145-8; Pierson E, 2021, NAT MED, V27, P136, DOI 10.1038/s41591-020-01192-7; Pramanik R, 2021, NIGHTINGALE OPEN SCI, DOI [10.48815/N54W2V, DOI 10.48815/N54W2V]; Price WN, 2019, NAT MED, V25, P37, DOI 10.1038/s41591-018-0272-7; Robicsek A., 2021, NIGHTINGALE OPEN SCI, DOI [10.48815/N5MW26, DOI 10.48815/N5MW26]; Yala A, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.aba4373	17	0	0	3	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2022	28	5					897	899		10.1038/s41591-022-01804-4	http://dx.doi.org/10.1038/s41591-022-01804-4		MAY 2022	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	1J3AM	35534570	Bronze			2022-12-27	WOS:000792548400008
J	Franko, M; Escobar-Alvarez, S; Fuchs, Z; Lezak, K; Rivera, LR; Rose, MC; Mueller, KL				Franko, Maryrose; Escobar-Alvarez, Sindy; Fuchs, Zoe; Lezak, Kimberly; Rivera, Lindsay Redman; Rose, Miquella C.; Mueller, Kristen L.			Strategies for inclusive grantmaking	NATURE MEDICINE			English	Article								Grantmaking organizations play a crucial role in increasing diversity and equity in the biomedical workforce. Collecting demographic data, increasing the diversity of applicants and reducing bias in peer review are valuable strategies to achieve these goals.	[Franko, Maryrose] Hlth Res Alliance, Raleigh, NC 27709 USA; [Escobar-Alvarez, Sindy] Doris Duke Charitable Fdn, New York, NY USA; [Fuchs, Zoe] TSC Alliance, Silver Spring, MD USA; [Lezak, Kimberly; Rivera, Lindsay Redman] Hlth Resources Act, Boston, MA USA; [Rose, Miquella C.] Burroughs Wellcome Fund, Durham, NC 27703 USA; [Mueller, Kristen L.] Melanoma Res Alliance, Washington, DC 20005 USA; [Mueller, Kristen L.] Arthrit Fdn, Atlanta, GA 30309 USA	Burroughs Wellcome Fund	Franko, M (corresponding author), Hlth Res Alliance, Raleigh, NC 27709 USA.; Rose, MC (corresponding author), Burroughs Wellcome Fund, Durham, NC 27703 USA.; Mueller, KL (corresponding author), Melanoma Res Alliance, Washington, DC 20005 USA.; Mueller, KL (corresponding author), Arthrit Fdn, Atlanta, GA 30309 USA.	maryrose@healthra.org; kmueller@arthritis.org		Rose, Miquella/0000-0001-7780-171X; Fuchs, Zoe/0000-0002-1891-3196; Redman Rivera, Lindsay/0000-0003-2769-3196				Bendiscioli S, 2019, EMBO REP, V20, DOI 10.15252/embr.201949472; BMe, ASS FRAM; Canadian Institutes of Health Research, BIAS PEER REV VIDEO; Carnes M, 2019, ACAD MED, V94, P20, DOI 10.1097/ACM.0000000000002388; Disability & Philanthropy Forum, GUIDE INCREASING DIS; Dzirasa K, 2020, CELL, V183, P576, DOI 10.1016/j.cell.2020.09.026; Freeman RB, 2014, NATURE, V513, P305, DOI 10.1038/513305a; Gerwing TG, 2020, RES INTEGR PEER REV, V5, DOI 10.1186/s41073-020-00096-x; Ginther DK, 2011, SCIENCE, V333, P1015, DOI 10.1126/science.1196783; Harawa NT, 2017, J CLIN TRANSL SCI, V1, P167, DOI 10.1017/cts.2016.23; Health Research Alliance, MEMBER PROFILES; Health Research Alliance, WG SURVEY DOCUMENTS; Health Research Alliance, DIVERSITY EQUITY INC; Hofstra B, 2020, P NATL ACAD SCI USA, V117, P9284, DOI 10.1073/pnas.1915378117; Hoppe TA, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw7238; Kaatz A, 2014, TRENDS PHARMACOL SCI, V35, P371, DOI 10.1016/j.tips.2014.06.005; Lerback J, 2017, NATURE, V541, P455, DOI 10.1038/541455a; Nakamura RK, 2021, ELIFE, V10, DOI [10.7554/eLife.71368, 10.7554/eLife.71368.sa1, 10.7554/eLife.71368.sa2]; National Institutes of Health, INCLUSION WOMEN MINO; Stevens KR, 2021, CELL, V184, P561, DOI 10.1016/j.cell.2021.01.011; Tamblyn R, 2018, CAN MED ASSOC J, V190, pE489, DOI 10.1503/cmaj.170901; Teplitskiy M, 2018, RES POLICY, V47, P1825, DOI 10.1016/j.respol.2018.06.014; The Royal Society, UNDERSTANDING UNCONS; Yanagihara R, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18041569	24	0	0	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4					614	616		10.1038/s41591-022-01757-8	http://dx.doi.org/10.1038/s41591-022-01757-8			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0Q6DV	35440722				2022-12-27	WOS:000785007700008
J	Burke, JF; Thomas, SM				Burke, JF; Thomas, SM			Agriculture is biotechnology's future in Europe	NATURE BIOTECHNOLOGY			English	Editorial Material											Burke, JF (corresponding author), UNIV SUSSEX,SCH BIOL SCI,BIOCHEM LAB,BRIGHTON BN1 9QG,E SUSSEX,ENGLAND.							*U SUSS BUS DEC LT, 1997, BENCHM COMP BIOT EUR	1	7	9	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					695	696		10.1038/nbt0897-695	http://dx.doi.org/10.1038/nbt0897-695			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255772				2022-12-27	WOS:A1997XM70700004
J	Sah, DWY; Ray, J; Gage, FH				Sah, DWY; Ray, J; Gage, FH			Bipotent progenitor cell lines from the human CNS	NATURE BIOTECHNOLOGY			English	Article						progenitor cells; human neurons; CNS cell lines	ION CHANNELS; DIFFERENTIATION; CURRENTS; EXPRESSION; BRAIN	Human central nervous system (CNS) cell lines would substantially facilitate drug discovery and basic research by providing a readily renewable source of human neurons. We isolated clonal human CNS cell lines that had been immortalized with a tetracycline (Tc)-responsive v-myc oncogene; addition of Tc to the growth medium suppressed the oncoprotein rapidly and virtually completely, allowing differentiation to proceed. Two classes of bipotent precursor cells were immortalized: the first class had a default differentiation pathway of neurons only, and the second class had a default differentiation pathway of neurons and astrocytes. We found that after exposure to different external signals in vitro, the environment is capable of redirecting the fate of a particular cell, even in the case of the bipotent precursor cell whose default differentiation pathway was neurons only. These data suggest that extrinsic cues can prevail over intrinsic determinants in directing cell fate in the human CNS.	SALK INST BIOL STUDIES,GENET LAB,LA JOLLA,CA 92037	Salk Institute	Sah, DWY (corresponding author), SIGNAL PHARMACEUT INC,5555 OBERLIN DR,SUITE 100,SAN DIEGO,CA 92121, USA.				NATIONAL INSTITUTE ON AGING [R42AG012576, R41AG012576, R01AG006088] Funding Source: NIH RePORTER; NIA NIH HHS [AG06088, AG12576] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARREOLA J, 1993, J PHYSIOL-LONDON, V472, P289, DOI 10.1113/jphysiol.1993.sp019947; CARBONE E, 1990, PFLUG ARCH EUR J PHY, V416, P170, DOI 10.1007/BF00370239; CHEUN JE, 1991, INT J DEV NEUROSCI, V9, P391, DOI 10.1016/0736-5748(91)90061-P; FREDERIKSEN K, 1988, NEURON, V1, P439, DOI 10.1016/0896-6273(88)90175-4; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hoshimaru M, 1996, P NATL ACAD SCI USA, V93, P1518, DOI 10.1073/pnas.93.4.1518; KILPATRICK TJ, 1993, NEURON, V10, P255, DOI 10.1016/0896-6273(93)90316-J; KUBO Y, 1989, J PHYSIOL-LONDON, V409, P497, DOI 10.1113/jphysiol.1989.sp017510; LESSER SS, 1995, J NEUROSCI, V15, P253; LO LC, 1995, NEURON, V15, P527, DOI 10.1016/0896-6273(95)90142-6; MIENVILLE JM, 1992, CELL MOL NEUROBIOL, V12, P285, DOI 10.1007/BF00734929; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; RYDER EF, 1990, J NEUROBIOL, V21, P356, DOI 10.1002/neu.480210209; SEWARD EP, 1990, PFLUG ARCH EUR J PHY, V417, P223, DOI 10.1007/BF00370703; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; TEMPLE S, 1989, NATURE, V340, P471, DOI 10.1038/340471a0; TURETSKY DM, 1993, J NEUROBIOL, V24, P1157, DOI 10.1002/neu.480240904; YOUNKIN DP, 1993, P NATL ACAD SCI USA, V90, P2174, DOI 10.1073/pnas.90.6.2174	20	93	111	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1997	15	6					574	580		10.1038/nbt0697-574	http://dx.doi.org/10.1038/nbt0697-574			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XC772	9181582				2022-12-27	WOS:A1997XC77200035
J	Yarmush, ML; Berthiaume, F				Yarmush, ML; Berthiaume, F			Metabolic engineering and human disease	NATURE BIOTECHNOLOGY			English	Article							TRICARBOXYLIC-ACID CYCLE; RAT-LIVER CELLS; C-13 NMR; SUBSTRATE SELECTION; PERFUSED LIVER; UNTREATED RATS; GLUCONEOGENESIS; FLUX; PYRUVATE; GLUCOSE		SHRINERS BURN INST,BOSTON,MA 02114		Yarmush, ML (corresponding author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CTR ENGN MED,55 FRUIT ST,BIGELOW 1401,BOSTON,MA 02114, USA.		Berthiaume, Francois/ABD-2139-2020	Yarmush, Martin/0000-0003-4986-8444	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM021700] Funding Source: NIH RePORTER; NIGMS NIH HHS [5P50 GM-21700-21] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beylot M, 1996, REPROD NUTR DEV, V36, P363, DOI 10.1051/rnd:19960403; BROWN GC, 1994, BIOCHEM J, V297, P115, DOI 10.1042/bj2970115; CAMERON DC, 1993, APPL BIOCHEM BIOTECH, V38, P105, DOI 10.1007/BF02916416; COHEN SM, 1987, BIOCHEMISTRY-US, V26, P563, DOI 10.1021/bi00376a031; COHEN SM, 1987, BIOCHEMISTRY-US, V26, P581, DOI 10.1021/bi00376a033; COHEN SM, 1987, BIOCHEMISTRY-US, V26, P573, DOI 10.1021/bi00376a032; COLE PL, 1990, CIRCULATION, V81, P1260, DOI 10.1161/01.CIR.81.4.1260; Dahn MS, 1996, SHOCK, V6, P52, DOI 10.1097/00024382-199607000-00011; FELL DA, 1986, BIOCHEM J, V238, P781, DOI 10.1042/bj2380781; FELL DA, 1992, BIOCHEM J, V286, P313, DOI 10.1042/bj2860313; GROEN AK, 1983, J BIOL CHEM, V258, P4346; GROEN AK, 1986, BIOCHEM J, V237, P379, DOI 10.1042/bj2370379; Jeffrey FMH, 1996, AM J PHYSIOL-ENDOC M, V271, pE788, DOI 10.1152/ajpendo.1996.271.4.E788; JEFFREY FMH, 1995, BASIC RES CARDIOL, V90, P388, DOI 10.1007/BF00788500; JEFFREY FMH, 1995, J CARDIOVASC PHARM, V25, P469; JESSEN ME, 1993, J CLIN INVEST, V92, P831, DOI 10.1172/JCI116657; LAPIDOT A, 1994, J BIOL CHEM, V269, P27198; LIAO JC, 1993, BIOTECHNOL PROGR, V9, P221, DOI 10.1021/bp00021a001; MALLOY CR, 1990, AM J PHYSIOL, V259, pH987, DOI 10.1152/ajpheart.1990.259.3.H987; MIZOCK BA, 1995, AM J MED, V98, P75, DOI 10.1016/S0002-9343(99)80083-7; RIGOULET M, 1987, BIOCHEM J, V245, P661, DOI 10.1042/bj2450661; SHERRY AD, 1992, BIOCHEMISTRY-US, V31, P4833, DOI 10.1021/bi00135a014; Stephanopoulos Gregory, 1994, Current Opinion in Biotechnology, V5, P196, DOI 10.1016/S0958-1669(05)80036-9; SUMEGI B, 1994, BIOCHEM J, V297, P109, DOI 10.1042/bj2970109; Tayek JA, 1996, AM J PHYSIOL-ENDOC M, V270, pE709, DOI 10.1152/ajpendo.1996.270.4.E709; VARMA A, 1994, BIO-TECHNOL, V12, P994, DOI 10.1038/nbt1094-994; WOLFE RR, 1978, J TRAUMA, V18, P800, DOI 10.1097/00005373-197812000-00003; Yamaguchi Y, 1997, SURGERY, V121, P295, DOI 10.1016/S0039-6060(97)90358-5; Yang DW, 1996, AM J PHYSIOL-ENDOC M, V270, pE882, DOI 10.1152/ajpendo.1996.270.5.E882; YATT TM, 1992, TXB CARDIOPLEGIA DIF, P88; Zupke C, 1995, APPL MICROBIOL BIOT, V44, P27; ZUPKE CA, 1997, IN PRESS ANAL BIOCH	32	21	23	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1997	15	6					525	528		10.1038/nbt0697-525	http://dx.doi.org/10.1038/nbt0697-525			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XC772	9181573				2022-12-27	WOS:A1997XC77200026
J	Savka, MA; Farrand, SK				Savka, MA; Farrand, SK			Modification of rhizobacterial populations by engineering bacterium utilization of a novel plant-produced resource	NATURE BIOTECHNOLOGY			English	Article						Agrobacterium tumefaciens; pseudomonads; opine concept; rhizosphere ecology	PSEUDOMONAS-SYRINGAE; TRANSGENIC TOBACCO; PLASMID; COLONIZATION; RHIZOSPHERE; CATABOLISM; MUTANTS; STRAIN; ROOTS	The ability to catabolize distinct nutrients produced by a plant may be a factor in the successful colonization of that host by a bacterium when in competition with other rhizosphere microorganisms. We tested this hypothesis by examining the influence of a novel substrate produced by a transgenic plant on root colonization by near-isogenic bacteria, differing only in their ability to use the resource. When inoculated alone, both bacteria colonized the roots of the normal and transgenic plants with equal kinetics and to indistinguishable levels. When the two bacteria were coinoculated, the catabolizer reached a population density significantly higher than that of the noncatabolizer on the roots of the resource-producing plant. No such advantage was observed on the roots of normal plants. These results support the theory that resources produced and exuded by a plant host can confer a selective advantage to microorganisms that use the substrate.	UNIV ILLINOIS,DEPT CROP SCI,URBANA,IL 61801; UNIV ILLINOIS,DEPT MICROBIOL,URBANA,IL 61801; UNIV W FLORIDA,DEPT BIOL,PENSACOLA,FL 32514	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; State University System of Florida; University of West Florida								BOWEN GD, 1976, ANNU REV PHYTOPATHOL, V14, P121, DOI 10.1146/annurev.py.14.090176.001005; DESSAUX Y, 1987, MOL GEN GENET, V208, P301, DOI 10.1007/BF00330457; Dessaux Y., 1992, MOL SIGNALS PLANT MI, P109; DOWLING DN, 1986, ANNU REV MICROBIOL, V40, P131, DOI 10.1146/annurev.mi.40.100186.001023; ELLIS JG, 1984, MOL GEN GENET, V181, P466; GUYON P, 1993, MOL PLANT MICROBE IN, V6, P92, DOI 10.1094/MPMI-6-092; HWANG IY, 1994, APPL ENVIRON MICROB, V60, P913, DOI 10.1128/AEM.60.3.913-920.1994; JOHNSTON AWB, 1988, MOL GENETICS PLANT M, P374; LINDOW SE, 1987, APPL ENVIRON MICROB, V53, P2520, DOI 10.1128/AEM.53.10.2520-2527.1987; LYNCH JM, 1990, PLANT SOIL, V129, P1, DOI 10.1007/BF00011685; MURPHY JP, 1995, SOIL BIOL BIOCHEM, V27, P5525; MURPHY PJ, 1992, MOL SIGNALS PLANT MI, P377; OConnell KP, 1996, TRENDS BIOTECHNOL, V14, P83, DOI 10.1016/0167-7799(96)80928-0; Oger P, 1997, NAT BIOTECHNOL, V15, P369, DOI 10.1038/nbt0497-369; PETIT A, 1978, MOL GEN GENET, V167, P147, DOI 10.1007/BF00266908; ROSSBACH S, 1995, MOL PLANT MICROBE IN, V4, P549; RYDER MH, 1984, J BIOL CHEM, V259, P9704; SALOMON F, 1984, EMBO J, V3, P141, DOI 10.1002/j.1460-2075.1984.tb01774.x; SAVKA MA, 1992, PLANT PHYSIOL, V98, P784, DOI 10.1104/pp.98.2.784; SAVKA MA, 1990, PHYTOPATHOLOGY, V80, P503, DOI 10.1094/Phyto-80-503; SAVKA MA, 1993, THESIS U ILLINOIS UR; SCOTT DB, 1987, J BACTERIOL, V169, P278, DOI 10.1128/jb.169.1.278-282.1987; TATE ME, 1982, CARBOHYD RES, V104, P105, DOI 10.1016/S0008-6215(00)82224-7; Tempe J., 1979, PLASMIDS MED ENV COM, P353; TEPFER D, 1988, J BACTERIOL, V170, P1153, DOI 10.1128/jb.170.3.1153-1161.1988; TREVELYAN WE, 1950, NATURE, V166, P444, DOI 10.1038/166444b0; VANEGERAAT AWSM, 1975, PLANT SOIL, V42, P381, DOI 10.1007/BF00010013; WILSON M, 1995, APPL ENVIRON MICROB, V61, P2151, DOI 10.1128/AEM.61.6.2151-2158.1995; WILSON M, 1994, APPL ENVIRON MICROB, V60, P4468, DOI 10.1128/AEM.60.12.4468-4477.1994; ZAMBRYSKI P, 1988, ANNU REV GENET, V22, P1, DOI 10.1146/annurev.ge.22.120188.000245	30	91	106	0	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1997	15	4					363	368		10.1038/nbt0497-363	http://dx.doi.org/10.1038/nbt0497-363			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WQ554	9094139				2022-12-27	WOS:A1997WQ55400038
J	Dhami, S; Thompson, D; El Akoum, M; Bates, DW; Bertollini, R; Sheikh, A				Dhami, Sangeeta; Thompson, Deidre; El Akoum, Maha; Bates, David W.; Bertollini, Roberto; Sheikh, Aziz			Data-enabled responses to pandemics: policy lessons from COVID-19	NATURE MEDICINE			English	Editorial Material; Early Access							HOSPITAL ADMISSIONS; SCOTLAND	Most health systems struggled to obtain and analyze real-time data during the COVID-19 pandemic, but places that succeeded can be studied to provide a model for data-enabled responses to future epidemics and pandemics.	[Dhami, Sangeeta] NHS Lothian, Edinburgh, Midlothian, Scotland; [Thompson, Deidre; El Akoum, Maha] World Innovat Summit Hlth, Doha, Qatar; [Bates, David W.] Harvard Med Sch, Boston, MA 02115 USA; [Bertollini, Roberto] Minist Publ Hlth, Doha, Qatar; [Sheikh, Aziz] Univ Edinburgh, Usher Inst, Edinburgh, Midlothian, Scotland	Qatar Foundation (QF); World Innovation Summit for Health (WISH); Harvard University; Harvard Medical School; University of Edinburgh	Sheikh, A (corresponding author), Univ Edinburgh, Usher Inst, Edinburgh, Midlothian, Scotland.	aziz.sheikh@ed.ac.uk			Qatar Foundation	Qatar Foundation(Qatar Foundation (QF)Qatar National Research Fund (QNRF))	We thank S. Afdhal and Z. Sheikh for their comments and contributions to earlier drafts of this paper. The original report, of which this is an abridged version, was funded by the Qatar Foundation.	Allsopp R., 2021, OMDDAC, DOI [10.13140/RG.2.2.30601.98405, DOI 10.13140/RG.2.2.30601.98405]; [Anonymous], NHS DIGITAL; Chen CM, 2020, J MED INTERNET RES, V22, DOI 10.2196/19540; DbBee, US; Dong E., 2020, LANCET INFECT DIS, V20, P533, DOI [10.1016/S1473-3099(20)30120-1, DOI 10.1016/S1473-3099(20)30120-1, 10.1016/S1473-3099(20)30457-6, DOI 10.1016/S1473-3099(20)30484-9]; Katikireddi SV, 2022, LANCET, V399, P25, DOI 10.1016/S0140-6736(21)02754-9; Kerr S, 2022, PLOS MED, V19, DOI 10.1371/journal.pmed.1003927; Lewis S., TECHTARGET; Lv Y, 2021, ARCH MED SCI, V17, P829, DOI 10.5114/aoms/133522; NHS, 2021, US; NHS Research Authority, 2021, US; Shah SA, 2022, ECLINICALMEDICINE, V49, DOI 10.1016/j.eclinm.2022.101462; Sheikh A, 2022, LANCET INFECT DIS, V22, P959, DOI 10.1016/S1473-3099(22)00141-4; Sheikh A, 2021, LANCET, V397, P2461, DOI 10.1016/S0140-6736(21)01358-1; Simpson Colin R, 2020, BMJ Open, V10, pe039097, DOI 10.1136/bmjopen-2020-039097; Simpson CR, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19790; Stock S., 2021, WELLCOME OPEN RES, V6, P21, DOI [DOI 10.12688/WELLCOMEOPENRES.14687.1, 10.12688/wellcomeopenres.16507.1, DOI 10.12688/WELLCOMEOPENRES.16507.1]; Taiwan Centers for Disease Control, 2020, US; UNDP, COVID 19 SOC IMP; Vasileiou E, 2021, LANCET, V397, P1646, DOI 10.1016/S0140-6736(21)00677-2; Wang CJ, 2020, JAMA-J AM MED ASSOC, V323, P1341, DOI 10.1001/jama.2020.3151; WHO, 2015, PAND INFL PREP RESP; World Health Organization, WHO COR COVID 19 DAS	23	0	0	1	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02054-0	http://dx.doi.org/10.1038/s41591-022-02054-0		OCT 2022	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	5H3BX	36229666	Bronze, Green Accepted			2022-12-27	WOS:000867558300001
J	Adler, AI				Adler, Amanda, I			Endpoints and estimands: understanding trials of weight-loss drugs	NATURE MEDICINE			English	Editorial Material; Early Access								Challenges that characterize weight-loss drug trials necessitate good trial design - as highlighted by the STEP 5 trial of semaglutide.	[Adler, Amanda, I] Oxford Ctr Diabet Endocrinol & Metab, Diabet Trial Unit, Oxford, England	University of Oxford	Adler, AI (corresponding author), Oxford Ctr Diabet Endocrinol & Metab, Diabet Trial Unit, Oxford, England.	amanda.adler@dtu.ox.ac.uk						European Medicines Agency, 1998, US; European Medicines Agency Committee for Medicinal Products for Human Use, 2020, US; Garvey WT, 2022, NAT MED, DOI 10.1038/s41591-022-02026-4; Gonzalez E R, 1980, JAMA, V244, P1414, DOI 10.1001/jama.244.13.1414; National Institute for Health and Care Excellence, 2022, US; Patel MR, 2006, AM HEART J, V151, P633, DOI 10.1016/j.ahj.2005.03.006; Simons-Morton DG, 2006, JAMA-J AM MED ASSOC, V295, P826, DOI 10.1001/jama.295.7.826; US Department of Health and Human Services Food and Drug Administration, 2017, US; US Department of Health and Human Services Food and Drug Administration, 2007, US; Wharton S, 2021, INT J OBESITY, V45, P923, DOI 10.1038/s41366-020-00733-x; Wilding JPH, 2021, NEW ENGL J MED, V384, P989, DOI 10.1056/NEJMoa2032183	11	0	0	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02032-6	http://dx.doi.org/10.1038/s41591-022-02032-6		OCT 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	5E6FW	36216946				2022-12-27	WOS:000865719400006
J	Good, Z; Spiegel, JY; Sahaf, B; Malipatlolla, MB; Ehlinger, ZJ; Kurra, S; Desai, MH; Reynolds, WD; Lin, AW; Vandris, P; Wu, F; Prabhu, S; Hamilton, MP; Tamaresis, JS; Hanson, PJ; Patel, S; Feldman, SA; Frank, MJ; Baird, JH; Muffly, L; Claire, GK; Craig, J; Kong, KA; Wagh, D; Coller, J; Bendall, SC; Tibshirani, RJ; Plevritis, SK; Miklos, DB; Mackall, CL				Good, Zinaida; Spiegel, Jay Y.; Sahaf, Bita; Malipatlolla, Meena B.; Ehlinger, Zach J.; Kurra, Sreevidya; Desai, Moksha H.; Reynolds, Warren D.; Lin, Anita Wong; Vandris, Panayiotis; Wu, Fang; Prabhu, Snehit; Hamilton, Mark P.; Tamaresis, John S.; Hanson, Paul J.; Patel, Shabnum; Feldman, Steven A.; Frank, Matthew J.; Baird, John H.; Muffly, Lori; Claire, Gursharan K.; Craig, Juliana; Kong, Katherine A.; Wagh, Dhananjay; Coller, John; Bendall, Sean C.; Tibshirani, Robert J.; Plevritis, Sylvia K.; Miklos, David B.; Mackall, Crystal L.			Post-infusion CAR T-Reg cells identify patients resistant to CD19-CAR therapy	NATURE MEDICINE			English	Article							MASS CYTOMETRY; NK-CELLS; ANTIGEN; NEUROTOXICITY; CD57; MANAGEMENT; EXPANSION; LYMPHOMA; FEATURES; OUTCOMES	Approximately 60% of patients with large B cell lymphoma treated with chimeric antigen receptor (CAR) T cell therapies targeting CD19 experience disease progression, and neurotoxicity remains a challenge. Biomarkers associated with resistance and toxicity are limited. In this study, single-cell proteomic profiling of circulating CAR T cells in 32 patients treated with CD19-CAR identified that CD4(+)Helios(+) CAR T cells on day 7 after infusion are associated with progressive disease and less severe neurotoxicity. Deep profiling demonstrated that this population is non-clonal and manifests hallmark features of T regulatory (T-Reg) cells. Validation cohort analysis upheld the link between higher CAR T-Reg cells with clinical progression and less severe neurotoxicity. A model combining expansion of this subset with lactate dehydrogenase levels, as a surrogate for tumor burden, was superior for predicting durable clinical response compared to models relying on each feature alone. These data credential CAR T-Reg cell expansion as a novel biomarker of response and toxicity after CAR T cell therapy and raise the prospect that this subset may regulate CAR T cell responses in humans. Single-cell proteomic profiling of circulating CAR T cells in patients treated with CD19-CAR shows that CD4(+)Helios(+) CAR T cells on day 7 after infusion are associated with progressive disease and less severe neurotoxicity.	[Good, Zinaida; Spiegel, Jay Y.; Sahaf, Bita; Malipatlolla, Meena B.; Ehlinger, Zach J.; Kurra, Sreevidya; Desai, Moksha H.; Reynolds, Warren D.; Lin, Anita Wong; Vandris, Panayiotis; Wu, Fang; Prabhu, Snehit; Hamilton, Mark P.; Hanson, Paul J.; Patel, Shabnum; Feldman, Steven A.; Frank, Matthew J.; Baird, John H.; Muffly, Lori; Claire, Gursharan K.; Craig, Juliana; Kong, Katherine A.; Bendall, Sean C.; Miklos, David B.; Mackall, Crystal L.] Stanford Univ, Sch Med, Ctr Canc Cell Therapy, Stanford Canc Inst, Stanford, CA 94305 USA; [Good, Zinaida; Tamaresis, John S.; Tibshirani, Robert J.; Plevritis, Sylvia K.] Stanford Univ, Dept Biomed Data Sci, Sch Med, Stanford, CA 94305 USA; [Good, Zinaida; Bendall, Sean C.; Mackall, Crystal L.] Stanford Univ, Parker Inst Canc Immunotherapy, Sch Med, Stanford, CA 94305 USA; [Spiegel, Jay Y.; Hamilton, Mark P.; Hanson, Paul J.; Frank, Matthew J.; Baird, John H.; Muffly, Lori; Claire, Gursharan K.; Craig, Juliana; Miklos, David B.; Mackall, Crystal L.] Stanford Univ, Dept Med, Div Blood & Marrow Transplantat & Cellular Therap, Sch Med, Stanford, CA 94305 USA; [Patel, Shabnum; Feldman, Steven A.] Stanford Univ, Lab Cell & Gene Med, Sch Med, Stanford, CA 94305 USA; [Patel, Shabnum] Syncopat Life Sci, San Mateo, CA USA; [Wagh, Dhananjay; Coller, John] Stanford Univ, Stanford Genom Facil, Sch Med, Stanford, CA 94305 USA; [Bendall, Sean C.] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA; [Tibshirani, Robert J.] Stanford Univ, Dept Stat, Stanford, CA 94305 USA; [Plevritis, Sylvia K.] Stanford Univ, Dept Radiol, Sch Med, Stanford, CA 94305 USA; [Mackall, Crystal L.] Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA; [Spiegel, Jay Y.] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA; [Kurra, Sreevidya] Western Michigan Univ, Homer Stryker MD Sch Med, Kalamazoo, MI 49008 USA; [Lin, Anita Wong] Univ Calif Berkeley, Canc Res Lab, Flow Cytometry Core Facil, Berkeley, CA 94720 USA; [Baird, John H.] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Div Lymphoma, 1500 E Duarte Rd, Duarte, CA 91010 USA; [Craig, Juliana] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA	Stanford Cancer Institute; Stanford University; Stanford University; Stanford University; Stanford University; Stanford University; Stanford University; Stanford University; Stanford University; Stanford University; Stanford University; University of Miami; Western Michigan University; University of California System; University of California Berkeley; City of Hope; University of Wisconsin System; University of Wisconsin Madison	Miklos, DB; Mackall, CL (corresponding author), Stanford Univ, Sch Med, Ctr Canc Cell Therapy, Stanford Canc Inst, Stanford, CA 94305 USA.; Mackall, CL (corresponding author), Stanford Univ, Parker Inst Canc Immunotherapy, Sch Med, Stanford, CA 94305 USA.; Miklos, DB; Mackall, CL (corresponding author), Stanford Univ, Dept Med, Div Blood & Marrow Transplantat & Cellular Therap, Sch Med, Stanford, CA 94305 USA.; Mackall, CL (corresponding author), Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA.	dmiklos@stanford.edu; cmackall@stanford.edu	Bendall, Sean/AGG-0126-2022	Bendall, Sean/0000-0003-1341-2453; Muffly, Lori/0000-0002-9887-6136; Reynolds, Warren/0000-0002-1755-2835; Good, Zinaida/0000-0003-2343-5771; Vandris, Panayiotis/0000-0002-4917-9019; Spiegel, Jay/0000-0001-6491-0044	California Institute for Regenerative Medicine [CLIN2-10846]; National Cancer Institute (NCI) [5P30CA124435, 2P01CA049605-29A1, U54-CA209971]; Kite Pharma; St. Baldrick's/Stand Up 2 Cancer Pediatric Dream Team Translational Cancer Research Grant; Virginia and D. K. Ludwig Fund for Cancer Research; Parker Institute for Cancer Immunotherapy; Stanford Cancer Institute, an NCI-designated Comprehensive Cancer Center; National Institutes of Health [S10OD018220]	California Institute for Regenerative Medicine(California Institute for Regenerative Medicine); National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Kite Pharma; St. Baldrick's/Stand Up 2 Cancer Pediatric Dream Team Translational Cancer Research Grant; Virginia and D. K. Ludwig Fund for Cancer Research; Parker Institute for Cancer Immunotherapy; Stanford Cancer Institute, an NCI-designated Comprehensive Cancer Center; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank T. Murty and C. Ramello for critical review of the manuscript. R. Majzner, A. M. Tousley and S. Heitzeneder provided healthy T cells expressing the CD19-CD28. CAR construct. Monoclonal anti-FMC63 idiotype antibody was kindly provided by B. Jena and L. J. N. Cooper. This work was supported by the California Institute for Regenerative Medicine (award CLIN2-10846; principal investigator: C.L.M.); the National Cancer Institute (NCI) (5P30CA124435, C.L.M.; 2P01CA049605-29A1, C.L.M. and D.B.M.; and U54-CA209971, S.K.P.); a sponsored research agreement with Kite Pharma, a subsidiary of Gilead Sciences (D.B.M.); and a St. Baldrick's/Stand Up 2 Cancer Pediatric Dream Team Translational Cancer Research Grant (C.L.M.). Stand Up 2 Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research. This study was also supported by the Virginia and D. K. Ludwig Fund for Cancer Research (C.L.M.). Z.G. was supported by fellowships from the Parker Institute for Cancer Immunotherapy and the Stanford Cancer Institute, an NCI-designated Comprehensive Cancer Center. Z.G., S.P., S.C.B., D.B.M. and C.L.M. are members of the Parker Institute for Cancer Immunotherapy, which supports the Stanford University Cancer Immunotherapy Program. The Illumina HiSeq 4000 used here was purchased with National Institutes of Health funds (award S10OD018220).	ABO T, 1981, J IMMUNOL, V127, P1024; Abramson JS, 2020, LANCET, V396, P839, DOI 10.1016/S0140-6736(20)31366-0; Alfei F, 2019, NATURE, V571, P265, DOI 10.1038/s41586-019-1326-9; AZUMA M, 1993, J IMMUNOL, V150, P1147; Bendall SC, 2011, SCIENCE, V332, P687, DOI 10.1126/science.1198704; Bengsch B, 2018, IMMUNITY, V48, P1029, DOI 10.1016/j.immuni.2018.04.026; Brown CE, 2019, NAT REV IMMUNOL, V19, P73, DOI 10.1038/s41577-018-0119-y; Chen J, 2019, NATURE, V567, P530, DOI 10.1038/s41586-019-0985-x; Cheson BD, 2014, J CLIN ONCOL, V32, P3059, DOI 10.1200/JCO.2013.54.8800; Chou CK, 2019, BONE MARROW TRANSPL, V54, P780, DOI 10.1038/s41409-019-0602-5; Deng Q, 2020, NAT MED, V26, DOI 10.1038/s41591-020-1061-7; DOLSTRA H, 1995, BRIT J HAEMATOL, V90, P300, DOI 10.1111/j.1365-2141.1995.tb05150.x; Fienberg HG, 2012, CYTOM PART A, V81A, P467, DOI 10.1002/cyto.a.22067; Finck R, 2013, CYTOM PART A, V83A, P483, DOI 10.1002/cyto.a.22271; Fraietta JA, 2018, NAT MED, V24, P563, DOI 10.1038/s41591-018-0010-1; Frank MJ, 2021, J CLIN ONCOL, V39, P3034, DOI 10.1200/JCO.21.00377; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Gillespie M, 2022, NUCLEIC ACIDS RES, V50, pD687, DOI 10.1093/nar/gkab1028; Good CR, 2021, CELL, V184, P6081, DOI 10.1016/j.cell.2021.11.016; Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313; Gust J, 2017, CANCER DISCOV, V7, P1404, DOI 10.1158/2159-8290.CD-17-0698; Hafemeister C, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1874-1; Hahne F, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-106; Hao Yuhan, 2021, Cell, V184, P3573, DOI 10.1016/j.cell.2021.04.048; Huehn J, 2009, NAT REV IMMUNOL, V9, P83, DOI 10.1038/nri2474; Jacobson CA, 2020, J CLIN ONCOL, V38, P3095, DOI 10.1200/JCO.19.02103; Jena B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057838; Kared H, 2016, CANCER IMMUNOL IMMUN, V65, P441, DOI 10.1007/s00262-016-1803-z; Kebriaei P, 2016, J CLIN INVEST, V126, P3363, DOI 10.1172/JCI86721; Kern F, 1999, EUR J IMMUNOL, V29, P2908, DOI 10.1002/(SICI)1521-4141(199909)29:09<2908::AID-IMMU2908>3.0.CO;2-8; Khan O, 2019, NATURE, V571, P211, DOI 10.1038/s41586-019-1325-x; Kim HJ, 2015, SCIENCE, V350, P334, DOI 10.1126/science.aad0616; Kuhn M, 2008, J STAT SOFTW, V28, P1, DOI 10.18637/jss.v028.i05; Lamure S, 2021, CANCERS, V13, DOI 10.3390/cancers13174279; Lee DW, 2019, BIOL BLOOD MARROW TR, V25, P625, DOI 10.1016/j.bbmt.2018.12.758; Lee DW, 2015, LANCET, V385, P517, DOI 10.1016/S0140-6736(14)61403-3; Lee DW, 2014, BLOOD, V124, P188, DOI 10.1182/blood-2014-05-552729; Locke FL, 2022, NEW ENGL J MED, V386, P640, DOI 10.1056/NEJMoa2116133; Locke FL, 2020, BLOOD ADV, V4, P4898, DOI 10.1182/bloodadvances.2020002394; Locke FL, 2019, LANCET ONCOL, V20, P31, DOI 10.1016/S1470-2045(18)30864-7; Long AH, 2015, NAT MED, V21, P581, DOI 10.1038/nm.3838; Lopez-Verges S, 2010, BLOOD, V116, P3865, DOI 10.1182/blood-2010-04-282301; Lun ATL, 2017, NAT METHODS, V14, P707, DOI 10.1038/nmeth.4295; Lynn RC, 2019, NATURE, V576, P293, DOI 10.1038/s41586-019-1805-z; Majzner RG, 2020, CANCER DISCOV, V10, P702, DOI 10.1158/2159-8290.CD-19-0945; Majzner RG, 2018, CANCER DISCOV, V8, P1219, DOI 10.1158/2159-8290.CD-18-0442; Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866; Melenhorst JJ, 2022, NATURE, V602, P503, DOI 10.1038/s41586-021-04390-6; Nastoupil LJ, 2020, J CLIN ONCOL, V38, P3119, DOI 10.1200/JCO.19.02104; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; Neelapu SS, 2018, NAT REV CLIN ONCOL, V15, P47, DOI 10.1038/nrclinonc.2017.148; Norelli M, 2018, NAT MED, V24, P739, DOI 10.1038/s41591-018-0036-4; Parker KR, 2020, CELL, V183, P126, DOI 10.1016/j.cell.2020.08.022; Rossi J, 2018, BLOOD, V132, P804, DOI 10.1182/blood-2018-01-828343; Rowland M, 1995, CLIN PHARMACOKINETIC; Santomasso BD, 2018, CANCER DISCOV, V8, P958, DOI 10.1158/2159-8290.CD-17-1319; Sauter CS, 2019, BLOOD, V134, P626, DOI 10.1182/blood.2018883421; Schuster SJ, 2019, NEW ENGL J MED, V380, P45, DOI 10.1056/NEJMoa1804980; Scott AC, 2019, NATURE, V571, P270, DOI 10.1038/s41586-019-1324-y; Seo H, 2019, P NATL ACAD SCI USA, V116, P12410, DOI 10.1073/pnas.1905675116; Shah NN, 2020, NAT MED, V26, P1569, DOI 10.1038/s41591-020-1081-3; Sheih A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13880-1; Spiegel JY, 2021, NAT MED, V27, P1419, DOI 10.1038/s41591-021-01436-0; Stoeckius M, 2017, NAT METHODS, V14, P865, DOI [10.1038/nmeth.4380, 10.1038/NMETH.4380]; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Taraseviciute A, 2018, CANCER DISCOV, V8, P750, DOI 10.1158/2159-8290.CD-17-1368; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Van Gassen S, 2015, CYTOM PART A, V87A, P636, DOI 10.1002/cyto.a.22625; Walker AJ, 2017, MOL THER, V25, P2189, DOI 10.1016/j.ymthe.2017.06.008; Wang XL, 2016, BLOOD, V127, P2980, DOI 10.1182/blood-2015-12-686725; Wei JS, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00256-x; Zhang Z, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001150; Zunder ER, 2015, NAT PROTOC, V10, P316, DOI 10.1038/nprot.2015.020	74	1	1	8	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2022	28	9					1860	+		10.1038/s41591-022-01960-7	http://dx.doi.org/10.1038/s41591-022-01960-7		SEP 2022	30	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4S0LI	36097223	Bronze			2022-12-27	WOS:000852940800007
J	Isidro, J; Borges, V; Pinto, M; Sobral, D; Santos, JD; Nunes, A; Mixao, V; Ferreira, R; Santos, D; Duarte, S; Vieira, L; Borrego, MJ; Nuncio, S; de Carvalho, IL; Pelerito, A; Cordeiro, R; Gomes, JP				Isidro, Joana; Borges, Vitor; Pinto, Miguel; Sobral, Daniel; Santos, Joao Dourado; Nunes, Alexandra; Mixao, Veronica; Ferreira, Rita; Santos, Daniela; Duarte, Silvia; Vieira, Luis; Borrego, Maria Jose; Nuncio, Sofia; de Carvalho, Isabel Lopes; Pelerito, Ana; Cordeiro, Rita; Gomes, Joao Paulo			Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus	NATURE MEDICINE			English	Article							VACCINIA VIRUS; DNA	The largest monkeypox virus (MPXV) outbreak described so far in non-endemic countries was identified in May 2022 (refs. (1-6)). In this study, shotgun metagenomics allowed the rapid reconstruction and phylogenomic characterization of the first MPXV outbreak genome sequences, showing that this MPXV belongs to clade 3 and that the outbreak most likely has a single origin. Although 2022 MPXV (lineage B.1) clustered with 2018-2019 cases linked to an endemic country, it segregates in a divergent phylogenetic branch, likely reflecting continuous accelerated evolution. An in-depth mutational analysis suggests the action of host APOBEC3 in viral evolution as well as signs of potential MPXV human adaptation in ongoing microevolution. Our findings also indicate that genome sequencing may provide resolution to track the spread and transmission of this presumably slow-evolving double-stranded DNA virus.	[Isidro, Joana; Borges, Vitor; Pinto, Miguel; Sobral, Daniel; Santos, Joao Dourado; Nunes, Alexandra; Mixao, Veronica; Ferreira, Rita; Gomes, Joao Paulo] Natl Inst Hlth Doutor Ricardo Jorge INSA, Dept Infect Dis, Genom & Bioinformat Unit, Lisbon, Portugal; [Santos, Daniela; Duarte, Silvia; Vieira, Luis] Natl Inst Hlth Doutor Ricardo Jorge INSA, Dept Human Genet, Technol & Innovat Unit, Lisbon, Portugal; [Borrego, Maria Jose] Natl Inst Hlth Doutor Ricardo Jorge INSA, Dept Infect Dis, Natl Reference Lab Sexually Transmitted Infect, Lisbon, Portugal; [Nuncio, Sofia; de Carvalho, Isabel Lopes; Pelerito, Ana; Cordeiro, Rita] Natl Inst Hlth Doutor Ricardo Jorge INSA, Dept Infect Dis, Emergency Response & Biopreparedness Unit, Lisbon, Portugal; [Gomes, Joao Paulo] Lusofona Univ, Fac Vet Med, Lisbon, Portugal	Instituto Nacional de Saude Dr. Ricardo Jorge; Instituto Nacional de Saude Dr. Ricardo Jorge; Instituto Nacional de Saude Dr. Ricardo Jorge; Instituto Nacional de Saude Dr. Ricardo Jorge; Lusofona University; Universidade de Lisboa	Gomes, JP (corresponding author), Natl Inst Hlth Doutor Ricardo Jorge INSA, Dept Infect Dis, Genom & Bioinformat Unit, Lisbon, Portugal.; Gomes, JP (corresponding author), Lusofona Univ, Fac Vet Med, Lisbon, Portugal.	j.paulo.gomes@insa.min-saude.pt	Mixão, Verónica/ABC-8729-2020; Sobral, Daniel/B-4786-2014	Mixão, Verónica/0000-0001-6669-0161; Sobral, Daniel/0000-0003-3955-0117; Nunes, Alexandra/0000-0001-6449-8053	HERA project - European Commission through the European Centre for Disease Control and Prevention [2021/PHF/23776]; GenomePT project - COMPETE 2020-Operational Programme for Competitiveness and Internationalisation (POCI) [POCI-01-0145-FEDER-022184]; Lisboa Portugal Regional Operational Programme (Lisboa2020); Algarve Portugal Regional Operational Programme (CRESC Algarve2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF); Portuguese Science and Technology Foundation (FCT); ERINHA-Advance project (European Union's Horizon 2020 Research and Innovation program) [824061]; European Union's Horizon 2020 Research and Innovation program [773830]; FCT; FEDER [22153-01/SAICT/2016]	HERA project - European Commission through the European Centre for Disease Control and Prevention; GenomePT project - COMPETE 2020-Operational Programme for Competitiveness and Internationalisation (POCI); Lisboa Portugal Regional Operational Programme (Lisboa2020); Algarve Portugal Regional Operational Programme (CRESC Algarve2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF); Portuguese Science and Technology Foundation (FCT)(Portuguese Foundation for Science and Technology); ERINHA-Advance project (European Union's Horizon 2020 Research and Innovation program); European Union's Horizon 2020 Research and Innovation program; FCT(Portuguese Foundation for Science and TechnologyEuropean Commission); FEDER(European Commission)	We thank A. Rambaut from the University of Edinburgh for launching the discussion on MPXV genomics at virological.org, with emphasis on his first insights on potential APOBEC3-mediated genome editing. We also gratefully acknowledge the authors and the originating and submitting laboratories of the genetic sequences released in GenBank. The acquisition of WGS-associated equipment used in this study (including the Illumina NextSeq 2000) was funded by the HERA project (Grant/2021/PHF/23776) supported by the European Commission through the European Centre for Disease Control and Prevention and partially funded by the GenomePT project (POCI-01-0145-FEDER-022184), supported by COMPETE 2020-Operational Programme for Competitiveness and Internationalisation (POCI), Lisboa Portugal Regional Operational Programme (Lisboa2020) and Algarve Portugal Regional Operational Programme (CRESC Algarve2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF), and by the Portuguese Science and Technology Foundation (FCT). This study was also supported by the ERINHA-Advance project (funding from the European Union's Horizon 2020 Research and Innovation program, grant agreement no. 824061) and also benefited from co-funding from the European Union's Horizon 2020 Research and Innovation program, grant agreement no. 773830: One Health European Joint Programme (EJP), in particular by co-funding postdoctoral fellowships for J.S.D. and V.M. and INSaFLU development. We also thank M. Pinheiro (iBiMED/Universidade de Aveiro) for his continuous support on updating the INSaFLU platform and the Infraestrutura Nacional de Computacao Distribuida (INCD) for providing computational resources for testing it. INCD was funded by FCT and FEDER under project 22153-01/SAICT/2016. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Borges V, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0555-0; Bowie A, 2000, P NATL ACAD SCI USA, V97, P10162, DOI 10.1073/pnas.160027697; Bunge Eveline M, 2022, PLoS Negl Trop Dis, V16, pe0010141, DOI 10.1371/journal.pntd.0010141; Chen J, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005471; Duque MP, 2022, EUROSURVEILLANCE, V27, DOI 10.2807/1560-7917.ES.2022.27.22.2200424; European Centre for Disease Prevention and Control, 2022, RISK ASS MONK MULT C; European Centre for Disease Prevention and Control, 2022, EP UPD MONK MULT COU; Firth C, 2010, MOL BIOL EVOL, V27, P2038, DOI 10.1093/molbev/msq088; Gigante C. M., 2022, BIORXIV, DOI [10.1101/2022.06.10.495526v1, DOI 10.1101/2022.06.10.495526V1]; Giorgi EE, 2020, MBIO, V11, DOI 10.1128/mBio.00324-20; Hammarlund E, 2005, NAT MED, V11, P1005, DOI 10.1038/nm1273; Happi C., 2022, URGENT NEED NONDISCR; Isidro J., 2022, 1 DRAFT GENOME SEQUE; Kraemer MUG, 2022, LANCET INFECT DIS, V22, P941, DOI 10.1016/S1473-3099(22)00359-0; Kugelman JR, 2014, EMERG INFECT DIS, V20, P232, DOI 10.3201/eid2002.130118; Likos AM, 2005, J GEN VIROL, V86, P2661, DOI 10.1099/vir.0.81215-0; Mauldin MR, 2022, J INFECT DIS, V225, P1367, DOI 10.1093/infdis/jiaa559; Muhlemann B, 2020, SCIENCE, V369, P391, DOI 10.1126/science.aaw8977; Nakazawa Y, 2015, VIRUSES-BASEL, V7, P2168, DOI 10.3390/v7042168; Nitsche A, 2004, J CLIN MICROBIOL, V42, P1207, DOI 10.1128/JCM.42.3.1207-1213.2004; OToole A., INITIAL OBSERVATIONS; Pecori R, 2022, NAT REV GENET, V23, P505, DOI 10.1038/s41576-022-00459-8; Perdiguero B, 2009, J INTERF CYTOK RES, V29, P581, DOI 10.1089/jir.2009.0073; Rehm KE, 2010, VIROLOGY, V397, P176, DOI 10.1016/j.virol.2009.11.008; Rotmistrovsky K., 2011, J UNPUB; Sadeghpour S, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13071366; Soday L, 2019, CELL REP, V27, P1920, DOI 10.1016/j.celrep.2019.04.042; UK Health Security Agency, 2022, GUID MONK BACKGR INF; Vartanian JP, 2008, SCIENCE, V320, P230, DOI 10.1126/science.1153201; Vivancos R, 2022, EUROSURVEILLANCE, V27, DOI 10.2807/1560-7917.ES.2022.27.22.2200422; WHO, 2022, VACC IMM MONK INT GU; World Health Organization (WHO), 2019, MONK FACT SHEET; Yinka-Ogunleye A, 2019, LANCET INFECT DIS, V19, P872, DOI 10.1016/S1473-3099(19)30294-4	33	96	98	39	39	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2022	28	8								10.1038/s41591-022-01907-y	http://dx.doi.org/10.1038/s41591-022-01907-y		JUN 2022	8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4Q5FD	35750157	hybrid, Green Published, Green Submitted			2022-12-27	WOS:000826816800001
J	Rivellese, F; Surace, AEA; Goldmann, K; Sciacca, E; Cubuk, C; Giorli, G; John, CR; Nerviani, A; Fossati-Jimack, L; Thorborn, G; Ahmed, M; Prediletto, E; Church, SE; Hudson, BM; Warren, SE; McKeigue, PM; Humby, F; Bombardieri, M; Barnes, MR; Lewis, MJ; Pitzalis, C				Rivellese, Felice; Surace, Anna E. A.; Goldmann, Katriona; Sciacca, Elisabetta; cubuk, Cankut; Giorli, Giovanni; John, Christopher R.; Nerviani, Alessandra; Fossati-Jimack, Liliane; Thorborn, Georgina; Ahmed, Manzoor; Prediletto, Edoardo; Church, Sarah E.; Hudson, Briana M.; Warren, Sarah E.; McKeigue, Paul M.; Humby, Frances; Bombardieri, Michele; Barnes, Michael R.; Lewis, Myles J.; Pitzalis, Costantino		R4RA Collaborative Grp	Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial	NATURE MEDICINE			English	Article							CLINICAL-RESPONSE; B-CELLS; EXPRESSION; TISSUE	Biomarker analysis of the phase 4 R4RA trial identifies pretreatment synovial biopsy features selectively associated with response to rituximab or tocilizumab, and leads to the development of models that might predict treatment benefit in patients with rheumatoid arthritis Patients with rheumatoid arthritis (RA) receive highly targeted biologic therapies without previous knowledge of target expression levels in the diseased tissue. Approximately 40% of patients do not respond to individual biologic therapies and 5-20% are refractory to all. In a biopsy-based, precision-medicine, randomized clinical trial in RA (R4RA; n = 164), patients with low/absent synovial B cell molecular signature had a lower response to rituximab (anti-CD20 monoclonal antibody) compared with that to tocilizumab (anti-IL6R monoclonal antibody) although the exact mechanisms of response/nonresponse remain to be established. Here, in-depth histological/molecular analyses of R4RA synovial biopsies identify humoral immune response gene signatures associated with response to rituximab and tocilizumab, and a stromal/fibroblast signature in patients refractory to all medications. Post-treatment changes in synovial gene expression and cell infiltration highlighted divergent effects of rituximab and tocilizumab relating to differing response/nonresponse mechanisms. Using ten-by-tenfold nested cross-validation, we developed machine learning algorithms predictive of response to rituximab (area under the curve (AUC) = 0.74), tocilizumab (AUC = 0.68) and, notably, multidrug resistance (AUC = 0.69). This study supports the notion that disease endotypes, driven by diverse molecular pathology pathways in the diseased tissue, determine diverse clinical and treatment-response phenotypes. It also highlights the importance of integration of molecular pathology signatures into clinical algorithms to optimize the future use of existing medications and inform the development of new drugs for refractory patients.	[Rivellese, Felice; Surace, Anna E. A.; Goldmann, Katriona; Sciacca, Elisabetta; cubuk, Cankut; Giorli, Giovanni; John, Christopher R.; Nerviani, Alessandra; Fossati-Jimack, Liliane; Thorborn, Georgina; Ahmed, Manzoor; Prediletto, Edoardo; Humby, Frances; Bombardieri, Michele; Lewis, Myles J.; Pitzalis, Costantino] Queen Mary Univ London, Barts & London Sch Med & Dent, William Harvey Res Inst, Ctr Expt Med & Rheumatol, London, England; [Rivellese, Felice; Surace, Anna E. A.; Goldmann, Katriona; Sciacca, Elisabetta; cubuk, Cankut; Giorli, Giovanni; John, Christopher R.; Barnes, Michael R.; Lewis, Myles J.] Queen Mary Univ London, William Harvey Res Inst, Ctr Translational Bioinformat, Barts & London Sch Med & Dent, London, England; [Church, Sarah E.; Hudson, Briana M.; Warren, Sarah E.] NanoString Technol Inc, Seattle, WA USA; [McKeigue, Paul M.] Univ Edinburgh, Usher Inst, Coll Med & Vet Med, Edinburgh, Midlothian, Scotland	University of London; Queen Mary University London; University of London; Queen Mary University London; University of Edinburgh	Lewis, MJ; Pitzalis, C (corresponding author), Queen Mary Univ London, Barts & London Sch Med & Dent, William Harvey Res Inst, Ctr Expt Med & Rheumatol, London, England.; Lewis, MJ (corresponding author), Queen Mary Univ London, William Harvey Res Inst, Ctr Translational Bioinformat, Barts & London Sch Med & Dent, London, England.	myles.lewis@qmul.ac.uk; c.pitzalis@qmul.ac.uk	humby, frances/GSE-3706-2022; Celis, Raquel/K-5520-2017; Canete, Juan D/M-4428-2017	Pratt, Arthur/0000-0002-9909-8209; Goldmann, Katriona/0000-0002-9073-6323; RIVELLESE, Felice/0000-0002-6759-7521; Isaacs, John/0000-0002-6103-7056; Celis, Raquel/0000-0002-5096-4532; Pitzalis, Costantino/0000-0003-1326-5051; Sasieni, Peter/0000-0003-1509-8744; Lewis, Myles J/0000-0001-9365-5345; CUBUK, Cankut/0000-0003-4646-0849; Fossati-Jimack, Liliane/0000-0003-3757-3999; Nerviani, Alessandra/0000-0003-4064-4014; Canete, Juan D/0000-0003-2606-0573	Medical Research Council (MRC); National Institute for Health and Care Research (NIHR) [11/100/76]; NIHR [131575, TRF-2018-11-ST2-002]; MRC [MR/V012509/1]; Versus Arthritis [20022];  [21890]	Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health and Care Research (NIHR)(National Institute for Health Research (NIHR)); NIHR(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Versus Arthritis(Versus Arthritis); 	We thank all patients participating in the trial for their generous contribution of time, patience and willingness to consent to a minimally invasive procedure that they would not have had as part of their routine care; and the Patient Advisory Group, represented by Z. Ide, for their continuous support in evaluation of trial documentation and the linked research, as well as in dissemination of the importance of precision medicine among patients and through patient organizations (including the National Rheumatoid Arthritis Society).The R4RA trial was funded by the Efficacy and Mechanism Evaluation (EME) Programme, a partnership between the Medical Research Council (MRC) and the National Institute for Health and Care Research (NIHR) (grant no. 11/100/76). This study was further supported by NIHR (grant 131575) and MRC (MR/V012509/1). We would also like to thank the NIHR for supporting F.R.'s fellowship (no. TRF-2018-11-ST2-002), and Versus Arthritis for providing infrastructure support through the Experimental Arthritis Treatment Centre (grant no. 20022) and for supporting A.N.'s clinical lectureship (grant no. 21890). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, MRC, Versus Arthritis or the Department of Health. We thank A. Spiliopoulou (Edinburgh University) for statistical advice and discussions. Some of the illustrations were created using Servier medical art (smart.servier.com) under Creative Commons Attribution 3.0 Unported License.	Becht E, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1070-5; Bhattacharya Arjun, 2021, Brief Bioinform, V22, DOI 10.1093/bib/bbaa163; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Bresnihan B, 2009, J RHEUMATOL, V36, P1800, DOI 10.3899/jrheum.090348; Buch MH, 2018, ANN RHEUM DIS, V77, P966, DOI 10.1136/annrheumdis-2017-212862; Bugatti S, 2014, RHEUMATOLOGY, V53, P1886, DOI 10.1093/rheumatology/keu163; Choy EH, 2020, NAT REV RHEUMATOL, V16, P335, DOI 10.1038/s41584-020-0419-z; Croft AP, 2019, NATURE, V570, P246, DOI 10.1038/s41586-019-1263-7; Crozat K, 2011, J IMMUNOL, V187, P4411, DOI 10.4049/jimmunol.1101717; Curran AM, 2020, NAT REV RHEUMATOL, V16, P301, DOI 10.1038/s41584-020-0409-1; Ferrari N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07987-0; Giacomelli R, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2020.102738; Graham SA, 2009, J BIOL CHEM, V284, P18537, DOI 10.1074/jbc.M109.012807; Helmink BA, 2020, NATURE, V577, P549, DOI 10.1038/s41586-019-1922-8; Hill DG, 2021, CYTOKINE, V146, DOI 10.1016/j.cyto.2021.155650; Hogan VE, 2012, ANN RHEUM DIS, V71, P1888, DOI 10.1136/annrheumdis-2011-201115; Humby F, 2021, LANCET, V397, P305, DOI 10.1016/S0140-6736(20)32341-2; Humby F, 2019, ANN RHEUM DIS, V78, P761, DOI 10.1136/annrheumdis-2018-214539; Isaacs JD, 2013, ANN RHEUM DIS, V72, P329, DOI 10.1136/annrheumdis-2011-201117; Iwamoto T, 2006, RHEUMATOLOGY, V45, P421, DOI 10.1093/rheumatology/kei209; John CR, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58766-1; Kavanaugh A, 2008, ANN RHEUM DIS, V67, P402, DOI 10.1136/ard.2007.074229; Kawalec P, 2015, CLIN BREAST CANCER, V15, P90, DOI 10.1016/j.clbc.2014.10.006; Kelly S, 2015, ANN RHEUM DIS, V74, P611, DOI 10.1136/annrheumdis-2013-204603; Krenn V, 2006, HISTOPATHOLOGY, V49, P358, DOI 10.1111/j.1365-2559.2006.02508.x; Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29; Lewis MJ, 2019, CELL REP, V28, P2455, DOI 10.1016/j.celrep.2019.07.091; Li S, 2014, NAT IMMUNOL, V15, P195, DOI 10.1038/ni.2789; Lliso-Ribera G, 2019, ANN RHEUM DIS, V78, P1642, DOI 10.1136/annrheumdis-2019-215751; LOVE MI, 2014, GENOME BIOL, V15, DOI DOI 10.1186/S13059-014-0550-8; Marsh LJ, 2021, IMMUNOL REV, V302, P163, DOI 10.1111/imr.12986; McKeigue P, 2019, STAT METHODS MED RES, V28, P904, DOI 10.1177/0962280217738807; Mizoguchi F, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02892-y; Nerviani A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00845; Nouri B, 2020, RHEUMATOLOGY, V59, P3603, DOI 10.1093/rheumatology/keaa529; Patro R, 2017, NAT METHODS, V14, P417, DOI 10.1038/nmeth.4197; Pitzalis C, 2020, NAT REV RHEUMATOL, V16, P590, DOI 10.1038/s41584-020-0491-4; Ramwadhdoebe TH, 2019, RHEUMATOLOGY, V58, P1075, DOI 10.1093/rheumatology/key428; Raterman HG, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3819; Rivellese F, 2020, ARTHRITIS RHEUMATOL, V72, P714, DOI 10.1002/art.41184; Salomon S, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1244-x; Smolen JS, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.1; Smolen JS, 2014, ANN RHEUM DIS, V73, P492, DOI 10.1136/annrheumdis-2013-204573; Stephenson W, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02659-x; Teng YKO, 2007, ARTHRITIS RHEUM-US, V56, P3909, DOI 10.1002/art.22967; Thurlings RM, 2010, ARTHRITIS RHEUM-US, V62, P3607, DOI 10.1002/art.27702; Vandooren B, 2008, ARTHRITIS RHEUM-US, V58, P718, DOI 10.1002/art.23290; Wei KV, 2020, NATURE, V582, P259, DOI 10.1038/s41586-020-2222-z; YANNI G, 1994, ANN RHEUM DIS, V53, P39, DOI 10.1136/ard.53.1.39; Zhang F, 2019, NAT IMMUNOL, V20, P928, DOI 10.1038/s41590-019-0378-1	50	12	12	5	10	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2022	28	6					1256	+		10.1038/s41591-022-01789-0	http://dx.doi.org/10.1038/s41591-022-01789-0		MAY 2022	33	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E9IE	35589854	Green Accepted, Green Submitted, Green Published, hybrid			2022-12-27	WOS:000797762900001
J	Calvert, MJ; Rivera, SC; Retzer, A; Hughes, SE; Campbell, L; Molony-Oates, B; Aiyegbusi, OL; Stover, AM; Wilson, R; McMullan, C; Anderson, NE; Turner, GM; Davies, EH; Verdi, R; Velikova, G; Kamudoni, P; Muslim, S; Gheorghe, A; O'Connor, D; Liu, XX; Wu, ALW; Denniston, AK				Calvert, Melanie J.; Cruz Rivera, Samantha; Retzer, Ameeta; Hughes, Sarah E.; Campbell, Lisa; Molony-Oates, Barbara; Aiyegbusi, Olalekan Lee; Stover, Angela M.; Wilson, Roger; McMullan, Christel; Anderson, Nicola E.; Turner, Grace M.; Davies, Elin Haf; Verdi, Rav; Velikova, Galina; Kamudoni, Paul; Muslim, Syed; Gheorghe, Adrian; O'Connor, Daniel; Liu, Xiaoxuan; Wu, Albert W.; Denniston, Alastair K.			Patient reported outcome assessment must be inclusive and equitable	NATURE MEDICINE			English	Editorial Material								\	[Calvert, Melanie J.; Cruz Rivera, Samantha; Retzer, Ameeta; Hughes, Sarah E.; Aiyegbusi, Olalekan Lee; McMullan, Christel; Anderson, Nicola E.; Turner, Grace M.; Muslim, Syed; Liu, Xiaoxuan; Denniston, Alastair K.] Univ Birmingham, Inst Appl Hlth Res, Ctr Patient Reported Outcomes Res, Birmingham, W Midlands, England; [Calvert, Melanie J.; Cruz Rivera, Samantha; Hughes, Sarah E.; Aiyegbusi, Olalekan Lee; McMullan, Christel; Muslim, Syed; Liu, Xiaoxuan; Denniston, Alastair K.] Univ Birmingham, Birmingham Hlth Partners Ctr Regulatory Sci & Inn, Birmingham, W Midlands, England; [Calvert, Melanie J.; Cruz Rivera, Samantha; Denniston, Alastair K.] Univ Birmingham, DEMAND Hub, Birmingham, W Midlands, England; [Calvert, Melanie J.; Retzer, Ameeta; Hughes, Sarah E.; Aiyegbusi, Olalekan Lee] Natl Inst Hlth Res NIHR, Appl Res Collaborat ARC West Midlands, Birmingham, W Midlands, England; [Calvert, Melanie J.; Aiyegbusi, Olalekan Lee] Univ Birmingham, Univ Hosp Birmingham, NIHR Birmingham Biomed Res Ctr, Birmingham, W Midlands, England; [Calvert, Melanie J.; McMullan, Christel; Turner, Grace M.] Univ Birmingham, Univ Hosp Birmingham, NIHR Surg Reconstruct & Microbiol Res Ctr, Birmingham, W Midlands, England; [Calvert, Melanie J.; Denniston, Alastair K.] Hlth Data Res UK, London, England; [Calvert, Melanie J.; Muslim, Syed] Univ Birmingham, UK SPINE, Birmingham, W Midlands, England; [Campbell, Lisa; O'Connor, Daniel] Med & Healthcare Prod Regulatory Agcy MHRA, London, England; [Molony-Oates, Barbara] Hlth Res Author, London, England; [Stover, Angela M.] Univ North Carolina Chapel Hill, Chapel Hill, NC USA; [Wilson, Roger] NCRI Consumer Forum Natl Canc Res Inst, London, England; [Wilson, Roger] Hlth Res Author Patient Involvement Network, London, England; [Wilson, Roger; Verdi, Rav] Univ Birmingham, Patient Partner, Birmingham, W Midlands, England; [McMullan, Christel] Univ Birmingham, Trauma Sci Res, Birmingham, W Midlands, England; [Anderson, Nicola E.; Liu, Xiaoxuan; Denniston, Alastair K.] Univ Birmingham, Inst Inflammat & Ageing, Acad Unit Ophthalmol, Birmingham, W Midlands, England; [Davies, Elin Haf] Aparito Ltd, Wrexham, Wales; [Velikova, Galina] Univ Leeds, Leeds Inst Med Res St Jamess, Leeds, W Yorkshire, England; [Kamudoni, Paul] Healthcare Business Merck KGaA, EMD Serono Inc, Darmstadt, Germany; [Gheorghe, Adrian] Imperial Coll London, London, England; [Liu, Xiaoxuan; Denniston, Alastair K.] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England; [Wu, Albert W.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; [Denniston, Alastair K.] Moorfields Eye Hosp NHS Fdn Trust, Natl Inst Hlth Res Biomed Res Ctr Ophthalmol, London, England; [Denniston, Alastair K.] UCL, Inst Ophthalmol, London, England	University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; The Medicines & Healthcare Products Regulatory Agency; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Birmingham; University of Birmingham; University of Birmingham; University of Leeds; Merck KGaA; EMD Serono Inc.; Imperial College London; University of Birmingham; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust; University of London; University College London	Calvert, MJ (corresponding author), Univ Birmingham, Inst Appl Hlth Res, Ctr Patient Reported Outcomes Res, Birmingham, W Midlands, England.; Calvert, MJ (corresponding author), Univ Birmingham, Birmingham Hlth Partners Ctr Regulatory Sci & Inn, Birmingham, W Midlands, England.; Calvert, MJ (corresponding author), Univ Birmingham, DEMAND Hub, Birmingham, W Midlands, England.; Calvert, MJ (corresponding author), Natl Inst Hlth Res NIHR, Appl Res Collaborat ARC West Midlands, Birmingham, W Midlands, England.; Calvert, MJ (corresponding author), Univ Birmingham, Univ Hosp Birmingham, NIHR Birmingham Biomed Res Ctr, Birmingham, W Midlands, England.; Calvert, MJ (corresponding author), Univ Birmingham, Univ Hosp Birmingham, NIHR Surg Reconstruct & Microbiol Res Ctr, Birmingham, W Midlands, England.; Calvert, MJ (corresponding author), Hlth Data Res UK, London, England.; Calvert, MJ (corresponding author), Univ Birmingham, UK SPINE, Birmingham, W Midlands, England.	m.calvert@bham.ac.uk	; McMullan, Christel/F-4948-2017; Turner, Grace/K-6073-2014	Calvert, Melanie/0000-0002-1856-837X; McMullan, Christel/0000-0002-0878-1513; Syed, Muslim Abbas/0000-0003-4372-1935; Turner, Grace/0000-0002-9783-9413; Retzer, Ameeta/0000-0002-4156-8386; Anderson, Nicola/0000-0002-0614-3198; Denniston, Alastair/0000-0001-7849-0087; Hughes, Sarah/0000-0001-5656-1198; Aiyegbusi, Olalekan Lee/0000-0001-9122-8251	Health Research (NIHR), UK Research and Innovation (UKRI); NIHR Birmingham Biomedical Research Centre; NIHR Surgical Reconstruction and Microbiology Research Centre; NIHR ARC West Midlands, UK SPINE; University Hospitals Birmingham NHS Foundation Trust; Innovate UK; UCB Pharma; Gilead; Takeda; Merck; Glaukos; Patient-Centered Outcomes Research Institute; NIHR Birmingham BRC; NIHR ARC West Midlands; Gilead Sciences Ltd; NIHR Applied Research Collaboration (ARC) West Midlands; Cochlear Ltd; Association of Community Cancer Centers; Pfizer; PCORI, NIH; AHRQ; Hematology/Oncology Pharmacy Association; Cancer and Aging Research Group (CARG); UroGen Pharma Ltd.; NIHR Surgical Reconstruction and Microbiology Research Centre (SRMRC); NIHR Postdoctoral Fellowship Award; NIHR Clinical Doctoral Research Fellowship Award; European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group; Roche; Eisai; Yorkshire Cancer Research; Merck Healthcare KGaA, Darmstadt, Germany; Medicines and Healthcare products Regulatory Agency	Health Research (NIHR), UK Research and Innovation (UKRI); NIHR Birmingham Biomedical Research Centre; NIHR Surgical Reconstruction and Microbiology Research Centre; NIHR ARC West Midlands, UK SPINE; University Hospitals Birmingham NHS Foundation Trust; Innovate UK(UK Research & Innovation (UKRI)Innovate UK); UCB Pharma(UCB Pharma SA); Gilead(Gilead Sciences); Takeda(Takeda Pharmaceutical Company Ltd); Merck(Merck & Company); Glaukos; Patient-Centered Outcomes Research Institute(Patient-Centered Outcomes Research Institute - PCORI); NIHR Birmingham BRC; NIHR ARC West Midlands; Gilead Sciences Ltd(Gilead Sciences); NIHR Applied Research Collaboration (ARC) West Midlands; Cochlear Ltd; Association of Community Cancer Centers; Pfizer(Pfizer); PCORI, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AHRQ(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Hematology/Oncology Pharmacy Association; Cancer and Aging Research Group (CARG); UroGen Pharma Ltd.; NIHR Surgical Reconstruction and Microbiology Research Centre (SRMRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIHR Postdoctoral Fellowship Award; NIHR Clinical Doctoral Research Fellowship Award; European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group; Roche(Roche Holding); Eisai(Eisai Co Ltd); Yorkshire Cancer Research; Merck Healthcare KGaA, Darmstadt, Germany; Medicines and Healthcare products Regulatory Agency	for Health Research (NIHR), UK Research and Innovation (UKRI), NIHR Birmingham Biomedical Research Centre, the NIHR Surgical Reconstruction and Microbiology Research Centre, NIHR ARC West Midlands, UK SPINE, European Regional Development Fund -Demand Hub and Health Data Research UK at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Innovate UK (part of UKRI), Macmillan Cancer Support, UCB Pharma, Janssen, GSK and Gilead. M.C. has received personal fees from Astellas, Aparito Ltd, CIS Oncology, Takeda, Merck, Daiichi Sankyo, Glaukos, GSK and the Patient-Centered Outcomes Research Institute (PCORI) outside of the submitted work. In addition, a family member owns shares in GSK. O.L.A. receives funding from the NIHR Birmingham BRC, West Midlands, Birmingham, NIHR ARC West Midlands, UKRI, Health Foundation, Janssen, Gilead and GSK; and declares personal fees from Gilead Sciences Ltd, Merck and GSK outside of the submitted work. S.E.H. receives funding from the NIHR Applied Research Collaboration (ARC) West Midlands and UKRI; and declares personal fees from Cochlear Ltd and Aparito Ltd outside of the submitted work. A.M.S. has received unrelated consulting fees or speaking honoraria in the last 24 months from Navigating Cancer, Association of Community Cancer Centers, Pfizer, Genentech, Purchaser Business Group on Health and Henry Ford Cancer Center; and receives unrelated research funding from PCORI, NIH, AHRQ, Bladder Cancer Advocacy Network, Hematology/Oncology Pharmacy Association (HOPA), Cancer and Aging Research Group (CARG), Sivan Innovation and UroGen Pharma Ltd. C.M. receives funding from NIHR Surgical Reconstruction and Microbiology Research Centre (SRMRC), UKRI, and declares personal fees from Aparito Ltd outside the submitted work. G.T. receives funding from a NIHR Postdoctoral Fellowship Award. N.E.A. receives funding from a NIHR Clinical Doctoral Research Fellowship Award; and declares personal fees from GSK outside of the submitted work. G.V. was past president of ISOQOL, the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group; and has received consultancy fees from Roche, Eisai, Novartis, Seattle Genetics and Sanofi related to her clinical work in breast cancer and grants from the Yorkshire Cancer Research, Pfizer, IQVIA, Breast Cancer Now and the EORTC Quality of Life Group. P.K. is an employee of Merck Healthcare KGaA, Darmstadt, Germany. All other authors declare no competing interests. The views expressed in this article are those of the author(s) and not necessarily those of the NIHR, Medicines and Healthcare products Regulatory Agency, Health Research Authority or the Department of Health and Social Care.	[Anonymous], 2018, PAT FOC DRUG DEV COL; Benkhalti M, 2021, INT J TECHNOL ASSESS, V37, DOI 10.1017/S0266462320002275; Braveman P, 2003, J EPIDEMIOL COMMUN H, V57, P254, DOI 10.1136/jech.57.4.254; Calvert M, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.k5267; Rivera SC, 2021, NAT MED, V27, P572, DOI 10.1038/s41591-021-01275-z; FDA, 2020, ENH DIV CLIN TRIAL P; Food and Drug Administration (FDA), 2009, HEALTH QUAL LIFE OUT; Hughes S, 2021, J ROY SOC MED, V114, P381, DOI 10.1177/01410768211014048; Hurst L., 2019, DEFINING VALUE BASED; Ibrahim H, 2021, LANCET DIGIT HEALTH, V3, pE260, DOI 10.1016/S2589-7500(20)30317-4; INVOLVE, 2012, STRAT DIV INCL PUBL; Jahagirdar D, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-431; Kunonga TP, 2021, J MED INTERNET RES, V23, DOI 10.2196/25887; Lavallee DC, 2016, HEALTH AFFAIR, V35, P575, DOI 10.1377/hlthaff.2015.1362; Masyuko S, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0245269; National Institute for Health Research(NIHR), 2020, IMPR INCL SERV GROUP; NHS, 2021, WHAT WE MEAN DIG INC; Pugh SL, 2020, INT J RADIAT ONCOL, V108, P950, DOI 10.1016/j.ijrobp.2020.06.030; Seyyed-Kalantari L, 2021, NAT MED, V27, P2176, DOI 10.1038/s41591-021-01595-0; Sisodia RC, 2021, J AM MED INFORM ASSN, V28, P2265, DOI 10.1093/jamia/ocab138; Slade AL, 2021, TRIALS, V22, DOI 10.1186/s13063-021-05255-z; Stamm, NEJM CATALYST INNOV, V2, DOI [10.1056/CAT.21.0146(2021, DOI 10.1056/CAT.21.0146(2021]; Virji A. Z., 2021, NEJM CATALYST INNOV, V2, DOI [10.1056/CAT.21.0043, DOI 10.1056/CAT.21.0043]; Wild D, 2005, VALUE HEALTH, V8, P94, DOI 10.1111/j.1524-4733.2005.04054.x; Wu AW, 2013, J CLIN EPIDEMIOL, V66, pS12, DOI 10.1016/j.jclinepi.2013.04.005	25	8	8	1	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2022	28	6					1120	1124		10.1038/s41591-022-01781-8	http://dx.doi.org/10.1038/s41591-022-01781-8		MAY 2022	5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E9IE	35513530	Bronze, Green Accepted			2022-12-27	WOS:000791071600003
J	Valiente, M				Valiente, Manuel			Towards personalizing radiotherapy for brain metastasis	NATURE MEDICINE			English	Editorial Material							CANCER	Secretion of S100A9 by brain metastatic cells activates radioresistance. Blood S100A9 could be used as a biomarker to predict responses to irradiation and to guide a combination therapy with a radiosensitizer.	[Valiente, Manuel] Spanish Natl Canc Ctr CNIO, Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO)	Valiente, M (corresponding author), Spanish Natl Canc Ctr CNIO, Madrid, Spain.							Burstein AH, 2018, JPAD-J PREV ALZHEIM, V5, P149, DOI 10.14283/jpad.2018.18; Mulvenna P, 2016, LANCET, V388, P2004, DOI 10.1016/S0140-6736(16)30825-X; Smart D, 2015, CLIN EXP METASTAS, V32, P717, DOI 10.1007/s10585-015-9739-9; Suh JH, 2020, NAT REV CLIN ONCOL, V17, P279, DOI 10.1038/s41571-019-0320-3	4	0	0	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4					643	644		10.1038/s41591-022-01776-5	http://dx.doi.org/10.1038/s41591-022-01776-5		APR 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0Q6DV	35411078				2022-12-27	WOS:000780688100005
J	Sano, T; Nagayama, A; Ogawa, T; Ishida, I; Okada, Y				Sano, T; Nagayama, A; Ogawa, T; Ishida, I; Okada, Y			Transgenic potato expressing a double-stranded RNA-specific ribonuclease is resistant to potato spindle tuber viroid	NATURE BIOTECHNOLOGY			English	Article						transgenic plants; resistance; pac1	TOBACCO MOSAIC-VIRUS; REPLICATION CYCLE; GENE SEQUENCE; ANTISENSE RNA; PLANT-VIRUSES; INFECTION; PROTEIN	We have produced transgenic potato lines expressing the yeast-derived double-stranded RNA-specific ribonuclease pad. Five lines of pad potato (Solanum tuberosum L., cultivar Russet Burbank) challenged with potato spindle tuber viroid (PSTVd) suppressed PSTVd infection and accumulation, All of the progeny potato tubers produced by resistant plants were also free of PSTVd. Because the pad gene product digested PSTVd in vitro, double-stranded regions in PSTVd molecule and/or replicative intermediates may be targeted by pad gene product in the transgenic potato plant.	Hirosaki Univ, Fac Agr, Phytopathol Lab, Hirosaki, Aomori 036, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanazawa Ku, Yokohama, Kanagawa 236, Japan; Teikyo Univ, Sch Sci & Engn, Dept Biosci, Utsunomiya, Tochigi 320, Japan	Hirosaki University; Kirin Brewery Company Limited; Teikyo University	Sano, T (corresponding author), Hirosaki Univ, Fac Agr, Phytopathol Lab, Hirosaki, Aomori 036, Japan.							ATKINS D, 1995, J GEN VIROL, V76, P1781, DOI 10.1099/0022-1317-76-7-1781; BEACHY RN, 1990, ANNU REV PHYTOPATHOL, V28, P451, DOI 10.1146/annurev.py.28.090190.002315; BONFIGLIOLI RG, 1994, PLANT J, V6, P99, DOI 10.1046/j.1365-313X.1994.6010099.x; BRANCH AD, 1984, SCIENCE, V223, P450, DOI 10.1126/science.6197756; Diener T.O., 1987, VIROIDS; ESTRADA R, 1986, PLANT CELL TISS ORG, V7, P3, DOI 10.1007/BF00043915; GOLEMBOSKI DB, 1990, P NATL ACAD SCI USA, V87, P6311, DOI 10.1073/pnas.87.16.6311; GROSS HJ, 1978, NATURE, V273, P203, DOI 10.1038/273203a0; IINO Y, 1991, EMBO J, V10, P221, DOI 10.1002/j.1460-2075.1991.tb07939.x; ISHIDA BK, 1989, PLANT CELL REP, V8, P325, DOI 10.1007/BF00716665; ISHIKAWA M, 1984, MOL GEN GENET, V196, P421, DOI 10.1007/BF00436189; LAPIDOT M, 1993, PLANT J, V4, P959, DOI 10.1046/j.1365-313X.1993.04060959.x; Li Shi-Fang, 1995, Annals of the Phytopathological Society of Japan, V61, P381, DOI 10.3186/jjphytopath.61.381; LINDBO JA, 1992, VIROLOGY, V189, P725, DOI 10.1016/0042-6822(92)90595-G; LOMONOSSOFF GP, 1995, ANNU REV PHYTOPATHOL, V33, P323, DOI 10.1146/annurev.py.33.090195.001543; MAITI IB, 1993, P NATL ACAD SCI USA, V90, P6110, DOI 10.1073/pnas.90.13.6110; MATOUSEK J, 1994, BIOL CHEM H-S, V375, P765, DOI 10.1515/bchm3.1994.375.11.765; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; OWENS RA, 1982, P NATL ACAD SCI-BIOL, V79, P113, DOI 10.1073/pnas.79.1.113; POWELL PA, 1989, P NATL ACAD SCI USA, V86, P6949, DOI 10.1073/pnas.86.18.6949; POWELLABEL P, 1986, SCIENCE, V232, P738, DOI DOI 10.1126/SCIENCE.3457472; QU F, 1993, EMBO J, V12, P2129, DOI 10.1002/j.1460-2075.1993.tb05861.x; RIESNER D, 1990, SEMIN VIROL, V1, P83; RIESNER D, 1987, VIROIDS, P63; Sano T., 1996, Archives of Phytopathology and Plant Protection, V30, P303, DOI 10.1080/03235409609383180; SANO T, 1995, PATHOGENESIS HOST SP, V3, P363; SINGH RP, 1987, PHYTOPATHOLOGY, V77, P1588, DOI 10.1094/Phyto-77-1588; SYMONS RH, 1990, SEMIN VIROL, V1, P117; WATANABE Y, 1995, FEBS LETT, V372, P165, DOI 10.1016/0014-5793(95)00901-K; [No title captured]	30	61	70	0	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1997	15	12					1290	1294		10.1038/nbt1197-1290	http://dx.doi.org/10.1038/nbt1197-1290			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YQ046	9359114				2022-12-27	WOS:000071342000033
J	Feng, MZ; Jackson, WH; Goldman, CK; Rancourt, C; Wang, MH; Dusing, SK; Siegal, G; Curiel, DT				Feng, MZ; Jackson, WH; Goldman, CK; Rancourt, C; Wang, MH; Dusing, SK; Siegal, G; Curiel, DT			Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector	NATURE BIOTECHNOLOGY			English	Article						gene therapy; chimeric viral vectors	ADENOVIRUS-MEDIATED TRANSFER; BRAIN-TUMORS; FAMILIAL HYPERCHOLESTEROLEMIA; RETROVIRAL VECTORS; CYSTIC-FIBROSIS; RECEPTOR GENE; THERAPY; HEPATOCYTES; EXPRESSION; MICE	Gene therapy to correct defective genes requires efficient gene delivery and long-term gene expression. The available vector systems have not allowed the simultaneous achievement of both goals. We have developed a chimeric viral vector system that incorporates favorable aspects of both adenoviral and retroviral vectors. Adenoviral vectors induce target cells to function as transient retroviral producer cells in vivo. The progeny retroviral vector particles are then able to stably transduce neighboring cells. In this system, the nonintegrative adenoviral vector is rendered functionally integrative via the intermediate generation of a retroviral producer cell. The chimeric vectors may allow realization of the requisite goals for specific gene-therapy applications.	UNIV ALABAMA,DEPT PATHOL,GENE THERAPY PROGRAM,BIRMINGHAM,AL 35294; MA BIOSERV INC,VIROL LAB,ROCKVILLE,MD 20850	University of Alabama System; University of Alabama Birmingham			Siegal, Gene/A-8653-2009	Siegal, Gene/0000-0003-3857-3368				ANDERSON WF, 1984, SCIENCE, V226, P401, DOI 10.1126/science.6093246; BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; CURIEL DT, 1994, NAT IMMUN, V13, P141; DAI Y, 1992, J CLIN INVEST, V89, P10892; DUNCKLEY MG, 1993, HUM MOL GENET, V2, P717, DOI 10.1093/hmg/2.6.717; FELGNER PL, 1991, NATURE, V349, P351, DOI 10.1038/349351a0; FERRY N, 1991, P NATL ACAD SCI USA, V88, P8377, DOI 10.1073/pnas.88.19.8377; FINER MH, 1994, BLOOD, V83, P43; Fisher KJ, 1996, HUM GENE THER, V7, P2079, DOI 10.1089/hum.1996.7.17-2079; FLAMANT F, 1995, VIROLOGY, V211, P234, DOI 10.1006/viro.1995.1396; FLAMANT F, 1994, INT J DEV BIOL, V38, P751; Fox JC, 1996, THER DRUG MONIT, V18, P410, DOI 10.1097/00007691-199608000-00018; HAAPALA DK, 1985, J VIROL, V53, P827, DOI 10.1128/JVI.53.3.827-833.1985; HAFFE HA, 1992, NAT GENET, V1, P372; HANNANIA EG, 1995, AM J MED, V99, P537; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; KLEIN HG, 1994, J CLIN APHERESIS, V9, P139, DOI 10.1002/jca.2920090210; KOLODKA TM, 1993, SOMAT CELL MOLEC GEN, V19, P491, DOI 10.1007/BF01233254; KOZARSKY K, 1993, SOMAT CELL MOLEC GEN, V19, P449, DOI 10.1007/BF01233250; Kozarsky KF, 1996, NAT GENET, V13, P54, DOI 10.1038/ng0596-54; LOZIER JN, 1994, JAMA-J AM MED ASSOC, V271, P47, DOI 10.1001/jama.271.1.47; MILLER AD, 1992, CURR TOP MICROBIOL, V158, P1; MILLER AD, 1990, BLOOD, V76, P271; MORLING FJ, 1995, GENE THER, V2, P504; MORSY MA, 1993, J CLIN INVEST, V92, P1580, DOI 10.1172/JCI116739; MOSCIONI AD, 1993, SURGERY, V113, P304; NoguiezHellin P, 1996, P NATL ACAD SCI USA, V93, P4175, DOI 10.1073/pnas.93.9.4175; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RAM Z, 1993, CANCER RES, V53, P83; RAM Z, 1993, J NEUROSURG, V79, P400, DOI 10.3171/jns.1993.79.3.0400; RAM Z, 1994, CANCER RES, V54, P2141; ROEMER K, 1992, EUR J BIOCHEM, V208, P211, DOI 10.1111/j.1432-1033.1992.tb17176.x; Rollins SA, 1996, HUM GENE THER, V7, P619, DOI 10.1089/hum.1996.7.5-619; Rosenfeld MA, 1996, CHEST, V109, P241, DOI 10.1378/chest.109.1.241; SHORT MP, 1990, J NEUROSCI RES, V27, P427, DOI 10.1002/jnr.490270322; SMITH TAG, 1993, NAT GENET, V5, P397, DOI 10.1038/ng1293-397; TAKAMIYA Y, 1993, J NEUROSURG, V79, P104, DOI 10.3171/jns.1993.79.1.0104; VILE RG, 1995, BRIT MED BULL, V51, P12, DOI 10.1093/oxfordjournals.bmb.a072941; Wilson JM, 1995, J CLIN INVEST, V96, P2547, DOI 10.1172/JCI118318; YANG Y, 1995, IMMUNITY, V1, P433; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995; YANG YP, 1995, J IMMUNOL, V155, P2564; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; Ye XH, 1996, J BIOL CHEM, V271, P3639	46	123	170	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1997	15	9					866	870		10.1038/nbt0997-866	http://dx.doi.org/10.1038/nbt0997-866			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XW410	9306401				2022-12-27	WOS:A1997XW41000028
J	Hawkins, GA; Hoffman, LM				Hawkins, GA; Hoffman, LM			Base excision sequence scanning	NATURE BIOTECHNOLOGY			English	Editorial Material							MITOCHONDRIAL-DNA				Hawkins, GA (corresponding author), EPICTR TECHNOL,1202 ANN ST,MADISON,WI 53713, USA.							[Anonymous], HUMAN GENE MUTATION; BERTRANPETIT J, 1995, ANN HUM GENET, V59, P63, DOI 10.1111/j.1469-1809.1995.tb01606.x; HAWKINS GA, 1997, IN PRESS EPICENTRE F; Nei M, 1996, ANNU REV GENET, V30, P371, DOI 10.1146/annurev.genet.30.1.371; WILSON MR, 1995, BIOTECHNIQUES, V18, P662	5	26	28	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					803	804		10.1038/nbt0897-803	http://dx.doi.org/10.1038/nbt0897-803			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255799				2022-12-27	WOS:A1997XM70700036
J	Christoffersen, RE				Christoffersen, RE			Translating genomics information into therapeutics: A key role for oligonucleotides	NATURE BIOTECHNOLOGY			English	Editorial Material											Christoffersen, RE (corresponding author), RIBOZYME PHARMACEUT,2950 WILDERNESS PL,BOULDER,CO 80301, USA.								0	22	23	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1997	15	6					483	484		10.1038/nbt0697-483	http://dx.doi.org/10.1038/nbt0697-483			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XC772	9181554				2022-12-27	WOS:A1997XC77200004
J	Stricker, NL; Christopherson, KS; Yi, BA; Schatz, PJ; Raab, RW; Dawes, G; Bassett, DE; Bredt, DS; Li, M				Stricker, NL; Christopherson, KS; Yi, BA; Schatz, PJ; Raab, RW; Dawes, G; Bassett, DE; Bredt, DS; Li, M			PDZ domain of neuronal nitric oxide synthase recognizes novel C-terminal peptide sequences	NATURE BIOTECHNOLOGY			English	Article						neurotoxicity; NO; PDZ; peptide display	MESSENGER MOLECULE; PROTEIN; LIBRARIES; BRAIN; LIGANDS	PDZ domains are multifunctional protein-interaction motifs that often bind to the C-terminus of protein targets. Nitric oxide (NO), an endogenous signaling molecule, plays critical roles in nervous, immune, and cardiovascular function. Although there are numerous physiological functions for neuron-derived NO, produced primarily by the neuronal NO synthase (nNOS), excess nNOS activity mediates brain injury in cerebral ischemia and in animal models of Parkinson's disease. Subcellular localization of nNOS activity must therefore be tightly regulated. To determine ligands for the PDZ domain of nNOS, we screened 13 billion distinct peptides and found that the nNOS-PDZ domain binds tightly to peptides ending Asp-X-Val. This differs from the only known (Thr/Ser)-X-Val consensus that interacts with PDZ domains from PSD-95. Preference for Asp at the -2 peptide position is mediated by Tyr-77 of nNOS. A Y77D78 to H(77)E(78) substitution changes the binding specificity from Asp-X-Val to Thr-X-Val. Guided by the Asp-X-Val consensus, candidate nNOS interacting proteins have been identified including glutamate and melatonin receptors. Our results demonstrate that PDZ domains have distinct peptide binding specificity.	JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL & NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MOL BIOL & GENET,BALTIMORE,MD 21205; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM BIOMED SCI,SAN FRANCISCO,CA 94143; AFFYMAX RES INST,DEPT MOL BIOL,PALO ALTO,CA 94304	Johns Hopkins University; Johns Hopkins University; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Bassett, Douglas/0000-0002-1619-4618				AOKI C, 1993, BRAIN RES, V620, P97, DOI 10.1016/0006-8993(93)90275-R; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1996, J NEUROSCI, V16, P7407; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Chao DS, 1996, J EXP MED, V184, P609, DOI 10.1084/jem.184.2.609; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; CULL MG, 1992, P NATL ACAD SCI USA, V89, P1865, DOI 10.1073/pnas.89.5.1865; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GALLOP MA, 1994, J MED CHEM, V37, P1233, DOI 10.1021/jm00035a001; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; Hantraye P, 1996, NAT MED, V2, P1017, DOI 10.1038/nm0996-1017; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Li XD, 1997, J BIOL CHEM, V272, P705, DOI 10.1074/jbc.272.2.705; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Niethammer M, 1996, J NEUROSCI, V16, P2157; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; RICHARME G, 1982, BIOCHEM BIOPH RES CO, V105, P476, DOI 10.1016/0006-291X(82)91459-0; Schatz PJ, 1996, METHOD ENZYMOL, V267, P171; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; SPARKS AB, 1995, METHOD ENZYMOL, V255, P498; VESELY DL, 1981, MOL CELL BIOCHEM, V35, P55, DOI 10.1007/BF02358188; ZHOU SY, 1995, METHOD ENZYMOL, V254, P523	35	207	213	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1997	15	4					336	342		10.1038/nbt0497-336	http://dx.doi.org/10.1038/nbt0497-336			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WQ554	9094134				2022-12-27	WOS:A1997WQ55400033
J	Surendran, P; Stewart, ID; Yeung, VPWA; Pietzner, M; Raffler, J; Worheide, MA; Li, C; Smith, RF; Wittemans, LBL; Bomba, L; Menni, C; Zierer, J; Rossi, N; Sheridan, PA; Watkins, NA; Mangino, M; Hysi, PG; Di Angelantonio, E; Falchi, M; Spector, TD; Soranzo, N; Michelotti, GA; Arlt, W; Lotta, LA; Denaxas, S; Hemingway, H; Gamazon, ER; Howson, JMM; Wood, AM; Danesh, J; Wareham, NJ; Kastenmuller, G; Fauman, EB; Suhre, K; Butterworth, AS; Langenberg, C				Surendran, Praveen; Stewart, Isobel D.; Yeung, Victoria P. W. Au; Pietzner, Maik; Raffler, Johannes; Worheide, Maria A.; Li, Chen; Smith, Rebecca F.; Wittemans, Laura B. L.; Bomba, Lorenzo; Menni, Cristina; Zierer, Jonas; Rossi, Niccolo; Sheridan, Patricia A.; Watkins, Nicholas A.; Mangino, Massimo; Hysi, Pirro G.; Di Angelantonio, Emanuele; Falchi, Mario; Spector, Tim D.; Soranzo, Nicole; Michelotti, Gregory A.; Arlt, Wiebke; Lotta, Luca A.; Denaxas, Spiros; Hemingway, Harry; Gamazon, Eric R.; Howson, Joanna M. M.; Wood, Angela M.; Danesh, John; Wareham, Nicholas J.; Kastenmueller, Gabi; Fauman, Eric B.; Suhre, Karsten; Butterworth, Adam S.; Langenberg, Claudia			Rare and common genetic determinants of metabolic individuality and their effects on human health	NATURE MEDICINE			English	Article; Early Access							GENOME-WIDE ASSOCIATION; INBORN-ERRORS; VARIANTS; DISEASE; IDENTIFICATION; DEFICIENCY; PREDICTION; IMPUTATION; DATABASE; KIDNEY	Garrod's concept of 'chemical individuality' has contributed to comprehension of the molecular origins of human diseases. Untargeted high-throughput metabolomic technologies provide an in-depth snapshot of human metabolism at scale. We studied the genetic architecture of the human plasma metabolome using 913 metabolites assayed in 19,994 individuals and identified 2,599 variant-metabolite associations (P < 1.25 x 10(-11)) within 330 genomic regions, with rare variants (minor allele frequency <= 1%) explaining 9.4% of associations. Jointly modeling metabolites in each region, we identified 423 regional, co-regulated, variant-metabolite clusters called genetically influenced metabotypes. We assigned causal genes for 62.4% of these genetically influenced metabotypes, providing new insights into fundamental metabolite physiology and clinical relevance, including metabolite-guided discovery of potential adverse drug effects (DPYD and SRD5A2). We show strong enrichment of inborn errors of metabolism-causing genes, with examples of metabolite associations and clinical phenotypes of non-pathogenic variant carriers matching characteristics of the inborn errors of metabolism. Systematic, phenotypic follow-up of metabolite-specific genetic scores revealed multiple potential etiological relationships. Analyses of the genetic architecture of the human plasma metabolome in two large population-based cohorts identify associations between genetically determined metabolite levels and health.	[Surendran, Praveen; Smith, Rebecca F.; Di Angelantonio, Emanuele; Howson, Joanna M. M.; Wood, Angela M.; Danesh, John; Butterworth, Adam S.] Univ Cambridge, British Heart Fdn Cardiovasc Epidemiol Unit, Dept Publ Hlth & Primary Care, Cambridge, England; [Surendran, Praveen; Di Angelantonio, Emanuele; Soranzo, Nicole; Wood, Angela M.; Danesh, John; Butterworth, Adam S.] Univ Cambridge, Addenbrookes Hosp, British Heart Fdn Ctr Res Excellence, Sch Clin Med, Cambridge, England; [Surendran, Praveen; Di Angelantonio, Emanuele; Wood, Angela M.; Danesh, John; Wareham, Nicholas J.; Butterworth, Adam S.] Hlth Data Res UK Cambridge, Wellcome Genome Campus, Cambridge, England; [Surendran, Praveen; Di Angelantonio, Emanuele; Wood, Angela M.; Danesh, John; Wareham, Nicholas J.; Butterworth, Adam S.] Univ Cambridge, Hinxton, England; [Surendran, Praveen] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England; [Stewart, Isobel D.; Yeung, Victoria P. W. Au; Pietzner, Maik; Li, Chen; Wittemans, Laura B. L.; Lotta, Luca A.; Wareham, Nicholas J.; Langenberg, Claudia] Univ Cambridge, MRC Epidemiol Unit, Cambridge, England; [Pietzner, Maik; Langenberg, Claudia] Charite Univ Med Berlin, Computat Med, Berlin Inst Hlth, Berlin, Germany; [Raffler, Johannes; Worheide, Maria A.; Kastenmueller, Gabi] German Res Ctr Environm Hlth, Inst Computat Biol, Helmholtz Zentrum Munchen, Neuherberg, Germany; [Raffler, Johannes] Univ Hosp Augsburg, Digital Med, Augsburg, Germany; [Wittemans, Laura B. L.] Univ Oxford, Big Data Inst, Oxford, England; [Wittemans, Laura B. L.] Univ Oxford, Nuffield Dept Womens & Reprod Hlth, Oxford, England; [Bomba, Lorenzo; Soranzo, Nicole; Danesh, John] Wellcome Sanger Inst, Dept Human Genet, Wellcome Genome Campus, Hinxton, England; [Bomba, Lorenzo; Soranzo, Nicole] Open Targets, Wellcome Genome Campus, Hinxton, England; [Menni, Cristina; Zierer, Jonas; Rossi, Niccolo; Mangino, Massimo; Hysi, Pirro G.; Falchi, Mario; Spector, Tim D.] Kings Coll London, Dept Twin Res & Genet Epidemiol, London, England; [Sheridan, Patricia A.; Michelotti, Gregory A.] Metabolon, Morrisville, NC USA; [Watkins, Nicholas A.] NHS Blood & Transplant, Cambridge Biomed Campus, Cambridge, England; [Mangino, Massimo] Guys & St Thomas Fdn Trust, NIHR Biomed Res Ctr, London, England; [Di Angelantonio, Emanuele; Soranzo, Nicole; Wood, Angela M.; Danesh, John; Butterworth, Adam S.] Univ Cambridge, NIHR Blood & Transplant Res Unit Donor Hlth & Gen, Cambridge, England; [Di Angelantonio, Emanuele] Hlth Data Sci Res Ctr, Human Technopole, Milan, Italy; [Soranzo, Nicole] Univ Cambridge, Dept Haematol, Cambridge, England; [Arlt, Wiebke] Univ Birmingham, Inst Metab & Syst Res, Birmingham, W Midlands, England; [Arlt, Wiebke] Univ Hosp Birmingham NHS Fdn Trust, NIHR Birmingham Biomed Res Ctr, Birmingham, W Midlands, England; [Arlt, Wiebke] Univ Birmingham, Birmingham, W Midlands, England; [Denaxas, Spiros; Hemingway, Harry] UCL, Inst Hlth Informat, London, England; [Denaxas, Spiros; Hemingway, Harry] Hlth Data Res UK, London, England; [Denaxas, Spiros] British Heart Fdn, Data Sci Ctr, London, England; [Gamazon, Eric R.] Vanderbilt Univ, Vanderbilt Genet Inst, Med Ctr, Nashville, TN USA; [Gamazon, Eric R.] Univ Cambridge, Clare Hall & MRC Epidemiol Unit, Cambridge, England; [Howson, Joanna M. M.] Novo Nordisk Res Ctr Oxford, Dept Genet, Oxford, England; [Wood, Angela M.] Univ Cambridge, Cambridge Inst Publ Hlth, MRC Biostat Unit, Cambridge, England; [Wood, Angela M.] Alan Turing Inst, London, England; [Fauman, Eric B.] Pfizer Worldwide Res Dev & Med, Internal Med Res Unit, Cambridge, MA USA; [Suhre, Karsten] Weill Cornell Med Qatar, Dept Biophys & Physiol, Doha, Qatar; [Langenberg, Claudia] Queen Mary Univ London, Precis Healthcare Univ, Res Inst, London, England	University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Oxford; University of Oxford; Wellcome Trust Sanger Institute; University of London; King's College London; Metabolon; Guy's & St Thomas' NHS Foundation Trust; University of Cambridge; Human Technopole; University of Cambridge; University of Birmingham; University of Birmingham; University of Birmingham; University of London; University College London; University of London; University College London; Vanderbilt University; University of Cambridge; MRC Biostatistics Unit; University of Cambridge; Pfizer; Qatar Foundation (QF); Weill Cornell Medical College Qatar; University of London; Queen Mary University London	Butterworth, AS (corresponding author), Univ Cambridge, British Heart Fdn Cardiovasc Epidemiol Unit, Dept Publ Hlth & Primary Care, Cambridge, England.; Butterworth, AS (corresponding author), Univ Cambridge, Addenbrookes Hosp, British Heart Fdn Ctr Res Excellence, Sch Clin Med, Cambridge, England.; Butterworth, AS (corresponding author), Hlth Data Res UK Cambridge, Wellcome Genome Campus, Cambridge, England.; Butterworth, AS (corresponding author), Univ Cambridge, Hinxton, England.; Langenberg, C (corresponding author), Univ Cambridge, MRC Epidemiol Unit, Cambridge, England.; Langenberg, C (corresponding author), Charite Univ Med Berlin, Computat Med, Berlin Inst Hlth, Berlin, Germany.; Butterworth, AS (corresponding author), Univ Cambridge, NIHR Blood & Transplant Res Unit Donor Hlth & Gen, Cambridge, England.; Langenberg, C (corresponding author), Queen Mary Univ London, Precis Healthcare Univ, Res Inst, London, England.	asb38@medschl.cam.ac.uk; Claudia.Langenberg@mrc-epid.cam.ac.uk	; Hemingway, Harry/C-1219-2009	Langenberg, Claudia/0000-0002-5017-7344; Raffler, Johannes/0000-0003-2495-4020; Gamazon, Eric/0000-0003-4204-8734; Hemingway, Harry/0000-0003-2279-0624; Pietzner, Maik/0000-0003-3437-9963; Worheide, Maria/0000-0002-9326-7227	Medical Research Council [MR/N003284/1 MC-UU_12015/1, MC_UU_00006/1, MC_PC_13048]; Cancer Research UK [C864/A14136]; MRC Cambridge Initiative in Metabolic Science [MR/L00002/1]; Innovative Medicines Initiative Joint Undertaking under EMIF [115372]; National Institute for Health Research (NIHR); NIHR BioResource; NIHR Cambridge Biomedical Research Centre [BRC-1215-20014]; Wellcome Trust [206194, 203810/Z/16/A, 221651/Z/20/Z]; NIHR Cambridge BRC [BRC-1215-20014]; NIHR Blood and Transplant Research Unit in Donor Health and Genomics [NIHR BTRU-2014-10024]; UK Medical Research Council [MR/L003120/1]; British Heart Foundation [SP/09/002, RG/13/13/30194, RG/18/13/33946]; Health Data Research UK - UK Medical Research Council; Engineering and Physical Sciences Research Council; Economic and Social Research Council; Department of Health and Social Care (England); Chief Scientist Office of the Scottish Government Health and Social Care Directorates; Health and Social Care Research and Development Division (Welsh Government); Public Health Agency (Northern Ireland); British Heart Foundation; Wellcome; Rutherford Fund Fellowship from the Medical Research Council [MR/S003746/1]; Cambridge Trust; German Federal Ministry of Education and Research [01ZX1912D]; Chronic Disease Research Foundation; European Commission H2020 grants SYSCID [733100]; National Institute for Health Research (NIHR) Clinical Research Facility; Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust; King's College London; BrightFocus Foundation [G2021011S]; Wellcome Trust Investigator grant [WT209492/Z/17/Z]; NIHR Birmingham Biomedical Research Centre [BRC-1215-20014, BRC-1215-20009]; National Institutes of Health [R35HG010718, R01HG011138, R01GM140287, NIH/NIA AG068026]; BHF Programme grant [RG/13/13/30194]; Innovative Medicines Initiative-2 Joint Undertaking [116074]; BHF-Turing Cardiovascular Data Science Award [BCDSA\100005]; NIHR Biomedical Research Centre at University College London (UCL) Hospital NHS Trust; BHF Data Science Centre; NIHR-UKRI CONVALESCENCE study; BHF Accelerator Award [AA/18/6/24223]; British Heart Foundation Professorship; NIHR Senior Investigator Award; National Institute on Aging (NIA) [U01 AG061359, RF1 AG057452, RF1 AG059093, U19 AG063744]; Biomedical Research Program at Weill Cornell Medicine in Qatar; Qatar Foundation; QNRF [NPRP11C-0115-180010]	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); MRC Cambridge Initiative in Metabolic Science(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Innovative Medicines Initiative Joint Undertaking under EMIF; National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); NIHR BioResource; NIHR Cambridge Biomedical Research Centre(National Institute for Health Research (NIHR)); Wellcome Trust(Wellcome Trust); NIHR Cambridge BRC; NIHR Blood and Transplant Research Unit in Donor Health and Genomics; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); Health Data Research UK - UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Department of Health and Social Care (England); Chief Scientist Office of the Scottish Government Health and Social Care Directorates; Health and Social Care Research and Development Division (Welsh Government); Public Health Agency (Northern Ireland); British Heart Foundation(British Heart Foundation); Wellcome; Rutherford Fund Fellowship from the Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cambridge Trust; German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); Chronic Disease Research Foundation; European Commission H2020 grants SYSCID; National Institute for Health Research (NIHR) Clinical Research Facility(National Institute for Health Research (NIHR)); Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust; King's College London(General Electric); BrightFocus Foundation(BrightFocus Foundation); Wellcome Trust Investigator grant(Wellcome Trust); NIHR Birmingham Biomedical Research Centre; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); BHF Programme grant; Innovative Medicines Initiative-2 Joint Undertaking; BHF-Turing Cardiovascular Data Science Award; NIHR Biomedical Research Centre at University College London (UCL) Hospital NHS Trust; BHF Data Science Centre; NIHR-UKRI CONVALESCENCE study; BHF Accelerator Award; British Heart Foundation Professorship; NIHR Senior Investigator Award; National Institute on Aging (NIA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Biomedical Research Program at Weill Cornell Medicine in Qatar(Qatar National Research Fund (QNRF)); Qatar Foundation(Qatar Foundation (QF)Qatar National Research Fund (QNRF)); QNRF(National Research Foundation of KoreaQatar National Research Fund (QNRF))	The EPIC-Norfolk study (https://doi.org/10.22025/2019.10.105.00004) has received funding from the Medical Research Council (MR/N003284/1 MC-UU_12015/1 and MC_UU_00006/1) and Cancer Research UK (C864/A14136). The genetics work in the EPIC-Norfolk study was funded by the Medical Research Council (MC_PC_13048). Metabolite measurements in the EPIC-Norfolk study were supported by the MRC Cambridge Initiative in Metabolic Science (MR/L00002/1) and the Innovative Medicines Initiative Joint Undertaking under EMIF grant agreement no. 115372. We are grateful to all the participants who have been part of the project and to the many members of the study teams at the University of Cambridge who have enabled this research. Participants in the INTERVAL randomized controlled trial were recruited with the active collaboration of NHS Blood and Transplant England (www.nhsbt.nhs.uk), which has supported field work and other elements of the trial. DNA extraction and genotyping were co-funded by the National Institute for Health Research (NIHR), the NIHR BioResource (http://bioresource.nihr.ac.uk) and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014)*. Sequencing was supported by the Wellcome Trust grant no. 206194. Metabolon metabolomics assays were funded by the NIHR BioResource and NIHR Cambridge BRC (BRC-1215-20014)*. The academic coordinating center for INTERVAL was supported by core funding from the NIHR Blood and Transplant Research Unit in Donor Health and Genomics (NIHR BTRU-2014-10024), the UK Medical Research Council (MR/L003120/1), the British Heart Foundation (SP/09/002, RG/13/13/30194 and RG/18/13/33946) and NIHR Cambridge BRC (BRC-1215-20014)*. A complete list of the investigators and contributors to the INTERVAL trial is provided in reference+. The academic coordinating center would like to thank blood donor center staff and blood donors for participating in the INTERVAL trial. This work was also supported by Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome. This work was supported in part by the Medical Research Council (MC_UU_00006/1 -Aetiology and Mechanisms) (C. Langenberg, I.D.S., V.P.W.A.Y., M.P., C. Li, L.B.L.W., L.A.L. and N.J.W.). P.S. is supported by a Rutherford Fund Fellowship from the Medical Research Council (grant no. MR/S003746/1). V.P.W.A.Y. was supported by the Wellcome Trust (grant reference no. 203810/Z/16/A) and Cambridge Trust. J.R. was supported by the German Federal Ministry of Education and Research within the framework of the e:Med research and funding concept (grant no. 01ZX1912D). M.A.W. is supported by grant no. U01 AG061359. L.B.L.W. is supported by the Wellcome Trust (221651/Z/20/Z). C.M. is funded by the Chronic Disease Research Foundation. M.M. is supported by the European Commission H2020 grants SYSCID (contract #733100) and by the National Institute for Health Research (NIHR) Clinical Research Facility and the Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London. P.G.H. is supported by the BrightFocus Foundation research grant no. G2021011S. W.A. is supported by Wellcome Trust Investigator grant no.; WT209492/Z/17/Z and the NIHR Birmingham Biomedical Research Centre (BRC-1215-20009)*. E.R.G. is supported by grants from the National Institutes of Health (R35HG010718, R01HG011138, R01GM140287 and NIH/NIA AG068026). J.M.M.H. was funded by a BHF Programme grant (RG/13/13/30194) and the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014)*. A.M.W., H.H. and S.D. are part of the BigData@Heart Consortium, funded by the Innovative Medicines Initiative-2 Joint Undertaking under grant agreement no. 116074. A.M.W. is supported by the BHF-Turing Cardiovascular Data Science Award (BCDSA\100005). H.H. and S.D. are supported by the NIHR Biomedical Research Centre at University College London (UCL) Hospital NHS Trust. S.D. is supported by the BHF Data Science Centre, the NIHR-UKRI CONVALESCENCE study and the BHF Accelerator Award (AA/18/6/24223). J.D. holds a British Heart Foundation Professorship and a NIHR Senior Investigator Award*. G.K. is supported by grants from the National Institute on Aging (NIA; U01 AG061359, RF1 AG057452, RF1 AG059093 and U19 AG063744). K.S. is supported by the Biomedical Research Program at Weill Cornell Medicine in Qatar, a program funded by the Qatar Foundation, and by QNRF grant no. NPRP11C-0115-180010. *The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. +E. Di Angelantonio et al.6. This research was conducted using the UK Biobank Resource (application no. 44448).	Aguet F, 2020, SCIENCE, V369, P1318, DOI 10.1126/science.aaz1776; Ananko EA, 2002, NUCLEIC ACIDS RES, V30, P398, DOI 10.1093/nar/30.1.398; Atzler D, 2016, BRIT J CLIN PHARMACO, V82, P1477, DOI 10.1111/bcp.13068; Audi S, 2018, BRIT J CLIN PHARMACO, V84, P2562, DOI 10.1111/bcp.13709; Balduzzi S, 2019, EVID-BASED MENT HEAL, V22, P153, DOI 10.1136/ebmental-2019-300117; Bomba L, 2022, AM J HUM GENET, V109, P1038, DOI 10.1016/j.ajhg.2022.04.009; Burgess S, 2013, GENET EPIDEMIOL, V37, P658, DOI 10.1002/gepi.21758; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Campeau PM, 2008, MOL GENET METAB, V95, P11, DOI 10.1016/j.ymgme.2008.07.001; CAMPION WM, 1989, J MARKETING RES, V26, P485, DOI 10.2307/3172772; Cheng YR, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20877-8; Day N, 1999, BRIT J CANCER, V80, P95; DeHaven CD, 2010, J CHEMINFORMATICS, V2, DOI 10.1186/1758-2946-2-9; Denaxas S., 2022, AMIA ANN S PROC, V2021, P362; Dennis J., 2017, NATURE, V551, P92, DOI [10.1038/nature24284, DOI 10.1038/NATURE24284]; Di Angelantonio E, 2017, LANCET, V390, P2360, DOI 10.1016/S0140-6736(17)31928-1; Diez-Fernandez C, 2015, J GENET GENOMICS, V42, P249, DOI 10.1016/j.jgg.2015.03.009; Ehret GB, 2016, NAT GENET, V48, P1171, DOI 10.1038/ng.3667; Evangelou E, 2018, NAT GENET, V50, P1412, DOI 10.1038/s41588-018-0205-x; Evans A. M., 2012, J POSTGENOMICS DRUG, DOI [10.4172/2153-0769.1000110, DOI 10.4172/2153-0769.1000110]; Finan C, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag1166; Foley CN, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20885-8; Fragkos KC, 2018, UNITED EUR GASTROENT, V6, P181, DOI 10.1177/2050640617737632; Frankish A, 2019, NUCLEIC ACIDS RES, V47, pD766, DOI 10.1093/nar/gky955; Froehlich TK, 2015, INT J CANCER, V136, P730, DOI 10.1002/ijc.29025; Furukawa Y., 2008, TYROSINE HYDROXYLASE; Garrod AE, 1996, MOL MED, V2, P274, DOI 10.1007/BF03401625; Grunert SC, 2020, ORPHANET J RARE DIS, V15, DOI 10.1186/s13023-020-1319-7; Hammarstrom P, 2001, SCIENCE, V293, P2459, DOI 10.1126/science.1062245; Howard DM, 2019, NAT NEUROSCI, V22, P343, DOI 10.1038/s41593-018-0326-7; Kamat MA, 2019, BIOINFORMATICS, V35, P4851, DOI 10.1093/bioinformatics/btz469; KANDA Y, 1974, J BIOL CHEM, V249, P6796; Karetnikova ES, 2019, ARTERIOSCL THROM VAS, V39, P869, DOI 10.1161/ATVBAHA.118.312218; Kastenmuller G, 2015, HUM MOL GENET, V24, pR93, DOI 10.1093/hmg/ddv263; Kettunen J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11122; Kim CH, 2002, AM J MED GENET, V108, P140, DOI 10.1002/ajmg.10196; Krumsiek J, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003005; Landrum MJ, 2018, HUM MUTAT, V39, P1623, DOI 10.1002/humu.23641; Lee JJY, 2018, GENET MED, V20, P151, DOI 10.1038/gim.2017.108; Lewis J. G., 1997, STEROIDS, DOI [10.1016/S0039-128X(97)00048-2, DOI 10.1016/S0039-128X(97)00048-2]; Li M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02287-x; Liu XY, 2018, CELL REP, V23, P1461, DOI 10.1016/j.celrep.2018.03.140; Loh PR, 2015, NAT GENET, V47, P284, DOI 10.1038/ng.3190; Long T, 2017, NAT GENET, V49, P568, DOI 10.1038/ng.3809; Lotta LA, 2021, NAT GENET, V53, DOI 10.1038/s41588-020-00751-5; Luo SY, 2021, KIDNEY INT, V100, P430, DOI 10.1016/j.kint.2021.03.026; Marchini J, 2010, NAT REV GENET, V11, P499, DOI 10.1038/nrg2796; Nag A., 2021, PREPRINT, DOI [10.1101/2021.12.24.21268381, DOI 10.1101/2021.12.24.21268381]; Nguyen DD, 2021, JAMA DERMATOL, V157, P35, DOI 10.1001/jamadermatol.2020.3385; NHS England, 2020, CLIN COMM URG POL ST; Peng H, 2020, ONCOGENE, V39, P6747, DOI 10.1038/s41388-020-01480-z; Pietzner M, 2021, NAT MED, V27, P471, DOI 10.1038/s41591-021-01266-0; Pilz S, 2015, AMINO ACIDS, V47, P1703, DOI 10.1007/s00726-015-1993-2; Popolo A, 2014, AMINO ACIDS, V46, P2271, DOI 10.1007/s00726-014-1825-9; Quell JD, 2017, J CHROMATOGR B, V1071, P58, DOI 10.1016/j.jchromb.2017.04.002; Revelle W., 2020, PSYCH PROCEDURES PER; ROBERTSON D, 1991, HYPERTENSION, V18, P1, DOI 10.1161/01.HYP.18.1.1; ROE CR, 1986, J CLIN INVEST, V77, P1391, DOI 10.1172/JCI112446; Ruth KS, 2020, NAT MED, V26, P252, DOI 10.1038/s41591-020-0751-5; Schiffer L, 2019, J STEROID BIOCHEM, V194, DOI 10.1016/j.jsbmb.2019.105439; Schlesinger S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165811; Seppala I, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01274-6; Shin SY, 2014, NAT GENET, V46, P543, DOI 10.1038/ng.2982; Staley JR, 2016, BIOINFORMATICS, V32, P3207, DOI 10.1093/bioinformatics/btw373; Storbeck KH, 2019, ENDOCR REV, V40, P1605, DOI 10.1210/er.2018-00262; Surendran P, 2020, NAT GENET, V52, P1314, DOI 10.1038/s41588-020-00713-x; Teumer A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06356-1; Traish AM, 2015, REV ENDOCR METAB DIS, V16, P177, DOI 10.1007/s11154-015-9319-y; van Buuren S, 2011, J STAT SOFTW, V45, P1; Warren H. R., 2017, NAT GENET, DOI [10.1038/ng.3768, DOI 10.1038/NG.3768]; Willeit P, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.001833; Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340; Wittemans LBL, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08936-1; Wu P, 2019, JMIR MED INF, V7, P360, DOI 10.2196/14325; Wuttke M, 2019, NAT GENET, V51, P957, DOI 10.1038/s41588-019-0407-x; Yap CX, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07862-y; Yarmolinsky J, 2018, JNCI-J NATL CANCER I, V110, P1035, DOI 10.1093/jnci/djy081; Yeung SLA, 2016, AM HEART J, V182, P54, DOI 10.1016/j.ahj.2016.07.021; Zheng JS, 2021, DIABETES CARE, V44, P98, DOI 10.2337/dc20-1328	80	0	0	3	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02046-0	http://dx.doi.org/10.1038/s41591-022-02046-0		NOV 2022	28	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	6B8KC	36357675	Green Published, hybrid			2022-12-27	WOS:000881574700007
J	Jhund, PS; Kondo, T; Butt, JH; Docherty, KF; Claggett, BL; Desai, AS; Vaduganathan, M; Gasparyan, SB; Bengtsson, O; Lindholm, D; Petersson, M; Langkilde, AM; de Boer, RA; DeMets, D; Hernandez, AF; Inzucchi, SE; Kosiborod, MN; Kober, L; Lam, CSP; Martinez, FA; Sabatine, MS; Shah, SJ; Solomon, SD; McMurray, JJV				Jhund, Pardeep S.; Kondo, Toru; Butt, Jawad H.; Docherty, Kieran F.; Claggett, Brian L.; Desai, Akshay S.; Vaduganathan, Muthiah; Gasparyan, Samvel B.; Bengtsson, Olof; Lindholm, Daniel; Petersson, Magnus; Langkilde, Anna Maria; de Boer, Rudolf A.; DeMets, David; Hernandez, Adrian F.; Inzucchi, Silvio E.; Kosiborod, Mikhail N.; Kober, Lars; Lam, Carolyn S. P.; Martinez, Felipe A.; Sabatine, Marc S.; Shah, Sanjiv J.; Solomon, Scott D.; McMurray, John J. V.			Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER	NATURE MEDICINE			English	Article							RECURRENT EVENTS	Whether the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a range of morbidity and mortality outcomes in patients with heart failure regardless of ejection fraction is unknown. A patient-level pooled meta-analysis of two trials testing dapagliflozin in participants with heart failure and different ranges of left ventricular ejection fraction (<= 40% and >40%) was pre-specified to examine the effect of treatment on endpoints that neither trial, individually, was powered for and to test the consistency of the effect of dapagliflozin across the range of ejection fractions. The pre-specified endpoints were: death from cardiovascular causes; death from any cause; total hospital admissions for heart failure; and the composite of death from cardiovascular causes, myocardial infarction or stroke (major adverse cardiovascular events (MACEs)). A total of 11,007 participants with a mean ejection fraction of 44% (s.d. 14%) were included. Dapagliflozin reduced the risk of death from cardiovascular causes (hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.76-0.97; P = 0.01), death from any cause (HR 0.90, 95% CI 0.82-0.99; P = 0.03), total hospital admissions for heart failure (rate ratio 0.71, 95% CI 0.65-0.78; P < 0.001) and MACEs (HR 0.90, 95% CI 0.81-1.00; P = 0.045). There was no evidence that the effect of dapagliflozin differed by ejection fraction. In a patient-level pooled meta-analysis covering the full range of ejection fractions in patients with heart failure, dapagliflozin reduced the risk of death from cardiovascular causes and hospital admissions for heart failure (PROSPERO: CRD42022346524). A pre-specified meta-analysis of pooled, individual patient-level data from the DELIVER and DAPA-HF trials, testing dapagliflozin in patients with heart failure, demonstrates reductions in risk of cardiovascular-associated deaths and hospital admissions for heart failure, regardless of ejection fraction.	[Jhund, Pardeep S.; Kondo, Toru; Butt, Jawad H.; Docherty, Kieran F.; McMurray, John J. V.] Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Sch Cardiovasc & Metab Hlth, Glasgow, Lanark, Scotland; [Claggett, Brian L.; Desai, Akshay S.; Vaduganathan, Muthiah; Solomon, Scott D.] Harvard Med Sch, Brigham & Womens Hosp, Cardiovasc Div, Boston, MA USA; [Gasparyan, Samvel B.; Bengtsson, Olof; Lindholm, Daniel; Petersson, Magnus; Langkilde, Anna Maria] AstraZeneca, Late Stage Dev Cardiovasc Renal & Metab, BioPharmaceut R&D, Gothenburg, Sweden; [de Boer, Rudolf A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands; [DeMets, David] Univ Wisconsin, Madison, WI USA; [Hernandez, Adrian F.] Duke Univ, Med Ctr, Durham, NC USA; [Inzucchi, Silvio E.] Yale Sch Med, New Haven, CT USA; [Kosiborod, Mikhail N.] Univ Missouri, St Lukes Mid Amer Heart Inst, Kansas City, MO USA; [Kober, Lars] Copenhagen Univ Hosp, Dept Cardiol, Rigshosp, Copenhagen, Denmark; [Lam, Carolyn S. P.] Natl Univ Singapore, Natl Heart Ctr Singapore, Singapore, Singapore; [Martinez, Felipe A.] Univ Cordoba, Cordoba, Argentina; [Sabatine, Marc S.] Brigham & Womens Hosp, Div Cardiovasc Med, TIMI Study Grp, Boston, MA USA; [Shah, Sanjiv J.] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA	University of Glasgow; Harvard University; Brigham & Women's Hospital; Harvard Medical School; AstraZeneca; University of Groningen; University of Wisconsin System; University of Wisconsin Madison; Duke University; Yale University; Saint Luke's Mid America Heart Institute; University of Missouri System; University of Missouri Kansas City; Rigshospitalet; University of Copenhagen; National Heart Centre Singapore; National University of Singapore; National University of Cordoba; Harvard University; Brigham & Women's Hospital; Northwestern University; Feinberg School of Medicine	McMurray, JJV (corresponding author), Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Sch Cardiovasc & Metab Hlth, Glasgow, Lanark, Scotland.	john.mcmurray@glasgow.ac.uk	Butt, Jawad Haider/AGB-5014-2022; Jhund, Pardeep/GLS-9508-2022; Kosiborod, Mikhail/HDO-1541-2022; de Boer, Rudolf/ABE-9879-2020	Butt, Jawad Haider/0000-0002-7380-4144; Jhund, Pardeep/0000-0003-4306-5317; Kosiborod, Mikhail/0000-0002-3750-9789; Kondo, Toru/0000-0001-6853-7574; Lindholm, Daniel/0000-0003-3526-0614; Gasparyan, Samvel B./0000-0002-4797-2208; Bengtsson, Olof/0000-0003-1315-8176	AstraZeneca; British Heart Foundation Centre of Research Excellence grant [RE/18/6/34217]	AstraZeneca(AstraZeneca); British Heart Foundation Centre of Research Excellence grant	AstraZeneca was the sponsor and funder of the DAPA-HF and DELIVER trials. AstraZeneca had organizational oversight over the DAPA-HF and DELIVER trials and was responsible for trial conduct, supervision and monitoring of the enrolling centers, data collection and storage. The trials were designed by the academic members of the executive committee in cooperation with representatives from AstraZeneca. Data analysis of each trial was performed by AstraZeneca according to the statistical analysis plan and independent academic statisticians at the University of Glasgow and the Brigham and Women's Hospital, Boston. Data analysis of the present study was conducted by the independent academic group at the University of Glasgow according to the pre-specified statistical analysis plans. J.J.V.M. and P.S.J. are supported by a British Heart Foundation Centre of Research Excellence grant (no. RE/18/6/34217).	Anker SD, 2021, NEW ENGL J MED, V385, P1451, DOI 10.1056/NEJMoa2107038; Berg DD, 2021, JAMA CARDIOL, V6, P499, DOI 10.1001/jamacardio.2020.7585; Bhatt DL, 2021, NEW ENGL J MED, V384, P117, DOI 10.1056/NEJMoa2030183; Butler J, 2022, EUR J HEART FAIL, V24, P245, DOI 10.1002/ejhf.2420; Butler J, 2022, EUR HEART J, V43, P416, DOI 10.1093/eurheartj/ehab798; Ghosh D, 2000, BIOMETRICS, V56, P554, DOI 10.1111/j.0006-341X.2000.00554.x; Heidenreich PA, 2022, CIRCULATION, V145, pE895, DOI 10.1161/CIR.0000000000001063; Kondo T, 2022, EUR HEART J, V43, P427, DOI 10.1093/eurheartj/ehab828; Lin DY, 2000, J ROY STAT SOC B, V62, P711, DOI 10.1111/1467-9868.00259; Lund LH, 2018, EUR J HEART FAIL, V20, P1230, DOI 10.1002/ejhf.1149; McMurray JJV, 2019, NEW ENGL J MED, V381, P1995, DOI 10.1056/NEJMoa1911303; McMurray JJV, 2019, EUR J HEART FAIL, V21, P665, DOI 10.1002/ejhf.1432; Munda M, 2014, PHARM STAT, V13, P145, DOI 10.1002/pst.1612; Nassif ME, 2021, NAT MED, V27, P1954, DOI 10.1038/s41591-021-01536-x; Packer M, 2020, NEW ENGL J MED, V383, P1413, DOI 10.1056/NEJMoa2022190; Rogers JK, 2016, STAT MED, V35, P2195, DOI 10.1002/sim.6853; Shen L, 2022, EUR HEART J, V43, P2573, DOI 10.1093/eurheartj/ehac210; Solomon SD, 2022, NEW ENGL J MED, DOI 10.1056/NEJMoa2206286; Solomon SD, 2021, EUR J HEART FAIL, V23, P1217, DOI 10.1002/ejhf.2249; Solomon SD, 2020, CIRCULATION, V141, P352, DOI 10.1161/CIRCULATIONAHA.119.044586; Solomon SD, 2016, EUR HEART J, V37, P455, DOI 10.1093/eurheartj/ehv464; Verbrugge FH, 2022, EUR HEART J, V43, P1941, DOI 10.1093/eurheartj/ehab911	22	9	9	2	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2022	28	9					1956	+		10.1038/s41591-022-01971-4	http://dx.doi.org/10.1038/s41591-022-01971-4		AUG 2022	16	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4S0LI	36030328	Green Published, Green Accepted, hybrid			2022-12-27	WOS:000846105000001
J	Adams, R; Henry, KE; Sridharan, A; Soleimani, H; Zhan, AD; Rawat, N; Johnson, L; Hager, DN; Cosgrove, SE; Markowski, A; Klein, EY; Chen, ES; Saheed, MO; Henley, M; Miranda, S; Houston, K; Linton, RC; Ahluwalia, AR; Wu, AW; Saria, S				Adams, Roy; Henry, Katharine E.; Sridharan, Anirudh; Soleimani, Hossein; Zhan, Andong; Rawat, Nishi; Johnson, Lauren; Hager, David N.; Cosgrove, Sara E.; Markowski, Andrew; Klein, Eili Y.; Chen, Edward S.; Saheed, Mustapha O.; Henley, Maureen; Miranda, Sheila; Houston, Katrina; Linton, Robert C.; Ahluwalia, Anushree R.; Wu, Albert W.; Saria, Suchi			Prospective, multi-site study of patient outcomes after implementation of the TREWS machine learning-based early warning system for sepsis	NATURE MEDICINE			English	Article							SEPTIC SHOCK; SURVIVAL; DEFINITIONS; MORTALITY; RISK	Early recognition and treatment of sepsis are linked to improved patient outcomes. Machine learning-based early warning systems may reduce the time to recognition, but few systems have undergone clinical evaluation. In this prospective, multi-site cohort study, we examined the association between patient outcomes and provider interaction with a deployed sepsis alert system called the Targeted Real-time Early Warning System (TREWS). During the study, 590,736 patients were monitored by TREWS across five hospitals. We focused our analysis on 6,877 patients with sepsis who were identified by the alert before initiation of antibiotic therapy. Adjusting for patient presentation and severity, patients in this group whose alert was confirmed by a provider within 3 h of the alert had a reduced in-hospital mortality rate (3.3%, confidence interval (CI) 1.7, 5.1%, adjusted absolute reduction, and 18.7%, CI 9.4, 27.0%, adjusted relative reduction), organ failure and length of stay compared with patients whose alert was not confirmed by a provider within 3 h. Improvements in mortality rate (4.5%, CI 0.8, 8.3%, adjusted absolute reduction) and organ failure were larger among those patients who were additionally flagged as high risk. Our findings indicate that early warning systems have the potential to identify sepsis patients early and improve patient outcomes and that sepsis patients who would benefit the most from early treatment can be identified and prioritized at the time of the alert Prospective evaluation of a machine learning-based early warning system for sepsis, deployed at five hospitals, showed that interaction of health-care providers with the system was associated with better patient outcomes, including reduced in-hospital mortality.	[Adams, Roy; Saria, Suchi] Johns Hopkins Univ, Malone Ctr Engn Healthcare, Baltimore, MD 21218 USA; [Adams, Roy; Henry, Katharine E.; Zhan, Andong] Johns Hopkins Med Inst, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; [Henry, Katharine E.; Zhan, Andong; Saria, Suchi] Johns Hopkins Univ, Dept Comp Sci, Baltimore, MD 21218 USA; [Sridharan, Anirudh; Linton, Robert C.] Howard Cty Gen Hosp, Columbia, MD USA; [Soleimani, Hossein] Univ Calif San Francisco, Hlth Informat, San Francisco, CA 94143 USA; [Rawat, Nishi; Wu, Albert W.] Johns Hopkins Sch Med, Armstrong Inst Patient Safety & Qual, Baltimore, MD 21205 USA; [Johnson, Lauren; Henley, Maureen; Houston, Katrina; Ahluwalia, Anushree R.] Johns Hopkins Univ Hosp, Dept Qual Improvement, Baltimore, MD 21287 USA; [Hager, David N.; Cosgrove, Sara E.; Wu, Albert W.; Saria, Suchi] Johns Hopkins Sch Med, Dept Med, Baltimore, MD 21205 USA; [Markowski, Andrew] Suburban Hosp, Bethesda, MD USA; [Klein, Eili Y.; Saheed, Mustapha O.] Johns Hopkins Sch Med, Dept Emergency Med, Baltimore, MD USA; [Miranda, Sheila] Johns Hopkins Univ Hosp, Dept Med, Baltimore, MD 21287 USA; [Wu, Albert W.; Saria, Suchi] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA; [Wu, Albert W.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; [Wu, Albert W.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA; [Saria, Suchi] Bayesian Hlth, New York, NY 10005 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; University of California System; University of California San Francisco; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Saria, S (corresponding author), Johns Hopkins Univ, Malone Ctr Engn Healthcare, Baltimore, MD 21218 USA.; Saria, S (corresponding author), Johns Hopkins Univ, Dept Comp Sci, Baltimore, MD 21218 USA.; Wu, ALW (corresponding author), Johns Hopkins Sch Med, Armstrong Inst Patient Safety & Qual, Baltimore, MD 21205 USA.; Wu, ALW; Saria, S (corresponding author), Johns Hopkins Sch Med, Dept Med, Baltimore, MD 21205 USA.; Wu, ALW; Saria, S (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA.; Wu, ALW (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA.; Wu, ALW (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA.; Saria, S (corresponding author), Bayesian Hlth, New York, NY 10005 USA.	awu@jhu.edu; ssaria@cs.jhu.edu		Henry, Katharine/0000-0002-0446-9717	Gordon and Betty Moore Foundation [3926]; National Science Foundation (NSF) Future of Work at the Human-technology Frontier [1840088]; Alfred P. Sloan Foundation	Gordon and Betty Moore Foundation(Gordon and Betty Moore Foundation); National Science Foundation (NSF) Future of Work at the Human-technology Frontier(National Science Foundation (NSF)); Alfred P. Sloan Foundation(Alfred P. Sloan Foundation)	We thank Y. Ahmad, M. Yeo and Y. Karklin whose work significantly contributed to early iterations of the development of the deployed system. Further, we thank R. Demski, K. D'Souza, A. Kachalia, A. Chen and clinical and quality stakeholders who contributed to tool deployment, education and championing the work. We gratefully acknowledge the following sources of funding: the Gordon and Betty Moore Foundation (award no. 3926), the National Science Foundation (NSF) Future of Work at the Human-technology Frontier (award no. 1840088) and the Alfred P. Sloan Foundation research fellowship (2018). This information or content and conclusions are those of the authors and should not be construed as the official position or policy of, nor should any endorsements be inferred by, the NSF of the US Government.	Bedoya AD, 2020, JAMIA OPEN, V3, P252, DOI 10.1093/jamiaopen/ooaa006; Burdick H, 2020, BMJ HEALTH CARE INFO, V27, DOI 10.1136/bmjhci-2019-100109; Chamberlain DJ, 2011, AUST CRIT CARE, V24, P229, DOI 10.1016/j.aucc.2011.01.003; Damiani E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125827; Desautels T, 2016, JMIR MED INF, V4, P67, DOI 10.2196/medinform.5909; Escobar GJ, 2020, NEW ENGL J MED, V383, P1951, DOI 10.1056/NEJMsa2001090; Ferrer R, 2014, CRIT CARE MED, V42, P1749, DOI 10.1097/CCM.0000000000000330; Giannini HM, 2019, CRIT CARE MED, V47, P1485, DOI 10.1097/CCM.0000000000003891; Ginestra JC, 2019, CRIT CARE MED, V47, P1477, DOI 10.1097/CCM.0000000000003803; Guy J. S., 2020, NEJM CATAL INNOV CAR, DOI [10.1056/CAT.19.1036, DOI 10.1056/CAT.19.1036]; Henry KE, 2022, NAT MED, V28, P1447, DOI 10.1038/s41591-022-01895-z; Henry KE, 2022, NPJ DIGIT MED, V5, DOI 10.1038/s41746-022-00597-7; Henry Katharine E, 2019, Crit Care Explor, V1, pe0053, DOI 10.1097/CCE.0000000000000053; Henry KE, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab3719; Hernan M., 2020, CAUSAL INFERENCE WHA; Hernan MA, 2016, AM J EPIDEMIOL, V183, P758, DOI 10.1093/aje/kwv254; Horng S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174708; HORVITZ DG, 1952, J AM STAT ASSOC, V47, P663, DOI 10.2307/2280784; JORDAN MI, 1993, IEEE IJCNN, P1339; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kumar A, 2006, CRIT CARE MED, V34, P1589, DOI 10.1097/01.CCM.0000217961.75225.E9; Liu VX, 2017, AM J RESP CRIT CARE, V196, P856, DOI 10.1164/rccm.201609-1848OC; Manaktala S, 2017, J AM MED INFORM ASSN, V24, P88, DOI 10.1093/jamia/ocw056; Marshall JC, 2014, TRENDS MOL MED, V20, P195, DOI 10.1016/j.molmed.2014.01.007; McCoy Andrea, 2017, BMJ Open Qual, V6, pe000158, DOI 10.1136/bmjoq-2017-000158; Norton EC, 2013, STATA J, V13, P492, DOI 10.1177/1536867X1301300304; Pedregosa F, 2011, J MACH LEARN RES, V12, P2825; Peltan ID, 2019, CHEST, V155, P938, DOI 10.1016/j.chest.2019.02.008; Peng LM, 2021, ANNU REV STAT APPL, V8, P413, DOI 10.1146/annurev-statistics-042720-020233; Rhee C, 2021, CLIN INFECT DIS, V72, P541, DOI 10.1093/cid/ciaa059; Rhee C, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.2899; Rhee C, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2018.7571; Rhee C, 2019, BMJ QUAL SAF, V28, P305, DOI 10.1136/bmjqs-2018-008331; Rhodes A, 2017, CRIT CARE MED, V45, P486, DOI 10.1097/CCM.0000000000002255; Riedemann NC, 2003, J CLIN INVEST, V112, P460, DOI 10.1172/JCI200319523; Robins J.M., 2000, STAT MODELS EPIDEMIO, P95, DOI DOI 10.1007/978-1-4612-1284-3_2; Rosenbaum PR, 2010, SPRINGER SER STAT, P1, DOI 10.1007/978-1-4419-1213-8; Saria S, 2020, CRIT CARE MED, V48, P137, DOI 10.1097/CCM.0000000000004144; Seabold S., 2010, P 9 PYTHON SCI C, P92, DOI [DOI 10.25080/MAJORA-92BF1922-011, 10.25080/MAJORA-92BF1922-011]; Seymour CW, 2017, NEW ENGL J MED, V376, P2235, DOI 10.1056/NEJMoa1703058; Seymour CW, 2016, JAMA-J AM MED ASSOC, V315, P762, DOI 10.1001/jama.2016.0288; Shashikumar SP, 2021, ARTIF INTELL MED, V113, DOI 10.1016/j.artmed.2021.102036; Shimabukuro DW, 2017, BMJ OPEN RESPIR RES, V4, DOI 10.1136/bmjresp-2017-000234; Topiwala Raj, 2019, Crit Care Explor, V1, pe0046, DOI 10.1097/CCE.0000000000000046; VanderWeele TJ, 2019, EPIDEMIOLOGY, V30, P334, DOI 10.1097/EDE.0000000000000991; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Wong A, 2021, JAMA INTERN MED, V181, P1065, DOI 10.1001/jamainternmed.2021.2626; World Health Organization, 1992, INT STAT CLASS DIS R	49	4	4	6	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2022	28	7					1455	+		10.1038/s41591-022-01894-0	http://dx.doi.org/10.1038/s41591-022-01894-0		JUL 2022	17	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3E5PS	35864252	Bronze			2022-12-27	WOS:000828446700006
J	Johnson, DL				Johnson, Deborah L.			Virtual conferences democratize access to science	NATURE MEDICINE			English	Editorial Material								Online access during the pandemic widened participation in scientific conferences for women, young scientists and those from low- and middle-income countries, and should be continued	[Johnson, Deborah L.] Keystone Symposia Mol & Cellular Biol, Silverthorne, CO 80498 USA; [Johnson, Deborah L.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine	Johnson, DL (corresponding author), Keystone Symposia Mol & Cellular Biol, Silverthorne, CO 80498 USA.; Johnson, DL (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	debbiej@keystonesymposia.org							0	2	2	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2022	28	7					1335	1335		10.1038/s41591-022-01849-5	http://dx.doi.org/10.1038/s41591-022-01849-5		JUN 2022	1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3E5PS	35710991	Bronze			2022-12-27	WOS:000811980700004
J	Jara, A; Undurraga, EA; Zubizarreta, JR; Gonzalez, C; Acevedo, J; Pizarro, A; Vergara, V; Soto-Marchant, M; Gilabert, R; Flores, JC; Suarez, P; Leighton, P; Eguiguren, P; Rios, JC; Fernandez, J; Garcia-Escorza, H; Araos, R				Jara, Alejandro; Undurraga, Eduardo A.; Zubizarreta, Jose R.; Gonzalez, Cecilia; Acevedo, Johanna; Pizarro, Alejandra; Vergara, Veronica; Soto-Marchant, Mario; Gilabert, Rosario; Flores, Juan Carlos; Suarez, Pamela; Leighton, Paulina; Eguiguren, Pablo; Carlos Rios, Juan; Fernandez, Jorge; Garcia-Escorza, Heriberto; Araos, Rafael			Effectiveness of CoronaVac in children 3-5 years of age during the SARS-CoV-2 Omicron outbreak in Chile	NATURE MEDICINE			English	Article							MODELS	The outbreak of the B.1.1.529 lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Omicron) has caused an unprecedented number of Coronavirus Disease 2019 (COVID-19) cases, including pediatric hospital admissions. Policymakers urgently need evidence of vaccine effectiveness in children to balance the costs and benefits of vaccination campaigns, but, to date, the evidence is sparse. Leveraging a population-based cohort in Chile of 490,694 children aged 3-5 years, we estimated the effectiveness of administering a two-dose schedule, 28 days apart, of Sinovac's inactivated SARS-CoV-2 vaccine (CoronaVac). We used inverse probability-weighted survival regression models to estimate hazard ratios of symptomatic COVID-19, hospitalization and admission to an intensive care unit (ICU) for children with complete immunization over non-vaccination, accounting for time-varying vaccination exposure and relevant confounders. The study was conducted between 6 December 2021 and 26 February 2022, during the Omicron outbreak in Chile. The estimated vaccine effectiveness was 38.2% (95% confidence interval (CI), 36.5-39.9) against symptomatic COVID-19, 64.6% (95% CI, 49.6-75.2) against hospitalization and 69.0% (95% CI, 18.6-88.2) against ICU admission. The effectiveness against symptomatic COVID-19 was modest; however, protection against severe disease was high. These results support vaccination of children aged 3-5 years to prevent severe illness and associated complications and highlight the importance of maintaining layered protections against SARS-CoV-2 infection. CoronaVac protects young children from severe COVID-19 during a SARS-CoV-2 Omicron surge, supporting the effectiveness and importance of vaccinating this pediatric population.	[Jara, Alejandro; Gonzalez, Cecilia; Acevedo, Johanna; Pizarro, Alejandra; Vergara, Veronica; Soto-Marchant, Mario; Gilabert, Rosario; Suarez, Pamela; Leighton, Paulina; Eguiguren, Pablo; Carlos Rios, Juan; Fernandez, Jorge; Garcia-Escorza, Heriberto; Araos, Rafael] Minist Hlth Santiago, Santiago, Chile; [Jara, Alejandro] Pontificia Univ Catolica Chile, Fac Matemat, Santiago, Chile; [Jara, Alejandro] Ctr Discovery Struct Complex Data MiDaS, Santiago, Chile; [Undurraga, Eduardo A.] Pontificia Univ Catolica Chile, Escuela Gobierno, Santiago, Chile; [Undurraga, Eduardo A.; Araos, Rafael] Initiat Collaborat Res Bacterial Resistance MICRO, Santiago, Chile; [Undurraga, Eduardo A.] Res Ctr Integrated Disaster Risk Management CIGID, Santiago, Chile; [Undurraga, Eduardo A.] CIFAR Azrieli Global Scholars Program, Toronto, ON, Canada; [Zubizarreta, Jose R.] Harvard Med Sch, Dept Hlth Care Policy, Boston, MA 02115 USA; [Zubizarreta, Jose R.] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Zubizarreta, Jose R.] Harvard TH Chan Sch Publ Hlth, Dept Stat, Boston, MA USA; [Pizarro, Alejandra; Flores, Juan Carlos; Carlos Rios, Juan] Pontificia Univ Catolica Chile, Fac Med, Santiago, Chile; [Araos, Rafael] Clin Alemana Univ Desarrollo, Fac Med, Inst Ciencias & Innovac Med, Santiago, Chile; [Araos, Rafael] Adv Ctr Chron Dis ACCDiS, Santiago, Chile	Pontificia Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Pontificia Universidad Catolica de Chile; Universidad del Desarrollo	Araos, R (corresponding author), Minist Hlth Santiago, Santiago, Chile.; Araos, R (corresponding author), Initiat Collaborat Res Bacterial Resistance MICRO, Santiago, Chile.; Araos, R (corresponding author), Clin Alemana Univ Desarrollo, Fac Med, Inst Ciencias & Innovac Med, Santiago, Chile.; Araos, R (corresponding author), Adv Ctr Chron Dis ACCDiS, Santiago, Chile.	rafaelaraos@udd.cl	; Undurraga, Eduardo A./I-3739-2014	Jara, Alejandro/0000-0002-2282-353X; Undurraga, Eduardo A./0000-0002-4425-1253; Acevedo, Johanna/0000-0002-6341-1865; Rios, Juan Carlos/0000-0003-0701-9604	Agencia Nacional de Investigacion y Desarrollo (ANID) through the Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT) [1220907]; Millennium Science Initiative Program-Millennium Nucleus Center for the Discovery of Structures in Complex Data (MiDaS) [NCN17_059]; Advanced Center for Chronic Diseases (ACCDiS) ANID FONDAP [15130011]; Research Center for Integrated Disaster Risk Management (CIGIDEN) ANID FONDAP [15110017]	Agencia Nacional de Investigacion y Desarrollo (ANID) through the Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT); Millennium Science Initiative Program-Millennium Nucleus Center for the Discovery of Structures in Complex Data (MiDaS); Advanced Center for Chronic Diseases (ACCDiS) ANID FONDAP; Research Center for Integrated Disaster Risk Management (CIGIDEN) ANID FONDAP	This research was supported by the Agencia Nacional de Investigacion y Desarrollo (ANID) through the Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT), grant 1220907, to A.J.; by the Millennium Science Initiative Program-Millennium Nucleus Center for the Discovery of Structures in Complex Data (MiDaS), grant NCN17_059, to A.J.; by the Advanced Center for Chronic Diseases (ACCDiS) ANID FONDAP, grant 15130011, to R.A.; and by the Research Center for Integrated Disaster Risk Management (CIGIDEN) ANID FONDAP, grant 15110017, to E.U.A. The funders of this study had no role in the study design; in the collection, analysis and interpretation of data; in the writing of this manuscript; or in the decision to submit the article for consideration for publication.	Altarawneh HN, 2022, NEW ENGL J MED, V386, P1288, DOI 10.1056/NEJMc2200133; Andrews N, 2022, NEW ENGL J MED, V386, P1532, DOI [10.1056/NEJMoa2119451, 10.1016/S1473-3099(22)00309-7]; [Anonymous], 2021, PFIZER BIONTECH PROV; [Anonymous], R PROJECT STAT COMPU; [Anonymous], NEW YORK TIMES; Cloete J, 2022, LANCET CHILD ADOLESC, V6, P294, DOI 10.1016/S2352-4642(22)00027-X; Cole SR, 2008, AM J EPIDEMIOL, V168, P656, DOI 10.1093/aje/kwn164; Collie S, 2022, NEW ENGL J MED, V386, P494, DOI 10.1056/NEJMc2119270; COX DR, 1972, J R STAT SOC B, V34, P187; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Dorabawila V., JAMA-J AM MED ASSOC, DOI [10.1001/jama.2022.7319(2022, DOI 10.1001/JAMA.2022.7319(2022]; Feikin DR, 2022, LANCET, V399, P924, DOI 10.1016/S0140-6736(22)00152-0; Gonzalez S., 2022, PREPRINT, DOI [10.1101/2022.04.18.22273978v1, DOI 10.1101/2022.04.18.22273978V1]; Hoffmann M, 2022, CELL, V185, P447, DOI 10.1016/j.cell.2021.12.032; Israeli E, 2022, ISR MED ASSOC J, V24, P257, DOI 10.1056/NEJMoa2117995; Iuliano AD, 2022, MMWR-MORBID MORTAL W, V71, P146, DOI [10.1101/2021.12.30.21268560v2, 10.15585/mmwr.mm7104e4]; Jara A., 2021, PREPRINT; Jara A, 2022, LANCET GLOB HEALTH, V10, pE798, DOI 10.1016/S2214-109X(22)00112-7; Jara A, 2021, NEW ENGL J MED, V385, P875, DOI 10.1056/NEJMoa2107715; Madhi SA, 2022, NEW ENGL J MED, V386, P1314, DOI 10.1056/NEJMoa2119658; Pajon R, 2022, NEW ENGL J MED, V386, P1088, DOI 10.1056/NEJMc2119912; Robins JM, 2000, EPIDEMIOLOGY, V11, P550, DOI 10.1097/00001648-200009000-00011; Therneau T, PACKAGE SURVIVAL ANA; Therneau T.M., 2000, MODELING SURVIVAL DA; Thompson MG, 2021, NEW ENGL J MED, V385, P320, DOI 10.1056/NEJMoa2107058; Walter EB, 2022, NEW ENGL J MED, V386, P35, DOI 10.1056/NEJMoa2116298; Wang, 2022, PREPRINT, DOI [10.1101/2022.01.12.22269179v1, DOI 10.1101/2022.01.12.22269179V1]; World Health Organization, TRACK SARS COV 2 VAR; Zimmermann P, 2022, ARCH DIS CHILD, V107, DOI 10.1136/archdischild-2021-323040	29	8	8	7	7	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2022	28	7					1377	+		10.1038/s41591-022-01874-4	http://dx.doi.org/10.1038/s41591-022-01874-4		MAY 2022	16	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3E5PS	35605637	hybrid, Green Submitted, Green Published			2022-12-27	WOS:000811448200001
J	Brizzi, A; Whittaker, C; Servo, LMS; Hawryluk, I; Prete, CA; de Souza, WM; Aguiar, RS; Araujo, LJT; Bastos, LS; Blenkinsop, A; Buss, LF; Candido, D; Castro, MC; Costa, SF; Croda, J; Santos, AAD; Dye, C; Flaxman, S; Fonseca, PLC; Geddes, VEV; Gutierrez, B; Lemey, P; Levin, AS; Mellan, T; Bonfim, DM; Miscouridou, X; Mishra, S; Monod, M; Moreira, FRR; Nelson, B; Pereira, RHM; Ranzani, O; Schnekenberg, RP; Semenova, E; Sonnabend, R; Souza, RP; Xi, XY; Sabino, EC; Faria, NR; Bhatt, S; Ratmann, O				Brizzi, Andrea; Whittaker, Charles; Servo, Luciana M. S.; Hawryluk, Iwona; Prete Jr, Carlos A.; de Souza, William M.; Aguiar, Renato S.; Araujo, Leonardo J. T.; Bastos, Leonardo S.; Blenkinsop, Alexandra; Buss, Lewis F.; Candido, Darlan; Castro, Marcia C.; Costa, Silvia F.; Croda, Julio; de Souza Santos, Andreza Aruska; Dye, Christopher; Flaxman, Seth; Fonseca, Paula L. C.; Geddes, Victor E. V.; Gutierrez, Bernardo; Lemey, Philippe; Levin, Anna S.; Mellan, Thomas; Bonfim, Diego M.; Miscouridou, Xenia; Mishra, Swapnil; Monod, Melodie; Moreira, Filipe R. R.; Nelson, Bruce; Pereira, Rafael H. M.; Ranzani, Otavio; Schnekenberg, Ricardo P.; Semenova, Elizaveta; Sonnabend, Raphael; Souza, Renan P.; Xi, Xiaoyue; Sabino, Ester C.; Faria, Nuno R.; Bhatt, Samir; Ratmann, Oliver			Spatial and temporal fluctuations in COVID-19 fatality rates in Brazilian hospitals	NATURE MEDICINE			English	Article							NCOV-19 AZD1222 VACCINE; HEALTH; EFFICACY	Analysis of individual-level patient records from Brazil reveals that the extensive shocks in COVID-19 mortality rates are associated with pre-pandemic geographic inequities as well as shortages in healthcare capacity during the pandemic. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Gamma variant of concern has spread rapidly across Brazil since late 2020, causing substantial infection and death waves. Here we used individual-level patient records after hospitalization with suspected or confirmed coronavirus disease 2019 (COVID-19) between 20 January 2020 and 26 July 2021 to document temporary, sweeping shocks in hospital fatality rates that followed the spread of Gamma across 14 state capitals, during which typically more than half of hospitalized patients aged 70 years and older died. We show that such extensive shocks in COVID-19 in-hospital fatality rates also existed before the detection of Gamma. Using a Bayesian fatality rate model, we found that the geographic and temporal fluctuations in Brazil's COVID-19 in-hospital fatality rates were primarily associated with geographic inequities and shortages in healthcare capacity. We estimate that approximately half of the COVID-19 deaths in hospitals in the 14 cities could have been avoided without pre-pandemic geographic inequities and without pandemic healthcare pressure. Our results suggest that investments in healthcare resources, healthcare optimization and pandemic preparedness are critical to minimize population-wide mortality and morbidity caused by highly transmissible and deadly pathogens such as SARS-CoV-2, especially in low- and middle-income countries.	[Brizzi, Andrea; Blenkinsop, Alexandra; Miscouridou, Xenia; Monod, Melodie; Semenova, Elizaveta; Xi, Xiaoyue; Ratmann, Oliver] Imperial Coll London, Dept Math, London, England; [Whittaker, Charles; Hawryluk, Iwona; Buss, Lewis F.; Mellan, Thomas; Mishra, Swapnil; Sonnabend, Raphael; Faria, Nuno R.; Bhatt, Samir] Imperial Coll London, MRC Ctr Global Infect Dis Anal, Sch Publ Hlth, Jameel Inst, London, England; [Servo, Luciana M. S.; Pereira, Rafael H. M.] IPEA, Inst Appl Econ Res, Brasilia, DF, Brazil; [Prete Jr, Carlos A.] Univ Sao Paulo, Dept Engn Sistemas Eletron, Escola Politecn, Sao Paulo, Brazil; [de Souza, William M.] Univ Texas Med Branch, World Reference Ctr Emerging Viruses & Arboviruse, Galveston, TX 77555 USA; [de Souza, William M.] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA; [Aguiar, Renato S.; Fonseca, Paula L. C.; Geddes, Victor E. V.; Bonfim, Diego M.; Souza, Renan P.] Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Genet Ecol & Evolucao, Belo Horizonte, MG, Brazil; [Aguiar, Renato S.] Inst DOr Pesquisa & Ensino IDOR, Rio De Janeiro, Brazil; [Araujo, Leonardo J. T.] Adolfo Lutz Inst, Ctr Pathol, Lab Quantitat Pathol, Sao Paulo, Brazil; [Bastos, Leonardo S.] Fundacao Oswaldo Cruz, Programa Comp Cient, Rio De Janeiro, Brazil; [Buss, Lewis F.; Costa, Silvia F.; Levin, Anna S.; Sabino, Ester C.; Faria, Nuno R.] Univ Sao Paulo, Dept Molestias Infecciosas & Parasitarias, Fac Med, Sao Paulo, Brazil; [Buss, Lewis F.; Costa, Silvia F.; Levin, Anna S.; Sabino, Ester C.; Faria, Nuno R.] Univ Sao Paulo, Inst Med Trop, Fac Med, Sao Paulo, Brazil; [Candido, Darlan; Dye, Christopher; Gutierrez, Bernardo; Faria, Nuno R.] Univ Oxford, Dept Zool, Oxford, England; [Castro, Marcia C.] Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA USA; [Croda, Julio] Yale Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT USA; [de Souza Santos, Andreza Aruska] Univ Oxford, Latin Amer Ctr, Oxford, England; [Flaxman, Seth] Univ Oxford, Dept Comp Sci, Oxford, England; [Lemey, Philippe] Univ Leuven, Rega Inst, Dept Microbiol Immunol & Transplantat, KU Leuven, Leuven, Belgium; [Mishra, Swapnil; Bhatt, Samir] Univ Copenhagen, Sch Publ Hlth, Sect Epidemiol, Copenhagen, Denmark; [Moreira, Filipe R. R.] Univ Fed Rio de Janeiro, Inst Biol, Dept Genet, Rio De Janeiro, Brazil; [Nelson, Bruce] Natl Inst Amazon Res, INPA, Environm Dynam, Manaus, Amazonas, Brazil; [Ranzani, Otavio] ISGlobal, Barcelona Inst Global Hlth, Barcelona, Spain; [Schnekenberg, Ricardo P.] Univ Oxford, Nuffield Dept Clin Neurosci, Oxford, England; [Faria, Nuno R.] Imperial Coll London, Dept Infect Dis Epidemiol, London, England	Imperial College London; Imperial College London; Instituto de Pesquisa Economica Aplicada (IPEA); Universidade de Sao Paulo; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Universidade Federal de Minas Gerais; IDOR - Instituto D'Or de Ensino e Pesquisa; Instituto Adolfo Lutz; Fundacao Oswaldo Cruz; Universidade de Sao Paulo; Universidade de Sao Paulo; University of Oxford; Harvard University; Harvard T.H. Chan School of Public Health; Yale University; University of Oxford; University of Oxford; KU Leuven; University of Copenhagen; Universidade Federal do Rio de Janeiro; Institute Nacional de Pesquisas da Amazonia; ISGlobal; University of Oxford; Imperial College London	Ratmann, O (corresponding author), Imperial Coll London, Dept Math, London, England.; Faria, NR; Bhatt, S (corresponding author), Imperial Coll London, MRC Ctr Global Infect Dis Anal, Sch Publ Hlth, Jameel Inst, London, England.; Sabino, EC; Faria, NR (corresponding author), Univ Sao Paulo, Dept Molestias Infecciosas & Parasitarias, Fac Med, Sao Paulo, Brazil.; Sabino, EC; Faria, NR (corresponding author), Univ Sao Paulo, Inst Med Trop, Fac Med, Sao Paulo, Brazil.; Faria, NR (corresponding author), Univ Oxford, Dept Zool, Oxford, England.; Bhatt, S (corresponding author), Univ Copenhagen, Sch Publ Hlth, Sect Epidemiol, Copenhagen, Denmark.; Faria, NR (corresponding author), Imperial Coll London, Dept Infect Dis Epidemiol, London, England.	sabinoec@usp.br; n.faria@imperial.ac.uk; s.bhatt@imperial.ac.uk; oratmann@gmail.com	Souza, Renan Pedra de/G-8394-2011; de Souza, William Marciel/D-3044-2017; Ranzani, Otavio T./K-1196-2012; Nelson, Bruce/G-4562-2013; Sabino, Ester C/F-7750-2010; Araujo, Leonardo/A-9733-2016	Souza, Renan Pedra de/0000-0002-9479-4432; de Souza, William Marciel/0000-0002-0025-8293; Ranzani, Otavio T./0000-0002-4677-6862; Nelson, Bruce/0000-0002-0488-6895; Sabino, Ester C/0000-0003-2623-5126; Semenova, Elizaveta/0000-0002-8271-2575; de Souza Santos, Andreza Aruska/0000-0003-3585-8683; Brizzi, Andrea/0000-0002-5639-8260; Hawryluk, Iwona/0000-0001-6919-4366; Geddes, Victor/0000-0002-0723-3873; Blenkinsop, Alexandra/0000-0002-2328-8671; Ratmann, Oliver/0000-0001-8667-4118; Bastos, Leonardo/0000-0002-1406-0122; Fonseca, Paula/0000-0002-8103-9235; Whittaker, Charles/0000-0002-5003-2575; Araujo, Leonardo/0000-0002-5427-4053	Medical Research Council-Sao Paulo Research Foundation (FAPESP) [MR/S0195/1, FAPESP18/143890]; Bill & Melinda Gates Foundation [OPP1175094]; EPSRC through the EPSRC Centre for Doctoral Training in Modern Statistics and Statistical Machine Learning at Imperial [EP/S023151/1]; MRC Centre for Global Infectious Disease Analysis [MR/R015600/1]; UK Medical Reseach Council (MRC); UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement; European Union; Rede Coronaomica BR MCTI/FINEP [01.20.0029.000462/20]; CNPq [310627/2018-4]; MEC/CAPES [14/2020 - 23072.211119/2020-10]; FINEP [0494/20 01.20.0026.00]; UK Research and Innovation [MR/V038109/1]; MRC [MR/R015600/1]; Novo Nordisk Young Investigator Award [NNF20OC0059309]; Danish National Research Foundation; Inova Fiocruz [48401485034116]; Clarendon Fund; University of Oxford Department of Zoology and Merton College; Wellcome Trust; Royal Society (Sir Henry Dale Fellowship) [204311/Z/16/Z]; EPSRC [EP/V002910/2]; FAPESP [2019/21858-0]; Fundacao Faculdade de Medicina and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior Brasil (CAPES); Instituto de Salud Carlos III (Sara Borrell fellowship) [CD19/00110]; Spanish Ministry of Science and Innovation and State Research Agency through the 'Centro de Excelencia Severo Ochoa [CEX2018-000806-S]; 'Generalitat de Catalunya' through the CERCA program; Medical Research Council [MR/V038109/1]; FAPEMIG [APQ-00475-20]; Global Virus Network Fellowship; National Institutes of Health [AI12094]; Medical Research Council (Doctoral Training Partnership Studentship) [1975152]; European Research Council [725422]	Medical Research Council-Sao Paulo Research Foundation (FAPESP)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); EPSRC through the EPSRC Centre for Doctoral Training in Modern Statistics and Statistical Machine Learning at Imperial(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); MRC Centre for Global Infectious Disease Analysis(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK Medical Reseach Council (MRC); UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Union(European Commission); Rede Coronaomica BR MCTI/FINEP; CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); MEC/CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); FINEP(Financiadora de Inovacao e Pesquisa (Finep)); UK Research and Innovation(UK Research & Innovation (UKRI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Novo Nordisk Young Investigator Award; Danish National Research Foundation(Danmarks Grundforskningsfond); Inova Fiocruz; Clarendon Fund; University of Oxford Department of Zoology and Merton College; Wellcome Trust(Wellcome Trust); Royal Society (Sir Henry Dale Fellowship)(Royal Society of London); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Fundacao Faculdade de Medicina and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior Brasil (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Instituto de Salud Carlos III (Sara Borrell fellowship); Spanish Ministry of Science and Innovation and State Research Agency through the 'Centro de Excelencia Severo Ochoa(Ministry of Science and Innovation, Spain (MICINN)); 'Generalitat de Catalunya' through the CERCA program; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); FAPEMIG(Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)); Global Virus Network Fellowship; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Research Council (Doctoral Training Partnership Studentship)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Research Council(European Research Council (ERC)European Commission)	We thank all contributors to GISAID for making SARS-CoV-2 sequence data and metadata publicly available, as listed in Methods; all contributors to Rede Genomica Fiocruz for making SARS-CoV-2 variant frequency data publicly available; all members of the CADDE network for their comments throughout the project and earlier versions of the manuscript; O. G. Pybus, A. Rambaut and J. T. McCrone for their insightful comments on SARS-CoV-2 phylogenetic analyses; and the Imperial College Research Computing Service (https://doi.org/10.14469/hpc/2232) for providing the computational resources to perform this study. This study was supported by the Medical Research Council-Sao Paulo Research Foundation (FAPESP) CADDE partnership award (MR/S0195/1 and FAPESP18/143890) (https://caddecentre.org), the Bill & Melinda Gates Foundation (INV-034540 and INV-034652) and the EPSRC through the EPSRC Centre for Doctoral Training in Modern Statistics and Statistical Machine Learning at Imperial and Oxford (EP/S023151/1). The authors acknowledge funding from the MRC Centre for Global Infectious Disease Analysis (MR/R015600/1), jointly funded by the UK Medical Reseach Council (MRC) and the UK Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement, and also part of the EDCTP2 programme supported by the European Union. R.S.A. acknowledges support from the Rede Coronaomica BR MCTI/FINEP affiliated to RedeVirus/MCTI (FINEP 01.20.0029.000462/20, CNPq 404096/20204), from CNPq (312688/2017-2 and 439119/2018-9), from MEC/CAPES (14/2020 -23072.211119/2020-10) and from FINEP (0494/20 01.20.0026.00). S.B. acknowledges support from UK Research and Innovation (MR/V038109/1), the MRC (MR/R015600/1), the Novo Nordisk Young Investigator Award (NNF20OC0059309), the Danish National Research Foundation via a chair position and the NIHR Health Protection Research Unit in Modelling Methodology. L.S.B. acknowledges support from Inova Fiocruz (48401485034116). D.S.C. acknowledges support from the Clarendon Fund, the University of Oxford Department of Zoology and Merton College. N.R.F. acknowledges support from the Wellcome Trust and the Royal Society (Sir Henry Dale Fellowship. 204311/Z/16/Z). S.F. acknowledges support from the EPSRC (EP/V002910/2). C.A.P. acknowledges support from FAPESP (2019/21858-0) and Fundacao Faculdade de Medicina and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior Brasil (CAPES). O.T.R. acknowledges support from the Instituto de Salud Carlos III (Sara Borrell fellowship, CD19/00110), from the Spanish Ministry of Science and Innovation and State Research Agency through the 'Centro de Excelencia Severo Ochoa 2019-2023' program (CEX2018-000806-S) and from the 'Generalitat de Catalunya' through the CERCA program. O.R. acknowledges support from the Bill & Melinda Gates Foundation (OPP1175094) and the Medical Research Council (MR/V038109/1). R.P.S. acknowledges support from the Rede Coronaomica BR MCTI/FINEP affiliated with RedeVirus/MCTI (FINEP 01.20.0029.000462/20 and CNPq 404096/2020-4), from CNPq (310627/2018-4), from MEC/CAPES (14/2020 - 23072.211119/2020-10), from FINEP (0494/20 01.20.0026.00) and from FAPEMIG (APQ-00475-20). W.M.S. acknowledges support from the Global Virus Network Fellowship and the National Institutes of Health (AI12094). C.W. acknowledges support from the Medical Research Council (Doctoral Training Partnership Studentship 1975152). P.L. acknowledges support from the European Research Council (grant 725422).	Andrade RD, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3032; [Anonymous], 2020, SRAG 2020 BANCO DADO; [Anonymous], 2020, PESQUISA NACL AMOSTR; [Anonymous], 2021, SRAG 2021 2022 BANCO; [Anonymous], ARTIC NETWORK FIELDB; [Anonymous], 2021, GENOMIC SEQUENCING S; [Anonymous], 2020, RESOLUTION 2 271 FEB; Baum F, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n91; Brazeau N, 2020, COVID 19 INFECT FATA, DOI [10.25561/83545, DOI 10.25561/83545]; Cadastro Nacional de Estabelecimentos de Sade, DATASUS; Carpenter B, 2017, J STAT SOFTW, V76, P1, DOI 10.18637/jss.v076.i01; Castro MC, 2021, NAT MED, V27, P1629, DOI 10.1038/s41591-021-01437-z; Castro MC, 2021, SCIENCE, V372, P821, DOI 10.1126/science.abh1558; Castro MC, 2019, LANCET, V394, P345, DOI 10.1016/S0140-6736(19)31243-7; Clark A, 2020, LANCET GLOB HEALTH, V8, P1003, DOI 10.1016/S2214-109X(20)30264-3; Clemens SAC, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25982-w; Davies NG, 2021, NATURE, V593, P270, DOI [10.1038/s41586-021-03426-1, 10.1101/2021.02.01.21250959]; Davies Nicholas G, 2021, Science, V372, DOI 10.1126/science.abg3055; de Albuquerque MV, 2020, CAD SAUDE PUBLICA, V36, DOI [10.1590/0102-311X00208720, 10.1590/0102-311x00208720]; de Oliveira M. H. S., 2021, PREPRINT, DOI [10.1101/2021.03.24.21254046(2021, DOI 10.1101/2021.03.24.21254046(2021]; Santos AAD, 2021, SCI DATA, V8, DOI 10.1038/s41597-021-00859-1; de Souza WM, 2020, NAT HUM BEHAV, V4, P856, DOI 10.1038/s41562-020-0928-4; Didelot X, 2021, MOL BIOL EVOL, V38, P307, DOI 10.1093/molbev/msaa193; du Plessis L, 2021, SCIENCE, V371, P708, DOI 10.1126/science.abf2946; Dyer O, 2021, BMJ-BRIT MED J, V375, DOI 10.1136/bmj.n3013; Faria NR, 2021, SCIENCE, V372, P815, DOI [10.1126/science.abh2644, 10.1101/2021.02.26.21252554, 10.1126/science.abh2644Article]; Fellows M, 2021, FRONT PSYCHIATRY, V12, DOI 10.3389/fpsyt.2021.638359; Freitas ARR, 2021, LANCET REG HLTH AM, V1, DOI 10.1016/j.lana.2021.100021; Fujino T, 2021, EMERG INFECT DIS, V27, P1243, DOI 10.3201/eid2704.210138; Funcia FR, 2019, CIENC SAUDE COLETIVA, V24, P4405, DOI 10.1590/1413-812320182412.25892019; Grint DJ, 2022, CLIN INFECT DIS, V75, pE1120, DOI 10.1093/cid/ciab754; Gutierrez B, 2021, VIRUS EVOL, V7, DOI 10.1093/ve/veab051; Haldane V, 2021, NAT MED, V27, P964, DOI 10.1038/s41591-021-01381-y; Harvey WT, 2021, NAT REV MICROBIOL, V19, P409, DOI 10.1038/s41579-021-00573-0; HASEGAWA M, 1985, J MOL EVOL, V22, P160, DOI 10.1007/BF02101694; Rocha TAH, 2018, CIENC SAUDE COLETIVA, V23, P229, DOI 10.1590/1413-81232018231.16672015; Hiam L, 2021, LANCET, V398, P646, DOI 10.1016/S0140-6736(21)01650-0; Hill V, 2019, MOL BIOL EVOL, V36, P2620, DOI 10.1093/molbev/msz172; Hoffman MD, 2014, J MACH LEARN RES, V15, P1593; JodoEduardo M., 2021, INFORM SOFTWARE TECH, V131; Jukes T., 1969, MAMMALIAN PROTEIN ME, P21; Kadri SS, 2021, ANN INTERN MED, V174, P1240, DOI 10.7326/M21-1213; Katoh Kazutaka, 2013, Mol Biol Evol, V30, P772, DOI 10.1093/molbev/mst010; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Lal A, 2021, LANCET, V397, P61, DOI 10.1016/S0140-6736(20)32228-5; Leite SN, 2021, CIENC SAUDE COLETIVA, V26, P1873, DOI 10.1590/1413-81232021265.01252021; Lemey P, 2021, NATURE, V595, P713, DOI 10.1038/s41586-021-03754-2; Lemey P, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000520; Li SL, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2021-004959; Lytras T, 2022, SCAND J PUBLIC HEALT, V50, P671, DOI 10.1177/14034948211059968; Machado FR, 2017, LANCET INFECT DIS, V17, P1180, DOI 10.1016/S1473-3099(17)30322-5; Madhi SA, 2021, NEW ENGL J MED, V384, P1885, DOI 10.1056/NEJMoa2102214; Malta M, 2021, ECLINICALMEDICINE, V32, DOI 10.1016/j.eclinm.2021.100757; Martins AF, 2021, EUROSURVEILLANCE, V26, P8, DOI 10.2807/1560-7917.ES.2021.26.12.2100276; Mendes Áquilas, 2018, Saúde debate, V42, P224, DOI 10.1590/0103-11042018s115; Noronha KVMD, 2020, CAD SAUDE PUBLICA, V36, DOI 10.1590/0102-311X00115320; Minh BQ, 2020, MOL BIOL EVOL, V37, P1530, DOI 10.1093/molbev/msaa015; Minin VN, 2008, PHILOS T R SOC B, V363, P3985, DOI 10.1098/rstb.2008.0176; Minin VN, 2008, J MATH BIOL, V56, P391, DOI 10.1007/s00285-007-0120-8; Naveca FG, 2021, NAT MED, V27, P1230, DOI 10.1038/s41591-021-01378-7; Nicolelis MAL, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-92263-3; O'Brien JD, 2009, MOL BIOL EVOL, V26, P801, DOI 10.1093/molbev/msp003; OToole A, 2022, PANGOLIN COVID 19 LI; Pereira RHM, 2021, SOC SCI MED, V273, DOI 10.1016/j.socscimed.2021.113773; Rambaut A, 2020, NAT MICROBIOL, V5, P1403, DOI 10.1038/s41564-020-0770-5; Rambaut A, 2018, SYST BIOL, V67, P901, DOI 10.1093/sysbio/syy032; Rambaut A, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew007; Ranzani O. T., BMJ, V374, pn2016; Ranzani OT, 2021, LANCET RESP MED, V9, P407, DOI 10.1016/S2213-2600(20)30560-9; Rocha R, 2021, LANCET GLOB HEALTH, V9, pE782, DOI 10.1016/S2214-109X(21)00081-4; Rossman H, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22214-z; S. Bhatt, 2021, medRxiv, DOI 10.1101/2021.08.21.21262393; Sheikh A, 2021, LANCET, V397, P2461, DOI 10.1016/S0140-6736(21)01358-1; Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494; Sirleaf EJ, 2021, LANCET, V398, P101, DOI 10.1016/S0140-6736(21)01095-3; Souza WM, 2021, LANCET MICROBE, V2, pE527, DOI 10.1016/S2666-5247(21)00129-4; Suchard MA, 2018, VIRUS EVOL, V4, DOI 10.1093/ve/vey016; Tegally H, 2021, NATURE, V592, P438, DOI 10.1038/s41586-021-03402-9; Silva LVE, 2020, J MED INTERNET RES, V22, DOI 10.2196/21413; Volz EM, 2017, VIRUS EVOL, V3, DOI 10.1093/ve/vex025; Volz E, 2021, NATURE, V593, P266, DOI 10.1038/s41586-021-03470-x; Voysey M, 2021, LANCET, V397, P881, DOI 10.1016/S0140-6736(21)00432-3; Walker PGT, 2020, SCIENCE, V369, P413, DOI 10.1126/science.abc0035	83	4	4	2	7	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2022	28	7					1476	+		10.1038/s41591-022-01807-1	http://dx.doi.org/10.1038/s41591-022-01807-1		MAY 2022	31	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3E5PS	35538260	Green Published, hybrid			2022-12-27	WOS:000793025400002
J	Qi, CS; Gong, JF; Li, J; Liu, D; Qin, YR; Ge, S; Zhang, M; Peng, Z; Zhou, J; Cao, YS; Zhang, XT; Lu, ZH; Lu, M; Yuan, JJ; Wang, ZH; Wang, YK; Peng, XH; Gao, HP; Liu, Z; Wang, HM; Yuan, DJ; Xiao, J; Ma, H; Wang, W; Li, ZH; Shen, L				Qi, Changsong; Gong, Jifang; Li, Jian; Liu, Dan; Qin, Yanru; Ge, Sai; Zhang, Miao; Peng, Zhi; Zhou, Jun; Cao, Yanshuo; Zhang, Xiaotian; Lu, Zhihao; Lu, Ming; Yuan, Jiajia; Wang, Zhenghang; Wang, Yakun; Peng, Xiaohui; Gao, Huiping; Liu, Zhen; Wang, Huamao; Yuan, Daijing; Xiao, Jun; Ma, Hong; Wang, Wei; Li, Zonghai; Shen, Lin			Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results	NATURE MEDICINE			English	Article							NAB-PACLITAXEL; DOUBLE-BLIND; THERAPY; CHEMOTHERAPY; ADENOCARCINOMA; MULTICENTER; RECURRENT; STOMACH	Despite success in hematologic malignancies, the treatment landscape of chimeric antigen receptor (CAR) T cell therapy for solid tumors remains limited. Claudin18.2 (CLDN18.2)-redirected CART cells showed promising efficacy against gastric cancer (GC) in a preclinical study. Here we report the interim analysis results of an ongoing, open-label, single-arm, phase 1 clinical trial of CLDN18.2-targeted CAR T cells (CT041) in patients with previously treated, CLDN18.2-positive digestive system cancers (NCT03874897). The primary objective was safety after CT041 infusion; secondary objectives included CT041 efficacy, pharmacokinetics and immunogenicity. We treated 37 patients with one of three CT041 doses: 2.5 x 10(8), 3.75 x 10(8) or 5.0 x 10(8) cells. All patients experienced a grade 3 or higher hematologic toxicity. Grade 1 or 2 cytokine release syndrome (CRS) occurred in 94.6% of patients. No grade 3 or higher CRS or neurotoxicities, treatment-related deaths or dose-limiting toxicities were reported. The overall response rate (ORR) and disease control rate (DCR) reached 48.6% and 73.0%, respectively. The 6-month duration of response rate was 44.8%. In patients with GC, the ORR and DCR reached 57.1% and 75.0%, respectively, and the 6-month overall survival rate was 81.2%. These initial results suggest that CT041 has promising efficacy with an acceptable safety profile in patients with heavily pretreated, CLDN18.2-positive digestive system cancers, particularly in those with GC.	[Qi, Changsong; Gong, Jifang; Li, Jian; Ge, Sai; Peng, Zhi; Shen, Lin] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Dept Gastrointestinal Oncol, Minist Educ, Beijing, Peoples R China; [Liu, Dan; Zhang, Miao; Wang, Yakun] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Early Drug Dev Ctr, Minist Educ, Beijing, Peoples R China; [Qin, Yanru] Zhengzhou Univ, Affiliated Hosp 1, Dept Oncol, Zhengzhou, Peoples R China; [Peng, Xiaohui; Gao, Huiping; Liu, Zhen; Wang, Huamao; Yuan, Daijing; Xiao, Jun; Ma, Hong; Wang, Wei] CARsgen Therapeut Co Ltd, Shanghai, Peoples R China	Zhengzhou University	Shen, L (corresponding author), Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Dept Gastrointestinal Oncol, Minist Educ, Beijing, Peoples R China.	shenlin@bjmu.edu.cn			CARsgen Therapeutics Co., Ltd.	CARsgen Therapeutics Co., Ltd.	This study was funded by CARsgen Therapeutics Co., Ltd. We acknowledge F. (X.) Zhang and C. Guo for their support with statistical output generation as well as Y. Li and A. Y. Hendrix for their support with manuscript revision. We thank Y. Wang for project management of this study.	Alvarez R, 2013, BRIT J CANCER, V109, P926, DOI 10.1038/bjc.2013.415; [Anonymous], 2022, NCCN GUID PANCR AD V; Badar T, 2020, CURR TREAT OPTION ON, V21, DOI 10.1007/s11864-020-0706-6; Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), 2019, GUID IND IMM TEST TH; Cheng JL, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01237; Corsaro B, 2021, BIOANALYSIS, V13, P415, DOI 10.4155/bio-2021-0007; Feng KC, 2018, PROTEIN CELL, V9, P838, DOI 10.1007/s13238-017-0440-4; Fitzgibbons PL, 2014, ARCH PATHOL LAB MED, V138, P1432, DOI 10.5858/arpa.2013-0610-CP; Fuchs CS, 2018, JAMA ONCOL, V4, DOI 10.1001/jamaoncol.2018.0013; Guo YL, 2018, CLIN CANCER RES, V24, P1277, DOI 10.1158/1078-0432.CCR-17-0432; Hong MH, 2020, CANCER CELL, V38, P473, DOI 10.1016/j.ccell.2020.07.005; Jain MD, 2019, BLOOD, V134, DOI 10.1182/blood-2019-129624; Jiang H, 2019, JNCI-J NATL CANCER I, V111, P409, DOI 10.1093/jnci/djy134; Jiang XJ, 2019, MOL CANCER, V18, DOI 10.1186/s12943-018-0928-4; Kang YK, 2017, LANCET, V390, P2461, DOI 10.1016/S0140-6736(17)31827-5; Keir ME, 2007, CURR OPIN IMMUNOL, V19, P309, DOI 10.1016/j.coi.2007.04.012; Lee DW, 2019, BIOL BLOOD MARROW TR, V25, P625, DOI 10.1016/j.bbmt.2018.12.758; Lee JH, 2018, ANN SURG, V267, P105, DOI 10.1097/SLA.0000000000002040; Li J, 2016, J CLIN ONCOL, V34, P1448, DOI 10.1200/JCO.2015.63.5995; Lin F, 2014, ARCH PATHOL LAB MED, V138, P1564, DOI 10.5858/arpa.2014-0074-RA; Liu Y, 2020, CYTOTHERAPY, V22, P573, DOI 10.1016/j.jcyt.2020.04.088; Locke FL, 2017, MOL THER, V25, P285, DOI 10.1016/j.ymthe.2016.10.020; Markman M, 2003, LANCET ONCOL, V4, P277, DOI 10.1016/S1470-2045(03)01074-X; Marofi F, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-020-02128-1; Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866; Michels T, 2012, J IMMUNOTOXICOL, V9, P292, DOI 10.3109/1547691X.2011.642418; Moentenich V, 2020, ONCOL LETT, V19, P3665, DOI 10.3892/ol.2020.11520; Munshi NC, 2021, NEW ENGL J MED, V384, P705, DOI 10.1056/NEJMoa2024850; Newick K, 2017, ANNU REV MED, V68, P139, DOI 10.1146/annurev-med-062315-120245; Pernot S, 2015, WORLD J GASTROENTERO, V21, P11428, DOI 10.3748/wjg.v21.i40.11428; Quintas-Cardama A, 2018, NEW ENGL J MED, V378, P1065, DOI 10.1056/NEJMc1800913; Rekik R, 2015, CELL MOL IMMUNOL, V12, P648, DOI 10.1038/cmi.2014.104; Rijken A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10214882; Sahin U, 2021, ANN ONCOL, V32, P609, DOI 10.1016/j.annonc.2021.02.005; Sasaki Y, 2014, CANCER SCI, V105, P812, DOI 10.1111/cas.12419; Schuster SJ, 2019, NEW ENGL J MED, V380, P45, DOI 10.1056/NEJMoa1804980; Shi M, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-09027-5; Shitara K, 2018, LANCET ONCOL, V19, P1437, DOI 10.1016/S1470-2045(18)30739-3; Tureci O, 2019, ANN ONCOL, V30, P1487, DOI 10.1093/annonc/mdz199; Von Hoff DD, 2011, J CLIN ONCOL, V29, P4548, DOI 10.1200/JCO.2011.36.5742; Yang TY, 2021, BIOANALYSIS, V13, P115, DOI 10.4155/bio-2020-0221; Zhan XB, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.2509	42	19	19	26	37	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2022	28	6					1189	+		10.1038/s41591-022-01800-8	http://dx.doi.org/10.1038/s41591-022-01800-8		MAY 2022	25	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E9IE	35534566	Green Published, hybrid			2022-12-27	WOS:000792548400002
J	Kim, ES; Velcheti, V; Mekhail, T; Yun, C; Shagan, SM; Hu, S; Chaes, YK; Leal, TA; Dowell, JE; Tsai, ML; Dakhil, CSR; Stella, P; Jin, YL; Shames, DS; Schleifman, E; Fabrizio, DA; Phan, S; Socinski, MA				Kim, Edward S.; Velcheti, Vamsidhar; Mekhail, Tarek; Yun, Cindy; Shagan, Sarah M.; Hu, Sylvia; Chaes, Young Kwang; Leal, Ticiana A.; Dowell, Jonathan E.; Tsai, Michaela L.; Dakhil, Christopher S. R.; Stella, Philip; Jin, Yanling; Shames, David S.; Schleifman, Erica; Fabrizio, David A.; Phan, See; Socinski, Mark A.			Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial	NATURE MEDICINE			English	Article							HETEROGENEITY; CHALLENGES; 1L	Tumor mutational burden (TMB) in circulating tumor DNA (ctDNA) has shown promise in predicting benefit from PD-L1/PD-1 inhibitors in retrospective studies. Aiming to assess blood TMB (bTMB) prospectively, we conducted B-F1RST (NCT02848651), an open-label, phase 2 trial that evaluated bTMB as a predictive biomarker for first-line atezolizumab monotherapy in locally advanced or metastatic stage IIIB-IVB non-small cell lung cancer (n = 152). The co-primary endpoints were investigator-assessed objective response rate (ORR) per RECIST version 1.1 and investigator-assessed progression-free survival (PFS) between high and low bTMB subgroups at the pre-defined bTMB >= 16 (14.5 mutations per megabase) cutoff. Secondary endpoints included investigator-assessed PFS, overall survival (OS) and duration of response at various bTMB cutoffs, as well as safety. Investigator-assessed PFS in the bTMB >= 16 versus bTMB < 16 groups was not statistically significant. However, bTMB >= 16 was associated with higher ORR, and ORR improved as bTMB cutoffs increased. No new safety signals were seen. In exploratory analyses, patients with maximum somatic allele frequency (MSAF) < 1% had higher ORR than patients with MSAF >= 1%. However, further analysis showed that this effect was driven by better baseline prognostics rather than by MSAF itself. At 36.5-month follow-up, an exploratory analysis of OS found that bTMB >= 16 was associated with longer OS than bTMB < 16. Further study and assay optimization will be required to develop bTMB as a predictive, standalone biomarker of immunotherapy or for use in conjunction with other biomarkers.	[Kim, Edward S.] City Hope Natl Med Ctr, Los Angeles, CA USA; [Velcheti, Vamsidhar] Cleveland Clin, Cleveland, OH 44106 USA; [Mekhail, Tarek; Socinski, Mark A.] AdventHlth Canc Inst, Orlando, FL USA; [Yun, Cindy; Shagan, Sarah M.; Hu, Sylvia; Shames, David S.; Schleifman, Erica; Phan, See] Genentech Inc, San Francisco, CA 94080 USA; [Chaes, Young Kwang] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Leal, Ticiana A.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA; [Dowell, Jonathan E.] Univ Texas Southwestern Med Ctr Dallas, Vet Affairs North Texas Healthcare Syst, Dept Med, Dallas, TX 75390 USA; [Tsai, Michaela L.] Minneapolis Clin, Minnesota Oncol, Minneapolis, MN USA; [Dakhil, Christopher S. R.] Canc Ctr Kansas, Wichita, KS USA; [Stella, Philip] St Joseph Mercy Hosp, Ann Arbor, MI 48104 USA; [Jin, Yanling] F Hoffmann La Roche, Mississauga, ON, Canada; [Fabrizio, David A.] Fdn Med Inc, Cambridge, MA USA; [Velcheti, Vamsidhar] NYU, Sch Med, New York, NY 10003 USA	City of Hope; Cleveland Clinic Foundation; Adventist Health Services; AdventHealth; Roche Holding; Genentech; Northwestern University; Feinberg School of Medicine; University of Wisconsin System; University of Wisconsin Madison; University of Texas System; University of Texas Southwestern Medical Center Dallas; Cancer Center of Kansas; Saint Joseph Mercy Health System (SJMHS); Roche Holding; Foundation Medicine; New York University	Velcheti, V (corresponding author), Cleveland Clin, Cleveland, OH 44106 USA.; Velcheti, V (corresponding author), NYU, Sch Med, New York, NY 10003 USA.	vamsidhar.velcheti@nyulangone.org						Borghaei H, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.9001; Cai WJ, 2015, J CLIN ONCOL, V33, P3701, DOI 10.1200/JCO.2014.58.8293; Carbone DP, 2017, NEW ENGL J MED, V376, P2415, DOI 10.1056/NEJMoa1613493; Carter GC, 2014, CANCER MANAG RES, V6, P437, DOI 10.2147/CMAR.S63603; Dziadziuszko R, 2021, ANN ONCOL, V32, pS950, DOI 10.1016/j.annonc.2021.08.1883; Gandara DR, 2018, NAT MED, V24, P1441, DOI 10.1038/s41591-018-0134-3; Goldberg SB, 2016, LANCET ONCOL, V17, P976, DOI 10.1016/S1470-2045(16)30053-5; Goodman AM, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00743-4; Hellmann MD, 2019, NEW ENGL J MED, V381, P2020, DOI 10.1056/NEJMoa1910231; Herbst RS, 2019, ANN ONCOL, V30, P916; Herbst RS, 2020, NEW ENGL J MED, V383, P1328, DOI 10.1056/NEJMoa1917346; Hirsch FR, 2008, J THORAC ONCOL, V3, P1468, DOI 10.1097/JTO.0b013e318189f551; Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288; Jardim DL, 2021, CANCER CELL, V39, P154, DOI 10.1016/j.ccell.2020.10.001; Kim ES., 2018, ANN ONCOL S8, V29, DOI 10.1093/annonc/mdy424.067; Kowanetz M, 2017, J THORAC ONCOL, V12, pS321, DOI 10.1016/j.jtho.2016.11.343; Lim C, 2015, ANN ONCOL, V26, P1415, DOI 10.1093/annonc/mdv208; Motta G, 1999, Ann Ital Chir, V70, P893; Nabet BY, 2020, CELL, V183, P363, DOI 10.1016/j.cell.2020.09.001; Peters S, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.AM2019-CT074; Raja R, 2018, CLIN CANCER RES, V24, P6212, DOI 10.1158/1078-0432.CCR-18-0386; Rizvi H, 2018, J CLIN ONCOL, V36, P633, DOI 10.1200/JCO.2017.75.3384; Rizvi NA, 2018, ANN ONCOL, V29; Sholl LM, 2020, J THORAC ONCOL, V15, P1409, DOI 10.1016/j.jtho.2020.05.019; Socinski MA, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.AM2019-CT194; Turajlic S, 2017, LANCET ONCOL, V18, P1009, DOI 10.1016/S1470-2045(17)30516-8	26	12	12	5	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2022	28	5					939	+		10.1038/s41591-022-01754-x	http://dx.doi.org/10.1038/s41591-022-01754-x		APR 2022	16	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	1J3AM	35422531	hybrid, Green Published			2022-12-27	WOS:000782536200001
J	Brower, V				Brower, V			Insurers keep genetic test options open	NATURE BIOTECHNOLOGY			English	News Item																			0	0	0	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					708	709		10.1038/nbt0897-708	http://dx.doi.org/10.1038/nbt0897-708			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9333518				2022-12-27	WOS:A1997XM70700008
J	Miller, DD; Nayak, AR				Miller, DD; Nayak, AR			India: 50 years after independence	NATURE BIOTECHNOLOGY			English	Article											Miller, DD (corresponding author), GOLDEN TRIANGLE ORG INC,SAN DIEGO,CA, USA.								0	1	1	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					727	729		10.1038/nbt0897-727	http://dx.doi.org/10.1038/nbt0897-727			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255782	Bronze			2022-12-27	WOS:A1997XM70700019
J	Ohno, K; Sawai, K; Iijima, Y; Levin, B; Meruelo, D				Ohno, K; Sawai, K; Iijima, Y; Levin, B; Meruelo, D			Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A	NATURE BIOTECHNOLOGY			English	Article						gene therapy vector; alphavirus; targeting; protein A	RETROVIRAL VECTORS; EXPRESSION VECTORS; GENE-EXPRESSION; RECEPTOR; ANTIBODIES; NEUROVIRULENCE; PATHOGENESIS; GENERATION; MICE; RNA	Sindbis virus can infect a broad range of insect and vertebrate cell types due to the widespread distribution of the cellular receptor for the virus. The development of Sindbis virus vectors that target specific cell types could have important implications for the design of gene therapy strategies. To achieve this goal we have designed and constructed Sindbis virus particles displaying the IgG-binding domain of protein A. The protein A-envelope chimeric Sindbis virus vector has minimal infectivities against baby hamster kidney and human cell lines. When used in conjunction with monoclonal antibodies that react with cell-surface antigens, however, the protein A-envelope chimeric virus was able to infect human cell lines with high efficiency. Infection rates were 90% or higher for human lymphoblastoid cells. A variety of cells could be targeted by changing the monoclonal antibody without generating a new recombinant virus.	NYU,MED CTR,DEPT PATHOL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University					NCI NIH HHS [CA68498, CA22247] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA022247, R01CA068498, R01CA022247] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BREDENBEEK PJ, 1993, J VIROL, V67, P6439, DOI 10.1128/JVI.67.11.6439-6446.1993; BREDENBEEK PJ, 1992, SEMIN VIROL, V3, P297; Douglas JT, 1996, NAT BIOTECHNOL, V14, P1574, DOI 10.1038/nbt1196-1574; DUBUISSON J, 1993, J VIROL, V67, P3363, DOI 10.1128/JVI.67.6.3363-3374.1993; FIERING SN, 1991, CYTOMETRY, V12, P291, DOI 10.1002/cyto.990120402; KASAHARA N, 1994, SCIENCE, V266, P1373, DOI 10.1126/science.7973726; LEVINE B, 1993, NATURE, V361, P739, DOI 10.1038/361739a0; LEVINE B, 1992, J VIROL, V66, P6429, DOI 10.1128/JVI.66.11.6429-6435.1992; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; LOWENADLER B, 1987, GENE, V58, P87, DOI 10.1016/0378-1119(87)90032-1; LUSTIG S, 1988, J VIROL, V62, P2329, DOI 10.1128/JVI.62.7.2329-2336.1988; Marin M, 1996, J VIROL, V70, P2957, DOI 10.1128/JVI.70.5.2957-2962.1996; NILSSON B, 1987, PROTEIN ENG, V1, P107, DOI 10.1093/protein/1.2.107; OLMSTED RA, 1986, VIROLOGY, V148, P245, DOI 10.1016/0042-6822(86)90322-3; POLO JM, 1988, J VIROL, V62, P2124, DOI 10.1128/JVI.62.6.2124-2133.1988; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; RUSSELL SJ, 1993, NUCLEIC ACIDS RES, V21, P1081, DOI 10.1093/nar/21.5.1081; SOMIA NV, 1995, P NATL ACAD SCI USA, V92, P7570, DOI 10.1073/pnas.92.16.7570; STANLEY J, 1985, J VIROL, V56, P110, DOI 10.1128/JVI.56.1.110-119.1985; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; SURCLIA A, 1982, TRENDS BIOCHEM SCI, V7, P74; UBOL S, 1991, J VIROL, V65, P6913, DOI 10.1128/JVI.65.12.6913-6921.1991; WANG KS, 1991, VIROLOGY, V181, P694, DOI 10.1016/0042-6822(91)90903-O; WANG KS, 1992, J VIROL, V66, P4992, DOI 10.1128/JVI.66.8.4992-5001.1992; XIONG C, 1989, SCIENCE, V243, P1188, DOI 10.1126/science.2922607	25	133	166	0	5	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					763	767		10.1038/nbt0897-763	http://dx.doi.org/10.1038/nbt0897-763			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255791				2022-12-27	WOS:A1997XM70700028
J	Gutterman, JU				Gutterman, JU			Clinical investigators: The driving force behind drug discovery	NATURE BIOTECHNOLOGY			English	Editorial Material							BIOMEDICAL-RESEARCH; INTERFERON; ALPHA				Gutterman, JU (corresponding author), UNIV TEXAS, MD ANDERSON CANC CTR, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA.							AHRENS EH, 1992, CIRSIS CLIN RES OVER; Axelrod R., 1984, EVOLUTION COOPERATIO, DOI DOI 10.2307/3323905; Belardelli F, 1996, IMMUNOL TODAY, V17, P369, DOI 10.1016/0167-5699(96)10027-X; BENNIS WG, 1997, ORGANIZING GENIUS SE; BURCH GE, 1976, AM HEART J, V92, P681, DOI 10.1016/S0002-8703(76)80002-6; Cockburn I, 1996, P NATL ACAD SCI USA, V93, P12725, DOI 10.1073/pnas.93.23.12725; *COMM SCI ENG PUBL, 1992, GOVT ROLE CIVILIAN T; COMROE JH, 1976, SCIENCE, V192, P105, DOI 10.1126/science.769161; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Flowers CR, 1997, NAT MED, V3, P136, DOI 10.1038/nm0297-136; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; KELLEY WN, 1994, CAREERS CLIN RES; Kirkwood JM, 1996, J CLIN ONCOL, V14, P7, DOI 10.1200/JCO.1996.14.1.7; KIRSCHNER MW, 1994, SCIENCE, V266, P49, DOI 10.1126/science.7939643; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; LEDERBERG J, 1989, CURR CONTENTS, V48, P4; LOLL PJ, 1995, NAT STRUCT BIOL, V2, P637, DOI 10.1038/nsb0895-637; LUCKY R, 1990, B MOYERS WORLD IDEAS, P201; Mitchison TJ, 1994, CHEM BIOL, V1, P3, DOI 10.1016/1074-5521(94)90034-5; POLANYI J, 1995, COMMUNICATION   0425; QUESADA JR, 1984, NEW ENGL J MED, V310, P15, DOI 10.1056/NEJM198401053100104; Senge P. M., 1999, 5 DISCIPLINE ART PRA; STROHMAN RC, 1997, NAT BIOTECHNOL, V15, P197; Thayer A, 1996, CHEM ENG NEWS, V74, P13, DOI 10.1021/cen-v074n016.p013; TORFGARD KE, 1994, CARDIOVASC DRUG THER, V8, P701, DOI 10.1007/BF00877117; VAGELOS PR, 1991, SCIENCE, V252, P1080, DOI 10.1126/science.252.5009.1080; VARMUS H, 1995, NEW ENGL J MED, V333, P811, DOI 10.1056/NEJM199509213331224; WEISBROD BA, 1994, MED INN CR, V4, P8	28	4	4	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1997	15	7					598	599		10.1038/nbt0797-598	http://dx.doi.org/10.1038/nbt0797-598			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XH583	9219248				2022-12-27	WOS:A1997XH58300003
J	Pasqualini, R; Koivunen, E; Ruoslahti, E				Pasqualini, R; Koivunen, E; Ruoslahti, E			alpha v Integrins as receptors for tumor targeting by circulating ligands	NATURE BIOTECHNOLOGY			English	Article						phage display; tumor targeting; RGD; angiogenesis; integrins	ENDOTHELIAL-CELLS; CANCER-THERAPY; SOLID TUMORS; ANGIOGENESIS; METASTASIS; ALPHA(V)BETA(3); GLYCOPROTEIN; VASCULATURE; ANTIBODIES; GROWTH	Phage displaying an Arg-Gly-Asp (RGD)-containing peptide with a high affinity for av integrins homed to tumors when injected intravenously into tumor-bearing mice. A substantially higher amount of av-directed RGD phage than control phage was recovered from malignant melanomas and breast carcinoma. Antibodies detected the av-directed RGD phage in tumor blood vessels, but not in several normal tissues. These results show that the alpha v integrins present in tumor blood vessels can bind circulating ligands and that RGD peptides selective for these integrins may be suitable tools in tumor targeting for diagnostic and therapeutic purposes.	UNIV HELSINKI, DEPT BIOSCI, DIV BIOCHEM, FIN-00014 HELSINKI, FINLAND	University of Helsinki	Pasqualini, R (corresponding author), BURNHAM INST, LA JOLLA CANC RES CTR, LA JOLLA, CA 92037 USA.			Koivunen, Erkki/0000-0002-6443-9595	NCI NIH HHS [CA 30199, CA 28896] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA030199, P01CA028896] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILLIE CT, 1995, BRIT J CANCER, V72, P257, DOI 10.1038/bjc.1995.323; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BUCKLE R, 1994, ANN ONCOL          S, V4, P45; BURROWS FJ, 1994, PHARMACOL THERAPEUT, V64, P155, DOI 10.1016/0163-7258(94)90037-X; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CONFORTI G, 1992, BLOOD, V80, P437; DVORAK HF, 1991, CANCER CELL-MON REV, V3, P77; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; GETER MR, 1973, NATURE, V246, P221; Goetz DJ, 1996, INT J CANCER, V65, P192, DOI 10.1002/(SICI)1097-0215(19960117)65:2<192::AID-IJC11>3.0.CO;2-G; Hammes HP, 1996, NAT MED, V2, P529, DOI 10.1038/nm0596-529; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; KOIVUNEN E, 1995, BIO-TECHNOL, V13, P265, DOI 10.1038/nbt0395-265; LAPPI DA, 1995, SEMIN CANCER BIOL, V6, P279, DOI 10.1006/scbi.1995.0036; MARTINYBARON G, 1995, CURR OPIN BIOTECH, V6, P675, DOI 10.1016/0958-1669(95)80111-1; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; NICOLSON GL, 1990, CANCER RES, V50, P515; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; PAULI BU, 1990, CANCER METAST REV, V9, P175, DOI 10.1007/BF00046359; PRICE JE, 1990, CANCER RES, V50, P717; RAK JW, 1995, ANTI-CANCER DRUG, V6, P3, DOI 10.1097/00001813-199502000-00001; RETTIG WJ, 1992, P NATL ACAD SCI USA, V89, P10832, DOI 10.1073/pnas.89.22.10832; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; SHOCKLEY TR, 1991, ANN NY ACAD SCI, V618, P367, DOI 10.1111/j.1749-6632.1991.tb27257.x; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; WELCH DR, 1991, INT J CANCER, V47, P227, DOI 10.1002/ijc.2910470211; ZETTER BR, 1990, NEW ENGL J MED, V322, P605	32	666	771	0	93	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1997	15	6					542	546		10.1038/nbt0697-542	http://dx.doi.org/10.1038/nbt0697-542			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XC772	9181576				2022-12-27	WOS:A1997XC77200029
J	Bialy, H				Bialy, H			Biotechnology, bioremediation, and blue genes	NATURE BIOTECHNOLOGY			English	Editorial Material							ESCHERICHIA-COLI; BIOSYNTHESIS; NAPHTHALENE; OXIDATION; INDIGO											BRESLOW R, 1996, CHEM ENG NEWS   0826; ENSLEY BD, 1982, J BACTERIOL, V149, P948, DOI 10.1128/JB.149.3.948-954.1982; ENSLEY BD, 1983, SCIENCE, V222, P167, DOI 10.1126/science.6353574; MURDOCK D, 1993, BIO-TECHNOL, V11, P381, DOI 10.1038/nbt0393-381	4	24	26	0	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1997	15	2					110	110		10.1038/nbt0297-110	http://dx.doi.org/10.1038/nbt0297-110			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WE998	9035117	Bronze			2022-12-27	WOS:A1997WE99800003
J	Lee, IM; Klopmeyer, M; Bartoszyk, IM; GundersenRindal, DE; Chou, TS; Thomson, KL; Eisenreich, R				Lee, IM; Klopmeyer, M; Bartoszyk, IM; GundersenRindal, DE; Chou, TS; Thomson, KL; Eisenreich, R			Phytoplasma induced free-branching in commercial poinsettia cultivars	NATURE BIOTECHNOLOGY			English	Article						phytoplasma; branching poinsettia; branching agent; poinsettia mosaic virus; nested-PCR	GRAFT-TRANSMISSIBLE AGENT; MYCOPLASMALIKE ORGANISMS	Free-branching poinsettia cultivars that produce numerous axillary shoots are essential for propagating desirable multi-flowered poinsettias (Euphorbia pulcherrima Wild. Klotz). For more than a decade, a biological agent has been suspected to cause free-branching in poinsettias. Attempts to identify the branching agent have failed. Isolation of the pathogen was accomplished using a living host and it was concluded that an unculturable phytoplasma is the cause of free-branching in poinsettias. This is the first reported example of a pathogenic phytoplasma as the causal agent of a desirable and economically important trait.	BALL FLORAPLANT,W CHICAGO,IL 60185		Lee, IM (corresponding author), ARS,MOL PLANT PATHOL LAB,USDA,BELTSVILLE,MD 20705, USA.							DOLE JM, 1991, J AM SOC HORTIC SCI, V116, P307, DOI 10.21273/JASHS.116.2.307; DOLE JM, 1992, J AM SOC HORTIC SCI, V117, P972, DOI 10.21273/JASHS.117.6.972; DOLE JM, 1993, CAN J BOT, V71, P1097, DOI 10.1139/b93-128; ECKE P, 1990, POINSETTA MANUAL; FULTON RW, 1980, PHYTOPATHOLOGY, V70, P321, DOI 10.1094/Phyto-70-321; GRIFFITHS HM, 1994, CAN J PLANT PATHOL, V16, P255, DOI 10.1080/07060669409500728; Gundersen D. E., 1996, Phytopathologia Mediterranea, V35, P144; KAPLAN JK, 1992, AGR RES, V12, P4; Koenig R., 1980, Plant Disease, V64, P782, DOI 10.1094/PD-64-782; KOENIG R, 1986, AAB DISCRIPTIONS PLA, V311; Lee I.-M., 1995, Phytopathology, V85, P1179; LEE IM, 1995, PHYTOPATHOLOGY, V85, P728, DOI 10.1094/Phyto-85-728; LEE IM, 1993, PHYTOPATHOLOGY, V83, P834, DOI 10.1094/Phyto-83-834; LEE IM, 1993, PHYTOPATHOLOGY, V83, P829, DOI 10.1094/Phyto-83-829; Lee Ing-Ming, 1992, P379; McCoy RE, 1989, MYCOPLASMAS, DOI DOI 10.1016/B978-0-12-078405-9.50019-7; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Preil W., 1988, Acta Horticulturae, P99; PREIL W, 1982, GARTENBAUWISSENSCHAF, V47, P241; RUIZSIFRE GV, 1993, THESIS OKLAHOMA STAT; STIMART DP, 1983, J AM SOC HORTIC SCI, V108, P419; *USDA, 1996, FLOR CORPS 1995 SUMM	22	53	59	0	23	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1997	15	2					178	182		10.1038/nbt0297-178	http://dx.doi.org/10.1038/nbt0297-178			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WE998	9035146				2022-12-27	WOS:A1997WE99800027
J	Liu, Y; Mounkes, LC; Liggitt, HD; Brown, CS; Solodin, I; Heath, TD; Debs, RJ				Liu, Y; Mounkes, LC; Liggitt, HD; Brown, CS; Solodin, I; Heath, TD; Debs, RJ			Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery	NATURE BIOTECHNOLOGY			English	Article						gene transfer; cationic liposomes; gene therapy	COLONY-STIMULATING FACTOR; CYSTIC-FIBROSIS; DNA-TRANSFECTION; CELLS; MICE; EXPRESSION; THERAPY; CHOLESTEROL; INVIVO; SERUM	We have characterized the relationships between the design of cationic liposomes as a gene transfer vehicle, their resulting biodistribution and processing in animals, and the level and sites of gene expression they produce. By redesigning conventional cationic liposomes, incorporating cholesterol (chol) as the neutral lipid and preparing them as multilamellar vesicles (MLV), we increased the efficiency of cationic liposome:DNA complex (CLDC)-mediated gene delivery, Expression of the luciferase gene increased up to 1,740-fold and of the human granulocyte-colony stimulating factor (hG-CSF) gene up to 569-fold due to prolonged circulation time of injected CLDC, and increased uptake and retention in tissues. The level of gene expression per microgram of DNA taken up per tissue was 1,000-fold higher in lung than in liver, indicating that in addition to issues of delivery and retention of injected DNA, tissue-specific host factors also play a central role in determining the efficiency of expression. Vascular endothelial cells, monocytes, and macrophages are the cell types most commonly transfected by intravenous injection of CLDC.	CALIF PACIFIC MED RES INST,SAN FRANCISCO,CA 94115; UNIV WASHINGTON,DEPT COMPARAT MED,SEATTLE,WA 98195; UNIV WISCONSIN,SCH PHARM,MADISON,WI 53706	California Pacific Medical Center; California Pacific Medical Center Research Institute; University of Washington; University of Washington Seattle; University of Wisconsin System; University of Wisconsin Madison					NCI NIH HHS [R01 CA58914] Funding Source: Medline; NIDDK NIH HHS [R01 DK49550, R01 DK45917] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049550, R01DK045917] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTON EWFW, 1993, NAT GENET, V5, P135, DOI 10.1038/ng1093-135; BENNETT MJ, 1995, BIOSCIENCE REP, V15, P47, DOI 10.1007/BF01200214; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRIGHAM KL, 1989, AM J MED SCI, V298, P278, DOI 10.1097/00000441-198910000-00013; CANONICO AE, 1994, J APPL PHYSIOL, V77, P415, DOI 10.1152/jappl.1994.77.1.415; CANONICO AE, 1994, AM J RESP CELL MOL, V10, P24, DOI 10.1165/ajrcmb.10.1.8292378; CAPLEN NJ, 1995, NAT MED, V1, P39, DOI 10.1038/nm0195-39; CONARY JT, 1994, J CLIN INVEST, V93, P1834, DOI 10.1172/JCI117169; DEBS RJ, 1987, AM REV RESPIR DIS, V135, P731; FASBENDER AJ, 1995, AM J PHYSIOL-LUNG C, V269, pL45, DOI 10.1152/ajplung.1995.269.1.L45; FELGNER JH, 1994, J BIOL CHEM, V269, P2550; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GERSHON H, 1993, BIOCHEMISTRY-US, V32, P71434; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; Hofland HEJ, 1996, P NATL ACAD SCI USA, V93, P7305, DOI 10.1073/pnas.93.14.7305; HYDE SC, 1993, NATURE, V362, P250, DOI 10.1038/362250a0; JIAO SS, 1992, EXP NEUROL, V115, P400, DOI 10.1016/0014-4886(92)90205-5; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KAWAKAMI M, 1990, BLOOD, V76, P1962; KNOWLES MR, 1995, NEW ENGL J MED, V333, P823, DOI 10.1056/NEJM199509283331302; KOZARSKY KF, 1994, J BIOL CHEM, V269, P13965; LESOONWOOD LA, 1995, HUM GENE THER, V6, P395, DOI 10.1089/hum.1995.6.4-395; LEVENTIS R, 1990, BIOCHIM BIOPHYS ACTA, V1023, P124, DOI 10.1016/0005-2736(90)90017-I; LIU Y, 1995, J BIOL CHEM, V270, P24864, DOI 10.1074/jbc.270.42.24864; LOGAN JJ, 1995, GENE THER, V2, P38; MAYHEW E, 1979, CANCER TREAT REP, V63, P1923; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P1130; PAUKSEN K, 1994, BRIT J HAEMATOL, V88, P256, DOI 10.1111/j.1365-2141.1994.tb05015.x; PETROS WP, 1992, PHARMACOTHERAPY, V12, pS32; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; Sambrook J., 2002, MOL CLONING LAB MANU; SENIOR J, 1982, LIFE SCI, V30, P2123, DOI 10.1016/0024-3205(82)90455-6; SOLODIN I, 1995, BIOCHEMISTRY-US, V34, P13537, DOI 10.1021/bi00041a033; SON K, 1994, P NATL ACAD SCI USA, V91, P12669, DOI 10.1073/pnas.91.26.12669; SORSCHER EJ, 1994, HUM GENE THER, V5, P1259, DOI 10.1089/hum.1994.5.10-1259; STERNBERG B, 1994, FEBS LETT, V356, P361, DOI 10.1016/0014-5793(94)01315-2; STEWART MJ, 1992, HUM GENE THER, V3, P267, DOI 10.1089/hum.1992.3.3-267; STRAUSS WM, 1993, SCIENCE, V259, P1904, DOI 10.1126/science.8096090; THIERRY AR, 1995, P NATL ACAD SCI USA, V92, P9742, DOI 10.1073/pnas.92.21.9742; WEIS J, 1991, J CELL BIOL, V113, P1385, DOI 10.1083/jcb.113.6.1385; Wheeler CJ, 1996, P NATL ACAD SCI USA, V93, P11454, DOI 10.1073/pnas.93.21.11454; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073	45	356	387	0	40	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1997	15	2					167	173		10.1038/nbt0297-167	http://dx.doi.org/10.1038/nbt0297-167			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WE998	9035144				2022-12-27	WOS:A1997WE99800025
J	Attia, ZI; Harmon, DM; Dugan, J; Manka, L; Lopez-Jimenez, F; Lerman, A; Siontis, KC; Noseworthy, PA; Yao, XX; Klavetter, EW; Halamka, JD; Asirvatham, SJ; Khan, R; Carter, RE; Leibovich, BC; Friedman, PA				Attia, Zachi I.; Harmon, David M.; Dugan, Jennifer; Manka, Lukas; Lopez-Jimenez, Francisco; Lerman, Amir; Siontis, Konstantinos C.; Noseworthy, Peter A.; Yao, Xiaoxi; Klavetter, Eric W.; Halamka, John D.; Asirvatham, Samuel J.; Khan, Rita; Carter, Rickey E.; Leibovich, Bradley C.; Friedman, Paul A.			Prospective evaluation of smartwatch-enabled detection of left ventricular dysfunction	NATURE MEDICINE			English	Article; Early Access							ARTIFICIAL-INTELLIGENCE; HEART-FAILURE; MYOCARDIAL-INFARCTION; ELECTROCARDIOGRAM; ALGORITHM; IMPACT; RISK	Although artificial intelligence (AI) algorithms have been shown to be capable of identifying cardiac dysfunction, defined as ejection fraction (EF) <= 40%, from 12-lead electrocardiograms (ECGs), identification of cardiac dysfunction using the single-lead ECG of a smartwatch has yet to be tested. In the present study, a prospective study in which patients of Mayo Clinic were invited by email to download a Mayo Clinic iPhone application that sends watch ECGs to a secure data platform, we examined patient engagement with the study app and the diagnostic utility of the ECGs. We digitally enrolled 2,454 unique patients (mean age 53 +/- 15 years, 56% female) from 46 US states and 11 countries, who sent 125,610 ECGs to the data platform between August 2021 and February 2022; 421 participants had at least one watch-classified sinus rhythm ECG within 30 d of an echocardiogram, of whom 16 (3.8%) had an EF <= 40%. The AI algorithm detected patients with low EF with an area under the curve of 0.885 (95% confidence interval 0.823-0.946) and 0.881 (0.815-0.947), using the mean prediction within a 30-d window or the closest ECG relative to the echocardiogram that determined the EF, respectively. These findings indicate that consumer watch ECGs, acquired in nonclinical environments, can be used to identify patients with cardiac dysfunction, a potentially life-threatening and often asymptomatic condition. In this proof-of-concept prospective study, single-lead electrocardiograms obtained by smartwatches were able to identify individuals with left ventricular dysfunction, potentially serving as an early warning system for heart failure.	[Attia, Zachi I.; Harmon, David M.; Dugan, Jennifer; Lopez-Jimenez, Francisco; Lerman, Amir; Siontis, Konstantinos C.; Noseworthy, Peter A.; Yao, Xiaoxi; Klavetter, Eric W.; Asirvatham, Samuel J.; Friedman, Paul A.] Mayo Clin, Dept Cardiovasc Med, Coll Med, Rochester, MN 55902 USA; [Harmon, David M.] Mayo Clin, Dept Internal Med, Sch Grad Med Educ, Rochester, MN USA; [Manka, Lukas; Khan, Rita; Leibovich, Bradley C.] Mayo Clin, Ctr Digital Hlth, Rochester, MN USA; [Yao, Xiaoxi] Mayo Clin, Robert D & Patricia E Kern Ctr Sci Hlth Care Deli, Rochester, MN USA; [Halamka, John D.] Mayo Clin, Mayo Clin Platform, Rochester, MN USA; [Carter, Rickey E.] Dept Quantitat Hlth Sci, Jacksonville, FL USA; [Leibovich, Bradley C.] Mayo Clin, Dept Urol, Coll Med, Rochester, MN USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Friedman, PA (corresponding author), Mayo Clin, Dept Cardiovasc Med, Coll Med, Rochester, MN 55902 USA.	friedman.paul@mayo.edu		Yao, Xiaoxi/0000-0001-9906-7106; Attia, Zachi/0000-0002-9706-7900; Lerman, Amir/0000-0002-9446-5313; Harmon, David/0000-0002-8102-3380	Ted and Loretta Rogers Cardiovascular Career Development Award Honoring H. C. Smith; Mayo Clinic CDH; Department of Cardiovascular Medicine; National Institutes of Health (NIH); National Institute on Aging [R01AG 062436-1]; Agency for Healthcare Research and Quality [R01HS 25402-3]; Food and Drug Administration (FDA) [FD 06292]; American Heart Association [18SFRN34230146]; NIH StARR Resident Investigator Award [5R38HL150086-02]	Ted and Loretta Rogers Cardiovascular Career Development Award Honoring H. C. Smith; Mayo Clinic CDH; Department of Cardiovascular Medicine; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Food and Drug Administration (FDA)(United States Department of Health & Human Services); American Heart Association(American Heart Association); NIH StARR Resident Investigator Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This publication was made possible through the support of the Ted and Loretta Rogers Cardiovascular Career Development Award Honoring H. C. Smith (to Z.I.A.). The Mayo Clinic CDH funded and developed the iPhone app used in the present study. The ECG dashboard used for clinician review was developed and supported by the Department of Cardiovascular Medicine. P.A.N. receives research funding from the National Institutes of Health (NIH, including the National Heart, Lung, and Blood Institute (grant nos. R21AG 62580-1, R01HL 131535-4 and R01HL 143070-2) and the National Institute on Aging (grant no. R01AG 062436-1)), the Agency for Healthcare Research and Quality (grant no. R01HS 25402-3), the Food and Drug Administration (FDA; grant no. FD 06292) and the American Heart Association (grant no. 18SFRN34230146). D.M.H. receives support from the NIH StARR Resident Investigator Award (grant no. 5R38HL150086-02). No technical or financial support was received from Apple.	Adedinsewo D, 2020, CIRC-ARRHYTHMIA ELEC, V13, DOI 10.1161/CIRCEP.120.008437; Ahn JC, 2022, AM J GASTROENTEROL, V117, P424, DOI 10.14309/ajg.0000000000001617; Ammar KA, 2007, CIRCULATION, V115, P1563, DOI 10.1161/CIRCULATIONAHA.106.666818; Apple Inc, 2020, US APPL WATCH ARRH D; Attia IZ, 2021, INT J CARDIOL, V329, P130, DOI 10.1016/j.ijcard.2020.12.065; Attia ZI, 2021, EUR HEART J, V42, P4717, DOI 10.1093/eurheartj/ehab649; Attia ZI, 2019, CIRC-ARRHYTHMIA ELEC, V12, DOI 10.1161/CIRCEP.119.007284; Attia ZI, 2019, LANCET, V394, P861, DOI 10.1016/S0140-6736(19)31721-0; Attia ZI, 2019, J CARDIOVASC ELECTR, V30, P668, DOI 10.1111/jce.13889; Attia ZI, 2019, NAT MED, V25, P70, DOI 10.1038/s41591-018-0240-2; Bahrarni H, 2008, ARCH INTERN MED, V168, P2138, DOI 10.1001/archinte.168.19.2138; BAILEY JJ, 1990, CIRCULATION, V81, P730, DOI 10.1161/01.CIR.81.2.730; Benjamin, 2018, CIRCULATION, V137, pE493, DOI 10.1161/CIR.0000000000000573; Bhalla V, 2005, AM J HYPERTENS, V18, p73S, DOI 10.1016/j.amjhyper.2004.11.044; Bui AL, 2011, NAT REV CARDIOL, V8, P30, DOI 10.1038/nrcardio.2010.165; Cardenas-Turanzas M, 2008, J LOW GENIT TRACT DI, V12, P269, DOI 10.1097/LGT.0b013e31816b44bc; Cohen-Shelly M, 2021, EUR HEART J, V42, P2885, DOI 10.1093/eurheartj/ehab153; Dargie HJ, 2001, LANCET, V357, P1385, DOI 10.1016/s0140-6736(00)04560-8; Echouffo-Tcheugui JB, 2016, JACC-HEART FAIL, V4, P237, DOI 10.1016/j.jchf.2015.09.015; Galloway CD, 2019, JAMA CARDIOL, V4, P428, DOI 10.1001/jamacardio.2019.0640; Grogan M, 2021, MAYO CLIN PROC, V96, P2768, DOI 10.1016/j.mayocp.2021.04.023; Guo YT, 2019, J AM COLL CARDIOL, V74, P2365, DOI 10.1016/j.jacc.2019.08.019; Harmon DM, 2022, CARDIOVASC RES, V118, pE23, DOI 10.1093/cvr/cvac006; Heidenreich PA, 2013, CIRC-HEART FAIL, V6, P606, DOI 10.1161/HHF.0b013e318291329a; Ko WY, 2020, J AM COLL CARDIOL, V75, P722, DOI 10.1016/j.jacc.2019.12.030; Kwon JM, 2021, ANN NONINVAS ELECTRO, V26, DOI 10.1111/anec.12839; Kwon JM, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.014717; McDonagh TA, 2021, EUR HEART J, V42, P3599, DOI 10.1093/eurheartj/ehab368; McDonagh Theresa A, 2008, Congest Heart Fail, V14, P5; Mozaffarian, 2015, CIRCULATION, V131, pE535, DOI 10.1161/CIR.0000000000000219; Nelwan SP, 2001, J ELECTROCARDIOL, V34, P213, DOI 10.1054/jelc.2001.28895; Noseworthy PA, 2020, CIRC-ARRHYTHMIA ELEC, V13, DOI 10.1161/CIRCEP.119.007988; Perez MV, 2019, NEW ENGL J MED, V381, P1909, DOI 10.1056/NEJMoa1901183; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; Pisano ED, 2005, NEW ENGL J MED, V353, P1773, DOI 10.1056/NEJMoa052911; Schijvenaars BJA, 1997, J ELECTROCARDIOL, V30, P247, DOI 10.1016/S0022-0736(97)80010-6; Shinar Z, 2003, MED BIOL ENG COMPUT, V41, P206, DOI 10.1007/BF02344890; Siontis KC, 2021, NAT REV CARDIOL, V18, P465, DOI 10.1038/s41569-020-00503-2; Steyerberg EW, 2016, J CLIN EPIDEMIOL, V69, P245, DOI 10.1016/j.jclinepi.2015.04.005; Thiele C, 2021, J STAT SOFTW, V98, DOI 10.18637/jss.v098.i11; Tseng AS, 2021, MAYO CLIN PROC, V96, P1835, DOI 10.1016/j.mayocp.2020.11.032; Williams GC, 2006, J CARDIOVASC ELECTR, V17, P352, DOI 10.1111/j.1540-8167.2005.00415.x; Yancy CW, 2017, J CARD FAIL, V23, P628, DOI [10.1161/CIR.0000000000000509, 10.1016/j.jacc.2017.04.025]; Yao XX, 2021, NAT MED, V27, P815, DOI 10.1038/s41591-021-01335-4	44	1	1	3	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.															NOV 2022	19	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	6E2MY	36376461				2022-12-27	WOS:000883217400002
J	Carrasco-Zanini, J; Pietzner, M; Lindbohm, JV; Wheeler, E; Oerton, E; Kerrison, N; Simpson, M; Westacott, M; Drolet, D; Kivimaki, M; Ostroff, R; Williams, SA; Wareham, NJ; Langenberg, C				Carrasco-Zanini, Julia; Pietzner, Maik; Lindbohm, Joni, V; Wheeler, Eleanor; Oerton, Erin; Kerrison, Nicola; Simpson, Missy; Westacott, Matthew; Drolet, Dan; Kivimaki, Mika; Ostroff, Rachel; Williams, Stephen A.; Wareham, Nicholas J.; Langenberg, Claudia			Proteomic signatures for identification of impaired glucose tolerance	NATURE MEDICINE			English	Article; Early Access							NEUTROPHIL SERINE PROTEASES; LIFE-STYLE INTERVENTION; HIGH-RISK; TYPE-2; PREVALENCE; DISEASE; A1C; INDIVIDUALS; ASSOCIATION; DYSGLYCEMIA	A new study combines large-scale proteomics and machine learning to identify proteins that can be used to identify individuals with isolated impaired glucose tolerance, who would otherwise only be detectable with oral glucose tolerance tests. The implementation of recommendations for type 2 diabetes (T2D) screening and diagnosis focuses on the measurement of glycated hemoglobin (HbA1c) and fasting glucose. This approach leaves a large number of individuals with isolated impaired glucose tolerance (iIGT), who are only detectable through oral glucose tolerance tests (OGTTs), at risk of diabetes and its severe complications. We applied machine learning to the proteomic profiles of a single fasted sample from 11,546 participants of the Fenland study to test discrimination of iIGT defined using the gold-standard OGTTs. We observed significantly improved discriminative performance by adding only three proteins (RTN4R, CBPM and GHR) to the best clinical model (AUROC = 0.80 (95% confidence interval: 0.79-0.86), P = 0.004), which we validated in an external cohort. Increased plasma levels of these candidate proteins were associated with an increased risk for future T2D in an independent cohort and were also increased in individuals genetically susceptible to impaired glucose homeostasis and T2D. Assessment of a limited number of proteins can identify individuals likely to be missed by current diagnostic strategies and at high risk of T2D and its complications.	[Carrasco-Zanini, Julia; Pietzner, Maik; Wheeler, Eleanor; Oerton, Erin; Kerrison, Nicola; Wareham, Nicholas J.; Langenberg, Claudia] Univ Cambridge, Inst Metab Sci, MRC Epidemiol Unit, Sch Clin Med, Cambridge, England; [Pietzner, Maik; Langenberg, Claudia] Charite Univ Med Berlin, Computat Med, Berlin Inst Hlth, Berlin, Germany; [Lindbohm, Joni, V; Kivimaki, Mika] Univ Helsinki, Dept Publ Hlth, Clinicum, Helsinki, Finland; [Lindbohm, Joni, V; Kivimaki, Mika] UCL, Dept Epidemiol & Publ Hlth, London, England; [Lindbohm, Joni, V] Broad Inst Massachusetts Inst Tech & Harvard Univ, Klarman Cell Observ, Cambridge, MA USA; [Simpson, Missy; Westacott, Matthew; Drolet, Dan; Ostroff, Rachel; Williams, Stephen A.] SomaLogic, Boulder, CO USA; [Langenberg, Claudia] Queen Mary Univ London, Precis Healthcare Univ Res Inst, London, England	University of Cambridge; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Helsinki; University of London; University College London; University of London; Queen Mary University London	Langenberg, C (corresponding author), Univ Cambridge, Inst Metab Sci, MRC Epidemiol Unit, Sch Clin Med, Cambridge, England.; Langenberg, C (corresponding author), Charite Univ Med Berlin, Computat Med, Berlin Inst Hlth, Berlin, Germany.; Langenberg, C (corresponding author), Queen Mary Univ London, Precis Healthcare Univ Res Inst, London, England.	claudia.langenberg@mrc-epid.cam.ac.uk		Carrasco-Zanini Sanchez, Julia/0000-0002-3988-7505; Wheeler, Eleanor/0000-0002-8616-6444; Pietzner, Maik/0000-0003-3437-9963; Langenberg, Claudia/0000-0002-5017-7344; Kivimaki, Mika/0000-0002-4699-5627	Medical Research Council [MR/N003284/1 MC-UU_12015/1, MC_UU_00006/1, MC_UU_12015/1, MC_PC_13046, R01HL36310, R01AG013196]; University of Cambridge [MC_UU_12015/1, MC_PC_13046]; Cancer Research UK [C864/A14136]; UK Medical Research Council [221854/Z/20/Z, MR/K013351/1, G0902037, R024227]; British Heart Foundation [MR/K013351/1, G0902037, RG/13/2/30098]; US National Institutes of Health [R01HL36310, R01AG013196, RG/13/2/30098]; Wellcome Trust [MC_UU_12015/1, 221854/Z/20/Z]; NIA, NIH [R01AG056477]; Academy of Finland [311492, 339568]; Helsinki Institute of Life Science [H970]; Paivikki and Sakari Sohlberg foundation; Cambridge Trust	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); University of Cambridge(University of Cambridge); Cancer Research UK(Cancer Research UK); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wellcome Trust(Wellcome Trust); NIA, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Academy of Finland(Academy of Finland); Helsinki Institute of Life Science; Paivikki and Sakari Sohlberg foundation; Cambridge Trust	The Fenland study (10.22025/2017.10.101.00001) is funded by the Medical Research Council (MC_UU_12015/1). We are grateful to all the volunteers and to the general practitioners and practice staff for assistance with recruitment. We thank the Fenland study investigators, Fenland study coordination team and epidemiology field, data and laboratory teams. We further acknowledge support for genomics from the Medical Research Council (MC_PC_13046). Proteomic measurements were supported and governed by a collaboration agreement between the University of Cambridge and SomaLogic. We thank I. von Carlowitz and K. Soucie for their contributions to the fasting proteome analysis.The EPIC-Norfolk study (10.22025/2019.10.105.00004) has received funding from the Medical Research Council (MR/N003284/1 MC-UU_12015/1 and MC_UU_00006/1) and Cancer Research UK (C864/A14136). We are grateful to all the participants who have been part of the project and to the many members of the study teams at the University of Cambridge who have enabled this research. We thank all participants in the Whitehall II Study, Whitehall II researchers and support staff who make the study possible. The UK Medical Research Council (MR/K013351/1; G0902037), British Heart Foundation (RG/13/2/30098) and the US National Institutes of Health (R01HL36310, R01AG013196) have supported collection of data in the Whitehall II Study. J.C.Z.S. is supported by a 4-year Wellcome Trust PhD Studentship and the Cambridge Trust, and C.L., E.W. and N.J.W. are funded by the Medical Research Council (MC_UU_12015/1). N.J.W. is an NIHR Senior Investigator. The WHII study and M.K. are supported by grants from the Wellcome Trust (221854/Z/20/Z), UK Medical Research Council (R024227) and NIA, NIH (R01AG056477). J.V.L. was supported by the Academy of Finland (311492 and 339568) and Helsinki Institute of Life Science (H970) grants paid to employer and by the Paivikki and Sakari Sohlberg foundation. The funders had no role in the study design, data collection and analysis and the decision to publish or in the preparation of the manuscript.	Amer Diabet Assoc, 2018, DIABETES CARE, V41, pS13, DOI 10.2337/dc18-S002; Balkau B, 2000, DIABETES METAB, V26, P282; Barron E, 2018, DIABETIC MED, V35, P513, DOI 10.1111/dme.13562; Bergman M, 2018, DIABETES-METAB RES, V34, DOI 10.1002/dmrr.2992; Bonate P. L., 2004, PHARMACOKINETICS DRU; Campbell MD, 2020, NAT REV ENDOCRINOL, V16, P395, DOI 10.1038/s41574-019-0316-1; Cederberg H, 2010, DIABETES CARE, V33, P2077, DOI 10.2337/dc10-0262; Chen YY, 2021, DIABETOLOGIA, V64, P1279, DOI 10.1007/s00125-021-05401-x; Cheng YLJ, 2019, JAMA-J AM MED ASSOC, V322, P2389, DOI 10.1001/jama.2019.19365; Cowie CC, 2010, DIABETES CARE, V33, P562, DOI 10.2337/dc09-1524; Day N, 1999, BRIT J CANCER, V80, P95; de Vries MA, 2015, METABOLISM, V64, P213, DOI 10.1016/j.metabol.2014.10.011; Deora AB, 2004, J BIOL CHEM, V279, P43411, DOI 10.1074/jbc.M408078200; Donath MY, 2011, NAT REV IMMUNOL, V11, P98, DOI 10.1038/nri2925; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Gerstein HC, 2007, DIABETES RES CLIN PR, V78, P305, DOI 10.1016/j.diabres.2007.05.004; Gold L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015004; Gong QH, 2021, DIABETES OBES METAB, V23, P2385, DOI 10.1111/dom.14481; Gong QH, 2019, LANCET DIABETES ENDO, V7, P452, DOI 10.1016/S2213-8587(19)30093-2; Guevara-Aguirre J, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001845; Haddad Y, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00509; Harrell FE., 2017, BIOS, V330, P14; Hessle L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063080; Hoffman GE, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-1323-z; Huang J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9111; Inker LA, 2012, NEW ENGL J MED, V367, P20, DOI 10.1056/NEJMoa1114248; Klement J, 2017, DIABETES, V66, P264, DOI 10.2337/db16-0569; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Kuhn M, 2008, J STAT SOFTW, V28, P1, DOI 10.18637/jss.v028.i05; Kundu S, 2011, EUR J EPIDEMIOL, V26, P261, DOI 10.1007/s10654-011-9567-4; Langenberg C, 2011, DIABETOLOGIA, V54, P2272, DOI 10.1007/s00125-011-2182-9; Lee CMY, 2019, BMJ OPEN DIAB RES CA, V7, DOI 10.1136/bmjdrc-2019-000794; Lindsay T, 2019, INT J BEHAV NUTR PHY, V16, DOI 10.1186/s12966-019-0882-6; Lotta LA, 2018, JAMA-J AM MED ASSOC, V320, P2553, DOI 10.1001/jama.2018.19329; Lunardon N, 2014, R J, V6, P79; Mahajan A, 2018, NAT GENET, V50, P1505, DOI 10.1038/s41588-018-0241-6; Marmot M, 2005, INT J EPIDEMIOL, V34, P251, DOI 10.1093/ije/dyh372; McCarthy S, 2016, NAT GENET, V48, P1279, DOI 10.1038/ng.3643; Mehta SR, 2008, WORLD J GASTROENTERO, V14, P3476, DOI 10.3748/wjg.14.3476; Meisinger C, 2010, DIABETIC MED, V27, P360, DOI 10.1111/j.1464-5491.2009.02905.x; Nathan DM, 2009, DIABETES CARE, V32, P1327, DOI 10.2337/dc09-9033; Nichols GA, 2008, AM J MANAG CARE, V14, P791; Pham CTN, 2006, NAT REV IMMUNOL, V6, P541, DOI 10.1038/nri1841; Pietzner M, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-27164-0; Pietzner M, 2021, SCIENCE, V374, P839, DOI 10.1126/science.abj1541; Pietzner M, 2021, NAT MED, V27, P471, DOI 10.1038/s41591-021-01266-0; Rahman M, 2008, FAM PRACT, V25, P191, DOI 10.1093/fampra/cmn024; Richter B, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012661.pub2; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Rohloff JC, 2014, MOL THER-NUCL ACIDS, V3, DOI 10.1038/mtna.2014.49; Rose SMSF, 2019, NAT MED, V25, P792, DOI 10.1038/s41591-019-0414-6; Saeedi P, 2019, DIABETES RES CLIN PR, V157, DOI 10.1016/j.diabres.2019.107843; Scott RA, 2012, NAT GENET, V44, P991, DOI 10.1038/ng.2385; Shaw JE, 1999, DIABETOLOGIA, V42, P1050, DOI 10.1007/s001250051269; Shen ZX, 1998, BIOCHEM J, V330, P549, DOI 10.1042/bj3300549; Silbernagel G, 2012, ATHEROSCLEROSIS, V225, P194, DOI 10.1016/j.atherosclerosis.2012.08.008; Slieker R.C., 2021, PREPRINT, DOI [10.1101/2021.04.22.21255625, DOI 10.1101/2021.04.22.21255625]; Tiaden AN, 2016, STEM CELLS, V34, P1601, DOI 10.1002/stem.2297; Weingarten MFJ, 2019, J CLIN ENDOCR METAB, V104, P5621, DOI 10.1210/jc.2019-00643; Wiedow O, 2005, J INTERN MED, V257, P319, DOI 10.1111/j.1365-2796.2005.01476.x; Williams SA, 2019, NAT MED, V25, P1851, DOI 10.1038/s41591-019-0665-2; Wu T, 2019, J MOL CELL BIOL, V11, P1083, DOI 10.1093/jmcb/mjz016; Yip WCY, 2017, NUTRIENTS, V9, DOI 10.3390/nu9111273; Zhong C, 2017, CELL REP, V20, P2328, DOI 10.1016/j.celrep.2017.08.031; Zhong W, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22767-z; Zhou WY, 2019, NATURE, V569, P663, DOI 10.1038/s41586-019-1236-x	66	0	0	1	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02055-z	http://dx.doi.org/10.1038/s41591-022-02055-z		NOV 2022	25	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	6B8KC	36357677				2022-12-27	WOS:000881574700005
J	Xu, E; Xie, Y; Al-Aly, Z				Xu, Evan; Xie, Yan; Al-Aly, Ziyad			Long-term neurologic outcomes of COVID-19	NATURE MEDICINE			English	Article; Early Access							OCULAR MANIFESTATIONS; CONSEQUENCES	Individuals with COVID-19 are at an increased risk for an array of neurologic disorders at 12 months, even in those who were not hospitalized during the acute phase of the infection. The neurologic manifestations of acute COVID-19 are well characterized, but a comprehensive evaluation of postacute neurologic sequelae at 1 year has not been undertaken. Here we use the national healthcare databases of the US Department of Veterans Affairs to build a cohort of 154,068 individuals with COVID-19, 5,638,795 contemporary controls and 5,859,621 historical controls; we use inverse probability weighting to balance the cohorts, and estimate risks and burdens of incident neurologic disorders at 12 months following acute SARS-CoV-2 infection. Our results show that in the postacute phase of COVID-19, there was increased risk of an array of incident neurologic sequelae including ischemic and hemorrhagic stroke, cognition and memory disorders, peripheral nervous system disorders, episodic disorders (for example, migraine and seizures), extrapyramidal and movement disorders, mental health disorders, musculoskeletal disorders, sensory disorders, Guillain-Barre syndrome, and encephalitis or encephalopathy. We estimated that the hazard ratio of any neurologic sequela was 1.42 (95% confidence intervals 1.38, 1.47) and burden 70.69 (95% confidence intervals 63.54, 78.01) per 1,000 persons at 12 months. The risks and burdens were elevated even in people who did not require hospitalization during acute COVID-19. Limitations include a cohort comprising mostly White males. Taken together, our results provide evidence of increased risk of long-term neurologic disorders in people who had COVID-19.	[Xu, Evan; Xie, Yan; Al-Aly, Ziyad] VA St Louis Hlth Care Syst, Clin Epidemiol Ctr, Res & Dev Serv, St Louis, MO 63106 USA; [Xie, Yan; Al-Aly, Ziyad] Vet Res & Educ Fdn St Louis, St Louis, MO 63103 USA; [Xie, Yan] St Louis Univ, Dept Epidemiol & Biostat, Coll Publ Hlth & Social Justice, St Louis, MO USA; [Al-Aly, Ziyad] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Al-Aly, Ziyad] VA St Louis Hlth Care Syst, Nephrol Sect, Med Serv, St Louis, MO 63106 USA; [Al-Aly, Ziyad] Washington Univ, Inst Publ Hlth, St Louis, MO 63110 USA	Saint Louis University; Washington University (WUSTL); Washington University (WUSTL)	Al-Aly, Z (corresponding author), VA St Louis Hlth Care Syst, Clin Epidemiol Ctr, Res & Dev Serv, St Louis, MO 63106 USA.; Al-Aly, Z (corresponding author), Vet Res & Educ Fdn St Louis, St Louis, MO 63103 USA.; Al-Aly, Z (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.; Al-Aly, Z (corresponding author), VA St Louis Hlth Care Syst, Nephrol Sect, Med Serv, St Louis, MO 63106 USA.; Al-Aly, Z (corresponding author), Washington Univ, Inst Publ Hlth, St Louis, MO 63110 USA.	zalaly@gmail.com	Al-Aly, Ziyad/S-4439-2016	Al-Aly, Ziyad/0000-0002-2600-0434; Xie, Yan/0000-0002-2457-9382; Xu, Evan/0000-0001-6132-8374	United States Department of Veterans Affairs; American Society of Nephrology and KidneyCure fellowship award	United States Department of Veterans Affairs(US Department of Veterans Affairs); American Society of Nephrology and KidneyCure fellowship award	This study used data from the VA COVID-19 Shared Data Resource. This research was funded by the United States Department of Veterans Affairs (Z.A.A. and Y.X.) and American Society of Nephrology and KidneyCure fellowship award (Y.X.). The contents do not represent the views of the US Department of Veterans Affairs or the US government.	A. Sharma, 2021, medRxiv, DOI 10.1101/2021.09.23.21263864; Al-Aly Z, 2022, NAT REV IMMUNOL, V22, P410, DOI 10.1038/s41591-022-01840-0; Al-Aly Z, 2021, NATURE, V594, P259, DOI 10.1038/s41586-021-03553-9; Alwan NA, 2021, SCIENCE, V373, P491, DOI 10.1126/science.abg7113; [Anonymous], 2020, LONG TERM IMM HLTH C; Austin PC, 2015, STAT MED, V34, P3661, DOI 10.1002/sim.6607; Ayoubkhani D, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n693; Boldrini M, 2021, JAMA PSYCHIAT, V78, P682, DOI 10.1001/jamapsychiatry.2021.0500; Bowe B, 2021, J AM SOC NEPHROL, V32, P2851, DOI 10.1681/ASN.2021060734; Bowe B, 2021, CLIN J AM SOC NEPHRO, V16, P14, DOI 10.2215/CJN.09610620; Briggs A, 2021, NATURE, V593, P502, DOI 10.1038/d41586-021-01392-2; Cai M, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-047369; Carfi A, 2020, JAMA-J AM MED ASSOC, V324, P603, DOI 10.1001/jama.2020.12603; Cole SR, 2008, AM J EPIDEMIOL, V168, P656, DOI 10.1093/aje/kwn164; Crook H, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n1648; Daugherty SE, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1098; Davis HE, 2021, ECLINICALMEDICINE, V38, DOI 10.1016/j.eclinm.2021.101019; Delorey TM, 2021, NATURE, V595, P107, DOI 10.1038/s41586-021-03570-8; Di Toro A, 2021, EUR HEART J SUPPL, V23, pE1, DOI 10.1093/eurheartj/suab080; Douaud G, 2022, NATURE, V604, P697, DOI [10.1038/s41586-022-04569-5, 10.1101/2021.06.11.21258690]; Feng YL, 2021, CLIN OPHTHALMOL, V15, P1551, DOI 10.2147/OPTH.S301040; Fernandez-Castaneda A, 2022, CELL, V185, P2452, DOI 10.1016/j.cell.2022.06.008; Hernan M., 2020, CAUSAL INFERENCE WHA; Huang CL, 2021, LANCET, V397, P220, DOI 10.1016/S0140-6736(20)32656-8; Jafari Z, 2022, CAN J NEUROL SCI, V49, P184, DOI 10.1017/cjn.2021.63; Jeong Minjin, 2021, Commun Med (Lond), V1, P44, DOI 10.1038/s43856-021-00044-w; Katsoulis M, 2021, EPIDEMIOLOGY, V32, P744, DOI 10.1097/EDE.0000000000001393; Kind AJH, 2018, NEW ENGL J MED, V378, P2456, DOI 10.1056/NEJMp1802313; Lipsitch M, 2010, EPIDEMIOLOGY, V21, P383, DOI 10.1097/EDE.0b013e3181d61eeb; McCaffrey DF, 2013, STAT MED, V32, P3388, DOI 10.1002/sim.5753; Merad M, 2022, SCIENCE, V375, P1122, DOI 10.1126/science.abm8108; Morgan SL, 2008, SOCIOL METHODOL, V38, P231, DOI 10.1111/j.1467-9531.2008.00204.x; Nalbandian A, 2021, NAT MED, V27, P601, DOI 10.1038/s41591-021-01283-z; Nasiri N, 2021, J OPHTHAL VIS RES, V16, P103, DOI 10.18502/jovr.v16i1.8256; Nolen LT, 2022, NAT MED, V28, P20, DOI 10.1038/s41591-021-01647-5; Novak P, 2022, ANN NEUROL, V91, P367, DOI 10.1002/ana.26286; Patel BC, 2020, OPHTHALMIC MANIFESTA; Reiken S, 2022, ALZHEIMERS DEMENT, V18, P955, DOI 10.1002/alz.12558; Schneeweiss S, 2009, EPIDEMIOLOGY, V20, P512, DOI 10.1097/EDE.0b013e3181a663cc; Song WC, 2020, J CLIN INVEST, V130, P3950, DOI 10.1172/JCI140183; Spudich S, 2022, SCIENCE, V375, P267, DOI 10.1126/science.abm2052; Taquet M, 2021, PLOS MED, V18, DOI 10.1371/journal.pmed.1003773; Taquet M, 2021, LANCET PSYCHIAT, V8, P416, DOI 10.1016/S2215-0366(21)00084-5; Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5; Vitalakumar D, 2021, ACS CHEM NEUROSCI, V12, P2776, DOI 10.1021/acschemneuro.1c00353; Xie Y, 2022, LANCET DIABETES ENDO, V10, P311, DOI 10.1016/S2213-8587(22)00044-4; Xie Y, 2022, BMJ-BRIT MED J, V376, DOI 10.1136/bmj-2021-068993; Xie Y, 2022, NAT MED, V28, P583, DOI 10.1038/s41591-022-01689-3; Xie Y, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26513-3; Xie Y, 2020, BMJ-BRIT MED J, V371, DOI 10.1136/bmj.m4677; Yang AC, 2021, NATURE, V595, P565, DOI 10.1038/s41586-021-03710-0; Zhang LG, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2105968118	52	5	5	29	29	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02001-z	http://dx.doi.org/10.1038/s41591-022-02001-z		SEP 2022	25	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4U8EW	36138154	Green Submitted, hybrid, Green Published			2022-12-27	WOS:000859021700002
J	Nadeu, F; Royo, R; Massoni-Badosa, R; Garcia-Torre, B; Duran-Ferrer, M; Dawson, KJ; Kulis, M; Diaz-Navarro, A; Villamor, N; Melero, JL; Chapaprieta, V; Dueso-Barroso, A; Delgado, J; Moia, R; Ruiz-Gil, S; Marchese, D; Verdaguer-Dot, N; Romo, M; Rozman, M; Frigola, G; Rivas-Delgado, A; Baumann, T; Alcoceba, M; Gonzalez, M; Climent, F; Abrisqueta, P; Castellvi, J; Bosch, F; Aymerich, M; Enjuanes, A; Ruiz-Gaspa, S; Lopez-Guillermo, A; Jares, P; Bea, S; Colomer, D; Lopez-Bigas, N; LlGelpi, J; Torrents, D; Campbell, PJ; Gut, I; Garcia-Roves, PM; Rossi, D; Gaidano, G; Puente, XS; Heyn, H; Maura, F; Martin-Subero, JI; Campo, E; Playa-Albinyana, H; Giro, A; Clot, G; Capella-Gutierrez, S; Li Gelp, J; Lopez-Bigas, N; Garcia-Roves, PM; Martin-Subero, JI				Nadeu, Ferran; Royo, Romina; Massoni-Badosa, Ramon; Garcia-Torre, Beatriz; Duran-Ferrer, Marti; Dawson, Kevin J.; Kulis, Marta; Diaz-Navarro, Ander; Villamor, Neus; Melero, Juan L.; Chapaprieta, Vicente; Dueso-Barroso, Ana; Delgado, Julio; Moia, Riccardo; Ruiz-Gil, Sara; Marchese, Domenica; Verdaguer-Dot, Nuria; Romo, Monica; Rozman, Maria; Frigola, Gerard; Rivas-Delgado, Alfredo; Baumann, Tycho; Alcoceba, Miguel; Gonzalez, Marcos; Climent, Fina; Abrisqueta, Pau; Castellvi, Josep; Bosch, Francesc; Aymerich, Marta; Enjuanes, Anna; Ruiz-Gaspa, Silvia; Lopez-Guillermo, Armando; Jares, Pedro; Bea, Silvia; Colomer, Dolors; Lopez-Bigas, Nuria; LlGelpi, Josep; Torrents, David; Campbell, Peter J.; Gut, Ivo; Garcia-Roves, Pablo M.; Rossi, Davide; Gaidano, Gianluca; Puente, Xose S.; Heyn, Holger; Maura, Francesco; Martin-Subero, Jose, I; Campo, Elias; Playa-Albinyana, Heribert; Giro, Ariadna; Clot, Guillem; Capella-Gutierrez, Salvador; Li Gelp, Josep; Lopez-Bigas, Niiria; Garcia-Roves, Pablo M.; Martin-Subero, Jose, I			Detection of early seeding of Richter transformation in chronic lymphocytic leukemia	NATURE MEDICINE			English	Article; Early Access							CLONAL EVOLUTION; SOMATIC MUTATION; HIGH-RISK; CANCER; GENOME; OUTCOMES; HETEROGENEITY; PROGRESSION; RESISTANCE; SIGNATURES	Richter transformation (RT) is a paradigmatic evolution of chronic lymphocytic leukemia (CLL) into a very aggressive large B cell lymphoma conferring a dismal prognosis. The mechanisms driving RT remain largely unknown. We characterized the whole genome, epigenome and transcriptome, combined with single-cell DNA/RNA-sequencing analyses and functional experiments, of 19 cases of CLL developing RT. Studying 54 longitudinal samples covering up to 19 years of disease course, we uncovered minute subclones carrying genomic, immunogenetic and transcriptomic features of RT cells already at CLL diagnosis, which were dormant for up to 19 years before transformation. We also identified new driver alterations, discovered a new mutational signature (SBS-RT), recognized an oxidative phosphorylation (OXPHOS)(high)-B cell receptor (BCR)(low)-signaling transcriptional axis in RT and showed that OXPHOS inhibition reduces the proliferation of RT cells. These findings demonstrate the early seeding of subclones driving advanced stages of cancer evolution and uncover potential therapeutic targets for RT. Single-cell genomic and transcriptomic analyses of longitudinal samples of patients with Richter syndrome reveal the presence and dynamics of clones driving transformation from chronic lymphocytic leukemia years before clinical manifestation	[Nadeu, Ferran; Garcia-Torre, Beatriz; Duran-Ferrer, Marti; Kulis, Marta; Villamor, Neus; Chapaprieta, Vicente; Delgado, Julio; Verdaguer-Dot, Nuria; Romo, Monica; Rozman, Maria; Rivas-Delgado, Alfredo; Aymerich, Marta; Enjuanes, Anna; Ruiz-Gaspa, Silvia; Lopez-Guillermo, Armando; Jares, Pedro; Bea, Silvia; Colomer, Dolors; Campo, Elias; Playa-Albinyana, Heribert; Giro, Ariadna; Clot, Guillem; Martin-Subero, Jose, I] Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain; [Nadeu, Ferran; Duran-Ferrer, Marti; Diaz-Navarro, Ander; Villamor, Neus; Delgado, Julio; Baumann, Tycho; Alcoceba, Miguel; Gonzalez, Marcos; Aymerich, Marta; Lopez-Guillermo, Armando; Jares, Pedro; Bea, Silvia; Colomer, Dolors; Puente, Xose S.; Campo, Elias; Playa-Albinyana, Heribert; Giro, Ariadna; Clot, Guillem; Martin-Subero, Jose, I] Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain; [Royo, Romina; Dueso-Barroso, Ana; Torrents, David; Capella-Gutierrez, Salvador; Li Gelp, Josep] Barcelona Supercomp Ctr BSC, Barcelona, Spain; [Massoni-Badosa, Ramon; Ruiz-Gil, Sara; Marchese, Domenica; Gut, Ivo; Heyn, Holger] Barcelona Inst Sci & Technol BIST, Ctr Genom Regulat CRG, CNAG CRG, Barcelona, Spain; [Dawson, Kevin J.; Campbell, Peter J.] Wellcome Sanger Inst, Hinxton, England; [Diaz-Navarro, Ander; Puente, Xose S.] Univ Oviedo, Inst Univ Oncol, Dept Bioquim & Biol Mol, Oviedo, Spain; [Villamor, Neus; Delgado, Julio; Rozman, Maria; Frigola, Gerard; Rivas-Delgado, Alfredo; Baumann, Tycho; Aymerich, Marta; Lopez-Guillermo, Armando; Jares, Pedro; Bea, Silvia; Colomer, Dolors; Campo, Elias] Hosp Clin Barcelona, Barcelona, Spain; [Melero, Juan L.] Omniscope, Barcelona, Spain; [Delgado, Julio; Lopez-Guillermo, Armando; Jares, Pedro; Bea, Silvia; Colomer, Dolors; Campo, Elias; Li Gelp, Josep; Garcia-Roves, Pablo M.; Martin-Subero, Jose, I] Univ Barcelona, Barcelona, Spain; [Moia, Riccardo; Gaidano, Gianluca] Univ Piemonte Orientale, Dept Translat Med, Div Hematol, Novara, Italy; [Alcoceba, Miguel; Gonzalez, Marcos] IBSAL Hosp Univ, Ctr Invest Canc IBMCC USAL CSIC, Biol Mol & Histocompatibilidad, Salamanca, Spain; [Climent, Fina] Hosp Univ Bellvitge, Inst Invest Biomed Bellvitge IDIBELL, Barcelona, Spain; [Abrisqueta, Pau; Castellvi, Josep; Bosch, Francesc] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Dept Hematol, Barcelona, Spain; [Lopez-Bigas, Niiria] Barcelona Inst Sci & Technol, Inst Res Biomed IRB Barcelona, Barcelona, Spain; [Gut, Ivo; Heyn, Holger; Lopez-Bigas, Niiria] Univ Pompeu Fabra UPF, Barcelona, Spain; [Torrents, David; Lopez-Bigas, Niiria; Martin-Subero, Jose, I] Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Spain; [Rossi, Davide] Oncol Inst Southern Switzerland, Bellinzona, Switzerland; [Garcia-Roves, Pablo M.] Inst Invest Biomed Bellvitge IDIBELL, Barcelona, Spain; [Maura, Francesco] Univ Miami, Sylvester Comprehens Canc Ctr, Myeloma Serv, Miami, FL USA; [Baumann, Tycho] Hosp Univ 12 Octubre, Madrid, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Universitat Politecnica de Catalunya; Barcelona Supercomputer Center (BSC-CNS); Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Wellcome Trust Sanger Institute; University of Oviedo; Instituto Universitario de Oncologia de Asturias; University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; University of Eastern Piedmont Amedeo Avogadro; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO); Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; Pompeu Fabra University; ICREA; Institute of Oncology Research (IOR); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Miami; Hospital Universitario 12 de Octubre	Nadeu, F; Campo, E (corresponding author), Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain.; Nadeu, F; Campo, E (corresponding author), Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain.; Campo, E (corresponding author), Hosp Clin Barcelona, Barcelona, Spain.; Campo, E (corresponding author), Univ Barcelona, Barcelona, Spain.	nadeu@recerca.clinic.cat; ecampo@clinic.cat	Díaz-Navarro, Ander/GSN-9663-2022; Nadeu, Ferran/O-7732-2017; Playa-Albinyana, Heribert/GYU-6382-2022; Alcoceba, Miguel/GXH-4002-2022; Gut, Ivo/ABF-3188-2020; Garcia-Roves, Pablo M./X-4585-2018	Díaz-Navarro, Ander/0000-0001-6808-4800; Nadeu, Ferran/0000-0003-2910-9440; Playa-Albinyana, Heribert/0000-0002-3447-3848; Alcoceba, Miguel/0000-0002-3819-4846; Gut, Ivo/0000-0001-7219-632X; Melero Ollonarte, Juan Luis/0000-0003-1387-6231; Clot, Guillem/0000-0003-2588-7413; Duran-Ferrer, Marti/0000-0003-1666-5819; Garcia-Roves, Pablo M./0000-0002-8371-2067; Kulis, Marta/0000-0001-8104-9620	la Caixa Foundation [LCF/PR/HR17/52150017, HR17-00221]; European Research Council under the European Union's Horizon 2020 Research and Innovation Program [810287]; Instituto de Salud Carlos III; European Regional Development Fund Una Manera de Hacer Europa [PMP15/00007, RTI2018-094584-B-I00]; American Association for Cancer Research (2021 AACR-Amgen Fellowship in Clinical/Translational Cancer Research) [21-40-11-NADE]; European Hematology Association (EHA Junior Research Grant 2021) [RG-202012-00245]; Lady Tata Memorial Trust (International Award for Research in Leukaemia 2021-2022) [LADY_TATA_21_3223]; Generalitat de Catalunya Suport Grups de Recerca AGAUR [2017-SGR-1142, 2017-SGR-736, 2017-SGR-1009]; Accelerator award CRUK/AIRC/AECC joint funder partnership [AECC_AA17_SUBERO]; Fundacio La Marato de TV3 [201924-30]; Centro de Investigacion Biomedica en Red Cancer (CIBERONC) [CB16/12/00225, CB16/12/00334, CB16/12/00236]; Ministerio de Ciencia e Innovacion [PID2020-117185RB-I00]; Fundacion Asociacion Espanola Contra el Cancer [FUNCAR-PRYGN211258SUaR]; Associazione Italiana per la Ricerca sul Cancro Foundation (AIRC) [21198]; CERCA Programme/Generalitat de Catalunya; Spanish Ministry of Science, Innovation and Universities [FPU19/03110]; Department of Education of the Basque Government [PRE_2017_1_0100]	la Caixa Foundation(La Caixa Foundation); European Research Council under the European Union's Horizon 2020 Research and Innovation Program; Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); European Regional Development Fund Una Manera de Hacer Europa; American Association for Cancer Research (2021 AACR-Amgen Fellowship in Clinical/Translational Cancer Research); European Hematology Association (EHA Junior Research Grant 2021); Lady Tata Memorial Trust (International Award for Research in Leukaemia 2021-2022); Generalitat de Catalunya Suport Grups de Recerca AGAUR; Accelerator award CRUK/AIRC/AECC joint funder partnership; Fundacio La Marato de TV3; Centro de Investigacion Biomedica en Red Cancer (CIBERONC); Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Fundacion Asociacion Espanola Contra el Cancer; Associazione Italiana per la Ricerca sul Cancro Foundation (AIRC)(Fondazione AIRC per la ricerca sul cancro); CERCA Programme/Generalitat de Catalunya; Spanish Ministry of Science, Innovation and Universities(Spanish Government); Department of Education of the Basque Government	The authors thank the Hematopathology Collection registered at the Biobank of Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS) and the Biobank HUB-ICO-IDIBELL (PT20/00171) for sample procurement, S. Martin, F. Arenas, the Genomics Core Facility of the IDIBAPS, CNAG Sequencing Unit, Mission Bio, Omniscope and Barcelona Supercomputing Center for the technical support and the computer resources at MareNostrum4 (RES activity, BCV-2018-3-0001). This study was supported by the la Caixa Foundation (CLLEvolution-LCF/PR/HR17/52150017, Health Research 2017 Program HR17-00221, to E.C.), the European Research Council under the European Union's Horizon 2020 Research and Innovation Program (810287, BCLLatlas, to E.C., J.I.M.-S., H.H. and I.G.), the Instituto de Salud Carlos III and the European Regional Development Fund Una Manera de Hacer Europa (PMP15/00007 to E.C. and RTI2018-094584-B-I00 to D.C.), the American Association for Cancer Research (2021 AACR-Amgen Fellowship in Clinical/Translational Cancer Research, 21-40-11-NADE to F.N.), the European Hematology Association (EHA Junior Research Grant 2021, RG-202012-00245 to F.N.), the Lady Tata Memorial Trust (International Award for Research in Leukaemia 2021-2022, LADY_TATA_21_3223 to F.N.), the Generalitat de Catalunya Suport Grups de Recerca AGAUR (2017-SGR-1142 to E.C., 2017-SGR-736 to J.I.M.-S. and 2017-SGR-1009 to D.C.), the Accelerator award CRUK/AIRC/AECC joint funder partnership (AECC_AA17_SUBERO to J.I.M.-S.), the Fundacio La Marato de TV3 (201924-30 to J.I.M.-S.), the Centro de Investigacion Biomedica en Red Cancer (CIBERONC; CB16/12/00225, CB16/12/00334, CB16/12/00236), the Ministerio de Ciencia e Innovacion (PID2020-117185RB-I00 to X.S.P.), the Fundacion Asociacion Espanola Contra el Cancer (FUNCAR-PRYGN211258SUaR to X.S.P.), the Associazione Italiana per la Ricerca sul Cancro Foundation (AIRC 5x1,000 no. 21198 to G.G.) and the CERCA Programme/Generalitat de Catalunya. H.P.-A. is a recipient of a predoctoral fellowship from the Spanish Ministry of Science, Innovation and Universities (FPU19/03110). A.D.-N. is supported by the Department of Education of the Basque Government (PRE_2017_1_0100). E.C. is an Academia Researcher of the Institucio Catalana de Recerca i Estudis Avancats of the Generalitat de Catalunya. This work was partially developed at the Center Esther Koplowitz (Barcelona, Spain).	Ahn IE, 2017, BLOOD, V129, P1469, DOI 10.1182/blood-2016-06-719294; Alexandrov LB, 2020, NATURE, V578, P94, DOI 10.1038/s41586-020-1943-3; Anderson MA, 2017, BLOOD, V129, P3362, DOI 10.1182/blood-2017-01-763003; Arthur SE, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06354-3; Aryee MJ, 2014, BIOINFORMATICS, V30, P1363, DOI 10.1093/bioinformatics/btu049; Baca SC, 2013, CELL, V153, P666, DOI 10.1016/j.cell.2013.03.021; Bagnara D, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.640731; Bea S, 2002, AM J PATHOL, V161, P957, DOI 10.1016/S0002-9440(10)64256-3; Beekman R, 2018, NAT MED, V24, P868, DOI 10.1038/s41591-018-0028-4; Benatti S, 2021, HEMATOL ONCOL, V39, P707, DOI 10.1002/hon.2915; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Bray NL, 2016, NAT BIOTECHNOL, V34, P525, DOI 10.1038/nbt.3519; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; Calissano C, 2011, MOL MED, V17, P1374, DOI 10.2119/molmed.2011.00360; Calissano C, 2009, BLOOD, V114, P4832, DOI 10.1182/blood-2009-05-219634; Caro P, 2012, CANCER CELL, V22, P547, DOI 10.1016/j.ccr.2012.08.014; Chakraborty S, 2021, BLOOD, V138, P1053, DOI 10.1182/blood.2020008276; Chan KL, 2017, BRIT J HAEMATOL, V177, P324, DOI 10.1111/bjh.14062; Chen CL, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22652-9; Chigrinova E, 2013, BLOOD, V122, P2673, DOI 10.1182/blood-2013-03-489518; Chitalia A, 2019, LEUKEMIA LYMPHOMA, V60, P971, DOI 10.1080/10428194.2018.1516878; Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695; Cui B, 2014, BLOOD, V124, P546, DOI 10.1182/blood-2014-03-559690; Dadashian EL, 2019, CANCER RES, V79, P360, DOI 10.1158/0008-5472.CAN-18-0781; Danecek P, 2021, GIGASCIENCE, V10, DOI 10.1093/gigascience/giab008; de Kanter JK, 2021, CELL STEM CELL, V28, P1726, DOI 10.1016/j.stem.2021.07.012; De Paoli L, 2013, LEUKEMIA LYMPHOMA, V54, P1087, DOI 10.3109/10428194.2012.723706; Dentro SC, 2021, CELL, V184, P2239, DOI 10.1016/j.cell.2021.03.009; Dentro SC, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a026625; Ding W, 2018, HEMATOL-AM SOC HEMAT, P256, DOI 10.1182/asheducation-2018.1.256; Duran-Ferrer M, 2020, NAT CANCER, V1, P1066, DOI 10.1038/s43018-020-00131-2; Fabbri G, 2013, J EXP MED, V210, P2273, DOI 10.1084/jem.20131448; Fan Y, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1029-6; Ferrando AA, 2017, NAT MED, V23, P1135, DOI 10.1038/nm.4410; Gaiti F, 2019, NATURE, V569, P576, DOI 10.1038/s41586-019-1198-z; Gemenetzi K, 2021, BLOOD, V137, P1895, DOI 10.1182/blood.2020005216; Gerstung M, 2020, NATURE, V578, P122, DOI 10.1038/s41586-019-1907-7; Gnaiger E, 1995, J BIOENERG BIOMEMBR, V27, P583, DOI 10.1007/BF02111656; Hao YH, 2021, CELL, V184, P3573, DOI 10.1016/j.cell.2021.04.048; Haradhvala NJ, 2016, CELL, V164, P538, DOI 10.1016/j.cell.2015.12.050; Hasan MK, 2021, LEUKEMIA, V35, P1621, DOI 10.1038/s41375-020-01055-7; Herling CD, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03170-7; Jain P, 2015, BLOOD, V125, P2062, DOI 10.1182/blood-2014-09-603670; Jones David, 2016, Curr Protoc Bioinformatics, V56, DOI 10.1002/cpbi.20; Kadri S, 2017, BLOOD ADV, V1, P715, DOI 10.1182/bloodadvances.2016003632; Kasar S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9866; Kim J, 2016, NAT GENET, V48, P600, DOI 10.1038/ng.3557; Klintman J, 2021, BLOOD, V137, P2800, DOI 10.1182/blood.2020005650; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Kopylova E, 2012, BIOINFORMATICS, V28, P3211, DOI 10.1093/bioinformatics/bts611; Korbel JO, 2013, CELL, V152, P1226, DOI 10.1016/j.cell.2013.02.023; Koren A, 2012, AM J HUM GENET, V91, P1033, DOI 10.1016/j.ajhg.2012.10.018; Korsunsky I, 2019, NAT METHODS, V16, P1289, DOI 10.1038/s41592-019-0619-0; Kucab JE, 2019, CELL, V177, P821, DOI 10.1016/j.cell.2019.03.001; Kuipers J, 2017, GENOME RES, V27, P1885, DOI 10.1101/gr.220707.117; Lai ZW, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw227; Landau DA, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02329-y; Lee-Six H, 2019, NATURE, V574, P532, DOI 10.1038/s41586-019-1672-7; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li YL, 2020, NATURE, V578, P112, DOI 10.1038/s41586-019-1913-9; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Maddocks KJ, 2015, JAMA ONCOL, V1, P80, DOI 10.1001/jamaoncol.2014.218; Maffei R, 2021, LEUKEMIA, V35, P1330, DOI 10.1038/s41375-021-01178-5; Maura F, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11680-1; Maura F, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11037-8; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Miller CR, 2017, BLOOD ADV, V1, P1584, DOI 10.1182/bloodadvances.2017007302; Minici C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15746; Molina JR, 2018, NAT MED, V24, P1036, DOI 10.1038/s41591-018-0052-4; Moncunill V, 2014, NAT BIOTECHNOL, V32, P1106, DOI 10.1038/nbt.3027; Mongini PKA, 2015, J IMMUNOL, V195, P901, DOI 10.4049/jimmunol.1403189; Monti S, 2005, BLOOD, V105, P1851, DOI 10.1182/blood-2004-07-2947; Morita K, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19119-8; Muller E, 2016, ONCOTARGET, V7, P79471, DOI 10.18632/oncotarget.13103; Nadeu F, 2018, LEUKEMIA, V32, P645, DOI 10.1038/leu.2017.291; Nadeu F, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17095-7; Nik-Zainal S, 2016, NATURE, V534, P47, DOI 10.1038/nature17676; Nik-Zainal S, 2012, CELL, V149, DOI 10.1016/j.cell.2012.04.023; Norberg E, 2017, CELL DEATH DIFFER, V24, P251, DOI 10.1038/cdd.2016.116; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Ntoufa S, 2016, SEMIN CANCER BIOL, V39, P15, DOI 10.1016/j.semcancer.2016.07.001; Parekh S, 2018, GIGASCIENCE, V7, DOI 10.1093/gigascience/giy059; Patterson DG, 2021, J IMMUNOL, V207, P1798, DOI 10.4049/jimmunol.2100440; Penter L, 2021, CANCER DISCOV, V11, P3048, DOI 10.1158/2159-8290.CD-21-0276; Picelli S, 2013, NAT METHODS, V10, P1096, DOI [10.1038/nmeth.2639, 10.1038/NMETH.2639]; Pich O, 2019, NAT GENET, V51, P1732, DOI 10.1038/s41588-019-0525-5; Puente XS, 2015, NATURE, V526, P519, DOI 10.1038/nature14666; Raine Keiran M, 2016, Curr Protoc Bioinformatics, V56, DOI 10.1002/cpbi.17; Raine Keiran M, 2015, Curr Protoc Bioinformatics, V52, DOI 10.1002/0471250953.bi1507s52; Rajbhandari P, 2018, CANCER DISCOV, V8, P582, DOI 10.1158/2159-8290.CD-16-0861; Rausch T, 2012, BIOINFORMATICS, V28, pI333, DOI 10.1093/bioinformatics/bts378; Rimmer A, 2014, NAT GENET, V46, P912, DOI 10.1038/ng.3036; Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754; Rossi D, 2012, BRIT J HAEMATOL, V158, P426, DOI 10.1111/j.1365-2141.2012.09155.x; Rossi D, 2011, BLOOD, V117, P3391, DOI 10.1182/blood-2010-09-302174; Rustad EH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15740-9; Scandurra M, 2010, HEMATOL ONCOL, V28, P62, DOI 10.1002/hon.932; Shen MM, 2013, CANCER CELL, V23, P567, DOI 10.1016/j.ccr.2013.04.025; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; Stoeckius M, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1603-1; Talevich E, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004873; Vangapandu Hima V, 2018, Oncotarget, V9, P24980, DOI 10.18632/oncotarget.25166; Varano G, 2017, NATURE, V546, P302, DOI 10.1038/nature22353; Villamor N, 2013, LEUKEMIA, V27, P1100, DOI 10.1038/leu.2012.357; Wala JA, 2018, GENOME RES, V28, P581, DOI 10.1101/gr.221028.117; Wilm A, 2012, NUCLEIC ACIDS RES, V40, P11189, DOI 10.1093/nar/gks918; Wolock SL, 2019, CELL SYST, V8, P281, DOI 10.1016/j.cels.2018.11.005; Yang F, 2021, NAT CANCER, V2, P819, DOI 10.1038/s43018-021-00230-8; Zhang L, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau1167; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	110	4	4	7	7	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01927-8	http://dx.doi.org/10.1038/s41591-022-01927-8		AUG 2022	37	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3S4NQ	35953718	Green Published, hybrid			2022-12-27	WOS:000839575100002
J	Rondina, R; Quan, C; Duke, K; Soman, D				Rondina, Renante; Quan, Cindy; Duke, Kristen; Soman, Dilip			A behavioral science framework to address latent demand in mental healthcare	NATURE MEDICINE			English	Editorial Material							TERMINATION; PREVALENCE; DISORDERS; THERAPY; CLIENTS		[Rondina, Renante; Duke, Kristen; Soman, Dilip] Univ Toronto, Rotman Sch Management, Toronto, ON, Canada; [Quan, Cindy] Univ Victoria, Dept Psychol, Victoria, BC, Canada	University of Toronto; University of Victoria	Rondina, R (corresponding author), Univ Toronto, Rotman Sch Management, Toronto, ON, Canada.	renante.rondina@rotman.utoronto.ca		Rondina, Renante/0000-0001-8555-881X; Quan, Cindy/0000-0001-9903-4558; Soman, Dilip/0000-0001-5998-4153				American psychiatric association, 2013, DIAGNOSTIC STAT MANU, DOI 10.1176/appi.books.9780890425596; Becker SJ, 2016, J CLIN PSYCHIAT, V77, pE1293, DOI 10.4088/JCP.15r10325; Cadario R, 2020, MARKET SCI, V39, P465, DOI 10.1287/mksc.2018.1128; Chiu M, 2018, CAN J PSYCHIAT, V63, P481, DOI 10.1177/0706743717741061; Connell J, 2006, COUNS PSYCHOTHER RES, V6, P60, DOI 10.1080/14733140600581507; Cooper M, 2016, INT J CLIN HLTH PSYC, V16, P87, DOI 10.1016/j.ijchp.2015.08.003; Cornish P., 2020, STEPPED CARE 2 0 PAR; Gore FM, 2011, LANCET, V377, P2093, DOI 10.1016/S0140-6736(11)60512-6; Henderson C, 2009, LANCET, V373, P1928, DOI 10.1016/S0140-6736(09)61046-1; Katigbak C, 2016, J NURS SCHOLARSHIP, V48, P210, DOI 10.1111/jnu.12194; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Kieling C, 2011, LANCET, V378, P1515, DOI 10.1016/S0140-6736(11)60827-1; Last BS, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2021-048801; Leonard TC, 2008, CONST POLITICAL ECON, V19, P356, DOI 10.1007/s10602-008-9056-2; Lewis ME, 2018, AM J COMMUN PSYCHOL, V62, P330, DOI 10.1002/ajcp.12288; Milkman KL, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2101165118; Mitchell MS, 2020, BRIT J SPORT MED, V54, P1259, DOI 10.1136/bjsports-2019-100633; O'Donnell ML, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16142537; Schroe H, 2020, INT J BEHAV NUTR PHY, V17, DOI 10.1186/s12966-020-01001-x; Soman D., 2015, LAST MILE CREATING S; Steel Z, 2014, INT J EPIDEMIOL, V43, P476, DOI 10.1093/ije/dyu038; Swift JK, 2012, PROF PSYCHOL-RES PR, V43, P379, DOI 10.1037/a0028291; West PM, 1996, J CONSUM RES, V23, P120, DOI 10.1086/209471; Windle E, 2020, JAMA PSYCHIAT, V77, P294, DOI 10.1001/jamapsychiatry.2019.3750; World Health Organization (WHO), MENT HLTH GAP ACT PR	25	0	0	1	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2022	28	6					1125	1127		10.1038/s41591-022-01782-7	http://dx.doi.org/10.1038/s41591-022-01782-7		MAY 2022	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E9IE	35513528				2022-12-27	WOS:000791071600004
J	Hoyle, R				Hoyle, R			General electric goes to the mat in the PCB wars	NATURE BIOTECHNOLOGY			English	Editorial Material																			0	0	0	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1997	15	12					1227	1227		10.1038/nbt1197-1227	http://dx.doi.org/10.1038/nbt1197-1227			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YQ046	9359095	Bronze			2022-12-27	WOS:000071342000006
J	Takai, T; Yokota, T; Yasue, M; Nishiyama, C; Yuuki, T; Mori, A; Okudaira, H; Okumura, Y				Takai, T; Yokota, T; Yasue, M; Nishiyama, C; Yuuki, T; Mori, A; Okudaira, H; Okumura, Y			Engineering of the major house dust mite allergen Der f2 for allergen-specific immunotherapy	NATURE BIOTECHNOLOGY			English	Article						allergen engineering; protein design; T-cell proliferation; immunotherapy	T-CELL EPITOPES; DER-P-II; DERMATOPHAGOIDES-FARINAE; IMMUNOGLOBULIN-E; HUMAN IGE; LOCALIZATION; RECOGNITION; ACTIVATION; ANTIBODIES; RECEPTORS	A major problem with allergen-specific immunotherapy involving repeated injections of allergens is the risk of an anaphylactic reaction, We engineered the major house dust mite allergen, Der f 2, to reduce its capacity to induce skin test reactivity and histamine release from peripheral blood basophils in allergic patients. The engineered allergen, in which the disulfide bond that linked the N- and C-terminal sequences of Der f 2 was disrupted, retained T-cell epitopes essential for immunotherapy and ability to stimulate T-cell proliferation. Such engineered allergens are potentially useful for safer and more effective immunotherapy for allergies.	UNIV TOKYO, FAC MED, DEPT MED & PHYS THERAPY, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo	Takai, T (corresponding author), ASAHI BREWERY CO LTD, BIOSCI RES & DEV LAB, 1-1-21 MIDORI, MORIYA, IBARAKI 30201, JAPAN.		Takai, Toshiro/K-5690-2013	Takai, Toshiro/0000-0001-8363-0355				AKAGAWA M, 1992, BIOSCI BIOTECH BIOCH, V56, P1725, DOI 10.1271/bbb.56.1725; BODMER JG, 1995, VOX SANG, V69, P359, DOI 10.1111/j.1423-0410.1995.tb00376.x; DAVIS MM, 1990, ANNU REV BIOCHEM, V59, P475, DOI 10.1146/annurev.biochem.59.1.475; DREDOG S, 1985, ALLERGY, V40, P55; HAIDA M, 1985, J ALLERGY CLIN IMMUN, V75, P686, DOI 10.1016/0091-6749(85)90094-6; Hoyne GF, 1995, CURR OPIN IMMUNOL, V7, P757, DOI 10.1016/0952-7915(95)80044-1; ISHIZAKA T, 1984, PROG ALLERGY, V34, P188; LOMBARDERO M, 1990, J IMMUNOL, V144, P1353; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; MIYAMOTO T, 1968, J ALLERGY, V42, P14, DOI 10.1016/0021-8707(68)90128-7; MOFFATT F, 1994, LANCET, V343, P1597, DOI 10.1016/S0140-6736(94)93057-0; Mori A, 1996, J IMMUNOL, V156, P2400; MORI A, 1997, IN PRESS BLOOD; NISHIYAMA C, 1994, INT ARCH ALLERGY IMM, V105, P62, DOI 10.1159/000236804; Nishiyama C, 1995, MOL IMMUNOL, V32, P1021, DOI 10.1016/0161-5890(95)00091-7; NISHIYAMA C, 1993, INT ARCH ALLERGY IMM, V101, P159, DOI 10.1159/000236514; Noon L, 1911, LANCET, V1, P1572; NORMAN PS, 1993, CURR OPIN IMMUNOL, V5, P968, DOI 10.1016/0952-7915(93)90114-8; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; OBRIEN RM, 1995, IMMUNOLOGY, V86, P176; OBrien RM, 1997, CLIN EXP ALLERGY, V27, P46, DOI 10.1046/j.1365-2222.1997.d01-424.x; OHEHIR RE, 1993, J ALLERGY CLIN IMMUN, V92, P105, DOI 10.1016/0091-6749(93)90044-G; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; PRUZANSKY JJ, 1983, J IMMUNOL, V131, P1949; SECRIST H, 1995, J EXP MED, V181, P1081, DOI 10.1084/jem.181.3.1081; Smith AM, 1996, MOL IMMUNOL, V33, P399, DOI 10.1016/0161-5890(95)00150-6; SUKO M, 1995, INT ARCH ALLERGY IMM, V107, P278, DOI 10.1159/000237002; TAKAI T, 1997, IN PRESS MOL IMMUNOL; Tsitoura DC, 1996, J IMMUNOL, V157, P2160; Valenta R, 1995, CURR OPIN IMMUNOL, V7, P751, DOI 10.1016/0952-7915(95)80043-3; vanNeerven RJJ, 1996, IMMUNOL TODAY, V17, P526, DOI 10.1016/0167-5699(96)10058-X; VANNEERVEN RJJ, 1993, J IMMUNOL, V151, P2326; VANTHOF W, 1991, MOL IMMUNOL, V28, P1225, DOI 10.1016/0161-5890(91)90009-9; VOOHORST R, 1967, J ALLERGY, V39, P325; YAMASHITA N, 1989, INT ARCH ALLER A IMM, V88, P173, DOI 10.1159/000234776; YSSEL H, 1992, J IMMUNOL, V148, P738; YUUKI T, 1991, AGR BIOL CHEM TOKYO, V55, P1233, DOI 10.1080/00021369.1991.10870757; YUUKI T, 1990, Japanese Journal of Allergology, V39, P557	41	149	161	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					754	758		10.1038/nbt0897-754	http://dx.doi.org/10.1038/nbt0897-754			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255789				2022-12-27	WOS:A1997XM70700026
J	Gold, L; Alper, J				Gold, L; Alper, J			Drug discovery - Keeping pace with genomics through combinatorial chemistry	NATURE BIOTECHNOLOGY			English	Editorial Material											Gold, L (corresponding author), NEXSTAR PHARMACEUT,BOULDER,CO 80302, USA.							Drews J, 1996, NAT BIOTECHNOL, V14, P1516, DOI 10.1038/nbt1196-1516; GALLOP MA, 1994, J MED CHEM, V37, P1233, DOI 10.1021/jm00035a001; GOLD L, 1995, J BIOL CHEM, V270, P13581, DOI 10.1074/jbc.270.23.13581; 1996, NATURE BIOTECHNOLOGY, V14, P1199	4	13	13	0	6	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1997	15	4					297	297		10.1038/nbt0497-297	http://dx.doi.org/10.1038/nbt0497-297			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WQ554	9094108				2022-12-27	WOS:A1997WQ55400006
J	Bowe, B; Xie, Y; Al-Aly, Z				Bowe, Benjamin; Xie, Yan; Al-Aly, Ziyad			Acute and postacute sequelae associated with SARS-CoV-2 reinfection	NATURE MEDICINE			English	Article; Early Access								First infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with increased risk of acute and postacute death and sequelae in various organ systems. Whether reinfection adds to risks incurred after first infection is unclear. Here we used the US Department of Veterans Affairs' national healthcare database to build a cohort of individuals with one SARS-CoV-2 infection (n = 443,588), reinfection (two or more infections, n = 40,947) and a noninfected control (n = 5,334,729). We used inverse probability-weighted survival models to estimate risks and 6-month burdens of death, hospitalization and incident sequelae. Compared to no reinfection, reinfection contributed additional risks of death (hazard ratio (HR) = 2.17, 95% confidence intervals (CI) 1.93-2.45), hospitalization (HR = 3.32, 95% CI 3.13-3.51) and sequelae including pulmonary, cardiovascular, hematological, diabetes, gastrointestinal, kidney, mental health, musculoskeletal and neurological disorders. The risks were evident regardless of vaccination status. The risks were most pronounced in the acute phase but persisted in the postacute phase at 6 months. Compared to noninfected controls, cumulative risks and burdens of repeat infection increased according to the number of infections. Limitations included a cohort of mostly white males. The evidence shows that reinfection further increases risks of death, hospitalization and sequelae in multiple organ systems in the acute and postacute phase. Reducing overall burden of death and disease due to SARS-CoV-2 will require strategies for reinfection prevention. A new analysis using US Department of Veterans Affairs databases showed that reinfection is associated with increased risk of all-cause mortality, hospitalization and a wide range of long COVID complications in individuals who have had SARS-CoV-2 compared to those with no reinfection.	[Bowe, Benjamin; Xie, Yan; Al-Aly, Ziyad] Vet Affairs St Louis Hlth Care Syst, Res & Dev Serv, Clin Epidemiol Ctr, St Louis, MO 63106 USA; [Bowe, Benjamin; Xie, Yan; Al-Aly, Ziyad] Vet Res & Educ Fdn, St Louis, MO 63103 USA; [Al-Aly, Ziyad] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Al-Aly, Ziyad] Vet Affairs St Louis Hlth Care Syst, Nephrol Sect, Med Serv, St Louis, MO 63106 USA; [Al-Aly, Ziyad] Washington Univ, Inst Publ Hlth, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Al-Aly, Z (corresponding author), Vet Affairs St Louis Hlth Care Syst, Res & Dev Serv, Clin Epidemiol Ctr, St Louis, MO 63106 USA.; Al-Aly, Z (corresponding author), Vet Res & Educ Fdn, St Louis, MO 63103 USA.; Al-Aly, Z (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.; Al-Aly, Z (corresponding author), Vet Affairs St Louis Hlth Care Syst, Nephrol Sect, Med Serv, St Louis, MO 63106 USA.; Al-Aly, Z (corresponding author), Washington Univ, Inst Publ Hlth, St Louis, MO 63110 USA.	zalaly@gmail.com	Al-Aly, Ziyad/S-4439-2016	Al-Aly, Ziyad/0000-0002-2600-0434; Xie, Yan/0000-0002-2457-9382	US Department of Veterans Affairs; American Society of Nephrology and KidneyCure fellowship	US Department of Veterans Affairs(US Department of Veterans Affairs); American Society of Nephrology and KidneyCure fellowship	This study used data from the VA COVID-19 Shared Data Resource. This research was funded by the US Department of Veterans Affairs (Z.A.-A.) and two American Society of Nephrology and KidneyCure fellowship awards (B.B. and Y.X.). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. The contents do not represent the views of the US Department of Veterans Affairs or the US	A. Sharma, 2021, medRxiv, DOI 10.1101/2021.09.23.21263864; Abu-Raddad LJ, 2021, NEW ENGL J MED, V385, P2487, DOI 10.1056/NEJMc2108120; Agency for Healthcare Research and Quality, 2019, HEALTHC COST UT PROJ; Al-Aly Z, 2022, NAT REV IMMUNOL, V22, P410, DOI 10.1038/s41591-022-01840-0; Al-Aly Z, 2021, NATURE, V594, P259, DOI 10.1038/s41586-021-03553-9; Altarawneh HN, 2022, NEW ENGL J MED, V386, P1288, DOI 10.1056/NEJMc2200133; Arnold N., 2006, 2 VIREC VANDI E HIN; Aubert Carole E, 2020, Mayo Clin Proc Innov Qual Outcomes, V4, P40, DOI 10.1016/j.mayocpiqo.2019.09.002; Ayoubkhani D, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n693; Bowe B, 2021, J AM SOC NEPHROL, V32, P2851, DOI 10.1681/ASN.2021060734; Bull-Otterson L, 2022, MMWR-MORBID MORTAL W, V71, P713, DOI 10.15585/mmwr.mm7121e1; Cai M, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-047369; Carfi A, 2020, JAMA-J AM MED ASSOC, V324, P603, DOI 10.1001/jama.2020.12603; Centers for Disease Control and Prevention, 2022, REINF CLIN CONS CAR; Chemaitelly H, 2021, NEW ENGL J MED, V385, P2585, DOI 10.1056/NEJMc2110300; Cohen K, 2022, BMJ-BRIT MED J, V376, DOI 10.1136/bmj-2021-068414; Coronavirus Resource Center, 2020, COVID 19 MAP; Daugherty SE, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1098; Davis HE, 2021, ECLINICALMEDICINE, V38, DOI 10.1016/j.eclinm.2021.101019; Goldberg Y, 2022, NEW ENGL J MED, V386, P2201, DOI 10.1056/NEJMoa2118946; Greene M, 2014, J AM GERIATR SOC, V62, P447, DOI 10.1111/jgs.12695; Kind AJH, 2018, NEW ENGL J MED, V378, P2456, DOI 10.1056/NEJMp1802313; Lipsitch M, 2010, EPIDEMIOLOGY, V21, P383, DOI 10.1097/EDE.0b013e3181d61eeb; Nalbandian A, 2021, NAT MED, V27, P601, DOI 10.1038/s41591-021-01283-z; Olvey EL, 2010, CLIN PHARMACOL THER, V87, P48, DOI 10.1038/clpt.2009.198; Pulliam JRC, 2022, SCIENCE, V376, P596, DOI 10.1126/science.abn4947; Schneeweiss S, 2009, EPIDEMIOLOGY, V20, P512, DOI 10.1097/EDE.0b013e3181a663cc; Shi X, 2020, CURR EPIDEMIOL REP, V7, P190, DOI 10.1007/s40471-020-00243-4; Spudich S, 2022, SCIENCE, V375, P267, DOI 10.1126/science.abm2052; Taquet M, 2021, PLOS MED, V18, DOI 10.1371/journal.pmed.1003773; Taquet M, 2021, LANCET PSYCHIAT, V8, P416, DOI 10.1016/S2215-0366(21)00084-5; Tillett RL, 2021, LANCET INFECT DIS, V21, P52, DOI 10.1016/S1473-3099(20)30764-7; Topol EJ, 2022, SCI IMMUNOL, V7, DOI 10.1126/sciimmunol.add9947; Wang JZ, 2021, J INVEST MED, V69, P1253, DOI 10.1136/jim-2021-001853; Wei YG, 2019, BMJ-BRIT MED J, V367, DOI 10.1136/bmj.l6258; Xie Y, 2022, LANCET DIABETES ENDO, V10, P311, DOI 10.1016/S2213-8587(22)00044-4; Xie Y, 2022, BMJ-BRIT MED J, V376, DOI 10.1136/bmj-2021-068993; Xie Y, 2022, NAT MED, V28, P583, DOI 10.1038/s41591-022-01689-3; Xie Y, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26513-3; Xu E, 2022, NAT MED, DOI 10.1038/s41591-022-02001-z; Yahav D, 2021, CLIN MICROBIOL INFEC, V27, P315, DOI 10.1016/j.cmi.2020.11.028	41	1	1	241	241	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02051-3	http://dx.doi.org/10.1038/s41591-022-02051-3		NOV 2022	14	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	6B8KC	36357676	Green Published, hybrid, Green Submitted			2022-12-27	WOS:000881574700002
J	Razo, C; Welgan, CA; Johnson, CO; McLaughlin, SA; Iannucci, V; Rodgers, A; Wang, N; LeGrand, KE; Sorensen, RJD; He, JW; Zheng, P; Aravkin, AY; Hay, SI; Murray, CJL; Roth, GA				Razo, Christian; Welgan, Catherine A.; Johnson, Catherine O.; McLaughlin, Susan A.; Iannucci, Vincent; Rodgers, Anthony; Wang, Nelson; LeGrand, Kate E.; Sorensen, Reed J. D.; He, Jiawei; Zheng, Peng; Aravkin, Aleksandr Y.; Hay, Simon, I; Murray, Christopher J. L.; Roth, Gregory A.			Effects of elevated systolic blood pressure on ischemic heart disease: a Burden of Proof study	NATURE MEDICINE			English	Article; Early Access							CONVERTING-ENZYME-INHIBITOR; PLACEBO-CONTROLLED TRIAL; CORONARY-ARTERY-DISEASE; CARDIOVASCULAR EVENTS; DOUBLE-BLIND; RANDOMIZED-TRIAL; J-CURVE; HYPERTENSION; MORTALITY; RAMIPRIL	A systematic review using the burden of proof meta-analytic method found a significant harmful effect between high systolic blood pressure and ischemic heart disease. High systolic blood pressure (SBP) is a major risk factor for ischemic heart disease (IHD), the leading cause of death worldwide. Using data from published observational studies and controlled trials, we estimated the mean SBP-IHD dose-response function and burden of proof risk function (BPRF), and we calculated a risk outcome score (ROS) and corresponding star rating (one to five). We found a very strong, significant harmful effect of SBP on IHD, with a mean risk-relative to that at 100 mm Hg SBP-of 1.39 (95% uncertainty interval including between-study heterogeneity 1.34-1.44) at 120 mm Hg, 1.81 (1.70-1.93) at 130 mm Hg and 4.48 (3.81-5.26) at 165 mm Hg. The conservative BPRF measure indicated that SBP exposure between 107.5 and 165.0 mm Hg raised risk by 101.36% on average, yielding a ROS of 0.70 and star rating of five. Our analysis shows that IHD risk was already increasing at 120 mm Hg SBP, rising steadily up to 165 mm Hg and increasing less steeply above that point. Our study endorses the need to prioritize and strengthen strategies for screening, to raise awareness of the need for timely diagnosis and treatment of hypertension and to increase the resources allocated for understanding primordial prevention of elevated blood pressure.	[Razo, Christian; Johnson, Catherine O.; McLaughlin, Susan A.; Iannucci, Vincent; LeGrand, Kate E.; Sorensen, Reed J. D.; He, Jiawei; Zheng, Peng; Aravkin, Aleksandr Y.; Hay, Simon, I; Murray, Christopher J. L.; Roth, Gregory A.] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA; [Razo, Christian; Zheng, Peng; Aravkin, Aleksandr Y.; Hay, Simon, I; Murray, Christopher J. L.; Roth, Gregory A.] Univ Washington, Sch Med, Dept Hlth Metr Sci, Seattle, WA 98195 USA; [Welgan, Catherine A.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Rodgers, Anthony; Wang, Nelson] Univ New South Wales, George Inst Global Hlth, Sydney, NSW, Australia; [Aravkin, Aleksandr Y.] Univ Washington, Dept Appl Math, Seattle, WA 98195 USA; [Roth, Gregory A.] Univ Washington, Div Cardiol, Seattle, WA 98195 USA	Institute for Health Metrics & Evaluation; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Johns Hopkins University; George Institute for Global Health; University of New South Wales Sydney; University of Sydney; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Razo, C (corresponding author), Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA.; Razo, C (corresponding author), Univ Washington, Sch Med, Dept Hlth Metr Sci, Seattle, WA 98195 USA.	razoc@uw.edu	Hay, Simon Iain/F-8967-2015	Hay, Simon Iain/0000-0002-0611-7272; Welgan, Katie/0000-0002-4310-1632	Bill & Melinda Gates Foundation	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR)	Research reported in this publication was supported by the Bill & Melinda Gates Foundation. The funders of the study had no role in study design, data collection, data analysis, data interpretation, writing of the final report or the decision to publish.	Abbafati C, 2020, LANCET, V396, P1135, DOI 10.1016/S0140-6736(20)31404-5; Alderman MH, 2005, HYPERTENSION, V46, P1, DOI 10.1161/01.HYP.0000168924.37091.58; AMERY A, 1985, LANCET, V1, P1349; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1993, Stroke, V24, P543; Asselbergs FW, 2004, CIRCULATION, V110, P2809, DOI 10.1161/01.CIR.0000146378.65439.7A; Beckett NS, 2008, NEW ENGL J MED, V358, P1887, DOI 10.1056/NEJMoa0801369; Benavente OR, 2013, LANCET, V382, P506; Bosch J, 2006, NEW ENGL J MED, V355, P1551; Braunwald E, 2004, NEW ENGL J MED, V351, P2058; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Bundy JD, 2017, JAMA CARDIOL, V2, P775, DOI 10.1001/jamacardio.2017.1421; Cushman WC, 2010, NEW ENGL J MED, V362, P1575, DOI 10.1056/NEJMoa1001286; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Elgendy IY, 2020, ESC HEART FAIL, V7, P124, DOI 10.1002/ehf2.12534; Filippone EJ., 2021, CARDIOL RES PRACT, V12, P100065; Forouzanfar MH, 2017, JAMA-J AM MED ASSOC, V317, P165, DOI 10.1001/jama.2016.19043; Fox KM, 2003, LANCET, V362, P782; Fuchs FD, 2020, HYPERTENSION, V75, P285, DOI 10.1161/HYPERTENSIONAHA.119.14240; Hannson L, 1994, Blood Press, V3, P248, DOI 10.3109/08037059409102265; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Kreutz R, 2022, J HYPERTENS, V40, P839, DOI 10.1097/HJH.0000000000003056; Law MR, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1665; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; Lewis CE, 2021, NEW ENGL J MED, V384, P1921, DOI 10.1056/NEJMoa1901281; Lithell H, 2003, J HYPERTENS, V21, P875, DOI 10.1097/00004872-200305000-00011; Liu LS, 2009, HYPERTENS RES, V32, P1032, DOI 10.1038/hr.2009.139; Liu LS, 2005, J HYPERTENS, V23, P2157, DOI 10.1097/01.hjh.0000194120.42722.ac; Liu LS, 1998, J HYPERTENS, V16, P1823, DOI 10.1097/00004872-199816120-00016; Lonn EM, 2016, NEW ENGL J MED, V374, P2009, DOI 10.1056/NEJMoa1600175; Luders S, 2008, J HYPERTENS, V26, P1487, DOI 10.1097/HJH.0b013e3282ff8864; MacMahon S, 2001, LANCET, V358, P1033, DOI 10.1016/S0140-6736(01)06178-5; MacMahon S, 2000, J AM COLL CARDIOL, V36, P438, DOI 10.1016/S0735-1097(00)00736-1; Mancia G, 2014, HYPERTENSION, V63, P29, DOI [10.1161/HYPERTENSIONAHA.113.01922, 10.1161/01.hyp.0000441190.09494.e9]; Marre M, 2004, BRIT MED J, V328, P495, DOI 10.1136/bmj.37970.629537.0D; McMurray JJ, 2010, NEW ENGL J MED, V362, P1477, DOI 10.1056/NEJMoa1001121; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; Messerli FH, 2009, J AM COLL CARDIOL, V54, P279, DOI [10.1016/j.jacc.2009.03.053, 10.1016/j.jacc.2009.05.073]; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; Nissen SE, 2004, JAMA-J AM MED ASSOC, V292, P2217, DOI 10.1001/jama.292.18.2217; Ogihara T, 2010, HYPERTENSION, V56, P196, DOI 10.1161/HYPERTENSIONAHA.109.146035; Page MJ, 2021, BMJ-BRIT MED J, V372, DOI [10.1136/bmj.n71, 10.1016/j.ijsu.2021.105906]; Patel A, 2007, LANCET, V370, P829, DOI 10.1016/S0140-6736(07)61303-8; Pitt B, 2000, CIRCULATION, V102, P1503, DOI 10.1161/01.CIR.102.13.1503; Poole-Wilson PA, 2004, LANCET, V364, P849, DOI 10.1016/S0140-6736(04)16980-8; Pouchain D, 2021, EXERCER, P262, DOI 10.1016/S0140-6736(21)00590-0; Rahman F, 2017, CURR ATHEROSCLER REP, V19, DOI 10.1007/s11883-017-0670-1; RUTAN GH, 1988, CIRCULATION, V77, P504, DOI 10.1161/01.CIR.77.3.504; RUTAN GH, 1989, J CLIN EPIDEMIOL, V42, P663, DOI 10.1016/0895-4356(89)90010-3; Salam A, 2019, J HYPERTENS, V37, P1567, DOI 10.1097/HJH.0000000000002089; Salam A, 2019, J HYPERTENS, V37, P16, DOI 10.1097/HJH.0000000000001994; Salvador VD., 2022, CARDIOL RES PRACT, V13, P100079; Schrier RW, 2002, KIDNEY INT, V61, P1086, DOI 10.1046/j.1523-1755.2002.00213.x; Shi LY, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015987; Stamler J, 1989, Hypertension, V13, pI2; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Stevens GA, 2016, LANCET, V388, pE19, DOI 10.1016/S0140-6736(16)30388-9; Stevens SL, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i4098; Unger T, 2020, J HYPERTENS, V38, P982, DOI 10.1097/HJH.0000000000002453; Verdecchia P, 2009, LANCET, V374, P525, DOI 10.1016/S0140-6736(09)61340-4; Vos T, 2020, LANCET, V396, P1562; Wang R, 2020, N ENGL J MED, V382, P1199; Whelton PK, 2018, J AM COLL CARDIOL, V71, pE127, DOI 10.1016/j.jacc.2017.11.006; Williams B, 2018, J HYPERTENS, V36, P1953, DOI 10.1097/HJH.0000000000001940; Wright JT, 2015, NEW ENGL J MED, V373, P2103, DOI 10.1056/NEJMoa1511939; Yusuf S, 2008, LANCET, V372, P1174, DOI 10.1016/S0140-6736(08)61242-8; Yusuf S, 2000, NEW ENGL J MED, V342, P145; Yusuf S, 2008, NEW ENGL J MED, V359, P1225, DOI 10.1056/NEJMoa0804593; Yusuf S, 2011, NEW ENGL J MED, V364, P928, DOI 10.1056/NEJMoa1008816; Zheng P., NAT MED; Zheng P, 2021, J COMPUT GRAPH STAT, V30, P544, DOI 10.1080/10618600.2020.1868303; Zhou B, 2021, LANCET, V398, P957, DOI 10.1016/S0140-6736(21)01330-1	73	3	3	2	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01974-1	http://dx.doi.org/10.1038/s41591-022-01974-1		OCT 2022	25	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	5E6IE	36216934	Green Published, hybrid			2022-12-27	WOS:000865725700007
J	Rebbeck, TR; Mahal, B; Maxwell, KN; Garraway, IP; Yamoah, K				Rebbeck, Timothy R.; Mahal, Brandon; Maxwell, Kara N.; Garraway, Isla P.; Yamoah, Kosj			The distinct impacts of race and genetic ancestry on health COMMENT	NATURE MEDICINE			English	Editorial Material								Genetic ancestry affects human health, but this is distinct from the impact of race, a social construct that has its foundations in systemic racism. These terms need to be better defined and understood in medical research to achieve health equity.	[Rebbeck, Timothy R.] Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA; [Rebbeck, Timothy R.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Mahal, Brandon] Univ Miami, Sylvester Canc Ctr, Miami, FL USA; [Maxwell, Kara N.] Univ Penn, Dept Med, Sch Med, Philadelphia, PA USA; [Maxwell, Kara N.] Univ Penn, Abramson Canc Ctr, Sch Med, Philadelphia, PA USA; [Maxwell, Kara N.] Univ Penn, Michael Crescenz VA Med Ctr, Sch Med, Philadelphia, PA USA; [Garraway, Isla P.] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA; [Garraway, Isla P.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA; [Garraway, Isla P.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA; [Yamoah, Kosj] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Dana-Farber Cancer Institute; University of Miami; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; H Lee Moffitt Cancer Center & Research Institute	Rebbeck, TR (corresponding author), Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA.; Rebbeck, TR (corresponding author), Dana Farber Canc Inst, Boston, MA 02115 USA.	timothy_rebbeck@dfci.harvard.edu	Rebbeck, Timothy/GLU-8348-2022	Rebbeck, Timothy/0000-0002-4799-1900; Yamoah, Kosj/0000-0001-9055-3538	Department of Defense award [CDMRP-PC181013]; Prostate Cancer Foundation; National Cancer Institute [P20-CA233255]; Jean Perkins Foundation; STOP Cancer Foundation; National Cancer Institute; Specialized Programs of Research Excellence grant [P50 CA092131]; Prostate Cancer Foundation Challenge Award [17CHAL04]; National Institutes of Health [K08CA215312]; Burroughs Wellcome Foundation [1017184]; Basser Center for BRCA at the University of Pennsylvania	Department of Defense award(United States Department of Defense); Prostate Cancer Foundation; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Jean Perkins Foundation; STOP Cancer Foundation; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Specialized Programs of Research Excellence grant; Prostate Cancer Foundation Challenge Award; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs Wellcome Foundation(Burroughs Wellcome Fund); Basser Center for BRCA at the University of Pennsylvania	This work was supported in part by Department of Defense award CDMRP-PC181013 and Prostate Cancer Foundation (K.Y.); National Cancer Institute grant P20-CA233255 (K.Y. and T.R.R.); Jean Perkins Foundation, STOP Cancer Foundation, National Cancer Institute and Specialized Programs of Research Excellence grant P50 CA092131 and Prostate Cancer Foundation Challenge Award 17CHAL04 (I.P.G.); and National Institutes of Health (K08CA215312), Burroughs Wellcome Foundation (1017184), Basser Center for BRCA at the University of Pennsylvania, and the Prostate Cancer Foundation (K.M.).	Awasthi S, 2021, CLIN CANCER RES, V27, P320, DOI 10.1158/1078-0432.CCR-20-2925; Barot R, 2001, ETHNIC RACIAL STUD, V24, P601, DOI 10.1080/01419870120049806; Braveman P, 2021, FRONT PUBLIC HEALTH, V9, DOI 10.3389/fpubh.2021.689462; Cooperberg MR, 2018, EUR UROL, V74, P444, DOI 10.1016/j.eururo.2018.05.014; DeSantis CE, 2019, CA-CANCER J CLIN, V69, P438, DOI 10.3322/caac.21583; Friebel TM, 2019, HUM MUTAT, V40, P1781, DOI 10.1002/humu.23804; Fuentes A, 2019, AM J PHYS ANTHROPOL, V169, P400, DOI 10.1002/ajpa.23882; GOLDBERG DT, 1992, ETHNIC RACIAL STUD, V15, P543, DOI 10.1080/01419870.1992.9993763; Hsu C, 2021, NEW ENGL J MED, V385, P1750, DOI 10.1056/NEJMoa2103753; Mahal BA, 2020, NEW ENGL J MED, V383, P1083, DOI 10.1056/NEJMc2000069; Manrai AK, 2016, NEW ENGL J MED, V375, P655, DOI 10.1056/NEJMsa1507092; Mathieson I, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008624; Mersha TB, 2015, HUM GENOMICS, V9, DOI 10.1186/s40246-014-0023-x; Office of the Assistant Secretary for Planning and Evaluation, 2021, HHS DATA; Omi M., 2015, RACIAL FORMATION US; Rebbeck TR, 2018, CANCER DISCOV, V8, P803, DOI 10.1158/2159-8290.CD-17-1415; Templeton AR, 2013, STUD HIST PHI PART C, V44, P262, DOI 10.1016/j.shpsc.2013.04.010	17	2	2	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2022	28	5					890	893		10.1038/s41591-022-01796-1	http://dx.doi.org/10.1038/s41591-022-01796-1		MAY 2022	4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	1J3AM	35534567				2022-12-27	WOS:000792548400004
J	Choutka, J; Jansari, V; Hornig, M; Iwasaki, A				Choutka, Jan; Jansari, Viraj; Hornig, Mady; Iwasaki, Akiko			Unexplained post-acute infection syndromesUnexplained post-acute infection syndromes	NATURE MEDICINE			English	Review							EBOLA-VIRUS DISEASE; CHRONIC-FATIGUE-SYNDROME; QUALITY-OF-LIFE; LONG-TERM SEQUELAE; RESTLESS LEGS SYNDROME; EARLY LYME-DISEASE; FOLLOW-UP; Q-FEVER; SIERRA-LEONE; RHEUMATIC MANIFESTATIONS	SARS-CoV-2 is not unique in its ability to cause post-acute sequelae; certain acute infections have long been associated with an unexplained chronic disability in a minority of patients. These post-acute infection syndromes (PAISs) represent a substantial healthcare burden, but there is a lack of understanding of the underlying mechanisms, representing a significant blind spot in the field of medicine. The relatively similar symptom profiles of individual PAISs, irrespective of the infectious agent, as well as the overlap of clinical features with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), suggest the potential involvement of a common etiopathogenesis. In this Review, we summarize what is known about unexplained PAISs, provide context for post-acute sequelae of SARS-CoV-2 infection (PASC), and delineate the need for basic biomedical research into the underlying mechanisms behind this group of enigmatic chronic illnesses.	[Choutka, Jan] Univ Chem & Technol, Dept Chem Nat Cpds, Prague, Czech Republic; [Jansari, Viraj; Iwasaki, Akiko] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA; [Hornig, Mady] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY USA; [Iwasaki, Akiko] Yale Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT 06510 USA; [Iwasaki, Akiko] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; [Iwasaki, Akiko] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA	University of Chemistry & Technology, Prague; Yale University; Columbia University; Yale University; Yale University; Howard Hughes Medical Institute	Choutka, J (corresponding author), Univ Chem & Technol, Dept Chem Nat Cpds, Prague, Czech Republic.; Iwasaki, A (corresponding author), Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA.; Iwasaki, A (corresponding author), Yale Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT 06510 USA.; Iwasaki, A (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA.; Iwasaki, A (corresponding author), Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.	choutka.jan@gmail.com; akiko.iwasaki@yale.edu		Hornig, Mady/0000-0001-7572-3092				Adaken C, 2021, NATURE, V590, P468, DOI 10.1038/s41586-020-03146-y; Adrion ER, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116767; Ankert J, 2022, TRANSBOUND EMERG DIS, V69, P2219, DOI 10.1111/tbed.14224; [Anonymous], 2020, COVID 19 RAP GUID MA; Aucott JN, 2022, INT J INFECT DIS, V116, P230, DOI 10.1016/j.ijid.2022.01.033; Aucott JN, 2013, QUAL LIFE RES, V22, P75, DOI 10.1007/s11136-012-0126-6; Ayoubkhani D., 2022, PREVALENCE ONGOING S; Ayoubkhani D., 2021, TECHNICAL ARTICLE UP; Ayres JG, 2002, QJM-INT J MED, V95, P539, DOI 10.1093/qjmed/95.8.539; Ayres JG, 1998, QJM-MON J ASSOC PHYS, V91, P105, DOI 10.1093/qjmed/91.2.105; Balakrishnan A, 2016, J MED VIROL, V88, P1856, DOI 10.1002/jmv.24545; Balcom EF, 2021, BRAIN, V144, P3576, DOI 10.1093/brain/awab302; Bastard P, 2020, SCIENCE, V370, P423, DOI 10.1126/science.abd4585; Bechtold KT, 2017, ARCH CLIN NEUROPSYCH, V32, P129, DOI 10.1093/arclin/acw098; BERLLY MH, 1991, ARCH PHYS MED REHAB, V72, P115; Bjornevik K, 2022, SCIENCE, V375, P296, DOI 10.1126/science.abj8222; Blettery M, 2016, ARTHRITIS RHEUMATOL, V68, P2817, DOI 10.1002/art.39775; Blitshteyn S, 2021, IMMUNOL RES, V69, P205, DOI 10.1007/s12026-021-09185-5; Blomberg B, 2021, NAT MED, V27, P1607, DOI 10.1038/s41591-021-01433-3; Bond NG, 2021, CLIN INFECT DIS, V73, P1046, DOI 10.1093/cid/ciab267; Bouquillard E, 2018, JOINT BONE SPINE, V85, P207, DOI 10.1016/j.jbspin.2017.01.014; Bronner MB, 2020, J PSYCHOSOM RES, V139, DOI 10.1016/j.jpsychores.2020.110258; Buchwald DS, 2000, AM J MED, V109, P531, DOI 10.1016/S0002-9343(00)00560-X; Canavan C, 2014, CLIN EPIDEMIOL, V6, P71, DOI 10.2147/CLEP.S40245; Caress JB, 2020, MUSCLE NERVE, V62, P485, DOI 10.1002/mus.27024; Carruthers BM, 2003, J CHRONIC FATIGUE SY, V11, P7, DOI [DOI 10.1300/J092V11N01_02, 10.1300/J092v11n01_02]; Carson PJ, 2006, CLIN INFECT DIS, V43, P723, DOI 10.1086/506939; Caspersen IH, 2022, EUR J EPIDEMIOL, V37, P539, DOI 10.1007/s10654-022-00847-8; Cerar D, 2010, AM J MED, V123, P79, DOI 10.1016/j.amjmed.2009.05.011; Chang AY, 2018, ARTHRITIS RHEUMATOL, V70, P578, DOI 10.1002/art.40384; Chang SE., 2021, NAT COMMUN, V12, P1, DOI [10.1038/s41467-020-20314-w, DOI 10.1038/S41467-020-20314-W]; Cheung CCL, 2022, GUT, V71, P226, DOI 10.1136/gutjnl-2021-324280; Chia J, 2010, J CLIN PATHOL, V63, P165, DOI 10.1136/jcp.2009.070466; Clark DV, 2015, LANCET INFECT DIS, V15, P905, DOI 10.1016/S1473-3099(15)70152-0; Combes AJ, 2021, NATURE, V591, P124, DOI 10.1038/s41586-021-03234-7; Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue S Board on the Health of Select P Institute of M. The National Academies Collection: Reports funded by National Institutes of Health, 2015, MYALGIC ENCEPHALOMYE; CONDON RJ, 1995, CLIN DIAGN VIROL, V3, P273, DOI 10.1016/S0928-0197(94)00043-3; Cook RL, 2010, AM J TROP MED HYG, V83, P1133, DOI 10.4269/ajtmh.2010.09-0717; Couturier E, 2012, RHEUMATOLOGY, V51, P1315, DOI 10.1093/rheumatology/kes015; Crook H, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n1648; Deng LS, 2020, J INFECTION, V81, pE1, DOI 10.1016/j.jinf.2020.03.002; Diallo B, 2016, CLIN INFECT DIS, V63, P1353, DOI 10.1093/cid/ciw601; DINERMAN H, 1992, ANN INTERN MED, V117, P281, DOI 10.7326/0003-4819-117-4-281; Dupuis-Maguiraga L, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001446; Duvignaud A, 2018, EPIDEMIOL INFECT, V146, P633, DOI [10.1017/S0950268818000031, 10.1017/s0950268818000031]; Estiri H, 2021, BMC MED, V19, DOI [10.1101/2021.04.25.21255923, 10.1186/s12916-021-02115-0]; Etard JF, 2017, LANCET INFECT DIS, V17, P545, DOI 10.1016/S1473-3099(16)30516-3; Fallon BA, 2019, FRONT MED-LAUSANNE, V6, DOI 10.3389/fmed.2019.00283; Fernandez-Castaneda A., 2022, BIORXIV, DOI [10.1101/2022.01.07.475453, DOI 10.1101/2022.01.07.475453]; Fischer WA, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx155; Frontera JAA, 2021, FRONT AGING NEUROSCI, V13, DOI 10.3389/fnagi.2021.690383; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; Gaebler C, 2021, NATURE, V591, P639, DOI [10.1038/s41586-021-03207-w, 10.1101/2020.11.03.367391]; Garcia G, 2011, INT J INFECT DIS, V15, pE38, DOI 10.1016/j.ijid.2010.09.008; Garcia MN, 2014, VIRAL IMMUNOL, V27, P327, DOI 10.1089/vim.2014.0035; Gerardin P, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-5; Gonzalez D., 2005, Dengue Bulletin, V29, P79; Groff D, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.28568; Guo LH, 2019, INT J CLIN EXP MED, V12, P12464; Halsey ES, 2014, AM J TROP MED HYG, V90, P449, DOI 10.4269/ajtmh.13-0544; Harley D, 2002, MED J AUSTRALIA, V177, P352, DOI 10.5694/j.1326-5377.2002.tb04836.x; Hatchette TF, 2003, EPIDEMIOL INFECT, V130, P491, DOI 10.1017/S0950268803008343; Havervall S, 2021, JAMA-J AM MED ASSOC, V325, P2015, DOI 10.1001/jama.2021.5612; Hickie I, 2006, BRIT MED J, V333, P575, DOI 10.1136/bmj.38933.585764.AE; Howlett PJ, 2018, EMERG INFECT DIS, V24, P1412, DOI 10.3201/eid2408.171367; Huang CL, 2021, LANCET, V397, P220, DOI 10.1016/S0140-6736(20)32656-8; Hung TM, 2019, TRENDS PARASITOL, V35, P673, DOI 10.1016/j.pt.2019.06.004; Hunskar GS, 2022, SCAND J PAIN, V22, P348, DOI 10.1515/sjpain-2021-0122; Iijima N, 2016, NATURE, V533, P552, DOI 10.1038/nature17979; Jagadesh S, 2018, CLIN INFECT DIS, V66, P131, DOI 10.1093/cid/cix705; Jason LA, 2021, CLIN INFECT DIS, V73, pE3740, DOI 10.1093/cid/ciaa1886; Jason LA, 2014, HEALTH PSYCHOL BEHAV, V2, P41, DOI 10.1080/21642850.2013.869176; Javelle E, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003603; Carod-Artal FJ, 2015, EXPERT REV ANTI-INFE, V13, P1185, DOI 10.1586/14787210.2015.1079128; Kaminska B, 2016, BBA-MOL BASIS DIS, V1862, P339, DOI 10.1016/j.bbadis.2015.10.026; Katz B, 2019, J PEDIATR-US, V209, P130, DOI 10.1016/j.jpeds.2019.01.035; Katz BZ, 2011, ARCH PEDIAT ADOL MED, V165, P765, DOI 10.1001/archpediatrics.2011.124; Katz BZ, 2009, PEDIATRICS, V124, P189, DOI 10.1542/peds.2008-1879; Keita AK, 2021, NATURE, V597, P539, DOI 10.1038/s41586-021-03901-9; Keita AK, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz482; Kibadi K, 1999, J INFECT DIS, V179, pS13, DOI 10.1086/514288; Klee AL, 2004, EMERG INFECT DIS, V10, P1405, DOI 10.3201/eid1008.030879; Klempner MS, 2001, NEW ENGL J MED, V345, P85, DOI 10.1056/NEJM200107123450202; Komaroff AL, 2021, TRENDS MOL MED, V27, P895, DOI 10.1016/j.molmed.2021.06.002; Korompoki E, 2021, J INFECTION, V83, P1, DOI 10.1016/j.jinf.2021.05.004; Kuberski T, 2008, INFECT MED, V25, P430; Kularatne Sam, 2005, Southeast Asian Journal of Tropical Medicine and Public Health, V36, P1198; Kularatne SAM, 2012, J TROP MED-US, V2012, DOI 10.1155/2012/639178; Lam MHB, 2009, ARCH INTERN MED, V169, P2142, DOI 10.1001/archinternmed.2009.384; Lanz TV, 2022, NATURE, DOI 10.1038/s41586-022-04432-7; LaVergne SM, 2020, J INFECT DIS, V222, P1488, DOI 10.1093/infdis/jiaa268; Leis AA, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00164; Leung-Shea C, 2006, CLIN INFECT DIS, V43, pE77, DOI 10.1086/507639; Li P, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.35397; Lim EJ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02269-0; Litleskare S, 2018, CLIN GASTROENTEROL H, V16, P1064, DOI 10.1016/j.cgh.2018.01.022; Loeb M, 2008, ANN INTERN MED, V149, P232, DOI 10.7326/0003-4819-149-4-200808190-00004; Logue JK, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.0830; Mac S, 2020, CLIN INFECT DIS, V71, P440, DOI 10.1093/cid/ciz1158; Magnus P, 2015, VACCINE, V33, P6173, DOI 10.1016/j.vaccine.2015.10.018; Malik P, 2022, J MED VIROL, V94, P253, DOI 10.1002/jmv.27309; Manimunda SP, 2010, T ROY SOC TROP MED H, V104, P392, DOI 10.1016/j.trstmh.2010.01.011; Marimoutou C, 2012, MEDICINE, V91, P212, DOI 10.1097/MD.0b013e318260b604; Marin LF, 2017, SLEEP MED, V37, P147, DOI 10.1016/j.sleep.2017.06.025; Marmion BP, 1996, LANCET, V347, P977, DOI 10.1016/S0140-6736(96)91469-5; Matthay MA, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0069-0; Mattia JG, 2016, LANCET INFECT DIS, V16, P331, DOI 10.1016/S1473-3099(15)00489-2; Mehandru S, 2022, NAT IMMUNOL, V23, P194, DOI 10.1038/s41590-021-01104-y; Michelen M, 2021, BMJ GLOB HEALTH, V6, DOI 10.1136/bmjgh-2021-005427; Moldofsky H, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-37; Morch K, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-28; Morin L, 2021, JAMA-J AM MED ASSOC, V325, P1525, DOI 10.1001/jama.2021.3331; Moro ML, 2012, J INFECTION, V65, P165, DOI 10.1016/j.jinf.2012.04.005; Morroy G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155884; Moss-Morris R, 2011, PSYCHOL MED, V41, P1099, DOI 10.1017/S003329171000139X; Murray K, 2010, J INFECT DIS, V201, P2, DOI 10.1086/648731; Murray KO, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102953; Mylonas AD, 2002, MED J AUSTRALIA, V177, P356, DOI 10.5694/j.1326-5377.2002.tb04837.x; Naess H, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-13; Nalbandian A, 2021, NAT MED, V27, P601, DOI 10.1038/s41591-021-01283-z; Nanyonga M, 2016, CLIN INFECT DIS, V62, P125, DOI 10.1093/cid/civ795; Nolan MS, 2012, J CLIN PSYCHOL, V68, P801, DOI 10.1002/jclp.21871; Nollet F, 1999, ARCH PHYS MED REHAB, V80, P136, DOI 10.1016/S0003-9993(99)90110-7; Nowakowski J, 2003, AM J MED, V115, P91, DOI 10.1016/S0002-9343(03)00308-5; O'Neal AJ, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.688486; Paixao ES, 2018, T ROY SOC TROP MED H, V112, P301, DOI 10.1093/trstmh/try063; Patel H, 2015, LANCET INFECT DIS, V15, P951, DOI 10.1016/S1473-3099(15)00134-6; Patnaik JL, 2006, EMERG INFECT DIS, V12, P1129, DOI 10.3201/eid1207.051399; Pedersen M, 2019, BRAIN BEHAV IMMUN, V75, P94, DOI 10.1016/j.bbi.2018.09.023; Peghin M, 2021, CLIN MICROBIOL INFEC, V27, P1507, DOI 10.1016/j.cmi.2021.05.033; Petersen I, 2006, QJM-INT J MED, V99, P49, DOI 10.1093/qjmed/hci149; Pretorius E, 2021, CARDIOVASC DIABETOL, V20, DOI 10.1186/s12933-021-01359-7; Proal AD, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.698169; Qadir MMF, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.151551; Qureshi AI, 2015, CLIN INFECT DIS, V61, P1035, DOI 10.1093/cid/civ453; R. A. Evans, 2021, medRxiv, DOI 10.1101/2021.12.13.21267471; Ragonese P, 2005, J NEUROL SCI, V236, P31, DOI 10.1016/j.jns.2005.04.012; Rahim AA, 2016, J RHEUMATOL, V43, P440, DOI 10.3899/jrheum.141609; Ramachandran V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051519; RAMLOW J, 1992, AM J EPIDEMIOL, V136, P769, DOI 10.1093/aje/136.7.769; Rebman AW, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00057; Rebman AW, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00224; Rodriguez-Morales AJ, 2016, ARTHRIT CARE RES, V68, P1849, DOI 10.1002/acr.22900; Rogers JP, 2020, LANCET PSYCHIAT, V7, P611, DOI 10.1016/S2215-0366(20)30203-0; Rojas M, 2020, J AUTOIMMUN, V106, DOI 10.1016/j.jaut.2019.102375; Rojas M, 2018, J AUTOIMMUN, V95, P100, DOI 10.1016/j.jaut.2018.10.012; Romigi A, 2015, EUR J NEUROL, V22, P472, DOI 10.1111/ene.12593; Rowe AK, 1999, J INFECT DIS, V179, pS28, DOI 10.1086/514318; Sadek JR, 2010, J CLIN EXP NEUROPSYC, V32, P81, DOI 10.1080/13803390902881918; Samaan Z, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158364; Schilte C, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002137; Seet RCS, 2007, J CLIN VIROL, V38, P1, DOI 10.1016/j.jcv.2006.10.011; Sejvar JJ, 2008, J NEUROPSYCHOL, V2, P477, DOI 10.1348/174866407X218312; Seltzer EG, 2000, JAMA-J AM MED ASSOC, V283, P609, DOI 10.1001/jama.283.5.609; SHADICK NA, 1994, ANN INTERN MED, V121, P560, DOI 10.7326/0003-4819-121-8-199410150-00002; Shadick NA, 1999, ANN INTERN MED, V131, P919, DOI 10.7326/0003-4819-131-12-199912210-00003; Shantha JG, 2017, CURR OPIN OPHTHALMOL, V28, P600, DOI 10.1097/ICU.0000000000000426; Shantha JG, 2017, OPHTHALMOLOGY, V124, P170, DOI 10.1016/j.ophtha.2016.10.011; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; Shing SLH, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00773; Sigera PC., 2021, T R SOC TROP MED HYG, V115, P669, DOI 10.1093/trstmh/traa110; Sigfrid L, 2021, LANCET REG HEALTH-EU, V8, DOI 10.1016/j.lanepe.2021.100186; Teixeira LD, 2017, REV INST MED TROP SP, V59, DOI [10.1590/S1678-9946201759065, 10.1590/s1678-9946201759065]; Sissoko D, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000389; Smith MP, 2022, J CLIN EPIDEMIOL, V142, P54, DOI 10.1016/j.jclinepi.2021.10.018; Smith RP, 2002, ANN INTERN MED, V136, P421, DOI 10.7326/0003-4819-136-6-200203190-00005; Sneller MC, 2019, NEW ENGL J MED, V380, P924, DOI 10.1056/NEJMoa1805435; Soumahoro MK, 2009, PLOS ONE, V4, pA221, DOI 10.1371/journal.pone.0007800; Stefano GB, 2021, MED SCI MONITOR, V27, DOI 10.12659/MSM.931447; Steptoe PJ, 2017, EMERG INFECT DIS, V23, P1102, DOI 10.3201/eid2307.161608; Stormorken E, 2017, BMC FAM PRACT, V18, DOI 10.1186/s12875-017-0614-4; Su YP, 2022, CELL, V185, P881, DOI 10.1016/j.cell.2022.01.014; Takemura J, 2004, J REHABIL MED, V36, P1, DOI 10.1080/16501970310017423; Tansey CM, 2007, ARCH INTERN MED, V167, P1312, DOI 10.1001/archinte.167.12.1312; Taquet M, 2021, PLOS MED, V18, DOI 10.1371/journal.pmed.1003773; Tiffany A, 2016, CLIN INFECT DIS, V62, P1360, DOI 10.1093/cid/ciw158; Torjesen I, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n829; Tozay S, 2020, CLIN INFECT DIS, V71, P1749, DOI 10.1093/cid/ciz1062; Tsai SY, 2014, EUR J CLIN MICROBIOL, V33, P1653, DOI 10.1007/s10096-014-2095-x; Umakanth M, 2018, OALIB, V05, P1; Ursinus J, 2021, LANCET REG HEALTH-EU, V6, DOI 10.1016/j.lanepe.2021.100142; US Centers for Disease Control and Prevention, 2021, POSTCOVID COND; Vallings R, 2010, J CLIN PATHOL, V63, P184, DOI 10.1136/jcp.2009.071944; van Loenhout JAF, 2015, J INFECTION, V70, P237, DOI 10.1016/j.jinf.2014.10.010; van Woerden HC, 2011, MICROBIOL RES-ITALY, V2, DOI 10.4081/mr.2011.e19; Vieira SM, 2018, SCIENCE, V359, P1156, DOI 10.1126/science.aar7201; Visconti A, 2021, BRIT J DERMATOL, V184, P880, DOI 10.1111/bjd.19807; Wallukat G, 2021, J TRANSL AUTOIMMUN, V4, DOI 10.1016/j.jtauto.2021.100100; Wang EY, 2021, NATURE, V595, P283, DOI [10.1038/s41586-021-03631-y, 10.1101/2020.12.10.20247205]; Weitzner E, 2015, CLIN INFECT DIS, V61, P1800, DOI 10.1093/cid/civ735; White PD, 1998, BRIT J PSYCHIAT, V173, P475, DOI 10.1192/bjp.173.6.475; Wiedemann A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17489-7; Wildman MJ, 2002, QJM-INT J MED, V95, P527, DOI 10.1093/qjmed/95.8.527; Wilson HW, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/1909410; Wong TL, 2021, MEDICINA-LITHUANIA, V57, DOI 10.3390/medicina57050418; Woodruff M. C., 2021, ARTHRITIS RHEUMATOL, DOI 10.1101/2020.10.21.20216192; World Health Organization, 2021, CLIN CAS DEF POST CO; Wormser GP, 2020, CLIN INFECT DIS, V71, P3118, DOI 10.1093/cid/ciz1215; Xie Y, 2022, BMJ-BRIT MED J, V376, DOI 10.1136/bmj-2021-068993; Yagiz A, 2006, J REHABIL MED, V38, P329, DOI 10.1080/16501970600722395; Yeung MW, 2017, HEALTH QUAL LIFE OUT, V15, DOI 10.1186/s12955-017-0787-5; Z. Amin-Chowdhury, 2021, medRxiv, DOI 10.1101/2021.03.18.21253633; Zhou YQ, 2020, CTS-CLIN TRANSL SCI, V13, P1077, DOI 10.1111/cts.12805; Zuniga M, 2021, EUR RESPIR J, V58, DOI 10.1183/13993003.00918-2021; Zuo Y, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abd3876	206	17	17	9	10	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2022	28	5					911	923		10.1038/s41591-022-01810-6	http://dx.doi.org/10.1038/s41591-022-01810-6			13	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	1J3AM	35585196	Bronze			2022-12-27	WOS:000797792500015
J	Nielsen, TH				Nielsen, TH			Behind the color code of ''no''	NATURE BIOTECHNOLOGY			English	Editorial Material											Nielsen, TH (corresponding author), UNIV OSLO,CTR TECHNOL & CULTURE,GAUSTADALLEEN 21,N-0371 OSLO,NORWAY.							*BIOT EUR PUBL CON, 1997, NATURE, V387, P845; Bud R., 1993, USELIFE HIST BIOTE; INRA, 1991, EUR 35 1 OP EUR BIOT; *INRA, 1997, EUR 46 1 EUR BIOT MO; INRA (Europe) & Marlier, 1993, EUR 39 1 BIOT GEN EN; Nelkin D., 1995, DNA MYSTIQUE GENE CU; Toulmin S., 1979, INTRO REASONING; Toulmin Stephen, 1958, USES ARGUMENT	8	8	8	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	1997	15	13					1320	1321		10.1038/nbt1297-1320	http://dx.doi.org/10.1038/nbt1297-1320			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YK361	9415871				2022-12-27	WOS:A1997YK36100004
J	Pipia, GG; Long, MW				Pipia, GG; Long, MW			Human hematopoietic progenitor cell isolation based on galactose-specific cell surface binding	NATURE BIOTECHNOLOGY			English	Article						CD34; lectin; progenitor; galactose; hematopoiesis	HUMAN BONE-MARROW; CORD-BLOOD; PERIPHERAL-BLOOD; STEM-CELLS; ENRICHMENT; EXPRESSION; MOLECULES	The ability to isolate functional populations of hematopoietic progenitor cells is important to the process of hematopoietic cell transplantation and to the understanding of hematopoietic cell biology in health and disease. We show that a subpopulation of human bone marrow hematopoietic cells bearing the pan-hematopoietic antigen CD34 also binds galactose-conjugated proteins. This lectin-positive subpopulation represents approximately 0.1 to 0.5% of the total bone marrow cells, and contains 100% of the hematopoietic progenitor cells. The galactose-binding lectin on these cells is specific for this sugar. Additionally, highly proliferative hematopoietic progenitor cells with very primitive phenotypes, including a newly identified progenitor cell that produces multiple lineages, express this lectin.	UNIV MICHIGAN,DEPT PEDIAT,ANN ARBOR,MI 48109; UNIV MICHIGAN,GRAD PROGRAM CELLULAR & MOL BIOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NHLBI NIH HHS [HL1459, HL58709] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIZAWA S, 1987, P NATL ACAD SCI USA, V84, P4485, DOI 10.1073/pnas.84.13.4485; BERARDI AC, 1995, SCIENCE, V267, P104, DOI 10.1126/science.7528940; CAROW CE, 1993, BLOOD, V81, P942; CRAIG W, 1993, J EXP MED, V177, P1331, DOI 10.1084/jem.177.5.1331; DEWYNTER EA, 1995, STEM CELLS, V13, P532; HARDY CL, 1991, EXP HEMATOL, V19, P968; HUYHN A, 1995, BLOOD, V86, P4474, DOI 10.1182/blood.V86.12.4474.bloodjournal86124474; LANSDORP PM, 1990, J EXP MED, V172, P363, DOI 10.1084/jem.172.1.363; LONG MW, 1988, J CLIN INVEST, V82, P1779, DOI 10.1172/JCI113791; LONG MW, 1992, EXP HEMATOL, V20, P288; LONG MW, 1992, J CLIN INVEST, V90, P251, DOI 10.1172/JCI115844; MCNEICE IK, 1989, BLOOD, V74, P609; MURRAY L, 1995, BLOOD, V85, P368; NAGLER A, 1994, EXP HEMATOL, V22, P1134; RUSTEN LS, 1994, BLOOD, V84, P1473; SULLENBARGER BA, 1995, BLOOD, V86, P135, DOI 10.1182/blood.V86.1.135.bloodjournal861135; Sutherland D R, 1992, J Hematother, V1, P115, DOI 10.1089/scd.1.1992.1.115; VANEPPS DE, 1994, BLOOD CELLS, V20, P411	18	7	7	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1997	15	10					1007	1011		10.1038/nbt1097-1007	http://dx.doi.org/10.1038/nbt1097-1007			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XZ285	9335055				2022-12-27	WOS:A1997XZ28500034
J	Zoubenko, O; Uckun, F; Hur, Y; Chet, I; Tumer, N				Zoubenko, O; Uckun, F; Hur, Y; Chet, I; Tumer, N			Plant resistance to fungal infection induced by nontoxic pokeweed antiviral protein mutants	NATURE BIOTECHNOLOGY			English	Article						transgenic plant resistance; pathogenesis related proteins; salicylic acid	RIBOSOME-INACTIVATING PROTEINS; SYSTEMIC ACQUIRED-RESISTANCE; PATHOGENESIS-RELATED PROTEINS; TRANSGENIC TOBACCO; RHIZOCTONIA-SOLANI; SALICYLIC-ACID; TRANSLOCATED SIGNAL; VIRUS-RESISTANCE; EXPRESSION; PROTECTION	Pokeweed antiviral protein (PAP), a 29-kD protein isolated from Phytolacca americana inhibits translation by catalytically removing a specific adenine residue from the large rRNA of the 60S subunit of eukaryotic ribosomes. Transgenic plants expressing PAP are resistant to a broad spectrum of plant viruses. Nontoxic PAP mutants have been isolated by random mutagenesis and selection in yeast. One of these mutants, PAP-X, had a point mutation at the active-site (E176V) that abolished enzymatic activity, and another mutant, Delta C25PAP, had a nonsense mutation near the C-terminus (W237stop) that deleted 25 C-terminal amino acids. Unlike the wild-type PAP, expression of neither mutant was toxic to transgenic plants. We show that both class I (basic) and class II (acidic) isoforms of pathogenesis-related (PR) proteins are overexpressed in transgenic plants expressing PAP and the nontoxic PAP mutants. Although PR-proteins are constitutively expressed, no increase in salicylic acid levels was detected. Homozygous progeny of transgenic plants expressing either PAP or the nontoxic PAP mutants displayed resistance to the fungal pathogen Rhizoctonia solani. These results show that expression of PAP or the nontoxic PAP mutants activates multiple plant defense pathways independently of salicylic acid and confers resistance to fungal infection. The C-terminal 25 amino acids of PAP, which are required for toxicity in vivo, are not critical for resistance to viral or fungal infection, indicating that toxicity of PAP can be separated from pathogen resistance.	RUTGERS STATE UNIV,COOK COLL,AGR BIOTECHNOL CTR,NEW BRUNSWICK,NJ 08903; HUGHES INST,ROSEVILLE,MN; HEBREW UNIV JERUSALEM,FAC AGR,IL-76100 REHOVOT,ISRAEL	Rutgers State University New Brunswick; Hebrew University of Jerusalem				Uckun, Fatih M./0000-0001-9334-183X; Hur, Yoonkang/0000-0002-2325-2249				ALEXANDER D, 1993, P NATL ACAD SCI USA, V90, P7327, DOI 10.1073/pnas.90.15.7327; ANDERSON NA, 1982, ANNU REV PHYTOPATHOL, V20, P329, DOI 10.1146/annurev.py.20.090182.001553; BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6; BEFFA R, 1995, EMBO J, V14, P5753, DOI 10.1002/j.1460-2075.1995.tb00264.x; BROGLIE K, 1991, SCIENCE, V254, P1194, DOI 10.1126/science.254.5035.1194; CHEN ZC, 1991, PLANT PATHOL, V40, P612, DOI 10.1111/j.1365-3059.1991.tb02426.x; Dangl JL, 1996, PLANT CELL, V8, P1793, DOI 10.1105/tpc.8.10.1793; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; ENDO Y, 1988, BIOCHIM BIOPHYS ACTA, V994, P224; GREENBERG JT, 1993, PLANT J, V4, P327, DOI 10.1046/j.1365-313X.1993.04020327.x; HammondKosack KE, 1996, PLANT CELL, V8, P1773, DOI 10.1105/tpc.8.10.1773; HUR Y, 1995, P NATL ACAD SCI USA, V92, P8448, DOI 10.1073/pnas.92.18.8448; Irvin JD, 1995, ANTIVIRAL PROTEINS H, P65; JACH G, 1995, PLANT J, V8, P97, DOI 10.1046/j.1365-313X.1995.08010097.x; LINTHORST HJM, 1990, MOL PLANT MICROBE IN, V3, P252, DOI 10.1094/MPMI-3-252; LODGE JK, 1993, P NATL ACAD SCI USA, V90, P7089, DOI 10.1073/pnas.90.15.7089; LOGEMANN J, 1992, BIO-TECHNOL, V10, P305, DOI 10.1038/nbt0392-305; MITTLER R, 1994, PLANT J, V5, P397, DOI 10.1111/j.1365-313X.1994.00397.x; OGOSHI A, 1987, ANNU REV PHYTOPATHOL, V25, P125, DOI 10.1146/annurev.py.25.090187.001013; RALS J, 1994, PLANT PHYSIOL, V104, P1108; ROSS AF, 1961, VIROLOGY, V14, P340, DOI 10.1016/0042-6822(61)90319-1; Ryals JA, 1996, PLANT CELL, V8, P1809, DOI 10.1105/tpc.8.10.1809; SHULAEV V, 1995, PLANT CELL, V7, P1691, DOI 10.1105/tpc.7.10.1691; Smirnov S, 1997, PLANT PHYSIOL, V114, P1113, DOI 10.1104/pp.114.3.1113; SNEDECOR GW, 1980, STATISTICAL METHODS, P201; STIRPE F, 1992, BIO-TECHNOL, V10, P405, DOI 10.1038/nbt0492-405; TAYLOR S, 1994, PLANT J, V5, P827, DOI 10.1046/j.1365-313X.1994.5060827.x; Tumer NE, 1997, P NATL ACAD SCI USA, V94, P3866, DOI 10.1073/pnas.94.8.3866; VERNOOIJ B, 1994, PLANT CELL, V6, P959, DOI 10.1105/tpc.6.7.959; VIERHEILIG H, 1993, MOL PLANT MICROBE IN, V6, P261, DOI 10.1094/MPMI-6-261; YALPANI N, 1993, PHYTOPATHOLOGY, V83, P702, DOI 10.1094/Phyto-83-702; YALPANI N, 1991, PLANT CELL, V3, P809, DOI 10.1105/tpc.3.8.809; ZHU Q, 1994, BIO-TECHNOL, V12, P807, DOI 10.1038/nbt0894-807	33	70	90	0	10	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1997	15	10					992	996		10.1038/nbt1097-992	http://dx.doi.org/10.1038/nbt1097-992			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XZ285	9335052				2022-12-27	WOS:A1997XZ28500031
J	Brismar, H; Ulfhake, B				Brismar, H; Ulfhake, B			Fluorescence lifetime measurements in confocal microscopy of neurons labeled with multiple fluorophores	NATURE BIOTECHNOLOGY			English	Article						neuropeptides; primary sensory neuron; immunohistochemistry; colocalization	VARIABLE-FREQUENCY PHASE; SENSORY NEURONS; MODULATION DATA; DORSAL HORN; SUBSTANCE-P; SPINAL-CORD; RESOLUTION; NEUROPEPTIDES; COEXISTENCE; LAMINAE	In order to resolve multiple fluorophores by their lifetimes in discrete tissue domains, the labeling intensity must be sufficiently strong and the intensity-difference between the labels must not be too large, the rate of fading should be similar for all fluorophores, and the lifetimes of the fluorophores should be sufficiently discrete. We could readily distinguish Cyanine-3.18 (Cy-3), Lissamine Rhodamine (LRSC), and Texas Red when they were not colocalized in tissue profiles. Colocalization of Cy-3 and LRSC, as well as Cy3 and Texas Red, could also be distinguished, while the combination of LRSC and Texas Red was more difficult. We have used fluorescence lifetime recordings in confocal microscopy to detect different neuropeptides in neurons. We demonstrate that somatostatin and galanin are colocalized in axon profiles of the spinal cord dorsal horn.	KAROLINSKA INST,DEPT NEUROSCI,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet	Brismar, H (corresponding author), ROYAL INST TECHNOL,S-10044 STOCKHOLM,SWEDEN.		Brismar, Hjalmar/E-8524-2011; Ulfhake, Brun/AAG-8969-2020	Brismar, Hjalmar/0000-0003-0578-4003; Ulfhake, Brun/0000-0001-5037-7461	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041301] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-41301] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1993, NEUROPROTOCOLS; ARVIDSSON U, 1990, SYNAPSE, V6, P237, DOI 10.1002/syn.890060305; ASLUND N, 1987, APPL OPTICS, V26, P3232; ASLUND N, 1994, SPIE P, V2184; BRISMAR H, 1995, J HISTOCHEM CYTOCHEM, V43, P699, DOI 10.1177/43.7.7608524; BUUMANN EP, 1992, SCANNING, V14, P155; CAMERON AA, 1988, NEUROSCIENCE, V27, P969, DOI 10.1016/0306-4522(88)90200-X; FLORIJN RJ, 1995, CYTOMETRY, V19, P77; GADELLA TWJ, 1993, BIOPHYS CHEM, V48, P221, DOI 10.1016/0301-4622(93)85012-7; GHIGGINO KP, 1992, REV SCI INSTRUM, V63, P2999, DOI 10.1063/1.1142599; GRATTON E, 1984, BIOPHYS J, V46, P479, DOI 10.1016/S0006-3495(84)84044-8; GRATTON E, 1983, BIOPHYS J, V44, P315, DOI 10.1016/S0006-3495(83)84305-7; Hunt S. P., 1983, CHEM NEUROANATOMY, P53; JU G, 1987, CELL TISSUE RES, V247, P417; KOLLNER M, 1992, CHEM PHYS LETT, V200, P199, DOI 10.1016/0009-2614(92)87068-Z; Lakowicz J.R., 2006, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LAKOWICZ JR, 1992, ANAL BIOCHEM, V202, P316, DOI 10.1016/0003-2697(92)90112-K; LAKOWICZ JR, 1984, BIOPHYS J, V46, P463, DOI 10.1016/S0006-3495(84)84043-6; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MORGAN CG, 1991, J MICROSC, V165, P49; MOSSBERG K, 1990, J HISTOCHEM CYTOCHEM, V38, P179, DOI 10.1177/38.2.1967620; O'Connor D. V., 1984, TIME CORRELATED SING; OIDA T, 1993, BIOPHYS J, V64, P676, DOI 10.1016/S0006-3495(93)81427-9; SASAKI K, 1991, APPL SPECTROSC, V45, P1041, DOI 10.1366/0003702914336336; SPENCER RD, 1969, ANN NY ACAD SCI, V158, P361, DOI 10.1111/j.1749-6632.1969.tb56231.x; TODD AJ, 1993, PROG NEUROBIOL, V41, P609, DOI 10.1016/0301-0082(93)90045-T; TUCHSCHERER MM, 1989, J NEUROSCI, V9, P195; WEBER G, 1981, J PHYS CHEM-US, V85, P949, DOI 10.1021/j150608a006; WESSENDORF MW, 1990, ANAL NEURONAL MICROC; Willis WD, 1991, SENSORY MECH SPINAL; XU Z, 1994, THESIS KAROLINSKA I	31	26	28	0	11	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1997	15	4					373	377		10.1038/nbt0497-373	http://dx.doi.org/10.1038/nbt0497-373			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WQ554	9094141				2022-12-27	WOS:A1997WQ55400040
J	Zhang, X; Gaubin, M; Briant, L; Srikantan, V; Murali, R; Saragovi, U; Weiner, D; Devaux, C; Autiero, M; PiatierTonneau, D; Greene, MI				Zhang, X; Gaubin, M; Briant, L; Srikantan, V; Murali, R; Saragovi, U; Weiner, D; Devaux, C; Autiero, M; PiatierTonneau, D; Greene, MI			Synthetic CD4 exocyclics inhibit binding of human immunodeficiency virus type 1 envelope to CD4 and virus replication in T lymphocytes	NATURE BIOTECHNOLOGY			English	Article						CD4 and HIV gp 120 interaction; rational drug design; AIDS	CLASS-II ANTIGENS; HLA-DR; MUTATIONAL ANALYSIS; ATOMIC-STRUCTURE; CELL ACTIVATION; HIV-1 INFECTION; SITE; ANTIBODY; GLYCOPROTEIN; MOLECULE	CD4 functions as a major T-cell surface receptor for human immunodeficiency virus by binding the human immunodeficiency virus type 1 (HIV-1) envelope protein gp120 with relatively high affinity, We have developed constrained aromatically modified analogs of the secondary structures of the first domain of CD4 in order to analyze surfaces involved in binding of gp120, Complementarity determining-like regions (CDRs) of the D1 domain of CD4 were reproduced as synthetic aromatically modified exocyclic (AMEs) forms. The exocyclic CDR3.AME(82-89), derived from the CDR3 (residues 82-89) region of CD4 D1 domain, specifically inhibited binding of recombinant gp120 to both recombinant soluble CD4, and CD4(+) Jurkat cells, and blocked syncytium formation and virus particle production caused by HIV-1 infection, We have previously shown that the CDR3.AME analog binds to the CD4 CDR3 region and creates a disabled CD4 heterodimer, We propose that the AME prevents the formation of an essential homodimeric surface needed for efficient HIV binding, Additionally the disabled CD4 receptor may be less able to signal the cell to allow HIV replication and HIV infection, Such compounds may represent a new receptor specific approach to modulate biological functions.	UNIV PENN, SCH MED, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, CTR RECEPTOR BIOL, PHILADELPHIA, PA 19104 USA; CNRS, UPR 420, VILLEJUIF, FRANCE; CNRS, ERS 155, LAB IMMUNOL INFECT RETROVIRALES, MONTPELLIER, FRANCE; UNIFORMED SERV UNIV HLTH SCI, DEPT SURG, BETHESDA, MD 20814 USA; MCGILL UNIV, DEPT PHARMACOL, MONTREAL, PQ H3A 2T5, CANADA	University of Pennsylvania; University of Pennsylvania; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Uniformed Services University of the Health Sciences - USA; McGill University			Murali, Ramachandran/D-1132-2009; Briant, Laurence/AAB-9281-2021	Murali, Ramachandran/0000-0002-8384-2793; Briant, Laurence/0000-0002-1995-3501				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; ASHKENAZI A, 1990, P NATL ACAD SCI USA, V87, P7150, DOI 10.1073/pnas.87.18.7150; AUTIERO M, 1995, INT IMMUNOL, V7, P191, DOI 10.1093/intimm/7.2.191; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; BRODSKY MH, 1990, J IMMUNOL, V144, P3078; CAMMAROTA G, 1992, NATURE, V356, P799, DOI 10.1038/356799a0; CHAO BH, 1989, J BIOL CHEM, V264, P5812; CHEN SX, 1992, P NATL ACAD SCI USA, V89, P5872, DOI 10.1073/pnas.89.13.5872; CLAYTON LK, 1988, NATURE, V335, P363, DOI 10.1038/335363a0; CORBEAU P, 1990, J VIROL, V64, P1459, DOI 10.1128/JVI.64.4.1459-1464.1990; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DOUGALL WC, 1994, TRENDS BIOTECHNOL, V12, P372, DOI 10.1016/0167-7799(94)90038-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FLEURY S, 1991, CELL, V66, P1037, DOI 10.1016/0092-8674(91)90447-7; GAY D, 1987, NATURE, V328, P626, DOI 10.1038/328626a0; HABEEB AFSA, 1973, ANAL BIOCHEM, V56, P60, DOI 10.1016/0003-2697(73)90169-3; HOULGATTE R, 1994, J IMMUNOL, V152, P4475; JANEWAY CA, 1989, IMMUNOL TODAY, V10, P234, DOI 10.1016/0167-5699(89)90260-0; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; LAMARRE D, 1989, SCIENCE, V245, P743, DOI 10.1126/science.2549633; LANGEDIJK JPM, 1993, J BIOL CHEM, V268, P16875; LIFSON JD, 1988, SCIENCE, V241, P712, DOI 10.1126/science.2969619; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MCDOUGAL JS, 1986, J IMMUNOL, V137, P2937; MIZUKAMI T, 1988, P NATL ACAD SCI USA, V85, P9273, DOI 10.1073/pnas.85.23.9273; MOEBIUS U, 1992, J EXP MED, V176, P507, DOI 10.1084/jem.176.2.507; MONTEFIORI DC, 1988, J CLIN MICROBIOL, V26, P231, DOI 10.1128/JCM.26.2.231-235.1988; PETERSON A, 1988, CELL, V54, P65, DOI 10.1016/0092-8674(88)90180-8; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; REED L. J., 1938, AMER JOUR HYG, V27, P493; REPKE H, 1992, J IMMUNOL, V149, P1809; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SAIZAWA K, 1987, NATURE, V328, P260, DOI 10.1038/328260a0; SARAGOVI HU, 1991, SCIENCE, V253, P792, DOI 10.1126/science.1876837; SRIKANTAN V, 1994, AIDS, V8, P1525, DOI 10.1097/00002030-199411000-00002; TADA H, 1986, J IMMUNOL METHODS, V93, P157, DOI 10.1016/0022-1759(86)90183-3; TRAUNECKER A, 1989, NATURE, V339, P68, DOI 10.1038/339068a0; TSUI P, 1992, J BIOL CHEM, V267, P9361; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WEINER DB, 1991, PATHOBIOLOGY, V59, P361, DOI 10.1159/000163679; Zhang X, 1996, NAT BIOTECHNOL, V14, P472, DOI 10.1038/nbt0496-472	44	37	49	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	FEB	1997	15	2					150	154		10.1038/nbt0297-150	http://dx.doi.org/10.1038/nbt0297-150			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WE998	9035140				2022-12-27	WOS:A1997WE99800021
J	Chen, LM; Zhernakova, DV; Kurilshikov, A; Andreu-Sanchez, S; Wang, DM; Augustijn, HE; Vila, AV; Weersma, RK; Medema, MH; Netea, MG; Kuipers, F; Wijmenga, C; Zhernakova, A; Fu, JY				Chen, Lianmin; Zhernakova, Daria, V; Kurilshikov, Alexander; Andreu-Sanchez, Sergio; Wang, Daoming; Augustijn, Hannah E.; Vila, Arnau Vich; Weersma, Rinse K.; Medema, Marnix H.; Netea, Mihai G.; Kuipers, Folkert; Wijmenga, Cisca; Zhernakova, Alexandra; Fu, Jingyuan			Influence of the microbiome, diet and genetics on inter-individual variation in the human plasma metabolome	NATURE MEDICINE			English	Article; Early Access							METACYC DATABASE; PATHWAYS	The levels of the thousands of metabolites in the human plasma metabolome are strongly influenced by an individual's genetics and the composition of their diet and gut microbiome. Here, by assessing 1,183 plasma metabolites in 1,368 extensively phenotyped individuals from the Lifelines DEEP and Genome of the Netherlands cohorts, we quantified the proportion of inter-individual variation in the plasma metabolome explained by different factors, characterizing 610, 85 and 38 metabolites as dominantly associated with diet, the gut microbiome and genetics, respectively. Moreover, a diet quality score derived from metabolite levels was significantly associated with diet quality, as assessed by a detailed food frequency questionnaire. Through Mendelian randomization and mediation analyses, we revealed putative causal relationships between diet, the gut microbiome and metabolites. For example, Mendelian randomization analyses support a potential causal effect of Eubacterium rectale in decreasing plasma levels of hydrogen sulfite-a toxin that affects cardiovascular function. Lastly, based on analysis of the plasma metabolome of 311 individuals at two time points separated by 4 years, we observed a positive correlation between the stability of metabolite levels and the amount of variance in the levels of that metabolite that could be explained in our analysis. Altogether, characterization of factors that explain inter-individual variation in the plasma metabolome can help design approaches for modulating diet or the gut microbiome to shape a healthy metabolome. The influence of an individual's genetics, diet and gut microbiome on their plasma metabolome was studied in 1,368 individuals and Mendelian randomization and mediation analyses were used to unveil causal relationships between diet, the gut microbiome and the metabolome.	[Chen, Lianmin; Zhernakova, Daria, V; Kurilshikov, Alexander; Andreu-Sanchez, Sergio; Wang, Daoming; Augustijn, Hannah E.; Vila, Arnau Vich; Wijmenga, Cisca; Zhernakova, Alexandra; Fu, Jingyuan] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands; [Chen, Lianmin; Andreu-Sanchez, Sergio; Kuipers, Folkert; Fu, Jingyuan] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat, Groningen, Netherlands; [Chen, Lianmin] Nanjing Med Univ, Affiliated Hosp 1, Dept Cardiol, Nanjing, Peoples R China; [Chen, Lianmin] Nanjing Med Univ, Gusu Sch, Suzhou Municipal Hosp, Affiliated Suzhou Hosp,Cardiovasc Res Ctr, Suzhou, Peoples R China; [Zhernakova, Daria, V] ITMO Univ, Ctr Comp Technol, Lab Genom Divers, St Petersburg, Russia; [Augustijn, Hannah E.; Medema, Marnix H.] Wageningen Univ, Bioinformat Grp, Wageningen, Netherlands; [Vila, Arnau Vich; Weersma, Rinse K.] Univ Groningen, Univ Med Ctr Groningen, Dept Gastroenterol & Hepatol, Groningen, Netherlands; [Netea, Mihai G.] Radboud Univ Nijmegen Med Ctr, Dept Internal Med, Nijmegen, Netherlands; [Netea, Mihai G.] Radboud Univ Nijmegen Med Ctr, Radboud Ctr Infect Dis, Nijmegen, Netherlands; [Netea, Mihai G.] Univ Bonn, Dept Immunol & Metab, Life & Med Sci Inst, Bonn, Germany; [Kuipers, Folkert] Univ Groningen, Univ Med Ctr Groningen, European Res Inst Biol Ageing, Groningen, Netherlands	University of Groningen; University of Groningen; Nanjing Medical University; Nanjing Medical University; ITMO University; Wageningen University & Research; University of Groningen; Radboud University Nijmegen; Radboud University Nijmegen; University of Bonn; University of Groningen	Fu, JY (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands.; Fu, JY (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Pediat, Groningen, Netherlands.	j.fu@umcg.nl	Zhernakova, Daria V./M-5619-2016	Zhernakova, Daria V./0000-0001-6531-3890; Medema, Marnix H./0000-0002-2191-2821; Wang, Daoming/0000-0003-4623-8527; Chen, Lianmin/0000-0003-0660-3518; Kuipers, Folkert/0000-0003-2518-737X; Andreu-Sanchez, Sergio/0000-0002-3503-9971; Netea, Mihai/0000-0003-2421-6052	Netherlands Heart Foundation (IN-CONTROL CVON grants) [2012-03, 2018-27]; Netherlands Organization for Scientific Research (NWO) [024.004.017, 864.13.013, VI.C.202.022, 194.006, SPI 92-266]; European Research Council (ERC) [2012-322698, 2019-833247, 101001678, 715772]; ZONMW MENORABEL Grant [733050814]; RuG Investment Agenda grant Personalized Health; Noaber Foundation; Netherlands Organ-on-Chip Initiative-an NWO Gravitation project - Ministry of Education, Culture and Science of the government of the Netherlands [024.003.001]; Natural Science Foundation of China [32270077]; De Cock-Hadders Foundation [20:20-13]; Natural Science Foundation of Jiangsu [BK20220709]; NJMU starting grant [303073572NC21]; China Scholarship Council [CSC201904910478]; Seerave Foundation; Dutch Digestive Foundation [16-14]	Netherlands Heart Foundation (IN-CONTROL CVON grants); Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); European Research Council (ERC)(European Research Council (ERC)European Commission); ZONMW MENORABEL Grant; RuG Investment Agenda grant Personalized Health; Noaber Foundation; Netherlands Organ-on-Chip Initiative-an NWO Gravitation project - Ministry of Education, Culture and Science of the government of the Netherlands; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); De Cock-Hadders Foundation; Natural Science Foundation of Jiangsu(Natural Science Foundation of Jiangsu Province); NJMU starting grant; China Scholarship Council(China Scholarship Council); Seerave Foundation; Dutch Digestive Foundation	Y We thank the participants and staff of the Lifelines cohort for their collaboration. We thank J. Dekens and J. Arends for management and technical support and K. Mc Intyre for English editing. We also thank the Genomics Coordination Center for providing data infrastructure and access to high-performance computing clusters, and M. van der Geest, M. Swertz and the MOLGENIS server for providing the platform for data access. This project was funded by the Netherlands Heart Foundation (IN-CONTROL CVON grants 2012-03 and 2018-27 to F.K., M.G.N., A.Z. and J.F.), Netherlands Organization for Scientific Research (NWO) (NWO Gravitation Exposome-NL (024.004.017) to J.F., A.K. and A.Z., NWO-VIDI 864.13.013 and NWO-VICI VI.C.202.022 to J.F., NWO-VIDI 016.178.056 to A.Z., NWO-VIDI 016.136.308 to R.K.W., NWO-VENI 194.006 to D.V.Z. and NWO Spinoza Prize SPI 92-266 to C.W.), European Research Council (ERC) (ERC Advanced Grant 2012-322698 to C.W., ERC Advanced Grant 2019-833247 to M.G.N., ERC Consolidator Grant 101001678 to J.F. and ERC Starting Grant 715772 to A.Z.), ZONMW MENORABEL Grant 733050814 to A.Z. and the RuG Investment Agenda grant Personalized Health to C.W. F.K. is also supported by the Noaber Foundation. J.F. and C.W. are also supported by the Netherlands Organ-on-Chip Initiative-an NWO Gravitation project (024.003.001) funded by the Ministry of Education, Culture and Science of the government of the Netherlands. L.C. is supported by the Natural Science Foundation of China (32270077), the De Cock-Hadders Foundation (20:20-13), the Natural Science Foundation of Jiangsu (BK20220709) and an NJMU starting grant (303073572NC21). D.W. holds a fellowship from the China Scholarship Council (CSC201904910478). R.K.W. is supported by the Seerave Foundation and the Dutch Digestive Foundation (16-14). The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.	AITCHISON J, 1982, J ROY STAT SOC B MET, V44, P139; Andreu V. P, 2021, BIORXIV, DOI [10.1101/2021.02.25.432841, DOI 10.1101/2021.02.25.432841]; Asnicar F, 2021, NAT MED, V27, P321, DOI 10.1038/s41591-020-01183-8; Bar N, 2020, NATURE, V588, P135, DOI 10.1038/s41586-020-2896-2; Bateman A, 2015, NUCLEIC ACIDS RES, V43, pD204, DOI 10.1093/nar/gku989; Beltowski J, 2015, PHARMACOL REP, V67, P647, DOI 10.1016/j.pharep.2015.01.005; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Biegel E, 2010, P NATL ACAD SCI USA, V107, P18138, DOI 10.1073/pnas.1010318107; Boomsma DI, 2014, EUR J HUM GENET, V22, P221, DOI 10.1038/ejhg.2013.118; Bowden J, 2017, STAT MED, V36, P1783, DOI 10.1002/sim.7221; Bowden J, 2015, INT J EPIDEMIOL, V44, P512, DOI 10.1093/ije/dyv080; Bradley PH, 2021, NATURE, V588, P36, DOI 10.1038/d41586-020-03122-6; Caspi R, 2018, NUCLEIC ACIDS RES, V46, pD633, DOI 10.1093/nar/gkx935; Caspi R, 2016, NUCLEIC ACIDS RES, V44, pD471, DOI 10.1093/nar/gkv1164; Chen LM, 2021, CELL, V184, P2302, DOI 10.1016/j.cell.2021.03.024; Chen LM, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108212; Chen LM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17840-y; Das S, 2016, NAT GENET, V48, P1284, DOI 10.1038/ng.3656; Duranton F, 2012, J AM SOC NEPHROL, V23, P1258, DOI 10.1681/ASN.2011121175; Fehrmann RSN, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002197; Francioli LC, 2014, NAT GENET, V46, P818, DOI 10.1038/ng.3021; Franzosa EA, 2018, NAT METHODS, V15, P962, DOI 10.1038/s41592-018-0176-y; Fuhrer T, 2017, MOL SYST BIOL, V13, DOI 10.15252/msb.20167150; Fuhrer T, 2011, ANAL CHEM, V83, P7074, DOI 10.1021/ac201267k; Gacesa R, 2022, NATURE, V604, P732, DOI 10.1038/s41586-022-04567-7; Hameed ASS, 2020, BIOTECHNOL ADV, V43, DOI 10.1016/j.biotechadv.2020.107576; Hemani G, 2018, ELIFE, V7, DOI 10.7554/eLife.34408; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Imhann F, 2016, GUT, V65, P740, DOI 10.1136/gutjnl-2015-310376; Jiang Q, 2001, AM J CLIN NUTR, V74, P714; Karcher N, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-02042-y; Khalili H, 2020, GUT, V69, P1637, DOI 10.1136/gutjnl-2019-319505; Krebs-Smith SM, 2018, J ACAD NUTR DIET, V118, P1591, DOI 10.1016/j.jand.2018.05.021; Kurilshikov A, 2019, CIRC RES, V124, P1808, DOI 10.1161/CIRCRESAHA.118.314642; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lee HH, 2017, BRIT J CLIN PHARMACO, V83, P1176, DOI 10.1111/bcp.13207; Levin J, 2010, DEMENT GERIATR COGN, V29, P553, DOI 10.1159/000314841; Link E, 2008, NEW ENGL J MED, V359, P789, DOI 10.1056/NEJMoa0801936; McCarthy S, 2016, NAT GENET, V48, P1279, DOI 10.1038/ng.3643; Menni C, 2017, SCI REP-UK, V7, DOI [10.1038/s41598-017-13722-4, 10.1038/s41598-017-10382-2]; Minelli C, 2021, INT J EPIDEMIOL, V50, P1651, DOI 10.1093/ije/dyab084; Moller G, 2017, NUTRIENTS, V9, DOI 10.3390/nu9070763; Ogawa M, 2011, IND HEALTH, V49, P195, DOI 10.2486/indhealth.MS1164; Ohtomo Y, 2005, PEDIATR NEPHROL, V20, P1744, DOI 10.1007/s00467-005-2025-3; Razavi AC, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.119.015118; Rios-Covian D, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00185; Sanna S, 2019, NAT GENET, V51, P600, DOI 10.1038/s41588-019-0350-x; Schlosser P, 2020, NAT GENET, V52, P167, DOI 10.1038/s41588-019-0567-8; Selinski S, 2013, ARCH TOXICOL, V87, P2129, DOI 10.1007/s00204-013-1157-7; Shin SY, 2014, NAT GENET, V46, P543, DOI 10.1038/ng.2982; Suhre K, 2011, NATURE, V477, P54, DOI 10.1038/nature10354; Tigchelaar EF, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006772; Tingley D, 2014, J STAT SOFTW, V59; Trichopoulou A, 2000, BRIT J NUTR, V84, pS205, DOI 10.1079/096582197388554; Truong DT, 2015, NAT METHODS, V12, P902, DOI 10.1038/nmeth.3589; Vila AV, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aap8914; Vinke PC, 2018, EUR J CLIN NUTR, V72, P1111, DOI 10.1038/s41430-018-0205-z; Visconti A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12476-z; Wang DM, 2021, CELL HOST MICROBE, V29, P1802, DOI 10.1016/j.chom.2021.11.003; Wang Y, 2022, IMETA, V1, pe14, DOI [10.1002/imt2.14, DOI 10.1002/IMT2.14]; Wang ZN, 2018, PROTEIN CELL, V9, P416, DOI 10.1007/s13238-018-0549-0; Watanabe K, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01261-5; Wendel-Vos GCW, 2003, J CLIN EPIDEMIOL, V56, P1163, DOI 10.1016/S0895-4356(03)00220-8; Wijmenga C, 2018, NAT GENET, V50, P322, DOI 10.1038/s41588-018-0066-3; Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD608, DOI 10.1093/nar/gkx1089; Yogalingam G, 1999, DNA CELL BIOL, V18, P187, DOI 10.1089/104454999315402; Zeevi D, 2019, NATURE, V568, P43, DOI 10.1038/s41586-019-1065-y; Zeller G, 2014, MOL SYST BIOL, V10, DOI 10.15252/msb.20145645; Zhao Y, 2010, J AGR FOOD CHEM, V58, P4844, DOI 10.1021/jf904464u; Zheng DC, 2020, PHARMACOL RES, V153, DOI 10.1016/j.phrs.2020.104655; Zhernakova A, 2016, SCIENCE, V352, P565, DOI 10.1126/science.aad3369; Zhernakova DV, 2018, NAT GENET, V50, P1524, DOI 10.1038/s41588-018-0224-7; Zou H, 2005, J R STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x	74	1	1	19	19	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02014-8	http://dx.doi.org/10.1038/s41591-022-02014-8		OCT 2022	24	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	5E6IE	36216932	hybrid, Green Published, Green Submitted			2022-12-27	WOS:000865725700011
J	Bhattacharya, D; Victora, GD				Bhattacharya, Deepta; Victora, Gabriel D.			Boosting with updated COVID-19 mRNA vaccines	NATURE MEDICINE			English	Editorial Material; Early Access								Emerging evidence shows that boosting with updated mRNA vaccines that target SARS-CoV-2 variants stimulates better neutralizing antibody responses than homologous boosters.	[Bhattacharya, Deepta] Univ Arizona, Coll Med, Dept Immunobiol, Tucson, AZ 85724 USA; [Victora, Gabriel D.] Univ Arizona, Dept Surg, Coll Med, Tucson, AZ 85724 USA; [Victora, Gabriel D.] Rockefeller Univ, Lab Lymphocyte Dynam, 1230 York Ave, New York, NY 10021 USA	University of Arizona; University of Arizona; Rockefeller University	Bhattacharya, D (corresponding author), Univ Arizona, Coll Med, Dept Immunobiol, Tucson, AZ 85724 USA.	deeptab@arizona.edu						Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bhattacharya D, 2022, IMMUNITY, V55, P945, DOI 10.1016/j.immuni.2022.05.004; Chalkias S, 2022, NAT MED, DOI 10.1038/s41591-022-02031-7; Collie S, 2022, NEW ENGL J MED, V386, P494, DOI 10.1056/NEJMc2119270; El Sahly HM, 2021, NEW ENGL J MED, V385, P1774, DOI 10.1056/NEJMoa2113017; Francis T, 1960, P AM PHILOS SOC, V104, P572, DOI DOI 10.1371/JOURNAL.PPAT.1005806; Gilbert Peter B, 2021, medRxiv, DOI 10.1101/2021.08.09.21261290; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; S. Chalkias, 2022, medRxiv, DOI 10.1101/2022.06.24.22276703; Schiepers A., 2022, BIORXIV, DOI [10.1101/2022.08.29.505743v1, DOI 10.1101/2022.08.29.505743V1]; Wang ZJ, 2021, NATURE, V595, P426, DOI 10.1038/s41586-021-03696-9; Weisblum Y, 2020, ELIFE, V9, DOI 10.7554/eLife.61312	12	0	0	3	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02048-y	http://dx.doi.org/10.1038/s41591-022-02048-y		OCT 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	5C9AF	36203000	Bronze			2022-12-27	WOS:000864544200002
J	Chalkias, S; Eder, F; Essink, B; Khetan, S; Nestorova, B; Feng, J; Chen, X; Chang, Y; Zhou, HH; Montefiori, D; Edwards, DK; Girard, B; Pajon, R; Dutko, FJ; Leav, B; Walsh, SR; Baden, LR; Miller, JM; Das, R				Chalkias, Spyros; Eder, Frank; Essink, Brandon; Khetan, Shishir; Nestorova, Biliana; Feng, Jing; Chen, Xing; Chang, Ying; Zhou, Honghong; Montefiori, David; Edwards, Darin K.; Girard, Bethany; Pajon, Rolando; Dutko, Frank J.; Leav, Brett; Walsh, Stephen R.; Baden, Lindsey R.; Miller, Jacqueline M.; Das, Rituparna			Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial	NATURE MEDICINE			English	Article; Early Access								Updated immunization strategies are needed to address multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. Here we report interim results from an ongoing, open-label phase 2/3 trial evaluating the safety and immunogenicity of the bivalent Coronavirus Disease 2019 (COVID-19) vaccine candidate mRNA-1273.211, which contains equal mRNA amounts encoding the ancestral SARS-CoV-2 and Beta variant spike proteins, as 50-mu g (n = 300) and 100-mu g (n = 595) first booster doses administered approximately 8.7-9.7 months after the mRNA-1273 primary vaccine series (). The primary objectives were to evaluate the safety and reactogenicity of mRNA-1273.211 and to demonstrate non-inferior antibody responses compared to the mRNA-1273 100-mu g primary series. Additionally, a pre-specified immunogenicity objective was to demonstrate superior antibody responses compared to the previously authorized mRNA-1273 50-mu g booster. The mRNA-1273.211 booster doses (50-mu g or 100-mu g) 28 days after immunization elicited higher neutralizing antibody responses against the ancestral SARS-CoV-2 and Beta variant than those elicited 28 days after the second mRNA-1273 dose of the primary series (). Antibody responses 28 days and 180 days after the 50-mu g mRNA-1273.211 booster dose were also higher than those after a 50-mu g mRNA-1273 booster dose () against the ancestral SARS-CoV-2 and Beta, Omicron BA.1 and Delta variants, and all pre-specified immunogenicity objectives were met. The safety and reactogenicity profile of the bivalent mRNA-1273.211 booster (50-mu g) was similar to the booster dose of mRNA-1273 (50-mu g). Immunization with the primary series does not set a ceiling to the neutralizing antibody response, and a booster dose of the bivalent vaccine elicits a robust response with titers that are likely to be protective against COVID-19. These results indicate that bivalent booster vaccines can induce potent, durable and broad antibody responses against multiple variants, providing a new tool in response to emerging variants. A bivalent vaccine encoding the ancestral and Beta variant SARS-CoV-2 spike proteins boosts neutralizing antibody responses against multiple viral variants, suggesting that a bivalent approach is an effective strategy to broadly enhance protection against COVID-19.	[Chalkias, Spyros; Nestorova, Biliana; Feng, Jing; Chen, Xing; Chang, Ying; Zhou, Honghong; Edwards, Darin K.; Girard, Bethany; Pajon, Rolando; Dutko, Frank J.; Leav, Brett; Miller, Jacqueline M.; Das, Rituparna] Moderna Inc, Cambridge, MA 02139 USA; [Eder, Frank] Meridian Clin Res, Binghamton, NY USA; [Essink, Brandon] Meridian Clin Res, Omaha, NE USA; [Khetan, Shishir] Meridian Clin Res, Rockville, MD USA; [Montefiori, David] Dept Surg, Durham, NC USA; [Montefiori, David] Duke Human Vaccine Inst, Durham, NC USA; [Walsh, Stephen R.; Baden, Lindsey R.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Chalkias, S (corresponding author), Moderna Inc, Cambridge, MA 02139 USA.	spyros.chalkias@modernatx.com		Walsh, Stephen/0000-0002-0817-9370	Moderna, Inc.	Moderna, Inc.	We thank J. E. Tomassini (Moderna consultant) for writing and editorial support. This study was funded by Moderna, Inc.	Baden LR, 2021, NEW ENGL J MED, V385, P2485, DOI 10.1056/NEJMc2115597; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Cele S., 2022, PREPRINT, DOI [10.1101/2022.04.15.22273711, DOI 10.1101/2022.04.15.22273711, 10.1101/2022.04.15.22273711v1, DOI 10.1101/2022.04.15.22273711V1]; Chalkias S, 2022, NEW ENGL J MED, V387, P1279, DOI 10.1056/NEJMoa2208343; Choi A, 2021, NAT MED, V27, P2025, DOI 10.1038/s41591-021-01527-y; Chu L, 2022, NAT MED, V28, P1042, DOI 10.1038/s41591-022-01739-w; Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9; El Sahly HM, 2021, NEW ENGL J MED, V385, P1774, DOI 10.1056/NEJMoa2113017; El Sahly HM, 2022, J INFECT DIS, V226, P1731, DOI 10.1093/infdis/jiac188; Gaebler C, 2021, NATURE, V591, P639, DOI [10.1038/s41586-021-03207-w, 10.1101/2020.11.03.367391]; Gagne M, 2022, CELL, V185, P1556, DOI 10.1016/j.cell.2022.03.038; Gilbert PB, 2022, SCIENCE, V375, P43, DOI 10.1126/science.abm3425; GISAID, 2022, OV VAR MUT; Goel RR, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abi6950; Hastie KM, 2021, SCIENCE, V374, P472, DOI 10.1126/science.abh2315; van der Straten K, 2022, medRxiv, DOI 10.1101/2022.01.03.21268582; Kaplonek P, 2022, SCI TRANSL MED, V14, DOI 10.1126/scitranslmed.abm2311; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Markov PV, 2022, NAT REV MICROBIOL, V20, P251, DOI 10.1038/s41579-022-00722-z; Pajon R, 2022, NEW ENGL J MED, V386, P1088, DOI 10.1056/NEJMc2119912; Pegu A, 2021, SCIENCE, V373, P1372, DOI 10.1126/science.abj4176; S. Chalkias, 2022, medRxiv, DOI 10.1101/2022.03.04.22271830; Wilks SH, 2022, bioRxiv, DOI 10.1101/2022.01.28.477987; Tenforde MW, 2021, MMWR-MORBID MORTAL W, V70, P674, DOI 10.15585/mmwr.mm7018e1; Thompson MG, 2021, NEW ENGL J MED, V385, P320, DOI 10.1056/NEJMoa2107058; Thompson MG, 2021, MMWR-MORBID MORTAL W, V70, P495, DOI 10.15585/mmwr.mm7013e3; Tseng HF, 2022, NAT MED, V28, P1063, DOI 10.1038/s41591-022-01753-y; UK Health Security Agency (2022), 2022, COVID 19 VACC SURV R	28	4	4	6	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02031-7	http://dx.doi.org/10.1038/s41591-022-02031-7		OCT 2022	17	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	5C9AF	36202997	hybrid, Green Published			2022-12-27	WOS:000864544200006
J	Okano, H				Okano, Hideyuki			A combined stem-cell-gene therapy strategy for ALS	NATURE MEDICINE			English	Editorial Material							GDNF	A gene therapy product combines astrocyte replacement with stable delivery of a neuroprotective factor; a first-in-human study demonstrated safety and will inform the design of further clinical trials for this neurodegenerative disease.	[Okano, Hideyuki] Keio Univ, Sch Med, Dept Physiol, Shinjuku Ku, Tokyo, Japan; [Okano, Hideyuki] MIT, McGovern Inst Brain Res, Dept Brain & Cognit Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA	Keio University; Massachusetts Institute of Technology (MIT)	Okano, H (corresponding author), Keio Univ, Sch Med, Dept Physiol, Shinjuku Ku, Tokyo, Japan.; Okano, H (corresponding author), MIT, McGovern Inst Brain Res, Dept Brain & Cognit Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	hidokano@keio.jp						Baloh RH, 2022, NAT MED, V28, P1813, DOI 10.1038/s41591-022-01956-3; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; Klein SM, 2005, HUM GENE THER, V16, P509, DOI 10.1089/hum.2005.16.509; Lepore AC, 2008, EXP NEUROL, V211, P423, DOI 10.1016/j.expneurol.2008.02.020; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Okano H, 2022, CELL STEM CELL, V29, P189, DOI 10.1016/j.stem.2022.01.007; Rushton DJ, 2017, NEUROLOGY, V89, P196, DOI 10.1212/WNL.0000000000004105; Suzuki M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000689; Thomsen GM, 2018, STEM CELLS, V36, P1122, DOI 10.1002/stem.2825	9	1	1	1	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2022	28	9					1751	1752		10.1038/s41591-022-01983-0	http://dx.doi.org/10.1038/s41591-022-01983-0		SEP 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4S0LI	36097225				2022-12-27	WOS:000852940800009
J	Kim, CH; Chung, WS				Kim, Chan Hyuk; Chung, Won-Suk			Toward inflammation-free therapeutics in Alzheimer's disease	NATURE MEDICINE			English	Editorial Material; Early Access								An engineered fusion protein exploits the efferocytosis pathway to clear amyloid-beta (A beta) from the brain without eliciting the severe inflammatory adverse effects associated with A beta-targeting antibody-based immunotherapies. In mouse models of Alzheimer's disease, this approach induced robust clearance of A beta without inflammation, improved synapse protection, and decreased brain microhemorrhage, which result in superior behavioral recovery.	[Kim, Chan Hyuk; Chung, Won-Suk] Korea Adv Inst Sci & Technol, Daejeon, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Kim, CH (corresponding author), Korea Adv Inst Sci & Technol, Daejeon, South Korea.							Busche MA, 2020, NAT NEUROSCI, V23, P1183, DOI 10.1038/s41593-020-0687-6; Doran AC, 2020, NAT REV IMMUNOL, V20, P254, DOI 10.1038/s41577-019-0240-6; Fuller JP, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00235; Lemke G, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a009076; Sevigny J, 2016, NATURE, V537, P50, DOI 10.1038/nature19323	5	0	0	3	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01972-3	http://dx.doi.org/10.1038/s41591-022-01972-3		SEP 2022	1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4J6DA	36076086				2022-12-27	WOS:000851351400002
J	Harari, S; Tahor, M				Harari, Sheri; Tahor, Maayan			Evolutionary insight into the emergence of SARS-CoV-2 variants of concern	NATURE MEDICINE			English	Editorial Material; Early Access								Analysis of SARS-CoV-2 evolution during chronic infection reveals that in this setting, the virus evolves to bear mutations similar to those seen in variants of concern, and that many of these mutations are associated with antibody evasion. However, as mutations associated with high SARS-CoV-2 transmissibility are not observed, the emergence of variants of concern during chronic infection might be rare.	[Harari, Sheri; Tahor, Maayan] Tel Aviv Univ, Tel Aviv, Israel	Tel Aviv University	Harari, S (corresponding author), Tel Aviv Univ, Tel Aviv, Israel.							Borges V, 2021, MSPHERE, V6, DOI 10.1128/mSphere.00244-21; Choi B, 2020, NEW ENGL J MED, V383, P2291, DOI 10.1056/NEJMc2031364; Corey L, 2021, NEW ENGL J MED, V385, P562, DOI 10.1056/NEJMsb2104756; Fung M, 2021, CLIN INFECT DIS, V72, P340, DOI 10.1093/cid/ciaa863; Kemp SA, 2021, NATURE, V592, P277, DOI 10.1038/s41586-021-03291-y	5	2	2	1	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01892-2	http://dx.doi.org/10.1038/s41591-022-01892-2		JUL 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2T2EO	35804153	Green Published, hybrid			2022-12-27	WOS:000822291700001
J	de Lemos, JA; Navar, AM				de Lemos, James A.; Navar, Ann Marie			A life-course approach to cardiovascular disease prevention	NATURE MEDICINE			English	Editorial Material							ATHEROSCLEROSIS; ADULTHOOD; RISK	Preventing atherosclerotic cardiovascular disease in adults will require innovative public health approaches focused on children and families, to improve risk factor trajectories across the lifespan and prioritize children at highest risk of future disease.	[de Lemos, James A.; Navar, Ann Marie] Univ Texas Southwestern Med Ctr Dallas, Dept Med, Dallas, TX 75390 USA; [Navar, Ann Marie] Univ Texas Southwestern Med Ctr Dallas, Dept Data & Populat Sci, Dallas, TX USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	de Lemos, JA (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Med, Dallas, TX 75390 USA.	James.delemos@utsouthwestern.edu						[Anonymous], 2011, PEDIATRICS, V128; Buttermore E, 2021, DIABETES METAB SYND, V15, DOI 10.1016/j.dsx.2021.102253; Ferranti SD, 2017, J PEDIATR-US, V185, P99, DOI 10.1016/j.jpeds.2016.12.078; Di Cesare M, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1449-8; HOLMAN RL, 1958, AM J PATHOL, V34, P209; Jacobs DR, 2022, NEW ENGL J MED, V386, P1877, DOI 10.1056/NEJMoa2109191; JUDSON JJ, 1971, J AMER MED ASSOC, V216, P1185; Li SX, 2003, JAMA-J AM MED ASSOC, V290, P2271, DOI 10.1001/jama.290.17.2271; McGill HC, 1997, ARTERIOSCL THROM VAS, V17, P95, DOI 10.1161/01.ATV.17.1.95; Navar-Boggan AM, 2015, CIRCULATION, V131, P451, DOI 10.1161/CIRCULATIONAHA.114.012477; Song PG, 2019, JAMA PEDIATR, V173, P1154, DOI 10.1001/jamapediatrics.2019.3310; Zhang YY, 2021, JAMA CARDIOL, V6, P1406, DOI 10.1001/jamacardio.2021.3508	12	1	1	3	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2022	28	6					1133	1134		10.1038/s41591-022-01870-8	http://dx.doi.org/10.1038/s41591-022-01870-8		JUN 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E9IE	35681104				2022-12-27	WOS:000808417500002
J	Fitzgerald, RC; Antoniou, AC; Fruk, L; Rosenfeld, N				Fitzgerald, Rebecca C.; Antoniou, Antonis C.; Fruk, Ljiljana; Rosenfeld, Nitzan			The future of early cancer detection	NATURE MEDICINE			English	Review							OFFSET RAMAN-SPECTROSCOPY; BREAST-CANCER; PROSTATE-CANCER; ARTIFICIAL-INTELLIGENCE; OXIDE NANOPARTICLES; GOLD NANOPARTICLES; CONTRAST AGENTS; RISK; MODEL; CARE	A proactive approach to detecting cancer at an early stage can make treatments more effective, with fewer side effects and improved long-term survival. However, as detection methods become increasingly sensitive, it can be difficult to distinguish inconsequential changes from lesions that will lead to life-threatening cancer. Progress relies on a detailed understanding of individualized risk, clear delineation of cancer development stages, a range of testing methods with optimal performance characteristics, and robust evaluation of the implications for individuals and society. In the future, advances in sensors, contrast agents, molecular methods, and artificial intelligence will help detect cancer-specific signals in real time. To reduce the burden of cancer on society, risk-based detection and prevention needs to be cost effective and widely accessible. Technological advances are producing exquisitely sensitive cancer detection tests. This Review discusses who should be tested, and how-and looks to the future of personalized, risk-based cancer screening.	[Fitzgerald, Rebecca C.] Univ Cambridge, Canc Res UK Cambridge Ctr, Early Detect Programme, Cambridge, England; [Antoniou, Antonis C.] Univ Cambridge, Dept Publ Hlth & Primary Care, Ctr Canc Genet Epidemiol, Cambridge, England; [Fruk, Ljiljana] Univ Cambridge, Dept Chem Engn & Biotechnol, Cambridge, England; [Rosenfeld, Nitzan] Univ Cambridge, Canc Res UK Cambridge Inst, Li Ka Shing Ctr, Cambridge, England	Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; University of Cambridge; University of Cambridge; Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Fitzgerald, RC (corresponding author), Univ Cambridge, Canc Res UK Cambridge Ctr, Early Detect Programme, Cambridge, England.	rcf29@cam.ac.uk		Fitzgerald, Rebecca/0000-0002-3434-3568				Abbosh C, 2019, ANN ONCOL, V30, P358, DOI 10.1093/annonc/mdy552; Abou-Elkacem L, 2015, EUR J RADIOL, V84, P1685, DOI 10.1016/j.ejrad.2015.03.016; Adeyemo A, 2021, NAT MED, V27, P1876, DOI 10.1038/s41591-021-01549-6; Al Zaki A, 2014, ACS NANO, V8, P104, DOI 10.1021/nn405701q; Aleshin-Guendel S, 2021, EVAL HEALTH PROF, V44, P42, DOI 10.1177/0163278720984203; Amos CI, 2017, CANCER EPIDEM BIOMAR, V26, P126, DOI 10.1158/1055-9965.EPI-16-0106; Arbyn M, 2021, CLIN MICROBIOL INFEC, V27, P1083, DOI 10.1016/j.cmi.2021.04.031; Ardila D, 2019, NAT MED, V25, P954, DOI 10.1038/s41591-019-0447-x; Augustine R, 2021, ADV COLLOID INTERFAC, V294, DOI 10.1016/j.cis.2021.102457; Bahcall OG, 2013, NAT GENET, V45, P343, DOI 10.1038/ng.2592; Baldacchini F, 2021, CLIN GASTROENTEROL H, V19, P2361, DOI 10.1016/j.cgh.2020.08.038; Banerjee S, 2017, P NATL ACAD SCI USA, V114, P3334, DOI 10.1073/pnas.1700677114; Bayoumy S, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-01191-x; Bohm D, 2012, ONCOL REP, V28, P429, DOI 10.3892/or.2012.1849; Bonvalot S, 2019, LANCET ONCOL, V20, P1148, DOI 10.1016/S1470-2045(19)30326-2; Botta M, 2012, EUR J INORG CHEM, P1945, DOI 10.1002/ejic.201101305; Bouche M, 2020, BIOCONJUGATE CHEM, V31, P303, DOI 10.1021/acs.bioconjchem.9b00669; Brown E, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.039636; Chan KCA, 2017, NEW ENGL J MED, V377, P513, DOI [10.1056/NEJMoa1701717, 10.1056/nejmoa1701717]; Clift AK, 2022, BRIT J CANCER, V126, P533, DOI 10.1038/s41416-021-01550-3; Cohen JD, 2018, SCIENCE, V359, P926, DOI 10.1126/science.aar3247; Conroy SM, 2017, CANCER EPIDEM BIOMAR, V26, P541, DOI 10.1158/1055-9965.EPI-16-0935; Davies S., 2020, WHOSE HLTH IS IT ANY; de Koning HJ, 2020, NEW ENGL J MED, V382, P503, DOI 10.1056/NEJMoa1911793; Dobrow MJ, 2018, CAN MED ASSOC J, V190, pE422, DOI 10.1503/cmaj.171154; Duran-Sierra E, 2020, ORAL ONCOL, V105, DOI 10.1016/j.oraloncology.2020.104635; Ehlerding EB, 2018, ACS NANO, V12, P2106, DOI 10.1021/acsnano.7b07252; Eklund M, 2021, NEW ENGL J MED, V385, P908, DOI 10.1056/NEJMoa2100852; Elemento O, 2021, NAT REV CANCER, V21, P747, DOI 10.1038/s41568-021-00399-1; Esteva A, 2017, NATURE, V542, P115, DOI 10.1038/nature21056; Faktor J., 2021, MASS SPECTROMETRY LI; Falcaro M, 2021, LANCET, V398, P2084, DOI 10.1016/S0140-6736(21)02178-4; Finlayson SG, 2019, SCIENCE, V363, P1287, DOI 10.1126/science.aaw4399; Fitzgerald RC, 2020, LANCET, V396, P333, DOI 10.1016/S0140-6736(20)31099-0; Food and Drug Administration, 2021, ARTIF INTELL; Garcia-Alvarez R, 2020, ACS PHOTONICS, V7, P646, DOI 10.1021/acsphotonics.9b01418; Gehrung M, 2021, NAT MED, V27, P833, DOI 10.1038/s41591-021-01287-9; Ghanouni A, 2020, J MED SCREEN, V27, P138, DOI 10.1177/0969141319883662; Hallouard F, 2011, RSC ADV, V1, P792, DOI 10.1039/c1ra00048a; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hao LL, 2021, NAT MATER, V20, P1440, DOI 10.1038/s41563-021-01042-y; Harrison H, 2021, EUR UROL FOCUS, V7, P1380, DOI 10.1016/j.euf.2020.06.024; He JX, 2019, NAT MED, V25, P30, DOI 10.1038/s41591-018-0307-0; Hindley JW, 2019, P NATL ACAD SCI USA, V116, P16711, DOI 10.1073/pnas.1903500116; Ho YJ, 2020, BIOMATERIALS, V232, DOI 10.1016/j.biomaterials.2019.119723; Huang SG, 2020, CANCER LETT, V471, P61, DOI 10.1016/j.canlet.2019.12.007; Hugosson J, 2019, EUR UROL, V76, P43, DOI 10.1016/j.eururo.2019.02.009; Hurson AN, 2021, INT J EPIDEMIOL, V50, P1897, DOI 10.1093/ije/dyab036; Imperiale TF, 2014, NEW ENGL J MED, V370, P1287, DOI 10.1056/NEJMoa1311194; Jiang QJ, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951-021-00811-w; Jiang YY, 2019, ADV MATER, V31, DOI 10.1002/adma.201808166; Karunamuni R, 2016, EUR RADIOL, V26, P3301, DOI 10.1007/s00330-015-4152-y; Kasivisvanathan V, 2018, NEW ENGL J MED, V378, P1767, DOI 10.1056/NEJMoa1801993; Kinsella JM, 2011, ANGEW CHEM INT EDIT, V50, P12308, DOI 10.1002/anie.201104507; Komor MA, 2020, J PATHOL, V250, P288, DOI 10.1002/path.5369; Kostevsek N, 2020, NANOMATERIALS-BASEL, V10, DOI 10.3390/nano10050889; Koudrina A, 2020, ACS OMEGA, V5, P22691, DOI 10.1021/acsomega.0c02650; Krimmel JD, 2016, P NATL ACAD SCI USA, V113, P6005, DOI 10.1073/pnas.1601311113; Kruger S, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1266-0; Kuchenbaecker KB, 2017, JAMA-J AM MED ASSOC, V317, P2402, DOI 10.1001/jama.2017.7112; Kwong GA, 2021, NAT REV CANCER, V21, P655, DOI 10.1038/s41568-021-00389-3; Lee A, 2021, J MED GENET, DOI 10.1136/jmedgenet-2021-107904; Lee A, 2019, GENET MED, V21, P1708, DOI 10.1038/s41436-018-0406-9; Lee J, 2016, J CONTROL RELEASE, V223, P197, DOI 10.1016/j.jconrel.2015.12.051; Lenaerts L, 2021, ECLINICALMEDICINE, V35, DOI 10.1016/j.eclinm.2021.100856; Lennon AM, 2020, SCIENCE, V369, P49, DOI 10.1126/science.abb9601; Li JP, 2020, NANOSCALE RES LETT, V15, DOI 10.1186/s11671-020-3252-z; Li Y, 2020, ADV MATER, V32, DOI 10.1002/adma.201906799; Liu MC, 2020, ANN ONCOL, V31, P745, DOI 10.1016/j.annonc.2020.02.011; Liu M, 2020, MED RES REV, V40, P909, DOI 10.1002/med.21642; Liu QY, 2020, FRONT CHEM, V8, DOI 10.3389/fchem.2020.00755; Lo YMD, 2021, SCIENCE, V372, P144, DOI 10.1126/science.aaw3616; Low CA, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-00351-x; Maas P, 2016, JAMA ONCOL, V2, P1295, DOI 10.1001/jamaoncol.2016.1025; Mahmoudi T, 2020, TRAC-TREND ANAL CHEM, V125, DOI 10.1016/j.trac.2020.115842; Marmot MG, 2013, BRIT J CANCER, V108, P2205, DOI 10.1038/bjc.2013.177; Martin RM, 2018, JAMA-J AM MED ASSOC, V319, P883, DOI 10.1001/jama.2018.0154; Martincorena I, 2018, SCIENCE, V362, P911, DOI 10.1126/science.aau3879; Mathios D, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24994-w; Mazzone PJ, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.8551; McGeoch L, 2019, CANCER EPIDEM BIOMAR, V28, P1580, DOI 10.1158/1055-9965.EPI-19-0059; McRae MP, 2016, ACCOUNTS CHEM RES, V49, P1359, DOI 10.1021/acs.accounts.6b00112; Menon U, 2021, LANCET, V397, P2182, DOI 10.1016/S0140-6736(21)00731-5; Moss J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07466-6; Mouliere F, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4921; Nagachinta S, 2020, COLLOID SURFACE B, V188, DOI 10.1016/j.colsurfb.2020.110793; Newman AM, 2014, NAT MED, V20, P552, DOI 10.1038/nm.3519; Nicolson F, 2021, CHEM SOC REV, V50, P556, DOI 10.1039/d0cs00855a; Nicolson F, 2019, THERANOSTICS, V9, P5899, DOI 10.7150/thno.36321; Nieuwenburg SAV, 2022, GASTRIC CANCER, V25, P375, DOI 10.1007/s10120-021-01264-8; Oh MH, 2011, J AM CHEM SOC, V133, P5508, DOI 10.1021/ja200120k; Oren O, 2020, JAMA-J AM MED ASSOC, V323, P603, DOI 10.1001/jama.2019.21813; Pan DPJ, 2012, ACS NANO, V6, P3364, DOI 10.1021/nn300392x; Park EY, 2021, APL BIOENG, V5, DOI 10.1063/5.0047660; Park SM, 2020, NAT BIOMED ENG, V4, P624, DOI 10.1038/s41551-020-0534-9; Pashayan N, 2021, J PERS MED, V11, DOI 10.3390/jpm11090916; Pashayan N, 2020, NAT REV CLIN ONCOL, V17, P687, DOI 10.1038/s41571-020-0388-9; Pashayan N, 2018, JAMA ONCOL, V4, P1504, DOI 10.1001/jamaoncol.2018.1901; Pence I, 2016, CHEM SOC REV, V45, P1958, DOI 10.1039/c5cs00581g; Peneder P, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23445-w; Pennycuick A, 2020, CANCER DISCOV, V10, P1489, DOI 10.1158/2159-8290.CD-19-1366; Perez-Medina C, 2015, J NUCL MED, V56, P1272, DOI 10.2967/jnumed.115.158956; Pharoah PDP, 2002, NAT GENET, V31, P33, DOI 10.1038/ng853; RABINOVITCH RA, 1994, J CLIN ONCOL, V12, P206, DOI 10.1200/JCO.1994.12.1.206; Ramos-Membrive R, 2021, J DRUG DELIV SCI TEC, V64, DOI 10.1016/j.jddst.2020.101809; Rieffel J, 2015, ADV MATER, V27, P1785, DOI 10.1002/adma.201404739; Sachdeva S, 2021, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.602659; Sarkeala T, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-046667; Shen SY, 2018, NATURE, V563, P579, DOI 10.1038/s41586-018-0703-0; Shen Y, 2019, STAT METHODS MED RES, V28, P1261, DOI 10.1177/0962280217754232; Shieh Y, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw290; Sood R, 2019, J GLOB ONCOL, V5, DOI 10.1200/JGO.19.00127; Sun MM, 2017, ACS APPL MATER INTER, V9, P10453, DOI 10.1021/acsami.6b16408; Taylor RM, 2011, J NANOPART RES, V13, P4717, DOI 10.1007/s11051-011-0439-3; Tomasetti C, 2015, SCIENCE, V347, P78, DOI 10.1126/science.1260825; Trentham-Dietz A, 2021, PLOS COMPUT BIOL, V17, DOI 10.1371/journal.pcbi.1009020; Turajlic S, 2019, NAT REV GENET, V20, P404, DOI 10.1038/s41576-019-0114-6; Turajlic S, 2018, CELL, V173, P581, DOI 10.1016/j.cell.2018.03.057; Tyrer J, 2004, STAT MED, V23, P1111, DOI 10.1002/sim.1668; UK National Screening Committee, AD SCREEN PROGR BOW; US Preventive Services Task Force, 2018, JAMA, V319, P1901, DOI 10.1001/jama.2018.3710; Van Poppel H, 2021, EUR UROL ONCOL, V4, P731, DOI 10.1016/j.euo.2021.06.006; Doan VHM, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-95660-w; Wand H, 2021, NATURE, V591, P211, DOI 10.1038/s41586-021-03243-6; Wang C, 2022, ANGEW CHEM INT EDIT, V61; Wang C, 2021, ANGEW CHEM INT EDIT, V61; Wang WW, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201800310; Wang Y, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-84072-5; Weber J, 2016, NAT METHODS, V13, P639, DOI [10.1038/NMETH.3929, 10.1038/nmeth.3929]; Wegwarth O, 2012, ANN INTERN MED, V156, P340, DOI 10.7326/0003-4819-156-5-201203060-00005; Welch HG, 2019, NEW ENGL J MED, V381, P1378, DOI 10.1056/NEJMsr1905447; Welch HG, 2017, NEW ENGL J MED, V376, P2208, DOI 10.1056/NEJMp1615069; Welch HG, 2016, NEW ENGL J MED, V375, P1438, DOI 10.1056/NEJMoa1600249; Williams RM, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aaq1090; Willmann JK, 2017, J CLIN ONCOL, V35, P2133, DOI 10.1200/JCO.2016.70.8594; World Health Organization, 2020, CERV CANC FREE FUT 1; Wu CC, 2015, PROTEOMICS, V15, P3394, DOI 10.1002/pmic.201500157; Xing ZW, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/14/145607; Yokoyama A, 2019, NATURE, V565, P312, DOI 10.1038/s41586-018-0811-x; Yu B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17380-5; Yu XG, 2019, NATURE, V575, P473, DOI 10.1038/s41586-019-1687-0; Yu XE, 2018, NAT BIOMED ENG, V2, P165, DOI 10.1038/s41551-018-0201-6; Yuan Y, 2021, ANGEW CHEM INT EDIT, V60, P3923, DOI 10.1002/anie.202014839; Zhai TL, 2020, ACS APPL MATER INTER, V12, P37470, DOI 10.1021/acsami.0c10131; Zhang CJ, 2016, ASIA-PAC J CLIN ONCO, V12, P13, DOI 10.1111/ajco.12437; Zhang T, 2019, NANOSCALE, V11, P21759, DOI 10.1039/c9nr05671h	146	6	6	27	43	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4					666	677		10.1038/s41591-022-01746-x	http://dx.doi.org/10.1038/s41591-022-01746-x			12	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0Q6DV	35440720				2022-12-27	WOS:000785007700023
J	Li, BT; Daly, B; Gospodarowicz, M; Bertagnolli, MM; Brawley, OW; Chabner, BA; Fashoyin-Aje, L; de Claro, RA; Franklin, E; Mills, J; Legos, J; Kaucic, K; Li, M; The, L; Hou, TN; Wu, TH; Albrecht, B; Shao, Y; Finnegan, J; Qian, J; Shahidi, J; Gasal, E; Tendler, C; Kim, G; Yan, J; Morrow, PK; Fuchs, CS; Zhang, LS; LaCaze, R; Oelrich, S; Murphy, MJ; Pazdur, R; Rudd, K; Wu, YL				Li, Bob T.; Daly, Bobby; Gospodarowicz, Mary; Bertagnolli, Monica M.; Brawley, Otis W.; Chabner, Bruce A.; Fashoyin-Aje, Lola; de Claro, R. Angelo; Franklin, Elizabeth; Mills, Jennifer; Legos, Jeff; Kaucic, Karen; Li, Mark; The, Lydia; Hou, Tina; Wu, Ting-Hui; Albrecht, Bjorn; Shao, Yi; Finnegan, Justin; Qian, Jing; Shahidi, Javad; Gasal, Eduard; Tendler, Craig; Kim, Geoffrey; Yan, James; Morrow, Phuong Khanh; Fuchs, Charles S.; Zhang, Lianshan; LaCaze, Robert; Oelrich, Stefan; Murphy, Martin J.; Pazdur, Richard; Rudd, Kevin; Wu, Yi-Long			Reimagining patient-centric cancer clinical trials: a multi-stakeholder international coalition	NATURE MEDICINE			English	Article							OSIMERTINIB; HOSPITALS	The Bloomberg New Economy International Cancer Coalition brings together academia, industry, government, patient advocacy and policy think tanks to leverage technology and collaboration to improve patient access to clinical trials and to harmonize regulations aiming to accelerate cancer cures and prevention worldwide in the post-pandemic era.	[Li, Bob T.; Daly, Bobby] Weill Cornell Med, Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; [Gospodarowicz, Mary] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada; [Bertagnolli, Monica M.] Harvard Med Sch, Dana Farber Brigham Canc Ctr, Boston, MA 02115 USA; [Brawley, Otis W.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Chabner, Bruce A.] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA; [Chabner, Bruce A.; Murphy, Martin J.] Soc Translat Oncol, Durham, NC USA; [Fashoyin-Aje, Lola; de Claro, R. Angelo; Pazdur, Richard] US FDA, Oncol Ctr Excellence, Silver Spring, MD USA; [Franklin, Elizabeth] Canc Support Community, Washington, DC USA; [Mills, Jennifer] Fdn Med Inc, Cambridge, MA USA; [Legos, Jeff] Novartis, Basel, Switzerland; [Kaucic, Karen] PPD Inc, Wilmington, NC USA; [Li, Mark] Agilent Technol, Resolut Biosci, Kirkland, WA USA; [The, Lydia; Hou, Tina; Wu, Ting-Hui; Albrecht, Bjorn; Shao, Yi] McKinsey & Co Inc, McKinsey Canc Ctr, New York, NY USA; [Finnegan, Justin] Bloomberg LP, Bloomberg New Econ, New York, NY USA; [Qian, Jing; Rudd, Kevin] Asia Soc Policy Inst, Asia Soc, New York, NY USA; [Shahidi, Javad] Daiichi Sankyo, Tokyo, Japan; [Gasal, Eduard] Innovent Biol, Suzhou, Peoples R China; [Tendler, Craig] Johnson & Johnson, Janssen, New Brunswick, NJ USA; [Kim, Geoffrey] BeiGene USA, BeiGene, Beijing, Peoples R China; [Yan, James] Zai Lab, Shanghai, Peoples R China; [Morrow, Phuong Khanh] Amgen Inc, Thousand Oaks, CA USA; [Fuchs, Charles S.] Genentech Inc, San Francisco, CA 94080 USA; [Fuchs, Charles S.] Yale Sch Med, Yale Canc Ctr, New Haven, CT USA; [Zhang, Lianshan] Jiangsu Hengrui Pharmaceut, Shanghai, Peoples R China; [LaCaze, Robert; Oelrich, Stefan] Bayer AG, Leverkusen, Germany; [Murphy, Martin J.] Shanghai TuoXin Hlth Promot Ctr, Shanghai, Peoples R China; [Murphy, Martin J.] CEO Roundtable Canc, Morrisville, NC USA; [Wu, Yi-Long] Guangdong Acad Med Sci, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Chinese Thorac Oncol Grp, Guangzhou, Peoples R China	Cornell University; Memorial Sloan Kettering Cancer Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Harvard University; Harvard Medical School; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Harvard University; Massachusetts General Hospital; US Food & Drug Administration (FDA); Foundation Medicine; Agilent Technologies; Bloomberg L.P.; Daiichi Sankyo Company Limited; Johnson & Johnson; Janssen Pharmaceuticals; Johnson & Johnson USA; Amgen; Roche Holding; Genentech; Yale University; Bayer AG; Guangdong Academy of Medical Sciences & Guangdong General Hospital	Li, BT (corresponding author), Weill Cornell Med, Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.	lib1@mskcc.org	Wu, Yi-Long/GRJ-9238-2022; Wu, Yi-Long/C-3396-2008	Wu, Yi-Long/0000-0002-3611-0258; Wu, Yi-Long/0000-0002-3611-0258; Li, Bob/0000-0001-6661-8733	Knowledge Partner McKinsey Company; Bayer; Dangote; ExxonMobil; HSBC; Hyundai; Mastercard; Tata; Vanke; Comprehensive Cancer Center Core Grant at Memorial Sloan Kettering Cancer Center from the US National Institutes of Health [P30 CA008748]	Knowledge Partner McKinsey Company; Bayer(Bayer AG); Dangote; ExxonMobil(Exxon Mobil Corporation); HSBC; Hyundai; Mastercard; Tata; Vanke; Comprehensive Cancer Center Core Grant at Memorial Sloan Kettering Cancer Center from the US National Institutes of Health	The Bloomberg New Economy International Cancer Coalition, as a part of the wider Bloomberg New Economy initiative, is supported by its Knowledge Partner McKinsey & Company, by select corporate sponsors (Bayer, Dangote, ExxonMobil, HSBC, Hyundai, Mastercard, Tata and Vanke, at the time of writing) and by Bloomberg Media, a business unit of Bloomberg L.P. B.T.L. and B.D. are supported by the Comprehensive Cancer Center Core Grant (P30 CA008748) at Memorial Sloan Kettering Cancer Center from the US National Institutes of Health.	Bertagnolli MM, 2017, NEW ENGL J MED, V376, P1178, DOI 10.1056/NEJMsb1702054; Chakravarty Debyani, 2017, JCO Precis Oncol, V2017, DOI 10.1200/PO.17.00011; China Association of Enterprises with Foreign Investment, 2021, FOST CHIN DRUG INN E; Daly B, 2020, JCO ONCOL PRACT, V16, P675, DOI 10.1200/OP.20.00214; de Claro RA, 2021, CLIN CANCER RES, V27, P11, DOI 10.1158/1078-0432.CCR-20-2220; Fashoyin-Aje L, 2021, JAMA ONCOL, DOI 10.1001/jamaoncol.2021.2137; Flaherty KT, 2021, CANCER DISCOV, V11, P1881, DOI 10.1158/2159-8290.CD-21-0850; Galsky MD, 2015, JAMA INTERN MED, V175, P293, DOI 10.1001/jamainternmed.2014.6300; Getz KA, 2017, CLIN THER, V39, P2203, DOI 10.1016/j.clinthera.2017.09.014; Hong DS, 2020, NEW ENGL J MED, V383, P1207, DOI 10.1056/NEJMoa1917239; Jee J, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.9009; Joura EA, 2015, NEW ENGL J MED, V372, P711, DOI 10.1056/NEJMoa1405044; Kann BH, 2021, CANCER CELL, V39, P916, DOI 10.1016/j.ccell.2021.04.002; Lee SJC, 2019, J CLIN ONCOL, V37, P1993, DOI 10.1200/JCO.19.00101; Li B. T., 2021, FORBES; Li N, 2019, LANCET ONCOL, V20, pE619, DOI 10.1016/S1470-2045(19)30491-7; Liu RS, 2021, NATURE, V592, P629, DOI 10.1038/s41586-021-03430-5; Merkel PA, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/s13023-016-0445-8; Mok TS, 2017, NEW ENGL J MED, V376, P629, DOI 10.1056/NEJMoa1612674; Murthy VH, 2004, JAMA-J AM MED ASSOC, V291, P2720, DOI 10.1001/jama.291.22.2720; Naing A, 2012, ANN ONCOL, V23, P2960, DOI 10.1093/annonc/mds130; Pfister DG, 2015, JAMA ONCOL, V1, P1303, DOI 10.1001/jamaoncol.2015.3151; Piantadosi S., 2020, PRINCIPLES PRACTICE; Skoulidis F, 2021, NEW ENGL J MED, V384, P2371, DOI 10.1056/NEJMoa2103695; Switzer JA, 2013, CIRC-CARDIOVASC QUAL, V6, P18, DOI 10.1161/CIRCOUTCOMES.112.967125; Unger JM, 2019, JNCI-J NATL CANCER I, V111, P245, DOI 10.1093/jnci/djy221; Wu YL, 2020, NEW ENGL J MED, V383, P1711, DOI 10.1056/NEJMoa2027071; Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333	28	2	2	0	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4					620	626		10.1038/s41591-022-01775-6	http://dx.doi.org/10.1038/s41591-022-01775-6			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0Q6DV	35440725	Bronze			2022-12-27	WOS:000785007700010
J	Chen, H; Ferbeyre, G; Cedergren, R				Chen, H; Ferbeyre, G; Cedergren, R			Efficient hammerhead ribozyme and antisense RNA targeting in a slow ribosome Escherichia coli mutant	NATURE BIOTECHNOLOGY			English	Article						ribozyme; gene inhibition; slow translation; ribosomes	GENE-EXPRESSION; CLONED GENES; POLYMERASE; PROTEINS; CELLS	We have evaluated inhibition of the plasmid-born chloramphenicol acetyl transferase gene (CAT) by the hammerhead ribozyme and antisense RNA in Escherichia coli where the translation and transcription rates have been modified. Whereas neither antisense nor the hammerhead had an inhibitory effect on CAT activity in wild-type E. coli, both reduced the level of the messenger RNA and the activity of the CAT gene by almost 60% in a slow ribosome mutant. Streptomycin, which increases the speed of translation in this mutant strain, restored full CAT activity. The level of CAT activity expressed from a T7 RNA polymerase promoter was not affected by the presence of either antisense RNA or the hammerhead ribozyme. When the target gene was expressed from a chromosomal locus in wild-type E. coli, both antisense RNA and the hammerhead ribozyme showed some inhibitory activity but the level of inhibition was significantly increased in the slow ribosome strain. This bacterial system offers a unique entry to the study of cellular factors which mediate the activity of ribozymes in vivo.	UNIV MONTREAL, DEPT BIOCHIM, MONTREAL, PQ H3C 3J7, CANADA	Universite de Montreal			Ferbeyre, Gerardo/A-1569-2010	Ferbeyre, Gerardo/0000-0002-2146-618X				ALTON NK, 1979, NATURE, V282, P864, DOI 10.1038/282864a0; BERTRAND E, 1994, NUCLEIC ACIDS RES, V22, P293, DOI 10.1093/nar/22.3.293; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRATTY J, 1993, BIOCHIM BIOPHYS ACTA, V1216, P345, DOI 10.1016/0167-4781(93)90001-T; BROSIUS J, 1981, PLASMID, V6, P112, DOI 10.1016/0147-619X(81)90058-5; CHUAT JC, 1989, BIOCHEM BIOPH RES CO, V162, P1025, DOI 10.1016/0006-291X(89)90776-6; COETZEE T, 1994, GENE DEV, V8, P1575, DOI 10.1101/gad.8.13.1575; CURRAN JF, 1995, NUCLEIC ACIDS RES, V23, P683, DOI 10.1093/nar/23.4.683; FERBEYRE G, 1995, GENE, V155, P45, DOI 10.1016/0378-1119(94)00891-U; Ferbeyre G, 1996, J BIOL CHEM, V271, P19318, DOI 10.1074/jbc.271.32.19318; FUQUA WC, 1992, BIOTECHNIQUES, V12, P223; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN PJ, 1986, ANNU REV BIOCHEM, V55, P569, DOI 10.1146/annurev.bi.55.070186.003033; GUERRIERTAKADA C, 1995, P NATL ACAD SCI USA, V92, P11115, DOI 10.1073/pnas.92.24.11115; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; INOKUCHI Y, 1994, J BIOL CHEM, V269, P11361; IOST I, 1995, EMBO J, V14, P3252, DOI 10.1002/j.1460-2075.1995.tb07328.x; IOST I, 1994, NATURE, V372, P193, DOI 10.1038/372193a0; JENSEN KF, 1988, EUR J BIOCHEM, V175, P587, DOI 10.1111/j.1432-1033.1988.tb14232.x; Lin-Chao S, 1992, MOL MICROBIOL, V6, P3385, DOI 10.1111/j.1365-2958.1992.tb02206.x; LOPEZ PJ, 1994, NUCLEIC ACIDS RES, V22, P1186, DOI 10.1093/nar/22.7.1186; Miller J.H., 1992, SHORT COURSE BACTERI, P150; PERRIMAN R, 1992, GENE, V113, P157, DOI 10.1016/0378-1119(92)90391-2; SIMONS RW, 1993, ANTISENSE RES APPLIC, P97; SIOUD M, 1991, P NATL ACAD SCI USA, V88, P7303, DOI 10.1073/pnas.88.16.7303; SORENSEN MA, 1989, J MOL BIOL, V207, P365, DOI 10.1016/0022-2836(89)90260-X; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUMMERS WC, 1970, ANAL BIOCHEM, V33, P459; VOGEL U, 1992, MOL MICROBIOL, V6, P2191, DOI 10.1111/j.1365-2958.1992.tb01393.x	30	29	32	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1997	15	5					432	435		10.1038/nbt0597-432	http://dx.doi.org/10.1038/nbt0597-432			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WX237	9131620				2022-12-27	WOS:A1997WX23700025
J	Oger, P; Petit, A; Dessaux, Y				Oger, P; Petit, A; Dessaux, Y			Genetically engineered plants producing opines alter their biological environment	NATURE BIOTECHNOLOGY			English	Article						transgenic plants; rhizosphere; plant-bacteria interactions	AGROBACTERIUM-RHIZOGENES; TRANSGENIC TOBACCO; PSEUDOMONAS-PUTIDA; CARBON SOURCE; HAIRY ROOT; GROWTH; BACTERIA; PLASMIDS; STRAIN; SOIL	Little is known about the consequences of releasing genetically engineered plants (GEP) into the environment. Using opine-producing GEP, we show that transgenic plants alter their biological environment, more precisely the root-associated bacterial populations. The alterations were both transgene-specific and target population-specific. Therefore, assessment studies on the introduction of a given transgene into a GEP will be valid on the given transgene. Evidence of any transgene-associated biological effect will depend on the determination of the pertinent target populations, the identification of which is a key step of such studies.	NATL CTR SCI RES, INST PLANT SCI, F-91198 GIF SUR YVETTE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Universite Paris Saclay			Oger, Phil/AAR-4752-2020; Oger, Phil M/C-8138-2012	Oger, Phil M/0000-0001-6298-6870				BREVET J, 1988, PLASMID, V19, P75, DOI 10.1016/0147-619X(88)90046-7; Brevet J., 1988, Molecular Plant-Microbe Interactions, V1, P75, DOI 10.1094/MPMI-1-075; CARDARELLI M, 1987, MOL GEN GENET, V209, P475, DOI 10.1007/BF00331152; COLBERT SF, 1993, APPL ENVIRON MICROB, V59, P2064, DOI 10.1128/AEM.59.7.2064-2070.1993; COLBERT SF, 1993, APPL ENVIRON MICROB, V59, P2056, DOI 10.1128/AEM.59.7.2056-2063.1993; Curl E. A., 1986, RHIZOSPHERE; DESSAUX Y, 1987, MOL GEN GENET, V208, P301, DOI 10.1007/BF00330457; Dessaux Y., 1992, MOL SIGNALS PLANT MI, P109; DOMMERGUE YR, 1970, ECOLOGIE MICROBIENNE; GAUDIN V, 1994, PLANT PHYSIOL BIOCH, V32, P11; GLICKMANN E, 1995, APPL ENVIRON MICROB, V61, P793, DOI 10.1128/AEM.61.2.793-796.1995; GUYON P, 1993, MOL PLANT MICROBE IN, V6, P92, DOI 10.1094/MPMI-6-092; Hiltner L., 1904, ARBEITEN DTSCH LANDW, V98, P59, DOI DOI 10.12691/AEES-1-6-1; KUNG SD, 1993, TRANSGENIC PLANTS, V2; MOREL G, 1951, AM J BOT, V38, P141, DOI 10.2307/2437837; NAUTIYAL CS, 1990, APPL ENVIRON MICROB, V56, P2576, DOI 10.1128/AEM.56.8.2576-2579.1990; OConnell KP, 1996, TRENDS BIOTECHNOL, V14, P83, DOI 10.1016/0167-7799(96)80928-0; OGER P, 1995, THESIS U PARIS SUD O; PETIT A, 1987, MOL GEN GENET, V207, P245, DOI 10.1007/BF00331585; PETIT A, 1978, MOL GEN GENET, V167, P147, DOI 10.1007/BF00266908; POTRYKUS I, 1991, ANNU REV PLANT PHYS, V42, P205, DOI 10.1146/annurev.pp.42.060191.001225; SAVKA MA, 1992, PLANT PHYSIOL, V98, P784, DOI 10.1104/pp.98.2.784; Savka MA, 1996, MOL PLANT MICROBE IN, V9, P310, DOI 10.1094/MPMI-9-0310; SAVKA MA, NATURE BIOTECHNOLOGY, V15, P363; SPENA A, 1987, EMBO J, V6, P3891, DOI 10.1002/j.1460-2075.1987.tb02729.x; TATE ME, 1982, CARBOHYD RES, V104, P105, DOI 10.1016/S0008-6215(00)82224-7; TREMBLAY G, 1987, APPL ENVIRON MICROB, V53, P1519, DOI 10.1128/AEM.53.7.1519-1524.1987; VAUDEQUINDRANSART V, 1995, MOL PLANT MICROBE IN, V8, P311, DOI 10.1094/MPMI-8-0311; WHITE FF, 1980, J BACTERIOL, V141, P1134, DOI 10.1128/JB.141.3.1134-1141.1980; WILSON M, 1995, APPL ENVIRON MICROB, V61, P2151, DOI 10.1128/AEM.61.6.2151-2158.1995; WILSON M, 1994, APPL ENVIRON MICROB, V60, P4468, DOI 10.1128/AEM.60.12.4468-4477.1994; ZAMBRYSKI PC, 1992, ANNU REV PLANT PHYS, V43, P465, DOI 10.1146/annurev.pp.43.060192.002341	32	125	176	0	23	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	APR	1997	15	4					369	372		10.1038/nbt0497-369	http://dx.doi.org/10.1038/nbt0497-369			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WQ554	9094140				2022-12-27	WOS:A1997WQ55400039
J	Schmidt, TSB; Li, SS; Maistrenko, OM; Akanni, W; Coelho, LP; Dolai, S; Fullam, A; Glazek, AM; Hercog, R; Herrema, H; Jung, F; Kandels, S; Orakov, A; Thielemann, R; von Stetten, M; Van Rossum, T; Benes, V; Borody, TJ; de Vos, WM; Ponsioen, CY; Nieuwdorp, M; Bork, P				Schmidt, Thomas S. B.; Li, Simone S.; Maistrenko, Oleksandr M.; Akanni, Wasiu; Coelho, Luis Pedro; Dolai, Sibasish; Fullam, Anthony; Glazek, Anna M.; Hercog, Rajna; Herrema, Hilde; Jung, Ferris; Kandels, Stefanie; Orakov, Askarbek; Thielemann, Roman; von Stetten, Moritz; Van Rossum, Thea; Benes, Vladimir; Borody, Thomas J.; de Vos, Willem M.; Ponsioen, Cyriel Y.; Nieuwdorp, Max; Bork, Peer			Drivers and determinants of strain dynamics following fecal microbiota transplantation	NATURE MEDICINE			English	Article							GUT MICROBIOME; DONOR FECES; THERAPY; BACTERIOTHERAPY; RESISTANCE; ACCURATE	Fecal microbiota transplantation (FMT) is a therapeutic intervention for inflammatory diseases of the gastrointestinal tract, but its clinical mode of action and subsequent microbiome dynamics remain poorly understood. Here we analyzed metagenomes from 316 FMTs, sampled pre and post intervention, for the treatment of ten different disease indications. We quantified strain-level dynamics of 1,089 microbial species, complemented by 47,548 newly constructed metagenome-assembled genomes. Donor strain colonization and recipient strain resilience were mostly independent of clinical outcomes, but accurately predictable using LASSO-regularized regression models that accounted for host, microbiome and procedural variables. Recipient factors and donor-recipient complementarity, encompassing entire microbial communities to individual strains, were the main determinants of strain population dynamics, providing insights into the underlying processes that shape the post-FMT gut microbiome. Applying an ecology-based framework to our findings indicated parameters that may inform the development of more effective, targeted microbiome therapies in the future, and suggested how patient stratification can be used to enhance donor microbiota colonization or the displacement of recipient microbes in clinical practice. Understanding the factors underlying colonization of donor microbes in recipients of fecal microbiota transplantation is a necessary first step to aid development of directed approaches that aim to couple colonization to clinical outcomes.	[Schmidt, Thomas S. B.; Li, Simone S.; Maistrenko, Oleksandr M.; Akanni, Wasiu; Coelho, Luis Pedro; Fullam, Anthony; Glazek, Anna M.; Kandels, Stefanie; Orakov, Askarbek; Thielemann, Roman; von Stetten, Moritz; Van Rossum, Thea; Bork, Peer] European Mol Biol Lab, Struct & Computat Biol Unit, Heidelberg, Germany; [Dolai, Sibasish; Borody, Thomas J.] Ctr Digest Dis, Sydney, NSW, Australia; [Hercog, Rajna; Jung, Ferris; Benes, Vladimir] European Mol Biol Lab, Genom Core Facil, Heidelberg, Germany; [Herrema, Hilde; Nieuwdorp, Max] Amsterdam Univ Med Ctr, Dept Expt Vasc Med, Amsterdam, Netherlands; [de Vos, Willem M.] Wageningen Univ, Lab Microbiol, Wageningen, Netherlands; [de Vos, Willem M.] Univ Helsinki, Fac Med, Human Microbiome Res Program, Helsinki, Finland; [Ponsioen, Cyriel Y.] Amsterdam Univ Med Ctr, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands; [Nieuwdorp, Max] Amsterdam Univ Med Ctr, Dept Vasc Med, Amsterdam, Netherlands; [Bork, Peer] Max Delbruck Ctr Mol Med, Berlin, Germany; [Bork, Peer] Yonsei Univ, Yonsei Frontier Lab, Seoul, South Korea; [Bork, Peer] Univ Wurzburg, Bioctr, Dept Bioinformat, Wurzburg, Germany; [Li, Simone S.] Tech Univ Denmark, Novo Nordisk Fdn, Ctr Biosustainabil, Lyngby, Denmark; [Li, Simone S.] Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld, Australia; [Maistrenko, Oleksandr M.] Royal Netherlands Inst Sea Res, Dept Marine Microbiol & Biogeochem, T Horntje, Netherlands; [Coelho, Luis Pedro] Fudan Univ, Key Lab Computat Neurosci & Brain Inspired Intell, Minist Educ, Shanghai, Peoples R China	European Molecular Biology Laboratory (EMBL); European Molecular Biology Laboratory (EMBL); Wageningen University & Research; University of Helsinki; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Yonsei University; University of Wurzburg; Novo Nordisk Foundation; Technical University of Denmark; University of Queensland; Utrecht University; Royal Netherlands Institute for Sea Research (NIOZ); Fudan University	Bork, P (corresponding author), European Mol Biol Lab, Struct & Computat Biol Unit, Heidelberg, Germany.; Bork, P (corresponding author), Max Delbruck Ctr Mol Med, Berlin, Germany.; Bork, P (corresponding author), Yonsei Univ, Yonsei Frontier Lab, Seoul, South Korea.; Bork, P (corresponding author), Univ Wurzburg, Bioctr, Dept Bioinformat, Wurzburg, Germany.	peer.bork@embl.org	; Van Rossum, Thea/N-3584-2013; Schmidt, Thomas/F-3022-2014	Li, Simone S/0000-0002-0073-3656; Maistrenko, Oleksandr/0000-0003-1961-7548; Van Rossum, Thea/0000-0002-3598-5001; Schmidt, Thomas/0000-0001-8587-4177; Hercog, Rajna/0000-0003-2587-9739; Jung, Ferris-Elias/0000-0002-5534-7832; Thielemann, Roman/0000-0003-2582-6178; Akanni, Wasiu A./0000-0002-2075-2387	European Research Council under the European Union's Horizon2020 research and innovation program [ERC-AdG-686070]; German Federal Ministry of Education and Research (LAMarCK) [031L0181A]; European Molecular Biology Laboratory; European Molecular Biology Organisation [ALTF 137-2018]; National Health and Medical Research Council of Australia [APP1166180]; Dutch Diabetes Research Foundation [2019.82.004]; Netherlands Organization for Scientific Research [024.002.002]; ZONMW VICI grant 2020 [09150182010020]	European Research Council under the European Union's Horizon2020 research and innovation program; German Federal Ministry of Education and Research (LAMarCK); European Molecular Biology Laboratory; European Molecular Biology Organisation; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Dutch Diabetes Research Foundation; Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); ZONMW VICI grant 2020	We thank A. Moss (Harvard University, USA), C. Morrow (University of Alabama at Birmingham, USA), S. Leo (University of Geneva, Switzerland), R. Goll (University of TromsO, Norway) and D. Podlesny (University of Hohenheim, Germany) for providing additional information on the cohorts used in this study. We further thank R. J. Alves, A. Schwartz, M. Kuhn, P. Ferretti, S. K. Forslund and members of the Bork laboratory at EMBL for support and constructive discussions. This work was supported by the European Research Council under the European Union's Horizon2020 research and innovation program (nos. ERC-AdG-669830 to T.S.B.S., S.S.L., O.M.M., R.H., F.J. and P.B.; and ERC-AdG-686070 to L.P.C. and T.V.R.), by the German Federal Ministry of Education and Research (LAMarCK, no. 031L0181A to A.O.) and by the European Molecular Biology Laboratory (to W.A., A.F., A.M.G., S.K., R.T., M.v.S., V.B. and P.B.). S.S.L. acknowledges support from the European Molecular Biology Organisation (no. ALTF 137-2018) and the National Health and Medical Research Council of Australia (no. APP1166180). H.H. is supported by a Senior Fellowship of the Dutch Diabetes Research Foundation (no. 2019.82.004). W.M.d.V. is supported by the Spinoza 2008 award and a SIAM Gravitation grant from the Netherlands Organization for Scientific Research (no. 024.002.002). M.N. is supported by a ZONMW VICI grant 2020 (no. 09150182010020). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Aggarwala V, 2021, NAT MICROBIOL, V6, P1309, DOI 10.1038/s41564-021-00966-0; Alcock BP, 2020, NUCLEIC ACIDS RES, V48, pD517, DOI 10.1093/nar/gkz935; Alneberg J, 2014, NAT METHODS, V11, P1144, DOI [10.1038/NMETH.3103, 10.1038/nmeth.3103]; Bar-Yoseph H, 2021, CLIN INFECT DIS, V73, pE166, DOI 10.1093/cid/ciaa737; Baruch EN, 2021, SCIENCE, V371, P602, DOI 10.1126/science.abb5920; Basson AR, 2020, TRANSL RES, V226, P1, DOI 10.1016/j.trsl.2020.05.008; Bojanova DP, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002503; Borody TJ, 2004, J CLIN GASTROENTEROL, V38, P475, DOI 10.1097/01.mcg.0000128988.13808.dc; Burrello C, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07359-8; Cao Y, 2014, BIOINFORMATICS, V30, P1674, DOI 10.1093/bioinformatics/btu104; Chaumeil PA, 2020, BIOINFORMATICS, V36, P1925, DOI 10.1093/bioinformatics/btz848; Coelho LP, 2022, NATURE, V601, P252, DOI 10.1038/s41586-021-04233-4; Coelho LP, 2019, MICROBIOME, V7, DOI 10.1186/s40168-019-0684-8; Costea PI, 2018, NAT MICROBIOL, V3, P388, DOI 10.1038/s41564-018-0114-x; Costea PI, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182392; Damman CJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133925; Danne C, 2021, NAT REV GASTRO HEPAT, V18, P503, DOI 10.1038/s41575-021-00441-5; Darzi Y, 2016, ISME J, V10, P1025, DOI 10.1038/ismej.2015.188; Davar D, 2021, SCIENCE, V371, P595, DOI 10.1126/science.abf3363; de Groot P, 2021, GUT, V70, P92, DOI [10.1136/gutjnl-2020-322630, 10.1136/gutjnl-2020-323252]; Debray R, 2022, NAT REV MICROBIOL, V20, P109, DOI 10.1038/s41579-021-00604-w; Draper LA, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0598-x; Duvallet C, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222881; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Fuentes S, 2017, ISME J, V11, P1877, DOI 10.1038/ismej.2017.44; Fujimoto K, 2021, GASTROENTEROLOGY, V160, P2089, DOI 10.1053/j.gastro.2021.02.013; Gibson MK, 2015, ISME J, V9, P207, DOI 10.1038/ismej.2014.106; Goll R, 2020, GUT MICROBES, V12, DOI 10.1080/19490976.2020.1794263; Goloshchapov OV, 2019, BMC MICROBIOL, V19, DOI 10.1186/s12866-019-1689-y; Gonze D, 2017, ISME J, V11, P2159, DOI 10.1038/ismej.2017.60; Gough E, 2011, CLIN INFECT DIS, V53, P994, DOI 10.1093/cid/cir632; Haifer C, 2020, CURR OPIN PHARMACOL, V55, P8, DOI 10.1016/j.coph.2020.08.009; Hanssen NMJ, 2021, CELL METAB, V33, P1098, DOI 10.1016/j.cmet.2021.05.005; Hildebrand F, 2021, CELL HOST MICROBE, V29, P1167, DOI 10.1016/j.chom.2021.05.008; Huerta-Cepas J, 2019, NUCLEIC ACIDS RES, V47, pD309, DOI 10.1093/nar/gky1085; Huerta-Cepas J, 2017, MOL BIOL EVOL, V34, P2115, DOI 10.1093/molbev/msx148; Hyatt D, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-119; Ianiro G, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18127-y; Jain C, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07641-9; Kang DWD, 2019, PEERJ, V7, DOI 10.7717/peerj.7359; Koopen AM, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.662159; Kootte RS, 2017, CELL METAB, V26, P611, DOI 10.1016/j.cmet.2017.09.008; Lahti L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5344; Lee STM, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0270-x; Leo S, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8060941; Leonardi I, 2020, CELL HOST MICROBE, V27, P823, DOI 10.1016/j.chom.2020.03.006; Li H., 2013, ARXIV, DOI DOI 10.48550/ARXIV.1303.3997; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Li SS, 2016, SCIENCE, V352, P586, DOI 10.1126/science.aad8852; Manrique P, 2021, GUT MICROBES, V13, DOI 10.1080/19490976.2021.1897217; Mende DR, 2020, NUCLEIC ACIDS RES, V48, pD621, DOI 10.1093/nar/gkz1002; Mende DR, 2017, NUCLEIC ACIDS RES, V45, pD529, DOI 10.1093/nar/gkw989; Mende DR, 2013, NAT METHODS, V10, P881, DOI [10.1038/NMETH.2575, 10.1038/nmeth.2575]; Milanese A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08844-4; Moss EL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182585; Narula N, 2017, INFLAMM BOWEL DIS, V23, P1702, DOI 10.1097/MIB.0000000000001228; Ng SC, 2022, GUT, V71, P716, DOI 10.1136/gutjnl-2020-323617; Nurk S, 2017, GENOME RES, V27, P824, DOI 10.1101/gr.213959.116; Nusbaum DJ, 2018, FEMS MICROBIOL ECOL, V94, DOI 10.1093/femsec/fiy133; Olesen SW, 2021, J CROHNS COLITIS, V15, P453, DOI 10.1093/ecco-jcc/jjaa170; Olm MR, 2017, ISME J, V11, P2864, DOI 10.1038/ismej.2017.126; Ondov BD, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0997-x; Orakov A, 2021, GENOME BIOL, V22, DOI 10.1186/s13059-021-02393-0; Ott SJ, 2017, GASTROENTEROLOGY, V152, P799, DOI 10.1053/j.gastro.2016.11.010; Page AJ, 2015, BIOINFORMATICS, V31, P3691, DOI 10.1093/bioinformatics/btv421; Parks DH, 2015, GENOME RES, V25, P1043, DOI 10.1101/gr.186072.114; Peri R, 2019, UNITED EUR GASTROENT, V7, P716, DOI 10.1177/2050640619839918; Podlesny D, 2022, MICROBIOME, V10, DOI 10.1186/s40168-022-01251-w; Price MN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009490; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Rodrigues JFM, 2017, BIOINFORMATICS, V33, P3808, DOI 10.1093/bioinformatics/btx517; Rossen NG, 2015, GASTROENTEROLOGY, V149, P110, DOI 10.1053/j.gastro.2015.03.045; Rossen NG, 2015, WORLD J GASTROENTERO, V21, P5359, DOI 10.3748/wjg.v21.i17.5359; Scheffer M, 2015, ANNU REV ECOL EVOL S, V46, P145, DOI 10.1146/annurev-ecolsys-112414-054242; Schmidt TSB, 2019, ELIFE, V8, DOI 10.7554/eLife.42693; Schmidt TSB, 2018, CELL, V172, P1198, DOI 10.1016/j.cell.2018.02.044; Seekatz AM, 2018, ANAEROBE, V53, P64, DOI 10.1016/j.anaerobe.2018.04.001; Seemann T, 2014, BIOINFORMATICS, V30, P2068, DOI 10.1093/bioinformatics/btu153; Sieber CMK, 2018, NAT MICROBIOL, V3, P836, DOI 10.1038/s41564-018-0171-1; Singh Ramandeep, 2018, BMC Res Notes, V11, P190, DOI 10.1186/s13104-018-3293-x; Smillie CS, 2018, CELL HOST MICROBE, V23, P229, DOI 10.1016/j.chom.2018.01.003; Suez J, 2018, CELL, V174, P1406, DOI 10.1016/j.cell.2018.08.047; Tian L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19940-1; Uritskiy GV, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0541-1; van Nood E, 2013, NEW ENGL J MED, V368, P407, DOI 10.1056/NEJMoa1205037; Vaughn BP, 2016, INFLAMM BOWEL DIS, V22, P2182, DOI 10.1097/MIB.0000000000000893; Vieira-Silva S, 2016, NAT MICROBIOL, V1, DOI [10.1038/nmicrobiol.2016.88, 10.1038/NMICROBIOL.2016.88]; Walter J, 2018, CURR OPIN BIOTECH, V49, P129, DOI 10.1016/j.copbio.2017.08.008; Watson A. R., 2021, ADAPTIVE ECOLOGICAL, DOI [10.1101/2021.03.02.433653, DOI 10.1101/2021.03.02.433653]; Wilson BC, 2021, MICROBIOME, V9, DOI 10.1186/s40168-021-01060-7; Wilson BC, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00002; Xiao YD, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17180-x; Zaneveld JR, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.121; Zhao HJ, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.554441; Zuo T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06103-6; Zuo T, 2017, GASTROENTEROLOGY, V152, pS140, DOI 10.1016/S0016-5085(17)30798-9	97	1	1	14	14	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2022	28	9					1902	+		10.1038/s41591-022-01913-0	http://dx.doi.org/10.1038/s41591-022-01913-0		SEP 2022	17	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4S0LI	36109636	Green Published, Green Accepted, hybrid			2022-12-27	WOS:000854720900001
J	Palmer, CD; Rappaport, AR; Davis, MJ; Hart, MG; Scallan, CD; Hong, SJ; Gitlin, L; Kraemer, LD; Kounlavouth, S; Yang, AR; Smith, L; Schenk, D; Skoberne, M; Taquechel, K; Marrali, M; Jaroslavsky, JR; Nganje, CN; Maloney, E; Zhou, RT; Navarro-Gomez, D; Greene, AC; Grotenbreg, G; Greer, R; Blair, W; Cao, MD; Chan, S; Bae, K; Spira, AI; Roychowdhury, S; Carbone, DP; Henick, BS; Drake, CG; Solomon, BJ; Ahn, DH; Mahipal, A; Maron, SB; Johnson, B; Rousseau, R; Yelensky, R; Liao, CY; Catenacci, DVT; Allen, A; Ferguson, AR; Jooss, K				Palmer, Christine D.; Rappaport, Amy R.; Davis, Matthew J.; Hart, Meghan G.; Scallan, Ciaran D.; Hong, Sue-Jean; Gitlin, Leonid; Kraemer, Lauren D.; Kounlavouth, Sonia; Yang, Aaron; Smith, Lindsey; Schenk, Desiree; Skoberne, Mojca; Taquechel, Kiara; Marrali, Martina; Jaroslavsky, Jason R.; Nganje, Charmaine N.; Maloney, Elizabeth; Zhou, Rita; Navarro-Gomez, Daniel; Greene, Adrienne C.; Grotenbreg, Gijsbert; Greer, Renee; Blair, Wade; Cao, Minh Duc; Chan, Shawn; Bae, Kyounghwa; Spira, Alexander I.; Roychowdhury, Sameek; Carbone, David P.; Henick, Brian S.; Drake, Charles G.; Solomon, Benjamin J.; Ahn, Daniel H.; Mahipal, Amit; Maron, Steve B.; Johnson, Benny; Rousseau, Raphael; Yelensky, Roman; Liao, Chih-Yi; Catenacci, Daniel V. T.; Allen, Andrew; Ferguson, Andrew R.; Jooss, Karin			Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results	NATURE MEDICINE			English	Article; Early Access							CLINICAL-RESPONSE; PD-1 BLOCKADE; LUNG-CANCER; T-CELLS; LANDSCAPE; MELANOMA; EPITOPES; ELISPOT; REVEALS; DESIGN	An individualized, heterologous chimpanzee adenovirus (ChAd68) and self-amplifying mRNA-based neoantigen vaccine is safe and well tolerated in patients, warranting further studies to test its potential to rescue response to checkpoint blockade in tumors of low immune reactivity. Checkpoint inhibitor (CPI) therapies provide limited benefit to patients with tumors of low immune reactivity. T cell-inducing vaccines hold promise to exert long-lasting disease control in combination with CPI therapy. Safety, tolerability and recommended phase 2 dose (RP2D) of an individualized, heterologous chimpanzee adenovirus (ChAd68) and self-amplifying mRNA (samRNA)-based neoantigen vaccine in combination with nivolumab and ipilimumab were assessed as primary endpoints in an ongoing phase 1/2 study in patients with advanced metastatic solid tumors (NCT03639714). The individualized vaccine regimen was safe and well tolerated, with no dose-limiting toxicities. Treatment-related adverse events (TRAEs) >10% included pyrexia, fatigue, musculoskeletal and injection site pain and diarrhea. Serious TRAEs included one count each of pyrexia, duodenitis, increased transaminases and hyperthyroidism. The RP2D was 10(12) viral particles (VP) ChAd68 and 30 mu g samRNA. Secondary endpoints included immunogenicity, feasibility of manufacturing and overall survival (OS). Vaccine manufacturing was feasible, with vaccination inducing long-lasting neoantigen-specific CD8 T cell responses. Several patients with microsatellite-stable colorectal cancer (MSS-CRC) had improved OS. Exploratory biomarker analyses showed decreased circulating tumor DNA (ctDNA) in patients with prolonged OS. Although small study size limits statistical and translational analyses, the increased OS observed in MSS-CRC warrants further exploration in larger randomized studies.	[Palmer, Christine D.; Rappaport, Amy R.; Davis, Matthew J.; Hart, Meghan G.; Scallan, Ciaran D.; Hong, Sue-Jean; Gitlin, Leonid; Kraemer, Lauren D.; Kounlavouth, Sonia; Yang, Aaron; Smith, Lindsey; Schenk, Desiree; Skoberne, Mojca; Taquechel, Kiara; Marrali, Martina; Jaroslavsky, Jason R.; Nganje, Charmaine N.; Maloney, Elizabeth; Zhou, Rita; Navarro-Gomez, Daniel; Greene, Adrienne C.; Grotenbreg, Gijsbert; Greer, Renee; Blair, Wade; Cao, Minh Duc; Chan, Shawn; Bae, Kyounghwa; Rousseau, Raphael; Yelensky, Roman; Allen, Andrew; Ferguson, Andrew R.; Jooss, Karin] Gritstone bio Inc, Emeryville, CA 94608 USA; [Spira, Alexander I.] Virginia Canc Specialists, Fairfax, VA USA; [Roychowdhury, Sameek; Carbone, David P.] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA; [Henick, Brian S.; Drake, Charles G.] Columbia Univ, Med Ctr, New York, NY USA; [Solomon, Benjamin J.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Ahn, Daniel H.] Mayo Clin, Phoenix, AZ USA; [Mahipal, Amit] Mayo Clin, Ctr Canc, Rochester, MN USA; [Maron, Steve B.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Johnson, Benny] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Liao, Chih-Yi; Catenacci, Daniel V. T.] Univ Chicago, Ctr Comprehens Canc, Chicago, IL USA	University System of Ohio; Ohio State University; Columbia University; Peter Maccallum Cancer Center; Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Memorial Sloan Kettering Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Robert H. Lurie Comprehensive Cancer Center; University of Chicago	Jooss, K (corresponding author), Gritstone bio Inc, Emeryville, CA 94608 USA.	kjooss@gritstone.com	Palmer, Christine/GXH-4415-2022	Jaroslavsky, Jason/0000-0002-9799-2397; Maloney, Elizabeth/0000-0002-5023-8573; Palmer, Christine Denise/0000-0003-3213-0398	Gritstone bio	Gritstone bio	We would like to thank the patients and their families; clinical staff and study coordinators; Bristol Myers Squibb for providing ipilimumab and nivolumab; and K. Caldwell, A. Dixon, C. Voong, J. Abhyankar, G. Talbot, A. Bezawada, W. Zhai, M. Zhong, T. Patch and J. Rouhana. We also thank T. Chan for critical review and guidance. Funding was provided by the study sponsor, Gritstone bio. Employees of Gritstone bio received salaries for study conceptualization, design, data analyses, decision to publish and manuscript preparation. No other authors received specific funding for this work from the sponsor.	Allen TM, 2001, J VIROL, V75, P738, DOI 10.1128/JVI.75.2.738-749.2001; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Bendell J, 2018, ANN ONCOL, V29, P123, DOI 10.1093/annonc/mdy208.003; Bulik-Sullivan B, 2019, NAT BIOTECHNOL, V37, P55, DOI 10.1038/nbt.4313; Chalmers ZR, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0424-2; Chen EX, 2020, JAMA ONCOL, V6, P831, DOI 10.1001/jamaoncol.2020.0910; Chudley L, 2014, CANCER IMMUNOL IMMUN, V63, P1199, DOI 10.1007/s00262-014-1593-0; DuPage M, 2012, NATURE, V482, P405, DOI 10.1038/nature10803; Farber DL, 2014, NAT REV IMMUNOL, V14, P24, DOI 10.1038/nri3567; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Grothey A., 2018, ANN ONCOL, V29, pviii714, DOI DOI 10.1093/ANNONC/MDY424.020; Gubin MM, 2014, NATURE, V515, P577, DOI 10.1038/nature13988; Hilf N, 2019, NATURE, V565, P240, DOI 10.1038/s41586-018-0810-y; Janetzki Sylvia, 2005, Methods Mol Biol, V302, P51; Janetzki S, 2015, NAT PROTOC, V10, P1098, DOI 10.1038/nprot.2015.068; Ji Y, 2013, J CLIN ONCOL, V31, P1785, DOI 10.1200/JCO.2012.45.7903; Keskin DB, 2019, NATURE, V565, P234, DOI 10.1038/s41586-018-0792-9; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Lee CH, 2018, TRENDS IMMUNOL, V39, P536, DOI 10.1016/j.it.2018.04.005; Lennerz V, 2005, P NATL ACAD SCI USA, V102, P16013, DOI 10.1073/pnas.0500090102; Lopez-Camacho C, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04859-5; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lundstrom K, 2019, GENES-BASEL, V10, DOI 10.3390/genes10030189; Matsushita H, 2012, NATURE, V482, P400, DOI 10.1038/nature10755; McGranahan N, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax7918; McGranahan N, 2017, CELL, V171, P1259, DOI 10.1016/j.cell.2017.10.001; McNamara MA, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/794528; Moodie Z, 2010, CANCER IMMUNOL IMMUN, V59, P1489, DOI 10.1007/s00262-010-0875-4; Mulligan MJ, 2020, NATURE, V586, P589, DOI 10.1038/s41586-020-2639-4; Ogwang C, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa2373; Ott PA, 2020, CELL, V183, P347, DOI 10.1016/j.cell.2020.08.053; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Paulson KG, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06300-3; Piperno-Neumann S, 2021, CANCER RES, V81; Rappaport AR, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-31005-z; Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Robbins PF, 2013, NAT MED, V19, P747, DOI 10.1038/nm.3161; Roederer M, 2011, CYTOM PART A, V79A, P167, DOI 10.1002/cyto.a.21015; Rosenthal R, 2019, NATURE, V567, P479, DOI 10.1038/s41586-019-1032-7; Sadoff J, 2021, NEW ENGL J MED, V384, P1824, DOI 10.1056/NEJMoa2034201; Sahin U, 2020, NATURE, V585, P107, DOI 10.1038/s41586-020-2537-9; Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003; Shaw AR, 2019, MOL THER-METH CLIN D, V15, P418, DOI 10.1016/j.omtm.2019.11.001; Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498; Tran E, 2017, NAT IMMUNOL, V18, P255, DOI 10.1038/ni.3682; Trolle T, 2016, J IMMUNOL, V196, P1480, DOI 10.4049/jimmunol.1501721; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Wieczorek M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00292; Zhang Q, 2020, CANCER DISCOV, V10, P1842, DOI 10.1158/2159-8290.CD-20-0047; Zhao H, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00335	51	1	1	12	12	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01937-6	http://dx.doi.org/10.1038/s41591-022-01937-6		AUG 2022	39	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3T9PT	35970920	Bronze			2022-12-27	WOS:000840603000003
J	Islam, MT; Ross, AG; Sleigh, AC; Chowdhury, F; Khan, AI; McMillan, NA; Qadri, F				Islam, Md Taufiqul; Ross, Allen G.; Sleigh, Adrian C.; Chowdhury, Fahima; Khan, Ashraful Islam; McMillan, Nigel A.; Qadri, Firdausi			A blueprint for eliminating cholera by 2030	NATURE MEDICINE			English	Editorial Material								Cholera is endemic in 47 countries, but deaths from this disease can be eliminated with a package of low-cost measures implemented by community healthcare workers.	[Islam, Md Taufiqul; Chowdhury, Fahima; Khan, Ashraful Islam; Qadri, Firdausi] Int Ctr Diarrhoeal Dis Res, Dhaka, Bangladesh; [Ross, Allen G.; Sleigh, Adrian C.] Charles Sturt Univ, Rural Hlth Res Inst, Orange, NSW, Australia; [McMillan, Nigel A.] Griffith Univ, Menzies Hlth Inst Queensland, Gold Coast, Qld, Australia; [McMillan, Nigel A.] Griffith Univ, Sch Pharm & Med Sci, Gold Coast, Qld, Australia	International Centre for Diarrhoeal Disease Research (ICDDR); Charles Sturt University; Griffith University; Menzies Health Institute Queensland; Griffith University	Islam, MT (corresponding author), Int Ctr Diarrhoeal Dis Res, Dhaka, Bangladesh.	taufiqulislam@icddrb.org	Qadri, Firdausi/AAF-4583-2019	McMillan, Nigel/0000-0002-9471-1406				Abad Tent P, 2019, PRESENT STUDY PRETEN; Boncy J, 2013, DIAGN MICR INFEC DIS, V76, P521, DOI 10.1016/j.diagmicrobio.2013.03.010; Chibwe I, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa493; Chowdhury G, 2021, PLOS NEGLECT TROP D, V15, DOI 10.1371/journal.pntd.0009521; Connolly MA, 2004, LANCET, V364, P1974, DOI 10.1016/S0140-6736(04)17481-3; D'Mello-Guyett L, 2020, CONFL HEALTH, V14, DOI 10.1186/s13031-020-00294-w; Davies HG, 2017, J INFECTION, V74, pS66, DOI 10.1016/S0163-4453(17)30194-9; European Centre for Disease Prevention and Control, ECDC MON CHOL OUTBR; Federspiel F, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6227-6; Finger F, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002509; Harris JR, 2009, TROP MED INT HEALTH, V14, P1117, DOI 10.1111/j.1365-3156.2009.02335.x; Ingelbeen B, 2019, EMERG INFECT DIS, V25, P856, DOI 10.3201/eid2505.181141; Islam MT, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007124; Kar SK, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002629; Khan AI, 2020, LANCET DIGIT HEALTH, V2, pE250, DOI 10.1016/S2589-7500(20)30062-5; Kweku M., 2020, INT J INFECT CONTROL; Legros D, 2018, J INFECT DIS, V218, pS137, DOI 10.1093/infdis/jiy486; Ley B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036930; Pezzoli L, 2020, VACCINE, V38, pA132, DOI 10.1016/j.vaccine.2019.08.086; Pietroni MAC, 2020, VACCINE, V38, pA105, DOI 10.1016/j.vaccine.2019.09.098; Ross AGP, 2013, NEW ENGL J MED, V368, P1817, DOI 10.1056/NEJMra1207777; Saha D, 2006, NEW ENGL J MED, V354, P2452, DOI 10.1056/NEJMoa054493; Sousa FBM, 2020, J PHARM PHARMACOL, V72, P1715, DOI 10.1111/jphp.13344; Spiegel P, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2019-001709; TAUXE RV, 1995, EMERG INFECT DIS, V1, P141, DOI 10.3201/eid0104.950408; UNICEF, 2022 CHOL EM STOCKP; US Centers for Disease Control and Prevention, 2020, CHOL IS DIS CAUS BAC; Wierzba TF, 2019, HUM VACC IMMUNOTHER, V15, P1294, DOI 10.1080/21645515.2018.1504155; World Health Organization, 2022, WHO FACT SHEET CHOL	29	1	1	2	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2022	28	9					1747	1749		10.1038/s41591-022-01898-w	http://dx.doi.org/10.1038/s41591-022-01898-w		JUL 2022	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4S0LI	35869308				2022-12-27	WOS:000828957200003
J	Tegally, H; Moir, M; Everatt, J; Giovanetti, M; Scheepers, C; Wilkinson, E; Subramoney, K; Makatini, Z; Moyo, S; Amoako, DG; Baxter, C; Althaus, CL; Anyaneji, UJ; Kekana, D; Viana, R; Giandhari, J; Lessells, RJ; Maponga, T; Maruapula, D; Choga, W; Matshaba, M; Mbulawa, MB; Msomi, N; Naidoo, Y; Pillay, S; Sanko, TJ; San, JE; Scott, L; Singh, L; Magini, NA; Smith-Lawrence, P; Stevens, W; Dor, G; Tshiabuila, D; Wolter, N; Preiser, W; Treurnicht, FK; Venter, M; Chiloane, G; McIntyre, C; O'Toole, A; Ruis, C; Peacock, TP; Roemer, C; Pond, SLK; Williamson, C; Pybus, OG; Bhiman, JN; Glass, A; Martin, DP; Jackson, B; Rambaut, A; Laguda-Akingba, O; Gaseitsiwe, S; von Gottberg, A; de Oliveira, T; Bester, AP; Claassen, M; Doolabh, D; Mudau, I; Mbhele, N; Engelbrecht, S; Goedhals, D; Hardie, D; Hsiao, NY; Iranzadeh, A; Ismail, A; Joseph, R; Maharaj, A; Mahlangu, B; Mahlakwane, K; Davis, A; Marais, G; Mlisana, K; Mnguni, A; Mohale, T; Motsatsi, G; Mwangi, P; Ntuli, N; Nyaga, M; Olubayo, L; Radibe, B; Ramphal, Y; Ramphal, U; Strasheim, W; Tebeila, N; van Wyk, S; Wilson, S; Lucaci, AG; Weaver, S; Maharaj, A; Pillay, Y; Davids, M; Mendes, A; Mayaphi, S				Tegally, Houriiyah; Moir, Monika; Everatt, Josie; Giovanetti, Marta; Scheepers, Cathrine; Wilkinson, Eduan; Subramoney, Kathleen; Makatini, Zinhle; Moyo, Sikhulile; Amoako, Daniel G.; Baxter, Cheryl; Althaus, Christian L.; Anyaneji, Ugochukwu J.; Kekana, Dikeledi; Viana, Raquel; Giandhari, Jennifer; Lessells, Richard J.; Maponga, Tongai; Maruapula, Dorcas; Choga, Wonderful; Matshaba, Mogomotsi; Mbulawa, Mpaphi B.; Msomi, Nokukhanya; Naidoo, Yeshnee; Pillay, Sureshnee; Sanko, Tomasz Janusz; San, James E.; Scott, Lesley; Singh, Lavanya; Magini, Nonkululeko A.; Smith-Lawrence, Pamela; Stevens, Wendy; Dor, Graeme; Tshiabuila, Derek; Wolter, Nicole; Preiser, Wolfgang; Treurnicht, Florette K.; Venter, Marietjie; Chiloane, Georginah; McIntyre, Caitlyn; O'Toole, Aine; Ruis, Christopher; Peacock, Thomas P.; Roemer, Cornelius; Kosakovsky Pond, Sergei L.; Williamson, Carolyn; Pybus, Oliver G.; Bhiman, Jinal N.; Glass, Allison; Martin, Darren P.; Jackson, Ben; Rambaut, Andrew; Laguda-Akingba, Oluwakemi; Gaseitsiwe, Simani; von Gottberg, Anne; de Oliveira, Tulio; Bester, Armand Phillip; Claassen, Mathilda; Doolabh, Deelan; Mudau, Innocent; Mbhele, Nokuzola; Engelbrecht, Susan; Goedhals, Dominique; Hardie, Diana; Hsiao, Nei-Yuan; Iranzadeh, Arash; Ismail, Arshad; Joseph, Rageema; Maharaj, Arisha; Mahlangu, Boitshoko; Mahlakwane, Kamela; Davis, Ashlyn; Marais, Gert; Mlisana, Koleka; Mnguni, Anele; Mohale, Thabo; Motsatsi, Gerald; Mwangi, Peter; Ntuli, Noxolo; Nyaga, Martin; Olubayo, Luicer; Radibe, Botshelo; Ramphal, Yajna; Ramphal, Upasana; Strasheim, Wilhelmina; Tebeila, Naume; van Wyk, Stephanie; Wilson, Shannon; Lucaci, Alexander G.; Weaver, Steven; Maharaj, Akhil; Pillay, Yusasha; Davids, Michaela; Mendes, Adriano; Mayaphi, Simnikiwe		NGS SA Consortium	Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa	NATURE MEDICINE			English	Article							RECEPTOR-BINDING DOMAIN; MUTATIONS; IMMUNITY	Genomic characterization of the SARS-CoV-2 Omicron lineages BA.4 and BA.5, responsible for the fifth COVID-19 pandemic wave in South Africa, shows continued viral diversification and provides insights into the potential mechanisms underlying the ability of the new lineages to outcompete their predecessors. Three lineages (BA.1, BA.2 and BA.3) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern predominantly drove South Africa's fourth Coronavirus Disease 2019 (COVID-19) wave. We have now identified two new lineages, BA.4 and BA.5, responsible for a fifth wave of infections. The spike proteins of BA.4 and BA.5 are identical, and similar to BA.2 except for the addition of 69-70 deletion (present in the Alpha variant and the BA.1 lineage), L452R (present in the Delta variant), F486V and the wild-type amino acid at Q493. The two lineages differ only outside of the spike region. The 69-70 deletion in spike allows these lineages to be identified by the proxy marker of S-gene target failure, on the background of variants not possessing this feature. BA.4 and BA.5 have rapidly replaced BA.2, reaching more than 50% of sequenced cases in South Africa by the first week of April 2022. Using a multinomial logistic regression model, we estimated growth advantages for BA.4 and BA.5 of 0.08 (95% confidence interval (CI): 0.08-0.09) and 0.10 (95% CI: 0.09-0.11) per day, respectively, over BA.2 in South Africa. The continued discovery of genetically diverse Omicron lineages points to the hypothesis that a discrete reservoir, such as human chronic infections and/or animal hosts, is potentially contributing to further evolution and dispersal of the virus.	[Tegally, Houriiyah; Moir, Monika; Wilkinson, Eduan; Baxter, Cheryl; Naidoo, Yeshnee; Sanko, Tomasz Janusz; de Oliveira, Tulio; van Wyk, Stephanie] Stellenbosch Univ, Ctr Epidem Response & Innovat CERI, Sch Data Sci & Computat Thinking, Stellenbosch, South Africa; [Tegally, Houriiyah; Anyaneji, Ugochukwu J.; Giandhari, Jennifer; Lessells, Richard J.; Pillay, Sureshnee; San, James E.; Singh, Lavanya; Magini, Nonkululeko A.; Tshiabuila, Derek; de Oliveira, Tulio; Maharaj, Arisha; Ramphal, Upasana; Maharaj, Akhil; Pillay, Yusasha] Univ KwaZulu, KwaZulu Natal Res Innovat & Sequencing Platform K, Nelson R Mandela Sch Med, Durban, South Africa; [Everatt, Josie; Scheepers, Cathrine; Amoako, Daniel G.; Kekana, Dikeledi; Wolter, Nicole; Bhiman, Jinal N.; von Gottberg, Anne; Ismail, Arshad; Mahlangu, Boitshoko; Mnguni, Anele; Mohale, Thabo; Motsatsi, Gerald; Ntuli, Noxolo; Strasheim, Wilhelmina; Tebeila, Naume] Natl Hlth Lab Serv NHLS, Natl Inst Communicable Dis NICD, Johannesburg, South Africa; [Giovanetti, Marta] Fundacao Oswaldo Cruz, Lab Flavivirus, Rio De Janeiro, Brazil; [Giovanetti, Marta] Univ Campus Biomed Roma, Dept Sci & Technol Humans & Environm, Rome, Italy; [Giovanetti, Marta] Univ Fed Minas Gerais, Lab Genet Celular Mol, Belo Horizonte, MG, Brazil; [Scheepers, Cathrine; Bhiman, Jinal N.] Univ Witwatersrand, Fac Hlth Sci, Sch Pathol, South African Med Res Council Antibody Immun Res, Johannesburg, South Africa; [Subramoney, Kathleen; Makatini, Zinhle; Treurnicht, Florette K.; Davis, Ashlyn] Charlotte Maxeke Johannesburg Acad Hosp, Dept Virol, Johannesburg, South Africa; [Subramoney, Kathleen; Makatini, Zinhle; Wolter, Nicole; Treurnicht, Florette K.; Glass, Allison; von Gottberg, Anne] Univ Witwatersrand, Fac Hlth Sci, Sch Pathol, Johannesburg, South Africa; [Moyo, Sikhulile; Maruapula, Dorcas; Choga, Wonderful; Gaseitsiwe, Simani; Radibe, Botshelo] Botswana Harvard AIDS Inst Partnership, Botswana Harvard HIV Reference Lab, Gaborone, Botswana; [Moyo, Sikhulile; Gaseitsiwe, Simani] Harvard TH Chan Sch Publ Hlth, Boston, MA USA; [Moyo, Sikhulile; Matshaba, Mogomotsi] Botswana Presidential COVID 19 Taskforce, Gaborone, Botswana; [Althaus, Christian L.] Univ Bern, Inst Social & Prevent Med, Bern, Switzerland; [Viana, Raquel; Glass, Allison] Lancet Labs, Johannesburg, South Africa; [Maponga, Tongai; Preiser, Wolfgang; Claassen, Mathilda; Engelbrecht, Susan; Mahlakwane, Kamela; Wilson, Shannon] Stellenbosch Univ, Fac Med & Hlth Sci, Div Med Virol, Cape Town, South Africa; [Mbulawa, Mpaphi B.] Minist Hlth & Wellness, Natl Hlth Lab, Hlth Serv Management, Gaborone, Botswana; [Msomi, Nokukhanya] Univ KwaZulu, Discipline Virol, Sch Lab Med & Med Sci, Natl Hlth Lab Serv NHLS, Durban, South Africa; [Scott, Lesley; Stevens, Wendy] Univ Witwatersrand, Fac Hlth Sci, Sch Pathol, Dept Mol Med & Haematol, Johannesburg, South Africa; [Smith-Lawrence, Pamela] Minist Hlth & Wellness, Hlth Serv Management, Gaborone, Botswana; [Stevens, Wendy; Dor, Graeme] Natl Prior Program Natl Hlth Lab Serv, Johannesburg, South Africa; [Venter, Marietjie; Chiloane, Georginah; McIntyre, Caitlyn; Davids, Michaela; Mendes, Adriano] Univ Pretoria, Ctr Viral Zoonoses, Dept Med Virol, Zoonot Arbo & Resp Virus Program, Pretoria, South Africa; [O'Toole, Aine; Jackson, Ben; Rambaut, Andrew] Univ Edinburgh, Inst Evolutionary Biol, Edinburgh, Scotland; [Ruis, Christopher] Univ Cambridge, Dept Med, Cambridge, England; [Peacock, Thomas P.] Imperial Coll London, Dept Infect Dis, London, England; [Roemer, Cornelius] Univ Basel, Biozentrum, Basel, Switzerland; [Kosakovsky Pond, Sergei L.; Lucaci, Alexander G.; Weaver, Steven] Temple Univ, Inst Gen & Evolutionary Med, Dept Biol, Philadelphia, PA USA; [Williamson, Carolyn; Doolabh, Deelan; Mudau, Innocent; Mbhele, Nokuzola; Hardie, Diana; Hsiao, Nei-Yuan; Joseph, Rageema; Marais, Gert] Univ Cape Town, Fac Hlth Sci, Div Med Virol, Cape Town, South Africa; [Williamson, Carolyn; Hardie, Diana; Hsiao, Nei-Yuan; Marais, Gert] NHLS Groote Schuur Lab, Div Virol, Cape Town, South Africa; [Williamson, Carolyn; Martin, Darren P.; Hardie, Diana; Hsiao, Nei-Yuan; Olubayo, Luicer] Wellcome Ctr Infect Dis Res Africa CIDRI, Cape Town, South Africa; [Williamson, Carolyn; Martin, Darren P.; Hsiao, Nei-Yuan] Univ Cape Town, Inst Infect Dis & Mol Med, Cape Town, South Africa; [Pybus, Oliver G.] Univ Oxford, Dept Zool, Oxford, England; [Laguda-Akingba, Oluwakemi] NHLS Port Elizabeth Lab, Port Elizabeth, South Africa; [Laguda-Akingba, Oluwakemi] Walter Sisulu Univ, Fac Hlth Sci, Eastern Cape, South Africa; [von Gottberg, Anne] Univ Cape Town, Fac Hlth Sci, Dept Pathol, Div Med MicroBiol, Cape Town, South Africa; [de Oliveira, Tulio] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA; [Bester, Armand Phillip] Natl Hlth Lab Serv, Div Virol, Bloemfontein, South Africa; [Bester, Armand Phillip; Goedhals, Dominique; Mwangi, Peter; Nyaga, Martin] Univ Free State, Div Virol, Bloemfontein, South Africa; [Goedhals, Dominique] PathCare Vermaak, Pretoria, South Africa; [Iranzadeh, Arash; Olubayo, Luicer] Univ Cape Town, Fac Hlth Sci, Div Computat Biol, Cape Town, South Africa; [Mahlakwane, Kamela] NHLS Tygerberg Lab, Cape Town, South Africa; [Mlisana, Koleka] Natl Hlth Lab Serv NHLS, Johannesburg, South Africa; [Mlisana, Koleka] Ctr AIDS Programme Res South Africa CAPRISA, Durban, South Africa; [Mwangi, Peter; Nyaga, Martin] Univ Free State, Fac Hlth Sci, Div Virol, Next Generat Sequencing Unit, Bloemfontein, South Africa; [Mayaphi, Simnikiwe] Univ Pretoria, Dept Med Virol, Pretoria, South Africa	Stellenbosch University; University of Kwazulu Natal; National Health Laboratory Service; National Institute for Communicable Diseases (NICD); Fundacao Oswaldo Cruz; University Campus Bio-Medico - Rome Italy; Universidade Federal de Minas Gerais; University of Witwatersrand; University of Witwatersrand; University of Witwatersrand; Botswana-Harvard AIDS Institute Partnership; Harvard University; Harvard T.H. Chan School of Public Health; University of Bern; Stellenbosch University; University of Kwazulu Natal; University of Witwatersrand; University of Pretoria; University of Edinburgh; University of Cambridge; Imperial College London; University of Basel; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Cape Town; University of Cape Town; University of Oxford; Walter Sisulu University; University of Cape Town; University of Washington; University of Washington Seattle; University of the Free State; University of Cape Town; National Health Laboratory Service; University of the Free State; University of Pretoria	de Oliveira, T (corresponding author), Stellenbosch Univ, Ctr Epidem Response & Innovat CERI, Sch Data Sci & Computat Thinking, Stellenbosch, South Africa.; de Oliveira, T (corresponding author), Univ KwaZulu, KwaZulu Natal Res Innovat & Sequencing Platform K, Nelson R Mandela Sch Med, Durban, South Africa.; de Oliveira, T (corresponding author), Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.	tulio@sun.ac.za	Preiser, Wolfgang/J-4875-2016; Moyo, Sikhulile/E-1464-2015; Ismail, Arshad/B-8552-2019; Mahlakwane, Kamela/GMW-7195-2022; Mwangi, Peter Nthiga/AHE-0033-2022; Scheepers, Cathrine/ABC-9229-2021; Venter, Marietjie/P-9604-2016	Preiser, Wolfgang/0000-0002-0254-7910; Moyo, Sikhulile/0000-0003-3821-4592; Ismail, Arshad/0000-0003-4672-5915; Baxter, Cheryl/0000-0002-6033-7655; von Gottberg, Anne/0000-0002-0243-7455; Scott, Lesley/0000-0001-6573-9525; Venter, Marietjie/0000-0003-2696-824X; CHOGA, Wonderful T./0000-0001-7606-0569; Everatt, Josie/0000-0002-0373-2093; Mwangi, Peter/0000-0002-4732-2811; Olubayo, Luicer Anne Ingasia/0000-0002-7370-7272	South African Medical Research Council (SAMRC); National Department of Health; South African National Department of Health, emergency COVID-19; NICD of the NHLS; US Centers for Disease Control and Prevention (CDC) [U01IP001048, 1 NU51IP000930]; African Society of Laboratory Medicine (ASLM); Bill and Melinda Gates Foundation [INV-018978]; UK Foreign, Commonwealth and Development Office and Wellcome [221003/Z/20/Z]; UK Department of Health and Social Care; Coronavirus Aid, Relief, and Economic Security Act (CARES ACT) through the CDC; CDC [AF-NICD-001/2021]; World Health Organization; Rockefeller Foundation [HTH 017]; Abbott Pandemic Defense Coalition (APDC); US National Institutes of Health [U01 AI151698]; INFORM Africa project through IHVN [U54 TW012041]; South African Department of Science and Innovation (SA DSI); SAMRC under the BRICS JAF [2020/049]; Foundation for Innovation in Diagnostics; National Institutes of Health Fogarty International Centre [3D43TW009610-09S1]; HHS/NIH/National Institute of Allergy and Infectious Diseases (NIAID) [5K24AI131928-04, 5K24AI131924-04]	South African Medical Research Council (SAMRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)South African Medical Research Council); National Department of Health; South African National Department of Health, emergency COVID-19; NICD of the NHLS; US Centers for Disease Control and Prevention (CDC)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); African Society of Laboratory Medicine (ASLM); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); UK Foreign, Commonwealth and Development Office and Wellcome; UK Department of Health and Social Care; Coronavirus Aid, Relief, and Economic Security Act (CARES ACT) through the CDC; CDC(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); World Health Organization(World Health Organization); Rockefeller Foundation; Abbott Pandemic Defense Coalition (APDC); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); INFORM Africa project through IHVN; South African Department of Science and Innovation (SA DSI); SAMRC under the BRICS JAF; Foundation for Innovation in Diagnostics; National Institutes of Health Fogarty International Centre(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); HHS/NIH/National Institute of Allergy and Infectious Diseases (NIAID)	This research was supported by the South African Medical Research Council (SAMRC) with funds received from the National Department of Health. Sequencing activities for the National Institute for Communicable Diseases (NICD) are supported by a conditional grant from the South African National Department of Health as part of the emergency COVID-19 response; a cooperative agreement between the NICD of the NHLS and the US Centers for Disease Control and Prevention (CDC) (U01IP001048 and 1 NU51IP000930); the African Society of Laboratory Medicine (ASLM) and Africa Centers for Disease Control and Prevention through a sub-award from the Bill and Melinda Gates Foundation (grant number INV-018978); the UK Foreign, Commonwealth and Development Office and Wellcome (221003/Z/20/Z); and the UK Department of Health and Social Care, managed by the Fleming Fund and performed under the auspices of the SEQAFRICA project. This research was also supported by the Coronavirus Aid, Relief, and Economic Security Act (CARES ACT) through the CDC and COVID International Task Force (ITF) funds through the CDC under the terms of a subcontract with the African Field Epidemiology Network (AFENET) (AF-NICD-001/2021). Sequencing activities at KRISP and the Centre for Epidemic Response and Innovation are supported, in part, by grants from the World Health Organization, the Rockefeller Foundation (HTH 017), the Abbott Pandemic Defense Coalition (APDC), the US National Institutes of Health (U01 AI151698) for the United World Antivirus Research Network (UWARN) and the INFORM Africa project through IHVN (U54 TW012041) and the South African Department of Science and Innovation (SA DSI) and the SAMRC under the BRICS JAF (2020/049). Sequencing at the Botswana Harvard AIDS Institute Partnership was supported by funding from the Bill and Melinda Gates Foundation, the Foundation for Innovation in Diagnostics, the National Institutes of Health Fogarty International Centre (3D43TW009610-09S1) and the HHS/NIH/National Institute of Allergy and Infectious Diseases (NIAID) (5K24AI131928-04 and 5K24AI131924-04). The content and findings reported herein are the sole deduction, view and responsibility of the researchers and do not reflect the official position and sentiments of the funding agencies.	Campbell F, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.24.2100509; CDC, 2020, COR DIS 2019 COVID 1; Chen LL, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-31395-0; cran.r-project, PACKAGE EMMEANS ESTI; Davies NG, 2021, SCIENCE, V372, P149, DOI 10.1126/science.abg3055; Dellicour S, 2016, BIOINFORMATICS, V32, P3204, DOI 10.1093/bioinformatics/btw384; Fonager J, 2022, EUROSURVEILLANCE, V27, DOI 10.2807/1560-7917.ES.2022.27.10.2200181; github, NEHERLAB NEXTALIGN; Greaney AJ, 2022, VIRUS EVOL, V8, DOI 10.1093/ve/veac021; Greaney Allison J, 2021, Cell Host Microbe, V29, P463, DOI 10.1016/j.chom.2021.02.003; Greaney Allison J, 2021, bioRxiv, DOI 10.1101/2021.03.17.435863; Greaney Allison J, 2021, Cell Host Microbe, V29, P44, DOI [10.1101/2020.09.10.292078, 10.1016/j.chom.2020.11.007]; GRIFFITHS RC, 1994, PHILOS T ROY SOC B, V344, P403, DOI 10.1098/rstb.1994.0079; Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407; Khan K., 2022, PREPRINT, DOI [10.1101/2022.04.29.22274477v1, DOI 10.1101/2022.04.29.22274477V1]; Koeppel KN, 2022, VIRUSES-BASEL, V14, DOI 10.3390/v14010120; Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5; Lemey P, 2010, MOL BIOL EVOL, V27, P1877, DOI 10.1093/molbev/msq067; Lucaci A. G., BIORXIV, DOI [10.1101/2022.01.15.476448v1(2022), DOI 10.1101/2022.01.15.476448V1(2022)]; Madhi SA, 2022, NEW ENGL J MED, V386, P1314, DOI 10.1056/NEJMoa2119658; Marivate V., 2020, DATA SCI J, V19, P19, DOI DOI 10.5334/DSJ-2020-019; Motozono C, 2021, CELL HOST MICROBE, V29, P1124, DOI 10.1016/j.chom.2021.06.006; Msomi N, 2020, LANCET MICROBE, V1, pE229, DOI 10.1016/S2666-5247(20)30116-6; Murrell B, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002764; Nguyen Lam-Tung, 2015, Mol Biol Evol, V32, P268, DOI 10.1093/molbev/msu300; O'Toole A, 2022, BMC GENOMICS, V23, DOI 10.1186/s12864-022-08358-2; O'Toole A, 2021, VIRUS EVOL, V7, DOI 10.1093/ve/veab064; Pond SLK, 2005, MOL BIOL EVOL, V22, P1208, DOI 10.1093/molbev/msi105; Rahimi F, 2022, INT J SURG, V99, DOI 10.1016/j.ijsu.2022.106261; Rambaut A, 2020, NAT MICROBIOL, V5, P1403, DOI 10.1038/s41564-020-0770-5; Rambaut A, 2018, SYST BIOL, V67, P901, DOI 10.1093/sysbio/syy032; Rambaut A, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew007; Scott L, 2021, SCIENCE, V374, P1454, DOI 10.1126/science.abn4543; Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494; Suchard MA, 2018, VIRUS EVOL, V4, DOI 10.1093/ve/vey016; Sun K., SCI TRANSL MED, DOI DOI 10.1126/SCITRANSLMED.ABO7081(2022; Viana R, 2022, NATURE, V603, P679, DOI 10.1038/s41586-022-04411-y; Wickham H, 2011, WIRES COMPUT STAT, V3, P180, DOI 10.1002/wics.147; World Organisation for Animal Health, STAT ADV GROUP SARS; Yu Guangchuang, 2020, Curr Protoc Bioinformatics, V69, pe96, DOI 10.1002/cpbi.96; Zhou J, 2022, CELL REP, V38, DOI 10.1016/j.celrep.2022.110344	41	65	66	21	21	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2022	28	9					1785	+		10.1038/s41591-022-01911-2	http://dx.doi.org/10.1038/s41591-022-01911-2		JUN 2022	18	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4S0LI	35760080	Green Published, hybrid			2022-12-27	WOS:000832802600001
J	Tang, XZE; Tan, SX; Hoon, S; Yeo, GW				Tang, Xin-Zi Emily; Tan, Shu Xuan; Hoon, Shawn; Yeo, Gene W.			Pre-existing adaptive immunity to the RNA-editing enzyme Cas13d in humans	NATURE MEDICINE			English	Article								RNA-guided RNA-targeting nucleases, such as CRISPR-Cas13 proteins, have therapeutic potential for gene editing. Among Cas13d enzymes, Cas13d from the bacteria Ruminococcus flavefaciens (RfxCas13d) is of particular interest owing to its small size and high specificity. However, the existence of pre-existing immunity against RfxCas13d is unclear. In this study, we evaluated antibody and T cell responses to RfxCas13d in healthy donors using ELISA and T cell culture assays. We found RfxCas13d-reactive antibodies and CD4 and CD8 T cell responses in most donors, comparable to responses against Cas9 proteins from Staphylococcus aureus (SaCas9) and Streptococcus pyogenes (SpCas9). RfxCas13d-responding T cells could produce the inflammatory cytokines IFN-gamma, TNF-alpha and IL-17. These findings should be taken into consideration in the development of RfxCas13d for therapy. Healthy individuals have antibodies and T cells that are reactive to the Cas13d protein from the bovine bacteria Ruminococcus flavefaciens, which may have implications for clinical testing of CRISPR-Cas13 gene editing approaches.	[Tang, Xin-Zi Emily; Tan, Shu Xuan; Yeo, Gene W.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore, Singapore; [Tang, Xin-Zi Emily; Hoon, Shawn] Agcy Sci Technol & Res, Inst Mol & Cell Biol, Mol Engn Lab, Singapore, Singapore; [Yeo, Gene W.] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; [Yeo, Gene W.] Univ Calif San Diego, Stem Cell Program, La Jolla, CA 92093 USA; [Yeo, Gene W.] Univ Calif San Diego, Inst Genom Med, La Jolla, CA 92093 USA	National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Yeo, GW (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore, Singapore.; Yeo, GW (corresponding author), Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA.; Yeo, GW (corresponding author), Univ Calif San Diego, Stem Cell Program, La Jolla, CA 92093 USA.; Yeo, GW (corresponding author), Univ Calif San Diego, Inst Genom Med, La Jolla, CA 92093 USA.	geneyeo@ucsd.edu		Tang, Xin-Zi/0000-0001-6064-8624; Yeo, Eugene/0000-0002-0799-6037	Singapore National Research Foundation (NRF) Research Fellowship [NRFVI2017-01-01]; Agency for Science, Technology and Research [H17/01/a0/012]	Singapore National Research Foundation (NRF) Research Fellowship(National Research Foundation, Singapore); Agency for Science, Technology and Research(Agency for Science Technology & Research (A*STAR))	We thank A. Bertoletti and A. Tan for valuable feedback on the manuscript. We thank the staff at flow cytometry core facility (Life Science Institute, Immunology Programme, NUS) for their assistance. This project was supported by the Singapore National Research Foundation (NRF) Research Fellowship (NRFVI2017-01-01, G. W. Y) and the Agency for Science, Technology and Research (H17/01/a0/012, S. H.). The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.	Abbott TR, 2020, CELL, V181, P865, DOI 10.1016/j.cell.2020.04.020; Arruda VR, 2009, MOL THER, V17, P1492, DOI 10.1038/mt.2009.150; Charlesworth CT, 2019, NAT MED, V25, P249, DOI 10.1038/s41591-018-0326-x; Cox DBT, 2017, SCIENCE, V358, P1019, DOI 10.1126/science.aaq0180; Du MH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16806-4; Ferdosi SR, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09693-x; Gautier EL, 2012, NAT IMMUNOL, V13, P1118, DOI 10.1038/ni.2419; Gehring AJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023330; He BB, 2020, PROTEIN CELL, V11, P518, DOI 10.1007/s13238-020-00700-2; Jones Tim D., 2009, V525, P405, DOI 10.1007/978-1-59745-554-1_21; Konermann S, 2018, CELL, V173, P665, DOI 10.1016/j.cell.2018.02.033; Le Bert N, 2020, NATURE, V584, P457, DOI 10.1038/s41586-020-2550-z; Moreno AM, 2019, NAT BIOMED ENG, V3, P806, DOI 10.1038/s41551-019-0431-2; Simhadri VL, 2018, MOL THER-METH CLIN D, V10, P105, DOI 10.1016/j.omtm.2018.06.006; Swadling L, 2022, NATURE, V601, DOI 10.1038/s41586-021-04186-8; Tang X.-Z., 2020, PREPRINT, DOI [10.1101/2020.09.18.247742, DOI 10.1101/2020.09.18.247742]; Tang X.-Z., PRPRINT BIORXIV, DOI [10.1101/2020.09.18.247742(2020, DOI 10.1101/2020.09.18.247742(2020]; Tay LS, 2020, CRISPR J, V3, P253, DOI 10.1089/crispr.2020.0025; Wagner DL, 2019, NAT MED, V25, P242, DOI 10.1038/s41591-018-0204-6; Walker AW, 2011, ISME J, V5, P220, DOI 10.1038/ISMEJ.2010.118; Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033; Wessels HH, 2020, NAT BIOTECHNOL, V38, P722, DOI 10.1038/s41587-020-0456-9; Zhou HB, 2020, CELL, V181, P590, DOI 10.1016/j.cell.2020.03.024; Zhuang CL, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.646412	24	2	2	6	7	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2022	28	7					1372	+		10.1038/s41591-022-01848-6	http://dx.doi.org/10.1038/s41591-022-01848-6		JUN 2022	17	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3E5PS	35668177	hybrid, Green Published			2022-12-27	WOS:000806681900001
J	Morrow, AJ; Sykes, R; McIntosh, A; Kamdar, A; Bagot, C; Bayes, HK; Blyth, KG; Briscoe, M; Bulluck, H; Carrick, D; Church, C; Corcoran, D; Findlay, I; Gibson, VB; Gillespie, L; Grieve, D; Barrientos, PH; Ho, A; Lang, NNN; Lennie, V; Lowe, DJ; Macfarlane, PW; Mark, PB; Mayne, KJ; McConnachie, A; McGeoch, R; McGinley, C; McKee, C; Nordin, S; Payne, A; Rankin, AJ; Robertson, KE; Roditi, G; Ryan, N; Sattar, N; Allwood-Spiers, S; Stobo, D; Touyz, RM; Veldtman, G; Watkins, S; Weeden, S; Weir, RA; Welsh, P; Wereski, R; Mangion, K; Berry, C				Morrow, Andrew J.; Sykes, Robert; McIntosh, Alasdair; Kamdar, Anna; Bagot, Catherine; Bayes, Hannah K.; Blyth, Kevin G.; Briscoe, Michael; Bulluck, Heerajnarain; Carrick, David; Church, Colin; Corcoran, David; Findlay, Iain; Gibson, Vivienne B.; Gillespie, Lynsey; Grieve, Douglas; Barrientos, Pauline Hall; Ho, Antonia; Lang, Ninian N.; Lennie, Vera; Lowe, David J.; Macfarlane, Peter W.; Mark, Patrick B.; Mayne, Kaitlin J.; McConnachie, Alex; McGeoch, Ross; McGinley, Christopher; McKee, Connor; Nordin, Sabrina; Payne, Alexander; Rankin, Alastair J.; Robertson, Keith E.; Roditi, Giles; Ryan, Nicola; Sattar, Naveed; Allwood-Spiers, Sarah; Stobo, David; Touyz, Rhian M.; Veldtman, Gruschen; Watkins, Stuart; Weeden, Sarah; Weir, Robin A.; Welsh, Paul; Wereski, Ryan; Mangion, Kenneth; Berry, Colin		CISCO-19 Consortium	A multisystem, cardio-renal investigation of post-COVID-19 illness	NATURE MEDICINE			English	Article							GUIDELINES; STATEMENT; MANAGEMENT; CARDIOLOGY; RECOVERY; ETIOLOGY; SOCIETY; UK	The pathophysiology and trajectory of post-Coronavirus Disease 2019 (COVID-19) syndrome is uncertain. To clarify multisystem involvement, we undertook a prospective cohort study including patients who had been hospitalized with COVID-19 (ClinicalTrials.gov ID NCTO4403607). Serial blood biomarkers, digital electrocardiography and patient-reported outcome mea- sures were obtained in-hospital and at 28-60 days post-discharge when multisystem imaging using chest computed tomography with pulmonary and coronary angiography and cardio-renal magnetic resonance imaging was also obtained. Longer-term clinical outcomes were assessed using electronic health records. Compared to controls (n = 29), at 28-60 days post-discharge, people with COVID-19 (n =159 ; mean age, 55 years; 43% female) had persisting evidence of cardio-renal involvement and hemostasis pathway activation. The adjudicated likelihood of myocarditis was 'very likely' in 21(13%) patients, 'probable' in 65 (41%) patients, 'unlikely' in 56 (35%) patients and 'not present' in 17 (11%) patients. At 28-60 days post-discharge, COVID-19 was associated with worse health-related quality of life (EQ-5D-5L score 0.77 (0.23) versus 0.87 (0.20)), anxiety and depression (PHQ-4 total score 3.59 (3.71) versus 1.28 (2.67)) and aerobic exercise capacity reflected by predicted maximal oxygen utilization (20.0 (7.6) versus 29.5 (8.0) ml/kg/min) (all P < 0.01). During follow-up (mean, 450 days), 24 (15%) patients and two (7%) controls died or were rehospitalized, and 108 (68%) patients and seven (26%) controls received outpatient secondary care (P=0.017). The illness trajectory of patients after hospitalization with COVID-19 includes persisting multisystem abnormalities and health impairments that could lead to substantial demand on healthcare services in the future.	[Morrow, Andrew J.; Sykes, Robert; Kamdar, Anna; Corcoran, David; Lang, Ninian N.; Mark, Patrick B.; Mayne, Kaitlin J.; Rankin, Alastair J.; Sattar, Naveed; Touyz, Rhian M.; Welsh, Paul; Mangion, Kenneth; Berry, Colin] Univ Glasgow, Glasgow Cardiovasc Res Ctr, British Heart Fdn, Glasgow, Lanark, Scotland; [Morrow, Andrew J.; Sykes, Robert; Briscoe, Michael; Corcoran, David; Lang, Ninian N.; McGinley, Christopher; McKee, Connor; Nordin, Sabrina; Mangion, Kenneth; Berry, Colin] Queen Elizabeth Univ Hosp, Dept Cardiol, Glasgow, Lanark, Scotland; [McIntosh, Alasdair; McConnachie, Alex; Weeden, Sarah] Univ Glasgow, Robertson Ctr Biostat, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland; [Bagot, Catherine; Gibson, Vivienne B.] NHS Greater Glasgow & Clyde Hlth Board, Glasgow Royal Infirm, Dept Haemostasis & Thrombosis, Glasgow, Lanark, Scotland; [Bayes, Hannah K.; Allwood-Spiers, Sarah] NHS Greater Glasgow & Clyde Hlth Board, Dept Resp Med, Glasgow Royal Infirm, Glasgow, Lanark, Scotland; [Blyth, Kevin G.; Church, Colin] Queen Elizabeth Univ Hosp, Dept Resp Med, NHS Greater Glasgow & Clyde Hlth Board, Glasgow, Lanark, Scotland; [Blyth, Kevin G.] Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland; [Bulluck, Heerajnarain] St James Univ Hosp, Leeds Gen Infirm, Leeds, W Yorkshire, England; [Carrick, David; McGeoch, Ross; Weir, Robin A.] Univ Hosp Hairmyres, Dept Cardiol, E Kilbride, Lanark, Scotland; [Church, Colin; Robertson, Keith E.; Watkins, Stuart; Berry, Colin] NHS Golden Jubilee, West Scotland Heart & Lung Ctr, Clydebank, Scotland; [Findlay, Iain] Royal Alexandra Hosp, Dept Cardiol, Paisley, Renfrew, Scotland; [Gillespie, Lynsey] Greater Glasgow & Clyde Hlth Board, Project Management Unit, Glasgow Clin Res Facil, Glasgow, Lanark, Scotland; [Grieve, Douglas] Royal Alexandra Hosp, Dept Resp Med, Glasgow, Lanark, Scotland; [Barrientos, Pauline Hall] NHS Greater Glasgow & Clyde Hlth Board, Dept Med Phys, Glasgow, Lanark, Scotland; [Ho, Antonia] Univ Glasgow, MRC, Inst Infect & Immun, Ctr Virus Res, Glasgow, Lanark, Scotland; [Lennie, Vera; Ryan, Nicola] Aberdeen Royal Infirm, Dept Cardiol, Aberdeen, Scotland; [Lowe, David J.; Wereski, Ryan] Queen Elizabeth Univ Hosp, Dept Emergency Med, NHS Greater Glasgow & Clyde Hlth Board, Glasgow, Lanark, Scotland; [Macfarlane, Peter W.] Univ Glasgow, Inst Hlth & Wellbeing, Electrocardiol Core Lab, Glasgow, Lanark, Scotland; [Mark, Patrick B.; Mayne, Kaitlin J.] Queen Elizabeth Univ Hosp, Glasgow Renal & Transplant Unit, NHS Greater Glasgow & Clyde Hlth Board, Glasgow, Lanark, Scotland; [Payne, Alexander] Univ Hosp Crosshouse, Dept Cardiol, Kilmarnock, Scotland; [Roditi, Giles; Stobo, David] NHS Greater Glasgow & Clyde Hlth Board, Dept Radiol, Glasgow, Lanark, Scotland; [Veldtman, Gruschen] NHS Golden Jubilee, Scottish Adult Congenital Cardiac Serv, Clydebank, Scotland; [Wereski, Ryan] Univ Edinburgh, Fdn Ctr Cardiovasc Sci, British Heart, Edinburgh, Midlothian, Scotland	University of Glasgow; Queen Elizabeth University Hospital (QEUH); University of Glasgow; University of Glasgow; University of Glasgow; Queen Elizabeth University Hospital (QEUH); University of Glasgow; Leeds General Infirmary; Saint James's University Hospital; University of Leeds; University Hospital Hairmyres; University of Glasgow; University of Aberdeen; Queen Elizabeth University Hospital (QEUH); University of Glasgow; Queen Elizabeth University Hospital (QEUH); University of Edinburgh	Berry, C (corresponding author), Univ Glasgow, Glasgow Cardiovasc Res Ctr, British Heart Fdn, Glasgow, Lanark, Scotland.; Berry, C (corresponding author), Queen Elizabeth Univ Hosp, Dept Cardiol, Glasgow, Lanark, Scotland.; Berry, C (corresponding author), NHS Golden Jubilee, West Scotland Heart & Lung Ctr, Clydebank, Scotland.	colin.berry@glasgow.ac.uk	Bulluck, Heeraj/H-7425-2019; Mayne, Kaitlin/GQQ-2465-2022; Mark, Patrick/N-5536-2014	Bulluck, Heeraj/0000-0002-1985-1783; Bagot, Catherine/0000-0002-6439-9706; Sykes, Robert/0000-0003-1010-5474; Mark, Patrick/0000-0003-3387-2123; Rankin, Alastair/0000-0001-9031-481X; Mayne, Kaitlin/0000-0002-5695-0270; Kamdar, Anna/0000-0001-9194-547X	Chief Scientist Office of the Scottish Government (COV/GLA/Portfolio project) [311300]; British Heart Foundation [RE/18/6134217]; NHS Greater Glasgow & Clyde Health Board; University of Glasgow; Chief Scientist Office of the Scottish Government	Chief Scientist Office of the Scottish Government (COV/GLA/Portfolio project); British Heart Foundation(British Heart Foundation); NHS Greater Glasgow & Clyde Health Board; University of Glasgow; Chief Scientist Office of the Scottish Government	This was an investigator-initiated clinical study that was funded by the Chief Scientist Office of the Scottish Government (COV/GLA/Portfolio project no. 311300). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. C.B, C.D., N.S. and R.M.T. were supported by the British Heart Foundation (RE/18/6134217). The MRI study involved technologies provided by Siemens Healthcare and the National Institutes of Health. HeartFlow provided FFR<INF>CT.</INF> The study was co-sponsored by NHS Greater Glasgow & Clyde Health Board and the University of Glasgow. We thank the CISCO-19 Consortium members, the staff and patients who supported this study and the Chief Scientist Office of the Scottish Government for financial support.	Al-Aly Z, 2021, NATURE, V594, P259, DOI 10.1038/s41586-021-03553-9; [Anonymous], 2020, COVID 19 RAP GUID MA; [Anonymous], SCOTTISH INDEX MULTI; [Anonymous], EQ 5D 5L; Ayoubkhani D, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.n693; Baigent C, 2022, CARDIOVASC RES, V118, P1385, DOI 10.1093/cvr/cvab342; Baigent C, 2022, CARDIOVASC RES, V118, P1618, DOI 10.1093/cvr/cvab343; Blomberg B, 2021, NAT MED, V27, P1607, DOI 10.1038/s41591-021-01433-3; Broadbent E, 2009, J PSYCHOSOM RES, V67, P17, DOI 10.1016/j.jpsychores.2008.12.001; Broch K, 2012, SCAND CARDIOVASC J, V46, P65, DOI 10.3109/14017431.2011.652981; Caforio ALP, 2013, EUR HEART J, V34, P2636, DOI 10.1093/eurheartj/eht210; Carfi A, 2020, JAMA-J AM MED ASSOC, V324, P603, DOI 10.1001/jama.2020.12603; Cerqueira MD, 2002, CIRCULATION, V105, P539, DOI 10.1161/hc0402.102975; Chung MS, 2020, EUR RADIOL, V30, P2182, DOI [10.1148/radiol.2020200230, 10.1007/s00330-019-06574-1]; Cirulli E. T., 2020, PREPRINT, DOI 10.07.20208702v3; Collet JP, 2021, EUR HEART J, V42, P1289, DOI 10.1093/eurheartj/ehaa575; Connors JM, 2021, JAMA-J AM MED ASSOC, V326, P1703, DOI 10.1001/jama.2021.17272; Conway EM, 2020, J THROMB HAEMOST, V18, P2812, DOI 10.1111/jth.15050; Cury RC, 2016, J AM COLL RADIOL, V13, P1458, DOI 10.1016/j.jacr.2016.04.024; Daugherty SE, 2021, BMJ-BRIT MED J, V373, DOI 10.1136/bmj.n1098; Dekkers IA, 2020, MAGN RESON MATER PHY, V33, P163, DOI 10.1007/s10334-019-00797-5; Dennis A, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-048391; Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985; Drake TM, 2021, LANCET, V398, P223, DOI 10.1016/S0140-6736(21)00799-6; Evans RA, 2021, LANCET RESP MED, V9, P1275, DOI 10.1016/S2213-2600(21)00383-0; Ferreira VM, 2018, J AM COLL CARDIOL, V72, P3158, DOI 10.1016/j.jacc.2018.09.072; Flett AS, 2011, JACC-CARDIOVASC IMAG, V4, P150, DOI 10.1016/j.jcmg.2010.11.015; Ghadri JR, 2018, EUR HEART J, V39, P2032, DOI 10.1093/eurheartj/ehy076; Goligher EC, 2021, NEW ENGL J MED, V385, P777, DOI [10.1056/NEJMoa2103417, 10.1056/NEJMoa2100433]; Gorecka M, 2021, J CARDIOVASC MAGN R, V23, DOI 10.1186/s12968-021-00752-1; Grani C, 2019, J CARDIOVASC MAGN R, V21, DOI 10.1186/s12968-019-0520-0; Guzik TJ, 2020, CARDIOVASC RES, V116, P1666, DOI 10.1093/cvr/cvaa106; Hare SS, 2020, CLIN RADIOL, V75, P399, DOI 10.1016/j.crad.2020.04.002; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Ibanez B, 2018, KARDIOL POL, V76, P229, DOI 10.5603/KP.2018.0041; ISARIC4C (Coronavirus Clinical Characterisation Consortium), US; Joy G, 2021, JACC-CARDIOVASC IMAG, V14, P2155, DOI 10.1016/j.jcmg.2021.04.011; Khan Jamal N, 2015, BMC Res Notes, V8, P52, DOI 10.1186/s13104-015-1007-1; Khwaja A, 2012, NEPHRON CLIN PRACT, V120, pC179, DOI 10.1159/000339789; Kotecha T, 2021, EUR HEART J, V42, P1866, DOI 10.1093/eurheartj/ehab075; Lee PH, 2011, INT J BEHAV NUTR PHY, V8, DOI 10.1186/1479-5868-8-115; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Lowe B, 2010, J AFFECT DISORDERS, V122, P86, DOI 10.1016/j.jad.2009.06.019; Mandal S, 2021, THORAX, V76, P396, DOI 10.1136/thoraxjnl-2020-215818; Mangion K, 2020, CARDIOVASC RES, V116, P2185, DOI 10.1093/cvr/cvaa209; Martinez MW, 2021, JAMA CARDIOL, V6, P745, DOI 10.1001/jamacardio.2021.0565; Messroghli DR, 2004, MAGN RESON MED, V52, P141, DOI 10.1002/mrm.20110; Neumann FJ, 2019, EUR HEART J, V40, P87, DOI 10.1093/eurheartj/ehy394; Office for National Statistics, 2021, PREVALENCE ONGOING S; Office of National Statistics, 2022, SELF REP LONG COVID; Petersen SE, 2017, J CARDIOVASC MAGN R, V19, DOI 10.1186/s12968-017-0327-9; Steven P, 2021, NEW ENGL J MED, V385, P577, DOI 10.1056/NEJMp2109285; Puntmann VO, 2020, JAMA CARDIOL, V5, P1265, DOI 10.1001/jamacardio.2020.3557; Qanadli SD, 2001, AM J ROENTGENOL, V176, P1415, DOI 10.2214/ajr.176.6.1761415; Raman B, 2021, ECLINICALMEDICINE, V31, DOI 10.1016/j.eclinm.2020.100683; Shanbhag SM, 2019, EUR HEART J, V40, P529, DOI 10.1093/eurheartj/ehy713; Sianos Georgios, 2005, EuroIntervention, V1, P219; Singh T, 2022, HEART, V108, P46, DOI 10.1136/heartjnl-2021-319926; Sullivan MK, 2022, NEPHROL DIAL TRANSPL, V37, P271, DOI 10.1093/ndt/gfab303; The RECOVERY Collaborative Group, 2020, NEW ENGL J MED, V384; Thygesen K, 2019, EUR HEART J, V40, P237, DOI [10.1093/eurheartj/ehy462, 10.1016/j.jacc.2018.08.1038, 10.1016/j.rec.2018.11.011]; Ukena C, 2014, CLIN RES CARDIOL, V103, P743, DOI 10.1007/s00392-014-0709-z; Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Wakisaka M, 2016, NEW ENGL J MED, V375, P1799, DOI 10.1056/NEJMc1611290; Welsh P, 2013, EUR HEART J, V34, P443, DOI 10.1093/eurheartj/ehs239; Wolf M, 2018, NEPHROL DIAL TRANSPL, V33, pII41, DOI 10.1093/ndt/gfy198; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7	69	7	7	2	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2022	28	6					1303	+		10.1038/s41591-022-01837-9	http://dx.doi.org/10.1038/s41591-022-01837-9		MAY 2022	31	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E9IE	35606551	Green Published, Green Accepted, hybrid			2022-12-27	WOS:000800978300002
J	Goodman, NF				Goodman, Nancy F.			How to correct the market for children's cancer drugs	NATURE MEDICINE			English	Editorial Material								The development of pediatric cancer drugs is vastly underfunded compared with that for adults, but legislation can correct market failures.	[Goodman, Nancy F.] Kids V Canc, Washington, DC 20016 USA		Goodman, NF (corresponding author), Kids V Canc, Washington, DC 20016 USA.	nancygoodman@kidsvcancer.org							0	0	0	0	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4					613	613		10.1038/s41591-022-01747-w	http://dx.doi.org/10.1038/s41591-022-01747-w			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0Q6DV	35440718				2022-12-27	WOS:000785007700007
J	Mateo, J; Steuten, L; Aftimos, P; Andre, F; Davies, M; Garralda, E; Geissler, J; Husereau, D; Martinez-Lopez, I; Normanno, N; Reis, JS; Stefani, S; Thomas, DM; Westphalen, CB; Voest, E				Mateo, Joaquin; Steuten, Lotte; Aftimos, Philippe; Andre, Fabrice; Davies, Mark; Garralda, Elena; Geissler, Jan; Husereau, Don; Martinez-Lopez, Iciar; Normanno, Nicola; Reis-Filho, Jorge S.; Stefani, Stephen; Thomas, David M.; Westphalen, C. Benedikt; Voest, Emile			Delivering precision oncology to patients with cancer	NATURE MEDICINE			English	Article							REAL-WORLD EVIDENCE; CELL LUNG-CANCER; MEDICINE; FRAMEWORK; VARIANTS	Precision medicine is reshaping cancer care, but the benefits are not accessible to all patients. This Perspective outlines the major challenges to the implementation of precision oncology and discusses critical steps toward resolving these. With the increasing use of genomic profiling for diagnosis and therapy guidance in many tumor types, precision oncology is rapidly reshaping cancer care. However, the current trajectory of drug development in oncology results in a paradox: if patients cannot access advanced diagnostics, we may be developing drugs that will reach few patients. In this Perspective, we outline the major challenges to the implementation of precision oncology and discuss critical steps toward resolving these, including facilitation of equal access to genomics tests, ensuring that clinical studies provide robust evidence for new drugs and technologies, enabling physicians to interpret genomics data, and empowering patients toward shared decision-making. A multi-stakeholder approach to evidence generation, value assessment, and healthcare delivery is necessary to translate advances in precision oncology into benefits for patients with cancer globally.	[Mateo, Joaquin; Garralda, Elena] Vall dHebron Inst Oncol VHIO, Barcelona, Spain; [Mateo, Joaquin; Garralda, Elena] Vall dHebron Univ Hosp, Barcelona, Spain; [Steuten, Lotte] Off Hlth Econ, London, England; [Steuten, Lotte] City Univ London, London, England; [Aftimos, Philippe] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium; [Andre, Fabrice] Univ Paris Saclay, INSERM U981, Inst Gustave Roussy, Villejuif, France; [Davies, Mark] South Wales West Canc Ctr, Swansea, W Glam, Wales; [Geissler, Jan] Patvocates, Munich, Germany; [Husereau, Don] Univ Ottawa, Ottawa, ON, Canada; [Martinez-Lopez, Iciar] Son Espases Univ Hosp, Unit Genet & Genom Balearic Isl, Illes, Balears, Spain; [Normanno, Nicola] Ist Nazl Tumori IRCCS Fdn G Pascale, Cell Biol & Biotherapy Unit, Naples, Italy; [Reis-Filho, Jorge S.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Stefani, Stephen] UNIMED RS, Porto Alegre, RS, Brazil; [Thomas, David M.] Garvan Inst Med Res, Sydney, NSW, Australia; [Westphalen, C. Benedikt] Ludwig Maximilian Univ Munich, Comprehens Canc Ctr Munich, Munich, Germany; [Westphalen, C. Benedikt] Ludwig Maximilian Univ Munich, Dept Med 3, Munich, Germany; [Westphalen, C. Benedikt] German Canc Consortium DKTK Partner Site Munich, Heidelberg, Germany; [Voest, Emile] Netherlands Canc Inst, Amsterdam, Netherlands; [Voest, Emile] Oncode Inst, Utrecht, Netherlands	Vall d'Hebron Institut d'Oncologia (VHIO); Hospital Universitari Vall d'Hebron; City University London; Institut Jules Bordet; Universite Libre de Bruxelles; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; University of Ottawa; Hospital Universitari Son Espases; IRCCS Fondazione Pascale; Memorial Sloan Kettering Cancer Center; Garvan Institute of Medical Research; University of Munich; University of Munich; Netherlands Cancer Institute	Voest, E (corresponding author), Netherlands Canc Inst, Amsterdam, Netherlands.; Voest, E (corresponding author), Oncode Inst, Utrecht, Netherlands.	e.voest@nki.nl	Thomas, David/AAD-2877-2019	Thomas, David/0000-0002-2527-5428; Husereau, Don/0000-0002-4416-6876; Westphalen, Benedikt/0000-0002-5310-3754; Davies, Mark/0000-0002-0688-3129; Geissler, Jan/0000-0001-9058-5097	F. Hoffmann-La Roche	F. Hoffmann-La Roche(Hoffmann-La Roche)	Funding support and role of the funder/sponsor: F. Hoffmann-La Roche funded third-party writing assistance for the initial draft of this manuscript, furnished by S. Salem at Health Interactions. The sponsor was not involved in discussions relating to content. All subsequent versions were written, reviewed, and submitted solely by the authors.	Adashek JJ, 2021, TRENDS CANCER, V7, P15, DOI 10.1016/j.trecan.2020.08.009; Booth CM, 2019, NAT REV CLIN ONCOL, V16, P312, DOI 10.1038/s41571-019-0167-7; Brown NA, 2020, ANNU REV PATHOL-MECH, V15, P97, DOI 10.1146/annurev-pathmechdis-012418-012735; Cave A, 2019, CLIN PHARMACOL THER, V106, P36, DOI 10.1002/cpt.1426; Chakravarty D, 2017, JCO PRECIS ONCOL, V1; Chawla A, 2018, JCO PRECIS ONCOL, V2, DOI 10.1200/PO.18.00074; Condorelli R, 2019, ANN ONCOL, V30, P365, DOI 10.1093/annonc/mdz036; de Moor JS, 2020, JCO PRECIS ONCOL, V4, P620, DOI 10.1200/PO.19.00338; Deverka PA, 2020, VALUE HEALTH, V23, P540, DOI 10.1016/j.jval.2020.02.001; Dittrich C, 2016, ESMO OPEN, V1, DOI 10.1136/esmoopen-2016-000097; Ebi H., 2019, JCO PRECIS ONCOL, V19; Ettinger DS, 2017, J NATL COMPR CANC NE, V15, P504, DOI 10.6004/jnccn.2017.0050; European Commission , 2021, EUR BEAT CANC PLAN; Fatumo S, 2022, NAT MED, V28, P243, DOI 10.1038/s41591-021-01672-4; Faulkner E, 2020, VALUE HEALTH, V23, P529, DOI 10.1016/j.jval.2019.11.010; Feinberg BA, 2020, VALUE HEALTH, V23, P1358, DOI 10.1016/j.jval.2020.06.006; Food and Drug Administration, LIST CLEAR APPR COMP; Frampton GM, 2013, NAT BIOTECHNOL, V31, P1023, DOI 10.1038/nbt.2696; Gill J., 2020, ACCESS PERSONALISED, DOI [10.21953/lse.5zsbeehvd3u8, DOI 10.21953/LSE.5ZSBEEHVD3U8]; Gondos A, 2020, J CLIN ONCOL, V38; Goossens-Laan CA, 2014, SUPPORT CARE CANCER, V22, P189, DOI 10.1007/s00520-013-1946-9; Horgan Denis, 2020, Biomed Hub, V5, P182, DOI 10.1159/000511209; Hoxhaj I, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17218001; Janiaud P, 2019, CANCER TREAT REV, V73, P20, DOI 10.1016/j.ctrv.2018.12.003; Johnston JJ, 2012, AM J HUM GENET, V91, P97, DOI 10.1016/j.ajhg.2012.05.021; Kamps R, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020308; Kato S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18613-3; Korea University, 2015, KU MAGIC; Leighl NB, 2019, CLIN CANCER RES, V25, P4691, DOI 10.1158/1078-0432.CCR-19-0624; Luchini C, 2020, TRENDS CANCER, V6, P738, DOI 10.1016/j.trecan.2020.05.008; Malone ER, 2020, GENOME MED, V12, DOI 10.1186/s13073-019-0703-1; Mateo J, 2018, ANN ONCOL, V29, P1895, DOI 10.1093/annonc/mdy263; McCafferty J, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.e18031; Moore DA, 2019, ESMO OPEN, V4, DOI 10.1136/esmoopen-2018-000469; Moscow JA, 2018, NAT REV CLIN ONCOL, V15, P183, DOI 10.1038/nrclinonc.2017.186; Mosele F, 2020, ANN ONCOL, V31, P1491, DOI 10.1016/j.annonc.2020.07.014; Nagahashi M, 2017, J SURG RES, V220, P125, DOI 10.1016/j.jss.2017.06.077; National Cancer Institute, 2016, CANC MOONSH; National Comprehensive Cancer Network, 2021, NCCN GUID NONSM CELL; National Institute for Health (NIH), 2018, ALL US RES PROGR; Oehrlein EM, 2018, INT J TECHNOL ASSESS, V34, P111, DOI 10.1017/S0266462317004408; Pennell NA, 2019, JCO PRECIS ONCOL, V3, DOI 10.1200/PO.18.00356; Pishvaian MJ, 2019, JAMIA OPEN, V2, P505, DOI 10.1093/jamiaopen/ooz045; Presley CJ, 2018, JAMA-J AM MED ASSOC, V320, P469, DOI 10.1001/jama.2018.9824; Priestley P, 2019, NATURE, V575, P210, DOI 10.1038/s41586-019-1689-y; Rieke DT, 2018, JCO PRECIS ONCOL, V2, DOI 10.1200/PO.18.00098; Rodes Sanchez M., 2020, 002290 OFF HLTH EC; Brannon AR, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24109-5; Sharma V, 2018, JCO PRECIS ONCOL, V2, DOI 10.1200/PO.17.00296; Sicklick JK, 2019, NAT MED, V25, P744, DOI 10.1038/s41591-019-0407-5; Singh AP, 2020, CANCERS, V12, DOI 10.3390/cancers12051156; Siu LL, 2016, NAT MED, V22, P464, DOI 10.1038/nm.4089; Steuten L, 2019, JCO CLIN CANCER INFO, V3, DOI 10.1200/CCI.19.00002; Sukhai MA, 2016, GENET MED, V18, P128, DOI 10.1038/gim.2015.47; Tamborero D, 2020, NAT MED, V26, P992, DOI 10.1038/s41591-020-0969-2; Tan O, 2018, CLIN GENET, V93, P533, DOI 10.1111/cge.13199; Thavaneswaran S, 2018, MED J AUSTRALIA, V209, DOI 10.5694/mja18.00227; Thunnissen E, 2020, TRANSL LUNG CANCER R, V9, P887, DOI 10.21037/tlcr.2020.04.07; van de Haar J, 2021, NAT MED, V27, P1553, DOI 10.1038/s41591-021-01448-w; van de Haar J, 2019, ESMO OPEN, V4, DOI 10.1136/esmoopen-2019-000516; Van der Velden DL, 2019, NATURE, V574, P127, DOI 10.1038/s41586-019-1600-x; van der Velden DL, 2017, ANN ONCOL, V28, P3070, DOI 10.1093/annonc/mdx528; Verbaanderd C, 2020, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01664; Weda M., 2017, STUDY OFF LABEL USE; Westphalen BC, 2020, EUR J CANCER, V135, P1, DOI 10.1016/j.ejca.2020.04.019; Weymann D, 2018, JCO PRECIS ONCOL, V2, DOI 10.1200/PO.17.00311; Woodhouse R, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237802; Yates LR, 2018, ANN ONCOL, V29, P30, DOI 10.1093/annonc/mdx707	68	21	21	11	15	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4					658	665		10.1038/s41591-022-01717-2	http://dx.doi.org/10.1038/s41591-022-01717-2			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0Q6DV	35440717				2022-12-27	WOS:000785007700022
J	Betton, JM; Jacob, JP; Hofnung, M; Broome-Smith, JK				Betton, JM; Jacob, JP; Hofnung, M; Broome-Smith, JK			Creating a bifunctional protein by insertion of beta-lactamase into the maltodextrin-binding protein	NATURE BIOTECHNOLOGY			English	Article						protein engineering; rational design; hybrid protein	MALTOSE-BINDING; ESCHERICHIA-COLI; ACTIVE-TRANSPORT; CYTOPLASMIC MEMBRANE; CRYSTAL-STRUCTURE; PURIFICATION; EXPRESSION; RESOLUTION; GENE; CHEMOTAXIS	Hybrid proteins were generated by inserting the penicillin-hydrolyzing enzyme, TEM beta-lactamase (Bla), into the maltodextrin-binding protein (MalE). The inserted Bra was functionally accommodated by MalE when it was placed within permissive sites. The maltose binding and penicillinase activities of purified hybrids were indistinguishable from those of the wild-type MalE and Bla proteins. Moreover, these hybrids displayed an additional unexpected property: maltose stabilized the active site of inserted Bla.	Inst Pasteur, CNRS, URA 1444,Unite Programmat Mol & Toxicol Genet, Dept Biotechnol, F-75015 Paris, France; Univ Sussex, Sch Biol Sci, Biochem Grp, Brighton BN1 9QG, E Sussex, England	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Sussex	Betton, JM (corresponding author), Inst Pasteur, CNRS, URA 1444,Unite Programmat Mol & Toxicol Genet, Dept Biotechnol, 25 Rue Dr Roux, F-75015 Paris, France.		Wood, David W/B-2992-2012		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BANEYX F, 1989, ENZYME MICROB TECH, V11, P559, DOI 10.1016/0141-0229(89)90083-5; BETTON JM, 1994, EMBO J, V13, P1226, DOI 10.1002/j.1460-2075.1994.tb06372.x; Betton JM, 1996, J BIOL CHEM, V271, P8046, DOI 10.1074/jbc.271.14.8046; BETTON JM, 1993, FEBS LETT, V325, P34, DOI 10.1016/0014-5793(93)81409-S; BORK P, 1996, REV BIOPHYS, V29, P119; BULOW L, 1991, TRENDS BIOTECHNOL, V9, P226, DOI 10.1016/0167-7799(91)90075-S; DUPLAY P, 1987, J MOL BIOL, V194, P663, DOI 10.1016/0022-2836(87)90243-9; DUPLAY P, 1984, J BIOL CHEM, V259, P606; FERENCI T, 1978, FEBS LETT, V94, P213, DOI 10.1016/0014-5793(78)80940-5; FRERE JM, 1995, MOL MICROBIOL, V16, P385, DOI 10.1111/j.1365-2958.1995.tb02404.x; JELSCH C, 1993, PROTEINS, V16, P364, DOI 10.1002/prot.340160406; JELSCH C, 1992, FEBS LETT, V299, P135, DOI 10.1016/0014-5793(92)80232-6; LAMINET AA, 1989, EMBO J, V8, P1469, DOI 10.1002/j.1460-2075.1989.tb03530.x; Manoil C, 1997, J MOL BIOL, V267, P250, DOI 10.1006/jmbi.1996.0881; Martineau P, 1996, MOL IMMUNOL, V33, P1345, DOI 10.1016/S0161-5890(96)00091-0; MARTINEAU P, 1992, GENE, V113, P35, DOI 10.1016/0378-1119(92)90667-E; MELLING J, 1972, BIOCHEM J, V130, P55, DOI 10.1042/bj1300055; MITCHINSON C, 1985, J MOL BIOL, V184, P331, DOI 10.1016/0022-2836(85)90384-5; NIKAIDO H, 1994, FEBS LETT, V346, P55, DOI 10.1016/0014-5793(94)00315-7; NILSSON B, 1992, CURR OPIN STRUC BIOL, V2, P569; OCALLAGHAN CH, 1972, ANTIMICROB AGENTS CH, V1, P283, DOI 10.1128/AAC.1.4.283; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; RUSSELL RB, 1994, PROTEIN ENG, V7, P1407, DOI 10.1093/protein/7.12.1407; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SHARFF AJ, 1995, J MOL BIOL, V246, P8, DOI 10.1006/jmbi.1994.0059; SHUMAN HA, 1982, J BIOL CHEM, V257, P5455; SIGAL IS, 1984, J BIOL CHEM, V259, P5327; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; UHLEN M, 1990, METHOD ENZYMOL, V185, P129; WETLAUFE.DB, 1973, P NATL ACAD SCI USA, V70, P697, DOI 10.1073/pnas.70.3.697; ZHANG YB, 1990, GENE, V96, P51, DOI 10.1016/0378-1119(90)90340-W	31	47	53	0	9	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1997	15	12					1276	1279		10.1038/nbt1197-1276	http://dx.doi.org/10.1038/nbt1197-1276			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YQ046	9359111				2022-12-27	WOS:000071342000030
J	Helmlinger, G; Netti, PA; Lichtenbeld, HC; Melder, RJ; Jain, RK				Helmlinger, G; Netti, PA; Lichtenbeld, HC; Melder, RJ; Jain, RK			Solid stress inhibits the growth of multicellular tumor spheroids	NATURE BIOTECHNOLOGY			English	Article						tumor growth; apoptosis; proliferation	RESIDUAL STRAINS; BLOOD-FLOW; CELL; RAT; RESISTANCE; RADIATION; TISSUE; DRUG; APOPTOSIS; DORMANCY	In normal tissues, the processes of growth, remodeling, and morphogenesis are tightly regulated by the stress field; conversely, stress may be generated by these processes. We demonstrate that solid stress inhibits tumor growth iii vitro, regardless of host species, tissue of origin, or differentiation state. The inhibiting stress for multicellular tumor spheroid growth in agarose matrices was 45 to 120 mm Hg. This stress, which greatly exceeds blood pressure in tumor vessels, is sufficient to induce the collapse of vascular or lymphatic vessels in tumors in vivo and can explain impaired blood flow, poor lymphatic drainage, and suboptimal drug delivery previously reported in solid tumors. The stress-induced growth inhibition of plateau-phase spheroids was accompanied, at the cellular level, by decreased apoptosis with no significant changes in proliferation. A concomitant increase In the cellular packing density was observed, which may prevent cells from undergoing apoptosis via a cell-volume or cell-shape transduction mechanism. These results suggest that solid stress controls tumor growth at both the macroscopic and cellular levels, and thus influences tumor progression and delivery of therapeutic agents.	HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,DEPT RADIAT ONCOL,BOSTON,MA 02114	Harvard University; Harvard Medical School; Massachusetts General Hospital			Jain, Rakesh K/I-1384-2017	Jain, Rakesh K/0000-0001-7571-3548; NETTI, PAOLO/0000-0002-2435-7181	NATIONAL CANCER INSTITUTE [R35CA056591] Funding Source: NIH RePORTER; NCI NIH HHS [R35-CA-56591] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATES RC, 1994, J CELL BIOL, V125, P403, DOI 10.1083/jcb.125.2.403; BOUCHER Y, 1990, CANCER RES, V50, P4478; BOUCHER Y, 1992, CANCER RES, V52, P5110; Boucher Y, 1996, CANCER RES, V56, P4264; EAVES G, 1973, J PATHOL, V109, P233, DOI 10.1002/path.1711090308; FALK P, 1980, EUR J CANCER, V16, P203, DOI 10.1016/0014-2964(80)90152-8; FALK P, 1978, EUR J CANCER, V14, P237, DOI 10.1016/0014-2964(78)90187-1; FREYER JP, 1994, ADV EXP MED BIOL, V345, P335; FREYER JP, 1988, CANCER RES, V48, P2432; FREYER JP, 1989, J CELL PHYSIOL, V138, P384, DOI 10.1002/jcp.1041380222; Fung Y.C., 1990, BIOMECHANICS MOTION, P499; FUNG YC, 1989, CIRC RES, V65, P1340, DOI 10.1161/01.RES.65.5.1340; FUNG YC, 1991, ANN BIOMED ENG, V19, P237, DOI 10.1007/BF02584301; GARTNER MFRM, 1992, BRIT J CANCER, V65, P487, DOI 10.1038/bjc.1992.101; Gompertz B., 1825, PHILOS T ROYAL SOC L, V115, P515, DOI [DOI 10.1098/RSTL.1825.0026, 10.1098/rstl.1825.0026]; GYLLENBERG M, 1989, GROWTH DEVELOP AGING, V53, P25; HAN HC, 1991, J BIOMECH, V24, P307, DOI 10.1016/0021-9290(91)90349-R; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; IOZZO RV, 1995, LAB INVEST, V73, P157; ISCOVE NN, 1979, IMMUNOLOGICAL METHOD, P379; JAIN RK, 1988, CANCER RES, V48, P2641; Johnson EM, 1996, BIOPHYS J, V70, P1017, DOI 10.1016/S0006-3495(96)79645-5; KERBEL RS, 1994, COLD SPRING HARB SYM, V59, P661, DOI 10.1101/SQB.1994.059.01.076; Knight M. M., 1996, Cellular Engineering, V1, P97; KOBAYASHI H, 1993, P NATL ACAD SCI USA, V90, P3294, DOI 10.1073/pnas.90.8.3294; LI LM, 1989, JNCI-J NATL CANCER I, V81, P1406, DOI 10.1093/jnci/81.18.1406; MACPHEE PJ, 1995, J PHYSL, V1484, P183; Netti PA, 1996, MICROVASC RES, V52, P27, DOI 10.1006/mvre.1996.0041; NICOLSON GL, 1988, CANCER RES, V48, P399; OLIVE PL, 1994, CANCER METAST REV, V13, P121, DOI 10.1007/BF00689632; OMENS JH, 1990, CIRC RES, V66, P37, DOI 10.1161/01.RES.66.1.37; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAK JW, 1993, IN VITRO CELL DEV-AN, V29A, P742; StCroix B, 1996, JNCI-J NATL CANCER I, V88, P1285, DOI 10.1093/jnci/88.18.1285; StetlerStevenson WG, 1996, AM J PATHOL, V148, P1345; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; TANIGAWA N, 1981, LYMPHOLOGY, V14, P149; TOZER GM, 1990, BRIT J CANCER, V61, P250, DOI 10.1038/bjc.1990.46; VAAGE J, 1992, INT J CANCER, V51, P325, DOI 10.1002/ijc.2910510225; Wolff J, 1870, VIRCHOWS ARCH PATHOL, V50, P389, DOI [10.1007/BF01944490, DOI 10.1007/BF01944490]; YOUNG JS, 1959, J PATHOL BACTERIOL, V77, P321, DOI 10.1002/path.1700770203	42	581	591	5	89	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					778	783		10.1038/nbt0897-778	http://dx.doi.org/10.1038/nbt0897-778			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255794				2022-12-27	WOS:A1997XM70700031
J	Sonnewald, U; Hajirezaei, MR; Kossmann, J; Heyer, A; Trethewey, RN; Willmitzer, L				Sonnewald, U; Hajirezaei, MR; Kossmann, J; Heyer, A; Trethewey, RN; Willmitzer, L			Increased potato tuber size resulting from apoplastic expression of a yeast invertase	NATURE BIOTECHNOLOGY			English	Article						agricultural biotechnology; Solanum tuberosum; sink strength; metabolic engineering	TRANSGENIC TOBACCO PLANTS; SACCHAROMYCES-CEREVISIAE; SOLANUM-TUBEROSUM; SINK STRENGTH; METABOLISM; SUCROSE; GROWTH; MAIZE; CELLS; GENE	The role of sucrose cleavage in determining sink strength in potato was investigated by generating transgenic potato plants that expressed a yeast invertase in either the cytosol or apoplast of tubers. Cytosolic localization gave rise to a reduction in tuber size and an increase in tuber number per plant whereas apoplastic targeting led to an increase in tuber size and a decrease in tuber number per plant. Sink organ size can be manipulated through modification of sucrose metabolism.	INST GENBIOL FORSCH BERLIN GMBH, D-14195 BERLIN, GERMANY; INST PFLANZENGENET & KULTURPFLANZEUFORSCH, D-06466 GATERSLEBEN, GERMANY; MAX PLANCK INST MOLEK PFLANZENPHYSIOL, D-14475 GOLM, GERMANY	Leibniz Institut fur Pflanzengenetik und Kulturpflanzenforschung; Max Planck Society			Heyer, Arnd G./O-9828-2015; Willmitzer, Lothar/F-7377-2011; Sonnewald, Uwe/J-7875-2012	Heyer, Arnd G./0000-0003-2074-3234; Sonnewald, Uwe/0000-0003-1835-5339; Kossmann, Jens/0000-0001-8895-894X				Abel GJW, 1996, PLANT J, V10, P981, DOI 10.1046/j.1365-313X.1996.10060981.x; Bussis D, 1997, PLANTA, V202, P126, DOI 10.1007/s004250050111; CHOUREY PS, 1976, BIOCHEM GENET, V14, P1041, DOI 10.1007/BF00485135; Dietze J., 1995, P24; GIAQUINTA RT, 1983, ANNU REV PLANT PHYS, V34, P347, DOI 10.1146/annurev.pp.34.060183.002023; GILLIES RJ, 1981, P NATL ACAD SCI-BIOL, V78, P2125, DOI 10.1073/pnas.78.4.2125; GRANOT D, 1993, YEAST, V9, P465, DOI 10.1002/yea.320090503; GRANOT D, 1991, P NATL ACAD SCI USA, V88, P5724, DOI 10.1073/pnas.88.13.5724; HO LC, 1988, ANNU REV PLANT PHYS, V39, P355, DOI 10.1146/annurev.arplant.39.1.355; KEIL M, 1986, NUCLEIC ACIDS RES, V14, P5641, DOI 10.1093/nar/14.14.5641; Klann EM, 1996, PLANT PHYSIOL, V112, P1321, DOI 10.1104/pp.112.3.1321; Koch KE, 1996, ANNU REV PLANT PHYS, V47, P509, DOI 10.1146/annurev.arplant.47.1.509; MILLER ME, 1992, PLANT CELL, V4, P297, DOI 10.1105/tpc.4.3.297; MUNCH ERNST, 1927, BE R DEUTSCH BOI GES, V45, P340; OPARKA KJ, 1992, ENV PLANT B, P91; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; ROCHASOSA M, 1989, EMBO J, V8, P23, DOI 10.1002/j.1460-2075.1989.tb03344.x; SONNEWALD U, 1991, PLANT J, V1, P95, DOI 10.1111/j.1365-313X.1991.00095.x; THORPE MR, 1996, PHOTOASSIMILATE DIST; TOMOS AD, 1992, ENV PLANT B, P71; TRUMBLY RJ, 1992, MOL MICROBIOL, V6, P15, DOI 10.1111/j.1365-2958.1992.tb00832.x; VONSCHAEWEN A, 1990, EMBO J, V9, P3033, DOI 10.1002/j.1460-2075.1990.tb07499.x; Weber H, 1996, PLANT J, V10, P823, DOI 10.1046/j.1365-313X.1996.10050823.x; ZRENNER R, 1995, PLANT J, V7, P97, DOI 10.1046/j.1365-313X.1995.07010097.x; [No title captured], DOI DOI 10.1007/BF03044296	25	171	187	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					794	797		10.1038/nbt0897-794	http://dx.doi.org/10.1038/nbt0897-794			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255797				2022-12-27	WOS:A1997XM70700034
J	GarciaCampayo, V; Sato, A; Hirsch, B; Sugahara, T; Muyan, M; Hsueh, AJW; Boime, I				GarciaCampayo, V; Sato, A; Hirsch, B; Sugahara, T; Muyan, M; Hsueh, AJW; Boime, I			Design of stable biologically active recombinant lutropin analogs	NATURE BIOTECHNOLOGY			English	Article						lutropin; single chain gonadotropin; structure-function	HUMAN CHORIONIC-GONADOTROPIN; LUTEINIZING-HORMONE; BETA-SUBUNITS; ESCHERICHIA-COLI; GRANULOSA-CELLS; CHAIN; STABILITY; PROTEIN; EXPRESSION; SECRETION	Glycoprotein hormones are noncovalent heterodimers comprised of a common alpha subunit and a hormone-specific beta subunit, Secretion and biologic action of these hormones are dependent on the formation of the heterodimer. The human LH beta subunit is unique among the other beta subunits in that it assembles inefficiently with the alpha subunit. To bypass this rate-limiting step, we constructed the LH single chains where the carboxy terminus of beta was fused to the amino terminus of alpha subunit through a linker. Compared to the human LH heterodimer, the extent of secretion was greater for the tethers although the rate was dependent on the nature of the linker. The LH single chains were biologically active even though there was loss of recognition by a LH-specific monoclonal antibody. This suggests that receptor binding of the single chains is not impaired by changes in the heterodimeric configuration resulting from tethering the subunits. In addition, single chains exhibited a remarkably greater in vitro stability than the heterodimer, implying that these analogs will be useful as diagnostic reagents and that their purification will be facilitated.	WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110; STANFORD UNIV,MED CTR,DIV REPROD BIOL,DEPT OBSTET GYNECOL,STANFORD,CA 94305	Washington University (WUSTL); Stanford University			Muyan, Mesut/AAZ-4888-2020; Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X; Muyan, Mesut/0000-0003-3058-6228; Garcia-Campayo, Javier/0000-0002-3797-4218; Garcia-Campayo, Vicenta/0000-0002-5737-9897	NICHD NIH HHS [N01-HD 92922] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD092922] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARGOS P, 1990, J MOL BIOL, V211, P943, DOI 10.1016/0022-2836(90)90085-Z; ARORA N, 1994, J BIOL CHEM, V269, P26165; Catt KJ, 1986, REPRODUCTIVE ENDOCRI, P75; CORLESS CL, 1987, J CELL BIOL, V104, P1173, DOI 10.1083/jcb.104.5.1173; DAVOREN JB, 1985, BIOL REPROD, V33, P37, DOI 10.1095/biolreprod33.1.37; DEMEDEIROS SF, 1991, OBSTET GYNECOL, V77, P53; HALLEWELL RA, 1989, J BIOL CHEM, V264, P5260; HARIKRISHNA JA, 1993, DNA CELL BIOL, V12, P371, DOI 10.1089/dna.1993.12.371; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; HUTH JR, 1992, J BIOL CHEM, V267, P8870; JIA XC, 1991, MOL ENDOCRINOL, V5, P759, DOI 10.1210/mend-5-6-759; KEENE JL, 1989, J BIOL CHEM, V264, P4769; KESNER JS, 1995, REPROD TOXICOL, V9, P239, DOI 10.1016/0890-6238(95)00005-U; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LIVESEY JH, 1980, CLIN BIOCHEM, V13, P151, DOI 10.1016/S0009-9120(80)91040-1; LIVESEY JH, 1983, J ENDOCRINOL, V98, P381, DOI 10.1677/joe.0.0980381; MATZUK MM, 1989, J CELL BIOL, V109, P1429, DOI 10.1083/jcb.109.4.1429; MATZUK MM, 1988, J CELL BIOL, V106, P1049, DOI 10.1083/jcb.106.4.1049; MATZUK MM, 1988, MOL ENDOCRINOL, V2, P95, DOI 10.1210/mend-2-2-95; MATZUK MM, 1987, P NATL ACAD SCI USA, V84, P1173; Muyan M, 1996, MOL ENDOCRINOL, V10, P1678, DOI 10.1210/me.10.12.1678; NARAYAN P, 1995, MOL ENDOCRINOL, V9, P1720, DOI 10.1210/me.9.12.1720; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; POMERANTZ JL, 1995, SCIENCE, V267, P93, DOI 10.1126/science.7809612; RAO MC, 1977, ENDOCRINOLOGY, V101, P512, DOI 10.1210/endo-101-2-512; SAKETOS M, 1994, CLIN CHEM, V40, P749; SANO T, 1992, P NATL ACAD SCI USA, V89, P1534, DOI 10.1073/pnas.89.5.1534; SCHIMMEL P, 1992, PROTEIN SCI, V1, P1387, DOI 10.1002/pro.5560011018; SOMOZA JR, 1993, J MOL BIOL, V234, P390, DOI 10.1006/jmbi.1993.1594; Sugahara T, 1996, J BIOL CHEM, V271, P10445, DOI 10.1074/jbc.271.18.10445; SUGAHARA T, 1995, P NATL ACAD SCI USA, V92, P2041, DOI 10.1073/pnas.92.6.2041; Sugahara T, 1996, MOL CELL ENDOCRINOL, V125, P71, DOI 10.1016/S0303-7207(96)03944-5; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; TALMADGE K, 1984, NATURE, V307, P37, DOI 10.1038/307037a0; THORELL JI, 1971, BIOCHIM BIOPHYS ACTA, V251, P363, DOI 10.1016/0005-2795(71)90123-1; TOTH MJ, 1986, J BIOL CHEM, V261, P6643; WHITLOW M, 1991, Methods (Orlando), V2, P97, DOI 10.1016/S1046-2023(05)80209-9; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; YEH P, 1992, P NATL ACAD SCI USA, V89, P1904, DOI 10.1073/pnas.89.5.1904	39	35	39	2	9	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1997	15	7					663	667		10.1038/nbt0797-663	http://dx.doi.org/10.1038/nbt0797-663			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XH583	9219270				2022-12-27	WOS:A1997XH58300031
J	Campbell, RK; Bergert, ER; Wang, YH; Morris, JC; Moyle, WR				Campbell, RK; Bergert, ER; Wang, YH; Morris, JC; Moyle, WR			Chimeric proteins can exceed the sum of their parts: Implications for evolution and protein design	NATURE BIOTECHNOLOGY			English	Article						protein-protein interactions; human chorionic gonadotropin; thyrotropin; chimeric proteins; evolution	HUMAN CHORIONIC-GONADOTROPIN; FOLLICLE-STIMULATING-HORMONE; HUMAN THYROTROPIN RECEPTOR; FRTL-5 THYROID-CELLS; BETA-SUBUNIT; GLYCOPROTEIN HORMONES; FUNCTIONAL EXPRESSION; SIGNAL-TRANSDUCTION; ALPHA-SUBUNIT; BINDING	Chimeric analogs derived from pairs of homologous proteins routinely exhibit activities found in one or both parents, We describe chimeras of two glycoprotein hormones, human chorionic gonadotropin (hCG) and human follitropin (hFSH), that exhibit activity unique to a third family member, human thyrotropin (hTSH). The results show that biological activity can be separated from hormone-specific amino acid residues. This is consistent with a model for the evolution of homologous ligand-receptor pairs involving gene duplication and the creation of inhibitory determinants that restrict binding. Disruption of these determinants can unmask activities characteristic of other members of a protein family. Combining portions of two ligands to create analogs with properties of a third family member can facilitate identifying key determinants of protein-protein interaction and may be a useful strategy for creating novel therapeutics, In the case of the glycoprotein hormones, this showed that two different hormone regions (i.e., the seat-belt and the intersubunit groove) appear to limit inappropriate contacts with receptors for other members of this family, These observations also have important caveats for chimera-based protein design because an unexpected gain of function may limit the therapeutic usefulness of some chimeras.	RUTGERS STATE UNIV,ROBERT WOOD JOHNSON MED SCH,DEPT OBGYN,PISCATAWAY,NJ 08854; MAYO CLIN & MAYO GRAD SCH MED,DEPT ENDOCRINOL & INTERNAL MED,ROCHESTER,MN 55905	Rutgers State University New Brunswick; Rutgers State University Medical Center; Mayo Clinic			Campbell, Robert/G-4112-2012		NICHD NIH HHS [HD15454, HD14907] Funding Source: Medline; NIDDK NIH HHS [DK42008] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD015454, R01HD014907, R37HD014907] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042008] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brooker G, 1979, Adv Cyclic Nucleotide Res, V10, P1; CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; CARAYON P, 1981, ENDOCRINOLOGY, V108, P1891, DOI 10.1210/endo-108-5-1891; CHENG KW, 1973, J BIOL CHEM, V248, P7930; COLE ES, 1993, BIOTECHNOLOGY, V11, P1015; COMBARNOUS Y, 1981, J BIOL CHEM, V256, P9567; COSOWSKY L, 1995, J BIOL CHEM, V270, P20011, DOI 10.1074/jbc.270.34.20011; DIAS JA, 1994, J BIOL CHEM, V269, P25289; ELDEIRY S, 1991, MOL CELL ENDOCRINOL, V76, P105, DOI 10.1016/0303-7207(91)90265-T; GLINOER D, 1993, J ENDOCRINOL INVEST, V16, P881, DOI 10.1007/BF03348950; Han Y, 1996, MOL CELL ENDOCRINOL, V124, P151, DOI 10.1016/S0303-7207(96)03936-6; HOERMANN R, 1991, ENDOCRINOLOGY, V128, P1129; JENSEN RA, 1976, ANNU REV MICROBIOL, V30, P409, DOI 10.1146/annurev.mi.30.100176.002205; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; LEWIS EB, 1951, COLD SPRING HARB SYM, V16, P159, DOI 10.1101/SQB.1951.016.01.014; MARENGERE LEM, 1994, NATURE, V369, P50; MATZUK MM, 1989, J BIOL CHEM, V264, P2409; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MERZ WE, 1985, BIOCHIM BIOPHYS ACTA, V844, P62, DOI 10.1016/0167-4889(85)90234-4; MORRIS JC, 1990, J BIOL CHEM, V265, P1881; MORRIS JC, 1988, ENDOCRINOLOGY, V123, P456, DOI 10.1210/endo-123-1-456; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; MOYLE WR, 1982, P NATL ACAD SCI-BIOL, V79, P2245, DOI 10.1073/pnas.79.7.2245; MOYLE WR, 1990, J BIOL CHEM, V265, P8511; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; OHNO S, 1970, EVOLUTION GENE DUPLI, P59; PAVLAKIS GN, 1987, GENE TRANSFER VECTOR, P29; PEKARY AE, 1993, J CLIN ENDOCR METAB, V76, P70, DOI 10.1210/jc.76.1.70; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; SOUZA SC, 1995, P NATL ACAD SCI USA, V92, P959, DOI 10.1073/pnas.92.4.959; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; STRICKLAND TW, 1981, ENDOCRINOLOGY, V109, P1933, DOI 10.1210/endo-109-6-1933; Tian Y, 1996, J BIOL CHEM, V271, P20250, DOI 10.1074/jbc.271.34.20250; TOMER Y, 1992, J CLIN ENDOCR METAB, V74, P1477, DOI 10.1210/jc.74.6.1477; TSURUTA E, 1995, J CLIN ENDOCR METAB, V80, P350, DOI 10.1210/jc.80.2.350; Turner PR, 1996, J BIOL CHEM, V271, P9205, DOI 10.1074/jbc.271.16.9205; VANDEPOLL MLM, 1995, J BIOL CHEM, V270, P22337, DOI 10.1074/jbc.270.38.22337; VITTI P, 1983, J CLIN ENDOCR METAB, V57, P782, DOI 10.1210/jcem-57-4-782; VITTI P, 1993, J CLIN ENDOCR METAB, V76, P499, DOI 10.1210/jc.76.2.499; WANG Y, 1994, INT CONGR SER, V1046, P191; Ward D.N., 1979, ANIMAL MODELS RES FE, P151; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; YAMAZAKI K, 1995, J CLIN ENDOCR METAB, V80, P473, DOI 10.1210/jc.80.2.473; YCAS M, 1974, J THEOR BIOL, V44, P145, DOI 10.1016/S0022-5193(74)80035-4; YOSHIKAWA N, 1990, ENDOCRINOL JAPON, V37, P639; YOSHIMURA M, 1991, ACTA ENDOCRINOL-COP, V124, P173, DOI 10.1530/acta.0.1240173; YOSHIMURA M, 1994, EUR J ENDOCRINOL, V130, P92, DOI 10.1530/eje.0.1300092	49	37	42	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1997	15	5					439	443		10.1038/nbt0597-439	http://dx.doi.org/10.1038/nbt0597-439			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WX237	9131622				2022-12-27	WOS:A1997WX23700027
J	Saini, N; Neelapu, SS				Saini, Neeraj; Neelapu, Sattva S.			CAR T-reg cells: prime suspects in therapeutic resistance	NATURE MEDICINE			English	Editorial Material							DYSFUNCTION	Using comprehensive single-cell profiling, two studies reveal the molecular phenotypes of CAR T cells associated with durable response in patients with lymphoma, and highlight the role of CAR regulatory T cells in mediating resistance.	[Saini, Neeraj; Neelapu, Sattva S.] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Div Canc Med, Houston, TX 77030 USA; [Saini, Neeraj] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Div Canc Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Neelapu, SS (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Div Canc Med, Houston, TX 77030 USA.	sneelapu@mdanderson.org			MD Anderson Cancer Center [P30 CA016672]; US National Institutes of Health	MD Anderson Cancer Center; US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This was work is supported by the MD Anderson Cancer Center support grant P30 CA016672 from the US National Institutes of Health.	Deng Q, 2020, NAT MED, V26, DOI 10.1038/s41591-020-1061-7; Florek M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145763; Good Z, 2022, NAT MED, V28, P1860, DOI 10.1038/s41591-022-01960-7; Haradhvala NJ, 2022, NAT MED, V28, P1848, DOI 10.1038/s41591-022-01959-0; Humblet-Baron S, 2016, J ALLERGY CLIN IMMUN, V138, P200, DOI 10.1016/j.jaci.2015.12.1314; Jackson Z, 2022, CANCER DISCOV, V12, P1886, DOI 10.1158/2159-8290.CD-21-1586; Jacobson CA, 2022, LANCET ONCOL, V23, P91, DOI 10.1016/S1470-2045(21)00591-X; Lee JC, 2011, CANCER RES, V71, P2871, DOI 10.1158/0008-5472.CAN-10-0552; Lichtenstein DA, 2021, BLOOD, V138, P2469, DOI 10.1182/blood.2021011898; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; Scholler N, 2022, NAT MED, V28, P1872, DOI 10.1038/s41591-022-01916-x; Schuster SJ, 2019, NEW ENGL J MED, V380, P45, DOI 10.1056/NEJMoa1804980	12	0	0	2	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2022	28	9					1755	1756		10.1038/s41591-022-01998-7	http://dx.doi.org/10.1038/s41591-022-01998-7		SEP 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4S0LI	36109644				2022-12-27	WOS:000854720900003
J	Toledo, RA; Elez, E				Toledo, Rodrigo A.; Elez, Elena			A biomarker of response to therapy in metastatic BRAF(V600E) colorectal cancers	NATURE MEDICINE			English	Editorial Material; Early Access								Colorectal cancers expressing the mutant BRAF(V600E) comprise 10% of all metastatic colorectal cancers, present with a poor prognosis, and are refractory to common therapies. We discovered that a subgroup of these tumors that carries loss-of-function RNF43 mutations is associated with significantly improved response to the current standard-of-care anti-BRAF-anti-EGFR combination therapy.	[Toledo, Rodrigo A.; Elez, Elena] Vall dHebron Inst Oncol VHIO, Barcelona, Spain	Vall d'Hebron Institut d'Oncologia (VHIO)	Toledo, RA (corresponding author), Vall dHebron Inst Oncol VHIO, Barcelona, Spain.							Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Cremolini C, 2015, LANCET ONCOL, V16, P1306, DOI 10.1016/S1470-2045(15)00122-9; Koo BK, 2012, NATURE, V488, P665, DOI 10.1038/nature11308; Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075; Xi Y, 2021, TRANSL ONCOL, V14, DOI 10.1016/j.tranon.2021.101174	5	0	0	1	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01988-9	http://dx.doi.org/10.1038/s41591-022-01988-9		SEP 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4O5DX	36104595				2022-12-27	WOS:000854719500001
J	Bekker, LG				Bekker, Linda-Gail			Long-acting agents for HIV treatment and prevention	NATURE MEDICINE			English	Editorial Material; Early Access							LENACAPAVIR	Infrequently dosed, longer-acting antiretroviral agents are making adherence to medication easier, leading to better outcomes for those living with HIV or at risk of infection.	[Bekker, Linda-Gail] Univ Cape Town, Inst Infect Dis & Mol Med, Desmond Tutu HIV Ctr, Cape Town, South Africa; [Bekker, Linda-Gail] Univ Cape Town, Dept Med, Cape Town, South Africa	University of Cape Town; University of Cape Town	Bekker, LG (corresponding author), Univ Cape Town, Inst Infect Dis & Mol Med, Desmond Tutu HIV Ctr, Cape Town, South Africa.; Bekker, LG (corresponding author), Univ Cape Town, Dept Med, Cape Town, South Africa.	linda-gail.bekker@hiv-research.org.za						Delany-Moretlwe S, 2022, LANCET, V399, P1779, DOI 10.1016/S0140-6736(22)00538-4; Dvory-Sobol H, 2022, CURR OPIN HIV AIDS, V17, P15, DOI 10.1097/COH.0000000000000713; Hosek S, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.7.21107; Link JO, 2020, NATURE, V584, P614, DOI 10.1038/s41586-020-2443-1; Segal-Maurer S, 2022, NEW ENGL J MED, V386, P1793, DOI 10.1056/NEJMoa2115542; Shoupe D, 2016, CONTRACEP REPROD MED, V1, DOI 10.1186/s40834-016-0011-8; Stevens GL, 2016, EARLY INTERV PSYCHIA, V10, P365, DOI 10.1111/eip.12278; US Food and Drug Administration, US	8	0	0	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01917-w	http://dx.doi.org/10.1038/s41591-022-01917-w		JUL 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3C9TI	35869309				2022-12-27	WOS:000828957200002
J	Liu, RS; Zou, J				Liu, Ruishan; Zou, James			Advancing precision oncology with large, real-world genomics and treatment outcomes data	NATURE MEDICINE			English	Article; Early Access								Analysis of genomics data and medical records of over 40,000 patients with cancer identifies hundreds of mutations that are predictive of how well patients respond to specific cancer therapies. These predictive biomarkers could inform personalized treatment planning.	[Liu, Ruishan; Zou, James] Stanford Univ, Stanford, CA 94305 USA	Stanford University	Liu, RS (corresponding author), Stanford Univ, Stanford, CA 94305 USA.							Blonde L, 2018, ADV THER, V35, P1763, DOI 10.1007/s12325-018-0805-y; Hodson R, 2016, NATURE, V537, pS49, DOI 10.1038/537S49a; Ma X, 2020, COMP POPULATION CHAR, DOI 10.1101/2020.03.16.20037143; Marquart J, 2018, JAMA ONCOL, V4, P1093, DOI 10.1001/jamaoncol.2018.1660; Raponi M, 2008, CURR OPIN PHARMACOL, V8, P413, DOI 10.1016/j.coph.2008.06.006	5	0	0	3	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01904-1	http://dx.doi.org/10.1038/s41591-022-01904-1		JUL 2022	1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3C2GI	35864256				2022-12-27	WOS:000828446700002
J	Watkins, D; Moran, A				Watkins, David; Moran, Andrew			Renewed action on hypertension to improve health and reduce global inequalities	NATURE MEDICINE			English	Editorial Material; Early Access									[Watkins, David] Univ Washington, Seattle, WA 98195 USA; [Moran, Andrew] Resolve Save Lives New York, New York, NY USA	University of Washington; University of Washington Seattle	Watkins, D (corresponding author), Univ Washington, Seattle, WA 98195 USA.							Jeemon Panniyammakal, 2021, Glob Heart, V16, P63, DOI 10.5334/gh.1066; Prabhakaran D, 2018, LANCET, V391, P1224, DOI 10.1016/S0140-6736(17)32471-6; Roth GA, 2015, NEW ENGL J MED, V372, P1333, DOI 10.1056/NEJMoa1406656; World Health Organization, HEARTS TECHN PACK	4	0	0	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01903-2	http://dx.doi.org/10.1038/s41591-022-01903-2		JUL 2022	1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3C2GI	35864257				2022-12-27	WOS:000828446700001
J	Cao, LR; Lou, JZ; Chan, SY; Zheng, H; Liu, CQ; Zhao, S; Li, Q; Mok, CKP; Chan, RWY; Chong, MKC; Wu, WKK; Chen, Z; Wong, ELY; Chan, PKS; Zee, BCY; Yeoh, EK; Wang, MH				Cao, Lirong; Lou, Jingzhi; Chan, See Yeung; Zheng, Hong; Liu, Caiqi; Zhao, Shi; Li, Qi; Mok, Chris Ka Pun; Chan, Renee Wan Yi; Chong, Marc Ka Chun; Wu, William Ka Kei; Chen, Zigui; Wong, Eliza Lai Yi; Chan, Paul Kay Sheung; Zee, Benny Chung Ying; Yeoh, Eng Kiong; Wang, Maggie Haitian			Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance	NATURE MEDICINE			English	Article; Early Access							EFFICACY	A model that predicts the effectiveness of COVID-19 vaccines against circulating SARS-CoV-2 variants, before the acquisition of real-world effectiveness data, may help guide more rapid public health and research responses to new variants of concern. Timely evaluation of the protective effects of Coronavirus Disease 2019 (COVID-19) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern is urgently needed to inform pandemic control planning. Based on 78 vaccine efficacy or effectiveness (VE) data from 49 studies and 1,984,241 SARS-CoV-2 sequences collected from 31 regions, we analyzed the relationship between genetic distance (GD) of circulating viruses against the vaccine strain and VE against symptomatic infection. We found that the GD of the receptor-binding domain of the SARS-CoV-2 spike protein is highly predictive of vaccine protection and accounted for 86.3% (P = 0.038) of the VE change in a vaccine platform-based mixed-effects model and 87.9% (P = 0.006) in a manufacturer-based model. We applied the VE-GD model to predict protection mediated by existing vaccines against new genetic variants and validated the results by published real-world and clinical trial data, finding high concordance of predicted VE with observed VE. We estimated the VE against the Delta variant to be 82.8% (95% prediction interval: 68.7-96.0) using the mRNA vaccine platform, closely matching the reported VE of 83.0% from an observational study. Among the four sublineages of Omicron, the predicted VE varied between 11.9% and 33.3%, with the highest VE predicted against BA.1 and the lowest against BA.2, using the mRNA vaccine platform. The VE-GD framework enables predictions of vaccine protection in real time and offers a rapid evaluation method against novel variants that may inform vaccine deployment and public health responses.	[Cao, Lirong; Chan, See Yeung; Zheng, Hong; Liu, Caiqi; Zhao, Shi; Li, Qi; Mok, Chris Ka Pun; Chong, Marc Ka Chun; Wong, Eliza Lai Yi; Zee, Benny Chung Ying; Yeoh, Eng Kiong; Wang, Maggie Haitian] Chinese Univ Hong Kong, JC Sch Publ Hlth & Primary Care, Hong Kong, Peoples R China; [Cao, Lirong; Zheng, Hong; Zhao, Shi; Li, Qi; Chong, Marc Ka Chun; Zee, Benny Chung Ying; Wang, Maggie Haitian] CUHK Shenzhen Res Inst, Shenzhen, Peoples R China; [Lou, Jingzhi; Chan, See Yeung] Beth Bioinformat Co Ltd, Hong Kong, Peoples R China; [Mok, Chris Ka Pun; Wu, William Ka Kei] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China; [Chan, Renee Wan Yi] Chinese Univ Hong Kong, Dept Paediat, Hong Kong, Peoples R China; [Chan, Renee Wan Yi] Chinese Univ Hong Kong, Hong Kong Hub Paediat Excellence, Hong Kong, Peoples R China; [Wu, William Ka Kei] Chinese Univ Hong Kong, Dept Anaesthesia & Intens Care, Hong Kong, Peoples R China; [Wu, William Ka Kei] Chinese Univ Hong Kong, Peter Hung Pain Res Inst, Hong Kong, Peoples R China; [Wu, William Ka Kei] Chinese Univ Hong Kong, State Key Lab Digest Dis, Hong Kong, Peoples R China; [Chen, Zigui; Chan, Paul Kay Sheung] Chinese Univ Hong Kong, Dept Microbiol, Hong Kong, Peoples R China; [Wong, Eliza Lai Yi; Yeoh, Eng Kiong] Chinese Univ Hong Kong, Ctr Hlth Syst & Policy Res, Hong Kong, Peoples R China; [Chan, Paul Kay Sheung] Chinese Univ Hong Kong, Stanley Ho Ctr Emerging Infect Dis, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong	Wang, MH (corresponding author), Chinese Univ Hong Kong, JC Sch Publ Hlth & Primary Care, Hong Kong, Peoples R China.; Wang, MH (corresponding author), CUHK Shenzhen Res Inst, Shenzhen, Peoples R China.	maggiew@cuhk.edu.hk	Zhao, Shi/AAW-6992-2021; Zee, Benny Chung Ying/G-5606-2017; Wu, William K.K./A-3277-2009; Chen, Zigui/E-8490-2017; wu, william/HII-5817-2022; Chan, Renee Wan Yi/AAA-6598-2020	Zhao, Shi/0000-0001-8722-6149; Zee, Benny Chung Ying/0000-0002-7238-845X; Wu, William K.K./0000-0002-5662-5240; Chen, Zigui/0000-0002-8577-1298; Chan, Renee Wan Yi/0000-0001-6485-0926; Wong, Eliza/0000-0001-9983-6219; Chong, Ka Chun/0000-0001-5610-1298	Health and Medical Research Fund; Food and Health Bureau, the Government of the Hong Kong Special Administrative Region [COVID190103, INF-CUHK-1]; National Natural Science Foundation of China [31871340, 71974165]; Chinese University of Hong Kong [PIEF/Ph2/COVID/06, 4054600]; Guangdong-Hong Kong-Macau Joint Laboratory of Respiratory Infectious Disease [20191205]; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore	Health and Medical Research Fund; Food and Health Bureau, the Government of the Hong Kong Special Administrative Region; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese University of Hong Kong(Chinese University of Hong Kong); Guangdong-Hong Kong-Macau Joint Laboratory of Respiratory Infectious Disease; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore(Nanyang Technological University)	A complete GISAID acknowledgement table is in the online Supplementary Materials. We thank the contributions of all the healthcare workers and scientists, the GISAID team and the submitting and originating laboratories. This work was partially supported by the Health and Medical Research Fund, the Food and Health Bureau, the Government of the Hong Kong Special Administrative Region (COVID190103; M.H.W. and INF-CUHK-1; E.K.Y.), the National Natural Science Foundation of China (31871340; M.H.W. and 71974165; M.K.C.C.), Chinese University of Hong Kong grants PIEF/Ph2/COVID/06 and 4054600 (M.H.W.), the Guangdong-Hong Kong-Macau Joint Laboratory of Respiratory Infectious Disease (20191205; C.K.P.M.) and the visiting scientist scheme from the Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore (C.K.P.M.). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. We appreciate the constructive comments from the editor and reviewers that improved this work.	Abu-Raddad LJ, 2021, JAMA-J AM MED ASSOC, V326, P1930, DOI 10.1001/jama.2021.19623; Abu-Raddad LJ, 2021, NEW ENGL J MED, V385, P187, DOI 10.1056/NEJMc2104974; Altarawneh H. N., PREPRINT, DOI [10.1101/2022.03.22.22272745v1(2022), DOI 10.1101/2022.03.22.22272745V1(2022)]; Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436; Andeweg SP., 2022, MEDRXIV, DOI [10.1101/2022.02.06.22270457, DOI 10.1101/2022.02.06.22270457V3, DOI 10.1101/2022.02.06.22270457]; Andrews N, 2022, NEW ENGL J MED, V386, P1532, DOI [10.1056/NEJMoa2119451, 10.1016/S1473-3099(22)00309-7]; Andrews N, 2022, NEW ENGL J MED, V386, P340, DOI 10.1056/NEJMoa2115481; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Basta NE, COVID 19 VACCINE TRA; Bergwerk M, 2021, NEW ENGL J MED, V385, P1474, DOI 10.1056/NEJMoa2109072; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Bruxvoort Katia J, 2022, Lancet Reg Health Am, V6, P100134, DOI 10.1016/j.lana.2021.100134; Cai YF, 2021, SCIENCE, V373, P642, DOI [10.1126/science.abi9745, 10.1101/2021.04.13.439709]; Cao LR, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13040619; Cao LR, 2021, VACCINE, V39, P1030, DOI 10.1016/j.vaccine.2021.01.006; Cavanaugh AM, 2021, MMWR-MORBID MORTAL W, V70, P639, DOI 10.15585/mmwr.mm7017e2; Cele S, 2022, NATURE, V602, P654, DOI 10.1038/s41586-021-04387-1; Charmet T, 2021, LANCET REG HEALTH-EU, V8, DOI 10.1016/j.lanepe.2021.100171; Chemaitelly H., PREPRINT, DOI [10.1101/2022.02.07.22270568v1(2022), DOI 10.1101/2022.02.07.22270568V1(2022)]; Cheng SMS, 2022, NAT MED, V28, P486, DOI 10.1038/s41591-022-01704-7; Chung H, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n1943; Collie S, 2022, NEW ENGL J MED, V386, P494, DOI 10.1056/NEJMc2119270; Cui Z, 2022, CELL, V185, P860, DOI 10.1016/j.cell.2022.01.019; Dai LP, 2021, NAT REV IMMUNOL, V21, P73, DOI 10.1038/s41577-020-00480-0; Dejnirattisai W, 2022, CELL, V185, P467, DOI 10.1016/j.cell.2021.12.046; Dunkle LM, 2022, NEW ENGL J MED, V386, P531, DOI 10.1056/NEJMoa2116185; El Sahly HM, 2021, NEW ENGL J MED, V385, P1774, DOI 10.1056/NEJMoa2113017; Falsey AR, 2021, NEW ENGL J MED, V385, P2348, DOI 10.1056/NEJMoa2105290; Feikin DR, 2022, LANCET, V399, P924, DOI 10.1016/S0140-6736(22)00152-0; Feng S, 2021, NAT MED, V27, P2032, DOI 10.1038/s41591-021-01540-1; Gilbert P, 2001, J CLIN EPIDEMIOL, V54, P68, DOI 10.1016/S0895-4356(00)00258-4; Gobeil SMC, 2021, SCIENCE, V373, P641, DOI [10.1126/science.abi6226, 10.1101/2021.03.11.435037]; Gupta V, 2006, VACCINE, V24, P3881, DOI 10.1016/j.vaccine.2006.01.010; Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483; Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Kim SS., 2021, J INFECT DIS; Knowles J. E., 2020, MERTOOLS TOOLS ANAL; Kuznetsova A, 2017, J STAT SOFTW, V82, P1, DOI 10.18637/jss.v082.i13; Lin DY, 2022, NEW ENGL J MED, V386, P933, DOI 10.1056/NEJMoa2117128; LIN LI, 1989, BIOMETRICS, V45, P255, DOI 10.2307/2532051; Liu Y, 2021, NEW ENGL J MED, V384, P1466, DOI 10.1056/NEJMc2102017; Mathieu E, 2021, NAT HUM BEHAV, V5, P947, DOI 10.1038/s41562-021-01122-8; McCallum M, 2022, SCIENCE, V375, P864, DOI 10.1126/science.abn8652; McCallum M, 2021, SCIENCE, V373, P648, DOI 10.1126/science.abi7994; McCallum M, 2021, CELL, V184, P2332, DOI [10.1101/2021.01.14.426475, 10.1016/j.cell.2021.03.028]; Melo-Gonzalez F, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.747830; Mok CKP, 2022, RESPIROLOGY, V27, P301, DOI 10.1111/resp.14191; Muik A, 2022, SCIENCE, V375, P678, DOI 10.1126/science.abn7591; Munoz ET, 2005, VACCINE, V23, P1144, DOI 10.1016/j.vaccine.2004.08.028; Nasreen S, 2022, NAT MICROBIOL, V7, P379, DOI 10.1038/s41564-021-01053-0; Nemet I, 2022, NEW ENGL J MED, V386, P492, DOI 10.1056/NEJMc2119358; Pajon R, 2022, NEW ENGL J MED, V386, P1088, DOI 10.1056/NEJMc2119912; Piccoli L, 2020, CELL, V183, P1024, DOI 10.1016/j.cell.2020.09.037; Pilishvili T, 2021, NEW ENGL J MED, V385, DOI 10.1056/NEJMoa2106599; Pilishvili T, 2021, MMWR-MORBID MORTAL W, V70, P753, DOI 10.15585/mmwr.mm7020e2externalicon; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Regev-Yochay G, 2022, NEW ENGL J MED, V386, P1377, DOI 10.1056/NEJMc2202542; Rolland M, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009406; Rolland M, 2011, NAT MED, V17, P366, DOI 10.1038/nm.2316; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Sheikh A, 2021, LANCET, V397, P2461, DOI 10.1016/S0140-6736(21)01358-1; Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494; Tang P, 2021, NAT MED, V27, P2136, DOI 10.1038/s41591-021-01583-4; Thomas SJ, 2021, NEW ENGL J MED, V385, P1761, DOI 10.1056/NEJMoa2110345; Tseng HF, 2022, NAT MED, V28, P1063, DOI 10.1038/s41591-022-01753-y; Zhou DM, 2021, CELL, V184, P2348, DOI 10.1016/j.cell.2021.02.037	67	3	3	11	11	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01877-1	http://dx.doi.org/10.1038/s41591-022-01877-1		JUN 2022	16	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E1GB	35710987	hybrid, Green Published			2022-12-27	WOS:000811980700007
J	Khan, A; Turchin, MC; Patki, A; Srinivasasainagendra, V; Shang, N; Nadukuru, R; Jones, AC; Malolepsza, E; Dikilitas, O; Kullo, IJ; Schaid, DJ; Karlson, E; Ge, T; Meigs, JB; Smoller, JW; Lange, C; Crosslin, DR; Jarvik, GP; Bhatraju, PK; Hellwege, JN; Chandler, P; Torvik, LR; Fedotov, A; Liu, C; Kachulis, C; Lennon, N; Abul-Husn, NS; Cho, JH; Ionita-Laza, I; Gharavi, AG; Chung, WK; Hripcsak, G; Weng, C; Nadkarni, G; Irvin, MR; Tiwari, HK; Kenny, EE; Limdi, NA; Kiryluk, K				Khan, Atlas; Turchin, Michael C.; Patki, Amit; Srinivasasainagendra, Vinodh; Shang, Ning; Nadukuru, Rajiv; Jones, Alana C.; Malolepsza, Edyta; Dikilitas, Ozan; Kullo, Iftikhar J.; Schaid, Daniel J.; Karlson, Elizabeth; Ge, Tian; Meigs, James B.; Smoller, Jordan W.; Lange, Christoph; Crosslin, David R.; Jarvik, Gail P.; Bhatraju, Pavan K.; Hellwege, Jacklyn N.; Chandler, Paulette; Torvik, Laura Rasmussen; Fedotov, Alex; Liu, Cong; Kachulis, Christopher; Lennon, Niall; Abul-Husn, Noura S.; Cho, Judy H.; Ionita-Laza, Iuliana; Gharavi, Ali G.; Chung, Wendy K.; Hripcsak, George; Weng, Chunhua; Nadkarni, Girish; Irvin, Marguerite R.; Tiwari, Hemant K.; Kenny, Eimear E.; Limdi, Nita A.; Kiryluk, Krzysztof			Genome-wide polygenic score to predict chronic kidney disease across ancestries	NATURE MEDICINE			English	Article							RISK PREDICTION; CARDIOVASCULAR EVENTS; APOL1 VARIANTS; ASSOCIATION; POPULATION; GFR; LOCI; SCHIZOPHRENIA; HERITABILITY; TRAJECTORIES	A new study generated and optimized a polygenic score for chronic kidney disease with reproducible performance across 15 cohorts of different ancestries, and identified potentially clinically relevant thresholds with predicted effects comparable to having a family history of the disease. Chronic kidney disease (CKD) is a common complex condition associated with high morbidity and mortality. Polygenic prediction could enhance CKD screening and prevention; however, this approach has not been optimized for ancestrally diverse populations. By combining APOL1 risk genotypes with genome-wide association studies (GWAS) of kidney function, we designed, optimized and validated a genome-wide polygenic score (GPS) for CKD. The new GPS was tested in 15 independent cohorts, including 3 cohorts of European ancestry (n = 97,050), 6 cohorts of African ancestry (n = 14,544), 4 cohorts of Asian ancestry (n = 8,625) and 2 admixed Latinx cohorts (n = 3,625). We demonstrated score transferability with reproducible performance across all tested cohorts. The top 2% of the GPS was associated with nearly threefold increased risk of CKD across ancestries. In African ancestry cohorts, the APOL1 risk genotype and polygenic component of the GPS had additive effects on the risk of CKD.	[Khan, Atlas; Shang, Ning; Gharavi, Ali G.; Kiryluk, Krzysztof] Columbia Univ, Dept Med, Div Nephrol, Vagelos Coll Phys & Surg, New York, NY 10027 USA; [Turchin, Michael C.; Abul-Husn, Noura S.; Kenny, Eimear E.] Icahn Sch Med Mt Sinai, Inst Genom Hlth, New York, NY 10029 USA; [Patki, Amit; Srinivasasainagendra, Vinodh; Tiwari, Hemant K.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Biostat, Birmingham, AL USA; [Nadukuru, Rajiv; Cho, Judy H.; Nadkarni, Girish] Icahn Sch Med Mt Sinai, Charles Bronfman Inst Personalized Med, New York, NY 10029 USA; [Jones, Alana C.; Irvin, Marguerite R.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL USA; [Malolepsza, Edyta; Kachulis, Christopher; Lennon, Niall] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA; [Dikilitas, Ozan; Kullo, Iftikhar J.; Schaid, Daniel J.] Mayo Clin, Dept Cardiovasc Dis, Rochester, MN USA; [Karlson, Elizabeth] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA; [Ge, Tian; Smoller, Jordan W.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; [Meigs, James B.] Massachusetts Gen Hosp, Dept Med, Div Gen Internal Med, Boston, MA 02114 USA; [Meigs, James B.] Harvard Med Sch, Boston, MA 02115 USA; [Meigs, James B.] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA; [Lange, Christoph] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Crosslin, David R.] Tulane Univ, Sch Med, John W Deming Dept Med, Div Biomed Informat & Genom, 1430 Tulane Ave, New Orleans, LA 70112 USA; [Jarvik, Gail P.] Univ Washington, Dept Med Med Genet, Seattle, WA 98195 USA; [Jarvik, Gail P.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; [Bhatraju, Pavan K.] Univ Washington, Dept Med, Div Pulm Crit Care & Sleep Med, Seattle, WA 98195 USA; [Hellwege, Jacklyn N.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA; [Chandler, Paulette] Brigham & Womens Hosp, Dept Med, Div Prevent Med, 75 Francis St, Boston, MA 02115 USA; [Torvik, Laura Rasmussen] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; [Fedotov, Alex] Columbia Univ, Irving Inst Clin & Translat Res, New York, NY USA; [Liu, Cong; Hripcsak, George; Weng, Chunhua] Columbia Univ, Vagelos Coll Phys & Surg, Dept Biomed Informat, New York, NY USA; [Abul-Husn, Noura S.; Kenny, Eimear E.] Icahn Sch Med Mt Sinai, Dept Med, Div Genom Med, New York, NY 10029 USA; [Abul-Husn, Noura S.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA; [Ionita-Laza, Iuliana] Columbia Univ, Dept Biostat, New York, NY USA; [Chung, Wendy K.] Columbia Univ, Dept Pediat, Irving Med Ctr, New York, NY USA; [Chung, Wendy K.] Icahn Sch Med Mt Sinai, Div Gen Internal Med, Dept Med, New York, NY 10029 USA; [Limdi, Nita A.] Univ Alabama Birmingham, Sch Med, Dept Neurol, Birmingham, AL USA	Columbia University; Icahn School of Medicine at Mount Sinai; University of Alabama System; University of Alabama Birmingham; Icahn School of Medicine at Mount Sinai; University of Alabama System; University of Alabama Birmingham; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Mayo Clinic; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Harvard T.H. Chan School of Public Health; Tulane University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Vanderbilt University; Harvard University; Brigham & Women's Hospital; Northwestern University; Feinberg School of Medicine; Columbia University; Columbia University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Columbia University; Columbia University; NewYork-Presbyterian Hospital; Icahn School of Medicine at Mount Sinai; University of Alabama System; University of Alabama Birmingham	Kiryluk, K (corresponding author), Columbia Univ, Dept Med, Div Nephrol, Vagelos Coll Phys & Surg, New York, NY 10027 USA.	kk473@columbia.edu		Kullo, Iftikhar/0000-0002-6524-3471; Dikilitas, Ozan/0000-0002-9906-8608; Jones, Alana/0000-0003-3827-2426; Turchin, Michael/0000-0003-3569-1529; Shang, Ning/0000-0001-7040-5204	National Human Genome Research Institute eMERGE-IV [2U01HG008680-05, 1U01HG011167-01, 1U01HG011176-01]; National Institute of Neurological Disorders and Stroke [U01NS041588]; National Institute on Aging; National Institutes of Health (NIH); Department of Health and Human Services; NHLBI [R01HL055673, R01HL123782, R01HL092173, K24HL133373]; UKBB [41849];  [UG3DK114926];  [RC2DK116690];  [R01LM013061];  [K25DK128563];  [UL1TR001873];  [R01HL151855];  [UM1DK078616]	National Human Genome Research Institute eMERGE-IV; National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Health and Human Services; NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); UKBB; ; ; ; ; ; ; 	This work was funded by the National Human Genome Research Institute eMERGE-IV grant nos. 2U01HG008680-05, 1U01HG011167-01 and 1U01HG011176-01. Additional sources of funding included grant nos. UG3DK114926 (K.K.), RC2DK116690 (K.K.), R01LM013061 (C.W., K.K.), K25DK128563 (A.K.), UL1TR001873 (A.K., K.K.), R01HL151855 (J.B.M.) and UM1DK078616 (J.B.M.). The parent REGARDS study was supported by cooperative agreement no. U01NS041588 cofunded by the National Institute of Neurological Disorders and Stroke and the National Institute on Aging, the National Institutes of Health (NIH) and the Department of Health and Human Services. The HyperGEN (R01HL055673), GenHAT (R01HL123782) and WPC (R01HL092173, K24HL133373) studies were all supported by the NHLBI. Parts of this study were conducted using the UKBB resource under UKBB project no. 41849. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.	1000 Genomes Project Consortium, 2015, Nature, V526, P68, DOI 10.1038/nature15393; Abraham G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093766; Aly M, 2011, EUR UROL, V60, P21, DOI 10.1016/j.eururo.2011.01.017; [Anonymous], 2022, CHRON KIDN DIS US; Arnett D. K., 2002, Pharmacogenomics Journal, V2, P309; Belbin GM, 2021, CELL, V184, P2068, DOI 10.1016/j.cell.2021.03.034; Bycroft C, 2018, NATURE, V562, P203, DOI 10.1038/s41586-018-0579-z; Coresh J, 2007, JAMA-J AM MED ASSOC, V298, P2038, DOI 10.1001/jama.298.17.2038; CROW J F, 1970, P591, DOI 10.1093/bioinformatics/btr330; Das S, 2016, NAT GENET, V48, P1284, DOI 10.1038/ng.3656; Delanaye P, 2019, J AM SOC NEPHROL, V30, P1785, DOI 10.1681/ASN.2019030238; Delgado C, 2021, J AM SOC NEPHROL, V32, P2994, DOI 10.1681/ASN.2021070988; Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; Ehret GB, 2016, NAT GENET, V48, P1171, DOI 10.1038/ng.3667; Fahed AC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17374-3; Fox CS, 2004, J AM SOC NEPHROL, V15, P2457, DOI 10.1097/01.ASN.0000135972.13396.6F; Fritsche LG, 2018, AM J HUM GENET, V102, P1048, DOI 10.1016/j.ajhg.2018.04.001; Furberg CD, 2000, JAMA-J AM MED ASSOC, V283, P1967; Genovese G, 2010, SCIENCE, V329, P841, DOI 10.1126/science.1193032; Gladding PA, 2020, HEART LUNG CIRC, V29, P634, DOI 10.1016/j.hlc.2019.12.004; Groopman EE, 2019, NEW ENGL J MED, V380, P142, DOI 10.1056/NEJMoa1806891; Hellwege JN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11704-w; Hindy G, 2020, ARTERIOSCL THROM VAS, V40, P2738, DOI 10.1161/ATVBAHA.120.314856; Hoffmann TJ, 2017, NAT GENET, V49, P54, DOI 10.1038/ng.3715; Howard VJ, 2005, NEUROEPIDEMIOLOGY, V25, P135, DOI 10.1159/000086678; Huyghe JR, 2019, NAT GENET, V51, P76, DOI 10.1038/s41588-018-0286-6; Inker LA, 2021, NEW ENGL J MED, V385, P1737, DOI 10.1056/NEJMoa2102953; Inouye M, 2018, J AM COLL CARDIOL, V72, P1883, DOI 10.1016/j.jacc.2018.07.079; Jeon J, 2018, GASTROENTEROLOGY, V154, P2152, DOI 10.1053/j.gastro.2018.02.021; Khan A, 2021, J AM SOC NEPHROL, V32, P2031, DOI 10.1681/ASN.2020091371; Khera AV, 2019, CELL, V177, P587, DOI 10.1016/j.cell.2019.03.028; Khera AV, 2019, CIRCULATION, V139, P1593, DOI 10.1161/CIRCULATIONAHA.118.035658; Khera AV, 2018, NAT GENET, V50, P1219, DOI 10.1038/s41588-018-0183-z; Kiryluk K, 2014, NAT GENET, V46, P1187, DOI 10.1038/ng.3118; Ko WY, 2013, AM J HUM GENET, V93, P54, DOI 10.1016/j.ajhg.2013.05.014; Kottgen A, 2009, NAT GENET, V41, P712, DOI 10.1038/ng.377; Lall K, 2017, GENET MED, V19, P322, DOI 10.1038/gim.2016.103; Langefeld CD, 2004, AM J KIDNEY DIS, V43, P796, DOI 10.1053/j.ajkd.2003.12.043; Lata S, 2018, ANN INTERN MED, V168, P100, DOI 10.7326/M17-1319; Lee A, 2019, GENET MED, V21, P1708, DOI 10.1038/s41436-018-0406-9; Levey AS, 2010, AM J KIDNEY DIS, V55, P622, DOI 10.1053/j.ajkd.2010.02.337; Limdi NA, 2015, AM J KIDNEY DIS, V65, P701, DOI 10.1053/j.ajkd.2014.11.004; Martin AR, 2019, NAT GENET, V51, P584, DOI 10.1038/s41588-019-0379-x; Mavaddat N, 2019, AM J HUM GENET, V104, P21, DOI 10.1016/j.ajhg.2018.11.002; McCarthy S, 2016, NAT GENET, V48, P1279, DOI 10.1038/ng.3643; Nadkarni GN, 2018, NEW ENGL J MED, V379, P2571, DOI 10.1056/NEJMc1800748; Naghavi M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9; Neugut YD, 2019, ANN INTERN MED, V171, P659, DOI 10.7326/M19-1389; Orlando Lori A, 2013, N C Med J, V74, P287; Parsa A, 2013, NEW ENGL J MED, V369, P2183, DOI 10.1056/NEJMoa1310345; Polubriaginof Fernanda, 2015, AMIA Annu Symp Proc, V2015, P2035; Power RA, 2015, NAT NEUROSCI, V18, P953, DOI 10.1038/nn.4040; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Reginsson GW, 2018, ADDICT BIOL, V23, P485, DOI 10.1111/adb.12496; Satko SG, 2005, MED CLIN N AM, V89, P447, DOI 10.1016/j.mcna.2004.11.011; Seibert TM, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.j5757; Shang N, 2021, NPJ DIGIT MED, V4, DOI 10.1038/s41746-021-00428-1; Sheng X, 2021, NAT GENET, V53, P1322, DOI 10.1038/s41588-021-00909-9; Sirugo G, 2019, CELL, V177, P26, DOI 10.1016/j.cell.2019.02.048; Sohail M, 2019, ELIFE, V8, DOI 10.7554/eLife.39702; Tada H, 2016, EUR HEART J, V37, P561, DOI 10.1093/eurheartj/ehv462; Teumer A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11576-0; Thomson R, 2014, P NATL ACAD SCI USA, V111, pE2130, DOI 10.1073/pnas.1400699111; Timmerman N, 2020, ATHEROSCLEROSIS, V307, P121, DOI 10.1016/j.atherosclerosis.2020.04.013; Vilhjalmsson BJ, 2015, AM J HUM GENET, V97, P576, DOI 10.1016/j.ajhg.2015.09.001; Vyas DA, 2020, NEW ENGL J MED, V383, P874, DOI 10.1056/NEJMms2004740; Wand H, 2021, NATURE, V591, P211, DOI 10.1038/s41586-021-03243-6; Weinberger DR, 2019, AM J PSYCHIAT, V176, P3, DOI 10.1176/appi.ajp.2018.18111274; Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340; Williams RR, 2000, ANN EPIDEMIOL, V10, P389, DOI 10.1016/S1047-2797(00)00063-6; Wuttke M, 2019, NAT GENET, V51, P957, DOI 10.1038/s41588-019-0407-x; Xie JY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15383-w; Yu Z, 2021, J AM SOC NEPHROL, V32, P3161, DOI 10.1681/ASN.2020111599; Zanoni F, 2020, CURR OPIN ORGAN TRAN, V25, P35, DOI 10.1097/MOT.0000000000000718; Zhang J, 2021, AM J KIDNEY DIS, V77, P869, DOI 10.1053/j.ajkd.2020.11.012	75	1	1	3	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2022	28	7					1412	+		10.1038/s41591-022-01869-1	http://dx.doi.org/10.1038/s41591-022-01869-1		JUN 2022	20	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3E5PS	35710995				2022-12-27	WOS:000811980700001
J	Joutsa, J; Fox, MD				Joutsa, Juho; Fox, Michael D.			A human brain circuit for addiction remission	NATURE MEDICINE			English	Editorial Material							SYMPTOMS	Substance addiction is a major public health crisis. Neuromodulation treatments show promise, but the therapeutic targets remain unclear. Studying human brain lesions that led to addiction remission with the lesion-network-mapping approach resulted in the identification of a brain circuit shared across addiction disorders that may have therapeutic potential.	[Joutsa, Juho] Univ Turku, Turku, Finland; [Fox, Michael D.] Harvard Med Sch, Boston, MA 02115 USA	University of Turku; Harvard University; Harvard Medical School	Joutsa, J (corresponding author), Univ Turku, Turku, Finland.							Boes AD, 2015, BRAIN, V138, P3061, DOI 10.1093/brain/awv228; Fox MD, 2018, NEW ENGL J MED, V379, P2237, DOI 10.1056/NEJMra1706158; Joutsa J, 2018, ANN NEUROL, V84, P153, DOI 10.1002/ana.25285; Naqvi NH, 2007, SCIENCE, V315, P531, DOI 10.1126/science.1135926; Volkow ND, 2018, AM J PSYCHIAT, V175, P729, DOI 10.1176/appi.ajp.2018.17101174	5	0	0	5	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2022	28	6					1137	1138		10.1038/s41591-022-01864-6	http://dx.doi.org/10.1038/s41591-022-01864-6			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E9IE	35697843				2022-12-27	WOS:000812533400017
J	Newham, M; Vokinger, KN				Newham, Melissa; Vokinger, Kerstin N.			Adverse effects of acquisitions in the pharmaceutical industry	NATURE MEDICINE			English	Editorial Material							PRICES	Publicly funded research leads to the development of many new drugs, but the profits are largely reaped by big pharmaceutical companies through exclusive licensing deals, mergers and acquisitions, which can reduce competition and patients' access to medicines.	[Newham, Melissa] Swiss Fed Inst Technol, Dept Management Technol & Econ, Zurich, Switzerland; [Vokinger, Kerstin N.] Univ Zurich, Inst Law, Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich	Newham, M (corresponding author), Swiss Fed Inst Technol, Dept Management Technol & Econ, Zurich, Switzerland.; Vokinger, KN (corresponding author), Univ Zurich, Inst Law, Zurich, Switzerland.	mnewham@ethz.ch; kerstinnoelle.vokinger@usz.ch		Vokinger, Kerstin Noelle/0000-0002-6997-7384	Swiss National Science Foundation (SNSF)	Swiss National Science Foundation (SNSF)(Swiss National Science Foundation (SNSF))	This study was funded by the Swiss National Science Foundation (SNSF).	Anderson Richard, 2014, BBC NEWS; [Anonymous], 2019, NOVARTIS INC; [Anonymous], 2021, HCV EL; [Anonymous], IQVIA MIDAS DATABASE; [Anonymous], ADISINSIGHT; [Anonymous], 2017, FIERCEPHARMA; [Anonymous], KEI; [Anonymous], NOVARTIS INC; [Anonymous], 2019, GILEAD SCI; [Anonymous], STATISTA; Bennette CS, 2016, HEALTH AFFAIR, V35, P805, DOI 10.1377/hlthaff.2015.1145; Caffarra C., 2020, VOXEU; Cleary EG, 2018, P NATL ACAD SCI USA, V115, P2329, DOI 10.1073/pnas.1715368115; Cunningham C, 2021, J POLIT ECON, V129, P649, DOI 10.1086/712506; Ledley FD, 2020, JAMA-J AM MED ASSOC, V323, P834, DOI 10.1001/jama.2020.0442; Liu M., 2020, HLTH AFFAIRS FOREFRO, DOI [10.1377/hblog20200501.798711/full/, DOI 10.1377/HBLOG20200501.798711/FULL]; Love, 2018, KNOWLEDGE ECOLOGY IN; Patridge EV, 2015, DRUG DISCOV TODAY, V20, P1182, DOI 10.1016/j.drudis.2015.06.006; Sampat BN, 2011, HEALTH AFFAIR, V30, P332, DOI 10.1377/hlthaff.2009.0917; Schlander M, 2020, ANN ONCOL, V31, pS966, DOI 10.1016/j.annonc.2020.08.1912; Stern AD, 2021, HEALTH AFFAIR, V40, P989, DOI 10.1377/hlthaff.2020.02239; US Food and Drug Administration, 2018, ATR	22	0	0	1	1	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2022	28	7					1342	1344		10.1038/s41591-022-01784-5	http://dx.doi.org/10.1038/s41591-022-01784-5		MAY 2022	3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3E5PS	35538258				2022-12-27	WOS:000793025400001
J	Daws, RE; Carhart-Harris, R				Daws, Richard E.; Carhart-Harris, Robin			Psilocybin increases brain network integration in patients with depression	NATURE MEDICINE			English	Editorial Material								Clinical trial results show that psilocybin, a potent psychedelic, has antidepressant effects in patients with depression and is more effective than escitalopram. Functional MRI experiments revealed a decrease in brain modularity after psilocybin therapy, indicative of an increase in the global integration of the brain's functional networks.	[Daws, Richard E.] Kings Coll London, London, England; [Carhart-Harris, Robin] Univ Calif San Francisco, San Francisco, CA 94143 USA	University of London; King's College London; University of California System; University of California San Francisco	Daws, RE (corresponding author), Kings Coll London, London, England.							Beck A.T., 1988, ANXIETY RES, V1, P23, DOI [DOI 10.1080/10615808808248218, 10.1080/10615808808248218]; Carhart-Harris RL, 2017, J PSYCHOPHARMACOL, V31, P1091, DOI 10.1177/0269881117725915; Carhart-Harris RL, 2016, LANCET PSYCHIAT, V3, P619, DOI 10.1016/S2215-0366(16)30065-7; Hamilton JP, 2011, BIOL PSYCHIAT, V70, P327, DOI 10.1016/j.biopsych.2011.02.003; Roseman L, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00204	5	0	0	12	14	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2022	28	4					647	648		10.1038/s41591-022-01769-4	http://dx.doi.org/10.1038/s41591-022-01769-4		APR 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	0Q6DV	35411079				2022-12-27	WOS:000780688100002
J	Draghia-Akli, R; Li, XY; Schwartz, RJ				Draghia-Akli, R; Li, XY; Schwartz, RJ			Enhanced growth by ectopic expression of growth hormone releasing hormone using an injectable myogenic vector	NATURE BIOTECHNOLOGY			English	Article						gene therapy; growth hormone; DNA vaccine; skeletal alpha-actin	ALPHA-ACTIN GENE; MOUSE SKELETAL-MUSCLE; PLASMID DNA; CHROMOSOMAL ASSIGNMENT; FACTOR-I; SECRETION; GH; DEFICIENCY; INJECTION; MUTATIONS	Ectopic expression of a truncated growth hormone-releasing hormone (GHRH) from muscle tissues by a myogenic plasmid DNA vector directed by the skeletal alpha-actin promoter, pSK-GHRH, results in growth hormone (GH) secretion. Skeletal muscle-secreted GHRH is biologically active. The application of conditioned media harvested from pSK-GHRH transfected muscle cells to cultured pig primary anterior pituitary cells elicits GH release. A single intramuscular injection of 100 mu g pSK-GHRH DNA elevates serum GH levels threefold to fourfold for up to 2 weeks, enhancing liver IGF-1 gene expression and increasing body weight approximately 10%.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine	Schwartz, RJ (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	schwartz@bcm.tmc.edu		Draghia-Akli, Ruxandra/0000-0001-6372-4039	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049953] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL-49953, R01 HL-50422] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMSELEM S, 1993, HUM MOL GENET, V2, P355, DOI 10.1093/hmg/2.4.355; AMSELEM S, 1991, ACTA PAEDIATR SCAND, P81; BARB CR, 1991, DOMEST ANIM ENDOCRIN, V8, P117, DOI 10.1016/0739-7240(91)90046-M; BERGSMA DJ, 1986, MOL CELL BIOL, V6, P2462, DOI 10.1128/MCB.6.7.2462; BERTHERAT J, 1995, EUR J ENDOCRINOL, V132, P12, DOI 10.1530/eje.0.1320012; CAO Y, 1995, PEDIATR RES, V38, P962, DOI 10.1203/00006450-199512000-00022; CHOW KL, 1991, P NATL ACAD SCI USA, V88, P1301, DOI 10.1073/pnas.88.4.1301; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; COGAN JD, 1993, J CLIN ENDOCR METAB, V76, P1224, DOI 10.1210/jc.76.5.1224; CORPAS E, 1993, ENDOCR REV, V14, P20, DOI 10.1210/er.14.1.20; CORPAS E, 1993, J CLIN ENDOCR METAB, V76, P134, DOI 10.1210/jc.76.1.134; DANKO I, 1994, GENE THER, V1, P114; DAVIS HL, 1993, HUM GENE THER, V4, P151, DOI 10.1089/hum.1993.4.2-151; DCOSTA AP, 1993, J REPROD FERTIL, P87; DOUMIT ME, 1992, TISSUE CELL, V24, P253, DOI 10.1016/0040-8166(92)90098-R; ENRIGHT WJ, 1993, J ANIM SCI, V71, P2395, DOI 10.2527/1993.7192395x; ENRIGHT WJ, 1986, J DAIRY SCI, V69, P344, DOI 10.3168/jds.S0022-0302(86)80412-X; ESCH FS, 1982, BIOCHEM BIOPH RES CO, V109, P152, DOI 10.1016/0006-291X(82)91578-9; FRENCH BA, 1990, GENE, V88, P173, DOI 10.1016/0378-1119(90)90029-Q; IRANMANESH A, 1991, J CLIN ENDOCR METAB, V73, P1081, DOI 10.1210/jcem-73-5-1081; KOTZMANN H, 1994, NEUROENDOCRINOLOGY, V60, P618, DOI 10.1159/000126805; LEE TC, 1994, ONCOGENE, V9, P1047; LeRoith D, 1996, ENDOCRINOLOGY, V137, P1071, DOI 10.1210/en.137.3.1071; Levy MY, 1996, GENE THER, V3, P201; LING N, 1984, BIOCHEM BIOPH RES CO, V123, P854; LOW LCK, 1993, J PEDIATR ENDOCRINOL, V6, P15; MARCUS R, 1990, J CLIN ENDOCR METAB, V70, P519, DOI 10.1210/jcem-70-2-519; MAYO KE, 1985, P NATL ACAD SCI USA, V82, P63, DOI 10.1073/pnas.82.1.63; MAYO KE, 1983, NATURE, V306, P86, DOI 10.1038/306086a0; MEACHAM LR, 1993, J CLIN ENDOCR METAB, V77, P1379, DOI 10.1210/jc.77.5.1379; Parks John S., 1995, P473; PARKS JS, 1993, HORM RES, V40, P54, DOI 10.1159/000183768; RIDDELL DC, 1985, SOMAT CELL MOLEC GEN, V11, P189, DOI 10.1007/BF01534707; SALOMON F, 1989, NEW ENGL J MED, V321, P1797, DOI 10.1056/NEJM198912283212605; Scanlon MF, 1996, HORM RES, V46, P149, DOI 10.1159/000185014; TANNER JW, 1990, J ENDOCRINOL, V125, P109, DOI 10.1677/joe.0.1250109; THORNER MO, 1984, J CLIN ENDOCR METAB, V59, P846, DOI 10.1210/jcem-59-5-846; Tripathy SK, 1996, NAT MED, V2, P545, DOI 10.1038/nm0596-545; Tripathy SK, 1996, P NATL ACAD SCI USA, V93, P10876, DOI 10.1073/pnas.93.20.10876; VNENCAKJONES CL, 1988, P NATL ACAD SCI USA, V85, P5615, DOI 10.1073/pnas.85.15.5615; Wang YL, 1997, NAT BIOTECHNOL, V15, P239, DOI 10.1038/nbt0397-239; WELLS DJ, 1993, FEBS LETT, V332, P179, DOI 10.1016/0014-5793(93)80508-R; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Wolff Jon A., 1992, Human Molecular Genetics, V1, P363, DOI 10.1093/hmg/1.6.363; YAO SN, 1994, GENE THER, V1, P99	45	48	74	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1997	15	12					1285	1289		10.1038/nbt1197-1285	http://dx.doi.org/10.1038/nbt1197-1285			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YQ046	9359113				2022-12-27	WOS:000071342000032
J	Loisel, TP; Ansanay, H; St-Onge, S; Gay, B; Boulanger, P; Strosberg, AD; Marullo, S; Bouvier, M				Loisel, TP; Ansanay, H; St-Onge, S; Gay, B; Boulanger, P; Strosberg, AD; Marullo, S; Bouvier, M			Recovery of homogeneous and functional beta(2)-adrenergic receptors from extracellular baculovirus particles	NATURE BIOTECHNOLOGY			English	Article						protein expression; Sf9 cells; recombinant baculovirus	INFECTED INSECT CELLS; VIRUS-LIKE PARTICLES; NUCLEAR POLYHEDROSIS-VIRUS; BETA-2-ADRENERGIC RECEPTOR; STRUCTURAL PROTEINS; PEPTIDE RECEPTOR; GAG PRECURSOR; EXPRESSION; PURIFICATION; PHOSPHORYLATION	Expression in baculovirus-infected insect cells allows sufficient production of G-protein coupled receptor for structural studies. An important drawback of this expression system comes from the presence of unprocessed and biologically inactive receptors that have to be eliminated during receptor purification steps. We show that viral particles released from Sf9 cells infected with a recombinant baculovirus coding for the human beta(2)-adrenergic receptor (beta(2)AR) cDNA contain glycosylated and biologically active beta(2)AR. In addition, post-translational modifications known to modulate receptor activity were found to occur in these particles.	Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Grp Rech Syst Nerveux Autonome, Montreal, PQ H3C 3J7, Canada; Fac Med Montpellier, Inst Biol, Lab Virol & Pathogeneses Mol, CNRS,URA 1487, F-34060 Montpellier, France; CNRS, Inst Cochin Genet Mol, UPR 415, Lab Immunopharmacol Mol, F-75014 Paris, France; Univ Paris 07, F-75014 Paris, France	Universite de Montreal; Universite de Montreal; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Bouvier, M (corresponding author), Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada.	bouvier@bch.umontreal.ca	Marullo, Stefano/C-6142-2008; Bouvier, Michel/H-2758-2014	Marullo, Stefano/0000-0001-9604-9973; Bouvier, Michel/0000-0003-1128-0100				ALLARD WJ, 1987, NUCLEIC ACIDS RES, V15, P10604, DOI 10.1093/nar/15.24.10604; BELCHEVA MM, 1995, J PHARMACOL EXP THER, V274, P1513; BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; BOUVIER M, 1988, MOL PHARMACOL, V33, P133; BRAUNAGEL SC, 1994, VIROLOGY, V202, P315, DOI 10.1006/viro.1994.1348; CARRIERE C, 1995, J VIROL, V69, P2366; CHAABIHI H, 1994, BIOCHEM BIOPH RES CO, V203, P734, DOI 10.1006/bbrc.1994.2243; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DELCHAMBRE M, 1989, EMBO J, V8, P2653, DOI 10.1002/j.1460-2075.1989.tb08405.x; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GARNIER L, 1995, J VIROL, V69, P4060, DOI 10.1128/JVI.69.7.4060-4068.1995; GEORGE ST, 1989, BIOCHEM BIOPH RES CO, V163, P1265, DOI 10.1016/0006-291X(89)91114-5; GHEYSEN D, 1989, CELL, V59, P103, DOI 10.1016/0092-8674(89)90873-8; Gimpl G, 1996, EUR J BIOCHEM, V237, P768, DOI 10.1111/j.1432-1033.1996.0768p.x; HUNTER E, 1994, SEMIN VIROL, V5, P71, DOI 10.1006/smvy.1994.1008; KNUDSON DL, 1974, J VIROL, V14, P934, DOI 10.1128/JVI.14.4.934-944.1974; KOBILKA BK, 1995, ANAL BIOCHEM, V231, P269, DOI 10.1006/abio.1995.1533; KUSUI T, 1995, BIOCHEMISTRY-US, V34, P8061, DOI 10.1021/bi00025a012; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Loisel TP, 1996, BIOCHEMISTRY-US, V35, P15923, DOI 10.1021/bi9611321; MILLER LK, 1996, INSECT VIRUSES, V1, P533; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; NEBIGIL CG, 1995, BIOCHEMISTRY-US, V34, P11954, DOI 10.1021/bi00037a037; NG GY, 1994, EUR J PHARM-MOLEC PH, V287, P7; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; PARKER EM, 1991, J BIOL CHEM, V266, P519; PUDDINGTON L, 1985, J BIOL CHEM, V260, P5641; QUEHENBERGER O, 1992, J BIOL CHEM, V267, P19757; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; RAVET V, 1993, J RECEPTOR RES, V13, P541, DOI 10.3109/10799899309073678; RICHARDSON RM, 1992, J BIOL CHEM, V267, P22249; Roy P, 1996, CURR OPIN STRUC BIOL, V6, P157, DOI 10.1016/S0959-440X(96)80069-8; ROYER M, 1992, J VIROL, V66, P3230, DOI 10.1128/JVI.66.5.3230-3235.1992; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; THOMSEN DR, 1992, J GEN VIROL, V73, P1819, DOI 10.1099/0022-1317-73-7-1819	39	65	79	0	2	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	NOV	1997	15	12					1300	1304		10.1038/nbt1197-1300	http://dx.doi.org/10.1038/nbt1197-1300			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	YQ046	9359116				2022-12-27	WOS:000071342000035
J	Audic, S; BeraudColomb, E				Audic, S; BeraudColomb, E			Ancient DNA is thirteen years old	NATURE BIOTECHNOLOGY			English	Review						molecular evolution; polymerase chain reaction; archeology	POLYMERASE CHAIN-REACTION; AMINO-ACID RACEMIZATION; MITOCHONDRIAL-DNA; ARCHAEOLOGICAL SITE; SKELETAL REMAINS; FOSSIL PROTEINS; EGYPTIAN MUMMY; PCR INHIBITORS; SEQUENCE; BONES	The first successful recovery of ancient DNA, from quagga and human mummies inspired significant enough interest to open an entire field of research. Efforts from many research groups, often in a hunt for the oldest sequences, showed that ancient DNA was a poor substrate for the enzymes used in molecular biology; it is present in tiny amounts, hard to purify, and frequently damaged. These obstacles have been partially overcome by the use of drastic laboratory precautions and by the introduction of polymerase chain reaction and phylogenetic studies. Ancient DNA analysis now finds applications in many research domains.	CNRS, IBSM, EP STRUCT & GENET INFORMAT 91, F-13402 MARSEILLE, FRANCE	Centre National de la Recherche Scientifique (CNRS)								Abelson P., 1954, CARNEGIE I WASH YR B, V53, P5; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; ARMSTRONG WG, 1983, PHILOS T R SOC B, V301, P301, DOI 10.1098/rstb.1983.0026; ASCENZI A, 1985, P NATL ACAD SCI USA, V82, P7170, DOI 10.1073/pnas.82.21.7170; BERAUDCOLOMB E, 1995, AM J HUM GENET, V57, P1267; BeraudColomb E, 1997, AM J HUM GENET, V60, P1002; BROWN TA, 1994, EXPERIENTIA, V50, P571, DOI 10.1007/BF01921727; CANO RJ, 1993, NATURE, V363, P536, DOI 10.1038/363536a0; Cooper A, 1996, NATURE, V381, P484, DOI 10.1038/381484a0; DESALLE R, 1992, SCIENCE, V257, P1933, DOI 10.1126/science.1411508; DJOULAH S, 1994, TISSUE ANTIGENS, V43, P102, DOI 10.1111/j.1399-0039.1994.tb02308.x; FILON D, 1995, NAT GENET, V9, P365, DOI 10.1038/ng0495-365; FULLERTON SM, 1994, P NATL ACAD SCI USA, V91, P1805, DOI 10.1073/pnas.91.5.1805; GOLENBERG EM, 1990, NATURE, V344, P656, DOI 10.1038/344656a0; GOLOUBINOFF P, 1993, P NATL ACAD SCI USA, V90, P1997, DOI 10.1073/pnas.90.5.1997; GOODYEAR PD, 1994, BIOTECHNIQUES, V16, P232; HAGELBERG E, 1994, NATURE, V369, P25, DOI 10.1038/369025a0; HAGELBERG E, 1991, P ROY SOC B-BIOL SCI, V244, P45, DOI 10.1098/rspb.1991.0049; HANDT O, 1994, SCIENCE, V264, P1775, DOI 10.1126/science.8209259; HANNI C, 1995, NUCLEIC ACIDS RES, V23, P881, DOI 10.1093/nar/23.5.881; HANNI C, 1994, GENOMICS, V22, P487, DOI 10.1006/geno.1994.1417; HANNI C, 1995, J ARCHAEOL SCI, V22, P649, DOI 10.1016/S0305-4403(95)80150-2; HARDY C, 1994, EXPERIENTIA, V50, P564, DOI 10.1007/BF01921726; HAUSWIRTH WW, 1994, EXPERIENTIA, V50, P585, DOI 10.1007/BF01921729; HEDGES SB, 1995, SCIENCE, V268, P1191, DOI 10.1126/science.7761839; HEIN JL, 1986, HOMME SON EVOLUTION, P201; HERMAN B, 1994, ANCIENT DNA; HIGUCHI R, 1984, NATURE, V312, P282, DOI 10.1038/312282a0; HORAI S, 1991, PHILOS T ROY SOC B, V333, P409, DOI 10.1098/rstb.1991.0091; HOSS M, 1993, NUCLEIC ACIDS RES, V21, P3913, DOI 10.1093/nar/21.16.3913; Hoss M, 1996, NUCLEIC ACIDS RES, V24, P1304, DOI 10.1093/nar/24.7.1304; Hoss M, 1996, P NATL ACAD SCI USA, V93, P181, DOI 10.1073/pnas.93.1.181; HUQ NL, 1985, BIOCHEM BIOPH RES CO, V129, P714, DOI 10.1016/0006-291X(85)91950-3; JANCZEWSKI DN, 1992, P NATL ACAD SCI USA, V89, P9769, DOI 10.1073/pnas.89.20.9769; JONG EWD, 1974, NATURE, V252, P63, DOI 10.1038/252063a0; KRIAUSAKUL N, 1978, SCIENCE, V201, P1011, DOI 10.1126/science.201.4360.1011; Krings M, 1997, CELL, V90, P19, DOI 10.1016/S0092-8674(00)80310-4; LERMAN JC, 1971, NATURE, V232, P568, DOI 10.1038/232568a0; LINDAHL T, 1993, NATURE, V365, P700, DOI 10.1038/365700a0; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LOWENSTEIN JM, 1981, PHILOS T ROY SOC B, V292, P143, DOI 10.1098/rstb.1981.0022; OOTA H, 1995, AM J PHYS ANTHROPOL, V98, P133, DOI 10.1002/ajpa.1330980204; PAABO S, 1985, NATURE, V314, P644, DOI 10.1038/314644a0; PAABO S, 1988, NATURE, V334, P387, DOI 10.1038/334387b0; PAABO S, 1989, J BIOL CHEM, V264, P9709; Poinar HN, 1996, SCIENCE, V272, P864, DOI 10.1126/science.272.5263.864; PRAGER EM, 1980, SCIENCE, V209, P287, DOI 10.1126/science.6155699; Richards M, 1996, AM J HUM GENET, V59, P185; RICHARDS MB, 1995, J ARCHAEOL SCI, V22, P291, DOI 10.1006/jasc.1995.0031; ROGAN PK, 1990, YEARB PHYS ANTHROPOL, V33, P195; ROLLO F, 1994, EXPERIENTIA, V50, P576, DOI 10.1007/BF01921728; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SALO WL, 1994, P NATL ACAD SCI USA, V91, P2091, DOI 10.1073/pnas.91.6.2091; SIVORI E, 1968, NATURE, V219, P1926; STONEKING M, 1993, EVOLUTIONARY ANTHR, V2, P60; Sykes B, 1997, NATURE, V386, P764, DOI 10.1038/386764a0; THOMAS RH, 1989, NATURE, V340, P465, DOI 10.1038/340465a0; ULRICH MMW, 1987, BIOCHEM BIOPH RES CO, V149, P712, DOI 10.1016/0006-291X(87)90426-8; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; WEINER S, 1976, P NATL ACAD SCI USA, V73, P2541, DOI 10.1073/pnas.73.8.2541; WILLIAMS KM, 1977, ORIGINS LIFE EVOL B, V8, P91, DOI 10.1007/BF00927978; WOODWARD SR, 1994, SCIENCE, V266, P1229	62	20	20	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1997	15	9					855	858		10.1038/nbt0997-855	http://dx.doi.org/10.1038/nbt0997-855			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biotechnology & Applied Microbiology	XW410	9306399				2022-12-27	WOS:A1997XW41000026
J	Persidis, A; Menzel, GE				Persidis, A; Menzel, GE			Biotechnology valuation	NATURE BIOTECHNOLOGY			English	Editorial Material									GOLDMAN SACHS & CO,NEW YORK,NY 10004		Persidis, A (corresponding author), ARGONEX INC,BUSINESS DEV,2044 INDIA RD,SUITE 202,CHARLOTTESVILLE,VA 22901, USA.							BERNSTEIN K, 1997, BIOCENTURY, V5, pA1; Copeland T., 1996, VALUATION MEASURING; Fusfeld AR, 1996, CHEMTECH, V26, P46; Persidis A, 1997, NAT BIOTECHNOL, V15, P479, DOI 10.1038/nbt0597-479; STRUCK MM, 1994, BIO-TECHNOL, V12, P674, DOI 10.1038/nbt0794-674	5	1	1	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					813	814		10.1038/nbt0897-813	http://dx.doi.org/10.1038/nbt0897-813			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255802				2022-12-27	WOS:A1997XM70700040
J	Bennett, VC; Biswas, SJ				Bennett, VC; Biswas, SJ			Protecting the patentability of your collaborative research - Collaborations are great. But who gets the patent rights?	NATURE BIOTECHNOLOGY			English	Editorial Material											Bennett, VC (corresponding author), BELL SELTZER PARK & GIBSON,3605 GLENWOOD AVE,SUITE 310,RALEIGH,NC 27622, USA.							JOHNSON EA, 1996, NAT BIOTECHNOL, V14, P228; LINCK NJ, 1995, BIO-TECHNOL, V13, P962, DOI 10.1038/nbt0995-962; RZUCIDLO EC, NAT BIOTECHNOL, V14, P358; SUPERKO C, BIOTECHNOLOGY, V14, P41	4	2	2	0	1	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1997	15	5					472	474		10.1038/nbt0597-472	http://dx.doi.org/10.1038/nbt0597-472			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WX237	9131629				2022-12-27	WOS:A1997WX23700034
J	Palsson, BO				Palsson, BO			What lies beyond bioinformatics?	NATURE BIOTECHNOLOGY			English	Editorial Material											Palsson, BO (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOENGN,9500 GILMAN DR,LA JOLLA,CA 92093, USA.			Palsson, Bernhard/0000-0003-2357-6785				BOITEUX A, 1981, CURR TOP CELL REGUL, V17, P171; FELL D, 1996, UNDERSTANDING CONTRO; Karp PD, 1996, NUCLEIC ACIDS RES, V24, P32, DOI 10.1093/nar/24.1.32; Karp PD, 1996, TRENDS BIOTECHNOL, V14, P273, DOI 10.1016/0167-7799(96)10044-5; Lauffenburger D. A., 1993, RECEPTORS MODELS BIN; LEE ID, 1991, BIOMED BIOCHIM ACTA, V49, P771; MCADAMS HH, 1993, SCIENCE, V269, P651; Miklos GLG, 1996, CELL, V86, P521, DOI 10.1016/S0092-8674(00)80126-9; Mushegian AR, 1996, P NATL ACAD SCI USA, V93, P10268, DOI 10.1073/pnas.93.19.10268; PALSSON BO, 1987, FASEB J, V46, P2485; REICH JG, 1981, ENERGY METABOLISM CE; ROBINSON C, 1996, TRENDS BIOTECHNOL, V14, P261; SCHELLENBERGER W, 1981, ADV ENZYME REGUL, V19, P257; Tyson JJ, 1996, TRENDS BIOCHEM SCI, V21, P89; VARMA A, 1994, BIO-TECHNOL, V12, P994, DOI 10.1038/nbt1094-994; WALKER RT, 1996, NUCLEIC ACIDS RES, V24, P1	16	35	41	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JAN	1997	15	1					3	4		10.1038/nbt0197-3	http://dx.doi.org/10.1038/nbt0197-3			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WA729	9035092				2022-12-27	WOS:A1997WA72900004
J	Isidro, J; Borges, V; Pinto, M; Sobral, D; Santos, JD; Nunes, A; Mixao, V; Ferreira, R; Santos, D; Duarte, S; Vieira, L; Borrego, MJ; Nuncio, S; de Carvalho, IL; Pelerito, A; Cordeiro, R; Gomes, JP				Isidro, Joana; Borges, Vitor; Pinto, Miguel; Sobral, Daniel; Santos, Joao Dourado; Nunes, Alexandra; Mixao, Veronica; Ferreira, Rita; Santos, Daniela; Duarte, Silvia; Vieira, Luis; Borrego, Maria Jose; Nuncio, Sofia; de Carvalho, Isabel Lopes; Pelerito, Ana; Cordeiro, Rita; Gomes, Joao Paulo			Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus (vol 28, pg 1569, 2022)	NATURE MEDICINE			English	Correction; Early Access												j.paulo.gomes@insa.min-saude.pt	Sobral, Daniel/B-4786-2014	Sobral, Daniel/0000-0003-3955-0117; Nunes, Alexandra/0000-0001-6449-8053				Happi C., 2022, URGENT NEED NONDISCR; Happi C., URGENT NEED NONDISCR; WHO, 2022, MONK EXP GIV VIR VAR	3	0	0	5	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-02036-2	http://dx.doi.org/10.1038/s41591-022-02036-2		SEP 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4Q3MO	36131032	hybrid, Green Published			2022-12-27	WOS:000855988100001
J	Ianiro, G; Puncochar, M; Karcher, N; Porcari, S; Armanini, F; Asnicar, F; Beghini, F; Blanco-Miguez, A; Cumbo, F; Manghi, P; Pinto, F; Masucci, L; Quaranta, G; De Giorgi, S; Sciume, GD; Bibbo, S; Del Chierico, F; Putignani, L; Sanguinetti, M; Gasbarrini, A; Valles-Colomer, M; Cammarota, G; Segata, N				Ianiro, Gianluca; Puncochar, Michal; Karcher, Nicolai; Porcari, Serena; Armanini, Federica; Asnicar, Francesco; Beghini, Francesco; Blanco-Miguez, Aitor; Cumbo, Fabio; Manghi, Paolo; Pinto, Federica; Masucci, Luca; Quaranta, Gianluca; De Giorgi, Silvia; Sciume, Giusi Desire; Bibbo, Stefano; Del Chierico, Federica; Putignani, Lorenza; Sanguinetti, Maurizio; Gasbarrini, Antonio; Valles-Colomer, Mireia; Cammarota, Giovanni; Segata, Nicola			Variability of strain engraftment and predictability of microbiome composition after fecal microbiota transplantation across different diseases	NATURE MEDICINE			English	Article							CLOSTRIDIUM-DIFFICILE INFECTION; METABOLIC SYNDROME; DIVERSITY; METAGENOMICS; BLASTOCYSTIS; RESISTANCE; ALIGNMENT; EFFICACY; THERAPY; MEMBER	Fecal microbiota transplantation (FMT) is highly effective against recurrent Clostridioides difficile infection and is considered a promising treatment for other microbiome-related disorders, but a comprehensive understanding of microbial engraftment dynamics is lacking, which prevents informed applications of this therapeutic approach. Here, we performed an integrated shotgun metagenomic systematic meta-analysis of new and publicly available stool microbiomes collected from 226 triads of donors, pre-FMT recipients and post-FMT recipients across eight different disease types. By leveraging improved metagenomic strain-profiling to infer strain sharing, we found that recipients with higher donor strain engraftment were more likely to experience clinical success after FMT (P = 0.017) when evaluated across studies. Considering all cohorts, increased engraftment was noted in individuals receiving FMT from multiple routes (for example, both via capsules and colonoscopy during the same treatment) as well as in antibiotic-treated recipients with infectious diseases compared with antibiotic-naive patients with noncommunicable diseases. Bacteroidetes and Actinobacteria species (including Bifidobacteria) displayed higher engraftment than Firmicutes except for six under-characterized Firmicutes species. Cross-dataset machine learning predicted the presence or absence of species in the post-FMT recipient at 0.77 average AUROC in leave-one-dataset-out evaluation, and highlighted the relevance of microbial abundance, prevalence and taxonomy to infer post-FMT species presence. By exploring the dynamics of microbiome engraftment after FMT and their association with clinical variables, our study uncovered species-specific engraftment patterns and presented machine learning models able to predict donors that might optimize post-FMT specific microbiome characteristics for disease-targeted FMT protocols. Coupling microbial metagenomics with machine learning enables prediction of donor strain engraftment after fecal microbiota transplantation (FMT) for a range of diseases, and may help tailor design of FMT to optimize microbial engraftment and achieve clinical outcomes.	[Ianiro, Gianluca; Porcari, Serena; De Giorgi, Silvia; Sciume, Giusi Desire; Bibbo, Stefano; Gasbarrini, Antonio; Cammarota, Giovanni] Fdn Policlin Univ A Gemelli IRCCS, Digest Dis Ctr, Rome, Italy; [Ianiro, Gianluca; Porcari, Serena; De Giorgi, Silvia; Sciume, Giusi Desire; Bibbo, Stefano; Gasbarrini, Antonio; Cammarota, Giovanni] Univ Cattolica Sacro Cuore, Dept Translat Med & Surg, Rome, Italy; [Puncochar, Michal; Karcher, Nicolai; Armanini, Federica; Asnicar, Francesco; Beghini, Francesco; Blanco-Miguez, Aitor; Cumbo, Fabio; Manghi, Paolo; Pinto, Federica; Valles-Colomer, Mireia; Segata, Nicola] Univ Trento, Dept CIBIO, Trento, Italy; [Masucci, Luca; Quaranta, Gianluca; Sanguinetti, Maurizio] Fdn Policlin Univ A Gemelli IRCCS, Microbiol Unit, Rome, Italy; [Masucci, Luca; Quaranta, Gianluca; Sanguinetti, Maurizio] Univ Cattolica Sacro Cuore, Dept Basic Biotechnol Sci, Intensivol & Perioperat Clin, Rome, Italy; [Del Chierico, Federica; Putignani, Lorenza] Bambino Gesu Childrens Hosp IRCCS, Unit Parasitol, Dept Diagnost & Lab Med, Rome, Italy; [Del Chierico, Federica; Putignani, Lorenza] Bambino Gesu Childrens Hosp IRCCS, Multimodal Lab Med Res Area, Unit Human Microbiome, Rome, Italy; [Segata, Nicola] Ist Europeo Oncol IRCSS, IEO, Milan, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Trento; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; IRCCS Bambino Gesu; IRCCS Bambino Gesu; IRCCS European Institute of Oncology (IEO)	Ianiro, G (corresponding author), Fdn Policlin Univ A Gemelli IRCCS, Digest Dis Ctr, Rome, Italy.; Ianiro, G (corresponding author), Univ Cattolica Sacro Cuore, Dept Translat Med & Surg, Rome, Italy.; Segata, N (corresponding author), Univ Trento, Dept CIBIO, Trento, Italy.; Segata, N (corresponding author), Ist Europeo Oncol IRCSS, IEO, Milan, Italy.	gianluca.ianiro@unicatt.it; nicola.segata@unitn.it	Asnicar, Francesco/AAB-9255-2020; Del Chierico, Federica/J-4373-2016; Blanco-Miguez, Aitor/H-3628-2017	Asnicar, Francesco/0000-0003-3732-1468; Del Chierico, Federica/0000-0002-4204-4736; Sciume, Giusi Desire/0000-0003-4525-4779; Blanco-Miguez, Aitor/0000-0001-7386-5572; Karcher, Nicolai/0000-0001-7894-8182; Manghi, Paolo/0000-0003-0846-6529; Beghini, Francesco/0000-0002-8105-9607	European Research Council (ERC-STG project) [MetaPG-716575]; MIUR 'Futuro in Ricerca' [RBFR13EWWI_001]; European H2020 program [ONCOBIOME-825410, MASTER-818368]; National Cancer Institute of the National Institutes of Health [1U01CA230551]; Premio Internazionale Lombardia e Ricerca 2019; Italian Ministry of Health; EMBO [ALTF 593-2020]; Ricerca Finalizzata Giovani Ricercatori 2018 of the Italian Ministry of Health [GR-2018-12365734]; BIOMIS grant of the Italian Ministry of Research	European Research Council (ERC-STG project); MIUR 'Futuro in Ricerca'(Ministry of Education, Universities and Research (MIUR)); European H2020 program; National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Premio Internazionale Lombardia e Ricerca 2019; Italian Ministry of Health(Ministry of Health, Italy); EMBO(European Molecular Biology Organization (EMBO)); Ricerca Finalizzata Giovani Ricercatori 2018 of the Italian Ministry of Health; BIOMIS grant of the Italian Ministry of Research	We thank all study participants for their commitment and the following authors of included studies for their help in providing data and metadata: H. Bar-Yoseph, R. Goll, H. Koo, S. Leo, C. Morrow, A. Moss, D. Suskind and F. Zhang. We also thank all the members of the HPC and NGS facilities at University of Trento, the whole FMT staff at the Fondazione Policlinico Gemelli IRCCS of Rome, all the FMT Ospedale Pediatrico Bambino GesU Committee Collaborators (particularly P. Merli, P. De Angelis, G. Angelino, E. Francesco Romeo and L. Gargiullo, S. Pane, S. Martino, L. Romani, P. Bernaschi, A. Finocchi, G. Marucci, F. Rea, S. Faraci, P. D' Argenio, L. Dall'Oglio) and the biobank of the Ospedale Pediatrico Bambino GesU. Moreover, the staff of the Fondazione Policlinico Gemelli IRCCS thank the Fondazione Roma for the invaluable support to their scientific research. This work was supported by the European Research Council (ERC-STG project MetaPG-716575) to N.S., by MIUR 'Futuro in Ricerca' (grant no. RBFR13EWWI_001) to N.S.; by the European H2020 program (ONCOBIOME-825410 project and MASTER-818368 project) to N.S.; by the National Cancer Institute of the National Institutes of Health (1U01CA230551) to N.S.; by the Premio Internazionale Lombardia e Ricerca 2019 to N.S.; by the Italian Ministry of Health with Ricerca Corrente and 5x1000 funds to N.S.; by the EMBO ALTF 593-2020 to M.V.-C.; by the Ricerca Finalizzata Giovani Ricercatori 2018 of the Italian Ministry of Health (project GR-2018-12365734) to G.I.; by the BIOMIS grant of the Italian Ministry of Research to A.G., G.C. and G.I. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Study procedures of the newly collected datasets were performed in compliance with the Declaration of Helsinki. Ethical approval was granted by Ethics Committees of Fondazione Policlinico Gemelli IRCCS (ID 3555/2021) and Ospedale Pediatrico Bambino GesU IRCCS (1107_OPBG_2016). Written informed consent was obtained from all adult participants, and from parents of pediatric (2-17 years old) participants. The systematic review was not registered.	Aggarwala V, 2021, NAT MICROBIOL, V6, P1309, DOI 10.1038/s41564-021-00966-0; Albanese D, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02209-5; Asnicar F, 2021, NAT MED, V27, P321, DOI 10.1038/s41591-020-01183-8; Asnicar F, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16366-7; Bar-Yoseph H, 2021, CLIN INFECT DIS, V73, pE166, DOI 10.1093/cid/ciaa737; Baruch EN, 2021, SCIENCE, V371, P602, DOI 10.1126/science.abb5920; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Baunwall SMD, 2020, ECLINICALMEDICINE, V29-30, DOI 10.1016/j.eclinm.2020.100642; Beghini F, 2021, ELIFE, V10, DOI 10.7554/eLife.65088; Beghini F, 2017, ISME J, V11, P2848, DOI 10.1038/ismej.2017.139; Benson DA, 2011, NUCLEIC ACIDS RES, V39, pD32, DOI [10.1093/nar/gkw1070, 10.1093/nar/gks1195, 10.1093/nar/gkq1079, 10.1093/nar/gkt1030, 10.1093/nar/gkx1094, 10.1093/nar/gkn723, 10.1093/nar/gkp1024, 10.1093/nar/gkr1202]; Blanco-Miguez, BIORXIV, DOI [10.1101/2022.08.22.504593(2022, DOI 10.1101/2022.08.22.504593(2022]; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Buchfink B, 2015, NAT METHODS, V12, P59, DOI 10.1038/nmeth.3176; Cammarota G, 2019, GUT, V68, P2111, DOI 10.1136/gutjnl-2019-319548; Cao Y, 2014, BIOINFORMATICS, V30, P1674, DOI 10.1093/bioinformatics/btu104; Chang JY, 2008, J INFECT DIS, V197, P435, DOI 10.1086/525047; Chehri M, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011706; Csardi G., 2005, INTERJ COMPLEX SYST, P1695; Damman CJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133925; Davar D, 2021, SCIENCE, V371, P595, DOI 10.1126/science.abf3363; de Groot PF, 2017, GUT MICROBES, V8, P253, DOI 10.1080/19490976.2017.1293224; Truong DT, 2017, GENOME RES, V27, P626, DOI 10.1101/gr.216242.116; Ferri M, 2017, CRIT REV FOOD SCI, V57, P2857, DOI 10.1080/10408398.2015.1077192; Feuerstadt P, 2022, NEW ENGL J MED, V386, P220, DOI 10.1056/NEJMoa2106516; Gardiner BJ, 2015, J CLIN MICROBIOL, V53, P626, DOI 10.1128/JCM.02926-14; Goll R, 2020, GUT MICROBES, V12, DOI 10.1080/19490976.2020.1794263; Green JE, 2020, GUT MICROBES, V12, P1, DOI 10.1080/19490976.2020.1854640; Gulati M, 2020, PHARMACOL RES, V159, DOI 10.1016/j.phrs.2020.104954; Hourigan SK, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz379; Hu YJ, 2016, J AUTOIMMUN, V72, P47, DOI 10.1016/j.jaut.2016.05.001; Ianiro G, 2017, CLIN MICROBIOL INFEC, V23, P891, DOI 10.1016/j.cmi.2017.05.005; Ianiro G, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18127-y; Ianiro G, 2019, ANN INTERN MED, V171, P695, DOI 10.7326/M18-3635; Ianiro G, 2019, ALIMENT PHARM THER, V50, P240, DOI 10.1111/apt.15330; Ianiro G, 2018, UNITED EUR GASTROENT, V6, P1232, DOI 10.1177/2050640618780762; Jakobsson HE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009836; Kang DWD, 2019, PEERJ, V7, DOI 10.7717/peerj.7359; Kim S, 2017, IMMUNOL REV, V279, P90, DOI 10.1111/imr.12563; Kong LJ, 2020, GASTROENTEROLOGY, V159, DOI 10.1053/j.gastro.2020.08.045; Kootte RS, 2017, CELL METAB, V26, P611, DOI 10.1016/j.cmet.2017.09.008; Kumar R, 2017, NPJ BIOFILMS MICROBI, V3, DOI 10.1038/s41522-017-0020-7; Lacatusu CM, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16060942; Lang M., 2019, J OPEN SOURCE SOFTW, V4, P1903, DOI [10.21105/joss.01903, DOI 10.21105/JOSS.01903]; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]; Leo S, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8060941; Li SS, 2016, SCIENCE, V352, P586, DOI 10.1126/science.aad8852; Li YX, 2021, INT IMMUNOL, V33, P761, DOI 10.1093/intimm/dxab038; Lloyd-Price J, 2017, NATURE, V550, P61, DOI 10.1038/nature23889; Lozupone CA, 2012, NATURE, V489, P220, DOI 10.1038/nature11550; Mirdita M, 2017, NUCLEIC ACIDS RES, V45, pD170, DOI 10.1093/nar/gkw1081; Moayyedi P, 2015, GASTROENTEROLOGY, V149, P102, DOI 10.1053/j.gastro.2015.04.001; Moss EL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182585; Nurk S, 2017, GENOME RES, V27, P824, DOI 10.1101/gr.213959.116; Olm MR, 2021, NAT BIOTECHNOL, V39, P727, DOI 10.1038/s41587-020-00797-0; Ondov BD, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0997-x; Parks DH, 2015, GENOME RES, V25, P1043, DOI 10.1101/gr.186072.114; Pasolli E, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16438-8; Pasolli E, 2019, CELL, V176, P649, DOI 10.1016/j.cell.2019.01.001; Pasolli E, 2017, NAT METHODS, V14, P1023, DOI 10.1038/nmeth.4468; Pedregosa F, 2011, J MACH LEARN RES, V12, P2825; Podlesny D, 2022, CELL REP MED, V3, DOI 10.1016/j.xcrm.2022.100711; Podlesny D, 2021, INT J MED MICROBIOL, V311, DOI 10.1016/j.ijmm.2021.151483; Quagliariello A, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8101486; Rands CM, 2019, ENVIRON MICROBIOL, V21, P3989, DOI 10.1111/1462-2920.14746; Rossen NG, 2015, GASTROENTEROLOGY, V149, P110, DOI 10.1053/j.gastro.2015.03.045; Scanlan PD, 2014, FEMS MICROBIOL ECOL, V90, P326, DOI 10.1111/1574-6941.12396; Seemann T, 2014, BIOINFORMATICS, V30, P2068, DOI 10.1093/bioinformatics/btu153; Segata N, 2018, MSYSTEMS, V3, DOI 10.1128/mSystems.00190-17; Seymour L, 2017, LANCET ONCOL, V18, pE143, DOI 10.1016/S1470-2045(17)30074-8; Smillie CS, 2018, CELL HOST MICROBE, V23, P229, DOI 10.1016/j.chom.2018.01.003; Smith BJ, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-022-09307-5; Soldi S, 2015, CLIN EXP GASTROENTER, V8, P309, DOI 10.2147/CEG.S89999; Steinegger M, 2017, NAT BIOTECHNOL, V35, P1026, DOI 10.1038/nbt.3988; Suskind DL, 2015, INFLAMM BOWEL DIS, V21, P556, DOI 10.1097/MIB.0000000000000307; Suzek BE, 2015, BIOINFORMATICS, V31, P926, DOI 10.1093/bioinformatics/btu739; Terveer EM, 2020, CLIN INFECT DIS, V71, P2630, DOI 10.1093/cid/ciz1122; Tett A, 2021, NAT REV MICROBIOL, V19, P585, DOI 10.1038/s41579-021-00559-y; Tito RY, 2019, GUT, V68, P1180, DOI 10.1136/gutjnl-2018-316106; Van Rossum T, 2020, NAT REV MICROBIOL, V18, P491, DOI 10.1038/s41579-020-0368-1; Vaughn BP, 2016, INFLAMM BOWEL DIS, V22, P2182, DOI 10.1097/MIB.0000000000000893; Virtanen P, 2020, NAT METHODS, V17, P261, DOI 10.1038/s41592-019-0686-2; Watson A. R., BIORXIV, DOI [10.1101/2021.03.02.433653(2021, DOI 10.1101/2021.03.02.433653(2021]; Weimann A, 2016, MSYSTEMS, V1, DOI 10.1128/mSystems.00101-16; Willmann M, 2019, BMC BIOL, V17, DOI 10.1186/s12915-019-0692-y; Wilson BC, 2021, MICROBIOME, V9, DOI 10.1186/s40168-021-01060-7; Zellmer C, 2021, CLIN INFECT DIS, V72, pE876, DOI 10.1093/cid/ciaa1486; Zhao HJ, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.554441	88	2	2	14	14	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2022	28	9					1913	+		10.1038/s41591-022-01964-3	http://dx.doi.org/10.1038/s41591-022-01964-3		SEP 2022	29	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4S0LI	36109637	Green Published, hybrid			2022-12-27	WOS:000854720900002
J	Tcheandjieu, C; Zhu, X; Hilliard, AT; Clarke, SL; Napolioni, V; Ma, SN; Lee, KM; Fang, HY; Chen, F; Lu, YC; Tsao, NL; Raghavan, S; Koyama, S; Gorman, BR; Vujkovic, M; Klarin, D; Levin, MG; Sinnott-Armstrong, N; Wojcik, GL; Plomondon, ME; Maddox, TM; Waldo, SW; Bick, AG; Pyarajan, S; Huang, J; Song, R; Ho, YL; Buyske, S; Kooperberg, C; Haessler, J; Loos, RJF; Do, R; Verbanck, M; Chaudhary, K; North, KE; Avery, CL; Graff, M; Haiman, CA; Le Marchand, L; Wilkens, LR; Bis, JC; Leonard, H; Shen, BT; Lange, LA; Giri, A; Dikilitas, O; Kullo, IJ; Stanaway, IB; Jarvik, GP; Gordon, AS; Hebbring, S; Namjou, B; Kaufman, KM; Ito, K; Ishigaki, K; Kamatani, Y; Verma, SS; Ritchie, MD; Kember, RL; Baras, A; Lotta, LA; Kathiresan, S; Hauser, ER; Miller, DR; Lee, JS; Saleheen, D; Reaven, PD; Cho, K; Gaziano, JM; Natarajan, P; Huffman, JE; Voight, BF; Rader, DJ; Chang, KM; Lynch, JA; Damrauer, SM; Wilson, PWF; Tang, H; Sun, YV; Tsao, PS; O'Donnell, CJ; Assimes, TL				Tcheandjieu, Catherine; Zhu, Xiang; Hilliard, Austin T.; Clarke, Shoa L.; Napolioni, Valerio; Ma, Shining; Lee, Kyung Min; Fang, Huaying; Chen, Fei; Lu, Yingchang; Tsao, Noah L.; Raghavan, Sridharan; Koyama, Satoshi; Gorman, Bryan R.; Vujkovic, Marijana; Klarin, Derek; Levin, Michael G.; Sinnott-Armstrong, Nasa; Wojcik, Genevieve L.; Plomondon, Mary E.; Maddox, Thomas M.; Waldo, Stephen W.; Bick, Alexander G.; Pyarajan, Saiju; Huang, Jie; Song, Rebecca; Ho, Yuk-Lam; Buyske, Steven; Kooperberg, Charles; Haessler, Jeffrey; Loos, Ruth J. F.; Do, Ron; Verbanck, Marie; Chaudhary, Kumardeep; North, Kari E.; Avery, Christy L.; Graff, Mariaelisa; Haiman, Christopher A.; Le Marchand, Loic; Wilkens, Lynne R.; Bis, Joshua C.; Leonard, Hampton; Shen, Botong; Lange, Leslie A.; Giri, Ayush; Dikilitas, Ozan; Kullo, Iftikhar J.; Stanaway, Ian B.; Jarvik, Gail P.; Gordon, Adam S.; Hebbring, Scott; Namjou, Bahram; Kaufman, Kenneth M.; Ito, Kaoru; Ishigaki, Kazuyoshi; Kamatani, Yoichiro; Verma, Shefali S.; Ritchie, Marylyn D.; Kember, Rachel L.; Baras, Aris; Lotta, Luca A.; Kathiresan, Sekar; Hauser, Elizabeth R.; Miller, Donald R.; Lee, Jennifer S.; Saleheen, Danish; Reaven, Peter D.; Cho, Kelly; Gaziano, J. Michael; Natarajan, Pradeep; Huffman, Jennifer E.; Voight, Benjamin F.; Rader, Daniel J.; Chang, Kyong-Mi; Lynch, Julie A.; Damrauer, Scott M.; Wilson, Peter W. F.; Tang, Hua; Sun, Yan, V; Tsao, Philip S.; O'Donnell, Christopher J.; Assimes, Themistocles L.		Regeneron Genetics Ctr; CARDIoGRAMpIusC4D Consortium; Biobank Japan; Million Vet Program	Large-scale genome-wide association study of coronary artery disease in genetically diverse populations	NATURE MEDICINE			English	Article; Early Access							POLYGENIC RISK SCORES; SUSCEPTIBILITY LOCI; CLINICAL-ASSESSMENT; HEART-DISEASE; DATA QUALITY; HEALTH; HERITABILITY; METAANALYSIS; REGRESSION; PROGRAM	To overcome limitations of previous genome-wide association studies of coronary artery disease, this study incorporates a cohort of individuals containing large fractions of Black and Hispanic individuals to provide a wider view of the genetic landscape of this disease. We report a genome-wide association study (GWAS) of coronary artery disease (CAD) incorporating nearly a quarter of a million cases, in which existing studies are integrated with data from cohorts of white, Black and Hispanic individuals from the Million Veteran Program. We document near equivalent heritability of CAD across multiple ancestral groups, identify 95 novel loci, including nine on the X chromosome, detect eight loci of genome-wide significance in Black and Hispanic individuals, and demonstrate that two common haplotypes at the 9p21 locus are responsible for risk stratification in all populations except those of African origin, in which these haplotypes are virtually absent. Moreover, in the largest GWAS for angiographically derived coronary atherosclerosis performed to date, we find 15 loci of genome-wide significance that robustly overlap with established loci for clinical CAD. Phenome-wide association analyses of novel loci and polygenic risk scores (PRSs) augment signals related to insulin resistance, extend pleiotropic associations of these loci to include smoking and family history, and precisely document the markedly reduced transferability of existing PRSs to Black individuals. Downstream integrative analyses reinforce the critical roles of vascular endothelial, fibroblast, and smooth muscle cells in CAD susceptibility, but also point to a shared biology between atherosclerosis and oncogenesis. This study highlights the value of diverse populations in further characterizing the genetic architecture of CAD.	[Tcheandjieu, Catherine; Zhu, Xiang; Hilliard, Austin T.; Clarke, Shoa L.; Klarin, Derek; Sinnott-Armstrong, Nasa; Lee, Jennifer S.; Tsao, Philip S.; Assimes, Themistocles L.] VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA; [Tcheandjieu, Catherine; Clarke, Shoa L.; Assimes, Themistocles L.] Stanford Univ, Dept Med, Sch Med, Div Cardiovasc Med, Stanford, CA 94305 USA; [Tcheandjieu, Catherine] Gladstone Inst, Gladstone Inst Data Sci & Biotechnol, San Francisco, CA 94158 USA; [Tcheandjieu, Catherine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; [Zhu, Xiang; Ma, Shining] Stanford Univ, Dept Stat, Stanford, CA 94305 USA; [Zhu, Xiang] Penn State Univ, Dept Stat, University Pk, PA 16802 USA; [Zhu, Xiang] Penn State Univ, Huck Inst Life Sci, University Pk, PA 16802 USA; [Napolioni, Valerio] Univ Camerino, Sch Biosci & Vet Med, Camerino, Italy; [Napolioni, Valerio] Stanford Univ, Dept Neurol & Neurol Sci, Sch Med, Stanford, CA 94305 USA; [Lee, Kyung Min] VA Salt Lake City Hlth Care Syst, VA Informat & Comp Infrastruct, Salt Lake City, UT USA; [Fang, Huaying; Sinnott-Armstrong, Nasa; Tang, Hua] Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA; [Chen, Fei; Haiman, Christopher A.] Univ Southern Calif, Ctr Genet Epidemiol, Dept Prevent Med, Los Angeles, CA USA; [Lu, Yingchang] Vanderbilt Univ Sch Med, Vanderbilt Genet Inst, Nashville, TN USA; [Tsao, Noah L.; Damrauer, Scott M.] Univ Penn, Dept Surg, Perelman Sch Med, Philadelphia, PA 19104 USA; [Raghavan, Sridharan] VA Eastern Colorado Hlth Care Syst, Med Serv, Aurora, CO USA; [Raghavan, Sridharan] Univ Colorado, Dept Med, Anschutz Med Campus, Aurora, CO USA; [Koyama, Satoshi; Ito, Kaoru] RIKEN Ctr Integrat Med Sci, Lab Cardiovasc Genom & Informat, Yokohama, Kanagawa, Japan; [Gorman, Bryan R.; Klarin, Derek; Pyarajan, Saiju; Huang, Jie; Song, Rebecca; Ho, Yuk-Lam; Cho, Kelly; Gaziano, J. Michael; Huffman, Jennifer E.; O'Donnell, Christopher J.] VA Boston Healthcare Syst, Boston, MA USA; [Gorman, Bryan R.] Booz Allen Hamilton, Mclean, VA USA; [Vujkovic, Marijana; Levin, Michael G.; Kember, Rachel L.; Saleheen, Danish; Voight, Benjamin F.; Chang, Kyong-Mi; Damrauer, Scott M.] Corporal Michael J Crescenz VA Med Ctr, Philadelphia, PA USA; [Vujkovic, Marijana; Levin, Michael G.; Rader, Daniel J.; Chang, Kyong-Mi] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Klarin, Derek] Massachusetts Gen Hosp, Ctr Genom Med, Boston, MA 02114 USA; [Klarin, Derek; Kathiresan, Sekar; Natarajan, Pradeep] Broad Inst MIT & Harvard, Program Med & Populat Genet, Cambridge, MA 02142 USA; [Klarin, Derek] Univ Florida, Sch Med, Div Vasc Surg & Endovasc Therapy, Gainesville, FL USA; [Klarin, Derek] Stanford Univ, Sch Med, Stanford, CA 94305 USA; [Wojcik, Genevieve L.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Plomondon, Mary E.; Waldo, Stephen W.] Rocky Mt Reg VA Med Ctr, Dept Med, Aurora, CO USA; [Plomondon, Mary E.; Waldo, Stephen W.] VHA Off Qual & Patient Safety, CART Program, Washington, DC USA; [Maddox, Thomas M.] JC HealthCare Washington Univ Sch Med, Healthcare Innovat Lab, St Louis, MO USA; [Maddox, Thomas M.] Washington Univ, Sch Med, Div Cardiol, St Louis, MO USA; [Waldo, Stephen W.] Univ Colorado, Div Cardiol, Sch Med, Aurora, CO USA; [Bick, Alexander G.] Vanderbilt Univ Sch Med, Dept Biomed Informat, Div Genet Med, Nashville, TN USA; [Pyarajan, Saiju; Cho, Kelly; Gaziano, J. Michael; O'Donnell, Christopher J.] Harvard Med Sch, Brigham Womens Hosp, Dept Med, Boston, MA 02115 USA; [Huang, Jie] Peking Univ, Dept Global Hlth, Sch Publ Hlth, Beijing, Peoples R China; [Huang, Jie] Southern Univ Sci & Technol, Sch Publ Hlth & Emergency Management, Shenzhen, Peoples R China; [Buyske, Steven] Rutgers State Univ, Dept Stat, Piscataway, NJ USA; [Kooperberg, Charles; Haessler, Jeffrey] Fred Hutchinson Canc Ctr, Div Publ Hlth Sci, Seattle, WA USA; [Loos, Ruth J. F.; Do, Ron; Verbanck, Marie; Chaudhary, Kumardeep] Icahn Sch Med Mt Sinai, Charles Bronfman Inst Personalized Med, New York, NY 10029 USA; [Do, Ron; Verbanck, Marie; Chaudhary, Kumardeep] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA; [Verbanck, Marie] Univ Paris, EA 7537 BioSTM, Paris, France; [North, Kari E.; Avery, Christy L.; Graff, Mariaelisa] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA; [Le Marchand, Loic; Wilkens, Lynne R.] Univ Hawaii, Univ Hawaii Canc Ctr, Canc Epidemiol Program, Honolulu, HI USA; [Bis, Joshua C.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA; [Leonard, Hampton] NIA, Mol Genet Sect, Lab Neurogenet, Bethesda, MD 20892 USA; [Leonard, Hampton] Data Tecn Intl LLC, Glen Echo, MD USA; [Shen, Botong] NIA, Hlth Dispar Res Sect, NIH, Baltimore, MD 21224 USA; [Lange, Leslie A.] Dept Med, Div Biomed Informat & Personalized Med, Aurora, CO USA; [Lange, Leslie A.] Lifecourse Epidemiol Adipos & Diabet LEAD Ctr, Aurora, CO USA; [Lange, Leslie A.] Univ Colorado, Dept Epidemiol, Colorado Sch Publ Hlth, Anschutz Med Campus, Aurora, CO USA; [Giri, Ayush] Vanderbilt Univ Sch Med, Dept Med, Div Epidemiol, Nashville, TN USA; [Giri, Ayush] Vanderbilt Univ Sch Med, Dept Obstet & Gynecol, Div Quantitat Sci, Nashville, TN USA; [Dikilitas, Ozan; Kullo, Iftikhar J.] Mayo Clin, Dept Cardiovasc Med, Rochester, MN USA; [Stanaway, Ian B.] Univ Washington, Dept Med, Div Nephrol, Seattle, WA USA; [Jarvik, Gail P.] Univ Washington, Sch Med, Dept Med, Med Genet, Seattle, WA 98195 USA; [Jarvik, Gail P.] Univ Washington, Sch Med, Dept Genome Sci, Seattle, WA USA; [Gordon, Adam S.] Northwestern Univ, Ctr Genet Med, Feinberg Sch Med, Chicago, IL 60611 USA; [Hebbring, Scott] Marshfield Clin Res Inst, Ctr Precis Med Res, Marshfield, WI USA; [Namjou, Bahram; Kaufman, Kenneth M.] Cincinnati Childrens Hosp Med Ctr, Ctr Autoimmune Genom & Etiol, Cincinnati, OH 45229 USA; [Namjou, Bahram] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA; [Ishigaki, Kazuyoshi; Kamatani, Yoichiro] RIKEN Ctr Integrat Med Sci, Lab Stat Anal, Yokohama, Kanagawa, Japan; [Kamatani, Yoichiro] Univ Tokyo, Dept Computat Biol & Med Sci, Grad Sch Frontier Sci, Tokyo, Japan; [Verma, Shefali S.; Ritchie, Marylyn D.; Voight, Benjamin F.; Damrauer, Scott M.] Univ Penn, Perelman Sch Med, Dept Genet, Philadelphia, PA 19104 USA; [Verma, Shefali S.; Ritchie, Marylyn D.] Univ Penn, Inst Biomed Informat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Kember, Rachel L.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Baras, Aris; Lotta, Luca A.] Regeneron Genet Ctr, Tarrytown, NY USA; [Kathiresan, Sekar] Harvard Med Sch, Dept Med, Boston, MA 02115 USA; [Kathiresan, Sekar; Natarajan, Pradeep] Massachusetts Gen Hosp, Dept Med, Cardiol Div, Boston, MA 02114 USA; [Kathiresan, Sekar] Verve Therapeut, Cambridge, MA USA; [Hauser, Elizabeth R.] Durham VA Hlth Care Syst, Cooperat Studies Program Epidemiol Ctr Durham, Durham, NC USA; [Hauser, Elizabeth R.] Duke Univ Med Ctr, Dept Biostat & Bioinformat, Durham, NC USA; [Miller, Donald R.] Bedford VA Healthcare Syst, Ctr Healthcare Org & Implementat Res, Bedford, MA USA; [Miller, Donald R.] Univ Massachusetts, Ctr Populat Hlth, Dept Biomed & Nutr Sci, Lowell, MA USA; [Lee, Jennifer S.; Tsao, Philip S.] Stanford Univ, Dept Med, Sch Med, Stanford, CA USA; [Saleheen, Danish] Columbia Univ, Dept Med, Div Cardiol, New York, NY USA; [Reaven, Peter D.] Phoenix VA Hlth Care Syst, Phoenix, AZ USA; [Reaven, Peter D.] Univ Arizona, Coll Med, Phoenix, AZ USA; [Natarajan, Pradeep] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA; [Voight, Benjamin F.] Univ Penn, Perelman Sch Med, Dept Syst Pharmacol & Translat Therapeut, Philadelphia, PA 19104 USA; [Voight, Benjamin F.] Univ Penn, Inst Translat Med & Therapeut, Perelman Sch Med, Philadelphia, PA 19104 USA; [Lynch, Julie A.] VA Salt Lake City Hlth Care Syst, Salt Lake City, UT USA; [Lynch, Julie A.] Univ Massachusetts, Coll Nursing & Hlth Sci, Boston, MA USA; [Wilson, Peter W. F.] Atlanta VA Med Ctr, Atlanta, GA USA; [Wilson, Peter W. F.] Emory Univ, Sch Med, Div Cardiol, Atlanta, GA USA; [Sun, Yan, V] Atlanta VA Hlth Care Syst, Atlanta, GA USA; [Sun, Yan, V] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA; [Tsao, Philip S.; Assimes, Themistocles L.] Stanford Univ, Cardiovasc Inst, Sch Med, Stanford, CA USA; [Assimes, Themistocles L.] Stanford Univ, Sch Med, Dept Epidemiol & Populat Hlth, Stanford, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; Stanford University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Camerino; Stanford University; US Department of Veterans Affairs; Stanford University; University of Southern California; Vanderbilt University; University of Pennsylvania; Pennsylvania Medicine; University of Colorado System; University of Colorado Anschutz Medical Campus; RIKEN; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Booz Allen Hamilton Holding Corporation; University of Pennsylvania; Pennsylvania Medicine; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; State University System of Florida; University of Florida; Stanford University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Washington University (WUSTL); University of Colorado System; University of Colorado Anschutz Medical Campus; Vanderbilt University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Peking University; Southern University of Science & Technology; Rutgers State University New Brunswick; Fred Hutchinson Cancer Center; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; UDICE-French Research Universities; Universite Paris Cite; University of North Carolina; University of North Carolina Chapel Hill; Cancer Research Center of Hawaii; University of Hawaii System; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Colorado School of Public Health; University of Colorado System; University of Colorado Anschutz Medical Campus; Vanderbilt University; Vanderbilt University; Mayo Clinic; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Northwestern University; Feinberg School of Medicine; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; RIKEN; University of Tokyo; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Regeneron; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Duke University; University of Massachusetts System; University of Massachusetts Lowell; Stanford University; Columbia University; University of Arizona; Harvard University; Massachusetts General Hospital; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; University of Massachusetts System; University of Massachusetts Boston; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Atlanta VA Medical Center; Emory University; Emory University; Rollins School Public Health; Stanford University; Stanford University	Tcheandjieu, C; Assimes, TL (corresponding author), VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA.; Tcheandjieu, C; Assimes, TL (corresponding author), Stanford Univ, Dept Med, Sch Med, Div Cardiovasc Med, Stanford, CA 94305 USA.; Tcheandjieu, C (corresponding author), Gladstone Inst, Gladstone Inst Data Sci & Biotechnol, San Francisco, CA 94158 USA.; Tcheandjieu, C (corresponding author), Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.	catherine.tcheandjieu@gladstone.ucsf.edu; tassimes@stanford.edu	Napolioni, Valerio/GNH-5123-2022; Assimes, Themistocles Leonard/D-9696-2015; Huffman, Jennifer/HCH-8105-2022; Chaudhary, Kumardeep/Q-9740-2018; Vujković, Marijana/S-9414-2019	Assimes, Themistocles Leonard/0000-0003-2349-0009; Huffman, Jennifer/0000-0002-9672-2491; Chaudhary, Kumardeep/0000-0002-4117-6403; Vujković, Marijana/0000-0003-4924-5714; Clarke, Shoa/0000-0002-6592-1172; Voight, Benjamin/0000-0002-6205-9994; Hilliard, Austin/0000-0002-1289-4377; Hauser, Elizabeth/0000-0003-0367-9189; Natarajan, Pradeep/0000-0001-8402-7435; Levin, Michael/0000-0002-9937-9932; Shining, Ma/0000-0003-4277-1308	Veterans Administration [01-01BX003362, I01-BX004821, I01-BX003340, VA HSR RES 13-457]; NHGRI; National Institute on Minority Health and Health Disparities (NIMHD); CALiCo [U01HG007416]; ISMMS [U01HG007417]; MEC [U01HG007397]; WHI [U01HG007376, U01HG004790]; Coordinating Center [U01HG007419]; National Heart, Lung, and Blood Institute; National Institutes of Health; US Department of Health and Human Services [HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C, HHSN271201100004C]; ORIP [S10OD028685]; National Heart, Lung, and Blood Institute [HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, HHSN268201100012C]; NHLBI [HHSN268201200036C, HHSN268200800007C, HHSN268201800001C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, 75N92021D00006]; NHLBI grants [U01HL080295, R01HL085251, R01HL087652, R01HL105756, R01HL103612, R01HL120393, U01HL130114]; National Institute of Neurological Disorders and Stroke (NINDS); National Institute on Aging (NIA) [R01AG023629]; CTSI grant [UL1TR001881]; National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) [DK063491]; Tailor-Made Medical Treatment Program of the Ministry of Education, Culture, Sports, Science, and Technology; Japan Agency for Medical Research (AMED) [JP17km0305002, JP17km0305001]; Interlaboratory Proposal Funding of the Intramural Research Program of the National Institute on Aging (NIA), the National Institutes of Health (NIH), Baltimore, Maryland [AG000989]; Stein Fellowship from Stanford University; US Department of Veterans Affairs [IK2-CX001780]; NIH [R56HL150186, R01HL142302, R35GM124836, R01HL139865, R01DK101478]; AMED [JP20km0405209, JP20ek0109487]; NCI [T32CA229110]; NIH/NHLBI [R01HL142711, R01HL148050, R01HL127564, R01HL151152]; NIH/NHGRI [U01HG011719]; Fondation Leducq [TNE-18CVD04]; Massachusetts General Hospital (Fireman Chair); Institute for Computational and Data Sciences Seed Grant from The Pennsylvania State University; the National Human Genome Research Institute (NHGRI) [U01HG8657, U01HG8685, U01HG8672, U01HG8666, U01HG6379, U01HG8679, U01HG8680, U01HG8684, U01HG8673, U01HG8701, U01HG8676, U01HG8664, U01HG006828, U01HG006830, U01HG006389, U01HG006382]; National Human Genome Research Institute (NHGRI) [U01HG006375, U01HG006379, U01HG006380, U01HG006388, U01HG006378, U01HG006385, U01HG004438, U01HG004424, U01-HG-004610, U01-HG-004608, U01-HG-04599, U01HG004609, U01-HG-04603];  [U01 CA164973]	Veterans Administration(US Department of Veterans Affairs); NHGRI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); National Institute on Minority Health and Health Disparities (NIMHD)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); CALiCo; ISMMS; MEC(European Commission); WHI; Coordinating Center; National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Health and Human Services; ORIP; National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI grants; National Institute of Neurological Disorders and Stroke (NINDS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Institute on Aging (NIA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); CTSI grant; National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC); Tailor-Made Medical Treatment Program of the Ministry of Education, Culture, Sports, Science, and Technology; Japan Agency for Medical Research (AMED)(Japan Agency for Medical Research and Development (AMED)); Interlaboratory Proposal Funding of the Intramural Research Program of the National Institute on Aging (NIA), the National Institutes of Health (NIH), Baltimore, Maryland; Stein Fellowship from Stanford University(Stanford University); US Department of Veterans Affairs(US Department of Veterans Affairs); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AMED; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH/NHGRI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); Fondation Leducq(Leducq Foundation); Massachusetts General Hospital (Fireman Chair); Institute for Computational and Data Sciences Seed Grant from The Pennsylvania State University; the National Human Genome Research Institute (NHGRI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); National Human Genome Research Institute (NHGRI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); 	This research is based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration, and was supported by Veterans Administration awards I01-01BX003362, I01-BX004821 (K.-M.C., P.S.T.), I01-BX003340 (K.Cho, P.W.F.W.) and VA HSR RES 13-457 (VA Informatics and Computing Infrastructure). The content of this manuscript does not represent the views of the Department of Veterans Affairs or the United States Government. The eMERGE Network was initiated and funded by the National Human Genome Research Institute (NHGRI) through the following grants: Phase III: U01HG8657 (Kaiser Permanente Washington/University of Washington); U01HG8685 (Brigham and Women's Hospital); U01HG8672 (Vanderbilt University Medical Center); U01HG8666 (Cincinnati Children's Hospital Medical Center); U01HG6379 (Mayo Clinic); U01HG8679 (Geisinger Clinic); U01HG8680 (Columbia University Health Sciences); U01HG8684 (Children's Hospital of Philadelphia); U01HG8673 (Northwestern University); U01HG8701 (Vanderbilt University Medical Center serving as the Coordinating Center); U01HG8676 (Partners Healthcare/Broad Institute); and U01HG8664 (Baylor College of Medicine); Phase II: U01HG006828 (Cincinnati Children's Hospital Medical Center/Boston Children's Hospital); U01HG006830 (Children's Hospital of Philadelphia); U01HG006389 (Essentia Institute of Rural Health, Marshfield Clinic Research Foundation and Pennsylvania State University); U01HG006382 (Geisinger Clinic); U01HG006375 (Group Health Cooperative/University of Washington); U01HG006379 (Mayo Clinic); U01HG006380 (Icahn School of Medicine at Mount Sinai); U01HG006388 (Northwestern University); U01HG006378 (Vanderbilt University Medical Center); and U01HG006385 (Vanderbilt University Medical Center serving as the Coordinating Center). Phase II: U01HG004438 (CIDR) and U01HG004424 (the Broad Institute) serving as Genotyping Centers. Phase I: U01-HG-004610 (Group Health Cooperative/University of Washington); U01-HG-004608 (Marshfield Clinic Research Foundation and Vanderbilt University Medical Center); U01-HG-04599 (Mayo Clinic); U01HG004609 (Northwestern University); U01-HG-04603 (Vanderbilt University Medical Center, also serving as the Administrative Coordinating Center); U01HG004438 (CIDR) and U01HG004424 (the Broad Institute) serving as Genotyping Centers. The Population Architecture Using Genomics and Epidemiology (PAGE) program is funded by the NHGRI with co-funding from the National Institute on Minority Health and Health Disparities (NIMHD), supported by U01HG007416 (CALiCo), U01HG007417 (ISMMS), U01HG007397 (MEC), U01HG007376 (WHI), and U01HG007419 (Coordinating Center). The MultiEthnic Study (MEC) was supported by U01 CA164973. The Women's Health Initiative (WHI) program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services through contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, HHSN268201100004C and HHSN271201100004C. Scientific Computing Infrastructure at Fred Hutch is funded by ORIP grant S10OD028685. Funding support for the 'Exonic variants and their relation to complex traits in minorities of the WHI study is provided through the NHGRI PAGE program (U01HG004790).; The Atherosclerosis Risk in Communities (ARIC) Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C and HHSN268201100012C). The Cardiovascular Health Study (CHS) was supported by NHLBI contracts HHSN268201200036C, HHSN268200800007C, HHSN268201800001C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, 75N92021D00006; and NHLBI grants U01HL080295, R01HL085251, R01HL087652, R01HL105756, R01HL103612, R01HL120393 and U01HL130114 with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through R01AG023629 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR001881, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center. BioBank Japan (BBJ) was supported by the Tailor-Made Medical Treatment Program of the Ministry of Education, Culture, Sports, Science, and Technology and Japan Agency for Medical Research (AMED) under grant numbers JP17km0305002 and JP17km0305001. Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS) was funded by the Interlaboratory Proposal Funding of the Intramural Research Program of the National Institute on Aging (NIA), the National Institutes of Health (NIH), Baltimore, Maryland. Funding number: [AG000989]. X.Z. was supported by the Stein Fellowship from Stanford University and Institute for Computational and Data Sciences Seed Grant from The Pennsylvania State University. S.M.D., J.A.L. and K.M.L. were supported by the US Department of Veterans Affairs (IK2-CX001780). Y.L. is supported by NIH R56HL150186. S.Ko. and K.It. were supported by AMED under Grant Numbers JP20km0405209 and JP20ek0109487. K.E.N. is supported by NIH R01HL142302. R.D. is supported by NIH R35GM124836 and R01HL139865. F.C. is supported by NCI T32CA229110. B.F.V. was supported by the NIH R01DK101478 and a Linda Pechenik Montague Investigator Award. P.N. is supported by grants from the NIH/NHLBI (R01HL142711, R01HL148050, R01HL127564, R01HL151152), NIH/NHGRI (U01HG011719), Fondation Leducq (TNE-18CVD04) and Massachusetts General Hospital (Fireman Chair). Support for title page creation and format was provided by AuthorArranger, a tool developed at the National Cancer Institute. The authors thank C. D. Bustamante for his review and feedback of specific cross-population analyses involving the 9p21 region. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393; Assimes TL, 2016, J AM COLL CARDIOL, V68, P2797, DOI 10.1016/j.jacc.2016.10.039; Bai F, 2014, CANCER RES, V74, P6161, DOI 10.1158/0008-5472.CAN-14-1119; Barbalic M, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002199; Barbeira AN, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03621-1; Bulik-Sullivan BK, 2015, NAT GENET, V47, P291, DOI 10.1038/ng.3211; Buniello A, 2019, NUCLEIC ACIDS RES, V47, pD1005, DOI 10.1093/nar/gky1120; Byrd JB, 2013, AM HEART J, V165, P434, DOI 10.1016/j.ahj.2012.12.009; Centers for Disease Control and Prevention, 2019, HLTH US SPOTL RAC ET; Cheng P, 2022, CIRCULATION, V145, P469, DOI 10.1161/CIRCULATIONAHA.121.057789; Choi SW, 2019, GIGASCIENCE, V8, DOI 10.1093/gigascience/giz082; Churchwell K, 2020, CIRCULATION, V142, pE454, DOI 10.1161/CIR.0000000000000936; Clarke S. L., PREPRINT, DOI [10.1101/2021.06.15.21258993(2022, DOI 10.1101/2021.06.15.21258993(2022]; Clarke SL, 2021, CIRC-GENOM PRECIS ME, V14, DOI 10.1161/CIRCGEN.121.003178; Coram MA, 2015, AM J HUM GENET, V96, P740, DOI 10.1016/j.ajhg.2015.03.008; Das S, 2016, NAT GENET, V48, P1284, DOI 10.1038/ng.3656; de Leeuw CA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06022-6; de Leeuw CA, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004219; Deloukas P, 2013, NAT GENET, V45, P25, DOI 10.1038/ng.2480; Denny JC, 2010, BIOINFORMATICS, V26, P1205, DOI 10.1093/bioinformatics/btq126; Dikilitas O, 2020, AM J HUM GENET, V106, P707, DOI 10.1016/j.ajhg.2020.04.002; Erzurumluoglu AM, 2020, MOL PSYCHIATR, V25, P2392, DOI 10.1038/s41380-018-0313-0; Evangelou E, 2018, NAT GENET, V50, P1412, DOI 10.1038/s41588-018-0205-x; Evans LM, 2018, NAT GENET, V50, P737, DOI 10.1038/s41588-018-0108-x; Fahed AC, 2021, CIRC-GENOM PRECIS ME, V14, DOI 10.1161/CIRCGEN.120.003092; Fang HY, 2019, AM J HUM GENET, V105, P763, DOI 10.1016/j.ajhg.2019.08.012; Fardi M, 2019, J CELL PHYSIOL, V234, P14783, DOI 10.1002/jcp.28277; Fletcher R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095598; Gaziano JM, 2016, J CLIN EPIDEMIOL, V70, P214, DOI 10.1016/j.jclinepi.2015.09.016; Ghuran A, 2001, BMJ-BRIT MED J, V323, P464, DOI 10.1136/bmj.323.7311.464; Giambartolomei C, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004383; Graham SE, 2021, NATURE, V600, P675, DOI 10.1038/s41586-021-04064-3; Hartiala JA, 2021, EUR HEART J, V42, P919, DOI 10.1093/eurheartj/ehaa1040; Huang YF, 2021, CIRC-GENOM PRECIS ME, V14, DOI 10.1161/CIRCGEN.120.003147; Hunter-Zinck H, 2020, AM J HUM GENET, V106, P535, DOI 10.1016/j.ajhg.2020.03.004; Ibrahim N, 2010, CANCER RES, V70, P7155, DOI 10.1158/0008-5472.CAN-10-0668; Inouye M, 2018, J AM COLL CARDIOL, V72, P1883, DOI 10.1016/j.jacc.2018.07.079; Institute for Health Metrics and Evaluation (IHME), 2020, GBD COMP DAT VIS; Ishigaki K, 2020, NAT GENET, V52, P669, DOI 10.1038/s41588-020-0640-3; Khera AV, 2018, NAT GENET, V50, P1219, DOI 10.1038/s41588-018-0183-z; Ko CW, 2020, NAT REV GASTRO HEPAT, V17, P169, DOI 10.1038/s41575-019-0250-7; Koyama S, 2020, NAT GENET, V52, P1169, DOI 10.1038/s41588-020-0705-3; Lee SH, 2012, NAT GENET, V44, P247, DOI 10.1038/ng.1108; Lee SH, 2011, AM J HUM GENET, V88, P294, DOI 10.1016/j.ajhg.2011.02.002; Lettre G, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001300; Liu DJ, 2017, NAT GENET, V49, P1758, DOI 10.1038/ng.3977; Loh PR, 2016, NAT GENET, V48, P1443, DOI 10.1038/ng.3679; Loley C, 2016, SCI REP-UK, V6, DOI 10.1038/srep35278; Lowrie D. J., 2020, HISTOLOGY ESSENTIAL; Lu XF, 2012, NAT GENET, V44, P890, DOI 10.1038/ng.2337; Maddox TM, 2014, AM J CARDIOL, V114, P1750, DOI 10.1016/j.amjcard.2014.08.045; Maddox TM, 2014, JAMA-J AM MED ASSOC, V312, P1754, DOI 10.1001/jama.2014.14681; Magi R, 2017, HUM MOL GENET, V26, P3639, DOI 10.1093/hmg/ddx280; Maples BK, 2013, AM J HUM GENET, V93, P278, DOI 10.1016/j.ajhg.2013.06.020; Martin AR, 2019, NAT GENET, V51, P584, DOI 10.1038/s41588-019-0379-x; McPherson R, 2007, SCIENCE, V316, P1488, DOI 10.1126/science.1142447; Nagao M, 2020, CIRC RES, V126, P517, DOI 10.1161/CIRCRESAHA.119.315968; Natarajan P, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22339-1; National Center for Health Statistics (US), CRUD PERC ALL TYP HE; Nelson CP, 2015, NEW ENGL J MED, V372, P1608, DOI 10.1056/NEJMoa1404881; Nikpay M, 2015, NAT GENET, V47, P1121, DOI 10.1038/ng.3396; Ong JS, 2018, BRIT J CANCER, V118, P1262, DOI 10.1038/s41416-018-0063-4; Peden JF, 2011, NAT GENET, V43, P339, DOI 10.1038/ng.782; Pers TH, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6890; Popejoy AB, 2016, NATURE, V538, P161, DOI 10.1038/538161a; Roth GA, 2020, J AM COLL CARDIOL, V76, P2982, DOI 10.1016/j.jacc.2020.11.010; Salfati E, 2015, CIRC-CARDIOVASC GENE, V8, P803, DOI 10.1161/CIRCGENETICS.114.001071; Shungin D, 2015, NATURE, V518, P187, DOI 10.1038/nature14132; Singh KK, 2013, J THORAC CARDIOV SUR, V146, P949, DOI 10.1016/j.jtcvs.2012.12.064; Soini Y, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-73; Speliotes EK, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001324; Speliotes EK, 2010, NAT GENET, V42, P937, DOI 10.1038/ng.686; Tabas I, 2015, J CELL BIOL, V209, P13, DOI 10.1083/jcb.201412052; van der Harst P, 2018, CIRC RES, V122, P433, DOI [10.1161/CIRCRESAHA.117.312086, 10.1161/circresaha.117.312086]; Visscher PM, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004269; Vujkovic M, 2020, NAT GENET, V52, P680, DOI 10.1038/s41588-020-0637-y; Wainschtein P, 2022, NAT GENET, V54, P263, DOI 10.1038/s41588-021-00997-7; Watanabe K, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01261-5; Webb TR, 2017, J AM COLL CARDIOL, V69, P823, DOI 10.1016/j.jacc.2016.11.056; Wienke A, 2001, Twin Res, V4, P266, DOI 10.1375/twin.4.4.266; Willer CJ, 2013, NAT GENET, V45, P1274, DOI 10.1038/ng.2797; Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340; Wirka RC, 2019, NAT MED, V25, P1280, DOI 10.1038/s41591-019-0512-5; Wu HT, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02240-z; Wu P, 2019, JMIR MED INF, V7, P360, DOI 10.2196/14325; Xiao B., PREPRINT, DOI [10.1101/2022.02.02.22269844(2022, DOI 10.1101/2022.02.02.22269844(2022]; Xue A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04951-w; Yang J, 2015, NAT GENET, V47, P1114, DOI 10.1038/ng.3390; Yengo L, 2018, HUM MOL GENET, V27, P3641, DOI 10.1093/hmg/ddy271; Zdravkovic S, 2002, J INTERN MED, V252, P247, DOI 10.1046/j.1365-2796.2002.01029.x; Zhu X, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06805-x; Zore T, 2018, MOL METAB, V15, P35, DOI 10.1016/j.molmet.2018.04.003	92	7	7	8	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01891-3	http://dx.doi.org/10.1038/s41591-022-01891-3		AUG 2022	33	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3L4UI	35915156	Green Submitted			2022-12-27	WOS:000834757100001
J	Bates, DW; Syrowatka, A				Bates, David W.; Syrowatka, Ania			Harnessing AI in sepsis care	NATURE MEDICINE			English	Editorial Material									[Bates, David W.; Syrowatka, Ania] Brigham & Womens Hosp, Div Gen Internal Med, 75 Francis St, Boston, MA 02115 USA; [Bates, David W.; Syrowatka, Ania] Harvard Med Sch, Boston, MA 02115 USA; [Bates, David W.] Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Bates, DW (corresponding author), Brigham & Womens Hosp, Div Gen Internal Med, 75 Francis St, Boston, MA 02115 USA.; Bates, DW (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.; Bates, DW (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA.	dbates@bwh.harvard.edu						Adams R, 2022, NAT MED, V28, P1455, DOI 10.1038/s41591-022-01894-0; Bauer M, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02950-2; Bedoya AD, 2020, JAMIA OPEN, V3, P252, DOI 10.1093/jamiaopen/ooaa006; Henry KE, 2022, NAT MED, V28, P1447, DOI 10.1038/s41591-022-01895-z; Malone, 2020, DUKE HLTH REFERRING; Perlin JB, 2020, JT COMM J QUAL PATIE, V46, P381, DOI 10.1016/j.jcjq.2020.04.006; Sands KE, 1997, JAMA-J AM MED ASSOC, V278, P234, DOI 10.1001/jama.278.3.234; Wong A, 2021, JAMA INTERN MED, V181, P1065, DOI 10.1001/jamainternmed.2021.2626	8	0	0	2	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2022	28	7					1351	1352		10.1038/s41591-022-01878-0	http://dx.doi.org/10.1038/s41591-022-01878-0		JUL 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3E5PS	35864250				2022-12-27	WOS:000828446700004
J	Wu, T; Cooper, SA; Shah, VH				Wu, Tiffany; Cooper, Shawna A.; Shah, Vijay H.			Omics and AI advance biomarker discovery for liver disease	NATURE MEDICINE			English	Editorial Material								New technologies allow the noninvasive detection and staging of asymptomatic alcohol-associated liver disease; further refinement of this approach could transform clinical management and improve patient outcomes.	[Wu, Tiffany; Shah, Vijay H.] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN 55902 USA; [Cooper, Shawna A.] Mayo Clin, Grad Sch Biomed Sci, Dept Biochem & Mol Biol, Rochester, MN USA	Mayo Clinic; Mayo Clinic	Shah, VH (corresponding author), Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN 55902 USA.	Shah.Vijay@mayo.edu		Cooper, Shawna/0000-0003-2669-7275				Ahn JC, 2022, AM J GASTROENTEROL, V117, P424, DOI 10.14309/ajg.0000000000001617; Ahn JC, 2021, HEPATOLOGY, V73, P2546, DOI 10.1002/hep.31603; Boehm KM, 2022, NAT REV CANCER, V22, P114, DOI 10.1038/s41568-021-00408-3; Forlano R, 2020, CLIN GASTROENTEROL H, V18, P2081, DOI 10.1016/j.cgh.2019.12.025; Galior Kornelia, 2018, Bone Rep, V8, P268, DOI 10.1016/j.bonr.2018.05.003; Ioannou GN, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.15626; Morshid A, 2019, RADIOL-ARTIF INTELL, V1, DOI 10.1148/ryai.2019180021; Niu LL, 2022, NAT MED, V28, P1277, DOI 10.1038/s41591-022-01850-y; Sepanlou SG, 2020, LANCET GASTROENTEROL, V5, P245, DOI 10.1016/S2468-1253(19)30349-8; Singal AK, 2021, JAMA-J AM MED ASSOC, V326, P165, DOI 10.1001/jama.2021.7683; Yip TCF, 2017, ALIMENT PHARM THER, V46, P447, DOI 10.1111/apt.14172	11	1	1	13	14	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2022	28	6					1131	1132		10.1038/s41591-022-01853-9	http://dx.doi.org/10.1038/s41591-022-01853-9		JUN 2022	2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2E9IE	35710988				2022-12-27	WOS:000811980700009
J	Misteli, T; Spector, DL				Misteli, T; Spector, DL			Applications of the green fluorescent protein in cell biology and biotechnology	NATURE BIOTECHNOLOGY			English	Review						fluorescence; protein localization; gene expression; screening	LIVING CELLS; BUDDING YEAST; GFP; EXPRESSION; VISUALIZATION; MUTATIONS; REPORTER	The recent emergence of an autofluorescent protein, the green fluorescent protein (GFP), has opened the door for the convenient use of intact living cells and organisms as experimental systems in fields ranging from cell biology to biomedicine. We present an overview of some of the major applications of GFP, namely its use in protein tagging and in monitoring gene expression as well as its potential in a variety of biological screens.			Misteli, T (corresponding author), COLD SPRING HARBOR LAB, POB 100, COLD SPRING HARBOR, NY 11724 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042694] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM042694] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Chishima T, 1997, CANCER RES, V57, P2042; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; Connolly JB, 1996, SCIENCE, V274, P2104, DOI 10.1126/science.274.5295.2104; Cormack BP, 1997, MICROBIOL-UK, V143, P303, DOI 10.1099/00221287-143-2-303; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; DellArciprete R, 1996, J HISTOCHEM CYTOCHEM, V44, P629, DOI 10.1177/44.6.8666748; Dorsky DI, 1996, J ACQ IMMUN DEF SYND, V13, P308, DOI 10.1097/00042560-199612010-00002; Gervaix A, 1997, P NATL ACAD SCI USA, V94, P4653, DOI 10.1073/pnas.94.9.4653; Haseloff J, 1997, P NATL ACAD SCI USA, V94, P2122, DOI 10.1073/pnas.94.6.2122; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; KAETHER C, 1995, FEBS LETT, V369, P267, DOI 10.1016/0014-5793(95)00765-2; KAHANA J, 1996, CUR PROT MOL BIOL; KAHANA JA, 1995, P NATL ACAD SCI USA, V92, P9707, DOI 10.1073/pnas.92.21.9707; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; OLSON KR, 1995, J CELL BIOL, V130, P639, DOI 10.1083/jcb.130.3.639; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Palm GJ, 1997, NAT STRUCT BIOL, V4, P361, DOI 10.1038/nsb0597-361; Peel AL, 1997, GENE THER, V4, P16, DOI 10.1038/sj.gt.3300358; Phillips MI, 1997, HYPERTENSION, V29, P374, DOI 10.1161/01.HYP.29.1.374; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; PRASHER DC, 1995, TRENDS GENET, V11, P320, DOI 10.1016/S0168-9525(00)89090-3; Robinett CC, 1996, J CELL BIOL, V135, P1685, DOI 10.1083/jcb.135.6.1685; Romoser VA, 1997, J BIOL CHEM, V272, P13270, DOI 10.1074/jbc.272.20.13270; Sawin KE, 1996, P NATL ACAD SCI USA, V93, P15146, DOI 10.1073/pnas.93.26.15146; Shelby RD, 1996, J CELL BIOL, V135, P545, DOI 10.1083/jcb.135.3.545; Siemering KR, 1996, CURR BIOL, V6, P1653, DOI 10.1016/S0960-9822(02)70789-6; Straight AF, 1996, CURR BIOL, V6, P1599, DOI 10.1016/S0960-9822(02)70783-5; Straight AF, 1997, SCIENCE, V277, P574, DOI 10.1126/science.277.5325.574; Subramanian S, 1996, J BIOTECHNOL, V49, P137, DOI 10.1016/0168-1656(96)01536-2; Takada T, 1997, NAT BIOTECHNOL, V15, P458, DOI 10.1038/nbt0597-458; Wachter RM, 1997, BIOCHEMISTRY-US, V36, P9759, DOI 10.1021/bi970563w; Wacker I, 1997, J CELL SCI, V110, P1453; WANG SX, 1994, NATURE, V369, P400, DOI 10.1038/369400a0; Webb CD, 1997, CELL, V88, P667, DOI 10.1016/S0092-8674(00)81909-1; Wilson LE, 1997, BIOTECHNIQUES, V22, P674, DOI 10.2144/97224st02; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246; ZernickaGoetz M, 1997, DEVELOPMENT, V124, P1133; ZernickaGoetz M, 1996, DEVELOPMENT, V122, P3719; Zolotukhin S, 1996, J VIROL, V70, P4646, DOI 10.1128/JVI.70.7.4646-4654.1996	45	288	372	6	111	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1997	15	10					961	964		10.1038/nbt1097-961	http://dx.doi.org/10.1038/nbt1097-961			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XZ285	9335045				2022-12-27	WOS:A1997XZ28500024
J	Mascarenhas, D				Mascarenhas, D			Sustaining biotechnology education initiatives	NATURE BIOTECHNOLOGY			English	Article									CELTRIX PHARMACEUT INC,RES,SANTA CLARA,CA 95052		Mascarenhas, D (corresponding author), BABEC,SAN FRANCISCO,CA, USA.								0	2	3	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1997	15	9					850	851		10.1038/nbt0997-850	http://dx.doi.org/10.1038/nbt0997-850			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XW410	9306397				2022-12-27	WOS:A1997XW41000024
J	Holliger, P; Wing, M; Pound, JD; Bohlen, H; Winter, G				Holliger, P; Wing, M; Pound, JD; Bohlen, H; Winter, G			Retargeting serum immunoglobulin with bispecific diabodies	NATURE BIOTECHNOLOGY			English	Article						antibody engineering; diabody; immunotherapy	PHAGOCYTE RESPIRATORY BURST; AFFINITY HUMAN-ANTIBODIES; FC-GAMMA-RI; MONOCLONAL-ANTIBODIES; CELLS; PHAGE; REPERTOIRE; FRAGMENTS; THERAPY; CHAINS	Monospecific antibody fragments produced in bacteria lack the Fc portion of antibodies, and are therefore unable to recruit natural effector functions. We describe the use of a bispecific antibody fragment (diabody) to recruit the whole spectrum of antibody effector functions by retargeting serum immunoglobulin (Ig). One arm of the diabody was directed against the target antigen, and the other against the serum Ig. The bispecific diabodies were able to recruit complement, induce mononuclear phagocyte respiratory burst and phagocytosis, and promote synergistic cytotoxicity towards colon carcinoma cells in conjunction with CD8(+) T-cells, Further, by virtue of binding to serum Ig their half-life (beta-phase) was increased fivefold compared to a control diabody of the same molecular weight. Such bispecific diabodies may provide an attractive alternative to monoclonal antibodies for serotherapy.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,NEUROL UNIT,CAMBRIDGE CB2 2QQ,ENGLAND; UNIV BIRMINGHAM,SCH MED,DEPT IMMUNOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV COLOGNE,INNERE MED KLIN 1,D-50931 COLOGNE,GERMANY; MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Birmingham; University of Cologne; MRC Laboratory Molecular Biology	Holliger, P (corresponding author), MRC,CTR PROT ENGN,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.							BOHLEN H, 1994, J IMMUNOL METHODS, V173, P55, DOI 10.1016/0022-1759(94)90283-6; BRUGGEMANN M, 1989, J EXP MED, V170, P2153, DOI 10.1084/jem.170.6.2153; CHESTER KA, 1994, LANCET, V343, P455, DOI 10.1016/S0140-6736(94)92695-6; CLARKSON T, 1991, NATURE, V352, P624; CUMBER AJ, 1992, J IMMUNOL, V149, P120; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; Holliger P, 1996, PROTEIN ENG, V9, P299, DOI 10.1093/protein/9.3.299; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; Holliger Philipp, 1993, Current Opinion in Biotechnology, V4, P446, DOI 10.1016/0958-1669(93)90010-T; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; KING DJ, 1994, CANCER RES, V54, P6176; Low NM, 1996, J MOL BIOL, V260, P359, DOI 10.1006/jmbi.1996.0406; MARKS JD, 1992, BIO-TECHNOL, V10, P779, DOI 10.1038/nbt0792-779; McGuinness BT, 1996, NAT BIOTECHNOL, V14, P1149, DOI 10.1038/nbt0996-1149; MCINTIRE K R, 1970, Federation Proceedings, V29, P704; Neri D, 1996, BIOTECHNIQUES, V20, P708; NEUBERGER MS, 1985, NATURE, V314, P268, DOI 10.1038/314268a0; NEUBERGER MS, 1984, NATURE, V312, P604, DOI 10.1038/312604a0; NOSE M, 1983, P NATL ACAD SCI-BIOL, V80, P6632, DOI 10.1073/pnas.80.21.6632; PERELSON AS, 1989, IMMUNOL REV, V110, P5, DOI 10.1111/j.1600-065X.1989.tb00025.x; PERESICS O, 1994, STRUCTURE, V2, P1218; POUND JD, 1993, MOL IMMUNOL, V30, P233, DOI 10.1016/0161-5890(93)90052-D; POUND JD, 1993, MOL IMMUNOL, V30, P469, DOI 10.1016/0161-5890(93)90115-R; RETH M, 1979, EUR J IMMUNOL, V9, P1004, DOI 10.1002/eji.1830091216; RIECHMANN L, 1988, NATURE, V332, P323, DOI 10.1038/332323a0; SMITHGILL SJ, 1984, J IMMUNOL, V132, P963; TOMLINSON S, 1993, CURR OPIN IMMUNOL, V5, P83, DOI 10.1016/0952-7915(93)90085-7; TUTT A, 1991, J IMMUNOL, V147, P60; WALDMANN TA, 1991, SCIENCE, V252, P1657, DOI 10.1126/science.2047874; WALKER MR, 1989, BIOCHEM J, V259, P347, DOI 10.1042/bj2590347; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; YOKOTA T, 1992, CANCER RES, V52, P3402	34	69	86	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUL	1997	15	7					632	636		10.1038/nbt0797-632	http://dx.doi.org/10.1038/nbt0797-632			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XH583	9219264				2022-12-27	WOS:A1997XH58300025
J	Persidis, A				Persidis, A			The carbohydrate-based drug industry - Whether used as a target or a tool, carbohydrates face manufacturing challenges before they can realize their true value.	NATURE BIOTECHNOLOGY			English	Editorial Material											Persidis, A (corresponding author), ARGONEX INC,2044 INDIA RD,CHARLOTTESVILLE,VA 22901, USA.							BEDNARSKI M, 1991, ACS SERIES, V446; *BIOV IND REV CO D, 1997, CARB THER; Boons GJ, 1996, DRUG DISCOV TODAY, V1, P331, DOI 10.1016/1359-6446(96)10031-3; BORMAN S, 1994, CHEM ENG NEWS, V72, P37; Dwek RA, 1996, CHEM REV, V96, P683, DOI 10.1021/cr940283b; FRECHET JM, 1971, J AM CHEM SOC, V93, P492; PERSIDIS A, 1995, BIO-TECHNOL, V13, P1172, DOI 10.1038/nbt1195-1172; Persidis A, 1997, NAT BIOTECHNOL, V15, P391, DOI 10.1038/nbt0497-391; Rouhi M, 1996, CHEM ENG NEWS, V74, P4	9	15	16	0	3	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1997	15	5					479	480		10.1038/nbt0597-479	http://dx.doi.org/10.1038/nbt0597-479			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WX237	9131631				2022-12-27	WOS:A1997WX23700036
J	Takada, T; Iida, K; Awaji, T; Itoh, K; Takahashi, R; Shibui, A; Yoshida, K; Sugano, S; Tsujimoto, G				Takada, T; Iida, K; Awaji, T; Itoh, K; Takahashi, R; Shibui, A; Yoshida, K; Sugano, S; Tsujimoto, G			Selective production of transgenic mice using green fluorescent protein as a marker	NATURE BIOTECHNOLOGY			English	Article						transgenic mice; gene integration; embryo selection; green fluorescent protein	ELONGATION FACTOR-1-ALPHA; EMBRYOS; GENE; PROMOTER; INVITRO	The low efficiency of transgenic animal production by microinjection has been a serious problem especially for the production of transgenic livestock. We developed a method to selectively produce transgenic mice using green fluorescent protein (GFP) as a marker. Using this method, we obtained eight fetuses and four live-born mice derived from 55 GFP-positive blastocysts. PCR analysis showed II out of 12 mice (fetuses and newborn mice) were transgenic. Southern blot analysis showed that 8 out of 12 were transgenic. GFP expression was also observed in bovine blastocysts, suggesting that this method should contribute to the efficient production of transgenic livestock.	YS NEW TECHNOL INST INC,ISHIBASHI,TOCHIGI 32905,JAPAN; UNIV TOKYO,INST MED SCI,DEPT VIROL,TOKYO 108,JAPAN	University of Tokyo	Takada, T (corresponding author), NATL CHILDRENS MED RES CTR,TOKYO 154,JAPAN.			Shibui, Akiko/0000-0002-0428-5336				BRACKETT BG, 1975, BIOL REPROD, V12, P260, DOI 10.1095/biolreprod12.2.260; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; HAMMER RE, 1985, NATURE, V315, P680, DOI 10.1038/315680a0; HANAOKA K, 1991, DIFFERENTIATION, V48, P183, DOI 10.1111/j.1432-0436.1991.tb00256.x; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HOGAN B, 1994, MANIPULATING MOUSE E, P232; IKAWA M, 1995, FEBS LETT, V375, P125, DOI 10.1016/0014-5793(95)01162-8; IKAWA M, 1995, DEV GROWTH DIFFER, V37, P455, DOI 10.1046/j.1440-169X.1995.t01-2-00012.x; KIM DW, 1990, GENE, V91, P217, DOI 10.1016/0378-1119(90)90091-5; KING D, 1988, Molecular Reproduction and Development, V1, P57, DOI 10.1002/mrd.1080010109; NINOMIYA T, 1989, Molecular Reproduction and Development, V1, P242, DOI 10.1002/mrd.1080010404; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OSHIMA M, 1995, CANCER RES, V55, P2719; TAKAHASHI Y, 1992, THERIOGENOLOGY, V37, P963, DOI 10.1016/0093-691X(92)90096-A; THOMPSON EM, 1995, P NATL ACAD SCI USA, V92, P1317, DOI 10.1073/pnas.92.5.1317; UETSUKI T, 1989, J BIOL CHEM, V264, P5791	18	110	122	0	9	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1997	15	5					458	461		10.1038/nbt0597-458	http://dx.doi.org/10.1038/nbt0597-458			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WX237	9131626				2022-12-27	WOS:A1997WX23700031
J	Turajlic, S				Turajlic, Samra			Why I pivoted from COVID-19 back to cancer research	NATURE MEDICINE			English	Editorial Material								The COVID-19 pandemic showed what can be achieved with clear goals, less bureaucracy and enough funding - important lessons for cancer research.	[Turajlic, Samra] Francis Crick Inst, Canc Dynam Lab, London, England; [Turajlic, Samra] Royal Marsden NHS Fdn Trust, Renal & Skin Units, London, England; [Turajlic, Samra] Inst Canc Res, Melanoma & Kidney Canc Team, London, England	Francis Crick Institute; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Turajlic, S (corresponding author), Francis Crick Inst, Canc Dynam Lab, London, England.; Turajlic, S (corresponding author), Royal Marsden NHS Fdn Trust, Renal & Skin Units, London, England.; Turajlic, S (corresponding author), Inst Canc Res, Melanoma & Kidney Canc Team, London, England.	samra.turajlic@crick.ac.uk							0	0	0	4	4	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2022	28	9					1750	1750		10.1038/s41591-022-01994-x	http://dx.doi.org/10.1038/s41591-022-01994-x		SEP 2022	1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4S0LI	36109643	Bronze			2022-12-27	WOS:000854720900007
J	Gogishvili, M; Melkadze, T; Makharadze, T; Giorgadze, D; Dvorkin, M; Penkov, K; Laktionov, K; Nemsadze, G; Nechaeva, M; Rozhkova, I; Kalinka, E; Gessner, C; Moreno-Jaime, B; Passalacqua, R; Li, SY; McGuire, K; Kaul, M; Paccaly, A; Quek, RGW; Gao, B; Seebach, F; Weinreich, DM; Yancopoulos, GD; Lowy, I; Gullo, G; Rietschel, P				Gogishvili, Miranda; Melkadze, Tamar; Makharadze, Tamta; Giorgadze, Davit; Dvorkin, Mikhail; Penkov, Konstantin; Laktionov, Konstantin; Nemsadze, Gia; Nechaeva, Marina; Rozhkova, Irina; Kalinka, Ewa; Gessner, Christian; Moreno-Jaime, Brizio; Passalacqua, Rodolfo; Li, Siyu; McGuire, Kristina; Kaul, Manika; Paccaly, Anne; Quek, Ruben G. W.; Gao, Bo; Seebach, Frank; Weinreich, David M.; Yancopoulos, George D.; Lowy, Israel; Gullo, Giuseppe; Rietschel, Petra			Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial	NATURE MEDICINE			English	Article; Early Access							1ST-LINE TREATMENT; OPEN-LABEL; MONOTHERAPY	First-line cemiplimab (anti-programmed cell death-1 (PD-1)) monotherapy has previously shown significant improvement in overall survival (OS) and progression-free survival (PFS) versus chemotherapy in patients with advanced non-small cell lung cancer (aNSCLC) and PD-ligand 1 (PD-L1) expression >= 50%. EMPOWER-Lung 3 (NCT03409614), a double-blind, placebo-controlled, phase 3 study, examined cemiplimab plus platinum-doublet chemotherapy as first-line treatment for aNSCLC, irrespective of PD-L1 expression or histology. In this study, 466 patients with stage III/IV aNSCLC without EGFR, ALK or ROS1 genomic tumor aberrations were randomized (2:1) to receive cemiplimab 350 mg (n = 312) or placebo (n =154) every 3 weeks for up to 108 weeks in combination with four cycles of platinum-doublet chemotherapy (followed by pemetrexed maintenance as indicated). In total, 57.1% (266/466 patients) had non-squamous NSCLC, and 85.2% (397/466 patients) had stage IV disease. The primary endpoint was OS. The trial was stopped early per recommendation of the independent data monitoring committee, based on meeting preset OS efficacy criteria: median OS was 21.9 months (95% confidence interval (CI), 15.5-not evaluable) with cemiplimab plus chemotherapy versus 13.0 months (95% CI, 11.9-16.1) with placebo plus chemotherapy (hazard ratio (HR) = 0.71; 95% CI, 0.53-0.93; P=0.014). Grade >= 3 adverse events occurred with cemiplimab plus chemotherapy (43.6%,136/312 patients) and placebo plus chemotherapy (31.4%, 48/153 patients). Cemiplimab is only the second anti-PD-1/PD-L1 agent to show efficacy in aNSCLC as both monotherapy and in combination with chemotherapy for both squamous and non-squamous histologies.	[Gogishvili, Miranda] Univ Clin Ltd, High Technol Med Ctr, Tbilisi, Georgia; [Melkadze, Tamar] Acad F Todua Med Ctr, Tbilisi, Georgia; [Makharadze, Tamta] LTD High Technol Hosp, Med Ctr, Batumi, Georgia; [Giorgadze, Davit] David Tvildiani Med Univ, Tbilisi, Georgia; [Dvorkin, Mikhail] State Budgetary Healthcare Inst Omsk Reg, Omsk, Russia; [Penkov, Konstantin] Private Med Inst Euromedserv, St Petersburg, Russia; [Laktionov, Konstantin] Minist Hlth Russian Federat, Fed State Budgetary Inst, NN Blokhin Natl Med Res Ctr Oncol, Moscow, Russia; [Nemsadze, Gia] Inst Clin Oncol, Tbilisi, Georgia; [Nechaeva, Marina] Chelyabinsk Reg Clin Oncol Ctr, Chelyabinsk, Russia; [Rozhkova, Irina] Kaluga Reg Clin Oncol Dispensary, Kaluga, Russia; [Kalinka, Ewa] Polish Mothers Mem Hosp, Res Inst, Lodz, Poland; [Gessner, Christian] POIS Leipzig GbR, Leipzig, Germany; [Gessner, Christian] Univ Leipzig, Inst Clin Immunol, Leipzig, Germany; [Moreno-Jaime, Brizio] Hosp Reg ISSSTE, Leon, Mexico; [Passalacqua, Rodolfo] Ist Ospitalieri Cremona, Cremona, Italy; [Li, Siyu; McGuire, Kristina; Kaul, Manika; Paccaly, Anne; Quek, Ruben G. W.; Gao, Bo; Seebach, Frank; Weinreich, David M.; Yancopoulos, George D.; Lowy, Israel; Gullo, Giuseppe; Rietschel, Petra] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA	Ministry of Health of the Russian Federation; Polish Mother's Memorial Hospital - Research Institute; Leipzig University; Regeneron	Gogishvili, M (corresponding author), Univ Clin Ltd, High Technol Med Ctr, Tbilisi, Georgia.	mirandagogishvili@yahoo.com		Gogishvili, Miranda/0000-0002-5143-6379; Kalinka, Ewa/0000-0003-4791-8372	Regeneron Pharmaceuticals; Sanofi	Regeneron Pharmaceuticals(Regeneron); Sanofi	The authors thank the patients, their families, all other investigators and all investigational site members involved in this study. This study was funded by Regeneron Pharmaceuticals and Sanofi. Medical writing support under the direction of the authors was provided by J. Lee of Prime (Knutsford, United Kingdom) and funded by Regeneron Pharmaceuticals, according to Good Publication Practice guidelines (https://doi.org/10.7326/M15-0288).The sponsor was involved in the study design and in the collection, analysis and interpretation of data as well as data checking of information provided in the manuscript. The authors had unrestricted access to study data, were responsible for all content and editorial decisions and received no honoraria related to the development of this publication.	Bristol Myers Squibb, 2020, YERVOY IP INJ INTR U; Burova E, 2017, MOL CANCER THER, V16, P861, DOI 10.1158/1535-7163.MCT-16-0665; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Genentech Inc, TECENTRIQ ATEZOLIZUM; Gettinger S, 2016, J CLIN ONCOL, V34, P2980, DOI 10.1200/JCO.2016.66.9929; Herbst RS, 2020, NEW ENGL J MED, V383, P1328, DOI 10.1056/NEJMoa1917346; Merck & Co. Inc, 2017, EUROPEAN COMMISSION; Merck Sharp & Dohme Corp, KEYTRUDA PEMBR INJ I; Migden MR, 2018, NEW ENGL J MED, V379, P341, DOI 10.1056/NEJMoa1805131; National Comprehensive Cancer Network, CLIN PRACTICE GUIDEL; Osoba D, 1998, J CLIN ONCOL, V16, P139, DOI 10.1200/JCO.1998.16.1.139; Paz-Ares L, 2018, NEW ENGL J MED, V379, P2040, DOI 10.1056/NEJMoa1810865; Paz-Ares L, 2021, LANCET ONCOL, V22, P198, DOI 10.1016/S1470-2045(20)30641-0; Regeneron Pharmaceuticals Inc, LIBTAYO CEM RWLC INJ; Sezer A, 2021, LANCET, V397, P592, DOI 10.1016/S0140-6736(21)00228-2; Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660; Tsao MS, 2018, J THORAC ONCOL, V13, P1302, DOI 10.1016/j.jtho.2018.05.013	17	1	1	3	3	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01977-y	http://dx.doi.org/10.1038/s41591-022-01977-y		AUG 2022	15	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3Z7NO	36008722	Green Published, hybrid			2022-12-27	WOS:000844603700001
J	Yang, YZ; Yuan, Y; Zhang, G; Wang, H; Chen, YC; Liu, YC; Tarolli, CG; Crepeau, D; Bukartyk, J; Junna, MR; Videnovic, A; Ellis, TD; Lipford, MC; Dorsey, R; Katabi, D				Yang, Yuzhe; Yuan, Yuan; Zhang, Guo; Wang, Hao; Chen, Ying-Cong; Liu, Yingcheng; Tarolli, Christopher G.; Crepeau, Daniel; Bukartyk, Jan; Junna, Mithri R.; Videnovic, Aleksandar; Ellis, Terry D.; Lipford, Melissa C.; Dorsey, Ray; Katabi, Dina			Artificial intelligence-enabled detection and assessment of Parkinson's disease using nocturnal breathing signals	NATURE MEDICINE			English	Article; Early Access							CEREBROSPINAL-FLUID; FLUCTUATIONS; DYSFUNCTION; PROGRESSION; BETA; EEG	Using a neural network-based model, Parkinson's disease can be diagnosed and its severity monitored based on breathing patterns while someone is asleep, with the potential for at-home touchless monitoring. There are currently no effective biomarkers for diagnosing Parkinson's disease (PD) or tracking its progression. Here, we developed an artificial intelligence (AI) model to detect PD and track its progression from nocturnal breathing signals. The model was evaluated on a large dataset comprising 7,671 individuals, using data from several hospitals in the United States, as well as multiple public datasets. The AI model can detect PD with an area-under-the-curve of 0.90 and 0.85 on held-out and external test sets, respectively. The AI model can also estimate PD severity and progression in accordance with the Movement Disorder Society Unified Parkinson's Disease Rating Scale (R = 0.94, P = 3.6 x 10(-25)). The AI model uses an attention layer that allows for interpreting its predictions with respect to sleep and electroencephalogram. Moreover, the model can assess PD in the home setting in a touchless manner, by extracting breathing from radio waves that bounce off a person's body during sleep. Our study demonstrates the feasibility of objective, noninvasive, at-home assessment of PD, and also provides initial evidence that this AI model may be useful for risk assessment before clinical diagnosis.	[Yang, Yuzhe; Yuan, Yuan; Zhang, Guo; Wang, Hao; Chen, Ying-Cong; Liu, Yingcheng; Katabi, Dina] MIT, Dept Elect Engn & Comp Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA; [Wang, Hao] Rutgers State Univ, Dept Comp Sci, Piscataway, NJ USA; [Tarolli, Christopher G.; Dorsey, Ray] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA; [Tarolli, Christopher G.; Dorsey, Ray] Univ Rochester, Med Ctr, Ctr Hlth & Technol, Rochester, NY 14642 USA; [Crepeau, Daniel] Mayo Clin, Dept Neurol, Rochester, MN USA; [Bukartyk, Jan] Mayo Clin, Div Cardiovasc Dis, Rochester, MN USA; [Junna, Mithri R.; Lipford, Melissa C.] Mayo Clin, Dept Neurol, Rochester, MN USA; [Junna, Mithri R.; Lipford, Melissa C.] Mayo Clin, Ctr Sleep Med, Div Pulm & Crit Care Med, Rochester, MN USA; [Videnovic, Aleksandar] Massachusetts Gen Hosp, Div Sleep Med, Boston, MA 02114 USA; [Videnovic, Aleksandar] Massachusetts Gen Hosp, Div Movement Disorders, Boston, MA 02114 USA; [Ellis, Terry D.] Boston Univ, Coll Hlth & Rehabil, Ctr Neurorehabil, Dept Phys Therapy & Athlet Training,Sargent Coll, Boston, MA 02215 USA; [Katabi, Dina] Emerald Innovat Inc, Cambridge, MA USA	Massachusetts Institute of Technology (MIT); Rutgers State University New Brunswick; University of Rochester; University of Rochester; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Boston University	Yang, YZ; Yuan, Y (corresponding author), MIT, Dept Elect Engn & Comp Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	yuzhe@mit.edu; miayuan@mit.edu	Chen, Ying-Cong/ABE-3123-2020	Chen, Ying-Cong/0000-0002-9565-8205; Yuan, Yuan/0000-0002-6609-0542; Yang, Yuzhe/0000-0002-7634-8295; Liu, Yingcheng/0000-0001-7356-0699	National Institutes of Health [P50NS108676]; National Science Foundation [2014391]; Michael J. Fox Foundation [15069]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); Michael J. Fox Foundation	We are grateful to L. Xing, J. Yang, M. Zhang, M. Ji, G. Li, L. Shi, R. Hristov, H. Rahul, M. Zhao, S. Yue, H. He, T. Li, L. Fan, M. Ouroutzoglou, K. Zha, P. Cao and H. Davidge for their comments on our manuscript. We also thank all the individuals who participated in our study. Y. Yang, Y. Yuan, G.Z. and D.K. are funded by National Institutes of Health (P50NS108676) and National Science Foundation (2014391). H.W. is funded by Michael J. Fox Foundation (15069). Y.-C.C., Y.L., C.G.T. and R.D. are funded by National Institutes of Health (P50NS108676).	Adib F, 2015, CHI 2015: PROCEEDINGS OF THE 33RD ANNUAL CHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS, P837, DOI 10.1145/2702123.2702200; Armstrong MJ, 2020, JAMA-J AM MED ASSOC, V323, P548, DOI 10.1001/jama.2019.22360; Athauda D, 2015, NAT REV NEUROL, V11, P25, DOI 10.1038/nrneurol.2014.226; Baille G, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190400; Baille G, 2016, J PARKINSON DIS, V6, P463, DOI 10.3233/JPD-160804; Benarroch EE, 2003, BRAIN, V126, P2183, DOI 10.1093/brain/awg220; Blackwell T, 2011, J AM GERIATR SOC, V59, P2217, DOI 10.1111/j.1532-5415.2011.03731.x; Boser B. E., 1992, Proceedings of the Fifth Annual ACM Workshop on Computational Learning Theory, P144, DOI 10.1145/130385.130401; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Brunner H, 2002, MOVEMENT DISORD, V17, P928, DOI 10.1002/mds.10242; Delenclos M, 2016, PARKINSONISM RELAT D, V22, pS106, DOI 10.1016/j.parkreldis.2015.09.048; Dorsey ER, 2018, J PARKINSON DIS, V8, pS3, DOI 10.3233/JPD-181474; Gonzalez-Naranjo JE, 2019, BEHAV SCI-BASEL, V9, DOI 10.3390/bs9010006; Ellis TD, 2016, PARKINSONISM RELAT D, V25, P65, DOI 10.1016/j.parkreldis.2016.02.006; Evers LJW, 2019, MOVEMENT DISORD, V34, P1480, DOI 10.1002/mds.27790; Goetz CG, 2008, MOVEMENT DISORD, V23, P2129, DOI 10.1002/mds.22340; Guttman L., 1945, PSYCHOMETRIKA, V10, P255, DOI [10.1007/BF02288892, DOI 10.1007/BF02288892]; Hauser RA, 2000, CLIN NEUROPHARMACOL, V23, P75, DOI 10.1097/00002826-200003000-00003; He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90; Heck DH, 2017, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00115; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; Jankovic J, 2008, J NEUROL NEUROSUR PS, V79, P368, DOI 10.1136/jnnp.2007.131045; Kieburtz K, 2018, MOVEMENT DISORD, V33, P920, DOI 10.1002/mds.27220; Klassen BT, 2011, NEUROLOGY, V77, P118, DOI 10.1212/WNL.0b013e318224af8d; LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539; Lei T., 2018, P 2018 C EMP METH NA, P4470, DOI DOI 10.18653/V1/D18-1477; Marras C, 2018, NPJ PARKINSON DIS, V4, DOI 10.1038/s41531-018-0058-0; Mestre TA, 2021, J PARKINSON DIS, V11, P395, DOI 10.3233/JPD-202472; Newcombe RG, 1998, STAT MED, V17, P857, DOI 10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E; Noble WS, 2006, NAT BIOTECHNOL, V24, P1565, DOI 10.1038/nbt1206-1565; Parkinson J, 2002, J NEUROPSYCH CLIN N, V14, P223, DOI 10.1176/appi.neuropsych.14.2.223; Parnetti L, 2019, LANCET NEUROL, V18, P573, DOI 10.1016/S1474-4422(19)30024-9; Parnetti L, 2017, MOVEMENT DISORD, V32, P1423, DOI 10.1002/mds.27136; Platt JC, 2000, ADV NEUR IN, P61; Pokusa M, 2020, PHYSIOL RES, V69, pS69, DOI 10.33549/physiolres.934405; Quan SF, 1997, SLEEP, V20, P1077; Railo H., PREPRINT, DOI [10.1101/2020.05.08.084343(2020, DOI 10.1101/2020.05.08.084343(2020]; Regnault A, 2019, J NEUROL, V266, P1927, DOI 10.1007/s00415-019-09348-3; Ronneberger O., 2015, P INT C MED IM COM, P234, DOI DOI 10.1007/978-3-319-24574-4_28; Seccombe LM, 2011, RESP PHYSIOL NEUROBI, V179, P300, DOI 10.1016/j.resp.2011.09.012; Shichao Yue, 2020, Proceedings of the ACM on Interactive, Mobile, Wearable and Ubiquitous Technologies, V4, DOI 10.1145/3397311; Shichao Yue, 2018, Proceedings of the ACM on Interactive, Mobile, Wearable and Ubiquitous Technologies, V2, DOI 10.1145/3214289; SOIKKELI R, 1991, ELECTROEN CLIN NEURO, V79, P159, DOI 10.1016/0013-4694(91)90134-P; Tang Y, 2017, NEUROSCI LETT, V645, P1, DOI 10.1016/j.neulet.2017.02.056; Torsney KM, 2017, J ROY COLL PHYS EDIN, V47, P35, DOI 10.4997/JRCPE.2017.108; Wang Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116123; WELCH PD, 1967, IEEE T ACOUST SPEECH, VAU15, P70, DOI 10.1109/TAU.1967.1161901; Willis AW, 2011, NEUROLOGY, V77, P851, DOI 10.1212/WNL.0b013e31822c9123; Yang WY, 2020, NPJ PARKINSONS DIS, V6, DOI 10.1038/s41531-020-0117-1; Yang YZ, 2021, PR MACH LEARN RES, V139; Zahed H, 2021, MOVEMENT DISORD, V36, P1526, DOI 10.1002/mds.28562; Zhang J, 2013, ACTA NEUROPATHOL, V126, P671, DOI 10.1007/s00401-013-1121-x; Zhang L, 2020, IEEE INTERNET THINGS, V7, P1178, DOI 10.1109/JIOT.2019.2953488; Zhao MM, 2017, PR MACH LEARN RES, V70	54	0	0	27	27	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01932-x	http://dx.doi.org/10.1038/s41591-022-01932-x		AUG 2022	25	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3X2YG	35995955	Green Published, hybrid			2022-12-27	WOS:000842907100001
J	Hagey, RJ; Elazar, M; Pham, EA; Tian, SQ; Ben-Avi, L; Bernardin-Souibgui, C; Yee, MF; Moreira, FR; Rabinovitch, MV; Meganck, RM; Fram, B; Beck, A; Gibson, SA; Lam, G; Devera, J; Kladwang, W; Nguyen, K; Xiong, AM; Schaffert, S; Avisar, T; Liu, P; Rustagi, A; Fichtenbaum, CJ; Pang, PS; Khatri, P; Tseng, CT; Taubenberger, JK; Blish, CA; Hurst, BL; Sheahan, TP; Das, R; Glenn, JS				Hagey, Rachel J.; Elazar, Menashe; Pham, Edward A.; Tian, Siqi; Ben-Avi, Lily; Bernardin-Souibgui, Claire; Yee, Matthew F.; Moreira, Fernando R.; Rabinovitch, Meirav Vilan; Meganck, Rita M.; Fram, Benjamin; Beck, Aimee; Gibson, Scott A.; Lam, Grace; Devera, Josephine; Kladwang, Wipapat; Nguyen, Khanh; Xiong, Anming; Schaffert, Steven; Avisar, Talia; Liu, Ping; Rustagi, Arjun; Fichtenbaum, Carl J.; Pang, Phillip S.; Khatri, Purvesh; Tseng, Chien-Te; Taubenberger, Jeffery K.; Blish, Catherine A.; Hurst, Brett L.; Sheahan, Timothy P.; Das, Rhiju; Glenn, Jeffrey S.			Programmable antivirals targeting critical conserved viral RNA secondary structures from influenza A virus and SARS-CoV-2	NATURE MEDICINE			English	Article							LOCKED NUCLEIC-ACID; INFERRING BASE-PAIRS; ROBUST ANALYSIS; MAP STRATEGY; SHAPE; SEGMENTS; OLIGONUCLEOTIDES; OSELTAMIVIR; RIBONUCLEOPROTEIN; RESISTANT	Influenza A virus's (IAV's) frequent genetic changes challenge vaccine strategies and engender resistance to current drugs. We sought to identify conserved and essential RNA secondary structures within IAV's genome that are predicted to have greater constraints on mutation in response to therapeutic targeting. We identified and genetically validated an RNA structure (packaging stem-loop 2 (PSL2)) that mediates in vitro packaging and in vivo disease and is conserved across all known IAV isolates. A PSL2-targeting locked nucleic acid (LNA), administered 3 d after, or 14 d before, a lethal IAV inoculum provided 100% survival in mice, led to the development of strong immunity to rechallenge with a tenfold lethal inoculum, evaded attempts to select for resistance and retained full potency against neuraminidase inhibitor-resistant virus. Use of an analogous approach to target SARS-CoV-2, prophylactic administration of LNAs specific for highly conserved RNA structures in the viral genome, protected hamsters from efficient transmission of the SARS-CoV-2 USA_WA1/2020 variant. These findings highlight the potential applicability of this approach to any virus of interest via a process we term 'programmable antivirals', with implications for antiviral prophylaxis and post-exposure therapy. Targeting conserved secondary structure of RNA viruses offers the potential for a customizable therapeutic approach to viral variants.	[Hagey, Rachel J.; Elazar, Menashe; Pham, Edward A.; Glenn, Jeffrey S.] Stanford Med, ViRx Stanford, Stanford, CA 94305 USA; [Hagey, Rachel J.; Glenn, Jeffrey S.] Stanford Univ, Dept Microbiol & Immunol, Sch Med, Stanford, CA 94305 USA; [Hagey, Rachel J.; Elazar, Menashe; Pham, Edward A.; Ben-Avi, Lily; Bernardin-Souibgui, Claire; Yee, Matthew F.; Rabinovitch, Meirav Vilan; Fram, Benjamin; Lam, Grace; Devera, Josephine; Nguyen, Khanh; Xiong, Anming; Avisar, Talia; Liu, Ping; Pang, Phillip S.; Glenn, Jeffrey S.] Stanford Univ, Dept Med, Div Gastroenterol & Hepatol, Sch Med, Stanford, CA 94305 USA; [Tian, Siqi; Kladwang, Wipapat; Das, Rhiju] Stanford Univ, Dept Biochem, Stanford, CA 94305 USA; [Moreira, Fernando R.; Meganck, Rita M.; Sheahan, Timothy P.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA; [Beck, Aimee; Rustagi, Arjun; Blish, Catherine A.] Stanford Univ, Dept Med, Div Infect Dis & Geog Med, Stanford, CA 94305 USA; [Gibson, Scott A.; Hurst, Brett L.] Utah State Univ, Dept Anim Dairy & Vet Sci, Inst Antiviral Res, Logan, UT 84322 USA; [Schaffert, Steven; Khatri, Purvesh] Stanford Univ, Dept Med, Biomed Informat Res, Sch Med, Stanford, CA 94305 USA; [Fichtenbaum, Carl J.] Univ Cincinnati, Coll Med, Dept Internal Med, Div Infect Dis, Cincinnati, OH USA; [Tseng, Chien-Te] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA; [Tseng, Chien-Te] Univ Texas Med Branch, Ctr Biodef & Emerging Dis, Galveston Natl Lab, Galveston, TX 77555 USA; [Taubenberger, Jeffery K.] NIAID, Viral Pathogenesis & Evolut Sect, Lab Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Blish, Catherine A.] Chan Zuckerberg Biohub, San Francisco, CA USA; [Das, Rhiju] Stanford Univ, Dept Phys, Stanford, CA 94305 USA; [Glenn, Jeffrey S.] Vet Adm Med Ctr, Palo Alto, CA 94304 USA	Stanford University; Stanford University; Stanford University; University of North Carolina; University of North Carolina Chapel Hill; Stanford University; Utah System of Higher Education; Utah State University; Stanford University; University System of Ohio; University of Cincinnati; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Glenn, JS (corresponding author), Stanford Med, ViRx Stanford, Stanford, CA 94305 USA.; Glenn, JS (corresponding author), Stanford Univ, Dept Microbiol & Immunol, Sch Med, Stanford, CA 94305 USA.; Glenn, JS (corresponding author), Stanford Univ, Dept Med, Div Gastroenterol & Hepatol, Sch Med, Stanford, CA 94305 USA.; Glenn, JS (corresponding author), Vet Adm Med Ctr, Palo Alto, CA 94304 USA.	jeffrey.glenn@stanford.edu		Rustagi, Arjun/0000-0002-6921-1012; Schaffert, Steven/0000-0001-8842-0218; Ben-Avi, Lily/0000-0003-0154-3341; Khatri, Purvesh/0000-0002-4143-4708; Yee, Matthew/0000-0001-5354-9820; Das, Rhiju/0000-0001-7497-0972; Blish, Catherine/0000-0001-6946-7627; Meganck, Rita/0000-0003-2799-3754	Mona M. Burgess Stanford BIO-X Interdisciplinary Graduate Fellowship; National Institutes of Health (NIH) Graduate Training Grant [5T32AI007328-24]; NIH Training Grant [5T32DK007056]; NIH [R56A1111460, U19A1109662, RO1AI132191, U19AI171421]; US Army Medical Research Acquisition Activity, Department of Defense [W81XWH1810647]; Open Philanthropy and Good Ventures Fund; COVID-19 Harrington Scholar Innovator Grant; Fastgrants; Dr. Tri Cao Nguyen Fund for Pandemic Preparedness; Intramural Research Program of the National Institute of Allergy and Infectious Diseases, NIH	Mona M. Burgess Stanford BIO-X Interdisciplinary Graduate Fellowship; National Institutes of Health (NIH) Graduate Training Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH Training Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Army Medical Research Acquisition Activity, Department of Defense(United States Department of Defense); Open Philanthropy and Good Ventures Fund; COVID-19 Harrington Scholar Innovator Grant; Fastgrants; Dr. Tri Cao Nguyen Fund for Pandemic Preparedness; Intramural Research Program of the National Institute of Allergy and Infectious Diseases, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank H. Jin and her team at MedImmune for the kind donation of chicken eggs and technical guidance at the start of the project. We thank the Stanford in vitro BSL-3 Service Center and its director J. Garhyan for assistance with the SARS-CoV-2 research. We thank additional members of R.D.'s lab, I. N. Zheludev, R. Rangan and H. Wayment-Steele, for meaningful discussions of the SARS-CoV-2 structures and design of original SARS-CoV-2 RNA constructs for SHAPE experiments. The work was supported in part by a Mona M. Burgess Stanford BIO-X Interdisciplinary Graduate Fellowship (to R.J.H.), the National Institutes of Health (NIH) Graduate Training Grant (no. 5T32AI007328-24 to R.J.H.), NIH Training Grant (no. 5T32DK007056 to E.A.P.) and the following grants to J.S.G.: NIH research grants (nos. R56A1111460, U19A1109662, RO1AI132191 and U19AI171421), an influenza Harrington Scholar Innovator grant and grant no. W81XWH1810647 from the US Army Medical Research Acquisition Activity, Department of Defense, Open Philanthropy and Good Ventures Fund, Fastgrants, a COVID-19 Harrington Scholar Innovator Grant and the Dr. Tri Cao Nguyen Fund for Pandemic Preparedness. The work was also supported in part by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, NIH. The data presented in this manuscript are tabulated in the main paper and the supplementary materials. Chemical-mapping datasets for M2 and M2R experiments have been deposited at the RMDB (http://rmdb.stanford.edu).	Akbari A, 2008, ELECTROPHORESIS, V29, P1273, DOI 10.1002/elps.200700523; [Anonymous], 2019, INFL TREATM; [Anonymous], 2022, SARS COV 2 VAR CLASS; Bloom JD, 2010, SCIENCE, V328, P1272, DOI 10.1126/science.1187816; COMPANS RW, 1972, J VIROL, V10, P795, DOI 10.1128/JVI.10.4.795-800.1972; Cordero P, 2014, METHODS MOL BIOL, V1086, P53, DOI 10.1007/978-1-62703-667-2_4; Cordero P, 2012, BIOINFORMATICS, V28, P3006, DOI 10.1093/bioinformatics/bts554; Darty K, 2009, BIOINFORMATICS, V25, P1974, DOI 10.1093/bioinformatics/btp250; De Rijk P, 2003, BIOINFORMATICS, V19, P299, DOI 10.1093/bioinformatics/19.2.299; Deigan KE, 2009, P NATL ACAD SCI USA, V106, P97, DOI 10.1073/pnas.0806929106; Dinnon KH, 2021, NATURE, DOI 10.1038/s41586-020-03107-5; Fournier E, 2012, NUCLEIC ACIDS RES, V40, P2197, DOI 10.1093/nar/gkr985; Gao QS, 2012, J VIROL, V86, P7043, DOI 10.1128/JVI.00662-12; Gavazzi C, 2013, NUCLEIC ACIDS RES, V41, P1241, DOI 10.1093/nar/gks1181; Giannecchini S, 2009, ARCH VIROL, V154, P821, DOI 10.1007/s00705-009-0380-2; Gog JR, 2007, NUCLEIC ACIDS RES, V35, P1897, DOI 10.1093/nar/gkm087; Hai R, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3854; Hayden FG, 2011, J INFECT DIS, V203, P6, DOI 10.1093/infdis/jiq012; Hillebrand F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051088; Hoffmann E, 2000, P NATL ACAD SCI USA, V97, P6108, DOI 10.1073/pnas.100133697; Hou YXJ, 2020, CELL, V182, P429, DOI 10.1016/j.cell.2020.05.042; Hurt AC, 2012, J INFECT DIS, V206, P148, DOI 10.1093/infdis/jis337; Hutchinson EC, 2010, J GEN VIROL, V91, P313, DOI 10.1099/vir.0.017608-0; Javanbakht H, 2018, MOL THER-NUCL ACIDS, V11, P441, DOI 10.1016/j.omtn.2018.02.005; Kawakami E, 2011, J VIROL METHODS, V173, P1, DOI 10.1016/j.jviromet.2010.12.014; Kim H, 2013, NUCLEIC ACIDS RES, V41, pW492, DOI 10.1093/nar/gkt501; Kim J, 2009, BIOINFORMATICS, V25, P1137, DOI 10.1093/bioinformatics/btp110; Kladwang W, 2014, BIOCHEMISTRY-US, V53, P3063, DOI 10.1021/bi5003426; Kladwang W, 2011, NAT CHEM, V3, P954, DOI [10.1038/nchem.1176, 10.1038/NCHEM.1176]; Kladwang W, 2011, RNA, V17, P522, DOI 10.1261/rna.2516311; Kladwang W, 2010, BIOCHEMISTRY-US, V49, P7414, DOI 10.1021/bi101123g; Kurreck J, 2002, NUCLEIC ACIDS RES, V30, P1911, DOI 10.1093/nar/30.9.1911; Liang YH, 2008, J VIROL, V82, P229, DOI 10.1128/JVI.01541-07; Marsh GA, 2008, J VIROL, V82, P2295, DOI 10.1128/JVI.02267-07; Marsh GA, 2007, J VIROL, V81, P9727, DOI 10.1128/JVI.01144-07; Mathews DH, 2004, P NATL ACAD SCI USA, V101, P7287, DOI 10.1073/pnas.0401799101; Memoli MJ, 2010, CLIN INFECT DIS, V50, P1252, DOI 10.1086/651605; Mortimer SA, 2007, J AM CHEM SOC, V129, P4144, DOI 10.1021/ja0704028; Mortimer SA, 2009, NAT PROTOC, V4, P1413, DOI 10.1038/nprot.2009.126; Moss WN, 2011, RNA, V17, P991, DOI 10.1261/rna.2619511; Muramoto Y, 2006, J VIROL, V80, P2318, DOI 10.1128/JVI.80.5.2318-2325.2006; Noda T, 2010, REV MED VIROL, V20, P380, DOI 10.1002/rmv.666; Palese P., 2007, FIELDS VIROLOGY, P1647; Pang PS, 2012, J VIROL, V86, P1250, DOI 10.1128/JVI.06367-11; Pang PS, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr773; Priore SF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035989; Rangan R, 2020, RNA, V26, P937, DOI 10.1261/rna.076141.120; Romero-Lopez C, 2013, REV MED VIROL, V23, P340, DOI 10.1002/rmv.1756; Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883; Staedel C, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.18; Straarup EM, 2010, NUCLEIC ACIDS RES, V38, P7100, DOI 10.1093/nar/gkq457; Balish Amanda L, 2013, Curr Protoc Microbiol, VChapter 15, DOI [10.1002/0471729256.mc15g01s3, 10.1002/9780471729259.mc15g01s29]; Takashita E, 2019, EUROSURVEILLANCE, V24, P18, DOI 10.2807/1560-7917.ES.2019.24.3.1800698; Tian SQ, 2014, RNA, V20, P1815, DOI 10.1261/rna.044321.114; Vester B, 2004, BIOCHEMISTRY-US, V43, P13233, DOI 10.1021/bi0485732; Wang R, 2021, CELL, V184, P106, DOI 10.1016/j.cell.2020.12.004; Wilkinson KA, 2006, NAT PROTOC, V1, P1610, DOI 10.1038/nprot.2006.249; Yoon S, 2011, BIOINFORMATICS, V27, P1798, DOI 10.1093/bioinformatics/btr277	58	3	3	8	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2022	28	9					1944	+		10.1038/s41591-022-01908-x	http://dx.doi.org/10.1038/s41591-022-01908-x		AUG 2022	19	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	4S0LI	35982307	Bronze			2022-12-27	WOS:000842362900001
J	Kephart, JL; Sanchez, BN; Moore, J; Schinasi, LH; Bakhtsiyarava, M; Ju, Y; Gouveia, N; Caiaffa, WT; Dronova, I; Arunachalam, S; Roux, AVD; Rodriguez, DA				Kephart, Josiah L.; Sanchez, Brisa N.; Moore, Jeffrey; Schinasi, Leah H.; Bakhtsiyarava, Maryia; Ju, Yang; Gouveia, Nelson; Caiaffa, Waleska T.; Dronova, Iryna; Arunachalam, Saravanan; Roux, Ana V. Diez; Rodriguez, Daniel A.			City-level impact of extreme temperatures and mortality in Latin America	NATURE MEDICINE			English	Article; Early Access							HEAT-RELATED MORTALITY; AIR-POLLUTION; SAO-PAULO; VULNERABILITY; METAANALYSIS; PROJECTIONS; CLIMATE; COLD	Climate change and urbanization are rapidly increasing human exposure to extreme ambient temperatures, yet few studies have examined temperature and mortality in Latin America. We conducted a nonlinear, distributed-lag, longitudinal analysis of daily ambient temperatures and mortality among 326 Latin American cities between 2002 and 2015. We observed 15,431,532 deaths among approximate to 2.9 billion person-years of risk. The excess death fraction of total deaths was 0.67% (95% confidence interval (CI) 0.58-0.74%) for heat-related deaths and 5.09% (95% CI 4.64-5.47%) for cold-related deaths. The relative risk of death was 1.057 (95% CI 1.046-1.067%) per 1 degrees C higher temperature during extreme heat and 1.034 (95% CI 1.028-1.040%) per 1 degrees C lower temperature during extreme cold. In Latin American cities, a substantial proportion of deaths is attributable to nonoptimal ambient temperatures. Marginal increases in observed hot temperatures are associated with steep increases in mortality risk. These risks were strongest among older adults and for cardiovascular and respiratory deaths. An ecological analysis of 326 cities in 9 countries across Latin America found that changes in ambient temperature have a substantial contribution to all-cause mortality, with small increases in extreme heat associated with steep increases in mortality risk.	[Kephart, Josiah L.; Schinasi, Leah H.; Roux, Ana V. Diez] Drexel Dornsife Sch Publ Hlth, Urban Hlth Collaborat, Philadelphia, PA 19104 USA; [Sanchez, Brisa N.; Moore, Jeffrey; Roux, Ana V. Diez] Drexel Dornsife Sch Publ Hlth, Dept Epidemiol & Biostat, Philadelphia, PA USA; [Schinasi, Leah H.] Drexel Dornsife Sch Publ Hlth3, Dept Environm & Occupat Hlth, Philadelphia, PA USA; [Bakhtsiyarava, Maryia; Rodriguez, Daniel A.] Univ Calif Berkeley, Dept City & Reg Planning, Berkeley, CA 94720 USA; [Bakhtsiyarava, Maryia; Rodriguez, Daniel A.] Univ Calif Berkeley, Inst Transportat Studies, Berkeley, CA 94720 USA; [Ju, Yang] Nanjing Univ, Sch Architecture & Urban Planning, Nanjing, Peoples R China; [Gouveia, Nelson] Univ Sao Paulo, Dept Prevent Med, Med Sch, Sao Paulo, Brazil; [Caiaffa, Waleska T.] Univ Fed Minas Gerais, Observ Saude Urbana Belo Horizonte, Belo Horizonte, MG, Brazil; [Dronova, Iryna] Univ Calif Berkeley, Dept Environm Sci Policy & Management, Berkeley, CA 94720 USA; [Dronova, Iryna] Univ Calif Berkeley, Dept Landscape Architecture & Environm Planning, Berkeley, CA 94720 USA; [Arunachalam, Saravanan] Univ N Carolina, Inst Environm, Chapel Hill, NC 27515 USA	Drexel University; Drexel University; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Nanjing University; Universidade de Sao Paulo; Universidade Federal de Minas Gerais; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of North Carolina; University of North Carolina Chapel Hill	Kephart, JL (corresponding author), Drexel Dornsife Sch Publ Hlth, Urban Hlth Collaborat, Philadelphia, PA 19104 USA.	jlk465@drexel.edu	Bakhtsiyarava, Maryia/GPS-5031-2022; Gouveia, Nelson C/C-4580-2013; RODRIGUEZ, Daniel/GWC-3563-2022	Bakhtsiyarava, Maryia/0000-0001-5327-4556; Gouveia, Nelson C/0000-0003-0625-0265; Ju, Yang/0000-0002-1947-7533; Kephart, Josiah L/0000-0003-2556-4892	Wellcome Trust [216029/Z/19/Z, 205177/Z/16/Z]	Wellcome Trust(Wellcome Trust)	The present study was financially supported by the Wellcome Trust (grant nos. 216029/Z/19/Z to D.A.R. and 205177/Z/16/Z to A.V.D.R.). We thank R. Li for creating the accompanying interactive web application to visualize results and X. Delclos-Alio for his contributions to the study design and coordination. We thank all the SALURBAL project team members for their contribution. For more information on SALURBAL and to see a full list of investigators, go to https://drexel.edu/lac/salurbal/team.SALURBAL acknowledges the contributions of many different agencies in generating, processing, facilitating access to data or assisting with other aspects of the project. Please visit https://drexel.edu/lac/data-evidence for a complete list of data sources. The funding sources had no role in the analysis, writing or decision to submit the manuscript.	[Anonymous], 2021, INT STAT CLASS DIS R; [Anonymous], 2020, WHO METHODS DATA SOU; Arbuthnott K, 2016, ENVIRON HEALTH-GLOB, V15, DOI 10.1186/s12940-016-0102-7; Armstrong BG, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-122; Bell ML, 2008, INT J EPIDEMIOL, V37, P796, DOI 10.1093/ije/dyn094; Benmarhnia T, 2015, EPIDEMIOLOGY, V26, P781, DOI 10.1097/EDE.0000000000000375; Broadbent AM, 2020, P NATL ACAD SCI USA, V117, P21108, DOI 10.1073/pnas.2005492117; Buckley JP, 2014, EPIDEMIOLOGY, V25, P242, DOI 10.1097/EDE.0000000000000051; Burkart KG, 2021, LANCET, V398, P685, DOI 10.1016/S0140-6736(21)01700-1; Burr R.E, 2002, MED ASPECTS HARSH EN, V1, P351; Chen K, 2018, ENVIRON INT, V116, P186, DOI 10.1016/j.envint.2018.04.021; Chesini F, 2019, CAD SAUDE PUBLICA, V35, DOI [10.1590/0102-311x00165218, 10.1590/0102-311X00165218]; Diseases and Injuries Collaborators, 2020, LANCET, V396, P1204, DOI [10.1016/S0140-6736(20)30925-9, DOI 10.1016/S0140-6736(20)30925-9]; Ebi KL, 2021, LANCET, V398, P698, DOI 10.1016/S0140-6736(21)01208-3; Feron S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44614-4; Gasparrini A, 2012, STAT MED, V31, P3821, DOI 10.1002/sim.5471; Gasparrini A, 2015, LANCET, V386, P369, DOI 10.1016/S0140-6736(14)62114-0; Gasparrini A, 2017, LANCET PLANET HEALTH, V1, pE360, DOI 10.1016/S2542-5196(17)30156-0; Gasparrini A, 2014, STAT MED, V33, P881, DOI 10.1002/sim.5963; Gasparrini A, 2011, J STAT SOFTW, V43, P1, DOI 10.18637/jss.v043.i08; Gouveia N, 2003, INT J EPIDEMIOL, V32, P390, DOI 10.1093/ije/dyg077; Gouveia N, 2021, SCI TOTAL ENVIRON, V772, DOI 10.1016/j.scitotenv.2021.145035; Green H, 2019, ENVIRON RES, V171, P80, DOI 10.1016/j.envres.2019.01.010; Guo YM, 2014, EPIDEMIOLOGY, V25, P781, DOI 10.1097/EDE.0000000000000165; Hersbach H., 2018, ERA5 HOURLY DATA SIN, DOI [10.24381/cds.adbb2d47, DOI 10.24381/CDS.ADBB2D47]; Intergovernmental Panel on Climate Change (IPCC), 2014, CLIMATE CHANGE 2014, P1048; Jesdale BM, 2013, ENVIRON HEALTH PERSP, V121, P811, DOI 10.1289/ehp.1205919; Kassambara Alboukadel, 2020, CRAN; Lay CR, 2021, LANCET PLANET HEALTH, V5, pE338, DOI 10.1016/S2542-5196(21)00058-9; Lofgren E, 2007, J VIROL, V81, P5429, DOI 10.1128/JVI.01680-06; Martinez-Solanas E, 2021, LANCET PLANET HEALTH, V5, pE446, DOI 10.1016/S2542-5196(21)00150-9; Mendez-Lazaro PA, 2018, INT J BIOMETEOROL, V62, P699, DOI 10.1007/s00484-016-1291-z; Munoz-Sabater J, 2021, EARTH SYST SCI DATA, V13, P4349, DOI 10.5194/essd-13-4349-2021; N. N. C. f. E. Information, 2020, STAT CLIM GLOB CLIM; Quistberg DA, 2019, J URBAN HEALTH, V96, P311, DOI 10.1007/s11524-018-00326-0; Reid CE, 2012, ENVIRON HEALTH PERSP, V120, P1627, DOI 10.1289/ehp.1205251; Roux AVD, 2019, GLOB CHALL, V3, DOI 10.1002/gch2.201800013; ROWELL LB, 1983, CIRC RES, V52, P367, DOI 10.1161/01.RES.52.4.367; Scheelbeek PFD, 2021, ENVIRON RES LETT, V16, DOI 10.1088/1748-9326/ac092c; Son JY, 2016, INT J BIOMETEOROL, V60, P113, DOI 10.1007/s00484-015-1009-7; Steenland K, 2022, J EXPO SCI ENV EPID, V32, P590, DOI 10.1038/s41370-021-00393-7; Tuholske C, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2024792118; Turner H., 2020, GEN NONLINEAR MODELS; UNDESA, 2019, DEP EC SOCIAL AFFAIR; United Nations Department of Economic and Social Affairs Population Division, 2018, WORLD URB PROSP 2018; Weinberger KR, 2020, ENVIRON EPIDEMIOL, V4, DOI 10.1097/EE9.0000000000000096; Weinberger Kate R, 2019, Environ Epidemiol, V3, pe072, DOI 10.1097/EE9.0000000000000072; Zeng WL, 2022, ENVIRON RES, V203, DOI 10.1016/j.envres.2021.111834; Zhao L, 2014, NATURE, V511, P216, DOI 10.1038/nature13462; Zhao Q, 2021, LANCET PLANET HEALTH, V5, pE415, DOI 10.1016/S2542-5196(21)00081-4	50	6	6	19	19	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.												10.1038/s41591-022-01872-6	http://dx.doi.org/10.1038/s41591-022-01872-6		JUN 2022	10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	2L4UE	35760859	Green Published, hybrid			2022-12-27	WOS:000817012300003
J	Harari, S; Tahor, M; Rutsinsky, N; Meijer, S; Miller, D; Henig, O; Halutz, O; Levytskyi, K; Ben-Ami, R; Adler, A; Paran, Y; Stern, A				Harari, Sheri; Tahor, Maayan; Rutsinsky, Natalie; Meijer, Suzy; Miller, Danielle; Henig, Oryan; Halutz, Ora; Levytskyi, Katia; Ben-Ami, Ronen; Adler, Amos; Paran, Yael; Stern, Adi			Drivers of adaptive evolution during chronic SARS-CoV-2 infections	NATURE MEDICINE			English	Article							RECEPTOR-BINDING DOMAIN; TARGET	In some immunocompromised patients with chronic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, considerable adaptive evolution occurs. Some substitutions found in chronic infections are lineage-defining mutations in variants of concern (VOCs), which has led to the hypothesis that VOCs emerged from chronic infections. In this study, we searched for drivers of VOC-like emergence by consolidating sequencing results from a set of 27 chronic infections. Most substitutions in this set reflected lineage-defining VOC mutations; however, a subset of mutations associated with successful global transmission was absent from chronic infections. We further tested the ability to associate antibody evasion mutations with patient-specific and virus-specific features and found that viral rebound is strongly correlated with the emergence of antibody evasion. We found evidence for dynamic polymorphic viral populations in most patients, suggesting that a compromised immune system selects for antibody evasion in particular niches in a patient's body. We suggest that a tradeoff exists between antibody evasion and transmissibility and that extensive monitoring of chronic infections is necessary to further understanding of VOC emergence. Analysis of mutations that arise in chronic SARS-CoV-2 infections shows both overlap and differences with mutations present in pandemic viral variants of concern, highlighting their distinct drivers of evolution.	[Harari, Sheri; Tahor, Maayan; Rutsinsky, Natalie; Miller, Danielle; Stern, Adi] Tel Aviv Univ, Shmunis Sch Biomed & Canc Res, Tel Aviv, Israel; [Harari, Sheri; Miller, Danielle; Stern, Adi] Tel Aviv Univ, Edmond J Safra Ctr Bioinformat, Tel Aviv, Israel; [Meijer, Suzy; Henig, Oryan; Levytskyi, Katia; Ben-Ami, Ronen; Adler, Amos; Paran, Yael] Tel Aviv Sourasky Med Ctr, Dept Infect Dis & Epidemiol, Tel Aviv, Israel; [Meijer, Suzy; Henig, Oryan; Levytskyi, Katia; Ben-Ami, Ronen; Adler, Amos; Paran, Yael] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Halutz, Ora] Tel Aviv Sourasky Med Ctr, Clin Microbiol Lab, Tel Aviv, Israel	Tel Aviv University; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center	Stern, A (corresponding author), Tel Aviv Univ, Shmunis Sch Biomed & Canc Res, Tel Aviv, Israel.; Stern, A (corresponding author), Tel Aviv Univ, Edmond J Safra Ctr Bioinformat, Tel Aviv, Israel.	sternadi@tauex.tau.ac.il			European Research Council [852223]; Israeli Science Foundation [3963/19]; Edmond J. Safra Center for Bioinformatics at Tel Aviv University	European Research Council(European Research Council (ERC)European Commission); Israeli Science Foundation(Israel Science Foundation); Edmond J. Safra Center for Bioinformatics at Tel Aviv University	We would like to thank S. Fleishon, N. Zuckerman, T. Hagai, D. Burstein and N. Harel for critical reading and discussions. This study was supported by a European Research Council starting grant 852223 (RNAVirFitness) to A.S. and by an Israeli Science Foundation grant (3963/19) to A.S. This study was also supported, in part, by a fellowship to S.H. and D.M. from the Edmond J. Safra Center for Bioinformatics at Tel Aviv University. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Avanzato VA, 2020, CELL, V183, P1901, DOI 10.1016/j.cell.2020.10.049; Baang JH, 2021, J INFECT DIS, V223, P23, DOI 10.1093/infdis/jiaa666; Barton MI, 2021, ELIFE, V10, DOI 10.7554/eLife.70658; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Borges V, 2021, MSPHERE, V6, DOI 10.1128/mSphere.00244-21; Braun KM, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009849; Bronstein Y., J MED VIROL, DOI [10.1002/jmv.27445(2021, DOI 10.1002/JMV.27445(2021]; Canakoglu A, 2021, NUCLEIC ACIDS RES, V49, pD817, DOI 10.1093/nar/gkaa846; Cevik M, 2021, LANCET MICROBE, V2, pE13, DOI 10.1016/S2666-5247(20)30172-5; Chen L, 2021, MSPHERE, V6, DOI 10.1128/mSphere.00480-21; Chen RTE, 2021, NAT MED, V27, DOI 10.1038/s41591-021-01294-w; Choi B, 2020, NEW ENGL J MED, V383, P2291, DOI 10.1056/NEJMc2031364; Corey L, 2021, NEW ENGL J MED, V385, P562, DOI 10.1056/NEJMsb2104756; Davies Nicholas G, 2021, Science, V372, DOI 10.1126/science.abg3055; Elbe S, 2017, GLOB CHALL, V1, P33, DOI 10.1002/gch2.1018; Flammer JR, 2010, MOL CELL BIOL, V30, P4564, DOI 10.1128/MCB.00146-10; Fu Y, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01190-2020; Fung M, 2021, CLIN INFECT DIS, V72, P340, DOI 10.1093/cid/ciaa863; Gelbart M, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1009029; Ghafari M, 2022, MOL BIOL EVOL, V39, DOI 10.1093/molbev/msac009; Greaney AJ, 2021, CELL HOST MICROBE, V29, P44, DOI 10.1016/j.chom.2020.11.007; Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407; Harvey WT, 2021, NAT REV MICROBIOL, V19, P409, DOI 10.1038/s41579-021-00573-0; Hay J. A., PREPRINT, DOI [10.1101/2022.01.13.22269257v1(2022), DOI 10.1101/2022.01.13.22269257V1(2022)]; Jensen B, 2021, LANCET REG HEALTH-EU, V8, DOI 10.1016/j.lanepe.2021.100164; Karim F., PREPRINT, DOI [10.1101/2021.06.03.21258228v1(2021), DOI 10.1101/2021.06.03.21258228V1(2021)]; Kemp SA, 2021, NATURE, V592, P277, DOI 10.1038/s41586-021-03291-y; Kistler KE, 2022, CELL HOST MICROBE, V30, P545, DOI [10.1016/j.chom.2022.03.018, 10.1101/2021.09.11.459844]; Leung WF, 2022, INT J INFECT DIS, V114, P178, DOI 10.1016/j.ijid.2021.10.045; Lipsitch M, 1997, TRENDS MICROBIOL, V5, P31, DOI 10.1016/S0966-842X(97)81772-6; Lista M. J., 2021, BIORXIV, DOI [10.1101/2021.11.09.467693v1.full, DOI 10.1101/2021.11.09.467693V1.FULL]; Lundberg SM, 2017, ADV NEUR IN, V30; Lundberg SM, 2020, NAT MACH INTELL, V2, P56, DOI 10.1038/s42256-019-0138-9; Lythgoe KA, 2021, SCIENCE, V372, P256, DOI 10.1126/science.abg0821; MacLean OA, 2021, PLOS BIOL, V19, DOI 10.1371/journal.pbio.3001115; Martin D. P., BIORXIV, DOI [10.1101/2022.01.14.476382v1(2022), DOI 10.1101/2022.01.14.476382V1(2022)]; Meijer SE, 2021, OPEN FORUM INFECT DI, V8, DOI 10.1093/ofid/ofab120; Meng B, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.109292; Mlcochova P, 2021, NATURE, V599, P114, DOI 10.1038/s41586-021-03944-y; Moran E, 2021, LANCET INFECT DIS, V21, P1345, DOI 10.1016/S1473-3099(21)00464-3; O'Toole A, 2021, VIRUS EVOL, V7, DOI 10.1093/ve/veab064; Perez-Lago L, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9070808; Planas D, 2021, NATURE, V596, P276, DOI 10.1038/s41586-021-03777-9; Reily MM, 2006, EMBO J, V25, P108, DOI 10.1038/sj.emboj.7600919; Rochman ND, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2104241118; Saito A, 2022, NATURE, V602, P300, DOI 10.1038/s41586-021-04266-9; Starr Tyler N, 2021, Science, V371, P850, DOI [10.1101/2020.11.30.405472, 10.1126/science.abf9302]; Starr TN, 2020, CELL, V182, P1295, DOI 10.1016/j.cell.2020.08.012; Sudre CH, 2021, NAT MED, V27, DOI 10.1038/s41591-021-01292-y; Tao KM, 2021, NAT REV GENET, V22, P757, DOI 10.1038/s41576-021-00408-x; Tarhini H, 2021, J INFECT DIS, V223, P1522, DOI 10.1093/infdis/jiab075; Tonkin-Hill G, 2021, ELIFE, V10, DOI 10.7554/eLife.66857; Truong TT, 2021, EBIOMEDICINE, V67, DOI 10.1016/j.ebiom.2021.103355; Valesano AL, 2021, PLOS PATHOG, V17, DOI [10.1371/journal.ppat.1009499, 10.1101/2021.01.19.427330]; Wang YP, 2021, ECLINICALMEDICINE, V40, DOI 10.1016/j.eclinm.2021.101129; Wei CS, 2021, J GENET GENOMICS, V48, P1111, DOI 10.1016/j.jgg.2021.12.003; Zhang LP, 2021, P NATL ACAD SCI USA, V118, DOI [10.1101/2021.02.05.429982, 10.1073/pnas.2109905118j1of7, 10.1073/pnas.2109905118]; Zhang XL, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-2854-x; Zhou B, 2021, NATURE, V592, P122, DOI 10.1038/s41586-021-03361-1	59	4	4	6	6	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2022	28	7					1501	+		10.1038/s41591-022-01882-4	http://dx.doi.org/10.1038/s41591-022-01882-4		JUN 2022	13	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	3E5PS	35725921	Green Published, Green Submitted, hybrid			2022-12-27	WOS:000813559100001
J	Paleyanda, RK; Velander, WH; Lee, TK; Scandella, DH; Gwazdauskas, FC; Knight, JW; Hoyer, LW; Drohan, WN; Lubon, H				Paleyanda, RK; Velander, WH; Lee, TK; Scandella, DH; Gwazdauskas, FC; Knight, JW; Hoyer, LW; Drohan, WN; Lubon, H			Transgenic pigs produce functional human factor VIII in milk	NATURE BIOTECHNOLOGY			English	Article						transgenic animals; mammary gland; blood coagulation	CLOTTING FACTOR-VIII; HUMAN PROTEIN-C; VON WILLEBRAND FACTOR; MAMMARY-GLAND; PROCOAGULANT PROTEIN; PROMOTER DIRECTS; CODING REGION; EXPRESSION; CDNA; MICE	Deficiency or abnormality of coagulation factor VIII (FVIII) causes a bleeding disorder called hemophilia A. Treatment involves FVIII concentrates prepared from pooled human plasma or recombinant FVIII (rFVIII) prepared from mammalian cell culture, The cost of highly purified FVIII or rFVIII is a major factor in hemophilia therapy and restricts prophylaxis. We have sought to generate a new source of rFVIII by targeting expression of the human FVIII cDNA to the mammary gland of transgenic pigs using the regulatory sequences of the mouse whey acidic protein gene. The identity of processed heterodimeric rFVIII was confirmed using specific antibodies, by thrombin digestion and activity assays, The secretion of as much as 2.7 mu g/ml of rFVIII in milk was over tenfold higher than in normal plasma, Up to 0.62 U/ml of rFVIII was detected in an assay in which rFVIII restored normal clotting activity to FVIII-deficient human plasma.	GEORGE WASHINGTON UNIV, DEPT MED, WASHINGTON, DC 20037 USA; GEORGE WASHINGTON UNIV, DEPT GENET, WASHINGTON, DC 20037 USA; GEORGE WASHINGTON UNIV, DEPT BIOCHEM, WASHINGTON, DC 20037 USA; VIRGINIA POLYTECH INST & STATE UNIV, DEPT DAIRY SCI, BLACKSBURG, VA 24061 USA; VIRGINIA POLYTECH INST & STATE UNIV, DEPT CHEM ENGN, BLACKSBURG, VA 24061 USA; HOLLAND LAB, PLASMA DERIVAT DEPT, ROCKVILLE, MD 20855 USA; HOLLAND LAB, COAGULAT PROT DEPT, ROCKVILLE, MD 20855 USA	George Washington University; George Washington University; George Washington University; Virginia Polytechnic Institute & State University; Virginia Polytechnic Institute & State University								CAMPBELL SM, 1984, NUCLEIC ACIDS RES, V12, P8685, DOI 10.1093/nar/12.22.8685; CLARK AJ, 1989, BIO-TECHNOL, V7, P487, DOI 10.1038/nbt0589-487; DENMAN J, 1991, BIO-TECHNOL, V9, P839, DOI 10.1038/nbt0991-839; DROHAN WN, 1994, ADVANCES IN BIOPROCESS ENGINEERING, P501; DROHAN WN, 1994, TRANSGENIC RES, V3, P355, DOI 10.1007/BF01976767; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; EHMANN WC, 1995, NATURE, V378, P124, DOI 10.1038/378124a0; FULCHER CA, 1982, P NATL ACAD SCI-BIOL, V79, P1648, DOI 10.1073/pnas.79.5.1648; FULCHER CA, 1983, BLOOD, V61, P807; FULCHER CA, 1985, J CLIN INVEST, V76, P117, DOI 10.1172/JCI111933; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; GUNZBURG WH, 1991, MOL ENDOCRINOL, V5, P123, DOI 10.1210/mend-5-1-123; HOEBEN RC, 1995, BLOOD, V85, P2447, DOI 10.1182/blood.V85.9.2447.bloodjournal8592447; HOYER LW, 1993, METHOD ENZYMOL, V222, P169; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P1233, DOI 10.1128/MCB.9.3.1233; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; KOEBERL DD, 1995, HUM GENE THER, V6, P469, DOI 10.1089/hum.1995.6.4-469; KOEDAM JA, 1988, J CLIN INVEST, V82, P1236, DOI 10.1172/JCI113721; LEE TK, 1995, J BIOCHEM, V118, P81, DOI 10.1093/oxfordjournals.jbchem.a124895; LUBIN IM, 1994, J BIOL CHEM, V269, P8639; Lubon H, 1996, TRANSFUS MED REV, V10, P131, DOI 10.1016/S0887-7963(96)80089-7; LYNCH CM, 1993, HUM GENE THER, V4, P259, DOI 10.1089/hum.1993.4.3-259; MIKKELSEN TR, 1992, NUCLEIC ACIDS RES, V20, P2249, DOI 10.1093/nar/20.9.2249; OVER J, 1984, SCAND J HAEMATOL, V33, P13; PITTIUS CW, 1988, P NATL ACAD SCI USA, V85, P5874, DOI 10.1073/pnas.85.16.5874; PITTMAN DD, 1988, P NATL ACAD SCI USA, V85, P2429, DOI 10.1073/pnas.85.8.2429; REDDY V B, 1991, Animal Biotechnology, V2, P15, DOI 10.1080/10495399109525745; ROSEN S, 1984, SCAND J HAEMATOL, V33, P139; TOOLE JJ, 1986, P NATL ACAD SCI USA, V83, P5939, DOI 10.1073/pnas.83.16.5939; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; VELANDER WH, 1992, P NATL ACAD SCI USA, V89, P12003, DOI 10.1073/pnas.89.24.12003; WALL RJ, 1985, BIOL REPROD, V32, P645, DOI 10.1095/biolreprod32.3.645; WALL RJ, 1991, P NATL ACAD SCI USA, V88, P1696, DOI 10.1073/pnas.88.5.1696; WEISS HJ, 1977, J CLIN INVEST, V60, P390, DOI 10.1172/JCI108788; WEN JY, 1995, MOL REPROD DEV, V41, P399, DOI 10.1002/mrd.1080410402; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0; Yarus S, 1997, TRANSGENIC RES, V6, P51, DOI 10.1023/A:1018405116406	39	100	118	1	11	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	OCT	1997	15	10					971	975		10.1038/nbt1097-971	http://dx.doi.org/10.1038/nbt1097-971			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XZ285	9335047				2022-12-27	WOS:A1997XZ28500026
J	Auth, DR				Auth, DR			Are ESTs patentable?	NATURE BIOTECHNOLOGY			English	Editorial Material											Auth, DR (corresponding author), MORGAN & FINNEGAN LLP,345 PK AVE,NEW YORK,NY 10154, USA.							LEHMANN, 1997, COMMUNICATION   0402	1	6	6	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	SEP	1997	15	9					911	912		10.1038/nbt0997-911	http://dx.doi.org/10.1038/nbt0997-911			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XW410	9306410				2022-12-27	WOS:A1997XW41000037
J	Sultan, P; Schechner, JS; McNiff, JM; Hochman, PS; Hughes, CCW; Lorber, MI; Askenase, PW; Pober, JS				Sultan, P; Schechner, JS; McNiff, JM; Hochman, PS; Hughes, CCW; Lorber, MI; Askenase, PW; Pober, JS			Blockade of CD2-LFA-3 interactions protects human skin allografts in immunodeficient mouse/human chimeras	NATURE BIOTECHNOLOGY			English	Article						animal model; transplantation; T lymphocytes; costimulatory molecules	T-CELL RESPONSES; HUMAN CD2; ANTIGENS; ADHESION; MOUSE	A human skin allograft injury model in immunodeficient mice, engrafted with human peripheral blood mononuclear cells from a different donor, has been used to test whether reagents that block human T cell CD2 interactions with its principal ligand, LFA-3 (CD58), can inhibit immune reactions in vivo. In this model, human skin grafts show a reproducible pattern of progressive human T-cell infiltration and human graft microvascular injury that resembles human first-set skin graft rejection. Murine Mab to human LFA-3 or human LFA-3-IgG1 fusion protein, but not isotype-matched control antibodies, each markedly protected skin grafts from leukocyte infiltration and injury. These data provide the first evidence that LFA-3 functions in vivo and establish the ability of this new model to test human-specific immune modulators.	YALE UNIV, SCH MED, MOL CARDIOBIOL PROGRAM, NEW HAVEN, CT 06536 USA; YALE UNIV, SCH MED, DEPT BIOL, NEW HAVEN, CT 06536 USA; YALE UNIV, SCH MED, DEPT DERMATOL, NEW HAVEN, CT 06536 USA; YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06536 USA; YALE UNIV, SCH MED, DEPT MED, NEW HAVEN, CT 06536 USA; YALE UNIV, SCH MED, DEPT SURG, NEW HAVEN, CT 06536 USA; BIOGEN INC, CAMBRIDGE, MA 02142 USA; UNIV CALIF IRVINE, DEPT MOL BIOL & BIOCHEM, IRVINE, CA 92697 USA	Yale University; Yale University; Yale University; Yale University; Yale University; Yale University; Biogen; University of California System; University of California Irvine			Hughes, Christopher/F-7510-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043364, R01HL051014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007016] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-51014, HL-43364] Funding Source: Medline; NIAMS NIH HHS [2T32-AR07016-23] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Chisholm P L, 1994, Ther Immunol, V1, P205; COLLINS T, 1984, J IMMUNOL, V133, P1878; Kaplon RJ, 1996, TRANSPLANTATION, V61, P356, DOI 10.1097/00007890-199602150-00004; KATO K, 1992, J EXP MED, V176, P1241, DOI 10.1084/jem.176.5.1241; MAJEAU GR, 1994, J IMMUNOL, V152, P2753; MILLER GT, 1993, J EXP MED, V178, P211, DOI 10.1084/jem.178.1.211; MURRAY AG, 1994, P NATL ACAD SCI USA, V91, P9146, DOI 10.1073/pnas.91.19.9146; MURRAY AG, 1994, IMMUNITY, V1, P57, DOI 10.1016/1074-7613(94)90009-4; Pober JS, 1996, TRANSPLANTATION, V61, P343, DOI 10.1097/00007890-199602150-00001; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SHAW S, 1986, NATURE, V323, P262, DOI 10.1038/323262a0; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0	12	55	58	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	AUG	1997	15	8					759	762		10.1038/nbt0897-759	http://dx.doi.org/10.1038/nbt0897-759			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XM707	9255790				2022-12-27	WOS:A1997XM70700027
J	Agadjanyan, M; Luo, P; Westerink, MAJ; Carey, LA; Hutchins, W; Steplewski, Z; Weiner, DB; KieberEmmons, T				Agadjanyan, M; Luo, P; Westerink, MAJ; Carey, LA; Hutchins, W; Steplewski, Z; Weiner, DB; KieberEmmons, T			Peptide mimicry of carbohydrate epitopes on human immunodeficiency virus	NATURE BIOTECHNOLOGY			English	Article						applied immunology; peptide mimetic; carbohydrate; polysaccharide; HIV-1; Lewis Y	ALPHA-AMYLASE INHIBITOR; NEUTRALIZING ANTIBODIES; SPECIFICITY ANALYSIS; MONOCLONAL-ANTIBODY; TYPE-1 HIV-1; IDENTIFICATION; INFECTION; ANTIGENS; LIBRARY; GP120	Cancer-related, mucin-type carbohydrate epitopes, principally mannose and sialo-syl residues, are expressed on the envelope protein gp160 of the human immunodeficiency virus (HIV), Anticarbohydrate antibodies directed toward these and other carbohydrate epitopes are known to neutralize HIV-1 infection by cell-free virus, Carbohydrates, however, being T cell-independent antigens, typically elicit diminished immune responses. To overcome this potential draw back, we have examined the ability of peptides that mimic such epitopes to elicit immune responses that cross-react with carbohydrate structures, We report that mouse polyclonal antisera generated against peptides that mimic mucin-related carbohydrate epitopes have anti-HIV-1 activity. Generation of antibodies was not Ir-gene restricted, as at least two different strains of mice, Balb/c (H-2(d)) and C57BI/6 (H-2(b)), responded equally to the peptides, The antipeptide sera displayed neutralizing activity against HIV-I/MN and HIV-I/3B viral strains, This neutralization was as good as human anti-HIV sera. These results indicate that peptide mimics of carbohydrates provide a novel strategy for the further development of reagents that elicit immune responses to carbohydrate epitopes associated with many infectious organisms and tumor cells.	UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; THOMAS JEFFERSON UNIV,DEPT MED,PHILADELPHIA,PA 19107; MED COLL OHIO,DEPT MED,TOLEDO,OH 43699	University of Pennsylvania; Jefferson University			Weiner, David B/H-8579-2014					ADLURI S, 1995, CANCER IMMUNOL IMMUN, V41, P185, DOI 10.1007/BF01521345; AGADJANYAN MG, 1994, J VIROL, V68, P485, DOI 10.1128/JVI.68.1.485-493.1994; BOLMSTEDT A, 1992, J GEN VIROL, V73, P3039; DIAKUN KR, 1989, J IMMUNOL, V142, P2037; EARL PL, 1994, J VIROL, V68, P3015, DOI 10.1128/JVI.68.5.3015-3026.1994; FURUKAWA K, 1993, P NATL ACAD SCI USA, V90, P1972, DOI 10.1073/pnas.90.5.1972; GATTEGNO L, 1992, AIDS RES HUM RETROV, V8, P27, DOI 10.1089/aid.1992.8.27; GRAM GJ, 1994, ARCH VIROL, V139, P253, DOI 10.1007/BF01310789; HANSEN JES, 1991, J VIROL, V65, P6461, DOI 10.1128/JVI.65.12.6461-6467.1991; HOESS R, 1993, GENE, V128, P43, DOI 10.1016/0378-1119(93)90151-R; Hutchins WA, 1996, MOL IMMUNOL, V33, P503, DOI 10.1016/0161-5890(96)00012-0; IMBERTY A, 1994, GLYCOBIOLOGY, V4, P351, DOI 10.1093/glycob/4.3.351; KITAMURA K, 1994, P NATL ACAD SCI USA, V91, P12957, DOI 10.1073/pnas.91.26.12957; MIRKOV TE, 1995, GLYCOBIOLOGY, V5, P45, DOI 10.1093/glycob/5.1.45; MOND JJ, 1995, ANNU REV IMMUNOL, V13, P655, DOI 10.1146/annurev.iy.13.040195.003255; MONTEFIORI DC, 1988, J CLIN MICROBIOL, V26, P231, DOI 10.1128/JCM.26.2.231-235.1988; MOORE JP, 1995, J VIROL, V69, P101, DOI 10.1128/JVI.69.1.101-109.1995; MULLER WEG, 1991, J ACQ IMMUN DEF SYND, V4, P694; MURAI H, 1985, J BIOCHEM-TOKYO, V97, P1129, DOI 10.1093/oxfordjournals.jbchem.a135157; NARA PL, 1988, NATURE, V332, P469, DOI 10.1038/332469a0; OLDENBURG KR, 1992, P NATL ACAD SCI USA, V89, P5393, DOI 10.1073/pnas.89.12.5393; PRAMMER KV, 1994, RECEPTOR, V4, P93; ROBINSON WE, 1987, AIDS RES HUM RETROV, V3, P265, DOI 10.1089/aid.1987.3.265; SCOTT JK, 1992, P NATL ACAD SCI USA, V89, P5398, DOI 10.1073/pnas.89.12.5398; SHIKHMAN AR, 1994, J IMMUNOL, V152, P4375; STEPLEWSKI Z, 1990, HYBRIDOMA, V9, P201, DOI 10.1089/hyb.1990.9.201; SUGIYAMA T, 1991, J IMMUNOL, V146, P3097; THURINBLASZCZYK M, 1996, PROTEIN ENG, V9, P101; Trkola A, 1996, J VIROL, V70, P1100, DOI 10.1128/JVI.70.2.1100-1108.1996; Tsuyuoka K, 1996, J IMMUNOL, V157, P661; UGEN KE, 1993, MODERN APPROACHES NE, P215; WESTERINK MAJ, 1995, P NATL ACAD SCI USA, V92, P4021, DOI 10.1073/pnas.92.9.4021; Willey RL, 1996, J VIROL, V70, P6431, DOI 10.1128/JVI.70.9.6431-6436.1996	33	80	85	0	4	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1997	15	6					547	551		10.1038/nbt0697-547	http://dx.doi.org/10.1038/nbt0697-547			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XC772	9181577	Bronze			2022-12-27	WOS:A1997XC77200030
J	Cannizzo, SJ; Frey, BM; Raffi, S; Moore, MAS; Eaton, D; Suzuki, M; Singh, R; Mack, CA; Crystal, RG				Cannizzo, SJ; Frey, BM; Raffi, S; Moore, MAS; Eaton, D; Suzuki, M; Singh, R; Mack, CA; Crystal, RG			Augmentation of blood platelet levels by intratracheal administration of an adenovirus vector encoding human thrombopoietin cDNA	NATURE BIOTECHNOLOGY			English	Article						gene therapy; adenovirus; thrombopoietin; lung epithelium	MEDIATED GENE-TRANSFER; HEMATOPOIETIC GROWTH-FACTORS; C-MPL LIGAND; ERYTHROPOIETIN GENE; AIRWAY EPITHELIUM; CYSTIC-FIBROSIS; CFTR CDNA; LUNG; REGULATOR; THERAPY	This study was designed to evaluate the hypothesis that administration of a replication-deficient, recombinant adenovirus vector to the epithelial surface of the respiratory tract can be used to deliver a recombinant protein to the systemic circulation in sufficient quantities to evoke a systemic response appropriate to the recombinant protein. We administered AdCMV.TPO-an adenovirus vector containing an expression cassette coding for the human thrombopoietin (TPO) cDNA-to the respiratory epithelium of immunocompetent Balb/c mice. Over the following week, serum human TPO levels were elevated, platelet levels increased more than sixfold, and megakaryocytosis was evident in bone marrow. This strategy may be a useful approach to the nonparenteral administration of a variety of therapeutic recombinant proteins, such as those relevant to clotting, endocrine function, and bone-marrow function.	NEW YORK HOSP,CORNELL MED CTR,DIV PULM & CRIT CARE MED,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,JAMES EWING LAB DEV HEMATOPOIESIS,NEW YORK,NY 10021; NEW YORK HOSP,CORNELL MED CTR,DIV HEMATOL ONCOL,NEW YORK,NY 10021; GENENTECH INC,DEPT CARDIOVASC RES,S SAN FRANCISCO,CA 94080	Cornell University; NewYork-Presbyterian Hospital; Memorial Sloan Kettering Cancer Center; Cornell University; NewYork-Presbyterian Hospital; Roche Holding; Genentech			Singh, Ravi/B-1221-2010; Singh, Ravi N/A-5740-2011	Singh, Ravi N/0000-0003-0750-1804	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL051746, K08HL002926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042693] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08-HL-02926, P01 HL51746-03] Funding Source: Medline; NIDDK NIH HHS [R01-DK-42693] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPELBAUM FR, 1995, STEM CELLS, V13, P344, DOI 10.1002/stem.5530130404; BOUT A, 1994, HUM GENE THER, V5, P3, DOI 10.1089/hum.1994.5.1-3; BROUDY VC, 1995, J LEUKOCYTE BIOL, V57, P719, DOI 10.1002/jlb.57.5.719; CHANDRA T, 1992, ANN BIOMED ENG, V20, P481, DOI 10.1007/BF02368138; CRYSTAL RG, 1994, NAT GENET, V8, P42, DOI 10.1038/ng0994-42; CRYSTAL RG, 1994, 9409085 RAC; CRYSTAL RG, 1992, 9212034 RAC; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; DESCAMPS V, 1994, HUM GENE THER, V5, P979, DOI 10.1089/hum.1994.5.8-979; EFFROS RM, 1997, LUNG SCI FDN, P1567; ENGELHARDT JF, 1993, HUM GENE THER, V4, P759, DOI 10.1089/hum.1993.4.6-759; Frey B. M., 1996, Experimental Hematology (Charlottesville), V24, P1056; HERSH J, 1995, GENE THER, V2, P124; KAUSHANSKY K, 1995, BLOOD, V86, P419, DOI 10.1182/blood.V86.2.419.bloodjournal862419; KAUSHANSKY K, 1993, BLOOD, V82, P3229; MASTRANGELI A, 1993, J CLIN INVEST, V91, P225, DOI 10.1172/JCI116175; NEIDHART JA, 1993, CANCER, V72, P3381, DOI 10.1002/1097-0142(19931201)72:11+<3381::AID-CNCR2820721604>3.0.CO;2-0; Ohwada A, 1996, BLOOD, V88, P778; PARKER JC, 1986, MICROVASC RES, V31, P1, DOI 10.1016/0026-2862(86)90002-6; RIPPE B, 1991, LUNG, P349; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; SETOGUCHI Y, 1994, BLOOD, V84, P2946; SIEGFRIED W, 1995, AM J RESP CELL MOL, V12, P379, DOI 10.1165/ajrcmb.12.4.7695917; TRIPATHY SK, 1994, P NATL ACAD SCI USA, V91, P11557, DOI 10.1073/pnas.91.24.11557; Tripathy SK, 1996, NAT MED, V2, P545, DOI 10.1038/nm0596-545; Whetton AD, 1993, CURR OPIN CELL BIOL, V5, P1044, DOI 10.1016/0955-0674(93)90090-D; Xing Z, 1996, J LEUKOCYTE BIOL, V59, P481, DOI 10.1002/jlb.59.4.481; Xing Z, 1996, J CLIN INVEST, V97, P1102, DOI 10.1172/JCI118503; YEI SP, 1994, HUM GENE THER, V5, P731, DOI 10.1089/hum.1994.5.6-731; ZABNER J, 1994, NAT GENET, V6, P75, DOI 10.1038/ng0194-75	31	18	20	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	1997	15	6					570	573		10.1038/nbt0697-570	http://dx.doi.org/10.1038/nbt0697-570			4	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	XC772	9181581				2022-12-27	WOS:A1997XC77200034
J	Goldman, CK; Soroceanu, L; Smith, N; Gillespie, GY; Shaw, W; Burgess, S; Bilbao, G; Curiel, DT				Goldman, CK; Soroceanu, L; Smith, N; Gillespie, GY; Shaw, W; Burgess, S; Bilbao, G; Curiel, DT			In vitro and in vivo gene delivery mediated by a synthetic polycationic amino polymer	NATURE BIOTECHNOLOGY			English	Article						gene transfer; gene therapy; transfection; liposome	IN-VIVO; BLOOD-VESSELS; ADENOVIRUS; THERAPY; CELLS; BRAIN; TRANSFECTION; LIPOSOME; DISEASE; RAT	A synthetic polyamino polymer with a glucose backbone was used for gene transfer in vitro and in vivo. Gene transfer in vitro to various human carcinoma cell lines was achieved with an efficiency superior to a commercially available cationic liposome preparation. The polymer was resistant to inhibition by serum, which allowed for efficient gene transfer in vivo. Direct intracranial turner injection using this reagent resulted in reporter gene expression revels comparable to those achieved by a recombinant adenoviral vector. Thus, this compound represents a new class of agent that may have broad utility for gene transfer and gene therapy applications.	UNIV ALABAMA, GENE THERAPY PROGRAM, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DIV NEUROSURG, BIRMINGHAM, AL 35294 USA; AVANTI POLAR LIPIDS, ALABASTER, AL 35007 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham				Gillespie, George/0000-0001-6436-9542				BASS C, 1995, CANCER GENE THER, V2, P97; BLASESE M, CANCER GENE THER, V2, P291; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; BYRNES AP, 1995, NEUROSCIENCE, V66, P1015, DOI 10.1016/0306-4522(95)00068-T; CAO L, 1995, HUM GENE THER, V6, P1497, DOI 10.1089/hum.1995.6.11-1497; COOK DR, 1994, CANCER BIOTHERAPY, V9, P131, DOI 10.1089/cbr.1994.9.131; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; ENOMAA N, 1995, HUM GENE THER, V6, P723, DOI 10.1089/hum.1995.6.6-723; Felgner PL, 1995, ANN NY ACAD SCI, V772, P126, DOI 10.1111/j.1749-6632.1995.tb44738.x; Gao X, 1995, GENE THER, V2, P710; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; HANANIA EG, 1995, AM J MED, V99, P537, DOI 10.1016/S0002-9343(99)80232-0; HOEBEN RC, 1993, HUM GENE THER, V4, P179, DOI 10.1089/hum.1993.4.2-179; LEMARCHAND P, 1993, CIRC RES, V72, P1132, DOI 10.1161/01.RES.72.5.1132; LOZIER JN, 1994, HUM GENE THER, V5, P313, DOI 10.1089/hum.1994.5.3-313; LUTZ J, 1994, LIFE SCI, V56, P99, DOI 10.1016/0024-3205(94)00930-9; Mizuguchi H, 1996, BIOCHEM BIOPH RES CO, V218, P402, DOI 10.1006/bbrc.1996.0070; MULDOON LL, 1995, AM J PATHOL, V147, P1840; NABEL EG, 1992, HUM GENE THER, V3, P649, DOI 10.1089/hum.1992.3.6-649; OOBOSHI H, 1995, CIRC RES, V77, P7, DOI 10.1161/01.RES.77.1.7; ROESSLER BJ, 1994, NEUROSCI LETT, V167, P5, DOI 10.1016/0304-3940(94)91015-4; SAMBROOK J, 1989, MOL CLONING LABORATO, pCH6; SAWA Y, 1995, CIRCULATION, V92, P479, DOI 10.1161/01.CIR.92.9.479; SCHOFIELD JP, 1995, BRIT MED BULL, V51, P56, DOI 10.1093/oxfordjournals.bmb.a072953; SOLODIN I, 1995, BIOCHEMISTRY-US, V34, P13537, DOI 10.1021/bi00041a033; SZILVASSY SJ, 1994, BLOOD, V84, P74; TERAMOTO S, 1995, HUM GENE THER, V6, P1045, DOI 10.1089/hum.1995.6.8-1045; THIERRY AR, 1995, P NATL ACAD SCI USA, V92, P9742, DOI 10.1073/pnas.92.21.9742; VINCENT MC, 1995, HUM GENE THER, V6, P1019, DOI 10.1089/hum.1995.6.8-1019; YAGI K, 1994, BIOCHEM MOL BIOL INT, V32, P167	30	96	127	1	14	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	MAY	1997	15	5					462	466		10.1038/nbt0597-462	http://dx.doi.org/10.1038/nbt0597-462			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WX237	9131627				2022-12-27	WOS:A1997WX23700032
J	Wang, T; Lacik, I; Brissova, M; Anilkumar, AV; Prokop, A; Hunkeler, D; Green, R; Shahrokhi, K; Powers, AC				Wang, T; Lacik, I; Brissova, M; Anilkumar, AV; Prokop, A; Hunkeler, D; Green, R; Shahrokhi, K; Powers, AC			An encapsulation system for the immunoisolation of pancreatic islets	NATURE BIOTECHNOLOGY			English	Article						transplantation; encapsulation; diabetes; capsules; xenograft	BIOARTIFICIAL PANCREAS; RAT ISLETS; MICROENCAPSULATION; CELLS; XENOTRANSPLANTATION; IMMUNOSUPPRESSION; PORCINE; TRANSPLANTATION; XENOGRAFTS; SURVIVAL	Over a thousand combinations of polyanions and polycations were tested to search for new polymer candidates that would be suitable for encapsulation of living cells. The combination of sodium alginate, cellulose sulfate, poly (methylene-co-guanidine) hydrochloride, calcium chloride, and sodium chloride was most promising. In parallel, a novel multiloop chamber reactor was developed to control the time of complex formation and to negate gravitational effects such as pancreatic islet sedimentation and droplet deformation during the encapsulation process. Encapsulated rat islets demonstrated glucose-stimulated insulin secretion in vitro, and reversed diabetes in mice. This new capsule formulation and encapsulation system allows independent adjustments of capsule size, wall thickness, mechanical strength, and permeability, which may offer distinct advantages for immunoisolating cells.	VANDERBILT UNIV,DEPT BIOCHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT CHEM ENGN,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT MED,DIV ENDOCRINOL,NASHVILLE,TN 37232; DEPT VET AFFAIRS MED CTR,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Wang, T (corresponding author), VANDERBILT UNIV,SCH ENGN,CTR MICROGRAV RES,221 KIRKLAND HALL,NASHVILLE,TN 37235, USA.			Lacik, Igor/0000-0001-6037-3747	NIDDK NIH HHS [DK 20593] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brissova M, 1996, ANAL BIOCHEM, V242, P104, DOI 10.1006/abio.1996.0435; Calafiore R, 1996, TRANSPLANT P, V28, P812; Chang T M, 1992, ASAIO J, V38, P128, DOI 10.1097/00002480-199204000-00013; COLTON CK, 1991, J BIOMECH ENG-T ASME, V113, P152, DOI 10.1115/1.2891229; CROOKS CA, 1990, J BIOMED MATER RES, V24, P1241, DOI 10.1002/jbm.820240908; DEVOS P, 1993, INT J ARTIF ORGANS, V16, P205, DOI 10.1177/039139889301600407; GOOSEN MFA, 1985, BIOTECHNOL BIOENG, V27, P146, DOI 10.1002/bit.260270207; GOOSEN MFA, 1994, IMMUNOISOLATION PANC, P21; KENDALL JM, 1986, PHYS FLUIDS, V29, P2086, DOI 10.1063/1.865595; KENDALL JM, 1982, J VAC SCI TECHNOL, V20, P1091, DOI 10.1116/1.571574; KENDALL JM, 1988, AM I PHYSICS P, V197, P487; LACY PE, 1995, SCI AM, V273, P50, DOI 10.1038/scientificamerican0795-50; LANZA RP, 1994, TRANSPLANTATION, V57, P1371, DOI 10.1097/00007890-199405150-00015; LANZA RP, 1991, P NATL ACAD SCI USA, V88, P11100, DOI 10.1073/pnas.88.24.11100; LANZA RP, 1992, DIABETES, V41, P1503, DOI 10.2337/diabetes.41.12.1503; LANZA RP, 1995, TRANSPLANTATION, V59, P1377, DOI 10.1097/00007890-199505270-00003; Lardner TJ., 1980, MECH TODAY, V5, P161; LEE CP, 1988, J FLUID MECH, V188, P411, DOI 10.1017/S0022112088000783; LIM F, 1980, SCIENCE, V210, P908, DOI 10.1126/science.6776628; LIN KC, 1992, AIAA; LUM ZP, 1991, DIABETES, V40, P1511, DOI 10.2337/diabetes.40.11.1511; MAKI T, 1995, CLIN PHARMACOKINET, V28, P471, DOI 10.2165/00003088-199528060-00005; NAVE R, 1993, J CHROMATOGR A, V654, P229, DOI 10.1016/0021-9673(93)83366-Z; OSHEA GM, 1986, DIABETES, V35, P943, DOI 10.2337/diabetes.35.8.943; REACH G, 1994, TRANSPLANT P, V26, P397; Ricordi C., 1992, PANCREATIC ISLET CEL, P137; SCHARP DW, 1994, DIABETES, V43, P1167, DOI 10.2337/diabetes.43.9.1167; SOONSHIONG P, 1993, P NATL ACAD SCI USA, V90, P5843, DOI 10.1073/pnas.90.12.5843; SOONSHIONG P, 1994, LANCET, V343, P950, DOI 10.1016/S0140-6736(94)90067-1; SUN YL, 1993, ARTIF ORGANS, V17, P727; WEBER C, 1991, TRANSPLANT P, V23, P764	31	266	282	0	79	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	APR	1997	15	4					358	362		10.1038/nbt0497-358	http://dx.doi.org/10.1038/nbt0497-358			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	WQ554	9094138				2022-12-27	WOS:A1997WQ55400037
